,nct_id,primaryOutcomes,startDate,status,study_type,phases,otherOutcomes,secondaryOutcomes
0,NCT01976351,The relationship between the mucosal morphology by imaging enhanced endoscopy and the presence of high-grade intraepithelial neoplasia from non-dysplastic specialized intestinal metaplasia.,2009-09,TERMINATED,OBSERVATIONAL,['NA'],,
1,NCT00759109,Number of Participants With the Development of Hepatocellular Carcinoma (HCC),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline,Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)
2,NCT04806243,os（overall survival）,2021-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DoR
3,NCT00877136,Evaluate patient experience with Therasphere.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response to treatment with TheraSphere®
4,NCT01217450,"Tumor response, as evaluated by the RECIST",2012-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicities graded using the NCI Common Toxicity Criteria
5,NCT01674309,Tumor control rate of the primary tumor and metastasis,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,metastasis response rate
6,NCT05626309,1-year disease-free survival rate,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants With Adverse Events
7,NCT03979131,Pathological complete response (pCR) rate,2019-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical complete resection rate (R0)
8,NCT00890188,Overall response(CR+PR) and Clinical benefit (CR+PR+SD),2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To determine the progression free survival, overall survival (OS)and assess the safety profile"
9,NCT04209491,Proportion of the following missions of the coordinator Nurse,2019-09-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of early unscheduled readmissions during the first month following interventional radiology treatment for patients included in the study.
10,NCT04249739,ORR (objective response rate) per RECIST 1.1,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Genomic analysis
11,NCT00003046,Maximum Tolerated Dose (MTD) of Intraperitoneal Interleukin-12,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12,NCT03789162,Blood-based biomarkers associated with genetic and epigenetic alterations,2018-12-20,RECRUITING,OBSERVATIONAL,['NA'],,
13,NCT01749865,Time to recurrence,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],Adverse Events,Disease Free Survival
14,NCT03476434,polyp miss rate,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,adenoma miss rate
15,NCT05201885,The positive rate of oncological contamination of peritoneal washings,2022-01-15,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
16,NCT02527824,overall response rate,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity profiles - the number of participants and grade of intensity of treatment related adverse events
17,NCT03982641,Cost relate to HCRU,2019-04-16,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of preoperative chemo-radiation therapy in patients with rectal cancer
18,NCT00689702,Complete pathological remission rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rate of sphincter sparing surgical procedure Toxicity/safety
19,NCT04556344,Change in patient emotional skills from baseline to 15 days after the end of intervention,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],,Patient satisfaction
20,NCT03418584,radical rate,2017-12-05,UNKNOWN,INTERVENTIONAL,['NA'],,operation time
21,NCT01979549,Adverse events,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],,
22,NCT00811447,Time to progression,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Laboratory toxicities/symptomatology
23,NCT04213794,Incidence of adverse events of cytoreductive surgery (CRS) with heated intra-peritoneal chemotherapy (HIPEC) in this patient population,2019-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival (PFS)
24,NCT01830907,Infectious complication,2012-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Length of hospital stay
25,NCT02017509,Correlation of the number of infiltrating leukocytes within a biopsy sample with pathologic response,2014-01-24,COMPLETED,OBSERVATIONAL,['NA'],,
26,NCT00982449,To evaluate the potential for enzymatic targeting as evidenced by the ability to image 124I-FIAU tracer uptake in tumor at baseline and following chemotherapy or biologic therapy with agents that may induce viral TK activation.,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,To describe changes in viral DNA in plasma as a function of chemotherapy and the association with imaging by FIAU-PET
27,NCT00427804,Fractional Absorption of Calcium,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
28,NCT03110068,Presence of microvascular invasion,2017-04-10,UNKNOWN,OBSERVATIONAL,['NA'],,
29,NCT03714555,CA19-9 Plasma Level,2019-10-17,TERMINATED,INTERVENTIONAL,['PHASE2'],Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC),Incidence of Toxicities
30,NCT03904927,Progression-free survival,2019-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Local control
31,NCT03730558,Evaluate the efficacy of aflibercept in terms of progression-free survival (PFS) in association with FOLFIRI in patients treated in common practice for metastatic colorectal cancer (CCRM) after failure of oxaliplatin + anti-EGFR-based treatment,2017-11-08,UNKNOWN,OBSERVATIONAL,['NA'],,
32,NCT00002896,,1993-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
33,NCT03714958,Part1: Dose Maximum Tolerated,2018-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
34,NCT04731428,Use of analgesic (See Table 1)(postoperative 3rd day),2018-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative serum cortisol levels (3rd. assessment)
35,NCT05945823,ORR by investigator assessment,2023-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,6-month PFS rate
36,NCT02270554,Incidence of pancreatic fistula grade B/C,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma
37,NCT02324023,T-stage in left sided colonic cancer determined by endoscopic ultrasound compared to histological stage,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,Perfusion in left sided colonic cancer determined by contrast enhanced endoscopic ultrasound compared to histological vascular immunostaining
38,NCT00066430,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
39,NCT05999162,Onset time,2023-08-04,COMPLETED,OBSERVATIONAL,['NA'],,Re-admission
40,NCT03199989,3-year disease free survival,2017-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Major adverse events
41,NCT00359333,Tumor response,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to tumor progression Overall survival Quality of life
42,NCT03170115,Tumor downstaging after induction chemotherapy followed by chemoradiotherapy with or without aspirin,2017-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
43,NCT05519930,Evaluation of endoscopic ultrasound for early detection of pancreatic cancer in the high-risk group as defined by inclusion criteria to determine their level of risk and perform surveillance accordingly,2016-10-18,SUSPENDED,OBSERVATIONAL,['NA'],,
44,NCT04083365,Pathological complete response (pCR) rate after durvalumab treatment,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DSF)
45,NCT00553683,Overall tolerability,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Overall survival at 6, 12, and 24 months"
46,NCT01479465,Progression Free Survival (PFS),2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
47,NCT04695782,1-year local control,2020-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes
48,NCT04846842,Objective response rate (ORR),2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
49,NCT02934464,Progression-Free Survival (PFS),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life EuroQol EQ-5D
50,NCT02901600,Determination of the histological localisation of DMBT1,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
51,NCT01394939,Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
52,NCT03785743,5-year overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,['NA'],,intraoperative indicators
53,NCT02504983,Complete remission,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Safety and tolerability of TACE plus sorafenib therapy recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
54,NCT00576498,Proportion of patients with biopsy confirmed intestinal metaplasia,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,Inter observer variability in reading of mucosal and vascular patterns
55,NCT05609370,Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C,2023-01-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of Participants with anti-drug antibodies (ADAs) to Tislelizumab, and Bevacizumab in Arm A, Arm B and Arm D"
56,NCT04721223,Objective response rate (ORR),2021-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants with Treatment-related Adverse Events(TRAE)
57,NCT04666688,Part 2: PFS or ORR [Preliminary Efficacy],2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 1: Pharmacodynamics (PD) of LYT- 200
58,NCT05000554,pCR rate,2021-07-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,operative mortality
59,NCT05640726,progression free survival,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,objective response rate
60,NCT05445973,Local tumor progression rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical success rate of radiofrequency ablation using contrast-enhanced US-CT/MRI fusion image
61,NCT05273931,Changes in adherence to the lifestyle recommendations between baseline and the 4 week follow-up,2022-03-16,COMPLETED,INTERVENTIONAL,['NA'],,
62,NCT00527891,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,
63,NCT03115398,Number of Missed Scheduled Radiotherapy Treatments,2017-02-16,COMPLETED,INTERVENTIONAL,['NA'],,Survival Status
64,NCT01791322,Correct identification of tumor mutant genes,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
65,NCT00493402,Overall survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
66,NCT04685525,PRO-CTCAE questionnaire scores,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
67,NCT04991948,The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15]),2021-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,
68,NCT01445327,"Number of Participants With Specific Tumor Markers in Stool, Urine, or Serum Detected Prior to Treatment and After Treatment",2007-02-20,TERMINATED,OBSERVATIONAL,['NA'],Here is the Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Toxicity Criteria (CTC) v3.0.,Number of Participants With Chronic Gastrointestinal Injury After Radiotherapy
69,NCT05570279,Complete clinical response,2016-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of pelvis fractures
70,NCT03515850,classifications vascular branches of IMA,2018-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,
71,NCT00464893,rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"disease-free survival at 3, 6, 9, 12 18 and 24 months after EOT, defined as the time from study enrolment to the point of diagnosis of recurrent disease or death, whichever occurred first"
72,NCT06255912,Treatment Emergent Adverse Events,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall response rate
73,NCT03575806,Recurrence-free Survival (RFS) Time,2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate at 24 Months
74,NCT02188901,False referral rate of HCC,2014-10-15,COMPLETED,INTERVENTIONAL,['NA'],,
75,NCT00000764,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
76,NCT03961867,disease-free survival,2020-09-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment related Adverse Events
77,NCT00932308,The degree of inflammation in the rectosigmoid epithelium as judged by the density and composition of the cellular infiltration.,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,Changes in bulk fecal and epithelial associated microbiota that may determine changes in colorectal epithelial cell biologic pathways.
78,NCT05095714,Incremental cost / QALY ratio,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Compliance
79,NCT03621852,tissue yield,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
80,NCT05534087,3-year disease-free survival rate,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 scale
81,NCT00072748,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
82,NCT01871363,Pathological complete remission rate (pCR),2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],Disease-free survival,Acute and late toxicity
83,NCT00467922,"Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay",2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.
84,NCT03620643,Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of overall survival in each cohort
85,NCT02311361,Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug,2015-03-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
86,NCT00531180,Correlation between 4-dimensional computed tomography (4D CT) derived ventilation and single photon emission tomography (SPECT) aerosol Tc-99m determined ventilation,2007-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,
87,NCT05868317,Pathologic complete response,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,objective response rate to induction chemotherapy
88,NCT03312374,Disease Free Survival,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
89,NCT04384601,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease free survival (DFS)
90,NCT05443230,Long-term results,2022-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
91,NCT04455932,HCC detection with US surveillance versus aNC-MRI surveillance,2022-01,RECRUITING,INTERVENTIONAL,['NA'],,
92,NCT05374252,cCR rate,2022-05-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence rate of Grade ≥3 PD-1monoclonal antibody-related adverse events
93,NCT00313872,Second progress-free survival,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity, overall survival"
94,NCT05244174,Level of Fecal elastase-1,2022-01-25,RECRUITING,INTERVENTIONAL,['NA'],,Prevalence of PEI
95,NCT01759238,Progression free survival rate,2013-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
96,NCT03992664,Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Assessing the quality of life in relation to the rash through the QLQI questionnaire.
97,NCT05617755,Maximal tolerated dose of AB-1015,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Co-expression of ALPG and MSLN targets on tumor cells
98,NCT00201747,Most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate if pre- and/or post-treatment Topo I-, CE and NQ01-gene expression in fresh tumor specimens and adjacent tissue, are associated with antitumor efficacy or toxicity."
99,NCT00747292,Length of hospital stay,2007-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pain, time till flatus, time till bowels open, incidence of nausea and vomiting, quality of life"
100,NCT01265979,WB-DWI as early predictor for regorafenib treatment response,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation WB-DWI parameters in correlation with progression free survival (PFS)
101,NCT01016639,,2003-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
102,NCT04770896,Overall Survival (OS),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Serum Concentration of Atezolizumab
103,NCT02550769,Evaluate the effectiveness of the T-TME versus L-LAR with the LARS score in patients with rectal cancer.,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,
104,NCT02607072,3-year disease free survival,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
105,NCT00003125,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
106,NCT05045573,Pathological tumor response,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of Healthy liver hypertrophia
107,NCT04821284,Progression-free survival,2021-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor stiffness
108,NCT01397305,Feasibility of Pemetrexed Prior to Surgery,2011-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma"
109,NCT05484908,Mortality rate,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Model for end-stage liver disease (MELD) score variation
110,NCT04550663,The occurrence of AEs and SAEs during the study treatment,2020-09-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
111,NCT00593723,The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate overall survival rates
112,NCT01970748,Bleeding,2009-08,RECRUITING,INTERVENTIONAL,['PHASE4'],,Complication survival
113,NCT05692895,Diagnosis and prognosis of colorectal carcinoma,2023-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
114,NCT03256994,Description of the clinical context in which SIR-Spheres are applied,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],,Diagnosis- and treatment-related considerations
115,NCT00473980,Immune reactivity,1998-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
116,NCT02588781,overall response rate,2015-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects with Adverse Events as a measure of safety and Tolerability
117,NCT05035914,Objective response rate,2021-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Score of quality of Life
118,NCT06017661,IL-8 level,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Patients' quality of life
119,NCT06259292,Prospective Longitudinal Clinical Outcomes Assessment using HHT Clinical Outcomes Scale,2023-11-13,RECRUITING,OBSERVATIONAL,['NA'],,Treatment Outcomes Assessment with HHT Treatment Outcomes Scale
120,NCT04857684,Proportion of patients with grade 3-4 treatment-related adverse events as assessed by CTCAE v5.0,2021-06-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Recurrence-free survival (RFS) after resection
121,NCT05541146,Rate of complete peritoneal response after 04 cycles of intraperitoneal (IP) chemotherapy (CMT) associated with systemic CMT with XP.,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
122,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",2018-07-26,RECRUITING,OBSERVATIONAL,['NA'],,
123,NCT05131698,Objective response rate,2021-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
124,NCT01859728,Overall Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Biomarker evaluation,Safety
125,NCT02112656,Overall Survival (OS),2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free survival (PFS)
126,NCT03843853,Progression-free Survival(PFS),2019-05-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
127,NCT00989469,disease control,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
128,NCT01627080,Evaluation of Cardiac Biomarker Elevation with Radiation Therapy,2014-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Incidence of Adverse Cardiac Outcomes
129,NCT04830618,Metachronous recurrence,2012-09-11,COMPLETED,OBSERVATIONAL,['NA'],,
130,NCT00700258,"Efficacy: best response, progression-free survival, overall survival",2008-02-13,COMPLETED,OBSERVATIONAL,['NA'],,Safety: absolute and relative incidence of therapy interruption
131,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,2018-01-19,RECRUITING,OBSERVATIONAL,['NA'],,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes
132,NCT01211379,Change in Colorectal Cancer Screening Rate,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
133,NCT03167112,Time to Progression (TTP).,2017-07-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
134,NCT00492999,Resectability rate,2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Survival
135,NCT00991614,Patency of the stent,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,"Procedural success, implant duration, symptom resolution"
136,NCT02003339,Modifications of functional MRI parameters,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Change of VEGF (vascular endothelial growth factor) release
137,NCT06015022,Change in Prognostic Liver Secretome signature (PLSec) score,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],HCC incidence,Change in quality of life measured by the chronic liver disease questionnaire
138,NCT02401815,Part 2e: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with sunitinib for further evaluation,2015-03-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: To determine the progression-free survival of PLX9486 treatment in combination with PLX3397 or sunitinib.
139,NCT03175146,Response rate within the treated liver lesion,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
140,NCT01692873,Biomarkers,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Histology
141,NCT01100814,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
142,NCT03381651,Progression free survival,2018-02-22,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
143,NCT00659113,Response rate,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival
144,NCT00072033,Feasibility of successful study therapy completion and survival after surgery,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility in Switzerland after surgery
145,NCT00564694,Reliability and clinical and psychometric validity of the European Organization of Research for the Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-CR29),2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
146,NCT02112240,Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Feasibility
147,NCT05911789,Response rate after surgery,2023-08-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Margins for clinical target volume(CTV) and gross tumor volume (GTV)
148,NCT04208724,Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention,2020-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
149,NCT04304001,Rate of Colorectal Cancer Screening,2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Colorectal Cancer Screening Self-Efficacy Scale
150,NCT04048421,Postoperative complications,2019-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
151,NCT03026881,"DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Plasma Clearance (CL/F)
152,NCT00869739,"Relationship functioning in survivors and partners as assessed by the Dyadic Adjustment Scale (129) and the Miller Social Intimacy Scale (130) at baseline, 2 months, and 5 months",2008-08,COMPLETED,INTERVENTIONAL,['NA'],,"Coping skills in survivors and partners as assessed by the Coping Strategies, Social Problem Solving Scale-Revised, and La Trobe Communication Questionnaires at baseline, 2 months, and 5 months"
153,NCT03821909,The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,The difference of the exosomes between portal venous and peripheral blood
154,NCT05169437,Overall Response Rate (ORR) - Independent Central Review (ICR),2022-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
155,NCT00017212,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
156,NCT05643417,ORR,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,OS
157,NCT05320497,"Intubation rates of bile duct ends, cystic duct openings, and left and right hepatic duct bifurcations",2022-04-14,UNKNOWN,INTERVENTIONAL,['NA'],,Biopsy accuracy
158,NCT04418401,Recurrence-free rate in one year,2020-06-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse effects
159,NCT00073736,Safety and tolerability,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine effect of MB07133 on tumor size
160,NCT03695250,Objective Response Rate (ORR),2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
161,NCT00039403,Recommended phase II doses,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Frequency, extent, and duration of any tumor responses"
162,NCT01732393,lower grade of mucositis,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,duration of mucositis
163,NCT04646928,5-year Cumulative hepatocellular carcinoma incidence,2017-03-17,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of cirrhosis regression
164,NCT05084859,Part 2 - Objective response rate,2021-11-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite
165,NCT01671449,Progression-free survival,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Adverse Events
166,NCT00687778,Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units,2008-05,UNKNOWN,OBSERVATIONAL,['NA'],,
167,NCT05056116,Objective response rate(ORR),2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
168,NCT03746353,perioperative complications,2018-09-05,TERMINATED,INTERVENTIONAL,['NA'],,Measure quality of life
169,NCT00622674,Maximum tolerated dose (MTD) of bortezomib,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease response as measured by RECIST criteria
170,NCT01403402,Congenital Muscle Disease Patient and Proxy Reported Outcomes,2009-09,RECRUITING,OBSERVATIONAL,['NA'],,
171,NCT03291561,Gastrointestinal function score,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,Physical fitness index
172,NCT05253053,Dose limiting toxicity (DLT),2022-04-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",changes of main circulating metabolites of TT-00420 in plasma,Volume of Distribution
173,NCT00003780,,1998-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
174,NCT02750657,The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.,2015-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.
175,NCT06182865,Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients after proton therapy.,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
176,NCT00016965,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
177,NCT00081315,- Acute radiochemotherapy-induced esophagitis will be assessed from the time of randomization through up to 3 months after completion of radiochemotherapy treatment.,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,- Acute radiochemotherapy-induced pneumonitis will be assessed until 6 months after the last dose of XRT.
178,NCT05657743,Safety - Adverse events,2023-08-16,RECRUITING,INTERVENTIONAL,['NA'],Urine radioactivity measurements,Efficacy-Alpha DaRT seeds
179,NCT04422249,Survival rate,2019-12-23,RECRUITING,INTERVENTIONAL,['NA'],Incidence of postoperative complications,intraoperative parameters
180,NCT02762721,Estimate the frequency of FGFR2 fusions in archived iCCA or mixed HCC-CCA tumor tissue samples,2016-06-06,COMPLETED,OBSERVATIONAL,['NA'],,Formulate genetic screening recommendations for newly diagnosed patients with iCCA or mixed HCC-CCA
181,NCT02050737,Disease free survival or progression free survival,2013-10,TERMINATED,OBSERVATIONAL,['NA'],,To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.
182,NCT01212887,Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose),2007-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Long-term follow up for insertional mutagenesis
183,NCT02680990,Feasibility of Large-Scale Trial: Adherence & Contamination,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Assessing the interaction between frailty and the Band Together program
184,NCT03904537,Disease-free survival (DFS）,2019-02-19,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"The quality of life by EQ-5D-5L (EuroQol Group, Chinese versions )"
185,NCT02869269,Circulating helper T cell activity,2015-10,COMPLETED,OBSERVATIONAL,['NA'],CD4 and Treg cell activity and change of percentage of CD39 and CD73,Cytotoxic T cell and natural killer cell activity
186,NCT02324127,Hsp90α Concentration of plasma,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,
187,NCT02663427,detection rate of gastric cancer among all group,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
188,NCT04602299,focal lesion detection rate,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,rate of procedures reaching the minimal time
189,NCT04767503,Metabolomics,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,I-FEED scoring
190,NCT03569488,validation of the French version of the LARS score,2020-01-24,RECRUITING,OBSERVATIONAL,['NA'],,
191,NCT05631613,Deposition of of lipiodol-idarubicin emulsion,2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Visibility of lipiodol-idarubicin emulsion under X-ray: image quality
192,NCT01285102,Overall Survival,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
193,NCT03777943,Immunohistochemistry (IHC) analysis,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Laser capture microdisssection (LCM) followed by gene expression analysis
194,NCT03867409,Interpersonal Distance,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],,
195,NCT01633411,Esophageal Stricture,2011-12,COMPLETED,OBSERVATIONAL,['NA'],,Presence of Residual Barrett's Esophagus
196,NCT00733889,• Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,• To determine EGFR expression in the tumour and attempt to correlate it with efficacy
197,NCT00270543,high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival.
198,NCT00055848,,2001-12,COMPLETED,OBSERVATIONAL,['NA'],,
199,NCT06085365,the incidence of chemotherapy related adverse reactions,2023-07-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,changes in immune microenvironment
200,NCT05693649,CRC screening completion at 3 years,2023-06-07,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Choice of test
201,NCT02207465,Number of Adverse Events,2014-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
202,NCT01126840,Compare Predictors of Health-Related Quality of Life (QOL) among Colorectal Cancer (CRC) Survivors who have Lynch Syndrome (LS) with patients who have Sporadic CRC,2010-06-20,COMPLETED,OBSERVATIONAL,['NA'],,
203,NCT02305758,Progression-Free Survival (PFS): Time to Event,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
204,NCT00956930,Time to Progression (TTP) in Patients Treated With TACE and Y90,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
205,NCT03672422,Length of time from progression from Acute Recurrent Pancreatitis to Chronic Pancreatitis,2017-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Number of subjects with abnormal oral glucose tolerance test (OGTT)
206,NCT03518502,Overall survival,2012-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Median survival time (MST)
207,NCT00063401,"To determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.",2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To access EGFR expression by immunohistochemical assay.
208,NCT02326727,Plasma concentration of cytokines,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,
209,NCT00394433,10-month Progression-Free Survival Rate,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
210,NCT05930860,Recurrence rate,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
211,NCT02551250,sensitivity for detecting HCC,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,false referral rate for HCC
212,NCT01102088,Maximum Tolerated Dose (MTD) of Simultaneous Integrated Boost (SIB),2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pathologic Response
213,NCT05489289,Recurrence free survival (RFS) by BICR,2022-09-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Types and proportions of adverse events (AEs)
214,NCT05045976,Change of Functional Assessment of Cancer Therapy- Colorectal,2021-09-19,RECRUITING,INTERVENTIONAL,['NA'],,M.D. Anderson Symptom Inventory
215,NCT04150705,Technical Feasibility of PET/MRI as Measured by the Completion of the Study With Acceptable Image Quality in ≥70% of Scans,2020-06-01,TERMINATED,INTERVENTIONAL,['NA'],,Percentage of Scans With Changes in Perceived Disease Status as Measured by PET/MRI Tumor Regression Grade Relative to the Conventional MRI Only Tumor Regression Grade
216,NCT05280210,pathological complete response rate(pCR),2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,prediction accuracy of PTC
217,NCT02004262,"2nd-line Cohort: OS (All Data, FAS)",2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events in Each Treatment Arm Treatment Regimen
218,NCT03059147,Rate of dose limiting toxicities,2017-03-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression-free survival
219,NCT05286086,Comprehension Complication Index (CCI),2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale
220,NCT03073226,Sensitivity,2016-02-06,COMPLETED,INTERVENTIONAL,['NA'],,Endoscopists confidence
221,NCT00489671,Risk of pancreatic cancer as determined by urine cadmium levels,2003-06,COMPLETED,OBSERVATIONAL,['NA'],,"Predictive value of urinary cadmium alone, CA 19-9 alone, and both tests together on development of pancreatic cancer"
222,NCT00500188,Disease-free survival (DFS) time,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
223,NCT04380480,Percentage of Recent Weight Loss,2020-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Changes of participants' intestinal flora assessed by blood, urine and stool test"
224,NCT04077372,Difference in proportions of patients with documented goals of care,2019-09-16,TERMINATED,INTERVENTIONAL,['NA'],,Overall comparison of QOL survey
225,NCT03010085,"Checklist of functional recovery (Questionnaire, liver function test of aspartate aminotransferase and alanine aminotransferase)",2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
226,NCT00414843,Establish Repository of Human Bile,2006-12,TERMINATED,OBSERVATIONAL,['NA'],,
227,NCT05381792,Serial gut microbiome changes after endoscopic resection of colorectal advanced neoplasia.,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,"The differences in the bacterial gene markers (Fn, m3, Bc and Ch) between advanced adenoma and CRC"
228,NCT04427527,CRC screening - clinic level,2020-08-19,RECRUITING,INTERVENTIONAL,['NA'],,CRC screening - community level
229,NCT00878215,The Number of Participants Who Have Complete Ablation According to Early Post-ablative Imaging Studies as Well as no Recurrence of the Tumor Within 6 Months (Phase 4 Portion of the Study),2002-10-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,
230,NCT05381636,Progression free survival (PFS),2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
231,NCT04940286,Incidence of adverse events,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Change in circulating tumor deoxyribonucleic acid (ctDNA) levels,
232,NCT03355443,Adenoma miss rate in the proximal colon (AMR),2017-12,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma Detection Rate in the proximal colon (ADR)
233,NCT00392899,Disease-free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Types and severities of adverse events
234,NCT00003810,,1999-08-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
235,NCT01790035,Safety (phase I safety lead-in),2014-08-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Serum citrulline
236,NCT02534961,Infection after radiofrequency ablation,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
237,NCT02143115,"Compare the test characteristics (sensitivity, specificity, positive and negative predictive value) of Computed Tomography colonography (CT-C) in the post Colorectal cancer resection using optical colonoscopy as the reference standard",2011-08,COMPLETED,OBSERVATIONAL,['NA'],,Compare the costs and outcomes of Computed Tomography Colonography versus independent Optical Colonoscopy plus Computed Tomography for post Colorectal Cancer resection surveillance.
238,NCT01754896,FIT Kit uptake,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Rejection rates
239,NCT04592393,Detection of pancreas cancer,2020-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Identification of super-high risk group of developing pancreas cancer,Detection of pancreas cancer
240,NCT01336049,Objective response rate,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
241,NCT03158610,Progression Free Survival 2 (PFS2),2018-01-29,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of participants with quality of life (QoL) as assessed by CTCAE v4.0
242,NCT01927146,Overall survival,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
243,NCT02014025,survival rate,2013-03,COMPLETED,INTERVENTIONAL,['NA'],postoperative complications,intraoperative parameters
244,NCT01901042,Changes in quality of life,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
245,NCT03283540,Average intra-balloon pressure,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,Low Anterior Resection Syndrome score (LARS)
246,NCT04501913,Staff ability to act on identified threshold healthcare parameters,2019-12-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Changes in PGHD/PROs
247,NCT06041425,Pain intensity at 24hours after the end of TACE.,2023-08-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Nausea and vomiting scale
248,NCT06226857,progression-free survival,2024-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,progression-free survival based (per protocol)
249,NCT04130854,Pathological Complete Response Rate,2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Immunological Response,Disease free survival
250,NCT01071941,Characterize rRp450 pharmacokinetics and viral shedding.,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Correlate radiographic and pathologic assessments of tumor response.
251,NCT00109031,Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With WHO Grade 4 Oral Mucositis
252,NCT04576572,Tumor recurrence,2020-06-15,COMPLETED,OBSERVATIONAL,['NA'],,The Best Criteria
253,NCT01929902,Placement of Aquamantys Device,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,Device Complications
254,NCT00005843,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
255,NCT05451160,30-day complete ablation rate,2022-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Equipment failure rate
256,NCT04852250,Secondary intervention rate,2021-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Type, incidence, relatedness, and severity of adverse events with severity ≥ Grad 3 (severity according to NCI CTCAE version 5.0)"
257,NCT03250273,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2017-11-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) at 24 Months
258,NCT05889949,Progression-Free Survival (PFS),2019-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
259,NCT06144853,The number of patients with metabolic response according to FDG-PET/CT evaluated by PERCIST 1.0 one lesion after PIPAC 3,2024-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The number of patients where FDG-PET/CT evaluated by PERCIST one lesion agrees with histological response according to PRGS after PIPAC 1 and 3
260,NCT00380055,"Proportion of individuals receiving recommended screening for prostate, breast, colorectal, and cervical cancer.",2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness of using community navigators to improve cancer care among rural Native Americans.
261,NCT00376909,"Screening rates as measured by mammography, Pap test, hfoBT, sigmoidoscopy, barium enema and colonoscopy",2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
262,NCT03878472,Immunotherapy-related biomarkers,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
263,NCT04401709,Two-year disease free survival (DFS),2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
264,NCT04638036,Feasibility of molecular fluorescence-guided surgery using Cetuximab-800CW,2020-11-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluation of the distribution of Cetuximab-IRDye800CW
265,NCT01499576,Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events
266,NCT03403101,progression free survival (PFS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity evaluated according to the Common Terminology Criteria Adverse Events
267,NCT00795301,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
268,NCT01892527,Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects
269,NCT01349309,Functional Oral Intake Scale (FOIS),2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
270,NCT04898504,Overall survival at 2 years,2021-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life using EQ-5D-5L
271,NCT05087459,Comparison of total amount of postoperative drainage fluid between treatment group and control group,2021-06-30,UNKNOWN,OBSERVATIONAL,['NA'],,The change of platelet count from baseline at different time points
272,NCT00003332,,1997-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
273,NCT06268379,RFS,2010-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
274,NCT05675904,disease-free survival,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
275,NCT02119676,Overall Survival (OS),2014-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
276,NCT01435525,Number of Adverse Drug Reactions,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Rate of H.Pylori eradication
277,NCT02147145,Determine the natural history of small (< 30 mm) SELs discovered evaluated by EUS.,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,"Compare SEL size estimation based on EUS, EGD and computer tomography (CT)."
278,NCT01558583,Participant-reported most important attribute from survey,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Unlabeled screening test options
279,NCT01271504,Phase 2: Number of Participants With Markedly Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters,2011-07-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Overall Response
280,NCT06283576,Cancer detection,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Overall survival
281,NCT05495685,The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm,2022-03-24,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.
282,NCT05688761,Gastric adenocarcinoma,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Esophageal cancer
283,NCT05519410,1-year DFS%,2022-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year DFS%
284,NCT04821765,Locoregional control rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiomics analysis
285,NCT01904942,Proteomic investigations,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,Infrared spectroscopic investigations
286,NCT00923897,To determine the change in index symptom(s) using an 11 point numerical rating scale for patients with locally advanced hepatocellular cancer or hepatic metastases treated with 8Gy,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine serum marker and radiographic response with 8Gy
287,NCT00279292,injection for pain in pancreatic cancer patients at 1 month and 3 months.,2004-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,To estimate the effect of treatment on quality of life at 1 month and 3 month
288,NCT04980287,metastasis rate,2021-01-12,RECRUITING,OBSERVATIONAL,['NA'],,3-year DFS
289,NCT02378948,Functional recovery,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
290,NCT04611711,Overall response rate (ORR),2020-11-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
291,NCT04432870,Interest in colon cancer screening,2020-06-09,COMPLETED,OBSERVATIONAL,['NA'],,Risk perception on COVID-19
292,NCT01506336,overall progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
293,NCT05134961,3-year survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Duodenal cancer recurrence
294,NCT00914615,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria.",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cytokine response to radiation and association with complications
295,NCT05023928,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Disease-free Survival
296,NCT04961918,PFS,2021-07-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
297,NCT04797624,Comparison of the clinical staging and pathologic TNM staging of the patients,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of the demographic data
298,NCT02150447,Time-to-bleeding event,2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall survival
299,NCT01476631,"Exercise will decrease serum markers (insulin, C-peptide, IL-6 and PGE-2) in a dose response manner.",2008-11,TERMINATED,INTERVENTIONAL,['NA'],,Participants in the 60 minute intervention will have significantly higher physical activity levels (measured by pedometer and accelerometer) than those in the 30 minute intervention at three months.
300,NCT01580631,Determine the inter-observer agreement of a consensus driven NBI classification system in Barrett's esophagus.,2012-10,SUSPENDED,OBSERVATIONAL,['NA'],,Negative predictive value of the newer NBI classification in identifying dysplasia in Barrett's esophagus.
301,NCT04246710,Reliability of PDAC molecular subtyping on biopsy samples,2018-01-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
302,NCT00409994,Phase II: Tumour blood flow assessed CT-PET + CTp,2006-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0"
303,NCT02584998,The Number of Participants Who Completed the Mailed FIT Test Screening Within 6 Months,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,The Number of Participants Who Received Any Colorectal Cancer Screening Test in the 6-month Period After Enrollment Into the Study.
304,NCT06278064,Plasma proteins in patients with esophagus cancer,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
305,NCT00041665,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
306,NCT04501887,Progression-free survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Positive rate
307,NCT04796818,Absolute change in the true diffusion coefficient (D),2020-08-12,RECRUITING,INTERVENTIONAL,['NA'],,Diffusion related parameters in intravoxel incoherent motion diffusion weighted imaging
308,NCT02785263,The fraction of enrolled patients choosing the lower radiation dose,2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Response evaluation assessed by diffusion weighted imaging
309,NCT02418052,Incidence of post-operative cervical esophagogastric anastomotic leakage,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,
310,NCT02452021,Rate of CTCAE acute grade 3 or higher adverse effects possibly attributed to neoadjuvant CRT,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Assessment of early cardiac toxicity after CRT using cardiac MRI
311,NCT02744729,Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan,2015-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Contrast-enhanced CT
312,NCT03620877,Evaluation of coordinated transmission,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA'],,Adherence to personalized intervention
313,NCT00002897,,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
314,NCT03186326,Progression-free survival (PFS) according to the investigator,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
315,NCT00898781,"Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers",2007-11,TERMINATED,OBSERVATIONAL,['NA'],,
316,NCT03999658,Objective Response Rate,2023-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031
317,NCT03208283,The mean independently performed flexible sigmoidoscopy completion rate in each study group,2014-10-28,COMPLETED,INTERVENTIONAL,['NA'],,Patients' satisfaction
318,NCT05844865,Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT),2023-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
319,NCT06281886,Progression free survival rate,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant metastasis-free survival
320,NCT05713994,Number of Patients Amendable to Curative Surgical Interventions,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
321,NCT03152565,Progression Free Survival,2018-03-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunophenotype signature in tumor biopsies before and during treatment.
322,NCT05247346,Incidence of intervention-emergent adverse events and serious adverse events,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Scattering parameters
323,NCT00728078,morbility,2008-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,recurrence rate
324,NCT05741255,Montreal Cognitive Assessment,2022-01-05,COMPLETED,INTERVENTIONAL,['NA'],,
325,NCT03854890,The positive number of lymph nodes retrieved,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Detection rate of indocyanine green-positive para-aortic lymph node
326,NCT04714814,recurrence or metastasis provened by imageologic diagnosis (PFS),2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
327,NCT02971956,Overall Response Rate (ORR),2017-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Experiencing Grade 3-4 Treatment-Related Toxicity
328,NCT04778345,Maximum standardized uptake value [SUVmax (for PET/CT only)] for peritoneal carcinomatosis,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,1-year progression patterns
329,NCT02741401,Change from baseline in anxiety and depression as assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Patients' opinion and need about hand-foot massage's utility as assessed by questionnaire
330,NCT04540081,Overall Adherence to CLOVER Metrics,2020-10-05,COMPLETED,INTERVENTIONAL,['NA'],,Hepatitis C screening
331,NCT04538404,New surgical score using preoperative parameters to predict 30-day mortality after colon cancer surgery in the elderly population,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
332,NCT00593060,To determine the pharmacokinetics of combined treatment with cetuximab and temsirolimus.,2007-11-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,To document objective response rate and progression-free survival in patients treated with the combination.
333,NCT01482299,4-month progression-free survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarker assessment
334,NCT01829035,The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects,2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,Evaluation of adverse events
335,NCT00586235,"Primary Endpoints: Global Fiducial Registration Error (FRE) of real-time US and fused CT images, Target Registration Error (TRE) and distance between lesional epicenters of real-time US and fused CT images.",2007-02,COMPLETED,OBSERVATIONAL,['NA'],,Secondary Endpoint: Number of coregistration attempts to realize separation of lesional epicenters of real-time US and fused CT images of ≤2 cm and the number of attempts to realize a separation of ≤0.3 cm.
336,NCT05275985,Overall Survival (OS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,
337,NCT01512407,1-year recurrence rate,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Health-related quality of life assessment
338,NCT01395030,Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
339,NCT04609176,Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment,2020-11-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing an Adverse Event (AE)
340,NCT05592886,The incidence of metachronous recurrent colorectal adenoma at year 1 (local or at other sites),2022-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Changes in the levels of bacterial gene markers
341,NCT03638141,Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria.,2019-10-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
342,NCT03613389,Clinical assessment of Oral Mucositis,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
343,NCT00624182,Safety (toxicities as assessed by NCI CTCAE version 3),2008-02,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Survival rate
344,NCT04813913,Difference in carotid stiffness between baseline and at 4 months of bevacizumab treatment.,2019-05-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-free survival at 12 months.
345,NCT04136236,The diagnosis efficiency of Artificial Intelligence,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Contrast the diagnosis efficiency of Artificial Intelligence with endoscopists
346,NCT02391038,Phase 2- Overall Response Rate,2014-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Phase 2- Number of Participants With ATA in Serum
347,NCT04597710,Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery.,2021-02-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Proportion of patients for whom actionable biomarkers of drug sensitivity are identified with WGS.
348,NCT01355302,Time to Maximum Concentration (Tmax) of Golvatinib,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression (TTP)
349,NCT03930368,the change of glycated albumin,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,the change of uric acid
350,NCT00554892,Overall morbidity including infectious and non infectious complications,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the postoperative complications classified according to the DINDO classification.
351,NCT04260191,Number of Participants Who Experienced a Treatment-emergent AE (TEAE),2020-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
352,NCT06222619,Overall survival,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence free survival
353,NCT02289053,Prevalence of advanced adenomas among 40-49 year old individuals with and without a family history of colorectal cancer,2006-04-01,COMPLETED,OBSERVATIONAL,['NA'],Risk factors associated with the presence of advanced adenomas,Absolute prevalence of advanced adenomas in 40-49 year old individuals with a family history of colorectal polyps
354,NCT06147492,urinary retention,2016-01-30,COMPLETED,INTERVENTIONAL,['NA'],,
355,NCT00075738,Objective response rate,2003-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
356,NCT01531777,ORR (Objective Response Rate),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL (Quality of Life)
357,NCT03439085,Objective response rate (ORR),2018-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
358,NCT02968069,Accuracy of the diagnostic model in histological prediction of gastric cancerous lesions,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,
359,NCT01253837,Phase II: Investigation of the anti-cancer activity of L19TNFα as measured by Objective Response Rate (ORR),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Investigation of early signs of anti-tumor activity of L19TNFα
360,NCT05934643,Average daily energy expenditure in MET.h,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,30-day complication rate
361,NCT05339984,Estimation of the intraoperative portocaval post-procedural gradient.,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],,Prediction of the evolution of hepatic artery and portal vein flows after surgery
362,NCT02301338,acute healthcare utilization (AHCU) rates,2014-11,TERMINATED,OBSERVATIONAL,['NA'],,
363,NCT01256034,Postoperative Infectious Complication,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Plasma IL-6, CRP, Th1/Th2 Balance"
364,NCT04709445,anastomotic leak,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of hospital stay
365,NCT02266849,Output weight,2014-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Patient evaluation,Gastrointestinal transit time
366,NCT02267343,Overall survival,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety will be analyzed through the incidence of laboratory abnormalities
367,NCT05587556,The survial rate of the patients,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
368,NCT02535117,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
369,NCT02926716,Accuracy for identifying the status of resection margin,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],,Microvessel density
370,NCT04322539,Overall Survival (OS),2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed
371,NCT05210049,Sensitivity and Specificity of Esocheck/Esoguard in a Veteran population,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost of two screening strategies
372,NCT00242086,,2004-10,COMPLETED,INTERVENTIONAL,['NA'],,
373,NCT04913480,Progression-free survival at 1 year,2020-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in PD-L1 and PD-1 positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab
374,NCT06090994,3-year disease-free survival rate (DFS),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Changes in carcinoembryonic antigen (CEA) compared to baseline period (difference),"The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)"
375,NCT00033241,,2001-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,
376,NCT06018077,Dİetary Total Antioxidant Capacity (DTAC),2022-10-15,RECRUITING,OBSERVATIONAL,['NA'],,
377,NCT00004256,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
378,NCT04701060,objective response rate,2021-01-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Camrelizumab and apatinib,Feasibility as measured by rate of enrollment
379,NCT01015118,"PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).",2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.
380,NCT02657044,Recurrence rate at follow-up colonoscopy after 6 months,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,R0-resection rate
381,NCT04612712,Phase II part - Objective response rate(ORR),2021-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival (PFS)
382,NCT05359406,Early Tumor Shrinkage,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Acute toxicity associated with immunotherapy
383,NCT05465590,Volume of distribution (VZ),2022-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
384,NCT01914744,Incidence rate of HBV reactivation,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],Incidence of drug resistance of viral variants,Incidence rate and median time of HBV DNA level normalization
385,NCT05656326,Successful implementation,2021-08-23,RECRUITING,OBSERVATIONAL,['NA'],,Satisfaction of the patient-led home-based follow-up
386,NCT04588025,Measure change in blood flow within the pancreatic cancer as measured by the P4.,2020-10-14,RECRUITING,INTERVENTIONAL,['NA'],,
387,NCT03791398,Progression Free Survival,2019-11-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
388,NCT05168527,ORR,2021-09-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,DOR
389,NCT01413295,Progression Free Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
390,NCT02751086,Rate of patients alive,2016-04,RECRUITING,OBSERVATIONAL,['NA'],,Rate of complications after discharge
391,NCT03730948,Adverse events experienced by subjects (i.e. safety of DC vaccine in subjects with surgically resected hypermutated CRC),2019-03-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Percentage of CD8+ cells in primary tumor tissue
392,NCT02439086,Accuracy of Texture analysis PET-CT,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,Accuracy of Texture analysis MRI
393,NCT00718211,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
394,NCT03344614,PFS,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
395,NCT06111872,To evaluate the efficacy of Ketamine- Midazolam as a sedative agent in ERCP in terms of sedation failure rate.,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,To compare the depth of sedation
396,NCT02797197,"number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures",2016-05-18,COMPLETED,INTERVENTIONAL,['NA'],,to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic)
397,NCT03744962,Frequency of microsatellite instability,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],,
398,NCT00901173,Esophageal squamous cell carcinoma,2014-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
399,NCT00746161,The %body weight ratio,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"preoperative complication, PNI and QOL score"
400,NCT04074447,The proportion of ctDNA content decreased in patients with good therapeutic effect,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
401,NCT01718808,Progression free survival in week 12,2012-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)"
402,NCT04233840,"Phase II portion - Recurrence-free survival (defined as the time from randomization to HCC recurrence or death from any cause, whichever occured first)",2019-02-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,HBsAg level
403,NCT06189560,Video fluoroscopic swallowing study,2022-06-21,TERMINATED,INTERVENTIONAL,['NA'],,Rosenbek penetration-aspiration scale
404,NCT04868149,Amount of future liver remnant volume increment by percentage after stage I ALPPS,2020-09-02,RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS
405,NCT03377842,Progression-free survival (PFS),2018-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
406,NCT00529984,determine the safety of immunization with CEA(6D) VRP,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluate CEA-specific immune response to immunizations
407,NCT02987907,proportions of participants with severe adverse events according to CTCAE v4.03,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression (TTP)
408,NCT00197405,,1999-08,UNKNOWN,OBSERVATIONAL,['NA'],,
409,NCT00696345,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
410,NCT04764240,OS,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
411,NCT03881501,PFS,2019-03-05,UNKNOWN,OBSERVATIONAL,['NA'],,Safety as measured by number and grade of adverse events
412,NCT02571036,Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies
413,NCT05988372,R0 Surgical Resection Rate,2023-10-23,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QOL)
414,NCT02269332,Adenomatous Polyps,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
415,NCT01465464,Overall Survival(OS),2010-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Transcatheter Arterial Chemoembolization (TACE) Failure
416,NCT05895942,Degree of tumor regression,2021-09-10,RECRUITING,OBSERVATIONAL,['NA'],,
417,NCT04351880,Anxiety and Depression measured through the Hospital Anxiety and Depression Scale,2020-04-16,COMPLETED,INTERVENTIONAL,['NA'],,Re-hospitalization and Emergency Department Visits
418,NCT03130166,Postoperative recovery,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Whole blood gene expression profiling
419,NCT03233711,Disease free survival,2018-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of toxicities
420,NCT02959359,The primary objective of the study is annual recurrence-free survival after curative resection of HCV-HCC for up to 5 years.,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Overall survival
421,NCT05114213,Mean cumulative pain index,2021-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Death from any cause
422,NCT00842244,Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs),2009-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine,Progression-Free Survival (PFS)
423,NCT02646514,Patency of metal stent,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
424,NCT05400681,Relative frequency of ctDNA in peritoneal lavage and peripheral blood,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Prognostic value of ctDNA in peritoneal lavage and peripheral blood
425,NCT04780789,Interobserver variability of the methods used for assessing tumor response to the treatment,2015-02-01,COMPLETED,OBSERVATIONAL,['NA'],,"Response to the treatment, as assessed by volumetric analysis"
426,NCT00667641,Maximum tolerated dose of paclitaxel in combination with bortezomib,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
427,NCT05162248,Disease-Free Survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
428,NCT05052801,Overall Survival,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants with an Anti-bemarituzumab Antibody Formation
429,NCT00851968,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,"serum alanine aminotransferase (ALT), bilirubin, prothrombin time, serum albumin and pre-albumin on postoperative 1, 3, 7 day, resection rate, procedure-related complications and hospital mortality,expression of HIF and P-, E-, and L-selectin"
430,NCT03236051,Numeric rating scales (NRS) score with 24 hours after the surgery,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Prealbumin
431,NCT06162468,The proportion of patients in whom EUS-PCA was completed as planned.,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The IPMN complete response rate in the injected lesion(s) on imaging 3 months post-EUS-PCA.
432,NCT03613142,Rate of reflux esophagitis after operation,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative quality of life
433,NCT03113214,Maximum Tolerated Dose,2017-02-02,COMPLETED,INTERVENTIONAL,['NA'],,Time to Local Failure
434,NCT00134069,Pharmacodynamics of the combination of irinotecan when given in combination with sorafenib and cetuximab in tumor tissues,2005-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
435,NCT01545544,"presentation of NHL and HCV infection, and treatments of NHL and HCV infection",2006-11,UNKNOWN,OBSERVATIONAL,['NA'],,haematological response
436,NCT02480114,"Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))",2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)"
437,NCT05667298,Safety (proportion of patients developing Grade 3 or above adverse events),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
438,NCT02423811,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
439,NCT06143722,Progression-Free Survival (PFS),2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
440,NCT04576208,Number of Participants with Treatment Emergent Adverse Events (TEAEs) of ≥Grade 3 Diarrhea Occurring During the First 4 Cycles of TAK-788 Dosing,2020-11-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Health-Related Quality of Life (HRQoL) as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Score
441,NCT06015035,Primary Endpoints: pCR,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
442,NCT05622825,Image Assessment,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life assessment.
443,NCT01733628,Progression Free Survival (PFS),2012-10-23,COMPLETED,OBSERVATIONAL,['NA'],,"Number of Participants With ""White Coat"" AHT With 24 Hours Ambulatory BP Measure"
444,NCT00829595,"Response, defined by postvaccination antibody titers",2005-05,COMPLETED,INTERVENTIONAL,['NA'],,
445,NCT06261125,Progression-free survival (PFS),2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between serum cytokines and overall survival and immune-related adverse events,Treatment-related adverse events
446,NCT03385018,3 year relapse-free survival,2018-04-05,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life(EORTC QLC STO22)
447,NCT00005616,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
448,NCT05214820,Tumor uptake of 68Ga-PSMA,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radiation dose (mGy)
449,NCT05659381,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Residual Disease
450,NCT05407584,Confirmed ORR,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,second objective disease progression
451,NCT03057288,Success rate evaluation of the placement of two fiducial markers,2017-02-03,COMPLETED,INTERVENTIONAL,['NA'],,The presence of the markers at the end of the radiotherapy
452,NCT02907385,Incidence of overall anastomotic leak,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of post operative anastomotic leaks
453,NCT00819208,Disease-free survival,2009-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire
454,NCT05436275,Nasal Congestion Score (NCS),2022-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Anti-drug antibodies (ADA)
455,NCT06105515,Severe complication,2023-12,RECRUITING,INTERVENTIONAL,['NA'],,Health-related quality of life
456,NCT05431244,Objective Response Rate (ORR),2022-07-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Best Overall Response Rate (BOR)
457,NCT04365751,Overall survival,2019-12-26,RECRUITING,INTERVENTIONAL,['NA'],,Local rate of progression
458,NCT04510935,mean percentage change from post- to pre-operative values of invasion of HepG2 cells cultured in patients' serum,2020-08-20,COMPLETED,INTERVENTIONAL,['NA'],,serum IL-2 level
459,NCT02893982,maximum tolerated dose,2017-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,local control
460,NCT03742453,Diagnostic performance of CEUS for diagnosing HCC,2018-10-16,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018
461,NCT00332280,Improvement in clinical benefit response,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety and tolerability
462,NCT01324284,Quality of bowel preparation in Same day Low volume PEG with placebo versus same day low volume PEG with Lubiprostone,2011-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
463,NCT05304481,Relapse-free survival rate,2022-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in respiratory rate
464,NCT05585437,patient complication rate,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],,
465,NCT01189877,Measure pO2 in rectal cancers,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Correlate immunohistochemical analysis of endogenous markers of hypoxia
466,NCT00584597,The specific aim will be to determine the safety of TRAUMEEL S for mucositis in head and neck cancer patients undergoing radiation therapy,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
467,NCT03879395,Overall survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Complications according to Clavien-Dindo within 90 days.
468,NCT03589443,Validate the binding of the peptides using the SFE,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Use of the SFE to detect QRH and KSP via contrast
469,NCT05282433,Progression-free survival,2022-04-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,
470,NCT02376452,progression free survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life questionnaire
471,NCT05251038,Objective Response Rate (ORR),2022-09-13,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
472,NCT02495311,The corrleation coefficient between the size of myoma and Overactive Bladder Symptoms Scores,2014-11-15,RECRUITING,OBSERVATIONAL,['NA'],,Comparisons of the constipation/diarrhea rates between the adenomyosis group and the control group
473,NCT00103142,Recurrence-free Survival at 2 Years,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay
474,NCT04634357,The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT,2022-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the pharmacokinetics of ET140203 T cells after infusion.
475,NCT05431621,Establish and evaluate the non-invasive early detection model for hepatocellular carcinoma,2020-11-15,RECRUITING,OBSERVATIONAL,['NA'],,
476,NCT04303403,Maximum Tolerated Dose,2018-07-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
477,NCT02976142,Overall 2-year survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
478,NCT05032027,grade 3 entiritis,2021-08-27,RECRUITING,INTERVENTIONAL,['NA'],,Changes in intestinal flora
479,NCT00003018,Overall Survival,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resectability of patents who respond to this regimen
480,NCT04133155,Progression-free survival,2019-09-16,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity profile
481,NCT00827684,Objective response rates,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational Research
482,NCT04587310,endoscopy performed on patients,2008-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
483,NCT02421536,"Change from baseline in ""out of clinic"" pain at 2 months",2016-01-14,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline mucositis pain at 2 months
484,NCT04317248,"Progression-Free-Survival (PFS), month",2020-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events
485,NCT00352638,Colorectal cancer screening compliance,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cost
486,NCT01577758,AUC0-21 Days: Area Under the Curve Day 0 to Day 21 for MMAE,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Antitherapeutic Antibodies (ATA)
487,NCT01762293,Progression Free Survival(PFS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"body vitals, laboratory parameters",Number of Participants with Adverse Events as a Measure of Safety
488,NCT04418739,Overall Complications,2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Ease of surgery
489,NCT03937830,"To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab",2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC"
490,NCT04493632,Resection Rates,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],,
491,NCT01831245,Pathological Anatomic diagnosis (PAD) on a tumor biopsy,2011-01,COMPLETED,OBSERVATIONAL,['NA'],Leakage of anastomosis,C - reactive protein
492,NCT00605150,Progression,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Unacceptable Side Effects After Treatment
493,NCT06318793,Concentration of C-reactive protein (CRP),2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
494,NCT05573282,Progress Free Survival,2022-10-16,RECRUITING,OBSERVATIONAL,['NA'],,Tumor Response
495,NCT05999396,Safety 3-Hematology-White Blood Cells,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,
496,NCT05810792,Incidence and severity of Treatment-Emergent Adverse Events as assessed by NCI-CTCAE,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Carbohydrate antigen 19-9
497,NCT05971069,The safety and efficacy of the decision algorithm for the aberrant left hepatic artery preservation/ligation with real time near-infrared fluorescence imaging,2021-12-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with liver-related postoperative complications as assessed by serum aspartate transaminase(AST) and alanine transferase(ALT)
498,NCT05213312,Pathological Complete Response (pCR) rate,2022-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Treatment-Emergent Adverse Events
499,NCT06298916,Primary Part 2 - Correlation of 64Cu-LNTH-1363S biodistribution with Immunohistochemistry FAP expression,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Part 1 and Part 2,Secondary Part 2 Validate optimal radioactivity in patients with sarcoma or GIT cancer
500,NCT04377048,response rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
501,NCT05578287,Feasibility,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
502,NCT04704661,Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase),2021-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],"Association of TP53, ATM, and RAS mutations with ORR",PD markers
503,NCT05612347,"Incidence of advanced neoplasia in each study group, annual FIT and colonoscopy, assessed by comparing the detection of advanced neoplasia between the two study groups.",2023-06-14,RECRUITING,INTERVENTIONAL,['NA'],,"Major and minor harms within 30 days of colonoscopy, as measured through chart review and telephone interview."
504,NCT01575574,hepatocellular carcinoma diagnosed,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,magnetic resonance imaging sensitivity
505,NCT04481828,Tumor stage (American Joint Committee on Cancer 8th Edition),2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
506,NCT06191185,Colonoscopy completion,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Scheduled by GI for colonoscopy
507,NCT00815113,"Characterization of the high-rik individual for gastric cancer - ""Gastric Cancer Phenotype""",2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Establish a screen plan for high-risk population for gastric cancer
508,NCT00151671,Factor V at day 3 after surgery,2003-04,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Infections
509,NCT01227772,Optimal dosing schedule,2010-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Induction of specific cytotoxic T-lymphocyte (CTL) response
510,NCT04951804,Change in Likert pain scores,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],,Difference in Global Rating Scale of Change at T3 vs all other follow-up time points
511,NCT02908204,Overall survival,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,Long-term complications incidence rate
512,NCT04612569,Impact of a multimodal package of prehabilitation and rehabilitation in patients with low anterior resection syndrome,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of the improvement of pelvic floor contractility
513,NCT03476421,Rates of local recurrence,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
514,NCT01278537,Quality of life,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Stress
515,NCT05117723,Risk stratification for patients with IPMN into those that require more intensive screening and possibly intervention versus those that are unlikely to progress to malignancy.,2021-08-26,RECRUITING,OBSERVATIONAL,['NA'],,
516,NCT00288444,Determine the molecular interaction,2006-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine safety and efficacy
517,NCT04794465,Time to treatment,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time to symptoms
518,NCT00060502,"Change in Lean Body Mass (LBM) from baseline to the end of first cycle, as measured by bioelectrical impedance analysis (BIA).",2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Change in 6-minute walk test distance from baseline to the end of the first cycle; Safety, Karnofsky performance status; Survival."
519,NCT00066846,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
520,NCT02557724,post operative liver injury,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,(AST) Aspartate Aminotransferase
521,NCT00408772,Conversion rate of nonresectable disease to resectable disease,2007-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Duration of response
522,NCT00729677,Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
523,NCT04108494,3 years relapse-free survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative morbidity,5 years overall survival
524,NCT04624217,ORR,2020-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
525,NCT02154737,Rate of dose limiting toxicities of each subject,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Adverse events related to pulse dose erlotinib and gemcitabine
526,NCT03833700,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),2019-03-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
527,NCT03433703,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2018-04-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression (TTP)
528,NCT04111380,Objective Response Rate [ORR],2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
529,NCT04569799,No Viable Disease on CT/MRI Imaging.,2020-10-14,COMPLETED,INTERVENTIONAL,['PHASE4'],,Lesions Missed or Miscategorized on CT/MRI Imaging.
530,NCT00826501,Compare median time to pseudocyst recurrence between patients undergoing EUS or Surgical Cysto-gastrostomy,2009-01,COMPLETED,INTERVENTIONAL,['NA'],Compare pain medication usage,Median time to pseudocyst recurrence at 24 month follow-up.
531,NCT00316745,PFS of 1st line treatment,2006-04,SUSPENDED,INTERVENTIONAL,['PHASE3'],,safety
532,NCT03377361,Objective response rate (ORR) by investigator (Part 1B and Part 2),2018-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
533,NCT05327517,Overall Survival,2022-04-10,RECRUITING,INTERVENTIONAL,['NA'],,Laryngo-esophageal dysfunction free survival
534,NCT01127425,primary: Length of stay,2006-07,TERMINATED,INTERVENTIONAL,['NA'],,"secondary: Nursing hours, pain and recovery"
535,NCT02547480,Area Under the Curve (AUC),2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Technical success - total dose delivered
536,NCT05015296,1-year recurrence-free survival after surgery,2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
537,NCT03579836,DCR(Disease Control Rate) in combination therapy of BEY1107 and Gemcitabine (Phase II),2018-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects with Adverse events in BEY1107 and Gemcitabine combination (Phase II)
538,NCT00444041,The primary objective of this study is the Resectability (R0) rate after neoadjuvant Bevacizumab in potentially resectable mCRC.,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
539,NCT05227378,Objective Response Rate (ORR),2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Lymphocyte
540,NCT04263948,Rates and grades toxicity and early tumor responses,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
541,NCT02319018,"Maximum tolerated dose and the recommended phase II doses of mFOLFOX given in combination with alisertib, defined as the dose level at which the probability of dose limiting toxicities is 30%",2015-08-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Tumor expression by immunohistochemistry,"Anti-tumor activity associated with this treatment, evaluated using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors version 1.1"
542,NCT03063918,Quality of life assessed by City of Hope-Quality of Life-Colorectal Cancer,2017-04-28,COMPLETED,INTERVENTIONAL,['NA'],Scores from the Decisional Conflict Scale,
543,NCT05330429,Randomized Cohort: Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2022-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety Run-in and Randomized Cohorts: Antidrug Antibodies (ADA) to Magrolimab
544,NCT02605044,Overall survival,2014-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
545,NCT04505696,Pre-post Questionnaire,2020-08-05,COMPLETED,INTERVENTIONAL,['NA'],,
546,NCT04425564,Peak and trough levels of capecitabine and relation to dosing,2016-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
547,NCT03771508,Prospective collection of PillCam SB3 videos,2018-12-13,RECRUITING,OBSERVATIONAL,['NA'],,
548,NCT02092519,diagnostic accuracy,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
549,NCT01808417,Feasibility of real-time intraoperative NIR lymphatic mapping,2013-06-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Identification of sentinel lymph nodes
550,NCT02333188,"DLT rate in course 1 for each of the three genotype groups, graded according to NCI CTCAE v 4.0",2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cumulative doses of the drugs will be calculated as the sum of all doses received on protocol therapy for each patient
551,NCT02949258,2-year survival rate,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,in-hospital mortality rate
552,NCT01362582,Questionnaire EORTC - Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Assessment of nutritional status
553,NCT04567069,Health-related quality of life (QoL): 36-Item Short Form (SF-36),2020-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Health-related quality of life (QoL): 36-Item Short Form (SF-36)
554,NCT05985109,Overall response rate,2023-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,treatment-related adverse event
555,NCT02235246,pain score,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
556,NCT03795311,Number of Participants with Acute toxicities as a Measure of treatment specific Safety and Tolerability,2018-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
557,NCT05903703,Evaluation the clinical disease progression (PD) at 6 weeks intervals,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
558,NCT06252142,International Prostate Symptom Score (IPSS),2024-02-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment-related toxicities
559,NCT05694949,All-cause mortality at 30 days after operation,2023-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Major Adverse Cardiovascular Events (MACE)
560,NCT03172403,Correlation between skeletal muscle and degree myostatin,2018-08-02,TERMINATED,INTERVENTIONAL,['NA'],,Analysis level of myostatin muscular expression and blood samples results
561,NCT00669370,To determine the quality of life (EORTC QLQ-C30 and QLQ-STO22),2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To evaluate time to progression (TTP), overall response rate (ORR) and overall survival (OS)."
562,NCT06301386,objective response rate (ORR),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,advert events
563,NCT04380337,Clinical complete response (cCR),2020-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
564,NCT01411176,The proportion of patients had no or mild peristalsis during the therapeutic procedures,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events and adverse drug reactions
565,NCT00250822,"Response Rate ( CR + PR rate); namely, to determine response rate to the Gemcitabine and Oxaliplatin combination administered to patients with hepatocellular cancer. Furthermore, patients who achieve a response leading to tumor respectability.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
566,NCT03253536,Quality of life,2017-07-10,RECRUITING,OBSERVATIONAL,['NA'],,correlation Qol with late toxicity
567,NCT04540146,cytokine levels,2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
568,NCT04761172,Primary tumor detection,2020-06-17,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tumor to background ratio
569,NCT01617382,To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.,2012-05,RECRUITING,OBSERVATIONAL,['NA'],,
570,NCT00814086,Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST)
571,NCT00954174,Overall Survival,2009-08-17,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient-reported Peripheral Neuropathy Symptoms - Post Baseline
572,NCT06266832,Organ retention rate,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL
573,NCT00689364,The recurrence and metastasis rates for 1、2、3、4 and 5-year.,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],,Survival index: the survival rate for1、2、3、4 and 5-year.
574,NCT03595540,Quantification of FMD-emergent adverse events,2017-11-22,COMPLETED,INTERVENTIONAL,['NA'],,
575,NCT02788214,Bacterial DNA sequence,2016-07-27,TERMINATED,OBSERVATIONAL,['NA'],,
576,NCT00896467,Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires,2007-09,TERMINATED,OBSERVATIONAL,['NA'],,
577,NCT00002470,,1990-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
578,NCT04281784,Proportion of Patients With EHR Documentation of Goals of Care Discussions,2020-04-23,COMPLETED,INTERVENTIONAL,['NA'],,All-cause Mortality at 1 Year (Safety Outcome)
579,NCT01288625,Incidence and duration of oral mucositis,na,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
580,NCT01564810,the rate of patients converted to resection for liver metastases,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,tumor response
581,NCT03755440,Response rate,2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
582,NCT00031863,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
583,NCT03843749,Objective Response Rate(ORR),2019-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,
584,NCT04599179,Quality of life (QoL) after endoscopic or surgical treatment,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
585,NCT00262210,We expect to enter 25 patients per year and finish accrual of patients within 4 years.,1995-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
586,NCT02789826,The number of lymph nodes in the postoperative spicement.,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Duration of Surgery
587,NCT00074009,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
588,NCT04440930,Incidence of oral mucositis grade 2 or higher as measured by the Revised Oral Assessment Guide.,2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],,Date of onset of oral mucositis grade 2 or higher as measured by Revised Oral Assessment Guide.
589,NCT02560974,Disease-free survival rate,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
590,NCT04052152,Adverse reaction rate,2019-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
591,NCT04650451,Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE),2020-12-07,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Antitumor activity of BPX-603
592,NCT01860144,Objective response rate,2012-06,UNKNOWN,OBSERVATIONAL,['NA'],,resection rate
593,NCT04391933,Is MRI usefull in colon cancer patients,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
594,NCT05545124,1-year recurrence-free survival,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
595,NCT04823793,Sensitivity and specificity of methylation biomarker and FIT for adenoma and colorectal cancer screening,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
596,NCT01443481,Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics and Hepatic Function Abnormalities
597,NCT05661357,ORR,2023-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
598,NCT01524848,Disease control rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate
599,NCT01830647,Safety: Incidence of adverse events,2013-04,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy: Time to disease progression
600,NCT06205706,"identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safety",2023-12-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response (DoR).
601,NCT05233553,Incidence of SSC-COVID in hospitalized COVID-patients of the first wave,2020-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
602,NCT02699047,Serum albumin,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,
603,NCT05734105,Progression-free Survival (PFS),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
604,NCT05883176,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
605,NCT05587738,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
606,NCT03174444,Colorectal Cancer Screening,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,
607,NCT01239095,Number of patients with adverse events or complications,2011-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
608,NCT00379782,subject satisfaction with navigation,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,
609,NCT04606914,Radiographic tumor assessment per RECIST v1.1 criteria,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety profile of treatment with carboplatin-mirvetuximab soravtansine according to CTCAE v4.03
610,NCT02188342,VO2 peak,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
611,NCT05821582,Primary Objective- Intestinal side effects of chemotherapy,2023-03-27,WITHDRAWN,OBSERVATIONAL,['NA'],,
612,NCT05747482,disease free interval,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperatory mortality
613,NCT00078897,Median Selenium Blood Levels at One Year.,2005-01-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
614,NCT02473003,Change in Fatigue,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Treatment completion rate
615,NCT03958890,OS,2019-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of response
616,NCT00525915,Pathologic Complete Response Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
617,NCT04804696,Pathologic complete response rate,2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
618,NCT00582400,Number of Patients With Response to Treatment (RECIST Criteria),2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
619,NCT03306693,Change in patient emotional skills from baseline to 15 days after intervention,2017-10-26,TERMINATED,INTERVENTIONAL,['NA'],,Patient satisfaction
620,NCT00938080,"Safety (Adverse Events, laboratory assessments and the presence of sAGX0085 bacteria in blood)",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics of serum samples, buccal smears and saliva samples"
621,NCT04840056,Gastric cancer and gastric dysplasia,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],,Area under the receiver operating characteristic curve of machine learning model
622,NCT04251403,Correlation of pathologic diagnosis from gastric aspirate compared with diagnosis from standard endoscopic inspection and biopsies.,2020-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
623,NCT04357158,Diagnostic accuracy in distinguishing colorectal carcinoma from healthy controls,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Acceptance rate
624,NCT05298020,PFS,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
625,NCT05156463,Use of Actigraph to measure changes in activity and sedentary behavior,2022-04-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Exercise Self-Efficacy Scale This scale assesses an individual's beliefs in their ability to continue exercising on a 3 time/week basis at moderate intensities for 40+ min. per session in the future.
626,NCT01068327,Maximally tolerated dose (MTD) of stereotactic radiotherapy and concurrent nelfinavir mesylate,2007-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacogenomic status of CYP2C19*2 (G681A) (correlative)
627,NCT01437007,"To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT.",2011-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the potential conversion rate from unresectable to resectable disease.
628,NCT03829462,Overall survival,2019-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Deterioration
629,NCT05911243,Acceptability (feasibility),2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in body weight (kg)
630,NCT03690921,Acute Toxicity,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete Response at 24 Weeks
631,NCT04961138,1-year disease free survival,2021-08,UNKNOWN,INTERVENTIONAL,['NA'],,objective response rate
632,NCT03774680,Measurement of pharmacokinetics parameters of Cetuximab for targeted colon cancer,2020-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
633,NCT02436902,Overall survivals,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence rates
634,NCT02989922,6-month Overall Survival Rate,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
635,NCT03428958,"Number of patients with treatment-emergent clinically significant changes in laboratory parameters, ECG changes, or changes in physical examinations",2018-10-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tolerability of NUC-3373 in each combination cohort measured by dose intensity in Cycle 1
636,NCT03750786,Overall Response Rate,2018-12-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
637,NCT05959395,"Safety of the VectRx treatment evaluated by incidence of Adverse events (AEs) such as first and second-degree burns, edema and abdominal pain, will be assessed [safety and tolerability].",2023-08-15,RECRUITING,INTERVENTIONAL,['NA'],,
638,NCT03297996,Prevalence and relative abundance of selected fecal microbial taxa,2011-11-23,COMPLETED,OBSERVATIONAL,['NA'],,
639,NCT00247260,"This is a multicentre, open label study to evaluate the safety and efficacy of three escalating radioactivity levels (MBq) of 32P BioSiliconTM in patients with unresectable hepatocellular carcinoma",2005-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the association between tumour marker serum alpha-fetoprotein (AFP) and target tumour response with the three radioactivity levels (MBq)
640,NCT00904839,Progression-free Survival Rate at 9 Months (PFS-9),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Exploratory Biomarker and Pharmacogenetic Analysis for VEGF
641,NCT06001268,Participant Rating on Ease of Use the Mobile Application - Usability,2023-08-14,RECRUITING,INTERVENTIONAL,['NA'],,Malnutrition -Nutritional Status
642,NCT04915807,Progression-free survival,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events of special interest
643,NCT02753127,Overall Survival (OS),2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events in the General Population
644,NCT01730586,Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA),2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS)
645,NCT04827485,Left colon distension score,2022-01-13,TERMINATED,INTERVENTIONAL,['NA'],,Left colon sessile serrated lesion detection rate
646,NCT05338866,3-year progression free survival rate,2022-01-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Patients' quality of life scale
647,NCT03784417,Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor,2019-10-15,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
648,NCT03788447,total dose of remifentanil,2019-06-04,COMPLETED,INTERVENTIONAL,['NA'],,
649,NCT00543777,Overall Image Quality of Magnetic Resonance Elastography (MRE),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Hepatic Steatosis
650,NCT01641458,Predefined fluoropyrimidine-related (index) toxicity,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression-free survival
651,NCT03154983,progress-free survival time,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease control rate
652,NCT00296062,Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.,2006-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Phase I: Maximum tolerated dose in patients ≥ 65 years of age measured by CTC version 3.0 at end of Safety in the Elderly component of study
653,NCT02670746,Adverse Event (AE),2015-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Evaluate the resources utilized for treatment of pancreatic adenocarcinoma with the combination nab-paclitaxel/gemcitabine in routine clinical practice
654,NCT00252564,Progression-free Survival (PFS) Rate at 1 Year.,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate
655,NCT05651594,Overall response rate (ORR),2023-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR
656,NCT06317896,2-year recurrence-free survival rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between metastasis，primary tumor and CTCs in blood through NGS and CTC-DNA
657,NCT02042430,Number of participants with an increase in CD8+ T cells,2014-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in IDO1 expression by IHC
658,NCT00142038,Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
659,NCT05141721,Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC),2022-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase 2 and 3: The feasibility of manufacturing a patient-specific vaccine defined by the proportion of patients for whom vaccine was successfully manufactured from those randomized to the vaccine arm.
660,NCT03167775,DCR and/or 6-months survival rate,2016-11-28,UNKNOWN,INTERVENTIONAL,['NA'],,the rate of incidence of adverse events
661,NCT01904890,Receipt of CRC Screening,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,CRC screening Intention
662,NCT04548765,Colonoscopy Ordered at 6 months,2020-07-24,COMPLETED,INTERVENTIONAL,['NA'],,Colonoscopy Result
663,NCT03750175,Feasibility of ctDNA analysis for RAS mutation analysis,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Lead time
664,NCT05639972,Feasibility of administering E7 TCR-T cell therapy as induction treatment for LAHPVC,2024-06-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2-year and 5-year disease free survival (DFS)
665,NCT00003714,Patient Response,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
666,NCT04902352,SMA margin status,2021-04-06,RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival
667,NCT04013347,number of patient with surgical complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,number of patient with anastomotic dehiscence
668,NCT05061082,Genetic and epigenetic changes of the tumor,2021-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
669,NCT04593407,Percentage of surgical referral after treatment,2020-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Cumulative complications rate after treatment
670,NCT05194878,Disease-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,CT assessment of response to neoadjuvant treatment
671,NCT04578444,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
672,NCT01801085,"Composite preparation, dispensing and administration time",2011-10,TERMINATED,OBSERVATIONAL,['NA'],,Capital item utilization (hospital bed and infusion pump)
673,NCT01995591,number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
674,NCT05252390,Phase 1b Food Effect Substudy: Effect of Food on the Pharmacokinetics (PK) of NUV-868,2022-03-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
675,NCT02125396,Overall survivals,2019-05-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Recurrence rates
676,NCT01765582,Progression-Free Survival During First-Line Therapy (PFS1),2013-01-23,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
677,NCT00549276,,2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
678,NCT03253939,3-years overall survival,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
679,NCT02900248,Time to Treatment Progression,2017-10-02,TERMINATED,OBSERVATIONAL,['NA'],,To determine rate of enrollment into existing and future therapeutic clinical trials.
680,NCT00973869,Concentration of curcumin in colorectal tissue after treatment,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Presence of curcumin and its metabolites in peripheral blood and urine
681,NCT00008047,,1999-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
682,NCT03551470,Operative time,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
683,NCT01882660,"Wnt target gene expression (APCDD1, AXIN2, DKK1, LGR5 and ASCL2)",2013-07,TERMINATED,INTERVENTIONAL,['NA'],,Tumor differentiation
684,NCT02729948,Incidence of adverse events associated with TCE use,2016-07-28,COMPLETED,INTERVENTIONAL,['NA'],,
685,NCT01056913,Anastomotic Leakage,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Clinical Relevant Stenosis
686,NCT00131911,Confirmed Response Rate,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
687,NCT00041197,Recurrence-free survival (RFS),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes
688,NCT04808466,overall survival,2021-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,The positive rate of cancer cells of participants by exfoliative cytology examination
689,NCT01497964,Objective Response Rate,2011-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameter Vss
690,NCT04298489,ex vivo Maximal Inhibition Index (MI),2017-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Progression free survival (PFS) after chemotherapy
691,NCT00047112,overal survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,recurrence free survival
692,NCT00470782,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
693,NCT05951231,Lactate level in microdialysate from hilar plate after normothermic machine perfusion - 4 hours,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Donor associated variables - Donor risk index,Pyruvate level in microdialysate from hilar plate after of Dual-end-ischemic Hypothermic Oxygenated Perfusion machine perfusion in extended criteria donors livers - 2 hours
694,NCT02527967,Hospital length of stay (days),2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate (%)
695,NCT03233360,Time to treatment recurrence,2017-04-17,COMPLETED,OBSERVATIONAL,['NA'],,
696,NCT01762514,Effect on improving mucositis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence and severity of Hypocalcemia
697,NCT02330536,Respiratory change,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
698,NCT03776370,The five-year survival rates of rectal cancer between the two groups were compared.,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
699,NCT03387774,Incidence of Severe Acute Oral Mucositis (Grade of CTC-AE ≥ 3),2018-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The Adverse events Related to Ulinastatin
700,NCT03652467,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer,2018-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of Participants With Drug-Related Treatment-Emergent Adverse Events
701,NCT00293462,Comparison of the Mean Number of Days for Mucositis to Heal Across by Group,2005-06-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Comparison of Combined Mean Score on the Pain Questionnaire by Group
702,NCT03192644,recurrence-free survival (RFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
703,NCT04652492,TTP assessed by independent review committee(IRC),2020-10-27,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
704,NCT01269970,early metabolic response to predict pathological response and outcome,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,"to study correlations between early metabolic response, late metabolic response, histopathological response and outcome."
705,NCT01726309,Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region.,2011-05,TERMINATED,OBSERVATIONAL,['NA'],,Correlation between the SNP profile(s) and disease response
706,NCT04004650,Perineal wound healing rate 30 days,2019-06-28,UNKNOWN,INTERVENTIONAL,['NA'],,Female sexual distress
707,NCT03731754,Complication rate of perineal wound,2018-11-20,UNKNOWN,INTERVENTIONAL,['NA'],,The operation time
708,NCT03431311,"Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0",2018-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
709,NCT03322969,disease free survival,2017-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
710,NCT04172402,Overall response rate (ORR),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
711,NCT05661643,Objective respone rate in SDH deficiency wild type GIST,2023-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,
712,NCT02524119,Progression Free Survival,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR) Based on mRECIST and RECIST 1.1
713,NCT00836303,Completion of Colorectal cancer screening,2005-12,COMPLETED,INTERVENTIONAL,['NA'],,Patient adherence to physician recommended colorectal cancer screening test
714,NCT03639792,Postoperative Morbidity and mortality,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
715,NCT03756051,Psychosocial Harms,2018-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Physical Harms
716,NCT04131426,Recruitment and Retention,2020-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Porportion of subjects with improved cachexia-related symptoms 3 months
717,NCT06090656,progression free survival，PFS,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Patient-reported outcomes, PRO"
718,NCT01696630,Variation of intraoperative Mean Arterial Pressure (MAP),2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Delay to intestinal transit recovery
719,NCT04718402,adverse events (AEs),2021-03-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,overall survival (OS)
720,NCT02786524,Change in Patient-Reported Symptom Burden as Determined by the National Comprehensive Cancer Network Distress Screening Tool,2016-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival Rate
721,NCT01514110,to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin,2008-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction
722,NCT03822130,Successful conversion rate of operation,2019-02-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
723,NCT05221957,Complications,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Mortality
724,NCT05800106,Relative bioavailability (F),2018-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of subjects with abnormal 12-lead electrocardiogram (ECG)
725,NCT06184841,Adverse Events,2020-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,The overall survival (OS)
726,NCT05905887,Disease control rate,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
727,NCT00355355,Overall survival,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
728,NCT05959356,Progression free survival,2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],"Treatment-emergent genetic mutations (e.g., KRAS, NRAS, BRAF, SMAD4, HER2, Etc.)",Quality-adjusted time without symptoms or toxicity
729,NCT03404661,Methylated DNA markers as measured by mean percentage of total human DNA per pancreatic juice volume,2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
730,NCT00337545,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
731,NCT02738359,"Prevalence of advanced colorectal neoplasia or cancer identified by each screening strategy (OC, CC and FIT)",2017-11-03,RECRUITING,OBSERVATIONAL,['NA'],Quality assessment of colonoscopy and capsule endoscopy,Rate of colorectal cancer identified by each screening strategy
732,NCT04548752,Progression-free survival (PFS),2021-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
733,NCT03009461,Overall survival,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
734,NCT01768104,En bloc resection,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
735,NCT01211210,3-year disease free survival,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life
736,NCT01836653,Progression-free survival,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Progression-free survival among the RAS wild type subpopulation,Response rate
737,NCT02108782,Progression-free survival,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Plasma levels of circulating angiogenic factors and soluble receptors,Incidence of adverse events graded according to National Cancer Institute (NCI) CTCAE version 4.0
738,NCT05965466,Number of gallstone patients,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with bile duct stones
739,NCT02202317,Number of Subjects Whose Y-90 Based PET/CT (Positron Emission Tomography/Computed Tomography)Scans Detected Extrahepatic Non-target Embolization.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Y-90 PET/CT to Y90 SPECT
740,NCT02502630,Overall Survival (OS),2010-06,COMPLETED,INTERVENTIONAL,['NA'],,Treatment related adverse events
741,NCT03712943,Maximum Tolerated Dose,2018-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Frequency and Severity of Adverse Events
742,NCT06084299,Maximum tolerated dose [Safety and Tolerability],2020-05-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
743,NCT03200249,Complete histological response rate,2016-12-22,COMPLETED,INTERVENTIONAL,['NA'],,Tolerance
744,NCT00860860,Toxicity defined by NCI Common Terminology Criteria for Adverse Events version 3.0,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"pharmacokinetics and biodistribution of TF2 and Lu-177-labeled IMP-288, sensitivity of pretargeted imaging with In-111-labeled IMP-288, and tumor response using RECIST criteria"
745,NCT04458740,Assess how the patients and their family members face the disease,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
746,NCT01739894,Overall survival (OS) rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
747,NCT06015659,6-month Progression-Free Survival (PFS) Rate,2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-5 Treatment-related Toxicity Rate
748,NCT01224652,progression-free survival,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
749,NCT01678027,Gastric cancer incidence,2004-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,All-cause mortality
750,NCT04739696,Caregiver: Change in Center for Epidemiological Studies Depression Scale (CESD),2021-02-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Caregiver: Job Satisfaction
751,NCT04858334,Improvement in relapse-free survival (RFS),2021-06-22,RECRUITING,INTERVENTIONAL,['PHASE2'],RFS and OS differences with those who had resectable disease at diagnosis,OS in those who received any platinum-based perioperative chemotherapy versus no platinum-based perioperative chemotherapy
752,NCT01386502,To determine the safety and tolerability of escalating doses of anti PD1 antibody (CT-011) in combination with subcutaneous p53 vaccine.,2011-06-15,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,To determine the clinical efficacy of this combination.
753,NCT04605731,Overall response,2021-08-03,RECRUITING,INTERVENTIONAL,['PHASE1'],Gene expression signatures,Overall survival
754,NCT04634526,Rate of R1 cases assessed by surgeon,2018-04-18,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
755,NCT05512260,Feasibility regarding iDA format,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],Satisfaction with the iDA and the decision,Self-reported lifestyle behaviors
756,NCT00842491,Progression free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The alteration of relative regional blood volume of the tumor
757,NCT04247958,Number of SureForm™ Stapler fires and reload colors,2020-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of peri-operative and short term outcomes
758,NCT00747097,Progression-free survival,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, objective response, safety"
759,NCT04930315,1-year tumor recurrence-free rate,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
760,NCT04192565,Complication rate (%),2020-09-09,COMPLETED,INTERVENTIONAL,['NA'],,
761,NCT05775900,Pharmacokinetic (PK) characteristics 2,2023-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Treatment-emergent genetic mutations,Quality of Life (QOL)
762,NCT02643498,maximum tolerated dose (MTD) of SBRT,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
763,NCT00333788,Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks),2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period
764,NCT02907099,Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors 1.1,2016-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
765,NCT01044732,Detection Rates for Adenomas and for Total Polyps,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,Times for Withdrawal Phase and for Complete Procedure
766,NCT00217711,"Efficacy of Oxaliplatin, Irinotecan, and Capecitabine",2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
767,NCT01984580,Changes in zinc-regulated cellular proteins within Barrett's tissue,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Changes in cellular microRNA profile; changes in protein cancer biomarkers
768,NCT05231382,Two-years progression-free survival rate,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30."
769,NCT02537158,recurrence-free survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
770,NCT00920803,To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.,2008-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.
771,NCT06020885,Tolerated fraction dose,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,The rate of grade 3 or 4 toxicities according to CTCAE5.0
772,NCT06267378,"The sensitivity & specificity of blood based biomarkers for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events",2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival at 3 months and 5 years (the latter via cancer registry returns)
773,NCT04871204,Weight change in percent (%),2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients completing treatment
774,NCT04599920,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification.,2020-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Changes in the concentrations of N-nitroso compounds in feces.
775,NCT04942626,Identification of the maximum tolerated dose for capecitabine administered concomitantly with standard radiotherapy in combination with Anakinra at a fixed dose of 100 mg s.c,2021-08-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Quality of life based on treatment arm and surgical procedures/organ preservation
776,NCT00675194,response rate,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients
777,NCT04813432,time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma,2018-09-10,UNKNOWN,OBSERVATIONAL,['NA'],,
778,NCT01408407,Maximum skin toxicity,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
779,NCT01238965,To assess the safety of this regimen,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
780,NCT04466696,Postoperative length of stay,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
781,NCT02110953,"Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2016-01-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression
782,NCT03983993,Clinical benefit rate (CBR),2019-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
783,NCT01850368,Tumor stabilization rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment related toxicity
784,NCT00307866,"To assess the proportion of correct final, therapy deciding diagnosis based on unenhanced plus SH U 555 A enhanced MR imaging compared to contrast-enhanced dual-phase spiral CT.",2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,To assess safety and tolerability of SH U 555 A administration.
785,NCT05176964,pathological complete response(pCR),2021-12-31,RECRUITING,OBSERVATIONAL,['NA'],,predictive biomarkers andquality of life(QoL)
786,NCT04260139,Lymph Node Yield in Colon Cancer Resection Specimens,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
787,NCT01287130,"To assess for evidence of anti-tumor activity with this combination, per tumor measurements",2011-01-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the safety and tolerability of the combination of AZD6244 and cetuximab in patients with K-RAS mutated metastatic colorectal cancer
788,NCT01143922,,2009-08,UNKNOWN,OBSERVATIONAL,['NA'],,
789,NCT02569242,Overall Survival,2015-12-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
790,NCT05775419,5-years overall survival (OS),2021-06-30,RECRUITING,INTERVENTIONAL,['NA'],,5-year progression-free survival (PFS)
791,NCT01431599,downstaging effect of tumor,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,bladder and small bowel toxicity after chemoradiation
792,NCT04777604,Overall survival rate,2021-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
793,NCT00632515,Psychosocial + External factors influencing CRC patients' communication with FDRs about CRC risk & screening information,2008-01-29,COMPLETED,OBSERVATIONAL,['NA'],,
794,NCT01585727,Urogenital function,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Fecal incontinence
795,NCT00332865,Objective swallowing using videofluoroscopy and endoscopic evaluation of swallowing,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Swallowing scale of EORTC HN 35
796,NCT06253650,ctDNA clearance (negative ctDNA status) at 1 year,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Translational analyses,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
797,NCT02173080,Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score,2014-06,RECRUITING,OBSERVATIONAL,['NA'],,Total kidney volume
798,NCT03977233,Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,proportion of patients whose tumor/stroma subtype changes after treatment with FOLFIRINOX
799,NCT00234416,Incidence of DLT,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)"
800,NCT02032485,fluorescence intensity of tumoral and healthy tissues after IV injection of ICG to patients with peritoneal carcinomatosis from colorectal origin.,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
801,NCT01652079,Progression Free Survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analysis of biopsies
802,NCT02979795,Tumor regression rate,2016-11,UNKNOWN,OBSERVATIONAL,['NA'],,Distant metastasis
803,NCT05351983,Feasibility of the process,2022-09-22,RECRUITING,INTERVENTIONAL,['NA'],,Chemosensitivity testing
804,NCT00729482,Progression-free Survival Rate at 4-month (16 Weeks),2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
805,NCT02244632,Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE),2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
806,NCT04931394,Disease free time,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).
807,NCT02628093,Versatility Score,2016-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Operative Procedure Time
808,NCT02402036,Serum microRNA Quantification,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
809,NCT06157814,Number of participants retained for entirety of the study,2023-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Symptom Measures
810,NCT06209970,Numerical Rating Scale,2024-01-20,RECRUITING,INTERVENTIONAL,['NA'],,
811,NCT03730441,"correlation between ADR of screening and all colonoscopies (screening, surveillance, diagnostic)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
812,NCT06216405,"Comparing the percentage of patients with at least one right colon polyp detected according to the randomization group, and adjusted for Boston Bowel preparation scale, for the operator, for the endoscope and for stratification factors.",2022-01-20,COMPLETED,INTERVENTIONAL,['NA'],,
813,NCT03812562,Recurrence rate,2019-02-07,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall increase in future liver remnant (FLR)
814,NCT05029869,The specificity of MRD detection using ctDNA as the biomarker,2021-10-04,RECRUITING,OBSERVATIONAL,['NA'],,Mutation profile of gastric cancer
815,NCT05367687,"Recurrence-Free Survival (RFS), as Determined by the investigator",2022-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
816,NCT03053167,Progression Free Survival [PFS],2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of Life [WHO-QOL],Disease Control Rate [DCR]
817,NCT01442974,"Effect of nab-paclitaxel on pancreatic cancer stroma, new vessel formation and tumor cell metabolism.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],,Activity of nab-paclitaxel in combination with gemcitabine against PDA in relation with changes in tumor stroma and tumor metabolic activity.
818,NCT03542136,"To evaluate the efficacy of evaluating the vibrotactile sense using a multi frequency tactilometry, in patients hand and foot. This is by assessing the changes in the measurements of a multi frequency tactilometry device in between each two time points.",2018-06-04,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate if Oxaliplatin induced polyneuropathy can be earlier detected by using a multi frequency tactilometry compared with Common Terminology Criteria for Adverse Events scale (CTCAE).
819,NCT01489410,Number of Patients with Post-Embolization Syndrome,2012-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall Survival
820,NCT04287400,K-RAS Mutation,2019-03-05,RECRUITING,OBSERVATIONAL,['NA'],,Radiomics - MR image findings
821,NCT00551057,,2007-10,UNKNOWN,OBSERVATIONAL,['NA'],,
822,NCT01721785,Diagnostic performance of the techniques under investigation,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,To determine the inter-observer agreement for the imaging techniques under investigation
823,NCT03186014,Recurrent dysphagia,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
824,NCT01374750,To evaluate recurrence-free survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the safety with sirolimus
825,NCT02917798,baseline to post-results change in distress levels,2016-07-12,RECRUITING,OBSERVATIONAL,['NA'],,
826,NCT02272738,Number of patients with Adverse Events,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival time
827,NCT04621370,Complete response,2020-12-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Euro Qol-5 dimensions 3 levels (EQ5D-3L)
828,NCT04447352,Comparison of progression-/disease-free survival (PFS/DFS) between arms,2020-12-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification
829,NCT01083875,Evaluation of mucositis using the Oral Mucositis Assessment Score,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Frequency of treatment-emergent, drug-related Serious Adverse Events"
830,NCT02229136,Incidence of Grade ≥ 2 stomatitis,2014-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Time to Disease Progression of next anti-cancer therapy,Reduction in pain score on questionnaires
831,NCT01742806,Time to drain removal,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],Time to discharge after surgery and postoperative complication,total amount of exudate drainage
832,NCT06006338,R0 resection rate,2023-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Blood loss
833,NCT05418543,CH-EUS FNA has higher diagnostic accuracy for bile tuct tumors,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
834,NCT00005590,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,
835,NCT05603065,Pathological complete response rate (pCR),2022-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of life measurement and evaluation 2
836,NCT01018381,Patient survival,2006-06,COMPLETED,INTERVENTIONAL,['NA'],,Disease recurrence
837,NCT01172860,treatment safety,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
838,NCT02969681,Progression Free Survival,2017-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assessment of treatment-related adverse events
839,NCT00037089,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
840,NCT03329534,Ratio of non-acidic to acidic reflux events,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Gastroesophageal reflux disease-health related quality of life instrument
841,NCT04107324,Liver Function,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Resection rate
842,NCT00996333,To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Assessment
843,NCT01297998,Maximum tolerated dose,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with dose limiting toxicity
844,NCT01532804,Disease-free survival,2011-07-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life by using the quality of life questionnaire score
845,NCT02713529,Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST),2016-04-14,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AMG 820 Pharmacokinetic Parameter by Dose Group: Accumulation Ratio (AR)
846,NCT01434550,Number of Participants With Overall Survival (OS),2012-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events (AEs)
847,NCT01283217,3-year disease free survival(DFS),2010-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
848,NCT00003424,,1997-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
849,NCT00955591,Comparison of anal cytology screening outcome derived from specimens collected by a flocked nylon swab vs a Dacron swab,2009-03-12,COMPLETED,INTERVENTIONAL,['NA'],,
850,NCT00005094,"Percentage of patients with adenomas, aspirin use at baseline, and covariates",2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events coded using the MedRA dictionary
851,NCT01379521,Time to Progression (TTP) Based on the Modified RECIST Criteria,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months
852,NCT03775395,Overall survival,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
853,NCT05230771,2-year overall survival rate,2022-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
854,NCT01171482,Progression free survival (PFS),2015-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
855,NCT02288507,Safety and tolerability of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measures by Adverse events,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,"Efficacy of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measured by response rate, time to progression (TTP), progression free survival (PFS), overall survival (OS)"
856,NCT00591123,"Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the Combination of 5-fluorouracil, Leucovorin, Oxaliplatin, and Erlotinib.",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicity of the Combination of FOLFOX, 5-FU, and Erlotinib"
857,NCT02239900,Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),2014-08-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)
858,NCT05714644,CRC Screening Completion Rates,2023-05-31,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Diagnostic Colonoscopy Completion Rates
859,NCT02005965,To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.,2007-08-13,UNKNOWN,OBSERVATIONAL,['NA'],,Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.
860,NCT02961140,Incidence of postoperative complication,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Length of stay
861,NCT03000816,Progression-free survival,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
862,NCT06092944,Heart rate (HR),2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Analgesia satisfaction
863,NCT05060471,cCR rate,2021-09-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,overall sruvival
864,NCT06124378,pCR,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Gene mutation signatures of colon cancer
865,NCT04823403,Maximum Tolerated Dose (MTD),2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,
866,NCT03045484,Total Dose of Oxycodone,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Quality-of-Life Index
867,NCT03793335,Colorectal cancer prevention,2019-04-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
868,NCT06304545,Pathological Complete Response rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,3-years Overall Survival rate
869,NCT05862051,Progression free survival (PFS),2021-12-14,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life measure
870,NCT06069960,Overall survival（OS）,2023-10-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease-free survival，DFS
871,NCT02923622,Overall survival,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0
872,NCT03882866,Objective Response Rate (ORR),2019-03-28,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life of two treatment regimens in patients
873,NCT03428321,Thermal ablations,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
874,NCT00459108,Four Month Progression-free Survival (PFS),2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
875,NCT02795429,Phase II: Overall Response Rate (ORR) Per RECIST v1.1,2016-06-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib and Phase II: PD-L1 Percent Positive Tumor
876,NCT05663203,Attentional Function Index,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Short Form Health Survey
877,NCT04005690,Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline,2019-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of >= grade 3 toxicities for each assigned window treatment (as described in sub-protocol)
878,NCT00282672,5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years,2006-02,COMPLETED,INTERVENTIONAL,['NA'],,5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.
879,NCT00407654,Progression-free Survival (Bevacizumab-treated Group),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Response (Bevacizumab-treated Group)
880,NCT05360420,Time benefits based on US and immediate CEUS with current routine,2022-10-26,RECRUITING,INTERVENTIONAL,['NA'],,The economic benefit based on US and immediate CEUS with current routine
881,NCT04714190,Overall survival (OS),2021-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Tumor progression time (TTP)
882,NCT01689376,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
883,NCT00142467,"Time to disease progression of gemcitabine, oxaliplatin and bevacizumab regimen in patients with hepatocellular carcinoma.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
884,NCT00733850,Progression-free survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
885,NCT03630354,Perceived physical function incongruence,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],,Fear of recurrence
886,NCT00677443,To compare the combination of S-1 and oxaliplatin to the combination of capecitabine and oxaliplatin in terms of progression free survival in patients previously untreated by systemic therapy for advanced or metastatic colorectal carcinoma.,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.
887,NCT05631041,The change between groups in response rate (RECIST),2022-12-31,RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in serum levels of the measured biological marker serum permeability glycoprotein in ng/ml
888,NCT03707444,Change in Average pain as assessed by Brief Pain Inventory Question 3,2018-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Change in opioid use
889,NCT00656123,Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percent Fold change in amount of interferon gamma-producing Ep-CAM-specific CD8 T cells after vaccination
890,NCT06202131,mOS,2023-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
891,NCT05827471,Detection of protein for early rapid diagnosis of colon cancer.,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
892,NCT00753441,Serum bilirubin,2009-02-01,TERMINATED,INTERVENTIONAL,['NA'],,Procedure-related complications
893,NCT03956641,evolution of exercise tolerance,2019-09-17,UNKNOWN,INTERVENTIONAL,['NA'],,measurement of parameters reflecting the physical condition
894,NCT04906733,Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes,2021-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,
895,NCT02738697,Overall survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
896,NCT05185245,Overall Survival,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Disease-Free Survival
897,NCT01379807,Objective response rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Exploratory Objectives
898,NCT02029326,To explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform,2010-02-01,COMPLETED,OBSERVATIONAL,['NA'],,3. To analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab
899,NCT00388700,"Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.",2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Explore progression-free survival (PFS) and survival
900,NCT00513539,Overall survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ 30 and PAN 26 at baseline and 1, 3, and 6 months after completion of study treatment"
901,NCT04098796,Objective response rate (ORR),2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Exploration of biomarkers (PD-L1 expression, TMB at the baseline, changes of AFP and T lymphocyte in peripheral blood)"
902,NCT05700188,Overall survival (OS),2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (PFS)
903,NCT00004210,"Assessment of cancer risk perception, cancer screening practices, views regarding genetic services, and family communication about HNPCC / Lynch syndrome by family members",2000-02,COMPLETED,INTERVENTIONAL,['NA'],,
904,NCT02967848,Change in global and local liver function,2016-10-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Radiotherapy dose sparing of functional liver
905,NCT05926726,RP2D of JWATM214 in HCC patients,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,overall survival (OS)
906,NCT05208762,Number of participants with DLTs by dose level,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-drug antibodies (ADAs)
907,NCT01533311,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
908,NCT02565667,anastomotic leak rate,2015-09,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
909,NCT02190656,Number of participants with no LARS; minor LARS and major LARS,2014-05,COMPLETED,OBSERVATIONAL,['NA'],LARS score in participants who have had laparoscopic surgery and participants who have had open surgery,Correlation between LARS score and EORTC QLQ-C30 questionnaire score
910,NCT01438385,Establishing a database that contains all Interventional Endoscopies,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,
911,NCT01949870,The Number of Dose-limiting Toxicities,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
912,NCT02459457,overall survival,2015-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse event
913,NCT05182762,Clavien-Dindo Grade,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Age comparison
914,NCT03086291,maximum tolerated dose,2018-01-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
915,NCT05783076,Overall survival will be determined,2023-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life will be determined
916,NCT00755534,Time To Progression,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of the molecular characteristics of the tumor with the clinical outcome
917,NCT00003923,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
918,NCT02953782,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2016-11-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
919,NCT05826743,Study Success Case(Avoidance of ostomy),2023-12-04,RECRUITING,INTERVENTIONAL,['NA'],,
920,NCT04457297,Disease-free survival 1 (DFS1),2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Completion Rate
921,NCT06084689,Disease control rate (DCR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of the combination
922,NCT06252649,PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Maximum Plasma Concentration (Cmax) of Sotorasib
923,NCT04947371,Adverse events rate,2018-12-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
924,NCT01273662,disease stabilization,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,time-to-tumor progression
925,NCT00844727,,2003-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
926,NCT04094675,Change in colon polyp burden by staging,2019-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in well-being assessment
927,NCT03636308,Objective response rate,2018-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of treatment related emergent adverse events（Safety and Tolerance）
928,NCT06005974,To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR),2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the anti-tumor activity of REC-4881 as measured by to other efficacy endpoints
929,NCT05585073,surgery complicated,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
930,NCT05931445,HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) global health status score,2021-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Communication between patients and healthcare providers (EORTC QLQ-COMU26 score)
931,NCT02695966,T lymphocyte changes,2015-05,COMPLETED,OBSERVATIONAL,['NA'],,T lymphocyte localisation
932,NCT00330915,Feasibility of Pemetrexed Prior to Surgery,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Receiving Sphincter Saving Surgery
933,NCT03980704,Infectious complications,2019-04-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Length of stay
934,NCT04977596,CT value of lesion portal phase,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
935,NCT01296984,3-year local recurrence,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,Stoma function
936,NCT04706910,Minimum lesion detectability (SUV),2021-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Gallbladder disease questionnaire
937,NCT02785146,Disease-free survival (DFS),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],The effects of Huaier Granule on adverse events of adjuvant chemotherapy.,Metastasis-free survival (MFS)
938,NCT02941562,Pathological Response,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year Overall Survival
939,NCT02895464,Adverse events,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Discharge destination
940,NCT05824559,Progression Free Survival (PFS) rate at 16 weeks,2023-08-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of ME-344 administered in combination with bevacizumab
941,NCT05185947,"Evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Inde...",2022-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess clinicopathologic response to therapy
942,NCT04089150,Locoregional control (Locoregional Response Rate LRR),2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],ePRO Acceptability,Overall Survival (OS)
943,NCT01957241,BIOMARKER PANEL SELECTION AND MODELING,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,SURVIVAL AND RT-RELATED TOXICITY ANALYSIS AND MODELING
944,NCT05830292,Diagnostic accuracy of DRS probe to differentiate normal versus tumour tissue in vivo,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of DRS probe to differentiate normal versus tumour tissue in vivo
945,NCT03001505,Overall survival,2017-05-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Local recurrence
946,NCT02000739,Time to Disease Progression,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,
947,NCT06257264,Part 2: Objective Response Rate,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: Plasma concentrations for BG-68501
948,NCT00383149,Percentage of Participants Surviving at 6 Months,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in FHSI-8 Total Score by Time-point
949,NCT06173466,Cumulative opioid consumption of 72 hours after surgery,2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Sleep quality
950,NCT01718821,"Changes in pain, assessed by BPI-SF.",2012-09,COMPLETED,OBSERVATIONAL,['NA'],,"Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions."
951,NCT03822936,Progression free survival,2018-02-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,intra and perioperatory complications
952,NCT05731947,Phase 2: Progression Free Survival (PFS),2023-04-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: DOR as Assessed by the Investigator
953,NCT02424864,The estimation of tumor size of the primary esophageal tumor on 4Dvs 3D FDG PET,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,"Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of esophageal cancer and lymph nodes and number of suspected involved lymph nodes"
954,NCT02671890,Maximum tolerated dose (MTD) (Cohort I),2016-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in muscle messenger ribonucleic acid (mRNA) levels via real-time polymerase chain reaction,Changes in fist-grip strength as measured by hand dynamometer (Cohort II)
955,NCT01545141,Change in the Number of Tumor-infiltrating CD8+ Cells.,2012-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Related Adverse Events
956,NCT03206125,Esophageal squamous cell carcinoma,2017-08-01,TERMINATED,OBSERVATIONAL,['NA'],,
957,NCT03958500,Rate of anastomotic leakage,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Timing of anastomosis leakage
958,NCT05669807,Objective Response Rate,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life assessment
959,NCT02045680,Improved tissue oxygen delivery,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Time taken for patient to first mobilise following surgery
960,NCT03624725,Effects of quality of life,2018-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
961,NCT06023121,Detection of levels of an exosome-based liquid biopsy signature,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
962,NCT01405638,Colorectal Cancer Screening,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,
963,NCT00216788,Urine sucrose level falls below 90 mg after 8 weeks of therapy,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Reduction of patient symptoms consistent with GERD
964,NCT04459754,Disease-free Survival,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,
965,NCT05043688,pCR,2021-09-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PD-L1 expression,AE
966,NCT00152087,- Adverse experience,2002-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
967,NCT04534543,Change in PME/PDE (ΔPME/PDE): predictive,2021-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Response to treatment
968,NCT02066259,"Number of participants in each of the clinicaly defined groups (0,1 and 2).",2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,
969,NCT05771480,Number of participants with Grade 3 or 4 possibly related adverse event (PRAE),2023-08-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-BIL21 Score
970,NCT05286320,objective response rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immune biomarkers,Progression-free survival and overall survival
971,NCT05017922,Number of bleeding episodes,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
972,NCT05913583,Graft rejection,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],pDC to mDC ratio,Early allograft dysfunction (EAD)
973,NCT06250166,Change from baseline in mean platelet-lymphocyte ratio at 12 weeks,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,Change in mean daily energy and protein intake at 12 weeks
974,NCT03723720,correlation between ADR and PDR for all and screening colonoscopies,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
975,NCT01836432,Overall Survival,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Immune Response
976,NCT02587884,Overall Survival,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Time to recurrence
977,NCT00808379,Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Comparison of pathological downstaging between the two groups who undergo surgery.
978,NCT01360892,Cumulative incidence of carcinogenesis of hepatocellular carcinoma,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,The cumulative incidence and severity of decompensated cirrhosis
979,NCT00681499,Quality of Life,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
980,NCT05650918,Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiological response rate as defined by RECIST version 1.1 and iRECIST
981,NCT00003139,Acute salivary gland toxicity,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Effects of continuing pilocarpine out to 6 months from the start of treatment
982,NCT02580253,Desease free Survival,2017-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
983,NCT00004193,"Determine the response rate, duration of response, and time to progression in patients with metastatic and/or locally recurrent adenocarcinoma of the colon or rectum treated with ISIS 2503, an antisense inhibitor of H-ras",1999-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine the safety profile of this regimen in these patients.
984,NCT06111105,Collection of clinical plasma samples at relevant time points,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Prognostic value of ctDNA analysis at relevant time points
985,NCT00100945,1-year overall survival rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
986,NCT06161818,Disease-free survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Future ctDNA analysis
987,NCT06034977,Overall survival,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
988,NCT02606994,Oral mucositis changes,2018-05-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life changes
989,NCT03642561,overall survival,2019-09-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,objective response rate
990,NCT03829098,90 day mortality,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Hospital based costs
991,NCT04557969,Assess disease-free intervals (DFIs) between surgical resection of disease for at least 5 years,2020-12-18,RECRUITING,OBSERVATIONAL,['NA'],,Characterize genomic and clinicopathologic features of GISTs
992,NCT01523431,"Incidence of toxicity, especially neutropenia and diarrhea",2012-03-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G."
993,NCT01885702,Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients,2010-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Clinical responses, e.g. disease-free survival, determined according to the standard protocol."
994,NCT01448655,Disease-free survival time (DFS).,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,"Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy)."
995,NCT02842047,Repeated Measures ANCOVA Model (F-Statistic),2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in FAMCARE Scale
996,NCT04073615,(Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment,2019-11-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,(Phase 1b and 2) Number of Participants with Adverse Events (AEs) that Worsen in Severity as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
997,NCT03109041,Safety & Toxicity of Delivering Primary Radiation Therapy with CivaSheet using the CTCAE 4.0 scale,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
998,NCT00532909,"Maximum tolerated dose of vandetanib in combination with capecitabine, oxaliplatin and bevacizumab",2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose limiting toxicities associated with the combination
999,NCT01706809,"The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.",2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1000,NCT04426669,Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events,2020-05-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes
1001,NCT00005878,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1002,NCT06055010,Subproject dependent,2014-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
1003,NCT05539417,The variation in treatment and awareness of lateral lymph nodes in patients with rectal cancer.,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Presence of presacral abscess
1004,NCT04094454,incidence and grade of vaginal fibrosis,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],,assessment of quality of life
1005,NCT03546660,Feasibility of imaging of the Esophagus using a SECM Capsule,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
1006,NCT01770132,Evaluate the number of subjects with adverse events which occur when up to 3 sites within the pancreas are treated with PDT using a total dose of 50 or 100 J per site,2013-04-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
1007,NCT00423150,Tumor Responses (Complete and Partial Response),2007-01-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1008,NCT01042782,maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"safety and tolerability of the combination of RAD001 and Mitomycin C as assessed by frequency, severity, and duration of treatment-related adverse effects"
1009,NCT02653521,Toxicity of treatment,2015-12-30,UNKNOWN,INTERVENTIONAL,['NA'],Dosimetric Parameters,Overall Survival（OS）
1010,NCT01271582,Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Progression-free survival
1011,NCT02866045,Proportion of patients receiving a definitive histologic diagnosis for gastrointestinal SELs by single incision needle-knife biopsy (SINK biopsy) vs. EUS-guided fine needle biopsy (EUS-FNB).,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proportion of patients for whom a mitotic rate may be calculated for gastrointestinal stromal tumors (GISTs) using SINK biopsy vs. EUS-FNB
1012,NCT02178358,Overall Survival (OS): Number of Events,2014-08-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in EORTC QLQ Hepatocellular Carcinoma (HCC-18) Questionnaire Score
1013,NCT03013010,Disease free survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proportion of patients with surgery-related complication
1014,NCT04539769,Diabetes remission rate,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1015,NCT01033578,Overall Survival,1999-10,UNKNOWN,INTERVENTIONAL,['NA'],,Time to Recurrence
1016,NCT01108107,The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation.,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1017,NCT02216487,Safety,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1018,NCT02935764,progression free survival,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life questionnaire
1019,NCT05896787,pCR,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
1020,NCT05359393,NED rate,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Acute toxicity associated with immunotherapy
1021,NCT06223022,Patients' reported Quality of life,2024-01-20,RECRUITING,INTERVENTIONAL,['NA'],Sick-leave,Patients' experiences of prostata cancer related to symptoms and side effects of treatment and diagnosis.
1022,NCT03579732,Number of subjects with gastric cancer,2018-06-29,COMPLETED,OBSERVATIONAL,['NA'],,Number of fatal cases due to colorectal cancer
1023,NCT01926769,Disease Control Rate,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1024,NCT03511170,time to failure of strategy（TFS）,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,time to failure of strategy（TFS）
1025,NCT02164916,Progression-free Survival,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Response Rate in Patients Who Register to Arm 3 (Crossover) After Disease Progression on Arm 1,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
1026,NCT02812186,Peak Airway Pressures,2016-12-27,COMPLETED,INTERVENTIONAL,['PHASE4'],,Surgical Rating Scale
1027,NCT02115373,Phase 2: Number of Participants Who Were Progression-free at 12 Weeks (PFS Status) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2014-05-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1b: Accumulation Ratio of AUC (Racc (AUC)
1028,NCT03800953,overall radiographic response,2019-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,New metastasis-free survival
1029,NCT04940546,Adverse events,2021-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
1030,NCT03887702,"Time until adverse liver outcome, assessed by incidence of adverse liver outcome",2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE3'],,Death due to any cause
1031,NCT02092389,Percentage of Patients With Fecal Calprotectin (fC) Level ≤ 150 µg/g After 12 Months of Treatment With Adalimumab,2014-07,TERMINATED,OBSERVATIONAL,['NA'],,Correlation Between fC and Workability Determined by WPAI:UC Questionnaire
1032,NCT00107536,Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Expression Profile and Mutations of Genes Critical for EGFR and ERBB2 Signaling Pathways
1033,NCT02804737,Effectiveness of Web-based instructions,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,Benefit of web-based instructions
1034,NCT04037241,Assess efficacy by overall survival,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Assess the persistence of CAR-T cells in liver tumor biopsies over time.,Evaluation of Quality-of-Life using the 5-level EQ-5D version (EQ-5D-5L) questionnaire
1035,NCT05056051,To assess the additive diagnostic yield as assessed by proportion of patients with recurrence be use of WATS-3D,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,To assess if the order by which tissue is sampled affects the diagnostic yield of WATS-3D by comparing the proportion of patients with recurrence between groups.
1036,NCT05081687,cCR + PathCR,2020-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall toxicity
1037,NCT03176264,Overall Response Rate (ORR) per investigator assessment using RECIST v1.1,2017-09-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Antidrug antibodies (ADA)
1038,NCT00019747,Time to Progression,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1039,NCT00079833,Control is defined as gastric acid secretory rate below 10 mEq/h or below 5 meq/h for patients with prior gastric acid reducing Surgery,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The following safety variables will be assessed at Month 6 and Month 12: adverse events, clinical laboratory results (ie, chemistry, hematology, urinalysis), physical examinations, and EGDs."
1040,NCT01108705,Compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,2010-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Assess serious and nonserious adverse events, laboratory evaluations, significant physical examination findings and ECG results"
1041,NCT00354224,Response Rate as Determined by RECIST.,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
1042,NCT03577067,renal resistive index (RRI),2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
1043,NCT00622999,Complication rate,2003-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
1044,NCT04013152,Collection of clinical data following surgery with robotic assistance in colorectal pathologies,2018-06-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of the mesorectum by using Quirke classification
1045,NCT05909995,"Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs",2023-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response
1046,NCT00006269,,1999-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,
1047,NCT03804203,Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale,2017-11-08,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life (QoL): EORTC questionnaire C15-PAL
1048,NCT01028495,Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Karnofsky Performance Scale, Clinical Laboratory Assessment, and Molecular Markers"
1049,NCT00341484,Genetic determinants,1998-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
1050,NCT04264702,Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™,2020-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Examine the number of Stage I CRC patients that have recurrent disease detected post-surgery based on SIGNATERA™ test results
1051,NCT05980221,Metabolome,2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],,Response of the fed and fasted metabolome to PERT
1052,NCT03346980,Inter-observer agreement of the Spigelman Score evaluated by expert endoscopists.,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Inter- and intra-observer agreement of the Spigelman Score and the endoscopic sub-scores evaluated by novices.
1053,NCT05353127,Influence of different CPET data averaging intervals on the numerical values of CPET-,2022-04-12,COMPLETED,OBSERVATIONAL,['NA'],,High- or Low-risk for postoperative complications
1054,NCT00358566,Overall survival time,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival
1055,NCT05729867,Technical success rate,2020-04-27,RECRUITING,INTERVENTIONAL,['NA'],,Stent dysfunction rate
1056,NCT05275075,Proportion of African American pancreatic cancer patients with weight loss and cachexia.,2022-12-07,RECRUITING,OBSERVATIONAL,['NA'],,"Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups."
1057,NCT00016029,,2000-08,TERMINATED,INTERVENTIONAL,['NA'],,
1058,NCT02390947,Overall Survival(OS),2015-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,The severity of Adverse Events
1059,NCT03493009,rate of adequate cleansing level,2018-05-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1060,NCT01526590,Lesion Margin,2012-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Degree of venous washout
1061,NCT02938195,Percentage of patients completing adjuvant chemoradiotherapy and surgery,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of pathological complete response
1062,NCT01323166,Health Related Quality of life after rectal cancer surgery - possible differences due to choice of procedure,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Impact of rectal cancer surgery and the level of intrusive thoughts
1063,NCT06100003,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
1064,NCT03167970,The overall diagnostic accuracy of capsule endoscopy in predicting the presence and extent of Barrett's esophagus in comparison to standard esophagogastroduodenoscopy,2017-05-03,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Treatment related adverse events of capsule endoscopy in comparison to standard esophagogastroduodenoscopy
1065,NCT05893810,High-grade radiation-induced oral mucositis,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life according QLQ-H&N43
1066,NCT04705194,Correlation coefficient between preoperative FLR-GC and post-operative ICG R15,2019-07-08,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation coefficient between growth in FLR volume and growth in FLR-GC after the first stage
1067,NCT00049712,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1068,NCT06048146,3 year disease free survival,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
1069,NCT00277303,Safety and tolerability,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters
1070,NCT05468892,PFS,2019-10-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety and tolerability analysis: defined as the evaluation of incidence and severity of AEs, graded according to NCI- CTCAE, version 5.0 (v. 5.0)."
1071,NCT04194034,Disease Control Rate (Phase II part),2020-01-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1072,NCT04715321,Predictive performance of CT perfusion,2013-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,Disease-free survival (DFS)
1073,NCT01007617,Mucositis scale - World Health Organization (WHO),2009-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Psychological impact
1074,NCT04147078,Disease-free Survival (DFS),2019-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
1075,NCT04296019,PFS,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1076,NCT00069108,Progression Free Survival,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Marked Post-baseline Laboratory Abnormalities by Trial Treatment
1077,NCT03825887,Total opioid consumptions,2018-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assess serious adverse events
1078,NCT04707482,Difference of protein expression,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1079,NCT01043835,Disease free survival,2010-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Complications, recurrence, quality of life measured by EORTC QLQ-C30 V 3.0 and EORTC QLQ-STO22"
1080,NCT00004252,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1081,NCT01032850,Number of Participants Experiencing Adverse Events,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
1082,NCT06152783,Histopathology was used as the diagnostic gold standard to evaluate the diagnostic performance of CellTouch in the diagnosis of early gastric cancer.,2023-11-21,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Using histopathology as the diagnostic gold standard, the diagnostic performance of CellTouch and ME-NBI in the differential diagnosis of low-grade intraepithelial neoplasia and high-grade intraepithelial neoplasia was evaluated."
1083,NCT00591461,The primary outcome will be the interobserver variability in the presence of columnar epithelium as well as the measured lengths.,2007-12,TERMINATED,OBSERVATIONAL,['NA'],,variables that predict endoscopic interobserver agreement and path-confirmation
1084,NCT04481659,The damage degree of anal function,2020-07-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Local recurrence
1085,NCT05253716,3-year disease free survival after discharge,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,"toxicity of chemotherapy graded according to the CTCAE, version 5.0"
1086,NCT05245786,Number of patients with impactful finding using 64Cu-M5A positron emission tomography (PET) imaging.,2022-08-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Count of Adverse Events.
1087,NCT06144385,Rate and severity of clinically-significant abnormalities in laboratory testings,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overal survival (OS)
1088,NCT02581709,Feasibility of intervention implementation,2016-05,TERMINATED,INTERVENTIONAL,['NA'],,Cognitive Reserve Scale
1089,NCT06333665,Disease-free survival,2024-02-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,perioperative 90-day mortality
1090,NCT06187103,Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Patient experience of HyperSight imaging
1091,NCT00928928,Oxidative stress markers in patients with colorectal cancer operated with open or laparoscopic approach,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
1092,NCT01008358,Tumor response by Response Evaluation Criteria In Solid Tumors (RECIST),2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Hepatitis C Virus (HCV) viral load
1093,NCT04428437,Response rate (RR),2022-07-02,TERMINATED,OBSERVATIONAL,['NA'],,Adverse Events
1094,NCT01136031,response rate (phase II part),2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,toxicities
1095,NCT04745988,Major pathological response (MPR) rate,2021-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
1096,NCT01025882,Tumor samples for RNA and protein harvesting (when possible) from pretreatment biopsies and surgical specimens,2009-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1097,NCT03944421,Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],Blood Glucose,Changes in MicroRNA Expression
1098,NCT03403634,Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions,2018-04-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Survival,Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
1099,NCT01252628,"The evaluation of antitumor effects of PX-866 in combination with cetuximab versus cetuximab in patients with incurable metastatic colorectal cancer and/or patients with incurable progressive, recurrent or metastatic SCC of the head and neck.",2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1100,NCT03168139,"Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory",2017-04-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Combination Therapy: Efficacy - time to event analyses
1101,NCT03563170,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR for Phase 2 Single Arm Component
1102,NCT01442155,Disease-Free Survival (Time to Event),2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Safety: Percentage of Participants With Adverse Events
1103,NCT04965311,Rate of clinically relevant postoperative pancreatic fistula (POPF),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of any POPF
1104,NCT06040541,Dose Limiting Toxicities,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1105,NCT01962649,Measurement of fluorescence intensity within focal hepatic lesions,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1106,NCT01142388,Progression-free Survival,2010-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
1107,NCT00051480,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1108,NCT06313047,CYP2B6,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1109,NCT01456156,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events
1110,NCT00467129,Progressive disease-free survival,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
1111,NCT03158571,Overall survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1112,NCT05453851,Proportion of patients that are free of metastatic disease to the liver from a pancreatic primary,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Incidence of adverse events (AEs),Time to overall survival (OS)
1113,NCT03033186,Everolimus TDM to predict long-term toxicity,2017-05-16,UNKNOWN,OBSERVATIONAL,['NA'],,Everolimus TDM to predict dose reductions
1114,NCT03613168,Adverse events,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1115,NCT01226719,Overall Response Rate (ORR),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1116,NCT00386516,Stable disease (SD) rate and progression-free survival (PFS) times,2006-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"Safety, tolerability and Quality of Life (QoL)"
1117,NCT01609361,Post operative morbidity at 30 days according to DINDO CLAVIEN classification,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Duration of laxation (gas and stool)
1118,NCT04239781,HCC patients' willingness and expectation for post-operative treatment.,2020-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1119,NCT05606081,Rates of colorectal neoplasia per number of colonoscopies performed,2022-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
1120,NCT02884154,diagnostic sufficiency,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,complications
1121,NCT05493683,Objective response rate(ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
1122,NCT04573621,Number of participants with pelvic sepsis,2020-10,UNKNOWN,INTERVENTIONAL,['NA'],,Any complications associated with drain removal after surgery
1123,NCT06326346,16 week disease control rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event assessed by NCI-CTCAE Version 5.0
1124,NCT04406714,"Proportion of subjects, ages 50-75, who complete CRC screening within 6 months (Trial - Age Group 50-75)",2020-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of days from abnormal FIT result date to diagnostic colonoscopy (Trial - Age Group 50-75),Proportion of subjects who complete a follow-up diagnostic colonoscopy at 60 days (Sub-study - Age Group 45-49)
1125,NCT03734627,Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Duodenal enteroendocrine cell mRNA expression profile,EORTC health related quality of life
1126,NCT04278222,objective response rate,2020-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
1127,NCT02718430,Safety and tolerability taking into account treatment-limiting toxicities (TLTs),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biodistribution and shedding of VXM01
1128,NCT00767234,Identify Biomarkers,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
1129,NCT03516890,Overall survival of all patients,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free of staged partial hepatectomy patients
1130,NCT04510064,margin-free-(R0) resection rate,2020-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
1131,NCT05897749,PFS,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE4'],,quality of life
1132,NCT01806675,Change From Baseline in Maximum Standard Uptake Values (SUVmax),2013-03-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival (PFS)
1133,NCT03290937,Objective response rate (Dose expansion),2017-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response
1134,NCT00021398,tolerated dose of preoperative hyperfractionated radiation and concurrent chemotherapy,1996-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1135,NCT00699569,,2008-07,UNKNOWN,INTERVENTIONAL,['NA'],,
1136,NCT03215459,Survival at 6 months (followed up for 12mths),2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time-to-event endpoints
1137,NCT03662204,Biomarker Evaluation,2018-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
1138,NCT00725712,Number of Participants Who Required Concomitant Medications,2007-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Overall Survival (OS)of GSK1363089
1139,NCT00436501,Median Progression-Free Survival (PFS) (Phase II),2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With PFS (Phase II)
1140,NCT00844454,Local treatment responses,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survivals and overall survivals
1141,NCT04246684,organ preservation,2020-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Translational / biomarker studies
1142,NCT02056041,Safety of surgery for HCC,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,Score systems HCC
1143,NCT01943253,Procedure time,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,complication rate
1144,NCT05213195,Maximal Tolerable Dose#MTD#,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Overall survival (OS)
1145,NCT00346281,Safety profile of the patients defined by the Adverse Events profile.,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Will assess ease of use, tumour response, duration of response, progression free survival and overall survival. Target tumour response summaries for the study will be performed."
1146,NCT06291779,Urine,2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],,
1147,NCT00365508,24-hour Point Prevalence Abstinence at the 6-month Follow up,2006-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,Rate of Compliance During the First 2 Weeks
1148,NCT04878692,Measurement of the percentage of Onco-Rash failure by counting the number of patients with a rash grade ≥ 2 (NCI-CTCAE scale).,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Percentage of patients for whom treatment for acne (anti-inflammatory or antibiotic) has been introduced
1149,NCT04683965,Objective response rate(ORR),2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1150,NCT05183958,Progression-free survival (PFS),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Duration of Response (DoR),Adverse Events (AEs)
1151,NCT01500993,Overall survival,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Local recurrence rate
1152,NCT04452266,Correlation between endometrial cancer and predictif factors,2020-08-14,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between endometrial cancer and predictif factors in post menopausal woman
1153,NCT01234324,Frequency of pT3/T4 categories after surgery,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequencies of pN2/N3 categories after surgery
1154,NCT01767857,Overall Survival (OS),2013-03-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Disease Control
1155,NCT02017704,Number of Patients With Pathologic Complete Response,2014-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Local Disease Recurrence
1156,NCT01944930,Rate of Detectable Peritoneal Metastases,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1157,NCT01928290,Number of Participants With an Objective Response,2013-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events
1158,NCT00445549,Number of Participants With Clinical Efficacy,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Number of Participants With Adverse Events
1159,NCT02387138,Dose limiting toxicities,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1160,NCT02102789,Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms,2014-03,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Number of participants with surgical complications, AES and SAEs as a measure of safety"
1161,NCT05671809,ARP,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,MASCP and Wexner
1162,NCT00912743,Tumour Response,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1163,NCT05502276,R0 resection rate,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
1164,NCT05903885,Fecal Immunochemical Test (FIT) kite return rate,2023-10-02,RECRUITING,INTERVENTIONAL,['NA'],,Fecal Immunochemical Test (FIT) kit positive rate
1165,NCT03601234,operation time,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses
1166,NCT06045715,disease-free survival,2022-08-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,distant metastasis-free survival
1167,NCT06307938,Inflammatory bowel disease,2025-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment response
1168,NCT04888546,Overall response rate (ORR),2021-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The incidence and severity of SAE
1169,NCT00839332,Phase 2: Overall Survival (OS),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Deaths During the Phase 1 Post-study Period,Phase 2: Electrocardiogram QTc Prolongation
1170,NCT01044420,adverse events,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
1171,NCT01208194,Evaluation of median progression-free survival (PFS) in both treatment groups,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of the safety profile of MGN1703
1172,NCT05440357,Progression-free survival rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],To explore the association of cilinical outcomes with treatment pattern,Safety-TEAEs
1173,NCT06225609,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The number of patients with complications after total mesorectal excision for rectal cancer,Total hospitalization costs
1174,NCT04883450,Incidence of pancreatic ductal adenocarcinoma (PDAC) in the high predicted risk group,2021-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1175,NCT05202600,NNT of IA for the appendiceal neoplasm,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Definition of the elderly group for the complicated appendicitis or death,NNT of IA for the death due to appendicits in elderly
1176,NCT01662739,"Collection of life-style, familiar, clinical, histological and biomolecular data",2010-01,UNKNOWN,OBSERVATIONAL,['NA'],"Analysis of epidemiology, risk factors, family history and unidentified susceptibility genes and proteins",Collection of biological samples (blood and cancer tissue samples)
1177,NCT01063517,Progression Free Survival (PFS) in Patients With Tumours Defined as Homologous Recombination Deficient by Loss of Ataxia-Telangiectasia Mutation (ATM) Protein [ATM Negative Patients],2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Deterioration in QoL Anxiety Domain Score in the Overall Study Population
1178,NCT04524871,Objective Response Rate (ORR),2020-11-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Adverse Events During Stage 2
1179,NCT03443492,progression free survival (PFS),2018-03-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1180,NCT00734513,Patient's psychological adjustment,2003-01,COMPLETED,INTERVENTIONAL,['NA'],,Gender and marital satisfaction as moderators of the effects of partner-assisted ED.
1181,NCT03972527,IThe primary effectiveness endpoint is the severity of oral mucositis at week 6 of radiation treatment according to the Oral Mucositis Index (OMI) score.,2022-08-05,RECRUITING,INTERVENTIONAL,['NA'],,Changes in overall quality of life over the 6-week treatment period
1182,NCT04145297,"Recommended phase 2 dose of ulixertinib in combination with a fixed dose of hydroxychloroquine in subjects with advanced, RAS, non-V600 BRAF, ERK or MEK mutated gastrointestinal malignancies",2020-03-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy of ulixertinib and hydroxychloroquine in the study population: Objective response rate (PR and CR)
1183,NCT04714957,"genetic and epigenetic data available for 20 ""multiplets"" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )",2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1184,NCT04963283,Disease Control Rate (DCR),2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Exploratory Biomarker analysis - Tumor tissue
1185,NCT02368886,Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3,2015-03-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacokinetics (PK) Parameters of Regorafenib Using Liquid Chromatography Mass Spectrometry,Changes in QOL (According to the Linear Analogue Self-Assessment [LASA] Questionnaire)
1186,NCT03046862,Response rate,2017-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability as measured by number and grade of toxicity events
1187,NCT03855800,High grade dysplasia (HGD) or cancer diagnosis in Immediate Surgery group,2018-05-11,RECRUITING,INTERVENTIONAL,['NA'],,High grade dysplasia (HGD) or cancer diagnosis in clinical follow up group
1188,NCT02860546,Immune-Related Overall Response Rate (irORR),2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1189,NCT01402180,Local control,2010-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
1190,NCT03225937,Objective Response Rate according to RECIST 1.1 criteria,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
1191,NCT01035229,Overall Survival (OS),2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics Assessments - Cmax
1192,NCT03665506,Overall survival,2018-06-25,COMPLETED,OBSERVATIONAL,['NA'],Assessment of health economic parameters,Patient-reported outcomes (PROs) on quality of life (QoL)
1193,NCT00041249,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1194,NCT02763748,Tumor recurrence rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,"the all number of postoperative complications（ frequency,reflux esophagitis and bile reflux gastritis）"
1195,NCT00529113,Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.,2007-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F])."
1196,NCT05807646,The changes of the level of circulating tumor cells in the peripheral blood,2025-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course
1197,NCT05184400,Overall survival (OS),2015-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of adverse events
1198,NCT03631537,nutritional status,2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events
1199,NCT00604409,"To determine the safety, toxicity, and recommended phase II dose (RPTD) of capecitabine when administered concurrently with SIR-Spheres in patients with advanced cancer.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy
1200,NCT03586973,24-Week Progression-Free Survival Rate (PFSR),2018-08-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1201,NCT03531320,"Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug",2018-08-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: PK- AUC
1202,NCT00467142,Percentage of Participants in Objective Response (Partial or Complete Responses),2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Response
1203,NCT02851004,ORR,2016-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",safety according to immune status,Pharmacokinetic
1204,NCT03199274,Tumor perfusion measured by contrast-enhanced ultrasound between ultrasound-triggered microbubble destruction pulses,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
1205,NCT02626728,morbidity,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,short-term oncological result
1206,NCT01634126,FIT Kit adherence,2012-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
1207,NCT03628248,Colonic perfusion in the marginal artery after inferior mesenteric artery ligation between groups,2020-03-10,COMPLETED,INTERVENTIONAL,['NA'],,Presence of post-surgery complications
1208,NCT00190541,Relapse-free survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of sexual and urinary dysfunction
1209,NCT01793805,To characterize common genetic/molecular profiles associated with colorectal cancer (CRC),2013-02,COMPLETED,OBSERVATIONAL,['NA'],,To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance
1210,NCT02575313,Measurement of Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Treatment Break Measurement
1211,NCT01457846,Median Progression Free Survival,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients Without Progressive Disease at 8 Weeks
1212,NCT01048463,Serum level of proalbumin,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Records of food intake
1213,NCT05573776,Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups,2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
1214,NCT01773785,Progression free survival,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety of SPI-1620 when administered in combination with docetaxel
1215,NCT04834986,Feasibility as measured by rate of enrollment,2021-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Tislelizumab and Lenvatinib.,adverse reactions
1216,NCT01270893,Percent of Apoptotic Tumor Cells Pre- and 7 Days Post Nilotinib Treatment,2011-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1217,NCT00482365,Etiologic factors associated with hepatocellular carcinoma in different ethnic groups across the US,2002-04,COMPLETED,OBSERVATIONAL,['NA'],,Serum repository for registry patients
1218,NCT03039062,Relationship of serum miR-122 level and DILI or hepatic failure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Normal physiological range of miR-122 in healthy population
1219,NCT01357486,Time to radiologic progression,2011-11-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
1220,NCT01459965,Documented change in Quality Of Life,1993-07,COMPLETED,INTERVENTIONAL,['NA'],,Documented change in symptoms and concerns specific for patients with MBDO
1221,NCT03768375,Progression Free Survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1222,NCT00099294,Overall Survival,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Performance Status
1223,NCT04889820,3-year overall survival,2021-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,circulating tumor DNA
1224,NCT03672305,The efficacy of c-Met/PD-L1 CAR-T cells in the treatment of HCC,2018-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,The amplification and persistence of c-Met/PD-L1 CAR-T cell in the subjects varied with time
1225,NCT04389502,Correct Answers (60% group),2020-05-15,UNKNOWN,INTERVENTIONAL,['NA'],,Correct Answers (80% group)
1226,NCT04525326,Conversion liver resection rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
1227,NCT02182687,Freedom From Progression Over Time,2014-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life - Questionnaires Include PIQ-6 and SF-36v2 Health Survey
1228,NCT00857545,Progression-free Survival (PFS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1229,NCT00027833,,2001-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1230,NCT00536523,Alterations in serotonin levels associated with increased constipation,2007-04,TERMINATED,OBSERVATIONAL,['NA'],,
1231,NCT01713244,Recurrence-free Survival,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],Number of participants with adverse events,Overall Survival
1232,NCT03766945,Fatigue,2017-07-27,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of Life
1233,NCT02272504,Biomarker assays exceeding threshold,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,Surveillance until HCC development and detection
1234,NCT04321577,Gallbladder cancer risk score,2020-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Disease-free survival
1235,NCT04023448,anterior resection syndrome incidence,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term postoperative complication incidence
1236,NCT03791905,clinical complete response,2019-01-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Chemoradiotherapy-related toxicity
1237,NCT02614703,Total Number of Subjects With Neoplasia When Using Acetic Acid Chromoendoscopy Versus Standardized Random Biopsies.,2017-03-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1238,NCT05461664,Duration Of Response,2022-07-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,serious adverse events
1239,NCT00994526,"Urinary biomarker (DHN-MA:dihydroxynonene mercapturic acid), will be measured before and after every interventional period",2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Fecal biomarkers
1240,NCT05323890,Pathologic complete response rate,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related Adverse Events
1241,NCT02248038,5 years overall survival rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1242,NCT00220181,,2003-04,COMPLETED,OBSERVATIONAL,['NA'],,
1243,NCT00515866,To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To identify the dose-limiting toxicity of the combination therapy
1244,NCT02496273,ELISPOT assays,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,overall survival (OS)
1245,NCT05520801,Objective response rates (ORR),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
1246,NCT04354064,Freedom from progression,2019-05-29,RECRUITING,OBSERVATIONAL,['NA'],,Distant-metastasis-free survival
1247,NCT00903396,Complete Response (no Episodes of Nausea or Vomiting),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Average Level of Nausea Reported and the Proportion of Patients Experiencing a Complete Response Independent of Treatment Arm
1248,NCT01204177,Disease Control Rate (DCR),2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers
1249,NCT00049335,Feasibility of enrolling patients aged 70 years or older to a Phase II trial including pharmacokinetic sampling,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Explore, at a preliminary level, the feasibility of studying genetic polymorphisms and gene expression levels of enzymes involved in drug metabolism and resistance to capecitabine"
1250,NCT02251782,Comparison of Adherence to Screening for Each Group,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Diagnostic yield of colonoscopy:
1251,NCT00555295,,2007-12,UNKNOWN,OBSERVATIONAL,['NA'],,
1252,NCT03902678,Percentage of patients with portal vein thrombosis who underwent EUS guided FNA and had complications as a result of the invasive maneuver,2017-05-11,UNKNOWN,INTERVENTIONAL,['NA'],,
1253,NCT04561336,overall survival,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1254,NCT04145193,ctDNA clearance,2020-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of subjects with detectable anti-drug antibody (ADA) to novel agents in combination with mFOLFOX6
1255,NCT01166490,Incidence of adverse events and laboratory abnormalities,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of antitherapeutic antibodies in blood
1256,NCT05766605,The one-year DFS rate,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
1257,NCT02487225,Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1258,NCT02015923,Assess the impact of overall survival in patients with unresectable metastatic colorectal cancer treated with chemotherapy alone vs surgery followed by chemotherapy.,2013-12,TERMINATED,INTERVENTIONAL,['PHASE4'],,Study of possible survival factors
1259,NCT03607656,3-year Disease Free Survival rate,2018-06-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QLQ-C30 scale
1260,NCT02271646,pain score at recovery room both at rest and movement (cough),2014-08,COMPLETED,INTERVENTIONAL,['NA'],,"Distribution of local anesthetic drugs after performing ultrasound guided TPVB at T5-6, T7-8 and T9-10."
1261,NCT02111941,"Incidence of dose-limiting toxicities (DLT), graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2014-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Induction of antibodies specific for FRalpha,Time to disease recurrence (TDR)
1262,NCT01867892,"the response rate, disease control rate, overall survival, and patients' quality of life.",2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1263,NCT03570684,ratio of patients with 2 or more reloads,2018-01-05,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
1264,NCT04510285,Rate of ctDNA Clearance at 6 Months,2020-08-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1265,NCT05103501,Disease-free Survival (DFS),2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate
1266,NCT03569137,difference in microbiome biomarkers between patients developing colitis after exposure to targeted therapy and those not developing colitis,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Creation of a predictive score of the occurrence of diarrhea in patients treated with Ibrutinib for malignant hemopathy B, including the biomarkers of the intestinal microbiome and the clinical characteristics of the patient"
1267,NCT04511559,Analysis ctDNA methylation status and its Correlation to early diagnosis and prognostic evaluation of gastric cancer.,2020-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1268,NCT01178944,Overall Response Rate,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],MicroRNA Expression - miR-215-5p,Time to Progression (TTP)
1269,NCT03816774,Adequate bowel preparation rate,2019-06-15,COMPLETED,INTERVENTIONAL,['NA'],Patients characteristics questionnaire,Tolerability to the bowel cleansing regimen:questionnaire
1270,NCT04956107,Development of ´fear of cancer recurrence' after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors associated with developing psychological distress
1271,NCT00003296,,1998-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1272,NCT00522405,Survival rate- calculated from the start of TACE,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C"
1273,NCT03037034,Complete resection rate,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor status after endoscopic resection
1274,NCT03735589,Persistence of nCTLs after their adoptive transfer,2023-12-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival assessed by irRECIST,T cell populations and higher anti-tumor responses
1275,NCT04044430,Incidence of treatment-related grade 3 or higher adverse events (AEs),2020-08-31,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease control rate (DCR)
1276,NCT02569723,Feasibility of 14C Oxaliplatin Microdose as a Clinical Assay to Predict Oxaliplatin Exposure,2015-10-16,COMPLETED,INTERVENTIONAL,['NA'],,Response Rate Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
1277,NCT06084013,Perfusion status,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Best practice usage of ICG for pancreatic surgery
1278,NCT00002523,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1279,NCT01845805,Progression-free Survival,2014-01-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1280,NCT00026104,Overall survival,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
1281,NCT04745130,Overall Survival (OS),2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
1282,NCT03906565,Tumor response to utidelone treatment,2019-04-12,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Safety profile associated with utidelone injection
1283,NCT03796702,Postoperative morbidity,2011-11-01,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life of patients after ileostomy closure
1284,NCT02327065,Diagnostic Yield on malignancy,2014-12,UNKNOWN,INTERVENTIONAL,['NA'],,Blood contamination and cellularity in specimens obtained by EUS-FNA and EUS-FNB with Slow-pull or suction
1285,NCT00332696,Number of Participants With Treatment Success From Day 10 to Day 13,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Participant's Quality of Life Using the Edmonton Scale
1286,NCT04110977,Rate of radiation dermatitis grade ≥2,2020-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,Rate of radiation-induced oral mucositis grade ≥3
1287,NCT04701853,Parastomal hernia verified by computer tomography,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Back pain
1288,NCT04541173,Progression free survival (PFS) by RECIST 1.1,2020-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Subject function
1289,NCT04275557,Radiogenomic Analyses,2020-02-18,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
1290,NCT03079596,Afebrile status without major complications,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to first bowel motion
1291,NCT06031584,Phase II: Objective response rate (ORR),2024-01-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib/II: Anti-drug antibody (ADA)
1292,NCT05973227,"image quality (sharpness, brightness, etc) and surgeon's feedback regarding the ergonomics and safety of Trident System v1.0 during surgery.",2023-07-06,RECRUITING,INTERVENTIONAL,['NA'],,- level of oxygenation (StO2) of the exteriorized colon before resection with the Trident System v1.0 - the level of oxygenation (StO2) provided by the system at the site chosen by the surgeon based on the clinical evaluation.
1293,NCT03572582,Objective Response Rate (ORR),2018-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V4.03 (Safety and Tolerability)
1294,NCT05007145,Pathologic complete response (pCR) rate,2021-08-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS)
1295,NCT01167725,Overall survival (OS),2010-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of OS and PFS according to patients' peritoneal surface tumor genotype for the NAD(P)H
1296,NCT03803436,Overall Survival,2019-01-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Complications rate
1297,NCT03812874,Safety as measured by number of participants with a dose limiting toxicity (DLT),2020-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate change in AFP levels.
1298,NCT02319200,rate of HCC occurrence and liver related-death or transplantation.,2015-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,"occurrence of liver-related complications (Ascites , gastrointestinal bleeding, encephalopathy)"
1299,NCT01345773,The incidence of symptomatic or asymptomatic VTE,2010-05,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors for the development of VTE
1300,NCT04530981,AUC from time 0 and extrapolated to infinity (AUC0-∞),2021-09-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Adverse Events
1301,NCT03264404,Progression-Free Survival (PFS),2017-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
1302,NCT05997524,Loco-regional and Distant Tumor Control After Completion of Treatment,2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1303,NCT00004257,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1304,NCT06215677,the rate of R0 resection,2024-02-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Safety and tolerability of Camrelizumab administered
1305,NCT02495532,Lymph nodes harvested,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Adjuvant therapy
1306,NCT04424043,"Progression-free survival, PFS",2020-07-08,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
1307,NCT01915472,Safety,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Assess PK
1308,NCT02098291,Pharmacodynamic,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Serious and Non-Serious Adverse Events
1309,NCT06277453,3-year overall survival,2023-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1310,NCT00401570,"The proportion of patients, in each dose cohort, with a confirmed tumor response",2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the immunogenicity of M200
1311,NCT06010901,Objective response rate (ORR),2024-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Neutralizing antibodies (NaB)
1312,NCT03401957,Percentage of detected circulating DNA RAS mutations during 1st line cetuximab exposure.,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival from the start of 1st line treatment with cetuximab.
1313,NCT05835960,Establish the feasibility of immune analysis and NGS in informing patient treatment decisions.,2019-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
1314,NCT06169202,Progression-free Survival (PFS),2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Disease Control Rate (DCR)
1315,NCT03211416,Overall response rate defined as partial or complete response per immune-related Response Evaluation Criteria in Solid Tumors,2017-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in levels of immunosuppressive cells,Time to tumor progression
1316,NCT02921256,Neoadjuvant Rectal Cancer (NAR) Score,2017-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Relationship Between Radiographic Findings and Pathologic Outcomes,Rate of Sphincter Preservation
1317,NCT03117920,Disease Control rate (DCR),2017-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of response to Minnelide,Pharmacodynamic effect of Minnelide on tumour using PET Scans
1318,NCT00462852,Incidence of venous thromboembolism reduction,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of drug combination on serological markers of thromboangiogenesis
1319,NCT01549418,Clinically significant bleeding after colorectal polypectomy,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Proportion of clinically significant delayed bleeding in both groups
1320,NCT05913570,Pathological complete response (pCR) rates,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with any treatment-related delays in the planned surgery of no more than 28 days after the last preoperative Cadonilimab dose
1321,NCT01256203,Skin erythema responses of control (unprotected) and Solar Protection Formula® SPF 60-protected sites to light exposure,2013-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Proportion of subjects with adverse events as a measure of safety
1322,NCT00080873,Area under the curve (AUC) of the modified Walsh mucositis scale,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,Two sample t test and the Wilcoxon sum test.
1323,NCT00731445,Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Determine the PFS
1324,NCT06332274,Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost effectiveness analysis: ICER
1325,NCT00020930,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1326,NCT04512729,Colonic Adenoma,2020-08-04,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for Colonic adenoma
1327,NCT00465842,Number of participants with presence of serum protein markers,2006-06-20,TERMINATED,OBSERVATIONAL,['NA'],,Number of participants with presence of serum protein markers with resectable and unrsectable HCC.
1328,NCT05734430,Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parents,2022-11-11,RECRUITING,OBSERVATIONAL,['NA'],,"Association of germline genetic variants with clinical, pathologic and molecular features of appendix tumors"
1329,NCT00311610,Objective response rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1330,NCT03635619,MRI TN staging in Esophageal Cancer,2018-09-02,UNKNOWN,OBSERVATIONAL,['NA'],,MRI prediction of prognosis in esophageal cancer
1331,NCT00431756,early predictors of esophageal cancer,2002-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1332,NCT06128798,Physiology Return of Bowel Function,2023-09-26,RECRUITING,INTERVENTIONAL,['NA'],,Length of Hospital Stay
1333,NCT03469479,Overall survival,2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
1334,NCT00189345,Selection of better dose level based on the confirmed tumor response.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effects of removab(TM)
1335,NCT00951496,Median Progression-free Survival,2009-08-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient Reported Nausea
1336,NCT03958669,To prospectively evaluate molecular fingerprint analysis of HCC tumor tissue to predict therapy responses,2019-11-01,TERMINATED,OBSERVATIONAL,['NA'],,Changes of ultrasound elastography under treatment with Sorafenib
1337,NCT01646593,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1338,NCT01675908,Complications related to stent dysfunction,2012-08-22,COMPLETED,INTERVENTIONAL,['NA'],,Procedural complications
1339,NCT01121562,Clinical Benefit Response Rate (CBR),2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Dose-corrected Trough Plasma Concentrations of Sunitinib, SU012662 and Total Drug (Sunitinib + SU012662)."
1340,NCT00003524,,1996-10-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1341,NCT01751516,"Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
1342,NCT04390399,Progression Free Survival (PFS),2020-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
1343,NCT02315625,Median Amount of Time Subject Survives Without Disease Progression After Treatment,2015-04-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-Serious Adverse Events
1344,NCT00938470,Percentage of Participants With Pathologic Complete Response (PCR),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Clinical Tumor Response (CR or PR)
1345,NCT00058487,Toxic effects,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1346,NCT02595957,Health impacts of SF receipt,2014-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
1347,NCT00455091,Primary endpoint: Primary endpoint: the 3-years recurrence rate (excluding those recur within first year).,2007-05,TERMINATED,OBSERVATIONAL,['NA'],,"Secondary endpoints: the first 2 year tumor recurrence rates,the recurrence-free survival,the overall survival.anti-viral efficacy."
1348,NCT05756725,Number of open orders for mammography screening,2023-07-25,COMPLETED,INTERVENTIONAL,['NA'],,Appropriateness of Implementation Strategies
1349,NCT03642652,Follow-up colonoscopy 120 days after a positive fecal occult blood test,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
1350,NCT06010303,Overall Response Rate (ORR),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events (AEs)
1351,NCT05838768,Frequency of dose reductions as a measure of tolerability,2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with anti tislelizumab antibodies
1352,NCT05927844,severity of TEAE and SAE,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1353,NCT05709886,Effectiveness analysis,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Alpha-fetoprotein levels
1354,NCT01888978,Timing of biopsy and treatment,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
1355,NCT01759706,Adherence to the pathway,2010-10,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative outcome
1356,NCT01037049,"The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI].",2009-10-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiotherapy related toxicity rates.
1357,NCT02710838,the lesion of early gastric cancer by infrared endoscopy,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,the invasive depth of early gastric cancer by infrared endoscopy
1358,NCT00836407,Percent of Patients Experiencing an Unacceptable Toxicity,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
1359,NCT06254300,Aerobic capacity,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
1360,NCT05645679,Efficacy of the Hybrid Argon Plasma Coagulation Technique,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
1361,NCT02427269,Collaboration with other investigators,2015-04-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
1362,NCT04693377,Pain response,2021-03-16,RECRUITING,INTERVENTIONAL,['NA'],,Technical success for cryoablation
1363,NCT01546519,The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours]) Following Multiple Doses of Vismodegib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent Non-renal Clearance (CLNR/F) of Vismodegib
1364,NCT02794805,13CO2/12CO2 ratio,2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1365,NCT00784290,Step 2(Phase II) Response rate(RR),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Step 2(Phase II) Safety
1366,NCT04057274,Cell viability (%),2019-09-23,UNKNOWN,INTERVENTIONAL,['NA'],,Concentration of Insulin-like growth factor 1 (ng/ml)
1367,NCT02762474,Progress free survival,2014-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CTCAE 4.0 toxicity
1368,NCT05871892,Metabolic function of the liver evaluated by the PET tracer 18F-FDGal,2023-09-11,RECRUITING,INTERVENTIONAL,['NA'],,
1369,NCT04961125,germline variant detection rate in the polyposis population,2021-08-02,RECRUITING,OBSERVATIONAL,['NA'],,
1370,NCT01126112,Progression-free survival rate at 6 months,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers for response.
1371,NCT05595811,overall survival,1999-01-01,COMPLETED,OBSERVATIONAL,['NA'],,adjuvant oncologic treatment
1372,NCT05203120,Number of participants with Radiation-induced liver disease (RILD),2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Reduction in mean liver dose
1373,NCT02873520,Quality of life,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1374,NCT05321134,Assess safety & quality event rate for SP platform transabdominal and transanal colorectal operations,2022-04-28,RECRUITING,INTERVENTIONAL,['NA'],,
1375,NCT05570942,Changes of irritable bowel symptoms,2021-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The presence of bacteremia
1376,NCT04541381,Grade 3 or Higher Toxicity (Co-Primary Endpoint),2022-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
1377,NCT03110939,local recurrent rate,2017-03-21,WITHDRAWN,INTERVENTIONAL,['NA'],,mortality rate after treatment
1378,NCT01861912,Time to Progression,2013-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Recurrence Rate,Safety
1379,NCT04049357,CCE detection rate of polyps compared to OC,2020-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
1380,NCT01439724,Incidence and / or Severity of Oral Mucositis,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Oral Mucositis Survival Free, Pain, Opioid Treatment, Hospitalization, Treatment Interruption, Treatment Delay, Patient Weight Loss, Nasogastric Tube or of a Gastrostomy."
1381,NCT05302011,pathological response,2020-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1382,NCT02876224,Percentage of Participants with Adverse Events,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants with Anti-therapeutic Antibodies (ATAs) Response to Atezolizumab
1383,NCT04563338,Progression-free survival,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival rate
1384,NCT05444478,Over-all survival (OS) rate at 36 months,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
1385,NCT01237990,The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data.,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy.
1386,NCT01191385,"Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)",2010-11,WITHDRAWN,OBSERVATIONAL,['NA'],,To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases)
1387,NCT05733598,Overall Response Rate per modified RECIST 1.1,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
1388,NCT02168426,ileus rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse effect rate
1389,NCT05300945,OS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
1390,NCT01526486,Nodal yield,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Oncologic outcomes--survival
1391,NCT01298011,Grade III/IV histological response in tumor specimen rate after induction therapy.,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1392,NCT04843943,Events Free Survival (EFS) Assessed by RECIST1.1,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
1393,NCT03209336,The basic information and medical history achieved (questionnaire),2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,The short-term complications
1394,NCT01100372,Remission rates (complete response and partial response),2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
1395,NCT02709213,Determination of the aetiologies of colitis using microbiological examination of the stools +/- colonoscopy,2016-11,COMPLETED,OBSERVATIONAL,['NA'],,"Identification of anamnestic, clinical and biological predicting factors for patients requiring diagnostic colonoscopy"
1396,NCT00294203,"Post-operative hemoglobin, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte fraction measured on post-operative days 1, 4, 8, and between days 20 and 30",2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Post-operative quality of life related to anemia measured by Functional Assessment of Cancer Therapy - Anemia (FACT-An) between post-operative day 20 and 30 and post-operative transfusion requirement
1397,NCT01417611,polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis),2010-09,COMPLETED,INTERVENTIONAL,['NA'],,characterization of polyp
1398,NCT02102893,"To establish the database for GEP-NET by register the clinical presentation, diagnosis, stages, treatment and clinical outcome of GEP-NET patients.",2014-02-13,COMPLETED,OBSERVATIONAL,['NA'],,
1399,NCT01346280,,2011-04-16,COMPLETED,OBSERVATIONAL,['NA'],,
1400,NCT01129310,Overall Response Rate and dose limiting toxicity,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression Free Survival, overall survival, death, alterations in quality of life outcomes"
1401,NCT00673504,Time to Progression,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
1402,NCT01589419,Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD),2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib
1403,NCT00870961,Rate of accrual,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,"Correlation of vitamin D levels with vitamin D modifiers (e.g., levels of skin pigmentation, dietary vitamin D intake, and sun exposure)"
1404,NCT02386618,Efficacy of endoscopic treatment od local residual neoplasia (absence of neoplastic tissue in post-EMR scar proven by endoscopic and histologic examination),2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
1405,NCT02454686,Accuracy of Fibroscan in predicting complication after hepatectomy,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,
1406,NCT00572143,Quality of life; EORTC-QLQ-C30 and EQ 5D,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness Serious clinical events
1407,NCT00897754,VEGF165b protein expression as measured by ELISA,2007-07-24,COMPLETED,OBSERVATIONAL,['NA'],,
1408,NCT02759588,Overall Response Rate (ORR) by RECIST 1.1 (Phase 2),2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Benefit Rate
1409,NCT02551471,Clinical resection rates in both countries,2015-05-01,COMPLETED,OBSERVATIONAL,['NA'],,Analyses of semi-structured interviews
1410,NCT00861783,maximum tolerated dose,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor measurement
1411,NCT03515538,Duration of Severe Oral Mucositis (SOM),2018-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient-reported pain
1412,NCT05587725,Prevalence of type-specific HPV types,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
1413,NCT02175654,Progression free survival rate at 6 months,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,Changes in ECOG performance status over time from baseline
1414,NCT04571489,Progression free survival (PFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Patient-reported outcome (PRO)
1415,NCT04220242,Validation of predictive accuracy biophysics-visualisation model,2019-12-30,UNKNOWN,OBSERVATIONAL,['NA'],,Realtime delineation display of tumour area including margins
1416,NCT03612531,Incidence of adverse events,2018-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Improvement in tongue innervation on Electromyography (EMG) findings
1417,NCT04032392,Overall survival (OS),2019-07-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Patients-based Quality of Life Evaluation
1418,NCT05166239,6-month progression-free survival rate,2022-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients with treatment-related adverse events
1419,NCT01976494,"Efficacy: Analgesic effect, Accuracy of bolus 2 mL administration",2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Safety: Frequency of complications occurring after bolus
1420,NCT00068003,"Bank of autologous blood, stem cells, and/or tumor tissue from patients currently with cancer",2003-09-08,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Long-term storage of data and biospecimens
1421,NCT02489838,Lung dose measured with actual lung mass vs Lung dose measured with conventional method.,2012-02-03,COMPLETED,OBSERVATIONAL,['NA'],,
1422,NCT01589471,Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of intra-rectal Botox-A injections as documented with adverse events monitoring
1423,NCT01236443,Toxicity of HPPH at different doses,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine optimal PDT parameters using HPPH in HGD, CIS and Barrett's esophagus"
1424,NCT01118897,To assess the feasibility of concurrent chemo-radiation with dose escalated IMRT in locally advanced inoperable gallbladder and pancreatic cancers,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
1425,NCT01446874,Adherence to the Pre-operative Toothbrushing Regimen,2011-09-22,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of Fever
1426,NCT05767697,Number of subjects who still survive at 1 year,2020-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
1427,NCT06324825,Recovery rate of Low-grade Intraepithelial Neoplasia,2022-10-24,RECRUITING,INTERVENTIONAL,['NA'],,Adverse event rate
1428,NCT02641691,Complete Response Rate,2016-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Anorectal Function as Measured by the FACT-C Questionnaire
1429,NCT05763277,progression free survival,2022-07-22,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
1430,NCT05733000,Overall response rate (ORR),2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1431,NCT01283204,progression free survival(PFS),2010-03-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1432,NCT02145416,Changes on DW MRI during CRT in anal cancer.,2015-01-27,COMPLETED,OBSERVATIONAL,['NA'],To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.,Correlation of the change in functional images over CRT with outcome of CRT
1433,NCT01103479,Colorectal Cancer (CRC) Screening Completion,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Provider Recommendation of CRC Screening
1434,NCT06287749,3-year Disease-free survival (DFS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
1435,NCT03838913,Determination of involved signal pathways,2019-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
1436,NCT02545725,Questionnaire on Quality of Life,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
1437,NCT04029857,Patient well-being improvement,2019-03-14,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
1438,NCT05032014,(objective remission rate)ORR,2021-11-19,UNKNOWN,INTERVENTIONAL,['NA'],,OS
1439,NCT01191411,"Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem.",2010-10,COMPLETED,INTERVENTIONAL,['NA'],,
1440,NCT02316340,Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib,2015-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (mOS)
1441,NCT01483027,Hepatic Progression-Free Survival (HPFS),2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
1442,NCT05985954,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
1443,NCT00575562,The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The secondary objectives are to determine the degree of immunogenicity, gain information on the pharmacokinetic profile, assess the anti-tumor effects of KRN330 and determine the maximum tolerated dose (MTD)."
1444,NCT02661945,Accuracy (accurate if the distance (between margin dots and tumor margin measured by histopathology) was less than 1 mm),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
1445,NCT01477177,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification",2011-08,TERMINATED,INTERVENTIONAL,['NA'],,"Reduction in Barrett's Histology Grade, Using the Modified Vienna Classification"
1446,NCT03291899,Response rate,2017-01-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
1447,NCT00551759,Proportion of Patients With Pathologic Complete Response,2008-10-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1448,NCT00006387,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1449,NCT05327582,Object response rate (ORR),2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
1450,NCT00817934,"TOTAL COLON CLEANSING, TO BE ABLE TO PERFORM COLONOSCOPY",2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1451,NCT00089362,"MTD, defined as the dose level where the observed DLT incidence in no more than one out of six patients treated at a particular dose level",2004-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1452,NCT06084780,Overall Rate of Survival,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Rate of Mortality
1453,NCT01012362,Number of Participants Who Experienced a Dose Limiting Toxicity (DLT),2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment-Related Adverse Events
1454,NCT04108481,Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC),2020-10-05,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Abscopal effects,Determine duration of response
1455,NCT04834661,overall postoperative complication rate,2021-10-20,COMPLETED,OBSERVATIONAL,['NA'],,
1456,NCT01649271,Dose Limiting Toxicities During cycle1,2012-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical Benefit
1457,NCT00860665,Correlation of adenoma detection rate with case volume of endoscopists,2006-10,COMPLETED,OBSERVATIONAL,['NA'],,Patient acceptance in relation to procedural factors (e.g. sedation)
1458,NCT02309632,Detection rate of PC and precancerous lesion,2015-11,WITHDRAWN,INTERVENTIONAL,['NA'],,
1459,NCT00699816,Recurrence Free Survival(RFS) Rate,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cancer-specific Survival Rate
1460,NCT03504618,Prognostic factor of progression free survival,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival after 24 months
1461,NCT03799731,Progression Free Survival (PFS) at 6 months,2018-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,AMHRII (Anti-Mullerian Hormone type II receptor) expression
1462,NCT00038701,Patient Survival Rate,1999-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1463,NCT00003029,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1464,NCT05653934,Anxiety assessment,2023-05,RECRUITING,INTERVENTIONAL,['NA'],,Morbidity
1465,NCT02112357,The percentage of patients in whom a currently actionable molecular alteration was detected by genetic sequencing.,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],Duration of response for patients who received a targeted treatment as a result of genetic sequencing.,The number needed to enroll into the trial to identify one patient with a targetable genetic alteration and the number needed to enroll into the trial to treat one patient with a targeted agent.
1466,NCT03271073,Progression-free survival (PFS),2016-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life(QoL)
1467,NCT00660582,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1468,NCT03697564,Progression Free Survival (PFS),2019-10-31,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1469,NCT01418222,"Progression-free survival: time from randomization to tumor progression or death, tumor assessments according to RECIST criteria",2011-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Incidence of adverse events
1470,NCT02381249,Progressive ratio task breakpoint for a sweet-fat reward,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Sigstad score,Subjective symptom score
1471,NCT03092128,Progression free survival,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,Number of patients with objective response and adverse events
1472,NCT01531595,Efficacy,2012-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Response
1473,NCT02379039,Loco regional control,2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Site specific toxicity
1474,NCT00152607,"The primary outcome for recipients will be the assessment of patient and graft survival. Comparison to results of contemporaneous, non-randomized cadaver donor transplants will be made.",2000-04,TERMINATED,INTERVENTIONAL,['PHASE4'],,
1475,NCT01197612,Olfaction,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Sinonasal Health
1476,NCT01250158,To demonstrate the feasibility of the liver PILP intervention.,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
1477,NCT01336881,Biomarkers associated with hepatoblastoma subtypes and cancer stages,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,Exome sequencing
1478,NCT00075452,Overall survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression-free survival
1479,NCT00049608,,2002-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1480,NCT02065765,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1481,NCT05748145,Impact of metronidazole on F.n. loads in CRC tissues.,2023-09-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Potential effects of metronidazole on the intestinal metabolic profile
1482,NCT03426397,2-year non-regrowth disease-free survival,2017-05-10,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life
1483,NCT05204173,1-year survival rate,2021-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year progressive free survival (PFS)
1484,NCT01129167,Frequency of local invasion modalities in surgical population,2009-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
1485,NCT04370925,Peritoneal recurrence free survival,2020-06-04,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
1486,NCT02734823,Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer,2016-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation
1487,NCT03573791,Comparing gene expression differences between poor response group and complete response group by using RNA sequencing.,2018-05-21,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival(PFS)
1488,NCT01737827,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,2013-03-25,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma pharmacokinetic parameter: Racc
1489,NCT00920751,Primary outcome - success of cecal intubation without sedation,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,"Diagnostic yield, patients' current experience, willingness to repeat future colonoscopy, turn around time, and staff rating of satisfaction, and medication-related complications."
1490,NCT04080843,Objective response rate(ORR),2019-11-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: NCI CTC AE Version 4.0.3
1491,NCT00782366,"Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes",2008-03,COMPLETED,OBSERVATIONAL,['NA'],,Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction
1492,NCT01303159,Change From Baseline in Bile Duct Stricture Diameter,2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants With Adverse Events
1493,NCT02292641,To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.,2014-09-25,RECRUITING,INTERVENTIONAL,['NA'],,To map original radiotherapy volumes (including integrated boosts) against types of recurrence
1494,NCT01758341,Number of RFA-procedures with technical failures,2012-12,COMPLETED,INTERVENTIONAL,['PHASE4'],Mortality,Number of patients with interventional complications
1495,NCT03756636,Rate of adverse events (according to the lexiconA ASGE).,2018-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
1496,NCT02574013,Length of hospital stay,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
1497,NCT02365480,Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of Histologic Inflammation
1498,NCT03673501,Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population,2019-02-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population
1499,NCT06323291,Feasibility of Utilizing the Digital Health Coaching Program,2024-03-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
1500,NCT00220116,Objective response rates,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number undergoing liver resections/curative resection (Ro) rate
1501,NCT04088955,Compare the duration of actual vs. intended treatment for cancer patients on capecitabine who are prescribed capecitabine with sensor.,2019-09-06,UNKNOWN,OBSERVATIONAL,['NA'],,
1502,NCT00829413,Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard',2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Inter-reader Agreement
1503,NCT03923309,3-year overall survival,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
1504,NCT04927780,Overall survival,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire
1505,NCT03718624,Conversion to negative rate,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
1506,NCT05765357,Area under drug concentration - time curve (AUC0-t),2017-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent volume of distribution (Vd/F)
1507,NCT04781192,Progressin Free Survival (PFS),2022-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
1508,NCT00202774,Determine time to disease progression,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time"
1509,NCT02571725,Phase 2: Objective response rate (ORR),2016-02-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Progression free survival (PFS)
1510,NCT06114251,Postoperative recurrence of liver cancer,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1511,NCT01694238,Stoma hernia frequency at 12 months,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,30 day mortality
1512,NCT04814043,conversion rate to resection,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1513,NCT02233205,Number of Participants with Serious and Non-Serious Adverse Events,2014-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Disease Progression
1514,NCT04751396,Decisional conflict scale,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,Patient's perception of usefulness of the tool
1515,NCT00634894,Median Progression-free survival (PFS): Time to progression or death from complete response (CR),2008-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
1516,NCT01684098,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1517,NCT04220827,Incidence of adverse events,2019-12-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
1518,NCT06304350,Pathological complete remission (pCR),2024-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse drug reactions)
1519,NCT01084460,,1997-01,COMPLETED,OBSERVATIONAL,['NA'],,
1520,NCT05060770,IBD associated CRC oncogenesis,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1521,NCT01094626,Difference in lesion conspicuity between S-MRI and N-MRI,2010-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Concordance of tumor measurements between S-MRI images and tumor specimens post-resection vs. concordance of tumor measurements between N-MRI and tumor specimens post-resection
1522,NCT02885142,Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.,2016-11,TERMINATED,INTERVENTIONAL,['NA'],,
1523,NCT06082648,Quality of life Scale (EORTC QLQ-CR38),2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Proctoanal manometry
1524,NCT01048320,The primary outcome measure for the study is to establish the Maximum Tolerated Dose of the drug regimen based on the endpoint of dose-limiting toxicity,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Characterise safety profile of Gemcitabine Plus Oxaliplatin in Combination with imatinib mesylate (Glivec) in Patients with Gemcitabine-Refractory Advanced Adenocarcinoma of the Pancreas
1525,NCT01403883,Evolution of Psychological anxiety score (STAI/Beck),2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Specific stoma related morbidity
1526,NCT04811833,Comparison of anastomosis leakage rate at different timepoints in postoperative course,2022-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Assessment of suture material handling parameters
1527,NCT04879979,Symbol Digit Modalities Test (SDMT),2021-01-12,RECRUITING,INTERVENTIONAL,['NA'],,PROMIS Short Form: Pain 3a.
1528,NCT00369460,"Collection of information on weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count",2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
1529,NCT01068132,Progression free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1530,NCT02992886,2-year disease-free survival probability (%),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory endpoints,QOL
1531,NCT04886193,TRG grade,2021-04-16,UNKNOWN,INTERVENTIONAL,['NA'],,the incidence and severity of adverse events
1532,NCT03468712,Postoperative overall morbidity rate,2018-03-31,UNKNOWN,INTERVENTIONAL,['NA'],,Completion rate of laparoscopic surgery
1533,NCT02838186,number of additional identified polyps with right colon scope retroflexion,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Rate of retroflexion-related adverse events.
1534,NCT05725200,"Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Main study: Patient-reported outcome measures.
1535,NCT05450835,Early operative morbidity,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The number of attempts to insert anvil fork into oesophagus
1536,NCT03237507,PFS: Progression Free Survival,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Safety
1537,NCT00967655,2-year survival rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1538,NCT04496765,Local recurrence,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1539,NCT06190639,Disease-free survival (DFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1540,NCT00300521,overall recurrence-free survival rate at three year,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,hazard rate of vascular invasion on survival rate and recurrence-free survival rate
1541,NCT02138981,overall survival time,2014-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
1542,NCT04660929,Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only),2021-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Estimate progression-free survival (PFS).
1543,NCT03937895,Phase 2a - Objective Response Rate (ORR),2019-12-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a - Toxicity (according to CTCAE 5.0)
1544,NCT06331273,Tumor recurrence rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1545,NCT06108596,cCR,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free survival (DFS) and overall survival (OS)
1546,NCT03485209,Confirmed ORR per blinded independent central review (BICR) (Part E),2018-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-therapeutic antibodies (ATAs)
1547,NCT00437424,The primary objective of this study is to determine the effect of BMS-582664 on subjects with varying levels of hepatic impairment and guide prescribers with regards to dosing in specialized populations,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess efficacy of BMS-582664 in subjects with advanced solid tumor malignancies and subjects with HCC by CT or MRI
1548,NCT03599778,Disease-free survival (DFS),2018-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1549,NCT04593134,Quality of Life (EORTC QLQ-STO22),2020-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Circadian rhythms(using Actigraph)
1550,NCT05019534,Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D),2021-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary efficacy
1551,NCT02114164,Intraoperative Pneumoperitoneal Pressure (mmHg),2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Smoke Evacuation Quality
1552,NCT03469596,presence of nodal status,2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
1553,NCT04795661,Rate of complete pathological response (pCR) after surgery,2021-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The prognostic value of lung immune prognostic index (LIPI)
1554,NCT04715633,Clinical complete response or pathological complete response,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1555,NCT04522336,Clinical complete response (cCR),2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor T cell infiltrate,PFS at 24 months
1556,NCT05092113,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of fecal flora and enteritis-associated inflammatory factors,Overall incidence of grade 3/4 gastrointestinal adverse events
1557,NCT00652054,Overall tumor response rate (ORR - the proportion of patients with objective evidence of PR or CR),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate the relationship of S-1 plasma levels (components and metabolites) with safety and efficacy parameters
1558,NCT01284231,Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of MED-565
1559,NCT04405206,OPR(organ preservation rate),2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,SFS(stoma-free survival)
1560,NCT00003001,,1997-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1561,NCT05224596,Sensitivity and specificity of the cfDNA methylation-based model in detecting gastric cancer.,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],Sensitivity and specificity of a blood miRNA-based model in detecting gastric cancer.,"Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting gastric cancer, respectively."
1562,NCT00425360,Survival at 1 year,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival and response as assessed by delayed-type hypersensitivity
1563,NCT03763266,Bowel preparation,2018-12-06,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal time
1564,NCT04539808,Proportion of participants with R0 resection,2021-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Proportion of LAPC participants who die within 30 days of surgery,Incidence of grade >= 3 toxicities
1565,NCT00014651,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,
1566,NCT01694966,To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1567,NCT01127555,Response rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To estimate overall survival
1568,NCT01040559,Dose-limiting toxicity assessed according NCI CTC AE v3.0,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics parameters of idarubicin and idarubicinol
1569,NCT03223662,BH3 Profiling of Pre-neoadjuvant Tumor Biopsy and Outcome of Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Adenocarcinoma or Squamous Cell Carcinoma,2017-10-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) in Esophageal Adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC) Patients Undergoing Neoadjuvant Chemoradiotherapy (nCRT) and Esophagectomy
1570,NCT04182724,ORR(phase II),2019-11-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS(phase I/II)
1571,NCT06322147,R0 resection rate,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Early Tumor Shrinkage
1572,NCT04697394,Continuous retention of patients completing electronic data.,2022-03-15,RECRUITING,OBSERVATIONAL,['NA'],,Symptom cluster identification
1573,NCT06241703,urinary dysfunction,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,International Prostate Symptom Score
1574,NCT04481100,Objective response rate (ORR),2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1575,NCT04215861,Raman spectra,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,objective response rate
1576,NCT04440332,Postoperative pulmonary infection rate and its relationship between peripheral blood of lymphocyte and immunocyte.,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1577,NCT00384176,Progression Free Survival,2006-08-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)
1578,NCT03124498,Phase II: Disease Control Rate,2017-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1579,NCT02219854,3-year disease free survival rate,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative recovery situation
1580,NCT03166436,Survival,2017-06-08,UNKNOWN,INTERVENTIONAL,['NA'],,Augmentation of antitumor immunity
1581,NCT03652428,Maximum Tolerated Dose of Gemcitabine and nab-Paclitaxel in LAPC patients receiving proton therapy,2019-04-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life through and after treatment
1582,NCT01160926,To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,To explore biological and radiological markers of response or toxicity
1583,NCT00259532,,2005-02,UNKNOWN,INTERVENTIONAL,['NA'],,
1584,NCT02891083,Disease free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,side effect of adjuvant therapy
1585,NCT06320080,Progression-free survival (PFS),2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
1586,NCT01214720,Duration of Overall Survival - Time to Event,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Bevacizumab Concentration in the Presence of Gemcitabine and Erlotinib
1587,NCT04863144,plasma concentrations of 3'-p-hydroxypaclitaxel,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse effects
1588,NCT00841191,Percentage of Participants With Clinical Benefit Response (CBR),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percent Change From Baseline in Hepcidin Level
1589,NCT01227746,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1590,NCT00003147,,1998-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1591,NCT02230176,To determine the 12 months PFS,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Best response
1592,NCT02578459,Visual Analog Scale Pain Scores,2016-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Adverse Events
1593,NCT06234007,pathology complete response(pCR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
1594,NCT01452295,Gather data,2010-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
1595,NCT00580359,To evaluate each response rate of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the duration of response, time to progression, progression-free survival,overall survival,the safety profiles,the quality of life,the CYP2A6 genetic polymorphism and its association with clinical outcomes in patients treated with S-1"
1596,NCT00094978,,2004-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1597,NCT01200316,Efficacy of Rocking Chair Motion on Surgical-Induced Stress,2012-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1598,NCT04580667,To determine the cut-off values from the RadTox test results during early radiation treatment from all evaluable subjects to differentiate high toxicity score from average or low toxicity score.,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],,To determine the cut-off values from the RadTox test performed during early radiation treatment with patients categorized according to demographics and treatment options to differentiate high toxicity score from average or low toxicity score.
1599,NCT01995942,The primary endpoint will be time to relapse pertaining to the primary objective of relapse rate at 1 year and 3 years.,2013-06-07,UNKNOWN,OBSERVATIONAL,['NA'],,"Measurement of the change in mrEMVI from pre to post pre-operative therapy, will be based on a new proposed EMVI-TRG classification (EMVI TRG 1-5)."
1600,NCT02490735,progression-free survival(PFS),2015-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Stage at diagnosis,overall survival(OS)
1601,NCT05508737,Objective response rate (ORR),2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with Adverse Events that are related to treatment
1602,NCT00202800,To evaluate the response rate,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To describe the toxicity profile
1603,NCT01198535,MTD of RO4929097,2010-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1604,NCT04476537,Number of participants assigned therapy with OncoTreat,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
1605,NCT05783622,Incidence of Clinically Significant Laboratory Abnormalities,2023-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Correlation of EGFR expression level with anti-tumor activity and safety
1606,NCT05983133,Number of participants with DLTs by dose level,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
1607,NCT04385147,procedure related complications,2020-05-18,COMPLETED,OBSERVATIONAL,['NA'],,Effect of COVID-19 precautions on staff number
1608,NCT00710697,ECG interval change,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Safety/Efficacy
1609,NCT04098471,5-years disease free survival rate,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
1610,NCT04528745,Thrombocytopenia,2020-05-04,COMPLETED,OBSERVATIONAL,['NA'],Other adverse event(s) added by patient,Hospitalization
1611,NCT01526239,Communication with primary care physicians about CRC screening,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
1612,NCT06316908,Pain Score using the Visual Analog Scale,2020-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of Vomiting
1613,NCT05473325,Signal to Noise,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1614,NCT00555672,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
1615,NCT05604378,EBV positive gastric cancer is associated with increased Ki-67 and decreased EGFR.,2022-08-03,COMPLETED,OBSERVATIONAL,['NA'],,
1616,NCT03735407,Number of Incidence of Device and Procedure Related Serious Adverse Events (SAE),2019-02-01,COMPLETED,INTERVENTIONAL,['NA'],,To Evaluate Subject's Satisfaction
1617,NCT03000374,Pathologic complete response (pCR),2017-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1618,NCT00897039,Correlation of a statistically significant discriminator of sensitivity with complete response rate,2006-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1619,NCT02572141,Disease-free survival,2015-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Postoperative complications
1620,NCT01506687,Completion of verified CRC screening event (FOBT;colonoscopy) event in experimental vs. control groups within 48 weeks,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Screening preferences; predictors of CRC screening and screening preference.
1621,NCT01135056,Overall Survival,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease control rate
1622,NCT03076502,Pathological diagnosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor status（worse/ maintain/ better）
1623,NCT02343835,Characterization of the intra-tumoral and systemic immune response to IRE in unresectable pancreatic cancers,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival and (local and distant) progression-free survival.,Comparison immune response between non-ablated and ablated pancreatic cancer and pre-ablated and post ablated serum
1624,NCT03405909,Diagnostic value of standardised CEUS-based algorithms for the non-invasive diagnosis of HCC in high-risk patients,2018-04-21,COMPLETED,OBSERVATIONAL,['NA'],,Influence of histological grading on contrast enhancement behaviour
1625,NCT02637596,Quality of life after RFA of pancreatic cancer,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Overall Survival,3- months perioperative morbidity and mortality
1626,NCT01080521,Cognitive function as measured by the HeadMinder Customized Research Tool (CRT),2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Patient-reported cognitive function as measured by Patient Assessment Own Functioning scale and web CRT
1627,NCT00601406,"Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity",2006-03,UNKNOWN,INTERVENTIONAL,['NA'],,"PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability"
1628,NCT03165344,Esophageal stenosis rate,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Side effect of drugs
1629,NCT01811277,Objective response rate for SOX sequential S-1,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
1630,NCT05191940,Locoregional tumor control,2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],,"Incidence of CTCAE v5.0 Grade 2 - Grade 5 acute, subacute and late toxicities"
1631,NCT00785122,Safety assessment,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Non-Cellular immunomonitoring
1632,NCT02282111,Diagnostic Accuracy,2014-07,TERMINATED,INTERVENTIONAL,['NA'],,Percent Sample Contribution to Immunohistochemistry Diagnosis
1633,NCT03273647,Disease-free survival time,2017-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,overall survival time
1634,NCT02890979,Detection of gene mutations using next generation sequencing (NGS),2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of the NGS probes to detect underlying esophageal dysplasia or cancer
1635,NCT00843375,Biospecimen Retention: Samples with DNA,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,
1636,NCT03758209,Change in preoperative functional status - FVC by the end of rehabilitation,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,"Delay in beginning of adjuvant oncotherapy (chemotherapy, radiotherapy)."
1637,NCT03253302,Positive rate of circumferential resection margin (CRM) of the specimens,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,the rate of postoperative complications
1638,NCT02715492,Number of patients with portal vein thrombosis,2018-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
1639,NCT02602249,Reduced size of the tumor.,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Safety, as measured by the rate of adverse events and serious adverse events"
1640,NCT05985239,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.,Total hospitalization costs
1641,NCT02805829,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T cell subsets figures,Number of Participants with tumor recurrence metastasis as a Measure of effectiveness
1642,NCT02539342,"Measure the Development of Oral Mucositis (Grade >/= 2) in Children, Adolescents and Young Adults.",2016-10,TERMINATED,INTERVENTIONAL,['PHASE3'],Tolerability of Four Times Daily Caphosol Therapy,
1643,NCT05241210,Adenoma Detection Rate,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1644,NCT00313794,"To assess the best overall response rate per RECIST (BRR) in patients with metastatic adenocarcinoma of the colon or rectum treated with CP-675,206 .",2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To obtain pharmacokinetic (PK) data to be evaluated in a future meta analysis of CP-675,206 pharmacokinetics."
1645,NCT06313801,Complications from polychemotherapy.,2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Аssessment of the quality of life
1646,NCT00174616,MRI staging and TME surgery,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Measure safety - NCI-CTC version 2
1647,NCT02719782,Safety of the TCR-T treatment,2015-07-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],"1-year PFS (progression free survival) which is measured by the number of patients with stable disease after 1 year, using mRECIST",Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline
1648,NCT00469339,"Examine whether a family-centered feedback approach, as compared to an individual-focused approach, encourages communications regarding family risk and the development of strategies to adopt health promoting behaviors within the household.",2007-04-27,COMPLETED,OBSERVATIONAL,['NA'],,
1649,NCT05445245,Self-report Questionnaire,2022-04-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1650,NCT02199236,maximum tolerated dose (MTD),2014-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,tumor response
1651,NCT00033657,Pathologic Complete Response Rate,2002-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Recurrence-free Survival Time
1652,NCT00055419,"The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1653,NCT04475640,Impact of germline genetic testing on both therapeutic management and targeted cancer prevention,2019-12-13,RECRUITING,INTERVENTIONAL,['NA'],,
1654,NCT00639509,Best Overall Response Rate (ORR),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
1655,NCT01303029,Progression free survival,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship
1656,NCT00923299,Objective response rate as assessed by RECIST criteria (Phase II),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
1657,NCT05867901,Drug retreatment response rate,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,MRD versus imaging examination
1658,NCT06061328,Maintenance as assessed by maintenance of other measures,2024-02-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Feasibility of Intervention Measure (FIM)
1659,NCT06173310,To measure the reproducibility of qDCE-MRI measurement of BRPC.,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1660,NCT02115022,Staging capability of each study procedure,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,"Patient survival time, and tumor recurrence-free survival"
1661,NCT04409340,Detection of focal HCC lesions,2020-10-05,RECRUITING,OBSERVATIONAL,['NA'],,
1662,NCT03508180,Evaluation of nausea and vomiting,2018-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Body image
1663,NCT03082833,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1664,NCT00677079,Objective response rate,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cancer antigen 125 response (participants with elevated CA125)
1665,NCT01904955,data concerning evolving relapse,2010-09,COMPLETED,OBSERVATIONAL,['NA'],,
1666,NCT02395016,overall survival（OS）,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,To determine the safety of the treatment with Nimotuzumab and Gemcitabine (NCI Common Terminology Criteria for Adverse Events v4.03)
1667,NCT00450424,Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction With the Preparation to Make a Decision
1668,NCT02313688,3-year disease free survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,The positive rate of proximal resection margin
1669,NCT01896310,The diagnostic accuracy of the new classification system,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,
1670,NCT00789893,To examine the effect of dilator use in minimizing vaginal stenosis so that patients are able to use the pre-radiation baseline dilator size 6 months after starting dilator use.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,To explore patient-reported self-efficacy as it relates to the use of the vaginal dilator.
1671,NCT02047188,NBI prediction for lesion histology and invasion,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,immunohistochemical outcome of microvessel count and MMP-7
1672,NCT00953511,histopathologic response to chemoradiation,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,prognosis
1673,NCT03448302,Blood flow of tumor,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,Permeability surface of the tumor
1674,NCT04128332,The feasibility of delivering pre-operative SABR followed by immediate surgery as determined by rate of post-operative complications at 30 days.,2020-10-26,UNKNOWN,INTERVENTIONAL,['NA'],,Acute and late toxicity of pre-operative SABR: Number of adverse events
1675,NCT04819971,Percentage of Participants With Pathological Complete Response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of All Participants That Discontinued Study Treatment Due to AE
1676,NCT03985046,Local Control Rate,2019-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
1677,NCT01606098,Overall survival,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival in patients in whom treatment according to protocol was initiated
1678,NCT02162641,The proportion of nodes detected will be expressed per inguinal nodal basin and per number of patients,2014-09,WITHDRAWN,OBSERVATIONAL,['NA'],,Delays in receiving radiotherapy treatment
1679,NCT05839197,Objective remission rate (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events and toxicities of Apatinib in combination with Camrelizumab
1680,NCT04529668,histopathology,2015-10-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
1681,NCT00328770,Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Sirolimus Toxicity/Intolerance
1682,NCT00615056,Progression Free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal"
1683,NCT01835041,Maximum Tolerated Dose,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Participants with a Clinical Response,
1684,NCT04809025,Diagnostic accuracy,2021-05-24,UNKNOWN,OBSERVATIONAL,['NA'],,Procedure duration
1685,NCT01256047,postoperative infectious complication,2009-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,"plasma IL-6, CRP, Th1/Th2 balance"
1686,NCT01613053,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1687,NCT02423278,Relapse-free Survival,2010-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Length of Hospital stay
1688,NCT04224779,Area under the Receiver Operating Characteristic (ROC) curve of total cfDNA (defined as circulating cell-free DNA in plasma) percent change between the baseline sample (T1) and the sample at the end of the neo-adjuvant treatment (T3),2021-02-18,RECRUITING,INTERVENTIONAL,['NA'],,Tumoral response assessed by Magnetic resonance Imaging (MRI)
1689,NCT05666271,Adjacent organ thermal injury rate,2022-08-29,RECRUITING,OBSERVATIONAL,['NA'],,
1690,NCT06320990,"Feasibility, by retention rate",2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR) of pancreatic MCN
1691,NCT05296369,Progression-free survival(PFS),2022-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1692,NCT00727441,"Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",2008-07-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival
1693,NCT01975064,Over all survival,2013-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Over all survival
1694,NCT01816659,Comparison of Ki-67 in Tumor Samples,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1695,NCT05482529,disease free survival rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,R0 resection rate
1696,NCT03587532,An ICGA based cutoff point to predict anastomotic leakage and graft necrosis after esophageal reconstructive surgery.,2021-12-13,RECRUITING,INTERVENTIONAL,['NA'],,pulse pressure
1697,NCT05965999,"Agreement between positive EsoGuard test results and upper endoscopy diagnosis (i.e., subjects with BE/EAC newly diagnosed by upper endoscopy)",2023-04-11,RECRUITING,OBSERVATIONAL,['NA'],,"Agreement between negative EsoGuard test results and upper endoscopy diagnosis (i.e., subjects determined not to have BE/EAC on upper endoscopy)"
1698,NCT00503685,"Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)]",2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Expression of IGF Binding Proteins (IGFBP2, IGFBP3)"
1699,NCT01804998,3 year disease free survival rate,2013-03-27,COMPLETED,INTERVENTIONAL,['NA'],,5 year disease specific death rate
1700,NCT05210283,To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI).,2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],,To assess time from positive ctDNA to clinical recurrence
1701,NCT00056030,Surgical resectability rate as assessed by surgical resection of liver metastases,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as assessed by UNISCALE and Symptom Distress Scale every 6 weeks
1702,NCT05912075,Dose-limiting toxicities (DLTs),2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Distant metastasis-free survival
1703,NCT03718897,Overall survival rate,2018-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
1704,NCT06115499,Overall Survival (OS) (Phase III),2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of adverse events
1705,NCT04913077,Rate of GIST tumors,2020-03-10,SUSPENDED,INTERVENTIONAL,['NA'],,data for cost-benefit calculation
1706,NCT04227353,Data completion rates,2021-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Change in Quality of life
1707,NCT03396029,A questionnaire-based lifestyle score,2014-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Body weight
1708,NCT02494791,Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome)
1709,NCT03109886,Overall Safety Profile,2017-07-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of overall Response (DoR)
1710,NCT00934882,"Effect of BAY73-4506 on the pharmacokinetics of mFOLFOX6 and FOLFIRI (Cmax, AUC, through concentration of BAY73-4506 and Cmax, AUC of Platinum, Irinotecan and its metabolite SN-38, 5-Flourouracil)",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response
1711,NCT06177496,overall survival,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
1712,NCT00251862,Patient Adherence (Test Completion),2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Screening Intentions
1713,NCT04536077,Amount of intratumoral conventional dendritic cells (cDCs),2021-08-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1714,NCT05721885,Degree of radiation-induced oral mucositis (RTOG criteria),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1715,NCT00507143,SLCO1B1 and PXR genotypes and pharmacokinetics of SN-38,2006-08,UNKNOWN,INTERVENTIONAL,['NA'],,"SLCO1B1 and PXR genotypes and response duration, time to progression and overall survival"
1716,NCT00897923,"Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
1717,NCT04809935,Pain score,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Cost-effectiveness of two types approach
1718,NCT04617821,overall survival,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,postoperative complications
1719,NCT03804372,Percentage of patients presenting hepatitis B virus reactivation,2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients experiencing adverse events.
1720,NCT00045526,Major response rate (complete and partial response),2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1721,NCT05997056,Efficacy of nab-sirolimus,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
1722,NCT01318239,MR perfusion parameter,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,diffusion parameter
1723,NCT03825328,OS,2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1724,NCT04677504,Progression Free Survival (PFS),2021-02-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of ADAs to Atezolizumab
1725,NCT05099848,Surgical conversion rate,2021-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1726,NCT05554367,ORR (Cohort 4),2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma RAS allelic burden in in relation to response (Cohorts 3 and 4),Incidence of adverse events (AE) (All Cohorts)
1727,NCT06324097,negative predictive value,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,intra-observer agreement
1728,NCT01111838,To Determine Overall Objective Response.,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1729,NCT04791735,The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients.,2021-05-21,RECRUITING,INTERVENTIONAL,['NA'],,Overall and disease free survivals.
1730,NCT05233358,Progression Free Survival,2022-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The incidence of adverse events and serious adverse events
1731,NCT01147380,Side Effect of Cadaveric Donor Liver NK Cell Infusion,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-HCV Effect of This Treatment (If Applicable)
1732,NCT00191646,Progression Free Survival (PFS),2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
1733,NCT02887235,Quality of life measurement,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Food security assessment plus HDMTM from baseline to 12 weeks
1734,NCT01556399,Significant differences in molecular abnormalities.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
1735,NCT02448056,Patient survival,2015-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1736,NCT03657641,Overall survival (OS),2019-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1737,NCT01523639,Reduction in the chemotherapy-associated steatosis,2012-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Reduction in chemo-therapy associated steatohepatitis (CASH)
1738,NCT00209742,3-years disease-free survival rate (DFS),2005-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Dose intensity (compliance), 5-year disease-free survival rate, 3- and 5-year survival rate, incidence of other adverse drug reactions, QOL"
1739,NCT06160323,The mean change in VAS pain score at 3 months,2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
1740,NCT05349045,PFS,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,OS
1741,NCT00016978,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1742,NCT00191568,"To evaluate recurrence free one year survival, time to disease progression and local recurrence rate, analyzed at the end of the study",2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess overall survival at the end of the 24 months follow up period;To assess acute and late toxicity (every month for the first 3 months and then every three months for 24 months after treatment discontinuation)
1743,NCT01872377,Toxicity defined as grade 3 or 4 gastro-intestinal or other non-haematological toxicity,2013-07,TERMINATED,INTERVENTIONAL,['NA'],,CyberKnife radiation dose measured in Gy delivered to the tumour and surrounding organs vs. the frequency of grade 3-4 toxicity defined by CTCAE v4.0
1744,NCT04253249,Treatment pancreatic cyst without surgery,2018-05-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
1745,NCT06073483,The rate of postoperative complications,2023-10-15,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative instrument operation error rate
1746,NCT00814619,Pathological complete or near-complete response (Dworak grade 3 and 4),2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
1747,NCT03021668,Rate of Surgical Site Infection,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,30-d Readmission
1748,NCT01350206,overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Time to progression
1749,NCT04663035,1-year recurrence-free survival (RFS) rate,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30 and the EORTC QLQ-HCC18."
1750,NCT02009631,To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF),2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Assessment
1751,NCT01534546,3 year Disease Free Survival,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Event
1752,NCT04181645,ORR：Objective Response Rate by IRC,2019-06-29,UNKNOWN,INTERVENTIONAL,['NA'],,OS: overall survival
1753,NCT03880721,Specificity,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1754,NCT05659290,Progression-free Survival (PFS),2023-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
1755,NCT02626312,Maximum dose constraint,2016-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor biomarker expression in serum,Overall survival
1756,NCT00188565,- To determine the efficacy of celecoxib in combination with preop RT and continuous infusional 5-FU. Pathologic complete response rate (pCR) will be used as the endpoint.,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Quality of life (FACT, EORTC)"
1757,NCT01940237,Change in Hamilton Depression Scale (HAMD-17),2012-04,TERMINATED,INTERVENTIONAL,['NA'],,
1758,NCT01675934,Percentage of cases in which right-sided retroflexion is successful with the adult and pediatric colonoscopes.,2012-02,WITHDRAWN,INTERVENTIONAL,['NA'],,Reasons for failure of retroflexion.
1759,NCT00354887,Number of Participants With Overall Response,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1760,NCT04698915,Median Overall Survival after SBRT completion,2021-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Progression Free Survival after SBRT Completion per RESIST 1.1
1761,NCT00891930,Part 2: Objective Response Rate (ORR),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Subjects With Worst Post-baseline Grade 3 or Higher Laboratory Toxicities
1762,NCT05284864,Determine and compare morbidity and mortality rates in patients with early and late stoma closure,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],"Determine the patient's percentage with anterior resection syndrome, after early and late ileostomy closure assisted by the LARS scale.",Determine and analyze quality of life assisted by the SF36 scale in early vs late ileostomy closure
1763,NCT01740648,Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.,2012-11-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of patients undergoing sphincter preserving surgery
1764,NCT00120939,"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.",na,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks"
1765,NCT03407417,Completion of initial FIT screening,2018-11-08,RECRUITING,INTERVENTIONAL,['NA'],,Completion of repeat Annual FIT screening
1766,NCT00216437,Dose-limiting toxicity.,2004-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1767,NCT05687318,PMR,2022-09-20,COMPLETED,INTERVENTIONAL,['NA'],,AMR
1768,NCT00098579,MTD of alvocidib when given every three weeks in conjunction with doxorubicin hydrochloride,2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic activity of alvocidib in combination with doxorubicin hydrochloride in patients with advanced solid tumors
1769,NCT00844168,Dose-limiting toxicity (DLT) as defined by the Common Terminology for Adverse Events (CTAE) version 3,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1770,NCT03125980,3-year disease free survival,2017-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Relapse-free survival (RFS)
1771,NCT02780284,Percentage of participants retained at the end of study,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,"Percentage of participants with collected, processed, and analyzed stool samples"
1772,NCT06256185,Sub-analysis (ML Model vs. Logistic Model vs. NCCN Guideline),2010-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
1773,NCT02745483,Cumulative 3-year LTP rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Technical success rate,3-year Recurrence free survival rate
1774,NCT00346099,Percentage of patients with clinical complete response rate in tumor in the pelvis at 4 to 6 weeks after completion of radiation therapy,2006-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The toxicity of panitumumab in combination with chemotherapy and in combination with chemoradiotherapy
1775,NCT05795374,Postoperative morbidity.,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence
1776,NCT06156748,Overall survival,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
1777,NCT01549756,,2012-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1778,NCT04046133,Safety and tolerability- 12 months post CRT,2020-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Patient reported outcome - 12 months follow up
1779,NCT05466565,recurrence-free survival time,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Dynamic changes of cccDNA
1780,NCT05356585,Detectable ctDNA at the Completion of TNT,2023-12-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The correlation of ctDNA at end of TNT with relapse-free survival,Correlation of Complete Response TNT
1781,NCT01847794,HER2 positive CTC,2013-06,UNKNOWN,INTERVENTIONAL,['NA'],,clinical significance of HER 2 positive CTC
1782,NCT05131958,Perception measure,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],,
1783,NCT03493152,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
1784,NCT03750669,Disease-free survival,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Serious adverse events incidence
1785,NCT02426762,freedom from surgical site infection,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pain Scores on the Visual Analog Scale
1786,NCT05620732,AE/SAE,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,ORR
1787,NCT02845973,differences in abundance of gut microbiota,2012-01,COMPLETED,OBSERVATIONAL,['NA'],diet difference in patients with different clinical outcomes,evidence of colorectal neoplasia
1788,NCT03111368,Diagnostic yield,2015-04-27,COMPLETED,INTERVENTIONAL,['NA'],,
1789,NCT00063427,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1790,NCT00980603,response rate,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,time to progression
1791,NCT02459041,Strain histogram and contrast enhancement during EUS in pancreatic masses and lymph nodes,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
1792,NCT00176787,"e. The relationship of intratumoral levels of thymidylate synthase, dipyrimidine dehydrogenase and thymidine phosphorylase determined immunohistochemically to response",2000-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
1793,NCT03878524,Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose),2020-04-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to decline (TTD)
1794,NCT06090825,Descriptions and scores of real status of hospice care in different hospitals,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
1795,NCT05669521,Mucositis,2022-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Secondary efficacy/outcome mucositis
1796,NCT01563133,Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes,2012-06,UNKNOWN,INTERVENTIONAL,['NA'],,Feasibility and safety data on nCLE during EUS-FNA procedure
1797,NCT03261947,Disease Control Rate (DCR) in Tumor-Specific Cohorts,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Percentage of Participants With Clinically Significant Changes in Vital Sign Measurements, Reported as Adverse Events in Tumor-Specific Cohorts"
1798,NCT04885283,Time to Start Postoperative Chemotherapy,2021-01-20,COMPLETED,OBSERVATIONAL,['NA'],,
1799,NCT01876901,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA,2010-08-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among CAA
1800,NCT02216149,Frequency of coronary artery dysfunction,2015-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival status
1801,NCT05634720,Feasibility of HA Chemotherapy for PDAC,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall Survival
1802,NCT00667628,Time to Appearance of New Lesions (TTNL),2008-04-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
1803,NCT03631173,Total hospital stay,2019-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Number of patients expired at an average of 10 days,Risk factors of postoperative pancreatic fistula at 90 days after surgery
1804,NCT03908788,Proportion of patients with mCRC (metastatic colorectal cancer) who develop a RAS (rat sarcoma viral oncogene homolog) mutation under anti-EGFR (epidermal growth factor receptor) therapy,2018-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of the following criterion: frequency of mutated alleles
1805,NCT05563766,Rate of pathological complete response with itraconazole,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine the utility of ctDNA and exosome characterization as a prognostic marker
1806,NCT00423293,Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Five-Year Rate of Colostomy-free Survival
1807,NCT00002933,Effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.,1996-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1808,NCT00262990,To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,To explore relationships between Cmin (pre-dose patupilone blood concentration) and efficacy/adverse events
1809,NCT06184152,Early HCC Detection,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],,Early HCC Detection
1810,NCT03150706,"Serum CEA, TSH, T3, free T4, EKG,CT (or MRI) scans of evaluable/measurable lesions by RECIST 1.1.",2017-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
1811,NCT04974047,pCR Rate,2021-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number Of Participants Experiencing Treatment-Emergent Adverse Events
1812,NCT03832985,Initiation of risk reduction behavior,2020-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Health Education Impact Questionnaire (heiQ)
1813,NCT03489707,Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening,2020-01-09,COMPLETED,INTERVENTIONAL,['NA'],Host/viral methylation and its association with high-grade squamous intraepithelial lesions.,Number of participants who attend high resolution anoscopy
1814,NCT02817126,Locoregional recurrence rate,2016-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Self reported sexual function for female patients
1815,NCT02228785,Antibody Levels,1994-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Intra-gastric pH
1816,NCT01104129,Positive mutation rate in tumors/IPMN lesions vs. control,2009-07-09,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients with genetic abnormalities correctly detected in stool samples
1817,NCT01104077,Percentage of IPMN patients with relatives with pancreatic cancer or IPMN,2008-11-17,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of IPMN patients exhibiting higher malignant potential or recurrence following surgical resection
1818,NCT05533541,Primary End point,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Secondary End point 4
1819,NCT03647839,Objective response per iRECIST,2018-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
1820,NCT04720521,Detection rate of gastric neoplastic lesion,2019-05-10,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of detecting gastric neoplastic lesion
1821,NCT02268435,Maximal tolerated dose and recommended dose,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,"Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters"
1822,NCT01196390,Disease-free Survival (DFS),2011-02-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Any Cardiac Adverse Events Regardless of Attribution
1823,NCT05214339,Objective response rate (ORR) by RECIST 1.1,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1824,NCT00637364,"Safety of the FEP-BY02 HIFU system determined by the frequency and severity of adverse events (AEs) categorized and graded for severity according to the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE)",2008-03,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1825,NCT00005077,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1826,NCT02316834,Change in ribonucleic acid (RNA) protein expression,2015-06-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in RNA protein expression
1827,NCT02576964,Objective response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
1828,NCT03396614,The cardiopulmonary (dys)function in EC survivors treated with neo-CRT followed by surgical resection will be compared to cardiopulmonary (dys)function in EC survivors treated with surgical resection alone.,2017-10-21,COMPLETED,OBSERVATIONAL,['NA'],,
1829,NCT04627142,Objective Response (OR) according to RECIST version 1.1,2020-11-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of patients experiencing grade ≥3 treatment-related AEs during the entire treatment period
1830,NCT03301454,Estimate the overall survival for patients suffering from Esophageal cancer,2018-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Estimate the consequences of pursuing chemotherapy
1831,NCT00005640,Number of Procedures Resulting in Improved Detection,1999-06,COMPLETED,INTERVENTIONAL,['NA'],,
1832,NCT03073694,Comprehensive Complication Index (CCI) score.,2017-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,
1833,NCT06060990,Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
1834,NCT01194206,Rate of downstaging of stage B and C Hepatocellular Carcinoma using Stereotactic Body Radiotherapy,2010-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Survival rate
1835,NCT02597465,"Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1",2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1836,NCT01606241,"Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)",2012-07-24,COMPLETED,INTERVENTIONAL,['PHASE1'],Percent change in antigen-specific cytokine profiles,Percentage change in plasma concentration of cytokines and chemokines
1837,NCT03744247,Overall Survival (OS),2019-04-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Time to Progression (TTP)
1838,NCT00199173,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1839,NCT05983367,Overall Response Rate,2023-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
1840,NCT04953585,overall survival time,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
1841,NCT05664178,Participant Treatment Outcome,2023-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1842,NCT05378867,AUCtau，Area under the curve over the dosing interval,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,DOR，Duration of response
1843,NCT01250015,Comparison of the two groups' overall wish to be screened,2007-09,COMPLETED,OBSERVATIONAL,['NA'],,Impact of different summary points on subject's desire to be screened
1844,NCT03245346,Overall survival (OS),2017-12-19,UNKNOWN,INTERVENTIONAL,['NA'],,Plasma levels of ropivacaine and sufentanil
1845,NCT03828318,Global quality of life (QoL),2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
1846,NCT04724070,Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.,2019-10-16,RECRUITING,OBSERVATIONAL,['NA'],,Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong
1847,NCT05040347,Concentration of NETs markers and anti-β2 glycoprotein I,2020-08-18,COMPLETED,OBSERVATIONAL,['NA'],,
1848,NCT04390243,Objective Response Rate (ORR) at 24 Weeks,2020-11-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3+ Adverse Events
1849,NCT01416168,Feasibility of the Intervention,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,Effect Size Estimates for Within-group Changes Between Baseline and 1-month
1850,NCT03812796,Main Phase IIB (efficacy) phase: Objective response rate using RECIST 1.1 criteria,2019-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of objective response according to RECIST 1.1
1851,NCT02931890,Event-Free survival,2017-12-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
1852,NCT00003137,response rate,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,survival
1853,NCT03026452,Tumor size assessed by MRI,2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Alpha Fetoprotein (AFP) level assessed by ELISA
1854,NCT04289792,Kaplan-Meier Estimate of Progression-Free Survival (PFS),2020-05-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Participants With Treatment Emergent Adverse Events (TEAEs)
1855,NCT02781337,Disease-free survival,2012-05,RECRUITING,OBSERVATIONAL,['NA'],,Molecular characteristics of colorectal adenocarcinoma.
1856,NCT01143285,Toxicities frequently associated with chemotherapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
1857,NCT06202066,PFS (Part 2),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (Part 2)
1858,NCT03198546,Number of Patients with Dose Limiting Toxicity,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median CAR-T cell persistence
1859,NCT02584400,"Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT",2016-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient
1860,NCT05190575,ORR,2022-01-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety & tolerability
1861,NCT05293496,Number of participants with AEs leading to study treatment discontinuation,2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of PSA response for mCRPC
1862,NCT01729221,Incidence of hepatocellular carcinoma post stem cell therapy in hepatitis C virus infected patients,2010-01,UNKNOWN,OBSERVATIONAL,['NA'],asses liver functions in both groups,Compare the incidence of hepatocellular carcinoma in patients who had received stem cell therapy to those who had received the standared line of care
1863,NCT03679910,Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1864,NCT04623749,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by Trans abdominal US-FNAC. diagnostic accuracy",2021-12,UNKNOWN,INTERVENTIONAL,['NA'],,"Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by EUS-FNAC. diagnostic accuracy"
1865,NCT00447122,Overall Survival for Patients With Metastatic Pancreatic Cancer.,2007-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
1866,NCT01966133,Disease-free survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],Health-related quality of life assessment,Complications of transarterial chemoembolisation
1867,NCT01425996,Adverse Event/Serious Adverse Event,2011-10-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change from baseline in tumor marker/biomarkers
1868,NCT05610163,Clincal Complete Response (cCR) Rates,2022-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
1869,NCT02654288,The dynamic change patterns of sera IgG4 and IL-10 of pancreatic cancer after gemcitabine-based chemotherapy will be recorded.,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,The correlation of the changes of IgG4 and IL-10 with the overall survival after chemotherapy will be analyzed.
1870,NCT04157140,Time To Progression(TTP),2019-11-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
1871,NCT01184482,Maximum tolerated dose,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Genetic variations and activation status for EGFR and ErbB2 pathways
1872,NCT05720676,To use PDX and PDO to evaluate the efficacy of various treatments.,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1873,NCT05221775,adverse effect,2021-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,OS
1874,NCT03768414,Overall survival (OS),2019-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in carbohydrate antigen 19-9 (CA 19-9) levels
1875,NCT05650216,pCR,2022-12-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
1876,NCT06257030,LPFS,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],,Post-treatment dosimetry analysis
1877,NCT04124991,TTP,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events
1878,NCT01216345,best overall response (according to RECIST 1.0),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of the treatment combination
1879,NCT02989870,Occurrence of Treatment Related Adverse Events,2017-03-27,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
1880,NCT00367861,Progression free survival,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity
1881,NCT06325826,Hepatocellular Carcinoma,2022-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
1882,NCT06239870,pCR,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TRG
1883,NCT03889795,Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess molecular changes induced by C3 administration in the blood for biomarker sensitivity/resistance assessment
1884,NCT04042805,Objective Response Rate (ORR),2019-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor mutation burden in association with ORR and survival.
1885,NCT02885753,progression-free survival,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,
1886,NCT00372944,Median time to death (TTD),2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety and tolerability of AZD6244 in the treatment of advanced or metastatic pancreatic cancer by review of adverse events (AEs) and laboratory parameters.
1887,NCT00937248,Comparing the use of a prone pillow and simple ankle fixation device vs. the use of a CVID for immobilization rectal patients during the course of preoperative radiation therapy using KV CBCT for IGRT.,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,quantify interfractional set-up displacements using either of the two devices;determine a standard planning target volume margin; evaluate the role of soft-tissue image matching for IGRT using CBCT.
1888,NCT00303914,"Prevalence, severity, and interference due to physical and psychological symptoms experienced by cancer patients as assessed by MD Anderson Symptom Inventory at baseline and days 28-35 following initial assessment",2006-03-14,COMPLETED,OBSERVATIONAL,['NA'],,Focus and scope of interventions chosen to improve symptom control
1889,NCT00020787,To determine whether a concomitant G17DT-chemotherapy regimen affects tumor response in subjects with gastric or gastroesophageal cancer.,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Time to disease progression, best overall response, and survival will be evaluated in the intent-to-treat population and the evaluable population."
1890,NCT05688020,Postprocedural bleeding,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Side effects
1891,NCT03778879,Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone,2019-08-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mean time to death
1892,NCT03518489,Change from Baseline Numeric Rating Scale for Pain(NRS scale) at 7 weeks,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,The Adverse events Related to lappaconitine
1893,NCT03381053,Number of participants with tumor metastasis,2017-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
1894,NCT02944188,incidence of postoperative complications,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],postoperative hospital stay,operative mortality
1895,NCT00154804,Clinical and pathological response rates,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
1896,NCT02610218,Correlation of HER2 status on CTCs and cfDNA with clinical outcomes,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,Gene variations associated with resistance in HER2-targeted therapy
1897,NCT01071655,progression-free survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of KRAS status as a molecular marker
1898,NCT02309177,Grade 3 or 4 TEAE,2015-01-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of Response
1899,NCT02435953,Overall survival rate,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse event rate
1900,NCT02659852,Median patency duration,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
1901,NCT00004195,Primary Goal to demonstrate that eniluracil at current clinical doses,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Specific Aims,Evaluate DPD recovery and uracil levels
1902,NCT04106856,Grade 3 or higher gastrointestinal toxicity rate,2019-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Patient reported quality of life assessment- review of symptoms and how they interfere in life,Number patients that require a medical intervention or hospitalization due to hypotension
1903,NCT05379595,Cohorts D and E: Number of Participants with Vital Signs Abnormalities,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cohorts D and E: Progression Free Survival (PFS)
1904,NCT00220246,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
1905,NCT04395469,Tumor Hypoxia,2021-05-18,RECRUITING,INTERVENTIONAL,['NA'],,
1906,NCT05619172,Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time course of ADAs against nanrilkefusp alfa
1907,NCT03894917,Characterize the Change in disease and treatment patterns of advanced hepatocellular carcinoma (HCC) in older patients in the US.,2019-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
1908,NCT05661292,Asian Pacific Colorectal Screening (APCS) score validation in Mexican population.,2019-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Optimal Fecal Immunochemical Test (FIT) valued for Advanced Colorectal Neoplasia (ACN) detection.
1909,NCT01736410,Overall Response Rate (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure (TTF)
1910,NCT05599932,Pharmacokinetics (PK): AUCinf,2022-12-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1911,NCT04776148,Overall Survival (OS),2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
1912,NCT02094625,Target Serum Level NAC,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Glutathione serum level
1913,NCT00001254,To determine an approach to the localization and management of tumor in patients with ZES.,1991-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
1914,NCT04638868,Number of circulating tumor cells,2020-11-17,UNKNOWN,INTERVENTIONAL,['NA'],,
1915,NCT03285906,progression-free survival,2017-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,median Overall Survival
1916,NCT03400592,Objective response rate,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Potential predictive biomarkers of nimotuzumab
1917,NCT03825705,Overall Response Rate(ORR),2019-04-23,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1918,NCT05743049,"To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.",2023-02-27,RECRUITING,OBSERVATIONAL,['NA'],,To integrate the data and specimens to permit the most informative clinical-biologic research platform.
1919,NCT00622440,Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL),2008-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response With >75% Adherence
1920,NCT00004187,,1999-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
1921,NCT02404363,Response to treatment based on RECIST 1.1 criterion,2016-01-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Bleedings
1922,NCT00154102,Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments,2004-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety - Number of Patients Experiencing Any Adverse Event
1923,NCT00533975,,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],,
1924,NCT00005060,Event-free survival,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Rate of complete resection (RO) and postoperative mortality as measured after surgery
1925,NCT02376985,Incidence of oral mucositis (Over Grade 1) after everolimus treatment,2015-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health-related quality of life (HRQOL)
1926,NCT05902988,Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,2023-10-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells
1927,NCT04469426,Assessing 'Change' via European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - C30 questionnaire after 6 months,2020-08-15,RECRUITING,INTERVENTIONAL,['NA'],,Bowel function Low Anterior Resection Syndrome score
1928,NCT01845467,Evaluating the additive benefit of Secretin MRCP in differentiating focal AIP and Pancreatic malignancy,2013-02,WITHDRAWN,OBSERVATIONAL,['NA'],,Efficacy of Secretin MRCP in monitoring therapeutic improvement in AIP patients on steroid trial
1929,NCT05718492,Progress Free Survival (PFS),2022-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
1930,NCT00629265,Change in Penetration-Aspiration Scale (PAS) Score,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Performance Status Scale for Head and Neck Cancer Patients (PSS); The Head and Neck Cancer Inventory (HNCI)
1931,NCT01372202,Pathological Complete Response,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Esophageal Tumor CHFR Methylation and Detection in Plasma
1932,NCT04229355,Progression-free survival,2021-02-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
1933,NCT04880772,Inflammatory cytokines,2021-07-15,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life measure (Mental Adjustment to Cancer Scale)
1934,NCT06053996,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
1935,NCT03888859,Frequency of ARTEMIS T cell treatment-related adverse events,2017-12-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,"Time to baseline for serum IL-2, IL-4, IL-6, IL-10, TNF-α and INFγ"
1936,NCT03050333,Proportion of complete resections without recurrence,2013-04-25,UNKNOWN,OBSERVATIONAL,['NA'],,
1937,NCT03888092,Number of patients with adverse events (AEs) as a measure of safety and tolerability,2017-08-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
1938,NCT00069940,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
1939,NCT06271291,Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
1940,NCT00427310,Survival,1984-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
1941,NCT03566797,Incidence of SC-CIP in patients at risk,2018-07-20,RECRUITING,OBSERVATIONAL,['NA'],,NOD2 polymorphisms
1942,NCT00640692,,2007-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
1943,NCT03364114,Rate of device- and procedure-related serious adverse events (SAEs),2018-02-09,RECRUITING,INTERVENTIONAL,['NA'],,Post Procedure Pain
1944,NCT03178812,Prediction of malignant potential of pancreatic cyst by measuring TNF levels,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,
1945,NCT03661671,Detection rate of gastric neoplastic lesion,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of detecting gastric neoplastic lesion
1946,NCT05111795,Lung shunt prediction,2022-01-17,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients downstaged to liver resection or liver transplantation
1947,NCT03464968,6 months overall survival rate,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events as Assessed by NCI CTC version 4.0
1948,NCT02400398,Weight,2015-04-27,COMPLETED,OBSERVATIONAL,['NA'],,Changes in microbiome analysis
1949,NCT05984589,To compare the difference in WCRF/AICR score between the intervention (RISE-PSMT) and control (SSMT) groups.,2024-01-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess percent change across the various component scores on the WCRF/AICR (e.g. grams of fiber) to better understand what might be driving any changes in the overall WCRF/AICR composite score.
1950,NCT05665348,Overall survival (Phase III),2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective response rate (OR) under treatment (Phase III)
1951,NCT02705105,Number of Subjects Experiencing Dose-limiting Toxicity,2016-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Tumor Response Rate According to RECIST
1952,NCT00825955,To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC,2009-02-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,"To assess safety profile of brivanib. Safety will be assessed by the number of adverse events (AEs), serious adverse events (SAEs), periodic data monitoring committee (DMC) review"
1953,NCT01388790,Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments
1954,NCT02073500,Overall survival (OS),2009-09,RECRUITING,OBSERVATIONAL,['NA'],,Disease-free survival (DFS)
1955,NCT03002051,Clinical success for obstructive jaundice,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
1956,NCT01704690,Response rate,2012-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Participants with Adverse Events and the degree of each adverse event
1957,NCT00062374,Histological Response Determined by FDG Uptake Correlates,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Free Survival (DFS),
1958,NCT00313599,Maximum tolerated dose (MTD) of lapatinib in course 1,2006-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics during the first 2 weeks of treatment
1959,NCT01316263,"Percentage of Participants With Tumor Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate) at 12 Weeks",2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Human Anti-Olaratumab (IMC-3G3) Antibody Results
1960,NCT05334849,Levels of circulating exosomal lncRNA-GC1,2018-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Survival outcomes of circulating exosomal lncRNA-GC1
1961,NCT04759638,Overall Survival (OS),2017-03-21,COMPLETED,OBSERVATIONAL,['NA'],,Pathological Complete Response (CR)
1962,NCT01373125,To characterize reflux symptomatology before and after radiofrequency ablation in subjects with dysplastic Barrett's Esophagus (BE).,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Correlate the physiologic and morphologic changes in the neosquamous epithelium (NSE) after ablation with the frequency and type of refluxate seen on pH-Impedance.
1963,NCT04224636,24-months survival rate,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
1964,NCT01998230,Postoperative complication,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Length of postoperative stay
1965,NCT01220999,Mean 111^In-CS-1008 Serum Maximum Concentration by Gamma Counting Following the Day 36 Infusion of 111^In-CS-1008,2010-10-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Subjects With Best Overall Metabolic Response
1966,NCT05816837,Displacement distance,2022-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
1967,NCT02564666,Drug compliance for patients with HCC who is taking Sorafenib compliance,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],The satisfaction with Information about Medicines Scale (SIMS) score,Duration of dosing period
1968,NCT02936856,Detection of numbers of confirmatory diagnosis of malignant lesions before and after hepatic arteriography,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Detection of distribution of confirmatory diagnosis of malignant lesions before and after hepatic arteriography
1969,NCT03104283,Progression-free survival (PFS),2017-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1970,NCT02715882,"Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings",2015-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Blood leukocytes by FACS
1971,NCT00768157,Overall survivals,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rate
1972,NCT05650151,Infection rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
1973,NCT04906434,vital signs changes from baseline,2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,PFS
1974,NCT02704156,The Median Survival Time Will be Determined.,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Quality of Life Will be Analyzed.
1975,NCT00910572,Time to progression (TTP),2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time-to-symptomatic progression (TTSP)
1976,NCT04575922,Overall response rate for unirradiated lesions (ORR),2020-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
1977,NCT00083785,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1978,NCT00625651,Progression-free survival,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The incidence of anti-AMG 655 antibody formation
1979,NCT05241249,R0 resection rate,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Ki-67 expression in tumor cells
1980,NCT02677038,Objective response rate (defined as complete response or partial response) assessed using Response Evaluation Criteria in Solid Tumors 1.1,2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of unacceptable toxicity
1981,NCT00808145,Safety of the combination of gemcitabine/cisplatin/sorafenib,2009-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease
1982,NCT02494687,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
1983,NCT03216135,Microbial community profiling,2017-07-20,UNKNOWN,OBSERVATIONAL,['NA'],,Generate a tissue microarray
1984,NCT04490733,Neuropsychological battery test,2020-08-17,RECRUITING,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
1985,NCT03200691,Pathologic Complete Response Rate,2017-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.
1986,NCT02226666,Survey,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Respiratory Rate
1987,NCT00512304,feasibility of treatment,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
1988,NCT05897268,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
1989,NCT01923155,Adenoma detection rate,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Cecal intubation TIME
1990,NCT03163992,Overall Response Rate,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS) and Overall Survival (OS)
1991,NCT04733963,Progression Free Survival,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint,QoL
1992,NCT02871804,the incidence of pancreatic fsitula grade B/C,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the incidence of conversion from laparoscopic surgery to open surgery
1993,NCT03781154,Physical Activity,2019-10-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life Assessment
1994,NCT04151524,Overall Survival,2019-10-23,UNKNOWN,OBSERVATIONAL,['NA'],,
1995,NCT04716257,Ovarian specific overall survival,2021-01-14,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of life questionnaire
1996,NCT02034968,Progression free survival(PFS),2014-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse events,Objective Response Rate
1997,NCT01173250,,na,COMPLETED,INTERVENTIONAL,['NA'],,
1998,NCT02828124,Incidence of Laboratory Test Toxicity Grade Shifting From Baseline,2016-08-23,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Positive Anti-drug Antibody (ADA)
1999,NCT05008809,Progression-free survival (PFS) time,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
2000,NCT00576680,Response Rate,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To Determine the Safety and Tolerability of This Drug Combination.
2001,NCT05144854,Overall survival (OS),2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event
2002,NCT00560560,Estimate of the 6 Month Survival Probability,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Counts of Circulating Tumor Cells (CTCs)
2003,NCT01857141,Heart rate variability analysis,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Epidural injection
2004,NCT04993846,Quantitative analysis of the dental plaque microbiome in patients with pancreatic cancer vs. healthy controls and IPMN patients,2021-07-26,UNKNOWN,OBSERVATIONAL,['NA'],,Qualitative analysis of OM and periodontal status between the various stages of PC
2005,NCT04065984,Mean muscle attenuation pre and postoperatively,2019-04-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Sequential CT changes in body composition
2006,NCT01924624,disease-free survival,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
2007,NCT03693378,Validation of IMMray™ PanCan-d test,2016-01-19,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of the IMMray™ PanCan-d test performance
2008,NCT05213637,Recurrence-free survival (RFS),2018-04-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events (AE)
2009,NCT03208777,presence of telomeric abnormalities,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2010,NCT02011594,PFS (Progression free survival),2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
2011,NCT01832467,overall response of re-treatment with cetuximab-based chemotherapy,2013-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
2012,NCT00361309,Progression free survival of hepatocellular carcinoma (HCC) patients treated with SU011248.,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2013,NCT03146637,OS,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,SRR
2014,NCT05191498,Feasibility of intratumoral implantation of QuiremSpheres® by SPECT imaging,2021-12-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Tumor response by RECIST 1.1
2015,NCT02781285,The influences of traditional Chinese medicine standardized treatment on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.,2014-12,RECRUITING,OBSERVATIONAL,['NA'],,The influences of Western Medicine treatment mainly by chemotherapy on the overall survival (OS) of patients with advanced gastric cancer by the method of Propensity Score.
2016,NCT00855634,Overall survival,2009-08,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life Perioperative morbidity and mortality 1-year survival and 2-year survival
2017,NCT02392377,Biological Pathway Perturbation Upon Exposure to Chemotherapy,2015-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Occurrence of Grade 3 or 4 Toxicity Per the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0
2018,NCT05559229,To evaluate the efficacy of measuring value of AFP for patients with gallbladder cancer.,2021-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
2019,NCT02422147,This study will evaluate the clinical outcomes (effectiveness) of all patients with pancreatic cyst lesions undergoing EUS-guided ethanol ablation. This will include complete resolution of the pancreatic cyst lesion at the end of the treatment period.,2016-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
2020,NCT05777707,Disease-free survival (DFS),2020-10-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
2021,NCT05514769,Gastroesophagus reflux disease apprised by questionnaire,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Long-term outcome
2022,NCT04299048,Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities,2020-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum Total Ctrough of PF-06946860
2023,NCT02008656,disease-free survival (DFS),2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,major adverse events
2024,NCT04862793,Feedback from CoPS results in change in patient discomfort.,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],,Make an immediate measure to assess the quality of individual colonoscopy performance.
2025,NCT01691391,The predictive value of 18F-FDG-PET for the absence of response compared to the lack of clinical benefit at convential CT at 2 months,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Grade of skin toxicity
2026,NCT04649671,Improvement of insulin resistance,2021-03-02,TERMINATED,INTERVENTIONAL,['NA'],,Adverse events
2027,NCT01751763,"Treatment pattern of Sorafenib: duration and doses of Sorafenib, dose modification/discontinuation of Sorafenib, concomitant anti-cancer therapy, treatment after observed radiological recurrence.",2013-07-09,COMPLETED,OBSERVATIONAL,['NA'],,Time to recurrence (TTR)
2028,NCT00094965,Adverse events.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor evaluations for response or progressive disease.
2029,NCT01726296,Percentage of eligible CRC and NSCLC survivors with medical record documentation of compliance with NCCN guidelines,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in percentage of eligible survivors with documentation of compliance with NCCN survivorship guidelines after conducting the targeted educational initiative at participating sites
2030,NCT01889303,Disease free survival,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,feasibility (including adverse events )
2031,NCT02969473,Overall survival (OS),2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute treatment-related toxicities
2032,NCT04932187,Rate of adverse events as assessed by CTCAE v5.0,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response
2033,NCT02662465,Oral mucositis WHO classification,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Visual analog scale
2034,NCT04354246,Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).,2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).,To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).
2035,NCT00658593,Overall survival,2008-10-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Toxicity
2036,NCT02437136,Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated),2015-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Response (TTR)
2037,NCT05114148,Rate of unacceptable toxicity.,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of regional liver function
2038,NCT05927298,Precision-Matched Treatment Utilization Rate,2023-03-06,RECRUITING,OBSERVATIONAL,['NA'],Genetic and Environmental Factors in Pancreatic Cancer,Correlation of Immune Phenotypes and Molecular Profiles
2039,NCT00400569,Number of Participants With Overall Response (OR),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
2040,NCT01896856,Progression Free Survival (PFS),2013-10-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
2041,NCT01575990,Appropriate colorectal cancer screening,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Appropriate screening for stool cards
2042,NCT01952210,General nutritional status,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Treatment tolerance
2043,NCT04136769,Feasibility of visceral debranching,2020-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
2044,NCT00923052,To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...,2009-02-09,TERMINATED,OBSERVATIONAL,['NA'],,"To determine whether SOCSC are present in the blood and/or bone marrow, and study their quantitative and/or qualitative changes over the course of the disease, from time of initial presentation to time of recurrence and/or metastasis.To sp..."
2045,NCT01106261,Feasibility of recruitment,2010-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Survival
2046,NCT04979611,Standard uptake value (SUV),2020-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2047,NCT01707121,Length of hospital stay,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,Health economic analysis
2048,NCT05702684,Patient experience,2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,
2049,NCT01602406,Incidence rate of Dose Limiting Toxicities,2012-09-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Frequency of stable disease according to RECIST
2050,NCT03407716,Change in general subscale of the Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF),2019-03-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Change in inflammation biomarkers (adiponectin, cortisol, IL-6)",Perceived treatment efficacy as measured by the Subject Global Impression of Change
2051,NCT02926040,Change from baseline in HRQol measured by health questionnaire,2016-10,TERMINATED,OBSERVATIONAL,['NA'],,
2052,NCT01945177,Detection rate of intestinal metaplasia,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Aggregate detection rate of focal gastric lesions
2053,NCT05582278,Cancer embolism withdraws,2021-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2054,NCT03203837,"Percentage change in angiogenic, inflammatory and immune biomarkers",2017-07-05,TERMINATED,OBSERVATIONAL,['NA'],,Treatment Response- Overall Survival
2055,NCT00580021,The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.,2006-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
2056,NCT03233776,"Establish the maximum tolerated dose of anakinra (MTD, 100, 200 or 300 mg).",2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Short term overall survival
2057,NCT03513705,1-year overall survival,2018-05-22,COMPLETED,INTERVENTIONAL,['NA'],Quality of life with Area Under the Curve (AUC) up to 1 year after diagnosis,Use of smartphone application
2058,NCT00405561,Progression free survival;at 18 weeks after registration,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety and Tolerability
2059,NCT00639314,delayed gastric empty after pancreaticoduodenectomy,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,"evaluation of quality of life, early and late complications after pancreaticoduodenectomy"
2060,NCT00198081,"Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Clinical Changes in IPMN Progression.
2061,NCT03486379,response rate (confirmed complete and partial response).,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity
2062,NCT05009069,Percentage of Participants With Pathological Complete Response (pCR),2022-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
2063,NCT01346410,Local Control Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Late Toxicity Rate
2064,NCT02465983,Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria,2015-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
2065,NCT03356535,Hepatocellular Carcinoma,2015-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
2066,NCT03969576,Objective response rate,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of response
2067,NCT03178409,Survival analysis,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2068,NCT02178956,Overall Survival,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Patients With Adverse Events
2069,NCT00263029,Response rate (both clinical and pathological) of the primary rectal cancer observed after the chemoradiotherapy. Histologically confirmed complete resection rate (R0 rate).,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events collection
2070,NCT05819099,Accuracy,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2071,NCT01630239,MR Images,2012-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
2072,NCT04204382,Clinical grade of radioactive oral mucositis,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recovery time of oral mucositis
2073,NCT03077334,Clinical PET type assessed by surgeons from preoperatively preformed PET imaging,2014-10-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with recurrence of cancer or mortality from cancer following operation
2074,NCT02991196,Dose Escalation Part: Number of Participants with Immune-related Response (per Criteria Modified from RECIST Version 1.1 [irRECIST]),2016-12-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Primary Pharmacodynamic (PDy) Effects of the Combination Regimen on Myeloid-Derived Suppressor Cells (MDSCs) and their Subsets in Peripheral Blood
2075,NCT03048266,Relationship of Serum Global Metabolic Profiles with Subsequent Development of Aggressive PNET,2015-11-05,RECRUITING,OBSERVATIONAL,['NA'],,Prospectively Identify Potential miRNA Biomarkers of Serum with miRNA Sequencing in MEN1 Patients Who Have Developed Aggressive PNETs (Cases) and MEN1 Patients Who Have Developed Non-Aggressive PNETs (Controls)
2076,NCT04654403,DOR,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,ORR
2077,NCT00255827,"To assess the side effects, dose-limiting toxicity and maximum tolerated dose.",2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To assess the rate of recurrence after treatment.
2078,NCT04126655,TS inhibition in plasma,2020-02-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2079,NCT01586611,The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma.,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related quality of life (HRQL) parameters in patients with metastatic pancreas adenocarcinoma treated in both treatment arms.
2080,NCT00679913,Survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Morbidity
2081,NCT01826396,R0 resection rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse reactions,disease free survival
2082,NCT01322152,Rate of Diarrhea,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
2083,NCT03511222,Recommended phase II dose (RP2D) of vorolanib plus nivolumab,2018-09-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant
2084,NCT03594929,"serum AST (unit/L) following liver resection, measured at 24 hours",2016-08-15,UNKNOWN,INTERVENTIONAL,['NA'],,Mortality
2085,NCT01422993,Number of Screened Patients Who Participate and Complete the Study,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Measured Improvement
2086,NCT00824161,Percentage of Progression Free Survival,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2087,NCT04109924,Median progression free survival (PFS),2019-12-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Aggregate rates of adverse events
2088,NCT03099382,Overall Survival (OS),2017-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2089,NCT00593008,To determine the dosing regimen appropriate for Phase 2 studies of the combination,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,To document objective response rate and progression-free survival in patients treated with this combination
2090,NCT00629486,cytokine polymorphisms increase risk for hepatocellular carcinoma,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,
2091,NCT03614910,Tumor response,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Cancer related pain
2092,NCT04571710,Objective response rate,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Cmax
2093,NCT01860222,overall survival,2011-01,UNKNOWN,INTERVENTIONAL,['NA'],,local tumor progression
2094,NCT03413904,Conversion to open,2018-03-27,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term postoperative complications
2095,NCT02634645,Overall improvement of patient outcomes in patients treated with endoscopic eradication therapy (EET).,2015-01,RECRUITING,OBSERVATIONAL,['NA'],,Median time to recurrence of neoplasia
2096,NCT03510871,the percentage of subjects with tumor shrinkage after study drug treatment,2019-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2097,NCT04718909,Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST),2021-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR assessed by investigators according to mRECIST.
2098,NCT05358704,Positron emission tomography (PET),2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST v1.1),Magnetic resonance imaging (MRI)
2099,NCT03790059,Tumor-free survival,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
2100,NCT01131689,MTD,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2101,NCT03198338,opioid consumption up to 24 hours,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,sedation score
2102,NCT05213221,Objective reponse rate (ORR),2022-03-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of treatment
2103,NCT03418428,Intestinal microbiome composition,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Serum DAO
2104,NCT01228734,Progression Free Survival (PFS) Time,2010-09-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Subjects With Curative Surgery of Liver Metastases
2105,NCT05183776,Safety of a fractional administration device for holmium radioembolization,2022-07-12,COMPLETED,INTERVENTIONAL,['NA'],,Accurate dosimetry based on MRI and SPECT imaging of holmium-166.
2106,NCT03941873,Phase 2: Objective response rate (ORR),2019-02-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2107,NCT02824484,Change in post-traumatic growth from baseline to post-intervention assessment and at 6 months follow-up. Post-Traumatic Growth Inventory (PTGI) will be used to assess this outcome,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],"Expectancy about change in personal growth as a result of the intervention (Treatment Expectancy, TE)",Change in anxiety and depression from baseline to post-intervention assessment and at 6 months follow-up. Hospital Anxiety and Depression Scale (HADS) will be used to assess this outcome
2108,NCT01775254,Change in Quality of Life,2013-01,COMPLETED,OBSERVATIONAL,['NA'],Psychometric analysis of a modified version of the Neurotoxicity Sub-scale.,Change in Demands of Illness
2109,NCT01291407,"To define dose limited toxicities(DLT) of S-1, peroral BID, in treatment days concurrently with radiation therapy (RT) in locally advanced or recurrent gastric cancer.",2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To define maximum tolerated dose(MTD) of S-1, peroral BID, in treatment days concurrently with radiation therapy"
2110,NCT00869843,Efficacy of the technique on surface liver tumors using saline lined RF Surface ablation.,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine a safe (non-popping upper limit) of power per area that will permit a 1 cm depth of tissue destruction without inflow occlusion and a 2 cm depth with inflow occlusion.
2111,NCT00503737,"Increase the knowledge of providers as it pertains to current guidelines and strategies about CRCS; assist offices design a CRCS policy, assist offices adopt a CRC reminder system and increase the screening rates of CRC.",2007-09,COMPLETED,INTERVENTIONAL,['NA'],,"synthesize information about the strengths and weaknesses of the toolbox from the primary care physician's (PCP) point of view to aid in future development of an interactive, web-based version of the Toolbox."
2112,NCT00366457,Time to Tumor Progression,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2113,NCT06009029,Overall survival (OS),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
2114,NCT00077259,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2115,NCT04340986,Overall survival,2020-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progression time under chemotherapy
2116,NCT05661110,"Relationship between the status, numerical changes of ctDNA during HIPEC combined with PD1/PDL1 inhibitor conversion therapy and postoperative R0 resection rate.",2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Genetic and transcriptional profiling results.,Genomic changes of ctDNA and see if they are predictive of relapse-Free Survival.
2117,NCT05937295,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of the peptide vaccine in combination with anti-PD-L1 immune checkpoint inhibition,2023-09-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2118,NCT03071198,Disease Free Survival (DFS),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Predictor efficacy of neoadjuvant chemotherapy for DFS
2119,NCT06203600,Overall survival (OS) (Phase III),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of adverse events
2120,NCT00683358,PhaseⅠ; safety (NCI CTCAE v.3) PhaseⅡ；time to progression (RECIST),2008-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor regression(Imaging study, tumor marker, etc.)"
2121,NCT04689594,Proportion of subjects without stenosis,2021-02-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2122,NCT01934829,Prophylactic topical application of ointment to reduce the hand-foot skin reactions in patients with hepatocellular carcinoma treated with sorafenib,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,The percentage of patients discontinuing treatment
2123,NCT00006221,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2124,NCT01668381,"variation of serum IL-10,TGF-β1,IFN-γ concentration of HCC patients before and 1,4 weeks after radiofrequency ablation therapy",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,"variation of suppression ability of CD4+CD25+ T cells of HCC patients on cytokine secretion before and 1,4 weeks after radiofrequency ablation therapy"
2125,NCT04196465,Major pathologic response rate,2019-09-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Discovery of predictive and/or prognostic biomarkers,Patterns of cancer progression/relapse
2126,NCT03128281,Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery,2018-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
2127,NCT03383367,participation rate at future colonoscopy,2017-08-24,UNKNOWN,INTERVENTIONAL,['NA'],,Cost-utility analysis of the reminder letter for surveillance colonoscopy
2128,NCT06135558,DFS,2016-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
2129,NCT01851941,"clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy",2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Pharmacologic Genetic Marker,overall survival
2130,NCT01086683,psychosocial well-being (as assessed by the EORTC-QLQ C30 Quality of life core questionnaire by the European Organization of Research and Treatment in Cancer (EORTC-QLQ C30) and the Profile of Mood States Short form (POMS-SF),2004-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,self-efficacy as measured with the General Self-Efficacy Scale (GSE)
2131,NCT04066491,Double-blind Part: Overall Survival,2019-09-20,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Double-blind Part: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), Treatment Related TEAEs and Adverse Events of Special Interest (AESIs) According to NCI-CTCAE Version 5.0"
2132,NCT04202523,DFS,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
2133,NCT06221423,Overall Survival (OS),2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2134,NCT04275986,Adverse events (AE),2020-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QOL): questionnaires
2135,NCT00126256,"Progression-free survival after two lines of chemotherapy, defined as the time duration from randomization until progression after two lines of chemotherapy or death whatever the cause in the absence of progression or last-follow-up",2002-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Costs
2136,NCT01398449,Overall survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Failure pattern
2137,NCT00002475,Survival (patients without evaluable disease),1991-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2138,NCT02153450,Dose-limiting toxicity (DLT) rate scored according to the National Cancer Institute Common Toxicity Criteria version 4,2015-05-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
2139,NCT03694522,Progression-Free Survival (PFS),2018-09-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-emergent Adverse Events (TEAEs)
2140,NCT05786482,Hospital Anxiety and Depression Scale (HADS),2023-02-12,RECRUITING,INTERVENTIONAL,['NA'],Sleep (Exploratory),Satisfaction and Adherence
2141,NCT04780802,The change in the perfusion pattern of HCC tumors,2022-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
2142,NCT02871115,Rates of study enrollment,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Rates Of Appropriate Influenza Vaccinations
2143,NCT03794440,Progression-free survival (PFS),2019-02-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EORTC QLQ-HCC18
2144,NCT02363374,"Number of patients with pathological complete response (pCR), i.e. ypT0N0.",2015-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2145,NCT01486745,,2008-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
2146,NCT02024217,R0 resection rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],over-all survival,safety and tolerability of the treatment regimen
2147,NCT00336609,,2005-11,UNKNOWN,OBSERVATIONAL,['NA'],,
2148,NCT03332433,Incidence of hypoxia,2017-11-10,COMPLETED,INTERVENTIONAL,['NA'],,Other adverse events
2149,NCT03820921,Feasibility of MMR status analysis on EUS-FNB pancreatic specimens,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Progression-free survival
2150,NCT04193696,Objective response rate,2020-01-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Abscopal effects rate
2151,NCT04831827,Primary Endpoint (intention-to-treat),2021-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Secondary Outcome (per protocol analysis)
2152,NCT02159898,Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,GERD-HRQL
2153,NCT03988556,Rate of discontinuation due to AEs,2019-07-04,COMPLETED,INTERVENTIONAL,['NA'],Use of the device - Cumulative dose,Oral mucosa lesions assessment - Time until resolution
2154,NCT01322178,Resection rate (R0),2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
2155,NCT00068380,"Baseline Gene Expression Levels of the Target Genes (PDGF-R and PDGF), Genes Associated With Induction of Apoptosis (Bcl-2, Bax), and Cell Cycle Regulatory Genes (p53, p21, p27",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2156,NCT01943786,To estimate the proportion of patients with advanced colorectal cancer in whom KRAS mutation can be detected in circulating extracellular DNA,2013-04,UNKNOWN,OBSERVATIONAL,['NA'],,Number of each adverse event per cycle
2157,NCT06158919,PFS,2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],,OS
2158,NCT03348150,overall survival,2017-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,costs and health benefits
2159,NCT02344810,Progression-free survival (Phase II),2015-03-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of MET amplification and MET expression as determined by DAKO IHC (Phase II)
2160,NCT02981524,Objective Response Rate (ORR),2017-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
2161,NCT00002716,Time to progression,1996-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2162,NCT00589030,,2007-04,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
2163,NCT00614653,"Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate of Addition of Bevacizumab and Erlotinib to Capecitabine-Based Chemoradiation
2164,NCT00215956,Side Effect Profile of Topotecan,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
2165,NCT00508443,Patient Response (Pain Relief),2002-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2166,NCT02964455,Maximum tolerated dose,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dynamic plasma concentration of docetaxel and nedaplatin
2167,NCT02449135,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
2168,NCT05451849,Phase 2 - Disease Control Rate (DCR),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2169,NCT02498353,pathological complete remission rate,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,toxicity of radiotherapy based on the CTCAE v3.0 (common terminology criteria for adverse events，CTCAE v3.0)
2170,NCT01909856,Complete Response(CR) within 24-120 hours after chemotherapy,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse events
2171,NCT00154531,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
2172,NCT02328664,Sensitivity of biopsies for residual cancer,2015-08,TERMINATED,INTERVENTIONAL,['NA'],,The proportion of patients with residual cancer in the resected specimen if malignancy was unsuspected during the endoscopic polypectomy
2173,NCT05352165,Pathologic Complete Response,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,anus-saving rate
2174,NCT01955837,Overall Survival（OS）,2013-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival (PFS) (Mutant Type KRAS)
2175,NCT00971841,Number of Adverse Events (AEs) Per Participant,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Complete Response to Tumor
2176,NCT02774447,Number of patients who were able to return home after day-case closure of loop-ileostomy,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
2177,NCT05672524,Clinical complete response of study participants,2022-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2178,NCT04693754,"Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever)",2020-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2179,NCT00602602,Progression-free survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of potentially resectable patients who are able to proceed to successful resection
2180,NCT04104074,Incidence of treatment-emergent adverse events,2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
2181,NCT02356471,Number of Patients Who Self-report Wearing the Consumer-based Activity Monitor at Least 16 Days of the 21 Day Period,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Change in Fatigue Assessment- Fatigue Visual Analog Scale (FVAS).
2182,NCT00819780,Progression-free Survival (PFS),2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs)
2183,NCT03375281,1 year local tumor progression,2017-11-20,COMPLETED,INTERVENTIONAL,['NA'],,
2184,NCT00508404,Objective Response Rate,2007-05-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Resection Rate
2185,NCT02060669,Progression free survival,2010-06-20,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2186,NCT00538850,Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30),2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
2187,NCT03061435,Prevalence of abnormal anal cytology and hrHPV DNA in women with VIN 2/3 or vulvar cancer,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,"Assess t he correlation between abnormal anal cytology, hrHPV DNA, and AIN"
2188,NCT01160419,Collection of the R0-Resection rate,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2189,NCT00699881,time to progression,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
2190,NCT02852525,Sensitivity and Specificity of probe based endomicroscopy as compared to histopathology in diagnosing Barrett's metaplasia,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Tissue and blood Biomarker evaluation in targeted biopsies obtained at endomicroscopy in patients diagnosed to have Barrett's metaplasia and dysplasia
2191,NCT01318447,Local recurrence-free survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Local recurrence-free survival
2192,NCT05394246,Tumor lesions,2022-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
2193,NCT01003808,"To evaluate the maximum tolerated dose, dose-limiting toxicities, type/frequency/degree of adverse events and NY-ESO-1 antigen-specific immune response of IMF-001 alone in patients with esophageal cancer.",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate clinical activity (tumor response and time to progression).
2194,NCT03413436,overall survival,2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE4'],,toxicities of adjuvant chemotherapy
2195,NCT01416688,Psychometric properties of the FACT-EGFRI 18,2011-11-15,COMPLETED,OBSERVATIONAL,['NA'],,"Feasibility as measured by accrual, time to specified accrual, time to complete forms"
2196,NCT05727852,Indicators of arterial stiffness,2023-01-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Composite of clinical records
2197,NCT01178801,the relationship between the clinical data and the decision of treatment strategies,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
2198,NCT01790633,Accessibility of Testing Results,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Proportion of Rapid Test Failures,Access to Care
2199,NCT03147768,PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss,2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE1'],SECONDARY EFFICACY: Total hospital stay (Duration and cost Metric ),SECONDARY SAFETY: Surgical space abscess
2200,NCT03444051,pancreatic mass anatomopathological characterization,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
2201,NCT03255343,size of tumor,2017-03-13,UNKNOWN,INTERVENTIONAL,['NA'],,HPFS
2202,NCT02563054,Time to disease progression,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
2203,NCT01869088,Overall survival time,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Tumor response
2204,NCT01374425,PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels
2205,NCT00422877,Response Rate,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival
2206,NCT05215574,Incidence of Adverse Events,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Patients with Objective Responses
2207,NCT04129177,Surgical site infection rate,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
2208,NCT02317731,Bowel preparation quality,2014-12,TERMINATED,INTERVENTIONAL,['NA'],,Tolerability will be measured by subjective survey including a 5-point scale and a visual analog scale filled by the subjects the day of the colonoscopy
2209,NCT05379985,Number of Participants with Dose-Limiting Toxicity (DLT),2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
2210,NCT02106884,QOL Global Health Status Deterioration-free Median Survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory Safety Assessment
2211,NCT00040599,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2212,NCT06034964,OS,2020-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Safety and Tolerability
2213,NCT04992143,1-year survival rate,2021-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
2214,NCT00749450,3-year disease-free survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4"
2215,NCT06308328,The AUC of the predictive model,2024-04-01,RECRUITING,OBSERVATIONAL,['NA'],,The important predictors of severe oropharyngeal mucositis in the predictive model
2216,NCT01444495,local and systemic recurrence rate,1999-01,COMPLETED,INTERVENTIONAL,['NA'],,downstaging of rectal cancer
2217,NCT03279289,Progression-free survival,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with efficacy parameters,VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration
2218,NCT00004931,DFS rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival rate
2219,NCT04319757,Phase Ib/II starting dose for ACE1702,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE1'],"Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)",Evaluate immune function after administering ACE1702
2220,NCT04941300,Colonoscopy after abnormal FIT (primary),2021-06-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],Repeat screening (exploratory outcome),Follow-up process
2221,NCT02139475,Boston bowel preparation scale (BBPS),2013-12,TERMINATED,OBSERVATIONAL,['NA'],,
2222,NCT02242786,oral morphine equivalent doseresponse criteria,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life
2223,NCT05448677,Progression-Free Survival (PFS),2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate (ORR)
2224,NCT02213497,Number of Adverse Events,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
2225,NCT03192618,Disease-free survival (DFS),2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
2226,NCT04175912,Objective response rate,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Specimen banking,Overall survival
2227,NCT01739465,stent patency,2012-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,overall survival rate
2228,NCT01217060,Pathologic Complete Response (PCR) Rate,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free Survival (DFS) Time
2229,NCT00832689,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2230,NCT04602026,Health-related quality of life (composite measure),2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2231,NCT05154474,Rate of patients with sarcopenia diagnosed with metastatic cancer.,2022-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Rate of patients with sarcopenia at diagnosis across the inclusive population
2232,NCT01192971,TTP (Time to Progression),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL (quality of life): EORTC QLQ-C30
2233,NCT05704192,Overall Survival(OS),2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],,Progression free survival(PFS) per mRECIST
2234,NCT02840331,Peritoneal metastases in terms of location,2017-07-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Histological evidence of apoptosis
2235,NCT00510692,Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum.,2006-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of Subjects With Adverse Events.
2236,NCT02640586,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pCR,2016-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Predictive value of preoperative MRI(7-9 weeks after the completion of preoperative chemo-radiotherapy) for assessing pathological response according to Tumour Regression Grade (TRG)
2237,NCT06100692,oral mucositis scale,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2238,NCT03724591,Anastomosis leakage rate,2019-01,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
2239,NCT03329183,Objective Response Rate(ORR),2019-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
2240,NCT03577535,Oral mucositis grade in patients during chemotherapy and radiotherapy treatments,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Nutritional status of the patients during Chemotherapy and radiotherapy treatments
2241,NCT02412579,Using next-generation sequencing methods to detect isomiRs across different HCC cohorts at all stages undergoing liver transplantation.,2015-03,COMPLETED,OBSERVATIONAL,['NA'],,
2242,NCT00158886,To determine the MTD of oral topotecan in combination with pelvic radiation,2001-11-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,To evaluate the toxicity and potential efficacy of oral topotecan and concurrent pelvic radiation for the treatment of rectal cancer. To determine pathologic response to treatment and assessment of sphincter preservation.
2243,NCT02971345,Overall Survival,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time To Progression
2244,NCT01560533,Body representations,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,
2245,NCT02033070,Endoscopic clearance rate for Barrett's Esophagus,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Histological clearance rate for dysplasia,Histological clearance rate for intestinal metaplasia
2246,NCT01141478,Overall Survival Rate Between Time of Consent and Time of Death,2010-09-08,TERMINATED,INTERVENTIONAL,['NA'],,
2247,NCT02406118,TME quality & circumferential resection margin (CRM),2015-03-01,UNKNOWN,INTERVENTIONAL,['NA'],5-year overall survival,Number of harvested Lymph Nodes
2248,NCT04522908,Treatment discontinuation rate due to treatment-related adverse events,2020-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR)"
2249,NCT00284258,Progression free survival,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Over all survival, Response rate, Adverse event, Medical economy"
2250,NCT02524925,"Analyzing Neuropeptide Y, Cortisol and Adrenocorticotropic hormones levels in blood samples",2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Evaluating postoperative pain between the two protocols with scale
2251,NCT02580422,"The number of patients who have changes in echocardiography, pulmonary function or one or more part of their functional evaluation tests",2015-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Change in levels of cytokines
2252,NCT02426034,"Safety, which was assessed by recording the incidence and severity of adverse events",2015-05-15,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Quality of life, measured by the questionnaire of EORTC QLQ-C30"
2253,NCT04280640,Correlation between treatment response in CTCs and in vivo,2021-06,WITHDRAWN,OBSERVATIONAL,['NA'],,"Sensitivity, specificity, and predictive values of CTC cultures' treatment response"
2254,NCT04729855,HOTTIP gene expression,2022-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,EIF4EBP
2255,NCT03753789,Percentage of Lesions Where Re-ablation is Suggested,2019-11-05,TERMINATED,INTERVENTIONAL,['NA'],,Hospital Resource Utilization
2256,NCT04755452,Surgical rating scale,2020-12-23,COMPLETED,INTERVENTIONAL,['NA'],,"Other Kidney injury markers, include; TFF,VEGF, Osteoactivin, Clusterin, and Calbindin"
2257,NCT05039060,The change of gut microbiota diversity,2021-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,The change of gut microbiota metabolite
2258,NCT00538291,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2259,NCT01868139,Response Rate to Therapy,2013-06,TERMINATED,INTERVENTIONAL,['NA'],,Safety of Spray Cryotherapy in This Setting;
2260,NCT02018757,time to progression,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Proportion of Participants with Adverse Events
2261,NCT00025246,Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria"
2262,NCT04717947,Quality of the specimen,2020-02-25,UNKNOWN,OBSERVATIONAL,['NA'],,
2263,NCT02538341,GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Enzyme-linked Immune Absorbent Spot (ELISpot) Interferon Gamma (IFNg) Levels From Baseline at 6 Weeks,2016-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate Rheumatoid Arthritis Disease Activity Using the Clinical Disease Activity Index (CDAI)
2264,NCT00336856,Response Rate (RR),2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2265,NCT05607186,Correlation between mrTRG and pTRG,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Prognostic value of mrTRG on survival outcomes of rectal cancer patients
2266,NCT06003673,recurrence-free survival (RFS),2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall Survival (OS)
2267,NCT03637686,Patients with high risk of recurrence can be identified with ctDNA profiling performed immediately after treatment for CRC.,2018-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Can ctDNA detect recurrence earlier than standard-of-care?
2268,NCT01289821,Objective Response (OR),2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Stable Disease (DOSD)
2269,NCT00004087,maximum tolerated dose,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2270,NCT05109130,Change of circulating tumor cells during laparoscopic or transanal endoscopic surgery,2021-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival
2271,NCT06335654,high confidence diagnosis rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2272,NCT00003307,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2273,NCT03852238,exposure to Viral hepatitis B,2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],fats,exposure to viral hepatitis C
2274,NCT01313416,"Toxicity Evaluation: From Time of First Treatment With CT-011 (Pidilizumab, MDV9300)",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease Response: Evaluated Using the Revised Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines (v1.1)
2275,NCT01333709,Ro resection rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of metastases
2276,NCT00741481,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by time to disease progression,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by tumour response rate following RECIST criteria.
2277,NCT00453323,To evaluate the response rate,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To estimate the overall survival
2278,NCT03013153,5-years overall survival rate,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,Sexual function scoring
2279,NCT06282809,Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
2280,NCT05964543,Objective response rate (ORR),2023-06-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival (PFS)
2281,NCT05873972,response rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,overall survival
2282,NCT02514525,percentage of all treated patients who have complete eradication of all dysplasia (CE-D),2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM
2283,NCT02728219,overall survival,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
2284,NCT03640208,Difference in paired pre-/post-test score,2019-02-27,RECRUITING,INTERVENTIONAL,['NA'],,Barriers faced to scheduling colorectal cancer screening
2285,NCT02325232,Identification of celiac patients at higher risk of developing small bowel neoplasia and evaluation of the the usefulness of VCE and DBE,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],A flowchart for early diagnosis of small bowel tumors in CD patients,The diagnostic yeld of DBE and VCE in this setting of patients
2286,NCT01031628,Evaluation of Lesions for Progression or Response Via RECIST Criteria,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,
2287,NCT00003076,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2288,NCT05040464,Variation of the endoscopic response between AZA and MTX groups,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2289,NCT00350142,Rate of Local Control,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival Time
2290,NCT04898426,Bowel preparation quality,2021-08-13,UNKNOWN,INTERVENTIONAL,['NA'],,Polyp detection rate
2291,NCT04401787,oncological outcome,2016-12-11,COMPLETED,INTERVENTIONAL,['NA'],,early locoregional recurrence
2292,NCT01763125,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,2003-11,RECRUITING,OBSERVATIONAL,['NA'],,
2293,NCT03659292,Overall survival (OS),2018-09,UNKNOWN,INTERVENTIONAL,['NA'],,Blood levels of ropivacaine and sufentanil
2294,NCT05568316,Biochemical Measurements,2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Lenght of Hospital Stay of Participants
2295,NCT03116152,Overall Survival,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
2296,NCT04535492,"Rate of successful completion of colorectal cancer screening noted via electronic health record having colonoscopy, fecal occult blood, or non invasive screening option result for the patient.",2022-01-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Average score of clinician experience and satisfaction as assessed via Likert scale survey.
2297,NCT05092880,progression-free survival,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost-effectiveness: Productivity Cost Questionnaire (PCQ)
2298,NCT05059665,Evaluate the performance (sensitivity/specificity) of the HelioLiver Test for all stage HCCs,2020-04-20,COMPLETED,OBSERVATIONAL,['NA'],,
2299,NCT00083720,Number of Participants With Serious Adverse Events,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2300,NCT04053231,Overall Survival,2019-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of redo-surgery
2301,NCT04711434,The percentage of patients from randomization to the first appearance of one of the following: adenomatous polyps or second primary tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival
2302,NCT02316028,toxicity of escalating doses of decitabine administered by HAI,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,measuring Global DNA methylation of cell free DNA
2303,NCT01939223,Disease Free Survival (DFS) as Assessed by the Investigator,2013-12-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
2304,NCT05035381,Objective response rate,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
2305,NCT00179751,"Phase II-To explore the anti-tumor activity of the combination of lenalidomide on days 1 - 21 and gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.",2005-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II-To evaluate the safety profile of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.
2306,NCT02804802,Colorectal cancer diagnosed by colonoscopy after a positive fecal occult blood test (Hemoccult II),2013-02,UNKNOWN,OBSERVATIONAL,['NA'],,
2307,NCT05662813,Objective response rate,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
2308,NCT00411450,Time to Response,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Developed Antibodies to Panitumumab
2309,NCT06190652,PFS,2018-10-13,COMPLETED,OBSERVATIONAL,['NA'],,RP
2310,NCT04178759,Volume of regenerated liver after liver resection,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of short term surgical outcomes
2311,NCT03813953,Overall survival in months,2019-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,Disease free survival
2312,NCT01248299,Overall survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cost analysis
2313,NCT00843830,"The Percentage of Participants That Patients Complete Radiation Therapy, All Three Vaccinations, and Evaluation for Tumor Response Four Weeks After the Third Vaccination.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Patients That Respond to Treatment
2314,NCT05634525,Overall survival (OS),2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2315,NCT05176834,Proportion of patients performing at least 50% of expected daily treatments during radiotherapy period.,2022-01-31,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of the patients that will experience severe oral mucositis
2316,NCT00540943,The safety and tolerability of the maximum tolerated dose defined as a dose regimen where no more than 1 of 6 subjects experiences a dose limiting toxicity.,2007-07-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression
2317,NCT05713903,Mesocolic Resection Plane,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
2318,NCT01189227,Recurrence-free Survival (RFS),2010-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Frequencies of Adverse Events as Assessed by the NCI CTCAE v4.0
2319,NCT01054274,Overall survival and Median Survival,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Successful rate of stent placement
2320,NCT04288661,POD of intra-abdominal complication detection,2020-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Readmissions
2321,NCT06289803,diagnostic efficacy,2023-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of R0 resection
2322,NCT01590147,"Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate, adherence, and retention)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],,"Mediating variables (self efficacy, response expectancies, inflammatory biomarkers) intervention effect on fatigue, treatment-related symptoms, and QOL"
2323,NCT01930383,Numbers of circulating tumor cells,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Clinical characteristics
2324,NCT02535988,The proportion of patients with an abscopal response assessed at 7-8 weeks after the initiation of treatment.,2015-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"The proportion of patients alive with abscopal responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study."
2325,NCT00513461,Change in Serum AFP Levels,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Quality of Life - Mental Score
2326,NCT00069121,Disease-Free Survival (DFS) [Time to Event],2003-04-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With at Least One Adverse Event by Most Severe Intensity
2327,NCT02009423,Recurrence Free Survival (RFS),2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
2328,NCT03500874,3 Year Relapse Free Survival Rate,2018-05-28,TERMINATED,INTERVENTIONAL,['PHASE3'],Serum ctDNA methylation levels,Liver-specific RFS
2329,NCT04523493,Overall survival (OS),2020-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor mutation burden (TMB),Immunogenicity
2330,NCT03459339,Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2331,NCT03093870,Progression-free Survival (PFS) - Part 1,2017-07-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,ECOG Performance Status - Part 1
2332,NCT01097265,Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2),2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2)
2333,NCT04168931,Frequency of HER2 expression,2020-01-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2334,NCT02948985,Correlation of RAS status on CTCs with clinical outcomes,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation of mutant gene in ctDNA with cetuximab resistance.
2335,NCT06016829,EORTC-QLQ-CR29,2021-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
2336,NCT01434069,Maximum Tolerated Dose (MTD),2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Tumor Response
2337,NCT04131062,MyCode enrollment decision,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
2338,NCT05116917,Objective response rate (ORR),2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related adverse events as assessed by CTCAE v5.0
2339,NCT01652833,Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
2340,NCT00087074,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
2341,NCT03750461,Number of Participants With Wound Occurrences in Current Study Compared to Historical Controls,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life After Mesh Implantation
2342,NCT00183885,Tumor Response,2004-10-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with grade 3 or higher toxicity
2343,NCT01086618,Overall survival for ≥ 2 years (phase III),2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Economic evaluation (phase III)
2344,NCT04140435,The increment in diagnostic yield,2019-10-22,RECRUITING,OBSERVATIONAL,['NA'],,The inter-observer agreement
2345,NCT05220722,Phase 2: To Assess Overall Response Rate (ORR),2022-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: To Assess Overall Survival (OS)
2346,NCT03259828,Interfraction sigmoid colon organ motion,2017-12-06,COMPLETED,INTERVENTIONAL,['NA'],,Setup errors
2347,NCT05861505,Overall survival (OS) per patient,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-effectiveness ratio (ICER)
2348,NCT00598546,"Instrument: EORTC QLQ-C30, QLQ-STO22, and MSK-10. The intent of this study is to assess QOL in long-term survivors of all surgical procedures performed for the treatment of gastric cancer.",2004-09,COMPLETED,OBSERVATIONAL,['NA'],,
2349,NCT00002783,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2350,NCT03015675,Progression Free Survival,2017-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Response Rate
2351,NCT03045770,Adverse Event（AE）,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
2352,NCT00132704,apoptotic response,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,
2353,NCT02850783,Identification rate of SLNM with preoperative PET/CT imaging and intraoperative NIR fluorescence imaging in patients with colon carcinoma.,2015-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
2354,NCT01774786,Overall Survival,2013-06-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cmin of Trastuzumab
2355,NCT06193356,Performance of detecting a recurrence at an endoscopic resection scar.,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Performance of a learning tool in improving detection of recurrence at an endoscopic resection scar compared between endoscopists with different experience level
2356,NCT04649372,Incidence of Treatment-Emergent Adverse Events (CTCAE),2021-01-13,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Pain pre and post-treatment
2357,NCT03362177,Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,AEs/SAEs overall safety of romiplostim
2358,NCT03804255,"Factors influencing heterogeneity of capacity for biomarker testing, from among modifiable testing practice-related factors, e.g. cost, complexity, technologic complexity, lack of familiarity, physician and patient demand",2019-01-08,WITHDRAWN,OBSERVATIONAL,['NA'],,Proportion of pathology practices testing for novel biomarkers using a standard reflexive testing protocol
2359,NCT02013089,Overall survival,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],Disease control rate,Response rate
2360,NCT00155272,The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.,2005-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.
2361,NCT04965259,Changes in the profile of metabolome in urine and plasma as high-risk patients develop HCC.,2021-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
2362,NCT04387903,Tumor recurrence,2000-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for surgical reoperation
2363,NCT01008917,Maximum tolerated dose,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Incidence of progression-free survival, overall survival, and disease control rate"
2364,NCT02507765,"Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures",2015-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in plateau signal intensity calculated from the DCE curve,Progression-free survival
2365,NCT05103631,Number of Patients with Dose Limiting Toxicity,2021-06-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
2366,NCT00873600,"Chemotherapy tolerability as measured by dose reduction, treatment delay, and incidence of grade 3-5 toxicities",2007-10,WITHDRAWN,OBSERVATIONAL,['NA'],,3-year disease-free survival
2367,NCT04288999,Locally recurrent free survival,2019-10-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,QOL
2368,NCT00054249,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2369,NCT03461354,AUC for the Oral Mucositis Daily Questionnaire mouth and throat soreness question #2,2018-04-09,RECRUITING,INTERVENTIONAL,['NA'],Drug-related adverse events,Oral mucositis grade
2370,NCT00343408,,2005-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2371,NCT03239184,Relief degree of tumors,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
2372,NCT05400408,identification of Volatile Organic Compounds that can be related to Colorectal malignancy.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Test Sensitivity and specificity for pancreatic cancer.
2373,NCT05065515,Degree of tumor regression,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],Species richness,The relative abundance of species
2374,NCT06295094,Peritoneal disease-free survival,2024-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients not receiving adjuvant chemotherapy
2375,NCT01774643,"Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
2376,NCT00002575,Overall survival,1994-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare the differences in quality of life of patients treated with these regimens
2377,NCT04546802,Viral eradication,2019-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Overall survival,Adverse events
2378,NCT04907643,Patient-Reported Outcomes Measurement Information System Gastrointestinal Belly Pain over 30 days from the baseline,2021-10-05,RECRUITING,INTERVENTIONAL,['NA'],Dosage of VR (minutes per week),Opioid prescriptions of Morphine Milligram Equivalents (MME)
2379,NCT03193216,Percentage of Patients With Successful Eradication,2017-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatments (Mean)
2380,NCT00427570,,1977-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2381,NCT01112046,Short-term morbidity,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Local recurrence
2382,NCT00550836,Overall Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Observed Adverse Effects
2383,NCT00138060,tumor response rate,2005-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,pharmacokinetics
2384,NCT01298999,Number of Participants That Experienced Change in Any Biomarker Expression,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants That Experienced Adverse Events
2385,NCT00220129,2 year overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to improvement of dysphagia
2386,NCT01376453,Maximum Tolerated Dose (MTD),2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Serious Adverse Events (SAEs)
2387,NCT05066139,Impact of EPODIG-G program on treatment.,2021-09-17,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
2388,NCT06019702,Dose-limiting Toxicity (DLT),2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
2389,NCT03740165,PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants,2018-12-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathological Complete Response (pCR) Rate
2390,NCT03306394,Abnormalities in vital signs,2016-10-18,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life using the questionnaire EORTC QLQ-C30
2391,NCT05410535,The survival rate of gastric cancer,2021-09-15,RECRUITING,INTERVENTIONAL,['PHASE4'],,
2392,NCT04316182,Rate of AEs leading to treatment discontinuation,2020-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of patients who develop new extra-hepatic spread
2393,NCT05248750,Overall survival,2021-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
2394,NCT01980407,Response rate,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
2395,NCT03011255,Local control,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2396,NCT05446558,Overall survival,2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Cost of tests during hospitalization
2397,NCT02729493,Disease control rates,2015-11-14,UNKNOWN,INTERVENTIONAL,['NA'],,
2398,NCT00362739,Establish a set of normal ranges for various parameters in healthy individual specimens and compare to specimens from individuals with lung disease to determine parameters resulting in disease susceptibility and severity.,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
2399,NCT04525807,Objective response rate,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
2400,NCT02298959,Recommended combination dose of ziv-aflibercept and pembrolizumab,2015-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Effects on tumor vasculature and vascular active molecules,Time-to-progression
2401,NCT06060769,HCC incidence rate,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
2402,NCT01675258,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
2403,NCT03896646,Tumor objective response rate (ORR),2019-10-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Development of a model correlating normal liver radiation dose to liver function using single-photon emission computed tomography computed tomography hepatobiliary iminodiacetic acid (SPECT CT HIDA) imaging
2404,NCT05962723,"sensitivity, specificity and accuracy",2023-08-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2405,NCT02293811,Analysis of expression of P2RX7,2015-02-09,TERMINATED,INTERVENTIONAL,['NA'],,Five isoforms of the P2RX7 protein
2406,NCT01197118,overall survival,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2407,NCT03929094,Progression Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
2408,NCT04410601,Evaluation of Dysphagia- Esophago-gastro-duodenoscopy (EGD),2020-05-14,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of Standard Dysphagia Rehabilitation
2409,NCT05493995,Disease Control Rate (DCR),2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
2410,NCT03960021,Immune response triggered by RFA: Quantification of interaction of PD-1 and PD-L1 in lung metastases using immune Förster Resonance Energy Transfer (iFRET).,2019-03-04,COMPLETED,INTERVENTIONAL,['NA'],,Change from baseline metastatic disease at 12 months
2411,NCT01483040,The primary endpoint is reaching the cecum of the colon with PeerScope B S,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
2412,NCT06155383,Pathological complete response (pCR) rate,2023-11-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
2413,NCT05751850,Overall survival (OS),2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression free survival (PFS)
2414,NCT00828594,Time to disease progression assessed when 60 events have been observed,2008-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmokinetics of RAD001 at pre-dose and 1 hour and 2 hours post-dose
2415,NCT01715363,Clinical tolerance of immediate preoperative chemotherapy,2012-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2416,NCT01923948,Postoperative Opioid Consumption,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative Pain Scores on the Visual Analog Scale
2417,NCT01771146,Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer,2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,• R0 resection as defined as microscopically negative margins
2418,NCT00147134,Overall survival,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,The proportion of completion of LAP
2419,NCT02908451,Adverse events (AEs) graded according to CTCAE v4.03.,2017-04-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Response Rate Evaluated by Response Evaluation Criteria in Solid Tumor (RECIST)
2420,NCT03641313,Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Presence of other deoxyribonucleic acid (DNA) damage response defects (DDRD),Overall survival (OS)
2421,NCT01085617,Event-free survival,2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Mucositis score in patients treated with palifermin
2422,NCT03393416,Incidence of Treatment-Emergent Adverse Events（Safety）,2018-04-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
2423,NCT02503111,Anal dysplasia treatment on a per-patient basis,2015-11,TERMINATED,INTERVENTIONAL,['NA'],,Acceptability of treatment
2424,NCT02845479,Feasibility of study protocol,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],Natural kill cell activation,Feasibility of recruitment
2425,NCT05723718,Tumor Regression Grade,2022-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life score
2426,NCT00897403,Collection of blood and tissue,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
2427,NCT00491855,Maximum Tolerated Dose (MTD),2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2428,NCT03400072,M6 Health-Related quality of life (HRQoL),2018-08-03,RECRUITING,INTERVENTIONAL,['NA'],,
2429,NCT02024438,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
2430,NCT05564338,Recurrence-free survival (RFS) as assessed by the investigator between Arm B and Arm D,2023-06-30,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Participants Reported Outcome as measured at Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and its hepatocellular carcinoma cancer module QLQ-HCC18
2431,NCT03592641,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),2019-07-25,TERMINATED,INTERVENTIONAL,['PHASE2'],,Months of Progression-Free Survival (PFS)
2432,NCT06045975,local recurrence-free survival,2023-12-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)",Safety of Durvalumab/Tremelimumab infusions
2433,NCT00001603,,1996-12,COMPLETED,OBSERVATIONAL,['NA'],,
2434,NCT02450656,Progression Free Survival (Phase II),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pharmacogenetics profiling to assess predictors of response and resistance- inducing mutations,"Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)"
2435,NCT01352728,Two-year survival rate,2011-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tissue and Serum Biomarkers
2436,NCT03722121,"distance ""home of patients - treatment center""",2017-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,
2437,NCT05361538,Comparison of progression-free survival between MSA and traditional MWA in HCC,2022-06-22,RECRUITING,INTERVENTIONAL,['NA'],,Comparison of the complications rate of MSA and traditional MWA in HCC
2438,NCT01961778,Percentage of Barrett's esophagus ablated during the initial treatment session.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Patient discomfort
2439,NCT00192088,The primary objective of this study is to determine the response rate of Pemetrexed plus oxaliplatin as first-line therapy in patients with advanced gastric carcinoma.,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Determinants of efficacy and toxicity of the treatment with pemetrexed and oxaliplatin in the patient population by means of pharmacogenomic and pharmacogenetics investigations: Quantitative analysis of TS, DHFR, GARFT, RFC, MRP5, DPD, TP, FPGS and ERCC1"
2440,NCT02877368,sarcopenia,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,Imatinib-induced toxicities
2441,NCT00041808,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2442,NCT05422547,Tumour recurrence,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Possible economic impact
2443,NCT01373164,Phase 2: Overall Survival (OS),2011-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up
2444,NCT01274624,Pharmacokinetic parameters for irinotecan and 5-FU when combined with REOLYSIN®,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,"In vitro studies in human-derived colorectal cancer cells including the isogenic cell lines, to study the mechanism and scientific basis of synergy between irinotecan and reovirus"
2445,NCT05681234,Evaluation of tissue distribution of 18F-RD2,2022-08-24,COMPLETED,INTERVENTIONAL,['NA'],,
2446,NCT03981510,Children with NF1 and gastrointestinal symptoms has a longer transit time through the colon and fewer fast bowel movements than healthy children.,2019-06-13,UNKNOWN,INTERVENTIONAL,['NA'],,
2447,NCT05530343,Diagnostic yield of intestinal metaplasia (Screening population only),2022-10-03,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic yield of dysplasia (Screening population only)
2448,NCT06196788,Overall survival，OS,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
2449,NCT01610895,Quality of Bowel Cleanliness,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Patient satisfaction with preparation
2450,NCT00121745,To determine the dose limiting toxicity and maximum tolerated dose of Rexin-G administered as intravenous infusions; To evaluate pharmacokinetics of Rexin-G,2005-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,To assess anti-tumor activity of intravenously administered Rexin-G and obtain preliminary data on biochemical markers of tumor response
2451,NCT05379790,Maximum-tolerated dose,2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Curve (AUC) ratio intraperitoneal/systemic irinotecan
2452,NCT01381913,,2005-10,COMPLETED,OBSERVATIONAL,['NA'],,
2453,NCT03871790,Identification of tumor specific mutations on the genomic level,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Identification of neo-antigens epitopes at protein level
2454,NCT00364078,,2006-06,COMPLETED,OBSERVATIONAL,['NA'],,
2455,NCT00027495,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2456,NCT05679674,Median Progression Free Survival (PFS),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapy-Free Interval
2457,NCT04343950,Intervention 3: Participation in breast cancer screening program,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,Incremental cost ratio
2458,NCT02994888,Track and validate specific known mechanisms of resistance/response to anti-EGFR therapies through,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Identify novel biomarkers of resistance to anti-EGFR therapies through whole exome sequencing
2459,NCT05668910,The performance of each single feature and the ensemble model with integrated features for early GC detection in each clinical stage,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,"The performance of the ensemble model in combination of possible GC related biomarkers such as PG, G17, and/or Hp levels for early GC detection"
2460,NCT00262847,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)
2461,NCT05724992,Presence - absence of predisposing mutations,2022-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Correlation of genetic mutations with familial oncological history
2462,NCT01630174,,2009-10,UNKNOWN,OBSERVATIONAL,['NA'],,
2463,NCT00424827,"Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Associated With This Regimen.
2464,NCT03950908,Identification of signet ring cell carcinoma (SRCC) foci.,2017-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Dose of sedation.
2465,NCT01433016,PDR Peak,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2466,NCT04988945,Downstaging for hepatectomy,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological response
2467,NCT04550897,Adverse Events related to BM7PE,2020-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Radiological response to BM7PE
2468,NCT01171924,Number of Participants With Adverse Events,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2469,NCT03349398,the incidence of Roux stasis syndrome,2017-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,the quility of life according to the RGB standards
2470,NCT06281145,Primary endpoint - Working memory,2024-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Secondary endpoint - Serious Adverse Events (SAE)
2471,NCT00695201,Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels."
2472,NCT06010212,ORR（Objective response rate）,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS（Progression-free survival）
2473,NCT06087263,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
2474,NCT03083951,Total number of lymph nodes and lymph node ratio.,2017-09-01,COMPLETED,INTERVENTIONAL,['NA'],Defecatory dysfunction assessed by FSFI and erectile dysfunction questionnaires,Survival
2475,NCT04347772,Length of hospital stay,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional status - Dietary Intake
2476,NCT05817370,Change in HSIL treatment,2023-05-02,RECRUITING,INTERVENTIONAL,['NA'],,Change in Maintenance of HSIL screening and treatment
2477,NCT03582306,Feasibility - adherence,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability
2478,NCT03002064,Progression free survival,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life--Score of the questionnaire
2479,NCT03338647,"Progression (total of local, intra- and extrahepatic)",2017-10-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Cost-benefit
2480,NCT06323421,Acceptability,2024-04-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Systemic inflammation,
2481,NCT05818982,Progression-free survival,2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
2482,NCT05948826,Recommended Phase 2 Dose (RP2D),2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-3-600
2483,NCT00971399,complete response of RINV (no vomiting and no rescue medication),2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2484,NCT04117958,Number of subjects with changes in electrocardiogram (ECG),2020-01-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Overall survival (OS), 2-year OS"
2485,NCT05208047,Part 2 - Progression Free Survival (PFS),2022-04-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
2486,NCT03998566,Safety Endpoint,2019-04-24,COMPLETED,INTERVENTIONAL,['NA'],"Changes From Baseline Final RT Appointment, 3 Months, 6 Months, 12 Months, and 18 Months in QLQ-PAN26","Changes From Baseline at the Final RT Appointment, 3 Month, 6 Month, 12 Month and 18 Month in EORTC QoL (QLQ-C30)"
2487,NCT03427684,Maximum tolerated dose AND Dose limited toxicity,2016-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2-year disease-free survival
2488,NCT01950572,sample aquisition,2013-09-09,RECRUITING,OBSERVATIONAL,['NA'],,
2489,NCT05398380,Five years overall survival,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Percentage of patients with circulating tumor DNA (ctDNA),Changes in quality of life assessed by EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30)
2490,NCT00888797,Rate of recurrent and metastatic cancer,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Early postoperative morbidity and mortality
2491,NCT02102022,Objective response rate (ORR),2014-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AFP (alpha feto-protein) changes
2492,NCT04258072,Progression-Free Survival (PFS),2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2493,NCT01669044,Cardiac output,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],Systemic Venous Resistance Index,Stroke Volume
2494,NCT03663062,Risk model of colorectal adenomas and CRC,2017-12-27,COMPLETED,OBSERVATIONAL,['NA'],,The incidence of colorectal adenomas or CRC in patients who are smokers or who have high alcohol intake
2495,NCT01529827,Transplant Related Mortality (TRM),2012-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Time to Neutrophil Engraftment
2496,NCT02598687,Dose Limiting Toxicity (DLT ),2015-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,metabolic response
2497,NCT00125034,Best Overall Response Rate - Independent Review Committee (IRC),2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety - Number of Patients Experiencing Any Adverse Event
2498,NCT01347333,Local Tumor Recurrence Rate,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Late Complication Rates
2499,NCT03730675,Overall survival,2018-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Treatment Safety in terms of type, incidence, severity timing, seriousness, and relatedness of adverse events and laboratory abnormalities"
2500,NCT02135822,Overall response rate,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
2501,NCT01770275,Overall survival,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Survival distinction
2502,NCT06284746,Objective Response Rate（ORR）,2023-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events during treatment
2503,NCT03931304,Evaluation of 3-years disease free survival,2018-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
2504,NCT00967616,"Percentage of Participants With Progression-Free Survival at 16 Weeks After Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer",2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following Administration of CS-7017 Combined With Irinotecan, Leucovorin, and 5-Fluorouracil (FOLFIRI) After Failure of First-line Therapy in Treatment of Metastatic Colorectal Cancer"
2505,NCT06178198,Duration of response according to localized mRECIST,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],Post-treatment dosimetry based on Y90 PET-CT,Changes in regional liver function
2506,NCT04724239,The progression-free survival (PFS) rates at 18 weeks,2021-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
2507,NCT05385900,"Pathological complete response, pCR",2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"major pathologic response, MPR"
2508,NCT03723915,Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,2018-11-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Immune Response Determined by Analysis of pre-and Post- Treatment Biopsies and Blood-based Immune Markers
2509,NCT01123876,Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens."
2510,NCT01749722,Number of adverse events,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,
2511,NCT05630937,Objective Response Rate (ORR) (Phase II),2020-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
2512,NCT03597204,"Number of subjects diagnosed colonic adenoma, advanced adenoma or cancer",2015-10-07,COMPLETED,INTERVENTIONAL,['NA'],,
2513,NCT03026140,Disease free survival,2017-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Relapse free survival
2514,NCT05578820,Pharmacokinetics (Quantitative content of plasmid DNA (pTKhGM) in patients' urine),2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2515,NCT01651832,proportion of eligible patients undergoing adjuvant chemo therapy,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Quality of inpatient care
2516,NCT04487717,Prognostic group's 5-yr Overall Survival(OS) rate,2020-07-29,RECRUITING,OBSERVATIONAL,['NA'],,Subgroup analysis
2517,NCT02371135,"association of the gut microbiome and dietary factors (To validate said associations, individual questions from the Brief Diet and Lifestyle Questionnaire will be primarily used in the overall analyses)",2015-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2518,NCT04425876,R0 resection rate,2020-12-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Minimum concentration (Cmin)
2519,NCT00921661,Dose-limiting toxicity (DLT) combination with FOLFIRI,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
2520,NCT04170257,"Negative predictive value (NPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus",2019-10-18,UNKNOWN,INTERVENTIONAL,['NA'],,Discrimination of visualized abnormal features
2521,NCT04822103,Feasibility of immunochemotherapy defined as at least 80% of the patients completed all planned courses,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Major pathological response
2522,NCT05157451,Feasibility of enrollment (enrollment rate),2023-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to next treatment
2523,NCT04844385,progression-free survival rate,2021-02-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life assessed by QLQ-C30
2524,NCT03841110,The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.,2019-02-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of FT500 persistence
2525,NCT00280007,"to assess collateral tumor vessel growth on MRT / CT after 3, 6, and 12 months",2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,cost
2526,NCT03283956,Safety of the DC bead TACE,2017-09-13,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor response
2527,NCT03607370,Complete pathologic response assessed by pathologist Dworak scale,2017-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Urinary catheter removal timing
2528,NCT03974542,rescreening of CRC,2019-10,UNKNOWN,INTERVENTIONAL,['NA'],,
2529,NCT05643859,Change in microbiome colonic mucosa: microbiome diversity,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
2530,NCT04134897,2-year local recurrence rate,2019-10-14,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Preoperative tumor-associated complications rate
2531,NCT02041507,Adenoma Detection Rate.,2014-02,COMPLETED,INTERVENTIONAL,['NA'],Patients willingness to repeat the examination.,Need for sedation/analgesia and its dosage
2532,NCT03744624,Operative time,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mortality
2533,NCT05411783,Anastomotic leak,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Post-operative complications
2534,NCT00193128,"Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery",2004-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
2535,NCT04394585,Eating restriction score (XEatR) at 3 months postoperatively,2020-04-20,RECRUITING,INTERVENTIONAL,['NA'],,seum hemoglobin
2536,NCT03492151,Accuracy of risk-stratification of IPMNs,2018-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Imaging quality
2537,NCT02613260,Completion of FIT- one year,2016-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Cost
2538,NCT00769405,Overall survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Morbidity from surgical complications (abdominal, extra-abdominal, aplasia)"
2539,NCT06029010,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥5 months",2023-08-31,COMPLETED,OBSERVATIONAL,['NA'],,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥4 months"
2540,NCT01897454,Percentage of Participants Achieving R0 Resection (R0 Resection Rate),2012-01-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,Vascular Reconstruction
2541,NCT01210235,Completion of colorectal cancer screening by eligible patients within 3 months of their flu shot,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
2542,NCT02576509,Overall Survival (OS),2015-12-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Efficacy Based on PD-L1 Expression - ORR
2543,NCT04017455,clinical complete and near-complete response rate,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,local recurrence rate at 1 year follow-up
2544,NCT03493763,Time of hepatocellular carcinoma recurrence,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse effect of 5hmC blood test
2545,NCT00648635,Quality of Life (QOL) Survey Responses,2008-03-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2546,NCT01944137,Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,"Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline"
2547,NCT00030862,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2548,NCT02461966,Serum Aflatoxin Level in Liver Cancer Patients,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
2549,NCT06239155,Progress free survival (PFS),2019-09-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2550,NCT02392143,Colorectal Cancer Screening,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,
2551,NCT04031625,Patient survival,2012-11-26,UNKNOWN,OBSERVATIONAL,['NA'],,Collection of patient and treatment characteristics
2552,NCT02465112,relapse-free survival (RFS),2015-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Impact of the therapy on 5-year RFS in treatment and control group
2553,NCT00931229,enroll 150 patients,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,
2554,NCT05511116,Inter-observer reproducibility,2022-07-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Tumor response on morphological imaging vs. tumor response grade on pathology
2555,NCT02028845,The cannulation success rate,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,"The duration of the cannulation, immediate and late complications."
2556,NCT03439462,"Progression-free Survival at 6 Months (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)",2018-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Overall Response Rate (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)"
2557,NCT02035072,Proportion of resectable patients,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS/local PFS)
2558,NCT00155727,,2000-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2559,NCT02301481,R0 resection rate,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Comparison of dosimetric differences between radiation techniques,Overall survival
2560,NCT05604560,Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS)
2561,NCT03158779,Overall survival,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free-survival of treated patients
2562,NCT01351194,overall survival,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
2563,NCT00632333,Safety(toxicities as assessed by NCI CTCAE version3),2008-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,survival
2564,NCT05178524,Species composition and differential analysis of gut microbiota,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
2565,NCT04296058,Disease free survival (DFS),2007-01-08,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2566,NCT02442583,Change in number of minutes per day of bouts of sedentary behaviors.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,"Covariation between baseline use of an ActiGraph, and self-reporting of sedentary behaviors"
2567,NCT05431530,Frequency of major LARS after surgery,2022-06-22,RECRUITING,OBSERVATIONAL,['NA'],,EOTC QLQ-C30
2568,NCT00721916,Progression free survival (PFS),2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
2569,NCT05281783,The efficacy,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events [Safety]
2570,NCT00096967,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2571,NCT01064622,Progression-free Survival,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Activity (Overall Response Rate) in Crossover Patients
2572,NCT04462354,Postoperative pancreatic fistula rate (PPF),2020-06-04,UNKNOWN,INTERVENTIONAL,['NA'],,Other complications.
2573,NCT05744219,Recovery after iv Iron,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Performance status
2574,NCT00005870,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
2575,NCT05497947,SOAL- VF,2021-07-03,COMPLETED,OBSERVATIONAL,['NA'],,
2576,NCT06157216,3-year Disease-Free Survival (DFS) rate,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],Association between prognosis with multi-omic sequences,3-year Overall Survival (OS) Rate
2577,NCT06184698,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
2578,NCT04140318,ORR,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
2579,NCT05447923,Colorectal cancer disparities seen in people of color and minority populations,2022-05-22,RECRUITING,INTERVENTIONAL,['NA'],,
2580,NCT01231399,Overall Survival,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2581,NCT00200200,To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer,2004-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors"
2582,NCT00145314,"To compare efficacy, as measured by time to disease progression, of treatment with cetuximab in combination with the FLOX regimen compared to FLOX alone, in first- line treatment of patients with metastatic cororectal cancer",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"To measure response rates, response duration, secondary surgical curative resection frequency, safety profile, overall survival and quality of life in the treatment groups."
2583,NCT01675505,,2012-05,UNKNOWN,OBSERVATIONAL,['NA'],,
2584,NCT05622357,Sphincter saving surgery,2018-03-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease free survival
2585,NCT02157246,Group B Percentage change in FMISO-PET SUVmax and uptake volume,2013-10,COMPLETED,INTERVENTIONAL,['NA'],Radiotherapy planning feasibility study,Comparison of changes in T1/T2* MRI
2586,NCT00563316,Number of Participants With Clinically Significant Adverse Events (AEs),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2587,NCT01459757,Mutational status data retrospectively accessed correlated with A6181036 clinical outcomes data in GIST subjects treated with sunitinib,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
2588,NCT06104215,Dose-limiting toxicity（DLT）,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
2589,NCT05642962,Change in body mass index/BMI from baseline to 4 months,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2590,NCT00341705,,2001-04-27,COMPLETED,OBSERVATIONAL,['NA'],,
2591,NCT00262951,Number of Patients in Whom Tumor Was Resectable,2005-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2592,NCT06168786,Progression-free survival (PFS),2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
2593,NCT02337465,Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound Probe,2015-09-22,COMPLETED,INTERVENTIONAL,['NA'],,
2594,NCT03717519,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Clinic-pathological variables
2595,NCT04050345,TRACC Part C (Randomised ctDNA guided adjuvant chemotherapy versus SoC study):,2016-12-05,RECRUITING,OBSERVATIONAL,['NA'],,"Relationship between ctDNA detection before, during and after treatment"
2596,NCT00056459,Progression free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tolerability and safety profile
2597,NCT05452382,Overall survival,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Positive resection margins
2598,NCT05807984,local control,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
2599,NCT05364788,Characterise the genes of appendiceal cancer.,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Descriptive analysis in proportions
2600,NCT02538913,Anal incontinence,2015-09,TERMINATED,INTERVENTIONAL,['NA'],,In-hospital time
2601,NCT02526134,Patients rate in which a significant variation in the area to be irradiated will be observed between before evaluation and evaluation after laying the trustees.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of trustees (2 up 6 maximum) and set up their positions estimated success rate of implementation and the evaluation of the safety and toxicity (complications) associated with the establishment trustees (composite measure)
2602,NCT06087289,"Evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as measured by lab safety tests",2023-04-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the plasma exposure of KAND567
2603,NCT01085331,Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS),2010-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Part 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death"
2604,NCT05451719,Progression-free Survival (PFS),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
2605,NCT06068127,GCSI score,2023-10-12,RECRUITING,OBSERVATIONAL,['NA'],,Pyloric distensibility
2606,NCT00987935,Time to Progression (TTP) in Phase II,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib"
2607,NCT01726010,diagnostic yield,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,
2608,NCT04465214,"Outcomes from: PRO-CTCAE, Neuro-QOL, Numeric Rating Scale for Pain, 6-Minute Walking Test, Stroop Test, and Normalized Reaction Time Tests",2020-11-23,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Evaluation of iPhone based tests of cognitive functioning and reaction time for reliability and validity
2609,NCT00411229,Clinical laboratory tests,2006-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2610,NCT01462903,• the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,• immune efficacy and anti-tumor effects of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).
2611,NCT00017537,Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer,2000-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Document any clinical responses to this drug in these patients.
2612,NCT03273686,postoperative complication,2017-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Length of postoperative stay
2613,NCT02811666,muscle strength using a hand gauge,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,
2614,NCT02871336,Optimization of the surgical care of the patients,2014-11,RECRUITING,OBSERVATIONAL,['NA'],,
2615,NCT02009774,Accuracy optical biopsy,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Adenoma detection rate
2616,NCT04936750,overall survival,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
2617,NCT06282484,corelation between the gastric xanthoma and gastric mucosa diseases,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
2618,NCT04994236,Objective response of intrahepatic lesions,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The rate of adverse events
2619,NCT04502082,The recommended phase 2 dose (RP2D) regimen of ET140203 T-cell therapy primarily based on DLT,2021-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the pharmacokinetics of ET140203 T cells after infusion.
2620,NCT01552434,"MTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLT",2012-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],The properties of the tissue microvasculature.,Levels of surrogate anti-angiogenesis markers
2621,NCT01567488,Percentage of patients with progression-free survival (PFS),2011-06-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of patients with Adverse Events
2622,NCT05317819,Overall Survival (OS),2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression free survival
2623,NCT06070740,Objective Response Rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
2624,NCT06144762,the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],,Correlate MRI results with hematological molecular biology results.
2625,NCT01661829,Incidence of anterior resection syndrome after stoma closure,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
2626,NCT03693248,Progression free survival,2018-12-19,UNKNOWN,INTERVENTIONAL,['PHASE3'],,days of management in intensive care unit
2627,NCT00455247,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2628,NCT04148092,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2629,NCT05021263,Quality of Recovery 40 Questionnaire,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,
2630,NCT01617876,Diagnostic accuracy of enhanced ME (combining ME-NBI and ME-AIM),2010-03,COMPLETED,OBSERVATIONAL,['NA'],,The relationships between the microsurface patterns and the histopathological findings
2631,NCT05643833,Overall survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2632,NCT01413451,Background ratio of maximum counts,2011-07-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Antibody uptake vs. IHC mesothelin expression
2633,NCT01505842,Prevalence of dysplastic lesions,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Number and rate of targeted and non-targeted biopsies detecting dysplasia and non-dysplasia
2634,NCT05462236,Objective response rate based on Response Evaluation Criteria in Solid tumors (RECIST) Version 1.1,2023-04-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,PK evaluation
2635,NCT04110769,The rate of genetic mutation,2019-07-17,RECRUITING,INTERVENTIONAL,['NA'],,oncologic outcome
2636,NCT05401045,Fatigue state using the Revised Piper Fatigue Scale (RPFS),2023-01-20,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life using the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-C30)
2637,NCT00844233,Tumour resectability at surgery,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)
2638,NCT03055130,The different incidence of cervical neoplasm between controls and patients by performing Thinprep Cytology Test,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Find drugs relating to HPV infection of IBD patients
2639,NCT02508883,mortality,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,"Finding the cut-off value of highest sensitivity and specificity of Rockall, Glasgow-Blatchford and AIMS65 scores employing the receiver operating curve (ROC)."
2640,NCT02760199,"The quantitative uptake op 89Zr-AMG211 in tumor tissue, organs and blood circulation expressed in SUV (Standardized Uptake Value)",2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate 89Zr-AMG211 as a complementary tool for improved patient selection for targeted therapy with AMG 211.,"Number of patients with adverse events after 89Zr-AMG211 injection as a measure of safety and tolerability. Incidence, nature and severity of adverse events (according to CTCAE version 4.03) will be measured."
2641,NCT02839109,Tumor response,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival (DFS)
2642,NCT04001569,Progression-free survival rate,2019-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse event
2643,NCT03317483,Treatment response,2015-11-12,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events (AEs)
2644,NCT02648841,Disease-free survival,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Event
2645,NCT01064999,toxicity,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,overall survival
2646,NCT03904732,Number of deaths due to any other cause,2019-04-15,COMPLETED,OBSERVATIONAL,['NA'],,
2647,NCT05216133,36-Item Short Form Survey Instrument (SF-36),2023-03-22,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
2648,NCT05659576,Reduce opioid use,2022-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2649,NCT05730686,To describe the natural history and clinical outcomes of patients with Fibrolamellar carcinoma of the liver,2023-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2650,NCT03277209,Causality of adverse events (AEs) and serious adverse events (SAEs) and grading according to NCI CTCAE v.4.03.,2017-07-25,TERMINATED,INTERVENTIONAL,['PHASE1'],Correlation between changes in T cell distribution and diurnal cortisol variation.,Assessment of metabolic changes in tumour using non-invasive imaging (18FDG-PET)
2651,NCT05551052,Specificity for CRC of the Next-Gen CRC Screening Test,2022-09-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Specificity for no colorectal neoplastic findings of the Next-Gen CRC Screening Test
2652,NCT00113763,Progression-free Survival Time,2004-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Stable Disease
2653,NCT01216644,median overall survival,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-Resection rate
2654,NCT00597610,To measure the response of primary rectal cancer to neoadjuvant chemotherapy and/or radiation therapy using 3-D TRUS,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,To correlate these findings with post-operative pathologic examination
2655,NCT00582296,"To assess adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations in patients with Lynch Syndrome.",2004-12,RECRUITING,OBSERVATIONAL,['NA'],,"To evaluate predictive factors for adherence to comprehensive, multi-organ screening and risk-reducing behavior recommendations."
2656,NCT05053555,To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.,2022-04-24,RECRUITING,INTERVENTIONAL,['NA'],,
2657,NCT06277531,Patient is diagnosed with malignant disease from biliary system,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2658,NCT02579460,Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,change in HIF expression from baseline to 14 days
2659,NCT00397384,MTD defined as the dose level at which fewer than 2 out of 6 patients experience DLT graded using CTCAE-v3,2007-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effect observed
2660,NCT00844064,To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers."
2661,NCT03086369,Phase 2: Overall Survival (OS),2017-06-22,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L)
2662,NCT00600522,"The primary outcome measure was the rate of failure of conservative resection, i.e. the rate of patients who received TSs or MHs despite they fitted in the eligibility criteria.",2004-01,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary outcome measure was the safety of the procedure. For that, we studied morbidity, mortality, amount of blood loss, rate of blood transfusions, and postoperative trend of liver function tests."
2663,NCT01369329,Number of Participants With Clinical Response at Week 6,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With CDAI 70-point Response at Week 3
2664,NCT02568787,Change from baseline in immunological markers,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,Change from Baseline in Quality of Life
2665,NCT05331040,Model,2020-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
2666,NCT03455608,Duration of feeding tube dependence,2018-09-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Hospitalization/Emergency Department (ED) Presentation
2667,NCT04324294,"The results obtained by EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Quantitative Parameters of Pancreas Lesions
2668,NCT05220800,Changes in T-cell function - mRNA expression analysis,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year cancer free survival
2669,NCT02851381,FG-3019 treatment regimen to increase OS (overall survival),2016-08,WITHDRAWN,INTERVENTIONAL,['NA'],,
2670,NCT00652366,OS Assessed From Point of Randomization,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS Assessed From the Start of 4-Week Run-In
2671,NCT00343239,"To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2672,NCT06136026,The detection rate of Colorectal Adenomatous Polyp.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The canceration rate of Colorectal Adenomatous Polyp.
2673,NCT02219529,Number of gastric focal lesions founded by MCE Versus Standard Gastroscopy,2014-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events of both procedures
2674,NCT00934791,Liver Volume at 2 Years After Kidney Transplantation,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
2675,NCT01941173,"Feasibility of a shorter infusion time, determined by rate of greater or equal to grade 2 hypersensitivity reactions as graded according to CTCAE version 4.0",2014-01,WITHDRAWN,INTERVENTIONAL,['NA'],Time on protocol therapy,"Incidence of grade 3 and above toxicities, graded according to CTCAE version 4.0"
2676,NCT00313560,Recurrence Free Survival,2006-03-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Death as Assessed by Median Overall Survival (Months)
2677,NCT03276091,Participation to the colonoscopy,2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,cancer and adenoma detected
2678,NCT03277235,Self-report Questionnaire,2017-09,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
2679,NCT01023412,Rate of post-operative complications,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Rate of post-operative infectious complications
2680,NCT04313868,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2014-06-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Clinical research testing for antibodies to retrovector gp70 env, replication-competent retrovirus in peripheral blood lymphocytes (PBLs); vector integration into genomic DNA of PBLs, and circulating hGM-CSF protein"
2681,NCT02670265,Weight loss,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
2682,NCT01157052,The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
2683,NCT03396354,Number of retrieved LN,2018-01-02,UNKNOWN,INTERVENTIONAL,['NA'],,
2684,NCT00017043,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2685,NCT02036112,The perioperative morbidity,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],Three years local recurrence postoperatively,Three years survival postoperatively
2686,NCT04006769,Adverse Events (AE) And Serious Adverse Events(SAE),2020-10-30,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of Life(QOL)
2687,NCT00197444,Response rate,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival rate
2688,NCT03164486,Assessment of safe administration of 18F-αvβ6-BP,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Level of αvβ6-BP expression in tumors
2689,NCT01163305,Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy,2010-06-30,COMPLETED,OBSERVATIONAL,['NA'],,RECIST-based tumor response at 10 weeks after chemotherapy
2690,NCT04835246,Sensitivity of Spectra IMDx system,2019-10-07,UNKNOWN,INTERVENTIONAL,['NA'],,Accuracy of Spectra IMDx system
2691,NCT03976999,Proportion of patients who gave their consent to participate in the study,2017-07-05,RECRUITING,INTERVENTIONAL,['NA'],,
2692,NCT02649790,Part H: 2- Year Progression-free Survival (PFS),2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part H: Overall Survival (OS)
2693,NCT02510001,Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066,2014-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Plasma t1/2 Etc for PF-02341066 and Binimetinib
2694,NCT00331682,Objective Response Rate as Measured by RECIST Criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2695,NCT00075218,Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in EQ-5D Health State Profile Index
2696,NCT01426646,Relapse-free survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
2697,NCT05636085,Specificity,2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value and negative predictive value
2698,NCT00553696,Number of Participants With First Cycle Dose-limiting Toxicities (DLTs),2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression (TTP)
2699,NCT06331260,Tumor recurrence rate,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2700,NCT01503372,progression-free survival rate at 6 months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,evaluation of the predictive and prognostic relevance of biomarkers
2701,NCT00941967,Progression-free survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2702,NCT03611504,Rebleeding rate,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
2703,NCT06022770,Nutritional risk screening（NRS） 2002 scale,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,quality of life of patients with esophageal and gastric cancer before and after chemotherapy
2704,NCT03541629,Data accuracy,2018-07-26,COMPLETED,OBSERVATIONAL,['NA'],,
2705,NCT00515411,6 Month Progression Free Survival (PFS),2006-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
2706,NCT04773769,Blood Counts,2018-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
2707,NCT00012922,,na,COMPLETED,INTERVENTIONAL,['NA'],,
2708,NCT05586516,Incidence of treatment-emergent adverse events [Safety and Tolerability],2022-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival [OS]
2709,NCT00030524,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2710,NCT01155440,Restoration of bowel function,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pain intensity
2711,NCT00747448,"Primary objectives of the study are to enable analysis of patient outcomes 2 years after final treatment and report on the effectiveness of the device in eradicating, decreasing or downgrading of the lesions.",2009-05,COMPLETED,OBSERVATIONAL,['NA'],,
2712,NCT01082419,The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease
2713,NCT06194786,Dietary target-red meat,2023-05-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Disease free survival
2714,NCT05493956,Overall survival,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Hepatobiliary symptom index
2715,NCT03208621,Change in treatment strategy,2017-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
2716,NCT00637390,safety & maximally tolerated dose,2008-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.
2717,NCT02037646,Time to diagnosis of advanced colorectal neoplasms,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient anxiety levels
2718,NCT03292289,"Quality of life 1 year after the second intervention, using LARS score",2018-01-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Quality of life of patients with a second stoma placement, using LARS score"
2719,NCT06024356,pathologic complete response,2023-09-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The expression of PD-1,overall survival (OS)
2720,NCT05435313,objective response rate (ORR),2022-07-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events as assessed by NCI CTCAE v5.0
2721,NCT02062749,Maximum Tolerate Dose (MTD) of Oxaliplatin in Hyperthermic Intraperitoneal Chemotherapy,2014-05-19,COMPLETED,INTERVENTIONAL,['PHASE1'],"Time to Recurrence After HIPEC in Pediatric, Adolescent and Young Adult Age Colon Cancer Patients",Differences in Genetic Aberrations in Pediatric Colon Cancer Patients and Adult Patients
2722,NCT05644379,Adverse Events (AEs),2022-11-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,
2723,NCT01394159,Compare the Median Number of Passes Required to Establish a Diagnosis,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Technical Failure
2724,NCT04233866,Overall survival (OS),2020-08-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Geriatric assessment scores and biomarkers of aging (CRP and IL-6),Instrumental Activities of Daily Living (IADL)
2725,NCT02395224,survival,2014-09,UNKNOWN,OBSERVATIONAL,['NA'],,Health related quality of life
2726,NCT05109468,Change in Sexual quality of life score,2021-06-06,RECRUITING,OBSERVATIONAL,['NA'],,
2727,NCT03581435,The expression of protein A in the circulating exosomes from patients,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2728,NCT03901651,Adenoma detection rate with standard colonoscope and retroview colonoscope.,2019-01-02,COMPLETED,INTERVENTIONAL,['NA'],,Size of lesions (adenomas and polyps) detected with the standard colonoscope and Retroview colonoscope.
2729,NCT03146377,Objective response rate,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
2730,NCT00020579,Pharmacology and pharmacokinetics,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response by CT scan every 12 weeks
2731,NCT05590117,variation in grades of mucositis,2022-10-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['EARLY_PHASE1'],,Change in the biological marker Citrulline
2732,NCT00002951,Locoregional control rate,1996-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2733,NCT02562716,Overall Survival (OS),2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival From the Time of R0 or R1 Resection.
2734,NCT04321850,Pain intensity: Visual analog scale,2019-06-10,TERMINATED,INTERVENTIONAL,['NA'],,Neutropenia
2735,NCT06046794,Percentage of alive GemCore+ patients treated with Gemcitabine,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival of GemCore- patients,Progression-free survival
2736,NCT01585805,Response rate of single-agent veliparib (Part II),2012-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Differentially expressed genes found,Overall survival (Parts I and II)
2737,NCT00561990,Time to tumor progression (TTP) and overall survival (OS) in chemotherapy-naive patients. To assess the efficacy of Nimotuzumab as add on therapy to Gemcitabine in comparison with Gemcitabine and placebo,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To evaluate the objective tumor response (overall response rate [ORR]) and duration of response (DR) To evaluate the safety profile of Nimotuzumab in combination with Gemcitabine To evaluate quality of life (QoL) according to EORTC
2738,NCT02673177,Incidence of sexual and urinary dysfunction,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Anus preservation rate
2739,NCT01468389,Progression free survival,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events
2740,NCT01544790,Postoperative complications modified Clavien-Dindo classification (MCDC) grade 2 and higher,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Costs (euro)
2741,NCT04400357,Percentage of patients with pancreatic adenocarcinoma who achieve administration of adjuvant chemotherapy at 8 weeks postoperatively,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Comparison of perioperative inflammatory response (Interleukin-6)
2742,NCT05903456,Objective Response Rate,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event
2743,NCT00827047,Overall survival and disease free survival,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,"Bleeding and blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications"
2744,NCT04284943,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5%
2745,NCT01788995,Treatment discontinuations/modifications,2012-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
2746,NCT03827967,Primary Immunologic Endpoint-Per Dosing Cohort Immunoscore of the tumor microenvironment,2019-07-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary Endpoint-CD4+ and regulatory T cells expression comparison within the Tumor Microenvironment
2747,NCT00954876,Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab,2009-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.
2748,NCT01215838,Accuracy of a new MR protocol in diagnosing HCC and other liver lesions.,2010-08,TERMINATED,OBSERVATIONAL,['NA'],,
2749,NCT01919541,Protein Synthesis,2016-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
2750,NCT04090645,Evaluate SAE's associated with TheraSphere® treatment,2014-05-22,COMPLETED,INTERVENTIONAL,['NA'],,
2751,NCT05928819,Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists and correlation with final histology reading.,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
2752,NCT02102984,Relief of malignant biliary obstruction,2014-04,COMPLETED,INTERVENTIONAL,['NA'],gallbladder in situ,cost/effecacy
2753,NCT03017326,Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria,2017-08-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adherence to surgical guidelines
2754,NCT05568667,Assessment of the programme feasability,2022-10-17,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the evolution on CRC risk factors knowledge
2755,NCT01885884,perceived effectiveness,2013-07,COMPLETED,INTERVENTIONAL,['NA'],caregiver depressive symptoms,patient quality of life
2756,NCT04155242,Diagnostic accuracy of methylation panel for diffuse IM at the GOJ,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Safety of Cytosponge
2757,NCT05840341,Overall survival (OS),2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
2758,NCT02419677,Recurrence-free survival,2010-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
2759,NCT00433927,Objective response rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety and toxicity (according to NCI-CTCAE)
2760,NCT05843955,Non-alcoholic fatty liver disease (NAFLD) grade,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
2761,NCT04145726,The portion of frail patients undergoing esophageal resection and 6 -month all-cause of mortality,2019-09-25,UNKNOWN,OBSERVATIONAL,['NA'],postoperatively complications in frail vs. non-frail,One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients One-year all-cause mortality in frail vs. non-frail patients
2762,NCT05917431,PFS,2023-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence pattern
2763,NCT00003994,Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC),1999-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2764,NCT05993234,Real-World Time to Next Treatment (rwTTNT1) in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma,2023-12-05,RECRUITING,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Stomach (EORTC QLQ-STO22) Score in Participants With HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
2765,NCT02229045,PFS(Progression-free survival ),2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],ORR (Overall tumor response),OS (Overall survival )
2766,NCT04135781,3 years Diseases-free Survival rate(3 years-DFS),2020-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety as measured by number and grade of adverse events
2767,NCT00005634,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2768,NCT01825824,Local control rate,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Treatment related toxicity
2769,NCT03472365,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2018-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Subjects With Treatment-related Adverse Events (AEs)
2770,NCT05034692,The incidence of early complications,2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],,pain score
2771,NCT05747716,Progression free survival,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicities
2772,NCT01942083,To investigate the maximum tolerated dose (MTD) of OPB-111077,2013-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Biomarker of OPB-111077
2773,NCT05532319,Progression-free survival,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,objective response rate
2774,NCT05111314,Intraindividual intralesional difference in maximum standardized uptake value (SUVmax),2022-02-11,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
2775,NCT00713427,Number of Participants With Absence of Recurrent Biliary Obstruction,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,Change in Bilirubin
2776,NCT04727996,Disease control rate,2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
2777,NCT01714622,the changes of metabolic syndrome,2012-10,WITHDRAWN,OBSERVATIONAL,['NA'],,the changes of insulin resistance after gastrectomy
2778,NCT05517343,Proportion of definite depression cases,2022-08-20,RECRUITING,INTERVENTIONAL,['NA'],,Depression score
2779,NCT00977613,Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
2780,NCT04348916,Recommended Phase 2 Dose (RP2D) of ONCR-177,2020-05-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in the level of HSV-1 antibodies compared to baseline
2781,NCT02199912,biological and radiological markers,2013-10-07,COMPLETED,INTERVENTIONAL,['NA'],,loss of fat body mass and/or lean body mass
2782,NCT02323464,Prevalence of sleep apnea,2015-01-07,COMPLETED,OBSERVATIONAL,['NA'],,Sex differences
2783,NCT02080702,Frequency of anastomosis leakage rate,2014-08,TERMINATED,OBSERVATIONAL,['NA'],,Handling of the device
2784,NCT05371223,Disease Control Rate (DCR),2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Identification of pancreatic cancer disease evolution trough pathway analysis a in primary tumor and peritoneal sites during treatments,The Overall Survival (OS)
2785,NCT00782886,"The overall purpose of this NIH-funded study is to evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
2786,NCT02100696,"Maintenance Phase: Percentage of Participants With Remission at Week 66 Among Participants Who Had Achieved a Clinical Response at Week 14, as Determined by the MCS",2014-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ)
2787,NCT03609892,Helicobacter pylori eradication,2018-08-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
2788,NCT01360853,Survival,2011-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Full Pharmacokinetics
2789,NCT03595722,Complications,2019-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,Radiological changes
2790,NCT00040092,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
2791,NCT05946226,Incidence and severity of dose-limiting toxicity (DLTs) within 28 days after IMC002 infusion,2023-09-07,RECRUITING,INTERVENTIONAL,['PHASE1'],long-term safety,CAR-positive cell counts in peripheral blood
2792,NCT06050317,AE,2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
2793,NCT05873829,Chemotherapy Induced Peripheral Neuropathy Symptoms Assessment,2022-04-25,COMPLETED,INTERVENTIONAL,['NA'],,
2794,NCT03421912,Overall patient satisfaction after 30 days treatment,2018-02-16,COMPLETED,INTERVENTIONAL,['NA'],,Use rate of dermocorticoids
2795,NCT06186089,Composition and diversity of gut microbiota,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Inflammatory factor
2796,NCT06248580,The frequency of HDV in certain regions of Southern Anatolia,2024-01-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The rate of HIV and HCV co-infection in HDV positive patients
2797,NCT02847767,Changes in tumour vasculature as assessed by changes PL derived model parameters,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Association (correlation) between aggregate QOL scores and PK derived model parameters
2798,NCT01882868,Percentage of Participants With Overall Response,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis
2799,NCT04884581,Negative Predictive Value (NPV),2021-05-12,COMPLETED,INTERVENTIONAL,['NA'],Performance metrics of the endoscopist with the aid of GI Genius CADx,
2800,NCT05771181,objective response rate (ORR),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,advert events
2801,NCT05064059,Overall Survival (OS),2021-11-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
2802,NCT04768660,Length of hospital stay,2021-02-14,UNKNOWN,INTERVENTIONAL,['NA'],,
2803,NCT03943043,maximum tolerated dose,2017-07-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of responder (in term of CR, PR, SD) to GEMOX plus nab-paclitaxel as assessed by RECIST 1.1"
2804,NCT03669237,Postoperative bowel function of 1 year after surgery,2018-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative bowel function of the long stable result
2805,NCT02079623,Tumor response,2013-11,COMPLETED,OBSERVATIONAL,['NA'],Pain registration,Overall survival
2806,NCT04201717,surgical site infection，SSI,2020-06-12,RECRUITING,INTERVENTIONAL,['NA'],,hospital stay
2807,NCT02784028,Maximum tolerated dose (MTD),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
2808,NCT03299036,Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria,2017-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Serum Level of AFP
2809,NCT05198609,Overall survival,2022-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate
2810,NCT06024837,Comparison of peritoneal and hepatic lesion mapping between spectral scanning and conventional scanning,2023-06-07,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of evaluation of response to chemotherapy (if indicated) in RECIST 1.1 and Radiomics
2811,NCT00587600,The primary assessment for our first specific aim will be to determine the effect of photodynamic therapy on biomarkers after photodynamic therapy.,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The primary assessment for our second specific aim will be to assess if specific biomarkers can be correlated with the confirmed histological elimination of their Barrett's esophagus.
2812,NCT02030769,Detection rate of high grade dysplasia and carcinoma in iodine void lesion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],observation time for esophagus,overall detection rate of iodine void lesion
2813,NCT01396681,recurrence/metastasis free survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
2814,NCT05245331,LARS score,2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects related to both treatments.
2815,NCT00727376,Clinical benefit of the Polyflex Esophageal Stent as a means to maintain oral nutrition during chemotherapy and/or radiation,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,
2816,NCT06136949,Frequency of overexpression of STARD3 in both early and advanced CRC patients,2023-05-22,RECRUITING,OBSERVATIONAL,['NA'],,Concordance between the presence of selected molecular alterations on primary tumour tissues and organoids
2817,NCT04504565,the sensitivity of SPECT/CT with 99mTc-3PRGD2 in the diagnosis of lymph node metastasis,2020-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,The Incidence of Adverse Events
2818,NCT05797883,Objective response rate (ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
2819,NCT00900016,Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme
2820,NCT04521153,The rate of subjects of major pathological response (MPR),2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Safety and toleraty
2821,NCT00233623,Time to progression (6 months after Last patient in),2004-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)"
2822,NCT00952016,"Objective response rate, to include complete response and partial response, as defined radiologically using RECIST (Response, Evaluation Criteria in Solid Tumours) on imaging CT scans performed during treatment.",2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Disease stabilisation rate; progression free survival; 1 year survival and median overall survival; Quality of Life assessment; toxicity assessment.
2823,NCT01765231,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis"
2824,NCT03546985,Area under the curve (AUC) of pain score of oral mucositis,2017-12-26,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse events
2825,NCT05513716,Proportion of genetic mutations,2024-02-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Association with molecular subtypes and categorical variables
2826,NCT00510354,Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).,2006-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional)
2827,NCT02863783,Relative Ease of Detection of the Tumor with Fiducial,2016-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Pancreatitis, abdominal pain, infection, bleeding following placement."
2828,NCT05724563,Objective Response rate of combination zimberelimab and domvanalimab.,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with Adverse Events (AEs) (serious / non-serious) as defined by CTCAE v5.0
2829,NCT04735900,Optimize cutoff value,2020-09-14,UNKNOWN,INTERVENTIONAL,['NA'],Exploratory objective 3,Determine progression free and 9-month survival
2830,NCT06310590,Localized Objective response rates (ORR),2023-08-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Radioactivity of Yttrium-90 for 9 participants, assessed by liquid scintillation counter"
2831,NCT01249443,"Incidence of adverse events during paclitaxel and carboplatin treatment according to dose-limiting toxicities (DLTs), graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)",2013-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Effects of therapy on HIV viral load and CD4 cell count
2832,NCT04008030,"PFS by BICR (arm B vs C, 1L, centrally confirmed)",2019-08-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,"ORR by BICR (crossover cohort, centrally confirmed)"
2833,NCT00466505,Progression-free Survival (PFS),2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum TGF-alpha: Treatment Cycle 2
2834,NCT03775473,progastrin rate,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],,
2835,NCT02086461,Symptoms suggestive of delayed gastric emptying,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],,Delayed gastric emptying
2836,NCT03417921,Emergent Adverse Events,2021-04-26,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2837,NCT00541021,Progression-free survival,2006-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Biomarkers of response
2838,NCT03782831,Progression Free Survival (PFS),2018-12-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
2839,NCT05675462,Serious adverse event (SAE).,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Detection of systemic and local immune activation in tumors and peripheral blood mononuclear cell will be assessed by single cell RNA seq and/or bulk RNA seq.
2840,NCT05510908,Number of cancers in people with HIV (PWH) who present for care at domestic AMC sites,2023-07-25,RECRUITING,OBSERVATIONAL,['NA'],3. State of planned cancer therapy for cancer patients with HIV initiating therapy or currently under treatment,Proportion of participants eligible for AMC trials who are successfully enrolled
2841,NCT03427411,Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response,2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Duration of Response (Complete Response or Partial Response)
2842,NCT00390364,Response Rate: The Total Number of Participants With Progression of Disease,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
2843,NCT00145665,correlation FLT-uptake in colorectal liver metastases and the histologically determined proliferation,2005-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,correlation FLT and recurrence rate
2844,NCT00008099,Disease Recurrence,1998-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
2845,NCT02934984,Rates of recurrence in pancreatic cancer patients,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Rates of death in pancreatic cancer patients
2846,NCT02578264,Determining sensitivity of assay in known cancer patients,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
2847,NCT00538954,Recovery of gastrointestinal function: Time to pass flatus/stool (hours following the end of surgery),2006-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient activity level: measured by activPAL® activity meter
2848,NCT01387295,Response Rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS
2849,NCT05420870,Anorectal manometry,2022-05-23,RECRUITING,INTERVENTIONAL,['NA'],,
2850,NCT03045952,overall survival,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,disease free survival
2851,NCT01472601,disease-free survival,2011-05-24,UNKNOWN,OBSERVATIONAL,['NA'],,
2852,NCT06005883,Recurrence of tumor,2021-04-10,COMPLETED,OBSERVATIONAL,['NA'],,
2853,NCT03974074,Serum albumin level,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of postoperative complications
2854,NCT03221608,Incidence of endoperitoneal recurrence at 36 months,2017-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,HIPEC toxicity rate
2855,NCT04888299,Feasibility of Raman spectroscopy to identify mucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,2021-04-14,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance of Raman spectroscopy for assessment of mmucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology
2856,NCT04407416,Breath analysis sensitivity,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,
2857,NCT03481296,Colorectal cancer screening test-specific adherence at 12 months (Colonoscopy),2018-08-20,COMPLETED,INTERVENTIONAL,['NA'],,Change in knowledge about colorectal cancer and colorectal cancer screening between baseline and 6 months
2858,NCT06206278,Overall survival (OS),2023-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2859,NCT02096354,Overall Survival,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL) by QOL questionnaire
2860,NCT00448136,PFS - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-C30 Functional and Symptom Scale Scores
2861,NCT01623258,Define the rate of upstaging of colon carcinoma lymph node metastasis with define the rate of upstaging of colon carcinoma lymph node metastasis with sentinel lymph node (SLN) mapping,2002-12,COMPLETED,OBSERVATIONAL,['NA'],,
2862,NCT02132325,Change in level of distress as measured by distress scores on the Distress Thermometer,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,
2863,NCT04661046,Progression Free Survival,2020-11-30,UNKNOWN,INTERVENTIONAL,['NA'],,
2864,NCT04620538,"Determine the diagnostic accuracy of breath test for detection of fibrosis, cirrhosis or hepatocellular carcinoma.",2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
2865,NCT03658772,Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Observed accumulation ratio
2866,NCT00052897,,2002-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2867,NCT05843877,"Duration between surgery and time ""fit for adjuvant treatment"" (postoperative day X)",2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Comparison of long-term oncological course (24 months) in both arms: occurence of metastases
2868,NCT00079872,The primary objective is to compare the antitumor activity of pemetrexed plus a comparator with that of leucovorin modulated 5 FU plus a comparator as measured by tumor response rate for patients with locally advanced or metastatic colorectal cancer,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,to characterize the quantitative and qualitative toxicities of both treatment arms in this patient population
2869,NCT03812705,Response rate,2018-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
2870,NCT05488522,Primary Objective,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression Free survival
2871,NCT01621048,"toxicity: EORTC QLQ H&N35 questionnaire, the university of Michigan Xerostomia questionnaire (XQ) and the MD Anderson Dysphagia Inventory.",2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],,
2872,NCT01418391,amount of post-operative morphine consumption,2011-06,UNKNOWN,INTERVENTIONAL,['NA'],,evaluation of post-operative pain status using visual analog scale (VAS) and superimposed face pain severity scale
2873,NCT03287453,Self-reported intentions to engage in behavior change to reduce risk of colorectal cancer,2017-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
2874,NCT00683631,,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
2875,NCT05913661,Objective Response Rate,2023-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
2876,NCT06078930,Overall Survival (OS),2021-04-06,RECRUITING,OBSERVATIONAL,['NA'],,Disease Free Survival (DFS)
2877,NCT05184946,3 years disease free survival rate,2021-10-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival time
2878,NCT03190616,Progression-free Survival(PFS),2017-07-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
2879,NCT01283893,Evaluation of operative procedure according to predetermined criteria,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
2880,NCT03986294,Progression free survival of NaI-IRI with S1,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],ctDNA,Quality of life QoL (QLQ-C30)
2881,NCT01606124,"Percent Change in Rectal ACF, Pre- and Post Intervention at 6 Months",2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tolerability as Estimated Using the Percent Dose of Treatment Received at 6 Months
2882,NCT00851084,Progression Free Survival (PFS) Rate at 12 Months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenicity of Intravenous (IV) Aflibercept
2883,NCT00192842,time to tumor progression,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
2884,NCT02581423,Incidence of treatment discontinuation due to AEs,2005-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of toxocity-related dose reductions
2885,NCT00976612,nilotinib pharmacokinetics,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
2886,NCT00956072,Progression-free survival,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life as measured by EORTC QLQ-C30
2887,NCT03412799,Recommended dose of SBP-101,2018-06-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak plasma concentration (Cmax) for all three drugs
2888,NCT00005842,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2889,NCT03862885,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2890,NCT05617378,Risk factor,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,
2891,NCT02349594,Change of TNF-α production in pg/ml,2014-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,(anti-) Oxidant status and oxidative damage
2892,NCT04447443,Therapeutic effect on the chemotherapy-related grade 2 to 4 diarrhea,2020-06-30,WITHDRAWN,INTERVENTIONAL,['NA'],,Gut microbiota changes in response to intervention
2893,NCT03140332,Scannographic evaluation of tumor response with mRECIST criteria,2017-02-27,COMPLETED,INTERVENTIONAL,['NA'],,
2894,NCT06189664,Detection of adenocarcinoma,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
2895,NCT00684229,cancer recurrence,2007-12,WITHDRAWN,INTERVENTIONAL,['NA'],,length of post operative hospitalization
2896,NCT02457390,Detection of synchronous liver metastases with CE-LUS,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,CE-LUS feasibility
2897,NCT00318370,Serologic Response (Change in Cancer Antigen [CA-125] Level),2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Who Had a Prolongation of Remission
2898,NCT01571284,Number of Participants With Cycle Delay and/or Dose Modification,2012-05-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in HRQL EQ-5D-3L VAS Score
2899,NCT00003797,,1999-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
2900,NCT04292990,Pain Intensity Measure,2020-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Quality-of-Life composite Index
2901,NCT03429530,the role of circulating miRNAs in diagnosis of HCV related hepatocellular carcinoma.,2018-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,
2902,NCT01281761,response rate,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2903,NCT03949231,Overall survival,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event rate
2904,NCT01333124,Complete resection rate,2011-09-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,The feasibility and compliance
2905,NCT02764944,En bloc resection,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,successful closure of resection site
2906,NCT00002801,,1996-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
2907,NCT04167293,24-week progression-free survival (PFS) rate,2019-11-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events
2908,NCT03391687,Incidence of Pancreatic Fistula,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,The mortality of Grade B and C Pancreatic Fistula
2909,NCT03515941,Number of Participants Who Complete the Recommended Therapy From Each Arm,2018-06-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Median Time to Recurrence
2910,NCT02937389,"The classification of gastric conduit ischemia by endoscopic findings predicts the major complications of gastric conduit (strictures, leakage, necrosis)",2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Biological examination of gastric conduit as assessed by the Mitochondrial DNA copy number
2911,NCT01446458,Maximum tolerated total dose of stereotactic body radiation to patients with resectable or borderline resectable pancreas cancer following FOLFIRINOX chemotherapy,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical and pathologic objective response rate as measured by MRI (clinical response) and histopathology and rate of complete resection (R0) (pathologic response)
2912,NCT01487785,Incidence rate and category of dose limiting toxicities (DLTs),2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum tumor marker Ca 19-9
2913,NCT05524974,Objective response rate,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The prediction performance of Exosome contents (including proteins, nucleic acids)"
2914,NCT03469726,Diagnostic accuracy of CE-DW-MRI,2017-12-22,UNKNOWN,INTERVENTIONAL,['NA'],Progression free survival,Assess local resectability
2915,NCT03597126,Change in Female Sexual Function Index [FSFI],2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2916,NCT05616390,Overall survival (OS),2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
2917,NCT01797224,Major malformations,2012-03,RECRUITING,OBSERVATIONAL,['NA'],,Infant follow-up
2918,NCT01807156,Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression,2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
2919,NCT04266548,surgical benefit rate of fluorescent image,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],,Post operative Mortality
2920,NCT03326375,Local tumor control (efficacy fo SBRT),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Radiation induced liver disease (RILD)
2921,NCT05354388,1-year Progression free survival rate,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Duration of continuous medication before surgery
2922,NCT00415454,Toxicity,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Gene expression in pancreas
2923,NCT02934529,Overall Survival,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety and tolerance as measured by the NCI-CTCAE version 4.03 criteria
2924,NCT03745326,Frequency and severity of treatment-related adverse events,2019-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
2925,NCT03331406,Number of participants that adhered to physical activity program,2017-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with adverse events
2926,NCT01276405,Disease-free survival,2010-03,TERMINATED,OBSERVATIONAL,['NA'],,Safety (Incidence of adverse events)
2927,NCT04764006,Objective response rate (ORR),2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assess the anti-tumor activity:DCR
2928,NCT06037954,Attrition rates,2023-09-07,RECRUITING,INTERVENTIONAL,['NA'],,Treatment satisfaction
2929,NCT03445936,Incisional hernia,2018-02-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Cost analysis
2930,NCT03271255,Progression-free Survival (PFS) Time,2018-05-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate)
2931,NCT03325361,Anastomotic leakage,2017-10,UNKNOWN,INTERVENTIONAL,['NA'],,
2932,NCT01821729,Number of Participants With R0 Resection,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To Measure Utilization of Health Services
2933,NCT01912586,Changes in sexual function based on the (IIEF)-5 score and NPT,2013-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compliance and overall patient satisfaction based on the self reported compliance diary and IIEF-5 score and NPT
2934,NCT03722511,Effect of amino acids in tightening the intestinal barrier and protecting from antigenic translocation by evaluating plasma circulating cytokine levels in peripheral blood sample.,2018-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of increased bacterial translocation and systemic inflammation.
2935,NCT06185374,National Annie Colonoscopy Survey Score,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Percentage of Participants who Had Adequate Bowel Preparation at Colonoscopy Appointment
2936,NCT01456585,Number of participants with adverse events,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
2937,NCT05319639,The maximum dose tolerated,2023-02-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
2938,NCT04712292,Rate of radical surgery,2020-09-08,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
2939,NCT02436044,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
2940,NCT00833508,Change of Anaerobic threshold of 1.5ml/min/kg or more,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Operative outcome
2941,NCT05710406,Disease free survival (DFS) (Phase III),2023-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']","• Patient Reported Outcomes Version of Common Terminology Criteria for Adverse Events for symptoms of rash, diarrhea, and fatigue",Alternative disease free survival
2942,NCT00003833,overall survival,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
2943,NCT03838406,Objective response rate,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
2944,NCT03231176,Objective Response Rate (ORR),2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of varlitinib when combined with capecitabine
2945,NCT01782690,Overall Survival Stratified by Rash,2012-03-31,COMPLETED,OBSERVATIONAL,['NA'],,Score in Participant Questionnaire: Quality of Life
2946,NCT02507882,"Specific miRNA levels and their association with degree of fibrosis, cirrhosis and HCC",2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,
2947,NCT02323776,Postoperative complications,2014-12,TERMINATED,OBSERVATIONAL,['NA'],,
2948,NCT01037790,Response Rates,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
2949,NCT00137683,colorectal cancer screening,2001-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,knowledge
2950,NCT01342354,Identify the appropriate dose for treatment of unresected carcinoma of the ampulla or pancreas,2009-04-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in patient reported outcomes using FACT-Hepatobiliary (FACT-Hep) quality of life questionnaire.
2951,NCT00036400,Number of red blood cell transfusions,2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Hemoglobin levels during preoperative chemoradiation; effect on quality of life measured by patient self-reported Linear Analog Scale Assessment, Functional Assessment of Cancer Therapy-Anemia, and Brief Fatigue Inventory; tumor response; safety"
2952,NCT03217773,Short-term morbidity,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Local recurrence
2953,NCT02917759,Number of successful xenografts established,2014-02,RECRUITING,OBSERVATIONAL,['NA'],,
2954,NCT00597129,safety MTD,2004-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,efficacy
2955,NCT04642690,Serum and Tissue Biomarkers,2020-09-24,TERMINATED,OBSERVATIONAL,['NA'],,Biomarkers and disease progression
2956,NCT03962179,Technique - % of patients with successful implantation of VACStent,2019-09-22,UNKNOWN,INTERVENTIONAL,['NA'],,Sealing of leak - % of patients with successful implantation of VACStent
2957,NCT06051851,Progression-free survival（PFS）,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
2958,NCT06085677,"Serologic concentrations of ghrelin, gastrin, pepsinogens and vitamin B12",2023-11-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
2959,NCT01852890,"Number of grade 3, 4, & 5 adverse events during radiation",2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Number of grade 3, 4, & 5 adverse events post-treatment"
2960,NCT03462524,Global health-related quality of life (HR-QL) score as assessed by Eastern Co-operative Oncology Group QLQ-C30 questionnaire,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
2961,NCT02159248,Evaluate safety and toxicity,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Assess the anti-tumor response.
2962,NCT03564405,Objective Response Rate,2016-12-05,COMPLETED,INTERVENTIONAL,['NA'],,
2963,NCT03948958,TIVAD function,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],Patient-reported outcome measure,Catheter tip and port chamber culture
2964,NCT04074135,Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions,2020-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,distribution of time from initial presentation with pancreatic tumors to the time that surgery is recommended
2965,NCT03356236,Progression-free survival (PFS),2018-04-17,RECRUITING,OBSERVATIONAL,['NA'],,severity of Adverse events (AE)
2966,NCT01641276,Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma
2967,NCT00641615,Safety (toxicities as assessed by NCI CTCAE version 3),2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Specific CTL induction in vitro, Objective rate as assessed by RECST criteria"
2968,NCT00165594,Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST),2005-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse drug reaction.
2969,NCT01155609,Decrease in mucositis severity and time to complete response,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,Improvement in quality of life
2970,NCT01904630,Data on association between sequence variants in exons and CRC risk,2012-12,COMPLETED,OBSERVATIONAL,['NA'],,
2971,NCT01760356,Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.,2011-05-01,TERMINATED,OBSERVATIONAL,['NA'],,Post transplant surgical complications
2972,NCT03699111,Stratification Tools,2018-09-19,COMPLETED,OBSERVATIONAL,['NA'],,
2973,NCT00027274,Risk of Cancer with Specific Mutations,2001-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
2974,NCT04868773,Recommended Phase 2 Dose [RP2D],2021-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of Participants with Objective Response Rate
2975,NCT04906954,"Step 2 : Number of patients with improvement of 10 points between baseline and week 8, assessed using the EORTC QLQ-C30 physical functioning scale",2021-06-29,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival (OS)
2976,NCT02545309,bile acid transporter genes,2015-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,upper gastrointestinal bleeding episodes
2977,NCT03510923,Costs,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Other aberrant findings requiring additional therapy
2978,NCT05376423,Recurrence-free survival rate,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2979,NCT03516994,Proportion of Whites who complete advance care planning,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient Quality of Life
2980,NCT03899428,Time to decline to ≥ 2 log10 IU/mL of serum HBsAg,2019-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Adverse events assessed in terms of seriousness, severity, and relationship to the study material according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0"
2981,NCT06190782,Progression-free survival difference of PD-1 inhibitor+radiotherapy and PD-1 inhibitor alone,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,local control rate
2982,NCT01030757,Tumor Response Rate (Complete Response + Partial Response).,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Toxicity, Progression Free Survival, Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease), Median Duration of Clinical Benefit, and Median Overall Survival of Subjects."
2983,NCT01111591,Short term outcome,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Long term outcome
2984,NCT00881816,maximum tolerated dose,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,dose limiting toxicity
2985,NCT01131078,Time to Progression (TTP),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Overall Complete Response
2986,NCT04926324,Determination of the clinical complete response rate,2022-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determination of the organ preservation rate
2987,NCT00651742,Overall Tumor Response Rate (ORR),2006-01-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)
2988,NCT01283802,the technical feasibility,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy
2989,NCT02335970,Degree of physical disability estimated by the Disability Rating Index (DRI),2005-09-05,COMPLETED,INTERVENTIONAL,['NA'],,PEF (Peak Expiratory Flow)
2990,NCT04011033,Disease Control Rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Alpha-fetoprotein (AFP)
2991,NCT02955069,Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC).,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,PDR001 ADA Incidence On-treatment
2992,NCT00548236,"To evaluate the ability of a multi-center, telephone-based physical activity intervention to increase weekly physical activity levels in sedentary patients treated with adjuvant chemotherapy for Stage I-III breast or colorectal cancer.",2007-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"To evaluate the impact of a physical activity intervention upon fitness, exercise self-efficacy, anthropometric measures, and quality of life in a group of patients with stage I-III breast or colorectal cancer."
2993,NCT01015833,Overall Survival,2010-02-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Best Overall Response Rate
2994,NCT04293835,the height of sigmoid take-off,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,"The distances of the sacral promontory, third sacral segment, and superior, inferior margin of cancers, and anterior peritoneal reflection from the anal verge."
2995,NCT01095523,To compare the overall survival of patients at high risk for developing peritoneal carcinomatosis from colorectal cancer who undergo mandatory second look surgery + HIPEC and CRS (if applicable) vs. similar patients who receive standard of care.,2010-01-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine recurrence-free survival in both arms. To investigate selection criteria for patients who might benefit from a strategy of MSLS with CRS + HIPEC.
2996,NCT01779583,"• Correlation of plasma level and kinetics of gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate.",2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,
2997,NCT05750290,Best objective response rate,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
2998,NCT04666090,Pathological Complete Response (PCR),2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The changes in the peripheral blood immunoprofile among non-PCR (NPCR) and PCR patients
2999,NCT03305146,Comparison between gene mutations found into the pancreatic cystic tumor fluid to gene mutations found into tissue specimen,2017-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the feasibility of the molecular biology analysis of the pancreatic cystic tumor fluid to distinguish the pancreatic cysts.
3000,NCT02148406,Changes in fatigue (recalled),2014-08,COMPLETED,INTERVENTIONAL,['NA'],Changes in circadian disruption (daily and recalled) as assessed by actigraphy and the Godin's Leisure Score Index,Regulation of psychological stress (daily and recalled) as assessed by Positive and Negative Affect Schedule-Expanded Form and Cancer Behavior Inventory
3001,NCT00103324,Confirmed response probability (complete and partial),2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3002,NCT03302637,Presence or absence of bacterial taxa will be compared in oral and pancreatic samples.,1992-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
3003,NCT02730702,Whether rectal LEBS readings can predict the presence of advanced adenomas in the colon.,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,
3004,NCT04452396,study arm 2 - using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose to optimise hypoglycaemia treatment in patients with an established diagnosis of spontaneous or reactive hypoglycaemia,2019-12-01,TERMINATED,INTERVENTIONAL,['NA'],,assessing concordance between CGMS and lab/finger prick glucose testing
3005,NCT05070104,Recommended Phase 2 Dose,2023-03-30,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall Survival
3006,NCT03015168,overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,grade 3 or higher treatment related small bowel toxicity
3007,NCT02318784,Overall Response Rate (ORR),2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
3008,NCT01387555,Survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time-to-symptomatic-progression
3009,NCT00416494,Response Rate (Percentage of Participants With Partial or Complete Response),2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect on Wound Angiogenesis,Safety and Tolerability
3010,NCT02809534,12-week Progression-free survival rate(PFR 12w),2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
3011,NCT06194981,Overall Survival,2024-01-11,RECRUITING,OBSERVATIONAL,['NA'],,Adverse Events
3012,NCT02485119,"tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me",2015-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity evaluation based on anti-BAY94-9343 antibody count
3013,NCT05201430,3-year disease free survival,2021-08-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,adverse event
3014,NCT00663819,Proportion of Subjects Who Experience a Clinical and/or Radiologic Anastomotic Leak,2008-04,TERMINATED,INTERVENTIONAL,['NA'],,"Determine the Efficacy and Further Substantiate Safety of CBSG Used in Conjunction With Circular Staplers When Performing High-risk Colorectal, Coloanal, and Ileoanal Anastomoses."
3015,NCT02284529,To evaluate the incidence of grade 0-3 neurosensory symptoms (paresthesia) in the end of study,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3016,NCT01699399,Proportions of patients requiring sedation,2012-08,COMPLETED,INTERVENTIONAL,['NA'],post-procedure discomforts and 30 days complication rate,patient pain during insertion
3017,NCT02991638,Adverse events and severe adverse events,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3018,NCT02151448,"Adverse Events Possibly, Probably or Definitely Related to Study Treatment",2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Necrosis Factor (TFNα) Cytokine Levels
3019,NCT03329495,number of lymph nodes retrieved,2018-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,operative time
3020,NCT01972490,the rate of patients converted to resection for liver metastases,2013-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,tumor response
3021,NCT02842203,ctDNA assessment and relation to clinical outcome,2016-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,ctDNA versus CEA
3022,NCT06076265,Positive detection rate of CEA,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
3023,NCT00074867,"At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Given the outcome of the primary objective, analysis of secondary objectives were not formalized."
3024,NCT04184960,Operative links on gastric intestinal metaplasia (OLGIM),2019-12-05,RECRUITING,OBSERVATIONAL,['NA'],,
3025,NCT03060642,Oral and esophageal 16S rRNA gene sequencing,2018-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Gastric aspirate mass spectrometry
3026,NCT02041897,Rate of change of diagnosis,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events
3027,NCT04109105,Effectiveness and security analysis in the prevention of anastomosis leakage through the protection of ileocolic anastomosis with NHS-PEG coated collagen patch.,2019-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,Number of hospital readmissions.
3028,NCT01439594,Feasibility of OFDI Imaging as Determined by Number of Successful Imaging Sessions,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
3029,NCT02668380,Adverse Events,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Objective response rate
3030,NCT01058655,Progression-Free Survival (PFS) [Phase II],2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) [Phase II]
3031,NCT04970316,Development of stoma-related issues after PE or CRS+HIPEC for colorectal cancer,2021-01-25,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors associated with developing organ specific late adverse effects
3032,NCT05996276,Overall survival (OS),2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival (PFS).
3033,NCT00822718,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
3034,NCT04209933,helicobacter pylori eradication,2020-05-25,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,symptoms effective rates
3035,NCT00388037,Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3036,NCT00578071,Number of Participants With Dose-limiting Toxicities (DLTs),2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathological Complete Response Rates Associated With This Regimen.
3037,NCT02817425,Overall Survial (OS),2013-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Dose intensity
3038,NCT05944237,Number AEs Related to Atezolizumab (Dose Escalation and Expansion Phase),2023-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assess change in tumour T cell infiltration in baseline and on-treatment biopsies
3039,NCT00081848,,2004-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3040,NCT04127734,1-year stomafree survival,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],Hospital related costs,1 year mortality
3041,NCT03699332,Fluorescent signal at time of surgery,2018-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Optimal dose of the dual-labeled antibody preparation
3042,NCT02673710,Sarcopenia quantified via CT-scan defined as a skeletal muscle index at the 3rd lumbar vertebra below 41 for women and below 43 or 53 for men with a Body Mass Index below or above 25 respectively,2016-03-14,COMPLETED,OBSERVATIONAL,['NA'],,First Progression Free Survival (PFS1) is defined as the time between initial diagnosis and first progressive disease
3043,NCT05982184,Patient reported anxiety measured by the 6-item Spielberger State-trait Anxiety (STAI-6) inventory at admission.,2023-10-03,RECRUITING,INTERVENTIONAL,['NA'],Rate and type of complications during surgery as recorded in the EHR,Quality of recovery is a comprehensive 40-item questionnaire (QoR-40) used to assess the rate of recovery after surgery.
3044,NCT05445570,Specificity of the InterVenn test,2022-05-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3045,NCT04519138,Proportion of patients with pre-specified adverse events,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],,Amount of visible biopsy material over or under 5 mm at endoscopy examination
3046,NCT05669339,Maximally tolerated dose,2024-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Change in the biomarker TGF-B
3047,NCT04624555,Participant acceptance of mt-sDNA as a follow up strategy compared to colonoscopy as measured by the Stool Test Satisfaction Survey.,2024-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3048,NCT03792854,Qol (EORTC QLQCR29) absolute values and change over time,2018-12-01,RECRUITING,OBSERVATIONAL,['NA'],,late toxicity
3049,NCT00974389,Disease-control rate,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
3050,NCT05506943,Best Overall Response,2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exposure Response by Pharmacokinetic (PK) Sampling
3051,NCT00504361,"Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained.",2006-05,COMPLETED,OBSERVATIONAL,['NA'],,
3052,NCT00185081,"Pharmacokinetics, biodistribution and dosimetry of In-IMP-205",2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3053,NCT00066651,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3054,NCT01853059,Functional quality of life after chemoradiotherapy for anal cancer,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer
3055,NCT03755739,Complete response (CR) rate before or at Month 6,2018-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Cause of death (COD) when appropriate
3056,NCT01156142,Total Pain Reduction (Mouth and Throat),2010-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient Preference for Continuing Therapy With Oral Doxepin Hydrochloride
3057,NCT04154748,Complete ablation rate 6 weeks after APC treatment.,2002-06-04,COMPLETED,INTERVENTIONAL,['NA'],,Complete ablation rate at the end of follow-up
3058,NCT03909724,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Liquid biopsies
3059,NCT03406299,6-month progression-free survival rate,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarker study
3060,NCT03957902,Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues,2019-05-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis
3061,NCT04729322,Objective response rate,2021-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3062,NCT06137170,Overall Survival (OS),2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Proportion of patients in the sequential treatment groups who received myelopoiesis supporting therapy, differentiating between prophylactic and for therapeutic purpose"
3063,NCT01205711,Progression-free survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3064,NCT03041532,Proximal retroflexion improve adenoma detection rate in colorectal cancer screening,2017-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Pre-procedure factors
3065,NCT00763646,To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3066,NCT02548910,Trial Feasibility,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Change in Physiologic Parameters (Cardiac Index)
3067,NCT05254327,Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic Toxicities,2022-08-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3068,NCT03679338,Rate of success of the use of a treatment based on radiofrequency for all the target stenosis.,2018-03-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3069,NCT00115765,Objective Tumor Response Through Week 12 (Irinotecan),2005-06-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure (Irinotecan)
3070,NCT02528110,overall survival,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,complication rate
3071,NCT00416858,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3072,NCT03362684,Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS),2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],Distribution of miR-31-5p expression,Prognostic and predictive value of miR-31-3p expression on SAR
3073,NCT02340949,Number of Patients Achieving Pathologic Complete Response (pCR).,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival (DFS) Rate at 3 Years
3074,NCT00020345,,2000-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3075,NCT02754180,Disease free survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
3076,NCT02361320,Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT),2015-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
3077,NCT02825550,Tumor Response (Efficacy),2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Serum Level of AFP
3078,NCT03685708,Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL),2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants That Did Not Complete Study Due to Intolerance of the HEPLISAV-B Vaccine Among CLL Patients.
3079,NCT01583686,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2012-05-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3080,NCT02575378,Progression-free survival,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
3081,NCT01143545,Tabulation of toxicity type and grade,2010-12-07,TERMINATED,INTERVENTIONAL,['PHASE1'],,"To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients."
3082,NCT03550625,Assessment of the computer- made optical diagnosis of each colorectal polyp,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],,
3083,NCT05185505,Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection,2023-01-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,Immune Cell Biomarkers
3084,NCT00256269,To assess the overall response rate,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of Time to Death
3085,NCT05944809,The highest grade of thrombocytopenia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.,2023-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The highest grade of leukopenia, neutropenia,anemia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy."
3086,NCT01151852,Progression-free Survival,2010-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety and Tolerability of Imatinib
3087,NCT05961982,Efficacy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA),2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],,Safety of EUS-guided RFA of pancreatic cystic neoplasms at one year
3088,NCT04190498,The study will compare OSA prevalence in a group of patient curatively resected for NASH-related HCC with a group of HCV-related HCC.,2020-01-21,WITHDRAWN,OBSERVATIONAL,['NA'],,The study will compare non-recurrence-free survival rate between groups.
3089,NCT03811431,Number of patients in whom contrast enhanced ultrasound guided liver biopsy leads to the final diagnosis as compared to conventional ultrasound guided liver biopsy. The final diagnosis will be assessed based on histological examination.,2011-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3090,NCT00234429,Determine the progression free survival,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Determine objective tumor response
3091,NCT02164149,CT scan after colon cancer surgery. The length of the tumour feeding artery will be measured on the images.,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
3092,NCT04451512,Complete resection rate,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,related costs of treatment
3093,NCT05343013,To determine the 6-month ctDNA clearance rate in colorectal cancer patients with minimal residual disease following 6 months of TAS-102 therapy.,2022-06-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3094,NCT06287723,3-year disease free survival,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to molecular recurrence
3095,NCT01930318,Insulin resistance in perioperative period of gastrointestinal laparoscopic surgery,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Self-rating anxiety scale and self-rating questionnaire for depression before surgery
3096,NCT05435014,Phase II part: target lesion response at 6 weeks after TAE/TACE treatment.,2022-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II part: Safety variables evaluation - ECG test
3097,NCT03985072,Incidence of treatment-emergent adverse events (TEAEs) through stages 1 and 2 of the study,2019-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the exploratory response of tumor markers,Incidence of Andes-1537 anti-drug antibodies (ADAs) in the plasma
3098,NCT03645187,number of patients with improved radiology,2018-08-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
3099,NCT04989855,ORR,2021-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
3100,NCT02314117,Progression-free Survival (PFS),2015-01-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,PK: Minimum Concentration (Cmin) of Ramucirumab
3101,NCT01375569,Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC).,2011-06-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Adverse Events
3102,NCT01569282,Morbidity,2011-10,WITHDRAWN,INTERVENTIONAL,['NA'],,"The numbers of Surgical, Radiological or Endoscopical therapeutic re-interventions"
3103,NCT03516695,Effectiveness of TheraSphere® treatment in participants with liver cancers in a real-life setting,2018-02-23,TERMINATED,OBSERVATIONAL,['NA'],,TheraSphere® Dosimetry in the subgroup of HCC participants
3104,NCT05342350,GALAD performance for liver cancer early detection,2022-04-15,RECRUITING,OBSERVATIONAL,['NA'],,Establishment of a bio-repository of longitudinally collected from patients with cirrhosis to be used for future studies
3105,NCT02145013,Mortality,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],Impact of PET CT on overall survival following liver resection,Survival outcomes
3106,NCT05474794,Sensitivity and Specificity of DFI-EUS in the diagnosis of SELS,2022-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
3107,NCT02121366,Safety of EUS-guided ethanol ablation,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],,Technical feasibility
3108,NCT05608200,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
3109,NCT01010360,,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,
3110,NCT04258644,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year OS
3111,NCT04359732,Imaging parameters as potential predictors of tumor response,2020-05-08,RECRUITING,INTERVENTIONAL,['NA'],,Early regression model (ERI)
3112,NCT02447679,tumor recurrence,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3113,NCT05970627,Rate of pathological complete responses (pCR),2023-07-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidences and types of adverse events (AE) and severe adverse events (SAE)
3114,NCT03269903,Through-the-scope stent placement (feasibility): incidence of device related adverse device events at moment of stent placement,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,"Retrosternal pain related to esophageal stent, measured with the Visual Analog Scale (functional outcome)"
3115,NCT03121729,occurrence rate of severe complications,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Procalcitonin
3116,NCT01900002,Median Progression Free Survival (PFS),2013-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0"
3117,NCT05956990,Fear of Progression Questionaire-Short Form (FoP-Q-SF),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Platelet count
3118,NCT04659382,Progression-free survival at 9 months,2020-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3119,NCT04573088,Postoperative pain as measured by VAS score,2020-06-22,UNKNOWN,INTERVENTIONAL,['NA'],,Anxiety and depression measured by State-Trait Anxiety (STAI) questionnaire
3120,NCT02856815,Recurrence Free Survival (RFS),2018-05-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hematological examination
3121,NCT06246344,surgical difficulty,2023-12-01,RECRUITING,OBSERVATIONAL,['NA'],,QLQ-CR29
3122,NCT05732623,Diet and the risk of eoCRC,2022-12-05,RECRUITING,OBSERVATIONAL,['NA'],,
3123,NCT00457743,Number of Subjects With Clinical Benefit Response (CBR) Based on the Extramural Review Committee Assessment in Recommended Dose Group,2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival Time
3124,NCT00287859,Maximum tolerated dose,2004-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3125,NCT01491217,Overall response rate(ORR) evaluation,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3126,NCT02057471,Hemoglobin levels,2009-09,COMPLETED,INTERVENTIONAL,['PHASE4'],Number of adverse events associated with intravenous iron infusion,C Reactive Protein levels
3127,NCT04235660,Feasibility of Recruitment (Recruitment Rate),2020-07-22,TERMINATED,INTERVENTIONAL,['NA'],,Objective Response Rate
3128,NCT05239741,Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) For RAS Wild-type Participants,2022-04-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
3129,NCT01549275,Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study.,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Correlation Between the Growth Speeds of Cultured Cells and Worsening of AJCC TNM Stages or HCC Related Death 6 Months After Plating of Cells
3130,NCT02748798,Signal to Noise Ratio,2020-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation with PFTs
3131,NCT03382327,Comparison of the intra-operative modifications rates,2017-10-16,COMPLETED,INTERVENTIONAL,['NA'],,Preoperative images independent analysis
3132,NCT04013841,Intestinal microbiome composition,2021-04-08,COMPLETED,INTERVENTIONAL,['NA'],,Intestinal microbiome composition
3133,NCT01325649,Locoregional recurrence rate,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,Rate of involvement of circumferential resection margin (pCRM positive of resected specimens
3134,NCT04158349,"Assess the maximum tolerated dose of intraperitoneal (IP) oxaliplatin with systemic IV 5-fluorouracil, leucovorin, and irinotecan (mFOLFIRI) every 2 weeks in patients with unresectable peritoneal carcinomatosis of colorectal or appendiceal origin",2021-03-22,TERMINATED,INTERVENTIONAL,['PHASE1'],,The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured.
3135,NCT01552200,NaviAid™ G-Eye procedure adenoma detection rate compared to the standard colonoscopy procedure adenoma detection rate,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,
3136,NCT04444167,Objective response rate (ORR),2020-07-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
3137,NCT00838656,Percentage of patients completing 12 courses of chemotherapy,2007-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rates of optimal and suboptimal interval debulking
3138,NCT02437656,The efficacy will be assessed on the operative specimen by the complete histological response rate (absence of tumor cells : pCR).,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate and downstaging rate
3139,NCT06068452,Cardiopulmonary Exercise Testing (CPET)/ Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted mortality versus actual 30 day mortality,2021-03-24,COMPLETED,OBSERVATIONAL,['NA'],,Cardiopulmonary Exercise Testing (CPET) / Portsmouth - Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM) predicted morbidity versus actual post-operative morbidity
3140,NCT01461525,Quality of life outcome,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Anal function
3141,NCT03956940,Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.,2019-10-04,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival
3142,NCT00826410,number of surgical site infections according to CDC guidelines after laparotomy in general surgery,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,risk factors for surgical site infections
3143,NCT03430700,Progression-Free Survival (PFS) measured from start of study treatment to the date of objective progression (investigator assessed using RECIST 1.1) or date of death from any cause (in the absence of progression).,2019-05-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease response
3144,NCT01043484,Rate complete pathologic responses,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of sphincter preservation
3145,NCT01572987,Complete histological eradication of Barrett's esophagus,2011-09,TERMINATED,INTERVENTIONAL,['NA'],,Complication rates
3146,NCT01905384,Rate of Long-term Stent Failure,2017-11-08,COMPLETED,INTERVENTIONAL,['NA'],,Rates of Adverse Stent-related or Intervention-related Outcomes
3147,NCT02270450,Number of Days Alive and Outside of the Hospital,2015-03-09,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
3148,NCT00309530,Overall survival,1990-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3149,NCT04850430,Mortality rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3150,NCT06258525,To evaluate the efficacy of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer.,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate safety and tolerability of SAMe in combination with SOC oxaliplatin based systemic therapy.
3151,NCT00140036,Correlation of genotype with safety and efficacy measures.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3152,NCT05307198,pCR rate,2022-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Concentration of DAMP
3153,NCT01478594,Investigator-assessed Progression-Free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival Events by Tumor Placental Growth Factor (PIGF) RNA Level
3154,NCT05148494,Quality of bowel preparation,2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE4'],,Post-operative complications
3155,NCT02890355,Overall Survival (OS),2016-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay,Duration of Response (DoR)
3156,NCT01571024,Maximum Tolerated Dose (MTD),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarkers of Clinical Benefit
3157,NCT06215651,Conversion success rate,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
3158,NCT04218253,Incidence of complications at 30 days after surgery,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative hospital stay
3159,NCT05963490,ORR,2023-04-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
3160,NCT00049400,dose defining,2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Symptomatic deterioration
3161,NCT04440605,Diagnostic Accuracy of cIII,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnostic Accuracy of cTN
3162,NCT05900583,pathological complete response (pCR),2023-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS)
3163,NCT03685799,Influence of histological concordance on the risk of recurrence,2016-05,COMPLETED,OBSERVATIONAL,['NA'],,Identification of histological factors of recurrence.
3164,NCT03097276,proportion of patients with total hospitalization of less than 15 days during the first postoperative month,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
3165,NCT04071184,Maximum tolerated dose (MTD) or Recommended phase 2 dose (RP2D),2019-05-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
3166,NCT00005021,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3167,NCT04812808,Change in IL-6/GP-130/STAT3 pathway expression (%),2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with adverse events
3168,NCT02150317,the overall survival rate of each group,2014-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3169,NCT02509143,Number of patients who experience moderate or severe level nausea or vomiting,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Serious adverse events
3170,NCT04257526,Improvement in lifestyle score assessed via lifestyle questionnaires,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,
3171,NCT00637091,Response rate,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression free survival, overall survival"
3172,NCT04066153,Unmet physical functioning needs,2019-08-20,COMPLETED,OBSERVATIONAL,['NA'],,Physical activity level
3173,NCT00024258,Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3174,NCT05366816,Number of Participants Achieving Overall Response,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Related Toxicity and Adverse Events
3175,NCT03349827,radical resection rate,2018-01-05,TERMINATED,INTERVENTIONAL,['NA'],,complication rate
3176,NCT05018208,Quantification of false alerts and downstream clinical actions (Arm 2),2021-12-15,RECRUITING,OBSERVATIONAL,['NA'],,Point-in-time assessment of physiological signals from standard of care devices (Arm 1)
3177,NCT02308319,Recurrence free survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reactivation of hepatitis B
3178,NCT05610826,Progression-free Survival,2023-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Difference in imaging characteristics
3179,NCT01774162,Sampling Adequacy,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
3180,NCT01351220,Change from Baseline in receipt of CRC screening at 6 months and 24 months,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Change from Baseline in frequency of patient provider communication at 6 months and 24 months
3181,NCT04808687,Objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3182,NCT06149481,Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC,2024-03-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
3183,NCT05531331,The change in the adaptation of the experimental group according to the Ostomy Adjustment Inventory-23 scores at the end of the second month,2021-11-01,COMPLETED,INTERVENTIONAL,['NA'],,The change in the ability of individuals with stoma to care for their stoma at the end of the 2nd month
3184,NCT00635323,Overall response rate,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory tests
3185,NCT01887041,Outcome of Quality of Life.,2010-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,"The incidence of surgical complications and complications, with regard to the endo-scopic stent insertion, are further aspects that shall be examined in this study."
3186,NCT03743883,Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use,2018-10-30,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention
3187,NCT05643105,Anastomotic leak,2022-12-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Intraoperative complications,Local recurrence
3188,NCT05602935,Pathologic complete response (pCR) rate,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
3189,NCT02882503,To evaluate pancreatic tumor ablation effect,2016-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Biochemical profile
3190,NCT01279330,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,Proportion of uninterpretable test.
3191,NCT05726097,Adequate cleanliness rate,2023-02-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Assessment of patient tolerance of the bowel preparations
3192,NCT04341909,any procedure related adverse outcome,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
3193,NCT04637048,Evaluate the overall survival rate of all patients with hepatobiliary tumor,2017-02-16,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Evaluate the Progression Free Survival rate of patients with hepatobiliary tumor
3194,NCT05872841,disease control rate (DCR),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival(OS)
3195,NCT00005979,,1998-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3196,NCT05629065,Proportion of patients with an SIC at 60 days for arm 1 (patient +clinician nudge) vs arm 2 (no nudge).,2022-11-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Patient preferences
3197,NCT02780700,Progression Free Survival (PFS),2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With Grade 3 or Worse Adverse Events
3198,NCT06213519,Overall survival,2024-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
3199,NCT05265663,Overall survival,2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],,Progression of disease (local and distant)
3200,NCT04955119,Positive predictive value,2021-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,The sensitivity and specificity of CEUS LR-5
3201,NCT00244348,overall survival of patients resected for cure versus (vs.) resected for palliation vs. not resected.,2005-10,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,cost
3202,NCT05766748,Recommended Phase 2 Dose,2023-06-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Body Weight
3203,NCT01985763,Percent Change in Tumor Size,2013-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
3204,NCT01342653,disease free survival,2011-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Quality of life after phase I and Phase II
3205,NCT05223036,Percentage change in duodenal polyp burden,2022-09-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Future candidate biomarkers measured by genomic and transcriptomic platforms in residual tissue biopsies of adenomas and normal mucosa
3206,NCT03668418,Correspondence with chemo-sensitivity data collected in zebrafish model,2018-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time to tumour progression
3207,NCT02898415,Cancer specific survival,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence Free Survival
3208,NCT00183833,To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity.
3209,NCT03024684,3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart,2017-01-03,RECRUITING,INTERVENTIONAL,['PHASE4'],,occurrence of clinical complications related to hepatic decompensation
3210,NCT02644148,Quality of life,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complications
3211,NCT05879328,Recurrence-free survival (RFS),2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,Comparison with historical series
3212,NCT01691625,the quality of life,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Immunological assessment,progression-free survival
3213,NCT04672980,Dose limiting toxicities (DLTs) of RTX-321:,2021-04-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Anti-tumor activity of RTX-321
3214,NCT05579444,Identification of microbial determinants of gastrointestinal diseases.,2022-11-11,TERMINATED,OBSERVATIONAL,['NA'],,Quantify change in microbial species over time post colonoscopy
3215,NCT01384240,to determine whether tissue in nepoplastic or non-neoplastic,2010-04,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,
3216,NCT02323360,Local control (efficacy of SBRT in selected HCC patients with an incomplete response after TACE/TAE),2014-11,TERMINATED,INTERVENTIONAL,['NA'],,toxicity (incidence of acute and late complications)
3217,NCT03076216,Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],Tumor Response,Pain Scores
3218,NCT01749332,ctDNA differences,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,collect preliminary data
3219,NCT01375738,Blood sugar stabilization after gastrectomy,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],,
3220,NCT03242369,Quality of bowel cleansing according to Boston Bowel Preparation Scale (BBPS),2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Detection of colorectal neoplasia
3221,NCT02128958,Number of Subjects With Overall Survival,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pharmacokinetics (PK) Parameters of CF102 - AUC_0-12, Steady State (ng*h/mL)"
3222,NCT05415475,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],2021-09-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive,Pharmacodynamics of CEA-CAR-T cells[Cell dynamics]
3223,NCT00000611,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3224,NCT01639326,Overall objective response rate (RR) by RECIST criteria v1.1,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall response duration
3225,NCT04386772,Hypertrophy degree of standardized FLR,2020-05-27,UNKNOWN,INTERVENTIONAL,['NA'],,Immunohistochemical stainings of liver parenchyma
3226,NCT04980443,Sensitivity of CELTiC,2021-08-03,COMPLETED,INTERVENTIONAL,['NA'],Association between CELTiC test score and FIT concentration,C-statistic of CELTiC
3227,NCT06202781,Single-cell profiling,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
3228,NCT00724503,Progression-Free Survival (PFS) at Any Site,2006-08,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Overall Response
3229,NCT01941641,Objective tumour response rate,2013-10-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of response to neoadjuvant therapy
3230,NCT01865071,Mortality,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
3231,NCT03447691,score of QoR40 (Quality of Recovery 40),2017-08-27,UNKNOWN,INTERVENTIONAL,['NA'],,score of QoR40 (Quality of Recovery 40)
3232,NCT01464593,Determine the Local Tumor Control at 1 Year Post Randomization,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3233,NCT05311319,Disease Free Survival (DFS),2022-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety: adverse events
3234,NCT00991094,Dose-response relationships for normal tissue toxicity after proton therapy,2005-05-27,RECRUITING,OBSERVATIONAL,['NA'],,Symptom burden
3235,NCT01359397,Progression free survival,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
3236,NCT01078311,To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],,To correlate trough sorafenib level with side effects (rash and hypertension)
3237,NCT00973440,To determine the feasibility and added clinical utility of a self-administered computer-based version of an abbreviated comprehensive geriatric assessment tool.,2009-03,COMPLETED,OBSERVATIONAL,['NA'],,
3238,NCT05881746,relapse-free survival,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,postoperative mortality
3239,NCT05584540,Enrollment Rate,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings,CSQ-I Score
3240,NCT04833387,Pathological complete response,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Clinical complete response (CCR)
3241,NCT04929015,Correlation of ctDNA clearance with activity of chemotherapy,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],,Associations between CA125 levels and ctDNA levels
3242,NCT02119026,Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination),2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Assessments (Based on RECIST Criteria) in 2nd-line
3243,NCT05939401,ctDNA,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3244,NCT00103168,Overall survival,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
3245,NCT04308837,Pathological Response,2018-12-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Peritoneal Disease-free Survival
3246,NCT05620771,Progression Free Survival (PFS),2022-11-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
3247,NCT01688557,Diagnostic accuracy of innovative colonoscopy,2012-09,COMPLETED,INTERVENTIONAL,['NA'],Area under the ROC curve (AUC),Pain intensity (VAS scale)
3248,NCT03954548,Adenoma miss rate [AMR],2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Polyp Miss Rate [PMR]
3249,NCT04479527,PFS,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of AE and SAE
3250,NCT02983578,Physical Examinations,2017-03-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Radiomic measurements,Overall survival
3251,NCT03613194,Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal),2018-06-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3252,NCT02273362,Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining),2014-11-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Erlotinib Hydrochloride Plasma Level,Adverse Event Profile
3253,NCT01180166,progression-free survival,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival time
3254,NCT01955096,food intake time,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,readmission
3255,NCT00846131,To Evaluate sorafenib as an adjunct to Y-90 for control of HCC as a bridge/downstage to transplant,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,To identify predictive and prognostic markers of how the liver cancer will respond to treatment.
3256,NCT04847297,rate of serious complications,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
3257,NCT02141295,"Progression-free Survival (PFS), Time to Event",2014-06-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cmax Accumulation Ratio (AR) of Vanucizumab
3258,NCT05833815,Progression free survival,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Chemotherapy Toxicity
3259,NCT04724226,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
3260,NCT03435107,Objective response rates (RECIST 1.1),2018-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3261,NCT05797805,Evaluate efficacy of tegavivint as a single agent,2023-09-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluate efficacy of combination of tegavivint plus pembrolizumab,
3262,NCT06065059,Measure anti-tumor activity using RECIST 1.1 (Phase 2 only),2023-12-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination
3263,NCT01432314,Time to tumor progression,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Best tumor response by modified RECIST (mRECIST) and RECIST criteria
3264,NCT00084604,"Time to progression, evaluated using RECIST",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of toxicity, evaluated using CTCAE version 3.0"
3265,NCT00077519,,2004-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3266,NCT05846594,Median Time to Diagnosis,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence and Severity of Liquid Biopsy Sample Collection-Related Adverse Events
3267,NCT02850172,severity of symptom (QLQ-OES18 questionnaire),2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,length of mechanical ventilation
3268,NCT00727831,Incidence and severity of CNS toxicity and neurocognitive changes taken from patients' medical records and measured using the Mini-Mental State questionnaire and MRI data,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy
3269,NCT01126346,"Assess feasibility of instituting an orientation program, brief follow up care and phone calls in this patient population",2010-05,COMPLETED,INTERVENTIONAL,['NA'],,"Improve overall post-operative QOL ratings at 3 months, relative to discharge"
3270,NCT04182386,Future liver remnant hypertrophy,2012-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Effect of sarcopenia on hypertrophy
3271,NCT04536922,Treatment,2021-01-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3272,NCT03716531,2 Year Overall Survival,2019-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events associated with IORT
3273,NCT06335147,pathologic complete response（pCR）,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
3274,NCT05620628,PFS (progression free survival),2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,ORR (objective response rate)
3275,NCT05291988,Demographic information,2022-10-08,TERMINATED,INTERVENTIONAL,['NA'],,COVID-19 impact assessment
3276,NCT04404777,3 year survival,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,MDT effect on treatment of local recurrence
3277,NCT00707681,To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight"
3278,NCT06013774,Device Feasibility,2021-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Radioactivity distribution in 3D
3279,NCT03563248,Proportion of participants with R0 resection,2018-08-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment related serious adverse events
3280,NCT00023634,toxicity,2001-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3281,NCT02887612,Positive Predictive Value,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,prognostic molecular markers
3282,NCT05994638,Side effects after radiotherapy,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,Impact of dysphagia on quality of life
3283,NCT01694342,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
3284,NCT00526578,Identification of susceptibility genes in high risk familial pancreatic cancer (FPC) pedigrees using cutting-edge genetic analysis methods,2002-06-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3285,NCT04738240,Clinical anastomotic leak,2019-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
3286,NCT02630420,Safety and tolerability based on regular clinical assessment and NCI Common Terminology Criteria for Adverse Events,2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],"Changes in genetic aberrations over the course of the disease by comparing archival, baseline and progression samples.",Progression free survival
3287,NCT04290364,Use of healthcare services,2019-09-21,COMPLETED,OBSERVATIONAL,['NA'],,Carer satisfaction with palliative care
3288,NCT04947826,Objective response rate,2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Discontinuation rate due to any adverse events,Overall survival rate at 12-month time point
3289,NCT04802954,Stratification of the risk of hepatocarcinogenesis in high-risk patients by a deep learning-based cross-analysis.,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Characterization of the interface of the nodules with the adjacent hepatic parenchyma by a deep learning-based cross-analysis
3290,NCT02112747,Successfully following screening guidelines appropriate to the participant's risk profile,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Cost effectiveness of the interventions
3291,NCT05327738,Proportion of progression-free participants,2022-12-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Descriptive summary of tumor and tumor immune cell populations,Incidence of grade >= 3 adverse events
3292,NCT02486497,Recurrence free survival,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Toxicity
3293,NCT05531864,visual analogue scale,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative heart rate changes
3294,NCT02157454,Self-efficacy for coping with cancer (measured by the German short form of the Cancer Behavior Inventory),2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient competence (assessed by a self-rating measure of patient competence in oncology in validation process)
3295,NCT00326911,Progression-free Survival (PFS),2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Change From Baseline in Assessment of Pain Using BPI Short Form, Interference, at Cycle 2 Week 4"
3296,NCT02219893,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease free survival
3297,NCT06061146,PFS,2023-10-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
3298,NCT06219096,Fluorescence imaging effect of the live,2023-12-10,RECRUITING,INTERVENTIONAL,['NA'],Disease-free survival,Postoperative hospital stay
3299,NCT03724071,Phase II part - Overall response rate,2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3300,NCT06017323,Proglumide Recommended Phase II dose and schedule (RP2D),2023-10,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Change in tumor marker (CA19-9)
3301,NCT04512833,Local control time,2020-08-12,RECRUITING,OBSERVATIONAL,['NA'],,Adverse reaction
3302,NCT03061162,Side effects of pulsed low dose rate radiation therapy,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to progression
3303,NCT02760537,self-reported status of the series of HBV vaccinations by follow-up calls in seven months after mailing the results verified by the medical records,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
3304,NCT03869892,Progression-free Survival (PFS),2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to treatment failure (TTF)
3305,NCT06063928,Changes in genomic knowledge,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,
3306,NCT05319431,Progression-free survival (PFS),2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
3307,NCT05727787,Maximum tolerated dose (MTD) of Single Fraction GRID SBRT,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],,Molecular correlatives: TCR repertoire analysis.
3308,NCT06141109,PFS,2022-01-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area Under the Plasma Concentration Versus Time Curve (AUC) of MB07133
3309,NCT02859753,Time to disease progression according to American Society of Interventional Radiology criteria,2014-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
3310,NCT00321100,Objective Response Rate (ORR),2006-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3311,NCT01065818,"Optimal Timepoint During the Course of Neoadjuvant Therapy [CRT, CT (Chemotherapy) or RT Radiotherapy)] That FLT-PET Imaging Can Predict Response",2009-08,TERMINATED,INTERVENTIONAL,['NA'],,
3312,NCT05646537,stoma compliance scores of the participants,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],,comfort level of the participants
3313,NCT02515734,Best deepness of response,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of adverse events
3314,NCT00030498,Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3315,NCT03401814,"Quantify tissue mechanical properties of the liver and liver tumor using MRE in patients receiving radiation therapy + immunotherapy at baseline, mid-treatment and time of followup imaging determined by standard of care to assess response to therapy",2018-08-02,COMPLETED,OBSERVATIONAL,['NA'],,
3316,NCT05544929,Dose intensity,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Elimination half-life (T1/2) of KFA115 or pembrolizumab
3317,NCT04764409,Identification of all the kinds of complications according to the Common Terminology Criteria for Adverse Events (CTCAE v4.0) and their systematization.,2021-01-12,UNKNOWN,OBSERVATIONAL,['NA'],,
3318,NCT03896958,Assessment of benefit of return of research results by SpeciCare Outcome Monitor Board,2019-03-21,UNKNOWN,OBSERVATIONAL,['NA'],,
3319,NCT05510895,Tumor regression grade (TRG),2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Translational research 3
3320,NCT00309543,Overall survival,1993-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3321,NCT02517554,Completion of Surveys,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,
3322,NCT05958433,duration of hospital stay,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,assess the effects of preoperative education using stoma appliance on quality of life in colorectal cancer patients with a stoma
3323,NCT05967533,Natural killer (NK) cell killing activity,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunologic effects of FWG (Immune Correlates): serum cytokines analysis
3324,NCT04132505,Maximum tolerated dose (MTD),2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Effect of this binimetinib/hydroxychloroquine treatment on changes in muscle and fat mass,Overall survival
3325,NCT04241276,To assess the efficacy of ATRA when given in combination with gemcitabine and nab-paclitaxel based on progression free survival (PFS).,2020-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess quality of life (QOL) of patients receiving ATRA in combination with Gemcitabine and Nab-Paclitaxel: EQ-5D-5L
3326,NCT04247256,Objective Response Rate,2020-05-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Biomarkers ABCG2, ABCB1, SRPK1"
3327,NCT00610636,Both groups of patients were analyzed with intention-to-treat principle. The primary end-point was time-to-progression. The secondary points were overall survival and surgical morbidity.,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Surgical morbidity, Chemotherapeutic complications"
3328,NCT03535259,MST,2018-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of III-IV grade adverse events
3329,NCT02198898,incidence of adhesive intestinal obstruction,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3330,NCT01843049,Dose limiting toxicity(DLT),2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Local recurrent rate within the >50% SUVmax region of the primary tumor,Late toxicity
3331,NCT01438476,Postoperative Pain Experience,2012-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3332,NCT03532204,Progression Free Survival,2019-04-15,WITHDRAWN,INTERVENTIONAL,['NA'],,Quality of life EORTC QLQ CR29
3333,NCT02744651,Number of correct histopathological diagnoses from submucosal tumors in the upper GI tract.,2017-02-17,TERMINATED,INTERVENTIONAL,['NA'],,
3334,NCT00576940,The ratio of postoperative complications (infectious and surgical),2004-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,assessment of visceral protein turnover
3335,NCT04514484,Incidence of dose limiting toxicities (DLTs),2021-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in infiltrating immune cell markers,Human immunodeficiency virus (HIV) viral loads
3336,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,2019-10-09,RECRUITING,OBSERVATIONAL,['NA'],,Cost-benefit analysis
3337,NCT03400657,overall survival,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Differences in overall survival after performing MDT at center
3338,NCT00081900,To establish the MTD and dose limiting toxicities of DENSPM intravenous infusion in patients with unresectable HCC.,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the pharmacokinetics of DENSPM in plasma and HCC tissue in patients unresectable HCC.
3339,NCT03506321,Compare chromoendoscopy predictions and HD-WL/NBI predictions of submucosal invasive cancer (SMIC) and residual or recurrent adenoma (RRA) to compare correlation with histological findings,2018-02-07,COMPLETED,INTERVENTIONAL,['NA'],,Compare the difference between live endoscopic assessment and use of carefully selected endoscopic images to predict SMIC
3340,NCT05955833,"89Zr-trastuzumab uptake (standard uptake values (SUVmean, %ID/kg) in normal organs/tissues and bloodpool in historical controls with HER2+ breast cancer (n = 20) who underwent 89Zr-trastuzumab PET imaging.",2023-06-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,HER2 expression measured by IHC on tumor biopsies
3341,NCT03255811,Evaluation of apatinib mesylate tablets as first-line maintenance treatment for advanced gastric or gastroesophageal junction progression free survival site adenocarcinoma,2017-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,
3342,NCT04893876,Global Quality of Life (QoL),2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Frailty
3343,NCT01658878,ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort,2012-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Effective T-Half of nivolumab
3344,NCT04861987,Maximum Plasma Concentration (Cmax) of capecitabine,2021-06-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with Adverse Events of Special Interest (AESI)
3345,NCT00976898,Median Overall Survival,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,Patterns of Failure
3346,NCT04873895,Serious adverse event (SAE) rate,2022-01-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,axitinib treatment intensity
3347,NCT05158374,"Relative genetic expression change of genes relating to energy, metabolism and stem cell signalling in the large bowel",2022-08,UNKNOWN,INTERVENTIONAL,['NA'],,Change in the proportions of bacterium the colorectal microbiome after aspirin and/or metformin medication
3348,NCT05515796,ORR (objective response rate) per RECIST 1.1,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],EORTC QLQ-CR29,R0 resection rate
3349,NCT05914077,Proportion of patients with IPMN with GNAS and KRAS mutations in intracystic fluid obtained by EUS-FNA versus pancreatic juice obtained by ADPJ-secr after both techniques.,2023-09-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Proportion of patients with Serious Adverse Events
3350,NCT05278728,The rate of grade 3/4 toxicity,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The disease control rate
3351,NCT03041129,Hepatic fat fraction,2017-04-14,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic phosphate concentrations
3352,NCT03084133,Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.,2017-04-10,COMPLETED,INTERVENTIONAL,['NA'],,"Quality criteria for screening colonoscopy using the following parameters: visualization rate of the bottom of the colon, the withdrawal time of the colonoscope (Withdrawal time), quality of the colic preparation using the Boston scale."
3353,NCT02674815,Compliance,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Clavien-Dindo Classification Sore
3354,NCT02912949,Duration of response per RECIST v1.1 as per local Investigator's assessment.,2015-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of overall survival (OS)
3355,NCT00096070,1-year survival rate,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
3356,NCT04889404,Incidence of adverse events related to the safety specifications,2021-05-22,RECRUITING,OBSERVATIONAL,['NA'],,
3357,NCT05518903,Relationship between 68Ga-FAPI-46 PET metrics and staging examinations in PDA,2022-11-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3358,NCT00112918,Disease-free Survival in Stage III Cancer Patients - Number of Events,2004-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival in Stage III Cancer Patients - Number of Events: Final Analysis
3359,NCT00199797,"Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.",2005-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin."
3360,NCT03916809,Feeding-tube-free food intake (days),2017-07-12,RECRUITING,INTERVENTIONAL,['NA'],M.D. Anderson Dysphagia Inventory (MDADI) (number),Upper esophageal sphincter (UES) opening width (mm)
3361,NCT04640103,Adverse event rate,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of second tumor in patients with Lynch syndrome
3362,NCT02062515,Number of Participants with Adverse Events,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3363,NCT02143401,Incidence of adverse events,2014-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in cleaved and total CK18 levels in serum,Time to treatment failure
3364,NCT01041612,Obstruction of 1st C-SEMS or presence of jaundice at death without stent exchange,2010-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Death of patients
3365,NCT04800549,Nurse Observation Chart of Child Mucositis Evaluation,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,
3366,NCT05512793,Adenoma miss rate (AMR),2023-05-24,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal time. (First/second colonoscopy)
3367,NCT00280332,The prevalence of advanced colonic adenoma in the re-screening population,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,The time to adenoma adenoma development according to different baseline characteristics of patients and colonoscopy findings
3368,NCT00936832,Response rate at 3 months as assessed by RECIST criteria,2009-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Translational research including pharmacodynamic studies of plasma and rectal tumor biopsies and histological and molecular studies
3369,NCT02195011,The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
3370,NCT05745558,Percentage of patients willing to participate in prehabilitation program,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Work status
3371,NCT00443040,Time to Return of Upper and Lower GI Function,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Laboratory Values
3372,NCT00569309,Number of Participants Experiencing Immune Reconstitution,2007-12-12,COMPLETED,INTERVENTIONAL,['NA'],,Collection of Baseline Immune Reconstitution and Quality of Life Pilot Data for Comparison in Future Post-transplant Immunotherapy Trials
3373,NCT00683085,Number of Participants Without Grade 4 Hematological or Grade 3 to 4 Non-hematological Adverse Events,2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Tumor Regression
3374,NCT00122291,response,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3375,NCT04301557,Pathological Complete Response(pCR),2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 year disease free survival
3376,NCT06067620,Time to first passage of faeces,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of incisional hernia
3377,NCT05162118,RP2D (phase 1),2022-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CEA
3378,NCT03908333,Disease Control Rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels: Brief Pain Inventory (BPI)
3379,NCT05173909,"Serum LEVELS of IL-2, IL-4, IL-6, IL-10, TNF-ɑ, IFN-γ",2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
3380,NCT05682794,disease-free survival ratev,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,DRM status
3381,NCT00006081,Number of Patients with Response after 2 Cycles of Treatment,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3382,NCT01878422,Progression Free Survival (PFS) of first and second line treatment strategy,2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of partecipants with adverse events as a measure of safety and tolerability
3383,NCT02366819,R0 (analysis will be performed evaluating the R0 rate),2014-12-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Change in SUVmax for the primary esophageal tumor,Progression free survival
3384,NCT00756548,Efficacy - Preparation Quality Using a 4 Point Scale,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Serum Chemistry Results (Osmolality)
3385,NCT00341276,Linkage of genetic markers,1995-07-06,COMPLETED,OBSERVATIONAL,['NA'],,Gene environment interactions (case control)
3386,NCT00056355,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3387,NCT00030108,Nerve growth factor levels before and after drug administration,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1"
3388,NCT04854434,Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2021-06-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs"
3389,NCT01772407,Cost during the 2 postoperative years,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,"Mortality, morbidity and quality of life during the 2 postoperative years"
3390,NCT00778102,Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Complications Related to Second Resective Surgery
3391,NCT05519319,Overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival(PFS)
3392,NCT02243358,Frequency of R0 Resection,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3393,NCT06238193,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],PD-L1 level,Copy-number variations (CNVs)
3394,NCT02597075,Change in Patient-reported symptoms as measured by ESAS-r,2016-03-17,TERMINATED,INTERVENTIONAL,['NA'],,Initiation or increase of anti-hypertensive drugs
3395,NCT01341132,,2011-05,UNKNOWN,OBSERVATIONAL,['NA'],,
3396,NCT01676714,Overall Response Rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Who Experienced Treatment Related Toxicities
3397,NCT00023946,Overall survival,2001-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3398,NCT04615013,Maximum tolerated dose and recommended phase 2 dose (RP2D),2020-11-23,RECRUITING,INTERVENTIONAL,['PHASE1'],Concordance of cell free deoxyribonucleic acid (DNA),Overall survival
3399,NCT04751773,Serious adverse events,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],LPS-induced TNF-a production of whole blood,Surgical stress: Noradrenaline
3400,NCT05890742,"Event Free Survival, EFS(EFS), defined as the time from randomization to the first determination using RECIST v1.1 of inoperable disease progression, local recurrence or distant metastasis after surgery, or death from any cause, whichever occurs first.",2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Overall-survival(OS), defined as the time from randomization to death from any cause"
3401,NCT03993743,Incidence and type of adverse events induced by CD147-CART hepatic artery infusions,2019-05-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CD147-CART detection in extrahepatic sites
3402,NCT06246630,Objective Response Rate,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Concordance between drug sensitivity test results and patients' treatment response
3403,NCT02965976,Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study,2016-12-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life Score as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 OES18
3404,NCT02207959,Gastric neoplasia presence,2015-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Specificity for the detection of neoplasia
3405,NCT00569699,Progression free survival,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation"
3406,NCT04070313,Relapse-free survival (RFS),2019-07-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety profile
3407,NCT04690972,Surgery for a hepato-bilio-pancreatic issue,2020-12-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3408,NCT05395780,Objective response rate (ORR),2022-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between expression level and mutation of FGFR1OP2-related proteins and efficacy
3409,NCT03993873,Define the Recommended Phase 2 Dose,2019-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
3410,NCT00673322,Determine the safety of using modified T cells by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamics
3411,NCT03702491,PFS,2018-08-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3412,NCT00120172,"To evaluate the efficacy (measured by time to progression) of oxaliplatin, capecitabine, and bevacizumab as first-line therapy in elderly patients with metastatic colorectal cancer.",2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Vulnerable Elders Survey (VES-13) and Geriatric Depression Scale (GDS) scores
3413,NCT03423056,Peak oxygen comsumption,2017-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Peak oxygen comsumption - 3 weeks
3414,NCT03598166,Percentage of Participants Who Undergo Screening Within 6 Months of Outreach,2018-10-11,COMPLETED,INTERVENTIONAL,['NA'],,Self-reported Most Common Reasons for Refusing Blood Test on Questionnaire in Intervention Group
3415,NCT02980029,Malonyl carnitine and tripalmitin levels will be measured in the preand post-treatment blood samples using mass spectrometry blood samples using mass spectrometry.,2017-10-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Toxicities will be graded as per NCI-CTCAE v4.03, based on recorded adverse events, physical examinations, and clinical laboratory assessments."
3416,NCT01908322,"Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).",2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Safety variables will be summarized using descriptive statistics based on adverse events collection.
3417,NCT05709197,Delayed gastric emptying (DGE),2023-04-17,RECRUITING,INTERVENTIONAL,['NA'],,Functional outcome at 12 months
3418,NCT01325883,The relative decrease in exercise capacity (LT) associated with NAC prior to upper gastrointestinal cancer resection will predict outcome (1 year mortality) following surgery.,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,Patients whose LT changes following NAC so that they move into a higher risk category will have a worse outcome (1 year mortality) when compared with those who do not increase risk category.
3419,NCT03082079,progression-free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,patient satisfaction scores
3420,NCT05687747,Sensitivity of FAPI-PET/MRI to detect intrahepatic HCC using contrasted multiphasic MRI liver as standard comparison,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Sensitivity estimation of 68Gallium-FAPI-46 PET/MRI in per-lesion analysis for all lesions with available surgical resection samples for histopathology assessment
3421,NCT02125929,Pancreatic fistula rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],Hospital stay time,Mortality rate
3422,NCT01222689,Survival at 24 Weeks,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Biomarkers Potentially Predictive of Dual MEK/EGFR Inhibition,Number of Patients With Dose Modifications and Reason for Dose Modification.
3423,NCT02510118,Quality of life,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression-free Survival (PFS)
3424,NCT06236464,Primary Endpoint,2023-09-25,RECRUITING,OBSERVATIONAL,['NA'],,Secondary Endpoint
3425,NCT02022033,Feasibility of Adjuvant FOLFOX-A,2014-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival
3426,NCT04454099,Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT.,2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Explore the effect of aspirin or other anticoagulants to the diagnose accuracy of qFIT
3427,NCT05502198,MELD-score,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life (Questionnaire)
3428,NCT00980382,"*phase I study:the maximum tolerated doses (MTD)of S-1 and docetaxel,recommended dose for subsequent phase II study *phase II study: evaluation of efficacy and toxicities of this new combination regimen in metastatic",2004-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To investigate the time to progression and overall survival
3429,NCT06032767,RTOG/EROTC Acute Radiation Reaction Scoring Standard,2023-08-14,RECRUITING,OBSERVATIONAL,['NA'],,
3430,NCT05448846,Change in functional capacity,2022-04-08,RECRUITING,INTERVENTIONAL,['NA'],Colorectal Surgery Procedure,Rate of mortality
3431,NCT00832637,Tumor Control Rate,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
3432,NCT04136600,Objective Response Rate,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Effect
3433,NCT00799474,Willingness to Receive the Human Papillomavirus (HPV) Vaccine,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,Knowledge of HPV
3434,NCT00390195,Disease control rate in Phase II,2006-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor marker
3435,NCT02627729,Short Form 36 Quality of life Questionnaire,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,Functional outcome measured with Overactive Bladder validated 8 scale
3436,NCT02352688,Length of postoperative hospital stay,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,30-day mortality
3437,NCT00559741,Improvement of hematologic and gastrointestinal tolerance to therapy,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression
3438,NCT01393340,Effect of Omalizumab on nasal polyp size and evolution of nasal polyps,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluation of adverse events, directly or by general physical examination, blood sampling , review of concomitant medication or symptom scores."
3439,NCT05414461,Durable clinical benefit,2019-03-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3440,NCT01176604,Overall survival,2010-08-04,COMPLETED,INTERVENTIONAL,['NA'],,
3441,NCT02837874,Dumping syndrome,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Gastritis
3442,NCT00001452,"Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions.",1995-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
3443,NCT05178576,Recurrence-free survival (RFS) at one year,2022-06-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Immunogenicity
3444,NCT04867590,"The rate of full eradication of Barrett esophagus (metaplasia), which is defined by the absence of residual Barrett esophagus in the check-up endocopy after 3 months",2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Build a model to predict incomplete response for eradication of Barrett's eosophagus on the basis of each independent predictor coefficient in the multivariate regression logistic model
3445,NCT04004234,Progression-free survival (PFS) at 6 months,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
3446,NCT00355212,Sustained complete response at one year after the treatment.,2001-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,costs.
3447,NCT03487523,Number of participants taking part in the Scottish national bowel cancer screening programme,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,
3448,NCT03542214,Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used),2018-04-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumorregression
3449,NCT04464967,Phase 2a - To assess objective response rate (ORR) of SNK01 in combination with cetuximab in subjects with advanced EGFR cancers.,2021-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a - Impact of SNK01 in combination with cetuximab on quality of life in subjects with advanced EGFR cancers evaluated using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13).
3450,NCT04327050,success rate,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,complications
3451,NCT02724358,Time to progression,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
3452,NCT03399071,Pathological complete response rate of combination FLOT-A,2017-07-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival by Kaplan Meir method
3453,NCT02118077,Number of Participants with Serious and Non-Serious Adverse Events,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective tumor response
3454,NCT06054685,PFS,2023-04-17,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3455,NCT00004235,objective tumor response rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,treatment response
3456,NCT03507998,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,2017-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CGX1321 half life
3457,NCT03766633,Accuracy of the LiverVision® software volumetric measurements,2018-04-29,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison
3458,NCT01862718,Safety of Ablation plus radiation,2013-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3459,NCT05873621,Number of harvested extra-mesorectal lymph nodes,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Time of surgery
3460,NCT02619266,Appetite Visual Analog Scale,2015-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The Questionnaire of Acupuncture-related Events(QAE),Nutritional status
3461,NCT03465202,Area under the curve (AUC) of capecitabine and metabolites,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Time of maximum plasma concentration (Tmax) of capecitabine and metabolites
3462,NCT00075686,Overall survival comparison between treatment groups,2004-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline, before each course, and then completion of study treatment"
3463,NCT03611712,Fatigue by the Brief Fatigue Inventory-Taiwanese Form,2019-02-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The change of of biomarkers (inhibitory immune factors, dendritic cells makers, tumor-associated macrophages, immune-regulatory markers and oncogenic-mediated immune markers) will be combined to report the immune profile."
3464,NCT00220051,Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Bowel function and quality of life
3465,NCT04767906,time on treatment (TT),2021-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,occurence of clinical symptoms of liver dysfunction (safety endpoint)
3466,NCT01192763,Frequency and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Proportion of cancer stem cells (CD44+, CD24+, ESA+ population of cells) self-renewal and tumorigenesis as measured by FACS"
3467,NCT02032914,The prevalence of colonic neoplasm,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Prevalence of intestinal tuberculosis
3468,NCT04476329,Overall Survival,2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,FACIT FACT-Hep Quality of Life Measurements
3469,NCT04615143,Disease-free survival,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Major pathological response rate
3470,NCT03938324,Change in Patient activation as measured by the Patient Activation Measure (PAM-13),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18)
3471,NCT02558868,Overall Survival,2015-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
3472,NCT05138159,Overall Survival,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
3473,NCT06184594,Colorectal Cancer (CRC) Screening completion,2024-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The Colorectal Cancer Screening Beliefs Instrument Score
3474,NCT01993472,Progression free survival (PFS),2013-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
3475,NCT02948426,Overall Maximum Tolerated Dose of Actimmune (Interferon Gamma-1b),2017-02-08,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants With a Grade 3 or Higher Dose-Limiting Toxicity (DLT),Time to Disease Progression
3476,NCT02817178,Progression-free survival,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
3477,NCT01334710,Comparison of MRI/CT Scans to Pre-treatment Scan,2011-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity Assessment
3478,NCT05113459,"pathologic Complete Response, PCR",2021-12-18,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Overall survival , OS"
3479,NCT06114082,Objective response rate (ORR),2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related serious adverse event
3480,NCT05092750,To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.,2021-09-15,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3481,NCT06270017,Tumour growth,2022-01-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,response evaluation
3482,NCT06269978,Half-life,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall response rate
3483,NCT05493358,5 year disease-free survival by Kaplan Mayer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The percentage of pattern of recurrence/metastasis
3484,NCT05101148,Proportion of patients who take each gastrointestinal medication,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to last measurable concentration (tlast) of selumetinib and N-desmethyl selumetinib
3485,NCT05534841,Complete response MRI criterion,2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],,MRI accuracy
3486,NCT00004005,Disease-free survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3487,NCT01038544,The primary outcome measure will be the accuracy of the combination of EUS and EBUS to correctly diagnose the presence or absence of mediastinal lymph node metastases compared to EUS alone.,2009-12,COMPLETED,INTERVENTIONAL,['NA'],,Change in treatment plan based on EBUS
3488,NCT05679583,R0 rate,2022-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor recurrence
3489,NCT01032291,Percentage of Participants With a Response to Treatment During the Proof of Concept Period,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Participants With Treatment-Emergent Adverse Events (TEAE)
3490,NCT02089737,Number of Participants With Adverse Drug Reactions,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
3491,NCT00291473,adverse events,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,immune responses including HER2 and NY-ESO-1 specific IgG and T cells
3492,NCT05653960,Adverse event rate of EMR or ESD for colorectal neoplasms,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3493,NCT06118060,Heart rate variability,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Abdominal pain
3494,NCT03484195,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
3495,NCT02372162,Availability of comprehensive imaging and molecular fingerprint data of individual tumors,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Biomarker analysis
3496,NCT04600466,To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes,2021-01-22,RECRUITING,OBSERVATIONAL,['NA'],,
3497,NCT03614546,Overall Survival(OS),2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,Minimal volume of liver free from radiation
3498,NCT02182804,Accuracy,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,
3499,NCT01265576,failure free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,clinical benefit response
3500,NCT00681330,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
3501,NCT02583815,Number of Participants Who Use PAM Device,2015-08,COMPLETED,OBSERVATIONAL,['NA'],,Brief Fatigue Inventory (BFI)
3502,NCT06181318,Predicting the posthepatectomy hemorrhage after major liver resection,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between remnant liver function after major liver resection and postoperative mortality
3503,NCT04750772,finial clinical staging（TNM）,2019-10-16,RECRUITING,INTERVENTIONAL,['NA'],,SUVmax
3504,NCT04503694,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy.",2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluation of the efficacy of the combination of nivolumab and regorafenib when administered before and after standard, pre-operative short-course radiation therapy."
3505,NCT04727723,Progression Free Survival (PFS),2021-03-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Information about the patient's diagnosis-related group (DRG)
3506,NCT01929460,Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Median Cyst Fluid Amylase
3507,NCT00703365,To evaluate the efficacy (progression free survival (PFS)) of sorafenib in patients with advanced/unresectable HCC.,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate overall, survival, overall response rate (RECIST), time to progression (TTP), disease control rate (DCR) and side-effect profile of sorafenib in combination with gemcitabine in patients suffering from HCC."
3508,NCT00342186,Collection of 3400 samples,2002-09-27,COMPLETED,OBSERVATIONAL,['NA'],,
3509,NCT00895388,Quality of LIfe (EQ 5D),2009-05,WITHDRAWN,INTERVENTIONAL,['NA'],,ICIQ Urinary function Short form
3510,NCT00107679,Time to high-grade anal dysplasia or anal cancer,2005-02,COMPLETED,OBSERVATIONAL,['NA'],,time from low-grade anal dysplasia to normal
3511,NCT03254121,"Characterisation of genomic mutations of HCC, developed in HCV patients with SVR",2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
3512,NCT00251186,To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.
3513,NCT04111029,Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment,2020-01-16,RECRUITING,OBSERVATIONAL,['NA'],,Mortality
3514,NCT00003411,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3515,NCT04214119,Difference in methylation of gene markers to discriminate gastric cancer from non-pathological esophageal squamous and gastric cardia tissue.,2016-01-12,RECRUITING,OBSERVATIONAL,['NA'],,Specificity of candidate biomarker HPP1
3516,NCT04155671,Overall Survival(OS),2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Overall Response Rate (ORR)
3517,NCT04118933,objective response rate,2019-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
3518,NCT03870607,Response rate (clinical and radiological),2019-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Variation of systemic immune parameters
3519,NCT01754636,Inclusion in at least one Clinical trial (amendment n°3 -02/2014),2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Invitation to participate in in at least one Clinical trial (amendment n°3 -02/2014)
3520,NCT03478488,Overall Survival (OS),2018-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to progression (TTP)
3521,NCT05471596,Prospective Power/Time Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics in Hepato-Pancreato-Biliary Sold Tumors Utilizing a Single Generator at a Single Surgical Center,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],,90 day complication rate
3522,NCT00515853,Cleveland Clinic Incontinence (CCI) Score,2006-11-27,COMPLETED,INTERVENTIONAL,['NA'],,
3523,NCT00238394,Time to disease progression,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Laboratory measures
3524,NCT04757311,Progression Free Survival (PFS),2020-08-01,COMPLETED,OBSERVATIONAL,['NA'],Percentage of use biologics in right side tumors.,Advers events
3525,NCT00382811,The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,The secondary efficacy end-point is overall survival (OS)
3526,NCT06111274,Objective Response Rate (ORR),2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,The Minimum Concentration of ABSK021
3527,NCT02526095,DIsease free survival,2014-06,RECRUITING,OBSERVATIONAL,['NA'],,Death
3528,NCT01761266,Overall Survival (OS),2013-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Percent Change From Baseline in Serum Biomarker,Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
3529,NCT03050814,"Progression Free Survival Between the Standard of Care (SOC) Arm A, and Standard of Care (SOC) Arm B + lead-in",2017-04-05,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Number of Participants That Are Hospitalized Because of Adverse Events Attributed to Disease Progression
3530,NCT03378128,Percentage of patients experiencing grade 3 or 4 post-operative complications,2018-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Score of Suidan preoperative predictive index parameters
3531,NCT05270642,local tumor progression,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3532,NCT00899002,Identification of proteomic profiles and molecular pathways involved in tumor progression,2007-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features
3533,NCT01175291,Progression Free Survival,2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
3534,NCT02342600,Disease Control Rate (DCR),2017-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number and type of adverse events
3535,NCT01077817,"Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)",2010-02-26,COMPLETED,OBSERVATIONAL,['NA'],,
3536,NCT01954732,"Pancreatic tumor cell proliferation and apoptosis as measured by the percentage of cells Ki-67+, percentage of cells TUNEL+, and mitotic counts in tissue samples",2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Percentage of pancreatic cancer stem cells in tissue samples
3537,NCT04660812,Number of Participants With Treatment-emergent Adverse Events,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Anti-Drug Antibodies to the Biologic Component(s) of Combination Therapy
3538,NCT00028834,Objective response rate (complete or partial responses),2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
3539,NCT05982197,Change in severity of radiation induced mucositis,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],,
3540,NCT00089635,Duration of Response,2004-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3541,NCT03077594,Mucosal Impedance as measured by an endoscopic probe,2016-09-26,COMPLETED,OBSERVATIONAL,['NA'],,Volumetric Laser Endomicroscopy
3542,NCT02500199,Part 2 Overall Response Rate (ORR),2015-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
3543,NCT02994693,Longitudinal assessment of the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy,2016-12,RECRUITING,OBSERVATIONAL,['NA'],,
3544,NCT01664494,Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,Median Dose of Capecitabine
3545,NCT05980481,Safety(adverse event),2023-08-04,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Duration of relief (DOR)
3546,NCT06220617,Sensitivity and specificity of the screening test with comparison to colonoscopy,2024-01-11,RECRUITING,OBSERVATIONAL,['NA'],,
3547,NCT01975688,"Area under the concentration-time curve extrapolated to infinity (AUC(0-∞)) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex",2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,The incidence of adverse events as a measure of subject safety
3548,NCT02892305,Overall Survival,2018-05-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Intraoperative estimated blood loss
3549,NCT00577889,Six Month Survival Rate,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Confirmed Response Rate
3550,NCT04385641,Non hematologic toxicity,2019-10-08,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor assessment
3551,NCT02460835,Median Time to Local Progression,2016-01-26,COMPLETED,INTERVENTIONAL,['NA'],Incidence of Radiation Induced Liver Disease (RILD),Overall Survival
3552,NCT00506571,Maximal overall response rate,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Overall survival, Toxicity assessment, & Pharmacokinetic characteristics and association with genetic polymorphism"
3553,NCT03804593,"Rate of SEPT9 gene promoter methylation positivity in patients with cirrhosis, based on the HCCBloodTest.",2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
3554,NCT00853203,To collect information about factors affecting colon and rectal cancer patients' quality of life (QOL) in order to develop a QOL program.,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,"To look at acceptability of an Expressive Disclosure Group Program for colon and rectal cancer patients, and examine its effect on quality of life."
3555,NCT00331422,Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Score of Patients Receiving Neoadjuvant Chemotherapy
3556,NCT05178030,The negative predictive value of the ddPCR assay with regard to KIT exon 11 circulating tumour mutation,2021-05-11,RECRUITING,OBSERVATIONAL,['NA'],,Determination of time between first detection of secondary mutations and progression
3557,NCT01731821,the postoperative pancreatic fistula(POPF) rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,morbidity and mortality
3558,NCT00319683,,na,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3559,NCT01946646,maximum-tolerated dose,2013-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
3560,NCT04130763,The number of adverse events,2019-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,The number of adverse events
3561,NCT06253598,Objective response rate using RECIST v1.1,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
3562,NCT04518449,incidence of diarrhea,2022-12-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
3563,NCT01035385,progression free survival (PFS),2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"response rate, incidence of postoperative complications,pathological response rate,R0 resection rate, 5-year overall survival,duration of disease control"
3564,NCT02929186,FIT Completion Rate,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Mail/Electronic Message Engagement
3565,NCT05998122,Complete response rate (CR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Wexner score
3566,NCT05796245,Incidence rate of Serious infections,2023-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Incidence rate of malignancy
3567,NCT01494077,Accuracy of diluted CEA level,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,
3568,NCT06078709,Pathologic complete response,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity of chemoradiation between groups receiving proton based versus photon-based radiotherapy
3569,NCT03149978,TRG,2014-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with chemoradiation-related adverse events as assessed by CTCAE v4.0
3570,NCT01576380,disease control rate (DCR),2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression free survival (PFS) per independent central review
3571,NCT05759923,Occurence of DLTs,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,PK parameter: AUCO-24
3572,NCT05891028,Standardized uptake value,2023-05-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
3573,NCT03433092,Gastrointestinal Tract Cancer Incident Measure,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
3574,NCT05824403,Diagnostic tools,2023-11-28,RECRUITING,OBSERVATIONAL,['NA'],,Clinical data access
3575,NCT04641923,Incidence of peri-hepatic adhesions at the time of repeat liver surgery,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,30-day mortality and morbidity
3576,NCT05716620,HCC detection rate of US vs AMRI in cirrhotic patients,2022-02-08,RECRUITING,OBSERVATIONAL,['NA'],,Survival of patients
3577,NCT02648386,Safety and Tolerability assessed by Adverse Events,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximum Flow Rate (Qmax)
3578,NCT02958566,Hospital stay cost,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Patient satisfaction
3579,NCT01744340,"If Eribulin Mesylate, up to a Maximum Dose of 1.4 mg/m2 Day 1 and 8 of a 21 Day Cycle, Can be Safely Combined With Full Dose Cetuximab for Patients With Advanced Head and Neck Cancer and Colon Cancer.",2012-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate (Whether Patient's Disease is Progressing or Being Controlled) of Patients With Head and Neck Cancer Treated With Eribulin Mesylate and Cetuximab.
3580,NCT05791136,Progression-free survival (PFS),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to death or distant metastasis (TTDM)
3581,NCT04812743,Increase in knowledge and intentions related to biospecimen donation and clinical trial participation.,2020-01-10,TERMINATED,INTERVENTIONAL,['NA'],,
3582,NCT01806740,Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib,2013-05-09,TERMINATED,INTERVENTIONAL,['PHASE4'],,Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression
3583,NCT01204749,Progression-Free Survival,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall health status using EuroQOL(EQ-5D)
3584,NCT02736448,Progression free survival,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity
3585,NCT04960072,Overall Survival (OS),2021-06-30,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life
3586,NCT00209638,objective tumor response,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response duration, time to progression, overall survival, and safety will also be assessed."
3587,NCT00003354,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3588,NCT05804799,Measurement of standard deviation of CT attenuation values at the liver,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sensitivity to detect malignant liver tumor
3589,NCT02494388,Accuracy of EUS-guided nCLE in a cohort of cystic pancreatic tumors,2015-06,TERMINATED,OBSERVATIONAL,['NA'],,Number of participants with adverse events as a measure of safety
3590,NCT02514278,Rate of organ preservation and absence of stoma,2016-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease-free survival
3591,NCT05802056,Incidence of adverse events,2023-11-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3592,NCT05028231,Pathologic Complete Response,2021-06-05,RECRUITING,OBSERVATIONAL,['NA'],Intestinal flora,Objective Response Rate
3593,NCT05160168,"Expansion (Phase 2): Expansion Cohorts 1, 2, 3 and 4: confirmed Objective Response Rate (ORR)",2022-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
3594,NCT01839604,Number of Participants With Dose Limiting Toxicities During Cycle 1,2013-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Evaluation of Pharmacokinetics (PK) of AZD9150 (Following Single Administrations in Patients With HCC) by Determining Tmax, Using the Plasma Concentration Data."
3595,NCT02530983,Completion of the Mayo Clinic Upper Digestive Disease Survey by patients at varying time points following surgery,2015-08,RECRUITING,OBSERVATIONAL,['NA'],,"Establishment of ""normal"" or expected scores from the Mayo Clinic Upper Digestive Disease Survey"
3596,NCT02324374,"Unblinded Analysis of Endocytoscopic Images of Colorectal Lesions (Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology)",2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
3597,NCT00686543,Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
3598,NCT00688766,Compare the progression free survival (PFS) in both study arms,2008-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Evaluate the safety and tolerability of IPI-504 in this patient population
3599,NCT02985944,Adenoma detection rate,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,Factors affecting the withdrawal time
3600,NCT03621319,Rate of stricture-free eradication of dysplastic BE,2019-07-24,TERMINATED,INTERVENTIONAL,['NA'],,Cost-effectiveness of HAPC vs. RFA in the treatment of dysplastic BE
3601,NCT01497457,Determination of the distance between a rectal tumor and the pouch of Douglas,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,
3602,NCT01286428,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
3603,NCT04309747,Effectiveness analysis,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Secondary validity analysis
3604,NCT03402607,Change in Quality of Life (QOL) Using EORTC C-30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30),2018-08-08,TERMINATED,INTERVENTIONAL,['NA'],,The Total Healthcare System Costs Associated With PLA vs HIGRT
3605,NCT04145388,Number of patients identified at high risk of cancer,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
3606,NCT04656249,Progression free survival (PFS),2018-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical benefit rate (CBR),The Rate of Treatment Related Adverse Events
3607,NCT05099549,Phase 2a/Expansion,2021-11-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a/Expansion
3608,NCT02377232,Colon Cancer Screening Intent,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Colon Cancer Screening Completed
3609,NCT00258180,"Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month",2005-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3610,NCT02328365,Postoperative mortality at one year,2014-03,COMPLETED,INTERVENTIONAL,['NA'],Findings and interventions at medical visits,Medical complications
3611,NCT05635630,Relapse-free survival (RFS) time,2022-06-24,RECRUITING,INTERVENTIONAL,['NA'],,The rate of achieving NED status when relapses happen.
3612,NCT02859155,Survival,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence
3613,NCT02885727,Improvement in median Progression Free Survival using the combination of RT and durvalumab.,2017-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3614,NCT03587818,The Longitudinal Preparedness for Colorectal Cancer Surgery Questionnaire (PCSQ),2012-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Behaviour pertaining when and how to seek health care for recovery support: Visits at outpatients clinics
3615,NCT02579330,Grade of macroscopic contamination according to adjusted Boston Bowel Preparation Score (0-3).,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative pain (VAS-score)
3616,NCT05051046,Rate of complete colonoscopies,2022-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Medico economic criteria
3617,NCT01210911,Survival after 6 months,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity profile
3618,NCT03829410,Phase 2: Number of Participants with an Objective Response Rate (ORR),2019-05-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Onvansertib
3619,NCT02076906,Toxicity,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune Markers
3620,NCT01627119,To measure the expression level of CTGF in patient blood and tissue,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],,To determine the survival probability of gastric cancer patients after surgery
3621,NCT05800080,The pathological complete response;,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"major pathologic response, MPR"
3622,NCT06276764,"The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods",2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU®,Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention.
3623,NCT02420509,Progression-Free Survival,2015-08-27,TERMINATED,OBSERVATIONAL,['NA'],,Quality of Life
3624,NCT05802394,Resection rate,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Major pathological response
3625,NCT05676190,objective response rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,['NA'],,
3626,NCT02133079,electrocardiogram,2012-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change from baseline in subpopulation of CD8+ T cells at the end of vaccination,changes in antigen specific T cells
3627,NCT06314646,Rate of anastomotic leak,2024-05-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Cancer recurrence
3628,NCT00002930,,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
3629,NCT03030404,Characterization of the natural and clinical histories of hereditary gastric cancer syndromes,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
3630,NCT03040453,Immunological response,2017-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Number of participants with complete radiological response at follow up 3, 6, 9 and 12 months."
3631,NCT03542799,Safety: Occurrence of study related adverse events,2018-05-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Effectiveness: duration of in vivo survival of EGFR CART
3632,NCT05600335,incidence of various postoperative complications,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,radicality of surgery
3633,NCT00096031,Overall Survival at 6 Months,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
3634,NCT03883919,Tolerability between two different dose levels of paricalcitol added to the combo regimen of liposomal irinotecan plus 5-FU / LV as measured by the occurrence of grade 3 and 4 toxicities,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of stable disease
3635,NCT03957564,The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Types of tumor-associated DNA in tumor tissues after operation.
3636,NCT05246982,PFS,2022-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DOR
3637,NCT02100254,Change in likelihood of CRC screening in previously unscreened subjects,2009-10-01,COMPLETED,INTERVENTIONAL,['NA'],,"Influential factors in behavior changes, assessed using qualitative analyses of text from participant interviews, including affective associations with the program, participants' cognitive-affective influences, and predisposing influences"
3638,NCT04146298,Objective response rate,2021-10-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
3639,NCT00950144,"Relationship among characteristics (i.e., sociodemographic, disease, health status) associated with illness perceptions, overall symptom distress, and QOL)",2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
3640,NCT00004873,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3641,NCT00253812,The primary outcome measure will be the mean number of adenomas detected on the blinded video review for each endoscopy,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],,Primary endoscopist adenoma count for each modality.
3642,NCT02399995,changes in the quality of life (QoL),2015-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
3643,NCT00544349,Efficacy: objective tumor response rate (RECIST criteria),2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor progression rate
3644,NCT06311032,Number of Decisions to Continue Surveillance Imaging,2023-03-29,COMPLETED,OBSERVATIONAL,['NA'],,
3645,NCT00394615,To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.,2003-10,TERMINATED,INTERVENTIONAL,['NA'],,
3646,NCT01999478,Early cancer changes in the colon,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
3647,NCT05674097,Six pattens of blood flow and AMCA based on the preoperative observation,2020-06-08,COMPLETED,OBSERVATIONAL,['NA'],,
3648,NCT01480128,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
3649,NCT04221854,"The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods",2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,
3650,NCT01231022,Protective effection of peripheral hematopoietic stem cell infusion for DILI,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Change of cytokines
3651,NCT00109941,Survival,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Opioid growth factor markers
3652,NCT00336960,Pathologic complete response rate,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
3653,NCT00172861,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3654,NCT05604716,scores of digestive physiological and social psychological functions,2001-01-01,RECRUITING,OBSERVATIONAL,['NA'],,progressive-free survival
3655,NCT03930043,Metagenomic Linkage Groups (MLGs),2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3656,NCT01479803,Diagnostic accuracy of fine needle aspiration Echo Tip® HD ProCore™ versus EchoTip® in the etiological cyto histological in pancreatic solid tumors explored under endoscopy ultrasonography.,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,ease of puncture between the 2 types of equipment.
3657,NCT05199285,Confirmed objective response rate (ORR),2023-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
3658,NCT04522544,Objective response rate (ORR) [according to RECIST 1.1] at 6 months.,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research,Quality of Life (QoL)
3659,NCT06208748,To estimate the median progression free survival (mPFS),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To describe patient-reported quality of life outcome measures.
3660,NCT02413437,diagnostic accuracy,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,
3661,NCT02484833,Incidence of grade 3-4 AEs,2015-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life assessed by EORT QLQ-C30 and DLQI questionnaires
3662,NCT00176761,To assess the antitumor response of this immunotherapy regimen.,2000-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity of this treatment regimen.
3663,NCT02831179,Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level
3664,NCT03414125,One-time Screening Completion,2018-09-07,COMPLETED,INTERVENTIONAL,['NA'],,Choice of FIT versus Colonoscopy
3665,NCT02767986,causal attributions of breast cancer,2016-05-10,COMPLETED,OBSERVATIONAL,['NA'],,
3666,NCT03736720,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2019-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Grade 3+ Treatment Related Adverse Events (TRAE)
3667,NCT00956475,Most common areas of concern,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,
3668,NCT02695628,Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue,2016-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events Related to 18F-fluoromisonidazole (18F-FMISO)
3669,NCT00539617,Progression Free Survival (PFS),2007-10-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression (TTP)
3670,NCT00016198,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3671,NCT05031975,"To assess the activity in terms of seroreversion of TEMIRI consolidation regimen administered to patients with high-risk stage II (pT4) or III MSS, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.",2022-05-02,RECRUITING,INTERVENTIONAL,['PHASE2'],To assess the accuracy of ctDNA as disease recurrence biomarker,Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L)
3672,NCT01009593,Overall Survival,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Response Rate (ORR)
3673,NCT05095831,Clinical condition at one-year follow-up,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3674,NCT04741152,No hidden insulinomas,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
3675,NCT04791293,MELD-Na score difference between the groups,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
3676,NCT04889768,R0 resection,2021-07-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
3677,NCT01146769,Maximum Squeeze Pressure,2010-04,UNKNOWN,INTERVENTIONAL,['NA'],,Functional Outcomes
3678,NCT00514930,To estimate the local and remote intra-hepatic and extra-hepatic recurrence rates and their impact on survival.,2007-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Complications and unexpected adverse events (early and late) related to RFA aspirator treatment to be assessed. Data points to be collected as per proforma for trial.
3679,NCT02273752,Incidence of Stomatitis,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
3680,NCT06192862,CRC screening uptake rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,qualitative factors checklist associated with CRC screening
3681,NCT04417764,Incidence of Adverse Events,2019-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
3682,NCT01741038,Overall Survival,2017-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Longitudinal changes in tumor burden,Health-Related Quality of Life (HRQoL)
3683,NCT00243841,6 Month Local In-field Control,2004-05,COMPLETED,INTERVENTIONAL,['NA'],,Phase II: Number of Patients With Treatment Related Grade 3 or 4 Adverse Events
3684,NCT01117428,Number of Participants With Adverse Events (AEs),2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Terminal Half-Life (T½)
3685,NCT01927978,"The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3686,NCT02428270,"Percentage of patients who experience complete response, partial response, or stable disease",2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause.
3687,NCT06196294,Number of Patients with Dose Limiting Toxicity,2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Median γδT cell persistence
3688,NCT04735133,surgical wound complications (SWC),2018-11-18,COMPLETED,INTERVENTIONAL,['NA'],,length of stay in the hospital
3689,NCT05185531,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2022-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
3690,NCT02388256,Recovery of physical function,2015-03,COMPLETED,INTERVENTIONAL,['NA'],Adherence to enhanced recovery program after surgery,Adverse events related to acupuncture
3691,NCT02575014,Number of participants with hyperbaric oxygen treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Carcinoembryonic antigen
3692,NCT05652361,Incidence of discrepancies between the surgeon's preparation and the prediction of the CoBot system,2021-05-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of oncological outcomes: Frequency of Loco-Regional Tumor Free Survival (LRFS)
3693,NCT00704600,phase I: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity (CTCAE v3.0) and of grade 4 or higher postoperative toxicity within 30 days post-surgery phase II:rate of pathological complete remission,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3694,NCT05316103,Accuracy of pCLE-targeted optical biopsy,2021-11-04,RECRUITING,INTERVENTIONAL,['NA'],,Complications of biopsy
3695,NCT02333409,pain scores in numeric rating scale (NRS),2015-03,TERMINATED,INTERVENTIONAL,['NA'],,Quality of Life scores
3696,NCT05953662,DFS rate,2023-09-15,RECRUITING,INTERVENTIONAL,['NA'],,3 years OS Rate
3697,NCT05954871,Number of Participants with Dose-Limiting Toxicities (DLTs),2024-01-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS) After Enrollment as Determined by Investigator According to RECIST v1.1
3698,NCT01441492,60-day ≥ Grade II Complication Rate,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Composite Quality of Life Scores
3699,NCT00064181,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3700,NCT02827786,"EMA (colour scale) images will be compared to baseline US grey-scale images for a specific target lesion, as determined by standard of care imaging (US, CT, MRI or PET) and/or histologically proven lesion in a given subject.",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,US grey-scale and EMA colour maps will be obtained from both target liver lesions and background liver tissue from the same subject and compared.
3701,NCT04613570,Carcinoma,2021-01-02,RECRUITING,INTERVENTIONAL,['NA'],,Advanced gastric cancer
3702,NCT00086762,Quality of life as measured by Functional Assessment of Cancer Therapy,2004-06,COMPLETED,INTERVENTIONAL,['NA'],,"Immune suppression as measured by cytotoxicity, stimulated release of IL-12, -4, -10, intracellular cytokines and lymphocyte phenotype"
3703,NCT05136326,To evaluate the rate of complete pathologic response (pCR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"To assess the incidence, nature, and severity of adverse events"
3704,NCT01589146,"symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death",2010-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
3705,NCT02353936,response rate,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
3706,NCT03261791,recurrence-free survival,2017-07-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety: the potential side effects
3707,NCT01415063,overall survival,2011-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],,disease-free survival
3708,NCT03675243,Fecal incontinence quality of life scale,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Sphinctrometry
3709,NCT02279719,Assessment of Disease Control Rate in the Intent to Treat Population- Phase II,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of the Pharmacodynamic Studies as Well as the Concentration of Study Drug (Either Napabucasin or Amcasertib) in Tumors
3710,NCT06036563,specificity,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3711,NCT02409199,Progression-free survival (PFS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety (incidence of adverse events)
3712,NCT06268015,Proportion of subjects with a best overall response of complete response or partial response according to iRECIST,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Months of progression-free survival
3713,NCT05775939,Change in mean standardized uptake value (SUV) changes in the heart,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Cardiac related death
3714,NCT01092689,"Quantify and characterize HCA-DNA adducts in resected human pancreatic tissue after a dietary relevant dose of PhIP, the most mass abundant HCA in charred meat.",2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Quantify [14C]PhIP and [14C]PhIP metabolites in urine and plasma.
3715,NCT03716063,Metastasis recurrence rate in 1 year,2018-10-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Metastasis recurrence rate in 3 years
3716,NCT03924466,Feasibility and added value of 68GaNOTA-Anti-HER2 in neoadjuvant setting of breast carcinoma,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Influence image-guide biopsy on patient management
3717,NCT05609656,The incidence rate of adverse events according to CTCAE v. 4.0,2023-01-26,RECRUITING,INTERVENTIONAL,['PHASE2'],immune infiltration by PD-1 and PD-L1 staining,Overall survival
3718,NCT05615129,Overall survival,2021-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Pathologic complete response rate (pCR)
3719,NCT03693846,Number of Participants With Progression-Free Survival at 6 Months,2019-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of Response
3720,NCT04981119,Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing,2021-10-29,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of enrolled participants who experience an adverse event (AE) related to apheresis
3721,NCT05945797,Shortening of CBD cannulation time,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
3722,NCT00587314,Response to treatment,2004-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3723,NCT05602792,"In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.",2020-04-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","In part II and part III,Exploring the proliferation and activity of immune cells in blood after IT T3011","In part III,Overall Survival (OS)"
3724,NCT00051545,"Time to relapse, relapse being defined as the first recurrence of HCC (intra- or extrahepatic).",1999-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Dose of Seocalcitol
3725,NCT05026268,Post-operative complications rate,2021-09,UNKNOWN,INTERVENTIONAL,['NA'],,The time to discharge from hospital
3726,NCT03093129,recurrence free survival 2 years after surgery,2018-01-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Predictive value of tumour biomarkers in terms of predicting response to artesunate therapy
3727,NCT02561273,Overall Response Rate,2015-09-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival
3728,NCT02038621,Progression Free Survival (PFS),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,health-related quality of life (HRQOL
3729,NCT00623883,"number, size, and location of ACF identified",1999-01,COMPLETED,INTERVENTIONAL,['NA'],,"complications of stain-enhanced, magnification colonoscopy"
3730,NCT03828799,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2019-05-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determination of circulating free DNA concentration
3731,NCT02831556,Experimental ultrasound diagnosis agreement with final reference standard diagnosis,2016-07,RECRUITING,OBSERVATIONAL,['NA'],,Experimental ultrasound image quality.
3732,NCT05518110,Patients free of disease progression,2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],Comparison of new methods of multi-omics data integration vs existing models using AUROC,Safety and tolerability
3733,NCT02423720,"Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)",2015-04-28,COMPLETED,INTERVENTIONAL,['NA'],"Sleep quality, as assessed by NCCN Distress Thermometer and NIH PROMIS instruments at the beginning, midpoint and end of the study","Adherence to the intervention, as assessed by frequency and duration of practicing the exercises (recorded in a log and responses to text messages)"
3734,NCT01210027,"Measure of Liver Function Before, During and After Radiation",2007-03,RECRUITING,OBSERVATIONAL,['NA'],,Association Between Liver Perfusion and Changes in Tumor and Clinical Outcomes
3735,NCT03597672,The number of new cases of gastric carcinoma,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Time of finding nee cases
3736,NCT04802486,Number of patients that adhered to the exercise conditions of the study,2016-06-29,COMPLETED,INTERVENTIONAL,['NA'],,Porportion of subjects with improved cachexia-related symptoms 3 months
3737,NCT04918459,Death adjusted cumulative incidence of rebleeding at 30-day,2021-08-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Mortality rate at 6 months
3738,NCT06103435,Survival,1996-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of readmissions
3739,NCT04988971,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],Changes of fecal flora and enteritis-associated inflammatory factors,Overall incidence of grade 3/4 gastrointestinal adverse events
3740,NCT00360971,Duration of Oral Mucositis as Measured in Terms of Days,2006-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Second Primary Tumor
3741,NCT02785068,To correlate disease response according to RECIST with levels of irinotecan and SN-38 in tumor tissue,2016-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Presence of anti-drug antibodies will be assessed
3742,NCT03140670,Progression-Free Survival (PFS) at 6 Months (PFS6),2017-09-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity at Least Possibly Related to Rucaparib
3743,NCT00889343,To compare the PFS between patients receiving chemotherapy (FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
3744,NCT01339754,Progression-free survival (PFS) rate at 6 months,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Impact of pharmacogenomic and pharmacokinetic profile on anti-tumor activity
3745,NCT04668781,Fluid volume intraoperatively and postoperatively,2020-12-21,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
3746,NCT04550494,Percent of patients who demonstrate simultaneous Rad51 activation,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor genomic alterations potentially associated with sensitivity or acquired resistance to talazoparib,Overall response rate
3747,NCT04264260,survival,2019-12-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,serious adverse effect
3748,NCT04027348,Proportion of Patients With Obstruction Clearance,2019-06-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3749,NCT00730158,Proportion of Participants With Grade 2-4 Toxicities,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Circulating Tumor DNA - Percentage of Patients With DNA Mutations
3750,NCT03708783,the incidence of postoperative complications within 30 days,2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,3-year disease free survival
3751,NCT03310892,Colonoscopy completion rate,2017-10-09,COMPLETED,INTERVENTIONAL,['NA'],,Colonoscopy scheduling rate
3752,NCT04837508,Objective Response Rate (ORR) by Independent Review Committee (IRC),2021-06-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of anti-drug antibody (ADA)
3753,NCT01759056,Safety and tolerability of AVX-470 over 28 days of treatment,2013-02,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the effects of AVX 470 on biomarkers of ulcerative colitis activity over 28 days of treatment compared to Baseline,Measure the induction of or change in a human anti-bovine immunoglobulin antibody (HABA) response to AVX 470
3754,NCT01229943,Progression Free Survival,2010-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
3755,NCT01795274,Acute toxicity of carbon ion radiotherapy observed within 3 months of study treatment,na,WITHDRAWN,INTERVENTIONAL,['NA'],,overall survival
3756,NCT01957852,Reoperation rate for intra-abdominal bleeding after CRS and HIPEC,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,Length of hospital stay
3757,NCT05600933,"To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors and hematologic malignancies",2023-05-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,"To collect detailed history, demographic, treatment data, and perioperative findings."
3758,NCT05543304,Objective response rate,2018-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Progression free survival
3759,NCT00914537,High resolution anoscopy,2009-06-02,COMPLETED,OBSERVATIONAL,['NA'],,
3760,NCT06327386,Evaluation efficacy of tumor regression level,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,SUV
3761,NCT04742959,Dose limiting toxicity (DLT),2021-03-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Genetic Alteration Status,Volume of Distribution (Vd)
3762,NCT05609253,Itraconazole drug and blood levels,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Effects of itraconazole on angiogenesis
3763,NCT03435666,AUC0-t,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,AUC_%Extrap_obs
3764,NCT02892643,Vitamin B12 cumulative supplement quantity,2016-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
3765,NCT05122091,Pathological remission rate (PRR),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
3766,NCT04193904,To assess the safety of MRx0518 in combination with hypofractionated preoperative radiation through the collection of adverse events,2019-12-20,TERMINATED,INTERVENTIONAL,['PHASE1'],Genomic changes,Margin status
3767,NCT03070574,Reduction in the occurrence of any colorectal neoplasia in LS patients,2017-11-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,Significant findings & illnesses - adverse events
3768,NCT06324032,Evaluation of EUS-E accuracy quantitative,2020-12-17,RECRUITING,OBSERVATIONAL,['NA'],,"Complication rate (perforations, bleeding) of the procedure"
3769,NCT03210129,Change in physical activity behavior,2017-07-06,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness of the intervention
3770,NCT03126058,occurrence rate of severe complications,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Procalcitonin
3771,NCT01152437,Percentage of Participants With Disease Control (DC),2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 8 (Cpre,ss,8)"
3772,NCT05052671,Progression free survival (PFS),2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS) in ctDNA positive versus ctDNA negative.
3773,NCT03689712,Cumulative Incidence of Severe Oral Mucositis,2018-10-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
3774,NCT03741517,Protocol adherence,2019-01-30,RECRUITING,OBSERVATIONAL,['NA'],Safety of core needle biopsy: NCI Common Terminology Criteria,
3775,NCT01675128,Number of Participants With a Change in elF4e Protein Levels in Matched Pre and Post Tumor Biopsies,2012-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With a Decrease in elF4E mRNA Expression in Peripheral Blood
3776,NCT00003546,overall survival,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3777,NCT03023436,2-year Median survival time,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Molecular biomarker alteration,Morbidity and mortality
3778,NCT00515216,Overall Response Rate (ORR),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)
3779,NCT00003531,Number of Participants With Objective Response and Stable Disease,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3780,NCT05041335,Aggregate specimen length (ASL),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adequacy of diagnosis
3781,NCT05821361,Overall response rate ( ORR) per RECIST 1.1,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR) per RECIST 1.1
3782,NCT02565017,Acceptability of IBM Watson Oncology,2015-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
3783,NCT02314052,Phase 2: Preliminary Antitumor Activity,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AUClast (hr*ng/mL) - DCR-MYC Levels in Blood (Phase 1b Only): Dosing Day 1 and Day 8
3784,NCT01320319,Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass,2011-03,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The secondary aim is to look at the aerobic performance.
3785,NCT02326779,Overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Adverse events
3786,NCT02567396,Tolerability of talazoparib in patients with varying degrees of hepatic and renal dysfunction,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],The pharmacodynamic effects of talazoparib,Response rate
3787,NCT02233712,Diptheria Toxoid Antibody Levels,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
3788,NCT02173353,Evaluate the use of ultrasound to detect motion of pancrease and surrounding structures,2014-02,COMPLETED,OBSERVATIONAL,['NA'],Assess organ motion and compare in conjunction with magnetic resonance imaging or CT,Quality of ultrasound imaging for Pancreas
3789,NCT03666442,tumor area in endoscopy,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,tumor thickness in TRUS
3790,NCT04948125,Objective response rate(ORR),2021-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of response(DOR)
3791,NCT01987726,Proportion of patients who have multiple options recommended,2013-09-03,COMPLETED,OBSERVATIONAL,['NA'],,Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort
3792,NCT01225523,Progression-free survival,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of local recurrences and metastasis
3793,NCT00003769,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3794,NCT02238613,Tumor Response rate,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events
3795,NCT00063986,Peri-operative Mortality at 30 Days,2004-06-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of Conversion to Open Operation After Neoadjuvant Therapy
3796,NCT04069949,Incidence of Treatment-Emergent Adverse Event,2019-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
3797,NCT02938481,Distribution of metastatic LNs,2013-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Prognostic outcomes according to the central radicality
3798,NCT02882659,Safety of DKC as assessed by laboratory examinations,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy of DKC as assessed by change in quality of life
3799,NCT00242788,Objective tumour response (CR and PR) at study closure based on the RECIST,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of controlled disease (CR, PR and SD) at study closure"
3800,NCT06024252,Overall survival,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Treatment pattern
3801,NCT02456285,Adherence to an evidence-informed common pathway assessed using guidelines suggested by the European Society of Medical Oncology (ESMO),2015-05-20,COMPLETED,OBSERVATIONAL,['NA'],,
3802,NCT02238821,Scoring the expression of COX-2 in colorectal cancer tissue sections by Immunohistochemical analysis,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
3803,NCT01790230,Assessment of subject's safety by incidence of related Adverse Events,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the device's application technique
3804,NCT05042336,MPR,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,ORR
3805,NCT01113736,If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Decrease in operative time and a promotion of peritoneal remodeling
3806,NCT05001347,Objective Response Rate (ORR) in each Tumor Type,2021-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of PK parameter: tmax
3807,NCT05151068,The change of sleep,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3808,NCT04443816,Loss of health related quality of life (HRQL),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Disability
3809,NCT04281511,progressive-free survival,2019-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
3810,NCT01796782,overall survival (OS),2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of adverse events of QYHJ Formula
3811,NCT03267173,Number of patients with tumor response,2017-06-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of patients with adverse event
3812,NCT01384227,To determine whether tissue is neoplastic or non-neoplastic,2009-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
3813,NCT06148298,Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction,2023-05-24,RECRUITING,OBSERVATIONAL,['NA'],,
3814,NCT05911217,Disease free survival (DFS),2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,The immunogenicity in subjects receiving CT041 infusion in this study
3815,NCT01905969,Relapse free survival,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3816,NCT00810771,Colorectal Cancer (CRC) Screening Rate.,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,If Colorectal Cancer Screening Screening (CRCS) Discussed With Provider.
3817,NCT00260585,,1999-06,RECRUITING,OBSERVATIONAL,['NA'],,
3818,NCT01492127,Variation of plasma proteasome,2011-12,UNKNOWN,INTERVENTIONAL,['NA'],,Variation of plasma proteasome
3819,NCT05631574,"To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.",2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC."
3820,NCT01356628,Time to Disease Progression,2011-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response Rate (RR)
3821,NCT03566056,"Hypotension, defined as mean arterial bloodpressure <65 mmHg, measured by invasive arterial blood-pressure, the first morning after surgery at 06.00 (AM)",2018-01-18,COMPLETED,OBSERVATIONAL,['NA'],,
3822,NCT00072787,,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
3823,NCT04625543,Major Pathological Response (MPR) rate,2020-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events
3824,NCT04552236,Predicting early HCC recurrence after treatment by Ultrasound elastography,2021-01,UNKNOWN,OBSERVATIONAL,['NA'],,
3825,NCT02607540,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"disease control rate,DCR"
3826,NCT01077739,Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression
3827,NCT01648894,Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group,2012-10-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Functional results (LARS score)
3828,NCT05803382,Recommended phase 2 dose (RP2D),2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Molecular subpopulations particularly sensitized to BETi and capecitabine
3829,NCT03380858,fistula incidence,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],,infection
3830,NCT03886571,"Measuring cell-free and exosomal-miRNA biomarkers using small RNA-Seq in matched tissue and plasma from patients with PDAC, PNs, pancreatitis and normal pancreas for early detection.",2018-09-15,RECRUITING,OBSERVATIONAL,['NA'],,
3831,NCT01902823,Satisfaction with Care,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The Inventory of Recent Life Experiences for Cancer Patients
3832,NCT05543863,platelet function testing at 5 days,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,postoperative complications
3833,NCT03857815,PFS,2019-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR
3834,NCT00949182,Safety and tolerability as assessed by NCI CTCAE v3.0,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"AFP and VEGF serum levels as assessed at baseline, prior to each HACE treatment, and then every 3 months thereafter"
3835,NCT03117023,sleep time,2017-04-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,side effects
3836,NCT04374877,[Part D] Objective response rate (ORR),2020-04-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,[Part D] Summary of adverse events (AEs) based on treatment emergent AEs (TEAEs)
3837,NCT00606385,Recurrence rate,2007-12,UNKNOWN,INTERVENTIONAL,['NA'],,Survival
3838,NCT02454790,Late toxicity,2014-09,RECRUITING,OBSERVATIONAL,['NA'],Patient-rated symptoms and Quality-of-Life,Loco-regional tumor control
3839,NCT05451862,confirmed Objective Response Rate (ORR) by localized mRECIST,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life using EQ-5D-5L questionnaire
3840,NCT00719641,Number of Participants Without Re-looping Among Those With Looping,2008-08-05,COMPLETED,OBSERVATIONAL,['NA'],,
3841,NCT02624895,"average relative dose intensity of every drug""",2015-12-30,COMPLETED,OBSERVATIONAL,['NA'],,Questionnaire score
3842,NCT00588367,"A reproducible technique to measure CT perfusion parameters may provide a method for non-invasively monitoring tumor response during treatment, or differentiating between autoimmune and chronic pancreatitis.",2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
3843,NCT02854839,Time To progression,2016-11-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety of MG4101 as evaluated by Incidence of adverse events (AEs), serious adverse events (SAEs)"
3844,NCT05377034,Best Overall Response Rate (BORR) at 12-months post-randomization.,2022-10-26,RECRUITING,INTERVENTIONAL,['PHASE2'],Occurrence of adverse events leading to death.,Quality-adjusted life years at 18 months.
3845,NCT01004003,Time to Progression (TTP) in Phase II,2009-10-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
3846,NCT00644254,Overall cancer-specific survival,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival (DFS)& Correlation of ECLNI with other pathological variables
3847,NCT03435536,Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.,2018-02-26,COMPLETED,INTERVENTIONAL,['NA'],,Correlation between circulating tumor DNA rate and Ca19.9 dosage
3848,NCT03285867,The change of LSM(kpa) measured by FibroScan(a kind of external harmless ultrasonoscope),2018-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,
3849,NCT03796884,Pharmacodynamics effect on cGMP levels,2019-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],PCNA expression,Guanylin levels
3850,NCT01103128,BRCA1 vs. BRCA2 mutations,2009-03,TERMINATED,OBSERVATIONAL,['NA'],,Interaction of other cancer genes with BRCA1 and BRCA2
3851,NCT06208397,Radiological assessment of CRLM,2023-12-24,RECRUITING,OBSERVATIONAL,['NA'],,
3852,NCT01978808,the overall diagnostic accuracy rate of both needles,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,
3853,NCT06121700,Overall survival (OS),2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical mortality
3854,NCT03090139,Time-to-first Indicator of Sub-optimal Therapy,2017-03-28,COMPLETED,OBSERVATIONAL,['NA'],,Physician Survey Questionnaire
3855,NCT04500990,Objective Response Rate,2020-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
3856,NCT04103372,Demonstrate a change in rectal preservation rates,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Assess patient willingness to be randomised
3857,NCT05097911,Evaluable Non-Target Disease Response,2021-08-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of Best Overall Response
3858,NCT01019382,Objective response rate (complete and partial response) on CT according to RECIST criteria,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic analysis of blood samples
3859,NCT04687410,Total tissue area,2020-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Suitability for molecular analyses
3860,NCT05371197,Pathological complete response (pCR) rates,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug feasibility
3861,NCT04694391,genomic characteristics of relapsed esophageal cancer,2012-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,
3862,NCT00801320,To gain experience in appropriate clinical processing of tumor samples and determining cell yield.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,"Based on feasibility of collection of blood samples of subjects, quantification of T cell subsets, regulatory T cells, activated memory effector cells, and DC phenotype at pre-surgery and post-surgery time points."
3863,NCT06126406,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],2023-11-06,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
3864,NCT02742935,The severity of adverse events (AEs) determined as per NCI CTCAE V4.03.,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3865,NCT03599947,Sensitivity and specificity of the model in the diagnosis of colorectal cancer,2018-07-16,UNKNOWN,OBSERVATIONAL,['NA'],,
3866,NCT04687969,Diagnostic value of multimodal imaging in primary prostate cancer patients,2022-10-23,RECRUITING,OBSERVATIONAL,['NA'],,Scan-rescan repeatability
3867,NCT03473574,Objective response rate (ORR),2018-05-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
3868,NCT05010863,Getting serum,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
3869,NCT01243619,Feasibility: Determined by the Number of Participants Who Had All Three Sets of Completed Serial PET Scans That Were Imported for Analysis,2010-08,COMPLETED,INTERVENTIONAL,['NA'],"Analyze Correlation Between FDG and FLT PET Scans, and the Correlation Between Both Types of PET Scan and the Response to Treatment.",
3870,NCT02319187,progression free survival,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
3871,NCT06165380,Objective Response Rate,2023-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
3872,NCT00034034,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3873,NCT06221878,Short-term outcome,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term Oncologic outcome
3874,NCT00585221,Time to Progression (TTP).,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
3875,NCT05888675,Overall survival,2016-07-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Immune function
3876,NCT02117479,Overall Survival (OS),2014-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Participants With Treatment-Emergent Adverse Events (TEAEs)
3877,NCT02604615,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"disease control rate,DCR"
3878,NCT03308773,Time to development of type 2 diabetes,2009-01-05,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
3879,NCT02246049,Progression-free survival (PFS) at 10 months,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment duration
3880,NCT00602745,Overall Survival,2008-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,Clinical Benefit assessed by Time to Symptoms Worsening (TTSW)
3881,NCT04835142,ORR,2021-02-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
3882,NCT03796429,overall survival (OS) of GS regimen plus PD-1 antibody (Toripalimab),2018-12-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse Events of GS regimen plus PD-1 antibody (Toripalimab)
3883,NCT04087421,"Bowel function, change in symptom 1 score assessed using the Measure Yourself Medical Outcome Profile (MYMOP2) Score.",2019-09-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Health economics assessed using the ICEpop CAPability measure for Adults (ICECAP-A).
3884,NCT01624285,"Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Committee",2012-07-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to first HCV viral recurrence
3885,NCT05253313,One-year survival after randomization,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
3886,NCT00047710,"Safety of combination Radiation, Bevacizumab, and Capecitabine.",2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate quality of life in patients receiving this therapy.
3887,NCT00660205,,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
3888,NCT05997459,PFS,2023-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3889,NCT03385577,Program Acceptability - Plan to continue intervention exercises after completion of the study,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],,Depressive Symptoms
3890,NCT03387904,Disease Control Rate (DCR),2019-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,NGS(Next Generation Sequencing) detecting
3891,NCT00003704,overall survival,1999-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3892,NCT03829969,OS,2019-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient-Reported Outcomes collected via the EORTC QLQ-OES18
3893,NCT04985357,Best overall response (BOR),2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
3894,NCT02385630,Post-prandial satiety gut hormone area under the curve,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Fasting ghrelin concentration
3895,NCT02233374,Predictive value of PET/CT and MRI 2 weeks into chemo-irradiation for developing a pathologic complete response at surgery.,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Impact of pCR rates on long term disease control
3896,NCT03221127,Death,1984-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Infectious disease
3897,NCT05394740,ORR in Phase II part,2022-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarkers in the PhIb and PhII cohort,Incidence of adverse events
3898,NCT02722395,Planning target volume (PTV),2016-08,COMPLETED,OBSERVATIONAL,['NA'],,
3899,NCT05998447,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator.,2023-09-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
3900,NCT02178436,Overall Survival (Phase II),2014-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Change in Gene Expression (Including Forkhead Box Protein O, I-kappaB, Cyclin-dependent Kinase Inhibitor 1B, Par4 and Phosphorylated Signal Transducer and Activator of Transcription 3) (Phase II)",Progression Free Survival (Phase II)
3901,NCT00891878,Comparison of Progression-free Survival,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
3902,NCT02780648,Acute toxicity rates of grade 3 gastrointestinal and hematologic toxicities (as raw percentage),2016-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient self-report of quality of life
3903,NCT00630084,"Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",2006-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety - adverse event rate and profile
3904,NCT05862792,Postoperative Dysphagia with Dysphagia Survey,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative Pain Medication Usage
3905,NCT06123117,cumulative opioid consumption during the stay at the recovery,2024-01-16,RECRUITING,INTERVENTIONAL,['NA'],pain-control failure & possible causes,cumulative opioid consumption (emergency and inpatient surgery)
3906,NCT00084643,"MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0",2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in biochemical and molecular correlates
3907,NCT05699655,Pathological complete response,2023-05-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Objective Response Rate (ORR)
3908,NCT04842916,Peripheral blood mononuclear cells (PBMCs) and host immunity parameters in responders and non-responders,2020-09-22,UNKNOWN,OBSERVATIONAL,['NA'],,Psychological status of patients in relation to therapy response
3909,NCT01591733,Rate of R0 Resection,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Utilization of Health Services (Emergency Room, Hospital and Intensive Care Unit)"
3910,NCT00617708,Progression-Free Survival,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity
3911,NCT05697198,The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period,2021-04-19,RECRUITING,OBSERVATIONAL,['NA'],,
3912,NCT03223779,The Duration of Local Control,2017-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serial ctDNA
3913,NCT00516347,"Gene-environment interactions, such as smoking, alcohol, and Helicobacter pylori status, on familial susceptibility to heartburn and Barrett's esophagus",2002-06,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison of the mortality from esophageal adenocarcinoma in family members with heartburn and Barrett's esophagus with deaths from other causes
3914,NCT05595122,Stentdysfunction after technical successful EUS-CDS,2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],,Costs
3915,NCT05472948,Progression-free survival (PFS),2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety variables (Incidence of Adverse Events [Safety and Tolerability])
3916,NCT05447715,Sequential treatment of PFS with furoquitinib in second-line (F-C group) versus third-line (C-F group),2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
3917,NCT01525771,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,efficacy
3918,NCT03114631,Number of Participants Who Survived at 1 Year,2017-01-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Who Survived at 3 Years or more
3919,NCT04601961,HIF-1 gene expression,2020-03-04,RECRUITING,INTERVENTIONAL,['NA'],,Number of Circulating tumour cells
3920,NCT00718354,Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT"
3921,NCT00080951,tumor response rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
3922,NCT02549456,Major postoperative complications,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Functional outcome
3923,NCT03950609,Objective response rate,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
3924,NCT00909103,Value of endoscopic ultrasound elastography for the differential diagnoses of pancreatic masses.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
3925,NCT03477019,difference in measured response between treated and untreated lesions,2018-11-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Occurrence of adverse effects
3926,NCT01172028,Maximum-tolerated dose (MTD) of combination ALIMTA and Taxotere,2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
3927,NCT01005199,Progression-free survival,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between vitamin B12 and overall survival
3928,NCT05176223,Time to progression,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,
3929,NCT00052689,Proportion of patients alive at 6 months (Arm II),2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
3930,NCT01248637,correlation of intratumoral hypoxia with patient survival rate,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,to assess utility of circulating osteopontin and miR-210 for identifying hypoxia
3931,NCT05320029,Number of Participants With Anastomosis Success,2018-08-30,COMPLETED,INTERVENTIONAL,['NA'],,
3932,NCT05142033,Percent of patients referred for molecularly targeted clinical trials,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Percent of patient participating in microbiome collection and analysis
3933,NCT00715325,To determine the success rate in reaching within working distance of the Cecum with no complications.,2008-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To assess the ability to perform routine therapeutic interventions such as biopsies, polypectomies, APC etc. as compared to therapeutic interventions with standard colonoscopes found in the literature."
3934,NCT04982276,Objective response rate (ORR),2021-07-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
3935,NCT00308516,"Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment",2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death"
3936,NCT03142282,Progression free survival,2019-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
3937,NCT03946917,Objective response rate (ORR),2019-03-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Intestinal microorganism
3938,NCT00089960,Objective response rate as defined using modified RECIST criteria.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships"
3939,NCT01481805,Biomarkers predictive,2010-01-14,COMPLETED,OBSERVATIONAL,['NA'],,The RTK activation status.
3940,NCT02415023,safety and tolerance,2014-11-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic profiles of Fruquintinib combined with Paclitaxel
3941,NCT03170869,Local Recurrence Rate (LRR),2017-04-12,TERMINATED,INTERVENTIONAL,['NA'],,Survival Time
3942,NCT05755594,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
3943,NCT05107219,Cyclic guanosine monophosphate (cGMP) levels,2022-10-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Cellular response,Vasodilator-stimulated phosphoprotein (VASP) phosphorylation in normal appearing duodenal mucosa
3944,NCT03073785,Local control,2016-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacokinetics parameters of zoledronic acid,Tumor and organ motion
3945,NCT04749108,3-year Disease free survival (DFS) for Phase III,2021-11-26,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Evaluation of sexual function in women by Female Sexual Function Index (FSFI) questionnaire score
3946,NCT06285019,objective response rate (ORR),2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event (AE)
3947,NCT06283303,Treatment Emergent Adverse Event（TEAE）,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
3948,NCT01836913,"Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based",2009-05,COMPLETED,OBSERVATIONAL,['NA'],,Cost-effectivity analyses
3949,NCT02428907,patient perception of colonoscopy,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Staff perception of teamwork
3950,NCT03491878,R0 rescetion rate,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,
3951,NCT05138302,OS,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,
3952,NCT02345746,Determine response rate,2012-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
3953,NCT04093141,2-year survival proportion from 1) diagnosis and 2) IRE,2019-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status assessment (PG-SGA-SF)
3954,NCT01643499,DLT rate in course 1 for each of the two most common genotype groups (*1*1 and *1*28),2012-03-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cumulative dose intensity of irinotecan hydrochloride
3955,NCT05103020,curative-intent resection rate,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall response rate (ORR)
3956,NCT00988936,To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To gain experience with [F-18]RGD-K5 PET/CT in order to improve the study design and conduct of future studies.
3957,NCT00578396,Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.
3958,NCT04341012,Utility of breath profiles for disease diagnosis or prognosis,2019-09-10,COMPLETED,OBSERVATIONAL,['NA'],,
3959,NCT02417753,Changes in Immune Parameters in the Malignant Ascites of Patients With Advanced Cancer Following Therapy With AZD9150,2015-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (PFS) in Patients With Malignant Ascites Treated With AZD9150
3960,NCT06009705,Assessment of the incidence of treatment-related adverse events Incidence of Treatment-Emergent Adverse Events.,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of progression-free survival (PFS) in elderly esophageal cancer patients treated with toripalimab in combination with S-1 and radiotherapy.
3961,NCT02148549,Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
3962,NCT05593458,Major Pathological Response rate,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,pathological Complete Response rate
3963,NCT04029909,Dose limiting toxicity(DLT),2019-07-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],T1/2,Maximal tolerable dose(MTD)
3964,NCT01133990,Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter,2010-03-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
3965,NCT05144698,Safety of RAPA-201 Cell Therapy,2021-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T Cell Immune Reconstitution,Quality of Life (QOL)
3966,NCT03088163,Response rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
3967,NCT04816045,Tumor stage,2021-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,VAR2
3968,NCT04599777,Overall survival (OS),2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DOR assessed by investigators according to mRECIST.
3969,NCT06152263,"Microvascular density differences between the atrophic and non-atrophic mucosa, as well as cancerous and non-cancerous mucosa",2023-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
3970,NCT04744649,Major pathologic response (MPR),2021-03-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event incidence rate
3971,NCT00713128,frequency of delayed emesis (vomiting/retching),2008-04,COMPLETED,OBSERVATIONAL,['NA'],,"Freq. of mild-severe nausea D 2-6 Freq. use of antiemetics D 2-6, Pts.with complete response(no emesis/use of rescue antiemtics)D 1, Pts. with total control (no:emesis,nausea, use of rescue antiemetics)D 2-6, Overall satisfaction"
3972,NCT05746195,Feasibility of Intervention Measure (FIM),2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Change in mean total daily fiber intake (g/d) reported on the Food Frequency Questionnaire (FFQ)
3973,NCT06072287,Illness-related distress,2023-06-28,RECRUITING,OBSERVATIONAL,['NA'],,Cognitive and Behavioural Responses to Symptoms
3974,NCT02845999,number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3975,NCT03360695,Disruptions in Cancer Care,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,PHQ-9
3976,NCT05174117,3 month objective response rate,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 month Quality of Life score
3977,NCT00842257,Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate as Defined by RECIST Criteria
3978,NCT02834013,Overall response rate (ORR),2017-01-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
3979,NCT03200821,Survival,2000-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Gastrin-17 Antibodies
3980,NCT04843215,Disease Free Survival(DFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],Postoperative morbidity,Overall Survival(OS)
3981,NCT00111761,Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1),2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Initial Objective Tumor Response (Part 1)
3982,NCT00556803,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
3983,NCT00834236,Number of Participants With Accurate Diagnosis for Gastric Cancer,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,
3984,NCT06078982,Objective response rate (ORR),2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Drug-related safety indicators
3985,NCT05823987,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
3986,NCT03988998,the 2-years recurrence rate,2022-01-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the 2-years overall survival.
3987,NCT04920019,Amount of postoperative opioid consumption,2020-10-22,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
3988,NCT03633539,Postoperative complications,2020-08,WITHDRAWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
3989,NCT02704988,Increased lymph node sample,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Indication for adjuvant treatment
3990,NCT00001191,,1983-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
3991,NCT04908813,Objective Response Rate (ORR) per RECIST 1.1 assessed by IRRC,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
3992,NCT06079242,Liver-specific overall response rate (ORR) according to RECIST 1.1,2023-10-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Duration of liver-specific DOR assessed by the investigator
3993,NCT01912222,Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
3994,NCT00789841,Gastrointestinal transit time in NET patients,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,Changes in carcinoid symptoms and biomarkers
3995,NCT05628610,objective response rate,2022-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
3996,NCT02529579,6-month SR,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Serum tumor biomarker,QOL
3997,NCT03469375,Progression free survival,2014-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Histopathologic staging
3998,NCT00262769,Overall Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity
3999,NCT05854368,"Characterization and validation of a signature combining plasmatic proteins related to inflammation and carcinogenesis process, associated with the presence of gastric mucosal dysplasia lesions compared with an H. pylori negative control group.",2023-07-03,RECRUITING,INTERVENTIONAL,['NA'],,"Characterization of the plasma levels of the proteins biomarker composing these signatures specific for the different stages of gastric cancer cascade, between the different studied pathology groups"
4000,NCT03813381,Body weight change,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Waist circumference reduction
4001,NCT02399228,"Patients Achieving Less Than or Equal to ""2"" RTOG Score At Visit 9",2015-10-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Safety Will be Assessed Based on the Frequency and Severity of Adverse Events.,NRPS (Numerical Rating Pain Scale)
4002,NCT01257360,Rate of pathological complete remissions,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlative biomarker analyses
4003,NCT05427383,Overall Survival (OS) according to RECIST 1.1 by IRC,2022-04-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from baseline in CA72-4 (carbohydrate antigen 724),Incidence of neutralizing Antibody，Nab
4004,NCT05350007,Tanatophobia,2022-05-25,RECRUITING,OBSERVATIONAL,['NA'],,lack of social support
4005,NCT04247165,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities",2020-06-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of downstaging to surgical resection
4006,NCT01471132,Overall Survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
4007,NCT01924260,"Dose-limiting toxicity (DLT) defined as any related (possibly, probably, or definitely) grade 3 non-hematological toxicity or any attributable grade 4 toxicity graded according to the National Cancer Institute (NCI) CTCAE version 4.0",2013-08-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than 2 patients experience DLT graded according to NCI CTCAE version 4.0
4008,NCT00539877,"The objectives of this study are to assess the feasibility, to determine the maximum tolerated dose, and to assess the toxicities of intraperitoneally administered CPT-11 in gastric cancer patients with peritoneal seeding.",2004-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4009,NCT02503969,Individual attended colorectal cancer screening,2015-09,COMPLETED,OBSERVATIONAL,['NA'],,Individual accepted colorectal cancer screening after refusing the initial invitation for colorectal cancer screening
4010,NCT04495621,Best overall response rate (ORR) according to RECIST v.1.1,2020-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of treatment emergent adverse events (TEAEs)
4011,NCT05677113,The primary outcome will be the 2-year Progression-Free Survival (PFS) rate,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Five-year overall survival
4012,NCT02112214,The incidence of gastric cancer between the intervention and placebo groups,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Modification of atrophy score
4013,NCT03013712,Toxicity profile of the EpCAM targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0,2017-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti-tumor efficacy of CAR-T therapy by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
4014,NCT02672657,Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaire,2016-02,UNKNOWN,OBSERVATIONAL,['NA'],,"Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scale"
4015,NCT02450032,Change in Subject's World Health Organization Performance Status,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events
4016,NCT04076761,Median progression-free survival (PFS),2019-12-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30
4017,NCT00477880,Response,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4018,NCT03521765,WHOQOL-BREF(the World Health Organization Quality of Life-BREF),2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Barthel Index (BI)
4019,NCT00452751,overall survival,2006-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,cost-effectiveness
4020,NCT02449967,Number of participants with Adverse events,2015-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
4021,NCT01542294,chemotherapy complete rate,2011-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival(OS)
4022,NCT00902291,Survival rate at 6 months,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control (Stable Disease or better per RECIST criteria)
4023,NCT05052099,Overall response rate (ORR),2021-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events (AEs) (with severity determined according to NCI CTCAE v5.0)
4024,NCT03748134,OS in PD-L1 positive population,2018-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,PFS - PD-L1 positive
4025,NCT04009876,cCR (clinical complete response) rate in LARC ( locally advanced rectal cancer ) patients treated with chemo - chemoradiation.,2019-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity
4026,NCT03258450,The acceptability of the intervention will be assessed through the Client Satisfaction Questionnaire.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Psychological distress will be accessed through The Hospital Anxiety and Depression Scale (HADS)
4027,NCT04338763,Determination of the maximum tolerated dose (MTD) and the recommended dose for phase II of RP72 monotherapy and RP72 in combination with Gemcitabine,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4028,NCT05152147,Overall survival,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of anti-drug antibodies (ADAs)
4029,NCT06203587,Establishment and optimization of imaging method for [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347 PET/CT.,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
4030,NCT03918499,Progression-free Survival,2019-04-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Response
4031,NCT01658917,"To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors.",2012-07-24,COMPLETED,OBSERVATIONAL,['NA'],,"To collect detailed history, demographic, treatment data, and perioperative findings."
4032,NCT04589247,Proportion of participants with change in their physician-assessed burden score,2020-11-16,RECRUITING,OBSERVATIONAL,['NA'],Management changes as assessed by a Clinician Feedback Form,
4033,NCT00872014,Progression free survival (PFS) rate at 4 months,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Baseline values of and changes from baseline in pharmacodynamic, immunologic, biochemical, transcriptional, pharmacogenetic and angiogenic markers"
4034,NCT03098758,specific markers in peritoneal cells,2017-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
4035,NCT04352894,Best modality of ICG injection,2020-09,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity of ICG fluorescence
4036,NCT02651987,Median Progression Free Survival (PFS),2015-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon
4037,NCT05796700,Progession-free survival,2008-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
4038,NCT02466724,Patients with Excelent Colonoscopy preparation,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,Use of web-based educational platform
4039,NCT06047379,Phase 2b: Determine the intracranial progression-free survival rate at six months (PFS6) of orally administered NEO212 in combination with select SOC regimens in patients with select solid tumors with uncontrolled metastases to the brain.,2023-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4040,NCT03151213,visual analogue pain scale (VAS Pain) post operatively,2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
4041,NCT03998033,The recommended phase 2 dose (RP2D) regimen of ET140202 T-cell therapy,2019-05-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,Assess the persistence of ET140202 T cells circulating in blood over time.
4042,NCT02078700,percentage of cancer patients that accept and attend the early palliative care programme,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists
4043,NCT04165018,Diagnostic yield between FNB samples placed in formalin for pathology evaluation from two different types of needle,2021-04-09,COMPLETED,OBSERVATIONAL,['NA'],,"Rate of adverse events of utilizing the FNB technique, including pancreatitis, bleeding, or perforation"
4044,NCT06232759,Progression-free survival,2022-04-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
4045,NCT00984048,Changes in biomarkers in patients that have acquired clinical resistance.,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with adverse events relating to the liver biopsy procedure
4046,NCT00436774,Quality of life (QOL) as measured by pediatric cancer quality-of-life inventory or Short Form 36 questionnaires,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,
4047,NCT04564313,Objective Response Rate (ORR),2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Graft Rejection (GR)
4048,NCT03139487,Rate of clinical relevant bleeding,2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to recurrent or aggravated venous thromboembolism
4049,NCT01926444,"Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS)",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Subject Satisfaction and Acceptability of the Colonic Analgesia - Patient's Global Impression of Abdominal Pain
4050,NCT02551991,Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT),2015-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Duration of Response (DoR)
4051,NCT02575859,Positive predictive value of preoperative/intraoperative assessment of primary tumor-related risk factors for the development of metachronous peritoneal metastases in patients undergoing curative surgery for colorectal cancer.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-free survival,Peritoneal progression-free survival
4052,NCT05640791,Incidence of adverse events,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4053,NCT01579812,Recurrence-Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4054,NCT02728427,Catherization time,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Catheter obstruction
4055,NCT04958044,Safety,2021-05-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,90 days survival
4056,NCT03228667,Objective Response Rate,2018-12-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
4057,NCT02902575,Morbidity,2016-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
4058,NCT01794676,Modified genetic factors that exist and may influence the phenotypic presentation of disease in unrelated MEN 1 families.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
4059,NCT02215044,Occurence of dose limiting toxicity according to CTCAE,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tumor marker (CA19-9) response to treatment with BI 2536 and gemcitabine
4060,NCT05428553,Adverse events,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of clips,Recurrence after 6 months
4061,NCT01565811,complication rate,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate prognostic significance of perihepatic LN involvement with overall survival and disease free survival
4062,NCT01835223,"PFS, Assessed Using Standard RECIST Criteria",2013-07-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Drug Exposure, as Assessed by Steady State PK",Overall Survival Rate
4063,NCT03907527,Maximal tolerated dose of PRGN-3005,2019-04-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of PRGN-3005 T Cells
4064,NCT01943864,Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12,2013-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Independent Radiologist Assessed Duration of Response
4065,NCT01411826,Feasibility,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,Colon cancer screening attitudes
4066,NCT05014360,Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24,2021-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps
4067,NCT05841706,Rate of Protocol adherence,2023-08-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of blood products received
4068,NCT02430701,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
4069,NCT06133023,Clinical success within 180 days of randomisation,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of new pancreatic cancer
4070,NCT05240950,Efficacy (recurrence-free survival),2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) indicator (AUC)
4071,NCT05812430,Objective Response Rate(ORR),2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
4072,NCT01910610,Duration of Disease Control (DDC),2013-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety profile of each treatment sequence
4073,NCT03798769,Rates of completion,2019-01-31,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,Cumulative dose of FOLFIRINOX received
4074,NCT01026753,Fecal Occult Blood Test (FOBT) completion rate,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,"The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey."
4075,NCT00966667,Normative influences of family and friends,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,
4076,NCT02681601,Anthropometric measurement: Body Composition,2016-07-19,TERMINATED,INTERVENTIONAL,['NA'],,Quality of life: Appetite
4077,NCT02047474,Progression free survival rate,2014-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate
4078,NCT02599103,The changs of metabolomics profile between before and after oil consumption,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,
4079,NCT02503384,Annual caseload for pediatric liver transplantation,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
4080,NCT06023147,Objective response rate (ORR),2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease control rate (DCR)
4081,NCT02669914,Overall Response Rate of Intracranial Disease,2016-09-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4082,NCT05585554,Overall Survival (OS),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Treatment-related toxicity
4083,NCT00165568,To compare the percent change in tumor radioactivity uptake and retention after radiolabeled fluorouracil administration in subjects who receive bevacizumab versus those who do not receive bevacizumab.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,to evaluate the relationship between initial change in tumor radioactivity uptake and retention.
4084,NCT05781581,All-cause mortality at 30 days after operation,2023-03-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Major Adverse Cardiovascular Events (MACE)
4085,NCT03311776,Predictive biomarkers,2008-07-03,RECRUITING,OBSERVATIONAL,['NA'],,
4086,NCT01955122,Adenoma and Polyp Miss Rate,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction
4087,NCT05420480,Overall survival(OS),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival (DFS)
4088,NCT01722903,Quantity of CTCs isolated during liver and/or lung metastasectomy,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
4089,NCT04409990,SWE accuracy,2020-03-02,COMPLETED,INTERVENTIONAL,['NA'],,SWE and ADC measurement
4090,NCT05048017,Progression Free Survival (PFS),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse Drug Reaction (ADR),Mortality at 12 months
4091,NCT02202928,Progress-free survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
4092,NCT03850912,'Emergency Department - Treat and Release' (EDTR) Rate at 30-days,2019-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Sustainability of ePRO symptom management within a health system
4093,NCT04780477,Change in Ki-67+ Level,2021-06-29,RECRUITING,INTERVENTIONAL,['NA'],,Change in CD68+ Lamina Propia Macrophages Count
4094,NCT01167049,Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4095,NCT02487992,Overall Survival(OS),2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Disease-free survival
4096,NCT01248403,overall survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,disease control rate
4097,NCT03705013,The number of subjects with discordant results that can be attributed to intercurrent disease,2018-10-30,TERMINATED,OBSERVATIONAL,['NA'],,
4098,NCT01248273,To determine the maximum tolerated dose over three dose levels.,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To record the progression free interval
4099,NCT05233098,Effective dose (Gy) for the whole body,2023-02-04,COMPLETED,OBSERVATIONAL,['NA'],,
4100,NCT01114035,gene identification,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,mutation identification
4101,NCT01401309,Detecting,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
4102,NCT00375999,Overall Survival,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4103,NCT01251640,Tumor Response (Adjudicated Blinded Read Assessment): Phase II,2011-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS): Phase II
4104,NCT05740111,Number of resectable cancers detected in patients diagnosed through the surveillance programme compared to the unscreened individuals as reported to the Cancer Registry of Norway.,2022-09-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The psychological well-being of participants undergoing surveillance as assessed by the Psychological Well-being Questionnaire
4105,NCT00427089,"Efficacy was measured as the degree of cleansing using a 5 grades scale for each of the predefined colon areas resulting into a final grading of the overall quality of gut preparation (A or B: ""success"" versus C or D: ""failure"").",2004-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Laboratory tests (such as blood chemistry and hematology) were conducted to support the safety data as well as measurement of body weight, blood pressure and pulse rate, but also tolerance."
4106,NCT00102011,Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy,2000-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
4107,NCT00215722,Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluate the Quality of Life
4108,NCT06123156,the patient's response,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse and suspected adverse events
4109,NCT04014478,Visual Analog Scale Changes over the time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life Score Changes over the time
4110,NCT05392413,Imaging examination,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
4111,NCT06018246,Patient-generated subjective nutrition assessment,2021-07-20,COMPLETED,INTERVENTIONAL,['NA'],Adverse reaction,Walking time
4112,NCT03110484,Overall response rate,2021-07-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4113,NCT05821452,MPR rate,2023-05-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
4114,NCT02362048,Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4115,NCT02873741,Presence of Anal hr-HPV,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,
4116,NCT00332163,Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score
4117,NCT04840264,60-day Obstruction Clearance Rate,2022-01-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life assessed by EORTC QLQ-OG25
4118,NCT05255588,"Sensitivity and specificity of the EarlyTect® CRC test for detecting CRC compared to the colonoscopy, both in terms of detecting CRC.",2022-02-10,RECRUITING,OBSERVATIONAL,['NA'],,Clinical sensitivity of the EarlyTect® CRC for detecting Tis
4119,NCT04695262,EUS-E accuracy in terms of qualitative and quantitative elastography,2021-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
4120,NCT00827580,the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4121,NCT05129215,Area under the curve (AUC),2020-03-06,COMPLETED,OBSERVATIONAL,['NA'],Net reclassification index (NRI),Negative prediction value (NPV)
4122,NCT05387876,Microbiome alterations,2022-02-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4123,NCT01741636,"Satisfaction with the timing, content, and delivery of the intervention",2013-01,COMPLETED,INTERVENTIONAL,['NA'],,
4124,NCT01804621,Colorectal cancer screening,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,
4125,NCT01580202,The cumulative probability of HBV reactivation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of hepatic decompensation and liver-related mortality
4126,NCT01519609,Degree of bowel cleansing,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
4127,NCT02445209,Overall Survival,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety as assessed by adverse events according to CTCAE v4.0
4128,NCT01446666,Detection Rate of Patients With HCC,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Positive Predictive Value for HCC
4129,NCT00398398,Overall Response Rate,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
4130,NCT03524820,response to treatment,2017-10-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4131,NCT03588533,Adverse event,2018-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survivals (OS)
4132,NCT01282658,,2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4133,NCT06208046,5-year overall survival,2023-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
4134,NCT00264446,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4135,NCT01406249,Progression-free survival rate,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
4136,NCT05692284,Patient Identification Form,2022-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,SELF CARE ABILITY SCALE
4137,NCT00427375,"Compare the proportion of patients presenting at least 1 component of the composite outcome (4 components: death, recurrence, major morbidity and severe after effects) at 2 years after",2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QLQ C30 - CR38)
4138,NCT05698459,MTD (Maximum Tolerance dose),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity
4139,NCT01129570,The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response as measured by RECIST criteria and AFP concentrations
4140,NCT01182116,Improved function and capacity of the neorectum.,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,
4141,NCT05723965,accuracy of artificial intelligence with experienced physician,2010-10-01,COMPLETED,OBSERVATIONAL,['NA'],,real life survival outcome of diagnosis by artificial intelligence.
4142,NCT00096733,Survival of the potential liver transplant recipient,2004-10,COMPLETED,OBSERVATIONAL,['NA'],Recipient complications,Recipient survival from time of transplant (either living or deceased donor)
4143,NCT00022334,Dose limiting toxicity and maximum tolerable dose.,2001-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,clinical response in patients with measurable disease.
4144,NCT04499833,hepatocellular carcinoma recurrence,2021-03-25,RECRUITING,INTERVENTIONAL,['NA'],,hepatocellular carcinoma recurrence through liquid biopsy
4145,NCT05922930,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-10-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4146,NCT06275204,Healthcare workers' assessment of feasibility and acceptability of the proposed practical implementation of a screening program,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],,Participation rate of subjects selected for the program
4147,NCT02474537,Vz/F of INC280,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Unbound fraction and Vz/F based on unbound concentration in plasma
4148,NCT04046887,Frequency of Dose Limiting Toxicities (DLTs),2019-09-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,European Organization for Research and Treatment of Cancer quality of life questionnaire
4149,NCT00719303,Progression-free survival,2012-06-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],Vitality measured using RAND-36 and GSRS-IBS,Change in self-reported quality of life measured using RAND-36
4150,NCT03911167,Postoperative complication rate，%,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],,"hospitalization expenses,yuan"
4151,NCT02284802,accuracy of confocal endomicroscopy,2014-09-10,COMPLETED,INTERVENTIONAL,['NA'],,
4152,NCT05759325,Progression-free survival,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4153,NCT01971775,Amount of drain at postoperative period,2011-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,4. Postoperative hospital stay Complications
4154,NCT00034333,,2002-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4155,NCT04245644,Overall survival,2019-03-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4156,NCT02227914,Time To Progression (TTP) - Phase 2,2014-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS) - Phase 2
4157,NCT00236249,"Readiness for discharge, checked twice a day",2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Clinical side effects twice a day
4158,NCT01648465,15 month PFS (Progression-Free Survival) rate,2012-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Association of biologic markers with disease progression
4159,NCT04931381,6-month disease control rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).
4160,NCT02139215,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
4161,NCT06060704,ORR（Objective response rate）,2023-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life: EORTC QLQ-C30
4162,NCT03104569,Number of participants with Acute cholangitis,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with Post-ERCP pancreatitis
4163,NCT02370849,Objective response rate as measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment safety and toxicity as measured by Common Toxicity Criteria for Adverse Effects(CTCAE 3.0)
4164,NCT00804817,Health Related Quality of Life (HRQoL),2007-12,COMPLETED,INTERVENTIONAL,['NA'],,Symptom experience (Common Terminology Criteria for adverse events - CTCAE v. 3.0)
4165,NCT04646187,cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up,2021-03-11,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE4'],Patients' attitudes towards deprescribing anti-TNF agents,Identification of predictors of successful de-escalation.
4166,NCT01929915,Perioperative immunoprofile,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,survival rate
4167,NCT03251417,Disease control rate,2017-09-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median overall survival time
4168,NCT05192018,Feasibility of early reversal of adefunctioning ileostomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
4169,NCT04730544,Progression-free survival (PFS) at week 24 for two combination schemes.,2021-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Health-related quality of life (HRQoL) score definitive deterioration (TUDD)
4170,NCT00529412,incidence of small bowel obstruction,2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,intraoperative and postoperative morbidity and mortality.
4171,NCT01994681,Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Pancreatic Cancer sick population and healthy population.,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,
4172,NCT00215644,Percentage of Participants With Objective Response Assessed by Independent Review Committee,2005-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Matuzumab Serum Concentration
4173,NCT05730192,Positive percent agreement (PPA),2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],,
4174,NCT00845884,response rate,2009-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety, PFS, overall survival"
4175,NCT01569620,"Change from baseline of colonoscopy at 3 months, 6 months, and 12 months.",2012-04,COMPLETED,INTERVENTIONAL,['NA'],,
4176,NCT03830606,objective response rate（ORR）,2016-03-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety profile: assessed by CTCAE v4.0
4177,NCT03264716,Hepatic Progression free survival,2017-08-31,COMPLETED,INTERVENTIONAL,['NA'],,An overall tumor response classification
4178,NCT03039595,Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer,2017-03-29,COMPLETED,OBSERVATIONAL,['NA'],,Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer
4179,NCT05131815,Feasibility of BurnAlong,2022-01-10,COMPLETED,INTERVENTIONAL,['NA'],,Measure of Experiential Aspects of Participation (MeEAP)
4180,NCT04512209,Biophysical properties of the tumor tissue - measurement of hydraulic conductivity,2019-10-11,RECRUITING,INTERVENTIONAL,['NA'],,Measurement of Pt penetration
4181,NCT04062656,Rate of pathological complete responses,2019-09-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient-reported outcome (PRO)
4182,NCT04686942,sensitive of detection tumor,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],,
4183,NCT02130752,Surgical duration,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative Mortality and Morbidity
4184,NCT03152487,Subject assessment of abdominal pain,2017-04-24,COMPLETED,INTERVENTIONAL,['NA'],,Pain per the VAS tool.
4185,NCT03398122,PFS,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA'],,QOL
4186,NCT00838578,Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4187,NCT00903136,Comparison of participants' satisfaction with the TCE vs esophagogastroduodenoscopy (Phase II),2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Results of the histologic analysis of any biopsy specimens (Phase II)
4188,NCT01715233,Response,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4189,NCT01795027,overall survival,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events
4190,NCT01801904,number of patients alive and without disease progression,2012-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],gene expression on tumor tissue,worst grade toxicity per patient
4191,NCT05809869,Rate of abscopal effect,2023-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant control rate
4192,NCT01077986,phase II part: response rate,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamics: biomarkers in blood and tumor tissue
4193,NCT05429203,Number of participants with procedure-related adverse events,2022-10-25,RECRUITING,INTERVENTIONAL,['NA'],,Ability to perform interventions
4194,NCT00405873,Best overall tumour response according to RECIST; within 20 weeks after registration; confirmation 6 +/- weeks later,2007-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
4195,NCT01443260,"Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)",2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of Anti-tumor Activity
4196,NCT04187937,R0 resection rate,2020-06-17,TERMINATED,INTERVENTIONAL,['NA'],,Time for resection
4197,NCT06148402,Objective Response Rate,2024-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,ctDNA and efficacy
4198,NCT05956847,Changes in ecDNA content in different gastric precancerous lesions,2023-08-10,RECRUITING,OBSERVATIONAL,['NA'],,
4199,NCT02529007,Number of polyps detected per patient,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Patient comfort score
4200,NCT03915171,Sensitivity and specificity of blood MSI detected by NGS,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation between MMR gene and other gene mutations
4201,NCT03202992,Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL,2017-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.
4202,NCT02898649,Safety (frequency of procedure-related complication and death),2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Change in CA 19-9
4203,NCT02806661,Recurrence rate,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Inflammatory factors
4204,NCT00352404,Histological proof of neoplastic tissue (Intraepithelial neoplasia or cancer),2003-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Prediction of extent and severity of inflamed mucosa
4205,NCT00564265,Number of Patients Who Survived,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
4206,NCT01912131,assess the acceptability of this piloted P-COCC intervention,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,qualitative analyses
4207,NCT00790218,Maximum Plasma Concentration of CF102 (Cmax),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102
4208,NCT03531632,Number of Participants With Adverse Events,2018-06-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Number of Participants With Response Based on the Change in Tumor Volume
4209,NCT05963724,Adenoma Detection Rate,2022-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Withdrawal Time
4210,NCT02897778,Change from Baseline in T-Cell Morphology,2016-08-24,COMPLETED,INTERVENTIONAL,['PHASE1'],"Variability and Changes in Protein Lysine Acetylation in Peripheral Blood Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose and Examine the Underlying Biological Variation",λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose
4211,NCT04684355,Quality of life degree,2020-12-22,UNKNOWN,INTERVENTIONAL,['NA'],,Anxiety and depression degree
4212,NCT01013805,Tolerability Rate of patients treated with integrated pre-operative radiotherapy with FOLFOX chemotherapy regimen,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose Intensity of the treatment drug
4213,NCT04450758,Number of patients with 90 day mortality,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,colorectal surgeon performing resectional surgery
4214,NCT03337087,Best response rate (Phase II),2018-11-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events (Phase II)
4215,NCT04271657,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiopathomics artificial intelligence model,2020-01-10,COMPLETED,OBSERVATIONAL,['NA'],,The sensitivity of the radiopathomics artificial intelligence model
4216,NCT00743964,Failure-free survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
4217,NCT02324114,Hsp90α Concentration(ng/ml) of plasma,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,
4218,NCT06154785,To assess the impact of the stable low-pressure approach (using Airseal Insufflator) and its associated parameters into the the early rehabilitation program after colorectal surgery on length of stay.,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],,The Surgical and Medical morbidity at 30 days
4219,NCT01350726,,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4220,NCT03085992,Disease-free survival rate at 2 years,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pathological complete response rate
4221,NCT02446379,The location of PET imaging agent as measured by the LightPathTM Imaging System,na,WITHDRAWN,OBSERVATIONAL,['NA'],,Number of participants with adverse events
4222,NCT00423254,To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,to describe any objective tumor responses to the treatment with MKC1106-PP
4223,NCT00004066,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4224,NCT03313596,"Progression-free survival, PFS",2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Median overall survival time
4225,NCT03187184,PGx Test Interpretation,2017-05-20,COMPLETED,INTERVENTIONAL,['NA'],,Chemotherapy Toxicity
4226,NCT05329766,Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of participants with anti-drug antibodies to zimberelimab
4227,NCT02108444,the incidence of hepatitis B virus delayed reactivation,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival rate
4228,NCT05039944,Optimal combination dose (only IIa),2021-11-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,ADA
4229,NCT01177007,Progression-free Survival (PFS) of the Treated Lesion(s) According to RECIST and EASL Criteria,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean Radiation Dose Delivered to Total Liver
4230,NCT05980689,Complete response (CR) rate,2023-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Long-term anal function
4231,NCT06218420,To evaluate the efficacy of stereotactic body radiotherapy (SBRT) as bridging therapy for patients with hepatocellular carcinoma (HCC) enlisted for liver transplantation (LT).,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the occurrence of adverse events related to SBRT during waiting time period and after LT
4232,NCT01695772,Percentage of Participants Achieving Complete Resection (R0 Resection),2012-10-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Percent Probability Of Being Alive and Disease Free at Months 3, 6, 9, and 12"
4233,NCT00544011,Objective response (complete and partial) rate,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Biomarkers predictive of efficacy
4234,NCT05138887,acute radiation-induced proctitis (ARP) incidence,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],adverse events,cancer remission rate assessed by imaging
4235,NCT01982487,PFS (Phase IIb),2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity rate, graded according to NCI CTCAE version 4.0"
4236,NCT03047603,PIVKA-II,2016-05-01,COMPLETED,OBSERVATIONAL,['NA'],,"ALT, AST，γ-GT， AFU"
4237,NCT02205008,relapsed free survival,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],surgery and intraperitoneal chemotherapy-related morbidity and mortality,overall survival
4238,NCT05225207,Number of Participants With Non-serious ADRs,2019-05-28,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Overall Response
4239,NCT05501379,Comparison of physical activity assessments within 1 week after initiation of cancer therapy,2022-09-21,RECRUITING,OBSERVATIONAL,['NA'],,Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy
4240,NCT02436018,Low pulse oximetry incidence,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Other adverse events
4241,NCT03883802,ctDNA as surrogate marker for disease free period,2019-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Thymidine Kinase activity,ctDNA in Wnt-5a high patients
4242,NCT00979329,,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
4243,NCT00068744,"Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry"
4244,NCT01426490,Antioxidant and DNA methylation,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4245,NCT01761461,The primary endpoint of the study is disease-free survival (DFS).,2013-02-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4246,NCT01104181,HC2 can accurately test for oncogenic HPV in anal specimens,2010-03,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of cytology with HC2
4247,NCT04111978,Progression-free survival (PFS) for each study group,2020-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group
4248,NCT00937482,MTD defined as the dose at which no patients develop treatment-related grade 5 toxicity and less than 30% of patients develop acute dose limiting toxicities (DLT) assessed using NCI CTCAE version 4.0,2009-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Vascular MRI studies
4249,NCT04091295,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4250,NCT04605913,Determine safety of (m)-GCN+TTF,2022-04-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
4251,NCT06094868,Progression-free survival (PFS),2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Security
4252,NCT00511446,Progression-free survival rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median overall survival
4253,NCT01057953,genetic variation assessment,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
4254,NCT06261047,Progression free survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Duration of control
4255,NCT04099134,Quality of life in pancreatic cancer patients,2018-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of predictive and prognostic markers
4256,NCT04305145,Proportion of patients with Steroid-Free Colitis,2020-08-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
4257,NCT02889276,"Change in Global Health Status/QoL (subscale of EORTC QLQ-C30, Version 3) scores in cancer survivors",2017-02-20,TERMINATED,INTERVENTIONAL,['NA'],,Change in Self-efficacy to regulate exercise scale score
4258,NCT05374122,Cholangiocarcinoma diagnosis confirmation after biopsy and six-month follow-up,2022-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Insufficient biopsy sample rate
4259,NCT03867084,Overall Survival (OS),2019-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Health Utility Score"
4260,NCT00483782,Progression-free survival,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economics
4261,NCT05191667,Number of participants with Dose Limiting Toxicities (DLTs),2022-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4262,NCT04408599,Define a maximum tolerated dose (MTD) or pharmacologically active dose (PAD),2020-06-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Half-life (t1/2) of NC410
4263,NCT05012527,Completeness rate of the procedures,2021-06-11,COMPLETED,OBSERVATIONAL,['NA'],,
4264,NCT00122876,Safety,2005-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
4265,NCT02483884,Sensitivity and specificity of [68Ga]RM2 PET to identify lesions in comparison to whole-mount histopathology (number of histologically verified cancer lesions identified),2015-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients with adverse events,Evaluation of SUV threshold
4266,NCT00387387,"Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1",2006-10-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging"
4267,NCT01027221,Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity,2009-11,COMPLETED,INTERVENTIONAL,['NA'],,"quality of life according to the EORTC QoL questionnaire after 6, 12, 18 and 24 months"
4268,NCT03407001,Accuracy of contrast enhanced ultrasound (CEUS) with contrast agent sulfur hexafluoride lipid-type A microspheres and B-mode non-contrast enhanced ultrasound,2018-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Assessment of CEUS and contrast enhanced magnetic resonance imaging (CE-MRI) Liver Imaging Reporting and Data Systems (Li-Rads)
4269,NCT01754272,Primary colorectal cancer tumor blocks,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],Residual blood samples,Metastatic tumor blocks
4270,NCT05517681,The number of positive lymph nodes,2020-09-07,COMPLETED,INTERVENTIONAL,['NA'],,The incidence of postoperative complications
4271,NCT03549494,Quality of Life,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Results of laboratory tests
4272,NCT03308552,Overall survival（OS）,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse events
4273,NCT02647476,Postoperative complication rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
4274,NCT00025025,,2001-10,COMPLETED,OBSERVATIONAL,['NA'],,
4275,NCT01738633,"items DY (dyspnoea), AP (appetite loss) and QL2 of the QLQ C30",2013-01,TERMINATED,INTERVENTIONAL,['NA'],,item EA (eating) of OES18
4276,NCT00001805,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4277,NCT01167738,Progression-free survival at 6 months,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
4278,NCT03615599,Incident cases of breast cancer among subjects with documented dietary habits.,2002-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Incident cases of colorectal cancer among subjects with documented dietary habits.,Incident cases of prostate cancer among subjects with documented dietary intakes.
4279,NCT05462496,Achievement of overall immune response,2023-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate (OS)
4280,NCT02745197,Muscle fatty acid content,2017-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Plasma C-reactive protein
4281,NCT04194879,Sensitivity & specificity of colorectal cancer detection,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4282,NCT00321958,HGD or inoperable intramucosal or submucosal carcinoma and severe squamous dysplasia: measure of reduction in size of HGD or carcinoma,2006-04,TERMINATED,OBSERVATIONAL,['NA'],,Number of treatment sessions needed to ablate dysplasia
4283,NCT02656524,Number of participants with treatment emergent adverse events as a measure of safety and tolerability,2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],Time frame between the baseline computed tomography and the first drug delivery,Resource utilization per patient
4284,NCT03536208,Determine change in AXL pathway,2019-05-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Antitumor effect
4285,NCT03657914,Number of lymph nodes dissected,2017-07-12,UNKNOWN,INTERVENTIONAL,['NA'],Local recurrence rate of tumor within 3 years,Postoperative drainage tube indwelling time
4286,NCT04046575,Maximum tolerated dose (MTD) of hypofractionated IMRT with chemotherapy,2019-11-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number and type of adverse events experienced by patient
4287,NCT03741088,Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors,2018-03-21,COMPLETED,INTERVENTIONAL,['NA'],,Analgesic Requirements After the Ablation Procedure
4288,NCT05124743,Results of HLA typing in combination with tumor genetic testing of subjects to identify a TCR match for treatment on the TCR001-201 study.,2021-09-24,SUSPENDED,OBSERVATIONAL,['NA'],,
4289,NCT05068752,Disease Control Rate of Vemurafenib in Combination with Sorafenib,2021-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Clinical Activity of Vemurafenib in Combination with Sorafenib,Measure phospho ERK and phospho AKT in plasma
4290,NCT05163236,sensitivity of the fecal immunochemical test for the detection of colorectal cancers,2021-04-20,COMPLETED,OBSERVATIONAL,['NA'],,Treatment
4291,NCT05063019,"Predicting intraoperative PCI scores for patients with peritoneal carcinomatosis, using MR Enterography and CT",2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,
4292,NCT01167374,Maximum Tolerated Dose (MTD),2011-08,TERMINATED,INTERVENTIONAL,['NA'],,Progression-free Survival
4293,NCT03160924,Post-operative hospital stay,2016-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Direct hospital costs
4294,NCT00387348,Change in Hamilton Depression Rating Scale (HAM-D) Scores,2006-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Side Effect Burden
4295,NCT03515369,3-year disease free survival,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],safety and tolerability,EORTC QLQ-C30
4296,NCT02618356,Median disease progression free survival (mPFS) of Raltitrexed combined with S-1,2015-12-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4297,NCT03991104,Response rate,2019-05-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Health-related Quality of life (HR-QoL, Phase II)",Progression-free survival time
4298,NCT04644250,Pathologic complete response rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4299,NCT03355391,colorectal cancer rate,2018-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,
4300,NCT01190462,Percentage of patients free from progression and alive after 12.5 weeks following the first dose of treatment,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Correlation between overall response rate, progression-free survival, overall survival, and safety with skin toxicity and efficacy"
4301,NCT03071094,Overall Response Rate (ORR) According to RECIST 1.1.,2017-07-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4302,NCT06041477,OS,2023-09,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety profiles of all participants
4303,NCT02706301,Change in Pain Severity assessed using the Brief Pain Inventory (BPI),2016-07,COMPLETED,INTERVENTIONAL,['NA'],Patient Satisfaction assessed using the Client Satisfaction Questionnaire 10-item version,Change in Self-Efficacy for Pain Control assessed using the subscale of the Chronic Pain Self-Efficacy Scale
4304,NCT00450788,cancer incidence,2007-03-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Mortality
4305,NCT03820544,Intraoperative Estimated Blood Loss,2017-09-01,TERMINATED,INTERVENTIONAL,['NA'],,
4306,NCT05583890,Health inequalities,2022-08-25,RECRUITING,OBSERVATIONAL,['NA'],,
4307,NCT03596411,Sleeve gastrectomy,2018-05-17,UNKNOWN,OBSERVATIONAL,['NA'],,Obesity related comorbidity
4308,NCT03144661,Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs),2017-05-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Analysis of biomarkers
4309,NCT04629326,Standardized uptake value（SUV）,2021-07-20,RECRUITING,INTERVENTIONAL,['NA'],,
4310,NCT03160209,Risk factors for ESCC - Tobacco and alcohol consumption,2017-07-26,COMPLETED,OBSERVATIONAL,['NA'],,The germline genetic and epigenetic alterations associated with susceptibility to ESCC.
4311,NCT04834011,"Preoperative radiologic assessment of patients with diagnosis of right-sided colon cancer. The investigators evaluated: fascia of Fredet; vascular structures (ileocolic vessels; right colic artery, middle colic artery, trunk of Henle); lymph nodes.",2013-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,perioperative outcomes: rate of conversion
4312,NCT04950166,Clinically Significant Events (CSE),2021-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pegsitacianine fluorescence and imaging performance
4313,NCT05848739,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,ST316 Assessment Objective Response Rate (ORR)
4314,NCT02151032,Gist and Verbatim Knowledge for a Colorectal Cancer Screening Program,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,
4315,NCT03686709,Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging,2018-06-19,RECRUITING,INTERVENTIONAL,['NA'],,
4316,NCT01995084,Optimal time frame between administration of 18F-HX4 and PET scan,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
4317,NCT06006260,Self-report Questionnaire,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],,
4318,NCT00700102,Overall Survival: Time From Randomization to Death From Any Cause,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response Rate: Participants With Response Status Based on RECIST Criteria
4319,NCT05742438,MMP,2023-04-12,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
4320,NCT03313700,3-year disease free survival rate,2017-09-25,COMPLETED,INTERVENTIONAL,['NA'],,operation time
4321,NCT05141617,24-week re-bleeding,2021-11-03,UNKNOWN,INTERVENTIONAL,['NA'],,24-week adverse events
4322,NCT02005913,tumor recurrence,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4323,NCT04658589,Number of harvested lymph nodes in D2 lymph node dissection,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Conversion to open surgery
4324,NCT03959696,Shared Decision Making Process (SDMP) Scale Score,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Clinician attitude toward shared decision making,Clinician satisfaction with the visit
4325,NCT00833131,The rate of patients with R0 resection,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of complete pathological response
4326,NCT00280761,Correlation of NF-kappa B pathway activation with therapeutic outcomes,2003-12,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of p53 pathway-mediated events with clinical outcomes
4327,NCT04702230,DWI/IVIM values,2017-09-11,TERMINATED,OBSERVATIONAL,['NA'],,early responders
4328,NCT04371224,Progression-free survival,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,QOL: eortc qlq-c30
4329,NCT00091195,Survival,2004-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4330,NCT01895530,Difference in gene expression of citokynes,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complications
4331,NCT00188266,Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.,2002-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival and disease-specific survival
4332,NCT04789980,Overall Survival (OS),2021-01-29,RECRUITING,OBSERVATIONAL,['NA'],Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy,Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores
4333,NCT01505530,Overall Survival (OS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-LY2495655 Antibodies
4334,NCT04926532,Objective response rate (ORR),2019-08-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
4335,NCT02291133,Number of Participants With Toxicity Related to Electrochemotherapy,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Response Evaluation According to RECIST v1.1
4336,NCT04358328,Mortality,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Mortality
4337,NCT03303352,"Cytological diagnostic accuracy of EUS FNA, for ""fast"" and ""slow"" passages",2017-07-24,COMPLETED,INTERVENTIONAL,['NA'],Subgroup analysis for trans-gastric and trans-duodenal route,"The linear relationship between needle acceleration and outcomes 1,2,3 and 4"
4338,NCT02079389,"A change in the stage of Tumor, lymph Node and metastases (TNM-stage)",2013-05,COMPLETED,INTERVENTIONAL,['NA'],Does the use of contrast enhanced ultrasound examination during surgery for colon and rectum cancer provides more findings of liver metastases?,A change in the postoperative treatment strategy
4339,NCT05477576,Phase 3: PFS as determined by BICR,2022-03-24,RECRUITING,INTERVENTIONAL,['PHASE3'],Phase 3: QTc,Phase 3: DoR
4340,NCT00087334,Response rate,2004-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival in (phase II)
4341,NCT01092091,Tumor response,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Plasma arginine levels
4342,NCT03076567,Relation of DNA methylation marakers to gastric cancer status,2017-03-09,COMPLETED,OBSERVATIONAL,['NA'],,
4343,NCT04761783,Examine the impact of SIGNATERA on treatment decisions on tumor assessment timepoints after initiation of immunotherapy,2021-05-28,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Determine the impact of SIGNATERA on patient reported outcomes
4344,NCT04048278,Upregulation or Downregulation of Gene Expression.,2018-11-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Specimen outcome measure
4345,NCT01326845,Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms,2011-12,TERMINATED,INTERVENTIONAL,['PHASE4'],,Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups
4346,NCT01287585,Overall survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety and tolerability - number of participants with adverse events.
4347,NCT03609710,Anastomotic leak rate,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Reoperation rate after anastomotic leak
4348,NCT00061958,"Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity graded according to the Common Toxicity Criteria version 2
4349,NCT05565066,Diagnostic yields of EUS-FNA with EUS-FNB for solid masses,2014-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Quality of histologic specimen
4350,NCT02603757,Increase in serum Vitamin D3 level during chemotherapy in the active supplementation group compared to the control group.,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
4351,NCT00024063,,na,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4352,NCT06074432,Mortality,2023-07-25,COMPLETED,OBSERVATIONAL,['NA'],,
4353,NCT01712958,"identifying specific, relevant miRNAs that may serve as biomarkers to stratify CRC patients according to their clinical characteristics",2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4354,NCT04642664,Objective Response Rate (ORR),2018-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Clinical benefit rate (CBR),Incidence of Treatment-Emergent Adverse Event
4355,NCT00746590,Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Changes in Laboratory Measurements
4356,NCT04440865,Adenoma Detection Rate (ADR),2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Morbidity: bleeding rate (%)
4357,NCT03121807,Overall survival,2014-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Cycles of salvage chemotherapy completed
4358,NCT01002287,"The Incidence of Adhesions, Defined as the Proportion of Subjects Presenting at the Follow-up Surgery (10-12 Weeks) With One or More Adhesions to the Midline Incision, Regardless of Extent and/or Severity.",2009-10,TERMINATED,INTERVENTIONAL,['NA'],,Mobilization Time
4359,NCT01604798,Serum peptide mass fingerprinting (PMF),2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Expressed peptide peaks
4360,NCT04386057,Dose Limiting Toxicity-Lead In,2020-05-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4361,NCT01110941,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)"
4362,NCT00270166,Proportion of patients without transfusion after first month.,1995-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Proportion of responders, change of hemoglobin (not by transfusion), cumulative transfusion rate, proportion of patients transfused during the double-blind phase, excluding the first month; mean change score of baseline quality of life parameters; safety"
4363,NCT04380103,objective response rate (ORR),2020-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,the surgical resection rate of patients with liver-only metastases
4364,NCT03704077,Overall response rate (ORR),2019-10-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4365,NCT06003998,Overall survival,2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Peritoneum/plasma ratio of intraperitoneal irinotecan
4366,NCT05845450,major pathological response rate,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,microbiota
4367,NCT01126463,Maximal tolerated dose,2010-05-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Bio-availability
4368,NCT05068739,Success rate of cannulation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Procedure time
4369,NCT04045496,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Duration of response ( DOR )
4370,NCT01349881,"Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)",2013-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cancer type (colorectal vs rectal)
4371,NCT06119425,Opted to be screened by either SOC or study diagnostic test,2023-10-12,RECRUITING,INTERVENTIONAL,['NA'],,Opted to be screened by the study diagnostic test instead of SOC
4372,NCT01849588,Decline in HCV-RNA Level,2013-05,TERMINATED,INTERVENTIONAL,['PHASE4'],Decrease Alpha-fetoprotein(AFP) Level > 20% From the Baseline,Overall Survival
4373,NCT05603572,To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To assess area under the curve (AUC) of KAT (oral and oral + IT)
4374,NCT03806075,Mutation of gene associated with Peutz-Jeghers syndrome,2018-03-01,UNKNOWN,INTERVENTIONAL,['NA'],The association of STK11 with intestinal microbiota of patients with PJS,Intestinal microbiota of patients with PJS
4375,NCT06059885,Tumor recurrence rate (DRR),2021-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4376,NCT05402592,Shorter Length Of Hospitalization,2022-07-13,COMPLETED,INTERVENTIONAL,['NA'],,Higher quality of life on the 30th day after surgery in patients given a carbohydrate-rich beverage before surgery
4377,NCT06281379,Postoperative outcome,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
4378,NCT04287218,Change of total score on Fear of Cancer Recurrence Inventory (FCRI) from baseline to 2nd follow-up,2023-05-10,RECRUITING,INTERVENTIONAL,['NA'],Perceived risk of recurrence measured by the visual analogue scale from 1-100,Comparison of changes in health care usage between intervention arm and aTAU
4379,NCT04939103,the accuracy of predicting pCR after nCRT,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
4380,NCT05043857,Local Recurrence Rate,2021-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
4381,NCT00681421,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
4382,NCT03465722,"Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1",2018-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30). Change in Individual Scores in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib
4383,NCT06221748,Overall Survival (OS)(Phase III),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of echocardiograms abnormalities
4384,NCT02536183,Feasibility of treatment,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine the Changes in Pharmacodynamic Immune Markers in Participants
4385,NCT05047510,HCC lesions,2021-09-10,RECRUITING,INTERVENTIONAL,['NA'],,
4386,NCT05969847,Organ preservation,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Anorectal function
4387,NCT01983371,Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.,2013-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
4388,NCT02930902,Incidence of toxicities as defined by Common Terminology Criteria for Adverse Events version 4.0,2017-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Overall survival (OS),Resection rate
4389,NCT04858009,Progression-free survival,2024-01-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Morbidity
4390,NCT01744639,Nutritional Status,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Minimal hepatic encephalopathy
4391,NCT01465802,Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III,2011-12-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Mean Plasma Ctrough for PF-05199265 by Visit for Cohorts I, II and III"
4392,NCT05247164,Proportion of patients with procedure-related Adverse Events,2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Baseline portal CTC concentration in patients with progressive versus non-progressive diseases
4393,NCT06255041,"Sensitivity of detection of any cancer (breast, lung, prostate or colorectal cancer) by the breath test.",2021-02-10,RECRUITING,OBSERVATIONAL,['NA'],The duration for which a breath sample collected on an alternative mask substrate remains effective for detection by a detection dog,Intra-observer variability among the detection dogs
4394,NCT05453760,Area under the curve (AUC) of the Lung ultrasound score,2022-08-21,RECRUITING,OBSERVATIONAL,['NA'],,Complications according to the Dindo-Clavien classification
4395,NCT03700593,Rate of postoperative complications and mortality of the SP robot,2018-10-15,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of patients' postoperative body image satisfaction
4396,NCT05034783,Metabolic parameters,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],GLP-1R expression and SUV,Diagnostic value
4397,NCT02507414,"Relative changes in plasma-hormone concentrations (pro-ANP, PGF2, GLP-1, ACTH, cortisone, adrenaline, IL-1, IL-6, TNF-alfa and CRP (stress hormones)) from baseline.",2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Relative changes in systemic vascular resistance from baseline measured in dyn.s/cm5
4398,NCT01899976,Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of >30% if baseline value was greater than 3.0 mg/dL,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,total number of adverse events
4399,NCT00144378,median survival,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"quality of life, response rates, time to tumor progression, toxicity"
4400,NCT04258150,Objective response rate (ORR),2020-04-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Incidence of treatment-related AEs, SAEs, AEs leading to discontinuation, death, and laboratory abnormalities"
4401,NCT02550613,The recurrence rate at 3 months after treatment,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,The overall survival after treatment
4402,NCT03524300,3-year disease free survival rate,2018-06-01,RECRUITING,INTERVENTIONAL,['NA'],,operation time
4403,NCT02631499,Early recurrence rates,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall Survival
4404,NCT01705340,MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Overall response rate (ORR), evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"
4405,NCT02784470,Gastric Outlet Obstruction Scoring System (GOOSS) score,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4406,NCT03028584,EHR-based SCPs and care planning,2017-09-11,COMPLETED,OBSERVATIONAL,['NA'],,Impact of providing EHR-based care planning
4407,NCT00536874,Overall Survival at 18 Months,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Specific Tumor Marker Response (Ca 19-9) to Neoadjuvant Therapy
4408,NCT02599662,Maximum Tolerated Dose,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,QOL surveys
4409,NCT00822562,Overall survival rate,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,"non-tumor life span, intra-liver recurrence rate, metastasis rate"
4410,NCT04652180,Respiratory postoperative complications.,2020-11-06,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative quality of life.
4411,NCT00303771,Progression Free Survival (survie sans progression),2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival (survie globale)
4412,NCT02557490,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
4413,NCT06067438,"Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone",2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Serum amiodarone level, classified as therapeutic or subtherapeutic"
4414,NCT04069468,QoL Measurements Using FACT-HEP Questionnaire Before and After Treatment,2019-03-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Determination of a correlation between Dose volume histogram (DVH) for total perfused tumour, Index lesion and whole normal liver tissue, using 99mTc-MAA (SPECT or SPECT/CT) and Y-90 (PET/CT or PET/MRI)."
4415,NCT05673148,Overall Survival (OS),2023-01-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to local recurrence (TLR)
4416,NCT05185869,Adverse Events (AEs),2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
4417,NCT01330823,TNF-alpha,2006-06,SUSPENDED,INTERVENTIONAL,['PHASE3'],,hospital stay
4418,NCT01389583,disaese control rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
4419,NCT05939063,Lymph node positive rate,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
4420,NCT05737615,SUV mean measurement,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
4421,NCT05411679,Overall Response Rate (ORR) as measured using RECIST v1.1,2023-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Magnitude of response to first-line chemotherapy,Incidence of treatment-emergent AEs leading to dose reduction of trial treatment
4422,NCT03718650,Radiosensitivity Index and Degree of Pimonidazole Staining,2021-04-01,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Correlative Biomarkers
4423,NCT06205173,The effectiveness of Cold and Hot Compress Nursing Interventions on the Quality of Life,2020-08-19,COMPLETED,INTERVENTIONAL,['NA'],,The Effectiveness of Cold and Hot Compress Nursing Interventions on the Neurological Changes in the Hands and Feet.
4424,NCT04481256,Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa,2020-11-11,RECRUITING,INTERVENTIONAL,['NA'],Biomarker,adverse events
4425,NCT01786980,Overall survival,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,
4426,NCT03219918,Adenoma detection rate,2017-06-19,TERMINATED,INTERVENTIONAL,['NA'],,Malignancy detection
4427,NCT02358070,Lifestyle factors,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
4428,NCT03333967,Progress free survival,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],adverse events,Disease-free survival
4429,NCT05627427,Progression-free Survival (PFS) (RECIST1.1),2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TEAE rates
4430,NCT01572974,Health State Utility as measured by the Time Trade-off (TTO) method/Standard Gamble (SG) method,2010-01,TERMINATED,OBSERVATIONAL,['NA'],,SF-36 general health (GH) subscale
4431,NCT02494973,3-year RFS rate,2015-05-26,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4432,NCT06212817,Dietary fiber intake,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
4433,NCT00161460,Colorectal cancer screening test utilization,2005-06,COMPLETED,INTERVENTIONAL,['NA'],,Cancer worry score
4434,NCT03399253,Overall survival,2017-12-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,progression free survival
4435,NCT00003753,,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4436,NCT02682589,disease-free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire
4437,NCT01700283,"Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors",2012-10,UNKNOWN,INTERVENTIONAL,['NA'],,
4438,NCT05572801,Disease free survival,2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Health related quality of life
4439,NCT01717014,Distal Margins,2013-05,TERMINATED,INTERVENTIONAL,['NA'],,Usability: Manueverability
4440,NCT06151262,Incidence of CIM,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
4441,NCT01016860,Maximum tolerated dose (MTD) and the recommend phase II dose (RP2D) for the combination of irinotecan and OSI-906 in patients with advanced cancer.,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,
4442,NCT02359058,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies (TE-ADA)
4443,NCT04637893,Colorectal Cancer prevention,2020-12-16,COMPLETED,OBSERVATIONAL,['NA'],,
4444,NCT00445965,response rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,cumulative toxicities
4445,NCT01977066,"Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30",2013-11,COMPLETED,INTERVENTIONAL,['NA'],Fatigue (Multidimensional Fatigue Inventory (MFI)),Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26)
4446,NCT02255669,duration of stent patency,2014-10,UNKNOWN,INTERVENTIONAL,['NA'],,stent related complication
4447,NCT00851305,To compare the rate of EGCs/GCs using CLE versus conventional gastroscopy.,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the efficacy of in vivo CLE on different pathological characteristics of EGCs.
4448,NCT01875380,Progression-free survival rate at 6 months,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,Changes in ECOG performance status over time from baseline
4449,NCT00313755,with at least one adenoma after white light NBI in the right colon.,2006-04,COMPLETED,INTERVENTIONAL,['NA'],,Number of hyperplastic polyps detected by white light vs NBI.
4450,NCT02089633,Time To Progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],To evaluate the association between the biomarkers of ornithine transcarbamoylase (OTC) and argininosuccinate synthetase (ASS) in liver tissue and clinical response treated with PACOX regimen,Safety events
4451,NCT05478083,Liver growth,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Symptoms of depression
4452,NCT06196775,Progression-Free-Survival,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
4453,NCT04797884,Quality of Life Survey,2023-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Frequency of Adverse Events - PRO-CTCAE
4454,NCT03397745,Change in Bispectral index score,2018-01-15,COMPLETED,INTERVENTIONAL,['NA'],,The changes of BIS
4455,NCT00145769,Local recurrence,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
4456,NCT01834469,Feasibility study of the (intravenously injected) ICG imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4457,NCT03316872,Overall response rate,2018-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate
4458,NCT02278458,The number of patients who suffer adverse events,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
4459,NCT02595021,Postoperative complications,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Hospitalization days
4460,NCT00354978,Median Progression-free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4461,NCT05159479,Relationship of baseline cardiovascular risk with FIC,2021-10-13,RECRUITING,OBSERVATIONAL,['NA'],,Cardiovascular symptom assessment
4462,NCT05524012,Tumor regression grading (TRG),2022-11-30,RECRUITING,OBSERVATIONAL,['NA'],,Surrogate marker: Carcinoembryonic Antigen (CEA)
4463,NCT03465982,pathologic complete response (pCR),2018-06-05,RECRUITING,INTERVENTIONAL,['NA'],,OS
4464,NCT04776421,comprehensive complication index,2021-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
4465,NCT03228147,A tea product with the highest total average nutrition supplement scores as assessed by questionnaires,2017-07-25,COMPLETED,INTERVENTIONAL,['NA'],,
4466,NCT02842580,The primary objective is the percentage of patients without failure of the strategy 16 months after the randomization.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS) at 2 years and at 3 years
4467,NCT01538498,Devleopment for the peritoneal carcinomatosis index (PCI),2008-04,COMPLETED,OBSERVATIONAL,['NA'],,
4468,NCT05246943,Compare the D-dimer results of DVT positive subjects to DVT negative subjects to identify a specific result range seen in the DVT positive subjects.,2022-05-25,WITHDRAWN,OBSERVATIONAL,['NA'],,
4469,NCT00813072,objective tumor response,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"progression-free survival, duration of tumor response, time to progression, time to treatment failure, disease control rate, 1-year survival rate,and overall survival; pharmacokinetics and pharmacogenetics of PEP02 and irinotecan"
4470,NCT04140500,"Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs First",2019-11-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: Percentage of Participants with Adverse Events
4471,NCT04017650,Incidence of treatment-related grade 3 adverse events,2019-06-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
4472,NCT01963429,local progression-free survival(LPES),2013-09-30,COMPLETED,INTERVENTIONAL,['NA'],overall survival (OS),disease-free survival (DFS)
4473,NCT04389177,Major pathologic response,2020-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
4474,NCT02513784,Difference in Esophageal F. Nucleatum Between Experimental Group and no Intervention Group,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
4475,NCT00964457,response rate,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4476,NCT03604614,PFS,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Median survival
4477,NCT04714086,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4478,NCT06031129,Visceral Pain,2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Visceral Pain
4479,NCT05444491,To investigate the prediction and monitoring effect of plasma ctDNA methylation on postoperative recurrence of primary colorectal cancer patients after radical surgery,2022-06-20,RECRUITING,OBSERVATIONAL,['NA'],,
4480,NCT06115655,Specificity,2023-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4481,NCT05803928,"Recurrence-free Survival, RFS",2023-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Biomarkers in tumors and peripheral blood
4482,NCT05044312,Correlating the sleep disturbance and its types among patients with gastrointestinal cancers.,2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4483,NCT04791254,Differences in patterns of plasma gut hormone and cytokine levels as measured by ELISA between study participants.,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],,"Correlation between nutritional status, body composition and physical fitness"
4484,NCT04324567,"Peak value of surgically induced C-reactive protein (CRP), expected to occur 1-3 days after surgery",2019-10-09,COMPLETED,OBSERVATIONAL,['NA'],Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor in up to 10 patients with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,Dehiscence of the perineal wound at 3 months follow-up
4485,NCT03609359,"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST",2018-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Tests of various biomarkers,Disease control rate (DCR)
4486,NCT05689138,microbial features by 16s rRNA sequencing,2020-09-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4487,NCT02233595,tumor volume,2014-10-15,TERMINATED,OBSERVATIONAL,['NA'],,
4488,NCT00851955,All cause mortality,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,"For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice."
4489,NCT04745403,Analysis of modifications of tumour microenvironment caused by mRNA HBV/TCR T-cell treatment,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of anti-tumor efficacy of mRNA HBV/TCR T-cell treatment
4490,NCT04422730,comparaison of quality of life score between 4 groups,2020-06-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4491,NCT04508387,respiratory parameters: tidal volume,2019-04-22,COMPLETED,INTERVENTIONAL,['NA'],,morphine consumption
4492,NCT03223818,Length of post-operative hospital Stay,2018-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
4493,NCT03245736,Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE),2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Increased Prostate Specific Antigen (PSA)
4494,NCT02395523,local progression - free survival,2015-03-05,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
4495,NCT05136092,The abundance of fructose in tumor extracts,2022-02-16,RECRUITING,INTERVENTIONAL,['NA'],,The abundance of Xylose and [13C]-Xylose in the in the tumor
4496,NCT02399137,Progression Free Survival,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm
4497,NCT05935579,Objective response rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival rate
4498,NCT05772923,Rate of successful organ preservation,2021-04-16,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients with complications after completion or salvage TME-surgery
4499,NCT00254137,Objective response rate (CR+PR),2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 3/4- toxicities.
4500,NCT04131946,Characterize individual -level facilitators and barriers to engaging in CRC screening and related diagnostic tests and treatment when applicable,2019-11-12,COMPLETED,INTERVENTIONAL,['NA'],,
4501,NCT01341366,Duration of hospital stay,2010-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Lymphocyte subsets
4502,NCT01885351,CRCS adherence provided by the electronic medical record,2013-03-01,COMPLETED,INTERVENTIONAL,['NA'],Development of MyCRCS+ intervention content,Feasibility of MyCRCS+ in target setting - patient survey
4503,NCT02734004,Second Stage Cohorts: DCR at Week 24,2016-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Initial and Second Stage Cohorts: Number of Participants With Anti-Drug Antibody (ADA) Response to MEDI4736
4504,NCT01387880,Clinical benefit (SD+PR+CR),2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4505,NCT02021500,Overall Survival,2014-01-02,COMPLETED,OBSERVATIONAL,['NA'],,Disease progression
4506,NCT00305838,Number of patients required to detect a significant difference in CA 125 doubling time before and after starting tamoxifen,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4507,NCT02841657,Postoperative complications,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Oncological radicality
4508,NCT00669734,"MTD of falimarev, defined as the dose level that 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) and that at least 2/3 or 2/6 patients treated with the next higher dose have had DLT",2010-02-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokine production
4509,NCT04656041,Pathologic Complete Response Rate,2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4510,NCT05041153,Overall response rate,2022-02-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
4511,NCT06054984,Characterize the Peak of Peripheral Blood Concentration and Area under the Peripheral Blood concentration versus time curve of TCRT cells and observe their proliferation and persistence in body,2021-09-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To explore the correlation between the proliferation and persistence of TCRT cells in body and the efficacy,"Evaluate tumor size (mm) , tumor biomarker CA19-9 (U/ml), ORR/DCR/PFS and OS of patients with advanced pancreatic cancer"
4512,NCT02861885,patients with sessile serrated lesions,2016-02-24,UNKNOWN,OBSERVATIONAL,['NA'],,Detection techniques diagnosis performance
4513,NCT00005036,Overall survival,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
4514,NCT05559775,ORR,2022-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4515,NCT00127036,"Number of Participants Per Treatment Arm, Per Tumor Tissue Response Classifier",2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious Adverse Events (SAEs)
4516,NCT03379844,"Safety, expressed as the rate of unacceptable toxicity.",2017-08-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in hepatic function as determined by hepatobiliary scintigraphy
4517,NCT00310362,Appointment Nonadherence-colonoscopy,2007-07,COMPLETED,INTERVENTIONAL,['NA'],,Preparation Non-adherence-flexible Sigmoidoscopy
4518,NCT00087256,To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,To monitor the toxicity and safety of celecoxib in this population.
4519,NCT00943280,The primary outcome variable for this aim will be the number of subjects in each group that need to be contacted until 20 in each group agree to participate in this study.,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,"To access variables for prediction of non-participation: age, gender, education level, employment, marital status, esophageal symptoms"
4520,NCT06012318,Prevalence and severity of adverse symptoms,2023-09-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Trajectory of adverse symptoms
4521,NCT00248053,polyp number and size,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,side effects and medication compliance
4522,NCT02024009,Progression free survival,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
4523,NCT04899492,Testing the feasibility of smoking cessation interventions evaluated in French cancer patients undergoing surgery,2021-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the efficacy of interventions on patient quality of life
4524,NCT03718351,En-block resesction rate,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity defined by the Clavien-Dindo classification
4525,NCT05200325,CPV-measured cost savings,2021-06-06,COMPLETED,INTERVENTIONAL,['NA'],,CPV-measured use case analysis
4526,NCT05572528,The recurrence rate after LDLT in high risk patients,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
4527,NCT00116454,"to determine if the Lipiocis treatment decreases the % of tumoral recurrence after 24 months, judged on the rise of alpha-fetoprotein and the reappearance of one or more tumours on the hepatic CT scan",2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Deterioration of the hepatocellular function
4528,NCT03006302,6 Month Survival,2018-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation
4529,NCT00227773,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
4530,NCT05570487,The number of lymph nodes,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4531,NCT03177382,disease free survival,2017-06-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,assessment of nutritional status
4532,NCT02599909,"To collect blood/urine/tumor samples, stool, and rectal swabs from HCC patients undergoing resection of primary liver tumors at the Mount Sinai Medical Center and to perform an analysis of the interaction of tumors, immune responses and the gut ...",2015-11-06,WITHDRAWN,OBSERVATIONAL,['NA'],,Correlation between microbiome and patients' clinical outcome
4533,NCT04657042,DVF errors in healthy volunteers and cancer patients,2020-11-05,RECRUITING,OBSERVATIONAL,['NA'],,
4534,NCT04852211,2-year recurrence-free survival,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,5 - year Overall survival
4535,NCT03278015,median overall survival time (mOS),2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
4536,NCT05371873,MRD monitor,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4537,NCT00062426,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4538,NCT01312389,Number of Participants With Adverse Events,2011-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical Response
4539,NCT00126633,Micrometastases for predicting time to progression and overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4540,NCT03124212,Establishing the CASCADE Cohort,2017-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Cancer Surveillance
4541,NCT03958812,Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC),2019-06-15,UNKNOWN,OBSERVATIONAL,['NA'],,Comprehensive diagnostic model of VOCs and CTCs
4542,NCT04640480,"Number of clinically significant Chest radiograph findings(chest x-ray, CXR)",2024-06-21,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Time to progression(TTP)
4543,NCT03468335,Time to Treatment Failure of second-line treatment (TTF2),2018-03-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Growth modulation index (GMI)
4544,NCT05858385,Incidence of severe RTOM,2022-09-22,RECRUITING,OBSERVATIONAL,['NA'],Changes from the pain in xerostomia combined with RTOM patients,Risk factors of severe RTOM
4545,NCT02231385,Additional serrated lesions diagnosed after acetic acid spraying,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
4546,NCT03450889,Incidence of colorectal cancer during protocolled endoscopic surveillance,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of post-colonoscopy complications
4547,NCT05718284,POST-OPERATIVE PULMONARY COMPLICATIONS,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,CARDIO-VASCULAR COMPLICATIONS
4548,NCT00636948,Symptomatic anastomotic leakage following low anterior resection of the rectum for cancer with and without a defunctioning stoma. Anorectal function after one and five years without defunctioning stoma.,1999-12,COMPLETED,OBSERVATIONAL,['NA'],,Reoperation within 30 days of initial surgery.
4549,NCT02578368,Overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
4550,NCT01632722,2 years recurrence-free survival (2Y-RFS),2012-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4551,NCT01520779,Recurrence of hepatocellular carcinoma,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
4552,NCT03785496,To evaluate efficacy of PDR001 by Objective Response rate by RECIST(Response Evaluation Criteria In Solid Tumors),2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate antitumor efficacy of PDR001
4553,NCT00003530,,1977-03-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4554,NCT03503071,Brief pain inventory (BPI),2018-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Brief pain inventory (BPI)
4555,NCT03812289,Proportion of participants who are transplanted or with localized disease control per Milan criteria,2019-02-07,TERMINATED,INTERVENTIONAL,['NA'],Proportion of histopathologic changes in irradiated tumor sites relative to uninvolved liver tissue,Incidence of liver toxicity assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0
4556,NCT02452424,Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With Pembrolizumab,2015-07-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Summary of the Percentage of Participants With Objective Response Rate Assessed by RECIST v1.1 During Pembrolizumab and PLX3397
4557,NCT00558233,Receipt of colorectal cancer screening,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of polyps and cancers found by screening tests performed
4558,NCT06018896,Quality of life (QOL),2023-08-25,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
4559,NCT06212128,operative time required for primary resection of rectal tumour,2016-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,duration of hospitalisation
4560,NCT01411579,Apparent Diffusion Coefficient (ADC) value changes of the lesion during chemotherapy.,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
4561,NCT04973046,The tissue oxygen saturation score of gastric tube during esophagectomy,2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],,The rate of anastomotic leakage
4562,NCT05544474,Degree of consensus,2023-11-28,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4563,NCT03415815,Numbers of lymph nodes and percentages of patients with surgeries,2017-12-12,UNKNOWN,OBSERVATIONAL,['NA'],Effects of surgeries on the extents of the patients with esophageal cancer who received surgeries,Impact factors of lymph metastases
4564,NCT04893408,long time survival in patients operated for pancreatic cancer,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4565,NCT03682276,Incidence of treatment-emergent adverse events [Safety and Tolerability],2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathologic response rate
4566,NCT00040859,Objective tumor response rate,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
4567,NCT01738620,items SL (sleep disorder) and QL2 of the QLQ C30,2013-01,TERMINATED,INTERVENTIONAL,['NA'],,PSQI score
4568,NCT02758951,Phase III (n=358): histological response of colorectal PM to neoadjuvant systemic therapy,2017-06-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
4569,NCT05932836,Accuracy of Organoid drug sensitivity test in predicting the response to mFOLFOX6 infusion in HCC patients with successful Organoid culture,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,The predictive effect of Organoid drug sensitivity test on the survival of patients with HCC.
4570,NCT05752357,Percentage of disease recurrence,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
4571,NCT00020774,,1998-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
4572,NCT04605042,diagnostic specificity of WS technique and SNP technique by EUS-FNB,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cell density of WS technique and SNP technique by EUS-FNB
4573,NCT00436267,Hepatic and systemic toxicity,2006-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival
4574,NCT00550563,"Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity",2007-08,COMPLETED,INTERVENTIONAL,['NA'],,
4575,NCT04908176,area under the plasma concentration-time curve (AUC) of midazolam,2022-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],,"area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite"
4576,NCT01469598,Response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
4577,NCT03350126,Disease Control Rate (DCR),2017-12-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),"
4578,NCT03159585,treatment-related adverse events as assessed by CTCAE v4.03,2017-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,assess the expression of tumor markers
4579,NCT01344538,"Evaluate Whether 2.0g of Ginger Taken Daily, Standardized to 5%-Gingerols for Four Weeks Will Result in Bioactive Levels in Colonic Tissue Sufficient to Reduce Mucosal Prostaglandin E2 (PGE2), a Marker of Cyclooxygenase Function Versus Placebo.",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4580,NCT00583479,Compare the clinical effectiveness of EUS-guided CB performed with a single injection versus two injections of medication into the celiac ganglion region,2002-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,complications related to CB
4581,NCT00582647,"To obtain & store tissues, blood, peritoneal, pleural, cyst & other gastrointestinal fluid from patients with benign or malignant tumors in order to carry out future laboratory studies on the causes, prevention, diagnosis & treatment of certain cancers.",2000-03,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
4582,NCT04207918,Local control rate,2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ctDNA in predicting tumor response rate and prognosis
4583,NCT05451043,Investigating and establishing the efficacy of propranolol in boosting the effects of immunotherapy in biliary tract tumors,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
4584,NCT02961296,The rate of exceeding the resistance criteria in Helicobacter pylori(H. pylori) antibiotic susceptibility test(Agar dilution method),2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,The success rate of H. pylori strain separation
4585,NCT04594863,SIRT-6 expression,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
4586,NCT03115008,Number of polypectomies for gastroenterology trainees to achieve competency,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
4587,NCT01460745,Percentage of patients who undergo liver resection following downsizing chemotherapy with or without Erbitux,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,"Percentage of liver resection outcomes R0, R1 and R2"
4588,NCT03278925,"Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) expression in cirrhotic liver",2018-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Incidence of hepatocellular carcinoma,Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis
4589,NCT03488667,Number of Adverse Events related to toxicity.,2018-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Programmed cell death ligand 1 (PD-L1) expression in tumor cells
4590,NCT01717729,recurrence rate,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complete Ablation
4591,NCT01092078,Colon Cancer Screening Behavior,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Social Influence relating to colon cancer screening
4592,NCT00978549,Overall survival,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economic evaluation as assessed by EQ-5D
4593,NCT00253383,Correlate preferences for care and care received as measured by After Death Bereaved Family Member Interview with a family member of the deceased,2003-01,COMPLETED,INTERVENTIONAL,['NA'],,"Caregiver burden as measured by Montgomery-Borgatta Caregiver Burden Scale at baseline, one month, and every three months thereafter (given to caregivers of patients)"
4594,NCT00019110,,1995-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4595,NCT00968175,The efficacy of EUS-CPN and analgesic therapy in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the efficacy of EUS-CPN and analgesic therapy in improvement of quality of life (QOL)
4596,NCT03519074,Efficacy Evaluation: Timing,2016-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4597,NCT01575340,change in inflammatory markers,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,assessing the risk of inflammatory and nutritional complications
4598,NCT01786850,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
4599,NCT01688336,Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],"Correlation of Tumor Markers (Ca19-9, CEA) With Outcomes (RR, DCR, PFS, and OS).",Rate of Resectability (RR)
4600,NCT04022746,Change in percent non-viable/necrotic tumor,2019-06-11,RECRUITING,INTERVENTIONAL,['NA'],,Change in tumor size and enhancement
4601,NCT04670718,Visualisation of gastrointestinal tract,2020-12-10,COMPLETED,INTERVENTIONAL,['NA'],,Ability to asses depth of invasion of resected GI early tumor
4602,NCT00825669,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,the changes of the PVTT
4603,NCT00001693,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4604,NCT00730353,Progression Free Survival Rate at 24 Weeks,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
4605,NCT05278351,Progression free survival time (PFS),2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4606,NCT02526836,Lymph nodes harvest,2014-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Survival outcome
4607,NCT02869581,Survival of patients with pancreatic neoplasms,2000-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4608,NCT03120104,Change of The Wexner Score,2017-06,UNKNOWN,INTERVENTIONAL,['NA'],,Change of Functional assessment of Cancer Therapy - Colorectal (FACT-C)
4609,NCT02491372,Change in psychological flexibility assessed using the Acceptance and Action Questionnaire II,2015-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in Quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Oesophageal and Gastric Cancer
4610,NCT03064308,Feasibility of a home based exercise programme following surgery in the older patient.,2017-06-26,COMPLETED,INTERVENTIONAL,['NA'],Intervention Compliance Questionnaire,Hand Strength Test
4611,NCT05551416,New strategies for gastric cancer (GC) early diagnosis,2021-09-09,RECRUITING,OBSERVATIONAL,['NA'],,Characterization of the microbiome: 16S rRNA studies
4612,NCT04444232,Alters' intent to become screened for CRC in the next six months,2014-09-09,COMPLETED,INTERVENTIONAL,['NA'],,
4613,NCT01079767,3-month disease-control rate according to RECIST criteria,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,3-month objective response rate according to RECIST criteria
4614,NCT03522649,Overall Survival (OS),2018-04-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease Control Rate in biomarker positive patients
4615,NCT04072198,ORR,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life with QLQ-C30 questionnaire
4616,NCT00583271,,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
4617,NCT00622622,Safety(toxicities as assessed by NCI CTCAE version 3),2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,survival
4618,NCT03529669,Completion Rate,2018-04-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Who Would be Prepared to Repeat the Procedure
4619,NCT03035279,Number of participants with dose-limiting toxicities (DLT),2017-03-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Maximum observed serum concentration (Cmax) of SC-006
4620,NCT05433402,Disease-free survival,2022-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biological Markers,Time occurrence of new primary colon cancer and new polyps
4621,NCT04798612,T-cell infiltration in tumor,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunological and inflammatory cytokines and interleukins
4622,NCT01882933,Overall survival,2013-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Score QLQ-STO 22
4623,NCT04213222,estimated ORR,2020-10,UNKNOWN,OBSERVATIONAL,['NA'],,estimated OS
4624,NCT03469284,Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool,2019-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pain Duration
4625,NCT02215070,Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide,2015-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate GI Toxicity Assessment by Video Capsule Endoscopy.,Disease Free Survival Compared to Historical Controls
4626,NCT02632864,two-year overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Hepatobiliary phase signal change after proton beam therapy
4627,NCT05982834,objective response rate,2023-05-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
4628,NCT02585687,Global survival,2012-07,TERMINATED,INTERVENTIONAL,['NA'],,
4629,NCT00378066,time to progression,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, safety, response"
4630,NCT04526314,Overall survival,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4631,NCT04103697,3-year disease-free survival,2019-08-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Preoperative tumor-associated complications rate
4632,NCT01843829,Efficacy,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Efficacy
4633,NCT04081779,Response rate among primary care providers (PCPs) to the PCP survey,2020-02-19,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Local oncology clinics' attitudes towards survivorship care implementation
4634,NCT00477841,"Relief of dysphagia measured by dysphagia scores, survival time from the interventional procedure to the last follow-up.",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Successful rate of stent placement, Stent-related complications and morbidity, Overall rate of mortality"
4635,NCT05024097,Number of treated patients who achieve complete pathologic response,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
4636,NCT03030508,Disease-free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Three year disease free survival rate
4637,NCT04310839,30-day readmission rate,2020-11-03,COMPLETED,OBSERVATIONAL,['NA'],,Ileus
4638,NCT01008566,Toxicities and tolerability of this regimen as assessed by NCI CTCAE version 4.0,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free rate according to the Response Evaluation Criteria in Solid Tumors (RECIST)
4639,NCT02323906,Dose-Limiting Toxicity (DLT),2015-01-16,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression (TTP)
4640,NCT03407040,Availability of stored specimens and/or data,2018-01-30,TERMINATED,OBSERVATIONAL,['NA'],,
4641,NCT03874871,R0 resection rate,2019-03-20,RECRUITING,OBSERVATIONAL,['NA'],,overall survival
4642,NCT04083378,Impact of software use on the minimal margins of ablated lesions properly covered by ablation on a three-dimensional analysis,2020-01-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Liver function
4643,NCT05876338,Change from Baseline in Quality of Life Level on the EORTC QLQ-CR29 Quality of Life,2023-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
4644,NCT03425058,"The concordance and accuracy of response evaluation results determined by ctDNA, CTCs compared with imaging and serum tumor biomarkers(CEA, CA19-9,CA72-4 et al)",2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],,The concordance of mutations in tumor tissue and ctDNA
4645,NCT06168357,Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4646,NCT01862003,Best overall response,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Occurrence and Severity of Adverse Events
4647,NCT02288195,Local-regional failure-free survival,2014-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of receiving pre-operative or post-operative chemoradiation
4648,NCT01819766,Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.
4649,NCT01053182,morbidity of postoperative pulmonary complications,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"diaphragm movement, pulmonary function, stomach emptying"
4650,NCT00296114,,2004-02,COMPLETED,OBSERVATIONAL,['NA'],,
4651,NCT00630045,disease free survival rate,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,response rate and safety of XELOX as a neoadjuvant regimen
4652,NCT00107861,- Evaluate the safety of a single IV administration of Ad.hIFN-β.,2005-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Explore preliminary clinical activity.
4653,NCT05333809,Objective response rate (ORR),2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4654,NCT06178848,frontal spectral power,2023-06-26,COMPLETED,INTERVENTIONAL,['NA'],,Riker sedation-agitation score
4655,NCT01003015,Adverse Event Collection,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only)
4656,NCT01263353,Evaluate safety and tolerability profile of pasireotide LAR in combination with everolimus in patients with advanced metastatic NET,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the biochemical response (chromograninA, CgA) to pasireotide LAR in combination with everolimus"
4657,NCT05993923,Change in functional status after colorectal cancer surgery between groups,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The rate of early unscheduled re-hospitalizations or admissions to the emergency department between groups
4658,NCT00622557,,2007-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
4659,NCT01281943,Progression free survival (PFS),2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Polymoprhism assessment
4660,NCT05687552,comparison of pet -ct finding with ct finding,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4661,NCT04518852,overall survival (OS),2020-09-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],conversion rate of hepatectomy,duration of response
4662,NCT05394714,Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D),2022-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Changes in Biomarkers (CEA and CA19-9)
4663,NCT06061744,recurrence,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4664,NCT05110378,Oxford NOTECHS II,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
4665,NCT03766607,"Progression free survival, PFS",2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse event
4666,NCT02727153,Mortality,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Readmission rate
4667,NCT00489515,Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor,1999-02,COMPLETED,OBSERVATIONAL,['NA'],,
4668,NCT01617278,Mean number of adenomas per colonoscopy,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,To estimate the recruitment rate
4669,NCT05639153,"Part 2: Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0",2022-05-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity by measurement of Incidence of anti-drug antibodies (ADA)
4670,NCT00842686,Pathological complete remission rate (pCR),2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
4671,NCT05070156,Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability] after B010-A injection.,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Disease control Time (DDC)
4672,NCT03462992,AUC of the MonoMark test,2012-12-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4673,NCT04278144,"Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)",2020-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of potential-immune related toxicities
4674,NCT02613156,Perioperative complications,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,relapse-free survival
4675,NCT02706184,Common toxicity criteria for diarrhea Version 4.0,2015-07,COMPLETED,INTERVENTIONAL,['PHASE3'],stool microbiome analyses,ECM/BCM-Index
4676,NCT05523778,Rate of POPF within 3 months after EN.,2023-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Total cost of hospitalization
4677,NCT05464875,Duration Of Response,2022-07-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Assessment of dose effect of antineoplastic agents,Vd（volume of distribution）
4678,NCT03317119,"Maximum tolerated dose defined for the combination of trametinib, and Trifluridine and Tipiracil Hydrochloride (TAS?102) as the highest dose level at which 0-1 out of 6 patients experience dose limiting toxicities",2018-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
4679,NCT05609396,Uptake,2022-05-03,COMPLETED,INTERVENTIONAL,['NA'],,"Uptake by deprivation, sex and age"
4680,NCT02349412,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G),2015-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Concordance Between Patient and Family Caregiver Report of Prognosis/Curability
4681,NCT02818530,Changes in anterior chamber depth measured by ultrasound.,2017-06-21,TERMINATED,INTERVENTIONAL,['NA'],,Time dependent changes in anterior chamber depth during prolonged trendelenberg position.
4682,NCT00224692,Pain score,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
4683,NCT04121286,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response ( DOR )
4684,NCT05785975,To assess if positive subjects are complying with follow-up screening,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,
4685,NCT00152217,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Relapse-free survival, adverse events"
4686,NCT05994456,Pathological complete remission (pCR) rates,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Related Adverse Events
4687,NCT00073138,Objective Response Rate in subjects with Recurrent Colorectal Cancer,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities associated with treatment administration
4688,NCT02724202,Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.,2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Duration of Quality of Life
4689,NCT02931929,"Preliminary targeting properties of 68Ga-NeoBOMB1 in advanced, GRP positive GIST tumours as assessed by SUV",2016-11-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To extrapolate absorbed tumour doses for potential application of 177Lu NeoBOMB1 (in first 6 patients)
4690,NCT03085004,Incidence of serious and minor adverse events occurring within 30 days post ablation,2019-04-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,
4691,NCT00411762,Median Progression Free Survival,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
4692,NCT06135571,Metastatic rate of No.253 lymph node,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,5-year overall survival rate
4693,NCT03130621,Pedigree analysis,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,somatic mutation landscape of hereditary upper gastrointestinal cancer
4694,NCT03848182,Change in CD4 T cell responses after TT booster vaccine,2017-07-21,TERMINATED,INTERVENTIONAL,['PHASE2'],Change in myeloid-derived suppressor cells,Change in CD8 T cell responses after TT booster vaccine
4695,NCT02717923,Progression-Free Survival of maintaining treatment（mPFS）,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
4696,NCT04030637,Accuracy of COLOSAFE,2019-02-11,UNKNOWN,OBSERVATIONAL,['NA'],,
4697,NCT00973193,Pathological Complete Response (pCR),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research"
4698,NCT01251458,• To establish the maximum tolerated dose (MTD) and a suitable dose for Phase II evaluation of Torisel® given as a weekly dose in patients with advanced hepatocellular carcinoma (HCC),2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,• To determine overall survival (OS)
4699,NCT02210039,Number of Participants With Tolerability of the Procedure,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,
4700,NCT03278327,Suggest that there are significantly more than 60 % of patients with a relative decrease of at least 50 % between the total percentages of esophageal time crossed in pH4 (Ph metric dosage) before and after endoscopic treatment.,2017-06-27,UNKNOWN,INTERVENTIONAL,['NA'],,Use of Inhibitor of the pump with proton (PPI)
4701,NCT02968810,Change in serum AFP-L3%,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in serum immune markers,Change in Model for End-Stage Liver Disease score
4702,NCT02607787,Feasibility,2015-04,UNKNOWN,INTERVENTIONAL,['NA'],,Capillary blood sample
4703,NCT03231462,Pulmonary complications,2015-03-06,RECRUITING,OBSERVATIONAL,['NA'],,The change of symptom
4704,NCT02859415,Number of Participants Whose Best Response is a Complete Response (CR) or Partial Response (PR),2019-08-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose-limiting Toxicity (DLT),"To Develop Methodologies for Assessing Effects of Mithramycin on Cancer Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Circulating Tumor Cells (CTC)"
4705,NCT00594113,CRC screening completion,2007-08,COMPLETED,INTERVENTIONAL,['NA'],,"PAPM stage and perceived barriers among participants preferring various screening methods (iFOBT, Colonoscopy)"
4706,NCT03039608,the time when stricture occurs,2017-02-10,COMPLETED,INTERVENTIONAL,['NA'],,the frequency of complications
4707,NCT00598247,RECIST Response,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity
4708,NCT01023529,Effect on patient's target symptom.,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,Time to improvement in patient's symptoms and QoL.
4709,NCT05728606,Total incidence of postoperative complications,2023-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Robotic surgical completion rate
4710,NCT01937104,ONSD and PaCO2,2013-09,COMPLETED,INTERVENTIONAL,['NA'],ONSD and PaCO2,ONSD and PaCO2
4711,NCT01962376,progression-free survival(PFS),2013-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],Adverse events,Objective response rate (ORR)
4712,NCT00201318,"We expect to enter 33 patients per year. Taking into account 10﹪dropout rate, we may finish accrual of patients within 3 years.",2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4713,NCT01740375,2-year disease-free survival (DFS) rate,2012-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,treatment-related mortality
4714,NCT04653181,postoperative complications,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Need for red blood cell transfusion
4715,NCT02175914,CT and MRI imaging for desmoids,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
4716,NCT05555888,complete response (CR) rate,2022-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,10 year Quality of Life
4717,NCT04969107,disease-specific survival,2012-01-01,RECRUITING,INTERVENTIONAL,['NA'],,recurrence-free survival
4718,NCT00492193,Time to upper and lower GI recovery and post-operative hospital length of stay.,2007-06,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative ileus related mobidity.
4719,NCT05616039,Clinical outcomes- Microscopic positive resection margin rate,2022-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Complications
4720,NCT05854394,6-minute-walking-distance (6MWD),2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life Scale
4721,NCT05904886,Overall Survival (OS),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
4722,NCT01730937,Overall Survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality Adjusted Life Years
4723,NCT01996969,Predictive biomarker in terms of disease control rate,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of adequate response evaluation modality after regorafenib treatment
4724,NCT01669720,Number of Patients Who Progressed,2012-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Number of Participants Who Experienced a Toxicity Profile of Adjuvant Ziv-aflibercept, up to 2-years of Duration, for Patients Who Previously Received Systemic Perioperative Therapy (Regimen) and Surgical Resection/Ablation."
4725,NCT02576184,radiological incisional hernia rate,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Clinical incisional hernia rate
4726,NCT02484404,Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors,2015-06-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.
4727,NCT00075595,Time to death from progression,2002-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of grade 3 or 4 toxicity
4728,NCT06196658,Objective Response Rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,5) Volume of ascites measured by ultrasonography and/or frequency and volume of ascites aspiration
4729,NCT05655494,Proportion of patients who self-refer to cancer clinical trials,2023-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Mediators of intervention effectiveness
4730,NCT05113290,Objective response rate (ORR) according to mRECIST criteria,2021-12-28,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of participants with adverse events
4731,NCT03898895,"Progression-free survival, PFS",2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Disease control rate, DCR"
4732,NCT05830019,local progression-free survival,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,adverse events
4733,NCT04141566,Specific Quality of life of patients with PCPC and PLIC,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,90 day morbidity and mortality rate
4734,NCT01671891,circulating tumor cells level changes after radiotherapy,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,RECIST-based tumor response at 10 week after radiotherapy
4735,NCT03169842,Cyst fluid glucose level,2017-05-25,COMPLETED,INTERVENTIONAL,['NA'],,
4736,NCT01457287,Cognitive Function,2003-10,COMPLETED,OBSERVATIONAL,['NA'],,Potential mechanisms leading to fatigue and/or cognitive decline
4737,NCT00009893,survival at 6 months,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,tumor response rate
4738,NCT04677088,Safety evaluation of the TCR-T treatment,2018-03-29,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
4739,NCT04980157,Colorectal Cancer Screening Status,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
4740,NCT01544452,Synchronous colon cancers and liver metastasis,2010-08,TERMINATED,INTERVENTIONAL,['NA'],,sensitivity/specificity of CT versus MR versus Peroperative ultrasonography of the liver
4741,NCT03748485,disease free survival,2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],,complication in 30 days post surgery
4742,NCT02808780,"Long-term Safety: Participants with Adverse Events of Interest (AEIs) and Serious Adverse Events (AEs) Including Malignancies, Pregnancies, and Non-serious Malignancies",2016-12-16,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Health Care Utilization: Evaluate the Reasons for Hospitalization in Participants in Each Cohort
4743,NCT03006926,DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR,2017-02-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status
4744,NCT00988741,Evaluate time to progression among all patients treated with ARQ 197 compared to placebo,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further evaluate pharmacokinetics of ARQ 197.
4745,NCT00651677,operative time,2011-04,WITHDRAWN,INTERVENTIONAL,['NA'],,urinary and sexual function
4746,NCT02298907,Oxygen uptake at lactate threshold,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with adverse post-operative outcome measures
4747,NCT03951337,Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment,2019-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,64Cu-ATSM toxicity
4748,NCT06307314,Different grades radiotherapy-induced oral mucositis,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Tumor response
4749,NCT05419011,"Cumulative incidence rate of the composite endpoint of adenomas (tubular, tubulovillous and serrated), advanced adenomas and colon cancer",2023-03-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Immune cell gene enrichment analysis,Incidence of extracolonic neoplasms
4750,NCT03221335,Severe adverse events,2016-05,RECRUITING,INTERVENTIONAL,['NA'],,Survival
4751,NCT03276156,Incidence of adverse events,2016-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of life(QoL)
4752,NCT04336241,Recommended Phase 2 dose (RP2D) of RP2,2019-10-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of stable disease (SD)
4753,NCT02512263,Muscular strength measured by Microfet,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Depression measured by questionnaire
4754,NCT01897636,pancreatic tumor response rates,2013-12,UNKNOWN,INTERVENTIONAL,['NA'],,survival rates
4755,NCT01883336,Progress of pancreatic cyst,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
4756,NCT06046846,To investigate the usability in terms of user satisfaction of the asensei app to deliver a mHealth prehabilitation programme.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Semi structured interviews,To collect preliminary data and assess for change on a participants quality of life by using the EORTC QLQ-OG25 questionnaire in order to inform the sample size for a fully powered RCT as part of the feasibility study.
4757,NCT00088933,Number of patients experiencing each of the toxicities by grade for each treatment arm,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Average quantity of circulating CEA cells determined by quantitative real time RT-PCR
4758,NCT01821482,progression-free survival(PFS),2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Laboratory findings,quality of life (QOL)
4759,NCT01618474,disease free survival,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,CTC negative conversion rate
4760,NCT03126071,PFS,2017-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
4761,NCT00734890,Toxicity,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4762,NCT02549755,To Compare Changes in 11C-acetate Uptake at One and Three Months Following Radiotherapy With Pre-treatment Uptake of 11C-acetate,2015-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
4763,NCT00161213,Progression-free Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
4764,NCT05205187,Response of target organ,2022-02-28,RECRUITING,OBSERVATIONAL,['NA'],,
4765,NCT03319459,Incidence of dose-limiting toxicity (DLT),2018-01-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK) of FATE-NK100
4766,NCT03496441,Evaluate the feasibility of fecal samples' analysis,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation the presence of a correlation between fecal microbiota composition and the risk of anastomotic leak.
4767,NCT04192071,Information seeking behavior,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],,
4768,NCT05440708,Phase 2: Overall Response Rate (ORR) to TTI-101,2023-03-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cohort A and Cohort B: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples
4769,NCT04779554,Drug Half-Life (T1/2) - Pharmacokinetics,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,
4770,NCT01946854,Tumor Growth Rate,2013-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
4771,NCT01082224,Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC),2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal)
4772,NCT04302363,Diagnostic efficacy of colorectal cancer model in Chinese people,2018-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Effects of intestinal microflora and DNA methylation under different stool characteristics,Effect of diet on intestinal flora and DNA methylation in Chinese people
4773,NCT01234246,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
4774,NCT01962246,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Death related to operation
4775,NCT00385203,"Tumour Metabolic Activity as Assessed by Change in Central Review of Standardised Uptake Value (SUVMax) at Day 29, in Patients With GIST Tumours. SUVmax at Day 29 Minus SUVmax at Baseline.",2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Anti-tumour Activity as Measured by Total Lesion Volume at Week 16 in GIST Patients by Central Review of CT Images.
4776,NCT03500757,Standard System Usability Score on a Likert Scale,2018-04-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
4777,NCT03472833,25(OH) vitamin D,2018-04-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of Life questionnaire
4778,NCT00006009,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4779,NCT05533892,Objective response rate (ORR) at 6 months,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR)
4780,NCT02592603,Number of serrated lesions >=5mm,2015-10,COMPLETED,INTERVENTIONAL,['NA'],,Proportion of minor adverse events
4781,NCT02106871,Skeletal Muscle Fatigue,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
4782,NCT01460589,3-year disease free survival rate,2011-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,side effects of chemotherapy
4783,NCT01972373,Sensitivity of the marker bevacizumab-IRDye800CW,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Collection of safety regarding administration of Bevacizumab-IRDye800CW
4784,NCT02336724,Disease Control Rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
4785,NCT00507273,Current patterns of medical practice in management of patients with GIS,2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
4786,NCT01227239,Phase II: pathological complete response rate,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety
4787,NCT05818267,duration of disease control(DDC),2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of adverse events
4788,NCT03757754,The number of dose-limiting toxicity,2015-06-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Area under the concentration-time curve from zero extrapolated to infinity (AUC0-∞)
4789,NCT01071824,Pouch function 4 month after closure of protective ileostomy.,2009-06,UNKNOWN,INTERVENTIONAL,['NA'],,Pouch function 2 and 12 month respectively after closure of protective ileostomy.
4790,NCT05739110,Overall survival,2022-07-15,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
4791,NCT01211561,Reduction in ACF biomarkers,2010-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
4792,NCT06189898,Progression free survival,2023-12-15,RECRUITING,OBSERVATIONAL,['NA'],,loco-regional recurrence free survival
4793,NCT00003431,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4794,NCT04172532,Progression-free survival rate (Phase II),2021-01-11,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gene signature of cell-free DNA from peripheral blood,Gene signature of tumor
4795,NCT00795184,"Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.",2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
4796,NCT03043313,Confirmed Objective Response Rate (cORR) Per RECIST 1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B,2017-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry)
4797,NCT01834014,To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS),2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma
4798,NCT06164769,blood loss,2023-03-01,RECRUITING,INTERVENTIONAL,['NA'],,
4799,NCT00867724,Ability to screen the entire length of the colon to the cecum.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,"Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events"
4800,NCT02138929,"Maximum Tolerated Dose (MTD) of LDE225 in Combination with Everolimus in Participants with Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction (GEJ) or Stomach in the Second or Third Line Setting",2014-11-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety of LDE225 in Combination with Everolimus in a Cohort of Participants with Metastatic Nuclear Gli-1 Expressing Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach per CTCAE."
4801,NCT03404076,Progression free survival after a three year follow-up,2014-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
4802,NCT04246203,DFS,2021-12-12,RECRUITING,OBSERVATIONAL,['NA'],,
4803,NCT03042416,Immediate safety evaluation,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Perceived clinical benefit
4804,NCT00094809,Grade 4 Neutropenia,2003-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Antibiotic Use Due to Febrile Neutropenia
4805,NCT00451022,To facilitate the continuous usage of stored research specimens collected from subjects under completed and ongoing protocols.,2004-09-13,RECRUITING,OBSERVATIONAL,['NA'],,
4806,NCT02800330,"As primary endpoint, AUC of regorafenib alone and AUC of regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake, respectively) will be related.",2016-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,The clearance of regorafenib alone and regorafenib with esomeprazole (concomitantly and 3 hours before regorafenib intake respectively) will be related
4807,NCT00613743,difference of pain alleviation in the two branches one hour after mouthwash and as well as the duration of pain relief.,2007-12,COMPLETED,INTERVENTIONAL,['NA'],,the requirement of supplementary systemic analgesics
4808,NCT05280379,Levels of pro-inflammatory cytokines en chemokines,2022-09-19,RECRUITING,OBSERVATIONAL,['NA'],Carcino-embryonal antigen,
4809,NCT01246986,Time to Progression (TTP),2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Worsening (TTW) of Symptoms (FACT-Hep)
4810,NCT00010270,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
4811,NCT00982059,The proportion of screened patients with any polyp or any high risk polyp will be calculated.,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Proportion calculation/identification of: demographic/treatment influences on polyp prevalence; subgroups w/polyp prevalence >20%; pts with polyps beyond 30cm flexible sigmoidoscope; pts with adenomatous polyp(s) on colonoscopy in/outside prior RT fields
4812,NCT01640665,Maximum Tolerated Dose / Safety,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response
4813,NCT02915965,overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse event based on CTCAE 4.0
4814,NCT05638048,Incidence of Peripheral central venous catheter-associated thrombosis in patients with PICC tube,2022-07-10,COMPLETED,INTERVENTIONAL,['NA'],,Patients' satisfaction with health education after PICC catheterization
4815,NCT04622098,Estimating the prevalence and types of sub-epithelial lesions among patients undergoing EGDs in Egypt.,2020-11-18,UNKNOWN,OBSERVATIONAL,['NA'],,characterization of SEL in Egypt
4816,NCT02399943,"Percentage of patients who experience complete response, partial response, or stable disease",2015-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Date of first confirmed response to the first date in which progression is observed
4817,NCT06089369,Recurrence-Free Survival (RFS) at 24 Months,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
4818,NCT05987514,predicting HCC response to treatment,2021-10-07,RECRUITING,INTERVENTIONAL,['NA'],,predicting disease-free survival
4819,NCT02325648,pulmonary vascular permeability index,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,
4820,NCT01574027,Reduction in ACF biomarkers,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4821,NCT05686499,ratio of low-fidelity simulator trained endoscopists with improved colonoscopy performance on real patients to high-fidelity simulator trained endoscopists with improved performance on real patients,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
4822,NCT04555265,Early tumor recurrence,2020-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Other tutor recurrence
4823,NCT05303714,Secondary Resectability Rate (percent),2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complication rate
4824,NCT05880472,Number of adverse event per patient per grade by CTCAE v5.0,2023-05,RECRUITING,INTERVENTIONAL,['NA'],Implantation experience by questionnaire to the operator,Operator hand and total body dose (mSv)
4825,NCT01838317,Glucose to Insulin Ratio,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Serum and MRI End Points
4826,NCT04358354,Overall Survival (OS),2020-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment associated toxicities
4827,NCT00974948,"Absolute and relative changes in 7-point Likert-score for abdominal pain at 1 and 3 months post-randomization. Secondary endpoints were change in morphine equivalent consumption (MEQ), quality of life (DDQ-15), and overall survival.",2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,2. Quality of life 3. Survival
4828,NCT00994864,"Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS.",2009-11,COMPLETED,INTERVENTIONAL,['NA'],,Create a frozen tumour bank for future studies
4829,NCT04595838,The incidence of severe oral mucositis symptomatic events observed during the second cycle of chemotherapy.,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],,Analgesic use to control mouth pain
4830,NCT04736121,Duration of Response (DoR),2021-05-28,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life metrics - EQ-5D-5L Questionnaire
4831,NCT02988635,Functional Assessment of Cancer Therapy-General (FACT-G) (Quality of life measure),2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Resource utilization at the end of life (EOL): emergency room admissions
4832,NCT02621658,Adenoma Detection Rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Patient satisfaction
4833,NCT00882869,To evaluate the efficacy of AEG35156 in combination with sorafenib based on PFS(PII) using sorafenib alone for comparison,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine the response rate of AEG35156 in combination with sorafenib in advanced HCC
4834,NCT01560949,Number of Participants With Resectability Rate,2012-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Correlative Studies Including DPC4 (SMAD4) Staining and Circulating Tumor Cells (CTC) Post-Surgery
4835,NCT00758381,Progression Free Survival,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,- overall Response Rate (RECIST Criteria) - duration of response - overall survival time
4836,NCT03499626,Definition of MTD (maximum tolerable dose),2017-05-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression Free Survival
4837,NCT02074202,The pathological diagnosis of the liver tumor will be compared with the test result of the PET/CT scan findings.,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
4838,NCT02845986,overall postoperative morbidity rates,2016-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The variation of prealbumin
4839,NCT02415699,Disease free survival,2015-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Side Effect
4840,NCT02526043,Overall survival,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
4841,NCT01697072,Overall Survival,2012-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Immunogenicity
4842,NCT00983801,Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST),2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Best Response as Assessed With Modified RECIST,Number of Participants With Serum Chemistry Abnormalities
4843,NCT04695847,Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 2: Number of Participants with Corrected QT Interval (QTc)
4844,NCT06084234,Proportion of HCC detected at late stage,2023-12-26,RECRUITING,INTERVENTIONAL,['PHASE4'],,Number of participants who encountered screening related Psychological harm
4845,NCT04514497,Occurrence of grade 4 hematologic AEs (Dose Expansion Phase),2021-10-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor deoxyribonucleic acid damage response (DDR) gene mutations present,Changes in tumor expression patterns of pS343-NBS1
4846,NCT02961998,Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Overall survival
4847,NCT06252974,Accurate diagnose the invasion depth of early esophageal squamous cell carcinoma by endoscopy NBI images through deep neural network analysis,2024-02-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4848,NCT02499939,Functional Assessment of Cancer Therapy Gynecological Oncology Group Neurotoxicity-12 item scale,2016-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Balance Assessment
4849,NCT00062283,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4850,NCT01442324,Effectiveness of IRE for the treatment of metastatic liver cancer or cholangiocarcinoma.,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Time to in situ recurrence
4851,NCT05621707,Overall Survival Rate,2022-11-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment related complications
4852,NCT00593073,Baseline assessment while waiting to see primary care physician and 90-day follow-up telephone survey.,2005-07,COMPLETED,INTERVENTIONAL,['NA'],,Follow-up survey to assess participant discussion of colorectal cancer with their healthcare provider and compliance with CRC screening
4853,NCT05277675,1-year overall survival,2021-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,immune-related adverse events
4854,NCT01601808,Overall survival,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Patient pain assessment
4855,NCT03274427,Progression-free Survival,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
4856,NCT01984658,Safety and tolerability,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Safety & efficacy; Quality of life,Efficacy; Tumor change
4857,NCT02451384,the changes of CTCs countings between the pre and post-operation among the arms,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,
4858,NCT06149546,Effectiveness of a multi-modal nutrition-led intervention in preventing loss of muscle strength (hand-grip strength) during chemotherapy,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Effectiveness of the intervention compared to the control on Overall Survival
4859,NCT05708924,Determine Maximum Tolerated Dose (MTD) of FT538,2023-04-28,SUSPENDED,INTERVENTIONAL,['PHASE1'],Tumor biopsies (if feasible) at the time of catheter placement and catheter removal for study related analysis,Adverse Events
4860,NCT02448966,Long term survival,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative complications
4861,NCT00436514,,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,
4862,NCT05368051,pathologic complete response（pCR）,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
4863,NCT05612477,Feasibility -Accrual,2023-01-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Safety- HCC recurrence
4864,NCT03925883,Rate of follow-up colonoscopy,2019-07-29,COMPLETED,INTERVENTIONAL,['NA'],,
4865,NCT05022030,Progression free survival (PFS) rate at 9 months,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event rate
4866,NCT06181201,histological response according to Ryan classification,2024-01-19,RECRUITING,OBSERVATIONAL,['NA'],,
4867,NCT05983406,DEP accuracy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
4868,NCT01583699,Qualitative MALT-features on Endomicroscopy,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and Specificity of Endomicroscopy to diagnose GI-MALT-Lymphoma
4869,NCT04292496,Anastomotic leakage,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative surgical complications
4870,NCT04206254,2-year recurrence-free survival rate,2019-12-19,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival
4871,NCT00002655,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
4872,NCT05327452,Change in Physical Activity Participation,2022-10-31,RECRUITING,INTERVENTIONAL,['NA'],,Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein
4873,NCT05118724,Disease-free Survival (DFS),2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4874,NCT05617430,Progression free survival (PFS) per RECIST v1.1,2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
4875,NCT00124163,,2005-07,UNKNOWN,OBSERVATIONAL,['NA'],,
4876,NCT04430985,Disease-free Survival at 3 years,2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Explorative analysis of biomarkers predictive of response to the combination of nivolumab, ipilimumab in combination with FOLFOX",Safety and tolerability of the treatment
4877,NCT01347697,Performance in Timed-Stands Test,2011-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Local recurrence
4878,NCT01196494,,na,TERMINATED,INTERVENTIONAL,['NA'],,
4879,NCT05797870,The objective response rate,2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
4880,NCT03422601,disease-free survival (DFS),2017-07-13,UNKNOWN,OBSERVATIONAL,['NA'],,
4881,NCT02869503,Survival of patients with colorectal cancer,2001-01,RECRUITING,OBSERVATIONAL,['NA'],,Collection of patients characteristics
4882,NCT00077298,Time to tumor progression,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
4883,NCT02647671,Colonic-mucosal Associated Metabolomic Profile.,2016-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarkers of liver function
4884,NCT05030493,Progression-Free Survival (PFS),2021-08-31,RECRUITING,OBSERVATIONAL,['NA'],,"Evaluation of Correlation between Change in Gene Expression Region in Tumor Tissue at Baseline and Discontinuation of Protocol Treatment of Main Study, and Efficacy Endpoints (OS and PFS)"
4885,NCT03890354,Post operative compliction,2019-02-21,COMPLETED,OBSERVATIONAL,['NA'],,Surgical outcome
4886,NCT00524121,Overall Survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response by EGFR Mutation Status
4887,NCT02916199,Incidence rate of post-endoscopic retrograde cholangiopancreatography,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],,Success rate of stone removal
4888,NCT05969899,Objective Response Rate（ORR）,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate（DCR）
4889,NCT05175092,Overall Survival (OS),2023-11,WITHDRAWN,INTERVENTIONAL,['NA'],,Quality of Life Survey Score: EORTC QLQ-LMC21
4890,NCT06009484,Postoperative venous thromboembolic event,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
4891,NCT05453435,12-month HBV reactivation rate,2022-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of HBV-related chemotherapy disruption
4892,NCT02119065,Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values,2014-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient
4893,NCT04461561,"The NoMAD Instrument, to describe respondents' experiences of using the intervention in the workplace.",2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,"The interview, using framework analysis, informed by normalization process theory toolkit"
4894,NCT04847063,To determine the correlation between ex vivo simulated HIPEC in the SMART system and in vivo HIPEC with respect to two measures of response to treatment: percent necrosis and Ki-67,2021-10-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,To measure Quality of Life by FACT-C and EQ-5D-5L
4895,NCT00621036,Safety and tolerability,2007-10-19,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Kinetics of humoral immune response development
4896,NCT02699606,Objective Response Rate (ORR),2016-07-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentration of Erdafitinib
4897,NCT05512182,objective response rate (ORR),2022-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0
4898,NCT04687631,Conversion resection rate of liver metastases,2021-01-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,time interval from chemotherapy to hepatectomy
4899,NCT00940316,Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD),2010-01-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect on Downstream Targets of Epidermal Growth Factor Receptor (EGFR) in Skin Rash Associated With Pharmacologic EGFR Inhibition
4900,NCT01669668,"Local recurrence, defined as the recurrence at the size of original tumor",2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Ability of patients who develop recurrence to undergo salvage transplantation
4901,NCT03089268,Risk of developing metachronous advanced lesions or cancers,2017-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Prevalence of serrated lesions in FOBT screening population
4902,NCT03628079,Tumour response: CT/MRI assessed according to RECIST 1.1,2018-05-25,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Association between S-mebendazole and efficacy and safety,Change in tumour load and TTP according to irRECIST
4903,NCT01392027,Validation of glycoprotein panel as a pancreatic cancer biomarker,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,
4904,NCT01422928,Changes in immune biomarker levels,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Changes in Symptom Scores
4905,NCT05469061,pCR,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free Survival，DFS
4906,NCT04217083,Test Sensitivity and specificity for colorectal cancer,2019-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,Test Sensitivity and specificity for colorectal polyps
4907,NCT04787354,disease-free survival,2021-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity profiles
4908,NCT00159445,"To assess time to progression in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease, and having failed both CPT-11 and Oxaliplatin bas",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To test the hypothesis that increased gene expression levels predict chemoresistance to capecitabine.
4909,NCT01276379,Progression Free Survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumoral Response
4910,NCT02276300,Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4911,NCT04033107,Progression-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v3.0
4912,NCT03990532,Overall survival (phase II),2019-04-30,RECRUITING,INTERVENTIONAL,['NA'],,1-year local progression-free survival
4913,NCT02066233,Median Tolerability Score on 10-point Visual Analog Scale (VAS),2014-03,COMPLETED,INTERVENTIONAL,['NA'],,"Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy"
4914,NCT01693861,Effect of chemotherapy on urinary excretion of modified nucleosides,2012-10,COMPLETED,OBSERVATIONAL,['NA'],Identification of modified nucleosides as biomarkers for colorectal cancer,
4915,NCT00003652,,1999-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4916,NCT04512417,Progression-free Survival (PFS) per RECIST 1.1,2020-08-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Failure mode
4917,NCT03995017,Overall Response Rate (ORR),2020-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
4918,NCT04494945,Cascade screening rate among Lynch or HBOC positive carriers,2020-03-09,RECRUITING,INTERVENTIONAL,['NA'],,
4919,NCT02693847,Proportion of patients who developed a first liver decompensation of cirrhosis during follow-up,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,All cause mortality
4920,NCT05412576,The incidence of moderate to severe pain (NRS score≥4）during movement (i.e.deep breathing) 24 hours after surgery,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
4921,NCT00193817,Overall survival,2005-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of Life
4922,NCT01077869,Feasibility of FDG-PET in the evaluation of radiation-induced mucositis.,2010-01,TERMINATED,OBSERVATIONAL,['NA'],,
4923,NCT02638766,Disease Control Rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life by EQ-ED-5L questionnaire
4924,NCT00416793,Overall Survival Rate at 6 Months,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
4925,NCT04915599,Change in Feasability Questionnaire (regarding Patient reported tolerance of cryotherapy with Cooral ®),2021-06-22,COMPLETED,INTERVENTIONAL,['NA'],,Change in degree of acute OM up to 6 weeks after EOT
4926,NCT05801666,Arts' Dumping Questionnaire,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Medical charts and drug use.
4927,NCT06286956,Assess that the use of the device meet the established functional requiremnt of allowing the removal of polyps,2021-04-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of anorectal continence
4928,NCT00004234,,1999-08-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
4929,NCT03655223,Incidence Rates: Number of newborns who screen positive comparative to the whole sample,2018-10-15,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Impact of Screening: Semi-structured parent interviews.
4930,NCT04181970,Percentage of patients with advanced GIST with available molecular status of KIT/PDGFR before initiating systemic therapy for advanced disease,2019-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of amputation
4931,NCT01060423,Progression free survival rate,2010-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
4932,NCT03516448,OS （Overall Survival）,2016-03-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,RFS(Recurrence Free Survival)
4933,NCT02205398,Incidence of Dose Limiting Toxicities (DLTs),2014-07-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
4934,NCT05822752,Best Overall Response (BOR) per Investigator,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4935,NCT03196791,Number of Retrieved Lymph Nodes Per Participant,2017-10-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Intraoperative Blood Loss Amount
4936,NCT04718038,Progression-free survival(PFS),2016-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Safety
4937,NCT00633334,"The first goal of this proposal is to collect cells from the peripheral blood, tumor draining lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage gastrointestinal cancers.",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,"The second goal is to evaluate using novel proteomic, CellomicTM, and genomic techniques the serum and peripheral blood lymphocytes of these patients for protein, cellular changes and genetic markers that correlate with the presence of cancer."
4938,NCT02570893,The overall survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Scores of Quality of life
4939,NCT00225745,To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls,2004-04,COMPLETED,OBSERVATIONAL,['NA'],,To generate hypotheses for future studies and treatment based on the findings
4940,NCT03895359,Time to Intrahepatic Progression,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-benefit
4941,NCT03227926,Overall response rate (ORR) to panitumumab according to RECIST v1.1.,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity according to CTCAE version 4.03.
4942,NCT05174325,Pathologic complete remission (PCR),2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiographic response
4943,NCT06325267,Clinical characteristics of overall cohort by liver disease etiology,2010-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors of prognosis in overall cohort and different etiologies
4944,NCT00711412,Determine Pathologic Complete Response,2006-05-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlate Proteomic and Pharmacologic Characteristics With Prognosis and Response to Therapy.
4945,NCT05174286,CRC Screening Uptake,2023-03-19,RECRUITING,INTERVENTIONAL,['NA'],,Change in Life's Simple 7 Score (CVD Risk Screening Measure)
4946,NCT02164448,gas passing,2014-06,COMPLETED,INTERVENTIONAL,['PHASE4'],soft diet time,sips of water time
4947,NCT05179824,Create robust data set of health information,2020-10-19,RECRUITING,OBSERVATIONAL,['NA'],Review medical information for standard of care decisions and health outcomes,Evaluate longitudinal paired tissue and cell free molecular testing
4948,NCT04804956,Identification of mesorectal microbial biomarkers as prognostic factor for rectal cancer,2021-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of mesorectal dysfunctionality and dysbiosis on tumor progression
4949,NCT02192983,Response rate,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
4950,NCT05247905,Progression free survival (PFS),2022-03-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in Overall Quality of Life Question (Q30) from the EORTC QLQ-C30 questionnaire
4951,NCT01514045,Collect detailed clinical and epidemiological information on patients with gastric cancer; with a family history of gastric cancer in a first or second degree relative; or persons with a known germline mutation in their CDH1 (E-Cadherin) gene,2011-04,RECRUITING,OBSERVATIONAL,['NA'],,
4952,NCT05829291,Safety - Adverse events,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,To evaluate the radiological response of liver metastases using the RECIST criteria .
4953,NCT04554771,Efficacy defined as pathological response to chemoradiotherapy according to the Mandard criteria,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Predictive biomarkers using oa RNA sequencing,Feasibility delay
4954,NCT01595217,"EHCC performance on DWI, ADC map and MRCP",2012-03,COMPLETED,INTERVENTIONAL,['NA'],,"ADC, SNR, CNR and SIR for EHCC lesion under different b values"
4955,NCT02055313,Qualitative Data Collection: Patients' Experience of Exceptional Disease Course,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
4956,NCT02868242,Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event,2016-08-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Virologic Failure
4957,NCT05496270,3-year diseases free survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence rate
4958,NCT02335411,Objective Response Rate For PD-L1 Positive Participants in Cohorts 1 and 3,2015-02-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate For PD-L1 Positive Participants
4959,NCT01867918,Overall survival from time of randomization,2013-05,TERMINATED,INTERVENTIONAL,['NA'],,
4960,NCT02192541,Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept,2014-12-02,TERMINATED,INTERVENTIONAL,['PHASE1'],Number of Participants Who Had a Dose Limiting Toxicity (DLT),Number of Cycles on Treatment
4961,NCT01492907,Pharmacokinetic Metabolite Profile of Radiolabeled MeIQx in Urine,2012-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quantify ambient adducts in the human pancreas
4962,NCT04981665,2-year Recurrence Free Survival Rate (2-year RFS rate),2021-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
4963,NCT02157363,operating time,2014-06-16,TERMINATED,INTERVENTIONAL,['NA'],,
4964,NCT02072486,Overall survival (OS),2013-11-18,COMPLETED,INTERVENTIONAL,['NA'],Proportion of cluster of differentiation (CD)8+ T cells expressing granzyme B,"Granzyme B level variations by presence of grade 3 or higher AE, characterized using National Cancer Institute Common Terminology Criteria for Adverse Events severity grade"
4965,NCT05788874,SUVmax,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
4966,NCT01383707,Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS),2011-08-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
4967,NCT00719797,Progression free survival,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Surrogate markers predictive of bevacizumab activity
4968,NCT06147037,Maximum tolerated dose of [225Ac]-FPI-2068 and FPI-2053,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To assess the immunogenicity of [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053"
4969,NCT00303745,Stable disease rate,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free and overall survival
4970,NCT04829383,Frequency and severity of toxicities,2021-03-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival (OS)
4971,NCT05892354,The incidence of severe oral mucositis,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with adverse events
4972,NCT02382263,"PHASE II: Evaluate the effectiveness of two selected schemes of gemcitabine and nab-paclitaxel, vs. gemcitabine alone. (Six months overall survival)",2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: change in FAP and Cav-1 tumor markers as an inidicatior of treatment efficacy
4973,NCT02063230,"Dose Normalized Cmax, Unbound Selumetinib",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4974,NCT05648955,Change in cross-sectional skeletal muscle mass area on the third vertebral level (L3) [cm2],2023-03-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Change in physical function,Change in health-related quality of life as measured with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 global health score)
4975,NCT01349517,Health related quality of life,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Morbidity Mortality Survival rate
4976,NCT01688908,Cost for saving 1 quality-adjusted life year (QALY),2012-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change of life quality due to early diagnosis and treatment
4977,NCT03922152,"Assessment of symptoms [odynophagia, chest-back pain, dysphagia, regurgitation]",2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of the Overall Survival
4978,NCT04751955,Progression free survival,2022-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life by FACT-C v4.0
4979,NCT00868569,overall survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,resection rate of liver metastasis progression-free survival
4980,NCT05194072,Number of participants with dose limiting toxicities (DLTs),2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADAs)
4981,NCT02613650,Incidence of dose limiting toxicities (DLTs) of combination MEK162 and mFOLFIRI,2016-08-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
4982,NCT06167421,Severe complication rate,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative quality of life assessment
4983,NCT05051475,Level of late post-procedural pain (at day 30 after treatment),2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The rate of complications
4984,NCT03391934,Progression Free Survival (PFS),2018-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,immunogenicity
4985,NCT05180864,Overall survival,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness
4986,NCT00681876,Time To Progression,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Quality of life, Symptoms improvement"
4987,NCT01541709,progression-free survival (PFS),2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,percentage of successful dose escalation
4988,NCT06233708,Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate Cox regression analysis of overall survival at 5-year follow-up
4989,NCT03482791,Physician-reported toxicity of PBT for esophageal cancer,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)of PBT for patients with resectable versus unresectable esophageal
4990,NCT03449264,Proportion of patients who consent to participate in the study,2017-07-27,RECRUITING,INTERVENTIONAL,['NA'],Quality of life assessment at baseline for all participants in the study,
4991,NCT04751591,Early operative mortality rate,2021-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,En bloc resection rate
4992,NCT05030363,Change of FACIT-F score,2021-10-25,UNKNOWN,INTERVENTIONAL,['NA'],,"Exploratory biomarker studies - Urine malondialdehyde - ALDH2 polymorphism (ALDH2 *1/*2, rs671 A/G) - Change of inflammatory cytokines"
4993,NCT01369420,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy
4994,NCT03623984,Comparison of intraoperative findings to preoperative PET scan findings,2019-06-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement
4995,NCT05423886,Detection rate of colorectal cancer and advanced adenomas,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Acceptability
4996,NCT01339650,Pharmacokinetic profile,2011-05-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety (number of subjects with adverse events and/or dose limiting toxicities)
4997,NCT05788224,mortality and morbidity correlated with the management of older (=>75 years old) patients admitted to emergency department with a complicated colorectal cancer,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
4998,NCT05461430,BOR,2022-07-15,RECRUITING,OBSERVATIONAL,['NA'],,PFS
4999,NCT04679597,pathological complete response,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],number of participants with acute side effects,Neoadjuvant rectal cancer score
5000,NCT01415089,Quality of life,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Satisfaction with intervention
5001,NCT00965965,Comprehension of randomly assigned educational document,2009-08,COMPLETED,INTERVENTIONAL,['NA'],,Readiness to undergo colorectal cancer screening
5002,NCT05613478,Recurrence-free survival (RFS),2022-11,RECRUITING,INTERVENTIONAL,['PHASE3'],,Safety and toleraty
5003,NCT04282980,Progression-Free Survival(PFS) based on independent imaging review,2020-04-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate(DCR)
5004,NCT03389126,response rate,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5005,NCT06245356,Treatment specific safety,2024-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Colorectal (QLQ-CR29)
5006,NCT01789658,Mucositis grade - WHO Oral Toxicity Scale,2012-10,COMPLETED,INTERVENTIONAL,['NA'],S-Albumin,Emotional and Psychological status
5007,NCT01198145,Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT),2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Patients in Each Arm That Experience Clinically Significant Deficits in Overall Quality of Life and Fatigue
5008,NCT02797405,Validation of the correlation between the clinical tumor response and the results of A/MS bioassays using tumor samples,2016-10,TERMINATED,INTERVENTIONAL,['NA'],,Validation of the correlation between the healthy tissue response (i.e. AE reported as per CTCAE v4) and the results of MS/A bioassays using skin biopsies
5009,NCT03454620,Dose Limited Toxicity (DLT),2018-04-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunogenicity of GC1118
5010,NCT03258541,Clinical performance,2017-01-15,TERMINATED,INTERVENTIONAL,['NA'],,Comparative dosimetric studies
5011,NCT06066931,The assessment of the frequency of early postoperative complications,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The assessment of the frequency of late postoperative complications and quality of life
5012,NCT05674123,Incidence of adverse events,2020-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
5013,NCT00256334,Test the hypothesis that resveratrol modulates Wnt signaling in vivo in colon cancer and normal colonic mucosa,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5014,NCT05181488,3-year local recurrence rate,2020-04-02,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
5015,NCT04172571,Objective response rate (ORR),2018-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects who develop detectable anti-drug antibodies (ADAs)
5016,NCT04947020,Overall survival,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Lymph node ratio,Disease-free survival
5017,NCT06315101,Survival analysis,2023-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events assessment
5018,NCT04162535,Evaluation of patients serum on cell culture,2018-11-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival Comparison
5019,NCT04869618,Diagnostic performance of SPECTRA IMDx for assessment of lower risk lesion (GIM/LGD/Gastritis/Normal) and higher risk lesions (HGD/EGC) against the gold standard of histopathology from gastric resection specimen,2021-05,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of performance of HD-WLE combined with NBI in detection of HGD/EGD prior to ER.
5020,NCT05939687,hernia rate,2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life indicators by HerQLes scale
5021,NCT00101348,MTD of bevacizumab combined with cetuximab and erlotinib hydrochloride determined by DLT graded according to the CTCAE version 3 (Part II),2005-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
5022,NCT06166589,ORR,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
5023,NCT01798134,Freedom From Tumor Progression at 6 Months,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,12 Month Survival
5024,NCT01438450,Survival,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from baseline in Child status at 1 year
5025,NCT00376987,Reversal of cadmium-induced inhibition of mismatch repair,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5026,NCT04232384,Yield of malignant cells,2020-06-15,TERMINATED,INTERVENTIONAL,['NA'],,Cellularity of the smear of the smear
5027,NCT02087475,Progress Free Survival,2011-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Life Quality
5028,NCT01765673,Change in Swallowing Frequency 70 & 110 Hz,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Change in Swallow Initiation Time
5029,NCT03259035,Measurement of organ preservation rate,2018-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost effectiveness using the EQ-5D-5L questionnaire
5030,NCT00477711,Tumor response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety"
5031,NCT01381822,To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib.,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by the response rate and the progression-free survival in subjects with advanced RCC treated at the RP2D.
5032,NCT01004159,12-week Progression Free Survival Rate Upon Escalation of Cetuximab Dose to 500mg/m2 in Combination With Irinotecan After Progression on Standard Dose Therapy in Patients With KRS Wild Type Colorectal Cancer,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate of Cetuximab 500mg/m2/Week in Combination With Irinotecan in the Enrolled Patient Population
5033,NCT02748772,PFS,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,RR
5034,NCT01736904,Progression free survival which is calculated from the start of treatment to disease progression or death,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival which is calculated from the start to treatment to the death,Objective response rate which includes complete response(CR) and partial response(PR) participants
5035,NCT00974610,Detection of peptide and protein markers in serum,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,Identification of the protein/peptide involved
5036,NCT03250637,Colorectal cancer,1993-12,COMPLETED,OBSERVATIONAL,['NA'],,
5037,NCT01845675,overall response rate,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicities
5038,NCT06205836,Complete Response Rate,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing grade 3 or above drug-related toxicities requiring treatment discontinuation
5039,NCT01493336,Relative bioavailability: Area under the concentration-time curve (AUC),2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety: Incidence of adverse events
5040,NCT05171166,Progression-free survival,2021-12-24,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of paitents with treatment-related adverse events
5041,NCT02715141,life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,presence of previously identified progression biomarker on resected tissue samples of polyps
5042,NCT02273141,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
5043,NCT02788526,Overall survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
5044,NCT06214988,textbook outcome; stoma-free survival at two years without major LARS,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30)
5045,NCT00522665,To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001"
5046,NCT04846309,"frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment",2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pathological complete response (pCR) rate
5047,NCT05985252,Calculation postoperative of the Comprehensive Complication Index (CCI) for each patient,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adjuvant chemotherapy in patients after low anterior resection for rectal cancer.,Total hospitalization costs
5048,NCT00786006,Progression-free survival,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
5049,NCT06089382,Recurrence-Free Survival (RFS),2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
5050,NCT02336087,"Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4)",2016-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Quality of life, assessed using the FACT-G questionnaire",Time to treatment failure
5051,NCT01243372,Progression-free survival as measured by RECIST,2009-11,COMPLETED,OBSERVATIONAL,['NA'],,tumor response as measured by RECIST
5052,NCT04451603,"Use of prediction software or tools to estimate volume and health of the future liver remnant (FLR), monitor changes in liver volume and health post treatment",2018-10-19,COMPLETED,OBSERVATIONAL,['NA'],,
5053,NCT00898378,Creation of an OMIC profile to predict the risk of colorectal cancer (CRC),2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Identification of interactive molecular pathways that underlie the development and progression of CRC
5054,NCT03792932,Recurrence Free Survival,2019-02-02,RECRUITING,INTERVENTIONAL,['NA'],,Detected lymph node number
5055,NCT01646697,Local recurrence at the site of resection,2011-11-07,COMPLETED,INTERVENTIONAL,['NA'],,
5056,NCT06220058,Incidence of incisional hernia.,2024-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Morbidity and mortality rates
5057,NCT01391611,Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD),2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Per Choi Criteria
5058,NCT04548947,Incomplete resection rate (IRR),2021-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Incomplete resection of colorectal polyps
5059,NCT01075893,Number of stem cells in the colonic crypt,2010-02,COMPLETED,OBSERVATIONAL,['NA'],,Stem cell position in colonic crypt
5060,NCT01466569,"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination",2011-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
5061,NCT01532427,Safety,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,usability
5062,NCT04916054,to determine whether the time between each anti-tumor therapy has a prognostic impact on recurrence-free survival,2021-06-04,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate the impact on overall survival
5063,NCT04145141,"To establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression",2021-07-28,RECRUITING,OBSERVATIONAL,['NA'],,To estimate 3 years progression-free survival following immunotherapy for PLC
5064,NCT01489566,RFS(Recurrence Free Survival),2011-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QOL score
5065,NCT04715074,Impact of #iBeatCRC Mass Media Campaign on EOCRC early detection benefit.,2023-05-27,COMPLETED,INTERVENTIONAL,['NA'],,
5066,NCT03525067,Postoperative infectious complications at postoperative day 90,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality post operative day 90
5067,NCT02119663,Overall Survival (OS),2014-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Participants With Treatment-Emergent Adverse Events (TEAEs)
5068,NCT05435053,Incidence of treatment related adverse events [Safety and Tolerability],2022-09-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life using EORTC QLQ-C30
5069,NCT01242605,"To investigate the safety and tolerability of the combination of cisplatin, gemcitabine and selumetinib, and to establish the recommended phase II dose of selumetinib when given in this combination.",2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate
5070,NCT03746249,Progression Free Survival (PFS),2018-12-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
5071,NCT02646462,Ratio of malignant/total number of lymph nodes,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],,Number of N1 patients
5072,NCT01766661,post-operative morbidity,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],,local and/or distant recurrence of neoplasm
5073,NCT00601198,"Test Drug in 28 Patients and Assess PSN. If 5 or More Have Grade 3 & 4 PSN, Trial Will be Terminated.",2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assess PSN in 69 Patients. If Total Number of Cumulative PSN is > or Equal to 14, Drug Will be Rejected."
5074,NCT02395640,progression free survival,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life questionnaire
5075,NCT02889679,Incomplete resection rate (histologic),2016-09,COMPLETED,INTERVENTIONAL,['NA'],,
5076,NCT04888403,Pathologic Complete Response(pCR),2021-12-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,postoperative complications rate
5077,NCT04473625,Stool-based test for colorectal cancer,2020-07-21,COMPLETED,OBSERVATIONAL,['NA'],,
5078,NCT01286883,Primary endpoint: correlation of stem cell markers on CTCs with response to therapy,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs
5079,NCT02537340,Detection rate,2016-09,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
5080,NCT02351219,Radical resection rate,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Progression-free survival
5081,NCT02407977,Dosimetric accuracy of the device with reference to a commercially available dosimeter,2015-11-13,COMPLETED,OBSERVATIONAL,['NA'],,Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.
5082,NCT00053222,Objective response,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5083,NCT02550119,"Proportion of patients with complete response, defined as no emesis and no use of rescue medication",2006-04-19,TERMINATED,INTERVENTIONAL,['NA'],,Proportion of patients who agreed to be randomized out of all patients who qualify for randomization
5084,NCT01360086,Non-toxicity rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as assessed by QLC-C30 and STO-22 questionnaires
5085,NCT05221398,Recurrence-free survivial,2019-03-03,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
5086,NCT01217034,Overall Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to Extrahepatic spread
5087,NCT02585908,Reduced size of the tumor.,2019-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety, as measured by the rate of adverse events and serious adverse events"
5088,NCT04731220,Number and percentage of cases and controls who complete each part of the study,2020-07-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
5089,NCT05955196,Establishment of patient derived organoids (minimum n=30) resembling the primary tissue sample,2023-01-09,RECRUITING,OBSERVATIONAL,['NA'],,"To assess the effect of immunotherapy on the antitumor activity of autologous T cells from peripheral blood samples using tumor viability measurements (cell titer glo, FACS)"
5090,NCT03286348,Local Control rate,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
5091,NCT03100708,Overall Survival (years),2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of lfe questionnaire (EORTC QLQ-C15-PAL)
5092,NCT04037007,Cannulation success rate within 5 minutes,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,Technical success
5093,NCT01419483,Frequency of Adverse Events (Safety),2011-07,TERMINATED,INTERVENTIONAL,['NA'],,Progression Free Survival (months)
5094,NCT02827682,Duration time in PACU,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,length of hospital stay (LOS)
5095,NCT03698253,Progression-free survival,2013-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Rate of treatment-associated adverse events.
5096,NCT05038254,Rate of acute care visits,2021-05-12,RECRUITING,INTERVENTIONAL,['NA'],,Change in symptom management
5097,NCT03692429,Occurence of Dose Limiting Toxicities,2018-11-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5098,NCT05472753,Change in the alpha diversity index (Shannon),2022-11-16,UNKNOWN,INTERVENTIONAL,['NA'],,Change in stool calprotectin
5099,NCT02295774,Gamma H2AX Histone Levels in Colonic Biopsy During Standard White Light Colonoscopy and Colonoscopy for Which Methylene Blue MMX Was Taken Prior to Initiating the Colonoscopy,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To Evaluate the Staining Quality Obtained With Oral Methylene Blue MMX® Tablets.
5100,NCT04833036,PFS,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR
5101,NCT00003157,Maximum tolerated dose,1998-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
5102,NCT04166435,Overall Response Rate,2020-06-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5103,NCT01882478,Response,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,Predictors of response
5104,NCT02614157,3-year local recurrence,2016-05,TERMINATED,INTERVENTIONAL,['NA'],,postoperative complications
5105,NCT05746962,proportion of colonoscope loop formation,2023-03-06,RECRUITING,INTERVENTIONAL,['NA'],,evaluation of risk factors about loop formation
5106,NCT04984096,Progression-Free Survival (PFS),2021-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival (OS)
5107,NCT00534001,Prequit Change in Cigarettes Per Day,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abstinence
5108,NCT04781270,conversion resection rate,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Early tumor shrinkage
5109,NCT05147168,Quality of Life(SF-36),2021-11-22,RECRUITING,OBSERVATIONAL,['NA'],,
5110,NCT02565641,Overall objective response rate,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5111,NCT05571098,Psychosocial Adjustment to Illness Scale (PAIS-SR) scores should be lower in the NNP applied group than in the non-applied group.,2021-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
5112,NCT04049461,Bone alkaline phosphatase,2019-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Incidence of distant metastasis and local recurrence
5113,NCT02396498,DFS: Disease-Free Survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety as measured by Adverse Events and Serious Adverse events In the process of the total treatment according CTCAE4.0
5114,NCT03294343,Occult cancer or precancerous lesion in histological specimen,2017-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of primary uterine cancer
5115,NCT00378716,Compare the relative efficacy of UFT + LV with that of 5-FU + LV in prolonging disease-free survival and survival,1997-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare quality of life in patients with stage II and III carcinoma of the colon treated with either 5-FU + LV or UFT + LV regimen
5116,NCT01834235,Overall Survival,2013-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunologic Correlates
5117,NCT00007826,,2000-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5118,NCT03203525,Incidence of adverse events,2020-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarker analysis
5119,NCT02861209,Change in self-management skills,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure,Cost of care
5120,NCT00004879,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5121,NCT03601923,Progression Free Survival,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of the safety and tolerability of niraparib as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)
5122,NCT01902953,Efficacy of Lymphoseek for Detection of Sentinel Nodes,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Localization Rates
5123,NCT05943444,Low Anterior Resection Syndrome (LARS) score 1 year after surgery,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of postoperative anastomotic complications
5124,NCT01911988,Disease Free Survival,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],,5 years overall survival
5125,NCT01209325,Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants,2011-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level"
5126,NCT01749956,Pathologic Complete Response Rate,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experienced Serious or Non-Serious Adverse Events as a Measure of Safety.
5127,NCT04517643,Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT,2020-11-12,COMPLETED,INTERVENTIONAL,['NA'],,
5128,NCT00354705,Occurence of Recurrent Colon Cancer,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5129,NCT00066716,Pathological response rate at time of surgical resection,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities and safety
5130,NCT01923987,R0 resection rate,2012-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
5131,NCT06209099,Organ-preservation rate,2023-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Major adverse events
5132,NCT03337841,One-year recurrence-free survival rate,2017-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
5133,NCT04010006,operating time,2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,3-year overall survival rate
5134,NCT03560817,Health utilities for SF-6Dv2 after the start of the chemotherapy,2017-01-04,COMPLETED,OBSERVATIONAL,['NA'],,Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy
5135,NCT01619475,Pain control in living donors following partial hepatectomy,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
5136,NCT01695447,pancreatic fistula,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Hospital stay
5137,NCT00383760,Objective Response (Complete and Partial) Evaluated Using RECIST Criteria,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Stable Disease Rate
5138,NCT02287025,Proportion of Patients Who Discontinue Prior to Documented Progression of Disease (PD) or Death,2014-11-11,TERMINATED,INTERVENTIONAL,['PHASE4'],,Satisfaction of Investigator/Nurse With Enhanced Drug-specific Information Via SMART Questionnaire
5139,NCT02140723,Interaction between the status of the biomarker TP53 and response to treatment,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival
5140,NCT00003591,To determine the one-year and median survival rates after PXRT,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To correlate p53 status with treatment response to PXRT
5141,NCT01191814,Complications related to stent dysfunction,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Procedural complications
5142,NCT05289726,incidence of grade 3 hand-foot skin reaction,2022-04-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,tumor control rate
5143,NCT04919824,Procedure time,2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Delayed post-procedural adverse event
5144,NCT03096054,Determination of the maximal dose,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine the median progression
5145,NCT05170360,1. association between some risk factors and colorectal cancer,2021-12,UNKNOWN,OBSERVATIONAL,['NA'],,1. Estimation of KRAS and BRAF genes mutations associated with CRC. 3. Association between these risk factors and gene mutations on different types of CRC.
5146,NCT00568750,Response as assessed by fusion PET/CT scan according to EORTC PET Study Group criteria,2008-01-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse drug reactions according to NCI CTCAE v3.0
5147,NCT05143151,Objective response rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival rate (OS)
5148,NCT02588443,Number of Adverse Events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5149,NCT04797923,Rate of R0 resection,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5150,NCT03891784,Objective response rate (ORR),2019-10-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5151,NCT01882205,The difference in total number of neoplastic lesions detected by chromoendoscopy and virtual chromoendoscopy,2008-05,UNKNOWN,INTERVENTIONAL,['NA'],Number of biopsies per colonoscopy taken in the different groups.,The difference in the ratio number of neoplastic lesions/ total number of lesions between chromoendoscopy and virtual chromoendoscopy
5152,NCT01789983,"To measure the feasibility of implementing the WWE program among cancer patients, age ≥60, as they undergo cytotoxic chemotherapy treatment.",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,To measure relationships between physical activity levels and p16 levels.
5153,NCT03392571,To evaluate 2 year survival from date of entry into study,2018-08-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to Recurrence
5154,NCT01863745,Number of participants with adverse events,2013-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5155,NCT06303583,Complete pathological response rate,2022-06-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety will be analyzed through the incidence of adverse events, serious adverse events"
5156,NCT01819961,infective complications,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,plasma immunological markers
5157,NCT05741372,"Maximum measured concentration of the analyte in plasma) for each component of the transporter cocktail: digoxin, furosemide, metformin, and rosuvastatin (Cmax)",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,
5158,NCT00427973,Progression-free Survival,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5159,NCT05253651,Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR),2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to meaningful change in EORTC QLQ30 score
5160,NCT06162143,Low Anterior Resection Syndrome (LARS) score,2023-11-15,RECRUITING,OBSERVATIONAL,['NA'],,Diarrhea
5161,NCT05718349,Microbial composition,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5162,NCT04973098,Adverse Event of Special Interest,2021-08-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
5163,NCT00089024,Number of Participants Experiencing Grade 3-4 Toxicity While Receiving the Study Treatment,2004-02-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5164,NCT02508389,Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Tumor Outcomes Defined as Locoregional Failure, Distant Metastases, Disease Progression and Deaths"
5165,NCT04605796,ORR,2020-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],ADA,Overall survival (OS)
5166,NCT02720601,Progression-free survival (PFS),2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Toxicity
5167,NCT01750619,Technical success.,2011-07,RECRUITING,OBSERVATIONAL,['NA'],,Endoscopic en bloc resection rate
5168,NCT01175460,Maximum tolerated dose (MTD) of s-1 in combination with nedaplatin and thoracic radiotherapy,2010-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate
5169,NCT02446574,Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint),2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)
5170,NCT02765620,Evaluate treatment response by PERCIST to RECIST 1.1 criteria after the whole treatment process,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,PFS
5171,NCT01688232,relapse in relation with the immunoscore determined on a tumor section.,2012-09-27,UNKNOWN,OBSERVATIONAL,['NA'],,relapse in relation with the immunological events and psychological status of the patient during the monitoring
5172,NCT03910140,The response to treatment,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Lifetime (months)
5173,NCT02592902,Occurrence of EER (percentage),2014-04,COMPLETED,INTERVENTIONAL,['NA'],,Presence of pepsin
5174,NCT01092975,Safety: the presence or absence of mucosal or systemic toxicity related the the topical application of phenylephrine.,2010-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Efficacy: the the mucositis severity area-under-the-curve (AUC) where the severity of oral mucositis on each treatment day will be scored, summed, and plotted graphically."
5175,NCT03840928,RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health),2015-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
5176,NCT06229197,Incidence of reflux gastritis assessed according to RGB classification,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Long-term complications
5177,NCT04752670,Technical Success rate,2021-05-27,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events
5178,NCT05785234,Total consumption of fentanyl in 24 hours after surgery,2023-04,RECRUITING,INTERVENTIONAL,['NA'],,
5179,NCT06267703,Chronic atrophic gastritis,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5180,NCT04443049,Progressive disease requiring change of therapy in both groups,2020-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Decompensation of underlying cirrhosis in both groups
5181,NCT03989180,"Performance of the C-Scan system in terms of communication between the C-Scan Capsule and the System Track in different locations, positions and configurations.",2016-01-06,COMPLETED,OBSERVATIONAL,['NA'],,
5182,NCT03338543,pain score,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],complications,times of breakthrough pain (BTP)
5183,NCT00025142,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5184,NCT02169765,Overall survivals,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],morbidity,Recurrence rates
5185,NCT00868998,Response Rate,2005-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
5186,NCT01178151,To determine the response rate of Everolimus in patients with advanced cancer and PJS.,2010-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To assess markers for activated mTOR pathway (including phospho-S6 and phospho-4E BP1) in all pre-treatment tissue specimens and collected specimens during treatment and correlate with response to treatment.
5187,NCT05183295,Tolerability of the NEAAR medical food,2022-04-27,WITHDRAWN,INTERVENTIONAL,['NA'],,Progression-free Survival
5188,NCT05689775,Perineal wound healing,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Abdominal wall strength
5189,NCT00190515,Disease-free survival,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Rate of adverse event
5190,NCT03223740,Progression Free Survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,R0 Resection Rate
5191,NCT02860429,neural electrophysiological test,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"stress hormone,in blood."
5192,NCT02672488,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
5193,NCT01056809,Overall survival,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,Complications and side effects
5194,NCT00339183,Overall Survival,2006-06-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
5195,NCT01271166,Tumour response as assessed by CT scan and RESIST,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
5196,NCT05984485,3-year Disease Free Survival,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
5197,NCT02581462,Phase III: Median Progression Free Survival,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase III: Median OS
5198,NCT05047146,Clinicopathological factors of Hepatocellular Carcinoma,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5199,NCT03722056,rates of intraoperative tumour rupture,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
5200,NCT05164406,Transfusion,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5201,NCT05129774,5-year OS,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complications
5202,NCT02270606,Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation,2014-12-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Postoperative mortality rates
5203,NCT01401075,Quality of Life,2006-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety and tolerability
5204,NCT00470353,Change in proliferative labeling index of normal rectal mucosa as measured by Ki67 IHC staining,2006-09,TERMINATED,INTERVENTIONAL,['NA'],,"Effects of cholecalciferol on biological markers of proliferation (i.e., cyclin D1, protein kinase C, vitamin D receptor, p21, and p27) as measured by IHC at baseline and after 6 months of study treatment"
5205,NCT06229080,Mean absorbed dose ratio between the protected perfused liver and unprotected perfused liver,2023-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Serious adverse event
5206,NCT04808791,Safety/Tolerability,2021-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
5207,NCT00568646,Objective tumor response rate based on tumor measurements according to the RECIST,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5208,NCT02619942,Disease-free survival,2016-01-09,UNKNOWN,INTERVENTIONAL,['NA'],,Metastasis rate of central lymph node (3rd station)
5209,NCT05029882,Objective Response Rate (ORR),2021-10-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
5210,NCT04813523,Major pathologic response (MPR),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pathologic complete response (pCR)
5211,NCT01170104,Time to progression,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity profiles
5212,NCT05876026,Difference in T1 relaxation time (ms) in the rectal cancer tumor measured in IntelliSpace-software before and after neoadjuvant radiochemotherapy.,2023-05-08,RECRUITING,OBSERVATIONAL,['NA'],,
5213,NCT01589328,Reduction in depression score,2012-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
5214,NCT01324076,Progression-free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
5215,NCT03925870,Duration of response (DOR),2019-06-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) rates
5216,NCT04064034,Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
5217,NCT00985192,Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus.,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarker Correlations: Time to Progression
5218,NCT02584985,R1 resection rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease-free survival at 3 years
5219,NCT04493905,30-day postoperative morbidity assessed by Clavein-Dindo classification,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,"Cancer recurrence or cancer-related death at 90 days, 1, 3- and 5-years"
5220,NCT04498117,Investigator Assessed Progression Free Survival,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Potential Biomarkers,Change in Quality of Life
5221,NCT01439698,Number of Participants with Adverse Events,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of overall stent occlusion-free days post intervention
5222,NCT03215264,Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib,2017-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5223,NCT01815853,Disease-free Survival,2013-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse effects
5224,NCT05527301,Change in Low Anterior Resection Syndrome score from Baseline to 8 weeks,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of fecal metabolites assessed by fecal analysis
5225,NCT00659867,The primary objective is to investigate whether chromoscopy-guided endomicroscopy has a higher sensitivity than standard endoscopy with respect to detection of IN and to compare the proportion of patients with at least one IN,2008-12,TERMINATED,INTERVENTIONAL,['NA'],,Efficacy of chromoscopy-guided endomicroscopy in the detection of lesions and in the reduction of the number of biopsies. Time needed for the examination will be measured and compared between the two groups.
5226,NCT04572542,Objective response rate,2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate（DCR）
5227,NCT03014284,Expression of B7-H1,2017-01-20,WITHDRAWN,OBSERVATIONAL,['NA'],,
5228,NCT00896753,"Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum",2003-09,COMPLETED,OBSERVATIONAL,['NA'],,
5229,NCT04511455,Time-on-treatment,2020-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Translational research
5230,NCT03038217,5y OS,2017-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Changes of ctDNA level when disease recurs
5231,NCT06197438,Objective response rate(ORR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
5232,NCT05154812,Tumor progression rate,2020-10-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
5233,NCT00176800,Median Recurrence Free Survival Time,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients That Require Dose Modification Due to Toxicity
5234,NCT05194293,Objective response rate (ORR) (unconfirmed),2023-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],Immune biomarkers,Pathologic complete response
5235,NCT01514786,Number of Participants Reporting Preferred Screening Type as Reported by Chart Audits,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
5236,NCT06107413,Progression Free Survival (PFS),2023-11-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving Best Overall Response (BOR)
5237,NCT02400788,Phase 2 : Time To Progression (TTP),2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5238,NCT00828620,PET response on day 7,2009-01,TERMINATED,OBSERVATIONAL,['NA'],,To asses the correlations between biomarkers and PET changes after Cetuximab
5239,NCT01282502,To determine Maximum Tolerated Dose (MTD) of midostaurin in combination with standard 5-FU chemoradiation,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate proteomic markers of response and resistance to midostaurin-based chemoradiation
5240,NCT01657383,Surgical Outcome,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
5241,NCT03957096,Number of patients with dose-limiting toxicities (DLTs),2019-07-17,TERMINATED,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADA)
5242,NCT03118349,Occurrence of graded adverse events (AEs) in each subject,2017-06-01,TERMINATED,INTERVENTIONAL,['PHASE1'],Evaluate the relationship between circulating CA19-9 levels and MVT-1075 pharmacokinetics,Cl
5243,NCT04596384,Maximum CCI,2021-02-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Sleep
5244,NCT02730104,Time to disease progression,2015-11-23,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction with treatment
5245,NCT05957744,Length of stay,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5246,NCT03044587,Progression-free survival [PFS],2018-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor Evolution under systemic therapy,Retrospective central radiological review
5247,NCT04432597,Level increase in CD3+ tumor infiltrating T cells post-treatment compared to pre-treatment,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate (ORR)
5248,NCT06251297,number of sessions performed,2023-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,concordance of peripheral neuropathy evaluation
5249,NCT04635527,Number of participants experiencing clinical and laboratory adverse events (AEs),2020-12-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS) in two arms
5250,NCT03781934,Incidence of clinically significant changes in ECGs,2018-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Plasma levels of α fetoprotein (AFP)
5251,NCT01906021,To measure accuracy of temperature monitoring using non-invasive thermomap (temperature imaging profile) method compared to the currently accepted invasive thermocouples method,2013-09-23,COMPLETED,INTERVENTIONAL,['NA'],,
5252,NCT05173298,collected blood samples,2021-08-02,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC
5253,NCT00061815,"Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.
5254,NCT05555316,Down stage rate,2019-11-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,TACE frequency and ablation frequency
5255,NCT01411436,Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar,2009-05,COMPLETED,OBSERVATIONAL,['NA'],,"The status of therapy with Nexavar [duration of treatment, daily dose] in a various settings according to baseline data [such as demographic data, Child-Pugh status, ECOG-PS]"
5256,NCT03803930,The diagnostic yields,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,the tissue integrity
5257,NCT00386828,The primary endpoint is pathologic complete response (pCR) rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Post-Surgical Complication Rates:
5258,NCT05064670,Health-related quality of life,2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Health-related quality of life
5259,NCT05846867,recommended phaseII dose,2023-05-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Correlation between biomarkers and efficacy
5260,NCT02635347,Percentage of Participants Completing Entire Intervention Protocol,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Subjects Not Completing Intervention Protocol
5261,NCT05999019,ClassIntra grade,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,3-year disease-free survival
5262,NCT05867303,Incidence of Adverse Events [Safety and tolerability],2023-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
5263,NCT03520257,overall survival,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5264,NCT00119899,Economic evaluation (9 months),2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Economic evaluation
5265,NCT00928161,Frequency of acid reflux episode (during each 24 hour pH probe),2012-11,WITHDRAWN,INTERVENTIONAL,['NA'],,
5266,NCT05193292,Objective Response Rate,2022-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response
5267,NCT03152435,Occurrence of study related adverse events as assessed by CTCAE v4.0,2017-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine duration of in vivo survival of EGFR CART .
5268,NCT01265810,"Assess the severity of patient-reported oral adverse events as determined by the change in the Modified-VHNSS2.0 score 3 times a week, from onset of oral adverse events during the active oral rinse period with Caphosol versus NaCl 0.9%",2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Side Study: Explorative analysis of polymorphism in genes encoding for pharmacokinetic and pharmacodynamic variables related to the pharmacodynamics of the TKIs
5269,NCT06310993,Primary Outcome Measure,2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Outcome 7
5270,NCT00025337,Overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival
5271,NCT00457327,Morbidity and mortality until day 30 postoperative,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Ranking of factors influencing quality of life
5272,NCT02707796,"Evaluation of the correlation between partial oxygen pressure in arterial blood sample and oxygen reserve index calculated by pulse co-oximetry, and sensitivity and specificity of oxygen reserve index in patients undergoing hemicolectomy",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity and specificity of oxygen reserve index
5273,NCT00017199,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5274,NCT03401229,Change From Baseline in NBS at Week 40,2018-01-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in SF-36v2 Mental Health at Week 56
5275,NCT03299660,Pathological Response rate,2018-04-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine rate of downstaging
5276,NCT02555813,Number of participants with adverse events,2015-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Best Overall Response
5277,NCT03295006,Alternative two-compartment TheraSphere dosimetry methodology,2016-10-31,COMPLETED,OBSERVATIONAL,['NA'],Normal tissue dose and tumor dose using post-procedural PET/CT Imaging,Dose reproducibility
5278,NCT00601692,Maximum tolerated dose of docetaxel when administered together with irinotecan hydrochloride and radiotherapy,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical and pathological complete response rate
5279,NCT06001476,Incidence of complications in the application of cold snare polypectomy for 5-9mm small bowel polypectomy in patients with PJS,2023-08-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence of complications within 28 days after enteroscopy
5280,NCT04215731,Disease-free survival,2020-03-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,local recurrence rate
5281,NCT05351931,"Incidence of diarrhoea, fecal urgency, anal skin toxicity/mucositis and anal pain CTCAEv5.0 ≥ grade 2 during and up to 6 months after RCT. Anal skin toxicity/mucositis is to be verified by photos.",2022-06,UNKNOWN,INTERVENTIONAL,['NA'],Incidence of AEs CTCAEv5.0 grade ≥ 2 considered probably related to investigational products/placebo.,Disease free and overall survival at 3 and 6 months after stop of RCT.
5282,NCT01560377,PINPOINT System Utility in Left Colectomy Surgery,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of the PINPOINT System
5283,NCT05587452,Specificity,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5284,NCT00950417,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the complete response rate、partial rate、disease responserate、disease control rate in the patients subject to treatment
5285,NCT04380012,Objective Response Rate,2019-12-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The Incidence of Adverse Events
5286,NCT00011960,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5287,NCT05356117,Protein Supplementation (PS) Rate,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Psychosocial function - Physical Function
5288,NCT00877071,The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Local Effects of the LC BeadTM in the Explanted Liver of Those Patients Who go on to Receive Liver Transplantation
5289,NCT02775695,Determine the Efficacy of Doxycycline in Inducing Metakaryotic Cell Death in Primary Pancreatic Tumors as Measured by Pathologic Response,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5290,NCT00524069,Margin status after pancreatic resection,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Toxicity
5291,NCT02402062,Objective Response Rate,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers in Serum and Tumor Tissue
5292,NCT03616574,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2019-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],Analysis of urinary COX-2 metabolites by LC-MS/MS,Serum concentration of CA102N
5293,NCT05872334,Incisional hernia,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Wound dehiscence
5294,NCT05875870,Sleep-wake rhythm,2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,Survival rate
5295,NCT05195281,Evaluation of molecular subtype modification,2021-07-14,RECRUITING,INTERVENTIONAL,['NA'],,
5296,NCT02870920,Overall Survival,2016-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
5297,NCT03775707,overall survival (OS),2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
5298,NCT04323917,Assessments of diagnosis of PC by EMT-TF mRNA levels in blood,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction of prognosis of PC by EMT-TF mRNA levels in blood
5299,NCT02177552,The proportion of participants alive one year after randomisation,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Analysis of cmet by immunohistochemistry,Registration of further lines of therapy
5300,NCT00867477,Comparison Patient's PMRR + Mean Exhaled NO Measurement,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5301,NCT04478110,CRC screening rates,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,
5302,NCT01781520,Treatment toxicity,2013-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phenotypic analysis of peripheral blood immune cells
5303,NCT00681798,Define Recommended Dose (RD),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine antitumour activity as determined by overall response rate (RR), progression free survival (PFS), disease control rate and duration of response"
5304,NCT00119912,1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.,1999-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.
5305,NCT05493800,The incidence of Severe Oral Mucositis(SOM).,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Auto hematopoietic stem cell engraftment,Total cumulative dose of opioid analgesics
5306,NCT04159974,Evaluation of Safety and efficacy (measured by an increase of pathological complete response rate),2019-09-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of the subject's esophageal-cancer-related quality of life using the Functional Assessment of Cancer Therapy-Esophageal (FACT-E) questionnaire
5307,NCT01121848,Progression-Free Survival (PFS),2010-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Median Overall Survival (OS)
5308,NCT02289547,Progression free survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity profile of each patients measured by NCI-CTCAE ver 4.0
5309,NCT00498134,"Changes in cell proliferation, apoptosis and oncogene expressions",2004-03,UNKNOWN,INTERVENTIONAL,['NA'],,The incidence of gastric cancer in a high risk area
5310,NCT04660695,Clinical Success,2019-08-15,COMPLETED,OBSERVATIONAL,['NA'],,Type of fluid employed
5311,NCT03357757,Proportion of subjects who complete 4 doses of Avelumab in combination with VPA,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Hsp90 concentration in serum
5312,NCT03535207,overall survival rate,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,toxicities
5313,NCT00043004,Survival rate as measured by Kaplan Meier method at 30 months,2002-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response to treatment (arm II) as measured by RECIST criteria from start of treatment until disease progression
5314,NCT05111353,Safety of neoantigen SLP vaccine as measured by number of subjects experiencing each type of adverse event,2022-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity of neoantigen peptide vaccine as measured by the phenotype of neoantigen-specific T cells (only Arm 1 and Arm 2)
5315,NCT01271322,Correlation between change in tumor metabolism (detected by PET) and histopathological response,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,association between change in tumor metabolism between PET Baseline and PET1 and overall survival as well as disease-free survival
5316,NCT00327119,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5317,NCT01416714,create a database for the collected tissue,2008-07-02,SUSPENDED,OBSERVATIONAL,['NA'],,To create tissue microarrays for each gastrointestinal cancer subtype
5318,NCT02466906,Disease-free survival（DFS）,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse effects (AE)
5319,NCT06296056,potential efficacy,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5320,NCT04513418,Rate of postoperative nutrition and immune-related complications,2020-11-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Long-term survival
5321,NCT04389086,Proportion of patients with a clear resection margin,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Colorectal cancer specific quality of life
5322,NCT00196885,"muscle cross-sectional area, peak forces",2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,muscle 31Phospho-magnetic-resonance spectroscopy
5323,NCT06302751,Unplanned hospital readmissions,2024-02-26,RECRUITING,INTERVENTIONAL,['NA'],,Healthcare costs
5324,NCT02338778,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,immunology index
5325,NCT01262482,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
5326,NCT01736072,End of Conversion to Open Surgery,2011-12,COMPLETED,INTERVENTIONAL,['NA'],Sexual Disfunction Assessment,Oncological Efficacy
5327,NCT06277518,admitted to ICU after surgery,2023-09-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5328,NCT04940442,Number of patients with screening completion,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,
5329,NCT02965417,Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
5330,NCT06255262,Progress Free Survival 1 (PFS1),2024-02-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival(OS)
5331,NCT00540982,Number of Participants With Grade 3 and 4 Toxicities,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5332,NCT06225622,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2024-03-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Gene polymorphism,R0 resection
5333,NCT03747068,"to determine whether preoperative exposure to anti-TNF therapy affects histological measures of fibrosis in the rectum, as increased rectal fibrosis may be a potential factor in adverse anastomosis complications following IPAA surgery",2009-10-09,COMPLETED,OBSERVATIONAL,['NA'],,
5334,NCT06294808,Agreement between TBI calculated from pre-operative imaging versus those obtained from post-surgical pathological assessment.,2017-07-17,COMPLETED,OBSERVATIONAL,['NA'],,
5335,NCT02154646,Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT),2014-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants with a Tumor Response
5336,NCT06022887,Acceptability of the study,2023-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 region
5337,NCT04409002,Disease Control Rate With RECIST 1.1 Criteria,2020-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatment-Related Adverse Events Per CTCAE v5.0
5338,NCT00005877,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5339,NCT04728139,Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .
5340,NCT01833637,"Trend perceived symptom burden and quality of life in our female patients with advanced gynecologic, breast, thoracic, or gastrointestinal malignancies.",2012-10,COMPLETED,INTERVENTIONAL,['NA'],,Assess level of understanding about advance care planning in both the control and intervention group.
5341,NCT00291785,"Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity",2004-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5342,NCT02772575,response,2016-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
5343,NCT05646511,Organ-preservation adapted DFS,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3'],Artificial Intelligence (AI) (deep learning) analysis,Proportion of radical resection in salvage surgery cases in the NOM subgroup
5344,NCT06123338,Pathological Complete Response Rate (pCR),2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5345,NCT00058474,Loco-regional disease control as assessed by evidence of tumor at 3 years,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Convenience of care as assessed by NSABP C-06 convenience of care scale adapted from ECOG after definitive analysis
5346,NCT06259058,R0 resection rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
5347,NCT04673448,Best objective response,2021-10-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
5348,NCT04268654,Anastomotic leakage,2017-06-13,COMPLETED,INTERVENTIONAL,['NA'],,Hospital Stay
5349,NCT06122493,1-year progression-free survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
5350,NCT04379596,"Part 2, Part 3 and Part 4: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)",2020-06-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Comparison of OS
5351,NCT00559013,"Number of Participants With Major Colorectal Related Adverse Events: Leak, Stricture and Hemorrhage.",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
5352,NCT00557713,Pathologic Complete Response Rate,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical Morbility
5353,NCT00085410,Objective Response Rate,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers
5354,NCT00087503,To assess the antitumor activity of edotecarin by repeating radiographic assessments at 6-week intervals for all patients.,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Blood samples for PK evaluation will be collected during Cycles 1 and 2 and limited to the patients included in the first stage of the study.
5355,NCT04171986,Incidence of 3 and 4 degrees neutropenia within 6 weeks from the start of hyperfractionated radiotherapy,2019-11-10,UNKNOWN,INTERVENTIONAL,['NA'],,
5356,NCT00032344,"Phase I: Risk factors include: family history; dietary; fat, fiber, calcium; alcohol history; tobacco use; physical activity; obesity; NSAID use; and, biomarkers: BRDU, PCNA",1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Phase III: Medical outcomes including mortality. Colonoscopy outcomes in subgroup of polyp free patient at baseline to determine long term risk.
5357,NCT03956056,Safety of Neoantigen Peptide Vaccine as Measured by the Number of Serious Adverse Events,2020-02-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of the Neoantigen Peptide Vaccine as Measured by Multiparametric Flow Cytometry
5358,NCT00789763,TO DETERMINE MTD,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,RESPONSE (ACCORDING TO RECIST)
5359,NCT04821778,Overall survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Radiomics analysis,Distant metastasis free survival
5360,NCT02319356,maximal oxygen uptake (VO2Max),2015-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
5361,NCT04125914,Percent weight loss,2017-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity
5362,NCT02796820,Disease-free survival (DFS),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],The adverse events of Huaier Granule,Metastasis-free survival (MFS)
5363,NCT00516165,Progression-free Survival Rate at 24 Weeks,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
5364,NCT03677050,Boston Bowel Preparation Score,2018-09-14,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma detection rate
5365,NCT05276791,Primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Additional histopathologic evaluation may be performed to evaluate potential differences between the two techniques.
5366,NCT04729283,LARS score,2021-04-12,UNKNOWN,OBSERVATIONAL,['NA'],,IIEF5
5367,NCT04425122,Microbiological culture from biopsy specimens,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5368,NCT03419247,Number of participants with gene testing data available at 8 weeks from baseline tumor biopsy.,2020-01-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Potential predictive biomarkers of response to treatment such as BRCA, PALB2 and ATM mutations."
5369,NCT02736500,toxicity rate,2015-09-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival in association with the receptor and metabolic status at OctreoScan and FDG PET
5370,NCT03336775,The change of Videofluoroscopic Dysphagia Scale (VDS) from baseline to week 4.,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,The change of Quality of Life (QOL) scores from baseline to week 4 and week 16.
5371,NCT05798884,Score Changes on the FACT/GOG-Ntx questionnaire,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Short Form 12 item(version 2) Health Survey (SF-12V2)
5372,NCT00116935,Recurrence-free survival,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,GIST-specific survival
5373,NCT00114946,"To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.",2005-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.
5374,NCT02672774,Real-time imaging of angiogenesis in gastric and colorectal tumors by using M-NBI and pCLE examinations,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,Validation of endoscopic imaging findings from immunohistochemical analysis with MVD calculations
5375,NCT05622071,Objective Response Rate,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Hepatocellular Carcinoma (QLQ-HCC-18)
5376,NCT05395910,Safety Profile of PIPAC/ePIPAC with Paclitaxel by monitoring adverse events,2022-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area under the curve (AUC) of Paclitaxel administered via PIPAC/ePIPAC using blood drawn from patient.
5377,NCT04985604,Phase 2: Evaluate the efficacy of tovorafenib monotherapy or in combination with other therapies,2021-07-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 2: Assess the safety and tolerability of tovorafenib as monotherapy, or in combination with other therapies"
5378,NCT04531228,progression-free survival,2020-10-11,UNKNOWN,INTERVENTIONAL,['NA'],,adverse effects
5379,NCT05375708,Progression-free survival,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Depth of response
5380,NCT05509478,ORR,2022-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate at 12 months
5381,NCT00837135,"To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.",2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5382,NCT03468244,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival of Personalized mRNA Tumor Vaccine
5383,NCT01570166,overall survival,2011-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,disease-free survival
5384,NCT03109938,Diagnostic Accuracies,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,
5385,NCT03125343,3-year disease free survival.,2017-01,RECRUITING,INTERVENTIONAL,['NA'],,Health economic evaluation
5386,NCT04848753,To compare IRC-assessed events-free survival (EFS) in 2 arms,2021-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,5- year OS rate
5387,NCT03020342,vh-chimera DNA,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],current HCC marker (AFP ng/ml),recurrence-free survival time ----measurement in weeks
5388,NCT04323722,Evaluate using imaging techniques and dosimetric analysis the performance of empty versus filled bladder radiotherapy treatment,2020-09-08,RECRUITING,INTERVENTIONAL,['NA'],,IMRT (Intensity-Modulated Radiotherapy) dosimetric study in patients with filled or empty bladder
5389,NCT04390945,Progression-free survival，PFS,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate, ORR"
5390,NCT01311050,,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5391,NCT05398822,Local recurrence of rectal cancer,2019-07-18,COMPLETED,OBSERVATIONAL,['NA'],,
5392,NCT00005076,Determine the complete and partial response rates and time to progression in patients with refractory advanced colorectal carcinoma treated with cetuximab and irinotecan.,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the tumor epidermal growth factor receptor levels in patients treated with this regimen
5393,NCT06326892,Surgical Site Infections (SSI),2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,Overall postoperative complications
5394,NCT01511146,"tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.",2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Progression free survival, adverse events"
5395,NCT00217568,Overall survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5396,NCT04739202,Objective response rate,2021-03-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety, treatment-related adverse events"
5397,NCT00969410,To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To investigate the effect of AV-299 (formerly SCH 900105) on gene expression patterns in peripheral blood mononuclear cells and liver biopsies in subjects with advanced solid tumors who have liver metastases
5398,NCT03939975,Response,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
5399,NCT02561494,Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 day,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Change of the pain score from postoperative 6 h to postoperative 5 day
5400,NCT03570502,Postoperative pancreatic fistula according the 2016 update of the International Study Group (ISGPS),2016-11,UNKNOWN,OBSERVATIONAL,['NA'],,Diabetes
5401,NCT00660699,Incidence of Severe Toxicities,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
5402,NCT01813253,Overall Survival,2013-05-13,TERMINATED,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
5403,NCT02896803,Response rate,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicities according CTCAE v4.03
5404,NCT04076631,Pathological stage of liver cirrhosis,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,The effect of cirrhotic severity and extent of hepatectomy on the incidence of post-hepatectomy liver failure (PHLF)
5405,NCT04188990,Mortality rate,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Patient's functional status
5406,NCT04214990,The incidence of gastric cancer between the intervention and placebo groups,2020-02-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Improvement of atrophy and intestinal metaplasia
5407,NCT02862587,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5408,NCT02657850,Change in rate of dysphagia symptoms,2016-06-09,WITHDRAWN,OBSERVATIONAL,['NA'],,change in rate of secondary treatment side effect
5409,NCT05485077,Negative predictive value and positive predictive value of polygene methylation in colorectal cancer,2022-07-09,RECRUITING,OBSERVATIONAL,['NA'],,
5410,NCT01477866,All cause mortality,na,SUSPENDED,INTERVENTIONAL,['NA'],,
5411,NCT03204019,Objective Response Rate(ORR),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival(PFS)
5412,NCT02089763,Time to progression (TTP),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],"Biomarker study - to explore the predictive and prognostic functions of tissue biomarkers, ornithine transcarbamylase (OTC) and arginine succinate synthetase (ASS)",Safety profile of PEG-BCT-100 treatment
5413,NCT04868877,To evaluate the ORR of MCLA-129 alone or in combination with Osimertinib in molecularly defined populations of advanced/metastatic solid tumors.,2021-04-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Proportion of patient with treatment discontinuations
5414,NCT04556253,The rate of pathologic complete response(pCR%),2020-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5415,NCT02373020,"virulence genes: eaeA, bfpA and stx. PCR",2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Strains: OF E COLI
5416,NCT05068076,Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure using modified RECIST criteria for HCC.,2021-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Targeting of lesions (fulfilling CEUS LIRADS 4/5 criteria) in the Kupffer phase for ablation
5417,NCT01175317,Peak Value of I-FABP,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Average Intraoperative CO2 Gap
5418,NCT05673343,disease free-survival,2023-01-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,overall survival (OS
5419,NCT03567850,Healthcare Utilization of Patients,2018-10-19,COMPLETED,INTERVENTIONAL,['NA'],,
5420,NCT03418948,Adenoma miss rate (%),2017-12-08,UNKNOWN,INTERVENTIONAL,['NA'],,To compare patient reported outcomes e.g. pain
5421,NCT01294202,Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Treatment emergent adverse events, classified by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03."
5422,NCT04673955,Overall Survival,2020-09-03,RECRUITING,OBSERVATIONAL,['NA'],,Duration of treatment interruptions
5423,NCT05313906,ORR,2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
5424,NCT01461057,Number of Participants With Adverse Events (AEs),2011-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5425,NCT02370498,Overall Survival (OS) in PD-L1 Positive Participants,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of All Participants That Discontinued Study Treatment Due to AE
5426,NCT02057146,Accuracy of single operator endoscopy plus pCLE in the biliary and pancreatic ductal system diagnosing premalignant and malignant lesions.,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,
5427,NCT04695184,anastomotic leak,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of post-operative hospital stay
5428,NCT00737802,Pressure at the gastric sling and clasp fibers,2013-04-12,TERMINATED,OBSERVATIONAL,['NA'],,
5429,NCT03079427,2-year disease-free survival,2017-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
5430,NCT02597348,5 years overall survival (OS),2016-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Quality of life (QOL) of patients of Group LT followed by chemotherapy, using the NIDDK questionnaire of Liver Transplantation Database"
5431,NCT00391118,Part 2: Progression-Free Survival (PFS),2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"PK: AUC During the Dosing Interval at Steady State (AUCτ,ss) for Part 2 of Study"
5432,NCT04192734,Incidence of adverse events,2019-12-18,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events of special interest
5433,NCT04514835,Progression-free survival（PFS）,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory analysis of biomarkers for predicting efficacy,Objective Response Rate，ORR
5434,NCT03030937,Adverse Event（AE）,2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
5435,NCT04915833,Polyp detection rate of computer-aided following standard colonoscopy.,2021-04-26,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma miss rate of standard high-definition colonoscopy.
5436,NCT00093782,Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria),2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
5437,NCT01985958,Number of Participants With Adverse Events,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,
5438,NCT01131234,Incidence of adverse events as graded by the NCI CTCAE version 4.0,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Preliminary antitumor efficacy
5439,NCT01105650,Response Rate,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5440,NCT00006366,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5441,NCT03484000,Fatigue,2018-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
5442,NCT00858858,Protection Against DNA Damage by UDCA,2009-03,COMPLETED,INTERVENTIONAL,['NA'],,
5443,NCT00826982,To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,To determine the degree of RNA overexpression of pancreas cancer specific biomarkers in the pre-operative fine needle aspirate of lymph nodes and tumors of patients with pancreatic cancer using a set of pancreas cancer specific biomarkers
5444,NCT05768178,Durable Clinical Benefit (DCB),2023-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC)
5445,NCT05513261,Adenoma Detection Rate (ADR),2023-11-17,RECRUITING,INTERVENTIONAL,['NA'],,Characterization of the detected lesions.
5446,NCT00325078,Efficacy of Treatment With Study Drug,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Gut Immune Cell Types and Their Cytokine Profile,
5447,NCT00020917,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5448,NCT04631731,"Expression of TIM-3, LAG3, VISTA and other inhibitory checkpoint molecules on tumour-infiltrating T cells.",2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Association of pre-treatment BMI, neutrophil-to-lymphocyte ratio and other clinical parameters with irAEs."
5449,NCT06212635,Correlation between systemic inflammation and hemostasis measured by novel assays,2022-12-02,RECRUITING,OBSERVATIONAL,['NA'],,Number of participant going to transplant
5450,NCT01679054,Expected and Unexpected Provider Costs,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Expected and Unexpected Societal Costs
5451,NCT03823079,the duration after returning to normal,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the rate of pathological complete response.
5452,NCT02819869,relapse-free survival of hepatocellular carcinoma patients,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
5453,NCT02912052,Disease free survival，DFS,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],number of lymph nodes retrieved,Overall survival
5454,NCT02558205,Correlation of CT perfusion metrics to radiation dose deposition of Y-90 as measured by PET/CT,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],,Correlation between CT perfusion metrics and post treatment response as measured by RECIST 1.0 criteria
5455,NCT01683864,Disease Free Survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Kinetics of Mitomycin and Cisplatin,
5456,NCT03428074,Overall survivals in patients with esophageal cancer who received surgeries,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],Extents of lymph metastases,Death rates within 30 days after surgeries
5457,NCT04150874,Number of Participants with Early Tumor Response,2020-02-19,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants with Early Signs of Radiation Induced Liver Disease (RILD)
5458,NCT05566249,Cost,2022-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Oncologic outcomes
5459,NCT03543514,Crompehension Complexity Index (CCI),2022-02-02,RECRUITING,OBSERVATIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS)
5460,NCT05765214,CRC-KPSS change and screening uptake,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
5461,NCT00021047,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5462,NCT00290719,Pathological response (complete and partial) post-operatively,2005-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Compare the effects of gefitinib on biomarkers that effect EGF signaling and genomic composition of tumor samples before and after treatment
5463,NCT02616926,overall survival,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,disease free survival
5464,NCT02813096,early recurrence,2016-10,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
5465,NCT03616431,Determine prevalence of pancreatic enzyme insufficiency in patients with pancreatic neoplasms.,2018-07-03,COMPLETED,OBSERVATIONAL,['NA'],,"To identify, through semi structured interviews and thematic analysis, diet-related themes of interest in a subset of patients involved in this study"
5466,NCT05281211,Number of participants experiencing 90 day morbidity,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants being disease free (Disease free survival)
5467,NCT05047991,Progression-Free Survival (PFS),2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,UGT1A1
5468,NCT03511963,PFSR9m,2018-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Ctrough,SAE
5469,NCT04821258,Rate of complications.,2021-04,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life assessment.
5470,NCT01642797,number of participant with gastric IM/IN/CA,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,number of biopsies needed per patient
5471,NCT01438645,Sedation Score,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Ancillary maneuvers to facilitate procedure
5472,NCT04975932,Progression free survival(PFS),2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse event(AE)
5473,NCT05942560,Change in anxiety symptoms at 12 months,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
5474,NCT05692024,Change in hepatic fat fraction.,2024-03-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in stool metabolomics,Change in liver fibrosis assessment and plasma levels of liver enzymes
5475,NCT04752930,Peritoneal Metastasis Free Survival (PMFS),2020-08-24,RECRUITING,INTERVENTIONAL,['NA'],,The Overall Survival (OS) at 3 years after radical resection of colorectal cancer
5476,NCT04923932,Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria),2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,incidence of various adverse events (AE)
5477,NCT01152710,complete pathological remission rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,long-term rectal and urogenital morbidity
5478,NCT05336058,Screening of genetic targets for kit development,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5479,NCT05155124,Incidence of DLT（Dose-limited toxicity）,2022-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Adverse Eevents
5480,NCT05536102,Pathological complete remission rate,2022-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events (AEs),3-year PFS rate
5481,NCT02950025,"Number of Grade 3 or Greater Toxicity Occurring in Patients Receiving Online, Adaptive, MRI-guided SBRT to the Abdomen and in Patients Receiving Non-adaptive SBRT",2017-01-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Local Failure
5482,NCT05520788,Progression-free survival (PFS),2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
5483,NCT03148093,Reasons for dose adjustments and/or discontinuation of treatments,2017-06-30,TERMINATED,OBSERVATIONAL,['NA'],Progression free survival,Burden for caregivers providing support to patients enrolled in the registry per Modified Caregiver Strain Index (MCSI)
5484,NCT05465993,recurrence rate,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Incremental cost-effectiveness ratios (ICERs)
5485,NCT05825664,Curative rate,2023-04-07,RECRUITING,INTERVENTIONAL,['NA'],,Procedure time
5486,NCT02226289,Response rate,2020-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
5487,NCT05020132,Change in the Bristol stool chart between baseline and 12 months,2015-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate analysis of risk factors for LARS
5488,NCT03732768,Maximum Tolerated Dose (MTD),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,
5489,NCT04976439,Description of survival,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
5490,NCT04478175,Program faisability,2021-04-29,COMPLETED,INTERVENTIONAL,['NA'],,Patient's satisfaction measured by VAS
5491,NCT03007225,Number of Participants With Complete Response,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5492,NCT02976909,R0 resection rate,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse envents
5493,NCT03762837,Gallbladder cancer,2019-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
5494,NCT04923646,Return proportion,2021-06-30,COMPLETED,INTERVENTIONAL,['NA'],,Return proportion
5495,NCT00217581,Time to Progression,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5496,NCT06012734,The RP2D of LB-100 when given in combination with standard doses of atezolizumab,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Concentration of LB-100 and endothall in tumor tissue,The incidence of dose-limiting toxicity
5497,NCT03585673,Overall response rate,2018-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event
5498,NCT03572400,Disease-free survival rate,2018-11-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate
5499,NCT05828875,Quality of Life Assessment survey,2023-08-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
5500,NCT06233253,Satisfaction with the intervention (Acceptability),2023-09-29,RECRUITING,INTERVENTIONAL,['NA'],,Intent for future CRC screening
5501,NCT00003216,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5502,NCT04801511,PCR rate,2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year disease-free survival rate
5503,NCT05907642,Low Anterior Resection Syndrome Questionnaire Score,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,The European Organization for Research and Treatment of Cancer quality of life questionnaire c-30
5504,NCT01290783,Progression Free Survival (PFS),2011-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety
5505,NCT03843957,Percent of Patients Who Complete the mPATH-CRC Program,2019-10-31,COMPLETED,INTERVENTIONAL,['NA'],,mPATH-CheckIn Feasibility
5506,NCT04955730,Surgical Site Infection - Organ/Space Incisional,2021-08-05,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Initiation of Planned Oncologic Therapy
5507,NCT01063192,The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy ."
5508,NCT00005586,All-cause mortality,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease recurrence
5509,NCT01797770,anastomotic leak,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],,Readmission
5510,NCT05710809,Dynamic Gait Index (DGI),2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Recurrence of cancer,Body composition
5511,NCT00855218,Time to Progression (TTP) - Independent Radiological Review (Primary Analysis),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Response - Investigator Assessment
5512,NCT01129778,Percentage of Time Esophageal pH< 4,2009-11,TERMINATED,INTERVENTIONAL,['NA'],,Reflux Disease Questionnaire Score on Day 1 After Therapy Completion
5513,NCT06281405,Complete response (CR) rate,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of surgical complications
5514,NCT06218433,Sensitivity and specificity of positive utDNA for urothelial cancer within one year of follow-up,2023-04-10,RECRUITING,INTERVENTIONAL,['NA'],Cost of utDNA screening,Urothelial cancer grade
5515,NCT01555801,Diagnostic accuracy,2012-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5516,NCT00001240,,1989-01,COMPLETED,OBSERVATIONAL,['NA'],,
5517,NCT02611024,Response Rate,2016-05-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
5518,NCT02979470,progression free survival,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,
5519,NCT02122523,Number of fluorescent lymph nodes,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Lymph nodes with metastasis
5520,NCT03386825,"BRAF mutation (yes, no, unknown)",2018-01-31,COMPLETED,OBSERVATIONAL,['NA'],,Duration of treatment (months)
5521,NCT02156557,Validation of binding of peptide,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5522,NCT03606590,Overall response rate,2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Severity and frequency of adverse events
5523,NCT05722288,Percentage of patients completing 4 weeks of time-restricted eating during RT,2023-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Oxidative DNA damage
5524,NCT06115629,All-cause mortality,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Fear of cancer recurrence as determined by the cancer worry scale score
5525,NCT00010166,,2000-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5526,NCT00861107,evaluation of any drug-related toxicity associated with AlloStim administration as well as the reversibility of such toxicity.,2009-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,evaluation of the immunological response to AlloStim administration
5527,NCT00129870,Time to treatment failure (TTF) for the conventional oxaliplatin (CO) schedule in comparison with the intermittent oxaliplatin (IO) schedule,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,Reasons for treatment discontinuation
5528,NCT05270889,Overall Response,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5529,NCT00884520,Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.,2009-04,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
5530,NCT05182255,Number of participants with clinically relevant device migration,2022-04-28,RECRUITING,OBSERVATIONAL,['NA'],,
5531,NCT00003439,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5532,NCT00290316,To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,2.2.5 To study characteristic echoendoscopic findings of the primary and secondary liver tumor.
5533,NCT02567942,natural killer cell activity,2016-02,COMPLETED,INTERVENTIONAL,['NA'],change of percentage of CD39 and CD73,helper T cell activity
5534,NCT00059891,Determine the risk of complications and feasibility of total anorectal reconstruction using the Acticon Neosphincter prosthesis after abdominoperineal resection in patients with anal or rectal cancer.,2003-01,COMPLETED,INTERVENTIONAL,['NA'],,"Determine continence, bowel function, and quality of life of patients treated with this surgery."
5535,NCT05917990,Changes in constructive communication,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5536,NCT01202409,Response Rate (RR),2010-11-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Progression-free Survival (PFS) for CAPOX and Panitumumab
5537,NCT00557024,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
5538,NCT02845258,Repeated drainage frequency,2006-01,RECRUITING,OBSERVATIONAL,['NA'],,Long time complication rate
5539,NCT05257863,Development of a preoperative score for morbidity/mortality in colorectal surgery,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
5540,NCT00752063,Progression-free survival,2007-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Tumor response rate, overall survival and safety of the regimen in HCC patients"
5541,NCT05274204,,na,TEMPORARILY_NOT_AVAILABLE,EXPANDED_ACCESS,['NA'],,
5542,NCT01683357,feasibility on an intention-to-treat basis,2001-09,COMPLETED,OBSERVATIONAL,['NA'],reliability of the procedure from an oncological standpoint,safety of the procedure
5543,NCT04824053,"Change from baseline levels in pro-inflammatory circulating markers C-reactive protein (CRP), interleukin (IL)-6, macrophage inhibitory cytokine 1 (MIC-1) and tumour necrosis factor alpha (TNFα), as well as in fecal calprotectin.",2022-02-28,RECRUITING,INTERVENTIONAL,['NA'],,To assess the effect of treatment on colorectal adenoma recurrence
5544,NCT02632006,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
5545,NCT01930435,Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score.,2013-07,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification
5546,NCT02740985,The incidence of adverse events,2016-06-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival
5547,NCT00940030,"Anastomotic leakage, wound infection (including deep abscess)",2007-10,COMPLETED,INTERVENTIONAL,['NA'],,patient's symptoms (through questionaire)
5548,NCT03963544,Overall survival (OS),1990-01,RECRUITING,OBSERVATIONAL,['NA'],,
5549,NCT03364907,change in tissue platinum exposure before and after flushing,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,total and unbound platinum concentration in instillate
5550,NCT00227747,Rate of complete surgical resection,2005-11-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Acute and late toxicity
5551,NCT01209013,Incidence of esophageal stenosis,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Measure oligomer concentrations
5552,NCT01821612,Completion rate of all preoperative and operative therapy,2013-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
5553,NCT00666926,Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Caspase-3
5554,NCT06313970,Objective response rate (ORR),2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
5555,NCT00087191,Toxicity as assessed by NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,2004-05,TERMINATED,INTERVENTIONAL,['NA'],,
5556,NCT00687596,Overall Survival (OS),2008-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters"
5557,NCT04329299,Gastric cancer,2012-12-03,COMPLETED,OBSERVATIONAL,['NA'],,
5558,NCT05715255,Change in reported PRO-CTCAE Symptoms,2023-05-08,RECRUITING,INTERVENTIONAL,['NA'],,Change in unscheduled health care visits
5559,NCT00566644,Rate of atypical endometrial hyperplasia or endometrial cancer during the active follow-up period of the study,2007-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
5560,NCT03717402,Frequency of Symptom Survey Completion,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Usability
5561,NCT00468416,Functioning anastomosis and no occurrence of adverse events related to device use,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5562,NCT02141945,Performance of Metabiomics Colon Polyp and Colorectal Cancer Assay,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5563,NCT05902533,Assess patient reported GI toxicity using PRO-CTCAE Diarrhea,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Proportion of patients requiring a treatment break due to toxicity; measured by more than 3 consecutive fractions missed.
5564,NCT02928120,Diagnostic potential of hypermethylated DNA as a biomarker for colorectal cancer,2015-02,UNKNOWN,OBSERVATIONAL,['NA'],,Hypermethylated DNA as a follow-up biomarker for disease recurrence
5565,NCT04857203,The Role of Vitamin D in response to neoadjuvant therapy for the patients with locally advanced rectal cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
5566,NCT02403050,Intra- and inter-observer variability of tumor target volume (cubic centimetres) estimation,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],,local recurrence of tumor
5567,NCT06055166,PFS rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
5568,NCT05773248,Perioperative morbidity,2023-03-13,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate
5569,NCT05235932,3-year disease free survival rate,2022-02-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,inflammatory immune response
5570,NCT05237310,Additional Adenoma Detection,2022-02-02,UNKNOWN,INTERVENTIONAL,['NA'],,
5571,NCT00681577,safety (Phase I: toxicities as assessed by NCI CTCAE version 3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
5572,NCT02174549,Overall Response rate (ORR) by RECIST,2014-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progressive Free Survival,Duration of Response
5573,NCT04769414,Overall response rate (ORR),2021-02-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
5574,NCT00026234,Survival rate,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events as assessed by NCI CTC version 2.0
5575,NCT05902624,Effectiveness of Hepatitis B virus vaccine(HBV) in treatment of cutaneous warts .,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5576,NCT05673434,Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs),2023-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,CAR-T cell testing
5577,NCT06027515,Completion Rate (Feasibility),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],Patient-Reported Measures on Physical Function Score,Actigraphy Compliance Rate (Feasibility)
5578,NCT02076594,Progression Free Survival (PFS),2013-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Tolerability of the treatments evaluated in term of occurrence of: side effects graded according to the NCI-CTCAE scale (version 4.0); serious adverse reactions, expected and unexpected"
5579,NCT00445497,Incidence of serious adverse events (randomized and registered patients),2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health service costs (randomized patients)
5580,NCT00852228,Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The per-operative and post-operative complications associated to liver surgery
5581,NCT01910974,SAFETY THAT IS TO SAY PERFORATION RATE AND delayed BLEEDING ONE,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,
5582,NCT05280665,30-day mortality,2022-02-14,COMPLETED,OBSERVATIONAL,['NA'],Neoadjuvant treatment usage,Hospital stay
5583,NCT04828486,Progression-free survival (PFS),2021-05-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in quality of life (QOL)
5584,NCT00012363,6-month survival rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicities
5585,NCT00009880,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5586,NCT01391208,Safety of peptide application,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5587,NCT01258608,Time to Progression-Blinded Independent Central Review (BICR) Assessment,2011-02-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum Concentration of Mapatumumab
5588,NCT06117891,Overall survival (OS),2023-11-27,RECRUITING,OBSERVATIONAL,['NA'],,Treatment sequences post first-line AB or other IO combinations
5589,NCT01547845,PRO symptom measurement,2012-02-10,COMPLETED,OBSERVATIONAL,['NA'],,
5590,NCT03660449,Progression-Free Survival,2017-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,rate of grade 3-4 radiation pneumonitis
5591,NCT00416767,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5592,NCT03331562,Progression- Free Survival at 6 Months From Initiation of Trial Treatment,2017-12-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory: Monitor and Compare the Gut Microbial Communities in Both Arms of the Trial,Cellular VDR Targets in the Immune Microenvironment With PD1 Blockade
5593,NCT01519817,Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine,2012-01-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in Soluble Cluster of Differentiation 40L (sCD40L)
5594,NCT04191421,Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab,2020-01-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival time
5595,NCT06057831,Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,A feasibility study done to evaluate the benefit of using PET/MRI with respect to improved identification of the target and hence target delineation
5596,NCT00813605,Progression Free Survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of antibody formation
5597,NCT00364013,Progression-free Survival,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
5598,NCT02843802,Relief degree,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
5599,NCT00797485,Time to failure of strategy,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Quality of life as assessed by EORTC QLQ-C30 questionnaire (v 3.0) at baseline, every 3 months during induction chemotherapy, and at discontinuation of treatment"
5600,NCT02217020,The ratio of tumor downstaging to stage 0 and stage I,2014-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
5601,NCT03113604,"Rate of expression of SLAM3 and MDR transcripts, correlation with the responder status or not with Sorafenib",2015-11-20,WITHDRAWN,OBSERVATIONAL,['NA'],,
5602,NCT04930016,specific need for QoL therapy of colorectal cancers survivors in specific QoL dimensions,2021-04-14,COMPLETED,OBSERVATIONAL,['NA'],,colorectal cancer survivors' recollections of their illness an therapy
5603,NCT00942461,Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5604,NCT01087658,"Occurence of peripheral sensory neuropathy (PSN) grade 2, 3 and 4 assessed by the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE)",2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival / PFS (for metastatic patients)
5605,NCT02150746,Percentage of patients with successful in vivo animal engraftment of isolated circulating tumor cells,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
5606,NCT05201612,Objective response rate (ORR),2022-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarker molecular substudy,Duration of response (DOR)
5607,NCT01639443,Percentage of GI Clinic Capacity Filled,2013-07-08,COMPLETED,INTERVENTIONAL,['NA'],,Cost Comparisons
5608,NCT03743428,Identify biomarkers specific to apatinib or bevacizumab by proteomic analysis,2020-10-22,SUSPENDED,INTERVENTIONAL,['NA'],,Overall Survival (OS)
5609,NCT00870558,Tumor recurrence at 2 years,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5610,NCT02956772,Progression free survival,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life using EuroQol five dimensions five levels questionnaire,Incidence of adverse events
5611,NCT05850884,evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals,2023-11-30,RECRUITING,OBSERVATIONAL,['NA'],,
5612,NCT01875549,Stent patency,2013-05,WITHDRAWN,INTERVENTIONAL,['NA'],complication,survival period
5613,NCT05238922,Number of Participants Discontinue study due to TEAE,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
5614,NCT05999227,18F-FDG PET analysis,2023-06-20,RECRUITING,INTERVENTIONAL,['NA'],,
5615,NCT05859581,Coincidence rate with pathological result,2023-04-02,RECRUITING,INTERVENTIONAL,['NA'],,
5616,NCT00109850,Overall Survival at 2 Years,2005-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
5617,NCT02016274,progression free survival,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life,overall survival
5618,NCT02701088,Tolerance profile: Proportion of patients with no significant toxicities responsible for irradiation breaks,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The acute and late toxicities assessed according the SOMA/LENT scale
5619,NCT03088423,tumor response assessments,2011-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
5620,NCT05424432,Pathologic complete response,2022-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health related quality of Life related to esophageal carcinoma
5621,NCT02191761,Determine the MTD,2014-06-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Total Clearance of SM04755 after oral administration
5622,NCT01627808,Stroke volume variation,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Stroke volume variation
5623,NCT06232538,UCAD can be used as a diagnostic technology for gallbladder cancer with the sensitivity more than 90%,2024-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5624,NCT06253520,Safety,2024-04-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety
5625,NCT03017807,Number of patients with dose limiting toxicity.,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of anti-EGFR antibody after single dose and under the stable blood concentration.
5626,NCT04119830,Objective response rate,2022-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective response rate
5627,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,2019-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Open Tests
5628,NCT03260179,AE,2017-08-31,UNKNOWN,INTERVENTIONAL,['PHASE1'],Exosomes,PFS
5629,NCT03427814,Progression Free Survival (PFS) by Investigator Assessment,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
5630,NCT00620295,Maximum tolerated dose of bortezomib and gemcitabine,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors"")"
5631,NCT05692596,Database creation,2022-10-06,RECRUITING,OBSERVATIONAL,['NA'],,
5632,NCT02475499,Incident pancreatic cancer,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
5633,NCT03783871,Primary Technical Efficacy,2019-02-17,COMPLETED,INTERVENTIONAL,['NA'],EORTC QLQ-HCC18 Questionnaire,Local tumor progression (LTP)
5634,NCT01543620,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,
5635,NCT04235114,The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.,2020-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Lesion detection rate of FDG PET/CT compared with 89Zr-DFO-nimotuzumab in patients with EGFR-positive (by IHC) lung and colorectal cancers using PET/CT.
5636,NCT04859582,Overall Survival (OS),2018-11-08,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Discontinuing Study Drug Due to AEs
5637,NCT05584592,Changes in patient's comprehensive quality of life composite,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,"Skeletal muscle mass index (Skeletal muscle mass index, SMI) changes"
5638,NCT00532740,,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
5639,NCT00921869,Determination of the MTD of E7050 given orally twice daily. MTD is the highest dose at which no more than 1 out of 6 patients experiences dose-limiting toxicity (DLT),2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Best overall tumor response, duration of response and stable disease, assessed by Response Evaluation Criteria in Solid Tumors."
5640,NCT00728585,Incidence of WHO grade 3 or 4 oral mucositis,2008-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of febrile neutropenia and invasive bacterial infections
5641,NCT05418387,Acceptability of the intervention,2022-09-30,WITHDRAWN,INTERVENTIONAL,['NA'],,Proportion of patients who attend a scheduled appointment after their surgery with hepatologists or urologists in control vs. intervention group
5642,NCT03077685,Incidence of Treatment Emergent Adverse Events (safety and tolerability),2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in tumor markers
5643,NCT00112099,Overall survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,perioperative blood loss
5644,NCT00104065,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5645,NCT04798560,Development of Postoperative pancreatic fistula after pancreaticoduodenectomy,2018-10-10,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
5646,NCT00876551,Closure of postsurgical leak,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],,C reactive protein
5647,NCT00851136,Incidence and nature of dose-limiting toxicities,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of anti-PRO95780 antibodies
5648,NCT05262491,Phase Ib: Recommended Phase II Dose (RP2D),2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free Survival (PFS)
5649,NCT05012007,Percentage of returned FIT Kits,2021-08-01,COMPLETED,INTERVENTIONAL,['NA'],Interim analysis,Percentage of returned FIT Kits
5650,NCT00391183,Improvement in the physical functioning scale (containing five items) of EORTC QLQ-30 one month after after biliary stenting.,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Performance status change
5651,NCT01364376,overall survival,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with grade 3/4 adverse Events
5652,NCT02756455,% of patients without leaks after gastric surgery correctly identified by PCT and CRP,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,PCT cut-off that gives good negative predictive value for leak after gastric surgery in 5th POD
5653,NCT05916001,Surgical site infection (SSI),2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
5654,NCT02191878,Maximum tolerated dose (MTD),2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Assessment of Pharmacodynamic Effect,Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort
5655,NCT05304234,Feasibility of screening protocol,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
5656,NCT02052921,Disease-free survival (DFS),2011-11,TERMINATED,INTERVENTIONAL,['NA'],Overall survival (OS),Operative complication rate
5657,NCT05549960,Feasibility of pre-planned laser setting in lesion ablation,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of resectability
5658,NCT02236884,Composite mesure of prioperative feasibility and safety,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Composite mesure of oncological outcome
5659,NCT01668680,"Length of progression free survival (PFS), measured in months.",2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Quality of life, as expressed by FACT-C."
5660,NCT00278876,2-year Relapse Free Survival Rate,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
5661,NCT01613950,Incidence rate of Dose Limiting Toxicities.,2012-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of adverse events (AEs)
5662,NCT02508532,"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1",2015-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT"
5663,NCT04454762,Blood pressure [Safety and Tolerability],2020-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related quality of life (HRQOL)
5664,NCT04991090,the responsive rate of dose escalation of LLN,2021-08-13,RECRUITING,INTERVENTIONAL,['NA'],,prognosis outcome-3-year Lateral Local Recurrence
5665,NCT01640782,"Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.",2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
5666,NCT00075868,"Prevention of the incidence of moderate, severe, or life-threatening diarrhea",2003-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea"
5667,NCT01677468,Survival rate of the subjects,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate of TACE
5668,NCT00151476,Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA,2004-11,TERMINATED,OBSERVATIONAL,['NA'],,Rectal or Pouch Adenoma Burden Based on Polyp Counts
5669,NCT04984018,OS,2021-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],PD-L1 CPS,DCR
5670,NCT03724851,Maximum Tolerated Dose,2018-11-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamics of TEW-7197
5671,NCT05504265,Postoperative pain score,2022-08-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Rate of pulmonary infection
5672,NCT05628545,Overall Survival,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS（Progression-Free Survival )
5673,NCT03342937,Months of Progression-free Survival (PFS),2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Months of Overall Survival
5674,NCT04663763,pCR rate,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Scale
5675,NCT05709249,Two-year disease-free survival (DFS),2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in total score on the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM)
5676,NCT00855985,pancreatic fistula rate,2004-07,UNKNOWN,INTERVENTIONAL,['NA'],,major complication
5677,NCT03467308,Measure TRIM59 in the study groups.,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Targeting new prognostic and therapeutic markers for colorectal cancer.
5678,NCT05384444,Disease-free Survival,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],,insulin
5679,NCT01165346,non-progression part,2009-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Medical costs
5680,NCT03707080,Time to HCC recurrence - Prospective Cohort,2018-03-09,COMPLETED,OBSERVATIONAL,['NA'],,Number of events of early HCC recurrence - Prospective Cohort relative to Historical Cohort
5681,NCT02439385,Progression-free survival,2015-08-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Fatigue (FACIT-Fatigue scale (version 4, Korean version)"
5682,NCT00096278,Disease-free Survival,2004-09-15,COMPLETED,INTERVENTIONAL,['PHASE3'],Proteinuria After Completion of Bevacizumab,Survival
5683,NCT05627297,Good/Poor overall survival,2022-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
5684,NCT04599140,Incidence of adverse events (AEs),2020-10-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker analysis,Overall survival (OS)
5685,NCT00568529,Response Rate,2007-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],,time to progression and overall survival
5686,NCT02464215,Postoperative complication rate,2014-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,3-year disease free survival rate
5687,NCT03822572,Primary Endpoint - disease free survival (DFS),2019-02-14,RECRUITING,INTERVENTIONAL,['NA'],,Exploratory Endpoint - molecular and biochemical markers (will be defined during the course of the study)
5688,NCT04999332,Curative resection rate,2021-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-emergent adverse event rate
5689,NCT00084929,Number of Participants With Advanced Adenomas (>=5mm) Detected by CT Colonoscopy (Per Patient),2005-02,COMPLETED,INTERVENTIONAL,['NA'],,Interobserver Sensitivity Variability
5690,NCT06033482,The lymph node metastasis rates in No.12aa and No.12av groups.,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
5691,NCT04214418,Phase 1: Estimated maximum tolerated dose (MTD),2020-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability)
5692,NCT02515513,Identify gene networks within the skeletal muscle between the groups,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],,Survival data
5693,NCT01293448,Treatment effect,2010-12,COMPLETED,INTERVENTIONAL,['NA'],,Post procedure pain
5694,NCT03066557,PFS,2017-03-15,UNKNOWN,INTERVENTIONAL,['NA'],,QoL
5695,NCT04513951,Progression-free Survival,2020-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
5696,NCT03523312,The proportion of patients who undergo definitive surgery,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5697,NCT03375060,Composite histologic score of neosquamous epithelium following endoscopic eradication therapy (EET),2017-08-02,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence rate of intestinal metaplasia (Barrett's esophagus)
5698,NCT01585662,recurrence rate of pancreatic pseudocyst,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The complication rate
5699,NCT03309722,distant recurrence,2008-10-10,RECRUITING,OBSERVATIONAL,['NA'],,
5700,NCT03655002,Incidence of adverse events,2019-02-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Circulating immune cell profiles circulating tumor deoxyribonucleic acid (DNA),Overall survival
5701,NCT00480584,Maximum Tolerated Dose (MTD),2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recommended Phase II Dose (RPTD)
5702,NCT05626569,1-year progression-free survival,2022-12-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related adverse events
5703,NCT00003835,Survival,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5704,NCT01738217,"Third step: assess the rate of patients in whom, among the 7 liver segments, the surgeon will be able to selectively target a predefined area.",2013-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Third step: assess the ability of the medical device to detect tumor lesions which were previously known.
5705,NCT00902733,"Quality of life, psychological distress, symptom relief, geriatric assessment outcome, and resource use at 3 months",2008-07,COMPLETED,INTERVENTIONAL,['NA'],,Long-term impact at 6 months
5706,NCT01263002,Proportion of patients with HBV DNA levels < 60 IU/mL,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,
5707,NCT02633020,Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes,2016-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12
5708,NCT00209690,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.
5709,NCT00004103,,1998-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5710,NCT06161909,disease-free survival (DFS),2024-01-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,recurrent metastasis pattern
5711,NCT00166881,Overall survival (OS),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Objective response rates (CR, PR)"
5712,NCT05625737,Objective Response Rate (ORR),2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory endpoint,Adverse Event (AEs)
5713,NCT03895723,disease-free survival (DFS),2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sugical complications
5714,NCT04269941,number of patients operated for gastric GIST,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
5715,NCT01444014,Visual assessment of the distribution of gastric carcinoids.,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma or serum concentrations of biomarkers such as gastrin and chromogranin A (CgA)
5716,NCT05099211,Acceptability of the program in terms of the number of sessions attended,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5717,NCT00216034,Time of recurrence (calculation of 3-year disease-free survival and overall survival rates),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers"
5718,NCT02598414,Anastomotic leak rate,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Mortality
5719,NCT02454075,A Reduction of 25% in the Gastric ECL Cell Density.,2011-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Acid Control Study 3, Control of Gastric Acid Secretion Assess by Changes in Drug-controlled Gastric Acid Analysis: Acid Output"
5720,NCT01828918,postoperative early recurrence,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
5721,NCT02230410,Eradication of Barrett's Esophagus,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
5722,NCT01893801,Complete Response Rate,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival
5723,NCT00642733,Overall survival; time to progression,2007-08,TERMINATED,INTERVENTIONAL,['PHASE4'],,"AEs, lab parameters"
5724,NCT04143191,Recurrence-free survival,2019-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
5725,NCT05636618,Area under the concentration-time curve (AUC) [Time Frame: 42 days following last dose of [212Pb]VMT-α-NET; up to 3 years,2023-09-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Biodistribution of [212Pb]VMT-α-NET using a microdose of the therapeutic surrogate, [203Pb]VMT-α-NET"
5726,NCT01302613,The primary study endpoint for the phase I portion of this study is to assess surgical complications through the Clavien grading system.,2011-03,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The primary endpoint of the phase II portion of the study is complete pathologic response.
5727,NCT05562297,2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Correlation among ctDNA, serum tumor markers, and CT evaluations before and after neoadjuvant therapy, before and after curative resection, during and after adjuvant therapy, and during and after the maintenance treatment of immunotherapy."
5728,NCT04869956,Surgical site infection,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Recurrences of CRC after surgery
5729,NCT05801965,Cancer-specific Quality of Life,2023-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,User engagement
5730,NCT03521037,Area under the plasma rucaparib concentration-time curve from time zero up to the last time point with quantifiable concentration (AUC0-last),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],Cumulative amount of rucaparib metabolite(s) excreted in urine during urine collection period post rucaparib dose,Incidence of dose modifications [Safety and Tolerability]
5731,NCT03252808,Dose Limiting Toxicity (DLT),2017-09-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],1 year survival rate,Progression-free survival (PFS) by irRECIST
5732,NCT00699374,Overall Survival (OS),2008-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,European Quality of Life (EQ-5D)- Health State Profile Utility Score
5733,NCT04304209,complete response rate,2019-10-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor response
5734,NCT00611858,Pathological Complete Response Rate,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],1-Year Disease-Free Survival Rate,1-Year Overall Survival Rate
5735,NCT00245362,Overall survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5736,NCT03150615,Incident rate of delayed gastric emptying,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Maximum Plasma Concentration fasting plasma GLP-1 level
5737,NCT05297903,Objective Response Rate (ORR),2022-04-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR) in patients who did not received prior immunotherapy
5738,NCT05951842,Postoperative immune function (NK cell count),2018-04-16,WITHDRAWN,INTERVENTIONAL,['NA'],,
5739,NCT04792892,Toxicity related to treatment,2021-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Sexual function
5740,NCT01402687,Develop and validate a clinically applicable SNP-based screening platform for mucositis risk,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
5741,NCT03886753,Change in symptoms,2019-05-15,TERMINATED,OBSERVATIONAL,['NA'],,Assess therapeutic range
5742,NCT02606305,"Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",2016-03-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine
5743,NCT00281788,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5744,NCT06165328,Diagnostic yield in diagnosis colorectal tumor,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Procedure-related adverse events
5745,NCT04535401,"Maximum tolerated dose (MTD) of elimusertib (BAY 1895344) in combination with irinotecan, fluorouracil, and leucovorin (FOLFIRI)",2021-08-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Status of deoxyribonucleic acid damage repair (DDR) genes,ATM status
5746,NCT04566133,Median Progression Free Survival (PFS),2022-02-15,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Survival
5747,NCT03852290,Assessment of C677T and A1298C MTHFR polymorphisms and response rate,2019-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of C677T and A1298 MTHFR polymorphisms and toxicity
5748,NCT01425879,Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
5749,NCT05930496,Acceptability,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Effects of an 8 week supervised exercise intervention on fecal concentrations of other short chain fatty acids
5750,NCT00911092,Initial complete clinical response,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Prolonged clinical response at one year
5751,NCT01472250,chemotherapy regimen,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,treatment expense
5752,NCT01891552,time to progression,2013-05,COMPLETED,OBSERVATIONAL,['NA'],quality of life,number of adverse events
5753,NCT04651504,Number of colonoscopy completions after positive fecal immunochemical test,2020-12-02,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients who complete a complete diagnostic evaluation within 60 days of positive fecal immunochemical test
5754,NCT02542670,Number of cancer patients with abnormal genetic mutations .,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,
5755,NCT00427102,Determine pharmacokinetic parameters of oral MRX-1024.,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.
5756,NCT01050426,"One year overall survival, measured from the date of registration.",2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Evaluation of the role of FDG-PET in predicting overall survival, progression free survival and objective response rate in locally advanced pancreatic cancer."
5757,NCT00230451,To determine the rate of complete histologic response induced by this neoadjuvant chemotherapy and radiation therapy regimen.,1997-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the qualitative and quantitative toxicities of this regimen.
5758,NCT00518557,"Safety and tolerability, Mortality",2007-04,UNKNOWN,INTERVENTIONAL,['NA'],,"Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival"
5759,NCT01330186,Tumor response,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
5760,NCT00071994,Progression-free survival rate in patients treated with ZD 1839,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,EGFR expression
5761,NCT04571294,Overall Survival (OS),2020-05-26,RECRUITING,INTERVENTIONAL,['NA'],,post-operative outcomes
5762,NCT06078657,1 year overall survival rate,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],biomarker,adverse events
5763,NCT00447967,Objective Response Rates,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Symptoms improvement
5764,NCT05196334,Comparison between organoid's and patient's response,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
5765,NCT02761408,Number of participants with treatment-related adverse events assessed by CTCAEv5.0,2016-04,UNKNOWN,OBSERVATIONAL,['NA'],,
5766,NCT04015804,Conversion rate for robotic surgery,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Operating time
5767,NCT00152243,Overall survival and relapse-free survival,1997-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
5768,NCT00766142,Median Progression-free Survival (PFS) Time,2007-05-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Time
5769,NCT00637988,Measure PGE production in Barrett's metastatic tissue & determine the reduction from baseline of PGE production would be equivalent on Day 10 in esomeprazole 40mg bid + aspirin treatment compared to esomeprazole 40 mg bid + rofecoxib 25 mg qd treatment,2002-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,"To determine in which of the four treatment groups the reduction in the baseline in PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue is the greatest."
5770,NCT01926236,Overall survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality adjusted life years (QALYs)
5771,NCT02532803,Measurement of the accuracy of a novel MRI assessment tool to accurately stage Early Rectal Cancers and Polyps,2015-08-13,UNKNOWN,INTERVENTIONAL,['NA'],,Measurement of the Sensitivity and specificity of MRI for lymph node metastasis
5772,NCT02175992,Health-related quality of life,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
5773,NCT02975141,MTD of afatinib in combination with gemcitabine/nab-paclitaxel,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Emergent Adverse Events
5774,NCT00784446,Dose limiting toxicity.,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of overall response rate and progression free survival.
5775,NCT01239355,Progression-free Survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5776,NCT04082364,Objective response rate (ORR) for non-microsatellite instability-high (non-MSI-H) patients (Cohort A),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of patients who have ADA to tebotelimab
5777,NCT05290480,'Patient Mobility and Observer Mobility Scale,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
5778,NCT04852367,To quantify the enhancement in intratumoural doxorubicin concentration when delivered with ThermoDox® and mild hyperthermia generated non-invasively by focused ultrasound (FUS) compared to free drug alone,2021-06-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],To assess effects of ThermoDox® and FUS treatment compared to free drug alone on pancreatic tumour biomarkers,Change in patient symptom scores in patients with pancreatic cancer treated with of ThermoDox® and FUS compared to those treated with doxorubicin
5779,NCT02254941,Overall survival,2014-08,UNKNOWN,OBSERVATIONAL,['NA'],,Study other variables to identify whether there is group of patients who may benefit from monoclonal antibodies for the treatment of first-line chemotherapy
5780,NCT04534309,Weight change at 6 months in Coach-Directed Program,2020-09-22,COMPLETED,INTERVENTIONAL,['NA'],Weight change at 12 months by program,Weight change at 6 months in Self-Directed and App-Directed Weight Loss Programs
5781,NCT03342677,Comparison of Gd-EOB-DTPA enhanced liver MRI and CT scan images in characterizing cirrhotic nodules and HCC in liver transplant candidates,2017-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,Investigation of Gd-EOB-DTPA enhanced MRI efficacy in diagnosis and staging of HCC in cirrhotic patients and its potential impact on liver transplantation eligibility in patients who are liver transplant candidates
5782,NCT02877589,hepatitis B virus (HBV) serological status,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,hepatitis C virus (HCV) serological status
5783,NCT05204433,effectiveness of methylation markers from stool samples,2019-01-05,UNKNOWN,OBSERVATIONAL,['NA'],,assess the capacities of RF model in screening potential clinical biomarkers.
5784,NCT01523808,Number of Patients With Dose-limiting Toxicities up to Week 4 After Treatment,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Summary of CA 19.9 Over Time
5785,NCT02636738,Technique success,2016-06-06,TERMINATED,INTERVENTIONAL,['NA'],,
5786,NCT00210106,Complete Hepatic Response Rate at 3 Months,2003-06,COMPLETED,INTERVENTIONAL,['NA'],,Event-free Survival
5787,NCT05536362,Measurement of Post-operative Pain,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5788,NCT02818907,"disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014)",2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,
5789,NCT00601705,Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate,2008-01-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Postoperative Adjuvant Chemoradiotherapy Feasibility
5790,NCT01221324,postoperative inflammatory complications,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,Anastomotic leakage
5791,NCT01625351,Feasibility of haploidentical HSCT,2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,event-free survival
5792,NCT01787864,Presence of dysplasia before and after ablation,2013-02,COMPLETED,OBSERVATIONAL,['NA'],,
5793,NCT02359565,Change in the percentage of CD8+ T cells that are PD-1+ due to treatment with pembrolizumab (Stratum C),2015-05-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Changes in quantitative imaging parameters
5794,NCT04095364,Progression-free survival (PFS),2019-09-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adherence to letrozole maintenance therapy
5795,NCT00164944,To find the prevalence of adenomas and advanced neoplasms of the first degree relatives,2004-04,COMPLETED,OBSERVATIONAL,['NA'],,
5796,NCT05409417,Drug Safety,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,DCR
5797,NCT02975661,Disease free survival (DFS),2017-02-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Concomitant medication
5798,NCT00012389,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,
5799,NCT03716596,overall survival,2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Related tumor markers
5800,NCT01275664,Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis),2011-06,TERMINATED,INTERVENTIONAL,['NA'],,Percentages of Patients With NIDL Based on FLIE
5801,NCT03006705,Relapse-free survival (RFS),2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety will be analyzed through the incidence of laboratory abnormalities
5802,NCT01053104,"Toxicities (frequency at each of grades 2, 3 and 4, over all cycles)",2009-11,COMPLETED,OBSERVATIONAL,['NA'],,Dose intensity in mg/m2/week and toxicities as for stage 1
5803,NCT03447431,To develop biological tools to simplify screening in future clinical assays,2018-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,
5804,NCT02591030,overall survival,2015-12-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,quality of life (EORTC QLQ-C30 )
5805,NCT00991952,Overall Response Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5806,NCT04791644,This study will compare fecal microbiota richness and composition differences between LS patients with no previous adenoma at inclusion in AAS-Lynch study and LS patients with history of adenoma or adenoma at inclusion in AAS-Lynch study.,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],,Gut microbiota composition description
5807,NCT03748927,"Characterize the natural history of Fibrolamellar hepatocellular carcinoma (FL- HCC), including clinical presentation, family history, patterns of disease progression, response or lack of response to therapeutic interventions, disease recurre...",2019-04-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
5808,NCT01471249,improvement of dysphagia post stenting,2011-06,TERMINATED,OBSERVATIONAL,['NA'],,Quality of life post stenting
5809,NCT03721653,Progression Free Survival (PFS),2018-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,2nd-PFS
5810,NCT05128123,"The primary objective will be to assess the rates of curative treatment (either resection, ablation or liver transplantation) according to the social determinants of health",2022-01-21,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of the relationship between social health determinants and the quality of life of patients at 6 and 18 months after inclusion in the CHIEF cohort study
5811,NCT03751176,Progression-free survival at 6 months,2018-11-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Biomarkers analysis by liquid biopsies.
5812,NCT00438906,To determine the diagnostic yield of screening high risk patients,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
5813,NCT00503321,progression-free survival,2006-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors"
5814,NCT00083122,Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR),2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
5815,NCT01310972,"OS, PFS, DFS",2007-09,COMPLETED,OBSERVATIONAL,['NA'],,
5816,NCT03972956,Confirmation of diagnosis by pathologist,2020-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
5817,NCT04027088,Surgical fistulas,2019-08-10,UNKNOWN,INTERVENTIONAL,['NA'],,Weight loss
5818,NCT05019794,Objective Response Rate (ORR),2020-05-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Accumulation ratio (Racc)
5819,NCT03410914,Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF),2018-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Average Length of Stay in Hospital
5820,NCT01790139,Colonic bubble-related image quality,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,diagnostic performance
5821,NCT04820712,Overall survival,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Cancer-specific survival
5822,NCT00853684,Time to progression,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
5823,NCT04766502,Peritoneal Regression Grading Score (PRGS),2022-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life mesure
5824,NCT06216743,Sensitivity and specificity of different MRI sequences to diagnose T4 colon carcinoma.,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Establishing an MRI Protocol that is optimized for the clinical staging of colon tumors
5825,NCT05674773,Metachronous (advanced) neoplasia,2019-05-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Associations with treatment choice
5826,NCT00290615,Response Rate (Percentage of Participants With Partial or Complete Response),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Effect on Wound Angiogenesis,Overall Survival
5827,NCT02560623,DNA Yield,2015-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Specificity of Barrett's Dysplasia Detection
5828,NCT04269499,Feasibility of MR imaged administration of holmium microspheres,2019-11-11,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response after 3 months based on CT imaging (according to RECIST 1.1 criteria)
5829,NCT02776683,Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-Free Survival (PFS) Time as Assessed by Central Imaging Review
5830,NCT06251050,The incidence of Severe Oral mucositis (WHO grade ≥3),2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Taste function
5831,NCT04574245,5-year overall survival,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The prognostic predictive value for patients with different C-GCLM classification
5832,NCT04942665,Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Qualitative Assessment of Overall Intraoperative Visualization of the Extrahepatic Biliary Tree (Common Hepatic Duct, Cystic Duct, Common Bile Duct, Aberrant Ducts)"
5833,NCT02077777,Molecular analysis of gene expression levels of μ-protocadherin and other related proteins,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid"
5834,NCT00402025,Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change From Baseline in Pain Intensity
5835,NCT06314737,Overall Survival,2010-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5836,NCT04417699,Achieve a reduction by at least 5.8 in Neoadjuvant Response (NAR) score compared to historic controls with NAR of 14.59,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
5837,NCT02792023,The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value),2016-06-30,UNKNOWN,INTERVENTIONAL,['NA'],,The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy
5838,NCT00002689,Survival,1995-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patterns of failure
5839,NCT03547999,Overall Survival (OS),2018-06-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
5840,NCT01874938,Progression Free Survival (PFS) Rate,2013-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS
5841,NCT06223061,"Compliance to pre-, intra-, and post-operative audit standards",2023-07-31,RECRUITING,OBSERVATIONAL,['NA'],,Rates of unsuspected gallbladder cancer.
5842,NCT01133340,To define the usefulness of Endoscopic clip placement and 3T-MRI imaging for accurate target volume definition in rectal cancer patients undergoing pre-operative chemoradiation.,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,To assess the differences in pelvic lymph node (CTV) volume definition between Ct and MRI images.
5843,NCT00047762,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
5844,NCT02715089,Progression-free survival (PFS),2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse Drug Reaction (ADR)/Adverse Event (AE)
5845,NCT00349076,"Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.",2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Resection rate, rate of sphincter preservation, tumor regression, cumulative incidence of local and distant recurrences, overall survival, toxicity, quality of life"
5846,NCT05523960,the rate of major complications,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5847,NCT03975049,Disease-free survival,2019-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Tumor regression grade after neoadjuvant therapy,Treatment related quality of life
5848,NCT00489697,evaluation of the response to bevacizumab based chemotherapy by RECIST criteria,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,survival time
5849,NCT03434834,Percentage of Imaged Sites Correctly Categorized as Barrett's Mucosa,2018-09-25,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Imaged Sites With Adequate Tissue Contact to Acquire a High Quality Image
5850,NCT04258137,Assessment of cancer outcome in terms of overall survival (2 distincts population),2020-09-04,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of patients treated with a targeted therapy (in 2 distincts populations)
5851,NCT00084591,Acute toxicity by CTCAE at 6 weeks following study completion,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery
5852,NCT03564912,DFS,2018-08-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
5853,NCT00620607,response rate,2007-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,effect of huC242-DM4 on tumor uptake of FDG
5854,NCT00362102,Response according to the RECIST criteria accessed every 6 weeks,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to progression, duration of achieved response, and the disease control rate will be accessed in all patients who received Cetuximab. The worst toxicity grades per patients will be tabulated for adverse events and laboratory measurements."
5855,NCT06331988,Relapse free survival,2022-07-21,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5856,NCT02942329,Overall survival rate,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety as measured by the rate of AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4 )"
5857,NCT01978444,3-year disease free survival,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],Postoperative intraperitoneal free cancer cell (IFCC),3-year overall survival
5858,NCT04711473,Colorectal Cancer Screening Completion,2021-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Choice of Colorectal Cancer Screening Test
5859,NCT00587145,To evaluate the clinical responses to preoperative S-1 plus docetaxel,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the clinical downstaging,the pathologic responses, toxicity profile,the disease-free survival,overall survival,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics and the difference in pharmacokinetics between before and after gastrectomy"
5860,NCT05522894,Objective response rate (ORR),2022-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The level of ctDNA in blood,Incidence and severity of adverse events(AEs)
5861,NCT00858871,To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,To compare health-related quality of life
5862,NCT06134765,The incidence of reduced absolute neutrophil count(ANC) of grade ≥3 in the first cycle of chemotherapy,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5863,NCT03124394,Overall Survival,2015-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Cost-effectiveness
5864,NCT03064828,Sensitivity and specificity of low-dose CTC for the polyp detection,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,Sensitivity and specificity of CTC for the detection of poly malignancy
5865,NCT05137899,Hepatectomy,2022-10-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity to Atezolizumab/Bevacizumab
5866,NCT02570399,Feasibility in terms of toxicity related to radiation therapy,2015-02-26,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life questionnaire of treated patients
5867,NCT02019199,Tumor Motion,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
5868,NCT02329106,Evaluate the safety of IRE for unresectable liver cancer close to diaphragmatic dome using Common terminology Criteria for Adverse Events (CTCAE).,2014-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Evaluate the efficacy of IRE for unresectable liver cancer close to diaphragmatic as measured by cell death of CRLM after IRE is demonstrated macroscopically by using vitality-staining with triphenyl-tetrazoliumchloride (TTC)
5869,NCT03302858,Percent of patients who have histologically cleared high-grade squamous intraepithelial lesions (HSIL) at the SCJ at 12 months as measured by HRA,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percent of patients who have histologically cleared low-grade squamous intraepithelial lesions (LSIL) at the SCJ at 12 months as measured by HRA
5870,NCT03448731,Efficacy in the prevention of skin toxicity,2018-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
5871,NCT04843956,Quality of the sample in relation to the technique,2020-01-08,UNKNOWN,INTERVENTIONAL,['NA'],,Sample contamination relative to technique
5872,NCT03137004,six-month overall survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Event（AE）
5873,NCT01465451,disease-free survival,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety profiles
5874,NCT02498613,Objective response rate,2016-08-31,TERMINATED,INTERVENTIONAL,['PHASE2'],Changes in levels of angiogenesis/ inflammatory markers (angiome panel) (all cohorts),Progression-free survival
5875,NCT00033735,Survival of Irofulven vs. 5-FU,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Tumor Response of Irofulven vs. 5-FU and Clinical Benefit of Irofulven vs. 5-FU
5876,NCT02793479,Elimination Rate of Barrett's Esophagus in the study population,2017-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5877,NCT03386500,"Count of Adverse events, serious adverse events and dose limiting toxicities",2017-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Single-dose and repeated-dose pharmacokinetic profiles of BMX-001,Effect of study treatment on locoreginal progression free survival survival (PFS).
5878,NCT04800497,Association between circulating tumor cells and disease-free-survival,2019-02-07,RECRUITING,OBSERVATIONAL,['NA'],,Association between circulating tumor cells and overall survival
5879,NCT00321594,Tumor Response in Patients With Inoperable HCC Using Belinostat (Phase II),2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
5880,NCT05720598,The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients.,2022-11-04,RECRUITING,INTERVENTIONAL,['NA'],,Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapy
5881,NCT05022927,Safety of ERY974 (Dose limiting toxicities) [Mono dose escalation part],2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Biomarkers of ERY974 [Mono dose escalation part]
5882,NCT00597311,recurrence rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Impact on quality of surgical resection
5883,NCT03731819,Table time of Abbreviated PB MRI,2018-11-05,COMPLETED,INTERVENTIONAL,['NA'],,Requirement for re-examination
5884,NCT01860846,Total Activity Impairment (TAI),2013-05,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Serious Adverse Events
5885,NCT03516916,"Impact of demographic, socioeconomic and religious factors on HRQoL in rectal cancer survivors with a colostomy",2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5886,NCT01977053,"emotional state (anxiety, depression, confusion, angry, fatigue, force and interpersonal relation)",2013-09,COMPLETED,INTERVENTIONAL,['NA'],intervention cost,relationship between psychosocial criteria and anxiety
5887,NCT04947696,Changes in DNA-methylation patterns from the pre to postoperative setting,2021-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse of pancreatic cancer
5888,NCT00711191,Number of Participants With Dose Limiting Toxicities (DLTs),2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Recommended Phase 2 Dose (RP2D) of CP-870893 in Participants With Advanced Pancreas Cancer,Carbohydrate Antigen 19-9 (CA 19-9)
5889,NCT05566743,PFS,2022-09-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
5890,NCT02974556,Incidence of endoperitoneal recurrence at 36 months,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 Summary Score
5891,NCT02253602,Ferumoxytol dose response,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,
5892,NCT03671369,Number of Participants With Serious Adverse Events (SAEs) and Fatal SAEs,2018-10-02,COMPLETED,OBSERVATIONAL,['NA'],,
5893,NCT05197933,3-year disease-free survival rate (DFS),2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course（Highest Body Temperature）
5894,NCT00004248,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5895,NCT05364489,Progression Free Survival (PFS),2022-06-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-Related Safety Indicators
5896,NCT00091026,Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST),2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5897,NCT00004884,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
5898,NCT01539018,time to progression (TTP):recist criteria,2012-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Using EQ-5D questionnaire.
5899,NCT02309619,Mortality and complications.,2008-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life.
5900,NCT00386984,Overall survival time,1999-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Prognostic relevance of the Somatostatin receptors
5901,NCT00044967,overall survival,2002-05,COMPLETED,OBSERVATIONAL,['NA'],,
5902,NCT06236568,Survival,2024-02-06,RECRUITING,INTERVENTIONAL,['NA'],,Graft survival
5903,NCT05320692,PFS assessed by BIRC,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
5904,NCT00539643,Response to Treatment by RECIST Criteria,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
5905,NCT05292443,PFS: Progression-free survival,2021-12-20,WITHDRAWN,OBSERVATIONAL,['NA'],,TTD: Time to Treatment Discontinuation
5906,NCT02546973,HRQL in patient's with anal cancer 3 years after diagnosis,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"HRQL (measured by questionnaires) differences between patient groups such as age, gender and educational level"
5907,NCT02745639,Pathological response rate,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
5908,NCT01075633,Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No],2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complications rate
5909,NCT05034185,To evaluate the diagnostic performance of the CADx support tool compared to optical prediction of polyp histology by the Clinician in real-time colonoscopy in a clinical setting,2021-03-03,COMPLETED,OBSERVATIONAL,['NA'],,To determine the diagnostic performance of CADx versus optical prediction of polyp histology by endoscopist in the subgroup analysis
5910,NCT03703063,Treatment safety as assessed by CTCAE v4.03,2018-09-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Response rate
5911,NCT01057355,Decrease in volume of the pancreatic cyst by cross-sectional imaging studies (CT or MR) performed before and after treatment,2010-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
5912,NCT02482259,Time taken to complete assessments,2013-12-01,COMPLETED,OBSERVATIONAL,['NA'],Biomarker assessment of frailty and associated factors,Muscle mass and timed get up and go as predictors of outcome
5913,NCT05178745,Assessment of resection rate (R0/R1),2016-09-07,COMPLETED,OBSERVATIONAL,['NA'],,Safety (serious and non-serious adverse events occurring during treatment
5914,NCT05991947,Differences in ctDNA gene and tumor-specific proteins expression,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
5915,NCT00720993,- To select a threshold for Mahalanobis distance to determine the best operating characteristics (sensitivity and specificity) in subjects with cancer and subjects without cancer. - To explore other empirical metrics based on previous exploratory data,2008-08,UNKNOWN,OBSERVATIONAL,['NA'],,"- To obtain data to estimate sensitivity, specificity, and the ROC curve for a test based on M-distance. - To determine the variability of sensitivity and specificity estimates"
5916,NCT00428285,High grade dysplasia (AIN 2/3),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability and safety of the treatment
5917,NCT02151019,Reduction in incidence of grade 2 or higher GI toxicity,2014-10-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Differences in the toxicity profile between the two types of neoadjuvant concomitant chemotherapy, graded by the NCI-CTCAE Version 4"
5918,NCT01775449,Cold pain thresholds,2013-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,QLQ-C30 (Quality of Life questionnaire C30)scores
5919,NCT02612077,Progression-free Survival,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life - Global Health Status
5920,NCT01415479,Intention to undergo CRC screening in the next six months,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Completion of CRC screening
5921,NCT03832621,"Evaluate the efficacy, measured as 8-month PFS rate, of the combination of temozolomide, nivolumab and ipilimumab in patients achieving disease control following 2-month lead-in treatment with single agent TMZ",2019-03-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Evaluate the tumor mutational load,Assess quality of life
5922,NCT00423306,Response Rate,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicities
5923,NCT05871099,5-years Recurrence-free survival,2022-11-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxic and side effects of the program
5924,NCT04687384,Changes in levels of systemic inflammatory response expressed by CRP and IL-6 in serum between the two groups,2021-08-01,UNKNOWN,INTERVENTIONAL,['NA'],Time to local cancer recurrence or metastatic spread,Time to first bowel movement
5925,NCT04383210,Objective Response Rate,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
5926,NCT05231850,Primary End point: Disease Free survival [ Time Frame: 3 years ],2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5927,NCT02891538,Change in methylation from baseline when compared to the control arm,2017-01-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
5928,NCT01666145,Successful Insertion of Ablation Antenna Into Target Lesion,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Significant Ease of Lesion Targeting Using Advanced Image Guidance (AIM)
5929,NCT04599790,Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST),2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,DOR assessed by investigators according to mRECIST.
5930,NCT03807518,Change in Physical Fitness,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in concentration of blood markers of Inflammation- White Cell Differential
5931,NCT01279291,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,"To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy."
5932,NCT03034850,Blood loss,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,Maximum Lysis (ML) HEPTEM Rotational thromboelastometry (ROTEM)
5933,NCT01501240,"Diagnostic sensitivity of gadoxetic acid-enhanced MR imaging to detect HCC in the cirrhotic liver, using thin-section whole-explant as the standard of reference",2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],,To characterize borderline hepatocelluar nodules
5934,NCT02394535,Maximum tolerated dose defined as the highest dose level in which 6 patients have been treated with at most 1 instance of dose limiting toxicity (DLT) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2015-11-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI)
5935,NCT01657773,Statistical analysis,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Laboratory Assay and Measurement
5936,NCT02000089,Evaluate pancreatic juice for early cancer markers.,2014-01-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Diagnostic performance of a tumor marker gene test for CA19-9 interpretation,Compare pancreas juice with pancreas cyst fluid
5937,NCT04720716,Objective response rate (ORR),2021-02-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of Treatment-Emergent Adverse Events
5938,NCT02780921,percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
5939,NCT05887505,Ratio of liver failure,2023-06-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complications after surgery
5940,NCT02893930,Overall Response Rate,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
5941,NCT03839550,Recurrence-free survival(RFS),2019-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5942,NCT01673607,,2012-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5943,NCT03960775,CRP level in blood,2019-04-30,COMPLETED,INTERVENTIONAL,['NA'],,HOD (hospital days)
5944,NCT01466504,p63 expression levels,2011-05,TERMINATED,OBSERVATIONAL,['NA'],,Tumor response
5945,NCT06056726,Peri-operative complications,2021-02-18,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
5946,NCT00889187,Grade 3-5 Toxicity Rate [Phase II],2009-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical Mortality Rate [Phase II]
5947,NCT02133612,3 year overall survival,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants with Adverse Events,3 year disease-free survival
5948,NCT04887805,Progression free survival,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
5949,NCT05714878,Duke Activity Status Index before surgery,2023-03-22,RECRUITING,INTERVENTIONAL,['NA'],,30-day readmission rate
5950,NCT05021250,ORR,2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Frequency of AE
5951,NCT05853094,Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing,2023-06-23,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
5952,NCT03778593,Response rate of treated participants,2019-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC -QoL-C30,Incidence of Treatment-Emergent Adverse Events of participants
5953,NCT03970694,5-year overall survival rate,2019-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,3-year progression-free survival rate
5954,NCT00554125,Disease-free survival,2007-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
5955,NCT04177875,Objective Response Rate (ORR),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of adverse events and the incidence of severe adverse events（ grade 3-4)
5956,NCT02842749,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2016-03-14,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression free survival
5957,NCT01395563,muscle mass and strength,2009-01,WITHDRAWN,INTERVENTIONAL,['NA'],,quality of life
5958,NCT01421940,Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of patients with adverse events during 24 weeks of the study
5959,NCT06119867,Comparision of the incidence of stage III colon cancer between European and Japanese pathological investigation methods.,2023-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Comparison of the extramural invasion (venous, lymphatic, perineural) between the European and Japanese pathological approaches"
5960,NCT02837029,Phase IB: Objective Response Rate (ORR),2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Circulating Free DNA (cfDNA) Mutation Analyses,Disease Control Rate (DCR)
5961,NCT05745857,Evaluate if the combination of tracers improves lesion detection by the number of invisible lesions detected,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Eventually further specify and objectify the improvement of qFME by standardisation
5962,NCT03432806,successful isolation of exosomes,2017-11-28,RECRUITING,OBSERVATIONAL,['NA'],,
5963,NCT01946139,Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry,2013-12-04,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of Anal Cancer Screening
5964,NCT02909530,Correct histological diagnosis of the mass assessed by each needle,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
5965,NCT03529760,HBV-DNA positive,2018-05-08,UNKNOWN,OBSERVATIONAL,['NA'],,
5966,NCT01261962,Gene expression,2011-02,UNKNOWN,INTERVENTIONAL,['NA'],,Humoral immunity and neutrophil function
5967,NCT05525286,Parts C and D: The assessment of the efficacy of SOT102 in monotherapy and in combination with first-line SoC treatment,2022-03-31,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Parts C and D (monotherapy and combination with SoC): Relationship between the intensity of CLDN18.2 expression and clinical outcome,Parts C and D (monotherapy and combination with SoC): Number of participants with antibodies against SOT102
5968,NCT01488487,Time to Progression (TTP),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
5969,NCT02564146,Overall survival (OS),2016-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Neurotoxicity Assessment FACT taxane score
5970,NCT03897543,Incidence of adverse events (AEs),2019-08-30,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Alpha Fetoprotein Serum concentrations
5971,NCT06000553,"the aim is to search for immune and metabolic abnormalities in patients with at-risk TIPMP in the blood or by echo-endoscopic sampling, then compare and combine them with the criteria used in clinical practice.",2023-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
5972,NCT05083780,Number of participants with treatment-related adverse events assessed by CTCAE v5.0,2021-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
5973,NCT06230328,Epidemiological profile and pathological staging,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Description of clinical condition
5974,NCT06225011,Immune cell composition and microenvironment,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
5975,NCT01956812,overall survival,2013-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Clinical benefit
5976,NCT05954429,objective response rate (ORR),2023-07-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
5977,NCT05133102,Intra-class correlation coefficients (ICC) by BE status,2021-03-19,RECRUITING,OBSERVATIONAL,['NA'],,
5978,NCT06179602,Safety as assessed by complications according to CTCAE v6.0.,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
5979,NCT00300547,Feasibility of MR colonography to diagnose possible synchronous carcinomas and polyps,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Altered operative strategy due to findings on MR colonography
5980,NCT00189683,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
5981,NCT04406857,Incidence of Dose-limiting Toxicities (Part IB),2021-03-17,TERMINATED,INTERVENTIONAL,['PHASE1'],"Interactions of Capecitabine, IPdR and Their Metabolites",Neoadjuvant Rectal Score at the Maximum-tolerated Dose
5982,NCT02550743,Maximum Tolerated Dose of BYL719,2016-06-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Pathologic Complete Response for Patients With Rectal Cancer
5983,NCT06032338,Performance of colonoscopy in FIT positive patients,2023-09-14,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness analysis
5984,NCT04415853,Overall survival,2021-01-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Apparent Volume of Distribution (Vd/F) of Lerotinib
5985,NCT03938623,number of patients screened positive using the patient-centered approach after training of face to face training or e-learning,2018-01-24,UNKNOWN,OBSERVATIONAL,['NA'],,
5986,NCT01774266,Early detection of gastric cancer,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],Detection of H.pylori and gastric atrophy,Monitoring progression of disease
5987,NCT01558947,the relapse-free survival time/rate,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
5988,NCT04611035,Efficacy of second-line therapy,2020-01-20,UNKNOWN,OBSERVATIONAL,['NA'],,Haematologic and non-haematologic toxicities
5989,NCT01281683,,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,
5990,NCT02850874,Peritoneal disease-free survival,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Postoperative mortality
5991,NCT05794048,Theranostic metabolic signatures of TNEP.,2022-06-08,RECRUITING,INTERVENTIONAL,['NA'],,Comparison of metabolic profiles on surgical specimen
5992,NCT05945082,Presence of F.nucleatum in a colon cancer biopsy,2017-11-29,RECRUITING,INTERVENTIONAL,['NA'],,
5993,NCT02291614,Number of Participants With Treatment Emergent Adverse Events (TEAEs),2014-11-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS) at 6 Months in Participants Treated at the MTD
5994,NCT00595985,time to progression,2007-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,toxicity
5995,NCT02325323,Incidence of gastric cancer or high grade dysplasia of the gastric mucosa,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,Percentage of development of gastric cancer or high grade dysplasia
5996,NCT00209625,objective tumor response,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Response duration, time to progression, median survival time, and safety"
5997,NCT04435977,PFS,2020-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety and tolerability
5998,NCT01014039,Colorectal cancer mortality,1983-03,COMPLETED,INTERVENTIONAL,['NA'],,colorectal cancer incidence
5999,NCT05914766,Self-Efficacy (CASE-Cancer),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life (FACT-C)
6000,NCT01789502,Adverse events related to the stent insertion,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Surgical outcomes
6001,NCT04911647,Re-intervention rate,2021-06,UNKNOWN,INTERVENTIONAL,['NA'],,"Procedure related complication, Postoperative complication"
6002,NCT04713241,Feasibility as measured by acceptance rate of participation in study,2022-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Nasogastric tube (NG TB) output
6003,NCT04677673,Overall Survival,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease-free survival (DFS)
6004,NCT04119622,Major pathological response rate,2019-10-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6005,NCT05535569,(Phase II) PFS,2017-07-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PFS
6006,NCT00106054,To determine the rate of R0 resection or pathologically confirmed CR in patients with hepatic only metastases,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"oTo determine the resectable rate, defined as the number of subjects with R0 resection, pathologically staged CR, or undergoing non-surgical ablative procedures with curative intent divided by the total number of evaluable subjects following treatment"
6007,NCT03808272,Clinical success rate,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,
6008,NCT00969033,Determine the difference in progression-free survival (PFS) for CS-1008 administered in combination with irinotecan and irinotecan alone.,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the Incidence of anti- CS-1008 antibody formation.
6009,NCT04985136,Stage II：Overall survival （OS）,2021-09-26,TERMINATED,INTERVENTIONAL,['PHASE3'],,Proportion of neutralizing antibody (Nab)
6010,NCT00844675,Frequency of bleeding after EMR is performed,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Measurement of a change in the size of ulcer
6011,NCT03250078,Early Stage Pancreatic Cancer or Precursor Lesions,2016-11,RECRUITING,OBSERVATIONAL,['NA'],,Serum Bio-bank
6012,NCT01579591,The impact of the probiotic preparation on increasing the TRG1-2 rate.,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Determine whether VSL#3® can have an impact on reduction of late toxicity at 12 and 36 months.
6013,NCT01395017,Overall Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
6014,NCT00954525,"Safety, assessed by toxicity (graded by NCI CTC), urinalysis, ECG, basic metabolic panel, CBC, and osmolality.",2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free survival
6015,NCT04411589,detection rate of GIN and EGC,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,diagnostic accuracy in a per-biopsy analysis
6016,NCT05828446,To compare the diagnostic performance of US+/- CEUS and AMRI for HCC detection in an at-risk population,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,To perform a cost-effectiveness analysis comparing US to different alternative screening strategies for HCC in Switzerland.
6017,NCT00810953,"Any severe events, tumor marker CA19-9, and tumor size (CT scan)",2009-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TDP
6018,NCT03280407,Disease free survival,2017-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
6019,NCT00644020,DFS(disease free survival),2007-12,UNKNOWN,OBSERVATIONAL,['NA'],,1.OS （Overall Survival） 2.QOL (quality of life)
6020,NCT00669812,Survival at 1 year,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
6021,NCT03140189,rate of major postoperative complications,2017-06-14,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,disease-free survival
6022,NCT04483076,pCR rate,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE3'],,Five-year overall survival
6023,NCT03993353,Overall Survival (OS),2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event rates
6024,NCT01125865,Stent patency,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Technical success
6025,NCT04625894,Dose-limiting toxicities (DLT),2020-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of life assessment
6026,NCT02489201,Number of participants with Adverse Events,2015-07-21,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
6027,NCT03524508,Progression Free Survival by independent central reviewer,2018-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rates determined by the independent central reviewer
6028,NCT05346757,Sensitivity for advanced colorectal neoplasm,2022-03-23,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness for advanced colorectal neoplasm detection
6029,NCT01453452,"Increase in fruit and vegetable consumption by 1 full serving per day (not including iceberg lettuce, potatoes, or fruit juices) OR reduce caloric intake by 100 kcal/day",2012-03,COMPLETED,INTERVENTIONAL,['NA'],,DNA methylation patterns
6030,NCT05530785,Objective Response rate,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,number of participants with treatment-related adverse events
6031,NCT05173610,Treatment efficacy (Disease free survival),2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events (acute and late toxicity) as assessed by CTCAE v4.0
6032,NCT00603863,"safety will be evaluated based upon physical examinations, hematology and chemistry laboratory testing as well as toxicity",2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Efficacy and Clinical benefit measures such as quality of life, pain assessments, etc."
6033,NCT00002997,,1998-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6034,NCT03272984,Postoperative length of stay,2015-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Time to semi-liquid diet
6035,NCT04329429,Objective Response Rate (ORR),2020-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
6036,NCT02602327,Maximum tolerated dose (MTD),2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biomarker response
6037,NCT05933122,Number and proportion of women with sexual dysfunction defined as a total FSFI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"Differences (Month 6 - Month -1 and Month 12 - Month 6) in the score of the ""satisfaction"" dimension of the FSFI scale (Q14-Q16) between the groups with and without treatment by a sexologist (cohort here vs. elsewhere)"
6038,NCT01132755,Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety of Peritoneal Lavage in Place of Laparoscopic Lavage.
6039,NCT05391867,Overall survivability,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
6040,NCT05181826,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2019-05-21,RECRUITING,OBSERVATIONAL,['NA'],,Ascertain Sample Stability
6041,NCT01266720,Toxicities as assessed by NCI-CACAE ver3,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Survival
6042,NCT03809247,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
6043,NCT05349331,Progression-free survival,2022-05-05,RECRUITING,INTERVENTIONAL,['NA'],Correlation of serum tumor molecular marker with survival,pCR rate in surgery group
6044,NCT00296322,Relapse-free Survival,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
6045,NCT02422095,Natural history and disease progression in pancreatic cysts,2015-02,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluate the role of plastic stents in patients undergoing EUS-guided drainage of pancreatic fluid collections.
6046,NCT06040632,ctDNA analysis,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative morbidities
6047,NCT04169399,Progression free survival (PFS),2019-11-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
6048,NCT03006263,overall postoperative morbidity rates,2016-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The variation of C-reactive protein
6049,NCT05679050,Disease-free Survival(DFS),2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Event Rate
6050,NCT06085755,ORR (Objective response rate),2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
6051,NCT03038984,cancer,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Disease course, Copenhagen IBD Disease course Type"
6052,NCT02748551,"""Major"" Surgical Morbidity",2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Extent of lymph node dissection
6053,NCT01444521,Overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to event efficacy
6054,NCT04607057,Body weight change for 2 months after surgery,2020-12-22,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Mortality rate
6055,NCT05250648,Peritoneal Recurrence Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of Life with EORTC validated questionnaire Colorectal Cancer Module (QLQ-CR29).
6056,NCT02321579,Oxidative stress marker (MDA concentation),2014-12,UNKNOWN,INTERVENTIONAL,['NA'],,Glutathione related enzyme activities
6057,NCT03833661,Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC),2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Durable Response Rate (DRR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite Instability (MSI) Status
6058,NCT04595929,Comparison of Overall survival (OS) in both arms,2020-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification
6059,NCT00002506,,1992-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6060,NCT04342676,"LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).",2017-03-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,LNR and K ras were evaluated and ASSOCIATION with PFS and OS.
6061,NCT05757492,Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS) using RECIST v1.1 assessed by the investigator
6062,NCT02043184,Medication Adherence using pill count and self report,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,Healthcare Utilization is the use of Emergency room and Hospital admissions
6063,NCT04800991,Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators,2021-03-17,COMPLETED,INTERVENTIONAL,['NA'],Frequency of Adverse Events,The investigational device(application) usage compliance by underlying disease
6064,NCT04745091,Complete pathologic response,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6065,NCT05396560,Fecal Immunochemical Test Sensitivity and Specificity,2022-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
6066,NCT05645094,cCR and pCR rates,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Acute toxicity associated with Envafolimab
6067,NCT00819559,Disease-free survival,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival Local recurrence Early or late complication associated with preoperative radiotherapy Quality of life Accuracy of clinical staging Difference of surgical outcome between laparoscopic and open surgery
6068,NCT00629421,development of hepatocellular carcinoma,2001-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6069,NCT06328283,glutamine synthetase,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6070,NCT00613080,"The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0, Occurring Preoperatively",2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Who Underwent Abdominoperineal Resection
6071,NCT03579004,Disease free survival,2017-07-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pathological complete response rate following chemoradiotherapy
6072,NCT03475966,Change in functional walking capacity as measured by the six-minute walk test (6MWT),2017-02-22,UNKNOWN,INTERVENTIONAL,['NA'],Lower extremity strength - assessment of change over time,Heart rate - assessment of change over time
6073,NCT02047513,Time to Disease free survival (DFS),2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor recurrence
6074,NCT02983045,Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D),2016-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6075,NCT04605419,Registration of treatment related pain through a Visual Analogue Score (VAS),2020-10-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The rate of patient's that have gained from the treatment
6076,NCT02064803,Change from baseline Gastric Outlet Obstruction Score System - GOOSS,2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
6077,NCT02954302,"Delayed gastric emptying,rate",2016-09,UNKNOWN,INTERVENTIONAL,['NA'],"nonsurgical complications,rate","wound infection,rate"
6078,NCT02070419,Difference in tumor grade,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Survival rate
6079,NCT02363049,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of secondary curative resection (R0)
6080,NCT00310050,Quantitative Toxicity of Pemetrexed When Administered With Concomitant Radiation Therapy,2005-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants That Survived
6081,NCT03733197,Scale development,2024-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Pilot intervention
6082,NCT03688555,Change From Baseline to Week 12 in Nasal Polyp Score as Measured by Nasal Endoscopy (Assessed Centrally),2018-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient Global Impression of Change in Disease Severity
6083,NCT00126867,,2005-05,TERMINATED,OBSERVATIONAL,['NA'],,
6084,NCT01703910,gene expression profiles,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6085,NCT04927260,Survival,2021-03-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life in real-life according to FACT-G questionnaire
6086,NCT00188331,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,
6087,NCT04310709,Response rate,2020-06-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6088,NCT01386697,,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
6089,NCT04205071,Measure the improvement in balance for patients with chronic CIPN,2020-11-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Nerve conduction test (NCT) result analysis,Improvement in patient-reported chemotherapy-induced peripheral neuropathy symptoms
6090,NCT00349024,"Symptoms, other than pain, considered important to the pediatric population",2005-07,UNKNOWN,INTERVENTIONAL,['NA'],,
6091,NCT00400179,Median Survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure (TTF)
6092,NCT04705818,Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D,2021-07-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Blood kynurenin level
6093,NCT01786122,Changes in Health Related Quality of Life (EORTC QLQ-C30),2013-04,UNKNOWN,INTERVENTIONAL,['NA'],,progression-free survival
6094,NCT00966706,Progression-free survival at 6-months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
6095,NCT01102335,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall survival
6096,NCT00474812,Median Overall Survival,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Gait Speed
6097,NCT00536614,Overall survival,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"response to treatment, and toxicity"
6098,NCT01522677,Safety,2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Sustained immunity
6099,NCT01725321,Detection rate of proximal serrated polyp,2012-10,COMPLETED,OBSERVATIONAL,['NA'],Adenoma detection rate,Missed rate for proximal serrated polyps
6100,NCT02605265,Pathologic Complete Response,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Surgical complications
6101,NCT02189226,Complete resection rate,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,adverse event
6102,NCT04591379,Safety - Adverse reactions are classified according to CTCAE version 4.0,2021-02-26,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of recovery,Efficacy - local immunological changes
6103,NCT06331403,Acceptability of Intervention,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6104,NCT04494919,The technical success rate,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,The adverse events rate
6105,NCT02048943,Incidence of adverse events graded by NCI CTCAE version 4.0,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Biomarker expression levels in tumor specimens
6106,NCT03448874,Incidence of overall subject pre-specified* procedure related Adverse Events,2018-04,WITHDRAWN,INTERVENTIONAL,['NA'],,"Incidence of ""deployment failure"""
6107,NCT00230191,The primary objective of the study is to assess the effect of RK-0202 versus placebo on the incidence and severity of oral mucositis.,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The secondary objectives of the study are to assess the safety and tolerability of RK-0202 in these subjects and to explore whether the ProGelz™ vehicle alone is active in these subjects.
6108,NCT02563002,Overall Survival (OS),2015-11-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an AE
6109,NCT01936233,recurrence free survival,2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events
6110,NCT02784353,The incidence and severity of general complication,2016-10-04,COMPLETED,INTERVENTIONAL,['NA'],,"Grasping power(dynamometer, kg)(Changes in the parameters of rehabilitation)"
6111,NCT02500147,Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%),2011-09-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,"The association of percentage liver fat with M30, a hepatic apoptosis marker"
6112,NCT02227667,Best Response Rate,2014-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Evaluated for Toxicities to Determine Safety
6113,NCT03711890,Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.,2019-03-26,RECRUITING,INTERVENTIONAL,['NA'],,
6114,NCT05975645,Overall response rate (ORR),2023-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Serious adverse events (SAEs)
6115,NCT04937322,Adverse Events,2016-01-25,COMPLETED,OBSERVATIONAL,['NA'],,stent occlusion-free duration
6116,NCT00448838,Progression-free survival,2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Time to progression
6117,NCT02145559,Pharmacodynamic Biomarker p70S6K,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Fasting Serum Glucose and Triglycerides
6118,NCT06245798,overall survival rate,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6119,NCT03139058,"Determine the prevalence, by registry data analysis, of cirrhosis in patients with VADS cancer",2018-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,
6120,NCT03233724,Maximum Tolerated Dose (MTD) of Tetrahydrouridine,2018-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose Limiting Hematologic Toxicity (DLT),"Changes in Gene, Endogenous Retroviral (ERV), Micro Ribonucleic Acid (RNA) Expressions, Deoxyribonucleic Acid (DNA) Methylation Signatures and Tumor Microenvironment"
6121,NCT04072679,Incicende of Adverse Events (AEs),2018-10-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-drug antibody (ADA)
6122,NCT03443921,Overall mortality at one year after randomization;,2018-03,UNKNOWN,INTERVENTIONAL,['NA'],,Performance status at 3 years after randomization
6123,NCT00003087,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6124,NCT00689715,recurrence during follow up,2006-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,predictive factors for complete resolution
6125,NCT00586053,To optimize diagnostic performance of CTC in the unprepared colon for colorectal polyp detection using electronic stool subtraction and computer-aided diagnostic techniques.,2000-08,COMPLETED,OBSERVATIONAL,['NA'],,The cost-effectiveness ratio of CTC in the unprepared colon will compare favorably with other colorectal screening tests
6126,NCT05593328,Overall Response Rate,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety: Exposure Response Evaluation of Onvansertib
6127,NCT02910843,Pathological near complete or complete tumor response (npCR or pCR),2017-02-22,TERMINATED,INTERVENTIONAL,['PHASE1'],,Postoperative complications
6128,NCT04338191,3-year Disease-free survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life assessed by SF-36
6129,NCT04344158,Overall survival (OS),2020-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
6130,NCT04062721,Incidence of treatment-emergent adverse events,2021-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Potential predictive biomarkers
6131,NCT04046250,Mucositis,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence Adverse Events That Are Related to Treatment
6132,NCT03449914,Evaluate the prognostic value of baseline G8 screening tool for survival.,2017-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6133,NCT04520295,Change from baseline in molecular biomarkers at time on best overall response,2020-05-19,RECRUITING,OBSERVATIONAL,['NA'],,Change from baseline in molecular biomarkers at time on disease progression
6134,NCT05787587,Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy in participants by measuring Duration of Response using RECIST criteria v1.1,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Plasma Concentration Versus Time Curve (AUC) of IDE161
6135,NCT01630798,validate binding of the fluorescent-labeled peptide to esophageal neopla,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6136,NCT04401124,assorted surgical parameters,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,hospitals' protection measures and extent of implementation
6137,NCT05442138,Tumor Regression Grading,2022-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6138,NCT05001763,"Time to defaecation, measured in hours, from the time the surgery ends till the first observed",2021-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events related to drug usage
6139,NCT02131441,abdominal adhesion,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,time to disease recurrence
6140,NCT05500391,2-year compliance to the customized surveillance plan,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],Evaluation of the causes of recruitment failures,Support care needs identified
6141,NCT06280248,Complete resolution or a decrease in the sizes of pancreatic fluid collections (PFCs),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6142,NCT02167087,Number of procedures with successful identification of sentinel nodes,2015-03,COMPLETED,INTERVENTIONAL,['NA'],,"Localization of the identified sentinel nodes, and whether or not they are included within the normal resection lines"
6143,NCT00062023,"Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol",2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6144,NCT04633122,PFS assessed by independent central review,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To compare the safety profile of DCC-2618 (ripretinib, ZL-2307) to the safety profile of sunitinib by using AE/SAE/AESI collection during study."
6145,NCT01928524,Median Overall Survival,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6146,NCT05761717,Overall survival (OS) after initial administration.,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6147,NCT04762914,Complication rate,2018-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Anaerobic threshold
6148,NCT04066543,PFS,2019-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6149,NCT05078515,Specificity of PREDICT score,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6150,NCT04837118,Aerobic fitness,2021-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of Automated Self Assisted 24-hour recall (ASA24) (24-hour dietary recall)
6151,NCT02505750,"Rate of rectum preservation either with local excision or watch and wait strategy after neoadjuvant treatment without non salvageable locally progressive disease at 3 years post treatment, or permanent stoma.",2015-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life,Tumour regression score on the operative specimen
6152,NCT03697044,Time to Hepatic Progression (TtHP),2019-01,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of Life post DEBIRI delivery
6153,NCT01270438,Progression-free survival of patients treated with FOLFOX6 plus bevacizumab with or without gamma-secretase inhibitor RO4929097,2010-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics and pharmacodynamics of gamma-secretase inhibitor RO4929097
6154,NCT01905150,12-month survival rate,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse Events,Overall Survival
6155,NCT04009811,Voice Handicap Index (VHI) overall score,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],,Head and Neck quality of life EORTC QLQ-H&N35 questionnaire score
6156,NCT01298401,Dose-limiting toxicity of ganitumab and capecitabine given concurrently with radiotherapy,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival (for patients treated at maximum-tolerated dose of ganitumab)
6157,NCT00669292,Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2006-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,survival(Phase II)
6158,NCT01225757,Fluid administration decrease,2010-11,WITHDRAWN,INTERVENTIONAL,['NA'],,Cardiac complications
6159,NCT04267575,Number of Participants With Complications Due To Cold Plasma Application,2019-07-30,UNKNOWN,INTERVENTIONAL,['NA'],,
6160,NCT03563144,Progression-Free Survival,2018-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Evaluation of safety as determined by incidence or treatment-emergent adverse events
6161,NCT06159478,Overall response rate (centrally assessed),2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event rate
6162,NCT00045747,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6163,NCT03043508,Time to Pancreatic Neuroendocrine Tumors (PNET),2015-04-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival in Participants Who Have Confirmed MEN1 with or without PNET
6164,NCT02256800,Progression-free survival,2014-08-13,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
6165,NCT00051532,"Overall survival, defined as the time from start of treatment to death",1999-09,TERMINATED,INTERVENTIONAL,['NA'],,Dose of seocalcitol (seocalcitol treated patients)
6166,NCT01022541,Overall response rates,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Other parameters of efficacy (response and survival) in patients with unresectable liver-only metastases treated with this neoadjuvant combination
6167,NCT05381753,"Dose adjustment of avapritinib in cohort 1, 2, and 3",2022-08-29,RECRUITING,OBSERVATIONAL,['NA'],,
6168,NCT03867370,Pathological response rate,2019-04-26,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
6169,NCT02919644,immunological efficacy,2016-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,evaluation of the predictive role of immune cells in tumor microenvironment
6170,NCT02093104,Liver Tumour Perfusion using CT & C-arm systems in 40 patients at VGH over a 3 month period,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,
6171,NCT01246960,Progression-Free Survival (PFS),2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Adverse Events (AEs),Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
6172,NCT03109457,Hep C cAg by Immunohistochemistry,2017-09-06,COMPLETED,OBSERVATIONAL,['NA'],,
6173,NCT01903395,utilization of preventive colonoscopy,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,time delay between signed informed consent and utilization of colonoscopy
6174,NCT00007813,,1997-05-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6175,NCT03910387,Weight stability,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response
6176,NCT01551641,Treatment efficacy,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
6177,NCT00049699,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6178,NCT04400292,The number of lymph nodes visualized to be fluorescent and nonfluorescent.,2020-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
6179,NCT02122185,Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria,2015-02-25,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0"
6180,NCT06070636,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
6181,NCT05123209,Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0,2021-08-24,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)
6182,NCT02324335,Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy,2014-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Onset of Severe Oral Mucositis (WHO Grade ≥3)
6183,NCT01508520,diagnosis accuracy of ME-NBI,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,
6184,NCT04701476,Overall Response Rate (ORR) for the NSCLC cohort,2021-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,TTP
6185,NCT00063947,Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,2003-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
6186,NCT04665362,Treatment related adverse events,2021-01-25,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression free survival
6187,NCT05428358,Change in treatment strategy,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Healthcare costs
6188,NCT05293158,HBsAg change from baseline to week 6,2024-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change of Cellular response (IFN gamma)
6189,NCT03716518,Completion Rate of 8-cycle Adjuvant Chemotherapy,2018-12-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of SAEs
6190,NCT01411072,Overall Survival,2011-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6191,NCT02855944,Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population),2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival (ITT Population)
6192,NCT03785665,Measure the variability of the motility (Whole gut transit time from ingestion to excretion {hours}) of the MD1 (Motility dummy 1) capsules in the Gastrointestinal tract of human subjects with and w/out polyps in previous Colonoscopy.,2019-06-15,COMPLETED,INTERVENTIONAL,['NA'],,
6193,NCT00558155,"During the postoperative period, all patients were observed for both surgical and non-surgical complications",2001-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,"The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay."
6194,NCT01507103,Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA) by ELISpot at Post-baseline,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Immunological Response in Peripheral Blood at Week 18 (Follow-up / end-of Trial)
6195,NCT01179724,bleeding incidence after ESD,2009-07,UNKNOWN,INTERVENTIONAL,['NA'],,the size of healing ulcer after ESD
6196,NCT02125448,"Distinct and combined sensitivity, specificity, predictive values, and accuracy of MRI and PET-CT for identifying histopathological complete response.",2013-10,COMPLETED,OBSERVATIONAL,['NA'],,Experienced patient burden (UMC Utrecht only).
6197,NCT04668872,Correlation of tissue necrosis and radiation-induced cell injury levels with delivered dose at 14-21 days,2020-12-07,RECRUITING,OBSERVATIONAL,['NA'],,
6198,NCT03322280,Overall survival (OS),2018-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of portal patency
6199,NCT05750030,"Safety of atezolizumab/bevacizumab in combination with FMT, measured by incidence and severity of treatment-related adverse events, determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.",2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Differences in serum and stool metabolomic and lipidomic signatures in patients before and after FMT.,Quality of life (QoL) as assessed by the patient-reported outcome EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level Version) questionnaire.
6200,NCT00836992,"Overall quality of life (QOL) scores at baseline, weeks 1, 3, 5, and end of treatment as assessed by LASA",2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients for which physician reports indicate that availability
6201,NCT03487016,Progression-free survival,2019-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Kinetics of circulating tumor DNA during first-line chemotherapy,Quality of life as assessed by EORTC-QLQ-C30
6202,NCT01145456,"Recommended phase II dose of RO4929097 in combination with gemcitabine hydrochloride, defined as the dose level in which no more than 1 of 6 patients or 0/3 experience DLT, graded according to NCI CTCAE version 4.0",2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response according to RECIST criteria 1.1
6203,NCT03007212,changes in Radiological Response in the (CT/ MRI) after the intervention,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6204,NCT05450393,Prospective collection of PillCamTM SB3 capsule endoscopy and DAE procedures data,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6205,NCT02038738,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"We want to determine if the 68Ga-DOTATATE PET Scan changes care plans compared to conventional imaging/diagnostic techniques (Octreoscan, MRI, CT)"
6206,NCT02369757,Participation rates,2012-10,COMPLETED,INTERVENTIONAL,['NA'],,Qualitative analysis
6207,NCT02242409,4 month progression free survival,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6208,NCT01641939,Overall Survival (OS) - Phase 2 (Dose Selection Portion of the Study),2012-09-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Systemic Clearance (CL) - Stage 1
6209,NCT04127396,Time to progression,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,adverse events(AEs)
6210,NCT00326495,Overall Rate of Response,2006-05-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Count of Participants With Adverse Events
6211,NCT02674373,Progression free survival (PFS),2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS)
6212,NCT02833298,HCC screening rates,2016-11,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of liver transplant
6213,NCT00049348,Percentage of margin-free resections produced by each program,2003-10-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of therapy and recurrence on CA19-9 values
6214,NCT03900910,The reinfection rate,2018-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
6215,NCT01011010,Safety and toxicity as assessed by NCI CTCAE v3.0 criteria,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlative studies
6216,NCT03485196,Disease Free Survival,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival(OS)
6217,NCT01813942,The number of patients correctly identified by recurrence predictive model,2013-03,UNKNOWN,OBSERVATIONAL,['NA'],,
6218,NCT01243047,To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies
6219,NCT01234272,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6220,NCT00986661,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of hepatic administration of PV-10,2009-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory Correlative Endpoints,Overall survival
6221,NCT01164722,Complete Response Through 1 Year,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of Metachronous Lesions
6222,NCT05652348,Next generation sequencing of organoid cultures,2022-12-08,RECRUITING,OBSERVATIONAL,['NA'],,
6223,NCT06050200,Successful resection,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall morbidity
6224,NCT02966483,Overall survival,2016-04,RECRUITING,INTERVENTIONAL,['NA'],,The patient's Quality of life: EORTC QLQ-30 questionnaire
6225,NCT04203160,Phase 2: Overall Response Rate (ORR),2020-06-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Toxicities
6226,NCT04136002,Specificity of advanced neoplasia detection,2019-10-08,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity of advanced adenoma detection
6227,NCT06116019,Number of Successfully Completed Adaptive Radiotherapy Sessions in Patients with Various Tumor Entities,2023-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Local Control
6228,NCT03589339,[Dose Expansion Part]: Safety Evaluation at RP2D,2019-01-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of the body kinetic profile of intratumorally injected NBTXR3
6229,NCT03032874,To determine colonoscopy polyp and cancer detection rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,To detect colorectal cancer early using symptoms based assessment
6230,NCT01098422,PFS,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,60 Day All-cause Mortality Rate
6231,NCT02312817,Repeat Screening (Every 6 Months),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Suspicious Lesion
6232,NCT02067754,Circulating tumor cell,2013-09-11,COMPLETED,OBSERVATIONAL,['NA'],"Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer",mutation profiling of circulating free DNA
6233,NCT03062358,Overall Survival (OS),2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an AE
6234,NCT00601549,Oncologic Results,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Functional recovery of patients
6235,NCT04522752,Correlation between size and pathological type of benign epithelial gastric polyp and polyp development.,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between helicobacter pylori infection and pathological type of benign epithelial gastric polyp.
6236,NCT05411133,Incidence and severity of adverse events,2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Effect of Cabotamig (ARB202) on tumour as determined by changes in RECIST evaluation from baseline
6237,NCT02118064,Number of Patients with Serious and Non-Serious Adverse Events,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6238,NCT00768001,,2008-06,TERMINATED,OBSERVATIONAL,['NA'],,
6239,NCT04230018,Mutation Consistency of metastatic and primary sites of colorectal cancer patients with postoperative metastasis,2018-12-28,UNKNOWN,OBSERVATIONAL,['NA'],prediction accuracy of survival rate,Mutation Consistency of tissue and blood sample
6240,NCT05200221,Incidence of adverse events and serious adverse events.,2022-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival(OS)
6241,NCT01899118,Pathology complete remission rate,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6242,NCT04124406,Enrollment of Subjects,2019-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,National Rates Comparison
6243,NCT05869474,Overall survival (OS),2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Visual analog scale (VAS)
6244,NCT03287843,Pathological Complete Response Rate,2006-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
6245,NCT03933449,Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus,2016-12-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)
6246,NCT01098760,For subjects randomized into HFSR study subgroup: overall HFSR incidence in the first 3 weeks of Sorafenib treatment,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,For HFSR study subgroup: a mean HFSR grade determined at the end of the first 3 weeks of sorafenib treatment.
6247,NCT05165602,the relationship between 68Ga SUVmax before treatment and the therapeutic effect will be assessed by SPSS26.0,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,the relationship between the dynamic change of 68Ga SUVmax and the therapeutic effect will be assessed by SPSS26.0
6248,NCT06091748,Specificity of 68Ga-DOTATOC PET-CT Imaging for Detection of Somatostatin Receptor Positive GEP-NET,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence and severity of AE and SAE
6249,NCT02443883,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab,2015-07-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment
6250,NCT05528783,The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.,2022-04-25,RECRUITING,OBSERVATIONAL,['NA'],,3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.
6251,NCT03464305,5 year overall survival,2018-02-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure
6252,NCT03722498,Progression-free survival,2018-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective response rate
6253,NCT03417765,Incidence of treatment-emergent adverse events,2018-09-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Assessment of quality of life
6254,NCT03457896,Progression free survival (PFS) with neratinib plus cetuximab therapy,2018-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events assessed using CTCAE 4.0
6255,NCT06035133,"tumor regression grading, TRG",2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6256,NCT03941938,Anastomotic leak,2019-05-02,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
6257,NCT02842294,"time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning)",2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,treatment preference
6258,NCT00535041,safety,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
6259,NCT00512681,Maximal overall response rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes"
6260,NCT04844112,Rate of complete ablation of the tumor after 1 month clinical follow up,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Safety of the approach route before and after the fusion process
6261,NCT03314961,Lymph node metastases in rectal cancer,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
6262,NCT05222971,6-month progression-free survival rate,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6263,NCT02475889,PD-L1 expression in primary tumor,2007-11,COMPLETED,OBSERVATIONAL,['NA'],,
6264,NCT05755672,"Follow-up examination of tumour remission, progression or recurrence",2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life changes
6265,NCT01828762,Vital signs，physical examinations and adverse events,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
6266,NCT05337137,Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2022-05-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with adverse events (AEs)
6267,NCT05495152,Disease-free Survival (DFS),2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
6268,NCT01100801,Response Rate (RR),2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6269,NCT00143533,Dose limiting toxicities,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6270,NCT04068610,Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in Part 2,2019-09-13,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Positive ADA to Bevacizumab in Part 1 (S1)
6271,NCT02581501,Identification of Maximum Tolerated Dose and Dose Intensity in Patients with Pancreatic Cancer,2016-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Assess Safety and Toxicity based upon NCI Common toxicity criteria version 4.1.,Progression Free Survival
6272,NCT05376943,The occurrence of HCC after direct acting antiviral HCV treatment.,2022-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,The difference in liver function tests among the population of patients treated with DAAs and those who were not receiving the therapy.
6273,NCT02693236,objective rate response (CR+PR) as measured by RECIST criteria,2014-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,number of participants with adverse events
6274,NCT04030260,The progression-free survival (PFS) rates at 6 months,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
6275,NCT01461148,immune response against FSP peptides,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,safety
6276,NCT02478892,"identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.",2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
6277,NCT02387307,Recommended dose (RD) of rSIFN-co,2013-07,COMPLETED,INTERVENTIONAL,['PHASE1'],"Evaluation of levels (counts) of 2'5'-oligoadenylate synthetase, before and after administration of rSIFN-co",FDG-PET response (lesion volume) before and after administration of rSIFN-co
6278,NCT06201585,The rate of postoperative complications,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Intraoperative instrument operation error rate,
6279,NCT06246448,Time to functional recovery,2024-01-23,RECRUITING,INTERVENTIONAL,['NA'],,Abdominal wall complaints
6280,NCT00164918,Bowel function and related symptoms early post-op,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6281,NCT06008925,Phase IIa:ORR,2022-11-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib :Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses
6282,NCT03578445,Clinical impact of EUS-guided microbiopsies in patients with pancreatic cystic lesions,2018-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic values of gene mutations (NGS analyses) in microbiopsy material in the surgical subcohort
6283,NCT00063141,Overall Survival,2003-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health Economics
6284,NCT00172627,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6285,NCT04660123,helicobacter pylori eradication,2020-12-20,COMPLETED,INTERVENTIONAL,['PHASE4'],adverse events,symptoms improvement rates
6286,NCT03608046,Tumor response rate,2018-10-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
6287,NCT04456283,5 years Survival,2019-05-20,UNKNOWN,OBSERVATIONAL,['NA'],,
6288,NCT04786704,Detection of advanced colorectal neoplasia,2021-03-22,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy of sDNA in the detection of advanced colorectal neoplasia in low-risk asymptomatic subgroup.
6289,NCT04642547,Progression free survival,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Safety endpoint
6290,NCT01899261,Severe Treatment-related Toxicity,2010-10-07,COMPLETED,INTERVENTIONAL,['NA'],,Time to Local Progression (TTLP) of Treated Lesions
6291,NCT04107623,perfusion assessment,2020-06-16,COMPLETED,INTERVENTIONAL,['NA'],,Anastomotic leakage
6292,NCT04917263,pathological complete response on the operative specimen,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
6293,NCT02754661,Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy,2016-09,COMPLETED,INTERVENTIONAL,['NA'],,Predictive Value of a Negative (NPV) of CCE Versus CTC in the Detection of Polyps ≥6 mm
6294,NCT01278381,Major Complication rate,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
6295,NCT05406024,Acceptability rate,2022-09,UNKNOWN,OBSERVATIONAL,['NA'],,European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30)
6296,NCT00070434,"Response (confirmed and unconfirmed response, complete response, partial response)",2004-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6297,NCT00219557,Overall Survival (OS),2005-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in 26-item Pancreatic Cancer-specific Quality of Life Questionnaire (QLQ-PAN26) Score at Day 1 of Every Cycle and End of Study
6298,NCT01946711,Change of Inflammation of the Nasal Mucosa and Paranasal Sinus,2013-08-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Nasal Obstruction,Safety Assessment
6299,NCT05396781,Procedure time,2022-01-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Performance Characteristics,Clinical impact
6300,NCT04107766,Target lesion recurrence (local recurrence) rate,2020-01-15,RECRUITING,OBSERVATIONAL,['NA'],,Numeric Pain Rating Scale
6301,NCT05769725,DFS,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6302,NCT05296005,Incidence of adverse events,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Standard uptake value SUVmax Tumor-to-liver metrics,18F-FDG dPET/CT to evaluate and characterize residual primary tumor following neoadjuvant chemotherapy and initial chemoradiation therapy for subsequent adaptive boost radiation delivery.
6303,NCT05907824,Disease-free survival (DFS),2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Life quality satisfaction evaluated according to a scale.
6304,NCT04259398,five year survival,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3 year survival
6305,NCT01850667,Treatment related toxicity-free survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Local control rate
6306,NCT03189030,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2017-05-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6307,NCT03417843,Incidence of adverse and serious adverse events,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],,Technical efficiency of the method
6308,NCT01366144,"MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0",2011-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in gamma-H2AX levels,Time to progression
6309,NCT03421327,Qualitative analysis of how parents and children with either Huntington's Disease or hereditary cancer communicate about genetic risk information,2017-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
6310,NCT05690048,Adverse event documentation of FMT in advanced HCC,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of Hepatic function
6311,NCT01805622,Effectiveness (RE-AIM Framework),2012-08,UNKNOWN,INTERVENTIONAL,['NA'],Cost-effectiveness analysis,Implementation (RE-AIM Framework)
6312,NCT00017082,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6313,NCT01144195,Objective Response Rate,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
6314,NCT00041652,,2000-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6315,NCT00208546,toxicity,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,translational research
6316,NCT03314649,prognostic molecular markers,2017-12-21,COMPLETED,OBSERVATIONAL,['NA'],,DFS
6317,NCT03654534,"body weight loss ratio at 1, 3, 6 months",2019-04-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,severe side effects on digestive tract
6318,NCT04196075,Symptomatic relief and quality of life after AP,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,AP side effects
6319,NCT00327093,"Elaboration of a predictive model, based on biological and functional imaging parameters, for the response to monoclonal antibodies as assessed through RECIST criteria 2 months after the beginning of treatment",2006-05,TERMINATED,INTERVENTIONAL,['PHASE4'],,Correlation between the response at 2 months and that at 6 months of treatment (taking into account the therapeutic adjustments during the 6-month follow-up)
6320,NCT01010334,Number of courses delivered (relative dose intensity for adjuvant studies),2009-03,TERMINATED,INTERVENTIONAL,['NA'],,"Measure quality of life using a FACT G tool, before and at best response and at the end of the treatment"
6321,NCT00300027,Echocardiogram every 2 cycles (q 2 cycles),2006-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,Fluorodeoxyglucose positron emission tomography (FDG-PET) (3 scans prior to C3)
6322,NCT02435433,Overall Survival (OS),2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
6323,NCT04683744,"Identify patient knowledge, attitudes, and beliefs that influence decisions to engage in cancer screening and prevention during the COVID-19 pandemic, and barriers to uptake",2021-01-11,UNKNOWN,OBSERVATIONAL,['NA'],,
6324,NCT04634448,The Prevalence of Appendiceal Tumours in Periappendicular Abscess,2020-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Surgery after follow-up MRI
6325,NCT05700110,To develop a Radiomics model based on pre-operative CT porto-venous phase imaging that accurately predicts Resection Margin status in pancreatic head malignancy,2022-05-05,RECRUITING,OBSERVATIONAL,['NA'],,
6326,NCT05738980,RFS,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],,OS
6327,NCT03112668,Feasibility defined as survey follow ups,2017-12-06,COMPLETED,INTERVENTIONAL,['NA'],,
6328,NCT00006016,Survival,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6329,NCT05913895,"Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0,Change From Baseline in Pain Scores on the Brief Pain Inventory-Taiwan Scale at 2 Weeks",2023-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6330,NCT00003427,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6331,NCT05360745,Change in quality of life,2022-06-29,WITHDRAWN,INTERVENTIONAL,['NA'],,Adverse events due to chemotherapy
6332,NCT05845502,Overall survival (OS),2023-05-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6333,NCT05918224,The incidence of Severe Oral mucositis (WHO grade ≥3),2022-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Oral activities scores
6334,NCT01768741,Total survival time and disease free survival time,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Hospital costs,Regulatory T cells and associated cytokines in liver cancer、para-carcinoma and healthy liver tissue
6335,NCT03850769,R0 resection rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6336,NCT01612546,CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6337,NCT00172159,Response rate and resectability after neoadjuvant therapy.,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival of the patients.
6338,NCT05442632,The proportion of patients who require blood product infusion or intervention with platelet raising drugs due to bleeding during the perioperative period,2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of liver failure
6339,NCT03807999,3-months deterioration-free rate,2015-02-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6340,NCT03680508,Objective Response Rate,2019-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0
6341,NCT04188535,Ability to measure disease control (for imaging registry expansion cohort),2020-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Dosimetric change
6342,NCT04892810,To compare induced immunomodulation by RFA and MWA in HCC patients,2021-05-31,UNKNOWN,OBSERVATIONAL,['NA'],,To evaluate early induced immunomodulation after MWA in HCC patients
6343,NCT05438459,Progression Free Survival (PFS) rate at 6 months (Phase II),2022-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Biomarker of GAIA-102(Phase II)
6344,NCT00006062,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6345,NCT06245785,overall survival,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6346,NCT02314871,Change from baseline number of circulating cancer cells at 3 weeks after surgery,2015-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain intensity assessment
6347,NCT05810402,Percentage of patients with CTCs-PD-L1+ by CellSearch® technique,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Progression Free Survival
6348,NCT04796025,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2021-09-23,RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
6349,NCT03505320,Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1),2018-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Minimal Residual Disease (Cohort 5)
6350,NCT01651013,Percentage of patients with K-Ras mutation,2010-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],predictive factors for response to treatment,
6351,NCT01097304,Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections"
6352,NCT00103298,Response and duration of response,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation of health-related quality of life with length of survival
6353,NCT03303495,Overall survival,2011-11-14,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events (Adverse Reactions)
6354,NCT01482520,Genotypes,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,
6355,NCT02568748,Number of patients with ablated hcc,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6356,NCT02843191,Pathologic complete response,2016-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Peripheral neuropathy
6357,NCT03356002,Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy,2018-01-28,COMPLETED,INTERVENTIONAL,['NA'],,Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers
6358,NCT05924997,Adverse events (AEs) and serious adverse events (SAEs),2023-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6359,NCT00958841,Percentage of Responders at Month 6 - Pooled Pancreatic NETs (PNETs),2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker
6360,NCT05674526,Maximum Tolerated Dose,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Response Rate
6361,NCT05009953,Objective Response Rate (ORR),2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,UGT1A1
6362,NCT02486198,The relief of neurotoxicity in patients with grade 2 or higher neurotoxicity by means of CTC 4.03 and EORTC QLQ-CIPN20,2015-05-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life
6363,NCT02672865,Post Operative Complications,2016-02-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6364,NCT02811497,Overall response rate (ORR),2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of treatment-emergent adverse events (AEs)
6365,NCT01905202,Number of patients with adverse events,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],48 hour gastroesophageal pH measurement,Number of participants who develop C. difficile induced diarrhea
6366,NCT01345526,"PFS rate, toxicity, compliance",2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6367,NCT02774512,ZAK expression level by immunohistochemistry on frozen material (surgical specimen) by Western blot and on paraffinembedded tissues section using an immunohistochemistry approach,2016-05,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Half-life of nilotinib
6368,NCT03482102,Best Overall Response rate,2018-05-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to Disease Progression
6369,NCT04256707,Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs),2020-01-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Combination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1
6370,NCT05703750,Overall Survival(OS),2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],,Progression free survival(PFS) per mRECIST
6371,NCT04513119,The incidence of local tumor progression (LTP),2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor-free survival
6372,NCT00599833,Progression-free survival rate at 6 months,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Clinical benefit response
6373,NCT04066660,Disease Control Rate,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
6374,NCT05187481,Overall survival,2021-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,the United States Eastern Oncology Collaboration Group (ECOG) score scale
6375,NCT00559351,"mean, median, 1-year, 3-year, 5-year overall survival",2001-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,curative resection rate
6376,NCT02399306,Body Weight Change from baseline to the end of treatment,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
6377,NCT02789800,Evaluation of Intervention Effectiveness - Change in Self-Management outcomes,2016-04-22,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Intervention Effectiveness - Change in Patient-Centredness
6378,NCT05877573,pCR rate,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,SAE
6379,NCT03635489,Progression-Free Survival (PFS),2018-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events (AEs)
6380,NCT03388190,Primary - progression-free survival (PFS),2018-05-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory 5 - Histologic and molecular tumor biomarkers,Secondary 8 - Quality-of-life (QoL)
6381,NCT03350945,Tumor localization time,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Blood loss
6382,NCT02162758,Percentage of Participants With Recurrence of Intestinal Metaplasia (IM),2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) Total Score
6383,NCT02757859,Overall Survival,2016-04-27,RECRUITING,INTERVENTIONAL,['NA'],Presence of cells in cytologic washing,Site of first recurrence
6384,NCT05236972,Disease Free survival [ Time Frame: 3 years ],2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival [ Time Frame: 5 years ]
6385,NCT00803647,Reported Adverse Events.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.
6386,NCT04217954,Overall response rate,2020-07-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6387,NCT00059982,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6388,NCT03213314,Correlation between the pre-operative liver health assessment score and the post-operative liver function composite integer-based risk score.,2017-09-07,COMPLETED,INTERVENTIONAL,['NA'],,• To evaluate LiverMultiScan image interpretations correlated with post-operative length of stay.
6389,NCT01312857,to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases,2011-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,to analyze tumor tissue for predictive biomarkers
6390,NCT00051467,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6391,NCT04821895,genetic profiles in gastrointestinal stromal tumor (GIST) patients,2021-08-28,RECRUITING,OBSERVATIONAL,['NA'],,To help for search the potential targeted agents for the treatment of these wild type GIST patients
6392,NCT02231203,Change in ex vivo production of pro-inflammatory cytokine IL-6 in LPS stimulated whole blood,2014-10,COMPLETED,INTERVENTIONAL,['PHASE4'],Cognitive function,Change in in vivo systemic inflammatory response parameters
6393,NCT02435186,progress-free survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"safety as measured by adverse events, vital signs, clinical lab tests, ECG and physical examination"
6394,NCT00075504,Response Rate According to RECIST Criteria,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6395,NCT03914443,Rate of participants with dose limiting toxicities (DLTs),2019-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
6396,NCT03214939,Сytotoxicity,2016-09-27,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Relapse-free period
6397,NCT04517019,Evaluation of the impact of an Activity tracker based Fitness programme on the Qualitiy of Life after oncological Therapy,2020-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
6398,NCT01080248,Response Rate by RECIST Criteria.,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6399,NCT03654131,Freedom from local lesion progression (analyzed on patient-level),2018-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life as descriptive statistics: EORTC QLQ-C30
6400,NCT05593393,"The termination of the follow-up of IPMN patients, including death termination and recommended surgery termination.",2022-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The new development of worrisome features or high-risk stigmata
6401,NCT06017583,Complete response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease free survival
6402,NCT02051283,Predictive value of MRI determined contrast-enhanced and diffusion-weighted sequence pattern towards outcome (tumour recurrence < 1 year versus > 1 year),2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,"Correlation of predictive MRI parameters with histology obtained from biopsy during radio-frequency ablation (tumor grade, microvascular invasion, Keratin 19 status)"
6403,NCT04909866,PFS,2021-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,OS
6404,NCT05497531,Comparison of the amount of ctDNA in draining vein plasma sample to peripheral vein sample through ratio of mean allele frequency,2022-09-07,RECRUITING,INTERVENTIONAL,['NA'],,Number of unique alterations found in ctDNA compared to number of alterations derived next generation sequencing (NGS)
6405,NCT02071862,Safety and tolerability of CB-839: Incidence of adverse events,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical activity: Change in tumor volume from baseline
6406,NCT02523170,Diagnostic accuracy,2014-07,COMPLETED,INTERVENTIONAL,['NA'],,Assess margins
6407,NCT01070355,Histological Ki67 cancer cell proliferation index,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Urinary markers of prostaglandin metabolism
6408,NCT05894837,Objective Response Rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
6409,NCT00826384,Overall survival,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6410,NCT00393068,Pathologic Complete Response (pCR) Rate,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival
6411,NCT03528785,"Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)",2018-03-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,assess surgical morbidity
6412,NCT02425930,Disease-Free Survival,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Expenditure of hospitalization
6413,NCT00058201,Overall survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Survival rate at 2 and 5 years
6414,NCT05367284,Treatment acceptability questionnaire,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
6415,NCT03914170,Median Progression free survival (PFS),2017-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Liver metastases resection rate
6416,NCT00165490,"To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma.",2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the progression-free survival of patients treated with combination chemotherapy and radiation therapy.
6417,NCT02922049,Detection of persistent or recurrent intestinal metaplasia/dysplasia and esophageal and gastric lesions by confocal laser endomicroscopy and classic histopathology,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of the procedure
6418,NCT02172651,VDR Binding Sites,2014-07-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants with Serious and Non-Serious Adverse Events
6419,NCT03614013,Survival,2018-07-04,UNKNOWN,OBSERVATIONAL,['NA'],,
6420,NCT03078361,Rate of Feedback from Community Advisory Board,2014-04-28,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Receipt of Assessments from Participants
6421,NCT01139138,Dose limiting toxicities,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
6422,NCT01198704,Predictive factors of HCC recurrence,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of HCC differentiation between liver biopsy and explant liver
6423,NCT00421824,Response rate,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6424,NCT01459614,Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6425,NCT05632328,Objective Response Rate,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Grade 3-5 Treatment-related Toxicity Rate
6426,NCT06091423,Progression free survival (PFS),2023-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AEs)
6427,NCT04329000,Number of tablets consumed,2010-02-02,COMPLETED,INTERVENTIONAL,['NA'],,
6428,NCT05681949,The reproducibility of the therapy recommendations made by ADBoard (yes/no),2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time between primary presentation and start of diagnostics/therapy as recommended
6429,NCT02300922,To determine the maximum tolerated dose for 90Y-IMP288.,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6430,NCT04269746,Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression,2020-12,UNKNOWN,OBSERVATIONAL,['NA'],,
6431,NCT06308445,Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis.,2024-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis"
6432,NCT01344330,Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Cruciferous vegetable intake correlated with HDAC activity (in PBMCs)
6433,NCT01077999,Percentage of pathologic complete responses,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile
6434,NCT04610086,Satisfaction,2020-11-19,UNKNOWN,OBSERVATIONAL,['NA'],,Participation in cancer decision making
6435,NCT03097666,Efficacy: Percent Eradication by therapeutic dose,2017-03-20,COMPLETED,INTERVENTIONAL,['NA'],,Efficacy: Treatment
6436,NCT04491942,Recommended phase 2 dose (RP2D) of BAY 1895344,2021-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
6437,NCT03359850,Apparent Total Body Clearance (CL/F) of Niraparib and M1 During PK Phase,2018-02-20,COMPLETED,INTERVENTIONAL,['PHASE1'],Clearance of Unbound Niraparib and M1 (CLfu/F) During PK Phase,Change From Baseline in Temperature During Extension Phase
6438,NCT04952688,retinal vascular density retinal vascular density,2020-12-14,RECRUITING,INTERVENTIONAL,['NA'],,
6439,NCT01342705,Cumulative incidence of HepatoCellular Carcinoma during follow-up,2011-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
6440,NCT03367247,Feasibility of the BOLSTER Intervention,2018-04-24,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of the BOLSTER Intervention
6441,NCT02751892,Change in minutes spent in moderate and vigorous intensity physical activity measure with the International Physical Activity Questionnaire long version,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Change in minutes spent in moderate and vigorous intensity physical activity with accelerometry
6442,NCT03488537,sensitivity/specificity for CRC,2018-02-28,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity/specificity for detection of CRC and/or polyps before and after bowel preparation
6443,NCT02812628,3-year local recurrence,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],Perforation rate,3-year disease-free survival
6444,NCT03642067,Cohort C: Objective response rate (ORR),2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
6445,NCT01621295,Frequency/duration/content of routine cancer consultations surrounding key topics in the clinical dialogue.,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
6446,NCT03426904,Relapse free survival after randomization,2018-10-24,RECRUITING,INTERVENTIONAL,['PHASE3'],,Pathological tumor stage
6447,NCT00379743,Difference between the two intervention groups in the proportion of participants who complete at least one of the recommended screenings.,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Stage at diagnosis.
6448,NCT05415345,evaluate the concentration of IgG antibodies to HEV,2021-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Serious adverse events occurred throughout the study
6449,NCT03619668,Changes in position and shape of the tumour during RT.,2018-06-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in functional imaging parameter: Ktrans.
6450,NCT03727763,Objective Response Rate(ORR),2018-10-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
6451,NCT04670445,"Change in participant knowledge, using the Immunotherapy Knowledge Assessment",2021-01-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient questions asked in visit with oncologist
6452,NCT03667911,Boston bowel preparation score,2018-09-15,UNKNOWN,INTERVENTIONAL,['NA'],,cecal intubation rate
6453,NCT00504257,Six Month Progression Free Survival (PFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6454,NCT00003864,,1999-09-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6455,NCT03069664,Change in experienced quality of life,2017-11-17,RECRUITING,INTERVENTIONAL,['NA'],,Change in need for pancreatic enzyme supplements
6456,NCT04103567,"The ratio between the proportions of poor response to neoadjuvant treatment in populations so-called ""exposed"" (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins)",2020-01-14,RECRUITING,INTERVENTIONAL,['NA'],,Types of other bacteria forming the overall bacterial composition before neoadjuvant treatment
6457,NCT05317325,The number of treatment-related adverse events,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Disease-free Survival
6458,NCT00001568,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6459,NCT01477814,colorectal cancer screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,cost-effectiveness of various strategies for screening
6460,NCT04406831,Analysis of miRNA profile,2015-04,RECRUITING,OBSERVATIONAL,['NA'],,miRNA PCR expression
6461,NCT04229004,Overall Survival,2020-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Clinical Benefit
6462,NCT02375880,"Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.",2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1)
6463,NCT06294548,Phase II,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate (DCR)
6464,NCT06152419,Patient questionnaire on radiotherapy-related anxiety,2023-10-17,RECRUITING,INTERVENTIONAL,['NA'],,
6465,NCT01012011,Adverse events collection,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,Performance status
6466,NCT05252078,DFS,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,3-year OS rate
6467,NCT06109467,Objective Response Rate (ORR),2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6468,NCT03323996,Semi-Structured interviews,2017-07-26,UNKNOWN,OBSERVATIONAL,['NA'],,
6469,NCT02863770,"The yield of EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",2016-07,RECRUITING,INTERVENTIONAL,['NA'],,Quantitative Parameters of Pancreas Lesions
6470,NCT01351103,Maximum Tolerated Dose or Recommended Dose for Expansion of LGK974 as a single agent or in combination with PDR001 in patients treated,2011-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Absorportion and plasma concentrations of PDR001
6471,NCT03436563,Clearance of circulating tumor DNA (cohort D),2018-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease-Free Survival (DFS) - cohort D only
6472,NCT00949273,postoperative complications,2009-07,UNKNOWN,OBSERVATIONAL,['NA'],,3-years overall survival
6473,NCT00586404,"To determine the prevalence and incidence of low grade dysplasia, high grade dysplasia and adenocarcinoma in a large cohort of patients with Barrett's esophagus",2007-11,TERMINATED,OBSERVATIONAL,['NA'],,"To determine the magnitude of the contribution of selected factors (e.g. age, gender, ethnicity, obesity, tobacco use, alcohol use, ASA/NSAID/PPI use, duration of GERD symptoms, length of BE, HH) to the risk of HGD and CA"
6474,NCT00780169,"Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)",2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression and Overall Survival
6475,NCT01935778,disease-free survival,2013-10-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,safety profile
6476,NCT02522520,Maximum oxygen uptake - ( VO2 peak),2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Pedometer Step Count
6477,NCT02987296,"NK cell killing as measured on peripheral blood mononuclear cells (PBMC) between the control (placebo) and experimental cohorts, using a standard NK cell killing assay.",2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Compliance with perioperative arginine supplementation
6478,NCT01666184,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
6479,NCT02614339,Disease free survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,recurrence rate of polyps after polypectomy
6480,NCT00389935,Blood Transfusion requirements,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hemoglobin overall complication rate Constipation Neuropathy
6481,NCT03132922,Measurement of RCL in genetically modified T cells.,2017-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],MAGE-A4c1032T cell trafficking in tumor lesion(s).,Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)
6482,NCT05484687,the concentration of tumor micrometastasis markers were determined by ELISA,2020-03-24,COMPLETED,INTERVENTIONAL,['NA'],,the concentration of immune indexes were determined by ELISA
6483,NCT03217643,Evaluate the 2-year progression-free survival,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
6484,NCT02017015,Overall Response Rate (ORR) Based on Independent Radiological Review (IRR),2013-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kaplan-Meier Estimate of Overall Survival (OS)
6485,NCT02433938,bowel function recovery (Time to first bowel movement or flatus),2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Use of NG Tubes (Nasogastric tube (re)insertions)
6486,NCT05605197,Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability],2022-10-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacodynamics of U87 CAR-T cells
6487,NCT04666558,Lower Extremity Functional Scale (LEFS),2020-11-30,COMPLETED,INTERVENTIONAL,['NA'],Program acceptability (Unified Theory of Acceptance and Use of Technology - UTAUT),General health-related quality of life (5-Level EQ-5D [EQ-5D-5L])
6488,NCT05138094,Time to functional recovery,2021-08-06,RECRUITING,INTERVENTIONAL,['NA'],,Three and five-year overall survival
6489,NCT00702884,Progression-free Survival Rate,2008-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quantitative Assessment of Proliferating Tumor Cells and Apoptosis
6490,NCT03448341,To assess the changes of deglutition function by means of Videofluoroscopy (VFS) from before to after radiochemotherapy,2016-07-16,COMPLETED,OBSERVATIONAL,['NA'],,"To correlate radiation dose features received by the different swallowing related structures (SWOARs) to the changes of MDADI, FEES and VFS scores from before to after treatment by using a Machine Learning Methodology"
6491,NCT04229524,The incidence of anastomotic fistula,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6492,NCT02422680,Patient Satisfaction,2015-03-23,WITHDRAWN,OBSERVATIONAL,['NA'],,Patient Pain (own Perception)
6493,NCT02012231,Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394,2014-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,Identification of Recommended Phase 2 dose (RP2D)
6494,NCT02460198,Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR) Per RECIST 1.1 as Assessed by the Central Imaging Vendor
6495,NCT03581890,Postoperative 1-year mortality rate (study 2),2007-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative 90-day mortality (study 2)
6496,NCT04227808,1-year RFS rate,2019-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related quality of life
6497,NCT04337879,Progression-free survival (PFS),2020-07-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response (DOR)
6498,NCT06233994,Progression Free Survival (PFS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6499,NCT00898768,"The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.",2009-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.
6500,NCT05257135,Number of biological risk factors for colorectal cancer,2021-12-23,RECRUITING,INTERVENTIONAL,['NA'],,
6501,NCT00390416,1-year Survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients With Measurable Disease the Confirmed Response Rate
6502,NCT02870010,Tolerance: toxicities will be defined according to the scale: National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI CTC AE v3.0) to determine the limiting dose,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6503,NCT06115174,Difference in overall survival 'OS' between the two groups.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
6504,NCT05901519,Mitigation of liver inflammation as reflected by sTNFR1 levels,2024-02-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess tumor response
6505,NCT03310632,tumor assessment in millimeters,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Eastern Cooperative Oncology Group (ECOG) status
6506,NCT03038100,Overall Survival - PD-L1-Positive Subpopulation,2017-03-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
6507,NCT02839954,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells,2016-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Objective Response Rate
6508,NCT06037343,Hypervascular capsule,2023-02-23,RECRUITING,OBSERVATIONAL,['NA'],,Infiltrative nature Classification of the hepatic lesion by LI-RADS in MRI
6509,NCT05168163,Progression-free survival (PFS),2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
6510,NCT00696696,4-month Progression Free Survival (PFS) Rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (mOS)
6511,NCT01130142,Overall survival comparison,2010-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Comparison of PFS, TTP and ORR"
6512,NCT00228189,Toxicity,2003-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6513,NCT04559087,Postoperative complications,2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,survival
6514,NCT00582699,"The levels of specific cytokines (IL-1, Il-6, TNF-alpha, as well as IL-10, Il-15 and IFN-gamma), the diagnosis of Depression, depressive symptom severity, and the pattern of depressive symptoms.",2005-11,COMPLETED,OBSERVATIONAL,['NA'],,
6515,NCT04547725,6-month disease control rate,2020-09-16,RECRUITING,INTERVENTIONAL,['NA'],,Safety evaluation
6516,NCT05053191,Frequency of nurses' use of family centered care practices,2021-09-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
6517,NCT00028405,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6518,NCT02704130,Intrahepatic Disease-free Survival,2016-03,TERMINATED,INTERVENTIONAL,['NA'],,Postoperative Morbidity
6519,NCT01531712,Resectability rate after neoadjuvant treatment with chemotherapy plus chemoradiotherapy.,2011-02-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
6520,NCT05497726,Safety of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW,2023-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Number of SLN identified
6521,NCT02012023,mortality,2014-01,COMPLETED,INTERVENTIONAL,['NA'],hospital costs,operation data
6522,NCT00553332,Objective Response Rate (CR and PR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation
6523,NCT02609451,Quality Of Life (GQLI - Questionnaire),2007-11,TERMINATED,INTERVENTIONAL,['NA'],,Quality Of Life (GQLI - Questionnaire)
6524,NCT06106750,Clinical success,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
6525,NCT00813696,overall survival,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression
6526,NCT02198092,Septin9 Plasma Levels,2014-07,COMPLETED,OBSERVATIONAL,['NA'],Circulating Colonic Epithelial Cells at Blood Draws,Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers
6527,NCT02422433,Feasibility of the marking OFDI capsule for diagnosing BE by comparing OFDI images and biopsy diagnosis,2014-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Sensitivity of the marking OFDI Capsule to correctly detect and mark the region of interest in BE
6528,NCT04674228,Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms,2021-05-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with evidence of progression of upper GI disease
6529,NCT03526952,Change in mutual identity from four different time points,2018-05-04,UNKNOWN,INTERVENTIONAL,['NA'],Therapeutic Alliance,Patients' change in adjustment to bladder cancer from four different time points
6530,NCT04224480,Number of CD8+ Ki67+ T cells found in resected tumour from subjects,2019-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
6531,NCT02301091,Overall survival rates,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
6532,NCT05006326,Sensitivity and specificity of 68Ga-PSMA PET/MR for diagnosis and staging in hepatocellular carcinoma.,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation of 68Ga-PSMA uptake in HCC patients with PSMA expression levels in tissues.
6533,NCT03143140,completed tumor necrosis,2014-05-22,UNKNOWN,INTERVENTIONAL,['NA'],,tumor recurrence
6534,NCT02171286,Number of days between receipt of archival tumour tissue and generation of the OncoPanel Report,2014-10,COMPLETED,OBSERVATIONAL,['NA'],Concordance between Oncopanel results and ctDNA sequencing,Percent of cases in which a Oncopanel report is generated on a tumour specimen that has been received
6535,NCT02423226,Progression free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment related adverse events
6536,NCT04042298,Brachial artery flow mediated dilation (FMD),2019-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,Arterial blood pressure
6537,NCT05121571,Progression free survival,2016-04-21,COMPLETED,INTERVENTIONAL,['NA'],,tumor response
6538,NCT05375643,Genomic testing uptake,2023-04-03,RECRUITING,INTERVENTIONAL,['NA'],,Acceptability of questionnaire modality
6539,NCT03502317,Global Health Score,2018-08-14,UNKNOWN,INTERVENTIONAL,['NA'],,Health care utilization
6540,NCT03936179,overall survival rate,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,acute and late toxicities
6541,NCT00647153,Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of iodine I 123 anti-CEA recombinant diabody T84.66
6542,NCT00149578,chemotherapy and concurrent chemoradiotherapy in locally advanced pancreatic cancer. .,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The secondary end points are to evaluate the distant metastasis rate and time to tumor progression, overall survival time and quality of life after induction"
6543,NCT01309126,Overall Survival (OS),2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Change in Quality of Life
6544,NCT02832882,12 month local tumor progression (LTP) rate,2016-10-21,COMPLETED,INTERVENTIONAL,['NA'],Technical efficacy 2,Technical success rate
6545,NCT02164136,Sexual function,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,5-year recurrence pattern
6546,NCT05721846,Adverse events,2023-05-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,Disease control rate
6547,NCT00686114,overall survival,2008-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related quality of life
6548,NCT00692211,Colorectal Cancer Screening,2008-06,COMPLETED,INTERVENTIONAL,['NA'],,
6549,NCT03564834,Postoperative complication rate,2018-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative pain
6550,NCT03653377,HPV vaccination,2018-12-17,COMPLETED,OBSERVATIONAL,['NA'],,
6551,NCT03951324,Frequency and type of criteria visually identified on malignant VLE clips,2019-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,Number of procedures needed to view and conduct to use VLE for diagnostic confirmation
6552,NCT00966277,Number of Participants With Venous Thromboembolic Events (VTE),2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
6553,NCT04696757,DFS,2018-02-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
6554,NCT06168084,Helicobacter pylori eradication,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE4'],,adverse events
6555,NCT00268463,Progression-free Interval (PFI),2006-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Quality of Life as Measured by the Functional Assessment of Cancer Therapy Trial Outcome Index at Baseline, at 4-6 Weeks Following Surgery (Before Initiation of Chemotherapy), and Periodically During Study"
6556,NCT00788957,Part 2: Percentage of Participants With an Objective Response,2008-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Ganitumab
6557,NCT04956640,To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation,2021-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax)
6558,NCT04948034,Objective Response Rate,2021-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
6559,NCT03959150,One year disease-free survival,2020-01-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exploratory biomarkers
6560,NCT03299946,Number of patients who complete pre-op treatment and proceed to surgery.,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease free survival (DFS)
6561,NCT06189547,overall survival (OS),2023-02-02,COMPLETED,OBSERVATIONAL,['NA'],,cancer-specific survival (CSS)
6562,NCT04331184,Local tumor progression,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],,technical success rate
6563,NCT05667259,Overall Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6564,NCT01249638,TFS,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"ORR, OS, Quality of Life, PFS-1"
6565,NCT04080154,Progress free survival (PFS),2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
6566,NCT05322499,Objective response rate (ORR),2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6567,NCT01704703,Objective response rate (TRO),2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
6568,NCT02848638,Degree and distribution of Y90 particle uptake,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,
6569,NCT00568308,Disease-free Survival,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compliance
6570,NCT02337673,Change of regional ventilation partition (ROI analysis in 8 pulmonary ROIs) from preoperative to postoperative state.,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,Ventilator-obligatory-free days
6571,NCT03766776,PFS,2018-12-31,UNKNOWN,INTERVENTIONAL,['NA'],,
6572,NCT05153304,Treatment-related Adverse Events,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
6573,NCT05742568,Changes in the diversity and structure of fecal microbiota,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Eradication rate of Helicobacter pylori
6574,NCT01471470,R0 resection rate,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Angiogenetic biomarkers
6575,NCT05044676,Measurement of the phenotype of expression of CD226 3 weeks after the start of treatment,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between pathology features (tumoral and non-tumoral liver) and the frequency and phenotype of expression of CD226
6576,NCT00166465,Proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the exact binomial distribution.,2003-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6577,NCT03316053,Cell Markers,2017-11-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6578,NCT02997956,Median Progression Free Survival,2017-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients alive at two years post treatment
6579,NCT01203163,Proportion of patients experiencing Adverse Reactions of Special Interest,na,WITHDRAWN,OBSERVATIONAL,['NA'],,Overall safety in patients with renal insufficiency (disease)
6580,NCT02704299,Progression-Free-Survival(PFS),2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidences of adverse events or serious adverse events
6581,NCT04609813,Diagnostic performance of the sponge cytology-based machine learning model for the main target lesions,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Diagnostic performance of abnormal cell count
6582,NCT01964534,Progression-free survival (PFS),2013-12-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
6583,NCT00769652,Change in Patient Generated Subjective Global Assessment (PG-SGA) Score at Time of Initial Presentation and Throughout Study,2006-10,TERMINATED,INTERVENTIONAL,['NA'],,
6584,NCT00594984,Safety and tolerability of interventions will be collected,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy on tumor progression and progression free survival will be collected on all enrolled subjects
6585,NCT00700570,Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants by Best Overall Tumor Response According to RECIST Version 1.1
6586,NCT05663515,Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population,2024-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6587,NCT00004909,,1999-11,COMPLETED,OBSERVATIONAL,['NA'],,
6588,NCT02018107,"Number and Percentage of Tumors With Complete, Circumferential Ablation Margin Visibility During FDG PET/CT-guided Liver Ablations (AP-PET-1 v. Contrast-enhanced MRI)",2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Does an Inadequate Ablation Margin on PET Predict Local Progression? Compare to MRI?
6589,NCT01032057,Progression-free survival at 39 weeks (from registration) according to RECIST criteria,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Radiotherapy quality assurance (adherence to protocol)
6590,NCT01191632,Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria"
6591,NCT00730860,disease free survival,2009-12,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
6592,NCT01313078,"Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.",2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6593,NCT00040183,,2001-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6594,NCT06310473,Pathologic complete remission rate (pCR),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6595,NCT04675138,Concordance Rate,2020-08-20,UNKNOWN,OBSERVATIONAL,['NA'],,Reason for Discordance
6596,NCT04230187,Progression-free survival (PFS),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Toxicity assessed using the NCI common toxicity criteria, version 5.0."
6597,NCT02517268,Percentage of Patients Discharged by Post-operative Day 5,2015-06-24,COMPLETED,INTERVENTIONAL,['NA'],,"Incidence of Post-operative Complications (DGE, Anastomotic Leaks, Intra-abdominal Abscesses, Wound Infection, UTI, Respiratory Compromise, Renal Failure, Etc.)"
6598,NCT04798898,Overall survival,2022-11-14,RECRUITING,INTERVENTIONAL,['NA'],Complications,Recurrence rate
6599,NCT03500471,Overall postoperative morbidity and mortality,2018-04-16,COMPLETED,OBSERVATIONAL,['NA'],3-year Overall survival rate,cost
6600,NCT00227617,Best Objective Response,2005-06-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biochemical Marker Response
6601,NCT00875615,Number of Subjects Experiencing Adverse Events,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients Achieving Clinical Benefit
6602,NCT04952753,Expansion: Progression-free survival (PFS) by investigator assessment per RECIST 1.1,2021-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA incidence on treatment
6603,NCT02200315,Postoperative surgical site infection,2014-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hospital stay
6604,NCT00554372,Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
6605,NCT04569331,Quality of life related to health (European Organization for the Research and treatment of Cancer Quality of Life Questionnaire (QLQ-CR29).,2020-05-15,COMPLETED,INTERVENTIONAL,['NA'],Percentatge of patients with postoperative paralytic ileus,Low anterior resection syndrome (LARS)
6606,NCT00562640,Best Response,2007-10-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6607,NCT04892927,Improved information sharing,2021-05-03,UNKNOWN,OBSERVATIONAL,['NA'],,
6608,NCT02857608,Concordance (the proportion of the number of subjects with lymph nodes identified by Lymphoseek and standard of care methods compared to the number of subjects with lymph nodes identified by standard of care methods),2016-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
6609,NCT02531607,Sensitivity and specificity of biomarkers in the diagnosis of cancer,2014-11-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Medical Record Review
6610,NCT00080236,Peak absolute change in aspartate transaminase (AST) values measured from baseline to up to 3 days post-transplantation,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6611,NCT05448222,progression free survival,2022-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Hospital cost
6612,NCT05088811,Diagnostic value of long non coding RNA UCA-1 and WRAP53 in Hepatolcellular carcinoma,2021-08-21,UNKNOWN,OBSERVATIONAL,['NA'],,
6613,NCT04107077,The PD-L1 expression can be upregulated after administration of HIPEC with greater frequency,2019-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Perioperative mortality at 30 days
6614,NCT04434989,Disease-free survival,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events
6615,NCT01385748,Cumulative Radiation Dose at Which Severe Oral Mucositis (World Health Organization [WHO] Score ≥ 3) Was First Observed,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall Treatment Compliance According to the Patient Diary,Overall Survival
6616,NCT00897494,Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis,2005-02,COMPLETED,OBSERVATIONAL,['NA'],,
6617,NCT06196671,Overall survival，OS,2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
6618,NCT01528059,Glycemic control,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Nutritional status assessment
6619,NCT02502760,Post operative complications,2015-08,COMPLETED,INTERVENTIONAL,['NA'],Cost Effectiveness of treatment,Health Related Quality of Life
6620,NCT06332716,Progression-free survival（PFS）,2022-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival（OS）
6621,NCT01844375,Meters Walked During 2-Minute Walk Test,2013-05,COMPLETED,INTERVENTIONAL,['NA'],,Nitrogen Balance
6622,NCT03599362,Number of Participants Who Proceeded to Surgical Resection,2018-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6623,NCT00732745,Progression-free survival (Phase II) at 5 months,2008-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Correlation of tumor characteristics and tumoral expression with response and outcome (Phase II)
6624,NCT01264952,"Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)",2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology"
6625,NCT02005419,Recurrence-free survival at one year after curative resection,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0
6626,NCT05715905,Rate of patients who remain in a colon cancer clinical trial to trial completion,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6627,NCT06130644,MSI status,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Tumor Mutation Burden (TMB)
6628,NCT02809287,Blood loss,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
6629,NCT03428126,Immune-related Best Overall Response Rate.,2018-03-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
6630,NCT05314101,progression free survival,2022-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival (OS),Objective Response Rate (ORR)
6631,NCT04493060,Disease control rate at 12 weeks (DCR12),2020-12-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in the cytokine profile pre- and post-treatment,Incidence of adverse events (AEs)
6632,NCT06065371,Primary Endpoint,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory Endpoint,Overall Survival (OS)
6633,NCT01723969,Tumour markers assessment,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,
6634,NCT02556281,Number of patient with a first relapse,2012-10-15,UNKNOWN,INTERVENTIONAL,['NA'],,Number of free tumoral DNA in blood of patient with colorectal cancer
6635,NCT04489238,Establish a prospective database of patients with Young Onset Colorectal Cancer,2020-07-22,RECRUITING,OBSERVATIONAL,['NA'],,
6636,NCT00311272,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6637,NCT06091137,Appendectomy is associated with risk of subsequent CRC incidence,2022-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6638,NCT04755907,Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.,2021-03-01,RECRUITING,OBSERVATIONAL,['NA'],Response of the colorectal cancer patients to adjuvant chemotherapy.,Response of the colorectal cancer patients to neoadjuvant chemotherapy.
6639,NCT04111692,Change in Polycystic Liver Disease Quality of Life,2017-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
6640,NCT04857528,Rate of Participants With Detectable Circulating HPV DNA in Blood/Tumor Samples,2020-10-06,RECRUITING,OBSERVATIONAL,['NA'],,Accuracy of HPV DNA Levels in Predicting Cancer Recurrence at 24 Months
6641,NCT00710632,"Clinical condition, defined as diagnosis and stage of disease, treatment, and performance status at baseline",2007-09,UNKNOWN,INTERVENTIONAL,['NA'],,
6642,NCT01183780,Overall Survival (OS),2010-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab
6643,NCT05216653,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then Envafolimab Plus CAPEOX,2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life of the patients in a neoadjuvant setting of short-course radiation then Envafolimab Plus CAPEOX as assessed by FACT-C questionnaire
6644,NCT05991544,Oral Mucositis Grading Index:,2023-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
6645,NCT01034865,,2001-05,COMPLETED,OBSERVATIONAL,['NA'],,
6646,NCT04448652,Postoperative opioid-consumption,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,mortality
6647,NCT00486954,Overall Survival (OS) in the Randomized Part of the Study,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Mutations That May Correlate With Response and Toxicity to Lapatinib
6648,NCT04484636,"Distribution of mutations in patients with HCC, intra- and extrahepatic CCA, GBCA, PDAC and gastric cancer",2020-10-28,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients receiving therapies in accordance to their genomic profiles
6649,NCT04090450,MR radiomics extracted features.,2019-09-23,UNKNOWN,OBSERVATIONAL,['NA'],,
6650,NCT04672005,Time to treatment failure (TTF),2021-01-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between variation of ctDNA and progression free survival,Correlation between variation in variant allele fraction (% cfDNA) or amplifications and tumor objective response during chemotherapy
6651,NCT05537129,3 year-DFS,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,morbidity and mortality rates
6652,NCT01734967,"Describe confocal imaging criteria for pancreatic masses, lymph nodes or liver metastases",2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Feasibility
6653,NCT06138028,PFS,2023-09-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,toxicities
6654,NCT04603339,Feasibility - acceptability of the intervention (2),2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Bio-sample Collection
6655,NCT06121089,Disease-free survival.,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],Quality of life in patients after ICR and RHC using questionnaire.,Number of days of inpatient treatment.
6656,NCT06231524,Overall survival,2024-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
6657,NCT02195180,Progression free survival (PFS),2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life status
6658,NCT01049620,To assess the maximum tolerated dose (MTD),2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate
6659,NCT04006301,Part 2: Overall Response Rate (ORR),2019-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change From Baseline in QTc Interval Based on the Fridericia Correction (QTcF) Method
6660,NCT03416803,2-year overall survival,2018-02,UNKNOWN,INTERVENTIONAL,['NA'],,
6661,NCT03132025,Progression-free Survival of Patients with Apatinib and Capecitabine Combination That is prolonged,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6662,NCT01704664,Phagocytic activity of blood platelets in gastric cancer patients.,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6663,NCT00066274,,2002-07-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6664,NCT03673072,Primary efficacy endpoint is overall survival (OS),2019-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of patients with any serious perioperative morbidity or mortality
6665,NCT04822506,time to first flatus (TFF),2021-07-31,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Event Assessment
6666,NCT00445861,"Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the duration of response and patterns of failure
6667,NCT01008475,Randomized Part: Progression Free Survival (PFS),2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Treatment Failure (TTF)
6668,NCT03926039,Decisional Conflict Scale,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],Decision Regret Scale,Liver Cancer Treatment Options Related Knowledge Scale
6669,NCT02322593,Overall Survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Control Rate
6670,NCT03109639,Tissue adequacy rate will be measured by assessing for the presence of histological core tissue representative of the lesion in the samples obtained using the two needles,2017-04-13,COMPLETED,INTERVENTIONAL,['NA'],,Qualification of the sample obtained using the two needles will be performed by spectroscopic analysis.The ratio of absorbance at 260 nm and 280nm; the ratio of absorbance at 260nm and 230nm will be measured
6671,NCT03685591,"Number of Participants With Tumor Reponse per PCWG2 and RECIST v1.1 (Parts 2A, 2B)",2018-10-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Median Intra-Tumor T cells (Parts 2A, 2B)"
6672,NCT04371042,Registry creation,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
6673,NCT02908165,EASL criteria for tumor response,2016-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6674,NCT01596790,Predictive value of the CTC on the Progression Free Survival,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the results with the CellSearch system vs EPISPOT
6675,NCT00113360,Progression Free Survival (PFS),2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6676,NCT00047229,Rate of objective response (complete and partial),2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
6677,NCT02101918,Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Tumor Perfusion Parameters at Time of Progression,Baseline Permeability Surface (PS)
6678,NCT04254107,Number of participants with a dose-limiting toxicity (DLT) at each dose level,2020-05-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of participants with antidrug antibodies (ADA)
6679,NCT01708824,Whether the PA and dietary intake targets are met at the end of intervention;,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Possible side effects arising from the intervention
6680,NCT03589131,Operative time of robotic-assisted rectal cancer surgery.,2015-04-29,COMPLETED,INTERVENTIONAL,['NA'],,Accurate safety margin
6681,NCT01042028,Phase II: Progression-free survival as measured from inclusion to either documentation of disease progression or death,2010-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival All events grade 1-5 according to NCI-CTCAE in fase I All Adverse events grade 1-5 according to NCI-CTCAEW in Fase II Correlation between effect of treatment and tumourmarkers Quality of life - EORTC QLQ Time to failure of Strategy
6682,NCT00654342,Accuracy & sensitivity of sentinel lymph node mapping,2007-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6683,NCT01130363,Number of patients with fundic gland polyps and PPI use that have a higher gastric pH,2006-10,TERMINATED,OBSERVATIONAL,['NA'],,
6684,NCT06075836,Reader speed with vs without AI assistance.,2023-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
6685,NCT02199002,acid pocket position,2014-07,COMPLETED,INTERVENTIONAL,['NA'],acid pocket contents,number of reflux episodes
6686,NCT02268006,Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
6687,NCT00898495,Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection),2007-05-11,COMPLETED,OBSERVATIONAL,['NA'],,
6688,NCT04110093,Progress Free Survival,2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse Effect
6689,NCT04030624,The Feasibility of Remote Electronic Patient Monitoring Intervention,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Health Care Utilization
6690,NCT06242457,Complete resection of adenocarcinomas located in the jejunum or ileum is associated with 5-year survival rates of 20% to 30%.,2023-07-15,COMPLETED,OBSERVATIONAL,['NA'],,
6691,NCT04146441,Volume change of primary tumor,2020-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate of reported toxicity
6692,NCT04430738,Incidence of dose alterations (Cohort 1D),2020-09-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Objective response rate (ORR) (Cohorts 1C, 1E, 1F, and 1G)"
6693,NCT00051987,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6694,NCT03005756,"Total radiation exposure (DLP, mGy*cm)",2017-01-25,UNKNOWN,INTERVENTIONAL,['NA'],,Procedure time
6695,NCT04471194,Difference in Percentage of Participants Who Completed Any Cervical PLUS Colorectal Cancer Screening Tests,2021-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Difference in Percentage of Participants Who Completed At-home Cervical PLUS Colorectal Cancer Screening Tests
6696,NCT00039793,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
6697,NCT01031784,Toxicity of Ho-166 poly lactic microspheres using CTC vs 3 criteria,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor response according to RECIST criteria
6698,NCT04348084,impact of clinically relevant (CR-) POPF,2009-01-30,COMPLETED,OBSERVATIONAL,['NA'],,identifying positive and negative prognostic factors
6699,NCT05943951,"the analysis of lymphadenectomy in the course of right hemciolectomy, in relation to the radicality of surgical resection that is performed",2022-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Vascular anatomical variability
6700,NCT04490694,Objective remission rate（ORR）,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
6701,NCT01460641,Tumor stage change from Computed Tomography (CT) perfusion measurement,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Tumor perfusion as measured by perfusion CT.
6702,NCT06069297,Cancer cachexia related factors,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],,Disease-specific health-related quality of life
6703,NCT05628038,Local objective response rate,2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of the treatment
6704,NCT03298451,Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Summary of Tremelimumab Concentration Over Time
6705,NCT04683497,Number of new liver metastases identified using CE-IOUS,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of new liver metastases using CE-IOUS in the subgroup of patients with missing metastases.
6706,NCT05375604,To characterize the safety and tolerability of CDK-004.,2022-06-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6707,NCT00209651,objective tumor response,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Response duration, time to progression, overall survival, and safety will also be assessed."
6708,NCT05299411,Serum Hb level,2023-04-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life associated anemia,Serum hepcidin level
6709,NCT06172478,Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd
6710,NCT01346917,Prevalence of postoperative nausea and vomiting.,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Duration of postoperative hospital stay.
6711,NCT04144738,Specificity with the mt-sDNA 2.0 test,2019-11-15,COMPLETED,OBSERVATIONAL,['NA'],,Specificity for no colorectal neoplastic findings
6712,NCT06124729,cCR,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Disease-free survival (DFS) and overall survival (OS)
6713,NCT01099631,Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peripheral Blood T Cells Count
6714,NCT00177242,Ascertain the median survival of advanced pancreatic cancer patients treated with Gefitinib and docetaxel.,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the time course of serial CA19-9 measurements during treatment.
6715,NCT05708872,Effect of methods of self-regulation of mental state on postoperative pain perception changes,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Effect of methods of self-regulation of mental state on anxiety changes
6716,NCT01363739,Progression-Free Survival,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],,Overal survival
6717,NCT02525965,Overall survival rates of each group,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,Occurrence rate of recurrence of each group
6718,NCT01504711,Percentage of Participants With Control of Vomiting and Rescue Medication Control,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
6719,NCT05920863,Major pathological response,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence-free survival (RFS)
6720,NCT04436679,Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.,2021-02-02,RECRUITING,OBSERVATIONAL,['NA'],,Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.
6721,NCT03001726,overall survival,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],adverse events,progression-free survival
6722,NCT03944447,Treatment of Symptoms,2018-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Monitoring Adverse Events
6723,NCT05350501,Response to treatment at 6 months,2023-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenicity and cross-reactivity
6724,NCT01360801,Accuracy of Agreement Between Imaging and Histology,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Presence of Residual Disease
6725,NCT04943419,Level of MDSC in patients with postoperative complications,2016-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Level of MDSC in patients with left and right sided tumours
6726,NCT04851132,Progression-free survival (PFS),2021-03-11,UNKNOWN,INTERVENTIONAL,['NA'],Quality of Life (QOL): questionnaire EORTC QLQ-OES18,Quality of Life (QOL): questionnaire EORTC QLQ-C30 (version 3)
6727,NCT02195141,• Pathological complete remission rate (pCR),2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],• Disease-free survival,Number of participants with adverse events (according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
6728,NCT00716157,Assess incidence and patterns of nausea and vomiting in patients undergoing concurrent chemotherapy and radiation,2004-10,COMPLETED,OBSERVATIONAL,['NA'],,Study the incidence of mucositis and esophagitis
6729,NCT04482257,λz,2020-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
6730,NCT01125020,tumor recurrence and metastasis,2008-12,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative survival
6731,NCT00848783,Number of Patients With One-year Recurrence-free Survival,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients
6732,NCT00356889,Number of Confirmed Tumor Responses.,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
6733,NCT02421354,"Objective Response Rate, Defined as Complete Remission + Partial Remission + Clinical Improvement",2015-05-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6734,NCT03699319,MTD of CPI-613 when given in combination with mFOLFIRINOX,2018-12-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical resection rates
6735,NCT06200363,Adverse event,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Quality of life questionnaire (QLQ-C30)
6736,NCT01090505,overall survival,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,response rate
6737,NCT00960427,Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy,2009-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
6738,NCT03844620,"Treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity, intolerable grade 2 toxicity, or any toxicity requiring dose reduction) between arms",2019-01-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of patients referred to clinical trial
6739,NCT05212012,Disease control rate 12 weeks after randomization (ITT-population),2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
6740,NCT03298945,Population level adenoma detection rate (ADR),2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],renal failure,Adequate bowel prep quality
6741,NCT04965597,Graft-Versus Host-Disease (GVHD)-Free Event-Free Survival (EFS),2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of cytomegalovirus (CMV) reactivation requiring therapy by day 180 post-HCT
6742,NCT02290977,Adverse event assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 after scheduled TACE-RT for HCC with PVTT,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Radiologic response assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST) after scheduled TACE-RT for HCC with PVTT
6743,NCT03116984,3-year overall survival(OS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
6744,NCT00774839,Self-reported expenses associated with colon cancer treatment and living with this illness.,2008-10,COMPLETED,OBSERVATIONAL,['NA'],,"Identify the medical, social and economic risk factors that are most closely associated with perceived adverse impact on financial and social well-being and unmet resource and service needs."
6745,NCT04672603,Incidence of urinary dysfunction,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],,Positive Circumferential Resection Margin Rate
6746,NCT02013492,Effect of beta-adrenergic blockade on the host immune system,2014-01-21,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
6747,NCT05836246,Quantitative ultrasound information,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
6748,NCT04005170,clinical complete response rate,2019-06-25,COMPLETED,INTERVENTIONAL,['PHASE2'],The impact of IDO1 expression on clinical response,Incidence of treatment-related adverse events as assessed by CTCAE v4.0
6749,NCT05188573,Clinical performance of test: Specificity,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Stage Shift
6750,NCT00285701,,2006-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6751,NCT00416507,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
6752,NCT04500392,The incidence of hypoxia,2021-05-06,RECRUITING,INTERVENTIONAL,['NA'],,Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.
6753,NCT03294252,Recommanded dose for the extension phase,2017-05-24,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free Survival
6754,NCT00026364,,2001-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6755,NCT04993131,Overall survival,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Survival in relation to biological markers
6756,NCT05833672,ORR (objective response rate),2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
6757,NCT01584830,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
6758,NCT02781155,Adherence to moxa regimen assessed by Daily Moxa Diary,2016-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidents of additional interventions administered as prophylaxis or therapy to maintain or improve blood counts
6759,NCT06278493,Maximum tolerated dose (MTD),2018-08-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6760,NCT02547142,Quality Of Life,2016-01-18,TERMINATED,INTERVENTIONAL,['NA'],,Total duration of time from date of metastatic diagnosis to date of death
6761,NCT03029611,Rate of Pathologic Complete Response (CR),2017-04-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Predictive Signature of CR Induction When Vaccinated With an IGFBP-2 Vaccine in Combination With Neoadjuvant Chemotherapy Assessed by Whole Exome Sequencing on Vaccinated Patients' Tumors,Tumor Burden
6762,NCT05250791,Clinicians' reasons for not recruiting patients.,2023-02-02,RECRUITING,INTERVENTIONAL,['NA'],Pro-inflammatory cytokine levels,Total hospital stays including readmission
6763,NCT04488159,Disease-free survival (DFS),2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost analysis
6764,NCT00493428,"Document and Compare the effects of the GABAb receptor agonist Baclofen on the time to develop tumor metastasis in patients with non-metastatic HCC at diagnosis who subsequently undergo surgical resection, ablation or chemoembolization.",2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Document and compare the effects of the GABAb receptor agonist Baclofen on changes in serum tumor markers ( alpha-fetoprotein andd CA19-9 levels) in patients with no-metastatic HCC at diagnosis.
6765,NCT03824899,pathological response rate,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,
6766,NCT00057980,Overall survival,2002-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response
6767,NCT00815308,Number of Participants With Overall Response Rate (RR),2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With K-ras Gene Mutation
6768,NCT04525989,Incidence of acute grade 2-5 gastrointestinal toxicity,2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],Exploratory: Difference in concentrations of CEA (carcinoembryonic antigen) between treatment arms,Cost effectiveness analysis measured by QALY
6769,NCT02726243,Composition of fecal microbiota by 16S sequencing,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,Profile of fecal bile acids
6770,NCT01929122,Stool Microbiome Composition and Metabolome,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,"Navy Bean or Rice Bran metabolites in stool, urine and blood."
6771,NCT00507585,"To study the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver.",2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6772,NCT02129218,"Individual patient compliance, defined by following assigned target glycemic load index >= 75% of the time between weeks 4 and 12",2015-02-16,COMPLETED,INTERVENTIONAL,['NA'],Change in serum levels of proteins affected by carbohydrate metabolism,Hours of nutritionist time per week
6773,NCT03817567,Objective response rate (ORR),2018-07-17,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
6774,NCT04937738,Histopathological regression rate (Becker regression criteria),2021-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Median overall survival
6775,NCT01222208,Whole body protein balance,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Synthesis rates of hepatic secretory proteins
6776,NCT02984501,Incidence of Treatment-Emergent Adverse Events,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Local-regional Tumor Control
6777,NCT03164382,Overall survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Intrahepatic tumor Progression
6778,NCT01257035,Response to chemoradiotherapy measured by TRG,2010-11,TERMINATED,OBSERVATIONAL,['NA'],,Survival
6779,NCT02557061,Number of alive patients,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Rate of preoperative blood T-lymphocytes
6780,NCT01768195,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,the incidence of hepatitis B virus relapse and relapse related hepatitis
6781,NCT05199584,Objective Response Rate (ORR),2022-05-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in steady-state exposure to study medication
6782,NCT00766155,Disease-free survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion"
6783,NCT05958550,Whether hypothermia occurs,2024-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6784,NCT06040099,Progression Free Survival (PFS),2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR)
6785,NCT04966195,overall survival,2015-12-01,COMPLETED,INTERVENTIONAL,['NA'],,objective response rate
6786,NCT04906174,Incidence of complications after liver resection,2021-04-10,RECRUITING,OBSERVATIONAL,['NA'],,
6787,NCT01744054,Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization,2012-10-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,
6788,NCT05196867,Change in FIB-4 score,2022-02-11,RECRUITING,INTERVENTIONAL,['NA'],,
6789,NCT01525082,Radiographic Response (RR),2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,O6-methylguanine DNA Methyltransferase (MGMT) by Promoter Methylation
6790,NCT05551247,ORR,2022-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,SAE
6791,NCT03126435,Overall Survival,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE3'],"Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score",Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate
6792,NCT02564263,Overall Survival (OS) in All Participants,2015-12-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)
6793,NCT02290574,Adverse Event of Laparoscopic TME and Hyperthermia With CCRT,2014-11,TERMINATED,INTERVENTIONAL,['NA'],,Pathologic Complete Response of Hyperthermia With CCRT
6794,NCT05400031,Oral mucositis grading,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
6795,NCT03365986,The incidence of hereditary colorectal cancer,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,cost-effect for hereditary colorectal cancer screening
6796,NCT02368977,Device usability factors,2013-11-12,UNKNOWN,INTERVENTIONAL,['NA'],,Patient safety assessed by number of subjects with adverse events as a measure of safety and tolerability
6797,NCT02724436,Postoperative complication,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
6798,NCT02982486,Response to therapy as evaluated by RECIST 1.1,2017-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
6799,NCT05540951,objective response rate,2018-06-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
6800,NCT04290806,Course of treatment (treatment reality),2019-12-04,RECRUITING,OBSERVATIONAL,['NA'],,
6801,NCT03141034,Progression-free survival (PFS),2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity and tolerability of regimen as measured by the count of the worst grade of adverse event experienced by each participant
6802,NCT01436721,the size of any subphrenic collection or pleural effusion,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,incidence of postoperative morbidity
6803,NCT04970498,Changes of ADC map of MRI,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6804,NCT06205485,Quality of Life defined using the LARS score,2024-03-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Validate the magnetic resonance tumour regression grade (MR-TRG) in patients with T1 and T2 rectal cancer
6805,NCT01456598,3 year relapse free survival,2011-11-21,COMPLETED,INTERVENTIONAL,['NA'],,3 years overall survival
6806,NCT05749900,"Phase II: Objective response rate, ORR",2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of Life (QoL)
6807,NCT03352349,Change of Portal vein pressure,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse effect of Terlipressurinum
6808,NCT01032590,Impact of an Internet-based intervention on weight loss,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Potential moderators of weight loss
6809,NCT05141656,OS,2019-08-31,UNKNOWN,OBSERVATIONAL,['NA'],,PFS
6810,NCT05451901,Time to clinical success from randomization,2022-07-29,RECRUITING,INTERVENTIONAL,['NA'],,Morphological change of pancreas
6811,NCT01888965,Biomarker Discovery,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety
6812,NCT03856255,Mean Score Indicating Ease of Use in Taking a Picture That Included the Measuring Device and Polyp in Order to Photo-document the Measurement Reading,2019-06-24,TERMINATED,INTERVENTIONAL,['NA'],,Mean Difference in Size of Polyp
6813,NCT00588900,The Percentage of Patients Who Are Progression-free at 12 Weeks From the Start of Second-line Therapy,2008-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
6814,NCT04090554,Distribution of acceptability scores,2019-09-24,COMPLETED,INTERVENTIONAL,['NA'],,Prevalence of other benign esophageal pathologies
6815,NCT01618643,"Timing of disappearance of aceto-whitening for Barrett's metaplasia, HGD and cancer",2010-11,UNKNOWN,OBSERVATIONAL,['NA'],,To differentiate mucosal neoplasia from invasive cancer
6816,NCT00306137,Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period,2005-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Health related quality of life measurements
6817,NCT03838796,Disease free survival,2019-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
6818,NCT00316420,MTD and DLT for the combination therapy of gemcitabine and capecitabine,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Response
6819,NCT00139633,local control at 4 years,2000-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6820,NCT03419663,the relationship between overall cereal consumption and gastric cancer occurance,2017-09-12,COMPLETED,OBSERVATIONAL,['NA'],,the relationship between other grain and gastric cancer occurance
6821,NCT01776346,Progression to esophageal adenocarcinoma,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases"
6822,NCT01498289,Overall Survival (OS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
6823,NCT03093688,Objective Response Rate (ORR),2017-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Progression-Free Survival (PFS),Tumor Marker
6824,NCT04117945,Overall survival (OS),2020-03-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
6825,NCT00123825,To determine the response rate of the combination gemcitabine and cisplatin in patients with advanced biliary tract and gallbladder cancers,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the biomarker CA 19-9 response to the regimen and to correlate the CA 19-9 response with radiologic response and survival
6826,NCT01639352,Disease Control Rate (DCR),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity Profile of Protocol Therapy
6827,NCT04810585,Progression free survival,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4'],,Prognostic or Predictive Biomarker for Aflibercept (plasma biomarker)
6828,NCT01684904,To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer,2013-02-20,RECRUITING,INTERVENTIONAL,['NA'],,Number of participants with adverse events as a measure of safety and tolerability
6829,NCT06278454,Adverse events (AE) and severe adverse events (SAE),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Distribution of NRT6008 injection in human body and radioactivity of biological samples,Resection rate (R0 and R1)
6830,NCT06198400,Evaluation of the blood flow in pancreatic remnant with use of ICG,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Correlation between ICG perfusion and development of pancreatic fistula
6831,NCT05653453,Overall survival (OS),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression Free Survival rate at 6 months
6832,NCT04640792,Comparison of the Adenoma Per Extraction (APE) between the two arms,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the Adenoma Detection Rate (ADR) between the two arms
6833,NCT00052364,Time to progression,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
6834,NCT00469443,Time To Progression,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Symptoms improvement
6835,NCT04355156,Overall survival,2012-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Monitoring dose reductions and the reasons behind them
6836,NCT06242613,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of oncologic safety.,2023-05-13,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Compare robotic gastrectomy with the conventional laparoscopic approach in terms of cost-utility outcomes.
6837,NCT06070623,Role of elastography and color Doppler to follow up after TACE.,2023-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6838,NCT00386399,6-month overall survival,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To explore pharmacogenetic factors that may influence the toxicity and efficacy of MMC in this patient population.
6839,NCT01772706,To evaluate the efficacy of preventive and curative low energy laser induced mucositis in patients receiving concomitant chemotherapy and radiotherapy for squamous cell carcinoma of the head and neck with stage III-IV,2008-10-30,UNKNOWN,INTERVENTIONAL,['NA'],To document the Overall survival calculated from the date of randomization to death from any cause or up to 5 years.,To assess the quality of life using the QLQ-HN35 questionnaire.
6840,NCT02468726,Success of bowel cleansing,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,Stool weight
6841,NCT06110598,Relapse-free survival (RFS),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
6842,NCT05970705,PFS,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],AE,DOR
6843,NCT01831310,neutrophil functions,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Length of stay
6844,NCT00095992,Response,2005-03-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular correlates on archival tumor specimens and peripheral blood mononuclear cells (PBMCs)
6845,NCT01102556,Creation of a registry and blood/tissue bank,2004-07,RECRUITING,OBSERVATIONAL,['NA'],,"Improvement in the diagnosis, prevention, detection, and treatment of pancreatic cancer."
6846,NCT03721952,Hospital Anxiety and Depression Scale (HADS) - family,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Outcomes,QUAL-E (Fam)
6847,NCT00335491,Patient perception and pattern of change,2006-03,COMPLETED,INTERVENTIONAL,['NA'],,Structural and function changes
6848,NCT01799044,Safety,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Feasibility,Efficacy
6849,NCT01568151,Number of participants who undergo colorectal screening because of interventions,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Number of problems associated with intervention program
6850,NCT02685631,Response to treatment with Y90 microspheres either as mono therapy or as part of multidisciplinary management of their specific disease,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
6851,NCT05476796,Progression free-survival,2023-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire - Core 30 (QLQ-C30)
6852,NCT05652894,Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Independent Review Committee(IRC),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
6853,NCT06036745,Disease-free survival,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
6854,NCT05540925,Overall survival (OS),2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
6855,NCT05441475,To evaluate the objective response rate of ABSK-011 combined with atezolizumab in subjects with advanced FGF19 overexpression or unresectable HCC,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6856,NCT02173990,Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
6857,NCT05901376,The different of MiR-223 level between gastric cancer and control group,2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],,
6858,NCT04966143,Overall Response rate（ORR）,2021-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
6859,NCT02023541,Overall survival,2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Toxicity
6860,NCT05529940,2-year survival rate,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Response rate in neoadjuvant setting
6861,NCT02929797,Disease-free survival,2016-08,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Quality of life
6862,NCT02439580,Nutritional Status,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Cytotoxicity
6863,NCT05635279,Death,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Censored
6864,NCT02013986,Change from baseline in salivary cortisol at the first day after surgery,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Days of stay in intensive care unit (ICU) after surgery
6865,NCT05211388,Conformity with planned ablation zone,2022-07-11,RECRUITING,INTERVENTIONAL,['NA'],,
6866,NCT00444093,Treatment Efficacy,2007-03-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Diarrhea Assessment
6867,NCT06206096,ORR,2021-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerability by incidence, severity and outcome of adverse events"
6868,NCT03411707,"Sensitivity and Specificity of Multiple Screening Methods With Comparison to Colonoscopy, Both With Respect to Cancer.",2018-03-19,RECRUITING,OBSERVATIONAL,['NA'],,
6869,NCT00019006,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
6870,NCT05062889,ct-DNA clearance rate after the end of target-driven adjuvant treatment (ERASE-CRC part 1 target-driven),2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival TD1 (OS-TD1)
6871,NCT02900664,Frequency of dose reductions,2016-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Presence and/or concentration of anti-CJM112 antibodies.
6872,NCT02150135,ECOG score change,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival rate
6873,NCT03995459,Evolution from baseline of liver volume and liver function values,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Evolution from baseline of liver volume and liver function values
6874,NCT00202111,Five-year survival,1998-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life outcomes
6875,NCT00506207,Blood level of irinotecan and S-1 and their metabolites,2006-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Maximal response rate, progression-free survival, survival"
6876,NCT03246438,CRC screening completion,2017-11-14,COMPLETED,INTERVENTIONAL,['NA'],,Choice of screening test
6877,NCT00004897,,1999-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6878,NCT00571740,Progression-free survival (PFS) rate at 6 months,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life
6879,NCT00960167,Maximally tolerated dose of RT,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Tumor control, patterns of failure and survival"
6880,NCT05406167,Health Related Quality of Life (HRQOL) scores,2022-04-12,RECRUITING,OBSERVATIONAL,['NA'],,Long-term toxicities related to Radiotherapy
6881,NCT03704727,Intestinal permeability,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Gastrointestinal adverse events
6882,NCT05522738,RP2D,2022-08-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and tolerance evaluated by incidence of SAE
6883,NCT04796454,Progression-free survival (PFS),2022-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Jaundice scale
6884,NCT02665312,Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
6885,NCT04023136,"Estimation of the intraoperative portocaval post-hepatectomy gradient This pressure differential is performed before the parietal closure, after resection. We consider that the simulation is accurate if the difference with the measurement is ≤ 4 mmHg.",2019-07-15,UNKNOWN,INTERVENTIONAL,['NA'],,Prediction of changes in portal vein flow
6886,NCT01186705,Overall Objective Response Rate (ORR),2010-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
6887,NCT00303758,Overall survival,2005-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of hospitalization
6888,NCT00602147,Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis,2007-07,TERMINATED,OBSERVATIONAL,['NA'],,
6889,NCT03428477,Progression Free Survival (PFS),2018-05-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change in lean body mass (exploratory endpoint),New Primary Cancers
6890,NCT02129322,Time to Recurrence (TTR),2015-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Circulative tumor cell (CTC) level change,Overall survival (OS)
6891,NCT05737563,Overall survival (OS),2023-02-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Control Rate (DCR)
6892,NCT01893294,"MTD of gemcitabine hydrochloride defined as the dose at which no more than 3 of 6 patients experience grade 3 or greater adverse events, as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0",2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Incidence of delayed adverse events associated with this treatment, graded according to the NCI CTCAE v3.0"
6893,NCT02395705,Overall survival rate,2015-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,predictive factors
6894,NCT05225428,Video Education Acceptability (Qualitative Interview Study),2022-08-04,RECRUITING,INTERVENTIONAL,['NA'],,
6895,NCT01721954,Overall Survival (OS),2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival
6896,NCT01333917,Apoptosis,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Adverse Events
6897,NCT03096951,Change in cardiorespiratory fitness,2017-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Adherence
6898,NCT02720926,Determine the recommended phase 2 dose of TKI258 in combination with XELOX (Capecitabine and Oxaliplatin),2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Measure the Area under the plasma concentration versus time curve (AUC) of TKI258 at specific timepoints
6899,NCT02523911,Overall bowel cleansing,2016-03,WITHDRAWN,INTERVENTIONAL,['NA'],Degree of haziness,Number of patients completing the bowel preparation
6900,NCT05481476,objective response rate (ORR),2023-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
6901,NCT01702116,measurement of circumferential resection margin,2011-07,UNKNOWN,INTERVENTIONAL,['NA'],,estimated blood loss
6902,NCT05232357,"Expression levels of PGP9.5, GFAP, VIP, nNOS, TH, ChAT and SOM of different gastrointestinal lesions",2022-03-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
6903,NCT00297791,locoregional recurrence rate,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,out-of-hospital postoperative costs
6904,NCT00462553,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
6905,NCT01272791,Overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
6906,NCT02969148,the 3-year disease-free survival rate,2016-11,RECRUITING,INTERVENTIONAL,['NA'],the time of hospital stay,the number of bowel obstruction
6907,NCT03781193,Correlation between psychological predictors questionnaires outcome and quality of life,2018-03-06,UNKNOWN,OBSERVATIONAL,['NA'],,
6908,NCT03474861,The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor Response of the treatment in patients with advanced gastrointestinal cancer.
6909,NCT04838964,Objective Response Rate (ORR) by Independent Review Committee (IRC),2021-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of anti-drug antibody (ADA)
6910,NCT06109207,Feasibility of combination camrelizumab and dalpiciclib as assessed by number of participants who experience adverse events,2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
6911,NCT02081469,To compare the HBV relapse rate during the follow-up period in HBV carriers with malignant tumor receiving tenofovir for 24 and 48 weeks after the end of chemotherapy.,2014-03-17,COMPLETED,INTERVENTIONAL,['PHASE4'],,"To estimate the efficacy of TDF during chemotherapy with after chemotherapy and post-chemotherapy,as measure by the HBV reactivation, clinical relapse and adverse events in all patients."
6912,NCT03645980,Phase II: Time to progression (TTP2),2018-10-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Adverse Events
6913,NCT01995240,"Reproducibility of DCE, T2* and DWI MRI in pancreatic cancer.",2013-04,COMPLETED,INTERVENTIONAL,['NA'],,"To explore the relation between in vivo measurements of tumor vascularity, hypoxia and stroma using DCE-MRI, T2* MRI and DWI and treatment outcome."
6914,NCT03779009,Tumor status of the sentinel lymph node (SLN) and other lymph nodes (LN's),2018-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Immunological markers
6915,NCT03140007,Diagnostic accuracy of cholangioscopy or cholangiography,2017-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation between impression of malignancy and cytopathology in the ERCP arm compared to the cholangioscopy arm
6916,NCT01065441,The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration.
6917,NCT00342004,All cancer incidence,1997-05-01,COMPLETED,OBSERVATIONAL,['NA'],,All deaths
6918,NCT06081647,The incidence of hypoxia,2023-10-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],The incidence of other adverse events,The incidence of severe hypoxia
6919,NCT04046445,valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS),2019-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Assess shedding and viremia of VSV-GP128,Evaluate anti-tumor effect of study treatment by measure of Relapse Free Survival (RFS)
6920,NCT04058964,Progression free survival (PFS),2020-02-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Overall survival,Incidence of adverse events
6921,NCT01836120,Progression-free survival (PFS),2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6922,NCT06030895,Safety Outcomes,2022-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
6923,NCT00411112,Survival without recurrence after 3 years,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,
6924,NCT03482362,Doubling of progression free survival,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],"Overall response rate of vinorelbine in patients with KRAS mutant, BRAF wildtype, BRAF-like colon cancer vs. KRAS wildtype, BRAF mutant, BRAF-like colon cancer.","Gene alterations/expression profiles (i.e. baseline, relapse) in tumor tissue upon progression"
6925,NCT02443948,Correlation of change in cf-DNA levels with disease status in GIST patients harboring specific DNA mutations,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation of the level of cf-DNA related to disease status in GIST patients harboring specific DNA mutations
6926,NCT01238666,Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
6927,NCT05368805,PK parameter for dabigatran and rosuvastatin: Cmax:,2022-03-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK parameters of fruquintinib and metabolite M11: Cmax:
6928,NCT00229567,passage of stool.,2005-09,TERMINATED,INTERVENTIONAL,['NA'],,time to readiness for discharge from hospital
6929,NCT06281925,Proportion of Participants with Peripheral Neuropathy at Visit 5,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
6930,NCT05296681,Tumor Response by RECIST v1.1 Criteria,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6931,NCT01291420,Immunogenicity of intradermal DC vaccination,2010-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
6932,NCT01031056,None: Biospecimen will be collected for future research.,2010-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
6933,NCT02881554,Sulfur colloid (SC) uptake on single photon emission computed tomography/computed tomography (SPECT/CT) imaging,2016-12-21,RECRUITING,INTERVENTIONAL,['NA'],,Changes in sulfur colloid uptake in single photon emission computed tomography/computed tomography imaging
6934,NCT01677559,Dose-limiting toxicities (DLTs),2013-05-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity of MLN8237 and nab-paclitaxel combination therapy
6935,NCT00518349,Patient Assessment of Pain Experienced During Colonoscopy,2003-08,COMPLETED,INTERVENTIONAL,['NA'],,
6936,NCT01668498,Percentage of patients developing no skin toxicity ≥ grade 2,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Skin-toxicity related dose reductions of panitumumab
6937,NCT03452501,Incidence of adverse events (AEs) to Remsima®,2018-08-26,COMPLETED,OBSERVATIONAL,['NA'],,Proportion of switched patients with UC achieving disease control.
6938,NCT00112697,Progression-free survival rate at 6 months,2003-10-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
6939,NCT06100016,Specificity,2023-10-18,RECRUITING,OBSERVATIONAL,['NA'],,
6940,NCT04633382,Reduction of bed-days,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6941,NCT02351089,Change in incidence of loose/watery stools,2015-02,TERMINATED,INTERVENTIONAL,['NA'],,
6942,NCT01441453,Cut-off value of liver stiffness measured in kilopascal (kPa) able to predict the occurrence of postoperative liver failure.,na,UNKNOWN,INTERVENTIONAL,['NA'],,
6943,NCT02129829,Incidence of HCC or decompensated cirrhosis,2011-10,COMPLETED,OBSERVATIONAL,['NA'],Accuracy of non-invasive fibrosis assessment,Treatment rate
6944,NCT05596370,correlation of genetic mutation burden and prognosis,2022-01-06,RECRUITING,OBSERVATIONAL,['NA'],,correlation of microbiome in stool and prognosis
6945,NCT04866290,Overall Survival,2016-09-22,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
6946,NCT04659590,Stability of buffer transfer medium,2020-11-06,COMPLETED,OBSERVATIONAL,['NA'],,Comparison between tumour surface imprint and rectal mucous imprint
6947,NCT04449874,Percentage of Participants With Dose-Limiting Toxicities (DLTs),2020-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Relationship Between Tumor Pharmacodynamic Effects of GDC-6036
6948,NCT05179486,Significant factors that may contribute to the etiology of biliary tree cancer,2017-09-25,RECRUITING,OBSERVATIONAL,['NA'],,
6949,NCT05063565,Objective Response Rate (ORR),2023-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Whole liver and remnant liver volumes at baseline and follow-up imaging assessments measured using Simplicit90Y software.
6950,NCT03515252,Incidence of Treatment-Emergent Adverse Events [Safety],2005-04-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of Life (QOL)
6951,NCT03990675,Growth rate,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
6952,NCT05156307,Colorectal cancer,2021-05-20,RECRUITING,OBSERVATIONAL,['NA'],,
6953,NCT06202417,DCR,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
6954,NCT03254498,Adenoma miss rate,2016-04,COMPLETED,INTERVENTIONAL,['NA'],comparison of surveillance intervals,Comfort score
6955,NCT00048139,Tumor measurement (RECIST criteria),2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Efficacy: Time to progression, time to response, duration of response, time to treatment failure, survival."
6956,NCT03924804,1. The change of bladder volume,2019-06-19,COMPLETED,INTERVENTIONAL,['NA'],,
6957,NCT02149914,gastroesophageal reflux disease questionnaire,2014-05,UNKNOWN,INTERVENTIONAL,['NA'],,Upper gastrointestinal endoscopy
6958,NCT02618811,Complications,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Need for opioid analgesia postoperatively
6959,NCT01533090,Evaluation of the overall quality of bowel preparation,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,compliance
6960,NCT01127698,"Fractures, hip fractures",1987-03,COMPLETED,OBSERVATIONAL,['NA'],,
6961,NCT06008119,Progression-free Survival (PFS),2023-11-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate (DCR)
6962,NCT04510129,PD-L1/PD-1 inhibitor response,2020-02-05,RECRUITING,OBSERVATIONAL,['NA'],,
6963,NCT04114591,Life,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
6964,NCT01690715,Prognosis (disease graduation),2012-07,TERMINATED,OBSERVATIONAL,['NA'],,Relation established between survival and degree of underlying liver dysfunction
6965,NCT05799820,Objective Response Rate (ORR),2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
6966,NCT06031285,"RFS, recurrence-free survival",2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6967,NCT03862768,Progression-free Survival,2019-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall Survival
6968,NCT00423345,findings compared across investigation modes,2006-10,TERMINATED,OBSERVATIONAL,['NA'],,Delayed diagnosis of CRC
6969,NCT00637728,Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase,2006-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale
6970,NCT00165048,Symptom-free susrvival and the quality of life score within the two years of study period.,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival in long-term.
6971,NCT05789485,proportion of patients achieving (ratio of delivered to planned treatment) RDI ≥ 90%,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,
6972,NCT01114087,Average difference of the concentration of spermatozoa in the ejaculate measured before treatment and after 6 months of treatment.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,Plasmatic concentration of the inhibitors of tyrosine kinase
6973,NCT05339321,Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT),2021-04-14,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy: antiviral activity of SCG101
6974,NCT01579721,morbidity,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,oncology
6975,NCT00357682,Conversion of Barrett's esophagus to adenocarcinoma of the esophagus or high-grade dysplasia,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,All causes of mortality
6976,NCT04663789,Clinically relevant postoperative pancreatic fistula (CR-POPF),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of postoperative hospital stay
6977,NCT03473587,Change in colorectal cancer screening rate,2014-11-07,UNKNOWN,INTERVENTIONAL,['NA'],,
6978,NCT02873455,Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative hospital stay
6979,NCT01676259,ORR at 6 months,2018-03-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6980,NCT01325909,Maintain or improve physical fitness (anaerobic threshold measured by CPET)after treatment with neoadjuvant chemoradiotherapy in colorectal cancer patients.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Activity levels before during and after neoadjuvant chemoradiotherapy
6981,NCT03222076,"Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events.",2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
6982,NCT05197322,Pathological complete response rate (pCR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health-related Quality of Life (QoL) and functional outcome
6983,NCT05170802,CT scan finding new lymph nodes,2017-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Data on adverse events and complications related to Irreversible Electroporations.
6984,NCT02454673,Disease Free Survival,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,Estimate of TN Change From Baseline to Surgery
6985,NCT04341337,qualitative analysis of the interviews,2019-03-02,COMPLETED,OBSERVATIONAL,['NA'],,
6986,NCT05954702,Mortality,2023-07-21,RECRUITING,INTERVENTIONAL,['NA'],,Drain use time
6987,NCT03986502,Caregiver burden,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],,
6988,NCT00003326,,1997-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
6989,NCT04138212,overall survival,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,postoperative complications
6990,NCT06221657,Proportion of subjects maintained at HBV DNA <29 IU/mL,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,blood Phosphorus levels
6991,NCT06319404,The immune function of tumor draining lymph nodes of colorectal cancer patients was previously identified based on radiomics,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
6992,NCT01591109,,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
6993,NCT05113264,Patient Engagement with the Penny chatbot,2021-08-02,RECRUITING,INTERVENTIONAL,['NA'],,Patient Satisfaction with the Penny chatbot interactions will be measured by the Promoter Score
6994,NCT04370574,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2021-01-14,RECRUITING,OBSERVATIONAL,['NA'],,Identification of prognostically significant biomarkers
6995,NCT01308645,Evaluating Tumor Response Rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
6996,NCT03770988,Objective Response Rate,2019-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety assessed by incidence of treatment-emergent adverse events
6997,NCT05550701,cancer specific survival,2021-05-05,COMPLETED,OBSERVATIONAL,['NA'],,
6998,NCT03879811,response rate of TMZ followed by nivolumab in participants with MMR-proficient Colorectal Cancer,2019-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
6999,NCT02614534,Locoregional Control (LC),2015-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life questionnaires QLQ-CR29
7000,NCT05148767,Toxicity effect,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,
7001,NCT01154335,To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer.,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
7002,NCT04826432,postoperative digestive leakage,2020-09-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7003,NCT05657210,5-year Overall survival (OS) of KRAS wildtype and each codon-specific KRAS mutation,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-related factor
7004,NCT01537107,MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.,2012-03-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor effect of molecularly targeted agents non-invasively by F18-FDG PET or PET/CT (Cohort II)
7005,NCT03946033,Modification rate of adjuvant therapeutic strategy,2019-05,WITHDRAWN,INTERVENTIONAL,['NA'],,
7006,NCT00478309,Factors that moderate the impact of GERA feedback on CRC screening utilization,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
7007,NCT06236282,Operation time,2012-05-01,COMPLETED,OBSERVATIONAL,['NA'],,TME quality (Operative outcome)
7008,NCT06048926,PFS evaluated by IRC,2022-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Progression-free survival evaluated by Researchers
7009,NCT06316882,number of gastric adenocarcinoma,2023-02-03,RECRUITING,INTERVENTIONAL,['NA'],,Socio-demographic characteristics of population in screening program
7010,NCT04418843,Complete resection of the lesion,2020-06-08,COMPLETED,INTERVENTIONAL,['NA'],,Sub-analysis by center participating in the study
7011,NCT02813824,Number of patients with at least one adenoma seen on chromo-endoscopy 48 months after complete withdrawal of polyps and initiation of treatment (aspirin or placebo),2017-11-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Load serrated polyps after 24 and 48 months of treatment
7012,NCT02745847,The toxicities following SBRT will be determined.,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,The quality of life will be analyzed.
7013,NCT03614650,percentage of adverse effects after EIE cell injection,2018-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The anti-cancer effects
7014,NCT04291755,Checkpoint inhibitor response,2019-06-28,UNKNOWN,OBSERVATIONAL,['NA'],,
7015,NCT05468177,Objective response rate (ORR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
7016,NCT03706157,Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution,2018-11-26,COMPLETED,INTERVENTIONAL,['PHASE4'],,"In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution"
7017,NCT06184867,Number of Participants with Genetic Testing Uptake,2023-10-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Acceptance and Usability of the Relational Agent
7018,NCT02330497,Safety of the pancreatic radiofrequency ablation under EUS guidance,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Safety of the pancreatic radiofrequency ablation under EUS guidance
7019,NCT04618809,"Percentage of treatment plan changes. (Count # of treatment changes 2-3 months after comprehensive geriatric assessment. Site coordinators will complete follow-up chart review of each patient to see what, if any, changes were made)",2020-09-22,RECRUITING,INTERVENTIONAL,['NA'],,Fitbit assessed functional status. Fitbit data: heart rate
7020,NCT00602082,Objective response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
7021,NCT04982653,Radiographic incidence rate of incisional hernia,2022-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AEs)
7022,NCT00336648,Number of Patients with Resection,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7023,NCT05348668,Progression-free Survival,2022-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7024,NCT04737213,Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.,2020-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7025,NCT06311279,Anastomotic leak amount,2024-03-05,RECRUITING,INTERVENTIONAL,['NA'],,
7026,NCT04560894,Progression-free survival(PFS)evaluated by the Blinded Independent Central Review Committee (BICR) based on RECIST V1.1,2020-11-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Anti-drug antibody (ADA)
7027,NCT02716207,The maximum tolerated dose will be determined,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Pain intensity will be determined.
7028,NCT02289378,Progression-free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate
7029,NCT04169347,Efficacy/objective response rate,2019-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluating for the velocity of tumor response to this regimen
7030,NCT05226572,Diagnostic yield (%) of repeated EUS-fine needle biopsy of pancreatic masses after previous non-diagnostic or inconclusive results,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity (%), specificity(%), positive predictive value(%), negative predictive value(%), specimen adequacy(%), Bethesda classification, adverse events incidence (%) and factors that influenced repeated EUS-fine needle biopsy performance."
7031,NCT01496521,occurrence of high grade dysplasia and invasive ESCC,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,occurrence of high grade dysplasia and invasive ESCC
7032,NCT00002793,,1991-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7033,NCT05244798,"Pathology complete response rate, pCR",2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Circulating tumor DNA, ctDNA"
7034,NCT00069095,PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
7035,NCT05195970,Correlation of colonic lesion gene expression with urolithin production,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,Correlation of dietary behavior with urolithin production
7036,NCT05056896,Change of ISC marker gene expression,2022-06-03,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Microbiome
7037,NCT02628067,Objective Response Rate (ORR),2015-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants who Discontinue Study Intervention due to AEs
7038,NCT03813641,Progression-free Survival (PFS) Time,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate)
7039,NCT03681951,Percentage of Participants Achieving Complete Response or Partial Response Based on RECIST 1.1 Criteria-Part 4,2018-11-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time Invariance Following Repeat Dose of Pembrolizumab-Part 3
7040,NCT01547260,Immunomodulatory effect (phase II).,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical efficacy
7041,NCT03531125,Comparison of whole transcriptome RNA sequencing of EUS derived pre-operative sample and whole transcriptome RNA sequencing of biopsies either taken from the pancreatic cancer during resection or repeat biopsy using EUS,2018-07-02,TERMINATED,OBSERVATIONAL,['NA'],,"Percentage and number of patients that undergo EUS and follow up EUS or surgery that have a) histopathological evidence of adenocarcinoma in their biopsy and surgical samples, and b) of suitable RNA quality for analysis"
7042,NCT02234986,Overall Response Rate,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and severity of adverse events,Progression Free Survival (PFS6) rate
7043,NCT03300609,Progression free survival 1,2018-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,Treatment Response
7044,NCT04244552,"Incidence of DLTs (dose escalation cohorts only), treatment emergent adverse events (TEAEs), and changes in safety parameters",2020-02-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,For the PLD Combination Therapy Cohort: ATRC-101 immunoreactivity in tumor biopsies at baseline and during treatment
7045,NCT02981641,Overal survival,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Local control rate
7046,NCT01998009,The proportion of participants with a positive colonoscopy finding indicating an advanced colorectal neoplasia who also have a positive fecal occult blood test result,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,The proportion of participants with a negative colonoscopy finding who also have a negative fecal occult blood test result
7047,NCT04880044,Proportion of participants negative via EC/EG who subsequently are proven negative via EGD,2022-01-05,RECRUITING,INTERVENTIONAL,['NA'],,
7048,NCT03349762,Distant Metastasis-Free Survival rate,2018-11-02,RECRUITING,OBSERVATIONAL,['NA'],,Immunity function
7049,NCT05908643,"Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI).",2023-03-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Evaluation of the importance of neoantigen selection to clinical outcome.,Disease-specific survival
7050,NCT01229839,overall survival,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
7051,NCT03430843,Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set,2018-01-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Experiencing Adverse Events (AEs)
7052,NCT00986518,"Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)",2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Laboratory test: hepatic function, immune function, haematology"
7053,NCT01315795,Reduction of total liver volume after 18 months of treatment by means of CT-scan,2011-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Assessment of quality of life after 18 months of treatment
7054,NCT04560751,Objective response rate（ORR）,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse events(AEs)
7055,NCT01861691,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Health-related QOL score
7056,NCT02976896,Disease control rate,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life using esophageal special scale QLQ - OES18
7057,NCT02669992,Number of participants with postoperative stoma site hernia,2015-06,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Hospital stay
7058,NCT01433861,Rate of reflux esophagitis,2012-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
7059,NCT00280618,Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events collections and evaluation
7060,NCT03927898,1 year Progression-Free-Survival (PFS),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Expression of PD-L1 on circulation tumor cell
7061,NCT05883683,Identification of effective drugs or drug combinations,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation between organoid and PDX drug sensitivities
7062,NCT00234182,Occurrence of recurrent disease,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Death of the patient
7063,NCT04738188,Downstaging success rate,2020-03-18,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence rate of Hepatocellular carcinoma
7064,NCT01262560,Change in Radiation Esophagitis-related Pain at 4 Weeks as Measured by the Numerical Rating Pain Scale for Pain on Swallowing (NRPS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient Reported Difficulty in Swallowing Associated With Manuka Honey Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
7065,NCT05068635,Number of patients who developped morbidity after subgastrectmy for gastric cancer,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7066,NCT01239056,Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail Plastic Stent Inserted Through the Metal Stent Lumen,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,Adverse Events
7067,NCT02155088,Maximum Tolerated Dose (MTD),2014-10-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
7068,NCT00008281,,2000-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7069,NCT03145558,Progression Free Survival,2017-12-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],Time to local recurrence,Duration of CR
7070,NCT04371198,Number of Participants With Biopsies That Form Spherical Organoids,2020-09-18,COMPLETED,INTERVENTIONAL,['NA'],,
7071,NCT02128100,Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability,2014-09-19,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of Life Assessment at 12 Months Post-treatment,Overall Response Rate for Participants as Assessed by Contrast-enhanced CT Scan of the Abdomen at 12 Months.
7072,NCT04258111,ORR,2020-08-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events (AE)
7073,NCT03152370,Number of participants with any non-serious adverse event (AE),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Mean peak-trough fluctuation (PTF) of E7046 and its metabolite ER-888188 in plasma
7074,NCT01666730,Median Overall Survival (OS),2013-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Grade 3 and 4 Toxicities According to NCI CTCAE Version 4.0
7075,NCT05027711,Treatment related Toxicity,2021-08-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Evaluation of potential prognostic biomarkers
7076,NCT02689401,Assess the safety of intravenous ferumoxytol for the use in esophageal cancer patients,2016-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Determine the accuracy of MRI-ferumoxytol for the identification of positive metastatic nodes in patients with esophageal cancer
7077,NCT05007912,Anastomosis complication,2021-06-21,UNKNOWN,OBSERVATIONAL,['NA'],,
7078,NCT05756699,HCC detection rate,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value
7079,NCT06014372,Rate of pCR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],OS,DFS
7080,NCT05201404,Overall Survival (OS),2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],"Quality of Life (QOL), using the hepatocellular carcinoma- (HCC-) specific module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question Module (EORTC QLQ-HCC18)",Pharmacokinetics (PK) of namodenoson in this population
7081,NCT06326502,Dose-limiting Toxicity (DLT),2024-02-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
7082,NCT02941861,Recurrence rate of Liver Carcinoma after surgery,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,
7083,NCT02078804,Mortality from colorectal cancer in the Swedish population.,2014-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,To study the flora of fecal bacteria among participants and outcome of FIT and colonoscopy.
7084,NCT03683446,Postoperative Complications,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7085,NCT04156087,Progression-free survival (PFS),2020-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7086,NCT04352023,Comparison of analgesic efficacy after major surgery in pancreatobiliary cancers: Intravenous patient-controlled analgesia versus patient-controlled epidural analgesia,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Investigation and comparison of pain and clinical progress during rest after surgery, side effects of drugs administered to IV-PCA and PCEA, and complications related to PCEA procedure"
7087,NCT03694977,Identification of potential biomarkers of MCS110 in combination with PDR001,2019-01-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by number and grade of toxicity events
7088,NCT02822352,To compare the rates of neoplasia detection using virtual chromoendoscopy compared to high definition white light (HDWL) endoscopy,2016-08,COMPLETED,INTERVENTIONAL,['NA'],,To compare the duration of time taken using each technique
7089,NCT02745509,Overall survival,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative quality of life
7090,NCT03890731,Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs),2019-04-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Dose Modifications
7091,NCT04317599,First-line Systemic anticancer therapy (SACT) treatment patterns in BRAFV600E mutant mCRC patients,2020-04-12,COMPLETED,OBSERVATIONAL,['NA'],,Time to treatment cessation
7092,NCT04680598,HBV Reactivation rate,2020-12-25,RECRUITING,OBSERVATIONAL,['NA'],,adverse event
7093,NCT02364024,Time to Recurrence (TTR),2005-11,COMPLETED,OBSERVATIONAL,['NA'],,Disease-Free Survival (DFS)
7094,NCT00559455,"Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan",2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to Progression (TTP), 6 month survival, overall survival, AFP"
7095,NCT01664169,Number and percentage of responder,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7096,NCT02608229,Maximum Tolerated Dose (MTD) of BVD-523,2016-06-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
7097,NCT00237172,To study the antineoplastic effect of the investigational drug.,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To study the safety and pharmacokinetics of the investigational drug.
7098,NCT02632448,Maximum Tolerated Dose(s),2016-05-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
7099,NCT02718729,Incidence of anastomotic leakage,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],,30 days postoperative morbidity and mortality
7100,NCT02728167,Normalized blood loss (ml/cm2),2016-04,TERMINATED,INTERVENTIONAL,['NA'],,Number of patients with postoperative complications assessed using Dindo-Clavien classification
7101,NCT03330561,Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03,2017-09-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Biomarkers (CD137, soluable HER2, cell surface antigens for immunotyping) in tumor tissues and blood samples"
7102,NCT03937362,Accuracy of clinical response evaluations for detecting substantial residual locoregional disease,2019-08-08,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy of clinical response evaluations for detecting any residual locoregional disease
7103,NCT05238584,3y Disease Free Surveillance,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],Duration of the hospital stay,Postoperative immunological changes (Interleukin monitoring)
7104,NCT04853043,Progression free survival (PFS),2021-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS).
7105,NCT03952442,Quality of Life (QOL),2019-02-21,UNKNOWN,INTERVENTIONAL,['NA'],,Knowledge-Attitude-Practice
7106,NCT00150670,Overall survival,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile"
7107,NCT05192044,Feasibility of enhanced recovery after pancreatico-dudenectomy,2021-12-25,UNKNOWN,INTERVENTIONAL,['NA'],,
7108,NCT01042041,"Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Disease Progression
7109,NCT02785887,Relative dose intensity,2014-08-01,COMPLETED,INTERVENTIONAL,['NA'],Optional Translational Substudy: Blood metabolites,Early mortality
7110,NCT02017678,Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Time to progressive disease
7111,NCT03298204,Overall survival,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Distant metastasis free survival
7112,NCT03688906,"Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy",2018-01-12,COMPLETED,OBSERVATIONAL,['NA'],,
7113,NCT02821533,Tumor response,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
7114,NCT03492671,Curative Intent Resection (R0) rate,2019-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Rate
7115,NCT03732781,Explore efficacy (expansion cohort),2020-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7116,NCT01218880,Maximum tolerant dose,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,objective response rate
7117,NCT01492049,Colorectal cancer screening (CRCS) Rate of Participants,2012-08-07,COMPLETED,INTERVENTIONAL,['NA'],,
7118,NCT00464919,To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.
7119,NCT00447330,Median Progression-Free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival
7120,NCT01086267,Toxicity will be evaluated according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3,2010-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics (PK) for BMS-908662 as determined by accumulation index [AI].
7121,NCT02088775,Local control,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Change in dose measured by PET-CT scan
7122,NCT05116696,All-cause mortality,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Hospital adverse event
7123,NCT06099314,Overall survival 2(OS2),2023-10,RECRUITING,OBSERVATIONAL,['NA'],,"Disease control rate 2 (DCR2, investigators based on RECIST1.1)"
7124,NCT06197425,The time to recurrence (TTR),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
7125,NCT01693445,maximum tolerated dose,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,disease control rate
7126,NCT00189657,,na,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7127,NCT03413514,The cycle of neoadjuvant chemotherapy,2018-01-03,UNKNOWN,INTERVENTIONAL,['NA'],,The involvement of patients during the shared decision making
7128,NCT04534075,Intensity of the urgency syndrome,2020-09-02,RECRUITING,INTERVENTIONAL,['PHASE3'],Composition of microbiota,Acute side-effects
7129,NCT06237582,Evaluate the incidence of IELN invasion by ovarian cancer,2022-06-16,COMPLETED,INTERVENTIONAL,['NA'],,"In cases of IELN positivity, review thoroughly preoperative scans and MRIs in order to detect radiological features, usually overlooked, that could help identify the positivity of these LNs prior to pathological analysis."
7130,NCT05043987,Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.,2022-11-16,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA)
7131,NCT05219539,Change of general surgical skills score,2021-11-11,COMPLETED,OBSERVATIONAL,['NA'],,Changes of clinical research possibilities score
7132,NCT04090060,Number of persons who practice the companion examination,2020-01-17,COMPLETED,INTERVENTIONAL,['NA'],,Concordance between self-examination and clinician examination stratified by waist circumference.
7133,NCT05370001,Carbon dioxide level from an arterial line (PaCO2) after 15 minutes of HFJV.,2022-06-13,COMPLETED,INTERVENTIONAL,['NA'],,Injury of the airway following endotracheal intubation.
7134,NCT05131919,"To assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers by objective response rate (ORR)",2022-12-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the date of relapse
7135,NCT01343212,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,
7136,NCT06293898,To determine the maximum tolerated dose (MTD) if reached or maximum administered dose (MAD) and two or more recommended doses for dose expansion (RDEs) of BL-M07D1,2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,
7137,NCT05778851,The impact of EsoCheck/EsoGuard on health care provider's decision for upper endoscopy referral,2023-04-12,RECRUITING,INTERVENTIONAL,['NA'],,The impact of EsoCheck/EsoGuard on health care provider's patient risk assessment for BE
7138,NCT02617134,Adverse events attributed to the administration of the anti-MUC1 CAR-T cells,2015-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response Rate
7139,NCT00002625,,1995-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7140,NCT01938716,To Quantifiably Assess Intratumoral Gemcitabine Levels in Human Pancreatic Cancer Tissue After a Single Intraoperative Infusion in Patients.,2012-03,TERMINATED,INTERVENTIONAL,['NA'],,To Correlate Intratumoral Gemcitabine Levels and Its Tumoricidal Activity With Ki67 Index and Intratumoral Apoptosis.
7141,NCT05142709,OS from start of 1st line treatment in metastatic ESCC,2021-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,the role of radiotherapy for patients treated with 1st immunotherapy.
7142,NCT02053805,"Prevalence, stage and pathology of screen-detected prostate cancer in BRCA1/BRCA2 founder mutation carriers and Lynch mutation carriers",2014-02,UNKNOWN,INTERVENTIONAL,['NA'],Genomic and biological profiles in samples from BRCA and Lynch mutation carriers and characterize changes related to prostate cancer.,"Accuracy of different screening tests (PSA, free to total PSA, prostate MRI) in detecting prostate cancer among men with genetic predispositions."
7143,NCT00659022,Difference in response of liver metastases between control group and experimental groups determined by FDG-PET,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complications of surgery
7144,NCT04511039,Maximum tolerated dose/ recommended phase II dose,2021-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of subjects with DNA damage response
7145,NCT00471484,Objective tumor response rate as measured by RECIST criteria,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tissue VEGF expression
7146,NCT04999007,The morbidity of anastomotic leakage.,2021-09-02,RECRUITING,INTERVENTIONAL,['NA'],,
7147,NCT04473794,Clinical utility of Compcyst in pancreatic cysts as assessed by patient chart review,2022-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
7148,NCT01743300,The feasibility of midazolam as a phenotyping probe for sunitinib exposure (area under concentration time curve)in cancer patients,2007-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,The influence of sunitinib on CYP3A4 activity
7149,NCT04851054,VEGF in serum on postop day 4,2017-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7150,NCT03688230,Progression Free Survival (PFS),2019-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).
7151,NCT03336658,correlation of ITB based calculated N stage with real N stage in CRC - patients,2015-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,correlation of ITB based calculated DFS with real DFS in CRC - patients
7152,NCT04958720,Diagnostic and therapeutic approach,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],,Create and validate a predictive model
7153,NCT02596113,Genes' mutations rate in patients who are submitted screening colonoscopy and they presented with cancerous lesion,2015-07,COMPLETED,OBSERVATIONAL,['NA'],,
7154,NCT04297280,Objective Response Rate (ORR),2020-04-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
7155,NCT01390194,image quality outcome,2011-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
7156,NCT01516944,Disease-free survival(DFS),2012-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-resection rate
7157,NCT01450046,Number of Participants With Treatment Related Adverse Events,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic (PD) Markers of Vitamin E δ-Tocotrienol Activity in Peripheral Blood
7158,NCT05267275,incidence of complications related to rectal anastomosis,2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
7159,NCT00728650,Survival,2003-10,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy
7160,NCT01051167,Response rate (RECIST-Criteria),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary objectives: Safety, Quality of life"
7161,NCT01921751,Overall Survival,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation Between SMAD4 Status Determined by Immunohistochemistry (IHC) and Genetic SMAD4 Status
7162,NCT01516710,Perioperative morbidity,2012-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of incisional hernia
7163,NCT04555135,Average Number of Adenomas Per Extraction,2020-09-28,TERMINATED,INTERVENTIONAL,['NA'],,Procedure Time
7164,NCT02318095,Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen,2015-02-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants Who Received an R0 Resection
7165,NCT00460837,Patient experience and compliance with reduced laxative tagging versus standard preparation,2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Comparison of per polyp specificity between the two preparation regimens
7166,NCT00005858,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7167,NCT01897610,To assess progression-free survival (PFS),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
7168,NCT02786329,Incidence of recurrences:,2016-06,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Rate of local anaesthetics systemic toxicity incidence,Rate of postoperative complications after TIVA versus inhalation anaesthesia
7169,NCT00629863,Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized,2004-09,COMPLETED,INTERVENTIONAL,['NA'],,"Health resource utilization, including the selection of treatments and subsequent use of health service resources"
7170,NCT02032953,Net protein balance,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
7171,NCT03917173,Disease free survival,2020-06-01,RECRUITING,INTERVENTIONAL,['NA'],,patients performing the adjuvant chemotherapy.
7172,NCT06031779,serum bile acid profile before treatment,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,concentration of serum tumor markers before treatment
7173,NCT00116389,6 month survival,na,TERMINATED,INTERVENTIONAL,['PHASE2'],,performance status
7174,NCT00002722,,1996-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7175,NCT04917276,Specificity,2021-06-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7176,NCT00943449,Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To investigate biomarkers
7177,NCT04616534,Overall survival (expansion cohort),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],"Pharmacodynamic (biological endpoints, toxicity and efficacy) parameters",Increase in deoxyribonucleic acid (DNA) damage level (expansion cohort)
7178,NCT00290966,to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progression,1998-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Patients were to be followed until death (overall survival). Clinical and laboratory were assessed with NCIC-CTG scale, before each cycle. Quality of life and clinical benefit were assessed every 2 weeks until progression and then every 3 months."
7179,NCT00162526,To evaluate the tolerability and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.,2005-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicity and the safety of a Tocopherol formulation in the prevention or suppression of the serverity of oral mucositis induced by myeloablative agonist.
7180,NCT01245582,Overall Survival (OS),2011-07,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Response Rate (RR)
7181,NCT04548440,R0 resection rate of patients who underwent surgery following preoperative treatment,2020-08-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of patients with adverse events and severity according to NCI CTCAE v5.0
7182,NCT00084942,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7183,NCT06256315,30-day overall complication rate,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,The rehospitalization rate within 30 days after surgery
7184,NCT03610490,Objective response rate (ORR),2018-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Health-related quality of life,Incidence of adverse events
7185,NCT01524783,Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment,2012-03-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacokinetics (PK): Predose Concentration (Cmin) of Everolimus at Day 29
7186,NCT00385515,Duration of Ulcerative Oral Mucositis,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Ulcerative Oral Mucositis
7187,NCT02754856,Incidence of adverse events,2016-07-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7188,NCT05304741,Overall Survival,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic Indicators
7189,NCT01405183,Prevalence of hepatitis C in renal cell carcinoma patients,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
7190,NCT03681600,3-year disease free survival,2018-01-01,TERMINATED,OBSERVATIONAL,['NA'],,"Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging"
7191,NCT02940496,Incidence of dose limiting toxicity (DLT),2016-12-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7192,NCT05397171,All Substudies: Incidence of AEs leading to discontinuation of AZD8853,2022-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Substudy 1 - Part B: Change in CD8 tumor infiltration in paired biopsies
7193,NCT03724435,Survival,2019-12-06,TERMINATED,OBSERVATIONAL,['NA'],Impact on Quality of Life and Cost,
7194,NCT00854854,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Determine safety of combination,time to treatment failure, overall survival time"
7195,NCT05419479,Switch Maintenance-Progression Free Survival,2022-11-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment-Related Adverse Events
7196,NCT02201797,repeatability coefficient (RC),2014-10,COMPLETED,INTERVENTIONAL,['NA'],,
7197,NCT01812876,Number of participants with adverse events; incidence of Shenqifuzheng'ADRs and identify factors that contributed to the occurrence of the adverse reaction,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7198,NCT00611507,Response rate - RECIST criteria (unidimensional),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS)
7199,NCT04795180,Length of hospital stay (number of days),2013-12-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Anorectal functional outcome assessed by Colorectal Functional Outcome Questionnaire (COREFO) questionnaire
7200,NCT01964027,PFS and OS,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7201,NCT00422773,"To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer",2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival"
7202,NCT04783831,POPF,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Position and degradation of biodegradable stents
7203,NCT01659346,First Variceal Bleeding,2016-02,WITHDRAWN,INTERVENTIONAL,['NA'],,Reappearance of Esophageal varices in presence of Portal Vein Thrombosis
7204,NCT03734068,Tumor response,2018-06-13,UNKNOWN,OBSERVATIONAL,['NA'],,number of treatment required to achieve objective response in HCC patients
7205,NCT02984566,Difference in accumulated patient dose distribution with and without KIM,2020-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Hepatocellular Carcinoma 18 Module (EORTC QLQ-HCC18)
7206,NCT02879721,"Change in expression of proteins associated with inflammation, proliferation and cancer development",2009-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in regulation of potential new biomarkers associated with esophageal cancer
7207,NCT06265844,Serum prealbumin,2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
7208,NCT00004127,Clinical response rate,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7209,NCT01498757,Biomarkers predictive,2012-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
7210,NCT05648084,Artificial intelligence's sensitivity and accuracy to predict the stage of the cancer,2022-12-15,RECRUITING,OBSERVATIONAL,['NA'],,"to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients"
7211,NCT00350753,Time to progression,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarkers
7212,NCT02308345,Length of visit (minutes),2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Participant-rated usefulness of video summary
7213,NCT02638051,Objective Response Rate (ORR),2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
7214,NCT00250835,Pathologic Complete Response (PCR),2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pelvic Local Control Rate
7215,NCT06134011,The differences of the metabolism information,2023-09-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7216,NCT01538550,colorectal cancer mortality,2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Pain reduction during Colonoscopy,Psychological effects of screening
7217,NCT04677192,OS,2021-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Complete ablation rate
7218,NCT00387530,Evidence of Epstein-Barr virus (EBV) lytic phase activation (expression of EBV antigens BZLF1 and LMP2) as assessed by biopsy on day 3 of course 1,2006-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Tumor response in patients with measurable disease as assessed by RECIST criteria
7219,NCT03771456,Anastomotic Leakage rate,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA'],,Length of postoperative hospital stay
7220,NCT00031616,,2001-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7221,NCT05128890,Hospital charges,2016-04-16,RECRUITING,OBSERVATIONAL,['NA'],,
7222,NCT05625932,Incidence of any VTE,2023-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of bleeding events according to genetic risk
7223,NCT05529667,PFS,2019-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
7224,NCT01913223,Safety outcome,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Effectiveness of the procedure in terms of complete neoplasia resections
7225,NCT03042442,Rate of patients with loss of > 5% body weight,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,"Assessing the survival rate by phone-calls follow-up every 6 months, up to 2 years"
7226,NCT00900432,Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1),2004-07,COMPLETED,OBSERVATIONAL,['NA'],,
7227,NCT00293436,Disease-free survival (phase II),2005-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (phase II)
7228,NCT00128596,Safety and tolerability,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7229,NCT02575807,Phase 2: Progression Free Survival (PFS),2016-03-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
7230,NCT00604721,Number of Participants With Radiographic Objective Response (OR),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7231,NCT02124317,Objective response rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
7232,NCT01180088,OVERALL BLOOD LOSS,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],,BLOOD TRANSFUSION RATE
7233,NCT02338518,3 year progression free survival,2015-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Sensitivity analysis of primary outcome adjusted for stratification factors,Adverse events of preoperative chemotherapy
7234,NCT05763927,pCR following neoadjuvant chemotherapy,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,1 year OS(overall survival) rate
7235,NCT00680901,Overall Survival in All Randomized Participants,2008-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants With a Worst-case on Therapy Grade 3 or Grade 4 for the Indicated Hematology Parameters
7236,NCT05727163,Objective Remission Rate (ORR),2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety (including chemotherapy-related adverse events, catheterization-related adverse events, surgical complications, etc.)"
7237,NCT03982121,Recommanded phase 2 dose (RP2D),2019-06-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
7238,NCT01745874,Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,Tumoral regression after neoadjuvant treatment
7239,NCT01232829,Survival Rate,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Disease Progression
7240,NCT04230772,Incidence of surgical complications,2021-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of retrieved lymph nodes
7241,NCT03853733,Genitourinary toxicity after the end of radiotherapy,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],,palliative colostomy after the end of palliative radiotherapy
7242,NCT05509751,Acceptability of the intervention and the study,2023-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Effect of the intervention on unplanned healthcare utilization
7243,NCT00533884,Delirium and delirium symptoms by the NEECHAM Confusion Scale and Confusion Assessment Method (CAM),2007-10,COMPLETED,OBSERVATIONAL,['NA'],,"Falls, injuries, and other complications"
7244,NCT02005809,Post-ESD bleeding rate according to second look endoscopy,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Post ESD bleeding rate according to bleeding degree during endoscopic submucosal dissection
7245,NCT00478140,Objective Response (Complete and Partial Response),2007-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7246,NCT02261844,Improved metabolic profile of liver cells,2015-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Decreased hepatic inflammation
7247,NCT00322712,Time to Death,2006-09,TERMINATED,OBSERVATIONAL,['NA'],,
7248,NCT05229783,Rate of both high grade dysplasia and esophageal adenocarcinoma lesions detected by electronic chromoendoscopy versus rate of such lesions detected by white light endoscopy plus systemic biopsies according to Seattle protocol.,2022-05-11,RECRUITING,INTERVENTIONAL,['NA'],,Cost effectiveness of the detection of both early esophageal adenocarcinoma and high grade dysplasia with electronic chromoendoscopy versus cost effectiveness of Seattle protocol.
7249,NCT00949949,"MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin",2009-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Timed endpoints
7250,NCT06298123,Recurrence-Free Survival (RFS),2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],"Imaging data (enhanced CT and MRI） and histopathology data, if available.",Overall Survival (OS)
7251,NCT01963949,Biopsy of Liver Masses,2013-10,WITHDRAWN,OBSERVATIONAL,['NA'],,
7252,NCT00511264,,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
7253,NCT01949194,A biomarker (in blood or tissue) that may be predictive of level of response to regorafenib,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (RR)
7254,NCT00915382,progression-free survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,overall survival
7255,NCT00623805,Progression-free Survival,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With a R0 Resection
7256,NCT04404595,Phase 2: Objective Response Rate (ORR) per independent central read,2020-10-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1b/2: Cytokine expression level in blood after CT041 infusion
7257,NCT03099031,Venous thromboembolism recurrence,2015-05,COMPLETED,OBSERVATIONAL,['NA'],Premature treatment discontinuation,Heparin induced thrombocytopenia
7258,NCT02401971,time to progression(TTP),2014-08,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
7259,NCT01595321,Number of participants with adverse events as a measure of toxicity,2012-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Time to disease progression using immune correlates
7260,NCT05229874,Total Number of Retrieved Lymph Nodes,2022-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Postoperative lymph node anatomy duration
7261,NCT02604979,Evaluate the heart-rate corrected QT (QTc) interval (msec) during robotic-assisted laparoscopic gastrectomy,2015-09-23,COMPLETED,OBSERVATIONAL,['NA'],,
7262,NCT01697891,Change in Subjective Dysphagia Assessment Score: EAT-10 from baseline,2012-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in M. D. Anderson dysphagia inventory from baseline
7263,NCT03874026,Activity,2019-09-05,RECRUITING,INTERVENTIONAL,['PHASE2'],Type of cells infiltrating the tumor microenvironment.,Toxic effects
7264,NCT05055635,Local control,2021-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,To investigate 6-month surgical site morbidity
7265,NCT05839002,Five-year survival of patients,2010-05-21,COMPLETED,OBSERVATIONAL,['NA'],,
7266,NCT00137852,"Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma
7267,NCT01158274,Incidence of adverse events graded according to NCI CTCAE version 4.0 (Parts 2a and 2b),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall response rate (Parts 2a and 2b)
7268,NCT02624726,Overall Response Rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity profile (CTCAE v4.0)
7269,NCT05961423,The time to recurrence of cancer after curative resection,2020-06-19,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of disability
7270,NCT05313854,Patient overall survival,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Progression-free Survival,Pathology diagnosis
7271,NCT01954745,Median Progression Free Survival (PFS),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7272,NCT05462873,Dose intensity,2023-04-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-drug antibody (ADA)
7273,NCT05068531,Time to tumor recurrence as assessed by detection or change in level of circulating tumor DNA after tumor resection with curative intent,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Disease-specific survival after complete tumor resection
7274,NCT00642577,Progression-free survival.,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"AEs, laboratory tests"
7275,NCT02365441,Objective tumour response (complete or partial response) as determined by RECIST v1.1,2015-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Macroscopically complete removal of all residual disease by surgery,Overall survival
7276,NCT00220649,"To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To document any antitumor activity with biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine administered on this schedule"
7277,NCT00193167,overall response rate,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
7278,NCT05870748,Objective Response Rate (ORR),2023-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerabilty
7279,NCT01180153,objective response rate,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
7280,NCT02959385,Overall survival,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Determination of internal target volume (ITV) of thoracic esophageal cancer by evaluating movement of ultrasonic endoscopically placed titanium clips, with or without swallowing, during radiotherapy simulation"
7281,NCT03966209,Acute Graft Rejection Rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Over all survival Rate
7282,NCT00560365,Overall survival by intention-to-treat analysis,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,NHS cost per life-year saved
7283,NCT02978612,Functional decline in instrumental activities of daily living (IADL) and/or activities of daily living (ADL),2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
7284,NCT06011473,feasibility of CGM system,2023-08-27,RECRUITING,INTERVENTIONAL,['NA'],,SSI rate
7285,NCT05338307,Determine whether oral BHB supplementation is safe and tolerable,2022-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa
7286,NCT01632020,Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7287,NCT00002525,5-year Overall Survival Rate in Patients With Dukes' B3/C Disease,1993-10-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,5-year Disease-free Survival Rate in Patients With Dukes' B2 Disease
7288,NCT04718701,Progression-free survival (PFS),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence and severity of adverse events (AEs) and severe adverse events (SAEs)
7289,NCT00112658,Survival (Phase III),2004-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall response rate (Phase III)
7290,NCT02830594,Changes in Myeloid-derived Suppressor Cells (MDSC) in Non-irradiated Sites Assessed by Flow Cytometry,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7291,NCT05937438,1-year disease-free survival,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,3-year overall survival
7292,NCT01233505,Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)
7293,NCT03200340,Duration of Severe Oral Mucositis (SOM) during the active treatment and short-term follow-up periods,2018-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],"Healthcare resource use including reliance on gastrostomy feeding, unplanned office visits, emergency room visits, and hospitalizations",Reduction in patient-reported mucositis-related mouth pain and analgesic use
7294,NCT02921139,freedom form local progression,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Grade of toxicity
7295,NCT02603159,"overall survival, OS",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,pathologic complete response rate
7296,NCT04246125,Maximum absorbed skin dose and dose distribution,2020-10-13,COMPLETED,OBSERVATIONAL,['NA'],,
7297,NCT03346005,The ability of AeonoseTM to distinguish between patients with and without colorectal cancer in a FIT-positive population in terms of sensitivity and specificity.,2017-11-09,COMPLETED,INTERVENTIONAL,['NA'],,Acceptance rate of AeonoseTM.
7298,NCT01169558,Safety: Number of Participants With Serious and Specific Adverse Events,2006-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Efficacy: Progression-free Survival
7299,NCT05182112,determine the maximum tolerated dose of focal simultaneously integrated boost (SIB),2021-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7300,NCT02100189,Specificity of Sponge Cytology Using FISH,2014-02,COMPLETED,INTERVENTIONAL,['NA'],,Tolerability of FISH Spongy Cytology
7301,NCT04782557,"Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood",2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of EUS-PVA and HVA
7302,NCT01894828,Improvement of nutritional status,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reducing number of complications
7303,NCT03138044,Overall survival rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor response rate
7304,NCT03902600,Acute grade 3 or higher GI AEs,2018-05-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,overall survival
7305,NCT00145860,,2002-04,TERMINATED,OBSERVATIONAL,['NA'],,
7306,NCT00014456,Define dose limiting adverse events associated with the combination,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective antitumor response
7307,NCT04506398,molecular-subtype heterogeneity between primary HCC and post-transplant HCC recurrence,2020-09-10,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence-Free Survival (RFS)
7308,NCT05101616,major pathologic response rate,2022-07-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,perioperative complications
7309,NCT03365765,disease-free survival,2018-02-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,incidence of adverse reactions after chemotherapy
7310,NCT05240404,Disease-free survival,2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Predictive Biomarkers
7311,NCT05507632,Objective response rate (ORR),2022-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival rate
7312,NCT05518032,Objective response rate,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate
7313,NCT00494299,Time to Progression (TTP),2006-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
7314,NCT02061956,Efficacy,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Safety
7315,NCT00363051,Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on Response Evaluation Criteria in Solid Tumors (RECIST),2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of Octreotide Depot on the Trough Concentrations of Everolimus
7316,NCT01658943,Overall Survival,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Objective Response Rate,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
7317,NCT04767984,Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Banking of colorectal specimens
7318,NCT04741490,1-year disease-free survival rate (1-year DFS),2021-02,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival (OS)
7319,NCT04141995,Number of patients able to undergo resection surgery,2021-02-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of subjects with grade 4 thrombocytopenia and grade 3-4 diarrhea
7320,NCT02334332,"Patient/informal caregiver satisfaction with timing, content, and delivery of the intervention",2015-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in mean survey scores
7321,NCT06119906,Contrast of neoplastic vs non-neoplastic Barrett's,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Image quality of Hyper-Spectral Endoscopy after post-hoc analysis
7322,NCT04351321,The incidence of postoperative morbidity,2020-07,UNKNOWN,INTERVENTIONAL,['NA'],,Overall incidence of postoperative morbidity
7323,NCT02872779,Difference from baseline in the number of free mutant DNA in blood,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of response based on the RECIST 1.1 guideline
7324,NCT03088150,Overall survival (OS),2017-07-13,RECRUITING,INTERVENTIONAL,['NA'],,Time to progression
7325,NCT04172194,overall survival,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,tolerance
7326,NCT05740852,Pneumonia,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7327,NCT04172779,Modulation of gene expression signatures associated with hepatocellular carcinoma (HCC) risk,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in GSTp levels in the liver,Change in quality of life (QOL)
7328,NCT05424068,Measuring safety/practicality as assessed during one-on-one with the health coach (analyzed as qualitative data),2022-12-02,RECRUITING,INTERVENTIONAL,['NA'],Measure of performance status,Physiological measures of Performance
7329,NCT00474734,,2007-05,UNKNOWN,OBSERVATIONAL,['NA'],,
7330,NCT05100446,Helicobacter pylori eradication,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
7331,NCT05344820,level of fatigue,2022-05-19,RECRUITING,INTERVENTIONAL,['NA'],,level of rumination
7332,NCT01694511,Incidence of detected dysplasia by each endoscopic technique.,2009-11,COMPLETED,INTERVENTIONAL,['NA'],The endoscopic prediction capability of present dysplasia compared to histopathology for HRME.,The number of biopsies taken and the duration of the different endoscopic techniques.
7333,NCT02036216,"To collect the DNA samples from the plasma, blood cells and solid tumor tissues in the patients with HCC.",2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Early diagnosis, treatment monitoring and prognosis evaluation."
7334,NCT05514301,Sensitivity of polydeep vs high experienced endoscopist blinded to polydeep,2023-01-30,COMPLETED,INTERVENTIONAL,['NA'],,To compare the diagnostic yield of the optical diagnosis
7335,NCT00459030,Comparison of traditional print versus simple electronic communication versus usual care in terms of increasing colorectal cancer (CRC) screening rates,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,Mediating effect of potential cognitive-affective factors related to CRC screening
7336,NCT05368688,"The molecular features of Fusobacterium (Fn) correlated with colorectal cancer (onset, recurrence, metastasis and survival)",2022-06-30,TERMINATED,OBSERVATIONAL,['NA'],,
7337,NCT00652132,Rate of Brock grade ≥ 1 hearing loss,2007-12-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Feasibility of central audiology review
7338,NCT05216120,Overall response rate of pemigatinib,2022-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE V4.0
7339,NCT00732082,To determine the dose limiting toxicities of IMP321 in patients being treated with gemcitabine for advanced pancreas cancer.,2009-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,To evaluate the clinical response and time to disease progression with computed tomography examinations at two month intervals (current standard of care in gemcitabine-treated patients).
7340,NCT03087071,Response rate,2017-12-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7341,NCT03830801,The number of subjects from which we will be able to collect biopsy samples using IVLCM technique,2017-12-06,RECRUITING,INTERVENTIONAL,['NA'],,
7342,NCT01288612,Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability
7343,NCT04009954,The time ranging from operation day to the day of first defecation,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Concentration of fecal calprotectin
7344,NCT04978350,Reach of Genetic Testing Among Family Members,2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Integration of Workbook into Genetic Counselor Work Environment
7345,NCT05646030,Feasibility of CEA assessments at home using (automated) capillary sampling,2022-03-25,RECRUITING,INTERVENTIONAL,['NA'],,Clinical laboratory sample processing time:
7346,NCT05938322,Adherence to the ketogenic diet,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Investigate indices of quality of life
7347,NCT05181865,Phase 2a (Expansion): ORR (CR + PR) assessed centrally by RECIST v1.1,2022-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Phase 1 (Exploratory): Explore the predictive potential of biomarkers measured in blood and/or tumor tissue in response to FL-301,Phase 1: PK parameters - Half-life (t1/2)
7348,NCT02857218,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Sensitivity and specificity of PET/CT imaging
7349,NCT05690451,Accuracy per patient,2021-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity per patient
7350,NCT02280070,3-years Disease Free Survival rate,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Pattern of first recurrence
7351,NCT02393248,Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2,2015-02-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 3: Accumulation Ratio of Pemigatinib as Part of Combination Therapy on Cycle 1 Day 14 (Steady State)
7352,NCT05742620,3y-DFSR,2023-06-20,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3y-OSR
7353,NCT00060567,"To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety, E7070 activity and Pharmacokinetics"
7354,NCT05186402,Overall survival,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7355,NCT02552121,Part 2: Number of Participants Reporting One or More Treatment-related Adverse Events,2015-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Duration of Response
7356,NCT02529774,Liver Relapse-Free Survival Rate,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease free survival
7357,NCT00531245,"In a phase I study, to determine the maximum tolerated dose(MTD) In a phase II study, to evaluate the efficacy(response rates) and toxicities",2006-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To investigate the time to progression(TTP), overall survival and toxicity"
7358,NCT01539993,Assess efficacy of percutaneous and transarterial treatments for liver cancer.,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,long term follow up
7359,NCT00017056,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7360,NCT06155318,Diagnostic Accuracy,2019-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
7361,NCT00438737,Safety (rate of perioperative safety findings),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
7362,NCT06187961,Number of Patients Amendable to Curative Surgical Interventions,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) after treatment
7363,NCT02995096,Overall survival,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,Hepatocellular carcinoma specific survival
7364,NCT05859477,1-year progression-free survival (PFS),2022-06-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity Summary
7365,NCT05805956,progression-free survival,2022-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7366,NCT04994093,Optimization of pHLA:TCR binding affinity and toxicity,2021-10-06,UNKNOWN,OBSERVATIONAL,['NA'],,
7367,NCT05131243,ctDNA dynamic detection,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor Marker examination
7368,NCT01372735,Local recurrence rate,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
7369,NCT04047173,2-year local progression-free survival rate,2019-08-12,UNKNOWN,INTERVENTIONAL,['NA'],Radiation-induced liver injury,incidence of complications
7370,NCT02539537,Progression-Free-Survival (PFS),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life questionnaire - Core 30 (QLQ-C30)
7371,NCT01786694,functional success of microdialysis,2013-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,the quality of life after the surgery
7372,NCT05790590,lesion conspicuity on portal venous phase,2023-05-30,RECRUITING,INTERVENTIONAL,['NA'],,Contrast media (CM) dose
7373,NCT06030180,Clinical Utility,2023-02-23,RECRUITING,INTERVENTIONAL,['NA'],,Patient Compliance
7374,NCT00335829,Time to Tumor Progression (TTP) of Targeted Lesions,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Treatment Toxicity - Cycles 2 and 3
7375,NCT03235167,metastasis free survival time,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
7376,NCT01716546,Objective response rate,2011-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Maximum Tolerated Dose of the combination
7377,NCT02940067,Peak power - measured using cardiopulmonary exercise testing,2017-03-28,COMPLETED,INTERVENTIONAL,['NA'],,Well-being
7378,NCT00578838,To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer.,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
7379,NCT03585062,R0 resection rate,2017-11-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,The quality of life
7380,NCT00760721,Obtaining HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Knowledge and Attitudes Regarding HBV Screening
7381,NCT00726037,T-reg Suppression From a Fractionated Dose of Ontak in Patients With Metastatic Pancreatic Cancer,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Optimal Time for Future Dendritic Cell Vaccine Administration
7382,NCT02883790,Quality of sleep assessed using the PSQI scale,2015-10,TERMINATED,INTERVENTIONAL,['NA'],Number and typology of adverse events,Quality of Life evaluated according to SF-12 scale
7383,NCT01555762,Progression-Free Survival,2012-03-05,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Balducci Score
7384,NCT01181245,To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib,2008-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Maximal tumor response as determined by RECIST criteria
7385,NCT00513851,Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930,2006-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity"
7386,NCT04966819,Short Form-Survivor Unmet Needs Survey (Unmet needs) at 12 months,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Short Form-Survivor Unmet Needs Survey (Unmet needs)
7387,NCT02860234,Organ preservation rate,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29)
7388,NCT03186898,Overall Survival (OS),2017-06-22,RECRUITING,INTERVENTIONAL,['PHASE3'],,Exploratory - Overall Quality of Life (QOL)
7389,NCT00075465,Time to tumor progression,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerability
7390,NCT01993784,Objective response rate,2013-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,adverse events
7391,NCT00253370,The Proportion of Patients With Objective Response (Complete Response or Partial Response),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7392,NCT02148562,genetic variants of Hepatitis B,2014-04,UNKNOWN,OBSERVATIONAL,['NA'],,genetic variation in host-specific immune markers
7393,NCT01362127,Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,HRQOL and Swallowing Function
7394,NCT03156036,Pathologic complete response rate(Pathologic staging and tumor regression grade.),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7395,NCT01332669,tumor response,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of treatment required to achieve objective response
7396,NCT01013649,Overall survival (Phase III),2010-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in fatigue
7397,NCT06307327,Evaluation consistency,2024-03,RECRUITING,OBSERVATIONAL,['NA'],,
7398,NCT01423734,reproducibility of diffusion weighted imaging for neuroendocrine liver metastases.,2011-08-23,COMPLETED,OBSERVATIONAL,['NA'],,evaluate the reproducibility perfusion insensitive diffusion coefficients (ADC high) of liver metastases
7399,NCT04924179,Progression-free survival (PFS),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
7400,NCT04189393,"Compositional changes of the oral and gut microbiome, assessed by alpha-diversity using 16S rRNA (ribosomal ribonucleic acid) sequencing, described in a surgical patient journey from moment of diagnosis until full recovery",2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Compositional changes of the oral and gut microbiome, assessed by beta-diversity using 16S rRNA sequencing, correlated to the development of infectious complications (30-day)"
7401,NCT02829918,Overall Response Rate (ORR) After 4 Cycles of Treatment,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
7402,NCT00025441,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7403,NCT03734952,overall survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Side effects
7404,NCT04051450,Generation of candidate biomarkers PD-L1/PD1/GEP by laboratory assay qPCR for prognostication.,2020-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
7405,NCT00936572,"Primary Efficacy Parameters: morphological and microbiological evaluation of the colonic microflora, gastrointestinal function",2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary Efficacy Parameters: immune and inflammatory response, bacterial translocation"
7406,NCT00955097,identification of liver tumors,2008-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,improved ablation of liver tumors
7407,NCT01429961,Time to progression (TTP),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity
7408,NCT05178303,The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis (Arm 1),2015-11-30,COMPLETED,INTERVENTIONAL,['NA'],,The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis/Hcc (Arm 2)
7409,NCT03847532,Patients with germIine mutations in MutYH,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA'],,
7410,NCT00004941,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7411,NCT04208958,Objective Response Rate (ORR),2020-01-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of VE800 Bacterial Strain Colonization in Stool
7412,NCT02928627,presence of miR-221 and mR-222 in the blood,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,correlation of expression of miR-221 and miR-222 in tissue and blood samples
7413,NCT02213419,Rate of Subjects with Complete or Partial response of treatment,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Incidence rate of adverse events after treatment
7414,NCT05800561,predictive accuracy of HVPG and ICG-r15 on PHLF,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
7415,NCT06029829,Compare Progression Free Survival (PFS) Regimen using RECIST 1.1.,2023-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7416,NCT05361668,Incidence of treatment-emergent adverse events (TEAEs),2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics (PK) of paltusotine
7417,NCT03846726,PFS,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,OS
7418,NCT03775525,Dose-limiting toxicity,2019-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Apparent Volume of Distribution (Vd/F)
7419,NCT04152343,Rate of Local Occurrence,2019-12-07,COMPLETED,INTERVENTIONAL,['NA'],,
7420,NCT00415168,Percentage of Participants With Objective Response (Objective Response Rate),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Died During the Study
7421,NCT02664974,Maintenance of body weight,2008-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Improvement of tolerance to chemotherapy
7422,NCT02928081,5-year overall survival rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,5-year disease-free survival rate
7423,NCT02963207,Accuracy measures in comparison to the final histopathology in regards to polyps' subtype (SSA/P versus non-SSA/P),2013-06,COMPLETED,INTERVENTIONAL,['NA'],,Agreement in predicting post-colonoscopy surveillance interval with final histopathology
7424,NCT02208804,Posttreatment tumor to non-tumor activity concentration ratio on SPECT/CT,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Clinical and laboratory toxicity
7425,NCT02726334,Maximum Tolerated Dose,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7426,NCT00660140,To determine the response rate and time to failure for patients treated with this regimen,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival times
7427,NCT04106024,PFS,2018-10-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7428,NCT03244683,Postoperative complications,2017-08-28,TERMINATED,INTERVENTIONAL,['NA'],,Length of stay and readmission
7429,NCT05709899,postoperative analgesia,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7430,NCT02028949,tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose,2012-11-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate the rate of objective response
7431,NCT05471401,"Percentage of participants who undergo successful inflation of the gastric balloon with oral contrast agent, with verification by MR or CT imaging",2023-04-25,RECRUITING,INTERVENTIONAL,['NA'],,Translation movement of stomach between CBCT scans with and without balloon insufflation
7432,NCT05421702,Type of anastomosis,2022-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Preoperative colonoscopic examination result
7433,NCT05199168,Incidence of the recurrent laryngeal nerve injury,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Operation time (thoracic phase)
7434,NCT04721132,Incidence of adverse events (AEs),2021-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7435,NCT05159440,Recommended Phase 2 Dose (RP2D),2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-2-307-MAB
7436,NCT05561699,safety（AE or SAE）,2022-09-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival（DFS）
7437,NCT05704985,"Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation, chemotherapy, or checkpoint blockers in Parts B, C, D",2023-04-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Serum concentrations of proinflammatory cytokines such as IL-6, IL-10, TNFa, IL-1b, and interferon (IFN)-g will be assessed at various time points"
7438,NCT00123851,"To determine the response rate of OSI-774 when given in combination with oxaliplatin and capecitabine in patients with previously-treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the toxicities of the combination of OSI-774, oxaliplatin and capecitabine in this population of patients with colorectal cancer"
7439,NCT04392609,pTRG,2020-01-15,UNKNOWN,OBSERVATIONAL,['NA'],,
7440,NCT01870791,Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety profile
7441,NCT00051688,,2003-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7442,NCT02823860,Presence of biological and tumoral factors related to resistance to oncological treatments,2016-02-12,COMPLETED,INTERVENTIONAL,['NA'],,"behavioral characteristics of patients by HADS Scale, according to their therapeutic car modalities"
7443,NCT03914950,Participants With Increased Tracer Uptake Over the Pancreatic Lesion With and Without TOF,2014-02-07,COMPLETED,INTERVENTIONAL,['NA'],,Lesion Size
7444,NCT05044728,Immune Related Adverse Events (irAEs),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,2-year survival rate
7445,NCT01828047,Postoperative ileus symptoms; microvascular flow index (MFI),2013-11,COMPLETED,OBSERVATIONAL,['NA'],,
7446,NCT00508573,Number of Women Participating in Registry,2007-05,RECRUITING,OBSERVATIONAL,['NA'],,
7447,NCT06010862,Obtain the maximum tolerated dose of CEA CAR-T cells[Safety and Tolerability],2023-09-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Duration of Response (DOR) of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],Pharmacodynamics of CEA CAR-T cells[Cell dynamics]
7448,NCT00698204,Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of Pain Severity at 5000 cGy Radiation
7449,NCT00835679,Patients With a Biologic Response,2009-12,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Patients With the Given Severity of Post-operative Complications Within the Specified Duration
7450,NCT05678218,Lymph nodes identified compared to surgery,2022-09-05,RECRUITING,OBSERVATIONAL,['NA'],,Short term and long term complications of the EUS (+/- tissue acquisition) procedure for patients with pCCA and iCCA
7451,NCT05281276,Pharmacokinetics profiles-(DF),2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response
7452,NCT00830557,Collection of information regarding food preparation and intake by survey,2000-10,RECRUITING,OBSERVATIONAL,['NA'],,
7453,NCT01214512,Colonoscopy and CD24 assay correlation,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,
7454,NCT00019084,,1996-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7455,NCT03731910,Treatment response mRECIST,2018-12-11,UNKNOWN,INTERVENTIONAL,['NA'],,Time to Progression
7456,NCT01307878,Progression-free survival,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity of chemotherapy
7457,NCT04473677,The accuracy of the new qFIT to diagnose colorectal advanced adenoma.,2020-08-17,COMPLETED,OBSERVATIONAL,['NA'],,Develop a predictive model of advanced colorectal neoplasms which includes the value of qFIT.
7458,NCT03328065,Type of determinants which are privileged by the patients to choose a treatment,2017-12-19,TERMINATED,OBSERVATIONAL,['NA'],,
7459,NCT02140034,Overall Survival,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,Peritoneal Recurrence Rate
7460,NCT02269683,R1 resection rate,na,WITHDRAWN,INTERVENTIONAL,['NA'],,
7461,NCT06123637,Remifentanil requirement,2024-01-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7462,NCT00534664,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7463,NCT04722133,Objective response rate (ORR),2020-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of treatment related adverse events (TRAE)
7464,NCT03069599,Immunological outcome,2017-02-15,TERMINATED,OBSERVATIONAL,['NA'],,Cancer specific survival
7465,NCT00883454,The primary outcome was to investigate the value of preoperative cholinesterases in predict postoperative adverse outcome after hepatic resection for hepatocellular carcinoma in cirrhosis.,na,COMPLETED,OBSERVATIONAL,['NA'],,
7466,NCT03977090,"Extended period recommended dose,RDE",2019-04-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,"Antidrug antibody, ADA"
7467,NCT05744362,Overall survival,2022-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
7468,NCT01163396,Progression-free survival (PFS),2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of potential surrogate markers predictive of bevacizumab activity
7469,NCT05587972,Create data set,2022-10-06,RECRUITING,INTERVENTIONAL,['NA'],,
7470,NCT04114006,Diagnostic yield of the WATS approach versus standard gastric biopsy mapping,2019-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
7471,NCT02491593,Number of patients with high fecal blood output in relation to colorectal cancer,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,Number of patients with low fecal blood output in relation to colorectal polyps
7472,NCT04334395,Complication rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,The survival time
7473,NCT00132067,Toxicity as assessed by CTCAE v 3.0,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of survival
7474,NCT03281070,Anastomotic leakage,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7475,NCT00960557,To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine progression-free survival (PFS).
7476,NCT03285230,Health outcomes,1990-06-15,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7477,NCT01910909,To evaluate the SBRT effect on adverse events,2013-08,COMPLETED,INTERVENTIONAL,['NA'],RT response prediction probability evaluation by diffusion-weighted (DW) MRI and positron emission tomography,To measure the progression free survival
7478,NCT04519151,PFS of patients treated with pembrolizumab in combination with lenvatinib.,2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Impact of the treatment protocol on health-related quality of life using the QOL questionnaire (EORTC) QLQ-OV28.
7479,NCT01137162,,2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
7480,NCT04967482,Success rate of conversion to resection,2021-07-09,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival (OS)
7481,NCT00419627,,2007-02,UNKNOWN,OBSERVATIONAL,['NA'],,
7482,NCT00003220,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7483,NCT04813406,Overall survival(OS),2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Disease Control Rate (DCR)
7484,NCT02920944,single diagnostic yield of the histologic core,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,total diagnostic yield of the histologic core
7485,NCT03516942,Change in level of self-reported financial burden,2018-06-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in level of self-reported financial burden
7486,NCT02640924,Local control rate (treatment in-field control rate),2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient report outcome - quality of life as assessed by the EQ-5D-3L
7487,NCT02113683,active tumor growth before and after cancer therapy,2014-05,TERMINATED,OBSERVATIONAL,['NA'],,
7488,NCT00205322,"Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients",2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Is the oral drug an advantage in this patient population
7489,NCT03717935,Change in Hepatic Fat Fraction,2018-10-08,COMPLETED,INTERVENTIONAL,['NA'],,Change Bile Acid Metabolomics: sphingosine-1-phospate
7490,NCT02116894,Recommended phase II dose (RPTD) for the combination of PF-03446962 plus regorafenib,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival associated with PF 03446962 plus with regorafenib
7491,NCT01216813,Patients' opinion of how to manage any of the issues that arise,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Theories and a hypothesis from data collected for use in a future interventional study
7492,NCT00109226,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7493,NCT03340974,Radiographic Stable Disease (SD) or Better Based on RECIST Criteria,2018-02-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7494,NCT04204577,Progression-Free-Survival(PFS),2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life score(QOL)
7495,NCT02125409,Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.,2014-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway)."
7496,NCT05576506,AUC (95% CI),2022-10-08,RECRUITING,OBSERVATIONAL,['NA'],,To record and evaluate any unknown risks and adverse events of hyperspectral imaging in specimen image acquisition
7497,NCT02017002,Overall survival duration,2014-03,UNKNOWN,INTERVENTIONAL,['NA'],,Change of lung function after surgery
7498,NCT04995809,Reason for attrition,2021-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Microbiomic profiling by bacterial 16S rRNA metabarcoding sequencing,The number of participants required to take part in a larger multicentre trial which will identify potential therapeutic targets from metabolomic and microbiomic profiling
7499,NCT00320749,Maximum Tolerated Dose (MTD),2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic Response
7500,NCT02641873,AUC0-24h (Area under the plasma concentration versus time curve),2015-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
7501,NCT02630056,the grade of acute hematologic toxicity,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7502,NCT03975491,Interleukin-6,2019-08-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Tumor Fraction,Circulating Tumor Cells
7503,NCT05633641,ORR,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],,
7504,NCT05704010,Small bowel adenoma,2018-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
7505,NCT03671265,"Adverse events (AE), Serious Adverse Event(SAE) Adverse events",2018-09-17,UNKNOWN,INTERVENTIONAL,['NA'],,OS
7506,NCT00536809,Overall Response in Phase II,2007-09-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Change From Baseline to Study Completion in Aspartate Aminotransferase, Alanine Aminotranferease, and Alkaline Phosphatase"
7507,NCT03184493,Number of participants with tumor recurrence,2017-06-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7508,NCT06206876,CL/F,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
7509,NCT05687617,Number of patients with peritoneal metastases detected only with ICG.,2022-12-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7510,NCT01766349,"Changes of respiratory muscle performance (MIP/MEP, PFT)from baseline",2011-09,COMPLETED,OBSERVATIONAL,['NA'],,Total length of hospital stay
7511,NCT01727908,The percentage of increasement of endoscopic detection of (pre)malignant for gastric cancer by staining of the gastric mucosa.,2012-11,TERMINATED,INTERVENTIONAL,['NA'],,"To determine the psychosocial impact of the screening protocol in this population, measured as the amount of stress and anxiety by use of the Hospital Anxiety and Distress Scale and the amount of cancer-worry by use of the Cancer Worry Scale."
7512,NCT01202136,Prevalence and incidence of malignant pancreatic cysts,2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Model for prediction of malignant pancreatic cysts
7513,NCT04574050,Feasibility: the number of patients recruited into this study over a 12-month period,2021-01-11,COMPLETED,INTERVENTIONAL,['NA'],,
7514,NCT05257590,Objective Response Rate (ORR)_mRECIST,2022-05-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pharmacodynamics analysis for the relationship of AUC and AE
7515,NCT05241574,Rate of patients with clinical complete response.,2021-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Acute and late toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 5."
7516,NCT01155882,To determine range of morbidity and mortality,2010-09-20,COMPLETED,OBSERVATIONAL,['NA'],,Effect of occlusion of the splenic vein at the confluence.
7517,NCT04151719,Overall Survival,2020-02-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
7518,NCT03170310,Progress free survival,2017-02-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
7519,NCT05429697,Progression Free Survival,2022-06-09,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of Life
7520,NCT06041490,EFFICACY: One-year recurrence-free survival rate (1-year RFS rate),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,SAFETY: Incidence of adverse events and serious adverse events
7521,NCT03050879,Total Number of Retrieved Lymph Nodes,2017-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,3-year overall survival rate
7522,NCT00662688,Thromboembolic events,2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Tolerance of regimens
7523,NCT03274349,"Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis",2017-03-17,UNKNOWN,INTERVENTIONAL,['NA'],,Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters
7524,NCT05400915,(Phase II) Progression-free survival,2019-07-23,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Adverse Events That Are Related to Treatment
7525,NCT01814631,image quality,2013-03,WITHDRAWN,OBSERVATIONAL,['NA'],,
7526,NCT03130712,Safety of CAR-T cell infusion mediated by intratumoral injection as measured by number of participants with adverse Events,2017-04-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum cytokine levels
7527,NCT04595266,Objective response rate (ORR),2021-06-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of patients with liver surgery
7528,NCT05775120,"To assess the state of the gastric mucosa according to endoscopic and morphological studies using the OLGA system, and their correlation with serological markers of atrophy",2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],Develop recommendations for GC prevention and early detection strategy.,To determine the prevalence of H. pylori in the Moscow population according to the serological method - level of IgG antibodies to H.pylori.
7529,NCT05759975,Oral Mucositis evaluation according NCI scale,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Saliva analysis
7530,NCT06314022,Compliance with the laxative intake with the use of the mobile application,2024-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Evaluate colonoscopy quality indicators
7531,NCT00183807,To assess the time to progression of CPT-11 and cisplatin in combination with celebrex in patients with metastatic or unresectable carcinoma of the esophagus,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"To evaluate the effects of celebrex on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays on endothelial cell proliferation, migration and invasion."
7532,NCT05331911,The presence of disease progression,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE4'],blood loss and blood transfusion,Length of hospital stays
7533,NCT01661114,The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival of Previously Treated and Previously Untreated Patients
7534,NCT02144727,overall survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Finding biomarkers predicting lymph node metastasis and recurrence
7535,NCT04709510,The incidence of thromboembolic events by radiological assessment,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Rate of predisposing factors of the patients
7536,NCT03940131,Overall response rate (ORR),2020-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7537,NCT03881111,OS in PD-L1 biomarker-positive participants,2019-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score
7538,NCT03618758,Overall survival (Phase 2),2018-12-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Conversion surgery ratio
7539,NCT05629442,Rate of successful pathologic complete response,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival (OS)
7540,NCT02504229,Progression free survival,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7541,NCT00274885,Relationship between residual platinum levels in the blood and persistent neurotoxicity,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Pharmacokinetics
7542,NCT01209962,Diffusion MRI,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,Apparent Diffusion Coefficient (ADC)
7543,NCT02040142,Evaluate the technical parameters,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Patient Reported Outcomes,Progression-free survival
7544,NCT02162823,Survival,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,Factors influencing survival
7545,NCT04653818,HCC recurrence,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,changes in Child-Pugh scores over time
7546,NCT02307500,"activity of regorafenib screening, in terms of 2-months progression free survival rate",2014-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety profile of regorafenib according to NCI-CTC v.3
7547,NCT02610764,"Change of numbers of CTCs in patients with resectable EAC at diagnosis, after neoadjuvant treatment and after surgery.",2015-11,COMPLETED,INTERVENTIONAL,['NA'],Progression free survival,"Number of patients with detectable CTCs at diagnosis, after neoadjuvant treatment and after surgery."
7548,NCT00094861,Number of Participants With Grade 2 or Higher Dysphagia,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Maximal Body Weight Loss
7549,NCT05970900,Organ preservation,2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Anorectal function
7550,NCT04918992,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of AI prediction system in prediction radiation proctitis,2021-06-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],The sensitivity of AI prediction system in prediction the radiation proctitis candidates,The specificity of AI prediction system in prediction radiation proctitis
7551,NCT00044512,Percentage of Participants for Each Type of Response,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7552,NCT02787954,Time to progression,2016-01,TERMINATED,OBSERVATIONAL,['NA'],,1 year survival
7553,NCT02966054,Physical activity,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer-specific quality-of-life (FACT-C)
7554,NCT01096914,Tumor response,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,time to local recurrence
7555,NCT04050085,Incidence of adverse events,2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
7556,NCT00501306,,2007-06,COMPLETED,OBSERVATIONAL,['NA'],,
7557,NCT02512237,Maximum tolerated dose of ARX788,2016-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of subjects developed anti-ARX788 antibody
7558,NCT00410579,"Comparison of patient-reported outcomes prior to randomization, 1 year after completion of study treatment, and in long-term follow up > 5 years after diagnosis in patients treated in NSABP C-06 or NSABP C-07 trials",2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
7559,NCT06171321,Accuracy of postoperative ctDNA in monitoring recurrence and metastasis,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
7560,NCT04905082,Recall rates of personal genomic results,2021-12-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],HOPE-Genomics tool usage,Operationalization of contextual guideline concordant care
7561,NCT01931644,Biospecimen & Clinical Data Collection,2013-07,RECRUITING,OBSERVATIONAL,['NA'],,
7562,NCT02431715,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7563,NCT00178763,"Tumor response, disease-free survival",2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Allow inoperable pancreatic cancer to be converted to operable disease
7564,NCT00561522,The primary end point was to determine the effect on disease-free survival and overall survival by oral capecitabine.,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The secondary end point was to analyze the relationship between preventive effectiveness of capecitabine with thymidine phosphorylase expression level of tumor tissue.
7565,NCT04075305,Toxicity in common toxicity criteria for adverse events (CTCAE).,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
7566,NCT03356158,Incidence of Adverse Events [AEs],2017-11-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Cancer antigen [CA19-9]
7567,NCT05867810,nutrition assessment,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Biochemical data
7568,NCT02837159,Body Mass Index,2016-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Lower-body flexibility
7569,NCT05864105,Objective Response Rate,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,
7570,NCT02240212,Assessment of PR (vital signs) in Phase I Dose Escalation,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment of composite pharmacokinetics of afuresertib and paclitaxel in expansion cohort
7571,NCT01673269,the frequency of bacteremia after ERCP with direct cholangioscopic examination of the CBD,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,To measure the frequency of fever or sepsis after ERCP with direct cholangioscopic examination of the CBD
7572,NCT01336985,To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan,2011-03-28,TERMINATED,INTERVENTIONAL,['PHASE1'],,To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads
7573,NCT01955629,Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 2: Aflibercept Biomarkers Evaluation
7574,NCT00758186,The primary endpoint was postoperative complication rates.,2004-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Secondary outcomes evaluated included type of surgery performed, bowel preservation, presence of a stoma, postoperative bowel function, length of hospital stay, and hospitalization costs."
7575,NCT02799420,The percentage of cancer cells in biopsy samples,2016-06-20,COMPLETED,INTERVENTIONAL,['NA'],,The expression ratio of tumor marker in biopsy samples
7576,NCT03929666,Objective response rate (ORR) (Part 2),2019-08-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of lab abnormalities (Part 2)
7577,NCT03033225,Tumor response,2016-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7578,NCT05452668,Pain Assessment,2023-05-16,RECRUITING,INTERVENTIONAL,['NA'],,Oral Mucositis Severity:
7579,NCT00501605,"primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.",2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression"
7580,NCT04966611,OS,2021-07-15,RECRUITING,OBSERVATIONAL,['NA'],,PFS
7581,NCT01335555,What is the effect of chemotherapy on the fitness of patients prior to cancer surgery?,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,Survival outcome at 1 year
7582,NCT05965921,Number of additional Barrett's neoplasia found on quadrantic biopsies,2023-07-26,RECRUITING,OBSERVATIONAL,['NA'],,Impact of AI (WISE VISION) in real-life
7583,NCT00525655,Pilot Test FAP Website (Interviews),2007-08,COMPLETED,INTERVENTIONAL,['NA'],,Participant Assessment of FAP Website (Questionnaire)
7584,NCT04699188,Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only),2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM
7585,NCT02560779,Overall Response Rate (ORR),2016-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TRC105 Immunogenicity as Assessed by Anti-Product Antibody (APA)
7586,NCT04192929,Adenomas per colonoscopy,2023-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Inspection time
7587,NCT01823471,"The primary endpoint of the study was the difference in adenoma detection between HD-WLE and i-scan, expressed as the miss rate for polyps for each technique.",2010-11,COMPLETED,INTERVENTIONAL,['NA'],The difference in advanced adenomas between HD-WLE and i-scan and between the first and second inspection round.,The difference in overall adenoma detection between HD-WLE and i-scan
7588,NCT04810299,Nausea-vomiting,2021-04-16,COMPLETED,INTERVENTIONAL,['NA'],,
7589,NCT00835185,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response ),2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kirsten Rat Sarcoma (KRAS) Mutation Status
7590,NCT02454140,Maximum Tolerated Dose,2014-06-20,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
7591,NCT06218511,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2022-11-22,RECRUITING,INTERVENTIONAL,['PHASE1'],Assessment of the potential impact of the standard therapy on the natural immune response to peptides contained in IMA970A,OS
7592,NCT04730102,Existence of intraluminal malignant cells in fluid samples from rectal washout,2020-02-13,COMPLETED,OBSERVATIONAL,['NA'],,Fluid volume needed to perform rectal washout during transanal total mesorectal excision to eliminate intraluminal malignant cells
7593,NCT05064410,"Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening",2017-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7594,NCT05320328,Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.,2021-06-10,UNKNOWN,OBSERVATIONAL,['NA'],,Stent patency at 1 year
7595,NCT01521780,Expression Levels of Beta-catenin Protein From Core Needle Biopsy (CNB) Equivalents of Resected HCC.,2012-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,Expression Levels of Low Density Lipoprotein Receptor (LDL-R) in Resected HCC and Adjacent Liver From Whole Tissue Sections.
7596,NCT03680261,3-year Overall Survival,2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse effect (Safety and Tolerability)
7597,NCT00525200,Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free and overall survival and relation to p53 genotype
7598,NCT03559335,Postoperative inflammatory complications,2018-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
7599,NCT03460080,PIVKA-II,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prothrombin Time (PT) (%)
7600,NCT03097224,Change in cardiorespiratory fitness,2017-04-04,UNKNOWN,INTERVENTIONAL,['NA'],,Adherence
7601,NCT03032224,Changes in Body composition after surgery for esophageal cancer with curative intent.,2015-03-23,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
7602,NCT03593681,Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement,2018-08-27,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis"
7603,NCT00188305,Colon screening behaviour,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Satisfaction
7604,NCT01570452,,2005-09,COMPLETED,OBSERVATIONAL,['NA'],,
7605,NCT01142713,Dose and irradiated volume of small bowel and urinary bladder,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7606,NCT00561548,Relative variation (%) in apoptotic cells calculated according to the formula: (% of induced apoptotic cells) - (% of spontaneous apoptotic cells),2007-05,TERMINATED,INTERVENTIONAL,['NA'],,Lymphocyte activation markers and macrophage activation markers
7607,NCT03594188,cell proliferation,2018-07-23,COMPLETED,INTERVENTIONAL,['NA'],,cell metastasis
7608,NCT06149741,Low anterior resection syndrome (LARS),2023-11-20,RECRUITING,INTERVENTIONAL,['NA'],,Bowel ischaemia
7609,NCT05909423,Pathological response,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Analysis of perturbations in the immune activity with a focus on effector and memory CD8+ T cells
7610,NCT05269381,Incidence of adverse events,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],Pre-existing Immunity,Immunogenicity responders
7611,NCT01696695,PFS by Therapeutic Regimens,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Dose Modification of Capecitabine
7612,NCT01277120,Correlation of the time from the start of chemotherapy to the start of Avastin treatment with progression-free survival,2010-04,TERMINATED,OBSERVATIONAL,['NA'],,Safety: Incidence of adverse events
7613,NCT00909558,Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?,2009-05,SUSPENDED,INTERVENTIONAL,['PHASE1'],,"Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?"
7614,NCT00332943,Sensitivity of VAS score vs. ReCon score,2005-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,
7615,NCT04910386,Progression-free survival (PFS),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
7616,NCT00661167,Overall response rate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate
7617,NCT02932956,Number of Patients with Dose Limiting Toxicity,2018-12-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Median T cell persistence
7618,NCT02308722,Maximum tolerated dose (MTD),2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival and progression free survival at 12 and 24 months post D1 SBRT
7619,NCT00020605,,2000-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7620,NCT00270647,Major cardiovascular events,1997-07,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer
7621,NCT04031872,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,2020-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (phase II only)
7622,NCT03046979,Objective Response Rate(ORR),2016-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety]
7623,NCT02651415,Number of Participants That Have Any Grade HFSR Toxicity,2016-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Time to Progression Free Survival (PFS)
7624,NCT02726854,ORR (Objective response rate),2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by NCI-CTC（V3.0）
7625,NCT04124601,Incidence of treatment-emergent adverse events (safety and tolerability),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathologic therapy response to neoadjuvant treatment
7626,NCT01925274,Progression Free Survival (PFS) as Assessed by Investigators,2013-11-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Functional Assessment of Cancer Therapy-Colorectal (FACT-C)
7627,NCT01344902,Determine the carcinoma- and adenoma lesion true detection rate,2009-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7628,NCT02532478,Stoma closure rate,2007-02,COMPLETED,OBSERVATIONAL,['NA'],5-year overall survival,
7629,NCT04188145,The Time-to-Treatment Failure (TTF),2020-01-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life (QoL)
7630,NCT05782465,Gastric Cancer,2019-08-23,RECRUITING,OBSERVATIONAL,['NA'],,
7631,NCT04418895,complete pathologic response (pCR) rate,2021-08-13,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Median Neoadjuvant Rectal Score (NAR)
7632,NCT06282016,Asthma,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Area deprivation
7633,NCT01918527,Two-year disease free survival,2013-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Rate of patients fulfilling the criteria for adjuvant chemotherapy
7634,NCT04192539,serum taurine levels,2017-01-18,COMPLETED,INTERVENTIONAL,['NA'],,
7635,NCT03719573,30-second chair stand test (30s-CST),2019-02-21,COMPLETED,INTERVENTIONAL,['NA'],,doses of adjuvant chemotherapy
7636,NCT00461708,Overall Survival (OS) During the Study,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Disease Control According to RECIST
7637,NCT03042000,3y-DFS,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,pCR
7638,NCT04527939,"Degree of parietal invasion (T),",2020-08-07,UNKNOWN,INTERVENTIONAL,['NA'],,
7639,NCT03935763,Overall survival,2019-03-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Quality of life using Patients Reported Outcomes
7640,NCT00623077,Maximum tolerated dose of tomotherapy up to 12 Gy,2005-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Disease-Free Survival
7641,NCT01244022,Postoperative changes of serum cytokine levels,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Early postoperative complications
7642,NCT00003172,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7643,NCT04749381,Postoperative complications,2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Length of hospital stay
7644,NCT00565487,To determine optimal dosage for Capecitabine and Tarceva combination in the setting of radiation.,2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess treatment efficacy and overall survival.
7645,NCT02016534,Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1),2014-02,TERMINATED,INTERVENTIONAL,['PHASE2'],"Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens",Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).
7646,NCT00517621,Validation of a french version of FACT-GOG/NTX of peripheral neurotoxicity questionnaire,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,- Incidence of the thrombo-embolic events according to whether the patients are treated or not by EPO
7647,NCT00319007,"Pouch mucosal apoptosis index at 0, 1 and 2 months",2006-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Faecal cytotoxicity at 0, 1 and 2 months"
7648,NCT02951273,Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension,2016-12-08,COMPLETED,OBSERVATIONAL,['NA'],,Changes in Stroke Volume From Baseline Before Induction of Anaesthesia.
7649,NCT00652587,overall survival rates,2002-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7650,NCT06129812,Overall survival,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
7651,NCT00975897,Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Attitudes of patients about tests and treatment
7652,NCT02964468,Gastrointestinal toxicity,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life during the treatment
7653,NCT06042842,(1) To evaluate the clinical utility of plasma circRNAs (hsa_circ_0004001)by Q-PCR as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic disorders,2023-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7654,NCT05126290,Number of CTNNA1 genotypes associated with a cancer phenotype,2021-03-16,RECRUITING,OBSERVATIONAL,['NA'],,
7655,NCT00005871,,1998-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
7656,NCT01497392,"Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment",2012-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and tumor specimens
7657,NCT03451773,Duration of Treatment-related Adverse Events (AEs),2018-05-17,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Overall Progression Free Survival
7658,NCT02862704,Number of patients with adverse event,2016-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Detection of transferred T cells in the circulation using quantitative -PCR
7659,NCT02777801,Incidence of hepatitis B virus associated hepatitis,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interruption of chemotherapy due to hepatitis
7660,NCT01534923,describe doctor-patient communication about CRC screening,2012-02-07,COMPLETED,OBSERVATIONAL,['NA'],,examine the association between the quality of doctor-patient communication about CRC screening and low-income patients' screening outcomes
7661,NCT02291211,PFS: Progression Free Survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by recording the subjects' Adverse Events from randomization to termination
7662,NCT00961077,To evaluate response rate of attenuated SOX as first-line chemotherapy in elderly patients with relapsed or metastatic AGC,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To evaluate progression free survival, overall survival, and toxicities of aSOX-regimen"
7663,NCT04524442,Mean change from baseline in serum potassium levels over 24 hours,2021-01-27,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants with Notable Changes in Electrolyte and Blood Gas parameters
7664,NCT02114359,comparison of overall survival,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3'],comprehensive geriatric assessment,comparison of quality of life
7665,NCT01517009,"The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer
7666,NCT01842971,number of complete surgical procedure,2013-06-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,quality of life
7667,NCT05233332,ORR（by ICR）,2022-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
7668,NCT03531606,Anterior resection syndrome improvement change,2016-12-12,COMPLETED,INTERVENTIONAL,['NA'],,Other biomarkers
7669,NCT00735566,"Relationship between antiangiogenic factor and tumor, node, metastasis",2006-04,COMPLETED,OBSERVATIONAL,['NA'],,"Overall survival, treatment failure"
7670,NCT01089595,Progression Free Survival,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging"
7671,NCT00045175,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7672,NCT03935282,Proportion of patients reporting at least one non-ideal or missing CVH topic,2020-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Measure of tool acceptability with Tool Assessment
7673,NCT02192034,Navigation role in colorectal cancer screening,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,
7674,NCT04380766,Changes in pancreatic cancer management during the COVID-19 pandemic,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7675,NCT03788499,Incidence of severe radioactive oral mucositis,2019-01-11,COMPLETED,INTERVENTIONAL,['NA'],,the time at which the radioactive oral mucosa occurred; Difficulty in opening your mouth.
7676,NCT05637567,Hematogenous metastases-free survival,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of resected lymph nodes
7677,NCT04411524,Pathologic Complete Response Rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life."
7678,NCT02245217,RECIST 1.1 Therapeutic Responses to 1 Cycle,2014-12-12,COMPLETED,INTERVENTIONAL,['NA'],,
7679,NCT04759794,The usefulness of new staining method,2021-02-04,RECRUITING,INTERVENTIONAL,['NA'],,
7680,NCT04759846,Encorafenib AUC(0-inf),2021-01-21,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,MRAUC
7681,NCT05464706,Quality of life after liver surgery,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
7682,NCT00003873,Overall survival,1999-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7683,NCT03647540,the number of the dissected lymph nodes,2018-08-30,UNKNOWN,INTERVENTIONAL,['NA'],,The mean postoperative hospital stay
7684,NCT03698643,Patient effective radiation dose per TACE,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response
7685,NCT06084897,EFFICACY:1-year overall survival probability,2023-10-16,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers for the predicting of efficacy,QUALITY OF LIFE: Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants
7686,NCT02052557,PCA (Patient Controlled Analgesia) Usage,2013-02,COMPLETED,INTERVENTIONAL,['PHASE4'],NG (Nasogastric) Placement,Home Oral Narcotic Use
7687,NCT06162520,Area under the Receiver Operating Characteristic curve (AUROC) of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement,2021-12-17,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of the diagnostic models for the differential diagnosis of congenital and secondary biliary dilatation and the identification of intrahepatic involvement
7688,NCT00397878,Median Progression Free Survival (PFS),2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],Pre- and Post-treatment Expression Values for Each Biological Correlate,Time to Progression
7689,NCT00783172,progression measured with CT scan,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
7690,NCT02570529,Gastrointestinal ulcer incidence,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Adverse event of gastrointestinal hemorrhage
7691,NCT05536713,Blood-based test compliant rates,2023-02-09,RECRUITING,OBSERVATIONAL,['NA'],,Patient satisfaction with the blood-based test
7692,NCT01288833,Rate of Accurate High Confidence Polyp Histology Predictions by the Endoscopist in the Two Groups.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Learning Curve
7693,NCT00487552,Success Rate Associated With the Creation of a Gastro-jejunal Anastomosis Using the Cook Magnetic Anastomosis Device With Trans-anastomotic Deployment of a Gastro-jejunal or Duodenal Stent,2008-01,TERMINATED,INTERVENTIONAL,['NA'],,
7694,NCT02882269,disease-free survival,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,number of lymph nodes retrieved
7695,NCT00443196,"Complete Response, No Response",2006-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
7696,NCT00501176,Intra-operative measurement of the Culture from the bile.,2006-12,COMPLETED,INTERVENTIONAL,['NA'],,"Intraoperative measurements of inflammatory reaction in the liver, hepatoduodenal ligament and around the bile ducts with biopsies. Stent dysfunction and cholangitis after ERCP and pre-operative bile flow relief. Postoperative analysis."
7697,NCT03357978,Infections in A-T,2016-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cancer risk
7698,NCT00777894,Best objective response of target liver lesions (TLLs),2008-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum alpha-fetoprotein level (Phase II)
7699,NCT04993378,EV-Score,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Survival significance of EV-Score
7700,NCT02866383,Clinical benefit rate (CBR),2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,QoL
7701,NCT02405585,Progression Free Survival,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Resection Rate
7702,NCT05576909,Downstaging success rate,2023-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
7703,NCT03322995,Completion of all intended neoadjuvant therapy and surgical therapy,2018-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
7704,NCT03893695,Dose-limiting Toxicity(DLT),2019-05-25,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Exploratory Biomarker: circulating tumor deoxyribonucleic acid (ctDNA)
7705,NCT00149565,134 patients for each of the two treatment arms are needed.,1997-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7706,NCT05970159,Postoperative complications,2023-08,RECRUITING,OBSERVATIONAL,['NA'],Days of ICU stay,Mortality
7707,NCT03981497,Time to Local Progression,2018-02-28,RECRUITING,OBSERVATIONAL,['NA'],,Organ specific Progression Free Survival (PFS)
7708,NCT02542215,Overall mean Area Under the Curve (AUC) of oral mucositis severity over time,2015-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Mean cumulative radiation dose at time of severe (WHO grade 3 or 4) oral mucositis onset
7709,NCT04268290,Postoperative hospital stays,2020-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Morbidity and mortality rates
7710,NCT05396326,The incidence of treatment related adverse events (TRAE).,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progressive free survival (PFS)
7711,NCT03331055,visal analogue scale (VAS) score,2017-10-27,COMPLETED,INTERVENTIONAL,['NA'],complications,times of breakthrough pain (BTP)
7712,NCT02872831,Diagnostic Accuracy of the 22G SharkCore™ and the 22G BNX EUS-FNA needle,2016-07,TERMINATED,INTERVENTIONAL,['NA'],,Specificity of the 22G SharkCore™ needle and the 22G BNX EUS-FNA Needle for the diagnosis malignancy in solid lesions of the pancreas and gastrointestinal tract.
7713,NCT05251233,Incidence of delayed gastric emptying as measured by Modified Accordion Grading System (MAGS),2022-04-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Marginal ulcer-free survival (MUFS)
7714,NCT01503983,Overall Survival,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to response
7715,NCT05871333,change in severity of intestinal mucositis,2023-07-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Laboratory evaluation of Interleukin-1β level
7716,NCT00273247,Recurrence Free Survival,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Patient Survival
7717,NCT03561948,Positive peritoneal lavage,2018-01-09,COMPLETED,INTERVENTIONAL,['NA'],,
7718,NCT01276002,Recurrence of pancreatic pseudocyst,2011-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
7719,NCT05836064,Re-scheduled colonoscopy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,GastroBot functionality
7720,NCT00006357,,2000-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7721,NCT01116804,"To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer",2010-06-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7722,NCT03154190,Hospitalization Visits (Chart Review),2017-08-08,UNKNOWN,INTERVENTIONAL,['NA'],,Palliative Care Consult (Chart Review)
7723,NCT02243007,Survival Rate at 18 Month,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Local Control Rate
7724,NCT04987788,Colonoscopy completion,2021-08-19,COMPLETED,INTERVENTIONAL,['NA'],,
7725,NCT01383538,The maximum tolerated dose (MTD) for FOLFIRINOX plus IPI-926 in patients with advanced pancreatic cancer.,2011-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR) by RECIST criteria
7726,NCT01598194,Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.,2012-01-30,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Diagnostic Adequacy of Single Pass With 22G Core Needle and Standard 25G Needle for Cytologic Diagnosis
7727,NCT00673673,Progression Free Survival,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
7728,NCT03591705,progression-free survival,2018-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Downstage hepatectomy rate
7729,NCT00931840,Response Rate,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
7730,NCT03189576,ctDNA level,2015-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
7731,NCT06332079,Progression-free survival (PFS) Rate,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) assessed using the EuroQol EQ-5D questionnaire
7732,NCT01506167,Overall Survival,2012-07-06,COMPLETED,OBSERVATIONAL,['NA'],,Response to the Burden of Illness Question: Has your cancer resulted in a family member seeking support?
7733,NCT02692365,Exploratory study for the determination of tissue changes of advanced hepatocellular carcinoma induced by electromagnetic waves amplitude modulated low energy specific frequencies during image MRIstudy.,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,
7734,NCT04708951,Comparison between adenoma detection rate of G-EYE® colonoscopy and EndoCuff Vision®,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
7735,NCT03885817,Patient reported peripheral sensory neuropathy,2019-03-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Diagnosed with type 2 diabetes.,Overall- and disease free survival
7736,NCT02676791,Local carcinoma recurrence,2016-02-16,COMPLETED,INTERVENTIONAL,['NA'],,
7737,NCT02082691,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
7738,NCT03916510,MRI tumour regression grade,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE1'],Analyse the immune microenvironment as evidenced by immune cell infiltrates,Neoadjuvant Rectal (NAR) score
7739,NCT00487851,"Primary outcome consist of a composite score (i.e. number of hospitalizations, episodes of cholangitis, degree of jaundice, other complications requiring therapeutic interventions). Secondary outcome are QoL,hospital stay and health economic burden.",2007-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7740,NCT03806426,Total Number of Polypectomies (polyps > 5mm in the rectum) conducted during the 24 months study period,2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change in score on the InSIGHT Polyposis Staging System (IPSS) at 24 months
7741,NCT02848443,Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin,2016-05,COMPLETED,INTERVENTIONAL,['PHASE1'],Peripheral blood mononuclear cells,"PDL-1 expression, tumour-infiltrating CD8 T cell density, for S95005-oxaliplatin + nivolumab"
7742,NCT01387373,Response rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
7743,NCT01861678,Anastomotic leakage rate,2006-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Amount of blood loss
7744,NCT02807337,Oral mucositis will be assessed daily for all 75 pediatric patients at the oncology ward and at home by use of the Children International Mucositis Evaluation Scale (ChIMES scale) and WHO oral mucositis scale.,2016-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7745,NCT00738478,Quality of life,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"complication, hematological data,"
7746,NCT05281926,Area Under the Concentration-Time Curve(ACU 0-22 weeks),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Area Under the Concentration-Time Curve(ACU 0-24 weeks)
7747,NCT02184910,the change of pepsinogen level before and after H. pylori eradication,2013-12,UNKNOWN,OBSERVATIONAL,['NA'],,
7748,NCT05276973,Incidence of adverse events,2022-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],Tumor response,Tumor response
7749,NCT00428220,Number of Participants With Treatment-emergent AEs (Treatment-Related),2007-07,COMPLETED,INTERVENTIONAL,['NA'],Summary of Duration of Clinical Benefit,
7750,NCT05995821,Biological specimens obtained from cancer patients,2016-08-25,RECRUITING,OBSERVATIONAL,['NA'],,
7751,NCT02488746,Rate of cases in which a complete macroscopic en bloc resection of the gastric subepithelial tumor could be achieved,2015-03,TERMINATED,OBSERVATIONAL,['NA'],,Number of participants with needs of surgical therapy or endoscopic re-resection
7752,NCT01384994,Progression Free Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
7753,NCT01829178,Urine concentration of NGAL,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Tissue activity of caspase 3
7754,NCT02167321,Disease free survival (DFS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluation for rate of various events after surgery
7755,NCT03248661,Primary endpoint is a received completed FIT kit within 15 months after the participant received results from the original FIT test,2015-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
7756,NCT04776837,Treatment Response at 1st Scan,2019-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Skeletal Muscle Analyses
7757,NCT06228209,The proportion of screened eligible patients,2024-01-26,RECRUITING,INTERVENTIONAL,['NA'],,Patient-Reported Goals of Care Discussion (GOCD)
7758,NCT02327494,the central venous oxygen saturation (ScvO2),2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,postoperative outcome
7759,NCT01396707,Overall response rate,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
7760,NCT01750918,Part 3: Progression Free Survival (PFS),2012-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part 3: Number of Participants With Treatment Emergent Adverse Events
7761,NCT04359498,Surgical complications,2020-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
7762,NCT03468634,Device safety testing (no detectable damage in biopsy samples when reviewed by histopathology),2023-09-21,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic model developed (algorithm able to discriminate disease with >50% specificity and >50% sensitivity)
7763,NCT03644459,AUC(0-∞) of T1h after Each Subsequent Introduction (multiple dose),2019-04-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Half time (t1/2) of T1h after Each Subsequent Introduction (multiple dose),PGA after Each Subsequent Introduction (multiple dose)
7764,NCT06233864,"Object Response Rate, ORR",2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
7765,NCT06284226,To evaluate the safety and the efficacy,2022-03-25,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,To assess the modulation in tumor markers
7766,NCT02071069,The progression free-survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Grade 3 and 4 adverse Events as a Measure of Safety and Tolerability
7767,NCT03006432,progression-free survival,2016-12-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Toxicity events according to NCI-CTC v4.0
7768,NCT00016952,tumor response rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
7769,NCT05547828,Objective Response Rate (ORR),2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Drug-Related Safety Indicators
7770,NCT06324409,First round screening participation,2024-03-22,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall screening participation
7771,NCT01284413,one year survival rate,2010-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity and response rate
7772,NCT05171335,Percent Tumor Necrosis,2022-06-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,Explant Biomarkers
7773,NCT00802555,To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC,2009-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment"
7774,NCT03284684,Change in integrity index of circulating DNA for KRAS gene,2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],,Change in plasma concentration of BRAF DNA fragments with V600E mutation
7775,NCT01693835,Circadian rhythms in urinary excretion of modified nucleosides,2012-08,COMPLETED,OBSERVATIONAL,['NA'],,
7776,NCT01963117,Time to Local Tumor Progression After Combined Hyperthermia and RT,2013-10,TERMINATED,INTERVENTIONAL,['NA'],,Overall Survival Rate After Combined Hyperthermia and RT
7777,NCT04487067,Number of Participants With Grade 3-5 NCI CTCAE v.5 Bleeding/Haemorrhage,2020-08-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire
7778,NCT04205097,total dose of remifentanil,2019-12-23,COMPLETED,INTERVENTIONAL,['NA'],,
7779,NCT05121038,Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,2021-10-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pathological response rate (PCR) .
7780,NCT01830621,Overall Survival,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change of Global Quality of Life at 8 Weeks From Baseline
7781,NCT02692911,Cancer/precancer,2017-01-11,COMPLETED,OBSERVATIONAL,['NA'],,
7782,NCT06010225,Total medical costs,2020-05-01,COMPLETED,OBSERVATIONAL,['NA'],,adherence to the ERAS protocols
7783,NCT05171517,Microflora analysis accomplished,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7784,NCT05986383,Postoperative liver failure rate (50-50 criteria),2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Clavien-Dindo grade of postoperative complications
7785,NCT01946282,FIT Completion Among Patients Offered Any Incentive vs. Outreach Alone Each Year,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"FIT Completion for Groups Offered $5 vs. Outreach Alone, $10 vs. Outreach Alone, and $5 vs. $10 Incentive"
7786,NCT00176774,Toxicity,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy
7787,NCT04128657,Validation of the moroccan arabic version of the Wexner score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
7788,NCT00172640,,2005-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7789,NCT06211933,Survival rate at 12 months after HIFU intervention,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Clinical benefice rate regarding performance status
7790,NCT01529164,response rate,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
7791,NCT00222898,,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,
7792,NCT04547881,Total time for lesion removal,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],,
7793,NCT05838391,Time to plan and deliver treatment fractions.,2023-05-18,RECRUITING,INTERVENTIONAL,['NA'],,Complete Clinical Response Rate
7794,NCT00410774,Disease-free survival rate at 1 year,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median overall survival rate at 1 and 2 years
7795,NCT04358341,Disease control rate (DCR),2020-06-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores
7796,NCT04258566,ICG Fluorescene,2022-01-27,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],,Exvivo fluorescence
7797,NCT05738421,To provide objective data on the bolus transit during swallowing in tracheostomized patients with tracheal tube and without tracheal tube,2021-12-06,RECRUITING,OBSERVATIONAL,['NA'],,To evaluate the features of swallowing
7798,NCT00693342,Progression-free survival,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Correlation of outcome with antigen-specific immune titers in a limited sampling of patients
7799,NCT04561453,Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification and Ability to assess change in ctDNA levels across those time points,2020-07-08,RECRUITING,OBSERVATIONAL,['NA'],,Predictive Value of circulating tumor DNA (ctDNA) for Response to Medical Therapy
7800,NCT04379999,Genome-wide expression analyses using RNA-Seq,2018-09-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Acceptability of the pilot study intervention and the willingness of the subject to participate in a similar larger study.
7801,NCT00002773,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7802,NCT01633203,Rate of downstaging,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,HER 2 expression
7803,NCT00584129,"To test whether pre-treatment swallowing exercises compared with ""usual care"" (where exercises are taught post-treatment) improves quality of life in patients undergoing chemoradiation therapy for advanced head and neck cancer.",2006-02,COMPLETED,INTERVENTIONAL,['NA'],,To test whether pre-treatment swallowing exercises compared with usual care improves secondary outcome measures related to dysphagia in this patient population.
7804,NCT02253511,Overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],Number of participants with adverse events,Recurrence-free survival
7805,NCT03177681,Percentage Change in Firmicutes in Stool from Baseline to Day 12,2022-03-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Adherence Rate of Dannon® Oikos® Yogurt Intake
7806,NCT04161781,Feasibility of 18F-BMS-986229 PET in participants with Gastroesophageal Cancer,2019-11-12,COMPLETED,OBSERVATIONAL,['NA'],,
7807,NCT03008304,Relief degree of tumors,2016-12-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
7808,NCT02149771,Median survival time,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Time to Disease Progression
7809,NCT04486378,Disease-free survival (DFS),2021-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Occurrence of dose reduction and discontinuation of IMP due to a TEAE.
7810,NCT01628211,overall survival,2012-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,list of therapies and clinical outcomes of patients who had radiologic evidence of disease within 6 months after initial surgery
7811,NCT04694183,R0 resection rate,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serious adverse events(≥grade 3）
7812,NCT04775056,Immunogenicity index-seroconversion rates of neutralizing antibody,2022-08,WITHDRAWN,OBSERVATIONAL,['NA'],,Immunogenicity index-seropositive rates of neutralizing antibody
7813,NCT03192462,Number of Patients Who Received 6 Infusions of multiTAA-specific T Cells,2018-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival Using the Kaplan-Meier Method
7814,NCT03180411,Development of Decision Tool to Guide Participants in Making Individualized Decisions Regarding Colorectal Cancer (CRC) Surveillance Through the Use of Cognitive Testing Interviews,2017-02-14,COMPLETED,OBSERVATIONAL,['NA'],,
7815,NCT00633295,To evaluate the efficacy of nilotinib in GIST patients resistant or intolerant to imatinib and or 2nd line TK inhibitor as measured by tumor up take of FDG PET quantitated by maximum,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety and tolerability of nilotinib as measured by rate and severity of adverse events
7816,NCT04827732,Maximum tolerated dose (MTD) of reirradiation using hypofractionated IMPT,2021-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Frequency of late adverse events as measured by CTCAE v 5.0
7817,NCT00190554,Disease free survival,2000-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Operative morbidity
7818,NCT05187312,Diagnostic yield,2022-01-14,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
7819,NCT04855448,learning curve of surgicla failure,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival
7820,NCT05449860,Local tumor progression rate,2020-01-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Technical success rate
7821,NCT02457624,Detection rate for gastric premalignant lesion,2008-03,UNKNOWN,OBSERVATIONAL,['NA'],,Detection rate for gastric dysplasia
7822,NCT00972465,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment"
7823,NCT05768503,Progression-Free Survival (PFS),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29)
7824,NCT03191487,"The rate of prescriptions for chemotherapy in the outpatient clinic prepared at the latest the day before a session (except for predefined, limited stability products) and administered in full, per patient, during a follow-up period of 6 months",2018-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall costs
7825,NCT04673526,Quality of life associated to incontinence as assessed by Faecal incontinence quality of life scale (FIQL),2009-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative complications
7826,NCT00220168,Time to disease progression (TTP),2003-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements)."
7827,NCT00143403,Disease Free Survival (DFS),2001-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival Rates
7828,NCT06233877,Response Rate,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
7829,NCT03949907,Combined endpoint - overall survival and weight maintenance,2020-04-14,RECRUITING,INTERVENTIONAL,['NA'],Serum levels of immunologic profiles,Abnormal values in safety laboratory variables
7830,NCT05673772,5-year disease-free survival,2020-10-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Distant metastasis
7831,NCT01751919,Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Terminal Elimination Half-life (t1/2) of Imatinib mesylate
7832,NCT03812783,Overall Survival (OS),2018-11-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
7833,NCT00960518,the progression free survival (PFS),2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the rate of overall survival
7834,NCT05688033,Number of Participants Experiencing Adverse Events,2021-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Number of Participants in Who Experienced Tumor Down-staging
7835,NCT00883792,Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence,2009-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Mortality from all causes
7836,NCT04825834,"Accuracy of lung cancer detection measured by sensitivity, specificity, and the AUC of the ROC.",2021-03-22,RECRUITING,OBSERVATIONAL,['NA'],,"Accuracy of multi-cancer detection measured by sensitivity, specificity, and the AUC of the ROC and tissue of origin (TOO) accuracy"
7837,NCT02142322,response rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,resection rate
7838,NCT00003426,,1998-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7839,NCT03949777,Aer-O-Scope Validation of Cecal Intubation,2020-01-06,COMPLETED,INTERVENTIONAL,['NA'],,
7840,NCT05780736,Disease-free Survival (DFS),2023-08-04,RECRUITING,OBSERVATIONAL,['NA'],,Participant Treatment History
7841,NCT01029418,To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of AZD6244 and sorafenib in patients with advanced hepatocellular cancer.,2009-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To investigate if the combination sorafenib and AZD6244 increases Time To Progression (TTP) over sorafenib alone in patients with advanced hepatocellular carcinoma patients.
7842,NCT02934958,Colonoscopy Completion,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,
7843,NCT01522209,Detection of Liver Metastasis during Operation,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of Specicivity of all imaging modalities
7844,NCT03662412,overall survival,2018-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Response rate
7845,NCT04456218,Image quality evaluation: the light brightness and the imaging sharpness in Likert scale,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],,In biliary stricture arm: Number of the lesions with or without presenting of the specific features for DDx of the benign or malignant stricture
7846,NCT04411537,Pathologic Complete Response Rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of Life Scale, range 0-60. It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life."
7847,NCT03927495,Objective response rate assessed by investigator based on RECIST 1.1,2019-05-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
7848,NCT00019786,Overall survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7849,NCT01140347,Overall Survival (OS),2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]
7850,NCT00093496,Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria.,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
7851,NCT01169220,Quality of colon cleansing,2010-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Patient satisfaction
7852,NCT02165215,"Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)",2014-08-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ)
7853,NCT03234465,Efficacy of AG013 Compared to Placebo for Reducing OM as Measured by Duration (in Days) of Severe Oral Mucositis (WHO Grades 3 or 4),2017-07-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7854,NCT01366833,To investigate the change in dysphagia score (0-4 Likert scale) measured at baseline and at 10 weeks,2011-06,TERMINATED,INTERVENTIONAL,['NA'],,
7855,NCT03274882,Progression free survival (PFS) rate,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Abnormalities in 12-leads ECG parameters [safety and tolerability]
7856,NCT03432676,Best objective response rate,2019-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
7857,NCT05419531,rate of young endurance athletes that have colorectal cancer on screening colonoscopies.,2022-10-18,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).
7858,NCT00464620,6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Tumors With Mutations in Kinases
7859,NCT02415829,The tumor regression grade of all the patients enrolled,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
7860,NCT03321630,Progression-Free Survival (PFS),2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7861,NCT03748667,The presence or absence of deep invasion according to the gold standard (histology),2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of genome copies using SNP-arrays
7862,NCT02645084,"Percentage of all included patients who have received a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist.",2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Usability of the questionnaire for health care providers and patients by using a self-created online or paper questionnaire
7863,NCT01368419,Objective Response Rate (ORR),2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
7864,NCT01381211,Time to Progression (TTP).,2011-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicities and adverse events (recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 3.0)
7865,NCT05950503,Surgery conversion rates,2023-07-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
7866,NCT02269631,Change in Weight,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Satiety
7867,NCT00195585,Relapse-free survival time,2002-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Disease-free survival time, survival time, safety"
7868,NCT00354601,Objective Tumor Response,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
7869,NCT06157996,Progression-free Survival (PFS),2024-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DoR)
7870,NCT05316480,Overall response rate (ORR),2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7871,NCT05318404,Percentage of body weight loss,2020-12-08,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative daily protein intake
7872,NCT05108428,Feasibility of MRI guided dose adaptive chemoradiation therapy,2021-12-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Number of Participants with Disease-Free Survival (DFS),Number of Participants with Pathological Complete Response (pCR)
7873,NCT00057395,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
7874,NCT02436564,Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.,2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Proportion of tumour-derived organoids that are genetically identical to the source tumour.
7875,NCT05498506,the number of linear stapler cartridges,2022-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
7876,NCT02142803,Most Common Related Toxicities That Led to Dose Hold/Reductions,2014-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Mutation Analysis of Tissue From Biopsies of Patients With Ovarian and Endometrial Cancers,Number of Patients That Discontinue Study Drugs Due to Treatment Related Toxicity
7877,NCT00355238,The Number of Participants Experiencing Adverse Events (AEs),2006-12-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline to End of Treatment in FHSI-8 Total Score
7878,NCT05670561,Pain Intensity at 12hours after the beginning of TACE operation,2023-01-05,RECRUITING,INTERVENTIONAL,['PHASE4'],Quality-of-Life Assessment at 24hours after the beginning of TACE operation,Analgesic Consumption
7879,NCT01384617,Incidence of pancreatic fistula defined by ISGPF classification,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma
7880,NCT06203613,To assess the sensitivity and specificity of using [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 for the diagnosis of metastatic gastric and pancreatic cancer,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
7881,NCT00278863,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events
7882,NCT05043363,Clinician experience of LumenEye examination,2020-11-14,COMPLETED,OBSERVATIONAL,['NA'],,"Diagnostic accuracy of the LumenEye for the detection of rectal pathology including tumour, polyps and inflammation"
7883,NCT02812550,adenoma detection rate in the two different colonoscopies,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,colonoscopy withdrawal time
7884,NCT04696055,Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment,2021-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Dose Modification
7885,NCT04516174,The prognosis of aged patients,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7886,NCT05546411,Major pathological response rate (MPR),2023-01-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival (OS)
7887,NCT02885376,"Incidence of severe oral mucositis, defined as grade 3 or 4 on the World Health Organization (WHO) scale",2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Use of opioid analgesics for oral mucositis pain, as expressed in morphine equivalents."
7888,NCT05354856,Difference in gastric perfusion,2022-03-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Short term outcome
7889,NCT00267046,Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7890,NCT06157463,Change of FAPI SUV,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Correlation of FAPI SUV
7891,NCT03070613,Number of dysplastic and cancerous lesions identified under white light and under fluorescence,2017-04-23,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Resection margin of of lesions undergoing TEMS resection under white light and under fluorescence.
7892,NCT05617872,cfDNA concentration,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Weight
7893,NCT05936931,CRC screeningintentions,2024-02,WITHDRAWN,INTERVENTIONAL,['NA'],,
7894,NCT04923672,Steps per day,2023-02-20,RECRUITING,INTERVENTIONAL,['NA'],,Fitness level
7895,NCT02437851,To determine if the proportion of participants who develop treatment failure by 3 years is less than 25%.,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Collection of clinical specimens (composite),"The rate of treatment related adverse events including non-healing ulcer, fissure, persistent pain and bleeding, stricture, incontinence, and colostomy 6 months after excision of SISCCA."
7896,NCT00757640,Reduced biliary complications,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Improved quality of life
7897,NCT03523546,Utilization of acute and specialty care,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Survival
7898,NCT01911000,Hyperthermia effect and averse event in RT for HCC with PVTT,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate RT response prediction probability by diffusion-weighted (DW) MRI
7899,NCT03385434,Evaluation of the adenoma detection rate during screening colonoscopy,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7900,NCT03649945,3 year disease-free survival rate,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
7901,NCT05181332,Hepatic decompensation,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
7902,NCT03110328,overall survival,2018-02-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7903,NCT02782949,Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa,2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)",Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage
7904,NCT04246177,Overall Survival (OS),2020-05-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,TTP per RECIST 1.1
7905,NCT00918827,Relapse-free survival,2009-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
7906,NCT00002650,,1995-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7907,NCT03238404,Postoperative length of stay,2015-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Prealbumin
7908,NCT00339560,Gallbladder Cancer,1997-05-16,COMPLETED,OBSERVATIONAL,['NA'],,
7909,NCT06040177,Objective response rate(ORR),2023-02-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
7910,NCT05497869,pectoralis minor length through Rigid standard plastic transparent right angle,2022-08-10,COMPLETED,INTERVENTIONAL,['NA'],,
7911,NCT06318234,Evaluation efficacy of tumor regression level,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,SUV
7912,NCT04101929,Progression Free Survival,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
7913,NCT00276302,To recommend a dose for subsequent studies of IPI-504,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To explore potential pharmacodynamic (PD) markers of biologic activity of IPI-504 in GIST and STS.
7914,NCT05070598,ORR (Objective control rate),2021-09-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS(Overall survival)
7915,NCT05412706,Progression-Free Survival 1,2023-09-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Translational objectives 3 for evaluated association between in vitro drug screening sensitivity on Patient-derived organoids and clinical outcome,Incidence of Treatment-Emergent Adverse Events
7916,NCT02587247,Evaluate the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the clinical impact (new lecture of imaging, new examens)"
7917,NCT02649348,The proportion of postoperative complications,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,
7918,NCT02186886,Clinical response,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],molecular spectral range,Calprotectin stool levels
7919,NCT04232891,relapse rate in MRD- patients,2019-11-18,UNKNOWN,OBSERVATIONAL,['NA'],,minimal residual disease detection rate
7920,NCT02436395,Superficial incisional surgical site infections,2015-05,UNKNOWN,INTERVENTIONAL,['NA'],,
7921,NCT04662346,correlation to post-operative complication,2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,
7922,NCT03485027,PFS,2018-01-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
7923,NCT03912857,Objective Response Rates (ORR),2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
7924,NCT00002935,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7925,NCT05794750,Pathologic complete response rate (pCR),2023-04-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],"Relationship between the expression of immune markers in tumor tissues and blood,the distribution of immune cells, and the efficacy and prognosis of patients",Incidence and severity of adverse events (AEs) and clinically meaningful abnormal laboratory test results
7926,NCT00383695,Pathological complete response rate at time of total mesorectal excision (TME),2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Quality of life, including long-term bowel function"
7927,NCT00070213,Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap
7928,NCT05634590,Progression-Free Survival (PFS),2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
7929,NCT05362344,Sensitivity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],Ease of stool testing,Specificity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test
7930,NCT04212221,Objective response rate (ORR),2020-04-20,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
7931,NCT01972737,Antibody responses,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to recurrence and disease-free survival and immune responses,Persistent immunological responses
7932,NCT02138617,Progression Free Survival,2014-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
7933,NCT03884868,Grade of distress experienced by patients,2019-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Grade of understanding of the information reported by patients
7934,NCT03792048,Incidence of anastomotic fistula,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of pancreaticojejunostomic stricture
7935,NCT00561470,Overall Survival (OS),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
7936,NCT03670199,Variation of the Medical Outcome Study Short Form 36 score,2019-01-29,RECRUITING,INTERVENTIONAL,['NA'],,Length hospitalization
7937,NCT04093687,Endoscopist adjusted painful colonoscopy rate change,2019-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adjusted painful colonoscopy rate for screening centres (in which assessed endoscopists are working)
7938,NCT01707758,,2012-10,WITHDRAWN,OBSERVATIONAL,['NA'],,
7939,NCT05463328,"Rate of postoperative anastomosis leakage(pancreatic,billary and intestinal).",2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative 30 days mortality rate.
7940,NCT04183218,Cardiac event rate at 12 months,2019-09-23,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Imaging changes,Overall survival
7941,NCT02156700,Tumor stiffness,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,tumor to parenchyma stiffness ratio
7942,NCT00266097,Maximum Tolerated Dose (MTD) of erlotinib hydrochloride and gemcitabine hydrochloride (Part 2),2004-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7943,NCT00006001,,2000-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7944,NCT00958386,Objective response rate,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers
7945,NCT02630108,Overall Survival,2015-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events and severe adverse events in TACE alone and TACE combined with ablation groups
7946,NCT02310230,Average minute ventilation in patients cared for using the ExSpiron Respiratory Variation Monitor (RVM) compared to patients with routine monitoring in patients undergoing upper gastrointestinal endoscopy,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,The ability of respiratory parameters with capnography to assess states of hypoventilation between the two groups
7947,NCT04852679,Clinical Benefit Rate (CBR) of tumour response assessed using RECIST (Version 1.1) and confirmed by Blinded independent central review (BICR),2021-05-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events (AEs)
7948,NCT03142516,Progression-free survival at one year,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],RAS/BRAF mutations' detection proportion,Combined analysis of prognostic factors in metastatic disease
7949,NCT00003867,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
7950,NCT05799443,Objective response rate(ORR),2023-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
7951,NCT05234450,Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
7952,NCT06218888,Objective Response Rate（ORR）,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
7953,NCT05742425,Disease-free survival (DFS),2023-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of adverse events
7954,NCT00588263,determine the prevalence of recurring BRCA1 and BRCA2 mutations,2000-07,WITHDRAWN,OBSERVATIONAL,['NA'],,
7955,NCT06253949,rectal cancer-low anterior resection syndrome (LARS),2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,1-year overall survival
7956,NCT01787500,Maximum tolerated dose of vemurafenib defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33% as graded by the National Cancer Institute Common Toxicity Criteria version 4.0,2013-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
7957,NCT00950820,Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,safety-endpoints
7958,NCT00148226,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
7959,NCT00550589,Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis
7960,NCT00288275,Progression Free Survival,2004-07,TERMINATED,OBSERVATIONAL,['NA'],,Tumor Response
7961,NCT01703026,,2009-08,COMPLETED,OBSERVATIONAL,['NA'],,
7962,NCT01290523,Number of Participants With Adverse Events,2010-05,TERMINATED,INTERVENTIONAL,['NA'],,Radiographic Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
7963,NCT04819958,3-year disease free survival rate,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,Duration of postoperative hospital stay
7964,NCT04842968,At least 12 lymph nodes harvested,2021-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
7965,NCT03597581,RGX-202-01 treatment-emergent adverse events,2018-06-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,RGX-202-01 area under the curve
7966,NCT02863107,Adherence score,2012-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
7967,NCT02764268,Number of Participants With Dose Interruptions,2016-11-02,COMPLETED,INTERVENTIONAL,['NA'],,Disease Control Rate(DCR)
7968,NCT01313377,Quality of life,2009-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity of adjuvant chemotherapy
7969,NCT06018714,2-year recurrence and metastasis rate,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],completion rate of maintenance therapy,2-year disease-free survival rate
7970,NCT06217016,secondary catheterization owing to urinary retention,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative complications
7971,NCT02311803,Sexual function,2015-02,UNKNOWN,INTERVENTIONAL,['NA'],,5-year recurrence pattern
7972,NCT04487002,recurrence rate,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,post-operative complications
7973,NCT01303393,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Information needs - patients' and next of kins'
7974,NCT03168152,Time to local tumor progression,2017-05-11,WITHDRAWN,INTERVENTIONAL,['NA'],,Incidence of intrahepatic failure
7975,NCT02047500,Number of Subjects Experiencing Dose Limiting Toxicity (DLT),2014-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
7976,NCT01787006,Rate of Participants Who Were Alive at 2 Years,2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Quality of Life Between Baseline and End of Treatment (After 5 to 13 Weeks)
7977,NCT01824004,Disease free survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],Health -related quality of life,Number of participants with adverse events as a measure of safety and tolerability
7978,NCT02973685,Overall survival,2016-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
7979,NCT01373320,Proportion of participants reporting the health behavior of interest (depending on which intervention component(s) were selected),2010-03,COMPLETED,INTERVENTIONAL,['NA'],,"Retention (i.e., number of participants who complete all planned assessment timepoints)"
7980,NCT00677144,overall response rate,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety, time to progression, and overall survival"
7981,NCT06007846,Patients Progression Free Survival at 6 months,2023-07-31,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Change from baseline as assessed by the European Organization for Research and Treatment of Cancer (EORTC-HCC18) over treatment,
7982,NCT04367025,Major pathologic response (MPR),2020-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OSR
7983,NCT02024841,Maximum tolerated dose and recommended dose,2013-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
7984,NCT01203787,Cumulative Dose of Sorafenib,2010-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Subjects With Dose Reductions
7985,NCT05802485,Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma,2023-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
7986,NCT01458717,2-year survival rate,2011-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,efficacy of imaging study after neoadjuvant chemoradiation
7987,NCT00628186,the length of hospital stay after pancreaticoduodenectomy,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,early and late complications after pancreaticoduodenectomy
7988,NCT05476432,Overall survival,2022-07-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,the predictive power of thymidylate synthase (TYMS)
7989,NCT01336452,characteristic of Perfusion MR,2011-04,UNKNOWN,INTERVENTIONAL,['NA'],,
7990,NCT05593419,TIIC signature,2022-10-31,RECRUITING,OBSERVATIONAL,['NA'],,
7991,NCT00609310,Recurrence rate of neoplasia,2015-05,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Recurrence free survival, Overall survival, Serum-Flavonoid levels of patients"
7992,NCT01784861,Objective Response Rate (Complete Response + Partial Response) - Phase II,2013-05-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Toxicity - Phase II
7993,NCT05830097,Incidence and severity of Adverse Events (AEs),2023-03-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,MTD/RP2D of CBP-1019.
7994,NCT01402401,efficacy of AUY922 in combination with trastuzumab as assessed by RECIST,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
7995,NCT05468944,Complication rate,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival rate
7996,NCT01094600,Primary outcome: correlation between S-MRCP with ePFT,2012-06,WITHDRAWN,INTERVENTIONAL,['NA'],,
7997,NCT05516628,"Recurrence-free-survival (RFS) in relation to the multi-omics (epigenomics, genomics, transcriptomics, proteomics and metabolomics) and spatial TME profiles of both tissue and peripheral blood.",2023-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS).
7998,NCT02845908,"Progression-Free Survival,PFS",2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival(OS)
7999,NCT04606888,S100 calcium-binding protein β,2020-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Numeric Rating Scale score
8000,NCT04027764,objective response rate,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
8001,NCT03909997,Number of patients with severe 30-day or in-hospital morbidity,2019-04-05,UNKNOWN,OBSERVATIONAL,['NA'],,Median and percentage of patients with long-term survival
8002,NCT05178095,ADR,2020-09-30,COMPLETED,INTERVENTIONAL,['NA'],,Procedural time
8003,NCT03364621,Utilization rates of characterized genomic and epigenetic features associated with chemotherapy resistance and tumor recurrence in clinical environments,2017-08-29,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Non-invasive detection of cfDNA methylation profiles by performing cfMeDIP-seq on blood samples
8004,NCT02399033,Hepatocellular carcinoma recurrence rate in the three years after hepatectomy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The incidence of adverse reaction.
8005,NCT01598584,quality of life,2012-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,chemotherapy induced nausea and vomiting
8006,NCT00497497,Incidence and nature of dose-limiting toxicities,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence and severity of infusion reactions
8007,NCT03792269,Progression-free Survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
8008,NCT00042900,,2002-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8009,NCT03398512,radical resection rate,2018-02-01,TERMINATED,INTERVENTIONAL,['NA'],,complication rate
8010,NCT02170090,Disease free survival (DFS),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence)
8011,NCT02530593,QoL in colon cancer patients,2015-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Analyse health economy aspects of QoL and morbidity in the patient population
8012,NCT03925662,number of patients with tumour response,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8013,NCT04068896,Number of Patients with Clinically Significant Laboratory Abnormalities:,2019-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Skeletal muscle index during therapy with NGM120
8014,NCT03307941,Phase II: pCR rate,2017-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Number of the tumour-infiltrating lymphocytes (TILs)
8015,NCT01941992,"Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&N35),Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0)
8016,NCT02570711,Overall Response Rate (ORR),2015-10-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8017,NCT01915589,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events as a measure of safety and tolerability
8018,NCT04952272,Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8019,NCT00479817,Progression Free Survival,2007-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of the occurence of AMG 386 Antibody formation
8020,NCT05076591,Number of patients with Adverse Events（AEs）,2022-06-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8021,NCT02542436,Overall Survival (OS),2015-09-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Percentage of Participants with Adverse Events of Special Interest
8022,NCT02024412,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life
8023,NCT03458975,Objective response for liver metastases,2019-10-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dosage of cytokines
8024,NCT03567629,"Progression-free Survival: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first.",2018-05-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of treatment related emergent adverse events（Safety and Tolerance）
8025,NCT03698461,Serial changes in Cluster of Differentiation(CD) 8+ T cell densities,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Microbiome profile
8026,NCT02581215,Progression Free Survival (PFS),2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Characterize Adverse Events (AE)
8027,NCT01711450,Dose of intravenous sedation required during and after the procedure,2012-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Complication rate of paravertebral block
8028,NCT05344924,Progression free survival (PFS),2022-10-12,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse effects
8029,NCT05753163,1-year recurrence-free survival rate (1-year RFS),2022-08-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,health-related quality of life (HRQol)
8030,NCT02543762,"Prevalence and incidence of dysplasia and colitis-associated colorectal cancer in patients with longstanding colonic inflammatory bowel disease (N-IBD), in Spain",2012-02,COMPLETED,OBSERVATIONAL,['NA'],,Usefulness of advanced endoscopy in displasia characterization (chromoendoscopy ) for the diagnosis and endoscopic differential diagnosis of NIBD.
8031,NCT06044142,Assess the impact of photo-bio-modulation low level (LL) laser treatment in managing mucositis,2023-03-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8032,NCT06160557,"Disease Free Survival, DFS",2023-11-29,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8033,NCT05221320,"The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.",2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS) as defined as the time from study drug initiation to the time of documented disease progression (as assessed by RECIST 1.1) or death from any cause.
8034,NCT02774187,Overall survival,2016-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
8035,NCT04854668,Progression Free Survival (PFS) assessed by IRC,2020-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
8036,NCT05980182,Colorectal Screening Status,2023-08-05,RECRUITING,INTERVENTIONAL,['NA'],,Determine the feasibility of the mHealth Application - Sharing Content
8037,NCT04484909,Recommended phase II dose (RP2D),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Resection status,Overall survival (OS)
8038,NCT01157039,To evaluate potential pharmacokinetic interactions between oxaliplatin and glutamine at 30g and 40g in patients with metastatic colorectal cancer.,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To compare the toxicity profile of glutamine and FOLFOX to historical data.
8039,NCT00910494,surgical complication rate,2010-01,TERMINATED,INTERVENTIONAL,['NA'],,local control
8040,NCT05552729,Cognitive function,2022-09-22,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Asthenia
8041,NCT05040438,Objective Response Rate (ORR) of administering VAX-NK/HCC combined with HAIC,2019-10-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,The serum cytokine levels
8042,NCT05383976,Adenoma Detection Rate,2023-02-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8043,NCT01956864,Number of participants on high dose Vitamin D with adverse events,2013-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Changes in the expression of serum and imaging biomarkers
8044,NCT00136227,colorectal cancer screening initiation rate,2005-10,COMPLETED,INTERVENTIONAL,['NA'],,making decisions about colorectal cancer screening that are consistent with their values and preferences
8045,NCT03249727,"Test performance of NK Vue (ability of NK Vue to detect CRC in those subjects in risk categories P2, P3 or P4)",2017-07-05,TERMINATED,INTERVENTIONAL,['NA'],,Test performance of NK Vue in combination with FIT
8046,NCT06304597,Temperature,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate targeted detection with nivolumab-800CW and durvalumab-680LT of the tumor by ex vivo visualization of the resection specimen with PEARL Trilogy
8047,NCT03648879,Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1) Germline Mutation Carriers Compared to Current Method of Standard White Light Endoscopy,2019-02-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Percentage of Participants Who Have Signet Ring Cells (SRC) Foci Not Identified by Confocal Endoscopic Microscopy (CEM)
8048,NCT03136354,Complication,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Disease free survival
8049,NCT04654494,disease free survival,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
8050,NCT03570996,Pain scores,2018-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Hypotension
8051,NCT01068483,Maximum Tolerated Dose (MTD) of BKM120,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical tumor response in patients with tumors that show PI3K pathway activation
8052,NCT01818973,The pathologic tumor regression grade (TRG),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,5-y local relapse free survival
8053,NCT04621474,Inter-observer agreement,2019-04-08,UNKNOWN,OBSERVATIONAL,['NA'],,Preferred imaging modality
8054,NCT02241499,Improvement of dysphagia.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolic response,Endoscopic response of the primary tumor.
8055,NCT01627379,Overall Survival,2012-05,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life
8056,NCT01243346,The primary end-point is overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,PKPD analysis
8057,NCT03722628,The level of Matrix metalloprotinease-1 genotypes polymorphism in the study population,2018-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,
8058,NCT06044311,Metabolic Response,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Ability to take vactosertib before and after standard of care chemoradiation
8059,NCT03206827,Changes in the intake of nutrients and nutritional status of participants as a measure of diet modification,2016-11-29,COMPLETED,INTERVENTIONAL,['NA'],,Genotoxicity testing of human fecal water in 2D and 3D cell cultures
8060,NCT01224990,The aim of the study is to asses whole body diffusion weighted imaging (WB-DWI) in patients with proven gastro-intestinal tumors and to evaluate this non-invasive method for staging and therapy monitoring.,2010-11,UNKNOWN,INTERVENTIONAL,['NA'],,
8061,NCT05694559,genetic risk screening tool (GRST) questionnaire,2022-11-23,RECRUITING,INTERVENTIONAL,['NA'],,
8062,NCT04287868,Best Overall Response (BOR) in Checkpoint Naive and Immune Checkpoint Blockade (ICB) Resistant Disease in Participants With Advanced or Metastatic Human Papillomavirus (HPV) Associated Malignancies,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Duration of Response (DOR)
8063,NCT04161092,Five-year overall survival,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Health economic evaluation
8064,NCT06333769,complete response (CR) rate,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,3y-DFS
8065,NCT05702385,CPV-measured differences in cost of care between control and intervention arms,2023-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
8066,NCT01921283,procedure satisfaction score of propofol addition,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8067,NCT00327652,Dose-limiting toxicities (DLTs) for 7 days after dosing,2006-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8068,NCT04009265,Overall Survival,2019-08-23,RECRUITING,INTERVENTIONAL,['PHASE3'],,Scores of Quality of Life
8069,NCT05155475,Evaluation of the common bile duct size,2019-06-04,COMPLETED,OBSERVATIONAL,['NA'],,
8070,NCT02660671,Colonoscopy participation,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Scheduling of colonoscopy
8071,NCT04695470,PFS(progression free survival) rate at 6 months,2020-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8072,NCT04705363,Credibility score,2021-06-29,RECRUITING,INTERVENTIONAL,['NA'],,
8073,NCT03461341,Utilisation of routine surveillance imaging across European Centers,2009-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Health-related quality of life (HR-QL) as assessed by EORTC QLQ-C30 questionnaire
8074,NCT00625586,Number of Patients Alive at 8 Months,2008-04-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Cmax
8075,NCT05608213,Overall survival (OS),2022-11-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events (AEs)
8076,NCT05894824,PFS rate at 24 weeks,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,adverse events categorized in accordance with CTCAE 5.0 Criteria.
8077,NCT01722162,Progression Free Survival (Arm B),2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence and Severity of Adverse Events as Measured by Number of Participants Who Experience Grade 3 and Higher Adverse Events
8078,NCT03245190,16 weeks progression-free rate (16W-PFR),2018-04-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Screening characteristics of ctDNA measurement (multi-gene analysis).,12 months overall survival rate
8079,NCT03432624,Fourfold Table Analysis Indexes,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Statistical Analysis Indexes
8080,NCT03713229,Incidence of anal cancer,2010-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8081,NCT04348838,Variation of overall survival time (OS) after pharmaceutical treatment,2019-08-26,RECRUITING,OBSERVATIONAL,['NA'],,Variation of serious adverse event rate of HCC treatments in clinical practice
8082,NCT00004190,overall response rate,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,objective tumor response
8083,NCT06172205,ORR,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,conversion rate
8084,NCT02317471,Number of participants with adverse events related to gp96 immunotherapy,2014-11,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8085,NCT06041009,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)",2023-12-20,RECRUITING,OBSERVATIONAL,['NA'],,"The diagnostic value (sensitivity, specificity, accuracy, and positive and negative predictive values)"
8086,NCT02008422,progression-free survival (PFS),2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival (OS)
8087,NCT06301672,Body Mass Index,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
8088,NCT04018872,Percentage of pathological complete response with itraconazole,2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Levels of itraconazole and metabolites in esophageal tissue
8089,NCT05040425,Mucositis pain,2021-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],Electrical body conductivity,Body mass index (BMI)
8090,NCT03646409,VTE- and bleeding incidence,2018-06-11,COMPLETED,OBSERVATIONAL,['NA'],,Arterial thromboembolism (ATE) incidence
8091,NCT03037385,(Phase 2) Number of Participants with AEs and SAEs,2017-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,(Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC
8092,NCT00084721,,2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8093,NCT05957016,Pathologic complete response (pCR),2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
8094,NCT02246634,Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],,To describe the impact of MR screening on treatment received by patients who are diagnosed with liver metastases.
8095,NCT06129604,EP2 and EP4 receptor subtypes tumor biomarker expression within the PGE2 signaling pathway.,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidences of TPST-1495 drug therapy based potential adverse events
8096,NCT04832776,ORR,2021-04-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
8097,NCT00002692,,1994-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8098,NCT01269255,maximum tolerated dose,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8099,NCT00034827,Overall objective response and clinical benefit response,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Time to objective response, duration of response, time to progression and survival"
8100,NCT01833286,overall survival,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Morbidity,disease-free survival
8101,NCT03067792,response rate,2014-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,progression free survival
8102,NCT01196000,Rate of conversion to open surgery as an indicator of surgical technical difficulty,2011-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Health economics
8103,NCT02638857,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
8104,NCT04604158,Absolute change in patient-reported anxiety scores at Day 30 compared with baseline.,2020-12-02,UNKNOWN,INTERVENTIONAL,['NA'],,Participant's experience with Elly app at Day 180-360.
8105,NCT05053386,"Objective Response Rate, ORR",2021-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Overall survival, OS"
8106,NCT02556762,Overall survival,2015-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Biomarkers
8107,NCT02046174,Overall Survival,2014-04-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Necrosis Comparison of Tumors Using PET-CT Scan,Pain Assessment
8108,NCT00005053,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8109,NCT04202978,R0 resection rate,2020-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,pathologic complete response
8110,NCT00560846,Length of stay,2007-11,TERMINATED,INTERVENTIONAL,['NA'],,Body composition
8111,NCT00788125,Maximum Administered Dose of Dasatinib (Phase I),2008-09-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8112,NCT03252821,Change in fatigue,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Adherence
8113,NCT03997188,Degree of dysphagia,2015-12-21,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8114,NCT04416854,Overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,The proportion of surgical intervention in control group
8115,NCT01697488,Safety: Incidence of adverse events,2012-02-02,COMPLETED,OBSERVATIONAL,['NA'],,Treatment duration
8116,NCT05500027,Differentiation expression of serum sCD58 and TGfbeta1 among pancreatic cancer and other conditions,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
8117,NCT05816902,lung metastasis,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8118,NCT01062919,Postoperative functional recovery,2009-07,TERMINATED,INTERVENTIONAL,['NA'],,length of hospital stay
8119,NCT00004867,Proportion of these patients with FDG-PET findings that contraindicate surgery,1999-11,COMPLETED,INTERVENTIONAL,['NA'],,The proportion of false positive lesions found by FDG-PET.
8120,NCT00848094,"Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.",2005-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"1,2 and 3 years survival"
8121,NCT02369939,Improvement of complete remission,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
8122,NCT03775850,Evidence of anti-tumor activity of EDP1503 based on ORR,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
8123,NCT01933789,Occurrence of Discussion About Goals of Care at Target Visit,2013-09,COMPLETED,INTERVENTIONAL,['NA'],Group Differences - Stable Treatment Preference (Filter for Subgroup Analysis of Goal-concordant Care),Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit
8124,NCT04999306,patient adherent to the program.,2023-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life questionnaire-Core 30 (QLQ-C30)
8125,NCT02568046,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence Measured From Baseline to End of Trial Participation, as Assessed by the Common Terminology Criteria for AEs (Version 4.03) (CTCAE v4.03).",2016-03-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8126,NCT04270851,Change in decision making on technical resectability,2020-04,UNKNOWN,OBSERVATIONAL,['NA'],,Level of agreement between liver surgeons on technical resectability
8127,NCT01312467,"Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235)",2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability of Metformin Hydrochloride Treatment
8128,NCT02394769,Change in Urinary Prostaglandin Metabolites (PGE-M),2015-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Spectral Biomarkers of Colorectal Cancer
8129,NCT05996458,Cancer or precancerous lesions detected,2023-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8130,NCT02781532,Evaluation of ingesta,2014-04,COMPLETED,OBSERVATIONAL,['NA'],,
8131,NCT03542422,Progress free survival（PFS）,2018-06-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8132,NCT04054908,Acceptability of specimens for analysis,2018-04-13,COMPLETED,OBSERVATIONAL,['NA'],,Change in relative abundance of following gut bacteria that occur with oral fluoropyrimidine therapy
8133,NCT04069702,Number of Participants With VR Side Effects,2020-03-12,COMPLETED,INTERVENTIONAL,['NA'],,Change in Pain Self-efficacy as Measured Using Items Adapted From the Self-efficacy for Pain Management Subscale of the Chronic Pain Self-Efficacy Scale
8134,NCT00310882,,2006-05,WITHDRAWN,OBSERVATIONAL,['NA'],,
8135,NCT06027242,Change of area of psoas muscle,2023-02-21,RECRUITING,INTERVENTIONAL,['NA'],,Change of serum pre-albumin value
8136,NCT03793725,R0 (resection rate),2019-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,RFS
8137,NCT03980288,Dose limited toxicity and Maximum Tolerated Dose,2019-07-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor efficacy-Disease control rate (DCR)
8138,NCT00617071,Screening utilization over the 6-month observation period,2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Identification of predictors of CRC screening use and screening preference
8139,NCT00612586,Progression Free Survival (PFS),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,PFS From Start of First Line Therapy
8140,NCT02960282,"Best tumor response, defined as a complete response or a clear decrease in tumor burden",2016-10-20,TERMINATED,OBSERVATIONAL,['NA'],,
8141,NCT03353311,Adherance to ERAS protocol,2014-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Number of items of the ERAS protol correlated wih adverse events as described by the Clavien Dindo Classification and with a longer hospital stay
8142,NCT01044511,"HRQoL, EORTC C-30, EOS-18",2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8143,NCT00006994,Effectiveness of L-glutamine for mucositis,2001-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compliance (dose taken) in patients treated with L-glutamine when given with radiation treatment
8144,NCT03762590,"Change of genetic testing among family members of mutation positive PDAC patients, among family members of mutation positive individuals with a family history of PDAC and among first-degree relatives of PDAC patients",2019-05-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Uptake of surveillance for pancreatic, other associated cancers and health behaviors"
8145,NCT03237130,pathological local lymph node status,2017-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
8146,NCT03945799,Disease free survival,2019-04-22,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8147,NCT00010088,,1999-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8148,NCT05420584,Imaging Tumor Regression Rate,2022-11-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological Tumor Regression Rate
8149,NCT05908838,Overall survival,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Immune function
8150,NCT00665197,Dysphagia relief,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment Toxicity
8151,NCT02305459,Description of the clinical context in which SIR-Spheres are applied,2014-11,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic PFS
8152,NCT02724397,Number of Proximal Serrated lesions and colorectal adenomas in proximal colon,2016-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Improvement of histological diagnosis for serrated lesions and colorectal adenomas using LCI/BLI by comparing with that under white endoscopy
8153,NCT01158287,Disease control rate after 4 months,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability and toxicity
8154,NCT01608841,disease control rate,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression-free survival
8155,NCT03280511,The number of patients with peritoneal recurrence,2017-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,"1-, 3- and 5-year overall survival rate"
8156,NCT04984369,ORR,2021-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8157,NCT03776435,Age and sex-standardized incidence rate ratio (IRR) for malignancies of hematologic system,2018-01-15,UNKNOWN,OBSERVATIONAL,['NA'],Subgroup analysis,Age and sex-standardized incidence rate ratio (IRR) for all cancers
8158,NCT04006041,Pathologic complete response rate,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Perioperative mortality
8159,NCT05369234,Management of Oral Mucositis and Esophagitis,2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8160,NCT01522820,"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0",2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],Time to disease progression,NY-ESO-1 specific humoral immunity
8161,NCT03422120,Natural Killer Cell Activity (NKA) at baseline compared to POD1 in CRC surgery patients,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,Natural Killer Cell Activity (NKA) in healthy donors (HD) as compared to colorectal cancer (CRC) patients (at baseline)
8162,NCT03403465,Progression free survival (PFS),2018-03-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Measure the potential sparing of radiation dose to critical normal tissue
8163,NCT04327986,Best Overall Response (BOR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) of Bintrafusp Alfa (M7824) & NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy in Participants With Locally Advanced Pancreas Cancer,2021-06-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With a Dose-limiting Toxicity (DLT),Complete Pathological Response Rate(s) For Participants Who Underwent Surgical Resection After Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment
8164,NCT03662659,BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants,2018-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
8165,NCT01182831,immediate pain relief,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8166,NCT00595972,time to progression,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,toxicity
8167,NCT05961709,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2025-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8168,NCT06023758,pCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
8169,NCT03353753,Progression-Free Survival (PFS),2018-02-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale
8170,NCT02852915,Disease free survival,2016-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events (mortality and morbidity)
8171,NCT04262687,The rate of patients alive and without progression at 10 months after inclusion,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Histological response in case of secondary resection
8172,NCT05166577,Phase 2: Overall response rate (ORR),2021-10-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]
8173,NCT04682665,Effect of human faecal samples from patients treated with EPA or placebo on anti-tumour immune response in gnotobiotic mice with colorectal cancer liver metastasis,2021-09-16,RECRUITING,OBSERVATIONAL,['NA'],,
8174,NCT02801500,Bilioenteric anastomotic leakage,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Bilioenteric anastomotic stricture
8175,NCT01191684,Safety and tolerance of modified vaccinia virus ankara vaccine expressing p53 assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4 toxicity scale,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
8176,NCT00004002,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8177,NCT02919787,Overall survival 18 month after randomization,2016-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
8178,NCT00033371,Number of Participants With Adverse Events Occurring at a Frequency of 5% or Grade 3 and Higher,2001-12-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Percent Change in Polyp Size in Focal Area(s) of the Colorectum,Percent Change in the Area of Plaque-like Duodenal Polyps
8179,NCT01876927,the difference in percentage of patients receiving all the planned chemotherapeutic cycles between the two arms.,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biologcal profile of treatment response
8180,NCT06249672,Low anterior resection syndrome,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
8181,NCT03280277,Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest,2018-04-27,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Accuracy of USPIO - MRI
8182,NCT00155805,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],,
8183,NCT00508690,Incidence and classification of surgical site infection (SSI),2007-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Incidence of colitis, other infectious diseases and other postoperative complications."
8184,NCT00568425,Evaluate the late effects of radiation treatment,2005-09,TERMINATED,OBSERVATIONAL,['NA'],,
8185,NCT03358095,Emerged complications related to surgery or preoperative endoscopy within 120 days of surgery,2017-11-26,WITHDRAWN,INTERVENTIONAL,['NA'],,
8186,NCT00976976,"This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Investigate the safety profiles, patient tolerance, and overall survival in this population"
8187,NCT00508846,Patient Responses to Questionnaire,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,
8188,NCT03590275,Overall survival,2017-10-02,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity rate
8189,NCT02194829,Progression-free Survival,2014-08-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate
8190,NCT01897038,Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Anti-therapeutic Antibodies (ATAs) Against Onartuzumab
8191,NCT00155415,Cleansing level of colon and detected lesion number during colonoscopy,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,
8192,NCT00204373,"Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,The Median Survival From the Time of Diagnosis.
8193,NCT04222530,Diagnostic accuracy,2020-01-28,UNKNOWN,INTERVENTIONAL,['NA'],,Operating time
8194,NCT01901692,Progression-free survival (PFS) rate,2013-07-29,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Exploratory analysis for overall patient survival rate
8195,NCT03874559,Exosomal Biomarkers Assessment,2018-02-13,UNKNOWN,OBSERVATIONAL,['NA'],,Exosomal Functionality Assessment
8196,NCT02725125,Disease control rates,2015-11,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of remission
8197,NCT02999893,Establish the safety profile of combined APR-246 plus cisplatin and 5FU as measured by the satisfactorily low rate of adverse events described according to NCI CTCAE v 4.03.,2017-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of patients who will benefit from APR-246 therapy as assessed by quantitation of ctDNA levels in patient serum and plasma samples.,Evidence of clinical efficacy of a combined APR-246 and cisplatin/5FU chemotherapy regimen as confirmed by CT/PET/MRI scan.
8198,NCT00869271,overall survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,progression free survival
8199,NCT05934331,PFS,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8200,NCT00288093,MTD as assessed by the number of patients with dose-limiting toxicity (DLT),2006-12-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Therapeutic response as assessed using the Response Evaluation Criteria in Solid Tumors (RECIST)
8201,NCT04776590,Pathologic complete response rate,2021-01-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
8202,NCT00006981,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8203,NCT01978717,The changes of peripheral immune cells and cytokines,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8204,NCT04392050,Successful completion of the key contact interviews and focus groups leading to the development of the culturally tailored educational intervention,2020-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
8205,NCT01260168,The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,To collect samples from patients diagnosed with colorectal cancers.
8206,NCT01633333,Pain during colonoscopy,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Dose of medication
8207,NCT01903694,determination of the tumor according to the evaluation criteria of Response Evaluation Criteria in Solid Tumors,2010-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8208,NCT04595864,OS,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,PFS
8209,NCT05129787,Local tumor progression,2021-12-16,RECRUITING,INTERVENTIONAL,['NA'],,Inflammatory response
8210,NCT05215899,Mindfulness-based yoga and meditation intervention may reduce fatigue level of colorectal cancer patients,2021-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8211,NCT04411706,Objective Response Rate (ORR),2020-06-21,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by the rate of AEs
8212,NCT02942901,Overall Survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Number and sites of metastases detected by PET-CT
8213,NCT02779608,response rate of ascites,2017-01-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,side effects of chemotherapy
8214,NCT05882370,Objective response rate (ORR) by RECIST 1.1 and mRECIST,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment-related adverse events,Median overall survival time (mOS)
8215,NCT06203327,early gastric neoplasm,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8216,NCT00899210,Kinetics of postoperative changes of serum matrix metalloproteinases (MMP) and their inhibitors (TIMP),2003-09,COMPLETED,OBSERVATIONAL,['NA'],,Correlation of postoperative serum HGF/SF with plasma levels in MMPs
8217,NCT01082315,Safety,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,Clinical efficacy
8218,NCT01327521,Freedom from local progression at 6 months and 12 months,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Serum AFP levels
8219,NCT00952003,To determine efficacy in terms of response rate according to RECIST criteria,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine overall survival time following treatment with a chemoimmune therapy
8220,NCT03892681,Specificity,2019-04,UNKNOWN,INTERVENTIONAL,['NA'],,Inter-reader agreement between two radiologists
8221,NCT03645655,Change of PIVKA-II,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Change of AFP
8222,NCT00745134,Number of Participants With Pathologic Complete Response (pCR) Rate,2008-08-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Tumor Downstaging
8223,NCT02403544,Maximum Tolerated Dose (MTD) for capecitabine and oxaliplatin,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor response rate including complete response and partial response rates
8224,NCT00335959,Pathologic Complete Response,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
8225,NCT01719549,Progression-free survival,2012-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,FGFR2 copy number
8226,NCT03416478,Disease Free Survival,2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
8227,NCT04572633,Primary Safety: Procedure-Related Major Complications,2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Safety: All Adverse Events
8228,NCT02089269,Treatment reality in Germany,2013-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8229,NCT05637268,3-year DFS rate,2020-11-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,5 years OS rate
8230,NCT05194371,Overall survival,2021-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Proportion of using chemotherapy or target therapy concurrently with radiotherapy
8231,NCT06208436,Recurrence-free survival,2023-10-07,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
8232,NCT00862524,Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.,2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms."
8233,NCT03161925,Overall survival,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA'],,
8234,NCT04440735,DSP107 Serum Concentration,2020-10-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Preliminary Efficacy (Part 2 only)
8235,NCT01074333,Safety and toxicity of Erbitux treatment,2008-09,TERMINATED,OBSERVATIONAL,['NA'],,Clinical efficacy of Erbitux treatment
8236,NCT01568723,Response to therapy,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
8237,NCT00590278,"This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate",2002-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8238,NCT04704960,correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer,2021-02,UNKNOWN,OBSERVATIONAL,['NA'],,mutations related to target drug
8239,NCT01816256,Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs),2013-05,COMPLETED,INTERVENTIONAL,['NA'],Identify any genetic markers or biomarkers associated with asymptomatic PVT and PHTN,Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN
8240,NCT05498779,Recurrence after ablation,2022-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival related to HCV virus
8241,NCT04293458,Primary Efficacy,2020-02-28,COMPLETED,INTERVENTIONAL,['NA'],Safety of EsoCheck device administration,Secondary Efficacy
8242,NCT06313190,Progression-free survival (PFS) rate,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between ctDNA and overall survival,Treatment-related adverse events
8243,NCT03495674,Retention,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],,
8244,NCT04198766,MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab,2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE1'],Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab,Immunogenicity of INBRX-106
8245,NCT00088816,Overall survival,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
8246,NCT02919969,Overall Response Rate,2016-10-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events to Evaluate the Safety and Tolerability of Pembrolizumab
8247,NCT05354817,Assess response rate after 4 cycles of FOLFIRINOX,2021-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8248,NCT03974594,Bioequivalence based on Peak Plasma Concentration (Cmax),2019-05-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Adverse Event
8249,NCT01486251,Echography measure,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,
8250,NCT03332576,Safety as measured by adverse event reporting (CTCAE),2013-08-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Impact on residual tumour
8251,NCT04422002,Survival,2019-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgical complications
8252,NCT04295109,effective bolus times,2020-03-02,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative hospitalization days
8253,NCT01157598,the satisfaction of patients and endoscopist in midazolam and meperidine induced sedation with BIS monitoring during ESD,2009-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,the dose of midazolam and meperidine during ESD with BIS monitoring
8254,NCT00640081,Failure-free survival at 10 months,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity of each treatment regimen by NCI CTCAE v3.0
8255,NCT03592550,Difference in liver position after set-up,2018-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of available imaging positions
8256,NCT00500292,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8257,NCT02077881,Overall Survival,2014-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression of Disease
8258,NCT02007876,Muscle Mass,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],Effect of MAT of Hospital Length of Stay,Effects of Individual MAT Program Segment
8259,NCT04274868,Establish a national bank of rare biological material,2015-09-10,RECRUITING,OBSERVATIONAL,['NA'],,
8260,NCT02470559,Toxicity profile of IP and IV HER2Bi-aATC at the MTD or technically feasible dose graded using NCI CTCAE version 4.0,2015-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Progression free survival
8261,NCT02703571,Objective Response Rate (ORR),2016-06-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,overall survival
8262,NCT06061445,ORR,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8263,NCT04520737,Physical Fitness- 6MWT,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status- UMA
8264,NCT05576480,Pathological complete remission rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number and severity of adverse events
8265,NCT04544046,Proportion of participants requiring a hospital admission or emergency department visit,2020-09-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Instrumental Activities of Daily Living (IADLs)
8266,NCT00149266,overall survival,1995-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,quality of life
8267,NCT03844750,Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.,2019-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Relapse-free survival (RFS) per RECIST 1.1
8268,NCT01336062,Objective response rate,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,biomarkers
8269,NCT06263088,Biomarker testing rate of Black participants diagnosed with GI cancer,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in Health literacy score among black participants diagnosed with GI cancer
8270,NCT04032119,Overall procedural time,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Lymphovascular invasion
8271,NCT03391843,Pelvic complete resection rate,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of >=3 grade adverse events
8272,NCT02098239,Patient Survival,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Injection Tolerability
8273,NCT00948337,Screening behavior for second primary cancer,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Knowledge and attitudes of Secondary cancer screening and dietary supplement
8274,NCT05203627,Objective measures of patient nutrition - Skeletal mass Index,2020-01-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8275,NCT03652077,Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only),2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity of INCAGN02390
8276,NCT04777162,objective response rate,2021-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
8277,NCT01443065,Progression-free survival at 4 months,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerance of the treatment
8278,NCT02679495,gastric caner occurrence,2015-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,gastric tissue DNA methylation change of selected genes
8279,NCT05323929,scar area,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
8280,NCT01688817,Effect of primary care physician's (PCP) counseling on participation rate in primary colonoscopy screening program,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Effect of primary care physician's (PCP) counseling on a patient's decision to choose unsedated colonoscopy (not in sedation).
8281,NCT05993702,Progression-free Survival (PFS),2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Incidence and severity of adverse events (AE) and serious adverse events (SAE)
8282,NCT01393249,Risk of pancreatitis,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Course of pancreatitis
8283,NCT02851784,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test.",2009-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Local tumor progress rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test","disease free survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and combination treatment will be done by the log-rank test"
8284,NCT04678011,Advanced neoplasia,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],,Complications
8285,NCT01640522,Depression,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,Fatigue
8286,NCT05369650,Immediate postoperative plasma lidocaine concentration,2019-07-27,RECRUITING,INTERVENTIONAL,['NA'],,Patient satisfaction scores
8287,NCT02136836,The proportion of HER2 overexpression in gastric cancer patients,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],The practice pattern of Herceptin use in stage IV gastric cancer,Gastric cancer specific survival according to HER2 expression in each stage
8288,NCT05332002,Adverse Event Rates,2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8289,NCT06249841,"The primary endpoint of this study is feasibility of percutaneous cryobiopsy in the bile duct, i.e., successful retrieval of at least one cryobiopsy specimen per patient.",2024-03-04,RECRUITING,INTERVENTIONAL,['NA'],,"Rate of safety-relevant aspects, like for example bleeding, post-bleeding, perforation, infection and abscess"
8290,NCT02792881,Morbidity,2016-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,The Surgery Task Load Index (SURG-TLX)
8291,NCT04596865,Patterns of disease recurrence,2020-10-12,COMPLETED,OBSERVATIONAL,['NA'],,"Determine if/how specific patterns of recurrence (local only, distant only, synchronous local and distant) following pancreaticoduodenectomy for pancreatic head malignancy correlate with the following factors:"
8292,NCT02444572,Incidence of asymptomatic Deep Venous Thrombosis (DVT),2015-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Incidence of both Enoxaparin formulations immunogenicity
8293,NCT01317433,reduction of Grade > or = 2 acne-like skin rash by 30%,2010-12-29,TERMINATED,INTERVENTIONAL,['NA'],,Resectability rate
8294,NCT02081755,"Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.",2014-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Hepatic arterial thrombosis
8295,NCT02311907,"Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).",2009-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Times to Onset of CTCAE Grade 3+ PN
8296,NCT05711823,Complete response rate,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
8297,NCT05181605,Overall Survival,2022-04-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
8298,NCT00663741,Safety and pharmacokinetics,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of response
8299,NCT02640781,Duration of stent patency between stent insertion and recurrence of obstructive symptoms,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,Number of patients with complications
8300,NCT02008539,Safety and tolerability as indicated by Common Toxicity Criteria (CTC-AE) of the National Cancer Institute,2013-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8301,NCT03775863,Incidence of recurrent hepatocellular carcinoma after liver transplantation.,2017-11-11,COMPLETED,OBSERVATIONAL,['NA'],,Survival in patients with hepatocellular carcinoma after liver transplantation.
8302,NCT00534053,Our primary outcome is FOBT card return rate,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Predictors of Non-compliance to fecal occult blood testing
8303,NCT00060411,The relationship between CYP3A4 activity and OSI-774 clearance,2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics of OSI-774 given with FOLFOX 4, and Bevacizumab"
8304,NCT00075439,Proportion of patients progression-free at 6 months,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
8305,NCT02227940,"MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)",2015-01-08,COMPLETED,INTERVENTIONAL,['PHASE1'],Levels of serum and tumor biomarkers,Response rate as assessed by the RECIST 1.1
8306,NCT01673334,Diagnostic Yield,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8307,NCT01198743,local recidivism or metastasis reappearance,2005-11,COMPLETED,OBSERVATIONAL,['NA'],,specificity and global safety
8308,NCT00920023,To Determine the Specificity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable Lymph Node Metastases.,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8309,NCT01945879,Incidence of NCI CTC Toxicity III°/IV° and severe bleedings,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
8310,NCT04050462,Objective Response Rate (ORR) of Cabiralizumab or BMS-986253 in combination with Nivolumab in comparison to Nivolumab monotherapy,2019-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8311,NCT03046849,Pathogenic germline mutation,2017-03-08,COMPLETED,OBSERVATIONAL,['NA'],,Variant of uncertain significance of germline mutation
8312,NCT00482586,"Development of a data repository for health-related quality of life outcome measures by administering the Medical Outcomes Study Short Form questionnaire at baseline, during routine follow-up after image-guided therapy, and then annually thereafter",2003-10,COMPLETED,OBSERVATIONAL,['NA'],,
8313,NCT06276140,Overall morbidity,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Values of different erythrocyte indices
8314,NCT03257280,Hospital stay,2017-10-20,UNKNOWN,INTERVENTIONAL,['NA'],,Impedancemetry
8315,NCT02815150,preoperative gastric residual volume of gastric fluid,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Reoperation rate within 30 days post operation
8316,NCT01068769,"Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control",2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS)
8317,NCT06218810,1-year Progression Free Survival rate,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,irORR
8318,NCT00237185,Best Tumor Response (Core + Extension),2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression (Core + Extension)
8319,NCT03301805,Part II: Overall response rate (PR + CR),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Part II: Incidence of grade 3/4 hematological toxicity
8320,NCT03393234,3-year disease free survival,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,sexual function
8321,NCT04331743,Recommended Phase II Dose (RP2D),2021-06-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Duration of Response (DoR)
8322,NCT03498885,Anastomotic leakage,2018-01-01,RECRUITING,INTERVENTIONAL,['NA'],,5-years disease free survival rate
8323,NCT00650988,Number of patients that experience toxicity with cryotherapy,2005-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Assess the degree of tumor ablation of inoperable early esophageal cancer
8324,NCT05250843,Recurrence-free Survival,2022-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse effects
8325,NCT02163759,"Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population",2014-11-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28948 Population"
8326,NCT06249321,"progression-free survival, PFS",2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
8327,NCT02502474,Number of patient with Staphylococcus aureus colonic carriage,2015-02-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of patient with Staphylococcus aureus carriage in the groin
8328,NCT04340141,Overall survival (OS),2020-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Computed tomography (CT)-based radiomics as non-invasive predictors of overall survival
8329,NCT03816163,Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events,2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Health Related Quality of Life (HRQoL) measured by the Patient Global Impression of Severity (PGIS) Scale
8330,NCT01746771,Safety evaluation(phase I),2012-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy evaluation(Phase II)
8331,NCT03252938,Feasibility rate,2017-08-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immune response in whole blood and tumor tissue
8332,NCT01966289,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-04-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival (PFS)
8333,NCT03768687,Progression free survival,2018-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,
8334,NCT01477229,"To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients",2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,QoL in an unselected population of rectal cancer patients
8335,NCT02892721,Difference in sensitivity between arms,2017-04-20,COMPLETED,INTERVENTIONAL,['NA'],,Characteristics of radiologists performing well versus those that do not.
8336,NCT01189929,To determine the maximum tolerated dose of demcizumab (OMP-21M18) when combined with gemcitabine +/- Abraxane®,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the exploratory biomarker changes of gemcitabine plus demcizumab (OMP-21M18)
8337,NCT01549327,Empowerment,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Cost-effectiveness
8338,NCT00656838,"To determine the effectiveness and maintenance of a colon-rectal cancer screening patient reminder program.Identify patient, primary care team, and system factors important to implementation success.",2008-04,COMPLETED,INTERVENTIONAL,['NA'],,"Create, refine, and disseminate an implementation guide for colon-rectal cancer screening reminder programs by combining the findings from the primary aim."
8339,NCT02500043,Overall Survival (OS),2016-02-24,COMPLETED,INTERVENTIONAL,['PHASE3'],EORTC Quality of Life Questionnaire - Gastric-specific Module (EORTC QLQ-STO22): Percentage of Participants With Overall Compliance,Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
8340,NCT06138223,Quality of life (EORTC-QLQ-30) summary score,2023-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],(Serious) Adverse Events potentially related to the exercise intervention,Health-related quality of life: fatigue
8341,NCT00005639,Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate,2000-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene-re-expression of epigenetic modulation in Peripheral Blood Mononuclear Cells (PBMC) as measured by change in Epstein-Barr Virus (EBV) viral load (number of copies per 1 million cells) after treatment with Azacitidine
8342,NCT05789433,Whole-Body Intermuscular Adipose Tissue,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
8343,NCT02316496,Objective response rate (ORR),2015-09-23,TERMINATED,INTERVENTIONAL,['PHASE2'],,PFS
8344,NCT05156866,Recommended Phase 2 Dose (RP2D),2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-2-307-ADC
8345,NCT03445585,Number of participants in the study.,2017-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of clinical phenotypes and/or endpoints observed (per category)
8346,NCT01509911,Disease Control Rate as defined by Percentage of patients experiencing a Complete Response or a Partial Response or a Stable Disease according to RECIST measured at 16 weeks after treatment initiation,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
8347,NCT02331927,Randomized part: PFS rate at 6 months after first cycle after randomization,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Prognostic value of CAF at baseline and/or during treatment
8348,NCT00504998,"Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles.",2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To identify an objective tumor response to Rexin-G
8349,NCT04699994,"Histological response rate (Grade 2 or 3 in Japanese Classification of Esophageal Cancer, 11th Edition)",2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence rate of all adverse event
8350,NCT00003939,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8351,NCT04605237,Survival,2014-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of histologically confirmed recurrences
8352,NCT00764595,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Types and severities of adverse events
8353,NCT05775159,Progression free survival (PFS),2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective response rate (ORR)
8354,NCT01252498,Salivary levels of PGE2 and PGI2 during and after radiotherapy,2010-12,COMPLETED,OBSERVATIONAL,['NA'],,Patient reports of oral pain during and after radiation therapy
8355,NCT04315883,Evaluate the efficacy and clinical utility of TARE-Y90 by examining clinical course,2021-02-11,RECRUITING,OBSERVATIONAL,['NA'],,
8356,NCT05495776,Frequency of microsatellite instability and Lynch syndrome,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Impact of the presence of microsatellite instability/deficiency
8357,NCT01082757,Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,Subject and tumour characteristics and their association with KRAS mutational status
8358,NCT02139605,primary endpoint:Overall Survival,2013-07-05,RECRUITING,INTERVENTIONAL,['NA'],,Disease-free survival
8359,NCT00834158,the rate of tumor resection after intervention,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,rate of survival
8360,NCT05854498,Progression Free Survival (PFS),2023-10-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Efficacy of irinotecan measured by PFS for patients with and without irinotecan containing regimens
8361,NCT04120935,Number of patients longitudinally monitored,2019-10-15,RECRUITING,OBSERVATIONAL,['NA'],Correlation of new prognostic and predictive biomarkers with clinical outcomes,Number of patients triaged in proof-of-concept (POC) clinical trials
8362,NCT01034683,objective response rate(ORR) time to progression (TTP) toxicities,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,1-year survival rate KPS score
8363,NCT06271109,complete resection of the neoplasm,2021-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,recurrence rate
8364,NCT06026618,Change in Hemoglobin,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,number of complications related to IVI administration
8365,NCT05816980,Resection rate,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Comparative dose planning study
8366,NCT02980510,Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.,2016-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8367,NCT04810156,Time to response or downgrading of liver injury in days,2021-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],Description of changes in the fecal microbiome,Overall survival rates at 6 months
8368,NCT00838318,"To look at the knowledge, beliefs, and attitudes toward screening for colorectal cancer among Hispanic colorectal cancer patients and their close relatives.",2004-02,COMPLETED,OBSERVATIONAL,['NA'],,To study how these families communicate with each other and health care providers about colorectal cancer risk and screening.
8369,NCT04984733,Tumour Response to nivolumab,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,The percentage of patients who have achieved response
8370,NCT01867697,Response rate (RR),2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of secondary micro-radical surgical resection (R0 resection)
8371,NCT00920868,To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To explore any correlation between blood, urine, and paraffin biomarkers and clinical outcomes"
8372,NCT05494086,Early operative morbidity,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,5 year overall survival rate
8373,NCT01911273,Overall Survival (OS),2013-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Observed Serum Concentration of Circulating Protein
8374,NCT02279134,Disease-free survival (DFS),2014-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Adverse events,Overall survival (OS)
8375,NCT00257322,Participants Exhibiting Immune Response,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rates and Overall Survival.
8376,NCT05978193,PFS,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Grade III and higher treatment-related adverse events
8377,NCT01440959,Disease Control Rate (DCR; OR + Stable Disease),2011-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
8378,NCT04582981,progression free survival (PFS),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],quality of life score (QOL),disease control rate (DCR)
8379,NCT03862378,Predictive value of the nomogram prediction model (APPEAL-GC score),2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Abdominal infection outcome.
8380,NCT00184834,,1999-06,COMPLETED,OBSERVATIONAL,['NA'],,
8381,NCT02827201,Rate of patients alive without progression 6 months after inclusion,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival:
8382,NCT02675738,Number of cases with confirmed preoperative diagnosis,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,
8383,NCT05239169,Recurrence free survival at 12 months (RFS@12).,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL EQ-5D-5L
8384,NCT00009737,Disease-free Survival,1998-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Any Adverse Events and Serious Adverse Events
8385,NCT04276909,Assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery,2026-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Correlate resected tissue with LUM Imaging System to identify imaging threshold
8386,NCT00576134,Respiratory evaluation,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Nasofibroscopy
8387,NCT00356161,Safety of device and regional therapy,2002-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life
8388,NCT02726399,Progression Free Survival,2016-03-18,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8389,NCT00885469,"Accuracy parameters (sensitivity, specificity, NPV, PPV) of PillCam ESO 2 in detecting suspected Barrett's Esophagus (BE) as compared to standard EGD, using unblinded EGD as the reference standard.",2007-12,COMPLETED,OBSERVATIONAL,['NA'],,Subjects' satisfaction will be assessed by a post procedure questionnaire
8390,NCT05018182,Pathological response,2021-08-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of patients with 30-day post-operative mortality
8391,NCT01643070,R0 resection rate after simultaneous surgery of the rectum and the liver,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8392,NCT03519997,Overall Response Rate,2018-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Treatment response,Safety and Tolerability: rates of adverse events according to the CTCAE
8393,NCT03452774,Proportion of patients Eligible for CTE versus Actual CTE,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Time from Intervention to Actual CTE (months)
8394,NCT02113202,"Number of fluorescent adenomatous polyps during surveillance endoscopy using the near-infrared fluorescence endoscopy platform in patients with Familial Adenomatous Polyposis (FAP), after administration of the fluorescent tracer bevacizumab-IRDye800CW.",2014-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure the mean fluorescent intensity of adenomas and compare this between the three different dosing groups to determine the best tracer dose for the fluorescence endoscopy procedure.
8395,NCT01622569,Change in Total Polyp Grade,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Nasal Polyp Surgery Eligilbilty
8396,NCT00740753,"Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.",2004-08,COMPLETED,INTERVENTIONAL,['NA'],,
8397,NCT04166240,EPRP Outcome,2018-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8398,NCT03925428,Maximum tolerated dose,2020-09-18,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Effect of GSK525762C and entinostat combination therapy on gene expression patterns,Duration of response
8399,NCT00159471,"To see if patients with advanced pancreatic cancer treated with gemcitabine, docetaxel and capecitabine who bear more favorable genotypes of genes involved in drug metabolisms are more likely to have response and survive longer than those that do not.",2005-02,TERMINATED,INTERVENTIONAL,['NA'],,"To assess time to progression, toxicity and to identify other molecular correlates of response, toxicity, and survival."
8400,NCT00976768,Progression-free survival,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
8401,NCT03216174,Complete resection,2017-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,
8402,NCT05012540,The overall survival,2013-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
8403,NCT03442569,Overall Response Rate,2018-03-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity of Treatment
8404,NCT01152645,Antitumor effect,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
8405,NCT01305993,Evaluating Tumor Response Rate,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Determine duration of response rate by measuring time to progression
8406,NCT03876561,Severity of Low Anterior Resection Syndrome Score (LARS score),2019-05-27,UNKNOWN,INTERVENTIONAL,['NA'],,Medico-economic impact of pelvic floor prehabilitation including the fecal incontinence related costs
8407,NCT02930291,3-year disease free survival rate,2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Visual Analog Score for pain
8408,NCT02198976,Number of Serious and Non-Serious Adverse Events,2014-04,RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with Serious and Non-Serious Adverse Events
8409,NCT04825288,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2021-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Cardiotoxicity measured by the number of required ECGs and cardiotoxicity related events summarized by treatment arm and compared over time,Change in (CD14+CD16+IL-1⍺+) triple positive tumor associated monocytes in peripheral blood
8410,NCT01171755,Response rate,2008-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8411,NCT01766765,The time to the first adjuvant chemotherapy,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Rehospitalization rate
8412,NCT04656392,Specificity of the eNose for detecting confirmed BE,2021-04-20,RECRUITING,INTERVENTIONAL,['NA'],,Safety of eNose based on reported Adverse Events.
8413,NCT00837031,"Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment",2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death"
8414,NCT04719988,Clinical complete response (cCR) at 10 months,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
8415,NCT02562963,"Objective Response Rate (ORR), confirmed by CT or MRI, or confirmed by biopsy",2015-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Marker
8416,NCT03499808,Overall confirmed hematologic response rate,2018-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
8417,NCT05101382,Number of retrospectively recruited CRC cases,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers correlation with OS,
8418,NCT00466856,Tumor response,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Patient report of Health-related quality of life (HRQOL)
8419,NCT01449864,Acute Toxicity,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,
8420,NCT04160416,Incidence of adverse events,2019-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
8421,NCT04751448,Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer
8422,NCT04444622,Incidents of Adverse Events (AE),2021-07-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8423,NCT01821105,Detection of Position Accuracy With Handheld Probe on Anatomical Location.,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Detection
8424,NCT01458925,safety - transit time (less than 300 hours),2011-11-20,TERMINATED,INTERVENTIONAL,['NA'],,"Colon Capsule correlation map (Empirical, qualitative)"
8425,NCT03581773,CTCAE Mucositis,2017-12-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,QOL MDASI
8426,NCT04180072,Best overall response rate,2020-03-12,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
8427,NCT05832372,Prevalence or occurrence of upper gastrointestinal diseases,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8428,NCT05368506,Incidence of adverse events,2023-07-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],Cellular and molecular characteristics,Overall survival
8429,NCT00224601,Number of pre-cancer lesions or early cancer detected.,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Anatomopathologic criteria (size of lesions, …)."
8430,NCT03447951,Objective Response Rate (ORR),2018-06-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,EQ-5D-5L quality of life score
8431,NCT04406974,Patient experiences after local recurrence,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
8432,NCT02650271,overall survival,2021-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],Perioperative reactivation of hepatitis B virus replication,Recurrence rate
8433,NCT05699746,Recurrence-free survival,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Clearance of circulating tumor DNA (ctDNA)
8434,NCT01767597,Percentage of Patients Appropriately Seeking Care,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
8435,NCT02766842,Diagnostic accuracy of needle as assessed by diagnostic yield of needle and final diagnosis method,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Procedure time
8436,NCT03144843,Progression-free survival (PFS),2017-01-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse events) [
8437,NCT02656134,Genetic profile in FAP patients,2015-03,UNKNOWN,OBSERVATIONAL,['NA'],,
8438,NCT01185483,,2009-11,UNKNOWN,OBSERVATIONAL,['NA'],,
8439,NCT00441337,Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC),2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg, 3mg, and 10 mg Cohorts - Safety Population"
8440,NCT04273477,The prediction accuracy of the radiomics prediction model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiomics prediction model
8441,NCT03043950,Overall Survival (OS) of pre-defined risk groups low vs. high,2017-01-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Adverse Drug Reactions,Antineoplastic treatment in later lines
8442,NCT04726319,Changes in risk-appropriate screening based on family history,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Attitudes towards the FHAMe intervention
8443,NCT01763450,To assess the objective response rate(ORR),2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）,To assess the R0 resection rate of liver metastases
8444,NCT02858206,Adverse events,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recurrence rate
8445,NCT01792934,Overall survival,2013-05,RECRUITING,INTERVENTIONAL,['NA'],,Safety and efficacy of the additional local treatment measured by number of serious adverse events.
8446,NCT02200250,Reviewing patients symptoms following resection,2021-10-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
8447,NCT03840590,"Adenoma detection rate, ADR",2019-07-10,COMPLETED,INTERVENTIONAL,['NA'],,"Polyp detection rate, PDR"
8448,NCT05076305,Assessment of resectability,2021-10-15,UNKNOWN,OBSERVATIONAL,['NA'],,Assessment of staging
8449,NCT03921684,Incidence of Treatment-Emergent Adverse Events (Safety),2019-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8450,NCT05919758,Recurrence rate,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Health related Quality of Life at follow-up moment for this study
8451,NCT02078245,MRI accuracy,2010-08,RECRUITING,OBSERVATIONAL,['NA'],,Outcome of surveillance program
8452,NCT01303172,Safety and Tolerability.,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival in Metastatic Patients Only
8453,NCT05547568,Major postoperative complications (Dindo-Clavien ≥ 3 grade),2012-09,COMPLETED,OBSERVATIONAL,['NA'],,
8454,NCT00210184,2-month Response Rate,2004-07-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
8455,NCT04241887,Effectiveness of PVB on pain intensity,2017-09-09,COMPLETED,INTERVENTIONAL,['NA'],,Surgeon's satisfaction
8456,NCT00182611,Overall survival,2004-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
8457,NCT02618850,change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan),2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],"prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) by different cut off values (other than 50% reduction)","prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) and recist response"
8458,NCT05004350,Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR),2021-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening,Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data
8459,NCT02979691,Overall survival,2016-10,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Clinical target contouring guided by MRI or CT simulation,Chemoradiotherapy toxicities
8460,NCT05183425,The consistency of drug sensitivity,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,The establishment of PDO
8461,NCT04005742,Serum high-sensitivity C-Reactive Protein concentrations (marker of systemic inflammation),2017-03-13,COMPLETED,OBSERVATIONAL,['NA'],Sedentary behaviour assessed using Lifestyle Questionnaire,HbA1c in whole blood
8462,NCT01521702,progression-free survival,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,complication
8463,NCT05620485,Long-term complications,2022-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,length of nutritional support in hospital
8464,NCT00352833,safety and efficacy data,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8465,NCT04179773,"Frequency of patients with ENT, upper digestive-tract or colorectal cancer with a diagnosis of cirrhosis",2019-01-24,RECRUITING,OBSERVATIONAL,['NA'],,Frequency of chemotherapy side effects according to CTCAE version 5.0 classification in cirrhotic patients who have received chemotherapy
8466,NCT05924880,The incidence of Possible related adverse events(PRAE) Grade 3 or 4,2023-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events(AEs) resulting in study intervention interruption and discontinuation
8467,NCT03843905,Overall survival (OS),2018-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,Microbiota composition
8468,NCT00524186,"Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)",2007-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival
8469,NCT01593475,feasibility and compliance,2011-09-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,disease-free survival.
8470,NCT02054598,Colorectal cancer screening completion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening related intent
8471,NCT05665322,Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Reason for for failure of technique requiring switch to different guidance technique
8472,NCT02600481,Troponin T level is set as the marker of myocardial injuries after robot-assisted surgeries,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Chest CT scan is used to determine pulmonary complications
8473,NCT01777698,Changes in body composition,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8474,NCT03993327,Percent of known liver lesions per standard staging scans identified on iodine I-124 (I-124) M5A imaging,2020-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events
8475,NCT04665947,[177Lu]Lu DOTA-ABM-5G dose escalation therapy,2020-12-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G
8476,NCT03165721,Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST),2017-08-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Distress From Baseline
8477,NCT02891447,Patterns of tumor recurrence,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8478,NCT03093116,Overall Response Rate (ORR) Phase 2,2017-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Intracranial objective response rate (Phase 2)
8479,NCT01243398,Overall survival,2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free survival
8480,NCT03177317,Complete response (CR),2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Complete protection (CP)
8481,NCT01607255,Number of Participants With Detected Proximal Diminutive (<10 mm) Adenoma Detection Rate,2013-05-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8482,NCT01876069,The rates of diagnostic sufficiency,2013-07,COMPLETED,INTERVENTIONAL,['NA'],Procedure related complications,The presence of histologic core
8483,NCT06326736,Incidence of Treatment Emergent Adverse Events (TEAEs),2024-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Disease control rate (DCR)
8484,NCT05495048,disease-free survival rate,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
8485,NCT04303286,Species differential analysis,2018-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8486,NCT06178211,pCR rate,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Potential biomarkers such as ctDNA or PD-L1 expression
8487,NCT02031536,Disease Free Survival (DFS),2014-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8488,NCT04177797,Complete pathologic response rate,2020-03-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
8489,NCT01686880,Peri-operative morbidity,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Contra-lateral Lobe Hypertrophy
8490,NCT05643989,Bowel preparation (absence of feaces) according to Boston Bowel Preparation Scale,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Late complications rate during resectional surgery
8491,NCT03415126,"Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer.",2018-01-19,COMPLETED,INTERVENTIONAL,['PHASE1'],Evaluate the change from baseline in the amount of circulating tumor DNA,Calculate the terminal elimination rate (T 1/2).
8492,NCT03205176,Incidence of dose-limiting toxicity (DLT).,2017-06-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clearance (CL).
8493,NCT05002452,Tumor Response,2021-12-20,RECRUITING,OBSERVATIONAL,['NA'],,Distant control
8494,NCT05519202,Pathological complete response(pCR),2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,tumor regression grade(TRG)
8495,NCT06307548,Changes in carcinoembryonic antigen (CEA) and circulating tumor deoxyribonucleic acid (ctDNA) (Phase II),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Correlation between disease free survival and changes in levels of ctDNA (Phase II)
8496,NCT02943265,Patient Perception of Care (Scale),2017-09-18,COMPLETED,INTERVENTIONAL,['NA'],,
8497,NCT02473094,Pathological Complete Response,2015-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life
8498,NCT06228599,Adverse Events,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
8499,NCT01399684,Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in ATAs Levels of MEGF0444A
8500,NCT04680104,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2015-11-03,COMPLETED,OBSERVATIONAL,['NA'],,economical impact
8501,NCT02002195,progression-free survival,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,time to treatment failure
8502,NCT02427841,R0 Resection Rate Defined as Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins by Pathologic Assessment,2016-01-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Defined as the Percent of Subjects With Complete or Partial Disease Response as Confirmed Through Tumor Imaging With Computed Tomography (CT)
8503,NCT05253846,complete pathologic response (pCR),2022-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation of FFS and pCR with ctDNA status,Rectal Continence
8504,NCT00408070,Progression Free Survival Rate at 9 Months,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine Tolerability to 12 Months (q 3 Weeks) of Bevacizumab Maintenance Therapy
8505,NCT05793554,Validation of tissue classification through fluorescence perfusion,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Usability of video sharing and annotation technology in multiple sites
8506,NCT05061537,Objective response rate in the dose expansion (Part 2) arms,2021-10-20,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (Part 2)
8507,NCT04874259,1 year patient survival,2022-08-22,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence
8508,NCT05103904,Overall response rate (ORR),2022-04-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response (DR)
8509,NCT04464668,Change in Colorectal Cancer Screening Rates - Repeat FIT,2020-06-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Differences in Screening Rates
8510,NCT02843217,"Colorectal Cancer Screening, beginning age 50",2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
8511,NCT01205022,Maximum tolerated dose of yttrium-90 (90Y) M5A anti-CEA antibody when given in combination with FOLFIRI chemotherapy and bevacizumab,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Estimation of radiation doses to whole body, normal organs, and tumor through serial nuclear imaging"
8512,NCT05448157,"To evaluate the diagnostic efficacy and the safety of the combined approach with β-probe and 68Ga-DOTA-TOC PET/CT in the correct identification of primary tumor and lymph node metastases, in patients with GEP-NETs candidates to surgery",2022-05-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
8513,NCT06154538,pCR rate,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],serious adverse event,OS
8514,NCT00780117,Annual lumbar-sacral MRI is performed,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,Annual serum alpha-foeto protein level monitoring
8515,NCT04250402,Number of gallstone patients,2020-02-14,RECRUITING,OBSERVATIONAL,['NA'],,"Number of physical regurgitation, nausea, vomiting, diarrhea, constipation"
8516,NCT06107920,the success of a full curative therapeutic,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life evaluated using EORTC QLQ-C30 and QLQ-CR29 dedicated to CRC
8517,NCT03357991,Determine the predictive value of HPV E6/E7 mRNA for the detection of HSIL and its ability to predict incident cases.,2015-01-11,UNKNOWN,OBSERVATIONAL,['NA'],,Cost-effectiveness analysis of an anal cancer screening strategy based on HPV E6/E7 mRNA analysis.
8518,NCT00578721,Rectal Tissue Putrescine Reduction,2008-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety/Toxicity
8519,NCT06141031,Phase 2: To assess pathologic response rate (R0 resection) for those who revert to resectable status,2024-01-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Assess quality of life associated with treatment protocol using EORTC QLQ-C30
8520,NCT06080204,Disease-free survival time,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival time
8521,NCT00045461,Quality of life,2000-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
8522,NCT04258969,Feasibility of Pedaling Concurrent to Chemotherapy Infusion,2020-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Symptom Severity
8523,NCT05339230,Incidence of diarrhoea CTCAEv5.0 ≥ grade 2.,2020-12-15,RECRUITING,INTERVENTIONAL,['NA'],Change in liver metastasis tumor blood flow.,Incidence of adverse events CTCAEv5.0 grade ≥ 3 considered probably related to investigational products/placebo.
8524,NCT02307539,Qualitative interview data,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,"Patient/family out of pocket expenses, as measured by the Finances and Out of Pocket Costs Tool"
8525,NCT00002455,Survival rate,1971-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8526,NCT05845294,Anxiety of patients was assessed by Hospital Anxiety and Depression Scale,2019-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
8527,NCT03164655,Curative-intent (R0-R1) resection (and/or ablation) rate (CRR) of CRLM,2018-07-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8528,NCT05879861,Status of frailty,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,
8529,NCT01538680,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8530,NCT05769959,Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs),2023-06-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Part 1, 2, 3: Overall survival (OS)"
8531,NCT04466267,The molecular mechanism of patients primary or secondary resistance to cetuximab,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
8532,NCT02017600,the R0 resection rate of participants,2013-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,1-year overall survival rate of participants
8533,NCT02674100,Adverse Events,2016-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
8534,NCT00637559,"To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.",2002-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period.
8535,NCT04821843,Overall survival,2002-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Radiomics analysis,Distant metastasis free survival
8536,NCT04161560,relative adverse drug reaction,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
8537,NCT05286814,Determine overall response rates,2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine hepatic progression-free survival (PFS)
8538,NCT03334708,Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer,2017-10-30,RECRUITING,OBSERVATIONAL,['NA'],,
8539,NCT01659502,Clinical Benefit Measurement,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
8540,NCT01722175,Liver free of tumors,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Liver synthetic and transport function
8541,NCT05232721,Diagnostic performance of advanced neoplasms,2022-02-20,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnostic performance of Colorectal Cancer
8542,NCT02229058,Progression-free survival,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate
8543,NCT04652440,Measure Tolerability,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Disease-free survival (mDFS)
8544,NCT04917289,Overall Survival,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse event
8545,NCT01895504,Cecal intubation rate,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Pain
8546,NCT00578279,The Change in Mean Pain Scale Rating in Patients Following Treatment With 10mL or 20mL of Alcohol Injection,2007-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8547,NCT05372198,Progression-Free Survival (PFS),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
8548,NCT03721744,Overall survival (OS),2018-10-25,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of Life (QoL)
8549,NCT01473940,Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the Maximum Tolerated Dose (MTD),2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recovery of Tumor Immune Surveillance: T-cell Response to Defined Pancreatic Cancer Tumor Antigens
8550,NCT01845337,The primary endpoint of the study will be a difference in the duration of ST deviation pre-treatment and during treatment.,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8551,NCT00154778,To evaluate the response rate,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine time to progression and safety
8552,NCT03563157,"Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1",2018-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component"
8553,NCT06218914,Adverse events and Serious adverse events,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Preliminary anti-tumor activity of NT-112 in subjects with unresectable, advanced, and/or metastatic solid tumors"
8554,NCT04628182,post-operative anastomotic leakages,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
8555,NCT05582109,Objective response rate,2022-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
8556,NCT03417570,Number of Participants Who Had a Diagnostic Yield Obtained,2017-12-22,TERMINATED,INTERVENTIONAL,['NA'],,Safety as Measured by Number of Participants With Procedure-related Adverse Events
8557,NCT03678428,Overall Response Rate and bilateral 95% confidence interval,2021-12-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Adverse events, servere adverse events and surgery-related adverse events rates"
8558,NCT05250895,To investigate the variability of hypoxia in HCC at baseline as quantified by immunohistochemistry,2022-04-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Treatment response
8559,NCT02372929,Evaluate the relationship between tightness of esophageal stricture encountered at endoscopy with cancer staging at EUS.,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,
8560,NCT00486460,,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8561,NCT02887599,Difference of the severity of the pancreatic cancer,2016-08-08,COMPLETED,INTERVENTIONAL,['NA'],,Correlation of the cytotoxic immune status
8562,NCT05036486,To perform large-scale NGS analysis for specific populations,2021-10-25,RECRUITING,OBSERVATIONAL,['NA'],,"To correlate the clinical characteristics, treatment and outcome of Biliary tract cancer with the genetic profile in Taiwan."
8563,NCT03856658,Hepatic progression-free survival,2019-02-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,EORTC Quality of Life Questionnaire
8564,NCT03471403,Number of serious and non-serious adverse events,2017-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Change in Spigelman stage
8565,NCT02589483,"Evidence of clinical anastomotic leak( elevated C reactive protein and white blood corpuscles, fever, nausea). Suspicion of a leak will be investigated with a Ct scan.",2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8566,NCT02789371,the overall diagnostic accuracy of modified wet suction technique and 5ml dry suction technique to the solid occupying lesions,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Blood contamination and cellularity in specimens obtained by modified wet suction technique and 5ml dry suction technique
8567,NCT03231722,Overall response rate,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE3'],,R0 Resection Rate
8568,NCT05691491,Dose limiting toxicity and the maximum tolerated dose,2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of >= grade 3 adverse events (AE)
8569,NCT01138904,Response rate by RECIST,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
8570,NCT00647530,Pathological down-staging as measured by depth of extramural spread among patients allocated to preoperative chemotherapy with or without panitumumab,2008-05-15,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events
8571,NCT03171389,clinical benefit rate (CBR),2017-03-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Fatigue assessment
8572,NCT01923233,Safety,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Anti-Tumor Response
8573,NCT05591534,Tolerance,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgical morbidity for recurrence
8574,NCT00533078,efficacy of an omega-3 PUFA containing lipid emulsion in reducing the incidence of °3-4 colitis (CTC AE v3.0),2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8575,NCT00777478,Maximum Tolerated Dose,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,determine the safety and toxicity profile using the CTCAE criteria.
8576,NCT00898287,To determine the maximum tolerated dose (MTD) of P276-00 administered along with Gemcitabine.,2009-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To characterize toxicities of P276-00 in combination with Gemcitabine.
8577,NCT03914352,Disease-free survival,2019-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8578,NCT02321202,hospital stay (time of hospital stay after surgery),2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,mortality
8579,NCT00287755,Overall survival rate,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Side effect
8580,NCT05734300,Change in patient-reported postoperative recovery - Quality of Recovery 15,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Rate of secondary standard resection
8581,NCT05706558,. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery),2016-12-13,RECRUITING,OBSERVATIONAL,['NA'],,"Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy)."
8582,NCT01405573,overall survival,2011-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,progression free survival
8583,NCT00004136,Efficacy of Radiofrequency Ablation in Patients with Primary or Metastatic Liver Cancer,1998-03-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8584,NCT02117557,Early morbidity rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Inflammatory and immune response
8585,NCT05384184,Build the next generation biobank of liver-derived organoids,2019-06-06,RECRUITING,OBSERVATIONAL,['NA'],,Evaluate the clinical relevance of the generated organoids
8586,NCT01754623,Margin-negative (R0) Resection Rate,2013-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS) Rate
8587,NCT02192671,Hospital mortality,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence rate
8588,NCT06290505,Progression free survival rate is the proportion of patients alive and progression free (the cancer has not worsened) assessed by CT Scan and clinical review.,2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival.
8589,NCT03920202,Bowel function assessment using Low anterior resection syndrome questionnaire,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors: preoperative chemoradiotherapy
8590,NCT04903548,SPECT CT,2021-04-20,RECRUITING,OBSERVATIONAL,['NA'],,
8591,NCT01341197,Important Lower and Upper GI tract Lesions,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
8592,NCT04379830,Change in Mesorectal Fat Volume (efficacy),2022-08-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Intraoperative Adverse Events
8593,NCT03215017,"Bowel function, Low anterior resection syndrome (LARS)",2017-05-15,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
8594,NCT03086993,Overall Survival,2018-04-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Incidence of Treatment-Emergent Adverse Events (Safety),Objective response rate (CR + PR) as determined by the Investigator
8595,NCT03974984,Changes in neutrophil to lymphocyte ratio from preoperatively to day 1 postoperatively,2020-06-04,WITHDRAWN,OBSERVATIONAL,['NA'],,Changes in quality of recovery-15 score from preoperatively to day 1 postoperatively.
8596,NCT00006094,Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0,2000-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8597,NCT00381862,Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy.,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With no Emesis and no Rescue Therapy Within 5 Days of the First Course of Chemotherapy
8598,NCT03550482,Quality of life improvement,2017-11-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Nutritional level
8599,NCT01428141,Determination of the maximum tolerated dose (MTD),2011-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8600,NCT03827044,Primary End point: Disease Free survival,2018-08-31,TERMINATED,INTERVENTIONAL,['PHASE3'],,Secondary End Points: Toxicity of Investigational Medicinal Product according to the NCI-CTCAE (Common Terminology Criteria for Adverse Events) version 4.0.
8601,NCT02678806,overall survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,
8602,NCT05265169,Local tumor progression free survival at 24 months,2023-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of subjects with CTCAE grade 3 events or greater within 90 days after MWA
8603,NCT03083613,Objective Response Rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
8604,NCT05074966,median PFS,2021-09-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall Survival OS
8605,NCT01291823,Tumor response rate,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.)
8606,NCT04770207,Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
8607,NCT04164797,progression-free survival(PFS),2019-11-25,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
8608,NCT00892255,Measure of the tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System,2009-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
8609,NCT04298021,Disease control rate of AZD6738 + Olaparib cohort,2020-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life measurement of AZD6738 + Olaparib cohort
8610,NCT04662853,Gut-microbiota-based color-rectal cancer diagnosis.,2017-01-17,UNKNOWN,OBSERVATIONAL,['NA'],,Dietary habits
8611,NCT01791374,Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival."
8612,NCT01686412,Autonomic response monitoring (blood pressure digital and manual monitoring),2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Baroreflex sensitivity (by the method of sequence)
8613,NCT05875558,ORR,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,OS
8614,NCT04573738,The distant metastasis rates of rectal cancer,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
8615,NCT06271629,Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS).,2022-02-26,COMPLETED,OBSERVATIONAL,['NA'],,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29)
8616,NCT01681368,Objective Response (Complete Response (CR) or Partial Response (PR) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria) or Disease Stabilization for Greater Than 6 Months,2012-08-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Total Clearance of Birinapant After Administration
8617,NCT05001321,Texture of nuclei,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Recurrence/metastasis
8618,NCT01657695,Survival,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,Response to therapy
8619,NCT00069953,Overall Survival (1-year Rate Reported),2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection
8620,NCT06016725,Physical function,2023-08-28,RECRUITING,INTERVENTIONAL,['NA'],,Anthropometry measuring waist circumference in centimeters
8621,NCT05412628,To analyze the similarity of microbiota distribution between the buccal field and the esophageal area in the same patient,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],,To analyze the distribution difference of microbiota among the patients with esophageal cancer/oropharyngeal cancer and non-cancer control
8622,NCT05217446,Progression-free Survival (PFS),2022-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Objective Response (OR)
8623,NCT02343692,Presence of pancreatic cyst,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Preliminary health economics analysis from questionnaires and cost diaries (Self-completed EQ-5D-5L questionnaire and cost diary.)
8624,NCT04098081,response rate,2019-12-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
8625,NCT01358812,Response Rate,2010-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Analyses of Potential Predictive Factors
8626,NCT00226811,Objective Response (Complete Response (CR) or Partial Response (PR)),2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
8627,NCT01996306,Overall survival,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Correlation between UGT1A1 genotype and safety
8628,NCT04461275,Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.,2020-06-19,COMPLETED,INTERVENTIONAL,['NA'],• Groningen Frailty Index (GFI),• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.
8629,NCT04588051,Median Progression-free survival (PFS),2020-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of adverse events according to CTCAE v5.0
8630,NCT00828672,"Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.",2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Death Rates and Overall Survival
8631,NCT04669951,Tumor-to-background ratio,2019-11-18,COMPLETED,INTERVENTIONAL,['NA'],,uPAR in patient groups
8632,NCT00609622,Progression-free Survival (PFS),2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Functional Assessment of Cancer Treatment - Gynecologic Oncology Group Oxaliplatin-Specific Neurotoxicity (FACT&GOG-Ntx) Score
8633,NCT02970136,Percentage of Participants Who Are Screened for All Conditions,2017-04-11,COMPLETED,INTERVENTIONAL,['NA'],,Median Number of Screenings Completed
8634,NCT00004099,,1999-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
8635,NCT04454151,Evaluation of changes in size of adenomas measured by upper endoscopy,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Evaluation of changes in size of desmoid tumors,Evaluation of changes in size of adenomas measured by lower endoscopy
8636,NCT05081024,Complete clinical response (cCR),2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],Specificity,Overall survival
8637,NCT05268549,"The first recurrence of colorectal cancer with liver metastasis (CRLM) after radiofrequency/microwave ablation, assessed up to 18 months",2022-03-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Patients with colorectal cancer with liver metastases (CRLM) developed new metastases after radiofrequency/microwave ablation,assessed up to 18 months"
8638,NCT01392352,Change in endothelial dependent function,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in endothelial independent function
8639,NCT01631539,Feasibility of chemoembolization with DC Bead loaded with Irinotecan,2012-09,WITHDRAWN,INTERVENTIONAL,['NA'],,progression-free survival
8640,NCT03195699,Pharmacokinetics - AUC(0-t),2017-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Assess the bioavailability between different formulations of TTI-101,Best Overall Response
8641,NCT06109779,Recurrence free survival (RFS) for Arm A vs. Arm B,2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE3'],Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.,Overall Survival (OS) for Arm A vs. Arm B
8642,NCT05343832,Plasma samples of patients with and without HCC to evaluate test performance(accuracy) of the kit. diagnostic(sensitivity and specificity) of the kit.,2021-11-29,UNKNOWN,OBSERVATIONAL,['NA'],,
8643,NCT06008522,Number of Adverse Device-related Events (ADEs) and Serious Adverse Device-related Events (SADEs) using immuno-OCT,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,validation of OCT system: immunohistochemistry
8644,NCT05975593,Changes in tumor microenvironment,2023-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
8645,NCT05141643,Tumor drug uptake within PDAC tumors prior at pre-treatment baseline,2021-11-18,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,changes in [18F]-FAC drug uptake during or following SOC chemo- and/or radiation therapy.
8646,NCT04602013,PFS,2020-10-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,HRQoL
8647,NCT02721550,pathologic Complete Response,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Disease-Free Survival
8648,NCT00491140,Association of different biomarkers with Cetuximab sensitivity,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,Association of different biomarkers with time to progression and survival
8649,NCT01970722,Incidence of treatment-related toxicities according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) guidelines,2014-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
8650,NCT00440817,Occurrence of lymphoma,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of association of Epstein-Barr Virus (EBV) with the lymphoma
8651,NCT03936530,metastasis rate,2019-10-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,3-year DFS
8652,NCT04144751,Blood-based biomarkers associated with genetic and epigenetic alterations.,2019-11-15,COMPLETED,OBSERVATIONAL,['NA'],,
8653,NCT04348643,Adverse events that related to treatment,2020-02-20,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Levels of CRP in Serum
8654,NCT00867113,Kaplan-Meier Estimates for Recurrence-free Survival up to 60 Months,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months
8655,NCT01364454,Patient's participation to colorectal cancer screening program,2010-06,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
8656,NCT04373928,OS,2017-11-10,RECRUITING,INTERVENTIONAL,['NA'],,DFS
8657,NCT01739608,Participation rate to FS and CT Colonography,2013-12,COMPLETED,INTERVENTIONAL,['NA'],,Type of false positive detections of Computer-aided detection for CTC in a CRC screening program
8658,NCT02512224,Mortality Calculated From Outcome Section From DPC Database at 90 Days,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Mortality Calculated From Outcome Section From DPC Database at 30 Days
8659,NCT05520619,Progression-free survival,2022-09-15,RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor mutational burden at baseline,Treatment-related adverse events
8660,NCT02259725,PFS,2016-08-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Biomarkers Such as Messenger Ribonucleic Acid (mRNA) Levels or Germline Variations of Genes Related to Angiogenesis,"Incidence of Adverse Events, Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0"
8661,NCT03487939,The ratio of tumor downstaging to stage 0 and stage I,2018-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
8662,NCT05161143,1 year RFS rate,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AFP
8663,NCT00643682,Boston Bowel Preparation Scale Score,2006-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of Repeat Procedures Recommended Due to Inadequate Bowel Preparation.
8664,NCT05879172,success rate of anastomosis,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],,time period of recovery
8665,NCT04820179,Overall Response Rate or Stable Disease,2021-10-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,T2 Signal
8666,NCT04313114,CRC Screening,2021-09-20,RECRUITING,INTERVENTIONAL,['NA'],,
8667,NCT00970138,Progression free survival,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity
8668,NCT05867966,Change in emotional distress,2024-01-16,RECRUITING,INTERVENTIONAL,['NA'],,Change in perception about their fatigue
8669,NCT02376543,Total Time Comparison,2015-03-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Complication Comparison
8670,NCT04683783,Percentage of patients who complete the entire cycle,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Morbidity rate
8671,NCT00006155,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8672,NCT06112704,Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.,2024-02-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess the incidence of anti-drug antibodies (ADAs)
8673,NCT02905578,Overall survival,2018-11-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event frequency and categorization
8674,NCT00039078,Adverse experiences,2000-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8675,NCT02332551,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Progress free survival(PFS),Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.
8676,NCT00982618,Postoperative functional recovery,2009-07,COMPLETED,INTERVENTIONAL,['NA'],,opioid side effects
8677,NCT03727126,Lymph node yield,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Conversion rate
8678,NCT05863052,Treatment related Adverse Events,2022-01-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Demographic differences,Difference in cancer related mortality
8679,NCT00035087,Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST),2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8680,NCT04479111,1-year local recurrence,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,3-year disease free survival
8681,NCT02711969,Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer,2016-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Duration of Response(Stable disease, partial response or Complete response)"
8682,NCT04090164,Prevalence of HCV Seropositivity in Breast Cancer Patients.,2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-related Events
8683,NCT05493930,diagnosis of lymph node metastasis,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8684,NCT04163627,Technical procedures evolutiveness,2019-11-30,UNKNOWN,OBSERVATIONAL,['NA'],,Regional disparities
8685,NCT05014737,postoperative nausea and vomiting,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
8686,NCT06079554,Metabolomics results of lesions and atrophic gastritis.,2023-10-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],endoscopic observation,microbiomics of lesions and atrophic gastritis.
8687,NCT00101894,"Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen",2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706
8688,NCT05760391,OS from start of 1st line treatment in metastatic ESCC,2023-02-28,RECRUITING,INTERVENTIONAL,['NA'],,Disease control rate
8689,NCT05671822,Phase II: Objective Response Rate (ORR)[,2023-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Occurrence of adverse events (AEs), and serious adverse events (SAEs) （Phase II）"
8690,NCT05877352,Availability of potential primary outcome data,2022-05-18,RECRUITING,INTERVENTIONAL,['NA'],,Resource use and cost
8691,NCT04420013,Plasma CD154 level dosage,2020-09,UNKNOWN,OBSERVATIONAL,['NA'],,Clinical evolution parameters
8692,NCT02945267,TTP,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Adverse Events
8693,NCT04137289,"Phase Ib - Progression-free survival (PFS) is defined as the time from first treatment administration until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.",2020-03-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase Ib - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma
8694,NCT05629845,90-day death adjusted cumulative incidence of variceal rebleeding after secondary prevention by EUS-guided therapy or conventional endoscopic therapy,2022-11-22,RECRUITING,INTERVENTIONAL,['NA'],,procedure related adverse events within 30 days of secondary prevention
8695,NCT01175733,Phase II: safety and tolerability,2010-07-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time-to-progression (TTP) and overall survival
8696,NCT03815461,PFS,2019-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse reaction rate
8697,NCT00096083,To determine the response rate and duration of response to intra-hepatic infusion of melphalan with subsequent venous hemofiltration in patients with primary and metastatic hepatic malignancies,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the progression free and overall survival in patients with hepatic malignancies following this therapy
8698,NCT00494611,Safety of peri operative Cetuximab.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8699,NCT04273451,The prediction accuracy of the radiopathomics artificial intelligence model,2020-01-10,UNKNOWN,OBSERVATIONAL,['NA'],,The F1 score of the radiopathomics artificial intelligence model
8700,NCT03355495,Decrease in Cecal Intubation Time,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Increase in Adenoma Detection Rate
8701,NCT01171300,Pathologic complete response (ypT0N0) rate,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of mesorectal excision.
8702,NCT00582829,Phone follow-up interview. Participants will be contacted by study assistant and the survey administered.,2003-06,COMPLETED,OBSERVATIONAL,['NA'],,
8703,NCT02032368,Change of circulating tumor cell(CTC) count at different timepoints,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,
8704,NCT01623206,"Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.",2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of patients with partial or complete response in clinical endpoints
8705,NCT01262183,1-year overall survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,CTCs and CECs
8706,NCT00233935,Toxicity defined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (Version 3.0),2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose-related biologic effects and pharmacodynamic properties of Poly E
8707,NCT00807313,Metabolic complete remission rate,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,Late toxicity
8708,NCT01186263,Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events as elicited upon indirect questioning.
8709,NCT02074046,The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
8710,NCT00093652,Response (phase II),2003-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Immunohistochemistry
8711,NCT05839470,Overall Response Rate (ORR),2023-11-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
8712,NCT01665937,Phase 2 dose of STA 9090 given once weekly in patients with advanced hepatocellular carcinoma,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
8713,NCT04654247,Gastric precancerous detection rate,2019-04-20,COMPLETED,INTERVENTIONAL,['NA'],,Adcanced ADR
8714,NCT01605318,Percentage of Participants With Laboratory Abnormalities,2013-02-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change from Baseline in Carcinoembryonic Antigen (CEA) Serum Levels
8715,NCT01831609,Biomarker analyses to predict treatment response in metastatic cancer,2011-08-31,RECRUITING,OBSERVATIONAL,['NA'],,
8716,NCT01035008,"Differentiate between non-mucinous, mucinous non-malignant & malignant pancreatic cysts in vivo",2009-12,COMPLETED,INTERVENTIONAL,['NA'],,
8717,NCT02633436,optical density (ODs) of each slice by immunohistochemistry assay,2015-12,UNKNOWN,OBSERVATIONAL,['NA'],,SLC1A5 expression detected by WesternBlot
8718,NCT00081536,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
8719,NCT03143270,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
8720,NCT00979680,Sphincter preservation rate,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
8721,NCT01515046,Overall Survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Ascorbate Levels
8722,NCT00006368,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8723,NCT04296240,pathologic complete response rate,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity of neoadjuvant chemotherapy
8724,NCT00385970,3-Year recurrence-free survival rate,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"5-Year survival rate, incidence of adverse events, treatment compliance, QOL, type of metastasis/recurrence, and 3-year and 5-year recurrence-free survival rates and survival rates based on each parameter including colon/rectum, stage, and IAP."
8725,NCT00118105,Correlation of clinical outcome with expression of biomarkers and telomere length,2006-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
8726,NCT03335813,Percent Volume of the Tumor Receiving the Prescription Dose (V100),2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With the Need for Dilation
8727,NCT00866957,HIF-1alpha bio-marker,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Understand biological behavior of the tumors
8728,NCT01454180,Overall survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8729,NCT05143619,Teaching rates of the hepatocellular carcinoma diagnosis guidelines,2019-05-10,RECRUITING,OBSERVATIONAL,['NA'],,
8730,NCT03387098,Objective response rate by RECIST,2018-01-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03."
8731,NCT02942238,Disease-free survival,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,The accuracy of preoperative staging with CT
8732,NCT02514551,Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ,2015-10-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Anti-Ramucirumab Antibodies
8733,NCT03603756,objective response rate,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,treatment-related adverse events
8734,NCT00816491,"The primary endpoint of the study will be to compare the accuracy of two procedures (FICE with target biopsies only, versus conventional white light colonoscopy)",2008-10,COMPLETED,INTERVENTIONAL,['NA'],,To quantify the number of true positive and false positive lesions by comparing the number of targeted biopsies performed for suspicious lesions and the resulting histological findings.
8735,NCT01477190,postoperative pain,2010-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,opioid side effects
8736,NCT02773459,Progression-free survival (PFS),2016-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
8737,NCT02894775,Number of participants included in a clinical trial,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
8738,NCT01515787,DFS,2012-06-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Neoadjuvant Rectal Score
8739,NCT00500968,Drain fluid content analyses,2006-11,COMPLETED,INTERVENTIONAL,['NA'],,"Co-variables measured in the form of: operation time, complications in relation to diagnosis, duration of hospitalization and cost. Patients receiving a pancreas stent are followed in order to evaluate the natural course of the pancreas stent"
8740,NCT00955721,Phase II: Obtain an Estimate of the 9-month Progression-free Survival Rate in Patients With Advanced BTC Receiving the RPTD of the Combination Sorafenib and GEMOX.,2009-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Explore Biomarkers of Response to the Combination
8741,NCT03510858,Proportion of patients which have been tested for CRC,2018-03-14,UNKNOWN,INTERVENTIONAL,['NA'],,Intention to prescribe colonoscopy vs. FIT within the next 6 months
8742,NCT05177068,Surgical complete resection rate (R0),2022-05-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event (AEs)
8743,NCT05291728,the detection rate of early gastric cancer,2020-10-01,RECRUITING,OBSERVATIONAL,['NA'],,"the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of Shaanxi Province, as well as the prevalence of helicobacter pylori infection, radical treatment and recurrence rate."
8744,NCT05740189,Safety: Incidence of Dose-related SAEs,2023-02-19,RECRUITING,INTERVENTIONAL,['NA'],,BE regression
8745,NCT01997684,Rates of primary colorectal anastomosis,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],Clinical success,Recurrence of colorectal cancer
8746,NCT01485744,Toxicity,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response Rate
8747,NCT00363584,Survival at 2 years,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health economics
8748,NCT05129046,DFS,2021-11-15,UNKNOWN,OBSERVATIONAL,['NA'],,Surgical Outcomes
8749,NCT05307835,Relapse Free Survival Rate,2021-12-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,EORTC QLQ-C30 (version 3)
8750,NCT00296608,,1993-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8751,NCT05471674,Pathological tumour response rate,2020-07-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory analyses,Safety and tolerability of nivolumab
8752,NCT00254683,PET/CT specificity and sensitivity for tumor response,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between PET/CT and complete clinical Response
8753,NCT03634982,Number of participants with dose limiting toxicities (DLTs),2018-09-28,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
8754,NCT01557101,Participation to colorectal cancer screening in first-degree relatives of patients with colorectal cancer,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8755,NCT00091078,"Toxicity defined as any of the following events: regimen-related death, transaminitis, infection, or leukopenia grade 3 or higher using NCI CTCAE version 3.0",2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
8756,NCT05463796,"Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.",2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],,
8757,NCT05425472,Objective response rate,2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,ECOG Score for performance status
8758,NCT05491616,Disease Free survival 18 months,2022-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival at 2 years
8759,NCT02520154,Progression-free survival,2016-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in biomarker expression level,Overall survival
8760,NCT01747707,overall survival time (OS),2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety profile
8761,NCT05300269,Percentage of participants with Pathological complete response ( pCR ),2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival ( DFS )
8762,NCT03821545,Concentration of inflammatory markers,2019-01-28,COMPLETED,INTERVENTIONAL,['NA'],,Length of hospital stay
8763,NCT03236883,Survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Karnofsky Performance Status（KPS）
8764,NCT01035398,Analyses of dietary factors and Helicobacter pylori infection (previous vs current),2000-04,UNKNOWN,OBSERVATIONAL,['NA'],,
8765,NCT01121939,Objective Response Rate (ORR),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
8766,NCT05068180,Incidences of POD after general anesthesia in elderly patients undergoing non-cardiac major surgery,2021-10-05,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Duration of postoperative delirium
8767,NCT06207981,Disease-related event free survival (DREFS) at 2 years,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
8768,NCT05029973,Overall response rate ( ORR),2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
8769,NCT00468455,Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients,2005-10,COMPLETED,OBSERVATIONAL,['NA'],,
8770,NCT04542291,Tolerability as Measured by Number of Participants With Related Adverse Events,2021-02-25,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in Tumor Necrosis
8771,NCT01234051,Response rate,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
8772,NCT02365662,Recommended Phase 2 dose of ABBV-221,2015-01-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR)
8773,NCT04014465,progression free survival,2019-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse Events
8774,NCT03193814,Progression-free Survival (PFS) Time,2019-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8775,NCT03960008,To compare the duration of disease control in treated lesions when utilizing SBRT versus TACE as a bridging strategy for patients with HCC eligible for liver transplantation,2020-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,To assess 90 day Post-transplant mortality
8776,NCT04170556,Incidence of Treatment-Emergent Adverse Events,2020-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum and tissue marker characterization
8777,NCT00839111,"Progression-Free Survival (PFS) ,defined as the time from treatment to disease progression or death due to any cause",2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Secondary endpoints are disease control rate, defined as a complete response, partial response, and stable disease; Response rate and overall survival; and safety are also evaluated."
8778,NCT03527784,Incidence of parastomal hernia,2018-05-03,TERMINATED,INTERVENTIONAL,['NA'],,Quality of Life measured by RAND 36
8779,NCT04413526,The survival rates for one-year to five-year,2020-05-25,COMPLETED,OBSERVATIONAL,['NA'],,The Child-Pugh score after therapy
8780,NCT02407119,Incidence of metachronous gastric cancer,2003-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival
8781,NCT00576056,Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Determine the Overall Survival in Patients Treated With This Combination Regimen
8782,NCT02571374,Number of participants with colorectal cancer on symbiotic to prevent postoperative infection,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,
8783,NCT04890015,Anastomotic leakage rate between treatment arms,2017-07-10,UNKNOWN,INTERVENTIONAL,['NA'],,Definitive and / or temporary stoma rate after anastomotic leakage
8784,NCT04795063,Morbidity rates,2021-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time of digestive tract reconstruction
8785,NCT04685759,Proportion of patients with a primary GI tumor who complete neoadjuvant treatment and are cleared for surgical resection,2022-04,WITHDRAWN,INTERVENTIONAL,['NA'],Mean total Patient Satisfaction score of In-Person Exercise Therapy,Change in quality of life assessment
8786,NCT04883775,Biodistribution of MVT-2163,2021-05-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8787,NCT01141114,completion of colorectal cancer screening,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of detection of polyps and cancers in intervention vs. control groups
8788,NCT06195254,progression-free survival (PFS),2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Pain relief rate (PRR）
8789,NCT03884400,Distribution of Biospecimens From Biorepositories/Biobanks for Research Use,2021-01-01,WITHDRAWN,OBSERVATIONAL,['NA'],,
8790,NCT00039273,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8791,NCT05494658,The proportion of postoperative blood glucose>8mmol/L,2022-08-26,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative hospital stay
8792,NCT03520283,Retention Rate,2018-05-29,COMPLETED,INTERVENTIONAL,['NA'],,Qualitative Assessment of Changes in Outcomes With Semi-structured Interviews
8793,NCT04036643,Tumor response assessed by modified the Ryan tumor regression grading system obtained by quantification of the residual cancer cells compared to fibrosis on the surgical specimen,2019-11-27,UNKNOWN,INTERVENTIONAL,['NA'],,Calculation of the Net Reclassification Index (NRI) by comparing the sensitivity of [18F] -FDG-PET / MRI and the sensitivity of MRI alone for TRG1
8794,NCT04878783,Predictive performance of radiomics analysis on the pre-treatment CT scan.,2019-12-20,UNKNOWN,OBSERVATIONAL,['NA'],,Association between radiomics and molecular expression in regards to long-term outcomes
8795,NCT05595473,Number of participants with adverse events (AEs) in part 1 and 2 as graded by NCI-CTCAE,2022-07-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine safety and efficacy of RZ-001 by changes in overall survival (OS) of the partipants in Part 1 as graded by RECIST v1.1 and mRECIST
8796,NCT00926536,"Cumulative Dose (CD), a Measure of Radiation Dose",2009-04,COMPLETED,INTERVENTIONAL,['NA'],,
8797,NCT00868816,disease-free survival,2005-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,overall survival liver metastasis-free survival
8798,NCT01283906,To evaluate the efficacy of MuGard on reducing the symptoms of oral mucositis using an Oral Mucositis Daily Questionnaire (OMDQ),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,To evaluate the efficacy of MuGard on delaying the onset of oral mucositis symptoms and reducing the impact on health and resource outcomes.
8799,NCT02221245,"Percentage of samples with identifiable Notch, Wnt and Hedghog pathways in the chemo naive esophageal tumor as well as in cancer stem cell populations (CSC).",2013-04-05,TERMINATED,OBSERVATIONAL,['NA'],,
8800,NCT01056796,"To evaluate for the occurrence of adverse events related to the use of the CAR™ 27 device, include anastomotic leak, bleeding, ring evacuation and strictures at 6 months.",2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Evaluation of the creation of a functioning CAR™ 27 anastomosis in radiated patients
8801,NCT04057365,Overall Response Rate,2019-10-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
8802,NCT05576896,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
8803,NCT05941481,pathological complete remission (pCR) rate,2023-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8804,NCT04168346,The need for blood transfusion,2019-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Use of IV iron after operation
8805,NCT06205862,CRA recurrence rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in intestinal mucosal microbiota Pre- and Post-FMT
8806,NCT04006600,Persistence of a stomy 2 years after rectal surgery when stoma was primarily intended to be temporary,2018-03-16,COMPLETED,OBSERVATIONAL,['NA'],,
8807,NCT02351765,Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Exploration of the pharmacokinetic profile for the combination of Acelarin with Cisplatin
8808,NCT01950442,Safety of gentle dilation,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,impact on staging
8809,NCT02648880,Change in 400-meter Walk Time,2016-05-10,COMPLETED,INTERVENTIONAL,['NA'],,Determination of Hospital Readmission
8810,NCT00027638,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8811,NCT02747862,Chart Review of Outcomes of Participants with Attenuated Familial Adenomatous Polyposis (AFAP) and Deleterious Familial Adenomatous Polyposis (FAP) Undergoing Endoscopic Surveillance,2008-02,COMPLETED,OBSERVATIONAL,['NA'],,
8812,NCT01744821,Other Surrogate Endpoint Biomarkers Markers of Cancer Prevention,2012-10,TERMINATED,INTERVENTIONAL,['NA'],,Review of the Differences in the Types and Incidence of Toxicities Associated With Vitamin D3 Replacement.
8813,NCT02110329,Recurence rate according to molecular results,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Survival rate according to molecular results
8814,NCT02713386,Progression-free survival (PFS) (Phase II),2016-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in serum C-reactive protein (CRP),Overall survival (OS) (Phase II)
8815,NCT02226380,The 3-year overall survival rate in patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],The R0 resection rate in the patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,The 3-year disease-free survival rate in the patients who will receive mFOLFOX6 regimen neoadjuvant chemotherapy regimen
8816,NCT05807776,MPR rate,2023-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE and SAE
8817,NCT03203005,Immunogenicity (T-cell response in peripheral blood),2017-09-18,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
8818,NCT02559024,Immune Score,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE1'],,
8819,NCT00856115,Factors that influence appraisal and diagnostic delay,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
8820,NCT04792515,pathologic complete response (PCR),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Percentage of Progression-free survival (1-PFSR)
8821,NCT02269995,Safety and Tolerability as measured by Adverse Events,2014-03-06,COMPLETED,OBSERVATIONAL,['NA'],,Efficacy of DC bead as assessed by embolic performance
8822,NCT00109954,Toxicity as measured by NCI CTCAE version 3.0,2005-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
8823,NCT04080414,Feasibility of home-based high-intensity interval training among colorectal cancer survivors,2019-08-02,COMPLETED,INTERVENTIONAL,['NA'],,
8824,NCT02723604,Number of Participants With Severe World Health Organization [WHO] (Grade 3-4) Oral Mucositis in Patients Treated to a Cumulative Radiation Dose of at Least 5000 cGy,2016-03,COMPLETED,INTERVENTIONAL,['NA'],Time to Reach Planned Dose of Radiation Therapy,Time to Onset of Severe (CTCAE v. 4.0 Grade 3-4) Oral Mucositis Following the Initiation of Radiotherapy
8825,NCT04091620,Incidence rate of achieving a composite of pathologic endpoint indicating adequate surgical resection,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Direct/indirect medical costs and out-of-hospital economic costs
8826,NCT02216110,Patient's death,2003-05,COMPLETED,OBSERVATIONAL,['NA'],,Development of metachronous cancers
8827,NCT02101099,Peak push force is increased in patients receiving propofol as compared to conscious sedation.,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
8828,NCT05438108,AEs,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8829,NCT05660213,ORR,2024-01-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Incidence and severity of adverse events of special interest (AESI)
8830,NCT03557216,Presence of ACN,2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Fecal calprotectin test predictive value for ANC detection
8831,NCT00479752,"The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria",2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety
8832,NCT04478929,gastroscopy image data set,2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,
8833,NCT01053923,Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI,2009-12,WITHDRAWN,OBSERVATIONAL,['NA'],,Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI
8834,NCT05787535,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of TCR T cells in-vivo persistence
8835,NCT03129139,Anti-tumor activity,2017-10-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
8836,NCT05990231,Objective response rate,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
8837,NCT03035136,Adenoma detection rate,2017-01-15,COMPLETED,OBSERVATIONAL,['NA'],,Polyp detection rate
8838,NCT02409186,Over Survival,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
8839,NCT02570516,Number of adenomas and / or adenocarcinoma detected during each procedure (NBI vs Indigo carmine),2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of subject with adverse events as mesure of safety.
8840,NCT05146297,Change in Clinical Trial Accrual,2022-12-24,RECRUITING,INTERVENTIONAL,['NA'],,Physician Post -intervention survey
8841,NCT02293850,"Evaluation of safety parameters (adverse events, laboratory data, EKG, body weight, vital signs) on patient-base.",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Dose-Limiting Toxicity (DLT) for patients using OBP-301.
8842,NCT03428529,Clinical downstaging,2011-01-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Pathological downstaging
8843,NCT01561014,Toxicity rate of combination chemotherapy followed by surgery and erlotinib hydrochloride,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Test the predictive value of FDG-PET-CT imaging in identifying patients who will have a complete response
8844,NCT04686747,"Rate of advanced Esophageal, Gastric, Pancreatic and Colorectal cancer in 2020 compared to 2019.",2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of patient unable to performer adjuvant treatment in 2020 compared to 2019
8845,NCT02823691,incidence of SAEs and AEs,2016-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,biochemical responses to Lanreotide ATG 120 mg in combination with Metformin
8846,NCT04770623,Overall response rate (ORR),2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8847,NCT03241680,Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III),2017-08-02,UNKNOWN,INTERVENTIONAL,['NA'],,
8848,NCT04843397,Define the prevalence of pre-malignant upper GI tract lesions as measured by standardised endoscopy and biopsy protocol,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between life-style factors and pathological outcomes
8849,NCT03801668,Progression-free Survival (PFS),2019-03-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety as measured by number and grade of adverse events
8850,NCT01233544,Local progression-free survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Quality of life
8851,NCT00536770,Overall survival rate at 6 months,2007-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Duration of overall survival
8852,NCT03540953,dysphagia,2015-01-05,TERMINATED,INTERVENTIONAL,['NA'],,number of sessions of endoscopic dilations
8853,NCT00057876,Overall Survival Time,2003-08-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Response
8854,NCT05555901,Progression-Free Survival (PFS),2023-06-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
8855,NCT04232748,Overall survival,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Chemotherapy interruption
8856,NCT05013125,Adenoma missed rate,2021-08-09,UNKNOWN,INTERVENTIONAL,['NA'],,Number of CAD assisted abnormality
8857,NCT05928897,ORR,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
8858,NCT01051596,Percent of Patients With Disease Control,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percent of Patients With an Objective Response
8859,NCT01348256,Progression Free survival,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
8860,NCT00006786,,2000-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8861,NCT04677998,Advanced neoplasia,2020-11-24,RECRUITING,OBSERVATIONAL,['NA'],,Surgery
8862,NCT00954655,response,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
8863,NCT06334926,overall survival,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
8864,NCT00521404,Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer,2007-08-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to Gemcitabine Experienced by ≥5% of Participants by System Organ Class and Preferred Term
8865,NCT06043921,Cohort of patients with resectable pancreatic cancer; Success rate of WES assays and selections of personalized genes using tumor tissue specimens obtained by EUS-FNA/FNB,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Cohort of patients with resectable pancreatic cancer; to investigate the lead time of ctDNA detection of recurrence before detection of recurrence via imaging methods
8866,NCT02564835,Program Evaluation,2015-09,COMPLETED,INTERVENTIONAL,['NA'],Beliefs about Treatment,Pro-inflammatory Markers
8867,NCT01023984,Incidence of recurrence at 12 months,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Number of days not spent in hospital from initial treatment until 2 years afterwards
8868,NCT03732508,Duration of Progression-Free Survival (PFS),2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events(AE)
8869,NCT01356030,Direct comparison of tissue sampling techniques for patients with suspected pancreaticobiliary cancers.,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,
8870,NCT02595320,Twelve-week Progression Free Survival (cohort 1 only),2015-10-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],Objective response rate (cohorts 1 and 2),Grade 3 or higher toxicity (cohorts 1 and 2)
8871,NCT02707159,Change in levels of circulating tumor cells (CTCs) during treatment,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in quality of life during treatment
8872,NCT03783156,Number of participants with presence of adenomatous tissue al the base of polypectomy,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with Postpolypectomy Complications
8873,NCT05379907,Impact of SIGNATERA™ on treatment decisions,2022-08-23,WITHDRAWN,OBSERVATIONAL,['NA'],,Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations
8874,NCT00748449,Percentage of patients who refuse to undergo an examination,2008-06,TERMINATED,INTERVENTIONAL,['NA'],,
8875,NCT02688023,3-year disease-free survival,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with surgery complications
8876,NCT04095468,Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.,2017-09-18,RECRUITING,OBSERVATIONAL,['NA'],,Anorectal function assessed by low anterior resection syndrome (LARS) score
8877,NCT02215837,Progress-free survival,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Severity of adverse events
8878,NCT02906397,Safety based upon standard laboratory and clinical adverse event monitoring,2017-03-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Promotion of anti-tumor immunity with addition of intervention to SBRT
8879,NCT02092298,Overall Survival (OS) From the First Laparoscopic HIPEC,2014-05-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8880,NCT01806272,The incidence of grade II and less oral mucositis at the end of treatment,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tumor response to chemoradiotherapy
8881,NCT05889806,Enrollment and collection totals for a diverse population of subjects/conditions involved in diseases and in healthy/control populations.,2023-05-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
8882,NCT02699073,Tumor response rate at 2 months according Choi Criteria,2016-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlation between Baseline cell free DNA and survival outcomes (PFS and OS)
8883,NCT05832892,Objective response rate (RECIST 1.1),2023-10-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Predictive biomarkers
8884,NCT04115254,Rate of Improvement in Tumor Control-Phase II,2019-10-22,SUSPENDED,INTERVENTIONAL,['NA'],,Overall Survival Rate-Phase II
8885,NCT05336643,Lymph node detection with technetium 99m colloid and SENSEI gamma probe,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Concordance of nodes seen on PET MRI/CT and SPECTCT
8886,NCT03605706,Overall Survival,2019-05-31,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS) rate at 9 months and 12 months
8887,NCT05589675,Participation rates to the screening program,2023-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Participation rates to the screening program
8888,NCT02480361,Remnant sitz markers in small intestine at postoperative day 7,2013-01,COMPLETED,INTERVENTIONAL,['NA'],serum albumin level in postoperative day 7,hospital stay
8889,NCT01365910,Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Each Worst-Grade Toxicity
8890,NCT01548482,Safety profile of trebananib and temsirolimus as assessed by NCI CTCAE version 4.0,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,PD effects of both drugs when administered in combination
8891,NCT03904121,Postoperative mortality,2019-04-01,COMPLETED,OBSERVATIONAL,['NA'],,Functional performance
8892,NCT01084746,Increase patient completion of colorectal cancer screening (CRCS) among patients ages 50 to 64 years old.,2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Secondary goals are to increase understanding of factors that predict completion of CRCS and to assess the cost-effectiveness of the intervention.
8893,NCT00328887,"Since this is a dose escalation, phase I design to evaluate toxicity, the analysis for this section will be purely descriptive. Adverse events will be considered on an individual basis.",2004-11,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
8894,NCT00716820,Objective Response Rate,2008-04,COMPLETED,OBSERVATIONAL,['NA'],Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE),Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation
8895,NCT00849264,overall survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,disease-free survival
8896,NCT03754075,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of mesocolic lymph nodes
8897,NCT02604784,Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Peritoneal Carcinomatosis Index (PCI) before and after therapy
8898,NCT00325611,Quality and cost of care,2002-04,COMPLETED,INTERVENTIONAL,['NA'],,Lower total costs 6 months past hospitalization
8899,NCT01469611,Determine the maximum-feasible dose,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8900,NCT03918369,Rate of Re-interventions,2019-03-07,COMPLETED,INTERVENTIONAL,['NA'],,
8901,NCT02149108,Overall Survival (OS),2014-09-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment
8902,NCT00403052,Occurrence of adverse events,2006-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival time
8903,NCT05835947,The incidence of anal HSIL and cancer in women with genital HSIL and/cancer in England,2022-09-01,RECRUITING,OBSERVATIONAL,['NA'],,The amount of time in years and months between the diagnosis of genital HSIL/SCC and anal HSIL/SCC
8904,NCT04843306,Effectiveness of motion management for SBRT for pancreatic cancer with real-time coaching for the ABC procedure using an augmented reality platform,2021-06-24,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety of patient with the ABC procedure with real-time coaching using an augmented reality platform during SBRT for pancreatic cancer as assessed by patient reported outcome measures (PROMs)
8905,NCT05172713,Retrospective study of the patient outcomes who had an incomplete colonoscopy after a positive immunological fecal test,2021-01-16,UNKNOWN,OBSERVATIONAL,['NA'],,
8906,NCT01219543,To investigate the safety and tolerability of AZD1480,2010-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,To obtain a preliminary assessment of the anti-tumour activity of AZD1480
8907,NCT02347618,Incidence of grade 2 or greater toxicity,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Time to death
8908,NCT00259402,"Efficacy endpoints include tumor response, progression free and overall survival.",2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations."
8909,NCT00990860,"Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))",2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,No. of TACE cycles
8910,NCT03705442,Incidence of grade III/IV diarrhoea between the two groups of patients,2018-02-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Difference in quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) between the two groups of patients
8911,NCT03526328,cell-specific expression patterns of putative intestinal stem cell biomarkers in BE patients; correlation of markers with serum/plasma protein expression and disease progression.,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
8912,NCT02716766,Time to progression (TTP),2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),Frequency and severity of adverse events and laboratory abnormalities
8913,NCT03243734,Change from baseline dysphagia scale at 14 days post cryotherapy procedure,2017-11-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mean change in the amount of residual tumor from baseline to follow-up cryospray delivery session
8914,NCT05027737,Complications,2022-02-22,RECRUITING,INTERVENTIONAL,['NA'],,EORTC QLQ-CR29 score
8915,NCT00807300,Time to untreatable progression,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8916,NCT02366286,Rate of HBV vaccination in subjects with negative HBV serology,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of HCC over the period of the study
8917,NCT02955901,Score of mucosal visualization,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],Patients characteristics questionnaire,Withdrawal time
8918,NCT03022110,Cyst recurrence rate,2017-02,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate
8919,NCT01572324,Response rates,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
8920,NCT01362361,progression free survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
8921,NCT01609660,Mucosal cytokine,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Short chain fatty acids
8922,NCT00226941,Dose-limiting Toxicity (DLT) - Number of Participants Affected,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival at 5 Years
8923,NCT04050787,3-year disease free survival rate,2019-07-21,UNKNOWN,INTERVENTIONAL,['NA'],,The number of positive lymph nodes
8924,NCT06060847,Comprehensive Complication Index,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Control of obesity-induced comorbidities
8925,NCT05447221,The diagnostic performance of AI model to assess the severity of intestinal metaplasia,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,"Accuracy of digital pathological AI models to identify glands, mucosal epithelium, and intestinal metaplasia in non-neoplastic areas"
8926,NCT01268943,Dose Related Toxicity,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
8927,NCT01967823,Percentage of Participants With a Response,2013-10-24,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Treatment Related Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells
8928,NCT05147389,Neoplastic bile duct diagnosis confirmation after one year follow-up,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8929,NCT03329950,Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0,2017-12-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic evaluation
8930,NCT05115786,Recurrence of colorectal cancer,2023-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8931,NCT01855724,Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-06-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of potential prognostic and/or predictive biomarkers in tissue and blood samples
8932,NCT01180959,Progression Free Survival (PFS),2011-04-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
8933,NCT05187338,Duration of remission (DOR),2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
8934,NCT02136069,"Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS)",2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab
8935,NCT02355262,Total number of months uninsured (total gap months),2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
8936,NCT03304210,Maximally Tolerated Dose (MTD) of Abraxane,2017-09-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Decreased Platelets - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
8937,NCT03248375,Number of Participants With Local Tumor Response According to mRECIST,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Treatment-related Laboratory Adverse Events
8938,NCT03161522,Overall survival (OS),2018-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Time to disease progression,Time to local or regional disease recurrence
8939,NCT06227871,Complication occurrence,2019-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Associated intra-abdominal injuries
8940,NCT00035919,dose-limiting toxicity and maximum tolerated dose,2002-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,objective tumor response by CT scan or MRI
8941,NCT01009801,Time to progression (Phase II),2010-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to treatment failure (Phase II)
8942,NCT02468362,Disease Free survival,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,5 year survival
8943,NCT04597268,Ramsy sedation score (RSS),2020-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
8944,NCT04608786,Recommended phase II dose (RP2D),2021-02-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,the number of subjects presenting detectable anti drug antibodies (ADAs)
8945,NCT04177407,postoperative complications,2017-03-23,UNKNOWN,INTERVENTIONAL,['NA'],,Overall complication rate within 30 days after surgery.
8946,NCT00410618,Nature and long-term ramifications of CNS injury as a result of cancer treatment,2003-04,COMPLETED,OBSERVATIONAL,['NA'],,Relationship between MRI measures and cognitive performance
8947,NCT02043821,DDC:Duration of Disease Control,na,UNKNOWN,INTERVENTIONAL,['NA'],Safety,DCR:Disease Control Rate
8948,NCT04681274,Specific tumor phenotypes,2020-08-31,COMPLETED,OBSERVATIONAL,['NA'],,Small lesion detection and characterization
8949,NCT02375997,Overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse event
8950,NCT02564224,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
8951,NCT03038568,assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans,2017-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
8952,NCT03267641,Time to recurrence,2016-05-16,COMPLETED,OBSERVATIONAL,['NA'],,Overall Survival
8953,NCT03344172,Proportion of Grade IIb or Higher Histolopathologic Responses,2017-12-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Coagulation Index (CI)
8954,NCT04888663,"Phase 2: Progression-free survival in patients with HER2-positive gastric cancer receiving trastuzumab, ramucirumab, and paclitaxel combination treatment",2018-02-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE v4.02
8955,NCT01748851,Progression free survival,2012-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,performance status (quality of life)
8956,NCT05732129,"Objective response rate of Metastatic Colorectal Cancer,inculdthe proportion of patients with complete response or partial response",2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
8957,NCT02778308,Disease Free Survival,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Gastrointestinal system Adverse events
8958,NCT02485561,Intentions to Get Screened for Colon Cancer,2015-06-01,COMPLETED,INTERVENTIONAL,['NA'],Perceived Benefits and Barriers of Colorectal Cancer Screening,Absolute Perceived Susceptibility to Colon Cancer
8959,NCT04601727,16s rRNA pyrosequencing analysis of microbial flora of rectal cancer patients,2020-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Categorisation of microbial flora against response to neoadjuvant chemoradiotherapy
8960,NCT04787523,Immun cell infiltrate in pathology sections from the tumour,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,
8961,NCT05441163,HRQoL deterioration free survival (QFS),2023-04-08,RECRUITING,INTERVENTIONAL,['NA'],,
8962,NCT02363647,Overall response rate (ORR),2015-01,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival (OS)
8963,NCT02577588,Safety,2016-05-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,evaluation of p53 specific T cell Responses by analysing data from EliSpot assay
8964,NCT04508452,Reintroduction Rate,2020-05-18,UNKNOWN,INTERVENTIONAL,['PHASE2'],,ORR2
8965,NCT03802214,"Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells)",2020-10-29,TERMINATED,OBSERVATIONAL,['NA'],,Analysis of the serum and tissue concentrations of vedolizumab
8966,NCT04748744,Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases,2019-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
8967,NCT04296851,Mean percentage change of the number and size of polyps in colon and/or duodenum.,2020-02-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,A qualitative assessment of the total extent of colorectal polyposis
8968,NCT00280709,"Clinical follow-up every month, starting one month after stent insertion. Clinical and/or laboratory signs of stent dysfunction?",2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
8969,NCT01368094,Surgical Site Infection at D30,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,
8970,NCT00112086,proportion of clinical complete remission,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival among all enrolled patients.
8971,NCT03267524,Geriatric assessment,2017-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
8972,NCT05951127,2-year OS,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,3 years PFS
8973,NCT01004978,Progression-free Survival (PFS),2009-10-28,COMPLETED,INTERVENTIONAL,['PHASE3'],To Evaluate the Effects of Intra-hepatic vs. Extra-hepatic Progression on OS.,Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression
8974,NCT05289895,Proteomic analysis of blood and urine,2022-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
8975,NCT02437071,response rate,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
8976,NCT02296736,Review pre-operative imaging to distinguish the organ of origin of pancreatic head tumours,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Resectabilty of the pancreatic tumour
8977,NCT05130073,Overall survival (OS),2019-07-31,COMPLETED,OBSERVATIONAL,['NA'],,
8978,NCT02327481,Operating time,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence patterns
8979,NCT05981066,Clinically significant abnormal changes in laboratory tests,2023-07-10,RECRUITING,INTERVENTIONAL,['NA'],,"Overall Survival, OS"
8980,NCT05658016,Mucositis,2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence Adverse Events That Are Related to Treatment
8981,NCT04935853,Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months,2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],,The complications and postoperative mortality rates in patients who underwent surgery
8982,NCT05185739,"Major pathological response rate, defined as the proportion of patients with less than 10% viable tumour at resection.",2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Determine the toxicity of pre-operative therapy according to Common Terminology Criteria for Adverse Events (CTCAE) V5.
8983,NCT02050659,tumorload in the greater omentum,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
8984,NCT03019588,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2017-02-16,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinue Study Treatment Due to an AE
8985,NCT03639935,Proportion of patients alive and without radiological or clinical progression at 4 months,2019-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) time as measured from start of 1st line platinum therapy
8986,NCT01134666,Safety and tolerability evaluated based on the incidence and severity of AEs.,2009-11-30,TERMINATED,OBSERVATIONAL,['NA'],,Response rate
8987,NCT03602677,Anastomosis leakage rate,2018-09-24,RECRUITING,INTERVENTIONAL,['NA'],,Hospital costs
8988,NCT04624282,Metabonomic difference in patients with chronic gastritis and gastric carcinoma,2020-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Association of different metabolic substances and disease results in chronic gastritis and gastric carcinoma
8989,NCT00868114,Overall Survival,2006-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,
8990,NCT05657249,Comparison of alternative surveillance program (alternating focused MRI + US in 6 month interval) and conventional surveillance (biannual US) for HCC detection,2023-01-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],comparison between incidental findings between biannual US and annual focused MRI,comparison between false referral rates of biannual US and annual focused MRI
8991,NCT02376478,"Number of anogenital warts, anogenital HPV DNA positivity and mucosal HPV seropositivity",2009-12,COMPLETED,OBSERVATIONAL,['NA'],,
8992,NCT01714726,Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8,2013-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With ADA Positive to MEDI2070 in Open-label Period
8993,NCT05878977,response prediction in first line immune checkpoint inhibitors treatment in metastatic melanoma assessed by human gastrointestinal microbiome (bacterial and viral) and exosomal mRNA expression of PD-L1 and IFNγ,2022-10-05,RECRUITING,INTERVENTIONAL,['NA'],,
8994,NCT06101836,Patient comfort during colonoscopy - Sedation,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
8995,NCT04430231,Disease-free overall survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
8996,NCT01103492,Number of Participants With Adverse Events,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
8997,NCT05163028,"To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), of HBI-2376 as an oral monotherapy for advanced solid tumors harboring KRAS or EGFR mutations.",2021-12-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic variables including volume of distribution
8998,NCT00222469,"To determine the overall survival (OS) rate at 1 year in this patient population, treated with the combination therapy of bevacizumab plus gemcitabine and oxaliplatin",2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the tolerability and toxicity profile of this regimen in this patient population
8999,NCT03908255,Overall Survival,2021-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],International normalized ratio (INR),Quality of life using FACT-Hep
9000,NCT01279278,Completion of Fecal Occult Blod Test,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,"Compare the rate of completion of colonoscopy after a positive test (information received by ADECA in the follow-up), according to the specifications."
9001,NCT00314353,One-year Progression-free Survival (PFS),2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of Response
9002,NCT05243862,Administration safety,2022-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Measured Memory T Cell Immune Response
9003,NCT03245203,R0 resection rate,2017-08,UNKNOWN,INTERVENTIONAL,['NA'],,overall response rate (ORR)
9004,NCT04829032,Number of Hartmann's procedure vs colic resection with primary anastomosis performed in 3-months in urgent or emergency setting for left-sided acute colonic diseases.,2021-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,The number of patients treated with Hartmann's procedure with a permanent stoma after one year.
9005,NCT01318200,Freedom from local progression,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Freedom from local progression
9006,NCT05887531,Post-surgical readmisions,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Strength
9007,NCT05462470,overall survival,2008-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Severe complication rate after resection of primary and metastatic lesions
9008,NCT05546970,Efficacy of the echo-guided TAP Block on analgesia,2022-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
9009,NCT01255007,To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.
9010,NCT04896879,Needs and experiences of healthcare professionals caring for patients with LARS through focus groups,2016-11-22,COMPLETED,OBSERVATIONAL,['NA'],,
9011,NCT06085560,Anticipatory Racism,2023-07-12,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
9012,NCT01809756,severity of esophagitis (NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0 score),2014-02-25,TERMINATED,INTERVENTIONAL,['NA'],,weight loss (NCI CTCAE 4.0 score)
9013,NCT00899093,YKL-40 measurements,2007-09,TERMINATED,OBSERVATIONAL,['NA'],Variability of YKL-40 measurements,
9014,NCT05565417,Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohort,2022-11-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a Cohort(s)- Number of participants with adverse events following administration of IMT-009
9015,NCT06195904,Genetic variants of pancreatic cysts associated with malignancy assessed by next-generation sequencing,2024-01-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Genetic variants that differentiate mucinous from serous cysts assessed by next-generation sequencing
9016,NCT01887717,Overall Survival (OS) From Time of Randomization,2014-02-27,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment Emergent Adverse Events (TEAE)
9017,NCT03444194,Tissue biopsy,2017-05-12,UNKNOWN,INTERVENTIONAL,['NA'],,RECIST
9018,NCT05264688,diagnose accordance rate,2022-01-20,UNKNOWN,OBSERVATIONAL,['NA'],,Total Glycolysis (TLG)
9019,NCT04833699,time to the first passage of flatus after surgery,2021-04-05,COMPLETED,INTERVENTIONAL,['NA'],,The time to the first bowel movement
9020,NCT04655807,Change from Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12,2021-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Change in PD Biomarker Levels of Fecal Lactoferrin from Baseline Compared with Placebo
9021,NCT02931981,Overall Survival,2016-10,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse-free Survival
9022,NCT03951389,"The correlation between wild type PIK3CA, PIK3CA exon 9 and PIK3CA exon 20 mutations and developing of metastatic disease and overall colorectal patient survival",2012-05-22,COMPLETED,OBSERVATIONAL,['NA'],,
9023,NCT00191607,"- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments",2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life
9024,NCT01290536,Number of Participants With Adverse Events,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Radiographic Response
9025,NCT05811195,Oral mucositis Children's International Mucositis Evaluation Scale (CHIMES),2023-03-10,RECRUITING,INTERVENTIONAL,['NA'],,Analysis NET and TSE
9026,NCT01328223,Response rate,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
9027,NCT02649153,Time to first peristalsis,2021-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9028,NCT00019474,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9029,NCT03144856,Progression-free survival (PFS),2017-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety (incidence of adverse events)
9030,NCT06236594,Image quality rate,2023-09-18,RECRUITING,OBSERVATIONAL,['NA'],,Diagnosis accuracy according to image
9031,NCT00006479,,2000-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9032,NCT05550974,complication,2022-09,RECRUITING,OBSERVATIONAL,['NA'],,number of use for each surgical instruments
9033,NCT01417000,Overall Survival (OS) in Subjects Receiving Test Treatments (FAS),2011-09-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To Assess Safety of the Cyclophosphamide, GVAX Pancreas Vaccine, and CRS-207 Treatment Regimen"
9034,NCT01237132,Overall survival of resected patients for HCC,na,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival of resected patients for HCC
9035,NCT05995990,Raman spectroscopy is able to discriminate between healthy liver tissue and colorectal liver metastases.,2020-11-25,COMPLETED,INTERVENTIONAL,['NA'],,Tissue sections can be analysed by Raman spectroscopy more time effectively than normal clinical practice.
9036,NCT04563975,disease control rate,2020-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival rate
9037,NCT04257448,Recommended dose for expansion (RDE),2020-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
9038,NCT06223763,Overall Survival at 5 years,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Homologous Recombination Deficiency (HRD) deficiency influence
9039,NCT05365412,"Survival (overall/disease-specific) according to sex, molecular profiles and sex hormone receptors",2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],,"Disease-free survival according to sex, molecular profiles and sex hormone receptors"
9040,NCT00262808,Proportion of patients with a change in tumor-associated macrophage VEGF expression,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free and overall survival
9041,NCT05601609,Overall survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC),2020-11-11,COMPLETED,OBSERVATIONAL,['NA'],,Cancer-specific survival outcome in young colorectal cancer (yCRC) and elderly colorectal cancer (eCRC)
9042,NCT02619435,the rate of evaluable patients alive and not progressed at 6 months,2015-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
9043,NCT00095927,"Median duration of dependence on percutaneous endoscopic gastrectomy (PEG) for adequate nutrition at 8, 12, 24, and 52 weeks after completion of study treatment",2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Swallowing function
9044,NCT05957822,CRT maximal amplitude,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,re-operation
9045,NCT04716166,FEV1/FVC ratio,2020-10-01,COMPLETED,INTERVENTIONAL,['NA'],,
9046,NCT00065234,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9047,NCT00222664,,1983-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
9048,NCT00606788,weaning duration,2005-11,SUSPENDED,INTERVENTIONAL,['NA'],,reintubation rate
9049,NCT00823290,Maximum tolerated dose of LBH589,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,Laboratory abnormalities (CTC grade 3 or grade 4 toxicities)
9050,NCT06061874,Correlation of the Ga68-FAPI PET/CT derived PCI (peritoneal cancer index) score with the intraoperative PCI based on histopathology of resected specimen (the reference standard),2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Assessment of the impact of neoadjuvant chemotherapy on the FAPI expression of target lesions at baseline.
9051,NCT06052202,Receipt of Colorectal Cancer Screening Test at Month 6,2023-12-08,RECRUITING,INTERVENTIONAL,['NA'],,Change from Baseline in Colorectal Cancer Knowledge at Month 6
9052,NCT02066363,Changes in body composition,2014-03-01,TERMINATED,INTERVENTIONAL,['NA'],Survival in study,Time to to exacerbate Quality of Life
9053,NCT01111292,The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.,2010-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9054,NCT04248569,Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 4 (CD4) T cells at 10 weeks,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
9055,NCT02511756,CTP as predictive marker for efficacy measured by progression-free survival,2015-07,TERMINATED,INTERVENTIONAL,['NA'],,Local and distant recurrences
9056,NCT00292279,Systemic inflammatory response syndrome (SIRS),2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Post operative nutritional cost & total treatment cost
9057,NCT02090101,Response rate after 2 months in patients with colorectal cancer with liver metastases treated with anakinra and LV5FU2/bevacizumab,2014-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Rate and safety profile according to NCI-CTCAE v4
9058,NCT06133439,Implementation outcomes,2023-01-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Maintenance,
9059,NCT02807844,Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs) During the First 2 Cycles of Study Treatment,2016-06-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib and Phase II: All Collected Deaths
9060,NCT05394129,Diagnostic accuracy,2019-04-09,RECRUITING,OBSERVATIONAL,['NA'],,Cytomorphologic feature
9061,NCT06333392,Proximal sessile serrated lesion detection rate,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Single use accessories for the procedure
9062,NCT04850716,Progression-Free Survival (PFS),2021-04-27,RECRUITING,OBSERVATIONAL,['NA'],,Disease Control Rate (DCR)
9063,NCT02718235,The HCC immune score (HCCIS) is a survival prognosticator of patients after liver resection for HCC,2016-06,UNKNOWN,OBSERVATIONAL,['NA'],,The HCC immune score (HCCIS) to prognosticate disease free survival of patients after liver resection for HCC
9064,NCT04568200,pathological response,2020-06-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
9065,NCT02442362,Tumor respone,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Side-effect
9066,NCT00904813,Time to Local Recurrence.,1998-11,COMPLETED,INTERVENTIONAL,['NA'],,Tumour Regression Based on the Dworak Grading Scoring System
9067,NCT04071431,Rate change,2019-05-29,UNKNOWN,INTERVENTIONAL,['NA'],,
9068,NCT04563897,Diagnostic performance of contrast-enhanced ultrasound in different liver background and liver turmors by sonazoid,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9069,NCT05190042,The rates of complete closure of mucosal/submucosal defects,2022-01-18,COMPLETED,INTERVENTIONAL,['NA'],,Post polypectomy syndrome
9070,NCT02073435,Complications,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
9071,NCT04871321,collected blood samples,2021-04-14,RECRUITING,OBSERVATIONAL,['NA'],,Biomarkers on the efficacy of Gemcitabine/Cisplatin/Nab-paclitaxel for advanced biliary tract cancer
9072,NCT01489865,Dose limiting toxicities,2011-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective Response
9073,NCT01479608,Overall survival,2012-04-11,RECRUITING,INTERVENTIONAL,['NA'],,
9074,NCT02758977,1 Year Disease-free Survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Incidence of posthepatectomy renal failure
9075,NCT03680183,Average plasma concentration of the drugs (TKIs),2018-05-22,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse reaction caused by TKIs
9076,NCT05014776,Objective response rate (irORR) using immune Response Evaluation Criteria for Solid Tumors (iRECIST),2022-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing grade 3 or above drug-related toxicities
9077,NCT06136845,To characterize the microbiota of esophageal cancer patients differentiating it by: - demographic criteria - tumor characteristics,2020-01-13,RECRUITING,OBSERVATIONAL,['NA'],,
9078,NCT03411200,Lower body strength measured with the 30-second chair stand test,2018-04-04,COMPLETED,INTERVENTIONAL,['NA'],,Survival
9079,NCT05292417,Progression-free survival (PFS),2022-03-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety:Percentage of Participants With Adverse Events (AEs)
9080,NCT04972994,early recurrence of the cancer,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,
9081,NCT06048913,Overall Survival,2022-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE1'],,Toxic side reactions
9082,NCT03053544,Pathological Complete Response (pCR) rate,2016-12-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Hypoxia
9083,NCT00955240,Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of objective response
9084,NCT03868228,Progression free survival assessed by laparoscopy and cross sectional imaging,2019-02-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PIPAC related safety regulation breaches / adverse events in theatre
9085,NCT05159050,Determine the maximum tolerated dose (MTD) of intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM),2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess whether intra-abdominal pressure is location-dependent
9086,NCT04389151,effectiveness of neoadjuvant therapy,2020-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9087,NCT02870036,Adverse events (AE),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,accumulative excretion rate
9088,NCT06261814,False discovery rate,2024-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Ability of the model to predict binary treatment response
9089,NCT04262635,Efficacy: Maintenance PFS,2021-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Change from Baseline in Mutation Status of Selected Genes tested by Next-Generation Sequencing during Treatment Period,Overall Survival
9090,NCT02785783,Number of polyps per patient,2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],,
9091,NCT03852693,Frequency of distant metastases in aNET measuring 1-2 cm,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Long-term survival after complete resection of aNET measuring 1 - 2 cm with or without oncological right-sided hemicolectomy
9092,NCT01959087,Length of postoperative hospital stay,2014-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative quality of life
9093,NCT00436241,Overall response rate,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"AEs, laboratory parameters."
9094,NCT03257033,Overall Survival,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation"
9095,NCT03400280,Composite primary endpoint,2018-01-08,UNKNOWN,INTERVENTIONAL,['NA'],,Cost-effectiveness
9096,NCT03471052,Change in surface area of residual inlet patch post ablation,2018-03-06,UNKNOWN,INTERVENTIONAL,['NA'],,"Symptomatic response for cough, hoarseness and sore throat using Visual Analogue Scale (VAS)"
9097,NCT01926743,To compare the number of retrieved lymph node in each nodal station after additional application of near infra-red fluorescence imaging,2013-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
9098,NCT05654896,Liver abscess and intervention,2022-11-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9099,NCT00104689,Efficacy in terms of stabilization or improvement by 1 point on Katz's Activities of Daily Living scale,2003-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics
9100,NCT03171428,Short-term outcome: Occurrence of postoperative complications or death after surgery,2007-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9101,NCT04331041,Progression-free survival (PFS),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local control
9102,NCT05030870,The incidence of hypoxia,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,The incidence of other adverse events
9103,NCT01456923,,na,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9104,NCT00213486,clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival rate at one and two years
9105,NCT02678013,Recurrence-free survival,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
9106,NCT02247336,Number of Patients With Provider Referral for Risk-appropriate Colorectal Cancer Screening,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Who Received Referral for Genetic Consultation
9107,NCT00003544,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9108,NCT03640572,Overall survival (OS),2007-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Systemic recurrence
9109,NCT00881621,Overall Survival,2009-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse Events
9110,NCT03723304,Tumour-specific liver transplant failure rate,2018-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9111,NCT05859945,Number of hepatocellular carcinoma study participants who remain in clinical trial until completion.,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9112,NCT05248048,Maximal Tolerable Dose#MTD#,2021-09-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Antitumor efficacy-Overall survival (OS)
9113,NCT05965531,Objective response rate,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9114,NCT05927584,Success rate,2024-02-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Radical rescue surgery specimen quality
9115,NCT02866019,Proportion of participants without stenosis until 8 weeks after endoscopic submucosal dissection (ESD),2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,QOL assessed by the EORTC QLQ-OG 25
9116,NCT03198975,Presence of microvascular invasion,2017-06-23,UNKNOWN,OBSERVATIONAL,['NA'],,
9117,NCT00005629,Safety,1999-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
9118,NCT03716089,3-year disease free survival rate,2018-10-11,RECRUITING,OBSERVATIONAL,['NA'],,The variation of C-reactive protein
9119,NCT04224402,Regression Free Survival,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2'],EORTC Quality of Life Questionnaire(QLQ)-C30,Overall Survival
9120,NCT00485316,Overall survival and disease-free survival,1993-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Direct cost
9121,NCT01046864,"Safety-Toxicity, evaluated according to NCI Common Terminology Criteria for Adverse Events v3.0. Assessments based on medical review of adverse events, results of vital signs, ECGs, echocardiography, physical examinations, and clinical laboratory tests",2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Exploratory Measures (Biomarkers for Predictive Analysis): Potential predictive markers, including activity of FGF, VEGF and related pathways as well as K-RAS mutation status, will be evaluated based on blood or tumor samples"
9122,NCT05616403,Textbook outcome,2010-01-18,COMPLETED,OBSERVATIONAL,['NA'],,
9123,NCT01640405,Progression free survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)"
9124,NCT00037180,Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy,2002-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Health resource utilization (collected data to be evaluated separately from this protocol)
9125,NCT04272619,Change in intentions about communicating with healthcare provider - liver cancer risk,2020-02-11,COMPLETED,INTERVENTIONAL,['NA'],,
9126,NCT01786278,The highest improvement of stricture diameter,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost analysis,Quality of life
9127,NCT00081549,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9128,NCT02806648,Activity of palbociclib (PD0332991) considering objective response rate,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Positive expression of tumor biomarkers (Cdk4, Cdk6, fosfo-Rb1, D1 cyclin, p53, Ki67)"
9129,NCT00054873,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9130,NCT05916846,Assess the efficacy of EUS-RFA post-procedure after one year,2023-04-24,RECRUITING,INTERVENTIONAL,['NA'],,Assess the long-term response to EUS-RFA for efficacy of significant and durable ablation response
9131,NCT05133544,Adenoma detection rate,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Total number of polyp or adenoma per patient.
9132,NCT06280508,1-year EFS rate,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
9133,NCT03172884,Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.,2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.
9134,NCT03823144,"4. Tumor blood flow (velocity, mm/sec)",2019-02-28,COMPLETED,INTERVENTIONAL,['NA'],,Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.
9135,NCT03770559,Posteroperative length of stay,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,R0 resection
9136,NCT05657418,RP2D,2022-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,ORR
9137,NCT02312284,Distant metastasis free survival,2011-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgery complication
9138,NCT06153394,Number pf participants with hypercoagulability identified via TEG testing,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease Free Survival
9139,NCT01540461,Accumulation index calculated as the ratio: AUC(TAU) at steady-state (Day 8) divided by AUC(TAU) after the first dose (Day 1) [AI] of Brivanib,2012-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Preliminary evidence of anti-tumor activity as measured by objective response rate (ORR) and disease control rate (DCR) in Chinese subjects with advanced HCC treated with Brivanib
9140,NCT06126419,Liver regeneration improvement after high-dose insulin therapy after LVD measured CT volumetry,2023-11-08,RECRUITING,INTERVENTIONAL,['NA'],,
9141,NCT03009747,Risk factors of bowel dysfunction after sphincter-preserving surgery,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of bowel dysfunction after sphincter-preserving surgery
9142,NCT00287976,Best overall response (complete response and partial response),2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical resection (complete or incomplete)
9143,NCT04163068,Treatment burden,2020-01-08,COMPLETED,OBSERVATIONAL,['NA'],,
9144,NCT00032110,Objective response or disease stabilization,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular changes with therapy
9145,NCT05409482,Progression-free survival（PFS）,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,Occurence of AE and SAE
9146,NCT02023593,Disease control rate,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
9147,NCT00810719,Progression Free Survival,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9148,NCT03612726,Overall survival,2018-07-16,RECRUITING,OBSERVATIONAL,['NA'],,Frequency and Severity of Adverse Events
9149,NCT00003557,Objective Response Rate,1999-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9150,NCT02665299,Utility of plasma ctDNA measurements to detect colon cancer or precancerous conditions.,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,Determination of incident rate of new colon or other cancers in patients who underwent initial measurement of ctDNA
9151,NCT01646554,Progression free survival,2012-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety
9152,NCT03242187,Number of lymph nodes retrieved,2017-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Functional outcome
9153,NCT03619317,• Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise,2018-06-25,UNKNOWN,OBSERVATIONAL,['NA'],,Left ventricular systolic function estimated by 2D longitudinal strain (GLS) and ejection fraction (EF) at rest and peak exercise
9154,NCT01650766,,2012-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9155,NCT03370198,The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43),2017-10-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,The overall survival (OS).
9156,NCT04862260,Characterization of dose-limiting toxicities,2021-10-04,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],To explore the feasibility of a larger multicenter trial,CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo
9157,NCT06244537,Pathological complete response (pCR),2024-02-29,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
9158,NCT05160740,3-year disease free survival rate,2021-09-23,RECRUITING,INTERVENTIONAL,['NA'],,Mortality rates
9159,NCT06152276,Overall major complications,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9160,NCT01462890,Progression Free Survival (PFS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Translational Research - Complementary and Alternative Treatment Questionnaires
9161,NCT04725994,Dose Limiting Toxicities (DLTs),2021-06-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9162,NCT00556413,Complete response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival
9163,NCT01065688,the postoperative quality of life (QOL),2009-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"the incidence of postoperative complications, nutritional status, and the incidence of the remnant gastritis and the reflux esophagitis"
9164,NCT01904656,Rates of colorectal cancer screening-within-guidelines (status obtained by medical record review).,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Effect Modification
9165,NCT00940563,tumor response /RecIST criteria),2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"which early predictive factors of tumor response may be of relevance, i.e. conventional pathologic characteristics of tumor and radiological aspects."
9166,NCT04451343,"Assess how the patients, their relatives and their family members, face the disease.",2018-07-06,COMPLETED,OBSERVATIONAL,['NA'],,
9167,NCT04959448,Baseline Disease Characteristics,2021-08-12,RECRUITING,OBSERVATIONAL,['NA'],,Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)
9168,NCT00602329,"Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value",2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival"
9169,NCT01215565,Objective response,2009-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarkers of radiological response
9170,NCT01635595,,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
9171,NCT04653701,Technical success,2020-11-14,UNKNOWN,OBSERVATIONAL,['NA'],,
9172,NCT00335816,Effect of different chemoradiation-to-surgery intervals on postoperative complications,2008-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9173,NCT05407272,"the knowledge, attitudes, service intentions and service start-up effects of the eight major non-cancer disease end-stage caregivers on well-being and palliative care",2021-09-14,COMPLETED,INTERVENTIONAL,['NA'],,
9174,NCT00967291,Progression-free survival at 6 months,2006-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
9175,NCT00088894,Grade 3-4 neutropenia in terms of specific single-nucleotide polymorphisms (SNPs) and/or copy number variations that are associated with the prevalence of these events (Clinical endpoint),2004-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,OS (Clinical endpoint)
9176,NCT00901732,The primary objective is to estimate ht incidence of OM in H&N cancer patients undergoing radiation therapy with or without chemotherapy and/or sensitizer who receive Caphosol.,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"The secondary objective of this study is to correlate components of OM data with clinical outcomes (pain, narcotic use, oral intake)"
9177,NCT05004376,Screening,2022-01-03,COMPLETED,INTERVENTIONAL,['NA'],,Phone Interview for refinement of Intervention
9178,NCT02727309,Progression free survival,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Objective response rates
9179,NCT02903498,Progression Free Survival (PFS),2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
9180,NCT01437514,local recurrence,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,short-term complication of the surgery
9181,NCT04046601,impedance,2019-10-09,COMPLETED,INTERVENTIONAL,['NA'],,differences in impedance
9182,NCT02545751,The proportion of patients with tumor responses after the initiation of treatment.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The proportion of patients alive with tumor responses from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study."
9183,NCT05497778,"National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0",2022-10-21,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9184,NCT00082862,Changes in quality of life,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Changes in cellular and cytokine immune function
9185,NCT00195572,Survival time,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Response rate, duration of response, time to progression, safety, quality of life"
9186,NCT04034355,Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN),2019-01-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Patients With Disease Free Survival
9187,NCT02413476,Five-year disease free survival rate,2015-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Intraoperative situation (The number of lymph node dissection,the number of positive lymph nodes,extra-cavity anastomosis time,intraoperative blood loss,the rate of conversion)"
9188,NCT03767764,Yliver,2018-12-27,COMPLETED,OBSERVATIONAL,['NA'],,AAb AFP
9189,NCT05963087,Objective response rate (ORR),2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Overall survival time
9190,NCT04216251,Change in the Marine Omega-3 Polyunsaturated Fatty Acid (MO3PUFA) Composition in Colorectal Tissues as a Result of the AMR101 Treatment.,2020-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Stool Metabolite Profile
9191,NCT00575640,The study design calls for an initial phase of dose-escalation in cohorts of 3 patients. There are no intra-patient changes in dose.,2004-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Subsequent to this Phase I scheme, the study will continue with the selected dose-level (on toxicity and tolerability grounds) to accrue patients in a phase II scheme."
9192,NCT00276705,Event-free and overall survival following tumor resection,2005-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy
9193,NCT04491929,Feasibility and translational analysis,2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
9194,NCT00851045,Progression free survival based on tumor assessments (CT/MRI),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Safety in the CT-322 plus irinotecan, 5-FU and leucovorin arm as measured by incidence of serious and non-serious adverse events, significant laboratory evaluations and significant physical examination findings in subjects"
9195,NCT00606619,Days of hospital stay after operation,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative morbidity rate in hospital days: Clinically definite morbidity confirmed by physicians according to offered protocol
9196,NCT05265754,Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer,2022-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
9197,NCT00825110,the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology.,2008-11,UNKNOWN,OBSERVATIONAL,['NA'],,Secondary outcome measure is the survival and response to treatment of the identified cases.
9198,NCT02155140,Fatigue,2011-02,TERMINATED,INTERVENTIONAL,['NA'],,Health economic analysis
9199,NCT04190589,Lymph node count,2020-05-18,RECRUITING,INTERVENTIONAL,['NA'],Conversion rate,Readmissions
9200,NCT04160962,EORTC Questionnaire QLQ-C30,2020-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9201,NCT03264898,FIT Result,2017-10-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9202,NCT00081094,Relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,Obtain a preliminary estimate of the impact of PET on management of patients with HCC.
9203,NCT03148119,Incidence of QRH-882260 Heptapeptide administration-related adverse events,2017-03-31,TERMINATED,INTERVENTIONAL,['PHASE1'],Efficacy of QRH-882260 Heptapeptide administration for detection of dysplasia in the setting of IBD,Efficacy of QRH-882260 Heptapeptide administration for detection of polypoid and non-polypoid colonic neoplasia
9204,NCT03515356,Sensory neuropathy at 8 weeks,2018-06-13,COMPLETED,INTERVENTIONAL,['NA'],MI Fidelity Measure at 9 months,Mood at 8 weeks
9205,NCT00044031,Survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants with Serious and Non-Serious Adverse Events
9206,NCT00499486,Severity of Adverse Events as Assessed by NCI CTCAE v3.0,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9207,NCT06328868,Concentration of Serum prealbumin,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Feeding amount
9208,NCT02912559,Disease free survival (DFS),2017-10-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
9209,NCT03621644,Gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Patient-reported quality of life (QOL)
9210,NCT05288205,Number of participants with dose limiting toxicities,2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival (PFS)
9211,NCT00793455,Colorectal Cancer Screening Completion.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal Cancer Screening Completion
9212,NCT04795869,Overall objective response rate (ORR),2020-03-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
9213,NCT02803515,Changes in serum levels of HSP90 and 70 on peripheral venous samples.,2017-01-16,TERMINATED,INTERVENTIONAL,['NA'],,
9214,NCT01679340,replase free survival,2011-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
9215,NCT00335010,differences in microvascular hemoglobinsaturation,2005-05,COMPLETED,INTERVENTIONAL,['NA'],,differences in anastomotic stenosis
9216,NCT03193710,Cancer free survival,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],Days of hospitalization,Colorectal cancer antibodies
9217,NCT02048540,R0 resection rate,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",circulating tumor cell number change,safety of peroperative treatment and surgery
9218,NCT05287672,Weight gain by BMI by kg/m2,2022-06,UNKNOWN,OBSERVATIONAL,['NA'],,
9219,NCT05064618,Phase II study; response rate (based on RECIST ver1.1),2021-08-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response rate （Phase I）
9220,NCT01249352,Overall survival and assessment of the complete endoscopic response,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Complete clinical response rate
9221,NCT00318604,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
9222,NCT00628810,Tolerability evaluated by NCI CTC v. 2.0 criteria,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life using the EuroQOL EQ5D questionnaire
9223,NCT03917017,Postoperative survival,2019-01-01,RECRUITING,INTERVENTIONAL,['NA'],Intraoperative blood loss,Disease-free survival
9224,NCT03486678,Incidence of Treatment-Emergent Adverse Events,2018-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
9225,NCT05237921,Number of participants that adhere to a Combined Exercise and Dietary Intervention (CEDI),2018-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants that meet estimated dietary intake and exercise goals
9226,NCT01183559,Maximum Tolerated Dose of Vandetanib,2008-08-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,The Number of Participants With Adverse Events
9227,NCT06031480,"Objective response rate (ORR, RECIST v1.1)",2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9228,NCT05898854,Patient management,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Prognostic value
9229,NCT05520866,Proportion of days before surgery engaged in prehabilitation,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],Median Satisfaction Scores,Change in Mean score on the SF-36
9230,NCT05056714,Develop a severity score for PNS using latent variable modeling: Polyps Severity Index (PSI),2022-01-27,RECRUITING,OBSERVATIONAL,['NA'],,
9231,NCT04842565,Progression-free survival time (mPFS) (mRECIST),2021-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to Progression (TTP)
9232,NCT05568420,genomic analysis of tissue,2022-09-30,RECRUITING,OBSERVATIONAL,['NA'],,
9233,NCT05982301,"Progression-Free survival 2, PFS2",2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,After Effects
9234,NCT04506138,Major Pathologic Response (MPR),2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",FACT-E questionnaire,Event Free Survival（EFS）
9235,NCT03257332,Global health status/quality of life: EORTC QLQ-C30,2019-11-12,WITHDRAWN,OBSERVATIONAL,['NA'],Physical performance,Low anterior resection syndrome
9236,NCT01196260,To determine prognosis of patients with metastatic colorectal cancer received the combination of drugs,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To evaluate the time to progression of metastatic colorectal cancer after treatment
9237,NCT01697371,Phase I of study: Number of participants with adverse events as a measure of safety and tolerability,2012-08-22,RECRUITING,INTERVENTIONAL,['NA'],,Phase II -local control within irradiated fields at 2 years
9238,NCT02997228,Progression free survival (PFS),2018-01-19,RECRUITING,INTERVENTIONAL,['PHASE3'],Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected,Duration of SD
9239,NCT00969046,To identifymaximum tolerated dose (MTD),2003-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration"
9240,NCT02460991,Overall Survival,2015-11,TERMINATED,INTERVENTIONAL,['PHASE3'],FACT-Hep Quality of Life,Frequency of Treatment Emergent Adverse Events
9241,NCT00288119,Assay of DNA and RNA markers,2005-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Score of tolerability and acceptability
9242,NCT04744688,The difference between changes in concentration of prothrombin fragment 1+2.,2021-03-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Incidence of deep venous thrombosis measured by doppler ultrasonography in colorectal cancer patients undergoing cytoreductive surgery with HIPEC
9243,NCT01837446,Mucositis severity,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Patient's satisfaction
9244,NCT00920192,Safety and tolerability of foretinib at the MTD as measured by number and severity of AEs,2009-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,PK profile of foretinib
9245,NCT06105203,intersphincteric resection (ISR),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,3-year defecation function
9246,NCT00381173,"Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.",2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop."
9247,NCT01273805,2-month Progression-Free Survival Rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 4-5 Treatment-Related Toxicity
9248,NCT02649491,Change in Olfactory Signatures in patient sample,2015-11,UNKNOWN,OBSERVATIONAL,['NA'],,"Changes in the scores of Inflammatory Bowel Questionnaire,"
9249,NCT00657995,the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,the total amount of insulin required for glycemic control after pancreatic resection
9250,NCT05988814,Progression-free survival (PFS),2024-01-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
9251,NCT00226746,One-year overall survival rate,2003-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Occurrence of pathological response or shrinkage of the tumor (becomes resectable)
9252,NCT04524676,1-year rebleeding rate,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA'],,Complications of portal hypertension
9253,NCT01506115,Complications associated with the procedure,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,Survival time
9254,NCT05921942,Progression free survival,2020-04-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Common terminology criteria adverse events (CTCAE 4.0)
9255,NCT03559543,Nutritional status,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9256,NCT04165031,Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts),2019-11-28,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD"
9257,NCT05731726,Pathological complete response rates,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,single cell sequence
9258,NCT05557656,Overall survival (OS),2023-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Adverse events (AEs)
9259,NCT02272699,Disease-free survival,2014-11,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.
9260,NCT02585362,Change in physical performance,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival
9261,NCT05980416,Number of patients with clinically significant changes in laboratory tests,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,
9262,NCT01395537,PHASE II: To Assess the Response Rate to This Regimen.,2011-08,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To Determine the Overall Survival
9263,NCT03383159,Differences In Microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Predictive model validation
9264,NCT03777462,Overall time,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease free time
9265,NCT02841046,Number of Days Needed for Anal Exsufflation After Surgery,2016-07-27,COMPLETED,INTERVENTIONAL,['NA'],Complication After Surgery,Number of Days in Hospital
9266,NCT02555358,The pathological complete response rate,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
9267,NCT00027521,,2000-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
9268,NCT03061370,Survival,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9269,NCT01566942,disease-free survival（DFS）,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival(OS)
9270,NCT03747588,Intra-abdominal infection,2018-12-01,RECRUITING,INTERVENTIONAL,['NA'],progression-free survival,Length of hospital stay (day)
9271,NCT03891654,DCE-CT Perfusion Metrics: Blood Flow,2019-08-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation Between Patient Demographics and Blood Flow: Clinical Stage of Disease
9272,NCT00133913,,2004-03,UNKNOWN,OBSERVATIONAL,['NA'],,
9273,NCT03576872,80% or higher rate of completing at least 3 of 4 nurse-led encounters with participants,2018-07-09,COMPLETED,INTERVENTIONAL,['NA'],,80% or higher on the index of rates for follow-up phone calls and binder review prior to cycle 2 of chemotherapy
9274,NCT05184803,Evaluation of R0 resection rate in patients who underwent prior chemotherapy as a clinical trial.,2022-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,
9275,NCT01277406,Phase II: Progression free survival (PFS),2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: Pharmacokinetics: AUClast, AUCtau, cmax, tmax, t ½, CL/F of resminostat, Irinotecan (SN-38), 5-FU and folinic acid"
9276,NCT00963092,"Creation of repository of blood, saliva, and tumor samples",2002-08,UNKNOWN,OBSERVATIONAL,['NA'],,
9277,NCT02969122,Overall survival,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,morbidity and mortality of HIPEC and EIPL
9278,NCT01853618,Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution,2013-05-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
9279,NCT05093907,Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine,2021-08-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine
9280,NCT00720668,The Rate of Exacerbation of chronic hepatitis B after RFA,2006-06,UNKNOWN,OBSERVATIONAL,['NA'],,mortality
9281,NCT00001276,Treatment Outcomes,1991-05-21,RECRUITING,OBSERVATIONAL,['NA'],,
9282,NCT05547919,Number of patients with identified tumor lesion sites,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,PSMA uptake on 18F-PSMA-1007 PET
9283,NCT06301828,ORR,2024-02-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
9284,NCT03817411,ORR,2019-01-25,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
9285,NCT03382886,Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D),2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
9286,NCT00137449,Number of Participants With Clinical Benefit Response (CBR) According to RECIST,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Score of EQ-5D (Euro Quality of Life-5 Dimension) Weighted Health Index
9287,NCT00419978,,2004-06,TERMINATED,INTERVENTIONAL,['NA'],,
9288,NCT05839951,Cohort R-T or Cohort T-R: Descriptive analysis of biomarker Kirsten rat sarcoma 2 viral oncogene homolog (KRAS),2023-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cohort R-T or Cohort T-R: Overall survival of patients with Regorafenib followed by TAS-102 and vice versa in 3rd line treatment and 4th line treatment
9289,NCT06241066,DFS,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9290,NCT01856322,Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9291,NCT02274376,Safety and tolerability: incidence and nature of adverse drug reactions,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,Incidence and nature of dose interruptions
9292,NCT04700410,Boston Bowel Preparation scale (BBPS)-score after cleaning with the Pure-Vu system.,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of adverse events after study intervention
9293,NCT02985034,Local tumor progression (LTP),2010-10,COMPLETED,OBSERVATIONAL,['NA'],,immediate technical success on registration-software assessment
9294,NCT00831181,Pathologic Response and Complete Response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Comparison of Preoperative Stage With Post-treatment Pathologic Stage
9295,NCT01434485,Number of Adverse Drug Reactions,2011-09,COMPLETED,OBSERVATIONAL,['NA'],,
9296,NCT03930888,Progression of the self sufficiency,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Effect of tumor localization
9297,NCT05051423,"Correlations with statistical significance between time-intensity curve analysis parameters, immunohistochemical markers of angiogenesis and clinico-pathological parameters.",2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9298,NCT02967094,"""Visibility score"" evaluated by blinded performing endoscopist",2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,Duration of endoscopy
9299,NCT01522573,Safety,2011-11,UNKNOWN,OBSERVATIONAL,['NA'],,Survival duration
9300,NCT02646241,diagnostic accuracy,2016-01-02,COMPLETED,INTERVENTIONAL,['NA'],,accuracy of malignant potential on contrast enhanced EUS
9301,NCT00689624,Objective Response Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Q-Twist analysis of Quality of life
9302,NCT00003834,response rate,1999-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
9303,NCT05208372,Expression of ctDNA,2022-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9304,NCT02525952,overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,Time to recurrence
9305,NCT04224896,SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES,2011-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9306,NCT06187610,Symptom self-management knowledge,2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Patients engagement while learning
9307,NCT05981235,"Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG.",2023-12-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,PFS
9308,NCT01304602,Maximum tolerated dose,2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological half life of BKM120
9309,NCT06172647,Proportion and abundance of bacterial taxa (defined as total percentage of bacterial DNA sequences),2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
9310,NCT04694404,PFS,2016-05-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The number of participants with treatment-related adverse events as assessed by CTCAE v4.0
9311,NCT00598156,progression-free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,overall survival
9312,NCT02745561,response rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
9313,NCT00717990,Objective Response Rate,2008-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9314,NCT02488577,Overall percent of postoperative complications.,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,Recurrence.
9315,NCT00027534,Safety,2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immune response
9316,NCT04929587,Frailty assessed by Frailty Phenotype (FP),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sleep assessed by Pittsburgh Sleep Quality Index (PSQI)
9317,NCT05007015,EORTC-QLQ-C30,2022-01-15,RECRUITING,INTERVENTIONAL,['NA'],,Bowel diaries
9318,NCT03836131,The percentage of cancer in patients with GM-LSTs treated with endoscopic resection.,2018-12-31,COMPLETED,OBSERVATIONAL,['NA'],,
9319,NCT02650427,Safety (Number of adverse events. Toxicity grade > 3),2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Infiltration of leucocytes in tumor tissue
9320,NCT01218854,The difference between MD-NASS and standard method,2012-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9321,NCT05872828,Depression score,2023-04-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Immune variables 8
9322,NCT03780439,diagnostic accuracy of procalcitonin to detect post-operative infection,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,diagnostic accuracy of procalcitonin to detect overall post-operative complications
9323,NCT02045030,A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,The quality of life impact of treating with FOLFIRI in combination with Aflibercept
9324,NCT03620461,Assess adverse events (per CTCAE v4.0 criteria),2013-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
9325,NCT05957367,Objective response rate (ORR) (Expansion Phase),2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area under the concentration-time curve (AUC)
9326,NCT00747136,"Determine sensitivity/specificity to identify dysplasia/cancer in the esophagus WavSTAT System alone, endoscopist alone/combination of WavSTAT and endoscopist. Sensitivity of the endoscopist will be compared to combination of endoscopist and WavSTAT.",2008-08,TERMINATED,OBSERVATIONAL,['NA'],,
9327,NCT01475331,Number of Participants With the Changing in Cyst Volume,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9328,NCT02325999,DFS,2013-12,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
9329,NCT02465736,Toxicities of neo-adjuvant chemoradiotherapy,2015-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Health Related Quality of Life
9330,NCT04198337,Complete resection of GIST,2014-08-01,RECRUITING,INTERVENTIONAL,['NA'],,technical success in complete resection
9331,NCT00002828,,1995-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9332,NCT04515082,"Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.",2020-08,UNKNOWN,OBSERVATIONAL,['NA'],,"To compare the performance of the bi-target stool DNA testing to a commercially available FIT assay, both with respect to cancer and advanced precancerous neoplasm."
9333,NCT01306799,Volumetric bone mineral density as measured by pQCT,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,measure vitamin B12 levels at each study visit
9334,NCT02873195,Progression Free Survival (PFS),2017-07-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment (Toxicity)
9335,NCT05894694,PFS,2023-06-11,RECRUITING,INTERVENTIONAL,['PHASE4'],,1-year PFS rate
9336,NCT00780988,To assess the feasibility of using an autologous tumor cell vaccine in combination with standard chemotherapy followed by investigational autologous hematopoietic and immune cell rescue in terms of acceptable clinical toxicity.,na,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Ex vivo analysis of immune response
9337,NCT04865601,Correlation of DNA adduct and DNA repair products,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of DNA adducts with CRC causes
9338,NCT02933944,Immunological Activation in Tumour Mass by Assessing Number of Patients With Increased Intra-tumoural Lymphocytes.,2016-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in the Tumour Marker Carcinoembryonic Antigen (CEA) Throughout Treatment Will be Assessed by Analysis of Blood Samples to Follow the Evolution of Disease Under Treatment
9339,NCT00193882,Relief of dysphagia,2003-07-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to achieving a complete response i.e. dysphagia score of 0.
9340,NCT05861336,Resectability rate,2023-06-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life questionnaire (QLQ)
9341,NCT04203459,Animal model experiment: to verify the ability of intestinal bacteria to control anti msln car-t targeted killing pancreatic cancer cells.,2019-10-20,UNKNOWN,OBSERVATIONAL,['NA'],,
9342,NCT01921673,Progression-free survival,2013-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Biomarker
9343,NCT03033719,Global postoperative morbidity in both arms,2017-07-04,UNKNOWN,INTERVENTIONAL,['NA'],To compare our molecular classification with the different classifications already published in the literature on colorectal cance,Timed Get-up-and-go (TGUG)
9344,NCT01596582,Concordance Between Patient Preference and Test Ordered,2012-04,COMPLETED,INTERVENTIONAL,['NA'],Concordance Between Patient Preferences for a Screening Tests Other Than Colonoscopy and Test Ordered for High Versus Low Risk Patients,Provider Satisfaction
9345,NCT00841282,Increments of medications used for sedation,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,willingness to repeat colonoscopy
9346,NCT05857631,3-year cumulative incidence of grade ≥2 gastrointestinal or genitourinary toxicity,2023-05-29,RECRUITING,INTERVENTIONAL,['NA'],,C-MOSES scoring
9347,NCT03053999,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing,2012-10-09,UNKNOWN,OBSERVATIONAL,['NA'],,Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review
9348,NCT00259922,To compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerability, quality of life, pharmacogenetics (dependent on results from other data)"
9349,NCT03330028,Dose Limiting Toxicity (DLT) of Paclitaxel via Intraperitoneal Route Combined with Fixed Doses of Mitomycin and Cisplatin during Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC),2017-10-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9350,NCT00001165,,1978-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9351,NCT05879783,Accuracy of pCLE optical biopsy,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,The positive predictive value and negative predictive value of pCLE optical biopsy
9352,NCT04385316,DNA extraction of tumer tissue samples and high-throughput sequencing,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,"DNA extraction of tumer tissue samples, blood tissue and urine samples and high-throughput sequencing"
9353,NCT05053971,Objective response rate (ORR) (Phase II),2022-11-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Non-sequencing biomarker analysis,Progression free survival
9354,NCT05623787,Early peritoneal recurrence,2022-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Early distant recurrence
9355,NCT02021604,Accuracy of PET imaging compared to intraoperative pancreatic biopsy in patients with congenital hyperinsulinism,2013-10-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Ratio of Standard Uptake Value max to sub max
9356,NCT00256932,to compare alvimopan with placebo for efficacy in the treatment of OBD,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety and tolerability, quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data)"
9357,NCT02300727,Number of Participants With Serious and Non-Serious Adverse Events,2015-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Health Providers Assessment of Oral Mucositis and Healing Time Measured by the Common Terminology Criteria for Adverse Events (CTCAE) and World Health Organization's (WHO's) Oral Toxicity Scale (OTS)
9358,NCT00282100,To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.,2005-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.
9359,NCT00812942,Participation to colorectal cancer screening,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,
9360,NCT00019591,Response rate every 3 months for up to a year after completion of study treatment,1999-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9361,NCT00343668,response rate,2005-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,treatment-related toxicities
9362,NCT00064207,"Overall survival as measured by Logrank every 3 months in years 1-2, and every 6 months thereafter in phase III",2003-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) v3.0 and EORTC QLQ PAN-26 every 3 months in years 1-2 and every 6 months thereafter
9363,NCT03425773,Incidence of Serious Adverse Events assessed with CTCAE v4.03,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change of tumor burden
9364,NCT00105443,Time to Symptomatic Progression (TTSP),2005-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire
9365,NCT03984578,Immune T-cell infiltration before and after treatment,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of cell viability and cell death at fixed time points (e.g. 24 or 48 hours)
9366,NCT03278106,16-Week Progression-free Survival (PFS) Rate,2017-10-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Mutation Status of the Tumor,"Overall Toxicity Rates (Percentages) for Grade 3 or Higher Adverse Events Considered at Least Possibly Related to Treatment, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)"
9367,NCT00149396,Clinical Laboratory Safety - Coagulation,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha)
9368,NCT02662478,Success rate,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of classification system
9369,NCT05161572,Pathological complete regression (pCR) rate,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2'],To study the influence of preoperative therapy on the tumor immune microenvironment (TIME) and systemic immune status.,Safety of surgery after preoperative therapy include chemo(radio)therapy and PD-1 antibody.
9370,NCT04812054,Model for early graft dysfunction score,2021-04-05,UNKNOWN,INTERVENTIONAL,['NA'],Allograft ATP content,Postoperative complications
9371,NCT03189953,Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,GLP-1 receptor expression by histology compared to tracer uptake
9372,NCT04241523,Resection rate,2020-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Exploratory serum biomarker research
9373,NCT03516708,Phase II Treatment Cohort only: Neoadjuvant Rectal (NAR) Score,2019-10-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I and Phase II Treatment Cohort only: Complete clinical response rate (cCR)
9374,NCT03738787,Rate of postoperative mortality,2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Overall survival,Variation of Body Mass Index after pancreatoduodenectomy
9375,NCT05229900,Number of participants with DLTs by dose level,2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE1'],,Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only)
9376,NCT00101036,Response Rate,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate.
9377,NCT00785785,Time to Progression Free Survival (PFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9378,NCT00324428,"Pain (visual analog scale, CGI,PGA); Medication use (medication diary)",2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Safety (cognitive assessment - neuropsychological battery)
9379,NCT06289712,Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up,2023-11-23,RECRUITING,OBSERVATIONAL,['NA'],,Develop software solutions potentially usable in real-time and tailored for clinical use.
9380,NCT06096896,5-years overall survival (OS) after MWA for early HCC,2023-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Rate of completed ablation after MWA
9381,NCT05934058,Impact of major gastric cancer risk factors on its aetiology in rarer patients subgroups,2023-07-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Development of a genome-wide modelling of Polygenic risk score (PRS) in gastric cancer
9382,NCT02500004,Brown adipose tissue (BAT) activity measured by PET(-MRI),2015-06,COMPLETED,INTERVENTIONAL,['NA'],,"Lean tissue mass measured by MRI, DXA, and doubly labeled water"
9383,NCT01643460,Cyst resolution,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,
9384,NCT06205732,Progression-Free-Survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
9385,NCT02135419,Anal Cancer Incidence,2014-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Quality of Life Assessment Measured by the A-HRSI (Validated Tool),Change in Physical Symptom Score From Baseline (2-7 Days Post Randomization) Until 4 Weeks Post Randomization
9386,NCT02503631,To provide stool and blood specimens to assess new markers for the detection of CRC,2014-10,TERMINATED,OBSERVATIONAL,['NA'],,To provide quality control material for use in assessing performance of developed assays
9387,NCT05355155,"Objective Response Rate (ORR) ,Based on RECIST 1.1",2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety as measured by number and grade of adverse events
9388,NCT06104579,Rate of Organ-space surgical site infection,2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
9389,NCT04389957,Provider Screening Adenoma detection rate (Sceening colonoscopies only),2020-06-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Bowel Preparation Quality (provider level)
9390,NCT02595086,"Incidence of Dumping syndrome, assessed by Sigstad score (≥7)",2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Gross and microscopic changes measured by gastroscopy (composite)
9391,NCT05421689,Anterior tongue pressure measured from Iowa Oral Performance Instrument (IOPI),2022-05-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Patient-reported Quality of Life based on FACT-HN score,Patient-reported dysphagia symptoms based on Eating Assessment Tool EAT10 score
9392,NCT00710710,Best Objective Response Evaluated According to the RECIST Criteria by Independent Review,2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Incidence and Intensity of Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE)
9393,NCT01133951,Gastric cancer incidence,2010-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Histopathological changes
9394,NCT04684095,Changes of quality of life (QoL) at 1 year after randomization compared with baseline,2021-05-26,RECRUITING,INTERVENTIONAL,['NA'],Economic assessment for ePRO compared to regular follow-up,Patient satisfaction
9395,NCT01389986,Time to first flatus,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Patients' satisfaction
9396,NCT02406508,Progression free survival in months of patients receiving Melphalan/HDS treatment followed by Sorafenib,2014-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Quality of life questionnaires,
9397,NCT00614601,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,We will use overall survival and adverse events rates as secondary endpoints.
9398,NCT03594630,Time to surgery or death,2024-03-13,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Pathologic Findings
9399,NCT04059731,Postoperative complications,2019-06-20,UNKNOWN,INTERVENTIONAL,['NA'],,Hospital Stay
9400,NCT00003617,,1995-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
9401,NCT03007407,Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1,2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Frequency of Adverse Events Assessed by CTCAE 4.0, From Beginning of Treatment to 90 Days After Last Dose"
9402,NCT00756951,Efficacy of Oral Mucositis assessment will be completed by trained site personnel. The WHO score will be the primary measure and NCI CTCAE will be a secondary measure for assessing Oral Mucositis.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9403,NCT04457193,Percentage of participants with normal esophageal acid exposure time,2018-06-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Change in Gastroesophageal Reflux Disease (GERD) symptoms assessed by the Reflux Symptom Index (RSI)
9404,NCT00605800,To determine qualitatively and quantitatively whether bone marrow derived liver associated stem cells are mobilized from the bone marrow in patients undergoing major liver resections (3 or more liver segments).,2006-03,WITHDRAWN,OBSERVATIONAL,['NA'],,To determine whether a difference exist in the baseline levels of bone marrow derived liver associated stem cells between normal healthy subjects/ volunteers and cancer patients prior to liver surgery.
9405,NCT00021268,,2001-04,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9406,NCT06134388,Investigating the possible efficacy of sulfasalazine through evaluation of its impact on disease control rate (DCR).,2023-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluating the safety and tolerability of sulfasalazine through investigating Renal function test (serum creatinine (mg/dL), blood urea nitrogen (mg/dL) and creatinine clearance (mL/min))."
9407,NCT02345889,Adenomas Per Colonoscopy,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,"Percent of Sessile Serrated Polyps in the Right Side of the Colon, Which Includes the Cecum, Ascending Colon, and Hepatic Flexure."
9408,NCT01550510,Number of Participants That Experience Serious Adverse Events as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants That Are Alive After 11 Weeks.
9409,NCT01149434,Tumor Response in the Ovarian Cancer Cohort,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor Response
9410,NCT00182715,Overall survival at 2 years,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Time of disease control at 2 years
9411,NCT00182130,Hospital rate of local recurrence,2002-05,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
9412,NCT00685568,Toxicity,2002-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (plasma drug trough concentrations)
9413,NCT03188991,Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability),2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cyst Volume Response
9414,NCT05061017,Objective Response Rate (ORR) - (Cohorts 2 & 3),2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,2-year Overall Survival (OS)
9415,NCT05254847,1 year DFS rate,2021-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,AE
9416,NCT01378507,Short-term result after ESD,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,The safety of ESD procedure
9417,NCT05514158,The incidence and severity of adverse events (AE),2022-09-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
9418,NCT04896931,Establishment of BTC population,2022-07-12,RECRUITING,OBSERVATIONAL,['NA'],,establishment of sample collection (tumorblocks and blood)
9419,NCT03350490,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
9420,NCT00003368,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9421,NCT00033306,"Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.",2002-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Determine the response duration, time to progression, and survival in patients treated with this drug."
9422,NCT05057845,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9423,NCT05242757,The size (tumor diameter) and number (tumor recurrence lesions) of PHC tumors were examined by enhanced abdominal CT,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
9424,NCT02571946,one-year overall survival,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,Hepatobiliary phase signal change after proton beam therapy
9425,NCT00646139,Maximum tolerated dose,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological effects
9426,NCT02395250,Adverse events attributed to the administration of the anti-GPC3 CAR T cells,2015-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9427,NCT05088304,postoperative complications,2015-09-01,COMPLETED,OBSERVATIONAL,['NA'],,hospitalization cost
9428,NCT06022978,Diagnostic accuracy for T1a and T1b staging,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
9429,NCT01943318,"Liver-related outcome: Decompensated liver cirrhosis (ascites, variceal bleeding, hepatic encepahlopathy), occurence of hepatocellular carcinoma",2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Liver-related mortality
9430,NCT03853473,6 Minute Walk Test Distance (Pre Surgery),2019-02-22,COMPLETED,INTERVENTIONAL,['NA'],Length of Hospital Stay,Intraoperative Blood Pressure Variability
9431,NCT00552058,Percentage of Subjects in Clinical Remission at Week 6,2008-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
9432,NCT03123432,immunomodulating effects,2011-06-01,COMPLETED,INTERVENTIONAL,['NA'],,length of hospital stay after surgery
9433,NCT00900419,Genetic mutations or altered growth factor expression,2001-05-03,RECRUITING,OBSERVATIONAL,['NA'],,Establishment of a tissue repository of normal and dysplastic respiratory epithelium
9434,NCT03636607,Calculating the overall diagnostic sensitivity and specificity and ROC,2018-06-13,RECRUITING,INTERVENTIONAL,['NA'],,Calculating the overall diagnostic sensitivity and specificity and summarizing the intrinsic correlations
9435,NCT04312360,Change in bacterial composition (Exploratory primary outcome 2),2020-01-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assessment of any adverse events or side effects regarding the spraying of the right hemicolon with fosfomycin/metronidazole gel in track 2.
9436,NCT03167125,Increased colorectal cancer screening rates,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],,
9437,NCT02252926,Reduction of oral and pharyngeal pain measured on Visual Analogue Scale (VAS),2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Peak plasma concentrations of bupivacaine
9438,NCT03065257,Number of participants with reduction in clinical symptoms,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],Number of participants with successful completion of treatment,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
9439,NCT02961283,Part B: evaluates the preliminary efficacy of ASN003 in subjects with selected BRAF and PI3 kinase mutated cancers,2016-10,TERMINATED,INTERVENTIONAL,['PHASE1'],Change in tumor mutational status,Appearance of new tumor lesions
9440,NCT02700555,Incidence of newly developed diabetes mellitus,2016-02,TERMINATED,OBSERVATIONAL,['NA'],,3-year recurrence-free survival & 5-year recurrence-free survival
9441,NCT00005981,Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9442,NCT01105806,To document advance directive (AD)completion,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,To longitudinally follow discussions about ADs and nature of hospitalizations
9443,NCT05040360,Recurrence-free survival (RFS),2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
9444,NCT03070262,overall survival (OS),2017-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,progression-free survival (PFS)
9445,NCT04280393,adenoma detection rate per patient,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Demonstrate the non-inferiority of patient experience when comparing Endocuff Colonoscopy and Standard Colonoscopy
9446,NCT04739501,Post_TACE hepatic cell failure,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9447,NCT04445532,Collected samples,2020-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Multi-omics analysis to further type and find therapeutic targets
9448,NCT02743065,Progress-free-survival (PFS),2016-09,UNKNOWN,OBSERVATIONAL,['NA'],,Objective Response Rates
9449,NCT01540435,Failure-free survival (FFS@18),2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Pathologic response rate
9450,NCT04488549,Predictive power of respondents' and hospitals' demographics on delaying colorectal cancer care across 6 geographical regions,2020-05-20,COMPLETED,OBSERVATIONAL,['NA'],,
9451,NCT00585312,Time to Disease Progression,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,Colorectal Polyp Burden
9452,NCT00910819,Course of Antineoplastic Treatment,2006-09,COMPLETED,OBSERVATIONAL,['NA'],,
9453,NCT00565682,To measure the amount of rescue medication (opioid) needed to relief,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,To determine the overall analgesic effect using the visual analog scale (VAS)
9454,NCT05279677,ORR,2022-08-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
9455,NCT06253611,Objective response rate (ORR) at 4 months,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,1-year and 2-year PFS
9456,NCT00327457,Medical record verified flexible sigmoidoscopy or colonoscopy,2002-06,COMPLETED,INTERVENTIONAL,['NA'],,
9457,NCT05624099,Objective Response Rate(ORR),2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival(PFS)
9458,NCT01525069,Dose-limiting toxicities (DLTs),2012-04-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Time to progression (TTP)
9459,NCT05943041,Incidence of Adverse Events from baseline to 8 weeks,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes of LARS(Low Anterior Resection Syndrome) score from baseline to 8 weeks,
9460,NCT05346536,CTC-AXL measurement concordance rate,2022-06-16,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of circulating immune system: platelets
9461,NCT03906110,Fecal Immunochemical Test (FIT) Use- Time Point 3,2018-04-03,COMPLETED,OBSERVATIONAL,['NA'],,
9462,NCT00957424,Number of Participants Willing to Continue With Preferred HRP,2009-06,COMPLETED,INTERVENTIONAL,['NA'],,
9463,NCT05028725,Proportion of True-Negatives (specificity) detected with the EsoCAN assay after specimen collection using 'EsophaCap' sponge sampling (ESCC cases & controls only),2022-05-16,RECRUITING,INTERVENTIONAL,['NA'],,Median Acceptability Scores
9464,NCT05734820,Diagnostic performance of AI-assisted polyp detector,2020-01-11,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma Miss Rate (AMR)
9465,NCT00262171,,2002-05,UNKNOWN,OBSERVATIONAL,['NA'],,
9466,NCT04902144,Clinical and Patient Reported Outcomes Following Genetic Test Results,2020-08-03,COMPLETED,INTERVENTIONAL,['NA'],,
9467,NCT00320320,Response rate after FOLFIRI reintroduction,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
9468,NCT02887313,Pathological complete response rate,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease free survival
9469,NCT05846035,the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.,2023-04-15,RECRUITING,OBSERVATIONAL,['NA'],,
9470,NCT04547153,hematological response rate (HeRR),2021-01-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life assessed by EORTC QOL C-30 and STO-22 (QoL)
9471,NCT02353858,Pathological complete response rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,post operative morbidity
9472,NCT00265356,proportion of patients who have a change in management resulting from PET,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,prognostic ability of the PET standard uptake value (SUV) in predicting 3-year overall survival
9473,NCT02772029,time to progression,2016-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
9474,NCT01839539,Progression-free survival (PFS),2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Laboratory findings (The number of CD3+ (or CD8+ or CD4+ or CD56+)T cell)
9475,NCT00882973,The recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profiles
9476,NCT00436072,"To determine the tolerability and maximum tolerated dose of combining ZD6474, cetuximab and irinotecan in patients with metastatic colorectal cancer refractory to prior cytotoxic chemotherapy.",2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Determine response rate, progression-free survival and overall survival of adding ZD6474 to cetuximab and irinotecan in this patient population."
9477,NCT01653496,Overall compliance to the ERAS program,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mortality
9478,NCT05189730,Incidence of adverse events,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
9479,NCT02137356,Number of patients with adverse events,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of patients whose tumors demonstrate pathological complete response at resection
9480,NCT00611000,"DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells",2003-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Differential gene expression in colonic and PBMCs by microarray analysis
9481,NCT02471313,Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9482,NCT03259009,Progression-free survival (PFS),2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS)
9483,NCT00487409,this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.,2006-12,COMPLETED,INTERVENTIONAL,['NA'],,Will evaluate the surgical approach using electrocautery with surgical clips and staples
9484,NCT00748215,Number of Participants With Grade 3/4 Diarrhea,2009-02-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9485,NCT02569645,To determine the pathological complete response rate in patients with high-risk locally advanced rectal cancer treated with standard neo-adjuvant chemotherapy and radiation in combination with rosuvastatin.,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dose normalized AUC will be collected as pharmacokinetic data
9486,NCT02077868,Overall survival,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
9487,NCT00608595,Change of gene and protein expression pattern from pre- to post-treatment levels,2002-07,TERMINATED,INTERVENTIONAL,['NA'],,
9488,NCT06242470,Number of participants with adverse events (AEs) and serious AEs (SAEs),2024-03-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants who develop anti-MGC026 antibodies (immunogenicity)
9489,NCT01744353,"Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer.",2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Response Rate (if Patient's Tumor(s)Are Progressing or Being Controlled) Following Treatment With FOLFOX-A for Patients With Newly Diagnosed, Advanced Pancreatic Cancer."
9490,NCT01846520,Effects of FCPCI on psychological distress,2013-10,COMPLETED,INTERVENTIONAL,['NA'],,Caregiver out-of-pocket costs
9491,NCT02127541,Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT.,2014-01-06,COMPLETED,INTERVENTIONAL,['NA'],,Comparison of the angiogenesis markers with the those of breast carcinoma patients
9492,NCT05387681,pathological complete response (pCR),2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,pathological partial response(MPR)
9493,NCT06109805,Plasma metabolite content,2023-10-20,RECRUITING,OBSERVATIONAL,['NA'],,
9494,NCT02506803,Number of participants with toxicity of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The R0 resection rate of NAC-GEMABR therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
9495,NCT04985981,Occurrence of Anastomotic leak,2021-04-01,SUSPENDED,OBSERVATIONAL,['NA'],Additive curative surgery (no/yes: liver; lung; locoragional relapse),Time to diagnosis of anastomotic leak
9496,NCT06002789,pCR rate,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 years OS Rate
9497,NCT05630794,Mean change in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in polyps induced by ONC201,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Adenoma-derived organoid take rates between samples obtained prior to and following treatment,Proportion and severity of treatment emergent adverse events
9498,NCT00628368,Role of predictive factors in the EGFR signaling pathway in response to treatment,2005-11,UNKNOWN,INTERVENTIONAL,['NA'],,Establishment of a tissue bank
9499,NCT06202183,Gut Microbiome Genomes,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in Chemotherapy Toxicity
9500,NCT05942768,Overall Survival (OS),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment-Related Adverse Events (TRAE)
9501,NCT02511821,Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively,2015-07-22,COMPLETED,INTERVENTIONAL,['NA'],,"Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool"
9502,NCT06121622,Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours,2024-01-16,RECRUITING,OBSERVATIONAL,['NA'],,
9503,NCT01523353,Anaerobic threshold prior to liver resection,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Recovery of fitness
9504,NCT00187109,To evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9505,NCT04345770,overall survival,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,complication rate
9506,NCT05149807,Phase III : Event-free Survival (EFS),2022-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,30-day postoperative mortality.
9507,NCT03401294,Rate of liver metastasectomy,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9508,NCT00147147,Overall survival,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,the site of recurrence
9509,NCT02056691,Assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and assess the effects of preoperative exercise on the proliferation of colorectal cancer cells,2014-10,COMPLETED,INTERVENTIONAL,['NA'],,Irisin levels
9510,NCT05339763,bowel function,2019-08-12,COMPLETED,INTERVENTIONAL,['NA'],,fecal incontinence
9511,NCT03359616,Disease-free survival (DFS),2018-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,mortality rate
9512,NCT04207463,Overall response rate (ORR),2020-06-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9513,NCT00513331,"To standardize physician recommendations and provide cutting edge technology to patients with BE and GERD, and establish a Valley Hospital Center for Barrett's Esophagus and GERD",2007-07,COMPLETED,OBSERVATIONAL,['NA'],,"To assess clinical outcomes of patients enrolled in The Valley Hospital Center for Barrett's Esophagus and GERD, and modify algorithms as appropriate."
9514,NCT05022719,"The interference level of detrimental effects on the visualization of the colonic mucosa during CCE, due to use of MB-MMX per colonic segment.",2021-10-04,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the safety of CCE procedure while using MB-MMX.
9515,NCT01600209,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,
9516,NCT01697462,Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs),2009-07,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Hand-Foot Syndrome (HFS)
9517,NCT00003571,disease free survival,1998-08,COMPLETED,OBSERVATIONAL,['NA'],,determine the prognostic and predictive values for response to this therapy
9518,NCT01187641,"The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis.",2010-08-18,COMPLETED,OBSERVATIONAL,['NA'],,"We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images"
9519,NCT04683939,Occurrence of dose-limiting toxicities (DLTs) within a patient during the DLT evaluation period,2022-01-18,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,BNT141 - Duration of response (DOR)
9520,NCT06144827,Feasibility of Quantitative Multiparametric MRI,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in Total Liver Volume and Volume of non-irradiated and irradiated lobes
9521,NCT05720559,Overall Survival (OS),2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
9522,NCT02572687,Number of Participants with Dose Limiting Toxicities (DLTs),2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies
9523,NCT00394992,"3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.",2006-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Overall survival, defined as the percentage of patients alive 5 year after randomisation."
9524,NCT00797732,Treatment Compliance Rate,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,MDADI Scores
9525,NCT05571644,Pathological complete response (pCR) rates,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local recurrence rate
9526,NCT02601079,Highest proportion (number) of representative biopsies for diagnostic purposes from the tumor tissue.,2016-09,TERMINATED,INTERVENTIONAL,['NA'],,Number of fusion genes in tissue harvested from esophageal neoplasms prior to neoadjuvant oncological treatment.
9527,NCT03919461,Biomarkers in blood samples assessing pro- and anti-metastatic processes,2019-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Fatigue
9528,NCT04807972,Phase 2: Overall Survival,2021-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants Experiencing Adverse Events
9529,NCT05837065,the Harrell concordance index (C-index),2022-09-15,RECRUITING,OBSERVATIONAL,['NA'],,the time-dependent area under the receiver operating characteristic curve(tdAUROC)
9530,NCT01959061,Progression-free survivial,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
9531,NCT01807390,Change in pain perceptions,2012-07,UNKNOWN,OBSERVATIONAL,['NA'],,Change in general health related quality of life
9532,NCT02502656,"Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods",2015-07,UNKNOWN,OBSERVATIONAL,['NA'],,Comparisons of the costs between the two methods
9533,NCT05477836,Length of colon explored,2022-10-18,COMPLETED,INTERVENTIONAL,['NA'],,Perception of difficulty
9534,NCT04353882,MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue.,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],Concomitant Diseases,MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue.
9535,NCT02710812,Rate of organ preservation,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29
9536,NCT02451956,Object response rate (ORR),2015-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of subjects with Adverse Events as a Measure of safety and tolerability
9537,NCT00812240,Progression Free Survival (PFS),2009-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
9538,NCT05347745,therascreen® KRAS RGQ PCR Kit,2022-01-07,UNKNOWN,INTERVENTIONAL,['NA'],,
9539,NCT01975077,safety and tolerability,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
9540,NCT00587184,,2006-07,COMPLETED,OBSERVATIONAL,['NA'],,
9541,NCT05163483,Objective Response Rate（ORR）,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
9542,NCT05609695,Overall Survival,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Progress Free Survival
9543,NCT04093648,Dose Limiting Toxicity (DLT) Rate,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Response Rate according
9544,NCT06287671,Correlation between biomarker in plasma and tissue,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9545,NCT05027425,Cellular rejection rates,2021-12-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Recurrence-free survival and overall survival outcomes based on survival follow up reporting
9546,NCT00683241,To determine the feasibility and safety of administering DCVax-L intradermally combined with intravenous bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian or primary peritoneal cancer.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To assess the immunogenicity of DCVax-L administered intradermally in patients with recurrent ovarian or recurrent primary peritoneal cancer, combined with intravenous bevacizumab and oral metronomic cyclophosphamide."
9547,NCT04166604,Rate of patients free of trifluridine/tipiracil dose reduction or postponement of cycles of > 7 days at 6 months or at progression or death or stop of treatment for another cause than neutropenia if observed in 6 months.,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Clinical or biological factors at baseline associated with the occurrence of grade 3-4 neutropenia
9548,NCT05444088,Objective Response Rate,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-Free-Survival assessed by investigator
9549,NCT00357942,Use of supplemental analgesics,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Oral intake of food
9550,NCT00137761,To determine the response rate of Iressa and docetaxel in patients with advanced pancreatic cancer following failure of gemcitabine-based therapy,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine the safety, radiologic response rate, progression-free survival and overall survival of patients treated with Iressa and docetaxel"
9551,NCT04508764,Number of primary barriers to genetic testing for family members,2021-04-09,RECRUITING,INTERVENTIONAL,['NA'],,
9552,NCT05412082,Incidence of Toxicity Among Participants After Start Receiving MRI-g Pelvic ART,2022-10-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Health-related Quality of Life (HRQOL) Scores: Pittsburgh Sleep Quality Index (PSQI)
9553,NCT00003446,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9554,NCT00895323,Tissue distribution,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
9555,NCT03766295,Overall Survival (median),2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival
9556,NCT02824835,percentage of cells in G2/M arrest after dose-dependent exposure,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,
9557,NCT02177084,LARS score,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,morbidity
9558,NCT03558724,Safety of bevacizumab-800CW administration by monitoring vital signs and/or (serious) adverse events.,2018-10-29,TERMINATED,INTERVENTIONAL,['PHASE1'],,The variation in fluorescence intensity between fluorescence molecular endoscopy before and after neoadjuvant chemoradiotherapy defined as the tumor to background ratio and intrinsic fluorescence.
9559,NCT00145015,Apoptosis in colonic biopsy samples,2004-12,COMPLETED,INTERVENTIONAL,['NA'],,gene transcription
9560,NCT01666756,"Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2014-06-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in levels of soluble biomarkers,Sorafenib tosylate concentration after co-administration with Chinese herbal formulation PHY906
9561,NCT03260647,Optimization of multidisciplinary care,2017-08-04,RECRUITING,OBSERVATIONAL,['NA'],,Evaluate cannabis use in patient population
9562,NCT06097416,Overall survival,2024-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression-free survival
9563,NCT03022734,complete resection (R0) rate for rectal and liver lesions,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate (RECIST V1.1)
9564,NCT02552745,Pain scores,2014-10,COMPLETED,OBSERVATIONAL,['NA'],,Hospital Stay
9565,NCT00642603,Progression-free Survival (PFS) in U.S. Patients Only,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
9566,NCT03957031,Exposure to a variety of potential sources of GC risk factors,2019-05-31,UNKNOWN,OBSERVATIONAL,['NA'],,
9567,NCT03638206,"Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0",2018-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,CAR-T cells testing
9568,NCT01271192,5-year disease free survival,2010-12,UNKNOWN,INTERVENTIONAL,['NA'],,"Side effect of chemo radiotherapy, postoperative complications, recurrent rate, distant metastatic rate,biomarkers, quality of life, toxic profile, convenience"
9569,NCT02094105,incidence and mortality of ESCC,1999-11,COMPLETED,INTERVENTIONAL,['NA'],,"Cumulative incidence and mortality of total cancer, and gastric cardia cancer"
9570,NCT00031837,Quality of life as measured by FACT-Hep version 4 every 4 weeks,2002-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Safety as measured by the occurrence of bleeding complications
9571,NCT03300544,Incidence of dose limiting toxicities of TVEC,2017-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival
9572,NCT00526786,The eradication of LGD and HGD within BE at 24 months after the final treatment. The primary safety endpoint is the incidence of all adverse events.,2007-09,TERMINATED,INTERVENTIONAL,['PHASE4'],,1.Eradication of all BE by 24 months after the final treatment. 2.The proportion of lesions that decreased in length by the 24-month follow-up. 3.The proportion of lesions where severity was downgraded by the 24-month follow-up.
9573,NCT03421288,Comparison of Event free survival (EFS) between arms,2018-09-14,RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA clearance on treatment,Overall survival (OS) and EFS in the subgroup of patients with PD-L1 CPS score ≥ 5 and ≥ 10 and patients with MSI
9574,NCT02352259,Evaluation of Safety Related to Electrochemotherapy,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response to Treatment (Determined by Modified RECIST Criteria).
9575,NCT03803267,Postoperative pain score,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Serum C-reactive protein (CRP)
9576,NCT00475722,Adherence to Dietary Goals,2007-05,COMPLETED,INTERVENTIONAL,['NA'],,
9577,NCT01833546,Number of Participants Who Experienced Any Dose-Limiting Toxicity (DLT) During First Cycle - Day 1 to 28,2013-04-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
9578,NCT03760003,Modified Mayo Score,2019-09-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically-significant laboratory abnormalities
9579,NCT04387695,Progression-free survival (PFS) rate,2020-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Disease control rate
9580,NCT02106858,Percentage of patients with adverse drug reactions (ADRs),2014-06-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS)
9581,NCT03875781,Survival,2019-06-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life - physical functioning: QLQ-C30
9582,NCT03536793,"Measurement of the accuracy of protein markers (e.g., TF, AM) in detecting early stage pancreatic cancer by comparison of laboratory results from ELISA assays and platform technologies to patient clinical data.",2018-10-24,RECRUITING,OBSERVATIONAL,['NA'],,
9583,NCT01247506,,2010-02,UNKNOWN,OBSERVATIONAL,['NA'],,
9584,NCT05611034,safety as measured by acute lung injury findings,2023-02-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of mechanical ventilation
9585,NCT01671592,Ability to track the labeled DC vaccine by MRI,2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,May assess the disease-free survival and overall survival
9586,NCT04363801,Part C: Progression Free Survival (PFS) in G/GEJ DKK1 high and overall patients treated with DKN-01 in combination with tislelizumab and chemotherapy vs tislelizumab and chemotherapy as a first-line therapy,2020-07-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Dickkopf-1 (DKK1) concentration in serum and plasma relative to safety and efficacy outcomes in G/GEJ patients treated with DKN-01 in combination with tislelizumab as a second-line therapy,Part C:To characterize the frequency of toxicity ≥Grade 3 treatment-related adverse events (TRAE) associated with each of the treatment arms.
9587,NCT05872295,Objective Response Rate (Part 2),2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluation of the immunogenicity of IKS014 (Part 1 and 2)
9588,NCT03755921,M. D. Anderson Dysphagia Inventory (MDADI),2018-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Deglutition evaluation
9589,NCT04500548,Incidence of adverse events,2021-01-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Overall survival
9590,NCT01875198,Bleeding amount,2013-04,TERMINATED,INTERVENTIONAL,['NA'],,postoperative complication
9591,NCT02579278,To determine if there is a link between EMVI status and ctDNA,2015-11,RECRUITING,OBSERVATIONAL,['NA'],,To investigate the effect of ctDNA status on patient survival outcomes
9592,NCT06098560,Correlation of ctDNA changes with pCR rate and the duration of cCR,2023-08-16,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of ctDNA changes with 2 years PFS
9593,NCT00238160,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
9594,NCT05641233,"Hardness of pancreas texture, determined by Durometer measurement",2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,30-day mortality and in-hospital mortality
9595,NCT00006245,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9596,NCT04082455,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2018-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,progression-free survivals
9597,NCT06057350,CRC recurrence or sign of lymph nodes or distant metastases,2023-10-27,RECRUITING,INTERVENTIONAL,['NA'],Cost-effectiveness,Health related quality of life and functional outcomes after 30 days and one year
9598,NCT06172036,12-month EFS rate,2024-01-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
9599,NCT05396937,"Objective response rate, ORR",2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9600,NCT03209765,Compliance rate,2017-06-16,COMPLETED,INTERVENTIONAL,['NA'],,Compliance rate of second round
9601,NCT02384005,Kappa agreement will be calculated between lay person and nurse practitioner on the anal exam results.,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,Number of persons who state they intend to seek subsequent care in the event of an abnormal result to a self-DAE.
9602,NCT05101265,Total plasma dose-normalized AUC0-∞,2021-03-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacogenetics
9603,NCT05491889,mortality,2022-10-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9604,NCT05355662,Recurrence of the primary disease after surgery,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-operative complications in patients who underwent liver transplantation
9605,NCT03499795,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36,2018-05-15,COMPLETED,INTERVENTIONAL,['PHASE2'],"Percent Change From Baseline in the Size of Peri-Anal Lesions as Determined by the Investigator at Weeks 36, 64, and 88",Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL or no Evidence of HPV-16/18 at Week 36
9606,NCT04441580,Rate of patients detected with 3 or more adenomas.,2020-05-04,RECRUITING,INTERVENTIONAL,['NA'],,Specific contribution of AI
9607,NCT03630393,Postoperative Pain Medication Use,2019-05-09,TERMINATED,INTERVENTIONAL,['NA'],,Discharge Day (Post-operative Day 0 or 1)
9608,NCT02547610,The imaging biomarkers determined by MR-PET,2014-05,UNKNOWN,OBSERVATIONAL,['NA'],,
9609,NCT00603460,"Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.",2012-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9610,NCT00443573,"Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)",2006-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Tumor response rate, as assessed by RECIST criteria"
9611,NCT03561142,Clinical complete response rate,2018-06-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9612,NCT05086250,Feasibility of enrolling subjects which will be measured by the proportion of patients dropping out of study for any reason prior to the end of treatment visit.,2022-10-20,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,"To investigate the tolerability of oral ketamine in patients with pancreatic cancer and anxiety, which will be measured by patient-reported Ketamine Adverse Symptom Checklist and Impact scores."
9613,NCT03658044,Self empowerment measured by Cancer Behavior Inventory (CBI) scale,2018-12-01,COMPLETED,INTERVENTIONAL,['NA'],,Generated Knowledge in Online Discussions
9614,NCT00629759,"To determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 injected within unresectable solid tumor(s) within the liver",2006-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Secondary objectives include determination of JX-594 pharmacokinetics, replication and shedding, immune response, and injection site tumor responses."
9615,NCT05319054,Adherence of participants to the treatment programme,2022-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,LARS treatment history
9616,NCT06166147,Performance of cfDNA methylation-based model for discriminating pancreatic cancer versus non-cancer,2023-12-22,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Performance of pre-defined model in clinical sub-groups of interest
9617,NCT05707338,early postoperative complications,2023-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
9618,NCT02677389,Feasibility as defined by recruitment rate,2016-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm II)
9619,NCT05510388,The incidence of hypoxia,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complications related to high-flow nasal cannula
9620,NCT02870049,Screening completion rate,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,
9621,NCT01409499,Overall survival (OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,cost of treatments
9622,NCT04904042,Pathological evaluation,2021-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Global mortality.
9623,NCT02661971,Phase III: Overall Survival (OS): time from randomization to death of any cause,2016-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Phase II/III: Subgroup analyses: PFS (medians and rates) according to subgroup (intestinal vs. diffuse/mixed or unknown and GEJ vs. gastric)
9624,NCT04560270,Correlation of the ctDNA level to the response to chemotherapy,2016-04-25,COMPLETED,INTERVENTIONAL,['NA'],,Progression free survival
9625,NCT02606916,Clinical response rate,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,grade 3 or 4 toxicities according to CTCAE4.0
9626,NCT01622543,Progression Free Survival,2012-10-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9627,NCT00165061,Overall survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,4.Recurrence of the disease
9628,NCT05990543,Progression free survival,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
9629,NCT02211443,Number of participants with SCT200-related adverse events,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Time to Disease Progression (TTP) of SCT200,Area Under the plasma concentration versus time curve (AUC) of SCT200
9630,NCT03586869,Overall Response Rate by RECIST Version 1.1,2018-07-28,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life by patient-reported outcomes (PROs),ORR by RECIST Version 1.1
9631,NCT05319145,Short Physical Performance Battery (SPPB),2022-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Days spent at home (number of days)
9632,NCT06050707,Change in locoregional failure (LRF) at Year 2,2023-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL)
9633,NCT03072641,Changes in microbiota composition after probiotics use,2010-06-03,COMPLETED,INTERVENTIONAL,['NA'],,Epigenetic changes after probiotics use
9634,NCT00307736,"Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy",2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Pathologic Complete Response,"Post-operative Complications After Resection of Rectal Cancers Following Preoperative 5-FU, Bevacizumab, Erlotinib, and External Beam Radiation Therapy."
9635,NCT04975516,Progression free survival,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
9636,NCT05831488,"Assess the relationship between Seismofit®-estimated VO2 peak and CPET-measured VO2 peak in HPB, gastro-oesophageal or colorectal cancer patients undergoing preoperative assessment for major surgery.",2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Assess patient experience of the Seismofit® test using a brief measure that has been used previously in CPET research
9637,NCT01794793,Incidence of adverse events to evaluate long term safety data,2013-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,Percentage of patients with clinical benefit as assessed by the investigator
9638,NCT05754229,False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system,2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9639,NCT05978882,Detection rate of Sentinel lymph nodes,2023-08-17,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,5 year recurrence free survival rate
9640,NCT01890213,Number of participants with adverse events,2013-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9641,NCT05705791,Objective response rate,2023-02-07,RECRUITING,INTERVENTIONAL,['NA'],,Evaluate alternative response evaluation criteria
9642,NCT00790140,Preservation of body compostition after surgery,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Reduced immuno-inflammatory response to surgery
9643,NCT01374074,To examine the association between BE and environmental factors,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,To investigate the association between BE and genetic and epigenetic status of Cdx1/Cdx2
9644,NCT04096118,Survival rates,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
9645,NCT00171912,To assess the efficacy and the safety of imatinib mesylate therapy,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the effects of imatinib on quality of life and healthcare resource use
9646,NCT04906343,Advanced neoplasia and colorectal cancer incidence at 3 years,2021-06-05,UNKNOWN,INTERVENTIONAL,['NA'],,
9647,NCT02697058,Progression Free Survival (PFS) in Part 2 of Study,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Volume of Distribution at Steady-State (Vss)-Total Irinotecan, SN-38, and SN-38-Glucuronide (SN-38G)"
9648,NCT01972672,time to progress（TTP）,2013-10,COMPLETED,INTERVENTIONAL,['PHASE2'],Gene expression profiling of blood cells and tumor biopsies,Laboratory abnormal findings
9649,NCT06316466,OS,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,PFS
9650,NCT03114085,time to progression,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9651,NCT01273090,Toxicities of imetelstat sodium,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9652,NCT02402842,Progression-free survival rate,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment
9653,NCT06022692,disease control rate (DCR),2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival (OS)
9654,NCT04011969,Fecal immunochemical test (FIT),2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,
9655,NCT03151642,Number of MRIs,2017-04-05,COMPLETED,OBSERVATIONAL,['NA'],,
9656,NCT01052376,"Evaluate and validate CEM in terms of its ability to diagnose neoplastic lesions and to distinguish between normal and neoplastic mucosa in vivo, based on comparison between ""optical biopsies"" and standard histology.",2008-12,TERMINATED,INTERVENTIONAL,['NA'],,
9657,NCT05351398,Objective Response Rate,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,R0 resection rate
9658,NCT00769483,Progression Free Survival,2008-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation Between Plasma IGF-I Expression in Patients Treated With MK-0646 and OS,Treatment Toxicity
9659,NCT02490111,Proportion of patient developing gallstone at 12 month after gastrectomy,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to gallstone formation
9660,NCT02868151,World Health Organization criteria of grading oral mucositis.for head and neck cancer patients,2016-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
9661,NCT05205629,Progression Free Survival,2022-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,Conversion rate
9662,NCT02194387,Change in waist circumference (Pilot II),2014-09-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9663,NCT06043466,To obtain the maximum tolerable dose of C-13-60 cells [Safety and Tolerability],2023-08-11,RECRUITING,INTERVENTIONAL,['PHASE1'],Overall survival(OS) of C-13-60 cell treatment in patients with CEA-positive advanced malignancies[Effectiveness],The content of CEA in peripheral blood after infusion of C-13-60 cell [Cell dynamics]
9664,NCT02985801,Change in Body Weight,2016-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in Body Weight Composition
9665,NCT00812175,The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,Reports of adverse events
9666,NCT02404909,to investigate the influence of the liver resection on hemodynamic status in terms of hemodynamic indexes changes,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
9667,NCT05802407,Disease-free survival,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Overall survival
9668,NCT06186609,Progression-free survival,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
9669,NCT01091428,Phase 2: Progression-Free Survival (PFS),2010-04-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Banked Tumor Specimens for Candidate Markers of Response to Alisertib and Taxanes,Phase 2: Number of Participants With Clinically Significant Vital Sign Findings
9670,NCT01665625,overall surviva,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,surgical complications
9671,NCT06013657,Mortality,2021-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Length of stay
9672,NCT04582500,Patient Satisfaction,2021-02-15,RECRUITING,OBSERVATIONAL,['NA'],,Assessing Workflow of incomplete colonoscopies
9673,NCT00837876,Number of Patients With Progression-free Survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Worst Grade Toxicities
9674,NCT01484925,,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
9675,NCT04852653,Positivity of the liquid biopsy,2021-09-21,RECRUITING,OBSERVATIONAL,['NA'],,Genetic profile of the primary tumor predictive of the response to nCRT
9676,NCT02246322,Clinical performance of 22G and 25G needles,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,Major complications
9677,NCT06124131,Difference in proportion of participants completing colorectal cancer screening between study arms,2023-11-11,RECRUITING,INTERVENTIONAL,['NA'],Number of patients who receive intended treatment,"Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot"
9678,NCT00007618,,1998-01,COMPLETED,OBSERVATIONAL,['NA'],,
9679,NCT03794193,3-year Disease-free Survival,2016-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Distant organ metastasis rate
9680,NCT05823584,Sensitivity (vh-DNA vs AFP) (the vh-DNA which could be detected in the pre-operative plasma of participants.),2019-12-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity (TERT C228T vs AFP/AFP-L3/PIVKA-II)
9681,NCT02746224,Anorectal functional outcome at 12 months assessed by LARS scale,2016-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Distance to surgical margins
9682,NCT00482222,Progression-free survival,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety
9683,NCT01323400,Progression-free survival,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression"
9684,NCT04231929,Tumor response,2020-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Best overall response
9685,NCT00383266,Overall Response Rate (ORR),2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9686,NCT02706782,Number of patients with adverse event,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Detection of transferred T cells in the circulation using quantitative -PCR
9687,NCT03642093,Frailty Measurement,2018-08-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Quality of Life (QoL) Assessment
9688,NCT00628147,Neoplasm Miss Rate,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Procedure Complications
9689,NCT00655499,Objective Response Rate (ORR) During the Combination Therapy Phase,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9690,NCT05861947,Pharmacokinetics: Terminal elimination half life,2023-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory endpoint (PD biomarker): IFN-γ level,Laboratory abnormalities
9691,NCT05002608,change from baseline health insurance literacy to 5-month follow-up,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
9692,NCT00496509,Assess by dynamic contrast-enhanced magnetic resonance imaging the effect of once daily dosing with ZD6474 on tumour perfusion and vascular permeability in patients with advanced colorectal cancer and liver metastases.,2006-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment of the effectiveness of ZD6474 as measured by objective response rate and progression free survival based on RECIST.
9693,NCT01360411,Malignant or benign lesion,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Value of a Visual Analog Scale for strain image categorisation
9694,NCT00264979,Rate of patients with at least one postoperative severe complication within 60 days after each surgery,2006-03-02,TERMINATED,INTERVENTIONAL,['NA'],,Two years recurrence rate
9695,NCT01451658,Rebleeding,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE4'],,complication survival
9696,NCT03868215,Sensitivity,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9697,NCT03819088,Quality of life scores,2019-04-17,COMPLETED,INTERVENTIONAL,['NA'],,Serum albumin level
9698,NCT01712971,intra-operative blood loss,2012-11,WITHDRAWN,OBSERVATIONAL,['NA'],,hospital costs
9699,NCT02204150,Feasibility of OFDI Imaging in Subjects Swallowing the OFDI Capsule,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
9700,NCT02559687,Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR),2015-12-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9701,NCT01519999,Change in colorectal cancer screening adherence,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Providers'/staff shared decision-making experience
9702,NCT02726997,"Pharmacodynamic Changes Induced by Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Using a 2-Sample T-Test",2016-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Feasibility of Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Determined by Methods of Thall et all"
9703,NCT03556384,Overall Response Rate,2018-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events related to TMZ
9704,NCT05256381,Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1),2022-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-drug Antibodies (ADAs)
9705,NCT02251977,rates of grade 2 or more chronic cumulative neurotoxicity of both arms,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],genetic polymorphisms of oxaliplatin induced severe and cumulative neurotoxicity,rates of 3 year disease free survival of both arms
9706,NCT00579163,To establish a bank of DNA and frozen lymphoblastoid cell lines for the purpose of facilitating genetic epidemiology investigations of familial cancers.,1994-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,A related goal is to provide patients with cancer and their living relatives the opportunity to preserve DNA samples so that they may be used for future genetic counseling regarding inherited cancer risk.
9707,NCT04943406,Prognostic impact of ctDNA positivity,2020-05-08,RECRUITING,OBSERVATIONAL,['NA'],,Prognostic impact of ctDNA positivity in peritoneal lavage and peripheral blood on the risk of peritoneal and distant metastases
9708,NCT02869152,2nd Phase: Detection rate of refined protocol in identifying SLN,2016-08,UNKNOWN,INTERVENTIONAL,['NA'],,Ergonomic optimization of the protocol as measured by surgeon satisfaction
9709,NCT05279287,Number of errors in an operation using validated methodology- Objective Clinical Human Reliability Analysis (OCHRA),2023-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Application of Machine learning and Artificial Intelligence to video analysis
9710,NCT04223401,Postoperative morbidity rate by Clavien-Dindo,2020-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Psychological status by Hospital Anxiety and Depression Scale (HADS).
9711,NCT03973112,ORR,2019-09-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DOR
9712,NCT05843188,Overall response rate,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidences and severity of adverse events
9713,NCT02196935,Successful ERCP or EUS,2010-09,RECRUITING,OBSERVATIONAL,['NA'],,Definitive Diagnosis
9714,NCT03675737,Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10,2018-11-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)
9715,NCT00354679,Evaluation of Safety and Toxicity,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9716,NCT05038098,Safety of endoscopic peritumoral gastric injection of FerroTrace,2024-04-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
9717,NCT06229041,The PCR rate between total neoadjuvant treatment ±immunotherapy,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,
9718,NCT00177853,"Determine efficacy of combination of irinotecan, celecoxib and concurrent radiotherapy on pancreatic cancer; determine highest/safest doses of these drugs",2006-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tumor diminishment for safe excision
9719,NCT00417287,Determine if there is a difference in effect on circulating Trx-1 protein levels between two dose levels of PX-12,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Assess the effects of metabolic excretion of PX-12
9720,NCT03316677,the predictive value of intraoperative anastomosis testing on anastomotic leak.,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,The sensitivity of the 2 methods of intraoperative anastomosis testing.
9721,NCT00225784,Objective Response of Tumor by RECIST 1.0 Criteria,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pattern of Failure After Therapy
9722,NCT06022861,Objective Response Rate(ORR) as assessed by IRC,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (Nab)
9723,NCT01596634,Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire
9724,NCT01752933,Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib,2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9725,NCT06124001,Phase IIa:ORR,2023-11-30,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib and Phase IIa: herpes simplex virus type I antibodies
9726,NCT04753879,Progression-free Survival (PFS) after 6 months according to IRECIST criteria.,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing grade 3 or above drug-related toxicities
9727,NCT01764802,"Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version",2010-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Body change stress graded according to the Impact of Treatment Scale (ITS)
9728,NCT04989387,"Evaluation of Recommended Dose for Expansion (RDE) of INCA00186 as monotherapy and in combination with retifanlimab and/or INCB106385 as measured by safety, PK and PD data",2021-10-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"Duration of Response (DOR) from earliest date of disease response until earliest date of disease progression as determined by radiographic disease assessment, or death if occurring sooner than progression"
9729,NCT03718221,Patient-level Colorectal Cancer (CRC) Screening,2018-08-30,COMPLETED,INTERVENTIONAL,['NA'],,Neighborhood-level Screening
9730,NCT04927897,Maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen,2022-08-16,RECRUITING,OBSERVATIONAL,['NA'],Analysis of (re)biopsy material,Evaluation of risk factors for the presence and/or the extent of microscopic tumor spread identified by the meta-analysis we performed
9731,NCT03768531,Number of participants experiencing study drug-related toxicities,2019-06-14,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Disease free survival (DFS)
9732,NCT00132041,Proportion of Participants With Successful Control of Disease at 18 Months,2005-12,COMPLETED,INTERVENTIONAL,['NA'],,Remote Tumor Occurrence Rates
9733,NCT03189914,Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2),2017-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Quality of Life (QOL) (Phase 1 and 2),Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15
9734,NCT02762448,HCV clearance and complete regression of NHL by ASV+ DCV,2016-07,WITHDRAWN,OBSERVATIONAL,['NA'],,
9735,NCT02611700,Median time of overall survival(OS),2015-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
9736,NCT05722223,To explore the feasibility of a trimodal prehabilitation program in the hospital setting,2022-03-15,RECRUITING,INTERVENTIONAL,['NA'],Circulating tumor DNA and mutational variations,Anxiety and depression
9737,NCT03426514,Early morbidity rate,2018-03-25,RECRUITING,INTERVENTIONAL,['NA'],,5-year overall survival rate
9738,NCT00775073,Time to Progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
9739,NCT05850559,Assessment of the Diagnostic Role of Serum Insulin-like Growth Factor Binding Protein-3 as a Potential Biomarker for Colorectal Cancer (CRC) in Egypt,2023-10-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9740,NCT05616533,The coincidence rate of tumor response obtained from 50 PDX models with clinical real tumor response acquired from corresponding patients received neoadjuvant therapy.,2023-09-12,RECRUITING,OBSERVATIONAL,['NA'],,
9741,NCT00798746,Reflux Symptoms: Open Esophagectomy versus Minimally Invasive,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
9742,NCT05668793,validity,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,reliability
9743,NCT04825574,Safety as assessed by the number of serious adverse events and adverse events of special interest,2021-05-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],,
9744,NCT05952947,Adverse events and serious adverse events,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],T cell subgroup in peripheral blood,Concentration of Cytokines (IL-2、IL-6、IL-10、TNFα、IFNγ)
9745,NCT01559844,Number of Participants Who Died,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Participants With Virologic Failure Prior to Transplant
9746,NCT04736043,Overall survival rate,2021-01-31,RECRUITING,OBSERVATIONAL,['NA'],,
9747,NCT03153332,The primary outcomes was the precise allocation of hepatic disease,2017-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Time spent to judge tumor location
9748,NCT03814005,"Part A, Cmax: Maximum Observed Plasma Concentration for Pevonedistat Following a Single Dose",2019-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Part B, Percentage of Solid Tumors Participants with CR or PR"
9749,NCT05124704,Predicted effect-site concentration of propofol (Ceprop) at certain time points,2021-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative exhaust time
9750,NCT05220020,Two-Years Overall Survival Rate,2022-05-18,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluate the patients cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-C30."
9751,NCT04138654,Change in whole genome gene expression analyses in colonic biopsies and blood between baseline levels and each intervention period (transcriptomics),2014-04-17,COMPLETED,INTERVENTIONAL,['PHASE1'],Change in O6-MeG in colonic biopsies between baseline levels at the start of the intervention and each intervention period,Change in the microbiome in feacal samples and in saliva between baseline levels at the start of the intervention and each intervention period
9752,NCT04633512,"Support personnel satisfaction with ActivSightTM, as quantified by Likert scale.",2020-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Ability of ActivSightTM to display biliary tree.
9753,NCT05615818,Progression-free survival (PFS),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],Incidence of Adverse Events,Percentage change in tumour size
9754,NCT02530437,Pathologic Complete Response Rate (Phase II),2017-03-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
9755,NCT01271712,Progression-free Survival,2011-01-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response (DOR)
9756,NCT00484211,Antitumour activity defined as progression free survival (PFS),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Experimental imaging study (DCE-MRI)
9757,NCT06097078,Rate of patients with anastomotic leakage,2024-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Rate of intraluminal hemorrhage
9758,NCT05651672,Overall response rate (ORR),2022-12-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
9759,NCT01703585,Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.,2012-10-04,COMPLETED,OBSERVATIONAL,['NA'],,Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%
9760,NCT04635488,metastasis rate of lateral lymph node,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9761,NCT02051868,Best overall response rate by 24 weeks post treatment,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Identification of potential tumour biomarker
9762,NCT04544852,The proportion of participants that completed the FIT test within three months post enrollment.,2017-12-04,RECRUITING,INTERVENTIONAL,['NA'],,
9763,NCT04843189,Number of lymph nodes harvested,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival
9764,NCT03120195,Feasibility of EndoRotor® for the ablation of Barrett's mucosa,2017-01-27,COMPLETED,INTERVENTIONAL,['NA'],,Ease of performing the EndoRotor® procedure
9765,NCT02282722,Number of Patients With Accurate Understanding of Chemotherapy Benefits,2015-06-10,COMPLETED,INTERVENTIONAL,['NA'],,Patient-Reported Prognostic Understanding in Median Years
9766,NCT06242067,progression-free survival(PFS),2023-04-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
9767,NCT01735799,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
9768,NCT02781935,Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI),2016-11,COMPLETED,OBSERVATIONAL,['NA'],,Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery
9769,NCT06330441,Number of participants with newly diagnosed pancreatic ductal adenocarcinoma,2022-01-07,RECRUITING,INTERVENTIONAL,['NA'],,KRAS mutation status evaluation
9770,NCT03412877,Response rate,2018-09-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerance
9771,NCT03113318,5-year overall survival,2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality
9772,NCT03044743,Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients,2017-04-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Th1/Th2 change in the peripheral blood
9773,NCT00437502,Date of first objective finding will be used to define the date of relapse,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9774,NCT00545545,To determine safety and maximum tolerated dosage of Imprime PGGwhen used in combination with cetuximab with and without irinotecan therapy in patients with recurrent/progressive colorectal carcinoma previously treated with a 5-FU regimen.,2007-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To determine the tumor response rates (complete response, partial response, stable disease, overall response rate), time to progression, duration of overall tumor response, and the duration of stable disease in patients receiving the combination therapy."
9775,NCT03516071,Time to Progress (TTP),2017-05-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
9776,NCT04344847,Excision of GIST during LSG,2016-12-12,UNKNOWN,INTERVENTIONAL,['NA'],,
9777,NCT04312633,Primary Outcome Measure:,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Secondary Outcome Measure:
9778,NCT02972541,Rate of stoma formation,2016-09-30,UNKNOWN,INTERVENTIONAL,['NA'],,Chemotherapy related complication
9779,NCT03259867,Overall Response Rate,2017-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
9780,NCT06230471,Objective response rate,2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival rate
9781,NCT01868971,The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,7. Patient satisfactory.
9782,NCT00238212,Response probability (confirmed complete and confirmed partial responses),2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression
9783,NCT06006026,The safety profile of combining ropivacaine and lidocaine,2023-08-28,COMPLETED,INTERVENTIONAL,['NA'],,The plasma concentration of lidocaine
9784,NCT02746432,The anti-inflammatory effects of intraoperative hyper-insulinimic euglycemic therapy in patients undergoing colorectal cancer surgery.,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],Thirty days post-operative mortality,The immunomodulatory effect of intraoperative hyper-insulinimic euglycemic infusion.
9785,NCT03138720,CA19-9 value,2017-05-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
9786,NCT01460888,Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Exploration of blood and tissue borne pharmacodynamic markers to establish the biological efficacy of the addition of Olaparib to radiotherapy.
9787,NCT03621982,Part 1 Combination Therapy: Number of Patients who Experience a Dose Limiting Toxicity (DLT),2018-11-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Part 2 Combination Therapy: Number of Patients with Confirmed Positive Anti-drug Antibody (ADA) Responses
9788,NCT05055648,Pulmonary complications,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],Concordance of observed cardiac complications with predicted,Overall survival (OS)
9789,NCT03162510,MTD of Oxaliplatin,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
9790,NCT00260559,Change from baseline in SF36 Quality of Life Questionnaire at 36 month,1999-05,RECRUITING,OBSERVATIONAL,['NA'],,
9791,NCT04174079,Disease-free survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],,overall survival
9792,NCT05010681,Objective Response Rate (ORR),2021-08-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9793,NCT03368859,Progression Free Survival (PFS),2018-03-20,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
9794,NCT05266300,Adverse events,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Rate of discontinuation of fluoropyrimidines due to adverse events
9795,NCT03031691,Percentage of patients with anti-brontictuzumab antibodies,2017-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
9796,NCT02276768,Mean visceral pain intensity score following dosing with GIC-1001 375 mg TID,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Standard laboratory measures (biochemistry, hematology, urinalysis)"
9797,NCT05057052,Objective Response Rate (ORR),2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
9798,NCT04973306,Overall survival(OS),2022-03-02,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Correlation between genetic profile and tumor response
9799,NCT00003186,,1997-04,COMPLETED,INTERVENTIONAL,['NA'],,
9800,NCT04315311,Change In Coefficient Of Fat Absorption (CFA) From Baseline,2020-05-06,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Change In Gastrointestinal Quality Of Life Index (GIQLI) From Baseline
9801,NCT00305877,Proportion of Patients With Specific Protocol Defined Adverse Event at Conclusion of All Therapy,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Two-year Disease-free Survival (DFS)
9802,NCT04740346,3-year overall survival,2021-07-05,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of vitamin B12 deficiency
9803,NCT01868347,evaluation of arterial oxygenation,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],variation of gas exchange in post operative period,evaluation of difference between arterial end-tidal partial pressure of carbon dioxide
9804,NCT06178926,Sedation efficacy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Injection pain
9805,NCT00297128,feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"collection of response rate (T-downstaging, pCR), correlation of responsiveness with EGFR-status"
9806,NCT01186731,Response rate of tumor size reduction at 110 mg/m2 LE-DT dose level,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,SPARC tumor expression following the treatment of LE-DT at 110 mg/m2 dose level
9807,NCT04168944,Tumor free survival rate,2019-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",the side effects,Overall survival rate
9808,NCT04375930,means of quality of life change,2019-01-18,COMPLETED,INTERVENTIONAL,['NA'],,
9809,NCT02694562,Local Tumor Control,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,Time To Tumor Progression
9810,NCT01213004,To determine whether motion-corrected cone-beam CT (CBCT) can visualize and localize abdominal tumors using intravenous contrast enhancement.,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,To determine whether tumor and organ-at-risk positions localized in cone-beam CT (CBCT)
9811,NCT03606317,Prognosis and practice patterns in the management of cachexia and its associated symptoms.,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
9812,NCT02563158,Serum total bilirubin on postoperative day 5,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Long-term survival
9813,NCT02024607,The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer
9814,NCT01003600,"Assess colorectal cancer survivors' basic knowledge of their own cancer history, including date of diagnosis, stage, and treatments received.",2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Assess whether survivors who had concerns about working after cancer treatment spoke with health care professionals about their concerns.
9815,NCT01133132,Change in level of physical activity,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,
9816,NCT00114179,Overall survival rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
9817,NCT00002664,,1995-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
9818,NCT05425940,Overall Survival,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],Duration of Response (DOR) as assessed by the Investigator per RECIST 1.1,Overall Survival
9819,NCT01472029,"Rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference pathologist.",2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
9820,NCT03347630,diagnostic performance for staging,2017-10-02,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic performance to assess tumor response
9821,NCT04638959,differences in abundance of gut microbiota,2019-09-30,UNKNOWN,OBSERVATIONAL,['NA'],Basic information of patients with different clinical outcomes,evidence of gastric carcinoma
9822,NCT01474642,response rate,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,predictive marker
9823,NCT03300570,"Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After 7 Days of Intervention",2018-07-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percentage of Participants With Grade 3 or Higher Diarrhea Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
9824,NCT00892593,"rate of significant colon neoplasia among those who enter a screening or surveillance program with FIT testing added at yearly intervals vs. that of ""usual care"" patients in the same patient population.",2009-05,UNKNOWN,INTERVENTIONAL,['NA'],,the pathology found at repeat colonoscopy in each group.
9825,NCT00994903,Total complications,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change in functional recovery
9826,NCT01605734,Time to Progression,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AFP
9827,NCT04316000,Initial Fear of Cancer degree,2019-11-22,SUSPENDED,OBSERVATIONAL,['NA'],,Long-term Fear of Cancer degree
9828,NCT00590239,Pathologic and Clinical Outcomes,2007-05-15,RECRUITING,OBSERVATIONAL,['NA'],,Efficacy of endoscopic detection of early esophageal lesions
9829,NCT05732662,ORR,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment Related Severe Adverse Effects
9830,NCT06104241,Dose-limiting toxicity (DLT）,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,PFS
9831,NCT03171298,intraoperative complication,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Mesorectal completeness
9832,NCT04293497,The comparison of sensitivity between conventional staining method and new staining method,2020-02-17,COMPLETED,INTERVENTIONAL,['NA'],,The evaluation of correlation index of staining at three type slides
9833,NCT05172635,Pathological response of the primary tumour,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],,90 day mortality
9834,NCT05188209,Adverse Events (AEs),2021-05-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The proportion of patients with positive of anti-drug antibody (ADA)
9835,NCT04984980,objective response rate,2020-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,overall survival
9836,NCT05512520,1-year progression-free survival,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-related adverse events
9837,NCT06323382,Progression-Free-Survival (PFS),2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Adverse events
9838,NCT06051695,Phase 2: The Overall Response Rate (ORR) for patients,2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Cytokine analysis
9839,NCT04186117,Isolation of circulating tumoral cells,2016-09-09,RECRUITING,INTERVENTIONAL,['NA'],,
9840,NCT00535353,"Correlation, if any, between the toxicity profile and pharmacokinetics",2008-01-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic outcomes
9841,NCT00003381,Evaluate the quality of life of patients,1998-07,TERMINATED,OBSERVATIONAL,['NA'],,
9842,NCT04203641,Adverse events (as per CTCAE v. 5.0),2019-12-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Proportion of patients expressing anti-L-DOS47 antibodies
9843,NCT01528501,objective response rate within the first six treatment cycles,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of LBH 589
9844,NCT03343301,Number of Participants With Dose Limiting Toxicities (DLTs),2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies
9845,NCT04446793,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
9846,NCT03401827,survival rate,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,adverse event
9847,NCT03699371,Long-term quality of life at 6 months,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],PCS SF-36 change,Antibiotic-free days
9848,NCT02489214,Number of Participants with Adverse Events,2016-05-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival time
9849,NCT02442323,Patient-reported outcome of quality of life,2013-08-09,COMPLETED,INTERVENTIONAL,['NA'],,
9850,NCT04689347,"To evaluate the safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease",2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],OS of FLIRT bevacizumab,Quality of life as assessed using the Euro Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L)
9851,NCT00878657,Disease-free survival (Phase II),2009-04,TERMINATED,INTERVENTIONAL,['PHASE1'],,
9852,NCT04161287,Local control rates,2019-10-11,RECRUITING,OBSERVATIONAL,['NA'],,Adverse reaction
9853,NCT02069704,AUC at Steady State (AUCss) of BEVZ92 and Avastin®,2014-10-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Volume of Distribution (Vd) of BEVZ92 and Avastin®
9854,NCT02256514,Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance
9855,NCT03437200,12-Month Progression-free survival using RECIST 1.1,2019-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Relative dose intensity of 5FU
9856,NCT01364805,Determine safety of combined gemcitabine chemotherapy with IV ascorbate.,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess pharmacokinetic and pharmacodynamic interactions when adding IV AA to front-line gemcitabine chemotherapy in the treatment of locally advanced or metastatic pancreatic cancer not eligible for surgical resection.
9857,NCT02586701,Six Minute Walk Test (6MWT),2013-09,COMPLETED,INTERVENTIONAL,['NA'],,
9858,NCT00297648,Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Central Blinded Assessments,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 54
9859,NCT05829057,Number of participants with physical examinations,2023-05-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,changes of cytokines relative to the baseline
9860,NCT02664077,"Disease-free survival (DFS) - time from randomization until first colon cancer recurrence, second primary colon cancer, or death due to any cause.",2016-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Compare the symptoms experienced by patients receiving regorafenib to patients receiving placebo during treatment as measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
9861,NCT04866381,Objective Response Rate,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Subject safety
9862,NCT03839706,18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant,2018-08-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma
9863,NCT05059717,Magnetic Resonance Displacement Encoding with Stimulated Echo (MR DENSE) imaging data of patients treated with chemotherapy prior to resection of metastases to explore its utility in detecting sinusoidal liver injury.,2018-07-12,WITHDRAWN,INTERVENTIONAL,['NA'],,
9864,NCT02352337,Rate of patients alive and without radiological and/or clinical progression,2014-12-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression survival
9865,NCT02965209,Diagnostic yield of NMSE in patients with suspected small bowel diseases,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
9866,NCT04152889,DFS,2020-04-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9867,NCT04039360,stoma rate,2014-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
9868,NCT02600143,Genetic predisposition for immunotherapy-induced colitis,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Analysis of the gut microbiome in stool samples
9869,NCT05530746,Detection of advanced colorectal adenoma,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Detection of non-advanced colorectal adenoma
9870,NCT01659424,Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) Improve Compliance,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,4) Quality of Life
9871,NCT05594914,AE,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
9872,NCT01467921,disease-free survival,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
9873,NCT00002615,,1994-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9874,NCT01605305,TPP,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
9875,NCT03072472,Adenoma Detection Rate,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Compare the baseline ADR of each colonoscopist prior to trial recruitment with their individual ADR in patients where EndocuffTM Vision was not used.
9876,NCT01214343,Overall survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Biomarker predicting the efficacy
9877,NCT05856305,Acute Toxicity,2023-07-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Tumor Volume reduction kinetics
9878,NCT01725490,the mean percentage change of the number and size of polyps in colon and/or duodenum.,2013-02-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9879,NCT02837263,Recurrence rate at 1 year,2016-08-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Expression levels of PDL1,Overall survival estimated using the Kaplan-Meier method
9880,NCT04180761,Incidence of peritoneal metastases and proportion of patients free from peritoneal metastasis after one year after HIPEC.,2019-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by grading according to CTCAE v5.0 and Clavien-Dindo.
9881,NCT02176746,The number of participants with adverse events,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",The dose of CSC vaccine,The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
9882,NCT00971126,"Terms of efficacy assessment: objective tumor response, overall survival, progression-free survival. Terms of safety assessment: adverse effects, laboratory values.",2009-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9883,NCT01853319,Progression-Free Survival (PFS),2013-07-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,
9884,NCT01110798,Major anastomotic leak rate,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],,"Bowel function, fecal incontinence, and quality of life, evaluated with validated questionnaires"
9885,NCT03676075,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
9886,NCT04469556,Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.,2020-10-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Cluster Tendency analysis using artificial neural networks and radiomic methods combined
9887,NCT04704934,Overall Survival in Participants Who Were Administered Trastuzumab Deruxtecan Compared With Ramucirumab in Combination With Paclitaxel,2021-05-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Who Have Treatment-emergent ADAs
9888,NCT05694338,Percent of patients considered frail assessed by Clinical Risk Analysis Index (RAI-C) Scores of 21 or higher,2023-03-13,RECRUITING,OBSERVATIONAL,['NA'],,Adverse outcomes after major surgery
9889,NCT00188110,To evaluate the performances of the WE-CT in patients suspected of having a colon tumor,2003-03,UNKNOWN,INTERVENTIONAL,['NA'],,To demonstrate the advantages of the WE-CT compared to the CT and magnetic resonance (MR) colonography for the diagnosis and local staging of colon tumors
9890,NCT01269216,pathologic complete response rate,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9891,NCT02954913,Comprehensive Complication Index,2017-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Cost Analysis
9892,NCT05605600,Development of LARS Severity tool,2022-10-03,COMPLETED,OBSERVATIONAL,['NA'],,Commence initial psychometric evaluation of the New LARS score
9893,NCT04625803,Tumor regression rate of MSS/pMMR patients,2021-01-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,mortality rate
9894,NCT00769782,Recurrence-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Types and severities of adverse events
9895,NCT05051358,Safety of procedure,2021-02-11,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Cost Effectiveness
9896,NCT02665026,Postoperative complication,2016-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
9897,NCT00274209,Prevalence of dysplastic lesions by white light vs. chromoendoscopy,2005-12,COMPLETED,OBSERVATIONAL,['NA'],,
9898,NCT05480306,Progression Free Survival (PFS),2022-08-30,RECRUITING,INTERVENTIONAL,['PHASE2'],Exposure-response relationships for DKN-01 as data permit.,Incidence of ≥Grade 3 related treatment-related adverse events (TRAEs).
9899,NCT02140463,feasibility,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,response rate
9900,NCT04949672,Completeness of mesorectal fascia and specimen quality (specimen integrity after rectal resection),2017-01,COMPLETED,OBSERVATIONAL,['NA'],,Cancer specific survival (CSS)
9901,NCT02714374,Number of participants with treatment-related adverse events as defined by CTCAE v4.03.,2016-03-25,TERMINATED,INTERVENTIONAL,['PHASE1'],,Amount of lymphocyte infiltration in pre-treatment biopsy and post-treatment resected tumor tissue
9902,NCT03976739,corelation between the bile reflux and gastric mucosa diseases,2019-06-17,COMPLETED,OBSERVATIONAL,['NA'],,the risk factors of primary bile reflux gastritis
9903,NCT04361162,Overall response rate (ORR),2020-05-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS) in patients
9904,NCT04552093,Completion of 2 combined chemotherapy cycles (feasibility),2020-09-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Quality of life assessment,Conversion rate colorectal liver metastases (CRLM)
9905,NCT04521491,Recurrence free survival(RFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival(OS)
9906,NCT03609268,progression free survival,2018-06-30,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival
9907,NCT06210724,Colorectal Cancer,2023-10-09,RECRUITING,OBSERVATIONAL,['NA'],Blood tests,Microscopic colitis
9908,NCT02636088,Local tumour Control,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
9909,NCT01521104,,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
9910,NCT01802203,Collect efficacy and outcome data related to the use of trūFreeze® spray cryotherapy for treatment of unwanted tissue in the pulmonary and gastrointestinal settings.,2013-04,COMPLETED,OBSERVATIONAL,['NA'],,Collect safety data related to the use of trūFreeze® spray cryotherapy for treatment in the pulmonary and gastrointestinal settings.
9911,NCT01802320,Overall Response Rate (CR+PR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Validation of the Enrichment Biomarker Signature in Metastatic Sites,Progression-free Survival (PFS)
9912,NCT04450732,Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE),2020-07-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,Preliminary Efficacy
9913,NCT01505972,Participation rate,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Response rate in FOUR&TWO group
9914,NCT05613621,clinical outcomes of MAFLD vs. non-MAFLD.,2022-11-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
9915,NCT04793958,Progression-free Survival (PFS),2021-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life Assessment
9916,NCT05641896,Positive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Further characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5)
9917,NCT01662609,Number of Abnormalities Detected by EUS,2007-08-23,COMPLETED,OBSERVATIONAL,['NA'],,
9918,NCT06260293,Shorts Physical Performance Battery(SPPB),2023-01-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
9919,NCT03841799,Characterization of colorectal tissue microenvironment of patients with locally colorectal neoplasia.,2019-05-02,RECRUITING,OBSERVATIONAL,['NA'],,Identification of potential molecular abnormalities in cancer cells from colorectal tissue and from blood samples.
9920,NCT05181306,Recurrence,2010-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Cost
9921,NCT01876407,Evaluate the effectiveness of using low-intensity laser compared with placebo as preventive and therapeutic intervention of oral mucositis induced by radiation therapy and chemotherapy.,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Assess the intervention tolerance and side effects of it.
9922,NCT00176735,,2001-12,TERMINATED,INTERVENTIONAL,['NA'],,
9923,NCT05067153,Prothrombin fragment F1+2,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Mortality
9924,NCT01262040,"Determine the feasibility of Narrow Band Imaging (NBI) at the time of thorascopic, laparoscopic or robotic surgery.",2010-12-14,COMPLETED,INTERVENTIONAL,['NA'],,Determine what percentage of patients have surface metastasis identified with NBI that were not seen on white light imaging.
9925,NCT01214681,Faecal calprotectin concentration,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],,Plasma short chain fatty acid concentration
9926,NCT01456455,HER2 Status,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],Outcome according to ethnicity of patients,Outcome according to HER2 Status
9927,NCT00081289,Pathologic Complete Response Rate,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change From Baseline in EORTC QLQ-CR38 Defecation Symptom Score at Two Years
9928,NCT02785380,Overall survival,2016-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],Number of Participants With Treatment-Related Adverse Events as Assessed by,Recurrence-free survival
9929,NCT06054308,pathologic response,2024-02-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Disease free and overall survival
9930,NCT01438437,Local tumor response,2001-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Change from baseline in Child status at 1 year
9931,NCT04454476,Safety of Trametinib treatment: adverse events,2022-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
9932,NCT05013697,Progression free survival (PFS， RECIST assessment),2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related adverse Events
9933,NCT06006923,"Progression-free Survival (PFS), Randomize Phase",2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Objective Response Rate (ORR), Randomized Phase"
9934,NCT03111823,Total number of minutes exercised per week with >80% total weekly minutes (48/60 minutes) completed,2016-07-07,TERMINATED,INTERVENTIONAL,['NA'],Change in endothelial function,Change in QOL
9935,NCT02789891,3-year disease overall survival rate,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,EORTC QLQ-C30 and QLQ - STO22
9936,NCT01284504,"Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.",2011-01,TERMINATED,INTERVENTIONAL,['NA'],,"Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op."
9937,NCT05145647,To estimate the local control rate at primary tumor site,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival (OS),Treatment toxicity grading according to the CTCAE
9938,NCT04195373,Determine MTD and dose for phase II,2020-11-23,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy of therapy assessed by changes in tumor marker level
9939,NCT03563326,EpCAM CAR-T cells treatment related adverse events,2018-08-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progress free survival outcome
9940,NCT01915225,"Collection of biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets",2013-07-21,RECRUITING,OBSERVATIONAL,['NA'],,"Collection of detailed history, demographic, treatment data, and perioperative outcomes data related to surgical quality and safety in order to categorize and track the specific procedures."
9941,NCT04768218,To externally validate the EGGIM score classification using BLI,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
9942,NCT01032967,Overall survival and disease-free survival,2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life and function outcomes
9943,NCT00997685,To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To evaluate the safety profile of XELOX peri-operative treatment
9944,NCT05091346,Phase 2 Part: Objective Response Rate (ORR),2021-10-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 Part: Apparent Clearance for Lenvatinib When Co-administered With E7386 and Pembrolizumab
9945,NCT04868227,GENE EXPRESSION CHANGE,2014-03-28,COMPLETED,INTERVENTIONAL,['NA'],,VITAMIN D STATUS CHANGE
9946,NCT05382364,Percentage of participants discontinuing from study therapy due to AE,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
9947,NCT02958163,Objective response rate at 6 months,2017-02-20,TERMINATED,INTERVENTIONAL,['PHASE2'],MRI description of tumors at the hepatobiliary phase at 6 months after treatment,Overall response rate based on the MRI evaluation in Child Pugh B7 patients
9948,NCT05440552,Detection rate,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
9949,NCT03348241,The effect of Gum Arabic to prevent Chemotherapy-induced Oral Mucositis was the primary outcome that assessed using World Health Organization Mucositis Scoring.,2015-10-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9950,NCT00353015,Participant Response Rate of Irinotecan and Cisplatin,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9951,NCT04833959,Incidence of treatment emergent adverse events assessed by CTCAE v5,2021-03-26,SUSPENDED,INTERVENTIONAL,['PHASE1'],,
9952,NCT05156788,R0 resection rate,2021-12-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,RFS
9953,NCT00125021,To assess the response rate associated with capecitabine and OSI-774 in patients with advanced pancreatic cancer,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,to estimate the time to progression and overall survival of patients with advanced pancreatic cancer treated with capecitabine and OSI-774
9954,NCT03604991,Disease-free survival (DFS) (Step 2),2019-05-03,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Percent change in mean volumetric apparent diffusion coefficient (ADC),DFS
9955,NCT05225844,progression-free survival（PFS）,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
9956,NCT06207656,Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastases,2024-01-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],To determine the presence/expression level/levels of serum and tumour tissue biomarkers associated with cell and tumour growth and/or involved in the mechanisms of action of EBC,Incidence and severity of AEs CTCAE v5 criteria
9957,NCT02231723,Determination of the Recommended Phase 2 Dose by assessing dose-limiting toxicities (DLTs),2014-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assess pharmacodynamic activity of BBI608 when administered in combination with standard chemotherapies
9958,NCT02705651,Growth rate of the tumor in mm,2019-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Documentation of lymph node and/or distant metastases
9959,NCT04001101,Out-of-field ORR improvement,2019-10-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life score
9960,NCT05583292,rate of mortality,2023-02-11,COMPLETED,OBSERVATIONAL,['NA'],,
9961,NCT00054912,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
9962,NCT00408122,,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,
9963,NCT00361231,Median Progression Free Survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate
9964,NCT01691664,Disease free survival,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],Immunological assessment,quality of life
9965,NCT01099527,To assess response rate in phase II,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9966,NCT02350166,30-day complications,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,C-reactive protein
9967,NCT01188109,Recurrence-free Survival as Measured by CT Scan,2010-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Immunohistochemistry to Determine Status of Excision Repair Cross Complementation Gene-1 (ERCC1) Expression
9968,NCT05718882,Progression free survival,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Safety endpoint
9969,NCT00053924,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9970,NCT02235324,Progression-free survival during the second phase of the study,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"mRNA level of VEGFR1, VEGFR2, and VEGF-A",Incidence of adverse events graded according to NCI CTCAE version 4.0
9971,NCT01652196,Proportion of patients alive and progression-free,2012-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial
9972,NCT03757455,Days until discharge from university hospital,2020-09-01,TERMINATED,INTERVENTIONAL,['NA'],,Readmission frequency
9973,NCT05305001,BRCA 1/2 germline mutation prevalence,2020-09-09,COMPLETED,OBSERVATIONAL,['NA'],The proportion of germline mutation carriers who accept pancreatic cancer surveillance.,Clinical and pathological characteristics
9974,NCT05049317,Incidence of urinary dysfunction,2021-11-24,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of urinary dysfunction
9975,NCT00502177,PedsQL 4.0 Generic Core Scale,2007-06-19,COMPLETED,OBSERVATIONAL,['NA'],,
9976,NCT04186156,Proportion of patients alive and progression free at 4 months,2020-03-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine the pharmacodynamic response to KA2507
9977,NCT05449847,Relation between MicroRNA and HCV,2021-05-13,COMPLETED,OBSERVATIONAL,['NA'],,
9978,NCT01409005,8-weeks progression free survival rate (PFS rate),2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients with Adverse Events
9979,NCT03963206,survival of the patient after start of treatment,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of patients with each dose of Cabozantinib
9980,NCT01721941,Maximum tolerated dose of TH-302 use in TACE,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective response rate
9981,NCT03490461,A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.,2017-11-22,COMPLETED,OBSERVATIONAL,['NA'],,
9982,NCT06275997,Miss rate reduction,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,patient satisfaction
9983,NCT05314946,Feasibility of the trial,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Post-operative mortality
9984,NCT04727151,Phase 2: Evaluate Progression-Free survival (PFS) or Time to progression (TTP),2021-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and Phase 2: Cytokine level detection
9985,NCT00342472,PAH exposure,1998-02-12,COMPLETED,OBSERVATIONAL,['NA'],,
9986,NCT04397601,Overall Survival (OS).,2020-05-11,RECRUITING,OBSERVATIONAL,['NA'],Serum level of PlGF (Placental Growth Factor).,Progression-free survival (PFS).
9987,NCT02012699,Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC),2013-11-01,RECRUITING,OBSERVATIONAL,['NA'],"Collection and banking of blood, DNA, and urine samples for future analysis that will be proposed in future studies",Procurement and banking of excess biological material for future analysis
9988,NCT04294160,Dose intensity,2020-07-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments
9989,NCT01047293,"Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)",2010-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
9990,NCT00822991,Size of HCC which is detected first,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,The improvement of prognosis of patients who are diagnosed in this study
9991,NCT05992584,Progression free survival (PFS) according to mRECIST,2023-08-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
9992,NCT05116085,Major pathological response (MPR) rate,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants with Treatment-emergent Adverse Events (TEAEs)
9993,NCT06079229,Evolution in the ADL questionnaire score between pre-operative and post-operative 3 to 30 months after surgery.,2023-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
9994,NCT06091930,Part IV: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1),2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations
9995,NCT02702986,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease specific survival (DSS)
9996,NCT02384759,Radiological progression-free survival according to the investigator,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,progression-free survival
9997,NCT01608022,Overall Response Rate,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
9998,NCT03653052,Clinical response to therapy (durvalumab),2018-10-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Ex-vivo effect of compounds on tumour/cell models,
9999,NCT00021320,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10000,NCT03229096,Objective response rate (ORR),2017-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year overall survival rate
10001,NCT00940303,Progression-free survival,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Proportion of patients with NCI-CTC grade 3-5 adverse events; adverse events, laboratory parameters, ECOG performance status."
10002,NCT03797326,Percentage of Participants Receiving Lenvatinib Monotherapy who Discontinue Study Treatment Due to an Adverse Event (AE),2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Plasma Concentration of Lenvatinib
10003,NCT03099564,Progression free survival (PFS),2017-03-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Estimate overall survival (OS)
10004,NCT04295811,Primary Efficacy,2020-06-18,RECRUITING,INTERVENTIONAL,['NA'],"Safety outcome of EsoCheck Device (510k cleared, non-invasive, esophageal cell collection device) on all patients who undergo the device procedure.",Secondary Efficacy
10005,NCT06269341,Overall Survival,2010-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
10006,NCT01487343,adherence to oral chemotherapy,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,improve the care of patients
10007,NCT04692454,The number of CD8+ T,2020-08-31,COMPLETED,INTERVENTIONAL,['NA'],,
10008,NCT02319928,Colorectal cancer incidence,2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10009,NCT05610904,Accuracy of stoma implementation,2022-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of stoma reverse
10010,NCT00626639,Pharmacokinetics of Palifermin,2005-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
10011,NCT04151394,Overall survival,2019-01-31,COMPLETED,OBSERVATIONAL,['NA'],,
10012,NCT01314027,Progression-free survival,2009-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,feasibility of adjuvant chemotherapy
10013,NCT06227325,pathological complete response (pCR) rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Percentage of Participants who experience one or more adverse events (AEs).
10014,NCT01402089,Steady-state partial area-under the plasma concentration-time curve over 24 hours (AUC24h) of sunitinib and erlotinib and CYP3A4/1A2-phenotype activity as defined in the protocol,2012-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Concentrations of Sunitinib, Erlotinib and probe drugs (Midazolam, Caffeine) in whole blood, sampled from patient's dried blood spots (DBS)"
10015,NCT02821559,Evolution of Raltitrexed plasma levels,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
10016,NCT04877340,Compare the diagnostic yield,2020-11-26,UNKNOWN,INTERVENTIONAL,['NA'],,adverse event rate
10017,NCT05579353,expressional quantity,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10018,NCT04167436,Changes in immunological function,2019-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Remission and cancer free survival
10019,NCT02274753,Relapse in relation with the immunoscore determined on a tumor section and criteria defined in the monitoring of patients,2015-03-11,UNKNOWN,OBSERVATIONAL,['NA'],,Relapse in relation with the immunoscore on biopsies
10020,NCT06168812,Change in mean interstitial glucose level for Cohort 1 participants before and after initiation of glipizide,2023-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10021,NCT03131102,Acute Fatigue Score (AFS),2017-08-29,COMPLETED,OBSERVATIONAL,['NA'],Quality of life,Hospital length of stay
10022,NCT05291156,OS,2022-07-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of treatment-related adverse events as assessed by CTCAE v5.0
10023,NCT01091558,"L-Arginine (L-Arg) availability in ulcerative colitis (UC) patients and normal control subjects, and correlate with disease activity",2009-09,COMPLETED,OBSERVATIONAL,['NA'],,L-Arg intake in the diet of UC patients and control subjects
10024,NCT01611506,Dose limiting toxicity,2012-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity (according to NCI-CTCAE, Version 4.0)"
10025,NCT00474903,Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
10026,NCT02836535,Number of complications,2016-07,COMPLETED,OBSERVATIONAL,['NA'],,
10027,NCT02243267,Response to Treatment,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
10028,NCT02326948,Number of participants with alcohol consumption,2014-08,COMPLETED,OBSERVATIONAL,['NA'],Number of participants with polypoid lesions of gallbladder,
10029,NCT02399735,GVHD,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Acute rejection
10030,NCT00033319,,1997-05,UNKNOWN,INTERVENTIONAL,['NA'],,
10031,NCT02274012,Change of tumor burden (in centimeters) for participants during protocol therapy,2014-05-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,ErbB2 levels benefit during therapy.
10032,NCT03797443,Disease control rate (CR+PR+SD x18 weeks),2019-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels
10033,NCT02630004,Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale),2015-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number (percentage) of patients with progression disease using the RECIST 1.1 criteria,Pharmacokinetics evaluation [Clearance]
10034,NCT00134758,SPIGELMAN severity score of duodenal lesion after 2 years of follow-up,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Compliance to the treatment
10035,NCT05732389,Complete clinical response,2023-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in Quality of life (EORCT QLQ-CR29)
10036,NCT00047333,Progression-free survival,2002-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival
10037,NCT01933958,Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib,2013-09-04,COMPLETED,OBSERVATIONAL,['NA'],,Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.
10038,NCT01367275,Number of Participants With Median Progression-Free Survival (PFS),2011-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10039,NCT02874885,Change in circulating tumor cells status,2013-09-05,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10040,NCT04233151,Progression-free Survival（PFS）,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10041,NCT06194734,Overall survival (OS),2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of Life (QOL) scores
10042,NCT04222413,To determine the Objective Response Rate (ORR) according to Evaluation Criteria (RECIST 1.1) in patients treated with metarrestin at the MTD,2020-10-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,To assess safety and tolerability of metarrestin in subjects with metastatic solid tumors
10043,NCT03928678,length of hospital stay in days,2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
10044,NCT00452205,,2007-04,UNKNOWN,OBSERVATIONAL,['NA'],,
10045,NCT04171141,Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2),2019-11-19,TERMINATED,INTERVENTIONAL,['PHASE1'],,Change from baseline of immune cells from tumor biopsies
10046,NCT06329869,Overall objective response rates (ORR),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers-related endpoints,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10047,NCT01624363,Prevalence of Pancreatic Cysts During Routine EUS,2009-09,COMPLETED,OBSERVATIONAL,['NA'],,
10048,NCT00465023,"To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.",2003-06,COMPLETED,INTERVENTIONAL,['NA'],,"to evaluate tumor response, local control and survival in this patient population."
10049,NCT02953743,Mean area under the concentration-time curve over the dosing interval on multiple dosing (AUC(0-τ)),2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
10050,NCT03488953,Overall survival three years after 2nd-stage of hepatectomy,2018-04-10,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity of the donor
10051,NCT02364154,metabolic phenotype of colorectal cancer,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,tumor stage
10052,NCT05026905,Best objective response rate (ORR),2021-12-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-related Adverse Events [Safety and Tolerability]
10053,NCT00672828,Self-reported colorectal cancer (CRC) screening adherence with medical record verification of screening test completion,2008-01,COMPLETED,INTERVENTIONAL,['NA'],Clinic variables as CRC screening predictors,Self-reported stage of CRC screening test adoption
10054,NCT05114798,Weight change (% kg),2022-05-17,RECRUITING,INTERVENTIONAL,['NA'],,Saliva microbiota
10055,NCT05228743,R0 resection rate,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,1 year overall survival
10056,NCT05989789,Procedure-Safety (No residual source of radiation),2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients without side effects
10057,NCT00003486,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
10058,NCT00168155,disease free survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10059,NCT02020928,Incidence of Oral Mucositis,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Degree of mucositis
10060,NCT05293041,Blood loss,2022-03-27,RECRUITING,INTERVENTIONAL,['PHASE4'],,I-FABP (change in organ damage markers)
10061,NCT01388101,The performance of e- Ab sensor,2010-09,UNKNOWN,INTERVENTIONAL,['NA'],,
10062,NCT02592304,"DECT as imaging tool for diagnosing response to chemo radiotherapy of malignant lymph nodes, and tumors.",2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,
10063,NCT03707574,Obtaining tumor tissue and blood specimens,2019-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Genomic analysis
10064,NCT01574677,Performance characteristics of the Septin 9 biomarker among patients who have a positive FIT result,2012-06,WITHDRAWN,OBSERVATIONAL,['NA'],,Concordance and discordance (Kappa scores) between Septin 9 test results and colonoscopy findings associated with specific medication use practices.
10065,NCT02587689,Phase I: Adverse events attributed to the administration of the anti-MUC1 CAR T cells,2015-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10066,NCT03003065,Safety (will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0),2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life (in every visit, European Organization for Research and Treatment of Cancer core questionnaire [EORTC QLQ-C30] will be filled and specific symptom enquiry is made; itchiness, fever and general well-being over a Likert 0-4 scale."
10067,NCT00613665,Safety measures: injection site and systemic reactions,2001-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogencity measures: antigen-specific antibodies and cellular immune response
10068,NCT05528952,objective response rate (ORR),2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease control rate (DCR)
10069,NCT00845819,Incidence of oral mucositis of grade 2 or higher (NCI CTCAE 3.0),2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,OMDQ (oral mucositis daily questionnaire) score during treatment
10070,NCT01200121,paracentesis-free survival (ParFS),2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in laboratory values and vital signs.
10071,NCT02163785,Assessment of the circumferential resection margin,2014-06,TERMINATED,INTERVENTIONAL,['NA'],Morbidity of the perineal incision.,Histopathological quality of surgical specimen
10072,NCT04242199,Number of treatment-emergent adverse events,2020-09-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Vz/F of INCB099280
10073,NCT00427713,Disease-free survival at 3 years,2004-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity
10074,NCT00230399,"To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.",2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the time to progression of metastatic colorectal cancer after treatment with celecoxib, capecitabine, and irinotecan."
10075,NCT02620865,Median Overall Survival (OS),2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,TTP
10076,NCT02768428,knowledge about TACE (A 40-item exam is performed to test the patients' knowledge),2015-10,UNKNOWN,INTERVENTIONAL,['NA'],,
10077,NCT05007613,Overall response rate,2021-06-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety
10078,NCT03039322,Golgi protein correlated with presence of HCC,2014-12-22,COMPLETED,OBSERVATIONAL,['NA'],,
10079,NCT04034459,Overall Response Rate (ORR),2016-11-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10080,NCT06101277,Number of participants with controlled disease,2023-10-05,RECRUITING,INTERVENTIONAL,['NA'],,Time to treatment failure
10081,NCT05308732,Maximum tolerated dose,2021-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Oral Mucositis
10082,NCT02459652,R0 resection rate,2012-12-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,R0 resection rate in borderline resectable pancreatic cancer
10083,NCT01748773,Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score,2013-01-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10084,NCT03903185,Measurement of the pharmacokinetics of LDV\SOF,2019-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Measurement of the number of participants with sustained virological response (SVR12), 12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV-SOF)."
10085,NCT01326000,Progression-free survival: tumour assessments by CT scan or MRI according to RECIST criteria,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Effect of concomitant FOLFIRI on pharmacokinetics of RO5083945 and vice versa
10086,NCT05644249,Objective tumor response according to RECIST v 1.1 after second PIPAC,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse events of chemotherapy drugs
10087,NCT03027401,Identify incidental and secondary findings in germline DNA and actionable somatic mutations for reporting clinical results from a CLIA-certified lab into CRIS medical records.,2017-01-10,WITHDRAWN,OBSERVATIONAL,['NA'],,Assessment of effects of the informed consent process
10088,NCT05340569,Unexpected abortion,2022-03-28,RECRUITING,INTERVENTIONAL,['NA'],,Early distant recurrence
10089,NCT05535998,Progression-free survival,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Conversion rate
10090,NCT02582918,Patient satisfaction and acceptability,2018-03-26,COMPLETED,INTERVENTIONAL,['NA'],,Repeat Screening
10091,NCT02489916,Number of participants with Adverse Events,2014-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Area under the plasma concentration versus time curve (AUC),Progression Free Survival
10092,NCT00041262,Survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
10093,NCT03368131,The pathological complete response rate(pCR),2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
10094,NCT04484311,Residual neoplasia,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10095,NCT04265417,Disease-free survival,2015-01-06,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative C-reactive protein
10096,NCT03413254,Proportion of peritoneal metastases detected after a negative second look DLS,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life assessed with the EQ-5D-5L questionnaire
10097,NCT04095195,"This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals",2019-08-20,RECRUITING,OBSERVATIONAL,['NA'],,"This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals"
10098,NCT03029793,Pathologic Response,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
10099,NCT04798820,Change from preoperative weight change at postoperaive 18 months in SE and IE groups.,2021-03-09,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life of the patients
10100,NCT05427227,Tumor associated proteins expression level of exosomes,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
10101,NCT04602611,Overall Survival,2020-11-03,COMPLETED,INTERVENTIONAL,['NA'],Oncology Nurse Navigation Provider Comparison for Outcomes,Oncology Nurse Navigation Comparison for Satisfaction
10102,NCT00002711,,1995-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10103,NCT03200834,5-year survival,2017-01-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Disease free survival 5 years after initial surgery
10104,NCT00077545,Objective response rate (CR + PR),2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of improvement of dysphagia
10105,NCT05132244,Frequency of glucose levels maintained within range in Arm 1 compared to Arm 2,2024-02,RECRUITING,INTERVENTIONAL,['NA'],"Amount of circulating biomarkers, measured in molar, for participants in each study arm from screening until the end of study visit",Overall survival (OS) in each study arm from the initiation of FOLFIRINOX
10106,NCT01395459,Change in population level cancer screening level at the health clinics involved.,2008-09,COMPLETED,INTERVENTIONAL,['NA'],For the substudy: return rate of gFOBT kits vs. FITs,
10107,NCT02330913,Anastomosis related complication rate,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
10108,NCT00882310,Number of Subjects Who Experience Dose Limiting Toxicities (DLTs),2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Score on FACT-Hep (Version 4)
10109,NCT00910143,"Local recurrence, recurrence-free survival, overall survival",1993-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients undergoing transcatheter arterial embolisation
10110,NCT05953961,Disease Progression,2023-08-08,RECRUITING,INTERVENTIONAL,['NA'],,Duration of Response
10111,NCT05569668,OS(overall survival),2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,DFS(disease-free survival)
10112,NCT05110573,Major complication rate,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Oncological outcomes
10113,NCT04157322,clinically detectable recurrence at 1 year after surgery.,2019-08-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10114,NCT01858805,overall survival,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,recurrence-free survival
10115,NCT01476592,Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels,2011-12,COMPLETED,INTERVENTIONAL,['NA'],,Describe the effect of resveratrol on tumor growth as demonstrated by standard cross sectional imaging and tumor markers.
10116,NCT03046745,Prediction of risk factors for gastric cancer and definition of optimal endoscopic screening interval,2016-08,UNKNOWN,OBSERVATIONAL,['NA'],,Reservation of frozen serum for novel gastric cancer serologic marker analysis
10117,NCT00004547,Number of Participants With Adverse Events,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue
10118,NCT03548948,Change in colonic inflammation,2015-07-15,COMPLETED,INTERVENTIONAL,['NA'],,Change in serum hepcidin
10119,NCT00819754,"Phase II: Using the RD established in phase I, assess efficacy of the IXO with bevacizumab combination as measured by progression-free survival",2003-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Qualitative and quantitative toxicity
10120,NCT02246153,Postoperative complication rate,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Postoperative recovery index
10121,NCT06231017,Objective response rate (ORR),2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (Safety）
10122,NCT04638010,Number of participants who complete needed cancer screening and prevention services,2011-02-16,COMPLETED,INTERVENTIONAL,['NA'],,
10123,NCT01047618,To evaluate the incidence of VTE in advanced gastric cancer with chemotherapy and to identify risk factors and biomarkers for VTE in this population,2009-12,COMPLETED,OBSERVATIONAL,['NA'],,To investigate the significant impact of VTE on overall survival and in this population
10124,NCT01486134,Rate of complete ablation one month after one RFA procedure,2012-06-20,TERMINATED,INTERVENTIONAL,['NA'],,Agreement of 2D and 3D measurements of ablations zones on IRMT° images and those measured on conventional magnitude MR images.
10125,NCT02169388,Frequency and severity of Adverse effects during Chemotherapy,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The observed changes in nutritional status after chemotherapy
10126,NCT02659241,Change in level of protein expression in p53-related pathways,2016-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
10127,NCT03550885,Change in the mucosal abundance of bacterial genes associated with sulfur and bile acid metabolism,2018-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in colonocyte proliferation
10128,NCT01182922,Percentage of invitees attending screening colonoscopy in each invitation letter group,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,"Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation."
10129,NCT01822613,Phase II primary outcome measure: Progression free survival (PFS),2013-07-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival (PFS) per RECIST 1.1 (Ph 1b )
10130,NCT00942383,Comparison of transverse ablation diameter between intraoperative ultrasound elasticity imaging (USEI) and postoperative cross-sectional imaging (CT or MRI).,2007-09,TERMINATED,OBSERVATIONAL,['NA'],,Feasibility of image processing and image segmentation using this clinical free-hand system.
10131,NCT05845268,cCR rate,2022-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,immune-related adverse event rate
10132,NCT05420909,Duration of Systemic Treatment,2019-01-28,COMPLETED,OBSERVATIONAL,['NA'],,
10133,NCT05775146,Progression free survival (PFS),2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory endpoints/outcomes. To identify blood biomarkers that can correlate with disease events,Toxicity Assessment
10134,NCT01790425,Cecal intubation,2011-08,COMPLETED,INTERVENTIONAL,['NA'],Patient discomfort Patient pain rating during and after procedure,Amount of opiate and benzodiazepines used for sedation.
10135,NCT00909402,"Use National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to establish the MTD, Dose Limiting Toxicity (DLT(s)) and safety profile of BMS-833923 administered in combination with Cisplatin and Capecitabine",2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,The pharmacokinetic parameters that will be assessed include: AUC(TAU) (Area under the concentration-time curve in one dosing interval)
10136,NCT01329809,Delivery to and replication within tumors,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity: Grade I-IV Adverse Events (according to CTCAE)
10137,NCT03361150,Oxygen consumption (VO2),2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Hospital Anxiety and Depression Scale (HADS) score
10138,NCT03585166,"The survival rate of primary liver cancer treated by laparoscopic hepatectomy and laparoscopic hepatectomy,Telephone pays a return visit",2017-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Comparison between laparoscopic hepatectomy and laparoscopic hepatectomy in primary hepatocellular carcinoma Unit: times
10139,NCT01658813,Progression Free Survival,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival
10140,NCT02106650,Grade 2 Oral Mucositis Prevention,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
10141,NCT05095636,PFS,2021-03-17,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
10142,NCT01270698,Safety,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,efficacy
10143,NCT01198392,Time to progression,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Response rate
10144,NCT01735968,Characteristics of dose limiting toxicities (DLTs),2013-02-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Effect of basic PK parameter: CL/F
10145,NCT00373347,Identify new blood markers of liver cancer,2004-11,RECRUITING,OBSERVATIONAL,['NA'],,
10146,NCT05417230,ORR,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],ctDNA,AEs
10147,NCT02499783,Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4,2015-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)
10148,NCT05541445,Major pathologic response,2022-08-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
10149,NCT01067053,Time to progression,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety of treatment according to the number of adverse events reported
10150,NCT04223635,Volume of Distribution in the Terminal Phase (Vz/F) Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants,2020-01-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Participants Reporting Treatment-Emergent Adverse Events (TEAE) by System Organ Class and Preferred Term Following a Single Dose of Pexidartinib in Participants With Moderate Hepatic Impairment Compared to Healthy Participants
10151,NCT02591082,Survival,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response
10152,NCT05541601,Positive/Negative predictive values of novel diagnostic approaches for the early diagnosis of HCC in enrolled patients who are diagnosed with HCC by conventional approaches.,2022-02-23,RECRUITING,OBSERVATIONAL,['NA'],,To better understand the incidence of HCC in a UK population stratified by underlying cirrhosis aetiology
10153,NCT04198051,The change of concentration of P-hydroxyphenylalanine metabolites in urine during chemotherapy,2019-12-20,UNKNOWN,INTERVENTIONAL,['NA'],,The change of the number of tumor necrosis factor(TNF)-α in blood during chemotherapy
10154,NCT05280444,Objective Response Rate(ORR),2022-05-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse Events(AEs)
10155,NCT04899739,Rate of lymph nodes wrongly categorised by ultrasound endoscopy. (Specificity),2021-12-05,RECRUITING,INTERVENTIONAL,['NA'],,Development of an algorithm capable of characterizing lymph nodes metastases by the mean of artificial intelligence
10156,NCT05202314,Pathological complete remission,2021-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
10157,NCT00004258,To evaluate the safety and tolerability of escalating doses of twice weekly EMD 121974 in patients with cancer.,1999-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10158,NCT04801355,R1 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['NA'],,The incidence and structure of postoperative complications
10159,NCT00798447,reduction of pro inflammatory activity,2008-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10160,NCT00327132,Hp eradication rate and complete histological rate,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,overall survival (OS)Relapse-free survival (RFS)
10161,NCT06186700,The incidence of mucositis in the two groups using WHO grading of oral mucositis,2023-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The incidence of adverse effects
10162,NCT05325528,Objective Response Rate (ORR),2022-04-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,progression-free survival
10163,NCT01655693,Overall Survival (OS),2012-06,COMPLETED,INTERVENTIONAL,['PHASE3'],Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event,Objective Response Rate (ORR)
10164,NCT01896531,Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum Concentration of Ipatasertib
10165,NCT01762254,pain score,2009-06,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay,wound complication
10166,NCT00503035,13-HODE Colonic Tissue Levels,2003-08-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,PGE2 Colonic Tissue Levels
10167,NCT02694536,Percentage of Participants With Adverse Events (AEs),2006-08-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-Free Survival (PFS) According to RECIST
10168,NCT03917966,Major pathological response（MPR）,2020-04-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
10169,NCT05130710,presence of peritoneal seeding,2020-02-25,COMPLETED,OBSERVATIONAL,['NA'],,presence of peri-gastric lymph node involvement
10170,NCT01490866,Progression-free Survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of Adverse Events as a Measure of Safety
10171,NCT00310076,Time to Progression,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Events of Toxicity Graded 3 and 4
10172,NCT01671683,,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
10173,NCT01688700,Pathology complete remission rate,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
10174,NCT02951091,progression free survival,2016-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10175,NCT01863862,The final three-year rate of local and distant recurrences taking into consideration results of rescue surgery for pelvic recurrence.,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,Multivariable analysis of prognostic factors associated with clinical complete response.
10176,NCT00230646,Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months."
10177,NCT02278133,Overall response rate in phase II,2014-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with dose interruptions and dose reductions (phase Ib/II)
10178,NCT03583528,Sensitivity of 68Ga-DOTATOC PET/CT in the diagnosis of SSTR positive tumors.,2018-07-11,RECRUITING,OBSERVATIONAL,['NA'],,Total number of lesions per anatomic location identified by 68Ga-DOTATOC PET/CT
10179,NCT01333475,pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced Colorectal Cancer,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
10180,NCT06316401,Safety of ESD under SA,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Median ESD duration
10181,NCT05193604,Overall response rate (ORR),2022-03-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
10182,NCT00427492,Time to defecation after colonic resection,2007-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
10183,NCT02117466,Clinical Benefit Rate,2014-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life (QoL) and health related QoL
10184,NCT03412773,Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,2017-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings
10185,NCT04319302,Bile drainage,2005-01,COMPLETED,OBSERVATIONAL,['NA'],Complications,Complications of procedure
10186,NCT04230603,Inflammatory classification with HSI,2019-06-06,UNKNOWN,INTERVENTIONAL,['NA'],,Tissue perfusion
10187,NCT04194775,Overall survival (OS),2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Time to deterioration (TTD), defined as the time from randomization to the first deterioration of European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) scale"
10188,NCT02468076,Feasibility (ratio of technically successful RFA-applications to all examinations in which RFA-use was intended),2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety (number and type of adverse events)
10189,NCT04573881,Primary Safety: Procedure-Related Major Complications,2021-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Secondary Safety: All Adverse Events
10190,NCT05426850,Relationship between ctDNA status after chemoradiotherapy and relapse.,2021-06-01,RECRUITING,OBSERVATIONAL,['NA'],,"Relationships between radiomics features, ctDNA status and relapse."
10191,NCT01728480,"The percentage of patients with mucositis, measured using the World Health Organization (WHO) mucositis global severity score and the oral mucositis daily questionnaire (OMDQ)",2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
10192,NCT05970302,Objective Response Rate (ORR),2023-07-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10193,NCT05227014,Transfusion rate,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative hemoglobin values
10194,NCT04813627,Occurrence of ctDNA positivity in the first post-AdCTx blood sample,2021-07-02,RECRUITING,OBSERVATIONAL,['NA'],,Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial
10195,NCT00385177,Pharmacokinetic parameters for SN2310 and SN-38,2006-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10196,NCT03323944,Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.03,2017-09-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate
10197,NCT05721300,Incidence of early liver cancer,2023-02-10,RECRUITING,INTERVENTIONAL,['NA'],,
10198,NCT02730533,The total bleeding rate according to grading of intraoperative bleeding during ESD procedure,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.
10199,NCT02864043,Performance of manually identified VLE features in predicting biopsy defined dysplasia,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Per Biopsy performance of VLE compared to standard-of-care for detecting dysplasia
10200,NCT05692037,Progression Free Survival Rate of Liver Target Lesions,2022-12-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate (DCR)
10201,NCT01600196,Survival time,2006-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Adverse Events
10202,NCT01898741,Safety,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10203,NCT02911363,Histological quality of the EMR specimen obtained during the procedure will be analyzed and compared to cassette vs. no cassette for pathology review.,2016-01,COMPLETED,INTERVENTIONAL,['NA'],,Ease of use of the Captivator tissue cassette will be comparable to Standard of Care.
10204,NCT04202601,Arms 3:≥second-line therapy group,2019-12-13,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Arms 3:≥second-line therapy group
10205,NCT00627042,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Drug-Related Treatment-Emergent Adverse Events
10206,NCT05663788,Pooled sensitivity of endoscopic optical diagnosis for predicting deep submucosal invasion in routine colonoscopies,2022-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Pooled LR- of endoscopic optical diagnosis for predicting deep submucosal invasion in a 20-image test before and after the learning module in the intervention group
10207,NCT04831632,diagnostic performance,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,qualitative iFOBT positivity rate
10208,NCT06278701,Albumin rising,2023-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Improved quality of life
10209,NCT01333033,Complete Pathological Response (pCR) of PET/CT Non-responders,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group
10210,NCT05193253,Disease-free survival (DFS).,2000-02-01,COMPLETED,OBSERVATIONAL,['NA'],,
10211,NCT04518579,anti tumour immunity,2018-04-15,COMPLETED,INTERVENTIONAL,['NA'],,change in pain intensity
10212,NCT00225641,Overall and cancer-specific mortality,2006-03,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life. Cost-effectiveness of follow-up
10213,NCT06305728,Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma,2024-03-04,RECRUITING,OBSERVATIONAL,['NA'],,
10214,NCT05093608,Maximum Tolerated Dose,2021-11-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10215,NCT00502502,Patient Symptom Assessment (Questionnaire),2002-11,COMPLETED,OBSERVATIONAL,['NA'],,
10216,NCT03315195,Postoperative complications,2017-11-25,UNKNOWN,INTERVENTIONAL,['NA'],,
10217,NCT03291951,Number of moderate and severe chemotherapy-associated toxicities,2018-02-23,COMPLETED,INTERVENTIONAL,['NA'],,
10218,NCT00014079,Determine the clinical and pathologic significance of unstable DNA elements,1997-09,COMPLETED,OBSERVATIONAL,['NA'],,Determine the clinical and pathologic significance of loss of heterozygosity
10219,NCT06310902,Bioinformatics analysis of single-cell sequencing results,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
10220,NCT00499395,Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease,2005-07,COMPLETED,INTERVENTIONAL,['NA'],,Findings on day 7 after RFA using FDG-PET imaging
10221,NCT00008398,,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10222,NCT03740360,Mutations in pancreatic cystic neoplasm,2017-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Relation between pancreatic fluid and serum molecular analysis
10223,NCT03182179,Change in LARS score,2016-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Irritable Bowel Syndrome-Quality of Life
10224,NCT02215447,Response rate,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rates of adverse events as defined by NCI- Common Terminology Criteria for Adverse Events (CTCAE) V4.0
10225,NCT01383746,Progression -free survival at 6 months (from date of inclusion),2011-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety of RADIOEMBOLIZATION using the NCI-CTCAE V3.0 classification.
10226,NCT03116945,"Uptake of positron emitting radiotracer, 68Gallium Citrate will be measured in the lesions of hepatocellular carcinoma.",2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10227,NCT01385956,Number of Participants With Serious Adverse Events,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Overall Survival (OS)
10228,NCT02866344,Local disease control at the site of intervention,2016-08,TERMINATED,INTERVENTIONAL,['NA'],,Postoperative mortality
10229,NCT05592925,Postoperative pathological results of tumor N stage.,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10230,NCT03601988,DFS,2018-07-28,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
10231,NCT00540579,"The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0",2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10232,NCT00355862,Recurrence free survival,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10233,NCT00136669,To determine the duration of acupuncture effects,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10234,NCT05088889,"Objective tumor response rate 2 (ORR2) after first progression, assessed by RECIST v1.1",2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Assessment of disease biomarkers as a surrogates or predictors to response following administration of SBRT and immunotherapy: Exploratory,"Incidence of Treatment-Emergent Adverse Events, as assessed by CTCAE version 5.0"
10235,NCT02527772,Progression-Free-Survival,2015-09,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression
10236,NCT05537402,Progression-free survival,2023-09-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to deterioration of quality of life
10237,NCT00919009,Time to progression (TTP) in patients treated with TACE plus sorafenib,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate will be evaluated
10238,NCT05770635,Objective response rate (ORR) 1 month after the last TACE -mRECIST evaluation,2022-12-28,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
10239,NCT02764801,Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10240,NCT02756468,Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,PCT and CRP cuts-off in 5th POD with a good NPV for AL
10241,NCT01789073,Overall postoperative complications after major gastrointestinal (GI) elective surgery.,2013-02,COMPLETED,INTERVENTIONAL,['NA'],"Weight stability, functional capability and patients´ satisfaction with the overall study course.",Length of hospital stay after major gastrointestinal (GI) elective surgery
10242,NCT05515315,progression free survival,2022-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10243,NCT05139199,Quality of Life (EORTC QLQ-PAN26 ),2022-02-23,COMPLETED,INTERVENTIONAL,['NA'],,Physical Activity(Exercise Counseling and Programming Preferences)
10244,NCT04380506,Validate the ability of the diameter (in cm) of abdominal collection detected during the contrast-free abdomen CT in POD3 to predict risk of biliary fistula,2020-03-15,UNKNOWN,INTERVENTIONAL,['NA'],,
10245,NCT06099119,Change in body weight over study period.,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
10246,NCT03083002,Transcriptomics characterization of liver tissue: the purpose is molecular evaluation of possible predisposing factors to development of hepatocellular carcinoma in patients with cirrhosis.,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,Transcriptomics characteristics of newly diagnosed hepatocellular carcinoma: the purpose is to verify if we can predict the survival of patients considering the molecular features of HCC at first diagnosis.
10247,NCT04466254,Best of Response (BOR),2020-12-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Deepness of Response (DpR)
10248,NCT04809142,Overall survival (OS),2021-02-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival at 12 months
10249,NCT06223230,Median progression-free survival time,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Duration of Response
10250,NCT03108885,Esophageal Cancer Mutation,2017-10-01,TERMINATED,OBSERVATIONAL,['NA'],,Marker for Recurrence
10251,NCT04408859,Quality of life index,2018-04-17,UNKNOWN,OBSERVATIONAL,['NA'],,
10252,NCT00973609,Time to failure of maintenance and reinduction treatment strategy measured from randomization,2009-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,"TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research."
10253,NCT04021056,Evaluate the recurrence free survival rate of HCC patients after curative treatments,2011-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10254,NCT04130971,Tumour response to treatment,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Normal tissue response to treatment
10255,NCT05163977,Post-Operative Pancreatic Fistula,2021-06-12,UNKNOWN,INTERVENTIONAL,['NA'],,primary or reactionary hemorrhage
10256,NCT02817308,correlation of CA19-9 levels in urine and saliva with those in the serum,2016-07,UNKNOWN,INTERVENTIONAL,['NA'],,Number of participants needed to standardize the measurements in urine and saliva according to those measured in the serum.
10257,NCT00005874,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10258,NCT03384316,Recommended Phase 2 Dose (RP2D),2018-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],Number of Dose Limiting Toxicities (DLTs),Overall Survival (OS)
10259,NCT04592211,dose limiting toxicity,2021-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall response rate
10260,NCT00844077,Conversion from Barrett's intestinal metaplasia to dysplasia or esophageal adenocarcinoma.,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
10261,NCT00619541,"N° of non progressive disease (complete and partial responses, stable disease)",2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Toxicity of the combination,ORR,Duration of responses, TTP and OS.PK, PD,Baseline pERK concentration, phospho VEGF-R2 concentration, plasma proteomics and gene expression profiling on blood cells and tumor biopsy"
10262,NCT04817813,Survival and disease-free survival at 5th year.,2021-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Follow up- Date of death
10263,NCT01006577,Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score),2010-06,UNKNOWN,INTERVENTIONAL,['NA'],,cancer related deaths
10264,NCT01953406,Time-to-progression(TTP)of lung metastasis,2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Adverse Events,Disease control rates (CR + PR + SD)of lung metastasis
10265,NCT03961373,Overall survival analysis,2018-11-05,RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of completion of protocol treatment
10266,NCT00016042,,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
10267,NCT01442935,The main objective is to compare resection rates (R0 or R1) for hepatic metastases,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10268,NCT00107315,Time to Progression,2004-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Toxicity
10269,NCT04523389,Association between the number and size of exosomes and their content on cancer stage and progression,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10270,NCT02585479,Progression-Free-Survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time-to-Progression outside the liver
10271,NCT03801876,"Incidence of specific grade 3+ cardiopulmonary adverse events (AEs) that are definitely, probably, or possibly related to protocol treatment",2019-03-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cost-benefit economic analysis of treatment
10272,NCT01238055,time to progression,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
10273,NCT02525237,Safety will be assessed by incidence of adverse events,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL)
10274,NCT03375320,Progression-free survival (PFS),2018-10-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Radiographic response rate
10275,NCT03989310,Disease control rate (DCR),2019-03-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with laboratory test abnormalities
10276,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",2006-08,COMPLETED,OBSERVATIONAL,['NA'],,Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs)
10277,NCT04028375,MSCT and MRI staging in Gastric Cancer.,2019-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,MSCT and MRI prediction of prognosis in gastric cancer
10278,NCT05515185,Maximum tolerable dose,2022-09-09,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
10279,NCT00559676,Pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects,2005-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,Predictive value of pharmacogenetic and pharmacokinetic parameters on disease-free and overall survival
10280,NCT03275376,Overall survival,2017-12-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival
10281,NCT00769106,Time to recurrence (TTR),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,AEs and SAEs
10282,NCT05004441,objective response rate (ORR),2021-07-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
10283,NCT04678583,Intrahepatic disease-free survival (iDFS),2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,"Assessment of additional oncological and perioperative outcomes: Assessment of ""Quality of life"" (QoL)"
10284,NCT02831842,Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice,2016-06-09,COMPLETED,OBSERVATIONAL,['NA'],,OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice
10285,NCT02862613,Progress-free survival,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
10286,NCT05274945,pathological assessment of response to treatment,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,adverse events of chemotherapy
10287,NCT01318161,Long-term (up to 5 yrs) all-cause mortality,2011-03,TERMINATED,INTERVENTIONAL,['PHASE3'],Postoperative pain and early recovery,Cancer recurrence detected by MRI; perioperative complications
10288,NCT05307926,Disease-free survival,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
10289,NCT00271011,Percentage of Patients With an Objective Response,2005-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients Experiencing Hematologic and Non-hematologic Adverse Events
10290,NCT03199144,patient overall survival,2017-04-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,CEA level post operatively at one month
10291,NCT00318903,The determination of pathologic response in patients who undergo surgical resection.,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the toxicities associated with this treatment and any impact on surgery.
10292,NCT05959226,3-year overall survival rate,2023-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,QLQ-C30 assessment
10293,NCT01822444,Identification of biomarkers,2012-11,COMPLETED,OBSERVATIONAL,['NA'],,Validation of identified biomarkers
10294,NCT00152230,Relapse-free survival and overall survival,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events
10295,NCT02751606,Sensitivity and specificity of 7 Tesla MRI in combination with ferumoxtran-10 on nodal level.,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Comparison of 7 Tesla and 3 Tesla MRI
10296,NCT01198522,Maximum tolerated dose and the preliminary tolerability profile.,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
10297,NCT01822210,Change of tumor volume in the stomach.,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,performance status
10298,NCT03628651,Biomarker Identification,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],,
10299,NCT03801915,Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug,2019-11-13,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),Define Disease Free Survival (DFS) for Participants Treated With Preoperative MVT-5873
10300,NCT02623153,response rate,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
10301,NCT00033462,Proportion of patients who are progression-free at 24 weeks,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate in EGFR positive patients
10302,NCT05720195,Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score,2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI)
10303,NCT00519324,To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To describe the safety profile (incidence and severity of adverse events, serious adverse events) assessed by NCI CTCAE version 3.0"
10304,NCT01746043,Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10305,NCT04293315,Effective Screening,2018-06-09,UNKNOWN,INTERVENTIONAL,['NA'],,Implementation outcomes according to the RE-AIM framework
10306,NCT06096493,Disease free survival.,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,
10307,NCT02558504,complete histological eradication of the high grade glandular epithelial neoplasia,2013-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Percentage of patients with severe adverse reaction and minor adverse reactions linked to the procedure used, described by anatomical site"
10308,NCT06258434,Sensitivity and specificity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to colonoscopy,2024-02-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Sensitivity of the multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo) with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
10309,NCT03567863,cumulative length of tissue core biopsies per needle pass,2018-06-24,COMPLETED,INTERVENTIONAL,['NA'],,intra-observer evaluation of the anatomopathological criteria used
10310,NCT04906382,T-cell receptor (TCR) diversity,2021-07-01,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
10311,NCT01483638,progression-free survival,2012-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse events
10312,NCT01419769,Safety - Freedom From Major Complications: SAE's,2011-08,COMPLETED,INTERVENTIONAL,['NA'],,Clinical Success
10313,NCT02736552,Disease-free survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE3'],Treatment expense,Side effects
10314,NCT01801163,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2012-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],"3.2.4 To evaluate biologic markers such as VEGF, eNOS and HIF1-alpha, VEGF-R2 genetic polymorphisms as well as serum VEGF and soluble VEGFR2 levels and correlate with efficacy outcomes.",Time from start of treatment until death from any cause or date of last patient contact.
10315,NCT05241899,Progression free survival (PFS),2022-05-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
10316,NCT02166255,Overall survival,2014-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10317,NCT03720678,Incidence of dose-limiting toxicities (DLTs) during dose escalation phase,2018-11-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunomodulatory activity in subsets for AB928 in combination with mFOLFOX
10318,NCT01914692,fistula of pancreas,2013-01,COMPLETED,INTERVENTIONAL,['PHASE4'],postoperative pancreatitis,infection of incisional wound
10319,NCT03602703,Pattern of immunity in patients with de novo HCC develped after treatment with DAAs,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
10320,NCT05815082,5-year progression-free survival,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complications
10321,NCT04797507,ORR based on RECIST v1.1,2021-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
10322,NCT00885950,Histologically proven hepatic sinusoidal injury,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,90-day morbidity and mortality
10323,NCT05718232,Overall Survival (OS),2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Progression （TTP）
10324,NCT01666444,Overall Survival,2012-10-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Adverse Events (AEs)
10325,NCT04607421,Cohort 3: Objective response rate by blinded independent review,2020-12-21,RECRUITING,INTERVENTIONAL,['PHASE3'],,Cohort 3: Trough concentrations of encorafenib and its metabolite LHY746
10326,NCT04272034,Number of treatment-emergent adverse events,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Vz/F of INCB099318
10327,NCT05628194,MSM awareness of strategies to decrease anal cancer risk,2023-06-08,RECRUITING,OBSERVATIONAL,['NA'],,
10328,NCT00303927,Toxicity,2005-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
10329,NCT01188876,Best Overall Response,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Area Under the Plasma Drug Concentration-Time Curve (AUC)
10330,NCT06217250,Success rate of resection defined as absence of residual/recurrence in SC1 and/or SC2,2024-02-26,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Avarage time of procedure and polyp resection time
10331,NCT05620537,postoperative overall survival,2022-11-10,COMPLETED,OBSERVATIONAL,['NA'],,
10332,NCT03001518,immune response,2017-05-04,COMPLETED,OBSERVATIONAL,['NA'],,disease-free survival
10333,NCT02135757,The pharmacoeconomic impact of panitumumab for the treatment of metastatic colorectal cancer in a real-life setting,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Identification of blood biomarkers that confer significant improvement in progression-free survival in patients treated with panitumumab.
10334,NCT03243916,overall survival(OS),2017-08-15,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life (QOL)
10335,NCT05122221,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",2022-07-17,RECRUITING,INTERVENTIONAL,['PHASE1'],Negative conversion rate among HPV-16 positive patients detected by tissue biopsy,Progression-Free Survival（PFS）
10336,NCT06096779,Percentage of Participants with Adverse Events,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in IL46 Scores
10337,NCT01908478,Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I),2013-10-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells
10338,NCT01710215,Cost: Cost per-patient effectively screened.,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,Cost: Incremental costs for the FIT and Colo strategies relative to the Usual Care strategy.
10339,NCT01877096,Screening colonoscopy completion,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,Psychological mediators
10340,NCT02269904,DFS (Disease Free Survival),2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse event
10341,NCT04747600,the incidence of the pancreatic fistula,2014-06-01,COMPLETED,OBSERVATIONAL,['NA'],,recurrence rate in percentage
10342,NCT02809898,Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor status （worse/ maintain/ better）
10343,NCT01130337,Percentage of Participants With Disease-free Survival (DFS) at Month 18,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Objective Response
10344,NCT06272214,2-year DFS,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Recurrence
10345,NCT01995396,Rates ot postoperative surgical complications within 30 days.,2014-02,TERMINATED,INTERVENTIONAL,['NA'],Late complications after surgery,Other postop complications
10346,NCT02872519,Number of lesions detected by (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET imaging before and after neoadjuvant chemotherapy treatment,2018-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Conditional predictive models of imaging performance and agreement
10347,NCT06260943,Proportion of Participants Enrolled in Clinical Research,2024-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10348,NCT01843400,Number of patients with serious adverse events(SAEs) from the first administration of regorafenib.,2013-04-22,COMPLETED,OBSERVATIONAL,['NA'],,Tumor response assessed by RECIST or physicians own evaluation
10349,NCT04568330,Scale,2014-03-21,COMPLETED,INTERVENTIONAL,['NA'],Scale,Scale
10350,NCT05171075,"Time to first event of centrally adjudicated VTE recurrence consisting of new proximal deep venous thrombosis, new pulmonary embolism (PE) or fatal PE, including unexplained death for which PE cannot be ruled out",2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding"
10351,NCT04140552,Overall Survival,2008-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10352,NCT01719926,Number of dose limiting toxicities at each dosage cohort,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Efficacy
10353,NCT06265883,Time to progression (TTP),2019-07-01,COMPLETED,OBSERVATIONAL,['NA'],,treatment-related adverse events (TRAEs)
10354,NCT03565029,Distant Relapse-Free Survival (DRFS),2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes
10355,NCT04713618,Change in sexual function,2021-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in vaginal microbiome
10356,NCT02702401,Overall Survival (OS),2016-05-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
10357,NCT05967910,Effect of Chronic stress on efficacy of immune checkpoint inhibitors,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],The correlation between peripheral immune cells signature and chronic stress and the efficacy of ICIs,Effect of chronic stress on quality of life
10358,NCT03366155,Response rate (RR),2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Extra-hepatic progression-free survival
10359,NCT03174574,"Genomic and risk factor differences among family members who share identical predisposing CDKN2A gene mutations, with different phenotypes; will discover patterns of tumorigenesis, tissue specificity, gene-gene, and gene-environment interactions.",2016-08-17,COMPLETED,OBSERVATIONAL,['NA'],,
10360,NCT02250209,3-year disease-free survival (DFS),2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Prognostic value of biomarkers
10361,NCT01360541,Prevalence of low grade dysplasia 3 years after randomization,2010-12-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Detection rate of dysplasia and Barrett's oesophagus with the confocal endomicroscopy technique
10362,NCT05849571,Children's International Mucositis Evaluation Scale (ChIMES),2023-03-01,COMPLETED,INTERVENTIONAL,['NA'],,
10363,NCT03627728,PFS1,2018-06-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,biomarker evaluation
10364,NCT01886287,Number of Participants With Improved Frequency of Diarrhea,2013-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of Progression Free Survival (PFS) at 6 Months
10365,NCT00562380,Pharmacokinetic profile,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Circulating levels of IGF-1R and IGF-BP3
10366,NCT03244787,Percentage of patients in intervention and control groups who completed any colorectal cancer screening during the six-month study period,2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of polys found in intervention polyps (histology)
10367,NCT02510378,percentage of patients undergo R0 surgery during the follow-up,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)
10368,NCT01783171,MTD of dinaciclib in combination with Akt inhibitor MK2206 defined as the highest dose at which 0 or 1 dose-limiting toxicities are observed in six patients,2013-01-15,COMPLETED,INTERVENTIONAL,['PHASE1'],Protein expression in serum as measured by fluorescence activated cell sorting (FACS),Progression-free survival
10369,NCT01934634,Percentage of patients with Dose-Limiting Toxicities,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Objective Response Rate
10370,NCT01534637,Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based Chemotherapy With Upper Abdominal Radiation,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Taking Anti Nausea Drugs
10371,NCT06228963,6-months CR rate,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory biomarkers,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10372,NCT02871245,Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.,2016-09-21,UNKNOWN,INTERVENTIONAL,['NA'],,Immune cell number ratio in blood.
10373,NCT00003677,Number of Patients with Toxicity,1999-02-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10374,NCT00869570,Pathological near complete or complete tumor response (Dworak grade 3 and 4) (Phase II),2009-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events as assessed by NCI CTCAE v3.0
10375,NCT02639065,Percentage of Participants With One-Year Relapse Free Survival (RFS) With Post-Operative Durvalumab,2016-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety and Tolerability
10376,NCT04730388,predictive factor for progression-free survival,2021-01-18,UNKNOWN,OBSERVATIONAL,['NA'],,
10377,NCT05840263,Extract key themes to integrate into preliminary drafts,2023-05-31,RECRUITING,OBSERVATIONAL,['NA'],,
10378,NCT00741676,2 year survival,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,efficacy and clinical out come
10379,NCT02889328,Disease control rate,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile by the NCI-CTCAE v4.03
10380,NCT02437916,AMG 228 half-life (t1/2),2015-04-21,TERMINATED,INTERVENTIONAL,['PHASE1'],,Changes in numbers of cytotoxic T lymphocytes (CTL)
10381,NCT04970056,Development of PDAC,2020-09-18,RECRUITING,OBSERVATIONAL,['NA'],,
10382,NCT01992406,Transanal specimen extraction possible or not,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,quality of life
10383,NCT04692987,Number of participants with colorectal cancer screening completion,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Barriers towards the colorectal cancer screening uptake
10384,NCT01266187,Disease free survival,2011-07,TERMINATED,INTERVENTIONAL,['NA'],,Secondary objectives
10385,NCT00310115,Number of Patients with Smoking Abstinence,2002-04,COMPLETED,OBSERVATIONAL,['NA'],,Number of Cigarettes Smoked Daily
10386,NCT04117100,Assess the number of patients with intraprocedural bleeding,2018-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
10387,NCT04228614,prediction accuracy of recurrent rate,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mutation Consistency of tissue and blood sample
10388,NCT01473303,Convergent validity of each selected PRO-CTCAE item (phase II),2012-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Responsiveness (sensitivity to change) of PRO-CTCAE (phase II)
10389,NCT03955224,Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline,2021-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0
10390,NCT02455648,Post-operative stenosis,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,
10391,NCT02386397,Limiting toxicity,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10392,NCT06034860,Proportion of participants with objective response,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate the immunogenicity of MT-8421 in patients with selected advanced solid tumors.
10393,NCT03719924,survival at 9 months,2019-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life (questionnaires)
10394,NCT01145404,Objective response rate (ORR),2010-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Biomarker analysis
10395,NCT02652663,Disease free survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10396,NCT01953419,ORR,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10397,NCT01326065,Long term outcome,2011-02,TERMINATED,OBSERVATIONAL,['NA'],,Quality of the surgical specimen
10398,NCT06016400,Within two months from the start of chemotherapy,2021-06-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Length of hospital stay of patients in vitamin D treatment group and placebo group
10399,NCT01483014,Objective response using the RECIST criteria,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
10400,NCT04281290,Evaluation of feasibility and safety,2020-07-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
10401,NCT02218801,Number of post-operative complications,2015-05,COMPLETED,OBSERVATIONAL,['NA'],,Number of post-operative complications in the first 50 patients compared to the second 50 patients
10402,NCT02475772,Adverse events according to CTCAE criteria,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Plasma concentrations of cisplatin and doxorubicin,Clinical benefit according to RECIST criteria
10403,NCT03272659,fluorescence with photodynamic diagnostics (PDD) in colorectal cancer,2018-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Accurate depiction of the extent of disease burden by correlating pre-and post surgical results after neoadjuvant chemotherapy and radiation.,Detect malignant lesions
10404,NCT00022139,Proportion of successes,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
10405,NCT06256705,"Clinical response defined by the PFS as the time measured from the day of first administration of PRRT to first progression or death at 18 months, whichever occurs first",2024-03-25,RECRUITING,INTERVENTIONAL,['NA'],,
10406,NCT06241079,Overall survival,2003-03-31,COMPLETED,OBSERVATIONAL,['NA'],,
10407,NCT01428752,prevalence of colorectal adenoma(any size),2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,prevalence of advanced adenoma
10408,NCT03388047,Level of confidence in delineating the area of interest by multispectral imaging,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Correlation with molecular biomarkers
10409,NCT02264886,"Feasibility of the online, adaptive, MRI-guided SBRT",2015-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Patient-reported quality of life
10410,NCT01650428,Pathological Complete Response (PCR),2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Cell Density
10411,NCT00107341,Confirmed tumor response rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of response
10412,NCT00733746,Overall Survival at 2 Years,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
10413,NCT05003700,Objective response rate (ORR),2021-04-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10414,NCT05195502,Evaluation of metabolic profile,2022-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Colonic biofilm
10415,NCT01653327,Change in Pain Score,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Analgesic Effect
10416,NCT03476057,cfDNA,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor mutation burden
10417,NCT04137107,Chronic neuropathic pain response (Phase III),2020-05-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Incidence of adverse events, including duloxetine side effects of nausea, dry mouth, dizziness, somnolence, fatigue, and insomnia (Phase III)"
10418,NCT06048458,Change in myocardial blood flow from baseline with adenosine stress assessed by quantitative perfusion cardiac MRI,2022-05-18,RECRUITING,OBSERVATIONAL,['NA'],,Change in retinal vessel density
10419,NCT04354662,Pathological complete response rate (pCR),2019-09-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,5-year Survival Rate
10420,NCT04044313,Progression free survival rate at 6 months,2019-08-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
10421,NCT03459235,assessment of quality of life of patients operated for a rectal cancer (rectal resection) - Sexual sequelae (for men),2018-03-20,UNKNOWN,INTERVENTIONAL,['NA'],,
10422,NCT06320301,the effectiveness of first-line treatment with Adebrelimab and a tyrosine kinase inhibitor (TKI) in combination with gemcitabine and oxaliplatin (GEMOX) in patients with advanced BTC,2024-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],The DoR based on an immunomodified RECIST (imRECIST）,To evaluate the overall survival (OS).
10423,NCT01933945,Overall survival (OS),2013-10-28,COMPLETED,OBSERVATIONAL,['NA'],Duration of treatment of sorafenib after TACE,TTP from initiation of sorafenib
10424,NCT04332705,Prevalence of Cryptosporidium,2020-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Rate of development of a neoplastic lesion in the human explants
10425,NCT00856375,Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK Parameters of NKTR-102 or Irinotecan and Respective Metabolites
10426,NCT01084629,detection of dysplasic areas,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
10427,NCT05007548,Correlation of the ICGR15 with the conventional liver function tests,2021-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Comparison of CTV and Ga68-Dolacga PET parameters in patients with PHLF
10428,NCT03181334,Increase in colorectal cancer screening rate of the 5 tested invitation approaches.,2017-09-05,COMPLETED,INTERVENTIONAL,['NA'],,
10429,NCT05278195,Overall Survival(OS),2022-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Accuracy
10430,NCT04466124,Establish a cohort of liver cancer patients treadted with proton beam therapy.,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10431,NCT03470883,Complete long-term remission (> 12 months),2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Endoscopic description and anatomopathological results
10432,NCT03392103,The ratio of patients occured Grade 3 or higher adverse events,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year overall survival probability
10433,NCT06038578,Progression free Survival (PFS),2023-10-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change from Baseline in Patient Reported Quality of Life assessed by Questionnaire - EuroQOL Five Dimensions questionnaire 3L (EQ-5D-3L) scores
10434,NCT00601510,Overall tumor response as assessed by RECIST,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Quality of life
10435,NCT00016250,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10436,NCT01838109,Body weight decrease rate 8weeks after discharge compared with preoperative body weight,2013-04,COMPLETED,INTERVENTIONAL,['NA'],ONS related gastrointestinal adverse event,serum albumin
10437,NCT06014944,cCR rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10438,NCT02556619,Change in Health-Related Quality of Life (HRQoL),2019-04-02,UNKNOWN,INTERVENTIONAL,['NA'],,Cost Utilization
10439,NCT01853813,Response Rate,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],RECIST criteria and those defined by Chun,"evaluation of serum IL-8, bFGF, HGF, PlGF, SDF-1, MCP-3"
10440,NCT05526846,Effect of the intervention on participant's Healthy Plant-Based Diet Index,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Secondary health gains associated with adopting a plant-based diet
10441,NCT00625625,Disease-free survival,2004-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10442,NCT00999882,Evaluate the pharmacokinetics of AZD8055 following both single and multiple dosing,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,To collect and store DNA for future exploratory research that may influence response to AZD8055
10443,NCT03419481,Response rate (RR) according to RECIST1.1,2018-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10444,NCT05083247,R0 Resection rate,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Technical and quality success rate of EUS-delivered fiducials.
10445,NCT00006038,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10446,NCT05855200,Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR),2023-08-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants with Anti-Drug Antibodies against Dostarlimab
10447,NCT04963088,ORR,2021-03-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival
10448,NCT00504322,Expression of CD40L and cytokines,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10449,NCT05716594,Disappearance rate of pseudocyst（PDR） after stent implantation,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time of disappearance of pseudocyst after stent implantation
10450,NCT06151223,Collection of radiology images and videos,2021-07-13,RECRUITING,OBSERVATIONAL,['NA'],,
10451,NCT06328101,Standardized incidence ratio (SIR) of first invasive cancer,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Risk factor associated with cancer diagnosis.
10452,NCT02025842,risk for hepatocellular carcinoma,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,survival
10453,NCT01236300,NPV (Negative Predictive Value),2010-07,COMPLETED,INTERVENTIONAL,['NA'],,Overall Complication Rate
10454,NCT04241835,"To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasma",2020-01-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0
10455,NCT00122720,"The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life",2003-06,COMPLETED,INTERVENTIONAL,['PHASE4'],,Postoperative complications
10456,NCT03885219,6-month progression-free survival (PFS),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (ORR)
10457,NCT00079066,Overall survival,2003-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety profile
10458,NCT00575523,Occurrence of dysrhythmias,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Clinical complications
10459,NCT01275222,Progression-free Survival (PFS) - Phase II,2002-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology."
10460,NCT03524677,Early recurrence,2019-01-23,UNKNOWN,OBSERVATIONAL,['NA'],,N stage
10461,NCT02066272,The frequency of adverse events on induction of remission and maintenance treatment using anti-TNFs (including biosimilars) in a cohort of IBD patients,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10462,NCT06024980,Swallowing ability to four different textures,2023-01-03,RECRUITING,INTERVENTIONAL,['NA'],,The time in weeks of nasogastric feeding
10463,NCT01596283,Postoperative Complications,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative Length of Stay
10464,NCT03834701,Incidence of adverse events (AEs) after EUS-guided radiofrequency ablation (RFA),2019-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Rates of secondary surgery
10465,NCT02730663,Number of Participants With Clinical Success,2016-03-21,COMPLETED,INTERVENTIONAL,['NA'],,Other Adverse Events
10466,NCT00861094,Progression-free survival (Phase III),2008-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)
10467,NCT01718873,Objective Response Rate,2012-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxic Effects
10468,NCT04595604,Change in preoperative functional status - FVC by the end of rehabilitation,2020-09-07,SUSPENDED,INTERVENTIONAL,['NA'],,Change of alpha- and beta-diversity of fecal microbata
10469,NCT04150120,Cost-utility ratios,2019-10-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,EQ-5D-3L
10470,NCT05229003,ORR,2022-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs
10471,NCT05572788,Rate of post-procedure pancreatitis following EUS-guided fine needle aspiration of pancreatic cysts,2022-09-26,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospitalization in any patient hospitalized with acute pancreatitis
10472,NCT01556815,Effectiveness of sorafenib in increasing the effectiveness of transarterial chemoembolization (TACE),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Survival in the two treatment groups
10473,NCT04003181,Serum concentration of FGF19,2017-09-28,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life after treatment with antibiotics or bile acid binder
10474,NCT01341756,Response of bleeding to radiotherapy,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Number of patients who develop anorexia, nausea, vomiting as per common toxicity criteria v3.0"
10475,NCT03749083,One year local recurrence rate in participants that test positive for ctDNA compared to participants that tested negative for ctDNA,2019-12-31,WITHDRAWN,OBSERVATIONAL,['NA'],,Median Fecal Incontinence Severity Index (FISI) score
10476,NCT00084773,Safety profile,2004-03,COMPLETED,INTERVENTIONAL,['NA'],,Activity in terms of pathological complete response rate
10477,NCT05153746,Adenoma detection rate,2022-02-10,RECRUITING,INTERVENTIONAL,['NA'],,Flat adenoma detection rate
10478,NCT05364918,Acute radiotherapy-induced oral mucositis,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,Oral pain
10479,NCT04503967,Objective response rate,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10480,NCT00055250,6-month survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK
10481,NCT06126120,Participant non-adherence to 2-yearly colonoscopy check-up.,2024-01-17,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,The four most important challenges to having colonoscopy check-up for participants.
10482,NCT00817895,disease free survival,2008-12,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
10483,NCT04079049,Survival,2020-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10484,NCT05135364,Progression-free survival (according to mRECIST),2021-11-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (according to mRECIST and RECIST 1.1)
10485,NCT00630890,To determine the maximal tolerated dose of the Cyberknife radiosurgery boost,2007-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,To estimate disease specific and overall survival
10486,NCT00809081,To evaluate the impact of early postoperative enteral feeding,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,To evaluate the nutritional status
10487,NCT01927016,To identify predictors of recurrence after esophageal cancer surgery,2012-07,COMPLETED,OBSERVATIONAL,['NA'],,"Impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach…) on outcomes"
10488,NCT03045497,Ability of contrast-enhanced ultrasound to predict response to transarterial chemoembolization with drug eluting beads,2012-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in contrast fill time
10489,NCT00541125,Toxicities by NCI-CTC v. 2.0,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
10490,NCT04606992,Resection margin,2020-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Complication rate
10491,NCT01355107,measurement of selenium levels in hcv- infected patients,2011-04,COMPLETED,OBSERVATIONAL,['NA'],,selenium levels and MELD(Na)score
10492,NCT00891332,Overall Response Rate (ORR),2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetics
10493,NCT00570713,Overall Survival (OS),2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Best Overall Response Rate
10494,NCT01789229,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,2003-09,RECRUITING,OBSERVATIONAL,['NA'],,
10495,NCT00436657,Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer,2007-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10496,NCT04472767,Complete Response Rate,2020-08-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Conversion Rate to Resectable
10497,NCT03239158,Relief degree of tumors,2017-09-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall survival（OS）
10498,NCT00003298,Grade 3 or Higher Toxicity Incidence on Step 1,1999-06-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10499,NCT00828984,Difference (After Treatment Minus Before Treatment) of EGFR Expression,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in E-cadherin Expression as Measured in Endoscopically Normal (Non-ACF) Mucosal Biopsies
10500,NCT00237900,"Parts 2 and 3: Safety and tolerability of gefitinib in combination with 5-FU, LV and radiotherapy",2003-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Exploratory outcome: Parts 2 and 3: sVEGF levels, EGFR activation, Biomarkers such as cyclin D1, IL-1, GI-associated TOP2A, GAS, EST AA552509"
10501,NCT01150916,diagnostic accuracy of BNP for the diagnosis of ascites due to heart failure,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
10502,NCT00134589,Completion of colorectal cancer screening,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Patient's intention to ask/patient asking medical provider for colorectal cancer screening
10503,NCT02080260,Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects,2014-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control
10504,NCT03623464,Readmission rate,2017-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life: Return to Baseline Function-Activities of Daily Living (ADLs)
10505,NCT03449030,Recommended Phase 2 Dose (RP2D) of TAK-164,2018-04-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Positive Antidrug Antibody (ADA) Levels in Serum
10506,NCT01048580,"Safety and tolerability of the combination of perifosine and capecitabine (i.e., dose limiting toxicity)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) data for the combination of perifosine and capecitabine
10507,NCT02534142,Variables related to non-completion of colonoscopy following a positive fecal occult blood test,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,
10508,NCT01643447,the overall survival rate of each group,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,
10509,NCT02117674,polyp detection rate,2014-04,COMPLETED,INTERVENTIONAL,['NA'],,patients' satisfaction
10510,NCT01229813,To demonstrate that maintenance treatment with bevacizumab + erlotinib following first line chemo- and anti-angiogenetic therapy results in a significant increase in progression free survival (PFS) compared to treatment with only bevacizumab.,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,To explore the activity of bevacizumab and low dose metronomic capecitabine in patients with KRAS mutated tumors.
10511,NCT05874726,Tissue sample repository,2023-07-19,RECRUITING,OBSERVATIONAL,['NA'],,
10512,NCT01372527,Cancer completion for all eligible cancers,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,TopCare system measures (intervention practices)
10513,NCT01549795,Time to recurrence after liver transplant,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis)
10514,NCT06321913,vital signs,2024-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],CLDN18.2 expression level,Overall Survival (OS)
10515,NCT00436410,Comparison of the impact of distribution time and histology on accumulation of treatment particles in tumor vs normal tissues,2006-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Long-term toxicity of treatment as assessed by CTCAE v3.0
10516,NCT01895257,Time to progression (TTP1 overall),2013-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],SIR-spheres treatment,Overall Survival (OS)
10517,NCT02537171,Progression-free survival (PFS),2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events(AEs)
10518,NCT02425735,Reduced size of the tumors,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10519,NCT06248528,Overall survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects
10520,NCT05642338,HGD/EAC,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,The rate of progression to HGD/EAC after a WATS-positive-biopsy-negative diagnosis for HGD/EAC
10521,NCT06283121,Objective response rate (ORR),2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
10522,NCT02287597,"Effectiveness: Second-line time to progression, in months",2014-11-13,COMPLETED,OBSERVATIONAL,['NA'],,"Safety (composite outcome measure): Incidence, nature and severity of all serious adverse events reported in second line mCRC treatment with Avastin plus chemotherapy and information on outcome and action taken with the drug"
10523,NCT04239261,Development of Oral Mucositis during ChemoRadiation Treatment,2020-01-17,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Bowel Movements
10524,NCT00001332,,1992-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10525,NCT04616495,five year overall survival (OS),2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life using EORTC questionnaires: QLQ-C30
10526,NCT03135652,Disease free survival,2017-08-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Toxicities
10527,NCT03632850,Decisional Conflict Scale,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],,Usability: System Usability Scale (SUS)
10528,NCT01609075,Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events,2012-06,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes)
10529,NCT03503630,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269,2018-07-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire
10530,NCT01510730,Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of gastric tumor.,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,effect of eradication of Helicobacter pylori on incidence of High grade dysplasia development after endoscopic resection of gastric tumor.
10531,NCT05458791,Quantification of Parameters for Intra-arterial Perfusion,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Impact of low dose radiation technique on intra-arterial perfusion parameters
10532,NCT01197664,"Toxicity and tolerability of the paricalcitol regimen, as measured by calcium levels",2010-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Patterns of gene expression in tumor samples of patients who receive chemoradiation with and without paricalcitol
10533,NCT04485286,Ability of [68Ga]CBP8 to detect collagen deposition in areas of radiation injury.,2020-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10534,NCT01539824,Disease stabilisation rate,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumour Markers
10535,NCT02981719,Safety (number of adverse effects),2016-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Technical success of ablation
10536,NCT00956254,Cmax of Fentanyl,2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,AUC0-last of Fentanyl
10537,NCT00956241,Primary endpoint was the function of the neo-rectum as assessed by a validated functional outcome questionnaire at 4 months.,2002-04,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
10538,NCT01991379,Best Response Rate (phase II portion),2013-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,RR by EORTC criteria
10539,NCT04054713,Comparing the incidence of dysplasia by directed biopsies with acetic acid chromoendoscopy against taking non-directed protocolized biopsies( Seattle protocol) in patients with Barrett's esophagus.,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,
10540,NCT05924282,5-year overall survival,2010-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
10541,NCT04178642,The survival rate without hepatic recurrence at 1 year,2020-09-22,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10542,NCT02937519,Number of Participants with Adverse Events as a Measure of Safety,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10543,NCT04722055,Kappa coefficient,2021-01-26,COMPLETED,OBSERVATIONAL,['NA'],,
10544,NCT04721470,AFP variation rate,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
10545,NCT05426005,Objective response rate (ORR),2023-02-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Toxicity assessed using the The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0."
10546,NCT03899415,Safety evaluation based in Incidences of adverse events/serious adverse events,2019-04-20,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival rate
10547,NCT05658679,5-year survival rate,2016-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10548,NCT01766479,"Number of patients in whom colorectal polyps and colorectal neoplasia have been detected by CT colonography, by adopting colonoscopy as gold standard, as a measure of efficacy.",2009-05,COMPLETED,INTERVENTIONAL,['NA'],,
10549,NCT00594529,Curative resection rates of liver metastases,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Completion rates of neoadjuvant chemotherapy
10550,NCT05964361,Safety of IL15/IL15Ra/WT1 DC vaccine administration: total (S)AEs (grade),2023-12-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluation of changes in quality of life: How patient-reported quality of life evolves over time
10551,NCT02066064,G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.,2013-11,COMPLETED,INTERVENTIONAL,['NA'],,"polyp and adenoma detection, procedure times and safety"
10552,NCT03817866,Disease Progression,2019-01-29,COMPLETED,OBSERVATIONAL,['NA'],,
10553,NCT04245683,patient preferences for operative vs. non-operative management of rectal cancer,2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Patient adherence to surveillance protocols
10554,NCT05869097,Overall Survival (OS),2020-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Treatment-Related Adverse Events (TRAE)
10555,NCT00763425,Complete removal rate of colorectal polyps,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Complication rate
10556,NCT05856500,Appendicular skeletal muscle mass index(kg/㎡),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Survival rate(%)
10557,NCT00574353,"the feasibility of a non-invasive method of detecting hypoxia, using F-FMISO-PET imaging in colorectal cancer patients.",2007-12,WITHDRAWN,INTERVENTIONAL,['NA'],,"determine volume of hypoxic tumor ROIs as a proportion of the entire tumor volume by this non-invasive imaging technique. ROIs are defined as those voxels, within the tumor volume defined on FDG PET/CT, for which the 18F-F-FMISO radioactivity concent"
10558,NCT04072224,Description of volume of in vivo ablation,2018-10-23,COMPLETED,OBSERVATIONAL,['NA'],,liver response
10559,NCT01161316,progression-free survival,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse events
10560,NCT04149613,microRNA expression Level,2018-05-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Dietary pattern
10561,NCT00885885,Objective response rate,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of molecular predictive markers for response.
10562,NCT03399110,DFS,2017-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,OS
10563,NCT02987699,Tumor response,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of of Patients developed Adverse Events
10564,NCT01106066,MTD/pathologic CR,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10565,NCT00712790,Tumour response rate (liver ± any site).,2008-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of downstaging to surgical resection or ablative therapy.
10566,NCT05028933,Adverse Event(AE),2021-09-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of circulating tumor cells (CTC) in peripheral blood
10567,NCT03172377,Cumulative incidence of persistent disease flares.,2017-05-03,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The decremental cost effectiveness ratio of this interval lengthening strategy
10568,NCT03700398,detect rate,2017-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10569,NCT03729687,Pathological complete response (pCR) rate and clinical complete response (cCR) rate,2016-07-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Long-term Adverse Events
10570,NCT01457976,"Survey respondents are presented with scenarios that seek to elicit views and attitudes on the concepts of personal responsibility, and the acceptability of financial incentives. The analysis will present these views and attitudes in aggregate form.",2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],,
10571,NCT05088733,Survival rate,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
10572,NCT00454116,Number of Patients With an Objective Disease Progression Event,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10573,NCT04845490,overall survival,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The positive rate of cancer cells of participants by exfoliative cytology examination
10574,NCT04123574,To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.,2019-10-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Genomic analysis before and after treatment.
10575,NCT00263055,Occurrence of dose-limiting toxicity,2004-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Long term toxicity
10576,NCT05847855,Sensitivity and specificity,2023-04-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity and specificity in distinguishing different AJCC stages
10577,NCT00591045,5 year overall survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
10578,NCT00854971,Determine response rate,2009-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Determine safety of combination,time to treatment failure, overall survival time"
10579,NCT03985891,ORR,2020-12-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
10580,NCT05517239,Progression free survival,2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
10581,NCT05643677,Progression-free survival (PFS),2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival（OS）
10582,NCT00530010,Patient Completion,2004-12,COMPLETED,OBSERVATIONAL,['NA'],,
10583,NCT05025371,Overall survival,2021-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
10584,NCT05589480,Recurrence-free survival,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
10585,NCT04979663,Safety: the incidence of adverse events and serious adverse events,2020-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
10586,NCT00582452,To assess levels of intention in prophylactic colectomy among individuals at increased familial risk of colorectal cancer and to identify distinctive decision types based on profiles of perceived pros and cons of prophylactic colectomy;,2004-11,COMPLETED,OBSERVATIONAL,['NA'],,
10587,NCT03731442,"1-, 2-, 3-year overall survival",2018-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Toxicities according to RTOG and CTCAE criteria, including hematological and non-hematological toxicities"
10588,NCT02264665,Number of Participants With Adverse Events Leading to Death - Based on Treatment Received At-least Once During the Study,2015-05-12,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants With Types of Main Lines of Treatment Received During the Follow-up - Based on Targeted Therapy Group and Other Treatments Group at Inclusion
10589,NCT05408182,Postoperative pain score,2022-06-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Readmission rate
10590,NCT04912258,liver relapse-free survival,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,response rate
10591,NCT05493332,Conversion therapy success rate,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcome（PRO）
10592,NCT00792350,"Efficacy: status of tumor, patients performance status",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Reports of adverse events
10593,NCT02124148,Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE1'],,"B2, E2, E3 Dose Expansion: Duration of Response"
10594,NCT04104633,Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV),2018-06-14,UNKNOWN,INTERVENTIONAL,['NA'],,Identification of patient's tumor genomic profile with blood sample
10595,NCT04712604,Acceptability of the intervention,2021-03-14,COMPLETED,INTERVENTIONAL,['NA'],,Change in quality of life
10596,NCT05093231,Objective Response Rate (ORR),2022-03-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,European Organisation for Research and Treatment of Cancer Pancreatic Cancer Quality of Life Questionnaire (EORTC PAN26)
10597,NCT01505166,Percent of Patients Who Survived After Treatment (Part 2),2012-03,TERMINATED,INTERVENTIONAL,['PHASE2'],Number of Alive Subjects (Part 1),
10598,NCT03387982,Difference in pain quality 4 weeks post-procedure for subjects receiving Balloon Cryotherapy or Radiofrequency Ablation via the Pain Quality Assessment Scale (PQAS),2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
10599,NCT05104268,Change in Patient-Reported Oral Mucositis Symptom (The Modified PROMS Questionnaire) Pain Score,2024-11-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,"Change of oral mucositis grade in the World Health Organization Grade,(WHO Mucositis Grade)"
10600,NCT01285557,Overall Survival (OS),2011-04-14,TERMINATED,INTERVENTIONAL,['PHASE3'],,Time to Tumor Response (TTR)
10601,NCT05318027,Number of triage visits,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life scores
10602,NCT05355168,Major pathological remission rate,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"1-, 2-, 3-year Disease-free survival rate (DFS)."
10603,NCT02383797,Number and severity of adverse events to vaccination,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
10604,NCT00807911,disease-free survival,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"overall survival, pattern of failure,safety, quality of life"
10605,NCT01324882,Intubation of Cecum,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
10606,NCT01825603,"Recommended dose of ADH-1, defined as the highest dose tested which results in dose-limiting toxicities in no more than 1 of 6 evaluable patients based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",2013-04-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
10607,NCT02671357,The incidence of severe complications,2016-03,COMPLETED,OBSERVATIONAL,['NA'],Delayed gastric emptying (DGE) rate,"Postoperative in-hospital, 30-day and 90-day mortality"
10608,NCT03058289,Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5),2017-02-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory: Overall Subject Outcome,"Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6."
10609,NCT02751736,Low Anterior Resection Syndrome score,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complication
10610,NCT04996914,1-year local control rate,2022-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life based on EORTC QLQ-HCC18
10611,NCT06278883,Uptake of genetic testing recommendations by the provider,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10612,NCT00462501,Complete Pathologic Response,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,
10613,NCT00117299,Response rate,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10614,NCT02844075,complete pathologic response rate,2017-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of adverse event based on CTCAE 4.0.
10615,NCT00479050,overall survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,tumor response
10616,NCT00054262,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10617,NCT01643824,local progression-free survival,2012-06-07,COMPLETED,INTERVENTIONAL,['NA'],,overall survival
10618,NCT05178628,The number of VTE events during the trial,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from baseline in QoL
10619,NCT06199895,Objective Response Rate,2023-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10620,NCT03292991,"Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.",2015-06-09,UNKNOWN,OBSERVATIONAL,['NA'],,Liver transplantation rate
10621,NCT05755607,Rate of long-term Survival,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
10622,NCT00849979,Validation of M. D. Anderson Symptom Inventory - Gastrointestinal (MDASI-GI) Questionnaire (Response),2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
10623,NCT03466593,PaO2,2017-12-18,COMPLETED,INTERVENTIONAL,['NA'],,Lenght of stay
10624,NCT00020761,To determine the antitumor activity of irinotecan and paclitaxel in patients with unresectable adenocarcinoma of the esophagus and gastric cardia.,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicities of irinotecan and paclitaxel in this patient population.
10625,NCT02006030,Determine time to tumor progression (TTP),2014-10-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor response rates
10626,NCT00677924,Number of Participants With Adverse Events (AEs),2008-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Best Overall Tumour Response (BOR)
10627,NCT05760430,Conversion rate,2022-12-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
10628,NCT01260194,Median Progression Free Survival (PFS),2011-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer
10629,NCT02418988,overall survival,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression-free survival
10630,NCT00130689,Overall Response Rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10631,NCT05561907,Time to initiation of solid oral intake without symptoms of GOO,2022-10-28,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapeutic regimen tolerance
10632,NCT00746317,Determine the safety and tolerability of escalating doses of GC33,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Perform a preliminary assessment of anti-tumor activity of GC33
10633,NCT04053985,PFS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,DCR
10634,NCT00019344,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10635,NCT04152356,Disease-free Survival,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall Survival
10636,NCT00072553,Response rate,2003-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
10637,NCT00076609,"Alphafetoprotein measurements every 3 weeks for first 3 courses, then every 6 weeks thereafter",2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival follow-up every 2 months
10638,NCT02910960,Total area of procured tissue between the two FNB needles,2016-12,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic adequacy between the two FNB needles
10639,NCT04603040,Objective response rate (ORR),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],JS001 anti-drug antibody assessment,OS rates at 9 months and 12 months
10640,NCT00420394,Feasibility of the study regimen.,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall and progression free survival following the study treatment plan
10641,NCT00080002,,2003-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10642,NCT05503381,disease-free survival rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
10643,NCT04673968,Body composition,2020-02-25,RECRUITING,INTERVENTIONAL,['NA'],,Mitochondria functionality
10644,NCT00437268,Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) or Who Died
10645,NCT04597294,Peritoneal recurrence rate,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment-related quality of life assessed by Quality of Life Questionnaire-Stomach (STO22)
10646,NCT01482442,Median overall survival time,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Health care costs
10647,NCT05722275,The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],Overall survival,The accuray of intelligent analysis system in predicting peritoneal metastasis
10648,NCT04395118,Hepatitis C Screening,2020-08-15,WITHDRAWN,INTERVENTIONAL,['NA'],,Cost Per HCV Diagnosis
10649,NCT02045368,Maximum Tolerated Dose (MTD),2014-01-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,Disease Response based on RECIST Criteria
10650,NCT02902484,Maximum Tolerated Dose (MTD),2017-09-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10651,NCT05625893,Incidence of adverse event assessed according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0),2022-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Local tumor progression rate
10652,NCT05545046,Visual Analogue Scale (VAS),2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
10653,NCT00056446,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Tolerability and safety profile
10654,NCT01440855,Reported uptake of behavioral actions recommended in Facing Forward,2005-02,COMPLETED,INTERVENTIONAL,['NA'],,Usability of Facing Forward
10655,NCT03693807,% frequency liver toxicity,2018-10-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,progression free survival
10656,NCT01348503,Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.,2011-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10657,NCT05505370,Intubation of terminal ileum and cecum,2022-04-21,COMPLETED,INTERVENTIONAL,['NA'],,User feedback for operating characteristics of the device
10658,NCT04763824,Percent change in evidence based cancer screening,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Participation rates in the Telementoring and Practice Facilitation Sessions,
10659,NCT01526200,new colorectal liver metastases detected at contrast-enhanced intraoperative ultrasonography,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,new colorectal liver metastases detected during 6-month postoperative follow-up
10660,NCT05291338,Interleukin 28 B (IL28B) rs12979860.,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10661,NCT02056548,Cumulative incidence rate of hepatitis B viral reactivation,2014-03,UNKNOWN,OBSERVATIONAL,['NA'],,Severity of reactivation of hepatitis B
10662,NCT05858736,Incidence of treatment emergent adverse events (TEAE),2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Overall survival (OS),"
10663,NCT02217891,qualitive data,2014-08,COMPLETED,OBSERVATIONAL,['NA'],,
10664,NCT01182272,Significant pathological changes,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerance of liver resection after sorafenib tosylate treatment
10665,NCT05965817,To assess the feasibility of simultaneous use of ICG and SGM-101 for intraoperative imaging of colorectal liver metastases.,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
10666,NCT04058600,Hospital Anxiety and Depression Scale (HAD),2018-04-11,COMPLETED,INTERVENTIONAL,['NA'],,
10667,NCT01472419,Overall Survival,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
10668,NCT03100409,Changes in food intake,2017-02-01,TERMINATED,INTERVENTIONAL,['NA'],,Change in quality of life for cervical cancer patients: (European Organization for Research and Treatment of Cancer Cervical cancer module- EORTC QLQ-CX 24)
10669,NCT05424692,The difference of 3-year disease-free survival rate of patients in both group,2021-09-01,RECRUITING,INTERVENTIONAL,['NA'],,The difference of OS of patients in both group
10670,NCT04703101,Complete clinical response rate,2021-02-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Prediction of complete clinical response rate status by radiomics
10671,NCT05362617,ORR（objective response rate）,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QoL（quality of life）
10672,NCT03806244,"Accuracy of Surgical stereotactic navigation defined as the distance, in millimetres, between the position of the surgical landmark and the position determined by the navigation system",2019-07-17,TERMINATED,INTERVENTIONAL,['NA'],,Number of intra and/or postoperative complication
10673,NCT05948449,Pathological complete response rate (pCR),2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability
10674,NCT03095209,Serum inflammation markers,2017-02-24,COMPLETED,OBSERVATIONAL,['NA'],,Quality of life and pain
10675,NCT05988645,Number of mural injuries.,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,Perception of difficulty.
10676,NCT02930278,3-year disease overall survival rate,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Visual Analog Score for pain
10677,NCT02010801,Complete treatment,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,adverse effect
10678,NCT00019019,,1994-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10679,NCT00660426,"To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.",2005-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,To perform correlative pharmacogenomic and pharmacokinetic tests for this novel regimen.
10680,NCT02017366,overall survival from day of surgery,2018-10,WITHDRAWN,INTERVENTIONAL,['NA'],,postoperative weight loss
10681,NCT01637350,,2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,
10682,NCT00952497,The primary objective is to assess progression free survival (PFS). PFS will be measured from the date of first study drug administration to the date of first scan that first documents disease progression.,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Other efficacy variables are overall survival, overall response rate, safety and tolerability. Exploratory analyses may be performed to investigate the correlation of biomarker status with treatment effect and response."
10683,NCT05225038,"Change in participants physical capacity, as represented by hand grip strength",2022-06-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Physical capacity as represented by 6-Minute Walk Test
10684,NCT03533920,Objective Response Rate by independent evaluator,2017-10-25,COMPLETED,INTERVENTIONAL,['NA'],,
10685,NCT03500068,Developing organoids from advanced pancreatic cancer patients that predict non response or response,2017-09-04,UNKNOWN,INTERVENTIONAL,['NA'],,Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients.
10686,NCT03520790,Overall survival,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival
10687,NCT01134276,Incidence of Infectious Complications After Biliary Drainage,2010-08,COMPLETED,INTERVENTIONAL,['NA'],,Total Hospital Cost During Admission After Biliary Drainage
10688,NCT03450447,The first day of food intake of enrolled patients,2018-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,The severity of stenosis
10689,NCT00334984,,2007-01,WITHDRAWN,INTERVENTIONAL,['NA'],,
10690,NCT02933307,Expectations & experiences of care givers,2015-04,COMPLETED,INTERVENTIONAL,['NA'],Performed surgical procedure,System usability Scale
10691,NCT04012021,Evaluate the correlation between the characteristics detected by the MRI equipment and the histological composition of ex-vivo specimens from hepatic and pancreatic tissues and lesions,2019-05-24,UNKNOWN,INTERVENTIONAL,['NA'],,
10692,NCT00333099,Frequency and grade of mucositis,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Cost
10693,NCT05628857,Objective Response Rate (ORR),2022-11-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Terminal elimination half life
10694,NCT00004910,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10695,NCT01437618,Progression-Free Survival,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,
10696,NCT02728596,Incidence of Febrile Neutropenia Among Intermediate Risk Participants,2016-10-07,COMPLETED,INTERVENTIONAL,['NA'],Differences Among Cohort Components and Intervention and Usual Care Components,Overall Survival (OS)
10697,NCT04361682,Predictive value of PIBs and drains amylase values for Pancreatic Fistula (PF),2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10698,NCT00070265,Rate of complete resection (R0 resection),2003-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Positron emission tomography response rate
10699,NCT00995202,Overall survival rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease-free survival rate
10700,NCT00448682,Number of Patients Achieving Clinical Response,2005-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Adverse Events
10701,NCT05148572,Metabolome profiling for recurrence prediction.,2021-11-10,RECRUITING,OBSERVATIONAL,['NA'],,
10702,NCT03291054,Overall Response Rate,2018-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10703,NCT00504153,Progression-free Survival Rate,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Plasma Vascular Endothelial Growth Factor (VEGF) Levels Over 15 Days
10704,NCT00881036,,2006-08,COMPLETED,OBSERVATIONAL,['NA'],,
10705,NCT05806931,Disease control rate (DCR):,2023-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of Response
10706,NCT04965454,Lack of Objective Response,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control
10707,NCT05977478,Correlating tissue biochemical composition with the Raman spectra and histopathologic results to differentiate between the gastric disease states based on distinct features in the biochemical composition of pre-cancerous / cancerous lesions.,2022-10-27,RECRUITING,INTERVENTIONAL,['NA'],,
10708,NCT02453464,Maximum Tolerated Dose (MTD),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
10709,NCT05396755,"occurrence of cholangiosepsis (defined by SEPSIS-3 criteria and diagnosis of acute cholangitis according to the Tokyo Guidelines), whatever occurs first.",2022-11-14,TERMINATED,INTERVENTIONAL,['NA'],occurrence of serious adverse events,Occurrence of unplanned hospital admissions (necessity and days free of hospital care within 6 months)
10710,NCT04223141,Mortality,2020-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Medical complications
10711,NCT03759548,Impact in Quality of Life during pharmacological treatments,2018-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,Pharmacological treatment-related adverse events
10712,NCT04162158,Overall survival,2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease control rate
10713,NCT03528876,Progression free survival,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Decline in quality of life
10714,NCT03277716,Overall survival (OS),2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Distant metastasis-free survival
10715,NCT00239200,"Primary Objective: To determine the response rate of metastatic or recurrent squamous cell carcinoma of the esophagus, when treated with lapatinib (GW572016)",2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Secondary Objective: To determine the toxicity of this regimen
10716,NCT04622423,Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS,2019-11-06,RECRUITING,OBSERVATIONAL,['NA'],,Biobanking of biospecimens collected from CRC and PDAC patients and from healthy donors
10717,NCT03374293,Local control,2017-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
10718,NCT05238558,Summary of Adverse Events,2022-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10719,NCT02198274,Anti-tumour response,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Mean residence time (MRT)
10720,NCT00019760,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10721,NCT05969171,PFS,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
10722,NCT01798251,Progression Free Survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],K-ras gene type,adverse events (AE)
10723,NCT02301286,5 year overall survival,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Time to Treatment Failure
10724,NCT04949282,Overall response rate (ORR),2021-05-10,RECRUITING,OBSERVATIONAL,['NA'],,Health-related Quality of Life (HRQoL)
10725,NCT00002984,Number of subjects experiencing adverse events,1997-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy of treatment
10726,NCT01659619,degree of food stasis,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10727,NCT05991102,Overall response rate (ORR),2023-12-15,RECRUITING,INTERVENTIONAL,['NA'],,Acute and late toxicity
10728,NCT03314532,disease-progression-free period,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,overall survival period
10729,NCT00939666,Local recurrence,2009-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of patients that chooses the minimal invasive strategies over standard surgery
10730,NCT02879227,Feasibility of treatment: Number of patients with completed treatment,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
10731,NCT06060899,Intraoperative blood loss,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Length of hospital stay
10732,NCT01269229,complete resection (R0) rate for rectal and liver lesions.,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile
10733,NCT03132740,Impact on complication of three dimensional visualization technique,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative results of paraffin wax and immunohistochemical index
10734,NCT01319890,Return to normal activity/work,2011-07,UNKNOWN,OBSERVATIONAL,['NA'],,Cancer free survival
10735,NCT02295930,10 months-progression free rate (10m-PFR),2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity rate
10736,NCT03469258,Effect of Pancreatic Enzyme Replacement Therapy on the Completion Rate of Adjuvant Chemotherapy and Radiation After Surgery for Early Stage Pancreatic Cancer,2018-04-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Measure Grip Strength Before and After Surgery and Adjuvant Treatment for Early-stage Pancreatic Cancer
10737,NCT00083226,Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST),2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
10738,NCT01710293,Median Time from Initial Follow-up Delay to Follow-up Action,2017-01-27,WITHDRAWN,INTERVENTIONAL,['NA'],,
10739,NCT04943679,Incidence of adverse events,2021-06-15,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
10740,NCT02541149,"serum Annexin A2 in patients with hepatocellular carcinoma, chronic liver disease and healthy subjects",2014-06,COMPLETED,OBSERVATIONAL,['NA'],,
10741,NCT00605722,Percentage of Participants With Progression-free Survival (PFS),2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
10742,NCT01671488,"To Evaluate the 6-month Clinical Complete Response Rate for Patients With Anal Cancer Treated With ADXS11-001 Mitomycin, 5-FU and IMRT.",2013-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To Evaluate Progression-free and Overall Survival for Patients With Anal Cancer Treated With ADXS11-001, Mitomycin, 5-FU and IMRT."
10743,NCT01400620,Proportion of WHO score 3-4 Oral Mucositis at a Cumulative Radiation Dosage of 50 Gy in the active and Placebo Groups,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of grade 2-3-4 Oral Mucositis as measured by the WHO scale at increasing increments of cumulative radiation exposure
10744,NCT02775461,Number of individuals with pancreatic diseases,2013-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
10745,NCT03654950,Patient reported experiences in themes,2018-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Patient reported experiences divided into themes
10746,NCT02441998,"ASGE PIVI Thresholds: >90% NPV in rectosigmoid, > 90% agreement in surveillance intervals",2013-10,COMPLETED,OBSERVATIONAL,['NA'],,"Ex vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value"
10747,NCT04882423,Hydroxylated PhlP profile with both cruciferous and apiaceous vegetables,2013-09-19,TERMINATED,INTERVENTIONAL,['NA'],,
10748,NCT00576563,"The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63",2007-03,COMPLETED,INTERVENTIONAL,['NA'],,"Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)"
10749,NCT04179084,Objective Response Rate (ORR),2019-08-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
10750,NCT02147301,Number of Patients Who Developed New Severe Adverse Events,2014-12-17,TERMINATED,INTERVENTIONAL,['NA'],,Median Area Under Curve (AUC)
10751,NCT05978349,Follow-up and record DFS of patients,2022-02-14,RECRUITING,INTERVENTIONAL,['NA'],,Follow-up and record OS of patients
10752,NCT01047475,The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response),2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10753,NCT05893056,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
10754,NCT00541112,Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI,2007-10-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,Predictive biomarkers of response to cetuximab
10755,NCT03172559,Difference between the two treatment arms in the proportion of participants that get to be transplanted (do not drop-out from the waiting list due to tumor progression).,2020-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Difference between the two arms in disease-free survival
10756,NCT06241352,Decrease rate of CA19-9,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate
10757,NCT00059930,"Correlate thymidylate synthase, dihydropyrimidine dehydrogenase, and ERCC-1 with survival and recurrence as measured by normal and tumor liver tissue",2003-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
10758,NCT04774952,Number of participants with dose limiting toxicities (DLTs),2021-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of Response (DOR)
10759,NCT04105062,Phase II only: Ability of LS301 to predict presence of positive margins,2021-12-31,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10760,NCT00123318,The percentage of major radiotherapy protocol violations,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Median survival and overall survival at 3 years
10761,NCT01625702,circulating tumor cells in blood,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,
10762,NCT01189903,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
10763,NCT03336216,Progression free survival (PFS) by Blinded Independent Central Review (BICR),2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of clinically significant changes in lab assessment: Urine
10764,NCT05976282,Acceptability of Participants Who Feel FIT is an Acceptable Method of Screening,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],,
10765,NCT04611165,Progression-free survival (PFS),2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10766,NCT00844688,RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity evaluation in accordance with CTCAE v3.0
10767,NCT01727921,Diagnostic accuracy,2013-01,COMPLETED,INTERVENTIONAL,['NA'],Complications,Technical success
10768,NCT05257057,Lynch Syndrome Screen Positive Rate,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
10769,NCT06314971,Recurrence-free Survival,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,
10770,NCT01160367,family decision-making self-efficacy,2010-08-26,COMPLETED,INTERVENTIONAL,['NA'],,"family psychological outcomes (depression, caregiver burden, decision making distress)"
10771,NCT05828381,The pathological complete response rate,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The disease free survival rate
10772,NCT00041340,Response rate,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10773,NCT05983315,Correlation between endoscopic CONECCT's classification,2021-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
10774,NCT04142203,Analgesic consumption postoperatively,2017-05-16,COMPLETED,OBSERVATIONAL,['NA'],Adverse events after 23 h surgery,Analgesic use after 23 h surgery
10775,NCT03792347,Safety (Number of Participants With Grade 3 and Higher-grade Treatment-related Adverse Events),2019-01-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiographic Response
10776,NCT04231552,Pathological complete response,2019-11-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,3-year overall survival rate
10777,NCT05034627,Incidence of dose-limiting toxicities (DLTs),2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],Therapy induced changes in the tumor and tumor ecosystem,Mean plasma asparaginase activity
10778,NCT00573911,The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
10779,NCT00711672,"Correlation of degree of ""narrative agreement"" with validated quality of life measures",2008-07,COMPLETED,OBSERVATIONAL,['NA'],,
10780,NCT02919553,Rate of core tissue acquisition adequate for histologic analysis.,2018-01,WITHDRAWN,INTERVENTIONAL,['NA'],,"Cell block will be assessed of presence of any core tissue with intact architecture with this scale: graded 0 = none, 1 = present but marginal adequacy, 2 = present and adequate. Dimensions of the largest core will be noted if possible."
10781,NCT00414492,,2006-12,COMPLETED,OBSERVATIONAL,['NA'],,
10782,NCT04237740,3 years recurrence-free survival rate,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5 years overall survival rate
10783,NCT02185443,Local Progression Free Survival,2014-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
10784,NCT00902759,FACIT (Facit Fatigue Scale) and Medical Outcomes Study Short Form-36 (MOS-SF-36) questionnaires,2009-01-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
10785,NCT01991873,Progression-free survival,2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Health and skin related Quality of life
10786,NCT05714553,Number of patients achieving a reduction in tumour volume (Objective response rate; ORR),2023-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10787,NCT00428597,Progression Free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 - Pain Subscale
10788,NCT05174156,Objective Response Rate (ORR),2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
10789,NCT02261714,Patients' Immune Response,2012-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Relationship Between (KRAS) Status and Clinical Efficacy,Clinical Efficacy
10790,NCT04460352,Eating restrictions,2020-11-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Gender stratified analyses of all endpoints
10791,NCT01293942,conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer,2011-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A"
10792,NCT04374175,Serum adiponectin concentration,2020-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Serum adiponectin concentration
10793,NCT02320123,Intent to Discuss Hospice Care (Based on the Transtheoretical Stages of Change Model),2016-05-23,COMPLETED,INTERVENTIONAL,['NA'],,Health Care Utilization: Mean Number of Hospitalizations in Six Months by Group
10794,NCT02148731,Occurrence of Adverse Events,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Performance of the brief screening tool
10795,NCT05261113,Outcome relevance of CE-IOUS,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Sensitivity and Specificity of CE-IOUS compared to other imaging methods
10796,NCT00905047,patients preference after randomization and cross-over,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,safety of each treatment
10797,NCT02371304,Recurrence free at 3 year follow-up,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Treatment related morbidity
10798,NCT05263336,Anastomotic leak,2021-01-03,RECRUITING,INTERVENTIONAL,['NA'],,Postsurgical Ileus
10799,NCT05641129,Primary outcome,2023-01-16,COMPLETED,OBSERVATIONAL,['NA'],,Secondary outcome 9
10800,NCT04389632,Number of participants with dose-limiting toxicities (DLTs),2020-06-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with antidrug antibodies (ADAs)
10801,NCT03297255,Time of Death,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Time of metastasis
10802,NCT04618692,Biliary complications after living donor liver transplantation,2020-12-02,COMPLETED,INTERVENTIONAL,['NA'],,Time to biliary complications
10803,NCT00083616,Duration of Response,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
10804,NCT04097795,Costs,2019-07-01,TERMINATED,OBSERVATIONAL,['NA'],,Care-related burden among informal caregivers
10805,NCT04813861,Lesion Response,2010-01-04,COMPLETED,OBSERVATIONAL,['NA'],,Delayed Lesion Response
10806,NCT03998202,Number of Chemotherapy Toxicities (Grade 3 - 5),2019-09-23,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
10807,NCT02340975,Progression Free Survival at 6 (PFS-6) Month in Phase 2,2015-03-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Objective Response in Phase 2 by Programmed Death-ligand (PD-L1) Status
10808,NCT00959738,Severe stoma specific morbidity rate,2008-08,TERMINATED,INTERVENTIONAL,['NA'],Number of stoma bags and self-adhesive plates needed in the first month after the operation,Predictive factors for stomal complications
10809,NCT04823715,Disease-free survival of the patient after start of treatment,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],,
10810,NCT05810714,Number of Participants to Return Fecal Immunochemical Test (FIT),2021-11-20,COMPLETED,INTERVENTIONAL,['NA'],,
10811,NCT03801083,Objective Response Rate (ORR),2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,EuroQol 5 dimensions 5 levels (EQ-5D-5L)
10812,NCT01188980,determine if early increase blood supply (EIBS)can predict presence of Dysplasia,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,determine if EIBS can predict presence of BE in patients undergoing upper endoscopy
10813,NCT02430662,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
10814,NCT05616494,Overall response rate (ORR) by Independent Review Committee (IRC),2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],Plasma concentration of docetaxel (free and total),Disease control rate (DCR) by IRC and investigator
10815,NCT05938504,Skeletal Muscle Index (SMI) change rate,2023-03-14,RECRUITING,INTERVENTIONAL,['NA'],,Oral nutritional supplement (ONS) sensory evaluation
10816,NCT01540344,Progression-free survival (PFS),2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pathohistological regression
10817,NCT04242342,local control at 2 years,2020-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
10818,NCT03791073,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,2018-01-01,RECRUITING,OBSERVATIONAL,['NA'],,"Biomarkers that are prognostically significant on disease free or overall survival in patients with pancreatic cancer, identified using the survival analysis"
10819,NCT03650348,Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab,2018-08-21,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])
10820,NCT01862562,Early complication rate,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Health-related QOL score
10821,NCT05485909,Objective response rate (ORR),2022-07-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time to disease progression (TTP)
10822,NCT04002479,Safety - Adverse events,2020-10-20,RECRUITING,INTERVENTIONAL,['NA'],,Change in quality of life: QLQ-PAN26
10823,NCT05975463,Objective response rate (ORR),2023-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
10824,NCT01924741,Morbidity and mortality (peripoerative),2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Inclusion criteria by registry participants,Liver Growth as assessed by imaging-based volumetry
10825,NCT00516230,,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10826,NCT04583488,Maximum Tolerated Dose (MTD),2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival
10827,NCT06184555,postoperative complication,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10828,NCT00513266,Pathological complete response rate of lesions of less than or equal to 30 mm in size assessed by pathologic examination in resected specimens,2007-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity as assessed by NCIC criteria
10829,NCT05545436,"Pathological complete response rate (pCR, Becker criteria, TRG 1A)",2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,"R0 resection rate and objective response rate (ORR, RECIST 1.1)"
10830,NCT02721563,Objective response rate,2016-02-25,COMPLETED,INTERVENTIONAL,['PHASE4'],,Progression free survival
10831,NCT00338988,Number of Participants With Objective Response,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10832,NCT03334591,progress free survival(PFS),2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
10833,NCT00268840,Overall response rate,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the frequency and severity of the adverse events related to the combination of gemcitabine and docetaxel
10834,NCT02942706,Progression Free Survival 1 (PFS1),2021-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life (QoL)
10835,NCT02824185,Specificity of FCH-PET/MRI for the detection of preoperative lesions,2017-06-14,COMPLETED,INTERVENTIONAL,['NA'],,Costs avoided and induced by performing FCH-PET/MRI
10836,NCT05402124,Measurement of Adverse Events,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Factors related to uptake, in-study adherence and post-study maintenance using measurement of chemoprevention knowledge"
10837,NCT04402424,Colorectal Cancer,2019-07-16,COMPLETED,OBSERVATIONAL,['NA'],,Other Significant Colorectal Disease
10838,NCT06202001,Objective Response Rate (ORR),2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and tolerability by incidence, severity and outcome of adverse events"
10839,NCT01946061,3-year disease-free survival,2015-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10840,NCT01733147,Change in Esophageal Tissue PGE2 Levels,2012-11,COMPLETED,INTERVENTIONAL,['PHASE4'],,Change in Esophageal Macrophage Markers
10841,NCT03572101,Quality of life (EQ-5D-5L scores),2018-01-11,COMPLETED,OBSERVATIONAL,['NA'],"Overall level of support received by patients/caregivers from homecare, cancer centre, long term care, hospital and hospice services at end of life","Patient-reported concerns (emotional, social/family/spiritual, practical, physical, mobility, nutrition, informational, other)"
10842,NCT02897375,Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin,2016-10-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)
10843,NCT00503932,Maximum Tolerated Dose (MTD),2007-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10844,NCT03548844,DFS,2018-05-24,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
10845,NCT00190385,Incidence of small hepatocellular carcinoma (HCC),2000-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Clinical value of serum alfa-fetoprotein assay
10846,NCT00003344,,1998-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10847,NCT01924533,Overall Survival,2013-09-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of Response
10848,NCT01668849,Pain caused by oral mucositis,2012-08-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Level of immune biomarkers in mucosal tissue
10849,NCT04258956,"Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria",2019-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10850,NCT02552017,Adenoma detection rate,2014-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adenoma detection rate of individual endoscopist before and after trial commencement
10851,NCT05795595,Phase 2 (Cohort Expansion): Objective response rate (ORR),2023-03-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10852,NCT05430841,Diagnostic accuracy,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of lesions
10853,NCT01148056,Bowel Quality of Life,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Accuracy
10854,NCT06193733,Disease-free survival,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
10855,NCT04874519,Build a Fibrolamellar Cancer/FLC registry,2021-11-24,RECRUITING,OBSERVATIONAL,['NA'],,
10856,NCT02503696,Sensitivity and Specificity of the Exact CRC diagnostic screening test.,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
10857,NCT06200259,"Test the hypothesis that ""Spot Delete"" technique in proton therapy reduces late toxicity in low- and intermediate-risk prostate cancer patients",2024-01-08,RECRUITING,INTERVENTIONAL,['NA'],,
10858,NCT04210115,Overall Survival (OS),2020-02-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants discontinuing study treatment due to an adverse event (AE)
10859,NCT00963352,3-year disease free survival (DFS),2007-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival (OS)
10860,NCT06006650,Pathologic complete response rate (pCR),2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
10861,NCT04120701,3-year Disease-Free Survival in ctDNA positive patients,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10862,NCT04152018,Duration of Response (DR) for Dose Expansion,2019-11-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
10863,NCT00349336,Weekly Steady-state Exposure of Bevacizumab,2006-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Terminal Half-life of Bevacizumab
10864,NCT03627390,Sum CTC score,2014-12-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of registered adverse events
10865,NCT03478449,Migration of pN stage in gastric cancer patients,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
10866,NCT00256321,Determine time to progression,2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate the expression of the Cox-2 on paraffin-embedded tumor sections from patients enrolled on the study and correlate expression with clinical response
10867,NCT03779035,Disease free survival (DFS) rate,2018-12-15,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of patients with hepatic or locoregional recurrence
10868,NCT00531297,Recurrence rate,2005-12-01,TERMINATED,INTERVENTIONAL,['NA'],,Perioperative mortality
10869,NCT00573131,Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10870,NCT02424838,Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.,2014-07-28,COMPLETED,INTERVENTIONAL,['NA'],,Rate of complications
10871,NCT03173729,Sensitivity and specificity of a point of care device to diagnose colorectal cancer and polyps,2017-02-11,RECRUITING,OBSERVATIONAL,['NA'],,Cost per patient of point of care urine test for diagnosing patients with colorectal cancer and polyps.
10872,NCT01665274,3-year DFS,2013-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
10873,NCT05572684,Define a recommended Phase 2 dose (RP2D) of NC410 when combined with standard dose Pembrolizumab,2022-10-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival (PFS) per RECIST
10874,NCT02414009,Progression-free survival of FOLFIRI versus CAPTEM,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life measured by EORTC FACT-C
10875,NCT02849717,The primary outcome measure for this study is fatigue assessed by the FACIT-F fatigue subscale..,2016-03,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life (QOL) on self reported psychological distress questionnaires: Spielberg State/Trait Anxiety Inventory (STAI Form Y-1).
10876,NCT00531115,Confirmed objective response rate,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Treatment safety
10877,NCT00587067,Number of Patients With Treatment Related Toxicity,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Survival
10878,NCT03646110,Overall survival rate,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative pulmonary complication
10879,NCT05340231,PFS,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Pathological response rate (PCR+MPR)
10880,NCT00049322,Neovessel Formation as Measured by Angiogram at 14 Weeks,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab
10881,NCT05916040,Response to therapy,2023-10-03,RECRUITING,OBSERVATIONAL,['NA'],,Anxiety and depression state via HADS
10882,NCT02847429,Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival (OS) will be measured from the date of randomization to the date of death from any cause. OS will be estimated using the Kaplan-Meier method.
10883,NCT06328361,Disease-free survival,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complication rates
10884,NCT05794841,Diagnostic performance of positive predictive value (PPV) and negative predictive value (NPV).,2023-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
10885,NCT06235164,pathological complete response,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,major pathological response
10886,NCT04683731,"Decision Quality assessed using the multi-dimensional measure of informed consent (MMIC) which incorporates knowledge, intent, and behavior.",2021-01-19,COMPLETED,INTERVENTIONAL,['NA'],,Number of providers who open their provider notification
10887,NCT05563922,Organ preservation rate at 3 years,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,5-year overall survival（OS） rates
10888,NCT04891016,pathological complete response rate,2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,disease-free survival
10889,NCT02185937,imatinib area under the curve,2014-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,number of adverse events
10890,NCT05359861,"Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)",2022-04-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Serum concentrations of atezolizumab
10891,NCT03612674,Adenoma Detection Rate (ADR),2018-04-04,UNKNOWN,INTERVENTIONAL,['NA'],,Colonoscopists' ADR in the previous year
10892,NCT03009227,Overall survival,2017-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life in patients after D2 and D3 lymph node dissection using questionnaire
10893,NCT05585814,Tumor regression grade (TRG),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life score (QoL score)
10894,NCT03404921,The procedure time,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,The rate of injury to the muscular layer
10895,NCT06248879,Body Mass Index,2024-02-28,WITHDRAWN,INTERVENTIONAL,['NA'],,Feeding amount
10896,NCT03209076,Urinary dysfunction,2018-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Costs
10897,NCT05200611,The efficacy of fecal immunochemical test to detect advanced adenoma,2022-01-04,UNKNOWN,OBSERVATIONAL,['NA'],,The efficacy of fecal immunochemical test to detect colorectal neoplasms
10898,NCT04783844,Accuracy,2019-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,
10899,NCT01674907,Clinical/demographic patient characteristics at baseline,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,Relationship between termination of Avastin treatment and time point of progression
10900,NCT03191604,Altered chosen treatment modality due to NBI,2017-11-01,COMPLETED,OBSERVATIONAL,['NA'],,Differences in pathology identification between subgroups
10901,NCT04447092,Objective Response Rate,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Immune-related response
10902,NCT05877599,Adverse events and serious adverse events,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE1'],,"Preliminary anti-tumor activity of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors"
10903,NCT06210360,2-year Overall Survival Rate,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
10904,NCT00033748,Recurrence free survival,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
10905,NCT06293014,Time to treatment failure (TTF),2024-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30)
10906,NCT02647177,Detection of early progression to Tumor,2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
10907,NCT03494543,technical success,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,concordance of histology pre- and post endoscopi papillectomy
10908,NCT03263663,Progression-free-survival,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
10909,NCT02138422,Response Rate,2014-07-31,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10910,NCT00834028,tumor progression,2007-02,COMPLETED,OBSERVATIONAL,['NA'],,
10911,NCT00827554,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival (PFS)
10912,NCT01251666,Ratio of sensitivities (RSN) for detection of advanced neoplasias,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Positivity rate
10913,NCT03649035,Number of participants with feasible EUS-guided Cryothermal Ablation,2018-07-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
10914,NCT06071507,Clinical Success,2023-11-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Overall Survival,Nutritional status
10915,NCT03577808,Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.,2018-08-17,UNKNOWN,OBSERVATIONAL,['NA'],,Response of the rectal cancer patients to neoadjuvant chemoradiation.
10916,NCT03206866,serum regucalcin in HCC patients,2016-12-30,UNKNOWN,OBSERVATIONAL,['NA'],,
10917,NCT06187597,Progression-free survival,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Correlation between serum cytokines and overall survival and immune-related adverse events,Treatment-related adverse events
10918,NCT02790333,Pancreatic fibrosis accessed by histopathology and pancreatic stellate cell,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,Readmission rate
10919,NCT01101906,Time to progression (TTP),2011-01-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events"
10920,NCT04985071,Pancreatic fistula,2021-08-18,RECRUITING,OBSERVATIONAL,['NA'],,Bleeding complication
10921,NCT02112162,Radiosensitivity index,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
10922,NCT04466189,Establish a cohort of Pancreatic cancer patients treadted with proton beam therapy.,2018-09-21,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
10923,NCT00005910,,2000-06,COMPLETED,INTERVENTIONAL,['NA'],,
10924,NCT04969029,3-year relapse-free survival,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10925,NCT00469963,Tumor response,2003-12,TERMINATED,INTERVENTIONAL,['NA'],,Survival
10926,NCT03689231,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?,2018-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?
10927,NCT00008060,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
10928,NCT03674801,"Percentage of different managements according to the described method : The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon (Gastrointest. Endosc. 58, S3-43 (2003)",2019-02-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"""SF36"" questionnaire"
10929,NCT05010226,To evaluate clinical benefit response (CBR),2021-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Impact on Quality of Life and Cost,
10930,NCT00790569,CO-confirmed 7-day Abstinence,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,Change in Cigarettes Per Day
10931,NCT00544362,Tolerance to neoadjuvant therapy,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mortality
10932,NCT00457691,Progression-free Survival (PFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)
10933,NCT04518800,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,2020-08-18,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of patients receiving antibiotics during the entire chemotherapy period.
10934,NCT03458949,variation of the rate of participation in colorectal cancer screening,2018-06-18,UNKNOWN,INTERVENTIONAL,['NA'],,
10935,NCT00006468,,2000-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
10936,NCT03474341,Histopathologic response,2018-04-09,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival.
10937,NCT02476045,Efficacy,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
10938,NCT05016869,progression-free survival (PFS),2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events (AEs)
10939,NCT02581059,Subject Fatigue Assessment,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluate Overall Survival (OS)
10940,NCT02071043,The primary study end point was the response rate of preoperative XELOX followed by surgery in gastric cancer patients with PAN involvement,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade 3 or 4 Adverse Events as a Measure of Safety
10941,NCT05363007,12W-PFS,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
10942,NCT02899325,Sensitivity of 18F-FDGal in the diagnosis of HCC on per-patient basis,2019-10,WITHDRAWN,OBSERVATIONAL,['NA'],,Specificity of 18F-FDGal in the diagnosis of HCC
10943,NCT01321957,progression free survival rate,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life evaluated by questionnaire
10944,NCT00873756,Incidence and nature of dose-limiting toxicities,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of anti-dulanermin antibodies
10945,NCT03127007,Rate of complete pathological response,2017-04-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
10946,NCT06258824,Diagnostic Value as measured by Area under the Curve (AUC) for candidate miRNAs,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
10947,NCT01335958,Nature of dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.0,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Volume of distribution
10948,NCT00460603,Percentage of Participants With Objective Response: Phase 2,2006-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2
10949,NCT01762813,Cancer-specific survival,2013-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Recurrence-free survival
10950,NCT02853500,Capillary permeability (Ktrans) calculated by software that analyzes enhancement on post-contrast MRI.,2016-07,RECRUITING,INTERVENTIONAL,['NA'],,Time To Tumor Progression
10951,NCT00555620,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),2008-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS)
10952,NCT04716010,Percentage of Red Meat Containing Products,2021-10-18,COMPLETED,INTERVENTIONAL,['NA'],Ease of Store Use,Intention to Reduce
10953,NCT05245474,pCR rate,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life score
10954,NCT01831531,3-yr local control rate,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
10955,NCT01462513,Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival time in a subgroup of MUC1 positive cancers
10956,NCT05442749,Efficacy of niraparib in patients with HR-deficient pancreatic cancer,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE2'],PD biomarkers of response and resistance to niraparib,Safety and tolerability of niraparib in pancreatic cancer patients
10957,NCT03469557,Host immunogenicity: BGB-A317 anti-drug antibody (ADA),2017-07-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10958,NCT06026800,Number of Participants with Adverse Events (AEs) [safety and tolerability],2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
10959,NCT00516945,incidence of chemotherapy interruptions,2004-09,COMPLETED,INTERVENTIONAL,['NA'],,chemotherapy dose intensity reduction due to hepatitis B reactivation
10960,NCT00003487,"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable",1996-05-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,
10961,NCT02870582,Overall Survival (OS),2016-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety variables will be summarized using descriptive statistics based on adverse events collection
10962,NCT05494320,neurotoxicity,2021-08-15,RECRUITING,OBSERVATIONAL,['NA'],,
10963,NCT02296203,percentage of patients achieving a decrease equal or more than 30% in the sum of the longest diameters of target lesions,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
10964,NCT04506840,Strength,2020-01-21,RECRUITING,INTERVENTIONAL,['NA'],,Depression and anxiety
10965,NCT03355612,Disease Free Survival(DFS),2017-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events
10966,NCT04736472,Penetrance: proportion of pharmacogenetic tests ordered by providers,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Grade 3 or higher toxicity
10967,NCT00483834,Objective Response Rate,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
10968,NCT00444782,Response rate (Partial and Complete Response) according to modified RECIST.,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immune Response
10969,NCT01775514,"Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region",2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants Categorized by Tumor Localization
10970,NCT03899636,Overall Survival,2021-02-23,RECRUITING,INTERVENTIONAL,['PHASE3'],,
10971,NCT05450484,2) Incidence of (severe) adverse events (SAE/AEs) related to administration of durvalumab-680LT assessed by CTCAE,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,
10972,NCT05544812,AE,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,OS
10973,NCT02173756,change in pain of mucositis before and after meal,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Evaluation of the local tolerance and other topical treatment taken throughout the mucositis
10974,NCT04225364,Pathologic complete remission (PCR),2020-01-17,COMPLETED,INTERVENTIONAL,['PHASE2'],perioperative adverse events,Overall survival (OS)
10975,NCT02861300,PHASE 2: Number of patients with response to treatment,2016-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,PHASE 1: proportion of patient who respond to treatment
10976,NCT04835402,Serious adverse reaction (SAR) rate according to CTCAE v5,2021-05-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Adverse event rate (CTCAEv5, all grades)"
10977,NCT05497739,The incidence of peritoneal metastasis,2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,The safety
10978,NCT01806649,disease control rate,2013-07-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,overall survival
10979,NCT00272051,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment : Q2W ; response rate using RECIST criteria : Q8W,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety : Q2W ; Nerve conduction studies : Baseline + cycle 12 ; Progression Free Survival : Q8W ; Survival
10980,NCT05782608,Assessment of Pain,2023-04-01,COMPLETED,INTERVENTIONAL,['NA'],,
10981,NCT06060106,Recurrence free survival (RFS),2011-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Post-operative hospitalization days
10982,NCT03958032,Postoperative complications,2016-12-03,COMPLETED,OBSERVATIONAL,['NA'],,Major complication
10983,NCT02767557,Overall survival at 6 months,2017-01-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0).
10984,NCT01488045,Patient Satisfaction Scores (Absolute Value),2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Physician Perceptions (Absolute Value)
10985,NCT02497157,Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1),2015-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Deepness of response (DoR),Incidence of adverse events
10986,NCT00171977,To evaluate the relapse-free survival (RFS) in patients receiving postoperative adjuvant therapy,2004-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety
10987,NCT00135005,To determine the MTD which will be the Phase II dose of AMN107 when given in combination with Imatinib. The MTD is defined to be the highest dose of AMN107 in combination with Imatinib given for at least 21 days in the first treatment cycle,2005-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,patients showing progression of disease on Imatinib. The patient will be followed-up for at least 4 cycles (28 days for one cycle)
10988,NCT05862181,Overall Survival (OS),2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Duration of Response (DoR)
10989,NCT00937456,To decrease postoperative major 30-days morbidity from 45% in the open arm to 25% in the laparoscopically-assisted arm.,2009-10-07,COMPLETED,INTERVENTIONAL,['NA'],,economical interest of the surgical technique apprehended through a hospital point of view
10990,NCT06178809,The advance time of ctDNA dynamic detection compared with AFP+ imaging in monitoring of primary hepatocellular carcinoma recurrence or progression,2023-12-25,RECRUITING,OBSERVATIONAL,['NA'],,
10991,NCT02460432,Cumulative stent patency during 6months after stent placement,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
10992,NCT05785325,Objective Response Rate,2023-08-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overal survival
10993,NCT01442506,diagnostic yield of targeted biopsies with high definition endoscopy using i scan virtual chromoendoscopy and acetic acid guided biopsies,2009-04,UNKNOWN,OBSERVATIONAL,['NA'],,
10994,NCT04609592,Measure Complication free Surgery,2021-03-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
10995,NCT01896986,Immunogenicity to HPV Vaccine Gardasil,2012-03,TERMINATED,OBSERVATIONAL,['NA'],,
10996,NCT03840239,Rate of clinical complete response,2018-12-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year overall survival
10997,NCT04181931,"Progression-free survival, PFS",2019-12-16,RECRUITING,INTERVENTIONAL,['NA'],,"Overall survival, OS"
10998,NCT05414448,ADR,2023-03-07,RECRUITING,INTERVENTIONAL,['NA'],,False positive rate
10999,NCT04616183,Best overall response (complete response [CR] + partial response [PR]),2020-12-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events
11000,NCT00410462,"Six-month progression-free survival, in terms of complete response, partial response, or no change",2006-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11001,NCT03880877,Progression-free survival,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of treatment
11002,NCT00670553,Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD),2008-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profile of oral LBH589 when given in combination with standard Radiotherapy
11003,NCT04364373,5-year overall survival,2020-03-31,RECRUITING,INTERVENTIONAL,['NA'],,Late postoperative complications rate
11004,NCT01874665,Clinical Benefit Rate (CBR) in Cohort A,2013-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib"
11005,NCT02238769,SUVratio of FECH PET,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],Data analysis,Patients' lifespan
11006,NCT04768686,Overall response rate in subjects treated with FLX475 in combination with pembrolizumab,2021-05-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11007,NCT01663272,Maximum Tolerated Dose,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Median Progression-free Survival (PFS)
11008,NCT01049880,"Blood cell counts (neutropenia, thrombocytopenia) and serum chemistries (liver function tests, creatinine)",2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival
11009,NCT03781960,Objective Response Rate,2019-07-31,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11010,NCT00352755,Safety and Tolerability of the Planned Treatment Regimen as Measured by Number of Participants With Grade 3 or Higher Adverse Events,2006-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11011,NCT01334112,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety
11012,NCT05870969,Early diagnosis rate of HCC patients,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],The compliance rate of each risk group defined at the initial risk stratification,The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis
11013,NCT05366881,Detection of cancer,2022-05-03,RECRUITING,OBSERVATIONAL,['NA'],,Clinical outcomes
11014,NCT01292356,Main criteria is the variation of skin pro-inflammatory cytokines in pre and post-therapeutic punch skin biopsies,2010-12-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11015,NCT03373188,Evaluate treatment effects of the study drugs on tumor cluster of differentiation 8+ (CD8+) T cell infiltration between the treatment groups.,2017-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events scale version 4.0
11016,NCT03320317,Length of stay,2018-03-30,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Complication rate
11017,NCT02800005,postoperative complications,2015-07,UNKNOWN,INTERVENTIONAL,['NA'],,Change of the postoperative AFA
11018,NCT00438256,Number of Participants With Grade 3 or Greater Toxicity in Phase II,2007-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment Related Serious Adverse Events
11019,NCT05111860,Peri-operative complications,2022-11-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11020,NCT00692770,Recurrence Free Survival (RFS) by Independent Assessment,2008-08-15,COMPLETED,INTERVENTIONAL,['PHASE3'],The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET,Overall Survival (OS)
11021,NCT02360605,Repeat Screening,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,
11022,NCT04066894,Sacral Nerve Stimulation (SNS) Success,2019-04-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 29
11023,NCT06173375,Proportion of Follow-up colonoscopy after abnormal stool blood test result,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of colorectal cancer cases detected
11024,NCT02868632,Overall Survival,2016-08-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Immune-related Response Criteria (irRC)
11025,NCT03708705,relapse rate of tumor,2018-11-20,UNKNOWN,OBSERVATIONAL,['NA'],,
11026,NCT00565370,Progression-free Survival,2007-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity Profile (According to National Cancer Institute Common Terminology Criteria for Adverse Event Version 3.0)
11027,NCT00025129,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11028,NCT02181556,Rate of Patients Alive and Progression-free 6 Months After Inclusion.,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival
11029,NCT02425657,MCSAT (Mayo Clinical Skills Assessment Tool),2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],,Endoscopy training computer generated data - Total score
11030,NCT04890171,3-year disease-free survival in the ITT population,2021-06-11,RECRUITING,INTERVENTIONAL,['NA'],,Cost-effectiveness measured with Incremental cost effective ratio (ICER)
11031,NCT04219332,Total Number of Retrieved Lymph Nodes,2019-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,3-year overall survival rate
11032,NCT04086888,OS (overall survival),2016-12-12,UNKNOWN,OBSERVATIONAL,['NA'],,progression-free survival (PFS)
11033,NCT03253822,CRC screening participation,2017-08-15,COMPLETED,INTERVENTIONAL,['NA'],,Ethnicity
11034,NCT00680420,Gene expression profile is 95% accurate in diagnosis of malignancy,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11035,NCT00091286,Number of patients with an immune response to the peptides,2003-03-24,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Immunogenicity of the peptide mixture measured in the peripheral blood
11036,NCT05559151,mortality rate,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
11037,NCT00698451,The Primary Efficacy End Point is the Number of Patients With an Objective Response.,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Secondary Efficacy Endpoints is Duration of Objective Response.
11038,NCT01520324,Intraepithelial Neoplasia (IN) Detection Rate (False Negative Findings),2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Bowel Cleansing Quality Evaluated by Boston Bowel Preparation Scale After Intake of Bowel Cleansing Formulation and of a Total Dose of 200 mg of Methylene Blue MMX Tablets Administered During and at the End of the Intake of the Bowel Cleansing Formulation
11039,NCT02526953,3-year disease-free survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Quality of life according to European organization for research and treatment of cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 (v.3) scale,Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria
11040,NCT02828865,Tumor response,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Assess for presence of adverse events
11041,NCT00309517,Overall survival,1997-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,
11042,NCT01536054,"Safety of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine in combination with varying dose levels and schedules of sirolimus, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",2012-08-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to disease progression
11043,NCT00188292,,2002-08,COMPLETED,OBSERVATIONAL,['NA'],,
11044,NCT00893295,Intervention impact on colorectal cancer (CRC) screening utilization over the 6-month observation period,2008-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Intervention impact on population health-management representations related to CRC screening, as assessed by perceived salience and coherence and self-efficacy-related CRC screening measured with 6 to 10 Likert-type items on both the baseline and end ..."
11045,NCT02980146,"The phenotype of TIL will be precised by immunohistochemisry and flow cytometry using various combinations of monoclonal antibodies to identify different subset of TIL and their frequency, especially those expressing NKG2A or NKG2C chain.",2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11046,NCT03260842,Pancreas Cancer,2017-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
11047,NCT01270360,"To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers",2010-09,COMPLETED,OBSERVATIONAL,['NA'],,To create biological collections for screening purposes (asymptomatic subjects)
11048,NCT04497038,Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D),2021-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic (PK) profile: Elimination clearance (L/hr)
11049,NCT04062058,PCR rate,2019-11-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
11050,NCT00207298,Change in management based on PET procedure,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,Safety of 18F-FDG
11051,NCT04183088,Randomized cohorts: Progression-free survival (PFS) (co-primary),2020-12-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Randomized cohort: progression-free survival (PFS)
11052,NCT04008407,Rate of surgical referral,2017-08-14,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma recurrence rate
11053,NCT02174575,Postoperative acute kidney injury,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Urine albumin concentration
11054,NCT02544737,"The proportion of patients with response (CR, PR, SD and PD based on RECIST version 1.0) assessed at 5-6 weeks after the initiation of treatment.",2015-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"The proportion of patients alive (overall survival rate) from the date of enrollment until date of death from any cause, assessed up to 2 years from the opening of the study."
11055,NCT05648318,Bowel preparation,2022-01-08,COMPLETED,INTERVENTIONAL,['NA'],,withdrawal time
11056,NCT05216237,Objective Response Rate (ORR),2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11057,NCT02243735,Normalization of Hb-level.,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Difference in Morbidity score
11058,NCT01453894,Completion of a Fecal Occult Blood Test (FOBT),2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
11059,NCT06302400,"The incidence of adverse and serious adverse events in patients receiving individualized treatment with 166Ho- microspheres, using National Cancer Institute CTCAE v5.0.",2024-02-22,RECRUITING,INTERVENTIONAL,['NA'],,"The rate of efficacy as defined as overall response rate (ORR) in patients receiving individualized treatment with 166Ho- microspheres, using modified RECIST (mRECIST) response evaluation criteria."
11060,NCT00341575,,2005-09-28,COMPLETED,OBSERVATIONAL,['NA'],,
11061,NCT01099111,Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
11062,NCT03448757,non-invasive hemodynamic parameter measurements during exposure AM RF EMF,2018-02-15,RECRUITING,INTERVENTIONAL,['NA'],Searching for cancer-specific frequency modulation,Hemodynamic alteration´s comparison among advanced cancer patients and healthy controls
11063,NCT00331786,Effects of nitric oxide-releasing acetylsalicyclic acid (NCX 4016) on aberrant cryptic foci (ACF) multiplicity after the second dose at 6 months,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety and tolerability of long-term oral administration of NCX 4016 as measured by NCI CTCAE v3.0
11064,NCT02753465,disease-free survival rate,2016-04,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
11065,NCT00327496,,2005-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11066,NCT01555450,Reduction of social inequalities,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of psychological mechanisms
11067,NCT00737230,"Improvement in gastrointestinal symptoms as measured by the modified IBDQ-B score, Rockwood Fecal Incontinence Quality of Life score, St Mark's Incontinence score, and the LENTSOMA score at baseline, 6 months, and 1 year",2007-04,COMPLETED,INTERVENTIONAL,['NA'],,Other unmet healthcare needs as a direct result of pelvic radiotherapy
11068,NCT02221778,Local Progression Free Survival,2014-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
11069,NCT01189942,To the determine the maximum tolerated dose of OMP-21M18 plus FOLFIRI,2010-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine the preliminary efficacy of FOLFIRI plus OMP-21M18
11070,NCT04318756,Syntactic and semantic equivalence of Cancer worry scale' items between English and Italian language and vice versa,2020-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,Exploratory comparison between Patients Health Questionnaire and Irritability Depression Anxiety Scale and cancer worry scale
11071,NCT05420064,Comparison of participant perceived quality of care,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
11072,NCT05621499,1-year DFS rate,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
11073,NCT04137822,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
11074,NCT01909362,number of drug targetable genetic changes found in tumor tissue sample,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,number of physicians who took into consideration regimens that were suggested by the results of the sequencing analysis when deciding their patients' next line of therapies.
11075,NCT04116073,Disease Control Rate (DCR) at 4 months using RECIST 1.1,2020-04-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants experiencing study drug-related toxicities
11076,NCT03433014,measure pain scores (Visual Analog Scale) in the postoperative period,2018-03-31,COMPLETED,INTERVENTIONAL,['NA'],,objective is to compare the VAS scores between the two types of technique used for specimen retrieval incision
11077,NCT00767377,Time to progression,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],PET Scan response,Toxicity
11078,NCT04135313,3-year disease-free survival,2019-10-20,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3'],,Sphincter preservation rate
11079,NCT05193162,16sRNA and metagenomics,2019-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11080,NCT01686971,,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,
11081,NCT02519075,Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing TARE for HCC,2015-04,COMPLETED,OBSERVATIONAL,['NA'],,
11082,NCT00658801,all cause mortality,2007-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11083,NCT03790475,Completion of the assigned screening strategy within 18 weeks of enrollment,2018-08-25,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic yield for CRC and advanced adenomas
11084,NCT02606292,Sensitivity and specificity of PA endoscopic imaging for identification of Barrett's epithelium compared to esophageal biopsy,2014-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11085,NCT04948697,Objective Response Rate (ORR) as assessed by the investigator,2021-08-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Immunogenic Response to BAT1706
11086,NCT03040180,Histopathologic tumor regression following electrochemotherapy,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tumor Immunologic response following electrochemotherapy
11087,NCT03439761,Disease Control Rate (DCR),2018-03-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,AE
11088,NCT00196105,Time to Death,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
11089,NCT02632305,Overall response rates,2016-07-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11090,NCT06076252,The rate of POPF,2023-07-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11091,NCT04143516,Tumor response,2019-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11092,NCT00955019,,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,
11093,NCT01025570,To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination,2010-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination
11094,NCT02374255,Number of Patients Perception of Improved Goals of Care Discussions,2016-03-15,COMPLETED,INTERVENTIONAL,['NA'],,Communication Skills Training
11095,NCT01392131,Number of patients who have prolonged survival after receiving Oncoxin,2011-07,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Reduction in serum alpha-fetoprotein level and decrease in tumor size
11096,NCT02471170,Collection of blood and tissue samples from subjects with pancreatic diseases,2015-09-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11097,NCT02681796,Total consumption of morphine or morphine-equivalent in patients undergoing pancreatic resections in the control group compared with the study group,2016-06-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Effect of epidural analgesia during the initial post-operative period as measured by relative ratios of blood level inflammatory markers
11098,NCT01539681,Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma.,2012-02,COMPLETED,OBSERVATIONAL,['NA'],,Time to Progression
11099,NCT02564887,Tongue Pressure Generation (i.e. Tongue Strength) in Kilopascals (kPa) Using the IOPI Device,2016-01,TERMINATED,INTERVENTIONAL,['NA'],,Swallowing Impairment-Objective
11100,NCT00742729,Receipt of a colorectal cancer screening test,2004-09,COMPLETED,INTERVENTIONAL,['NA'],,Knowledge and attitudes regarding CRC screening.
11101,NCT00776399,Primary Outcome Measures:3-year survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies"
11102,NCT00927485,Size of Polyps,2007-11,COMPLETED,INTERVENTIONAL,['NA'],,
11103,NCT01301417,Rate of anastomotic leakage,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,Rate of other device related complications and measures during hospitalization and post procedure:
11104,NCT01470742,Overall survival of XELOX(XELODA/oxaliplatin) vs X(XELODA),2010-09,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,response rate
11105,NCT01294826,Incidence of dose limiting toxicity (DLT),2011-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival of patients treated with AUY922.
11106,NCT02528175,Acute toxicities,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,Assessment of radiologic response following treatment.
11107,NCT00165217,To assess the anti-tumor activity of capecitabine and thalidomide when administered to patients with previously treated metastatic colorectal cancer.,2001-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the safety of capecitabine and thalidomide in this patient population.
11108,NCT04879953,Overall survival at 6 months,2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour.
11109,NCT01258192,response to induction therapy,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability
11110,NCT05332496,Overall Survival(OS),2022-12-28,RECRUITING,OBSERVATIONAL,['NA'],,Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
11111,NCT02168608,survival rate,2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,complications
11112,NCT04518280,Complete response (CR) rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Scores of Quality of Life
11113,NCT06238167,1-year Disease-free survival rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety will be analyzed through the incidence of adverse events, serious adverse events"
11114,NCT02015754,"Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint - Angiogenesis,One-year Survival Percentage
11115,NCT01609231,Assessment of Progression-free Survival (PFS),2012-07-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Objective Response Rate (ORR)
11116,NCT00897819,Correlation of MSI and LOH to outcome and response,2007-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
11117,NCT01232296,Overall Survival - Overall Survival,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258
11118,NCT00824707,time-to-progression(TTP),2008-12,COMPLETED,INTERVENTIONAL,['NA'],,The overall response rate
11119,NCT02087878,Collection of Samples,2014-03-31,WITHDRAWN,OBSERVATIONAL,['NA'],,
11120,NCT05808712,Rate of supportive care needs in cancer,2023-03-01,RECRUITING,OBSERVATIONAL,['NA'],,
11121,NCT05682768,Post operative Pancreatic Fistula,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11122,NCT00082082,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11123,NCT02728804,Cumulative Incidence Rate of Treatment-related Major Financial Hardship,2016-06-22,COMPLETED,OBSERVATIONAL,['NA'],,"Financial Stress (Patient, Caregiver, or Bereaved Caregiver)"
11124,NCT05918094,Progression-Free Survival (PFS),2023-04-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-STO22 (EORTC QLQ- STO22)
11125,NCT05465512,AUC for BNCISS,2022-01-04,COMPLETED,OBSERVATIONAL,['NA'],,disease free survival
11126,NCT03107416,estimate the local tumor progression (LTP) rates (phase II),2017-04-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11127,NCT00320515,Objective Best Tumor Response,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11128,NCT05764551,The correlation between serum DNA methylation and HCC recurrence or treatment response,2023-03-28,RECRUITING,INTERVENTIONAL,['NA'],,
11129,NCT01687673,Median Time to Progression (TTP),2012-10-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Whom Discontinued Treatment Due to Intolerable Toxicity
11130,NCT02696408,prevalence of grade 3 mucositis and more,2016-06-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety
11131,NCT00445653,"Polymorphisms in DNA repair genes or the p53 pathways (e.g., ERCC2, XRCC1, p53, p73, CCND1, p21)",2005-08,COMPLETED,OBSERVATIONAL,['NA'],,
11132,NCT01693419,Objective response rate,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles
11133,NCT02027545,Number of Participants With CRC Screening Ordered,2015-11-20,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With CRC Screening Utilized
11134,NCT06307080,Safety and efficacy assessment,2023-10-08,RECRUITING,INTERVENTIONAL,['NA'],The application of medical-mechanical combination therapy mode,Survival benefit
11135,NCT01308840,The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants Who Experience an Adverse Event
11136,NCT04835324,overall survival,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of Adverse Events (AEs)
11137,NCT03962088,Change in expression levels of plasma miRNA,2019-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,miRNA expression and surveillance
11138,NCT03218345,Severe adverse events,2016-08,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11139,NCT00552149,Evaluation of treatment efficacy by assessing the crude progression-free survival (PFS) rate at 4 months,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluation of PFS and over
11140,NCT04391348,Demonstrate that the identification of new tumour lesions by an experimental procedure combining PET-TDMs with 18F-FDG and 18F-Fluorocholine in patients with HCC modifies the initially planned therapeutic strategy,2020-07-17,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients who had an additional examination proposed by the MCM (multidisciplinary consultation meeting) following the PET-TDMs performed
11141,NCT05720910,Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 ),2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,GERONTE patient-centered system implementation and usage
11142,NCT03163186,To assess potential patient preference for the performance of hepatic embolization procedures via transradial versus transfemoral approach.,2015-12-01,COMPLETED,OBSERVATIONAL,['NA'],,To identify potential risk factors for complications in transradial approach.
11143,NCT02562976,Number of patients with severe gastric atrophy and/or intestinal metaplasia in early gastric cancer and non-early gastric cancer,2013-05,COMPLETED,OBSERVATIONAL,['NA'],,"correlations between Helicobacter pylori infection and moderate-to-severe EGA classification, OLGA stage III-IV, OLGIM stage III-IV"
11144,NCT02615574,overall survival,2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Changes of tumor microenvironment,immune-related Progression-Free Survival (irPFS)
11145,NCT04581473,"Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's Choice",2020-10-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase II: Disease control rate (DCR), as assessed by IRC and by Investigators"
11146,NCT01927965,To establish the dose of Minnelide™ recommended for future phase 2 protocol,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.
11147,NCT02039336,Progression free survival,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11148,NCT00001576,,1997-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11149,NCT00004108,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11150,NCT03950102,Rate of transplant complication,2015-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Rate of dropout from transplant waitlist
11151,NCT01704651,Postoperative Length of Hospital Stay,2013-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Postoperative Ileus Incidence
11152,NCT00006467,overall survival at 6 months,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,response rate
11153,NCT04230499,Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes,Clinical effect of eRapa on duodenal polyp number and burden.
11154,NCT01171651,Determine safety and tolerability of intravenous infusion of JX-594 followed by intratumoral injections with JX-594 prior to standard sorafenib therapy,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine overall survival time
11155,NCT03676478,Functional recovery (6mWD - 6-minute Walked Distance),2019-03-25,RECRUITING,INTERVENTIONAL,['NA'],Levels of Haemoglobin A1c (HbA1c),Global Health status score
11156,NCT05743504,Pathological complete response rate,2023-09-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with delay in planned radical esophagectomy
11157,NCT00003485,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11158,NCT04368078,Objective Response Rate (ORR),2020-07-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AE)
11159,NCT00907166,"To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients.",2009-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To compare the safety and efficacy of CPI-613 Gemcitabine combination vs. Gemcitabine alone in patients with carcinoma of the pancreas.
11160,NCT06311851,Objective response rate,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse event
11161,NCT01512589,Total Toxicity Burden (TTB),2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11162,NCT05518201,Number of subjects with Severe adverse events (SAE),2022-09-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,The immunogenicity of subjects receiving 3 doses of vaccination was assessed by IgG antibodies and neutralizing antibodies
11163,NCT01489332,Pathological complete remission rate (pCR),2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
11164,NCT00365144,Safety and Toxicity,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With ≥ 25% Decline in Serum CA19-9 Biomarker
11165,NCT00281736,Efficacy,2004-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response
11166,NCT05529615,3-year disease-free survival rate,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11167,NCT01895673,Local site recurrence (LSR) detection,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,Patients experience with PET-CT and PET-MRI
11168,NCT01579071,Abdominal pain related to each insufflation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
11169,NCT01238042,Optimal Light Dose,2003-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Resolve Barrett's mucosa
11170,NCT05795296,Objective response rate (ORR),2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
11171,NCT02438436,xerostomia,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11172,NCT03034473,Number of patients with histopathologically confirmed complete remission (pCR) (ypT0N0 R0) after preoperative RCTx related to pretherapeutically determined gene expression signature predicting tumor response to RCTx.,2011-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Wexner-Score-Questionnaire
11173,NCT00155883,tumor response rate,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,"clinical benefit response, toxicities, quality of life, time to disease progression, overall survival"
11174,NCT01155258,To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST),2010-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-free and overall survival
11175,NCT03687515,"Clinical responses including 4 major symptoms(nasal obstruction, rhinorrhea, loss of smell,and headache/facial pain)",2015-01-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Physicians' assessment of nasal polyp size reduction
11176,NCT02188927,Participation rate,2014-08,UNKNOWN,INTERVENTIONAL,['NA'],Cost of including Advance Notification Letter,Response rate
11177,NCT00293124,Time to Disease Progression,2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Survival
11178,NCT00392366,Accuracy of predicted lesion geometry to histologically measured dimensions,2006-07,COMPLETED,INTERVENTIONAL,['NA'],,
11179,NCT00112528,Survival at 6 months,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11180,NCT00417976,Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rates Defined by RECIST 1.0
11181,NCT01457599,Sensitivity,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
11182,NCT00709826,Progression Free Survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11183,NCT02966509,Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled Medical Note Within 6 Months of Patient Enrollment in the Study.,2013-08,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction With Decision-Making Using the Satisfaction With Decision Survey
11184,NCT04592861,Overall survival duration,2020-11-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"Quality-of-life, measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaire"
11185,NCT00176813,"To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis
11186,NCT00003434,Progression Free Survival,1998-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11187,NCT04995354,WHO grade of mucositis,2022-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11188,NCT00335543,Median survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life before, during, and after therapy"
11189,NCT04425226,Recurrence-Free Survival (RFS),2020-08-06,RECRUITING,INTERVENTIONAL,['NA'],,Objective Response Rate (ORR)
11190,NCT01098344,Adverse event and severity according to NCI CTCAE Version 4.02,2010-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma concentrations of MK0752
11191,NCT02837679,Change in Quality of life,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Health costs per patient,Length of hospital stay
11192,NCT01533740,Impact of Tregs frequency on overall survival,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,Impact of Tregs frequency radiologic response rate
11193,NCT03836352,Safety as measured by the rate of adverse events,2018-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in immune cell infiltration,Overall survival
11194,NCT05862337,Recurrence-free survival (RFS),2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Objective response rate (ORR) after first recurrence
11195,NCT01212718,Best response to first-line chemotherapy (recist),2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"overall survival, toxicity, treatment related complications, time to progression"
11196,NCT04069455,CR29 scores,2019-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11197,NCT02409849,PFS,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
11198,NCT01379612,Tumor regression grade,2010-05,COMPLETED,OBSERVATIONAL,['NA'],,
11199,NCT00035035,,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11200,NCT00003610,severity of mouth pain,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11201,NCT02558881,Acceptance rate of colonic capsule versus virtual colonoscopy.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,Additional costs generated by the implementation of a complementary action of screening for patients with a positive FOBT and did not realize optical colonoscopy
11202,NCT06190665,Disease control rate (DCR) for target lesions 1 month after the last TACE treatment,2023-12-19,RECRUITING,INTERVENTIONAL,['NA'],,Number of TACE treatments for target lesions
11203,NCT04929223,Objective Response Rate,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Plasma Concentrations of Divarasib
11204,NCT05880446,Mean Delta of EORTC Proctitis Module (PRT20) score,2023-10-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Low Physical Activity Level prevalence and its association with PRT20 and QLQ-C30 Delta,Mean Delta of EORTC Quality of Life Questionnaire (QLQ-C30) score
11205,NCT00655655,"Efficacy outcomes in patients with metastatic kidney cancer, neuroendocrine carcinoma, non-small cell lung cancer, or melanoma (Cohort II)",2004-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11206,NCT00829335,Technical feasibility,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,Morbidity and mortality
11207,NCT04361227,Closure time after ESD,2020-07-02,COMPLETED,OBSERVATIONAL,['NA'],,Clips used post-ESD
11208,NCT02220062,percentage of participants with 50% decrease or less than 3 points in Pain Visual Analogue Scale (VAS),2014-08,UNKNOWN,INTERVENTIONAL,['NA'],,
11209,NCT00040820,,2002-01,COMPLETED,INTERVENTIONAL,['NA'],,
11210,NCT00678535,Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments,2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Safety - Number of Participants With Adverse Events (AEs)
11211,NCT06243393,Progression Free Survival (PFS),2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Survival (OS)
11212,NCT04027556,HCC conspicuity,2019-06-27,COMPLETED,INTERVENTIONAL,['NA'],,Radiation dose
11213,NCT04001478,Determine the diagnostic accuracy of breath test for detection of early oesophageal cancer and Barrett's high grade dysplasia,2019-10-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic validation study of the breath profile for prediction of early oeosphageal cancer and high grade dysplasia
11214,NCT02948348,Pathological complete response,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,macroscopic evaluation of (rectal cancer) resected specimen
11215,NCT00075712,Quality of life by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-ovarian cancer (QLQ-OV28),2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11216,NCT00655785,toxicities as assessed by NCI-CACAE ver3),2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Survival
11217,NCT01269060,Harvested numbers of lymph node,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Postoperative mortality, morbidity"
11218,NCT00467974,progression free survival,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,consumption of hospital resources
11219,NCT02959541,THF - adjacent mucosa,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,Gene expression - correlation adjacent mucosa tissue concentration of the reduced folates
11220,NCT04238637,Objective Response rate (ORR) according to RECIST 1.1,2019-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Translational research,Overall Survival (OS)
11221,NCT00238147,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11222,NCT03072095,FIT completion within 3 months,2017-04-17,COMPLETED,INTERVENTIONAL,['NA'],,Response to text-based CRC screening outreach
11223,NCT03598348,PFS,2018-01-16,UNKNOWN,INTERVENTIONAL,['PHASE3'],,OS
11224,NCT03816345,Clinical measures of interest,2019-07-16,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11225,NCT01549067,,2011-09,UNKNOWN,OBSERVATIONAL,['NA'],,
11226,NCT03175679,Incidence of Treatment-Emergent Adverse Events [Safety],2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease Control Rate (DCR),Biological activity of infused iNKT cells
11227,NCT05228431,Rate of pCR,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
11228,NCT05052086,"Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI",2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11229,NCT05726188,Recurrence,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,Cancer-related survival
11230,NCT02127645,incidence of local and distant recurrence,2011-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,anorectal function
11231,NCT04264962,Recurrance rate,2017-01-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,quality of life (QOL) questionnaire
11232,NCT05313191,To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.,2022-01-24,RECRUITING,INTERVENTIONAL,['NA'],,To characterize patient reported outcomes within 1 year of reirradiation using the MDASI SP form for spinal tumors.
11233,NCT02153398,Aggravation of Regurgitation at Week 8 by Investigators,2014-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose
11234,NCT05276037,Survival,2019-01-01,RECRUITING,OBSERVATIONAL,['NA'],,FDG PET-CT value in Milan-in patients
11235,NCT01914068,Change in physical fitness measured by CPET (ml/kg/min),2013-08,COMPLETED,INTERVENTIONAL,['NA'],TNM Staging,Physical activity
11236,NCT04188002,Metabolic Equivalent Task Hours (METs) for Physical Activity,2017-03-25,COMPLETED,INTERVENTIONAL,['NA'],,Number of Times Visiting the Site
11237,NCT03101475,Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation),2018-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety: Safety analyses will be performed on the Safety population. The worst toxicity grade per patient over the treatment period according to the CTCAE criteria version 4.0 will be displayed.
11238,NCT04495088,disease-free survival,2020-09-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient reported outcome: Functional outcome according to Wexner score
11239,NCT05208775,2-year disease-free survival rate,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Esophageal stenosis rate at 3 months
11240,NCT01522612,Progression free survival,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire"
11241,NCT00654160,Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response rate of genotype-based dosing in the subset of patients that has colorectal cancer
11242,NCT05382741,Disease Free Survival,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11243,NCT06069778,Phase 2 - Disease-free survival (DFS),2024-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 - Occurrence of abnormal laboratory parameters
11244,NCT00570531,Disease Free Survival Time,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Proportion of Toxicities Experienced by Participants
11245,NCT02969096,Rate of complete tumor ablation,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11246,NCT03820531,Pancreas cyst with HGD or carcinoma,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
11247,NCT03865563,"Safety as measured by number of participants with Grade 3, 4, and 5 toxicities",2019-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy as assessed by change in levels of gemcitabine and dFdu in peripheral blood samples
11248,NCT01512745,Overall Survival(OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events
11249,NCT01612325,Target lesions tumour response,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity according CTC v 4 criteria
11250,NCT03237325,Duration of Severe Oral Mucositis (SOM),2017-12-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11251,NCT01890291,To evaluate recurrence-free survival,2013-06,COMPLETED,OBSERVATIONAL,['NA'],,To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.
11252,NCT02717949,Number Subjects Who Experience Adverse Events on HCV Treatment as Assessed by Division of AIDS (DAIDS) Adverse Event (AE) Grading Table Version 2.0.,2016-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],,Number of Subjects Who Have a Change in Lymph Node Size From Baseline After HCV Treatment
11253,NCT04678349,ileostomy stoma output,2021-05-01,COMPLETED,INTERVENTIONAL,['NA'],,dietary intake
11254,NCT04512508,Percentage of positive results for Anal Test system versus anal liquid cytology and anoscopy for the presence of high-risk human papillomaviruses,2020-08-30,UNKNOWN,INTERVENTIONAL,['NA'],,Number and percentage of patients to have a positive opinion to use Self-Test system.
11255,NCT06090643,Return rate of completed FIT kits,2019-11-01,RECRUITING,INTERVENTIONAL,['NA'],,
11256,NCT00207155,Prediction of response to Erbitux in subjects with metastatic colorectal cancer,2003-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Radiographic Response
11257,NCT02950064,Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause.,2016-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],Part 1 - Plasma Pharmacokinetics (PK) estimates of platinum concentration Half-life (T1/2).,
11258,NCT02582970,Percentage of Participants With Adverse Events,2005-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,Mean Direct Medical Cost for Cancer Related Medical Care Utilization
11259,NCT05969444,High grade dysplasia/Gastric adenocarcinoma,2015-06-01,COMPLETED,OBSERVATIONAL,['NA'],,
11260,NCT02423174,Intraoperative Serious Adverse Events as a Measure of Safety and Feasibility,2016-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluation of post-operative complications
11261,NCT01378143,Overall survival (OS),2011-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of response (DR)
11262,NCT02203409,Safety of the procedure defined as the incidence of postoperative complications and mortality,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,survival rate
11263,NCT00217555,Quality of life,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11264,NCT01668017,Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT),2012-09-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,Percentage of Subjects With Disease Control
11265,NCT05601505,"Disease-related treatment failure, DrTF",2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,"overall survival, 2yOS"
11266,NCT05055323,Incidence of dose limited toxicity (DLT),2021-07-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Fatty tissue accumulation of PP
11267,NCT04748380,Change in CRC Screening Intentions,2023-01-18,RECRUITING,INTERVENTIONAL,['NA'],,Feelings of usefulness of the decision aid
11268,NCT00003843,,1998-10,TERMINATED,OBSERVATIONAL,['NA'],,
11269,NCT05714111,Local progression free survival,2022-03-04,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival
11270,NCT01187212,Progression-free survival,2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Biomarker for sorafenib
11271,NCT03813784,Overall survival (OS) of SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210+apatinib versus capecitabine + oxaliplatin in all subjects or programmed cell death ligand 1 (PD-L1) positive participants,2019-03-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Subjects with treatment-related adverse events (AEs)
11272,NCT02288728,postoperative mortality and morbidity,2014-12,TERMINATED,INTERVENTIONAL,['NA'],,reflux esophagitis
11273,NCT04150042,Overall incidence rate of Grade 3-5 adverse events,2021-01-13,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival
11274,NCT02146703,Objective reponse rate,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression free survival, median overall survival, disease control rate, and over grade 3 hematologic toxicities (neutropenia, thrombocytopenia, and febrile neutropenia)"
11275,NCT05000697,Decision to Watch and Wait due to clinical complete response,2021-07-14,RECRUITING,INTERVENTIONAL,['NA'],,Colostomy-free survival at 3 years
11276,NCT04232735,SOURCE observational scale,2020-10-13,RECRUITING,INTERVENTIONAL,['NA'],SOURCE evaluation questionnaire (tailor made evaluation questionnaire),Health care providers' (numerical) precision of treatment outcome information measured with SOURCE observational scale simulated patient consultations (effect intervention)
11277,NCT01876511,Progression Free Survival (PFS) at 20 Weeks in MSI Positive Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Does MSI as a Marker Predict Treatment Response
11278,NCT00919282,overall survival,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety of treatment
11279,NCT05378919,disease-free survival,2015-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
11280,NCT02589496,Response Rate,2016-03-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11281,NCT02186574,Rate of reverse seroconversion,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,All-cause mortality
11282,NCT03500380,Progression-free Survival (PFS) as Assessed by an IRC,2018-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Survival
11283,NCT05203549,Establishment of patient-derived organoids,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Correlation between results of the drug sensitivity tests in patient-derived organoid models and clinical outcomes
11284,NCT00026299,Recommended dose of ZD1839 in combination with oxaliplatin,2001-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11285,NCT04761614,Dose limiting toxicities (DLTs),2021-04-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],Change in levels of circulating cytotoxic T cells,Pharmacokinetic (PK) profile of riluzole (AUC)
11286,NCT00613730,Overall Survival at 1 Year,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Response
11287,NCT02779465,Change in serum levels of 25-hydroxy vitamin D,2016-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Number of participants on Vitamin D treatment with adverse events
11288,NCT00987766,Maximum tolerated dose and recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"E-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and their relationship to response"
11289,NCT02086656,Pathological response rate,2013-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,RECIST Response rate
11290,NCT04753203,Progression Free Survival,2021-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of response
11291,NCT06173726,Dose-Limiting Toxicity,2023-12-05,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
11292,NCT01837381,overall survival and treatment-related toxicity,2007-02,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response
11293,NCT03678883,Part 3 Arm B,2019-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
11294,NCT03818165,Assess preliminary efficacy by overall survival,2019-07-29,TERMINATED,INTERVENTIONAL,['PHASE1'],Assess if circulating tumor cells (CTC) correlate with response,Assess preliminary efficacy by in-liver progression free survival (PFS)
11295,NCT04779125,Complications,2021-03-19,COMPLETED,INTERVENTIONAL,['NA'],,Gluteus muscle function measured by time stands test
11296,NCT01992705,Rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy.,2014-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],Quality of life through and after treatment,Survival status (disease-free-survival vs. overall survival) time to recurrence and site of recurrence in patients with borderline resectable pancreatic cancer receiving preoperative FOLFIRINOX followed by SBRT
11297,NCT04382079,oral mucositis,2020-04-08,UNKNOWN,INTERVENTIONAL,['NA'],,"IL-1, IL-6, IL-10,TNF"
11298,NCT05013216,Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 and CD4 T cells,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 weeks.
11299,NCT01139242,"Higher incidence of CRC screening, if needed, among experimental participants.",2008-02,COMPLETED,INTERVENTIONAL,['NA'],,
11300,NCT03914820,Local recurrence free survival (LRFS),2020-06-19,RECRUITING,INTERVENTIONAL,['NA'],,mortality at 30 and 90 days from surgery
11301,NCT03061708,Objective response rate (ORR) by RECIST 1.1,2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11302,NCT02401802,Inadequate bowel preparation.,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,"Acceptability of the preparation (interference with work, leisure activities or sleep"
11303,NCT04293419,Pathological complete response (pCR) rate,2019-12-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Calculation of the neoadjuvant rectal (NAR) score
11304,NCT05760599,DCR per RECIST 1.1,2023-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Biomarkers such as PD-L1 expression
11305,NCT03320733,Negative predicative value,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,Parameters optimization keV
11306,NCT00016900,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11307,NCT00111904,Safety,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11308,NCT03941093,Overall Survival (OS),2019-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,"Best Overall Objective Response Rate (ORR), as Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1"
11309,NCT02948309,Overall survival (OS),2016-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of treatment-emergent adverse events (AE)
11310,NCT01188785,Number of Participants with Adverse Events,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11311,NCT01239082,The primary outcome is colorectal cancer mortality.,2012-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,FIT Positive - If Colonoscopy is Warranted
11312,NCT03028311,Incidence of adverse event assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2017-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11313,NCT03764137,Image Quality,2019-03-14,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11314,NCT06002425,Influence Rate of ChatGPT on Treatment Plans,2023-08-29,RECRUITING,INTERVENTIONAL,['NA'],5-year Overall Survival (OS) Rate,3-year Progression-Free Survival (PFS) Rate
11315,NCT04037046,Acceptance of the interventions,2019-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Effectiveness of each strategy: rate of HCV positivity
11316,NCT04836741,Disease free survival,2015-07-01,COMPLETED,INTERVENTIONAL,['NA'],,
11317,NCT01587534,the change in body weight at eight weeks after the randomisation,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of bowel movements per day
11318,NCT03274804,Feasibility Rate of a Combined Therapy,2018-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
11319,NCT01231347,To determine if AMG 479 in combination with gemcitabine improves overall survival as compared with placebo in combination with gemcitabine in subjects with metastatic adenocarcinoma of the pancreas,2011-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of subjects with adverse events
11320,NCT00147550,"Objective Response Rate, Safety.",2004-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Time to progression, overall survival, patient reported outcomes."
11321,NCT03395938,The proportion of siblings that contacted the study team within 4 weeks from point of engagement by the index colorectal cancer patient.,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,
11322,NCT01093755,Change in Esophageal Inflammation Biomarker COX-2 Gene Expression,2010-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11323,NCT04667351,overall survival,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
11324,NCT00787787,Median Progression-free Survival,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival
11325,NCT04560712,Retention,2020-08-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Postoperative length of stay,Satisfaction of pain control
11326,NCT04693546,"Sensitivity and specificity for the LifeKit Prevent Colorectal Neoplasia Test for adenoma, including advanced adenoma",2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,Sensitivity of the LifeKit Prevent Colorectal Neoplasia Test is superior to that of FIT for advanced adenoma
11327,NCT04034953,Breast cancer detection rate,2018-08-06,UNKNOWN,INTERVENTIONAL,['NA'],,
11328,NCT02864381,Objective Response Rate (ORR),2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
11329,NCT00486356,Toxicities of combined chemotherapy regimen,2004-10-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
11330,NCT05711433,incidence of postoperative pancreatic fistula,2014-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
11331,NCT03122548,Objective Response Rate (ORR),2017-08-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
11332,NCT04652271,Mortality,2021-09,UNKNOWN,OBSERVATIONAL,['NA'],,Morbidity
11333,NCT00467194,Maximum tolerated dose,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in DCE-CT scan assessment of angiogenesis
11334,NCT05596630,Local control rate（LC）,2023-05-08,RECRUITING,INTERVENTIONAL,['NA'],,Progression-free survival (PFS)
11335,NCT03687853,Death,2017-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
11336,NCT05375370,Change in tcDNA dosage between baseline and 3 Months,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Survival at 2 years
11337,NCT06132087,R0 resection rate,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Time to distant metastases
11338,NCT04526483,The success rate of laparoscopic gastric surgery,2020-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,Lymph node dissection rate
11339,NCT03295591,Cutoff value of CTC counts,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
11340,NCT00509561,Overall survival,2008-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Health economics
11341,NCT03944304,Disease control rate,2019-05-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11342,NCT02333721,3-year disease free survival rate,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Technical performance
11343,NCT01639911,Optimally Tolerated Dose,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Toxicity Profile
11344,NCT05237193,Assess the value of UCAD for malignant biliary obstruction patient follow-up,2021-09-03,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of the sensitivity and specificity of the UCAD analysis versus bile cytology
11345,NCT02686372,To Evaluate safety of the TCR-T treatment,2018-05-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate objective response rate
11346,NCT01132469,5-year disease(gastric cancer)-free survival rate after ESD procedure,2010-05,UNKNOWN,INTERVENTIONAL,['NA'],,The safety of ESD procedure
11347,NCT04287335,Sensitivity and specificity of the ColoClear screening test with comparison to colonoscopy,2018-09-18,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity of the ColoClear screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
11348,NCT00001241,,1989-01-27,COMPLETED,OBSERVATIONAL,['NA'],,
11349,NCT03853772,Demographic and clinical data obtained via chart review and questionnaires,2019-04-27,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,
11350,NCT04254939,Phase II: ORR based on mRESIST 1.1,2019-08-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11351,NCT05603039,Objective remission rate (ORR),2021-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR) Duration of remission (DOR)
11352,NCT03990974,30-day postoperative infection rate,2020-09,SUSPENDED,INTERVENTIONAL,['PHASE3'],,Distant infection rate
11353,NCT05022511,Participation,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],Survey evaluation,Rate of compliance to follow-up with colonoscopy after a positive FIT
11354,NCT01768988,Pain intensity (Visual Analogue Scale; VAS Score),2012-08,TERMINATED,INTERVENTIONAL,['PHASE4'],,Neuropathic Pain
11355,NCT05665868,Anxiety tendency of patients in the past week assessed by self rating anxiety scale,2022-04-01,RECRUITING,INTERVENTIONAL,['NA'],,
11356,NCT00947206,ever had a CRC screening test,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,up-to-date for CRC screening
11357,NCT00906997,Colorectal cancer-related mortality,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,Advanced colorectal neoplasm detection rate
11358,NCT01760694,Efficacy - Progression Free Survival,2013-01,TERMINATED,INTERVENTIONAL,['NA'],,Safety
11359,NCT05215535,Cost effectiveness,2022-04-12,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11360,NCT01535326,Proportion of Patients Without Pain,2012-02,COMPLETED,INTERVENTIONAL,['NA'],Post-procedure Discomforts and 30 Day Complication Rate,Number of Participants With at Least One Adenoma
11361,NCT05104567,Objective Response Rate (ORR),2021-12-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Cend of infusion of cetuximab
11362,NCT00126542,Response rate of patients treated with the combination of bevacizumab and OSI-774,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
11363,NCT04612309,effectiveness,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],,
11364,NCT03466424,Pathological complete response(pCR) rate,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of acute toxicities during radiation or chemotherapy
11365,NCT02304978,TNM primary colorectal tumor stage,2009-06-22,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Interaction plate / tumor cell
11366,NCT04404647,90-day complication rate and severity,2020-06-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Longitudinal changes in nutritional status assessment
11367,NCT01661270,Progression-free Survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Objective Response
11368,NCT01273493,Pharmacokinetics of trabectedin,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate survival data
11369,NCT04988191,"Pathological complete response rate based on blinded, independent, central review",2020-12-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Related Adverse Events
11370,NCT00165854,"to determine the safety, tolerability and efficacy (in terms of response rate and progression-free survival) of the combination in patients with metastatic CRC.",2003-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,measure duration of response and stable disease; to measure median and one year survival.
11371,NCT03787537,Change in nutritional status,2017-08-01,COMPLETED,OBSERVATIONAL,['NA'],,length of hospital stay
11372,NCT05727007,Diagnostic accuracy in T stage,2019-01-23,COMPLETED,INTERVENTIONAL,['NA'],,Diagnostic accuracy in peritoneal or nearby organ infiltration
11373,NCT02525380,The rate of Time to progression of hepatocellular carcinoma 30 patients.,2015-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
11374,NCT00527111,Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.,2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,KRAS Mutation Rate
11375,NCT04112836,Percent of planned chemotherapy delivered,2019-03-15,UNKNOWN,OBSERVATIONAL,['NA'],,Factors associated with the percent of chemotherapy received
11376,NCT01333631,Number of the patients with side effects,2011-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of the patients survived
11377,NCT03260712,Detection of progression-free survival (PFS) rate at 6 months defined according to RECIST 1.1.,2020-01-07,COMPLETED,INTERVENTIONAL,['PHASE2'],"Biomarkers predictive of response and toxicity (protein profiling, HLA typing)",Progression free survival rate at 6 months according to iRECIST
11378,NCT06266091,"Puncture-free survival, PuFS",2021-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Peak serum concentration (Cmax)
11379,NCT06251726,Lymph node invasion rate,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Molecular profile of the tumor
11380,NCT01662752,Subjects in Which the SLN(s) Are Identified,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],Frequency and Tumour-bearing Status of Aberrant SLN(s,Sensitivity and Specificity of Tumour-bearing Status of SLN(s) as a Measure of Lymph Node Status When Assessed by Standard Techniques
11381,NCT00544193,Measurement of biochemical parameters in tumors that may correlate with the effectiveness of therapy,1997-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11382,NCT02602067,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),2015-11,TERMINATED,INTERVENTIONAL,['PHASE1'],Tumor response,Adverse Events
11383,NCT03552744,"Number of PCPs who have at least one patient ever tested with FOBT, or who prescribe at least one FOBT to eligible patients (patients not already tested within recommended intervals, with no contra-indication for screening).",2018-04-26,COMPLETED,INTERVENTIONAL,['NA'],,Change in PCPs' future intentions to prescribe colonoscopy vs. FOBT over the next 6 months
11384,NCT05058846,Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],Change in scores on the Disease Specified Perceived Risk Survey,Proportion of participants who have additional medical procedures
11385,NCT01700062,biochemistry data; Various inflammation-related cytokines ;,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,clinical outcome(hospital stay..)
11386,NCT03923335,disease free survival,2019-04-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11387,NCT00585728,The utility of CT virtual proctoscopy (CTVP) for evaluation of rectal cancer.,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,
11388,NCT04664504,R0 resection rate,2020-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3yLRRFS
11389,NCT05070247,Dose Expansion: Overall Response Rate (ORR),2022-04-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Expansion: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations
11390,NCT05177484,"the feasibility of running the study, to see if it could be run as a large multi-centre study",2022-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,postoperative allogenic red blood cell transfusion rates
11391,NCT02752698,complication,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,change of blood and biochemiacl
11392,NCT01366586,,2011-05,COMPLETED,OBSERVATIONAL,['NA'],,
11393,NCT01670110,Change in Kidney Volume,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Quality of Life
11394,NCT00209677,Determine the clinical response rate with Recommended dose in Phase II setting.,2004-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the MST(Median Survival Time) and DFS(Disease Free Survival) in Phase II setting.
11395,NCT05139082,Overall response rate (ORR),2021-11-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
11396,NCT03899649,Overall Survival,2019-05-08,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11397,NCT03919383,6 months progression free survival rates,2019-04-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11398,NCT03346915,HPV vaccine series start and completion,2018-08-14,COMPLETED,INTERVENTIONAL,['NA'],,Wheel of Wellness (WoW) feasibility
11399,NCT00003543,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11400,NCT01441336,3 year recurrence free survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11401,NCT02867280,Recurrence free survival,2016-06-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Incidence of dose modification of sorafenib due to adverse events.
11402,NCT00373737,,1999-05,COMPLETED,OBSERVATIONAL,['NA'],,
11403,NCT00561275,Toxicity of multiple peptide vaccinations,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Immune responses including LY6K, VEGFR1 and VEGFR2 specific T cells"
11404,NCT03748680,DFS,2018-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,TR
11405,NCT00066677,Progression-free Survival,2003-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Thromboembolic Events
11406,NCT01584544,Number of Participants Experienced Dose Limited Toxicity,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11407,NCT01053013,Overall Survival - Based on Most Recent Scan,2010-04-15,COMPLETED,INTERVENTIONAL,['PHASE2'],Pain Assessment of Pancreatic Cancer Participants,Overall Survival - Based on Stage IV Disease Diagnosis
11408,NCT05203978,Complete colonoscopy defined by caecum intubation (binary criterion : yes or no),2022-03,UNKNOWN,OBSERVATIONAL,['NA'],,Polyp removal (binary criterion : yes or no)
11409,NCT03410758,Overall survival,2016-02-15,COMPLETED,OBSERVATIONAL,['NA'],,
11410,NCT01865565,progression free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival (OS)
11411,NCT05704413,"Relation between biological parameters and outcomes of digestive disease (IBD, CRC)",2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,Brain-microbiota interaction
11412,NCT00933816,Dose limiting toxicity in phase I and Time to progression in Phase II,2009-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase I and II: Adverse effect (AE)
11413,NCT01386242,Overall survival (OS),2011-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
11414,NCT02632019,Overall survival,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
11415,NCT03416244,Overall survival,2018-02-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
11416,NCT04417010,local tumor progression,2020-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11417,NCT03517618,Disease Control Rate (DCR),2014-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]"
11418,NCT03221400,"Phase 2a: Efficacy of PEN-866 in patients with squamous cell carcinoma of the genitalia (anus, cervix, vulva, or penis) using best overall response rate",2017-08-29,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2a: Overall survival
11419,NCT04170179,Progression free survival rate at 6 months,2019-11-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
11420,NCT01626001,Patient Percentage with 4DCT Acquisition Artifacts,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Artifact Reproducibility Reducing 4DCT Acquisition
11421,NCT01416662,capability of CDA to predict the occurrence of early severe hematological toxicity upon gemcitabine,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
11422,NCT05916014,Specificity of AI model to diagnose the Kimura-Takemoto classification,2023-06-01,RECRUITING,OBSERVATIONAL,['NA'],,The MIOU value of AI model in semantic segmentation of endoscopic atrophy picture
11423,NCT02862015,European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30 score change,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse effect
11424,NCT03755791,Duration of Overall Survival (OS) for the experimental arm vs. the control arm,2018-06-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Duration of Progression Free Survival (PFS) for the single-agent arm vs. the control arm
11425,NCT05797467,median of disease-free survival,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complications
11426,NCT01844908,Incidence of prolonged ileus,2013-05,UNKNOWN,INTERVENTIONAL,['NA'],,30-day mortality rate
11427,NCT05445778,Assess Progression-free survival (PFS),2022-12-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient-reported outcome health-related quality of life (HRQoL) of disease-related symptoms using the NCCN-FACT Ovarian Symptom Index (NFOSI-18) DRS-P (disease-related symptom subscale - physical).
11428,NCT04851106,The negative predictive value (NPV) determined from shear wave elastography,2021-09-21,UNKNOWN,OBSERVATIONAL,['NA'],,
11429,NCT06310564,Progression-free survival (PFS).,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,questionnaire QLQ-C30
11430,NCT05496491,Disease Free Survival,2022-08-30,RECRUITING,INTERVENTIONAL,['NA'],,Treatment Compliance
11431,NCT05069766,Registration of treatment related side effects assessed by CTCAE V 5.0,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,
11432,NCT00439517,Progression-free Survival (PFS),2007-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety - Number of Patients Experiencing Any Adverse Event
11433,NCT00389610,Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity,2006-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free Survival (DFS)
11434,NCT05223673,"Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)",2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE3'],,Adverse Events (Phase III Part)
11435,NCT05497271,diagnostic accuracy by cystic fluid analysis,2017-01-01,RECRUITING,OBSERVATIONAL,['NA'],,DNA mutation profile of cystic fluid
11436,NCT01694277,Overall Survival (OS),2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
11437,NCT05439993,Progression-free survival rate (PFSR) at 4 months,2022-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11438,NCT03550001,lymph node yield,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Local recurrence rate
11439,NCT01102569,Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients,2008-01,RECRUITING,OBSERVATIONAL,['NA'],,Frequency of disease modifying mutations
11440,NCT03225560,Quality of Bowel Preparation,2018-11-21,COMPLETED,INTERVENTIONAL,['NA'],,Patient reported adherence to bowel preparation instructions
11441,NCT04967183,Adverse effects,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Preferences of the subjects
11442,NCT05580393,The number of cases with subtypes of human Blastocystis isolates in Sohag,2022-11,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The number of cases with Blastocystis infection is recorded.
11443,NCT00474994,Overall Objective Response,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11444,NCT03780049,Overall survival (OS),2018-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Conversion rate to resection
11445,NCT03259763,Rate of gastric outlet obstruction recurrence,2020-10-26,RECRUITING,INTERVENTIONAL,['NA'],,Duration of stent patency
11446,NCT01373047,Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Designer T cell survival and phenotype following infusion
11447,NCT04216901,Accuracy of Vision location,2019-12-24,UNKNOWN,OBSERVATIONAL,['NA'],,Consistent of vision positioning between diagnostic system and endoscopists
11448,NCT00644618,Survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,"response rate, clinical benefit response, and safety"
11449,NCT00669136,Immunological response rate in PBMC as indicated by the ELISPOT assay,2009-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,Immunological response rate in lymph nodes as indicated by the ELISPOT assay
11450,NCT04185454,Osteocalcin ratio,2018-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Lipid profil 2
11451,NCT00490373,To evaluate the efficacy.,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To characterize the quantitative and qualitative toxicities of pemetrexed in this population of pancreatic cancer patients.
11452,NCT03370432,Incidence of colorectal cancer in the DCH cohort,1993-12,COMPLETED,OBSERVATIONAL,['NA'],,
11453,NCT00055692,To Collect Information on Hepatic Function and Hepatitis Viral Activity in Cirrhosis and Upon Potential Alterations in the Setting of VEGF-inhibition,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Disease Stability,
11454,NCT03524287,overall postoperative morbidity rates,2018-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Lymph node noncompliance rate
11455,NCT03609489,Progression-free survival,2018-09-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease Control rate
11456,NCT04647045,Serum cytokine level,2017-05-02,COMPLETED,INTERVENTIONAL,['NA'],,Constipation related symptoms
11457,NCT02563548,"Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",2015-10-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Dose-Expansion Phase: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
11458,NCT02325453,Compare the three treatment arms in terms of tumor recurrence after treatment. (Disease-free survival),2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,"Verify whether robotic gastrectomy, compared with laparoscopic or open techniques, is capable of improving postoperative surgical stress. (Granulocyte-to-lymphocyte ratio.)"
11459,NCT00606944,Recovery,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative Complication
11460,NCT02588560,Increase (log) of HCV Viral Load between Baseline and after Chemotherapy,2015-09,UNKNOWN,OBSERVATIONAL,['NA'],,Number of Participants with Early Stop of Chemotherapy due to Hepatotoxicity
11461,NCT01843725,To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept,2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1"
11462,NCT03843554,Oral mucosal severity,2019-09-23,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
11463,NCT05257122,progression free survival (PFS),2022-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety: the potential side effects
11464,NCT04747951,The rate of complete responses,2020-10-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],,rate of intraoperative and postoperative complications
11465,NCT00004042,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11466,NCT03405272,Objective response rate,2018-02-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11467,NCT02713269,Local tumor control rate,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Changes in quality of life (QOL) assessed by SF-12 healthy survey (v2)
11468,NCT05545293,Postoperative nutritional status and quality of life,2022-09-14,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative intestinal function recovery time
11469,NCT03384511,Tumor response defined by RECIST criteria,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4'],,Treatment-Related Adverse Events as Assessed by CTCAE
11470,NCT06265285,Change in patient-reported rating of Cancer CARE Cancer Connected Access and Remote Expertise (CARE) after 8 weeks,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11471,NCT00454636,Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Response
11472,NCT02129257,Progression-Free Survival (PFS) rate at 1 year,2014-05-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS."
11473,NCT03676426,New documentation of advance care planning in the EHR,2018-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Surrogate preferences
11474,NCT05997147,Recurrence-free survival,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
11475,NCT03549338,"Number of Participants With Adverse Events (AEs) by Nature, Severity, and Occurrence.",2018-11-29,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11476,NCT01183156,Attendance to screening colonoscopy,2010-08,UNKNOWN,INTERVENTIONAL,['NA'],,Response rate to the re-invitation letter or invitation to the educational meeting
11477,NCT06070376,Reinterventions,2023-06-26,RECRUITING,INTERVENTIONAL,['NA'],,Patency time of the prostheses.
11478,NCT05648487,R0 resection,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Relapse-Free Survival
11479,NCT04390958,Pathological complete response (pCR) rate,2020-05-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Surgical complications
11480,NCT01471756,Efficacy of Two Devices used in EMR,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare the Use of Two Injectates
11481,NCT02919878,Estimate the rate of pathological complete response following neoadjuvant combined-modality therapy using weekly Gemcitabine and radiation therapy in rectal cancer.,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,R0 resection rate
11482,NCT05382442,Number of participants with adverse events (AEs),2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11483,NCT00816777,Progression Free Survival,2008-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival
11484,NCT04139967,Number of participants who experience a grade 2 adverse event,2020-01-20,TERMINATED,INTERVENTIONAL,['NA'],,Number of participants with improved symptoms
11485,NCT06301464,The level of serum pepsinogens,2003-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11486,NCT05098197,Overall Survival (OS),2021-09-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life
11487,NCT03127111,Time to recurrence (TTR),2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival (OS)
11488,NCT05178043,The Objective Response Rate (ORR) (confirmed) as evaluated by an Independent Review Committee (IRC) according to RECIST v1.1,2021-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Presence of Anti-Drug Antibodies (ADAs) to GT90001 and Nivolumab during the study relative to the presence of ADAs at baseline
11489,NCT06287788,The AUC of the predictive model,2024-03-01,RECRUITING,OBSERVATIONAL,['NA'],,The important predictors of severe oropharyngeal mucositis in the predictive model
11490,NCT04154124,"Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT",2019-11-23,UNKNOWN,INTERVENTIONAL,['NA'],,
11491,NCT00261092,Overall response rate based on RECIST criteria,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
11492,NCT00041275,Survival measured weekly,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life as measured by EORTC quality of life instrument monthly
11493,NCT02864485,disease-free survival,2016-08-03,RECRUITING,INTERVENTIONAL,['NA'],,disease-free survival
11494,NCT04558684,Clinical complete response rate (cCR),2019-11-01,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events (AEs)
11495,NCT02305290,Observed procedural data,2014-08,RECRUITING,OBSERVATIONAL,['NA'],,Analysis of the costs of this procedure compared to previous treatments
11496,NCT02841436,Tumor response,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Assess for presence of adverse event
11497,NCT04535024,Objective Response Rate,2021-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Acute Toxicity
11498,NCT04357587,Treatment response as measured by Carcinoembryonic antigen (CEA) blood test,2020-08-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11499,NCT04856046,Multi-target hepatocellular carcinoma panel (MHP) score,2021-11-06,RECRUITING,OBSERVATIONAL,['NA'],,
11500,NCT03029988,Visualization of Lesions by FDG PET/CT Imaging and by Tc 99m Tilmanocept SPECT/CT Imaging.,2017-07-26,TERMINATED,INTERVENTIONAL,['PHASE1'],,
11501,NCT03191123,3-year overall survival,2016-07-05,UNKNOWN,INTERVENTIONAL,['NA'],mortality,Recurrence rates
11502,NCT06214611,Accumulated dose distribution in CTV,2023-11-15,RECRUITING,INTERVENTIONAL,['NA'],,Side effects (CTC AE)
11503,NCT00768937,Safety of Sorafenib in combination with TACE,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11504,NCT00599924,Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs),2005-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Initial Area Dnder the Contrast Agent Concentration-Time Curve (IAUC) of Tumors in a Selected Group of Subjects Assessed by DCE-MRI
11505,NCT00324753,Communication Content,2007-04,COMPLETED,INTERVENTIONAL,['NA'],,
11506,NCT02308384,The positive predictive value for detecting colorectal cancer in relation to indications of using iFOBT,2015-09,COMPLETED,INTERVENTIONAL,['NA'],,The rate of performed colonoscopies
11507,NCT05299840,progression-free survival,2023-06-07,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life of patients
11508,NCT02748304,Overall survival,2016-04,TERMINATED,INTERVENTIONAL,['NA'],,Number of patients with treatment-related bleedings who use aspirin
11509,NCT01348412,progression-free survival,2010-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Estimate the quality of life (QLQ C30) and the fatigue MFI20
11510,NCT03619681,The proportion of patients experiencing dose limiting toxicities.,2018-09-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival according to RECIST 1.1 criteria.
11511,NCT03563586,Surgical Site Infections,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,Time to beginning of adjuvant treatment for colorectal cancer
11512,NCT03087864,feasibility defined as percentage completion of treatment with atezolizumab.,2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE2'],"Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.",Overall survival
11513,NCT05520840,Number of patient with presence of best isolated serum biomarkers selected from different candidates,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Number of patient with presence of other isolated serum biomarkers selected from different candidates
11514,NCT04024358,PNI and VI correlation with DFS,2015-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Correlation of neurotoxicity with PNI
11515,NCT05764720,Acute Grade 3+ treatment related GI toxicities,2023-05-14,RECRUITING,INTERVENTIONAL,['NA'],,Progression Free Survival
11516,NCT02416609,Progression-free survival,2014-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
11517,NCT02332213,VOCs differentiating the study groups,2014-01,COMPLETED,OBSERVATIONAL,['NA'],Gastrointestinal microbiome in cancer patients,Groups of gastrointestinal microbiota correlating to VOCs
11518,NCT02078843,Number of patients correctly identified as not having GEP-NET by using Gallium-68-DOTATATE PET/CT and Indium-111-pentetreotide scintigraphy (SPECT/CT),2014-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with adverse events
11519,NCT02880020,Overall response rate defined as the number of subjects with a best objective response of confirmed CR or PR divided by the number of subjects,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate by Choi criteria
11520,NCT00685828,Progression-free survival,2001-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity as assessed by NCI CTC v2.0
11521,NCT05646043,Individual patient compliance,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Laboratory examinations - coagulation factors (fibrinogen)
11522,NCT01697943,Change in QOL (Quality of Life),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Nutritional status of patients
11523,NCT02686944,Adverse events according to CTCAE v 4.03,2016-06-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Levels of alloimmunization parameters
11524,NCT05229822,Change in number of Participants with Post-operative infectious and inflammatory complications,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,16s rRNA in mesenteric lymph nodes
11525,NCT02291289,Progression-Free Survival (PFS),2015-04-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
11526,NCT06248554,Disease-free survival,2019-12-01,RECRUITING,INTERVENTIONAL,['NA'],,Adverse effects
11527,NCT00927680,"We will recruit individuals with colorectal cancer with and without family history of CRC and their immediate family members and obtain the following: paraffin-embedded tumors blocks, blood samples, risk factor and food frequency questionnaires.",2007-07,RECRUITING,OBSERVATIONAL,['NA'],,"We will study the following parameters that we help us plan the larger population-based study such as: response rate of probands and their selected relatives, response rate of participants (probands and relatives), etcetera."
11528,NCT03192735,Radical surgical resection rate,2017-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse event
11529,NCT06173037,Overall Response Rate (ORR) by Independent Review Committee (IRC),2023-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Expression of MSLN using IHC
11530,NCT06166576,Duration of response according to localized mRECIST,2023-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Post-treatment dosimetry based on Y90 PET-CT,Changes in ECOG (Eastern Cooperative Oncology Group) performance status scale
11531,NCT00964171,Non-morphological progression as defined by RECIST criteria,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerability and safety as assessed by NCI CTCAE v 3.0
11532,NCT00865189,Percentage of Participants With Tumor Sterilization Defined by ypT0-N0,2007-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Surgery
11533,NCT05399394,Incidence of Treatment-Emergent Adverse Events,2016-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Local-regional Tumor Control
11534,NCT02415036,Objective response rate in percentage of Melphalan/HDS treatment,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression free survival in months of patients receiving Melphalan/HDS treatment.
11535,NCT00094003,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11536,NCT00286000,Response rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,TTP
11537,NCT03631407,Number of Participants Who Discontinued Study Treatment Due to an AE,2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Trough Plasma Concentration (Ctrough) of Vicriviroc
11538,NCT01880554,Clinical Utility of Intraoperative Contrast Ultrasound in the Surgery of Colorectal Cancer Liver Metastases.,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Performance Evaluation of Intraoperative Ultrasound Contrast Per Lesion: Characterisation Rate
11539,NCT00142428,Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
11540,NCT02966821,Progression-free survival (PFS) rate at Week 16,2017-01-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11541,NCT03139942,Diagnostic accuracy of hyperplastic vs adenoma classification,2017-03-14,COMPLETED,INTERVENTIONAL,['NA'],,Mean time added to endoscopy due to additional imaging
11542,NCT04724551,Incidence of clinically relevant pancreatic fistula,2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Biological markers
11543,NCT02697084,time of disease-free survival,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],,best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria
11544,NCT02613728,Cumulative Hospital Length of Stay (LOS),2016-05-13,COMPLETED,INTERVENTIONAL,['NA'],,Patient Satisfaction
11545,NCT03273608,Overall survival,2016-09-14,UNKNOWN,OBSERVATIONAL,['NA'],"Exploratory Objectives, Downstaging",Adverse Event (AE)
11546,NCT02608203,level of changes (%) between care management before DOTANOC PET and care management after DOTANOC PET,2016-05-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,number of patients for whom PET allowed the detection of lesions not described by standard imaging
11547,NCT06145074,Overall survival 5-years after surgery,2024-03-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Feasibility of implementing preoperative propranolol in the preoperative setting for patients with pancreatic cancer using the APEASE framework.,Safety of 40 mg propranolol twice daily on heart rate.
11548,NCT06054906,Percentage of participants with ≤10% tumor cell survival in resection specimens,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2'],Distribution of immune cells in tumor tissue,Number of participants with treatment-related adverse events as assessed by NCI-CTC
11549,NCT04617522,Percentage of Participants who Develop Positive Anti-Sacituzumab Govitecan-hziy Antibodies,2021-04-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11550,NCT03475680,Postoperative 30-day surgical site infection (SSI).,2018-08-08,TERMINATED,INTERVENTIONAL,['PHASE3'],,Date of adjuvant chemotherapy beginning
11551,NCT05336539,Application value of polygene methylation detection in colorectal cancer in community population,2022-04-01,RECRUITING,OBSERVATIONAL,['NA'],,
11552,NCT00006348,response,2000-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11553,NCT06244446,"Objective response rate (ORR), which is defined as the proportion of patients with complete response (CR) and partial response (PR) at 6 months . CR or PR is assessed in accordance with mRECIST.",2024-02-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Number of Participants with biomarkers change ( AFP , PIVKA II) in both groups."
11554,NCT00101582,Number of Participants With Severe (Grade 3 or 4) Oral Mucositis,2005-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Unplanned Breaks in Radiotherapy
11555,NCT00607828,Maximum tolerated dose,2007-11-16,COMPLETED,INTERVENTIONAL,['NA'],,
11556,NCT01511653,Measure the sensitivity of a blood based panel of biomarkers relative to fecal immunochemical testing,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,To measure the sensitivity and specificity of a combined panel of blood and stool based biomarkers for the detection of colorectal cancer
11557,NCT06001567,Proportion of patients with PLT >75×10^9/L or doubling from baseline,2023-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11558,NCT02037399,present pain intensity (PPI),2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,
11559,NCT02075086,Progression Free Survival,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Feasibility
11560,NCT02406170,Toxicity graded according to NCI Common Terminology Criteria for Adverse Events Version 4.0,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
11561,NCT05287165,Incidence of Treatment Related adverse events (AEs),2022-03-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)
11562,NCT04499586,ORR(Objective Response Rate) includes CR(Complete Rate) and PR(Partial Rate),2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0
11563,NCT05006131,Proportion of screening patients found to have high-risk pancreatic lesions amenable to treatment,2020-07-10,RECRUITING,OBSERVATIONAL,['NA'],,Proportion of screening patients who experience complications/adverse events of screen-related procedures
11564,NCT04907864,Median change (kg) in handgrip strength,2020-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Rate of toxicity with clinical significance, and possible relationship to either study intervention"
11565,NCT00268398,disease-free survival,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Pharmacogenetics
11566,NCT03063554,Efficacy of Stent Patency,2016-10-18,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life
11567,NCT00002570,Survival,1994-07-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,response duration
11568,NCT04709055,Percentage of patients with postoperative complications of grade II or higher in the Clavien-Dindo,2021-01-14,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Patient and professionals experience (ancillary study using semi-directive interviews)
11569,NCT00001228,,1988-10-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11570,NCT05220046,Retention Rate,2023-04-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Change in Demoralization Scale (D-II) total score from Baseline to 1 week post-dose
11571,NCT05855291,Overall survival,2018-01-22,COMPLETED,INTERVENTIONAL,['NA'],,
11572,NCT03359187,Change of mucositis grading,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Patient satisfaction with the mouth wash
11573,NCT02350530,The conversion rate of liver metastases,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
11574,NCT05385250,Rate of PIFs,2021-08-23,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life measures (EORTC)
11575,NCT00028626,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11576,NCT04527861,3-year disease free survival rate,2021-04-08,RECRUITING,INTERVENTIONAL,['NA'],,5-year overall survival rate
11577,NCT05685602,Dose limiting toxicity rate,2023-06-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Pharmacokinetics (PK) of both CA-4948 and nab-paclitaxel,Overall survival (OS)
11578,NCT02882620,Annual Completion of the FIT Kit,2016-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Change in Self-Efficacy
11579,NCT05913674,Feasibility of mEPIC,2024-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Satisfaction of care team
11580,NCT03130634,GI associated adverse events,2016-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
11581,NCT00323583,Quality of life,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Tolerance and Safety NCI-CTC version 2
11582,NCT04880811,Objective response rate,2021-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
11583,NCT05606848,Change in serum prealbumin,2022-11-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Energy intake in kcal / kg BW
11584,NCT02027363,progression-free survival (PFS),2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
11585,NCT05791448,Incidence of adverse events,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics evaluation - Peak time (Tmax)
11586,NCT01216189,Change in Sexual Function (Total FSFI Scores) Between Baseline and 2 Years Follow-up.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
11587,NCT03471273,recur or not in 2 years after endoscopic surgical procedure or surgery,2017-09-18,UNKNOWN,INTERVENTIONAL,['NA'],,
11588,NCT04815746,The Gastrointestinal Symptom Rating Scale (GSRS),2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
11589,NCT03251612,Progression free survival 8 weeks after start of treatment,2017-09-22,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life as measured by questionnaire EQ-5D-5L
11590,NCT01661088,The Percentage of Patients That Underwent an R0 Resection,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Median Overall Survival Time
11591,NCT04227886,Toxicities,2019-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,pCR
11592,NCT04657848,Rate of reflux esophagitis after operation,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative nutrition status
11593,NCT06013098,the occurrence of atelectasis,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE4'],,oxygenation index
11594,NCT06247293,Intra-abdominal recurrence-free survival (RFS),2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,survival rate
11595,NCT06192719,Gallbladder Cancer/Dysplasia development,2019-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
11596,NCT00539318,there is no primary outcome measures in this study,2007-08,TERMINATED,OBSERVATIONAL,['NA'],,
11597,NCT00054457,Proportion of successes,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Quality of life as measured by the LASA, FACT-E and Patient Uniscale Swallowing questionnaires"
11598,NCT04336839,Progression-Free Survival,2020-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Histology predictive value
11599,NCT00845247,Quality of Life measures(questionnaire),2009-03,COMPLETED,INTERVENTIONAL,['NA'],,Care process measures in terms of monitoring of data from the National Patient Registry
11600,NCT04717765,"Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy",2021-02-10,COMPLETED,INTERVENTIONAL,['NA'],,Pain assessed by EVA - score 0 to 10 - all patients
11601,NCT03717298,Quality of Life: EORTC QLQ-C30,2018-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Compliance with the treatment with chemotherapy (CT) and Immunotherapy (IT) test
11602,NCT03278626,Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response),2017-06-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11603,NCT05606549,Fear of Progression Questionnaire-Short form (FoP-Q-SF) for Partners,2022-10-19,RECRUITING,INTERVENTIONAL,['NA'],,Dyadic Coping Inventory(DCI)
11604,NCT01356264,six minute walk test,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Fatigue
11605,NCT03364582,Colorectal cancer risk,2016-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality
11606,NCT03486418,Optical diagnosis of each colorectal polyp,2018-04-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11607,NCT00655876,Overall Survival (24-month Rate Reported),2008-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Quality-adjusted Survival (Using EQ-5D), Only if Primary Hypothesis is Supported"
11608,NCT03303833,Overall cancer diagnoses,2006-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
11609,NCT02292745,overall survival,2014-12-02,COMPLETED,INTERVENTIONAL,['NA'],,predictive value of a set of biological markers for treatment response
11610,NCT00114231,3-Year Disease-free Survival,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Local Recurrence Rate
11611,NCT05789797,"Difference of average ALP values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines).",2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],,"Proportion of patients with detected toxic damage to at least one system or organ (by selected parameters), according to the criteria of common toxicity grade III of the CTCAE scale, from the baseline (Visit 1) to Visit 4, measured in both groups."
11612,NCT04191551,Progression of intestinal metaplasia,2018-07-30,RECRUITING,OBSERVATIONAL,['NA'],,
11613,NCT00509964,response rate,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
11614,NCT06122636,Quality of life rate,2022-10-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11615,NCT05627414,R0 resection rate,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,safety profile
11616,NCT00844883,Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Median Overall Survival OS Stratified by BCLC Criteria,Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE
11617,NCT00952029,Disease-control duration,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Geriatric evaluation
11618,NCT04618367,Progression free survival rate at 6 months,2021-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
11619,NCT00841607,pancreatic leak/fistula,2006-08,COMPLETED,INTERVENTIONAL,['NA'],,overall morbidity
11620,NCT06099951,Complete tumor response rate.,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate
11621,NCT04513808,Recurrence-free survival,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,QoR-15
11622,NCT04592289,Incisional surgical site infection (SSI) rate,2020-10-30,RECRUITING,INTERVENTIONAL,['NA'],,Bowel preparation compliance
11623,NCT00561418,Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Progression
11624,NCT03826862,postoperative complication,2018-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,disease-free survival
11625,NCT00348699,Plasma area under the curve (AUC) of AFP464,2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Percent change in CYP1A1
11626,NCT03651154,Packed Red Blood Cell Transfusion Rates,2018-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Changes in physiologic parameters (Pulse Pressure Variation)
11627,NCT02425059,Number of participants with Adverse events,2015-01-01,COMPLETED,INTERVENTIONAL,['NA'],Overall survival (OS),Percentage of lesions that show no sign of recurrence 12 months after IRE
11628,NCT05025033,Progression Free Survival,2019-05-30,COMPLETED,INTERVENTIONAL,['PHASE2'],biomolecular markers,adverse events
11629,NCT02419716,Positive and Negative Predictive Value,2015-04,COMPLETED,OBSERVATIONAL,['NA'],The adverse event rate (events occurring between collection kit distribution and sample submission),Colorectal Cancer Incidence
11630,NCT06300463,"Mean CD8:Treg ratio, as determined by flow cytometry of tumor tissue, at time of surgical resection in each treatment arm",2024-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Per Arm with ctDNA Clearance
11631,NCT00941655,Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II,2009-07-22,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patterns of Disease Recurrence Between the Two Therapeutic Approaches and Their Clinical Implications
11632,NCT06190847,pCR,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,the surgical conversion rate
11633,NCT04025567,To evaluate the effect of oral vancomycin therapy in the relative CXCR6 gene expression levels in the liver,2020-03-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
11634,NCT05184283,Change in mean muscle fat,2022-06-16,TERMINATED,OBSERVATIONAL,['NA'],,Delta HOMA-IR
11635,NCT05263830,evaluate concentration of circulating GPC-3,2023-09-08,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of the HCC response to treatment on Imaging assessment (CT-scan and MRI) every 3 months according to the miRECIST criteria (combination of mRECIST and iRECIST criteria)
11636,NCT03214835,Efficacy of EndoCDx brush,2018-02-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Assessment of pain
11637,NCT02412683,Oxaliplatin-Specific Neurotoxicity Scale,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Sense of Coherence scale (SOC-scale)
11638,NCT00939848,Progression free survival,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"• Response Rate (RECIST) • Toxicity • Survival (as part of the follow-on phase III study) • Biomarker evaluation (inc. circulating VEGF, sVEGFR-2, bFGF, LDH and CA 19-9) • Quality of Life"
11639,NCT05870800,"Determine the rate of complete histopathologic response to neoadjuvant immunotherapy with neoadjuvant chemotherapy in pMMR resectable, non-metastatic colon cancer.",2024-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Assess short and long-term quality of life through Patient-Reported Outcomes (PROs)
11640,NCT04071964,Number of participants with an anastomotic leak,2019-07-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of participants with cancer reoccurence
11641,NCT00020150,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11642,NCT00026403,overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,quality of life
11643,NCT05546619,RFS,2022-08-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,OS
11644,NCT01918683,Progression Free Survival,2013-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
11645,NCT00317772,Maximum Tolerated Dose (MTD) of Topotecan,2004-09-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Response Rate
11646,NCT06061276,Objective response rate (ORR),2023-10-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Overall survival (OS),Progression free survival (PFS)
11647,NCT01249521,Disease control (ie non progression) at 6 months,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Response rate
11648,NCT00825474,overall survival,2008-08,COMPLETED,INTERVENTIONAL,['NA'],,
11649,NCT03908671,Number of participants with treatment-related adverse events as assessed by CTCAE v4.03,2019-10-18,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival (OS)
11650,NCT04264676,"Disease Free Survival, DFS",2020-03-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Recurrence Rate, RR"
11651,NCT01032044,"Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of ""Optimally Treated""",2010-02,COMPLETED,INTERVENTIONAL,['NA'],,
11652,NCT02005484,Percentage of Participants With a Response by Response Evaluation Criteria In Solid Tumors (RECIST) Category,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression
11653,NCT01815307,1 year recurrent free survival rate,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of overall survival
11654,NCT03279601,Overall response rate (ORR),2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events （Safety and Tolerability）
11655,NCT06084884,"1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase",2023-11-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,12. Pharmacokinetics - Exposure of AZD5851
11656,NCT03175705,Incidence of Treatment-Emergent Adverse Events [Safety],2017-05-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],Disease Control Rate (DCR),Biological activity of infused T cells
11657,NCT02534389,Check effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on Glasgow Prognostic Score (GPS).,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Check for effects of daily consumption of 2.4 g of EPA + DHA for adults with rectal adenocarcinoma in neoadjuvant chemoradiation treatment on pathological response.
11658,NCT04308174,Ro resection rate,2020-05-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Response rate
11659,NCT03638193,Safety of CART-meso infusion: number of adverse events,2018-07-11,UNKNOWN,INTERVENTIONAL,['NA'],,CAR-T cell detection
11660,NCT03001362,"Feasibility of a ""wait and see"" approach",2015-03,RECRUITING,INTERVENTIONAL,['NA'],,
11661,NCT03245788,Rates of unplanned hospitalization and ER visits,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Utilization of non-treatment-related cancer services
11662,NCT03322267,1-year relapse-free survival (RFS) rate.,2018-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],Blood-based biomarkers,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
11663,NCT02646137,Number of patients with successful ablation,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11664,NCT05308446,Progression-free survival (PFS),2022-07-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11665,NCT04276090,Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy,2020-05-01,TERMINATED,INTERVENTIONAL,['NA'],,Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.
11666,NCT03858855,Effects of essential oils on nausea and anxiety,2019-02-18,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability of using a personal inhalation bottle for inhalation of essential oils - perception of benefit of essential oil for symptoms
11667,NCT03982407,Evaluation of PSMA PET-MR for identification of intra and extrahepatic hepatocellular carcinoma in patients,2019-06-27,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
11668,NCT02385604,Disease-free survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,Histopathologic response
11669,NCT03422432,Time to adjuvant systemic chemotherapy,2017-09-28,UNKNOWN,INTERVENTIONAL,['NA'],,
11670,NCT04920214,Specificity,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11671,NCT01307956,Complete Pathological Response (pCR) Rate,2011-02-28,TERMINATED,INTERVENTIONAL,['PHASE2'],Overall Survival,Number of Patients Who Can Undergo Resection
11672,NCT03958747,Tibial Nerve Cross-Sectional Area Comparison,2019-12-17,RECRUITING,INTERVENTIONAL,['NA'],,Reduction of Intraepidermal Nerve Fiber Density
11673,NCT03146520,Clinical performance of EarlyTect Colon Cancer to detect colorectal cancer,2016-12-13,COMPLETED,OBSERVATIONAL,['NA'],,Positive ratio of SDC2 methylation in other cancers
11674,NCT00079261,Complete response as assessed by Cheson criteria,2004-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Freedom from treatment failure as assessed by Cheson criteria
11675,NCT03291106,Distribution of Lynch syndromes in endometrial cancer,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Reliability of clinical criteria for screening Lynch syndromes
11676,NCT03236649,Overall survival (OS),2017-09-20,TERMINATED,INTERVENTIONAL,['PHASE3'],"Genome level (DNA, mRNA, miRNA) biomarker analysis",Assessment on Quality of life 2
11677,NCT01444456,Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL,2011-10,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Increase in Hemoglobin ≥ 1 g/dL at Any Time
11678,NCT05793593,number of people beyond the index participants who complete FIT screening,2023-03-17,RECRUITING,INTERVENTIONAL,['NA'],,
11679,NCT06118762,Progression free survival (PFS),2023-10-20,RECRUITING,INTERVENTIONAL,['PHASE4'],,Security
11680,NCT05472896,Progression-free survival (PFS) by Independent Review Committee,2022-06-09,RECRUITING,INTERVENTIONAL,['PHASE3'],Adverse event/ serious adverse event,2 year survival rate
11681,NCT05810805,Concentrations of different gas in digestive tract,2023-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The correlation between the severity of gastrointestinal symptoms and gas concentrations in various parts of the digestive tract.
11682,NCT05783570,Development of anti-drug antibodies (ADA),2023-08-24,RECRUITING,INTERVENTIONAL,['PHASE1'],Immunological assessment,OS
11683,NCT04194359,Adverse Events and Serious Adverse Events,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival
11684,NCT01088204,noncompliance rate,2010-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,3-year disease free survival
11685,NCT02551237,IADL (Instrumental Activities of Daily Living) Score,2016-01-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,EORTC QLQ-C30 + EDL14
11686,NCT02777814,Incidence of hepatitis B virus associated hepatitis,2015-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interruption of chemotherapy due to hepatitis
11687,NCT01879943,Number of patients with full colonic exploration and detection of lesions,2013-10-18,TERMINATED,INTERVENTIONAL,['NA'],,Health-economic assessment
11688,NCT00924092,To determine the safety and tolerability of escalating doses of a heated-killed yeast-based vaccine that targets tumors that express CEA.,2009-03-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate CD4 and CD8 immunologic response. To evaluate humoral immune response to yeast antigen. To evaluate evidence of clinical benefit such as PFS, OR, &amp; decreases in circulating tumor cells &amp; tumor markers."
11689,NCT03451643,POSTOPERATIVE MORBIDITY,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],,QUALITY OF LIFE
11690,NCT02374411,Collect questionnaire data from 150 HIPEC surgeons,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,HIPEC surgeon attitudes toward patient nutritional support self-assessed by questionnaire
11691,NCT01998347,median overall survival,2013-11,WITHDRAWN,INTERVENTIONAL,['PHASE3'],time to progression,median progression free survival
11692,NCT01755767,Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy,2012-12-27,COMPLETED,INTERVENTIONAL,['PHASE3'],,Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
11693,NCT02340065,number and rate of missed adenomas,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,mean number of adenomas per procedure
11694,NCT02510469,Disease free survival,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
11695,NCT06161233,Change in health-related QoL outcomes in RCC patients,2023-05-16,COMPLETED,INTERVENTIONAL,['NA'],,User experience of the CAPABLE system in other cancer types patients
11696,NCT04158635,Compliance,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE1'],Quality of life assessment,Time to treatment failure (TTF)
11697,NCT00855452,CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11698,NCT05482516,Rate of ctDNA Progression of Disease (POD) or Clinical/radiographic Relapse,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3'],,Reasons for failure of enrollment
11699,NCT02184182,Percentage of R0 resections,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,hepatic diesease free survival
11700,NCT00131638,Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale),2005-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT)
11701,NCT02904031,"Progression Free Survival (PFS). PFS is defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first.",2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11702,NCT04000529,"Dose interruptions, reductions and dose intensity, by treatment",2019-07-30,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall Survival
11703,NCT05482477,Clock Drawing Task(CDT),2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The time of get out of bed for the first time after operation
11704,NCT03931980,Conversion to open surgery,2019-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Time of surgery
11705,NCT05101629,Objective response rate (ORR) according to RECIST 1.1 criteria,2022-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and toxicity
11706,NCT02688699,effectiveness of EndoClotTM in preventing post-procedural bleeding,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,
11707,NCT02206360,Premalignant or malignant pancreatic conditions found with alternating EUS and MRI testing.,2014-04,RECRUITING,OBSERVATIONAL,['NA'],,Non-Pancreatic cancers diagnosed while on this protocol
11708,NCT05495529,Clinical success,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival
11709,NCT06059170,Frequency of LARS,2017-03-17,COMPLETED,INTERVENTIONAL,['NA'],,
11710,NCT02280278,Disease free survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,toxin-side effect
11711,NCT05303298,Objective gastro-oesophageal reflux (GOR),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Survival
11712,NCT00790322,Compare the proportion of patients in the two arms who develop severe oral mucositis,2008-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11713,NCT00002631,,1995-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11714,NCT00867750,Health-related quality of life (HRQL),2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pharmaco-economic assessment
11715,NCT03179579,Median overall survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Risk factors for morbidity and mortality
11716,NCT06313567,Disease-free survival,2024-03-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Side effects
11717,NCT03133650,Maximum tolerated laser fluence rate,2017-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11718,NCT02024087,Number of Participants With Adverse Events as a Measure of Safety and Tolerability.,2014-08-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Disease Control Rate (DCR)
11719,NCT00241020,Overall Survival,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,· Safety
11720,NCT03964753,OS,2019-04-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Adverse Event
11721,NCT00743678,To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival"
11722,NCT05800418,Area under drug concentration - time curve (AUC0-t),2019-11-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apparent volume of distribution (Vd)
11723,NCT06056804,pCR rate,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],The expression of CD8,irAE
11724,NCT01397747,"Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer.",2011-06,COMPLETED,OBSERVATIONAL,['NA'],,
11725,NCT05908747,Surgical complete resection rate (R0),2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
11726,NCT05957640,Objective response rates (ORR),2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Resection rate of liver target lesions
11727,NCT04996459,overall response rate,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Safety (the incidence of adverse events and serious adverse events)
11728,NCT06074029,Progression free survival,2021-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to treatment discontinuation
11729,NCT06219941,Objective Response Rate (ORR).,2023-12-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,"ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established."
11730,NCT03890198,Systemic Cytokine Concentrations,2019-04-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Survival (OS) after administration
11731,NCT04328740,Determine recommended Ph2 dose (RP2D) of TP-1454,2020-07-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Determine antitumor activity of TP-1454.
11732,NCT05322577,Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1),2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE1'],,Part 2: OS
11733,NCT01124630,Progression Free Survival,2010-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Serum concentrations
11734,NCT03857737,5-year DSS,2019-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Complication
11735,NCT02342847,Change from baseline of the Karnofsky index,2014-12-10,COMPLETED,OBSERVATIONAL,['NA'],,Physical examinations
11736,NCT04479436,Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer,2020-09-14,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer
11737,NCT05794971,Overall Survival (OS),2023-06-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse enents
11738,NCT05514561,The diagnostic performance of fecal calprotectin in diagnosis of significant ileocolonic lesions,2020-03-22,COMPLETED,OBSERVATIONAL,['NA'],,The diagnostic performance of fecal immunochemical test in diagnosis of significant ileocolonic lesions
11739,NCT01567930,Disease Progression,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Circulating tumor cells levels
11740,NCT02424955,Changes in Blood Perfusion (Relative Blood Flow),2014-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
11741,NCT05301465,PFS,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11742,NCT05446129,Composite endpoint: Proportion of patients with at least one occurrence of a safety or feasibility event,2022-09-27,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per response evaluation criteria in solid tumors (RECIST) v1.1"
11743,NCT00041639,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
11744,NCT03016026,Rehabilitative rate,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mortality rates
11745,NCT04749303,Adenoma Detection Rate (ADR),2020-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Severe adverse events
11746,NCT02575300,Overall Radiographic Response Rate (ORR),2015-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
11747,NCT02329860,Overall Survival,2014-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease Control Rate
11748,NCT03318380,Negative Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval,2018-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
11749,NCT00085163,"Disease-free survival as measured by Logrank every 3 months in year 1, every 6 months in years 2-3, and annually thereafter",2004-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity as measured by CTC AE version 2.0 every 3 months in year 1, every 6 months in years 2-3, and annually thereafter"
11750,NCT03957135,2 year survival,2019-05-20,RECRUITING,INTERVENTIONAL,['NA'],,
11751,NCT00501410,"Maximum Tolerated Dose (MTD) of Dasatinib, Cetuximab and FOLFOX",2007-04-23,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response-Rate of Dasatinib and Modified FOLFOX6 With or Without Cetuximab
11752,NCT04084158,PFS,2019-09-07,SUSPENDED,INTERVENTIONAL,['PHASE2'],,TTDM
11753,NCT02952859,Time from diagnosis to death for any reason,2017-01,TERMINATED,OBSERVATIONAL,['NA'],,
11754,NCT01338558,Progression-free survival: native versus mutated K-RAS; tumour assessments according to RECIST criteria,2011-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Progression-free survival: comparison of the two treatment regimens in the native K-RAS arms
11755,NCT00247338,Infectious complications,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Post-operative nutritional cost & total treatment cost
11756,NCT00436215,Clinical Response Rate.,2006-12-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
11757,NCT04227041,Progression-free survival (PFS),2020-01-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse Events [Safety]
11758,NCT05580224,Local tumor progression rate,2022-10-04,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence-free survival
11759,NCT06302660,Identify microbiome dysbiosis in stool associated with long-term functional symptoms.,2022-03-09,RECRUITING,OBSERVATIONAL,['NA'],,Propose a strategy for treatment of long-term symptoms in oesophageal adenocarcinoma survivors.
11760,NCT04666727,Somatic mutation burden,2020-09-29,RECRUITING,OBSERVATIONAL,['NA'],,
11761,NCT03829748,Increase in diagnostic yield of pancreatic solid lesions,2019-01-16,COMPLETED,INTERVENTIONAL,['NA'],,Number of passes to reach diagnosis
11762,NCT00489268,Percentage of Participants With Histological Clearance of Barrett's Metaplasia,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants With Sub-squamous Intestinal Metaplasia
11763,NCT00931203,"The primary objective is to determine the pathological complete response (pCR) of combining preoperative tegafur-uracil, folinate, radiation and celecoxib for locally advanced rectal cancer.",2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Sphincter preservation rate.
11764,NCT06311929,Disease-free survival,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall survival
11765,NCT02591784,The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.),2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
11766,NCT04248452,Overall survival,2020-05-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Progression-free survival
11767,NCT03978702,"Measurement of immune effectors (Tcells, NK) levels after pancreatectomy",2021-02-24,UNKNOWN,INTERVENTIONAL,['NA'],,
11768,NCT03697239,Disease Control Rate,2019-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in patient's self-reported pain levels
11769,NCT04319484,3 years recurrence-free survival rate,2020-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,5 years overall survival rate
11770,NCT03579784,Disease control rate,2018-11-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability as measured by number and grade of toxicity events
11771,NCT05722327,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)",2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11772,NCT01764087,Tumor Overall Response Rates (ORRs) in Phase II Portion,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Biomarker Evaluation in Phase II Portion,Pharmacokinetic (PK) Evaluation in Phase II Portion
11773,NCT03478943,Disease-free surviva,2016-01-30,UNKNOWN,OBSERVATIONAL,['NA'],,Disease Control Rate
11774,NCT05959564,Intentions toward HPV vaccination,2023-07-26,COMPLETED,INTERVENTIONAL,['NA'],,Ratings of the Chatbot
11775,NCT03110926,Disease-free survival rate,2017-06-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall disease-free survival
11776,NCT05105828,Shear wave elastography score,2020-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
11777,NCT01812577,Intensity of postoperative pain after radiofrequency ablation of liver lesion,2012-12,UNKNOWN,OBSERVATIONAL,['NA'],Satisfaction of patient and of the operator,Consumption of post-operative opioid
11778,NCT05068193,Cmax,2021-09-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11779,NCT02981862,Assessement of CaptHPV method,2016-12-19,COMPLETED,INTERVENTIONAL,['NA'],,
11780,NCT01127711,"Fractures, hip fractures",1997-09,COMPLETED,OBSERVATIONAL,['NA'],,
11781,NCT03480971,Mucositis,2019-05-13,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Mucositis
11782,NCT04067986,Objective response rate,2019-08-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse-Events
11783,NCT04903340,Average dose value (Gy) of tumor liver and healthy liver obtained according to reconstruction configuration.,2021-04-12,COMPLETED,OBSERVATIONAL,['NA'],,
11784,NCT03081494,Incidence of Dose-limiting toxicity (DLT),2017-06-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Severity of AEs and SAEs
11785,NCT01621217,To establish maximum tolerable dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab and radiotherapy in patients with locally advanced cancer in the anal region,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11786,NCT02624271,Sensitivity of GastroPanel blood test,2016-08-04,COMPLETED,INTERVENTIONAL,['NA'],,
11787,NCT01219920,Response rate (RR),2001-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of life (QoL)
11788,NCT03907579,Number of Participants With Varying Levels of Behavioral Intentions Related to Colorectal Cancer Screening and Prevention,2017-03-11,COMPLETED,INTERVENTIONAL,['NA'],,
11789,NCT01150877,"The metabolic consequences, including tolerability and toxicity, of prolonged, high-dose physiological vitamin D in patients with colorectal cancer.",2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Patient survival with regards to high-dose vitamin D supplementation.
11790,NCT03539822,Phase II- Overall Response Rate (ORR),2018-10-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
11791,NCT02509169,overall survival,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progression free survival
11792,NCT04665687,Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion.,2020-12-17,UNKNOWN,OBSERVATIONAL,['NA'],,"Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence."
11793,NCT04878185,Change in maximal walking distance,2021-05-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Mortality
11794,NCT02338297,APS improvement,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Response Rate
11795,NCT05452473,Gastric lesion detection rate,2022-07-06,RECRUITING,INTERVENTIONAL,['NA'],,Lesion classification accuracy
11796,NCT00766636,Difference in Positive Margin Resection (R1) Rate in Patients Undergo Surgery Between the Two Treatment Groups.,2008-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11797,NCT05647122,Proportion of patients with radiological response (ORR),2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity of AZD9592: Anti-Drug Antibodies (ADA)
11798,NCT01504126,Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride,2012-03-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],"Changes in immune response, measured by serum levels of VEGF",Changes in mood state as measured by Center for Epidemiologic Studies Depression Scale (CES-D
11799,NCT01112280,Adenoma detection rate,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Surveillance
11800,NCT03008278,Objective response rate (Phase II),2018-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']","Tumor cells for PDX model, and biobanked tumor tissue and peripheral blood",Incidence of adverse events
11801,NCT00435097,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
11802,NCT00393822,Incidence of Grade ≥ 2 (WHO scale) oral mucositis,2005-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of grade ≥ 2 (WHO scale) oral mucositis
11803,NCT05994859,Success rate of conversion to resection,2023-08-10,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events (AEs)
11804,NCT04612504,The response rate of patients with HCC receiving SynOV1.1,2022-06-23,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
11805,NCT05438836,"Early Rate of Common Terminology Criteria for Adverse Events (CTCAE) Gastrointestinal Toxicity grade 2 or more (scale from 0-5, 5 being the highest)",2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Treatment Related Hospitalization
11806,NCT03676517,pathologic complete response (pCR) rate,2019-03,UNKNOWN,INTERVENTIONAL,['NA'],,Cost effectiveness
11807,NCT03340558,Change in CD8 T cell immune infiltrates,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
11808,NCT02021110,Effect of UDCA on total liver volume,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Adverse events as a measure of tolerability and safety of UDCA,Effect of UDCA on absolute total kidney volume
11809,NCT01743469,"Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).",2012-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further Cancer-related Treatment During Follow-up Period (All Cohorts).
11810,NCT01423708,Everolimus monotherapy,2010-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
11811,NCT05233787,Quality of life over the 12 months after surgery,2022-03-24,RECRUITING,INTERVENTIONAL,['NA'],,Changes in microbiome composition and diversity from baseline to 1 month
11812,NCT03863236,Postoperative complications,2019-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Hospital stay
11813,NCT06172049,Survival,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11814,NCT04866108,Objective Response Rate (ORR),2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL)
11815,NCT00557102,Tumor response rate,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tolerability
11816,NCT05731336,"Overall Survival, OS",2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,"Adverse events, AEs"
11817,NCT02454647,R0 resection rate,2013-09,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events are assessed according to CTC criteria v 4.0
11818,NCT00577902,"To study baseline antioxidant capacity (ORAC), selected biomarkers of nutritional status and nutritional risk of patients beginning therapy for head and neck cancers.",2005-06,COMPLETED,OBSERVATIONAL,['NA'],,"To assess antioxidant capacity, nutritional biomarkers and nutritional risk of patients during and after concurrent radiation and chemotherapy."
11819,NCT02584556,recurrence free survival,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time of tumor distant metastasis
11820,NCT05714475,Disease free survival,2023-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Disease free survival (12)
11821,NCT02901301,The overall response rate using RECIST 1.1,2017-02-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to response
11822,NCT02301143,Kaplan-Meier Estimates for Time to Treatment Failure (TTF),2015-04-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Participants With Treatment Emergent Adverse Events (TEAEs)
11823,NCT05835778,Incidence of ADRs,2023-06-07,RECRUITING,OBSERVATIONAL,['NA'],,
11824,NCT04907591,"Change of body composition (weight, kg)",2021-05-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,"Muscle mass (lumbar 2,㎠)"
11825,NCT00411151,Objective Response Rate (ORR),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and Tolerability: Adverse Events in ≥10% of Patients
11826,NCT00932724,Tumor assessment by using CT scans and/or MRIs,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Assessment of survival by ""physical exam"""
11827,NCT03443661,pCR,2016-02-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
11828,NCT03291288,Overall Summary of Treatment-emergent Adverse Events,2018-02-26,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic Analysis: Metabolite to Parent Ratio (MPR) for Midazolam
11829,NCT00447746,5 year overall survival,2007-03,UNKNOWN,INTERVENTIONAL,['NA'],,: Postoperative morbidity and mortality rates
11830,NCT00003912,Resection rate,1998-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,
11831,NCT06083974,OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.
11832,NCT04982939,Pathological complete response (pCR) rate,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
11833,NCT03699761,Grade III-IV complications,2020-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Treatment cost
11834,NCT05170282,The diagnostic accuracy of infantile liver tumors with deep learning algorithm,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,The diagnostic negative predictive value of infantile liver tumors with deep learning algorithm
11835,NCT00422864,Tolerability rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Distant response rate
11836,NCT04561791,Prevalence of Barrett's esophagus within the single Primary Care Practice cohort.,2019-01-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11837,NCT05277766,Maximally tolerated dose (MTD) of Nal-IRI,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE1'],Exploratory outcome: Expression of human carboxylesterase 2 (hCE2),Overall treatment response
11838,NCT05849480,Phase II: Overall response rate (ORR),2024-04-07,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,5-year overall survival
11839,NCT06126575,AUC from time zero to infinity (AUC0-∞),2024-01-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11840,NCT03513198,Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Tumor response to treatment
11841,NCT00906373,Progression Free Survival (PFS),2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Participants With Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)
11842,NCT02226224,the consistency between EUS and pathologic determination of tumor depth,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,
11843,NCT04198025,Number of post operative complications (Clavien-Dindo grade 3-4) during inpatient hospital stay.,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Post operative complications beyond hospital discharge.
11844,NCT00516841,Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria.,2007-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11845,NCT00089401,Duration of response,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
11846,NCT02964260,Overall survival,2016-05,UNKNOWN,INTERVENTIONAL,['NA'],,Times of interventional procedures
11847,NCT05779553,Tumor endothelial marker 1 in colorectal cancer,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11848,NCT02070146,Progression free survival,2013-05,RECRUITING,OBSERVATIONAL,['NA'],,Work Ability Index (WAI)
11849,NCT04460066,major pathologic response rate,2020-11-18,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,adverse events rate
11850,NCT01304160,Number of participants with adverse events,2010-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
11851,NCT04699487,Percentage of patients with at least one OM grade >2 at any time during radiotherapy.,2021-05-10,COMPLETED,INTERVENTIONAL,['NA'],"For each neck dermatitis lesion: date of onset, location and CTCAE v5 grade",Evolution of body weight over time
11852,NCT03080701,CRC Screening Within 6 Months Following Randomization,2017-03-23,COMPLETED,INTERVENTIONAL,['NA'],,
11853,NCT04069975,Detection rate of precancerous lesions and cancer of upper digestive system improvement,2019-06-02,UNKNOWN,OBSERVATIONAL,['NA'],,
11854,NCT01042743,surgical quality based on pathological examination,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,complication
11855,NCT02791503,Overall survival,2016-05-30,COMPLETED,INTERVENTIONAL,['NA'],,Tumor marker CA 19.9
11856,NCT03979547,Acceptability-scientifically adequate,2019-01-03,TERMINATED,INTERVENTIONAL,['NA'],,visceral adipose tissue (VAT)
11857,NCT02248805,Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule,2014-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Describe any evidence of anti-tumor activity
11858,NCT01570582,24month progression free survival,2010-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity Profile
11859,NCT03913962,Maximal lipid oxidation rate during submaximal incremental exercise,2019-05-02,RECRUITING,INTERVENTIONAL,['NA'],,Blood sample calprotectin
11860,NCT03473925,Number of Participants Who Discontinue Study Treatment Due to an AE,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Navarixin Trough Plasma Concentration (Ctrough)
11861,NCT02626091,Correlation between the perfusion evaluated by the ICG fluorescence-based enhanced reality and the metabolic state of the intestine,2016-09-14,COMPLETED,INTERVENTIONAL,['NA'],,Distance between the resection site based on the surgeon's appreciation and the resection site based on the digital analysis and the peri-operative samplings
11862,NCT04859400,QoL,2021-06-07,RECRUITING,INTERVENTIONAL,['NA'],,Success of recruitment rate in comparison to former studies
11863,NCT05079503,Immune modulation in tissue,2021-12-15,UNKNOWN,INTERVENTIONAL,['NA'],,Identify predictive biomarkers for pathologic responders
11864,NCT02718859,Relief degree,2016-03-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
11865,NCT01175447,Maximum tolerated dose (MTD) of s-1 in combination with thoracic radiotherapy in elderly patients (> 70 years old) with esophageal Cancer,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Objective response rate (e.g. complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD])."
11866,NCT04893252,Objective response rate,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
11867,NCT06321055,Time to Next Therapy (TTNT) therapy after regorafenib,2024-03-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of patients with evidence of surgery on or after the index date during the follow-up period using Current Procedural Terminology (CPT) codes and International Classification of Disease 9/10 Procedure codes (ICD-PC).
11868,NCT05571956,simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts,2020-07-01,RECRUITING,INTERVENTIONAL,['NA'],,
11869,NCT03736824,Correlation of endoscopic findings and symptoms,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,The infection rate of Helicobacter Pylori
11870,NCT04660760,Progression-free survival,2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
11871,NCT05880667,To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,
11872,NCT00088660,,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11873,NCT01732783,Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay,2012-12-10,COMPLETED,OBSERVATIONAL,['NA'],,Type of Post-Panitumumab Anti-cancer Treatment
11874,NCT00232453,Assess acute toxicity and complete remission rate of combined preoperative radiation and chemotherapy,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11875,NCT03506529,CT scan with measurement,2018-09-17,COMPLETED,OBSERVATIONAL,['NA'],,
11876,NCT00156975,Disease free survival,2004-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Secondary outcomes:overall survival,acute- and longtime toxicity of chemotherapy, molecular predictive markers for the risk of relapse and toxicity"
11877,NCT04937673,biomarkers related to pCR,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
11878,NCT03027427,Clinical and laboratory evaluation and molecular profiling of tumor tissue,2017-02-01,RECRUITING,OBSERVATIONAL,['NA'],,
11879,NCT02090153,Overall Response Rate (ORR),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
11880,NCT03505229,freedom of local failure,2018-12-18,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of Using Kilovoltage Intra-fraction Monitoring (KIM) to determine pancreas motion
11881,NCT01335945,Abdominal pain reduction following cryoablation of the celiac plexus,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Safety assessment
11882,NCT00352131,Maximum tolerated dose,2005-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Antitumor activity
11883,NCT00433550,Confirmed Tumor Response Rate (Proportion of Participants With Complete Response),2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
11884,NCT05189171,MOS generation,2022-10-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
11885,NCT01525940,To evaluate the completeness of colonic exploration in patients with a previous incomplete conventional colonoscopy due to technical failure (not due to inadequate cleansing level).,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,To evaluate the difference in terms of accuracy and completeness between PCCE and CT-colonography
11886,NCT05039177,Adverse Events,2021-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Response (DOR)
11887,NCT03042780,Objective Radiographic Response Rate (ORR),2017-02-01,TERMINATED,INTERVENTIONAL,['PHASE2'],Treatment Related Morbidity,Progression Free Survival (PFS)
11888,NCT00514228,Progression-free survival,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Serum alpha fetoprotein level
11889,NCT01830582,determine the best MR imaging schedule,2013-04-09,COMPLETED,INTERVENTIONAL,['NA'],,Determine if the best imaging schedule for DCE is the same as for DWI
11890,NCT02405416,Normalized transection-related blood loss,2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative mortality
11891,NCT03509298,Objective response rate,2018-04-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
11892,NCT02448173,Disease-Free Survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Recurrence-Free Interval
11893,NCT03553004,Objective Response Rate (ORR),2019-01-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with adverse events (AEs)
11894,NCT04566614,PREVAIL ctDNA Part 2 Study,2020-06-18,RECRUITING,OBSERVATIONAL,['NA'],,PREVAIL ctDNA Part 2 Study secondary end point 6d
11895,NCT03837782,overall survival,2019-02-15,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,
11896,NCT04280666,"sensitivity, specificity, positive predictive value, and negative predictive value",2019-06-20,UNKNOWN,OBSERVATIONAL,['NA'],,Characteristics of the gene map and the correlations with clinical characteristics
11897,NCT00385021,The primary objective is to determine if the rate of adverse events among patients receiving chronoFOLFOX plus Avastin is acceptable compared to that in previous studies using the FOLFOX4 regimen.,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
11898,NCT00036959,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11899,NCT01055743,To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
11900,NCT03082053,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) or Recommended Phase II Dose (RP2D) in Phase I setting.,2017-01-31,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Elimination half-life of Phase β (t1/2β)"
11901,NCT04920032,Percentage of ctDNA positivity in treatment cohort after 6 cycles or at least 3 months of adjuvant treatment,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of Grade 3-5 Adverse Events
11902,NCT03712774,Quality of life,2018-10-12,RECRUITING,OBSERVATIONAL,['NA'],,late toxicity
11903,NCT00875147,Overall complications,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,"specific complications such as liver insufficiency, length of hospital stay"
11904,NCT04103398,Overall Survival,2019-10-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Scoring of Quality of Life
11905,NCT02305043,Percentage of Participants With Objective Response,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
11906,NCT05179889,Disease free survival (DFS),2021-07-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Incidence of treatment-related adverse events
11907,NCT06206603,Traceability of microRNA/mRNA expression of polyps and cancer in blood,2024-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of Intestinal microbiota and microRNA/mRNA expression
11908,NCT01280825,Feasibility of incorporating pharmacogenomic testing into routine medical care,2011-01-14,RECRUITING,OBSERVATIONAL,['NA'],To determine whether access to pharmacogenomic information improves satisfaction with care.,Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting
11909,NCT00820053,Overall survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to recurrence
11910,NCT06202014,ORR,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of grade 3 and above adverse events
11911,NCT01092481,disease-free survival,2010-01-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,safety profiles
11912,NCT03565354,Preoperative change in serum ferritin (mcg/L),2018-07-01,COMPLETED,INTERVENTIONAL,['PHASE3'],Median waiting time to surgery (days),Days (alive and) at home within 30 days of surgery (DAH30)
11913,NCT05914610,Surgical conversion rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life (QOL)
11914,NCT00825240,Colorectal Cancer Patients' Concerns + Behavior Changes Post Treatment,2008-12,COMPLETED,OBSERVATIONAL,['NA'],,
11915,NCT04720430,"Incidence of ""Wait List Drop Off""",2019-12-03,COMPLETED,OBSERVATIONAL,['NA'],,Clinical Status of the subset of patients successfully reaching liver transplant
11916,NCT05101889,Severe oral mucositis graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 criteria,2013-01-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival (OS)
11917,NCT00253617,,na,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,
11918,NCT05514171,Disease free survival,2023-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
11919,NCT03508570,Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab,2018-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
11920,NCT02424279,Change from baseline pain intensity at 1 year (BPI questionnaires),2014-09,UNKNOWN,INTERVENTIONAL,['NA'],,"Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)"
11921,NCT03278444,Overall Survival,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score
11922,NCT04831528,Objective response rate,2021-04-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,duration of response
11923,NCT01340755,Adequacy of the total mesorectal excision based on standard guidelines on pathologic evaluation of TME specimens.,2011-03,COMPLETED,INTERVENTIONAL,['NA'],,Oncologic outcomes in subjects receiving transanal endoscopic rectosigmoid resection
11924,NCT00578201,"objective response rate (ORR) at 12 weeks with radiochemotherapy (first evaluation), and if applicable, within 2 to 4 weeks following the end of additional treatment with the combination Cetuximab-FOLFOX (second evaluation)",2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival Quality of life Dysphagia score Overall survival toxicity of this regimen
11925,NCT00922688,"The effect of intravenously and enterally administered dipeptide alanyl-glutamine preoperatively on postoperative insulin resistance in colon cancer patients.given, on postoperative insulin resistance in colon cancer patients.",2010-12,UNKNOWN,INTERVENTIONAL,['NA'],,The effect of dipeptide alanyl-glutamine on key enzymes involved in glucose production.
11926,NCT02008383,Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer
11927,NCT01676922,Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice,2011-08,COMPLETED,OBSERVATIONAL,['NA'],,Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment
11928,NCT04227951,30 day reoperation AND/OR additional drain placement,2019-12-17,COMPLETED,INTERVENTIONAL,['NA'],,Drain related complications
11929,NCT00002893,,1995-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
11930,NCT03847753,Risk of Cancers,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
11931,NCT00661882,"Development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure as a repository for socio-demographic, environmental, clinical, and family history data",2003-02,COMPLETED,OBSERVATIONAL,['NA'],,
11932,NCT00464295,To evaluate response rate and overall survival after completing minimum of three cycles of Capecitabine in Advance HCC,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the time to progression, toxicity and quality of life for patients on chemotherapy"
11933,NCT00429858,Correlate Intratumoral Expression Level of Ribonucleotide Reductase Subunit 1 (RRM1) With Response to Gemcitabine in Patients With Advanced Pancreatic Cancer.,2007-01-22,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percentage of Patients With at Biomarker Response
11934,NCT01481545,Percentage of Patients With Complete Tumor Regression Rate (TRG1),2006-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients With Metastatic Lymphnodes at Pathology Exam After Surgery
11935,NCT02504411,Complete adenoma resection rate (CARE) for adenoma > 10 mm in diameter as determined by Colonoscopy,2015-08,WITHDRAWN,INTERVENTIONAL,['NA'],,Cecal Intubation Rate (CIR)
11936,NCT06317272,Reproducibility DIBH,2021-02-10,TERMINATED,INTERVENTIONAL,['NA'],,
11937,NCT01801852,Occurrence of study related adverse events,2013-01,UNKNOWN,INTERVENTIONAL,['NA'],,Anti-tumor responses to NKT cells infusions
11938,NCT05039333,Complication rate,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,
11939,NCT04246970,Progression in the activities of daily life (ADL),2021-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Change in Quality of life
11940,NCT00005638,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
11941,NCT02675946,Number of participants with adverse events and/or abnormal laboratory values that are related to treatment,2016-02,UNKNOWN,INTERVENTIONAL,['PHASE1'],,CGX1321 half-life
11942,NCT02429622,Disease-free survival (DFS),2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Adverse events,Overall survival (OS)
11943,NCT05887661,The proportion of allogeneic red blood cell products transfusion,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Number of Participants with postoperative complications (overall)
11944,NCT01841294,Dosage of NKs activity after surgery,2012-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Major adverses events
11945,NCT03858712,ePRO Oral Response Rate,2019-03-13,COMPLETED,INTERVENTIONAL,['NA'],,ePRO oral ease of use
11946,NCT04562428,FACT-G,2020-11-20,UNKNOWN,INTERVENTIONAL,['PHASE4'],,pulse diagnosis
11947,NCT00396487,Response according to RECIST criteria.,2006-11,TERMINATED,INTERVENTIONAL,['PHASE3'],,Toxicity
11948,NCT04228601,Objective Response Rate,2020-01-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to maximum concentration (Tmax)
11949,NCT05730673,"Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)) in subjects with CCR5+ mCRC treated with Leronlimab (PRO 140) and Regorafenib.",2022-09-20,WITHDRAWN,INTERVENTIONAL,['PHASE2'],"Measure serum level of CCL2, CCL3, CCL4 and CCL5 and correlate with therapeutic benefit (PFS) in patient with mCRC.",The change from baseline in circulating tumor cells (CTC) in the peripheral blood.
11950,NCT04803994,Time to failure of treatment strategy,2021-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],Exploratory endpoint - PD-L1 expression,QoL (EORTC QLQ-C30 and HCC18 sub-questionnaire)
11951,NCT00001823,Results of screening tests,1999-07-11,RECRUITING,OBSERVATIONAL,['NA'],,
11952,NCT03439891,Overall response rate (ORR) (Part 2),2018-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with Child Pugh B Liver Function reporting immune-related adverse event (irAE)
11953,NCT05678257,Number of patients achieving progress-free survival (PFS),2023-04-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of patients reporting treatment-emergent adverse events (TEAEs)
11954,NCT00254267,The objective response rate as assessed by modified RECIST,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Duration of response, progression-free survival, time to response, overall survival, PK and safety profile"
11955,NCT00324415,Local Failure Rate at 3 Years,2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate (Complete and Partial)
11956,NCT02120885,QoL(quality of life),2014-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,nutrition condition
11957,NCT02956876,Number of side effects of chemotherapy for WHO grade greater than 2,2016-12-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of provisional chemotherapy orders
11958,NCT03218423,Detection of colorectal cancer,2017-08-18,UNKNOWN,OBSERVATIONAL,['NA'],,Assay Failure Rate
11959,NCT05927857,To evaluate disease objective response rate (ORR),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,•To study the blood biomarkers
11960,NCT03778957,Progression Free Survival (PFS) for Arm B vs Arm C,2018-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Pharmacokinetics (PK) of Durvalumab and Bevacizumab as determined by peak serum concentrations,Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)
11961,NCT02971631,Nadir Blood Glucose,2017-08-10,COMPLETED,INTERVENTIONAL,['NA'],,Total Meal Consumption
11962,NCT06282575,Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"TDD for all participants in patient-reported symptoms scores as measured by the EORTC QLQ-BIL21 (Pain, Jaundice, Abdominal Pain, and Pruritis)"
11963,NCT01651026,"list of diagnostic procedures used in clinical practice, according to participating Institute",2011-01,RECRUITING,OBSERVATIONAL,['NA'],predictive factors for response to treatment,
11964,NCT03781778,Feasibility: Retention,2019-05-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Variability in Gut Microbial Communities From Human Stool Samples -- BETA DIVERSITY
11965,NCT04305730,Rate of return of bowel function,2021-03,UNKNOWN,INTERVENTIONAL,['NA'],,Length of time under general anesthesia
11966,NCT03011268,Proportion of patients in sustained clinical remission,2017-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events and serious adverse events frequency and severity
11967,NCT01972919,Overall Survival,2015-12-10,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Efficacy of dose escalation
11968,NCT03776487,Incidence of adverse events,2019-01-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease-free survival
11969,NCT01648504,Completion rate of colonoscopy procedure,2012-06,COMPLETED,INTERVENTIONAL,['NA'],Feasibility of intervention in practice,Patient satisfaction
11970,NCT05045911,The technical success rate,2021-09-20,UNKNOWN,INTERVENTIONAL,['NA'],,Clips used post-ESD
11971,NCT05606523,Body weight changes in mice after fecal material transplantation.,2022-08-01,RECRUITING,OBSERVATIONAL,['NA'],,GALT function and systemic inflammation
11972,NCT02311595,Compliance rate (Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
11973,NCT03807687,Overall survival,2016-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative morbidity
11974,NCT01983878,Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks),2013-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,PK: Area Under the Curve Time Zero to Infinity (AUC[0-∞]) of Ramucirumab
11975,NCT01478685,Number of participants with adverse events,2011-11-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of Response
11976,NCT05655949,Incidence of Grade 3 or Higher Treatment-Related Toxicity,2024-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate (DCR)
11977,NCT03838029,Biomarkers in blood samples,2019-11-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Fatigue
11978,NCT00584363,To diagnose Pancreatic Cancer,2004-06,COMPLETED,OBSERVATIONAL,['NA'],,Preventing patient form being misdiagnosed
11979,NCT02935309,Maximum Tolerated Dose (MTD),2016-10-14,COMPLETED,INTERVENTIONAL,['PHASE1'],Radiosensitivity Index (RSI),Occurrence of Treatment Related Adverse Events
11980,NCT02977702,overall survival,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,
11981,NCT04442984,Progression-Free Survival,2019-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment associated toxicities
11982,NCT00032123,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
11983,NCT06192030,Peritoneal-free survival,2022-08-27,RECRUITING,OBSERVATIONAL,['NA'],,Rates of key gene mutation
11984,NCT06179459,Treatment outcomes in patients undergoing endoscopic treatment of pancreatic fluid collections.,2021-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Timing of intervention
11985,NCT01273051,Response,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,The number of sphincter saving procedures
11986,NCT01463605,Safety of Nimotuzumab combined with Radiotherapy for older patients,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy of Nimotuzumab combined with Radiotherapy for older esophageal cancer patients
11987,NCT06021015,Disease control rate (DCR) of target lesions 1 month after the last TACE treatment,2023-09-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Equipment performance evaluation
11988,NCT03281369,For Arm 1L-A : Percentage of Participants with Serious and Non-serious Treatment-related AEs,2017-10-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With ADA to BL-8040
11989,NCT00901901,Overall Survival,2009-05-21,COMPLETED,INTERVENTIONAL,['PHASE3'],Tumor Response,Health-related Quality of Life and Utility Values as Measured by EQ-5D - VAS
11990,NCT02354560,Evaluation of changes in size of desmoid tumors,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,
11991,NCT01398306,"Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.",2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.
11992,NCT01997957,Time to progression(TTP),2013-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Number of Participants with Serious and Non-Serious Adverse Events
11993,NCT05564403,Overall survival (OS),2024-02-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Detection of mutations as well as prediction of outcomes,Incidence of adverse events
11994,NCT06068257,"To Identify and test thresholds, specificity and sensitivity for FGF19, (and associated markers) for detection in human blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls.",2023-06-06,RECRUITING,OBSERVATIONAL,['NA'],,
11995,NCT01972451,Procedure time and withdrawal time,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],Colonoscopy procedure completeness,Number of people attending the screening
11996,NCT00777504,"Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan",2008-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Effect on Quality of life as record by questionaires
11997,NCT05482451,Overall response,2021-03-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],Overall survival,Progression-free survival
11998,NCT06089330,Incidence and severity of adverse events (AE) and serious adverse events (SAE),2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
11999,NCT00630786,Number of Participants With an Objective Response,2008-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher
12000,NCT03976284,Stool weight,2019-03-17,UNKNOWN,INTERVENTIONAL,['NA'],,Sugary beverage intake
12001,NCT04767750,"Measurement of the gene expression levels of LncRNA H19 & IGF-1R mRNA, normalized to the housekeeping gene GAPDH expression level, in HCC and T2DM in comparison with healthy controls using Real-Time Quantitative PCR (by the 2^-ΔΔCT method).",2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12002,NCT04632459,Objective Response Rate (ORR),2021-06-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Best Overall Response Rate (ORR)
12003,NCT05009979,Positive predictive value,2023-01-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Change in 18F-DCFPyL PET/CT uptake between pre- and post-treatment
12004,NCT05095467,"3-year Overall Survival, OS",2021-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,NCI CTC Adverse Events Version 4.0
12005,NCT04393220,OS,2020-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12006,NCT04977401,Increase the dissection speed of the ESD procedure,2021-09-21,TERMINATED,INTERVENTIONAL,['NA'],Adverse events,Total procedure duration
12007,NCT00820157,the overall survival rate of each group,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,the disease-free survival rate of each group
12008,NCT00372840,Number of sections of the Facing Forward manual read with satisfaction and comprehension,2006-05,COMPLETED,INTERVENTIONAL,['NA'],,Changes in psychological outcomes from baseline to 8-week follow-up
12009,NCT04367805,Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France,2020-04-27,RECRUITING,OBSERVATIONAL,['NA'],,
12010,NCT00459901,To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration
12011,NCT01996540,Quality of Life (QoL),2012-08,COMPLETED,INTERVENTIONAL,['NA'],,Overall survival (OS)
12012,NCT02430298,"Percentage of occurrence of mucositis level 3 or more by using the criteria of CTCAE version 4.0, World Health Organization scale and MTSscores",2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (FACT- H&N Version 4)
12013,NCT06254248,Rate of Acute cellular rejection (ACR) (defined by a Histological Banff score ≥ 5) at 6 months (confirmed by an external expert center),2024-05-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Donor Specific Antibodies (DSA) median
12014,NCT02662959,Overall Survival,2015-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
12015,NCT04901741,Go/no-go decision for a randomized expansion study,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Time-to-next-anticancer-treatment (TTNT)
12016,NCT01420588,Discrimination between Malignant and Benign Gastric Lesions with Na-nose,2011-08-01,COMPLETED,OBSERVATIONAL,['NA'],Proof seeking from metabolomics and transcriptomics,Geographical comparison of VOCs between China and Latvia
12017,NCT05996666,Performance of liver cancer early detection model based on selected cfDNA methylation markers using qPCR,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Comparison of currently used biomarkers for liver cancer detection
12018,NCT04276857,1 year progression free survival rate of patients with locally advanced pancreatic cancer who are treated with IRE and combination chemotherapy.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Prognostic bio-markers
12019,NCT00225290,overall survival,2003-02,TERMINATED,INTERVENTIONAL,['PHASE3'],,
12020,NCT00242190,Occurrence of dose limiting toxicity up to three weeks following the second cycle of chemotherapy.,2004-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Characterize pattern of responses, progression free survival, and survival after treatment"
12021,NCT03426371,Progression Free Survival (PFS) Time,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,quality of life score
12022,NCT03167268,Skin toxicity reduction,2016-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12023,NCT01412294,Progression-free survival,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
12024,NCT00289003,"To assess actual grade of mucositis upon completion of radiotherapy or chemoradiotherapy and after prophylactic treatment with soluble beta-1,3/1,6-glucan or placebo.",2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess the safety of the investigational product
12025,NCT04339374,Area under the receiver operating curve (ROC),2017-07-19,RECRUITING,OBSERVATIONAL,['NA'],,Performance characteristics of the novel endorectal ultrasound probe as measured by variability in image production
12026,NCT03225781,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],2017-07-01,TERMINATED,INTERVENTIONAL,['NA'],,Immunomonitoring
12027,NCT01802684,Progression free survival at 6 months,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Curative salvage surgery
12028,NCT00556023,Dose Limiting Toxicities: assessed through adverse event data collected weekly,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival:
12029,NCT05939661,Pathological complete response (pCR),2023-05-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,
12030,NCT05584137,Objective Response Rate (ORR) per RECIST 1.1 as Assessed by Investigator (the second stage),2023-06-15,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR) per RECIST 1.1 assessed by Investigator
12031,NCT01474187,toxicity,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,pathological complete response (pCR)
12032,NCT03959800,Tumor infiltrating cells which express immune checkpoints,2015-06-22,RECRUITING,OBSERVATIONAL,['NA'],,Response to chemotherapy
12033,NCT00583934,"Early detection of esophageal cancer or dysplasia in patients without symptoms, after treating their primary cancer, may improve their chances of being cured of a secondary disease.",2007-09,COMPLETED,OBSERVATIONAL,['NA'],,
12034,NCT00606398,two-year disease free survival (DFS),2007-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival rate (OS), patterns of treatment failure, treatment efficacy (R0 resection rate), peri-operative morbidity and mortality rates, health related quality of life, hospital length of stay"
12035,NCT02150408,"interest of the realization of 68Ga-DOTATATE PET-CT in the detection of tumor sites in TNE diagnosis, staging and restaging",2014-04-22,COMPLETED,INTERVENTIONAL,['NA'],"therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT","therapeutic impact of 68Ga-DOTATATE PET-CT in addition to reference imaging (SRS, CT, MRI): we will document the rate of changes in treatment options induced by PET-CT"
12036,NCT01540968,Quality of life,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,
12037,NCT05085548,Determine Recommended Phase 2 Dose (RP2D),2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Assess serum tumor marker CA19-9 or appropriate tumor specific marker.
12038,NCT01531452,Progression Free Survival,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of participants with adverse events
12039,NCT03058926,"Protocol and Regulatory Compliance for Consortium Studies for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)",2017-01-19,UNKNOWN,OBSERVATIONAL,['NA'],,
12040,NCT04707547,Analysis of the number of CD8+ T,2019-10-16,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12041,NCT00582062,The primary objective of this pilot trial is to investigate the ability of quantitative RT-PCR to detect cancer cells in peritoneal washings of patients undergoing laparoscopy for gastric or pancreatic cancer.,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary objective of this pilot study is to estimate the sensitivity, specificity, false positive, and false negative rate of peritoneal cancer cell detection by quantitative RT-PCR."
12042,NCT01280643,"Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects",2010-03,TERMINATED,INTERVENTIONAL,['NA'],,Progression-free Survival
12043,NCT03634202,"maximum tolerated radiation dose (MTD) delivered by IMRT with SIB, in combination with oral capecitabine, for initially metastatic, low and middle rectal cancer after 4 induction cycles of mFolfox6 regimen.",2015-05-05,TERMINATED,INTERVENTIONAL,['NA'],,The prognostic value of PET
12044,NCT00520013,Consolidation Treatment-related Toxicity Rate,2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Consolidation Objective Response Rate
12045,NCT01882218,Morbidity,2012-09,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Cytokine levels
12046,NCT03395847,Objective response rate (ORR),2018-02-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of adverse events
12047,NCT02967107,Number of participants with residual or recurrent adenoma as assessed at surveillance endoscopy,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of participants with pain after EMR as assessed by VAS score and telephone interview at 2 weeks
12048,NCT04274972,Microbiome evaluation,2020-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Microbiome long-term evaluation
12049,NCT04593277,Proportion of HCA-cancer surveillance (SM),2022-10-23,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of healthcare adherence (HCA)-all
12050,NCT05788744,Sub-study 2 eccDNA,2023-01-01,RECRUITING,INTERVENTIONAL,['NA'],,
12051,NCT06253897,Qualitative interview: patients' injection experiences and satisfaction with the Ipsen lanreotide syringe and with the Pharmathen lanreotide syringe;,2024-03-26,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Qualitative interview: experiences that are unique to patients between disease indications
12052,NCT01447199,Time to Onset for Colorectal Cancer,1994-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12053,NCT01628328,Changes of circulating tumor cell level before and after colonic stenting for patients with obstructive colorectal cancer,2010-07,COMPLETED,OBSERVATIONAL,['NA'],,
12054,NCT06256328,Progression-free survival (PFS) (site investigator assessment),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AE)
12055,NCT00040898,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12056,NCT02727179,Overall survival,2005-02,COMPLETED,INTERVENTIONAL,['NA'],,Morbidity
12057,NCT05494866,occurrence of DLTs,2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE1'],,
12058,NCT00608361,Pharmacokinetic parameters of dasatinib,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Liver dysfunction data,
12059,NCT03602092,To establish the database for GIST,2018-10-16,RECRUITING,OBSERVATIONAL,['NA'],,
12060,NCT01855854,Objective response rates,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12061,NCT00103545,The primary endpoint is drop-out due to toxicity as the overall measure of feasibility,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration and strength of the immune response induced by ACA 125 vaccination
12062,NCT00003950,Reduction in occurrences of severe diarrhea due to CPT-11 administration,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12063,NCT02135887,"The primary endpoint is the incidence of grade 4 neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.",2013-11-04,UNKNOWN,OBSERVATIONAL,['NA'],,Increase in Body Weight
12064,NCT03582618,Objective Response Rate (ORR),2018-07-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacodynamics analysis for the relationship of AUC and Adverse Event (AE)
12065,NCT03256201,Adherence,2016-02-01,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of Symptoms
12066,NCT03798132,peritoneal carcinomatosis,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,surgical decision making.
12067,NCT02402972,disease-free survival,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3'],,adverse events of Chemotherapy and IPC
12068,NCT04283994,EHR documentation of Goals of Care discussions,2021-07-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Key Implementation Factors,Goal concordance
12069,NCT00785889,Increments of medications used for sedation,2008-03,COMPLETED,INTERVENTIONAL,['NA'],,willingness to repeat colonoscopy
12070,NCT00344552,Safety,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression (TTP)
12071,NCT02489422,Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS),2016-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants With Successful Qualitative Data Collection
12072,NCT05108753,incidence of anastomotic leakage,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,incidence of positivecircumferential resection margin
12073,NCT06118437,Overall detection rate of gastrointestinal cancer,2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12074,NCT04920422,Percentage of patients that follow each dosing patterns during first two cycles of treatment,2021-07-15,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of patients that start cycle 3 based on dosing patterns.
12075,NCT04179305,Change in Prognostic Understanding,2020-10-25,COMPLETED,INTERVENTIONAL,['NA'],,Patient Performance Status
12076,NCT02115542,Overall Survival (OS) at 6 Months,2014-06-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
12077,NCT05396300,Obtain the maximum tolerated dose of CEA-CAR-T cells[Safety and Tolerability],2022-05-25,RECRUITING,INTERVENTIONAL,['PHASE1'],Changes in the number of tumor-infiltrating immune cells of CEA- CAR-T treatment in patients with CEA-positive,Pharmacodynamics of CEA-CAR-T cells[Cell dynamics]
12078,NCT03970616,Incidence of Treatment Emergent Adverse Events (TEAEs),2019-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Survival (OS)
12079,NCT04503902,Objective response rate（ORR） as determined by the Invertigator using RECIST V1.1,2020-10-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
12080,NCT01447667,Number of patients who experienced HCC recurrence after RFA,2011-10,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and specificity of each indicator of hepatic fibrosis compared to the gold-standard histology score
12081,NCT01964001,Antioxidant capacity,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Inflammation markers
12082,NCT03774134,Risk of recurrence,2008-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,Mesocolic lymph nodes yield
12083,NCT03608540,Incidence of all Adverse Device Effects,2018-07-09,TERMINATED,INTERVENTIONAL,['NA'],,R0 resection
12084,NCT01365169,ECOG Performance Status,2011-05-25,RECRUITING,INTERVENTIONAL,['NA'],,"CYCORE Data availability for clinicians and researchers in order to be able to daily monitor patients using home-based health monitor devices (e.g. Fitbit, Actigraph, CO monitor, weight scales)."
12085,NCT04595747,Objective radiographic response,2021-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Banking of tumor material, germline deoxyribonucleic acid, and peripheral blood",Incidence of adverse events
12086,NCT01640444,progression free survival (PFS),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)"
12087,NCT00202787,Determine confirmed objective response rate,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes"
12088,NCT00373906,to induce objective/histologic responses in patients with MALT-Lymphoma,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,to evaluate the impact of bortezomib on progression free survival
12089,NCT05087992,Phase 1b: Number of patients with DLTs during the MTD evaluation period assessed in the first 6 patients,2021-11-24,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase 1b: AUC0-t2: Area under the concentration-time curve of BI 9057 after multiple cycles
12090,NCT03044977,absolute neutrophil count decreased,2017-05-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival (OS)
12091,NCT05334251,sPO2,2022-04,UNKNOWN,OBSERVATIONAL,['NA'],,
12092,NCT01682031,Incidence of >= Grade 3 Mucositis,2009-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Plasma Cisplatin and Selenium PK and PD Markers (NZ Only)
12093,NCT05489419,Efficacy of a multimodal prehabilitation,2021-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of complications severity
12094,NCT02074124,Change in arterial flow during adenosine vasodilation test (CT perfusion parameter),2012-10,COMPLETED,OBSERVATIONAL,['NA'],,Change in Permeability (CT perfusion parameter) during adenosine vasodilation test.
12095,NCT01286064,Colorectal cancer detection by means of optical fluoroscopy,2010-10,UNKNOWN,INTERVENTIONAL,['NA'],,
12096,NCT03155542,colorectal cancer diagnosis,2016-12,COMPLETED,OBSERVATIONAL,['NA'],,
12097,NCT02041065,Peroperative bloodloss,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Hospital stay in days
12098,NCT04729205,Evaluate Disease Control Rate,2021-01-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Plasma MLP level after Promitil infusion
12099,NCT05150691,Phase 2: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.,2022-01-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2 Cohort b only: Overall Survival
12100,NCT00019773,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12101,NCT05836584,Event-free survival (EFS),2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,Circulating tumor-derived deoxyribonucleic acid (ctDNA)
12102,NCT06265272,Assessment of LI-RADS with Ga-PSMA-PET/MRI,2023-12-10,RECRUITING,OBSERVATIONAL,['NA'],,PET/MR protocol in liver cirrhosis
12103,NCT02967770,4 month progression free survival rate,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Change in tumor marker levels
12104,NCT02834546,Adverse events related to Sorafenib needing a dose adjustment or a symptomatic medication,2017-07-25,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12105,NCT01272557,Time to progression (TTP) according to RECIST 1.1 criteria,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response"
12106,NCT00369109,Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent
12107,NCT02795988,Clinical efficacy of IMU-131 (Phase 2),2017-08-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory Outcome (Phase 2): Measurement of immunological and biochemical markers,Incidence of TEAE's (Phase 2)
12108,NCT06181656,Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination,2024-02-05,RECRUITING,OBSERVATIONAL,['NA'],,
12109,NCT00172757,,2002-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12110,NCT01051284,To demonstrate that radiation treatments can be reproduced as determined by evaluation of the prescription isodose curves,2009-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,The feasibility of measuring pancreatic cancer stem cell populations by analysis of fine needle aspirate specimens
12111,NCT06044506,Optimal treatment dosage,2022-08-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12112,NCT00138242,Reduction rate of myelosuppression,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to disease progression
12113,NCT02915432,Objective response rate (ORR) evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1),2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Correlation of the changes of TBNK lymphocytes subgroup in patients receiving chemotherapy combined with JS001 and its correlation with the anti-tumor activity,Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb
12114,NCT03350763,"Stent failure rate, and need for re-procedure before pancreaticoduodenectomy.",2017-11-18,WITHDRAWN,INTERVENTIONAL,['NA'],,"Other complications related to preoperative biliary decompression, and post-surgical complications"
12115,NCT05106244,Degree of satisfaction of patients and their families,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,
12116,NCT02038296,overall survival,2008-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12117,NCT00431925,,na,UNKNOWN,OBSERVATIONAL,['NA'],,
12118,NCT00312000,Overall survival,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity profile
12119,NCT00898482,Test new hypotheses as they emerge,2005-05,COMPLETED,OBSERVATIONAL,['NA'],,
12120,NCT01441388,Dose Limiting Toxicities (DLTs).,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor
12121,NCT02918162,Pathologic Complete Response (pCR) Rate,2017-11-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
12122,NCT01870817,Participant recruitment and retention rates,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Nutritional parameters
12123,NCT00841035,Epidermal Growth Factor Receptor Signaling(EGFR) in the Presence of Pancreatic Tumor Related to the Mechanism to Erlotinib.,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,The Secondary Objectives Include Analysis of Recurrence-free and Overall Survival and the Development of a Predictive Assay for Response to Erlotinib Based on Selected Bio-markers in Endoscopic Ultrasound-Fine-needle Aspiration Specimens.
12124,NCT01075113,Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).,2010-08-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Anti-tumor effects of the combination of sorafenib tosylate and vorinostat
12125,NCT01777477,Maximum tolerated dose (MTD) of orally administered Chloroquine with concomitant intravenous Gemcitabine.,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12126,NCT04224363,Image Quality,2020-01,UNKNOWN,INTERVENTIONAL,['NA'],,Tolerance
12127,NCT03126708,Progression free survival,2017-04-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
12128,NCT00101686,Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL,2003-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall Relative Dose Intensity of Irinotecan
12129,NCT05877001,Safety profiles by NCI-CTCAE version 5 .0,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression free survival (PFS)
12130,NCT04969874,patient attendance at monthly remote monitoring,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,felt swallowing
12131,NCT03168737,Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.03,2017-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12132,NCT04601428,HCC blood flow,2021-01-26,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Determine tumor response to intra-arterial infusion of CSR02-Fab-TF
12133,NCT02936193,Progression-free Survival,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,3 years overall survival
12134,NCT01424293,Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively.,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,
12135,NCT04434508,the number of lymph nodes (LNs) harvested among both groups,2017-07-01,COMPLETED,INTERVENTIONAL,['NA'],,post-operative complications
12136,NCT01670409,Toxicities,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete blood count
12137,NCT00671463,Pancreatic leak,2008-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Clinical outcomes
12138,NCT02085005,Progression Free Survival rate at 10 months (PFS@10m),2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
12139,NCT06091683,Safety of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC),2021-04-30,RECRUITING,INTERVENTIONAL,['NA'],,Peritoneal disease-free survival
12140,NCT03185429,Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.,2017-12,UNKNOWN,INTERVENTIONAL,['NA'],,Quality score of life improvement
12141,NCT04515394,Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators,2021-01-28,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab
12142,NCT03323489,Change in Pain level from baseline - as measured using BPI,2018-01-01,COMPLETED,INTERVENTIONAL,['NA'],,hand grip strength
12143,NCT03098108,local control rate at 3-year,2017-02-09,UNKNOWN,INTERVENTIONAL,['NA'],,Colonrectum Quality of life (QOL-CR) assessment
12144,NCT00591981,"Morbidity (Cardiac, pulmonary, infectous, etc.) and Mortality in Cohort",2007-08,COMPLETED,OBSERVATIONAL,['NA'],,
12145,NCT04623515,Urinary Dysfunction - International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS),2021-05-05,TERMINATED,OBSERVATIONAL,['NA'],,Short Form-12 Questionnaire - General Health and Well Being
12146,NCT01515748,"Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1",2011-12-30,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Shift of Laboratory Parameters (Creatinine Clearance [Chronic Kidney Disease]) From Baseline Grade to Worst NCI-CTCAE Grade >=3
12147,NCT04831944,Pharmacokinetics Parameter : AUC(0-t) of parsaclisib,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics Parameter : Vz/F of parsaclisib
12148,NCT03698825,Maximum Tolerated Dose (MTD),2018-08-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",pSMAD as a pharmacodynamic marker,pharmacokinetics of TEW-7197
12149,NCT06008288,Objective response rate (ORR) by independent central radiological review (IRC) according to RECIST 1.1.,2023-10-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events
12150,NCT00004233,Six month survival,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,evaluate quantitative and qualitative toxicities
12151,NCT02271464,progression-free survival (PFS),2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall toxicity rate
12152,NCT00137878,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12153,NCT06018142,Perfusion ratio,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
12154,NCT03258034,3 year OS,2017-08-24,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events
12155,NCT02997553,Non-inferiority of indocyanine green guided sentinel lymph node biopsy,2017-11-29,COMPLETED,INTERVENTIONAL,['PHASE3'],,fluorescence imaging
12156,NCT01952951,downstaging rate,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of life
12157,NCT03025152,Changes from baseline in total scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale),2016-11-11,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of withdrawn due to adverse events
12158,NCT04607590,The patient 6-minute walk test (6-MWT) over the 6-month follow up (6-MFU),2019-05-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Treatment efficacy,Patient and partner short form survey (SF-36) domains
12159,NCT01703650,Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,comparison of perfusion parameters among the pancreas tumors and parenchyma
12160,NCT03176082,Polypectomies,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,
12161,NCT02319304,Primary Outcome Measure (Overall Survival Rate),2015-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Secondary Outcome Measure (Number of Adverse Events)
12162,NCT04949256,Part 2 (Main Study): Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in all Participants,2021-07-28,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2 (Main Study): TTD in HRQoL Score Using EORTC QLQ-OES18
12163,NCT03269526,Overall survival,2017-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Examine tumor tissue for immune system cells, cytokines and proteins to estimate whether the type and number of immune cells correlates with clinical responses"
12164,NCT02413853,Progression free survival (PFS),2015-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Intratumoral gene expression of Wnt related biomarkers,Survivin mRNA expression levels
12165,NCT04324476,Progression Free Survival 1 (PFS 1),2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The occurrence of adverse reactions (AEs)
12166,NCT00569387,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,We will use overall survival and adverse events rates as secondary endpoints.
12167,NCT05269056,Area under curve of the model for detecting stage I/II gastric cancer,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Area under curve of the early detection model at sequencing depth downsampling
12168,NCT04755920,To determine the feasibility of SGM-101 for intraoperative imaging of colorectal brain metastases.,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12169,NCT04443478,The number of lower mediastinal lymph nodes retrieved,2020-08-01,RECRUITING,OBSERVATIONAL,['NA'],Number of patients that can be screened and successfully recruited,Overall survival in 3 years
12170,NCT01697917,Change in QOL (Quality of Life),2012-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Nutritional status of patients
12171,NCT01079533,Colorectal Cancer Screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,
12172,NCT02079363,Number of methylated genes for each participant.,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],Number of methylated genes in patients with chronic pancreatitis.,Number of methylated genes for each participant related to prognosis
12173,NCT01959269,Overall survival,2013-10-31,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of treatment emergent adverse events (TEAE)
12174,NCT02585271,Creation of stoma,2015-10-01,TERMINATED,INTERVENTIONAL,['NA'],,Overall survival
12175,NCT02628665,Partial remission rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The recent incidence of adverse reactions
12176,NCT04896073,disease control rate,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12177,NCT01232101,The primary aim of the present study was to compare and stent patency between covered and uncovered bileduct SEMS,2007-03,COMPLETED,INTERVENTIONAL,['NA'],,"Secondary objectives were to study difference in technical success, efficacy of drainage and complication rate between covered and uncovered metal stents"
12178,NCT02781012,Berg's Interrogative Biology® Platform,2016-03,UNKNOWN,OBSERVATIONAL,['NA'],,
12179,NCT04435197,Pathologic complete response,2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12180,NCT01862198,The stent patency rate,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Complication rate related to the hybrid stents
12181,NCT04809870,Long-term survival,2020-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Pulmonary complications
12182,NCT03087591,Incidence of adverse events Common Terminology Criteria for Adverse Events version 4.0,2017-04-28,COMPLETED,INTERVENTIONAL,['PHASE1'],,Survival as assessed by RECIST
12183,NCT02285660,Whole body 4D PET-CT for improved Target Definition/Delineation (feasibility and benefit) (ability to identify the cancer and ability to show areas within the cancer that are potentially more active allowing target of higher dose to these areas),2011-06,UNKNOWN,INTERVENTIONAL,['NA'],,
12184,NCT04561830,feasibility of procedure,2015-04,COMPLETED,INTERVENTIONAL,['NA'],,recurrence
12185,NCT04459468,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for overall survival in hepatocellular carcinoma patients,2022-11-04,RECRUITING,OBSERVATIONAL,['NA'],,Predictive accuracy of Proteomic biomarker(s) measured with bead-based X-aptamer library for Progression free survival in Hepatocellular carcinoma patients.
12186,NCT01157013,Response to sorafenib therapy shown in PET Scans,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response evaluated by CT and MRI
12187,NCT02277158,Maximum Tolerated Dose (MTD),2014-11,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Quality of Life
12188,NCT01988493,Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC),2014-01-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Disease Control Based on Tumor Assessment by Investigator According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
12189,NCT02481635,Type and the severity of side effects,2016-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression
12190,NCT00725400,Objective tumor response rate,2010-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Quality of life
12191,NCT01744509,Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps,2011-03,UNKNOWN,INTERVENTIONAL,['NA'],,to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).
12192,NCT04752384,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in VAS pain score calculated from BPI questionnaire.,2021-07-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in average daily pain score calculated by OM pain app.
12193,NCT05965843,All-cause mortality in patients with underline disease after Covid-19 infection.,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Severe disease in patients with underline disease after Covid-19 infection.
12194,NCT02136277,Changes in microvascular blood flow during colorectal surgery,2015-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12195,NCT05476380,pCR,2021-02-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,DFS
12196,NCT04867525,Course of treatment (treatment reality).,2021-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Carcinoma Health-related quality of life (Patient-reported outcome, PRO)."
12197,NCT00456599,Two-year Disease Free Survival.,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12198,NCT01056601,Progression-Free Survival,2010-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Duration of Response
12199,NCT04746469,Overall colorectal cancer screening uptake (any modality),2020-09-02,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening uptake by modality
12200,NCT03586050,Number of Patients Whose Ablation Resulted in Technical Success,2017-12-11,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients Whose Ablation Resulted in Technique Efficacy
12201,NCT01387932,Median Overall Survival,2011-06,TERMINATED,INTERVENTIONAL,['PHASE3'],Number of TACE-Related Adverse Events in Subjects Treated With HepaSphere/QuadraSphere vs Subjects Treated With Conventional TACE.,Objective Response Rates (ORR)
12202,NCT01924819,Overall survival,2009-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Surgical complete resection rate (R0)
12203,NCT02349867,Recommended phase 2 dose and schedule,2015-01-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
12204,NCT04645160,Phase I: Determine safety and establish the recommended Phase II dose (RP2D) of tivozanib in patients with cholangiocarcinoma who were previously treated with first-line chemotherapy.,2022-03-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluate disease control response (DCR- complete response [CR] plus partial response [PR] plus stable disease [SD]) in patients with cholangiocarcinoma treated with tivozanib
12205,NCT02080221,Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.,2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen
12206,NCT00893503,"Compare the diagnostic performance characteristics of the guaiac based Hemoccult II FOBT and two FIT's, the Hemoccult ICT and MagStream HemSp, using colonoscopy as the gold standard.",2008-04,COMPLETED,OBSERVATIONAL,['NA'],,Estimate the probability of participants of the SCOPE pilot who have adenomas or colorectal cancer using urine metabolomics and correlate those with results from the FOBT / FIT's and screening colonoscopy.
12207,NCT00619814,,2003-09,COMPLETED,INTERVENTIONAL,['NA'],,
12208,NCT00458809,Maximum tolerated dose,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways
12209,NCT01908504,The number of subjects with benefit from an intra-treatment PET-CT,2012-01,COMPLETED,INTERVENTIONAL,['NA'],,Measure late toxicities
12210,NCT03484962,Objective response rate,2018-03-25,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Symptom remission rate
12211,NCT05542030,Lesions recurrence in a three-month follow-up after EMR,2022-09-12,RECRUITING,INTERVENTIONAL,['NA'],,Recurrence risk after EMR
12212,NCT05610332,Objective response rate,2022-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,"The prediction performance of Exosome contents (including proteins, nucleic acids)"
12213,NCT04108936,Overall survival,2016-10,RECRUITING,OBSERVATIONAL,['NA'],,Quality of life (Questionnaire-WHOQOL-BREF)
12214,NCT03835663,Difference in the amount of bacteria of the gastric mucosa between the three previously described groups.,2018-06-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12215,NCT06243757,Appetite level score according to the MDASI-GI,2024-01-08,RECRUITING,OBSERVATIONAL,['NA'],,
12216,NCT03608878,time-to-ITTVP,2019-04-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,
12217,NCT00023972,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12218,NCT04912765,Induced immune response against vaccinated NAs,2021-04-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
12219,NCT04060342,"Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)",2019-08-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275"
12220,NCT05499195,Disease-free Survival (DFS),2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12221,NCT00848952,Report of proportion of the positives truths and the positive wrong for an examination,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,
12222,NCT01035437,Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer,2009-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Evaluate the efficacy of PDT in palliation of dysphagia
12223,NCT05475366,Objective Response Rate (ORR) at 4 months based on thorax-abdomen-pelvis (TAP) CT scan every 8 weeks according to RECIST v1.1.,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,Feasibility of study procedure
12224,NCT05489458,The evolution of the degree of vascular involvement in 64-MDCT scans,2022-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,The Resection Rate at the end of the observation period.
12225,NCT04194801,Phase II: Objective Response Rate (ORR) Assessed by Investigator Based on RECIST Version 1.1,2019-12-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic Parameters of Time to Maximum Serum Concentration (Tmax) of Sugemalimab (CS1001)
12226,NCT01991522,Transfer of Skills to Clinical Colonoscopy,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Retention of Clinical Skills
12227,NCT03097848,Disease free survival,2017-05-04,UNKNOWN,INTERVENTIONAL,['NA'],,mortality
12228,NCT00666978,Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Slow and Fast Metabolizers by Genotype
12229,NCT04191655,Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy,2019-04-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Appropriateness of reported follow up recommendations per standard guideline recommendations
12230,NCT00224562,,2004-02,UNKNOWN,OBSERVATIONAL,['NA'],,
12231,NCT05200442,Phase 2 Primary Objective: Objective Response Rate of Participants Who Take Phase I /MTD Dose of VS-6766 combined with Cetuximab,2022-08-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II Objective: Stable Disease
12232,NCT06204523,"Investigate pathways of interest at a deeper level, as well as identify other potential pathways/functions impacting clinical outcomes.",2018-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
12233,NCT05622136,Proportion of patients who complete 4 cycles of treatment,2023-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Score in the The 5-level EuroQol EQ-5D-5L questionnaire
12234,NCT03790553,Overall survival in ITT population,2018-10-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Questionnaire EORTC-QLQ-OES18
12235,NCT01461915,Number of Patients who Achieved Progression-Free Survival,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients who Achieved Overall Survival
12236,NCT03102047,Median modified Neoadjuvant Rectal (mNAR) Score,2018-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events assessed by CTCAE 4.0
12237,NCT05065801,Progression-free survival,2022-01-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Collection of circulating tumor DNA (ctDNA)
12238,NCT02272894,overall survival,2014-07,UNKNOWN,OBSERVATIONAL,['NA'],,disease free survival
12239,NCT01329718,Effectiveness of the Epi proColon test,2011-05,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12240,NCT03772132,Progression Free Survival,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,percentage of patients with Clinical Benefit Response
12241,NCT01969292,%Clear,2013-09,TERMINATED,INTERVENTIONAL,['NA'],,Ottawa Stool Score
12242,NCT01483443,Overall survival,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
12243,NCT04785820,"Overall Survival, Defined as the Time from Randomization to Death from Any Cause",2021-06-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Baseline PDL1, CD8+PD1+, CD8+TIM3+, and CD8+LAG3+ Expression in the Tumor Microenvironment"
12244,NCT05238831,Proportion of participants who receive an ACT therapy based an ACT Tumor Board recommendation.,2023-01-30,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Overall survival
12245,NCT05086601,Disease-free survival time,2020-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,Pathological TNM stage
12246,NCT01814501,Progression free survival(PFS),2013-02-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
12247,NCT02557503,Progression-free survival (PFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival (OS)
12248,NCT03837132,Impact of early palliative care on quality of life in patients with advanced pancreatic cancer,2018-10-15,COMPLETED,OBSERVATIONAL,['NA'],,"To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer"
12249,NCT06152978,Event-free survival (EFS),2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events
12250,NCT05497453,Duration of Response (DOR) (for Part 1 and Part 2 expansion),2022-08-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12251,NCT02216578,Progression Free Survival (PFS),2017-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],circulating plasma DNA,Occurence of adverse events
12252,NCT05410977,Specificity of mt-sDNA 2.0 test to detect colorectal dysplasia,2022-03-30,RECRUITING,OBSERVATIONAL,['NA'],,
12253,NCT02140021,Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia,2014-10-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12254,NCT02106910,Mean Procedure Preference Rating,2014-10-27,COMPLETED,INTERVENTIONAL,['NA'],,Cytosponge™ Operating Characteristics
12255,NCT00087360,Colorectal cancer (CRC) screening rates by chart review at 4 months,2003-11,COMPLETED,INTERVENTIONAL,['NA'],,CRC risk perception by questionnaires at 4 and 12 months
12256,NCT03255070,Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.,2018-03-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity profile of ARX788
12257,NCT04437953,"Number of patients who achieve platelet counts of ≥ 100,000/mcL",2020-05-27,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Number of patients who can undergo systemic cancer therapy without more than one dose delay or dose reduction
12258,NCT01277653,the difference of curative treatments & survival rates,2007-06,UNKNOWN,OBSERVATIONAL,['NA'],,the difference of early detection rates of HCC between both groups
12259,NCT01991847,Target sample size,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Adverse and serious adverse events
12260,NCT00577109,Progression-free survival,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"AEs, laboratory parameters."
12261,NCT05637788,"Evaluate the association between different radiomics and computer-vision features, and the survival after surgery",2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,"Evaluate the association between different radiomics and computer-vision features, and the short-terms results after surgery"
12262,NCT00576199,Progression-free Survival,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tumor Necrosis
12263,NCT01411189,The proportion of patients had no or mild peristalsis during the therapeutic procedures,2011-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events and adverse drug reactions
12264,NCT06134687,Total Procedure Time,2024-03-18,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,User-feedback post-procedure
12265,NCT06030934,Objective Response Rate (ORR),2022-10-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,Adverse Events (AEs)
12266,NCT02777710,part 2 (extension part) : objective response rate (ORR),2016-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak Pexidartinib plasma concentration (Cmax)
12267,NCT00003276,objective tumor response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to progression
12268,NCT02282059,Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs),2014-12-12,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival by clinical judgment
12269,NCT03467529,Concordance between FFOCT findings and pathology based on the Paris classification of superficial esophageal cancer in pathology,2018-11-06,COMPLETED,OBSERVATIONAL,['NA'],,
12270,NCT05904665,Secondary resection rate,2023-06-15,RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
12271,NCT00294359,Phase III: - progression free survival,2005-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,- cost of therapy and assessment of gain in quality-adjusted progression free survival
12272,NCT02540850,Ct Value (Ct Values From PCR Reaction),2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Consistency (the Overall Ratio of True Positive and True Negative)
12273,NCT05262335,Objective response rate (ORR),2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Radical Resection Rate of Liver Metastases
12274,NCT03295084,Maximal Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of oral Irinotecan based on incidence of Treatment-Emergent Adverse Events,2015-07-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective tumor response to treatment based on RECIST 1.1 criteria
12275,NCT00599378,"Follow up survey to assess participant compliance with CRC screening. For those non compliant participants, randomized to either Control group or CPI2 group - active intervention with implementation intentions-based communication concepts",2007-09,COMPLETED,INTERVENTIONAL,['NA'],,120 day followup survey to assess perceived barriers and screening decisional stage
12276,NCT05554744,Imaging response,2015-06-18,RECRUITING,INTERVENTIONAL,['NA'],,Safety of EUS-FNI
12277,NCT01123811,objective response rate,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12278,NCT01260701,Overall Survival (OS),2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
12279,NCT03253250,Recurrence-free Survival Rate (RFS）,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Overall Survival Rate (OS）
12280,NCT01519232,Changes in hepatobiliary single photon emission tomography (SPECT) after radiation therapy,2008-08,COMPLETED,OBSERVATIONAL,['NA'],,"measuring values between regional radiation dose and local hepatic function as measured by hepatobiliary SPECT, in normal liver parenchyma"
12281,NCT04654975,Odds ratio (OR) for brain metastasis,2020-06-02,UNKNOWN,OBSERVATIONAL,['NA'],,Characteristics of brain metastases
12282,NCT00808743,Change in number and size of duodenal adenomas (assessed directly and by evaluation of video and photographic material from endoscopic procedures),2009-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Biliary acid profile (if present)
12283,NCT04183478,overall survival,2017-09-26,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Hematology Index,QOL
12284,NCT04753996,Number of participants in study.,2021-03-08,RECRUITING,OBSERVATIONAL,['NA'],,Number of clinical phenotypes and/or observations.
12285,NCT02163187,Change in Bowel Function,2014-06-10,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of Life
12286,NCT01259193,numbers of adverse events,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Overall survival (OS), time to progression (TTP)"
12287,NCT04652947,"compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules",2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12288,NCT03021135,Local recurrence.,2018-06-07,COMPLETED,INTERVENTIONAL,['NA'],,Sydney resection ratio (characterized by the following equation - lesion size in millimeters
12289,NCT00303628,5-year Overall Survival Rate,2006-05-11,TERMINATED,INTERVENTIONAL,['PHASE3'],Change in Oxaliplatin-related Neurotoxicity Between Baseline and 12 Months,Proportion of Patients Who Completed 12 Cycles of Treatment
12290,NCT04584996,circRNAs for diagnosis,2020-10-04,UNKNOWN,OBSERVATIONAL,['NA'],,Bioinformatics
12291,NCT02009176,Survival rate,2013-03,UNKNOWN,INTERVENTIONAL,['NA'],,postoperative complications
12292,NCT01128803,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Analysis of T lymphocytes
12293,NCT03599752,Overall survival (High risk),2018-07-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12294,NCT03393403,analgesic effect - pain intensity,2017-12-23,UNKNOWN,INTERVENTIONAL,['NA'],,analgesic effect - opioid consumption
12295,NCT01530503,Progression Free Survival (PFS),2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12296,NCT00203411,Number of Subjects Requiring Dose Modifications,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life of Patients
12297,NCT05594381,Pathological complete response rate (pCR),2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Genomic changes of ctDNA,Incidence of Treatment-Emergent Adverse Events（Safety）
12298,NCT03674294,Complete response rate during the overall phase,2015-08-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Effects of CINV on daily life
12299,NCT01575730,Area under the plasma concentration versus time curve (AUC) of platinum,2012-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],,Tissue Concentration (Cmax) of Platinum
12300,NCT05495308,The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR.,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],,"To analyze clinical data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths."
12301,NCT03699410,Negative Prognostic Value (NPV),2018-08-28,TERMINATED,OBSERVATIONAL,['NA'],,
12302,NCT05187182,Expansion dose of CA-4948 in combination with FOLFOX/PD-1 inhibitor with/without trastuzumab,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
12303,NCT04027543,Overall survival (OS),2018-11-14,COMPLETED,OBSERVATIONAL,['NA'],,30-day postoperative or in-hospital mortality
12304,NCT02054533,Post-Operative Infection,2014-02,COMPLETED,OBSERVATIONAL,['NA'],,Hypomotility complication
12305,NCT01322633,Incidence Rate of Gastric Cancer,2004-07,COMPLETED,OBSERVATIONAL,['NA'],,Incidence Rate of Overall Cancer
12306,NCT05199649,Species and abundance of gut microbiota,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Explore the changes of intestinal flora and metabolomics before and after medication
12307,NCT03092895,The safety and tolerability,2017-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12308,NCT02063412,"Composite preparation, dispensing, and administration time",2013-08,WITHDRAWN,OBSERVATIONAL,['NA'],,
12309,NCT04363983,Overall survival (OS),2021-01-13,RECRUITING,INTERVENTIONAL,['NA'],,Survival without progression (SWP)
12310,NCT02704520,To show that patients can successfully avoid surgery after achieving a good response to treatment as measured on MRI (mrTRG).,2016-03,RECRUITING,INTERVENTIONAL,['NA'],,To assess whether the detection of ctDNA predicts for relapse in patients with locally advanced rectal cancer
12311,NCT00073905,Ability of palliative capecitabine and gemcitabine,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Clinical benefit response alone as measured after 3 courses
12312,NCT04174781,Progression Free Survival (PFS) per mRECIST,2019-11-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events (AEs)
12313,NCT04084249,FCI,2020-01-01,RECRUITING,INTERVENTIONAL,['NA'],,CE
12314,NCT05716477,Beliefs about colorectal screening,2022-12-23,RECRUITING,OBSERVATIONAL,['NA'],,
12315,NCT03895008,Disease Free Survival（DFS）,2019-07-08,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival(OS)
12316,NCT00008294,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12317,NCT01646853,Objective Tumor Response,2012-08,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events
12318,NCT00754494,Change in ACF pERK Levels,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Reported at Least 1 Diarrhea Side Effect During the Study
12319,NCT06027086,Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2024-02-06,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
12320,NCT04732286,Incidence of Treatment Discontinuations of Atezolizumab and/or Bevacizumab Due to Adverse Events of Grade ≥ 3,2021-05-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Albumin-Bilirubin (ALBI) Assessment Grades of 1 to 3
12321,NCT03460483,Incidence of tumors with microsatellite instability and/or somatic POLE mutations,2018-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12322,NCT00873002,Assessment of Safety and Tolerability,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,Adverse events and abnormal laboratory value severity as assessed by NCI CTCAE version 3.0
12323,NCT03414983,Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR),2018-02-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease Control Rate (DCR) Per Investigator
12324,NCT01632306,Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation,2013-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
12325,NCT05453383,Objective response rate,2022-07-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12326,NCT00686166,Pathologic Complete Response Rate,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to This Regimen.
12327,NCT04157985,Progression-free Survival (PFS),2019-11-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Best Objective Response (BOR)
12328,NCT06301399,ORR,2024-03-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR
12329,NCT00271986,anastomotic leakage,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,
12330,NCT01507740,Progression free survival under antiangiogenic therapy,2009-07,TERMINATED,OBSERVATIONAL,['NA'],,
12331,NCT03964064,Progression-free survival (PFS),2019-06-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse reactions
12332,NCT05007132,Objective response rate,2021-12-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12333,NCT01839500,"Cohort III, V: Disease-Free Survival (DFS), as Assessed by the Investigator Using RECIST V1.1 Criteria",2013-04-25,COMPLETED,OBSERVATIONAL,['NA'],,Cohort II: Percentage of Participants Who Decline to the Recommendation Categorized by Reasons
12334,NCT06096623,Electronic patient-reported outcome (ePRO) confirming treatment initiation,2023-11-06,RECRUITING,INTERVENTIONAL,['NA'],,Time to treatment in days
12335,NCT04642924,Resection status,2019-10-22,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
12336,NCT06236633,Safety of endovascular inferior mesenteric artery embolisation prior to surgical resection of the rectum in patients with tumours of the lower and middle rectum.,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Operative data,Markers of epithelial-mesenchymal transition : transcription factors
12337,NCT00496704,Overall response rate as assessed by RECIST criteria,2007-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to response
12338,NCT04710758,Overall survival,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Postoperative recovery course
12339,NCT05025748,Self-efficacy in managing patient-physician interactions,2021-08-25,COMPLETED,INTERVENTIONAL,['NA'],,Perceptions of the Question Prompt List
12340,NCT02711033,Early complication rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Metastasis rate of lymph nodes posterior to splenic vessel
12341,NCT06225843,Treatment-Emergent Adverse Events,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Presence of ADA
12342,NCT00028015,,2001-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12343,NCT04016948,Accuracy of optical biopsy,2017-06-28,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative function recovery
12344,NCT01159171,Percentage of Participants by Best Overall Response,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12345,NCT04191889,Objective response rate (ORR) by RECIST 1.1,2020-04-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Exploratory outcome measure: The quality of life (QoL)
12346,NCT03042611,Overall Survival (OS),2017-03-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
12347,NCT04170530,MFS,2019-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
12348,NCT00359320,The primary endpoint will be the pancreatic fistula rate.,2006-05-25,TERMINATED,INTERVENTIONAL,['NA'],,Death
12349,NCT00833625,Pathologic Response,2009-02,COMPLETED,INTERVENTIONAL,['NA'],,
12350,NCT01061840,To determine safety following the administration of bi-shRNAfurin and GMCSF autologous tumor cell (Vigil™) vaccine in advanced solid tumor patients who have no acceptable form of standard therapy with curative intent.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To determine time to progression. To evaluate the effect of Vigil™ vaccine on immune stimulation. To evaluate whether lower cell doses would activate ELISPOT responses and to compare durability of dose elicited responses.
12351,NCT05772546,Response Rate of CIT Treatment in Placebo Group,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Serious Treatment-Emergent Adverse Events (TEAEs) in Placebo Group
12352,NCT00021281,,2000-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12353,NCT05692323,PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions.,2023-04-04,RECRUITING,INTERVENTIONAL,['NA'],,PREHAB Program safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.
12354,NCT00757172,Number of Participants With Pathologic Complete Response Following Surgery,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution
12355,NCT01651624,Costs of the three different screening strategies proposed,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,Number and type of complications in all groups
12356,NCT05675059,Malnutrition: Low Skeletal Muscle Mass,2022-12-21,RECRUITING,INTERVENTIONAL,['NA'],,
12357,NCT03086642,Maximum Tolerated Dose (MTD),2017-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
12358,NCT04996355,"The accuracy, specificity and sensitivity of organoids-on-chip for drug sreening",2021-05-31,RECRUITING,OBSERVATIONAL,['NA'],,
12359,NCT02249650,Dose limiting toxicities (DLTs),2017-07-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12360,NCT01834742,Primary Variable,2011-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety profile
12361,NCT05401318,"Induction of immunotherapy efficacy by chemotherapy in colorectal cancer, measured by advanced imaging analysis",2022-03-28,RECRUITING,OBSERVATIONAL,['NA'],,
12362,NCT00003422,"Local recurrence by biopsy, imaging, or imaging and carcinoembryonic antigen result",1998-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Economic implications
12363,NCT06326619,Survival,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12364,NCT00388206,,2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
12365,NCT02254486,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),2014-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Polyp Detection Rate (Overall Colon)
12366,NCT03411915,Identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and schedule of XmAb18087,2018-01-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12367,NCT05101772,The acquisition rate of the core tissue sample,2021-09-24,UNKNOWN,OBSERVATIONAL,['NA'],,the incidence of adverse events and the incidence of device defects
12368,NCT00202969,Response rate,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Safety profile, time to treatment failure"
12369,NCT01567917,The incidence of symptomatic or asymptomatic VTE,2011-06,UNKNOWN,OBSERVATIONAL,['NA'],,Risk factors for the development of VTE
12370,NCT03803553,Clearance rate of ctDNA,2020-04-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Clearance rate of Arm 6: Herceptin/Perjeta
12371,NCT01199250,"Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)",2100-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12372,NCT02295956,Feasibility of Prehabilitation Program Among Pancreatic Patients,2015-02-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12373,NCT03975452,The reduction of gastrointestinal (GI) toxicity,2007-11,UNKNOWN,INTERVENTIONAL,['NA'],,The disease-free survival (DFS)
12374,NCT04017845,Performance Indicators of Colonoscopic Examination,2015-04-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],safety and tolerance of colonoscopy.,
12375,NCT01476553,Peritoneal Conversion Rate (PCR),2011-02,TERMINATED,INTERVENTIONAL,['NA'],,Perioperative in-hospital morbidity
12376,NCT02161822,pathologic complete response rate,2014-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,lipid lowering effect of simvastatin
12377,NCT04177810,Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria,2020-11-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities
12378,NCT05023720,Regorafenib in combination with other drugs,2021-07-20,UNKNOWN,OBSERVATIONAL,['NA'],,Survival differences among the patients with different clinical phenotypes and genotypes
12379,NCT00159484,Once MTD is established we propose to expand the dose level of the MTD to 62 new patients to evaluate whether the addition of Celebrex to EPO906 can reduce the incidence of grade 3-4 diarrhea to 6% or less.,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"To investigate whether the molecular biomarkers including protein expression changes from plasma, the expression levels of VEGF, E-cadherin, TP, COX-2, and β-tubulin in tumor tissue associated with clinical outcome for this regimen."
12380,NCT05850130,2-point improvement in the global NRS,2023-11-22,RECRUITING,INTERVENTIONAL,['NA'],,Peripheral sensory neuropathy grading scale
12381,NCT03291574,Gastrointestinal function score,2017-07-29,UNKNOWN,INTERVENTIONAL,['NA'],,Physical fitness index
12382,NCT02299596,Recovery measured as physical recovery measured in questionnaire,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Health economic analysis
12383,NCT06234072,Objective response rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of participants with R0 resection
12384,NCT02583659,Overall survival(OS) . overall survival Overall survival(OS),2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
12385,NCT00714701,This clinical study will assess the diagnostic yield of a clinical screening program for early pancreatic neoplasia in high risk individuals.,2008-06,COMPLETED,OBSERVATIONAL,['NA'],,
12386,NCT06090916,Calorie intake from Myfitness Pal,2023-01-17,RECRUITING,INTERVENTIONAL,['NA'],,
12387,NCT01670851,Perineal wound healing,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of parastomal hernia
12388,NCT00026130,Overall Survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
12389,NCT05900648,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-05-17,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12390,NCT04594655,MPI and major morbidity,2017-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Prediction of complication
12391,NCT00173472,,2002-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12392,NCT03140592,Successful generation of pancreatic organoids,2015-01-14,UNKNOWN,OBSERVATIONAL,['NA'],,
12393,NCT05033522,overall survival,2023-08-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to Symptomatic Progression
12394,NCT06076837,Safety and Tolerability,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Baseline neutrophil lymphocyte ratio (NLR),"CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)"
12395,NCT00621556,"MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.",2008-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,Laboratory
12396,NCT02232152,"MTD of 6,8-bis(benzylthio)octanoic acid in combination with fluorouracil based on the incidence of dose-limiting toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",2015-01-06,COMPLETED,INTERVENTIONAL,['PHASE1'],"Disease control rate (DCR) (i.e., sum of CR, PR, and stable disease)","PK parameters (maximum observed concentration, area under the curve, half-life, elimination rate constant, drug clearance, and volume of distribution) of 6,8-bis(benzylthio)octanoic acid in plasma samples"
12397,NCT00929097,The number of colorectal cancer patients following the most optimal follow up program according to the guidelines.,2009-10,UNKNOWN,INTERVENTIONAL,['NA'],,Costs of the implementation procedure
12398,NCT03630978,Morbidity,2018-07-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission rate
12399,NCT04187352,Overall survival (OS),2019-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Duration of response (DoR) assessed by BICR and investigators according to RECIST v1.1
12400,NCT05973266,quality of bowel preparation,2021-06-03,RECRUITING,INTERVENTIONAL,['NA'],,Anxiety
12401,NCT02519348,Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events,2015-10-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12402,NCT01615653,Pain assessed using a numerical rating scale (NRS) from 0 to 10.,2009-09,COMPLETED,INTERVENTIONAL,['NA'],,
12403,NCT03222557,GI-2 recovery,2017-11,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events related to EA/SA
12404,NCT01813994,Proportion of the patients with high-risk (III/IV) OLGA stages,2014-11,COMPLETED,INTERVENTIONAL,['NA'],,
12405,NCT03895970,Progression-free Survival (PFS),2019-04-20,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Event,Stable Disease
12406,NCT02387203,Overall survival,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Analyze number of live bacteria in PMP tumor and mucin,"Progression-free survival measured by no evidence of disease progression, i.e. tumor markers within normal limits, no radiographical evidence of disease"
12407,NCT04475159,Best Overall Response Rates (BORR),2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recurrence free survival (RFS)
12408,NCT03984214,Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period.,2019-12-16,RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall survival (OS)
12409,NCT05662644,Nature of gross picture of specimen,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Occurence of ostoperative reflux
12410,NCT00159432,Median Time for Progression Free Survival,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Grade 3 or Higher Toxicity
12411,NCT04674956,Progress free survival,2021-03-04,RECRUITING,INTERVENTIONAL,['PHASE3'],CA19-9 in serum,Duration of Response
12412,NCT06147180,score of Quality of life,2023-11-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Recurrence or metastasis
12413,NCT02521649,Measurable Antibody Titer,1998-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Injection Site Reaction
12414,NCT04740307,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-03-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,TTP per mRECIST as assessed by BICR
12415,NCT05776524,Overall Survival,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease Control Rate
12416,NCT05328908,OS in all randomized participants,2022-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,DoR by investigator per RECIST v1.1 in all randomized participants
12417,NCT05311176,Objective Response Rate of HER-Vaxx in combination with chemotherapy or pembrolizumab,2022-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],"Exploratory Outcome: Associations between clinical outcome and HER2/neu, PD-L1 expression",Duration of Response
12418,NCT04567615,Overall response rate (ORR) assessed by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2021-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12419,NCT00209729,Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.,2005-04,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the OS(Overall Survival) and DFS(Disease Free Survival).
12420,NCT01382407,Relationship between acne and skin rash,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,
12421,NCT05516394,Postoperative complications,2020-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of patients readmitted to hospital after discharge
12422,NCT01073384,Preliminary Efficacy,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12423,NCT02200055,Bioimpedance Assessment,2012-05,COMPLETED,INTERVENTIONAL,['NA'],,Amount of Intraoperative Fluids
12424,NCT04299919,Three-year recurrence,2007-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
12425,NCT04818476,overall mortality,2020-02-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12426,NCT05141149,PART 1 (PHASE 1): Determine the recommended Phase 2a dose (R2PD) of PBP1510,2023-06-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PART 2 (PHASE 2a) Exploratory Endpoint: Analysis of PAUF in tumour tissue pre-treatment and after treatment with PBP1510 administered in combination with gemcitabine.,PART 2 (PHASE 2a): Presence of ADA and NAb against PBP1510 administered in combination with gemcitabine.
12427,NCT05882396,Total Neuropathy Score,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The 4-Stage Balance Test
12428,NCT02385552,Adenoma detection rate,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,Colonoscopy quality indicators
12429,NCT04996095,Analysis of Predictive Markers,2021-10-01,RECRUITING,OBSERVATIONAL,['NA'],,
12430,NCT01994213,Objective Response Rate,2011-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Percent of Participants with OS of one year
12431,NCT01387061,Overall survival plus multivariate analysis,2001-06,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
12432,NCT01383252,Success of colonoscopy,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Polyp detection
12433,NCT05516641,Gut Flora modulation,2022-07-25,RECRUITING,INTERVENTIONAL,['NA'],,Immune Profile
12434,NCT03599154,Overall survival,2018-01-30,COMPLETED,OBSERVATIONAL,['NA'],,
12435,NCT01264705,Number of Patients With Dose Limiting Toxicity,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.
12436,NCT06093009,Disease-free survival,2002-06,COMPLETED,OBSERVATIONAL,['NA'],,
12437,NCT01824875,Progression-free Survival,2013-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response
12438,NCT00359476,"The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]",2007-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The evaluation of the safety profile of vinflunine
12439,NCT04085055,Degree of cellularity in biopsy sample,2019-09-09,UNKNOWN,INTERVENTIONAL,['NA'],,Diagnostic operating characteristics
12440,NCT00185874,To determine the toxicity of this regimen,2004-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells
12441,NCT05461794,Arms A and C: Overall Response Rate (ORR),2022-10-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with clinically significant changes from baseline in vital signs
12442,NCT03284879,Change from baseline activity for arthritis,2017-09-05,COMPLETED,OBSERVATIONAL,['NA'],,
12443,NCT05402891,Change in clone size distribution positive for NOTUM.,2022-06-02,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],"History of smoking, if yes number of pack years","Safety outcomes by analysing reported adverse events, physical examination and laboratory findings."
12444,NCT02772965,Percent of Participants Experiencing Treatment Failure,2016-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percent of Patients With Positive Anti-TNF Antibody
12445,NCT02041312,Cholesterol level in paitents with and withoutgastric neoplasm,2014-02,UNKNOWN,OBSERVATIONAL,['NA'],,Degree of decresed serum cholesterol levels in paitents with gastric neoplasm
12446,NCT05105815,DFS,2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,EORTC-QLQ30
12447,NCT05635149,Progression-Free Survival (PFS),2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],Exploratory endpoint,Gut microbiome analysis
12448,NCT00579865,"To determine how surgical or percutaneous drainage affects HRQL scores in patients with MBO, and to determine if these changes are sustained or change over time.",2005-05,COMPLETED,OBSERVATIONAL,['NA'],,"To identify factors associated with changes in HRQL after drainage(e.g. diagnosis, level of obstruction, degree of pruritus)"
12449,NCT03279198,"Primary Outcome:differences in stage of adoption (precontemplation, contemplation, action) when controlling for adherence to BC screening at baseline, among women who are randomized to 1) usual care; 2) a TIWeb; 3) a CSC, and 4) a TIWeb plus a CSC.",2010-07-22,COMPLETED,INTERVENTIONAL,['NA'],,Secondary outcome:Intervention Costs
12450,NCT04220944,Progression Free Survival (PFS),2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment Emergent Adverse Events as assessed by NCI CTCAE V5.0 (Safety and Tolerability)
12451,NCT00442637,Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2),2007-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Translational research
12452,NCT00636610,Progression-free Survival (PFS),2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free Survival (PFS) in Patients With Various Degrees of Hedgehog Antigen Tumor Expression
12453,NCT03347162,Cohort 2: Medical treatment complications,2017-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in physical activity level
12454,NCT04314401,Percentage of minority and underserved study participants accrued,2020-11-11,RECRUITING,OBSERVATIONAL,['NA'],,Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
12455,NCT00537121,Recommended phase II dose (RPTD) of SAHA when administered continuously and intermittently with standard doses of FOLFIRI,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
12456,NCT02784262,adverse events,2016-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,change in quality of life expressed by Patients' Global Impression of Change (PGIC)
12457,NCT05943210,Number of research specimens obtained at the time of surgery.,2023-05-22,RECRUITING,INTERVENTIONAL,['NA'],,Comparing levels of cell death related to radio responsiveness will be measured by quantifying cleaved caspase-3
12458,NCT02378389,The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE1'],,preliminary antitumor activity for the regimen
12459,NCT03196232,Progression-free Survival (PFS),2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Treatment Delay or Reduction
12460,NCT01554969,Tumor response and disease progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST).,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12461,NCT02833363,Difference of Gastric Microbiota in the Process of Correa's Model.,2016-07,UNKNOWN,OBSERVATIONAL,['NA'],,Difference of Gastric Microbiota in the Process of Correa's Model.
12462,NCT03888638,Survival,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
12463,NCT02865811,Clinical Benefit Rate [CBR],2016-09-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12464,NCT04587739,Drop-out rate,2021-01-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Actuarial overall survival and disease-free survival.
12465,NCT06301763,Body Mass Index Level,2022-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Penetration-Aspiration Scale
12466,NCT00657371,Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER),2008-03,COMPLETED,INTERVENTIONAL,['NA'],,Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.
12467,NCT03320629,Progression free survival,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Side effects
12468,NCT04008537,"Feasibility of the device as measured by successful completion of the full CBCT-guided online ART workflow, from volumetric imaging through phantom delivery in at least 90% of attempted fractions",2019-09-04,COMPLETED,INTERVENTIONAL,['NA'],,
12469,NCT05034887,Major pathological response [MPR] rate: by central assessment,2022-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],AE rate in the Exploration Part,AE rate
12470,NCT03875612,Specificity of registered level of tie,2016-12-12,COMPLETED,OBSERVATIONAL,['NA'],,Cancer recurrence by tie level
12471,NCT02128425,Progression-free survival after induction and maintenance chemotherapy (PFS1),2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Translational research
12472,NCT00709462,"To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer, alone and in combination with adjuvants.",2004-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To evaluate dose-limiting toxicities, immune response, and clinical activity (tumor response and time to progression)"
12473,NCT02445456,Number of Operations Where There Was Any Surgical Difficulty Due to Tracer Injection Based on Qualitative Assessment by Surgeon,2016-12,TERMINATED,INTERVENTIONAL,['NA'],,Number of TEM Operations Where the Sentinel Lymph Node Can be Identified and Removed
12474,NCT05651971,The distance from LCA to IMA and IMV,2022-11-01,RECRUITING,OBSERVATIONAL,['NA'],,postoperative anastomotic leakage rate
12475,NCT01889680,The time to disease progression,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The severity of adverse events
12476,NCT05222204,overall survival,2021-07-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12477,NCT00997022,Maximum tolerated dose of daily sorafenib,2009-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Duration of progression free survival
12478,NCT02138383,Maximum Tolerated Dose (MTD),2014-05-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12479,NCT04368702,Rate of Pathologic complete response-Gastric,2021-05-01,SUSPENDED,INTERVENTIONAL,['NA'],,Characterizing MRI-based tumor alterations/changes following MR-image guided radiation
12480,NCT04200027,oncological outcomes RLAR vs TaTMe,2021-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12481,NCT04585516,Presence of upper GI pathology,2020-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Patients characteristics in patients < 50 years who were admitted for a gastroscopy 9,patient characteristics of colorectal cancer 7
12482,NCT00718055,,2006-11,WITHDRAWN,OBSERVATIONAL,['NA'],,
12483,NCT04068194,Objective response rate (ORR) (Phase 2),2020-04-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",T cell receptor (TCR) clonality,Differential response to therapy (Phase 2)
12484,NCT01207895,Utility of [18F]-FLT PET to assess cellular proliferation in neoadjuvant trials of patients with rectal cancer,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlative biology
12485,NCT04430842,Determination of maximum tolerated dose (MTD),2020-07-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to maximum concentration of QBS10072S in plasma (Tmax)
12486,NCT01738139,Maximum tolerated dose (MTD),2013-02-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12487,NCT00616941,Overview of Treatment-emergent Adverse Events (TEAEs),2008-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor Measurement Results According to the Response Evaluation Criteria for Solid Tumors (RECIST) Up to 16 Weeks Post-Baseline
12488,NCT00858429,Time to tumor progression,2009-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12489,NCT01683422,One-year Survival Rate,2013-01-02,TERMINATED,INTERVENTIONAL,['NA'],,
12490,NCT04258657,DFS,2020-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12491,NCT05785780,Up-to-date CRC screening,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],Implementation Fidelity,Rate of CRC Screening Uptake by Glucose Control (Controlled vs. Uncontrolled) Among Participants with Type 2 Diabetes
12492,NCT01975454,Progression-free survival(PFS),2012-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
12493,NCT06212700,Acceptability of the virtual multimodal hub.,2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Implementation Outcome: Maintenance
12494,NCT05171439,Bioinformatics analysis of single-cell sequencing in hepatocellular carcinoma,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,adverse events(AE)
12495,NCT00307723,to determine the survival of patients treated with this regimen.,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,to evaluate the toxicities.
12496,NCT02052908,Incidence of toxicity,2014-01-27,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in the number and type of immune and mesenchymal cells recruited to the colorectal mucosa
12497,NCT05992220,progression-free survival rate,2022-10-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Tumor marker response (AFP, PIVKA-II)"
12498,NCT04782791,Adverse events,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 rate
12499,NCT05669482,To determine the efficacy of the RP2D identified in Part A,2023-03-22,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of abnormal laboratory values
12500,NCT02083653,Overall Survival (OS) Time,2014-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life Assessed by FACT-EGFRI-18 for Skin Rash
12501,NCT03007550,Early operative morbidity and mortality rate,2017-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative hospital stay
12502,NCT04231175,Number of preventable unnecessary laparoscopies and explorative laparotomies defined as,2019-10-28,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of Life between diagnostic arms by EQ5D5L
12503,NCT02829385,Objective Response Rate (ORR),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12504,NCT05188586,Specificity,2022-12-06,RECRUITING,INTERVENTIONAL,['NA'],,Stage Shift
12505,NCT01147965,"The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).",2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.
12506,NCT03161574,The rate of R0 resection,2017-08-11,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
12507,NCT00716209,,2012-09,UNKNOWN,OBSERVATIONAL,['NA'],,
12508,NCT04659603,Incidence of dose-limiting toxicites (DLTs)- Cohort C Part 1,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Maximum concentration observed after infusion (Cmax) of gemcitabine metabolite
12509,NCT06263205,Rate of Postoperative Wound Healing Complications,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Medical Costs Associated with Wound Care
12510,NCT02054923,Change in screening centre adenoma detection rate before and after intervention,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Rates of proximal (to the splenic flexure) serrated polyps ≥10mm in size
12511,NCT00476970,Percentage of Eligible Patients In Study and Control Groups Who Undergo CRC Screening,2007-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of Polyps and Cancers per 100 Patients in the Study vs Control Group
12512,NCT05561504,H. pylori resistance profiles,2021-03-31,RECRUITING,OBSERVATIONAL,['NA'],,risk factors for gastric cancer
12513,NCT00352261,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state,2006-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state
12514,NCT02423343,Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab,2015-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
12515,NCT03010722,"disease control rate (DCR), measured in months",2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Median values of volume transfer constant (Ktrans) and enhancing fraction (EF) and their product KEF (product of summarised median values of Ktrans x EF/100) will be compared at baseline and on day 15
12516,NCT02946138,Progression-free survival of all patients,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Objective responses rate
12517,NCT01471743,Number of participants with post-op Infections,2011-11,COMPLETED,INTERVENTIONAL,['NA'],,
12518,NCT02092948,Assess the safety of [124I] PSCA-Minibody,2013-08-22,COMPLETED,INTERVENTIONAL,['PHASE1'],,Compare the sensitivity and specificity of [124I] PSCA-Minibody with conventional imaging
12519,NCT00905918,"Presence in colon tissue of α-, γ-, and δ-tocopherols, cell proliferation and apoptosis indicators, β-catenin localization, RXR expression, and cyclooxygenase-2, 8-OHdG, and 3-nitrotyrosine levels",2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12520,NCT02181075,Patients Demonstrating >Two-fold Increase in the Amount of Intratumoural Doxorubicin Before and After Focused Ultrasound,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to FUS Procedure
12521,NCT04855331,Postoperative complications,2021-04-15,RECRUITING,INTERVENTIONAL,['NA'],Postoperative quality of life,The 90 days mortality rate after operation
12522,NCT05864755,Overall response rate ( ORR) per RECIST 1.1,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time To Progress(TTP) per RECIST 1.1
12523,NCT04523467,Progression-free survival (PFS),2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Conversion rate,Adverse events
12524,NCT01892072,"the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.",2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12525,NCT01064375,To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF
12526,NCT03015389,Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma (HGD/EAC) using WATS3D and random 4 quadrant forceps biopsies taken at 2 cm intervals.,2017-09-27,COMPLETED,OBSERVATIONAL,['NA'],,Number of participants with Barrett's related dysplasia and adenocarcinoma diagnosed with random forceps biopsies and WATS3D biopsies used in alternating fashion.
12527,NCT03777813,cPFS (centrally reviewed cPFS),2018-12-05,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)"
12528,NCT04415385,ORR,2020-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events (AEs) in the treatment of Camrelizumab in combination with apatinib
12529,NCT03600831,Disease-free survival (DFS),2018-08-20,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life(QOL)
12530,NCT02260505,Disease Free Survival (DFS),2014-12-24,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient's Quality of Life (QoL)
12531,NCT02277834,"Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process",2014-08,COMPLETED,OBSERVATIONAL,['NA'],,Compare the proteomic profile between pancreatic cancer and pancreatitis
12532,NCT01479894,Compare the prognosis of colon cancer patients compared to gene expression.,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,
12533,NCT01276483,Radiologic-pathologic correlation,2011-02,COMPLETED,OBSERVATIONAL,['NA'],,
12534,NCT02420691,Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1,2015-08-25,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Ki-67 With Treatment,Progression Free Survival (PFS)
12535,NCT05922358,Completion rate of 3 cycles of re-chemotherapy with oxaliplatin,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Concordance rate between oxaliplatin skin test results and clinicians' judgment
12536,NCT02813928,The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.,2016-07,COMPLETED,INTERVENTIONAL,['NA'],,
12537,NCT03541304,clinical response rate,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
12538,NCT02266056,intra-abdominal pressure,2014-08,COMPLETED,INTERVENTIONAL,['NA'],,
12539,NCT01821963,Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant,2013-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Sustained Virological Response (SVR)
12540,NCT04342910,Overall Survival (OS) in PD-L1 Positive Participants.,2020-09-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Plasma concentration of apatinib
12541,NCT05039736,To evaluate overall response rate,2023-02-24,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12542,NCT04021589,progression free survival,2019-07-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
12543,NCT00725335,Disease free survival,2008-09,COMPLETED,INTERVENTIONAL,['NA'],,"overall survival,morbidity,postoperative mortality;blood loss,Liver function test,etc"
12544,NCT06325410,type of resected tumor,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
12545,NCT05064553,To demonstrate that Oncoguard™ Liver HCC specificity exceeds 82%,2021-07-26,RECRUITING,OBSERVATIONAL,['NA'],,To determine a point estimate and 95% confidence interval for Oncoguard™ Liver overall HCC sensitivity
12546,NCT03710486,Number of Participants With Change From Baseline in Endoscopic Findings,2019-02-19,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with AE Outcome
12547,NCT01343901,Percentage of Participants Without Detectable Metastatic Disease After a Complete Response Without Surgery,2010-09-30,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Unresectability Criteria
12548,NCT04137536,Evaluate toxicity,2019-10-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12549,NCT04222114,Overall survival (OS),2020-10-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Tendency of theperipheral blood lymphocyte counts change associated with the intra-peritoneal infusion of catumaxomab
12550,NCT06123494,Overall survival (OS),2024-01-09,RECRUITING,INTERVENTIONAL,['PHASE3'],,Serum concentrations of SHR-A1811 toxin-binding antibodies and free toxin SHR169265
12551,NCT01745107,Disease-free survival time,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival time
12552,NCT03109301,Efficacy,2017-04-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
12553,NCT03520088,Changes in sexual dysfunction pre- and post-Total Mesorectal Excision,2018-09-03,UNKNOWN,INTERVENTIONAL,['NA'],,
12554,NCT02272244,Overall Screening Adherence,2014-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Screening Knowledge and Perceptions
12555,NCT02900677,Self-report Questionnaire,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],Self-report Questionnaire,Self-report Questionnaire
12556,NCT04137679,Disease-free survival,2019-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
12557,NCT05779917,Number of Patients with Dose Limiting Toxicity,2023-03-10,RECRUITING,INTERVENTIONAL,['PHASE1'],,Median CAR-T cell persistence
12558,NCT00862082,Maximum Tolerated Dose (MTD) of PR104 When Used in Combination With Standard Dose Sorafenib in the Phase I Population,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics (AUC) of PR104 and PR104 Metabolites in Cohort 2 (550 mg/m^2 Dose Group)
12559,NCT05141747,Adverse Events (AEs),2022-01-19,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Immunogenicity (ADA)
12560,NCT02970916,FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms.,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2'],"Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS)",Number of participants with adverse events as assessed by CTCAE v4.0.
12561,NCT01628913,Progression Free Survival (PFS),2012-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure (TTF)
12562,NCT05996484,Pathologic complete remission (PCR),2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in HRQoL Score Using EORTC Quality of Life Questionnaire-Oesophageal Module (QLQ-OES18)
12563,NCT02724267,Overall Survival,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Time to Progression
12564,NCT00626054,"Cleanliness of the bowel, as determined by the examiner, and ease of use, as determined by a patient satisfaction questionnaire in the two study arms",2009-03,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Effect of external factors (demographic parameters, length of hospitalization, procedural diagnosis) on the quality of the bowel preparation"
12565,NCT05412355,long-term survival,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Postoperative complications
12566,NCT00276861,Response Rate as Measured by RECIST Criteria,2005-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Time to Progression as Measured by the Kaplan Meyer Curve at Completion of Study Treatment
12567,NCT05631873,Implement a new process using a structured result letter template to set the electronic health record follow-up interval after a screening colonoscopy.,2022-11-18,COMPLETED,INTERVENTIONAL,['NA'],,
12568,NCT05502666,Colorectal Cancer Screening,2017-07-08,COMPLETED,INTERVENTIONAL,['NA'],,
12569,NCT06040801,Assess the level of quality of life in frail and non-frail patient groups before and after treatment using EORTC QLQ-C30 v3 and EORTC QLQ-ELD14.,2021-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
12570,NCT06305364,Primary Efficacy Endpoint - Gixam's diagnostic accuracy,2023-08-01,RECRUITING,INTERVENTIONAL,['NA'],,
12571,NCT03456206,CID diagnosis,2018-11-10,UNKNOWN,OBSERVATIONAL,['NA'],,
12572,NCT02826837,Maximum tolerated dose,2022-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Changes in global health/QoL standardized score at post-treatment visits compared to baseline
12573,NCT02863172,Variations in Clinical Features Compared Between Proband Group and Family Member Group,2012-05-22,RECRUITING,OBSERVATIONAL,['NA'],,Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group
12574,NCT02140593,Surgical Rating Score,2014-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,The Surgical Rating Score During Fascial Closure
12575,NCT05128825,Overall Response Rate defined by the revised RECIST v1 .1. and assessed by ICR.,2022-02-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,Time To Response as defined by the revised RECIST v1 .1. and assessed by ICR and the Investigator.
12576,NCT02021253,Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels,2013-04,COMPLETED,INTERVENTIONAL,['NA'],,
12577,NCT06116864,Adenoma detection rate,2023-10-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Procedure complication (bleeding or perforation) by the end of the procedure. (Following lexicon for endoscopic adverse events methods)
12578,NCT02053324,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),2013-11-11,TERMINATED,INTERVENTIONAL,['PHASE1'],tumor response,Adverse Events
12579,NCT03638297,Response rate,2018-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,duration of response
12580,NCT03486574,Genes with logarithm of odds (LOD)>2 in linkage analysis,2016-12-07,COMPLETED,OBSERVATIONAL,['NA'],,
12581,NCT02672917,Group F - Determine the MTD and/or the RP2D of MVT-5873 administered in combination with the modified FOLFIRINOX regimen (mFOLFIRINOX) in the PDAC adjuvant setting,2016-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Group F - Evaluate time to recurrence
12582,NCT04566367,Detection rate of a second cancer or precancerous lesions,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12583,NCT02631590,Progression Free Survival (PFS),2016-07-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
12584,NCT00191412,Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival: Enroll. to death of any cause
12585,NCT03287947,Disease Control Rate,2017-11-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib."
12586,NCT04676633,Limited Dose Toxicity (LTD),2021-03-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12587,NCT00005832,Survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Assess confirmed response (complete & partial) in patients with measurable advanced adenocarcinoma of the pancreas
12588,NCT05390112,Radiological response at 1 month according to mRECIST and ctDNA detection,2021-05-20,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival and overall survival
12589,NCT01831037,Hepatocellular carcinoma,2015-07,WITHDRAWN,OBSERVATIONAL,['NA'],Regression of liver fibrosis,Profile with lowest risk for hepatocellular carcinoma
12590,NCT00260884,We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.,1993-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12591,NCT02729298,Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective response rate using RECIST v1.1 and iRECIST
12592,NCT04298008,disease control rate (DCR) of AZD6738 and Durvalumab combination,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of life measurement
12593,NCT05345054,A database linking socioecological determinants of health with nationally validated surgical outcomes.,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
12594,NCT04111172,Antigen-specific T-cell response to guanylyl cyclase C (GCC),2020-11-10,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
12595,NCT02131493,DFS,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,OS
12596,NCT05468008,Evaluate the utility of ESD for treatment of gastrointestinal lesions,2022-02-04,RECRUITING,OBSERVATIONAL,['NA'],,Safety- Adverse Events
12597,NCT01319942,Response rate,2010-06,UNKNOWN,OBSERVATIONAL,['NA'],,Time-to radiological progression interval
12598,NCT05194995,Dose Expansion phase: Overall response rate (ORR),2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Expansion phase: Progression-free survival (PFS)
12599,NCT00098982,Maximum tolerated dose and recommended dose of bortezomib as measured by CTC v3.0,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression as measured by Kaplan Meier and RECIST every 8 weeks
12600,NCT01001377,Overall Survival,2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
12601,NCT04843644,oral mucositis,2021-04-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Microbiota
12602,NCT00024427,Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer Patients,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12603,NCT02830620,chimiokine MCP1 expression,2012-08-01,COMPLETED,INTERVENTIONAL,['NA'],,
12604,NCT03204994,Number & location of lymph nodes identified with and without fluorescent probe during rectal cancer surgery,2017-08-01,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of lymph nodes lying outside the CRM identified by fluorescence
12605,NCT05265221,Resection speed,2022-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Complication rate
12606,NCT03568110,90-day mortality,2019-03-05,COMPLETED,OBSERVATIONAL,['NA'],,Health-related Quality of life at 12 months (EORTC-QLQ-STO22)
12607,NCT05086614,3-year disease-free survival rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,rate of adverse events related to thymosin-alpha 1
12608,NCT03042091,"Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak",2016-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of mortality
12609,NCT00006039,,1999-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12610,NCT00906984,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
12611,NCT01580410,"The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments",2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G)
12612,NCT00020826,psychometric validity of the STO22 module,2001-04,COMPLETED,OBSERVATIONAL,['NA'],correlation between QLQ-C30 and STO22 scores,debriefing questionnaire information
12613,NCT02620228,Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue,2016-06-09,COMPLETED,INTERVENTIONAL,['NA'],,
12614,NCT04977882,Tolerance to solid diet,2020-10-01,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,C-Reactive Proteine
12615,NCT01138124,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
12616,NCT05346146,R0-surgery resection rate,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers predictive of response and toxicity,All the adverse events by NCI CTCAE v 5.0
12617,NCT05982899,frailty trajectories,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12618,NCT00321828,Major Morbidity Related to the Intact Primary Tumor,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival as Measured by Death From Any Cause
12619,NCT01020812,Freedom From Local Progression of TACE and SBRT at 12 Months,2009-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Progression Free Survival
12620,NCT01479907,"Assessment of gastrointestinal function-related quality of life at 1, 3 and 6 months postoperatively",2010-11,COMPLETED,INTERVENTIONAL,['NA'],,
12621,NCT01912443,Laboratory parameters,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival (OS) of treatment line
12622,NCT04166383,Best Overall Response (BOR),2020-08-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),6-month Progression-free Survival (PFS)
12623,NCT01363843,Incidence of Complete Resection,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the Toxicity of Study Therapy
12624,NCT02066688,"The primary objective of this study is to investigate the incidence of colorectal adenoma (CRA) after Folic acid, calcium and vitamin D intervention.",2013-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']","Changes in routine blood count, urine and stool routine test, liver and kidney functions",differences in Histological types of CRA OR CRC
12625,NCT01850316,One year local progression-free rate,2013-07,UNKNOWN,INTERVENTIONAL,['NA'],,Functional imaging with 11C-choline/18F-FDG CT-PET and perfusion CT to that characterize treatment-related effects
12626,NCT02631564,number of adverse events,2015-06,UNKNOWN,OBSERVATIONAL,['NA'],,Time to progression
12627,NCT01525953,Identification of prognostic factors for overall survival,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
12628,NCT00066404,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12629,NCT00103103,Response rate as measured by RECIST every 8 weeks,2005-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Molecular correlates on and off study treatment
12630,NCT03127072,Overall survival in subjects receiving RFA plus chemotherapy ± target therapy compared to chemotherapy ± target therapy alone was assessed from the date of study entry until death from the disease.,2017-04-30,UNKNOWN,INTERVENTIONAL,['PHASE4'],,The differences in the incidence or severity of adverse events in the RFA plus chemotherapy ± target therapy arm compared to the chemotherapy ± target therapy only arm were was assessed by of complications after therapy.
12631,NCT06134024,Rate of safety of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate of long-term success of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of double pigtail plastic stents introduced through the LAMS.
12632,NCT02702960,1 year disease-free survival (at 1 year after BMT),2016-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Efficacy measure- proportion off immunosuppression without graft versus host disease (GVHD) or liver rejection,Liver allograft failure
12633,NCT03172572,Major morbidity,2017-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
12634,NCT02000180,Difference Between Progressive and High-Fidelity Groups on Clinical Colonoscopy Peformance (JAG/DOPS),2013-06,COMPLETED,INTERVENTIONAL,['NA'],,"Colonoscopy Specific Performance, Communication Skills, and Global Performance on an Integrated Scenario"
12635,NCT06238843,overall survival(OS),2024-03-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,neutralizing antibody (NAb)
12636,NCT01420874,"Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.",2011-08-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
12637,NCT00275119,Progression-free survival,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Locoregional and metastatic progression-free survival
12638,NCT00433602,"Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)",2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
12639,NCT04397783,parastomal hernia rate by imaging,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA'],,Ease / difficulty in the management of stomatherapy devices
12640,NCT01626781,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
12641,NCT05052931,AE,2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12642,NCT04123340,Feasibility of the use of co-registration software (>80%),2019-08-26,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quantitatively assessed ablation margin
12643,NCT04212598,Percentage of patients with disease progression within 2 years after treatment,2020-08-03,RECRUITING,INTERVENTIONAL,['PHASE2'],The number of patients with treatment-related toxicity between the treatment period and half a year after treatment,Percentage of patients who died within 2 years after treatment
12644,NCT02024633,The number of patients who suffer adverse events,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival
12645,NCT00590031,Pathologic Complete Response,2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate Toxicity and Tolerability Including Surgical Morbidity and Mortality
12646,NCT06125145,Describe the percentage of participants that complete 2 out of 3 study visits,2024-03-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life
12647,NCT04653389,Event Free Survival（EFS）,2020-12-26,TERMINATED,INTERVENTIONAL,['PHASE2'],,Tumor biomarker
12648,NCT01051479,To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy).,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Perform semi-quantitative analysis of tracer uptake using standard uptake values (SUV) and qualitative analysis using pure visual analysis.
12649,NCT03634332,Progression Free Survival,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],Evaluate Blood Translational Biomarkers--T cell receptor (TCR) sequencing,Overall Survival
12650,NCT01839877,Progression-free survival rate at 9 months,2013-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12651,NCT00912847,,1997-10,COMPLETED,OBSERVATIONAL,['NA'],,
12652,NCT00294476,"and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle",2005-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle
12653,NCT04482309,Objective Response Rate (ORR),2020-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd
12654,NCT02849106,Number of interpretable chemogram,2011-05,COMPLETED,INTERVENTIONAL,['NA'],,time to obtain chemogram
12655,NCT02834052,Phase 1 and 2: Determine the response rate of metastatic MRP colon cancer (that has progressed following two lines of therapy in the metastatic setting) to the combination of pembrolizumab and poly-ICLC,2018-01-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Determine the duration of response of recurrent metastatic MRP colon cancer to the combination of pembrolizumab and poly-ICLC
12656,NCT01060501,overall survival,1992-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Toxicity (WHO)
12657,NCT05841134,Percentage of Participants With Pathological Complete Response (pCR),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events during the treatment and follow-up (safety)
12658,NCT02755311,Overall survival,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Mortality
12659,NCT04500171,ColoCARE Completion Efficacy,2020-09-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12660,NCT04771988,Response to radioembolization,2013-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Progression-free survival
12661,NCT06055387,"Utilize CTCAE v5.0 to assess the grade and frequency of adverse events and treatment-related toxicity in frail and non-frail patient groups, and compare the differences between the two.",2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,To compare overall survival between two distinct groups: frail and non-frail patients.
12662,NCT04986085,Risk of malnutrition in GEP NET,2021-02-24,RECRUITING,OBSERVATIONAL,['NA'],,Subjective Global Assessment (SGA) rates
12663,NCT00636298,Progression-free survival,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Response rate
12664,NCT05468138,3 year Disease Free Survival,2022-08-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,5 year Overall Survival
12665,NCT04826406,Objective Response Rate (ORR),2021-02-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety as measured by the rate of AEs, SAEs and laboratory abnormalities"
12666,NCT05984602,Number of patients who proceeded to surgical resection,2023-07-14,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of changes in outcome of surgery that is attributed to study drug
12667,NCT05261542,Accuracy of intraoperative Flow Cytometry for cancer cell identification in colorectal cancer.,2017-01-26,COMPLETED,OBSERVATIONAL,['NA'],,
12668,NCT02539212,"Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between MWA and RFA was done by the log-rank test.",2008-10,COMPLETED,INTERVENTIONAL,['NA'],,Wilcoxon test was used for comparing liver function between MWA and RFA.
12669,NCT00429078,,2007-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
12670,NCT04734821,Evaluation of the usefulness of ICG fluorescence to guide lymphadenectomy in oncological esogastric resections,2021-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Evaluation of the impact of fluorescence guidance in intraoperative evaluation of pre-anastomotic tissue perfusion
12671,NCT01786538,Progression-free survival,2013-06,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Number of participants with adverse events
12672,NCT06063941,Visual analogue scale scores at 30 minutes after chromoendoscopy,2023-10-10,RECRUITING,INTERVENTIONAL,['NA'],,Associated factors for visual analogue scale scores
12673,NCT01804166,Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL),2013-03-21,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12674,NCT05360277,Disease-free survival,2023-08-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
12675,NCT05056337,Tumor response: Objective response rate (assessed based on mRECIST criteria),2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events as assessed by CTCAE 5.0 criteria
12676,NCT06335420,Number and size of polyps found at the one-year follow up colonoscopy,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Acceptability of treatment
12677,NCT02625623,Overall Survival (OS),2015-12-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Questionnaire Scores at End of Treatment (EOT)
12678,NCT00280176,Dose-limiting toxicity,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment
12679,NCT00060268,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12680,NCT02199223,Safety of regorafenib + panitumumab,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12681,NCT05113186,One-year local recurrence-free survival,2022-02-02,RECRUITING,INTERVENTIONAL,['PHASE2'],"Consittution of a sequential biobank comprising peripheral samples (serum, plasma)",Per nodule assessment of local recurrence
12682,NCT05770102,Durable Clinical Benefit (DCB),2023-10-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Mean change from baseline in the PedsQL 4.0 Standardised Area Under total Scale Score Curve (PedsSAUC) in parents from paediatric participants.
12683,NCT01729923,"Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",2013-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Relapse Free Survival in Patients Achieving CR
12684,NCT00778830,Percentage of Subjects With Best Overall Confirmed Response Rate (BORR),2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation and TEAEs Leading to Death"
12685,NCT06224738,Adverse effects,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Overall Survival (OS)
12686,NCT02018367,The diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRME with directed biopsy,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],The clinical impact of HRME on the diagnosis and endoscopic surveillance of BE- associated neoplasia,"The diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of HRME for the in-vivo diagnosis of neoplasia."
12687,NCT04310553,Overall survival,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,"clinical benefit rate, CBR"
12688,NCT03471468,"Microparticles level will be assessed by automated and standardised measure of their procoagulant power using Kit STA©Procoag-PPL (Diagnostica Stago, Asnière, France)",2018-07-23,TERMINATED,INTERVENTIONAL,['NA'],,"Khorana score does assess the risk of thrombosis uner chemotherapy according to 3 levels :Score 0, 1, 2 or 3"
12689,NCT04915144,Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.,2023-01-15,WITHDRAWN,INTERVENTIONAL,['PHASE2'],PFS and QoL scores to ctDNA levels,Correlation of QoL scores (EQ-5D) to ctDNA
12690,NCT03345563,Functional Assessment of Chronic Illness (FACIT)-Fatigue Scale,2019-07-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Consensus Sleep Diary
12691,NCT01930630,Number of participants with adverse events,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI
12692,NCT01423214,Surgical quality based on pathological examination,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5-year disease-free survival rate
12693,NCT05575635,pCR,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,TRAEs
12694,NCT04509635,disease control rate,2020-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,overall survival
12695,NCT02469480,Rise or normalization of hemoglobin,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12696,NCT04135664,5-year overall survival rate,2019-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life differences (EORTC QLQ-OES18)
12697,NCT02732860,Rate of pPDX engraftment,2015-12,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between pPDX and organoid drug sensitivities
12698,NCT00325494,"Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs",2006-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Tumor Response Rate Assessed by Investigator
12699,NCT01891539,tumor response,2013-05,UNKNOWN,OBSERVATIONAL,['NA'],,time to progression
12700,NCT06305169,Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway
12701,NCT00606983,Re-insertion rate of urinary catheter after removal,2007-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Scores of IPSS (International Prostatic Symptom Score) and the results of uroflowmetry
12702,NCT04584775,Change from baseline in FACT-G at week 4,2021-02,UNKNOWN,INTERVENTIONAL,['NA'],Overall survival,Change from baseline in FAMCARE-2 at week 4 and 8
12703,NCT05875584,"Evaluating the sensitivity, specificity, and accuracy of rbcDNA in colorectal cancer screening",2023-05-18,COMPLETED,OBSERVATIONAL,['NA'],,"Sensitivity of the rbcDNA screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC"
12704,NCT03340636,occurrence of severe adverse effects (grades 3-5),2018-01,UNKNOWN,OBSERVATIONAL,['NA'],,
12705,NCT02109341,Dose finding safety and activity,2014-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Safety profile
12706,NCT00395252,disease free survival,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events
12707,NCT03702998,Incidence of HCC,2018-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Mortality due to HCC or liver-related conditions
12708,NCT00160875,pathological complete response,2009-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,PET scan parameters (radiological)
12709,NCT04099641,Objective Response Rate (ORR),2019-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12710,NCT04431791,Time To Treatment Failure,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA'],,Incidence of adverse events（AEs）
12711,NCT02384811,Local control rate,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety: Frequencies of treatment-related adverse event categories by NCI-CTC
12712,NCT02002416,Overall survival,2006-01,UNKNOWN,OBSERVATIONAL,['NA'],,Positive rate of C-met
12713,NCT05410197,Objective Response Rate (ORR),2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events (AE)
12714,NCT01733004,Severity and number of adverse events related to escalating doses of MM-141,2012-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12715,NCT05625529,Clinical performance of ExoVerita™ assay,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],,Stage Shift
12716,NCT04906044,The incidence of serious adverse events,2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Wexner score
12717,NCT01980238,"anastomotic leakage, reoperation and mortality rate",2011-01,UNKNOWN,INTERVENTIONAL,['NA'],hospital stays and costs,ileus rate
12718,NCT01814345,Incidence of Her2 testing in Gastric cancer,2013-06,TERMINATED,OBSERVATIONAL,['NA'],,
12719,NCT01212822,Disease-free Survival,2011-04-27,COMPLETED,INTERVENTIONAL,['PHASE2'],Change in Biomarker Levels,Progression Free Survival
12720,NCT03323866,Disease specific quality of life questionnaire,2017-05-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,Endoscopic evaluation of the nasal cavities
12721,NCT06033716,depression,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
12722,NCT03809403,Presence of ctDNA,2019-02-05,UNKNOWN,OBSERVATIONAL,['NA'],,MSI status
12723,NCT00341523,esophageal squamous dysplasia and cancer,2016-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Death from any cause
12724,NCT02472249,Liver blood flow,2016-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
12725,NCT00591279,evaluate strategies for the surveillance of post-polypectomy patients,1981-02,COMPLETED,OBSERVATIONAL,['NA'],,
12726,NCT05915637,Fatigue Assessment,2021-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
12727,NCT00003748,To determine the antitumor activity of irinotecan hydrochloride (CPT-11) in patients with unresectable adenocarcinoma of the esophagus and gastric cardia who have failed prior chemotherapy,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Evaluate the toxicities of irinotecan hydrochloride (CPT-11) in the patient population
12728,NCT00712855,"Type, frequency, and severity of adverse events.",2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12729,NCT05649969,Efficacy of STRONG Program on Treatment Outcomes,2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
12730,NCT04913662,Recommended dose,2021-04-26,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
12731,NCT01662869,OS in the Intent-To-Treat (ITT) Population,2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score
12732,NCT00601627,One Year Survival Rate,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
12733,NCT03068403,Area under the echo-power curve (AUC),2018-06-18,COMPLETED,INTERVENTIONAL,['NA'],,mrTNM staging
12734,NCT02448810,Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT),2015-06-15,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
12735,NCT00397904,Complete and Partial Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12736,NCT03763526,postoperative complications,2018-12-20,COMPLETED,OBSERVATIONAL,['NA'],Length of hospital stay,operative nutrition status
12737,NCT02665702,Progression Free Survival,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12738,NCT01964235,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Tolerability of study drug
12739,NCT00797251,The primary outcome is the safety of the anatomical right posterior sectionectomy performed IOUS-guided finger compression.,2007-09,UNKNOWN,OBSERVATIONAL,['NA'],,The secondary outcome is the efficacy of the anatomical right posterior sectionectomy performed by IOUS-guided finger compression.
12740,NCT04741165,Objective Response Rate (ORR),2021-01-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events (AEs)
12741,NCT01308086,Relapse Free Survival,2010-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Safety Profil according to NCI-CTAE v 3.0
12742,NCT04401800,Overall Response Rate (ORR) as assessed by Central Imaging Facility based on RECIST v1.1,2020-09-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-Free Survival (PFS)
12743,NCT00407407,Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities,2006-11-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug"
12744,NCT00238407,Proportion of patients without local failure measured 6 months after completion of study treatment,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Dysphagia as measured 6 months after completion of study treatment
12745,NCT03686254,"Overall survival (OS), Month",2018-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Time to progression (TTP), Month"
12746,NCT00027768,Recurrence-free survival,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Overall survival
12747,NCT03210298,Overall survival,2016-01,UNKNOWN,OBSERVATIONAL,['NA'],,Quality of life according to QLQ-30 of EORTC
12748,NCT04229459,Incidence of Treatment-Emergent Adverse Events (Safety),2019-12-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
12749,NCT05984511,Overall survival (OS),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Adverse events (AEs)
12750,NCT00372567,Progression-Free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS) - Imatinib Treatment Arm
12751,NCT03694080,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),2018-11-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Cell proliferation as a marker for metastatic ability
12752,NCT03484949,Diagnostic rate of patients with early gastric cancer,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA'],,Characterization of the high-rik individual for gastric cancer
12753,NCT03488446,Pathological lymph node status of every station,2017-08-30,UNKNOWN,OBSERVATIONAL,['NA'],,Lymph node stage (N stage)
12754,NCT01898104,number of patients with complete pathological tumor regression,2012-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",predictive and prognostic factors of tumor and circulating cells,changes in quality of life from baseline
12755,NCT03853928,Number of patients developing Hepatocellular carcinoma,2019-05-01,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse events found in cirrhosis with or without treatment with probiotics.
12756,NCT06276686,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity levels
12757,NCT01641783,progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,biomarkers
12758,NCT05357846,Overall survival,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Perioperative mortality
12759,NCT04910789,3-year disease-free survival,2019-12-11,RECRUITING,INTERVENTIONAL,['NA'],,The incidence of perioperative mortality
12760,NCT05102110,Correlation of SNP allele frequency in genes associated with known aero-digestive cancers in paired samples of tumour type and rectal mucus.,2021-12-01,RECRUITING,OBSERVATIONAL,['NA'],,
12761,NCT06034197,Feasibility of VGT-309,2023-09-27,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
12762,NCT04139070,Incidence of Treatment-Emergent Adverse Events (CTCAE),2020-06-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Tumor volume
12763,NCT04428905,Quality of life: survey,2020-07-11,RECRUITING,INTERVENTIONAL,['NA'],Outcome Measure for facilitators,
12764,NCT04890054,Likelihood of any colorectal cancer (CRC) screening (for study-eligible patients),2021-05-14,RECRUITING,INTERVENTIONAL,['NA'],,Colonoscopy referral
12765,NCT02222259,Quality of life,2014-09,COMPLETED,INTERVENTIONAL,['NA'],,Functional status
12766,NCT05943288,Positive Predictive Value (PPV),2023-04-25,RECRUITING,OBSERVATIONAL,['NA'],Non-neoplastic resection rate,Endoscope withdrawal time
12767,NCT03800693,Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale,2019-03-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of dose holds or reductions
12768,NCT03981146,Durable Clinical Benefit,2019-08-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival Time
12769,NCT00400114,"To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.",2006-09-25,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy
12770,NCT04853784,Incidence of postoperative complications,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,5-year overall survival OS
12771,NCT05059821,Assessment of immunological response,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression free survival and overall survival time
12772,NCT03648632,Resection rate for all patients starting SBRT,2018-08-22,COMPLETED,INTERVENTIONAL,['NA'],,Mortality
12773,NCT01412684,Splenic function,2011-09,WITHDRAWN,OBSERVATIONAL,['NA'],,Lymph node retrieval
12774,NCT04722341,Patient-reported outcomes (PROs),2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Sleep
12775,NCT03781323,Proportion of Patients With a Complete Clinical Response.,2019-05-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of Patients With Survival
12776,NCT05275530,Overall completion of any Colorectal Cancer Screening test,2022-02-21,COMPLETED,INTERVENTIONAL,['NA'],,Colorectal cancer screening uptake by modality
12777,NCT02226107,Colonoscopy Completion,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,
12778,NCT06264921,Objective Response Rate (ORR),2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (AR)
12779,NCT00770991,Change in Burden of Rectal Polyps,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Apoptosis and Cell Proliferation Measured by Percent Difference in Staining.
12780,NCT04937647,neoplasia detection rate,2021-06-16,RECRUITING,OBSERVATIONAL,['NA'],,Endoscopist neoplasia detection rate
12781,NCT06109272,Stage 2: Overall Survival (OS),2024-01-11,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Domain as Measured by the GHS/QoL Domain of the EORTC QLQ-C30
12782,NCT03931044,Accuracy (%; 95% CI),2019-04,UNKNOWN,INTERVENTIONAL,['NA'],,Mean difference of total number of LNs retrieved during the lymphadenectomy of the D2 anatomical plane (mean±DS).
12783,NCT05507112,Pathological complete response (pCR) rates,2022-09-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Patient reported outcome: Functional outcome according to Wexner score
12784,NCT01827553,Overall survival,2013-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Changes in Quality of life
12785,NCT05866172,overall survival,2023-05-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events
12786,NCT05497336,Objective response rate (ORR),2022-08-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with abnormality in ECG parameters
12787,NCT00717756,Response Rate by Recist Criteria,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12788,NCT01683240,Efficacy of cholangioscopy in gallstone therapy and stricture diagnosis,2011-02,COMPLETED,INTERVENTIONAL,['NA'],,Stricture diagnostic
12789,NCT01840436,Incidence of grade 2 or higher oral mucositis,2013-03,COMPLETED,INTERVENTIONAL,['NA'],,Weight curve
12790,NCT02647125,Local control rate,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,progress-free survival
12791,NCT03484221,The ratio of tumor downstaging to stage 0 and stage I,2018-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
12792,NCT06084481,Objective Response Rate (ORR),2023-11-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Neutralizing Antidrug Antibody (nADA)
12793,NCT01938300,Change of MCF of EXTEM,2011-06,COMPLETED,INTERVENTIONAL,['NA'],,Change of Fibrinogen
12794,NCT02084524,Perioperative nutritional management,2013-10,UNKNOWN,INTERVENTIONAL,['NA'],,Evolution of the activities of daily living
12795,NCT06030622,Primary Outcome: Safety and tolerability,2023-12-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Secondary Outcome: Biomarkers
12796,NCT03572283,Change in cell proliferation by Ki-67 expression in tumor cells,2018-04-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of Adverse Events
12797,NCT03465501,Evaluation of the tolerance of interstitial brachytherapy of the anal canal,2007-08-17,COMPLETED,OBSERVATIONAL,['NA'],,Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups
12798,NCT04651634,Incidence of severe OM,2021-06-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Analgesic use for OM
12799,NCT00220142,,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,
12800,NCT04773626,Evaluate the relationship between tumor deposits and prognosis of colorectal cancer patient.,2021-06,UNKNOWN,OBSERVATIONAL,['NA'],,
12801,NCT01523457,Progression Free Survival,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Correlate Time to Progression, Objective Response, and Overall Survival With Early Changes in Glucose Metabolism Using FDG-positron Emission Tomography (PET) Scanning"
12802,NCT02988440,Dose intensity,2017-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Area Under the Plasma Concentration-time Profile (AUCtau) of sorafenib
12803,NCT00002947,,1996-10,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12804,NCT03958188,Standardization of a reading grid for PreOPerative Imaging of NeuroEndocrine Tumors,2019-03-31,UNKNOWN,OBSERVATIONAL,['NA'],,
12805,NCT00003548,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12806,NCT04598984,The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer,2020-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
12807,NCT00247676,Objective Response (CR or PR),2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentration of Soluble KIT (sKIT)
12808,NCT00493883,Survival time,2006-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12809,NCT00581724,Descriptive statistics will be generated to describe the prevalence of pain and its psychosocial correlates.,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,
12810,NCT02596256,Progression free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12811,NCT01847495,Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan,2013-10,WITHDRAWN,INTERVENTIONAL,['NA'],,Overall survival
12812,NCT04720924,Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract confirmed by pathological examination,2021-01-16,UNKNOWN,INTERVENTIONAL,['NA'],,"Detection rate of early cancer and precancerous lesions on upper gastrointestinal tract from senior, intermediate and primary endoscopist with assistance of AQCS."
12813,NCT02608879,Oral Mucositis Severity - NCI Scale,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Change in Quality of Life as Measured by the Composite Score of the EORTC
12814,NCT01718626,Progression-free survival(PFS),2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
12815,NCT03948100,Patient 6-minute walk test (6MWT),2018-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Patient and caregiver quality of life (QOL)
12816,NCT00763776,Intra-operative blood loss during liver transection (ml).,2008-07,TERMINATED,INTERVENTIONAL,['NA'],,60-day postoperative complications
12817,NCT02280694,The median progression free survival (mPFS),2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12818,NCT00405587,Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor Levels of Phosphorylated Extracellular Signal-Regulated Kinapse (ERK), Cyclin D1, and Ki-67"
12819,NCT01967875,Progression-Free Survival (PFS),2013-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life(QOL)
12820,NCT02443324,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
12821,NCT02683824,Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq),2016-01-12,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
12822,NCT02298010,Topographic pattern of metastasis to regional lymph node stations,2016-01,COMPLETED,OBSERVATIONAL,['NA'],,recurrence pattern
12823,NCT04517708,Change of quality of life after 8 weeks: European Organisation for Research and Treatment of Cancer (EORTC) version 3.0,2016-01-15,COMPLETED,INTERVENTIONAL,['NA'],,
12824,NCT04997850,Conversion resection rate,2020-05-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
12825,NCT03749005,Impact on operation strategy of three dimensional visualization technique,2017-04-18,UNKNOWN,OBSERVATIONAL,['NA'],,1-year disease free survival rate
12826,NCT05755685,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,the recurrence rate of metastasis and long-term survival of participants accepted the treatment of rmhTNF in the treatment of peritoneal metastases in colorectal cancer.
12827,NCT00646022,Study the natural history of familial carcinoid tumors,2008-08-25,RECRUITING,OBSERVATIONAL,['NA'],,Screen for occult disease and determine whether early detection affects the natural history of the disease
12828,NCT00623831,"Number of Participants With Pyrogenicity at Each Dose Level Tested in the Intrasubject Dose Escalation Performed Over a Dose Range of 250 to 547,000 EU",2007-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Best Overall Tumor Response
12829,NCT05456165,Incidence and Severity of Adverse Events,2022-05-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,T-cell response using Peripheral Blood Mononuclear Cells (PBMCs)
12830,NCT04115618,Toxicity Effect,2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
12831,NCT01741597,Change in volume transfer coefficient (Ktrans) during DCE-MRI with tumor-homing peptide iRGD compared to a baseline DCE-MRI without tumor-homing peptide iRGD,2014-07,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,The potential for tumor-homing peptide iRGD to enhance uptake of key anti-cancer agents
12832,NCT00003057,,1997-03-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,
12833,NCT05506696,25OHD level,2012-09-24,COMPLETED,INTERVENTIONAL,['NA'],,
12834,NCT05774964,Progression Free Survival (PFS),2023-03-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
12835,NCT06152289,Develop an artificial intelligence solution to help with diagnosis in VCE,2023-02-10,RECRUITING,OBSERVATIONAL,['NA'],,Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract
12836,NCT01882920,rate of abdominal complications,2010-06,COMPLETED,INTERVENTIONAL,['NA'],length of hospital stay,Overall Survival
12837,NCT05498168,The ratio of predicted neoantigens being immunogenic,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12838,NCT00005938,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12839,NCT05035108,The incidence of adverse events (safety and tolerability).,2020-11-10,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Electrolyte level
12840,NCT05115916,Overall Colorectal Cancer Screening Uptake,2019-08-28,COMPLETED,INTERVENTIONAL,['NA'],,Effect of electronic primer message on CRC uptake among participants who opened
12841,NCT04338685,Number of Participants with Adverse Events (AEs) According To NCI CTCAE v5.0,2020-07-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
12842,NCT05664906,Comparison of the proportion of the most severe modified WHO Mucositis Grades,2023-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of analgesic and antibiotics use daily
12843,NCT02647047,Assessment of postoperative pain control by mean of the visual analog scale at hospital discharge,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],,Ready to discharge status
12844,NCT02089386,Extent of Barrett's involvement and changes in histology,2014-07-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in the length of Barrett's esophagus involvement
12845,NCT03238820,Complications,2014-01-10,COMPLETED,INTERVENTIONAL,['NA'],,Body composition
12846,NCT01225744,Objective response rate (according to RECIST criteria),2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to progression (TTP)
12847,NCT05631015,The accuracy of recommentions for different disease with deep learning algorithm,2012-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The F-score of gastric diseases with deep learning algorithm
12848,NCT01608464,Pathological Complete Response ( regression score 1a- see response assessment) in each treatment group,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2'],,Rate of conversion from PET non responder to responder with each type of salvage therapy
12849,NCT01417494,"Tolerance, in terms of no grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy",2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival with no deterioration of autonomy
12850,NCT03286920,Percentage of 5% body weight loss on Day 30,2017-09-20,UNKNOWN,OBSERVATIONAL,['NA'],,Re-hospitalization ratio
12851,NCT04889456,30-day morbidity with Clavien-Dindo grading,2021-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,"Long term morbidity: incisional hernia, adhesion related small bowel obstruction, readmissions, reinterventions"
12852,NCT05051592,Detection rate of alterations of anti-epidermal growth factor receptor primary resistance using Circulating tumour DNA,2021-03-26,UNKNOWN,OBSERVATIONAL,['NA'],,Adverse reactions experience by patient
12853,NCT03263741,Objective response rate(ORR),2017-04-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate(DCR)
12854,NCT00335595,Determine the free time to disease progression,2006-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Prognostic factor of the K-Ras gene mutation
12855,NCT02929082,Tumoral environment invasion assessed by the presence of microvascular invasion of the tumor capsule after pathological examination of the surgical pieces,2018-01-23,COMPLETED,INTERVENTIONAL,['NA'],,Interstitial force and traction force at the cell/tumor interface assessed by FRM
12856,NCT03674073,Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.,2018-10-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival at 2 years
12857,NCT00183846,"To determine the maximum tolerated dose of irinotecan when administered as a 5-day continuous infusion with concomitant radiation therapy in patients with upper gastrointestinal tumors (pancreas, stomach, duodenum, and common bile duct)",2000-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To obtain preliminary information related to the efficacy of this combination
12858,NCT03992456,Overall survival (OS),2020-04-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Tumor tissue studies,Patient-reported quality of life
12859,NCT03867916,Rate of Participation,2018-12-13,COMPLETED,INTERVENTIONAL,['NA'],,Patient Acceptability
12860,NCT00243633,Medical and economic interest of CEUS,2005-04,COMPLETED,INTERVENTIONAL,['NA'],,Harmony inter-readers
12861,NCT02711553,Progression Free Survival (PFS),2016-05-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score
12862,NCT01505413,Response rate,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
12863,NCT03051464,TME-free survival,2017-04-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Overall Quality of life
12864,NCT01995227,Safety,2013-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall Survival (OS),Tumor Biomarker Status
12865,NCT01510561,Safety (change in hematology and chemistry laboratory values from baseline),2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy
12866,NCT00338039,Median Overall Survival,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12867,NCT02117895,Overall survival,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],Pain Control,"Disease-specific, recurrence-free survival"
12868,NCT04636008,Adverse reaction,2020-08-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life questionnaire
12869,NCT01041404,Overall Survival - Time to Event,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Trastuzumab Maximum Serum Concentration (Cmax)
12870,NCT00281996,Overall survival at 6 months,2005-03,TERMINATED,INTERVENTIONAL,['PHASE1'],,
12871,NCT04190121,infective complications,2019-03-26,UNKNOWN,INTERVENTIONAL,['NA'],patient's serum albumin changes,length of stay in the ICU
12872,NCT05573217,Evaluate efficacy,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
12873,NCT01918852,Incidence of HFS in first line treatment,2013-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response rate
12874,NCT00068068,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12875,NCT02339116,Progression Free Survival 2 (PFS2),2015-02-26,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Toxicity Rate
12876,NCT01655641,Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.,2012-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Secondary outcome measure
12877,NCT04523662,PFS,2020-08-30,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12878,NCT01789723,Optimal dose and schedule of Fusilev to prevent or reduce mucositis,2013-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],Overall Response Rate (ORR),Relationship between Fusilev use and oral mucositis
12879,NCT04617067,Overall survival (OS),2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],Incidence of hypercalcaemia,Tumour response rate Duration of response
12880,NCT03078348,Rate of Fecal Immunochemical Test (FIT) Kit Return Per Study Arm,2011-12-05,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Diagnostic Colonoscopy
12881,NCT04936399,Distribution of patient quality of life through EQ-5D-3L (EQ-5D) every two weeks for 24 weeks post-treatment initiation following patient enrolment into the EAMS,2020-06-25,COMPLETED,OBSERVATIONAL,['NA'],,
12882,NCT00178698,Survival,2002-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of Life
12883,NCT05883644,Objective response rate (ORR),2023-06-27,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change from baseline in HRQoL as assessed by EORTC QLQ-HCC18
12884,NCT05481463,Progression-Free Survival (PFS),2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,adverse events (AE)
12885,NCT05356039,Resection,2022-04-19,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life at 24 months after inclusion
12886,NCT06078787,To evaluate the ORR according to RECIST 1.1 following Olaparib administration,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate the OS according to RECIST 1.1 following Olaparib
12887,NCT04423354,Perioperative mortality,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA'],,5-year disease-free survival rate
12888,NCT04743479,Hazard ratio (HR),2020-12-01,RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic yield
12889,NCT03219372,Time to Recurrence,2018-09-27,TERMINATED,INTERVENTIONAL,['PHASE2'],,Levels of Liver Tissue Markers Related to HCC
12890,NCT04400383,Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period,2020-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
12891,NCT05078866,Rates of grade 2/3 adverse events and symptom reactivity following revaccination (Cohort II),2022-11-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Mismatch repair and/or microsatellite instability status of polyps (and adjacent normal mucosa as control)
12892,NCT01443377,Histopathological complete response rate (pCR),2011-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
12893,NCT00025090,Recurrence-free survival,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Cause-specific and overall survival
12894,NCT04095299,Rectal preservation at two years,2020-01-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of grade 3-4 toxicity according to CTCAE v4
12895,NCT04856423,The accuracy of us-qFIT to diagnose colorectal advanced adenoma.,2021-04-19,UNKNOWN,OBSERVATIONAL,['NA'],,Develop a predictive model of advanced colorectal neoplasms which includes the value of us-qFIT.
12896,NCT00030563,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
12897,NCT02002299,invasive front growth pattern,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,
12898,NCT05470738,"The main study's objective is to definite the effective rate of adjuvant chemotherapy performed after surgery (at the 3-month post operatively), which is essential marker recognized as improving overall survival.",2022-09-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"The secondary objective of the study is to know, in patients operated for pancreatic adenocarcinoma, the rate of postoperative complications, the rate of the postoperative morbidity and mortality, and the quality of the resection."
12899,NCT03150628,Mortality,2017-08-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Readmissions
12900,NCT00052559,Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery,2002-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival
12901,NCT02652702,colostomy associated complications,2016-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,
12902,NCT03943173,Feasibility of olaparib,2019-06-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Symptom burden and health status
12903,NCT03041662,death,2011-10-31,COMPLETED,OBSERVATIONAL,['NA'],,biliary dysplasia
12904,NCT00054951,,2001-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12905,NCT04526886,Unplanned chemotherapy treatment delay,2020-10-15,COMPLETED,INTERVENTIONAL,['NA'],,Out of pocket costs associated with chemotherapy treatment visits
12906,NCT01372787,"Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales",2011-04-12,UNKNOWN,OBSERVATIONAL,['NA'],,
12907,NCT04947930,Sensitivity and specificity of the screening tool generated from fecal metagenomics and metabolomics data.,2021-07,UNKNOWN,OBSERVATIONAL,['NA'],,
12908,NCT02387268,Safety as Measured by Number of Serious Adverse Events and Major Complications.,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Percentage of Participants in Whom the Cecum Was Reached
12909,NCT04710641,Progression free survival (PFS),2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
12910,NCT00792285,colorectal cancer screening,2005-03,COMPLETED,INTERVENTIONAL,['NA'],,colonoscopy screening
12911,NCT01719380,Phase 2: Progression Free Survival (PFS),2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Phase 2: Number of Participants With Any Variant in Gene Status at Baseline
12912,NCT03413605,Colorectal Cancer Screening Rate,2016-06-01,COMPLETED,INTERVENTIONAL,['NA'],,
12913,NCT06092112,The objective response rate based on mRECIST,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],The impact of CD-801 treatment on immune cell profiling in serum after treatment.,Overall Survival
12914,NCT04714983,Maximum tolerated dose (MTD) achieved during dose-escalation phase,2021-02-15,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Measure Immune response with ELISPOT
12915,NCT02906943,Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions,2016-08,RECRUITING,OBSERVATIONAL,['NA'],,Concordance between administrative data and clinically abstracted data comparing variables using 2x2 concordance tables
12916,NCT04094688,Progression-free survival (PFS),2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Prognostic effect of highest achieved 25(OH)D
12917,NCT02644408,Quality of Life (QoF),2014-10-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse events
12918,NCT04659005,HCC screening uptake rates,2021-02-01,COMPLETED,INTERVENTIONAL,['NA'],,Decisional conflict scale
12919,NCT03120572,Change of forced vital capacity (FVC),2013-08,COMPLETED,OBSERVATIONAL,['NA'],,Change of dyspnea
12920,NCT00454376,"Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)",2006-10,UNKNOWN,OBSERVATIONAL,['NA'],,Response to change after various treatments
12921,NCT00691691,Response rate to SBRT,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Treatment Related Toxicity
12922,NCT00874406,progression free survival,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival
12923,NCT03487484,Change in quality of life specific for the gastrointestinal tract,2018-03-22,TERMINATED,OBSERVATIONAL,['NA'],,Change in faecal Incontinence
12924,NCT03777657,Overall Survival (OS),2018-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,time to response (TTR)
12925,NCT00593866,The Maximum Tolerated Radiation Dose,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The Percentage of Participants Free From Local Progression at 2 Years
12926,NCT04161755,Drug related toxicity,2019-12-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
12927,NCT00059618,Maximum Tolerated Dose (MTD) of Bortezomib with Carboplatin Chemotherapy,2003-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
12928,NCT05909410,Perception about the impact of CHCs on favoring/contrasting specific symptoms onset,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12929,NCT01238094,Progression free survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
12930,NCT06028516,ctDNA positive patients are detedcted before PET-CT,2021-01-06,RECRUITING,OBSERVATIONAL,['NA'],,
12931,NCT03563651,"Detection rates of Kras, Braf, or PI3K tumor DNA extracted from urine in patients without pre-existing mutations",2014-02-06,COMPLETED,OBSERVATIONAL,['NA'],,
12932,NCT03841201,"Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)",2019-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Translational research
12933,NCT04008056,Authorization for preparation of chemotherapy based on patient reported outcome (decision 3),2019-11-16,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction with the patient reported outcome questionnaire
12934,NCT06056908,"Provide education on the diagnosis, medical management, and treatment of SDS/SDS-Like conditions for patients, families, and the medical/scientific community.",2016-01-19,RECRUITING,OBSERVATIONAL,['NA'],,
12935,NCT06206382,Mortality,2024-01-05,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Morbidity
12936,NCT01486329,Safety and tolerability,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumor perfusion
12937,NCT02513199,Number of Participants With Objective Response Rate,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Child-Turcotte-Pugh (CTP) Score
12938,NCT01642953,Drop rate from critical pathway,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Recovery after surgery
12939,NCT03015038,Immune cells trafficking,2017-02-05,UNKNOWN,OBSERVATIONAL,['NA'],,"Safety (Number of adverse events, ECOG status)"
12940,NCT00084617,Response Rates (RR) in Metastatic Gastric/GE Junction Tumors,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
12941,NCT02509507,Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE),2016-02-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12942,NCT02952989,Incidence of dose-limiting toxicities (DLTs),2017-02-23,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
12943,NCT04456933,Percentage of anastomotic leak (AL),2020-06-29,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of Re-interventions
12944,NCT02945033,"Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first",2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-related adverse events
12945,NCT05111626,Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining Participants,2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,Part 2: Number of Participants With Anti-Bemarituzumab Antibody Formation
12946,NCT04587128,Cohort B Progression Free Survival (PFS),2020-10-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Circulating Tumor DNA (ctDNA) at time of Progression,Overall Survival (OS)
12947,NCT02730546,Pathological Complete Response (PathCR) Rate,2016-06-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Dose-limiting Toxicities (DLTs) Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
12948,NCT01860742,Progression Free Survival (PFS),2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,"Tumor 18FDG PET/CT and 68Ga-octreotate PET/CT uptake at baseline, at mid and end of treatment"
12949,NCT00190801,Response rate according to RECIST criteria,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population
12950,NCT03074461,Stool frequency,2017-04-05,UNKNOWN,INTERVENTIONAL,['NA'],,Antimotility drug usage
12951,NCT02541461,Change in body composition (changes in lean tissue mass and fatty tissue mass Using DEXA machine produced by Hologic),2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Changes in lipid profile
12952,NCT00376948,Median Overall Survival Estimate,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation
12953,NCT01677312,Median Number of Passes to Establish Diagnosis,2012-08,COMPLETED,INTERVENTIONAL,['NA'],,Complications
12954,NCT02085031,Anastomosis-related early complication rate,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Postoperative quality of life
12955,NCT05169177,Standard deviation of difference between software and ground truth measure,2022-10-17,RECRUITING,OBSERVATIONAL,['NA'],,Modelling of patient or treatment features that contributed to the success or failure of the KIM method
12956,NCT04665921,Incidence of dose limiting toxicities,2021-01-18,TERMINATED,INTERVENTIONAL,['PHASE1'],,Incidence of antidrug antibodies (ADA)
12957,NCT00827723,concordance rate between ICGR-15 and Portal Pressure values in patients with resectable HCC and cirrhosis Child A from alcoholic and non-alcoholic origin.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,postoperative liver failure.
12958,NCT04323813,Assessments of diagnosis of CRC by EMT-TF mRNA levels in blood,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA'],,Prediction of prognosis of CRC by EMT-TF mRNA levels in blood
12959,NCT05933980,ORR,2023-12-19,RECRUITING,INTERVENTIONAL,['PHASE2'],,DoR
12960,NCT06102772,Progression Free Survival,2023-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
12961,NCT00003103,,1997-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
12962,NCT03431428,OS,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,QOL
12963,NCT04324307,ORR,2019-11-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,OS
12964,NCT04492215,Rate of organised colorectal cancer screening at 24 months,2021-05-31,RECRUITING,INTERVENTIONAL,['NA'],,Identification of denial of the colorectal cancer screening
12965,NCT00436423,Response rate by RECIST criteria,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate the following efficacy measure Duration of response,Time to treatment failure,Time to documented disease progression, Overall survival"
12966,NCT05947201,pathologic complete response (pCR) of the patients' resected tumors,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,R0 resection rate
12967,NCT02291744,"TFS time of failure of strategy (the second progression time after induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment)",2014-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
12968,NCT03247231,Removal of the subepithelial tumour (initial clinical success).,2017-03-31,TERMINATED,OBSERVATIONAL,['NA'],,Long-term recurrence.
12969,NCT02988921,Evaluation of tumor heterogeneity with IBEX software,2016-10,RECRUITING,INTERVENTIONAL,['NA'],,Reduction in acute and late side effects based on modified RT treatment volumes with pre- and post-chemoradiotherapy based on MRI and CT simulation
12970,NCT02403531,overall response rate (clinical complete response and partial response),2015-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival
12971,NCT02545556,Number of participants with Adverse events,2015-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
12972,NCT03250091,Risk stratification,2017-06-19,RECRUITING,OBSERVATIONAL,['NA'],,"Gastric, faecal microbiome in cancer patients and patients with precancerous lesions"
12973,NCT06065891,Prevalence of paraaortic lymph nodes in pancreatic cancer in patients submitted to a tentative curative resection,2023-09-05,RECRUITING,INTERVENTIONAL,['NA'],,To address the question of how to optimize the frozen section analyses (lgll station 16) as related to the final pathology report?
12974,NCT01681472,Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of AEs Per Severity
12975,NCT04984174,"age, sex, types of institutions and chemotherapy regimens",2021-08-04,RECRUITING,OBSERVATIONAL,['NA'],,
12976,NCT06134973,Application prospect of liquid biopsy technique in monitoring HCC in high risk population,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
12977,NCT05485974,"adverse events (AEs), and serious adverse events (SAEs) overall",2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic variables including volume of distribution
12978,NCT05420558,early postoperative recurrence,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],,diagnostic performance
12979,NCT05596435,Area under curve of the model for detecting stage I/II/III pancreatic cancer,2022-10-10,RECRUITING,OBSERVATIONAL,['NA'],,Specificity of the early detection model
12980,NCT03699657,Minimum diameter of ablative zone,2014-12-15,COMPLETED,INTERVENTIONAL,['NA'],Maximal diameter of ablative zone,2-year LTP
12981,NCT05707598,Hospital stay after surgery,2023-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Disease-free survival
12982,NCT02038283,Direct Health Care Costs for each CRC screening strategy,2009-10,COMPLETED,OBSERVATIONAL,['NA'],,Factors Associated with HRQOL
12983,NCT00470340,Survival without recurrence at 2 years,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Morbidity and mortality following adjuvant treatment
12984,NCT02583087,Rate of histologically complete (R0) resection of esophageal adenocarcinoma or high grade dysplasia,2016-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,rate of buried glands
12985,NCT00316862,Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Proportion of Patients Experiencing Grade 3 or Greater Hematologic and Non-hematologic Toxicity
12986,NCT05107661,: Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program,2021-09-26,TERMINATED,OBSERVATIONAL,['NA'],,Colorectal Screening Strategies in the High Risk Medically Underserved Population in a Hospital-based Community Outreach Program
12987,NCT05963776,pulmonary complications of liver cirrhosior or HCC,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
12988,NCT05302557,Ileus,2021-12-09,RECRUITING,INTERVENTIONAL,['NA'],,Hospital readmission
12989,NCT05551039,Proportion of patients with reasons for discontinuation,2022-08-15,COMPLETED,OBSERVATIONAL,['NA'],,Descriptive summary of Pre-existing comorbidities
12990,NCT05759858,Disease-free survival,2022-12-14,RECRUITING,OBSERVATIONAL,['NA'],,"The incidence and mortality of postoperative hemorrhage, bile leakage and other complications."
12991,NCT04617457,Overall survival after R0/R1 resection (OS-res),2021-10-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,QoL-adjusted OS
12992,NCT00577031,PFS: Time to Event,2008-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score
12993,NCT03997162,Rate and type of post-operative complications,2018-10-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival of enrolled patients,QoL after stomach cancer surgery
12994,NCT05547529,Disease-free survival,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE3'],,R0 resection rate
12995,NCT02350517,Progression free survival,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life
12996,NCT01236053,Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin,2010-06,COMPLETED,OBSERVATIONAL,['NA'],,
12997,NCT00562666,"Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction",2008-02,TERMINATED,INTERVENTIONAL,['PHASE1'],,"Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria."
12998,NCT05170438,Overall response rate,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
12999,NCT00375661,Incidence of adverse effect of interferon,2006-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13000,NCT03637647,Fitness,2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],,Sarcopenia defined by skeletal muscle radiation attenuation
13001,NCT01919242,the type of complications and the incidence of it,2013-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13002,NCT03199586,Establish the safe recommended phase 2 dose,2017-12-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Cmax
13003,NCT05836870,Safety and adverse events (AEs),2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13004,NCT01883297,Number of occurrences and severity of side effects,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of patients with an immunity and no immunity to the study treatment
13005,NCT05573035,Determine recommended Phase 2 Dose Range (RP2DR),2022-12-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
13006,NCT04709380,TTP,2021-03-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of grade 3 and above adverse events
13007,NCT00826579,To assess the extent of upstaging due to the SLN procedure for colon cancer.,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.
13008,NCT00397787,Response (CR/PR/stable disease) as measured by RECIST criteria,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13009,NCT03265743,Realization of human papillomavirus vaccination,2017-09-25,COMPLETED,OBSERVATIONAL,['NA'],,Reasons for non-vaccination
13010,NCT03947840,Rate of immunological response,2019-01-30,COMPLETED,OBSERVATIONAL,['NA'],,Rate of recovery in physical activity
13011,NCT02725424,major Pathological response rate,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13012,NCT03843229,tumor size,2019-01-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Interleukin(IL)-2,Interleukin(IL)-4,Interleukin(IL)-6,tumor necrosis factor(TNF)-α，interferon(INF)-γ in blood"
13013,NCT02286492,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA'],,
13014,NCT04840186,Median overall survival,2021-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life
13015,NCT04639180,"Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)",2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0
13016,NCT02858778,The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg,2016-06,UNKNOWN,INTERVENTIONAL,['NA'],,Time to consultation in Ig vs. Cg groups
13017,NCT05910099,Rate of patients who remain in a rectal cancer clinical study to completion,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13018,NCT05802420,Progression-free survival,2023-02-01,RECRUITING,INTERVENTIONAL,['NA'],The prognostic role of targeted therapy selected based on MRD,Overall survival
13019,NCT05259384,Complication Rate,2021-04-17,RECRUITING,INTERVENTIONAL,['NA'],,The rate of spleen-preservation
13020,NCT00098527,Radiographic response rate (complete response & partial response),2004-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in plasma and urine TGFB levels
13021,NCT05380557,Overall survival,2021-08-23,TERMINATED,OBSERVATIONAL,['NA'],,
13022,NCT00003365,,1996-08,TERMINATED,INTERVENTIONAL,['NA'],,
13023,NCT03052478,Objective response rate (ORR) by RECIST 1.1,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13024,NCT03851133,Presence of Visceral Adiposity,2019-03-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
13025,NCT05066048,Species composition of fecal microbial,2021-04-30,UNKNOWN,OBSERVATIONAL,['NA'],,age in year
13026,NCT03605186,"Change in ""patient-reported oral mucositis"".",2019-02,UNKNOWN,INTERVENTIONAL,['NA'],,"Change in ""Clinical assessment of oral mucositis""."
13027,NCT02391662,Efficacy of treatment through 3-months deterioration free rate,2015-06-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,CA 19.9 biomarker response
13028,NCT02350400,Establish safety and toxicity profile of the irinotecan loaded DEBIRI beads (number of patients with adverse events according to Health Science Authority's Safety Reporting for Clinical Trials),2014-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Tumour response (measured by mRECIST)
13029,NCT06088940,Effects of probiotic on depression symptoms,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Relationships between bacterial taxa and symptoms,Probiotic effects on gut microbiota differential taxonomic abundance
13030,NCT05853172,R0 surgical conversion rate,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse event (AE)
13031,NCT03418922,Part 1 and Part 2: Number of Participants with Any Serious and/or Non-serious Adverse Event,2018-01-30,COMPLETED,INTERVENTIONAL,['PHASE1'],,Part 1 and Part 2: Serum Concentration of Nivolumab
13032,NCT05074264,Most efficient algorithm for detection of anogenital human papillomavirus (HPV)-related cancers and high-grade squamous intraepithelial lesions (HSIL),2021-11-30,RECRUITING,INTERVENTIONAL,['NA'],,
13033,NCT04316013,Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE3'],MINS Substudy,Health utility with intravenous lidocaine versus no lidocaine
13034,NCT01170754,Boston Prep Scale,2010-04,COMPLETED,INTERVENTIONAL,['PHASE4'],Boston Prep Scale (Per Protocol Analysis),Phosphorus Level in mg/dl
13035,NCT00506623,Pathologic stage Tumor regression grade,2004-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Toxicity
13036,NCT04616768,Patient perceptions of symptom management,2020-11-19,COMPLETED,INTERVENTIONAL,['PHASE3'],Additional analysis of the primary outcome between different arms (3 month) (exploratory),Fitbit step data
13037,NCT01320241,Overall Mean Survival and Median Survival,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants with Adverse Events as a Measure of Technical Success, Clinical Success, Safety (including WBC and Immunological changes of lab, Leakage of the radioactive seeds and Complications related to the procedure."
13038,NCT05865132,ORR,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
13039,NCT01008657,2 years global (local+distant) recurrence rate,2010-02-09,COMPLETED,INTERVENTIONAL,['NA'],,Primary treatment effectiveness (assessed 1 month after completion of treatment course which can include up to 3 radiofrequency ablation (RFA) procedures performed monthly)
13040,NCT04847167,Enteroscopy success rate,2020-02-24,COMPLETED,INTERVENTIONAL,['NA'],,Therapeutic success rate
13041,NCT00879385,Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.,2009-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.
13042,NCT03336229,Change in cardiorespiratory fitness,2018-04,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility of home-based exercise,Survival
13043,NCT04025840,2-year overall survival,2019-09-11,RECRUITING,INTERVENTIONAL,['PHASE4'],Time to oral intake after surgery.,2-year progression-free survival
13044,NCT01924897,postoperative morbidity,na,UNKNOWN,INTERVENTIONAL,['NA'],Feasibility outcomes for exercise training,Admission to HDU/ITU
13045,NCT04838327,Feasibility and translational analysis,2021-08-16,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life by EORTC QLQ-C30
13046,NCT03608631,Progression-free survival (PFS),2021-01-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13047,NCT03898102,Difference in grade 2 or worse HFSR incidence within the first 8 weeks of regorafenib treatment between mCRC patients who receive regorafenib treatment with or without zinc supplementation,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of patients with adverse events (graded by NCI-CTCAE v4.03),Duration of treatment of regorafenib (DoT)
13048,NCT01254591,"Prognosis (6-month, 1-year, 3-year, and 5-year mortality including local/distance recurrence rates)",2006-11,UNKNOWN,INTERVENTIONAL,['NA'],,
13049,NCT00687830,"Comparing All Morning Bowel Prep to Evening Bowel Prep for Patients Undergoing Afternoon Colonoscopies. (Using Ottawa Scale Scores, Range 0-14) Lower Score Indicates a Better Outcome.",2008-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Patient Satisfaction in the Two Groups, All Morning Prep vs. All Evening Bowel Prep."
13050,NCT03742596,The Level of C-reactive protein (CRP),2018-11-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",The level of neutrophils,The gastrointestinal toxicity
13051,NCT02685046,Effects of treatment on the mesenchymal gene expression profile,2016-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAEv4.02
13052,NCT04273100,objective response rate (ORR),2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],conversion rate of hepatectomy,overall survival
13053,NCT02419586,Time to first flatus,2015-01,COMPLETED,INTERVENTIONAL,['NA'],,Length of stay
13054,NCT02072356,Adverse experiences,2010-10-11,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
13055,NCT04710589,Progression free survival time (PFS),2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],Side effects,Overall survival time (OS)
13056,NCT03507699,Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression free survival
13057,NCT05271110,Feasibility of treatment,2022-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life after surgery
13058,NCT00098787,Objective Response Rate,2005-09-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13059,NCT00024362,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13060,NCT02355119,Disease free survival (DFS),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
13061,NCT03236636,Overall survival (OS),2017-09-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],"Genome level (DNA, mRNA, miRNA) biomarker analysis",Assessment on Quality of life 2
13062,NCT02277548,Average/Cumulative Opioid Dose,2014-05,COMPLETED,INTERVENTIONAL,['NA'],,
13063,NCT06055439,Objective Response Rate (ORR),2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13064,NCT02210364,Recommended dose of PM01183 in combination with capecitabine,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13065,NCT00278694,Number of patients obtaining pCR,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Clinical, radiological and molecular response to treatment"
13066,NCT02817685,The incidence of Hepatocellular carcinoma,2016-05,UNKNOWN,OBSERVATIONAL,['NA'],,
13067,NCT00537823,All-cause Mortality,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Change in Tumor Size From Pretreatment to Preoperative CT Scan
13068,NCT00399009,Clinical anastomotic leak,2004-01,TERMINATED,INTERVENTIONAL,['NA'],,
13069,NCT04188158,Disease-free survival (SLE) at 2 years,2017-03-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To compare the postoperative morbidity and mortality of the neoadjuvant treatment in relation to the standard treatment
13070,NCT01340105,Complete ablation rate,2011-04,COMPLETED,INTERVENTIONAL,['NA'],,Hospital stay
13071,NCT01387503,For Phase III - Overall Survival,2011-01,COMPLETED,INTERVENTIONAL,['NA'],,Validation of the Metroticket model for the prognosis of survival after liver transplantation in patients exceeding Milan Criteria
13072,NCT02827565,"Technical Optimization of KRAS, BRAF and NRAS mutations detection",2016-02-03,COMPLETED,INTERVENTIONAL,['NA'],,"KRAS, NRAS et BRAF mutational status"
13073,NCT01668134,Stereotactic radiation therapy (either photon or proton) can be delivered to the liver with a less than 10% 3-month incidence of Grade 4 study related toxicity.,2009-12-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Measure the response rates associated with using SBRT in patients with resectable HCC and IHC
13074,NCT04430725,Time to local recurrence per treated nodule,2019-08-07,RECRUITING,OBSERVATIONAL,['NA'],,Changes in patient reported outcomes per patient
13075,NCT00216424,Tumor response and resectability of tumor following treatment with radiation and capecitabine (Xeloda).,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4'],,
13076,NCT02705118,Registration accuracy,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,Registration time
13077,NCT03598231,Proportion of Responders of Low Anterior Resection Syndrome,2018-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Urinary function
13078,NCT03857763,The pathological complete response rate(pCR),2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events Toxicity
13079,NCT05075421,5-year survival rates,2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13080,NCT00178243,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13081,NCT00043043,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13082,NCT03256084,Evaluation of CTC features,2017-07-17,RECRUITING,INTERVENTIONAL,['NA'],,
13083,NCT05859750,The number of subjects experiencing adverse events (AEs),2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of subjects who develop detectable anti-drug antibodies (ADAs)
13084,NCT04848311,number of harvested station 253 lymph nodes,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA'],complications,number of total lymph nodes harvested
13085,NCT05385809,Surgical conversion rate,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,adverse event (AEs)
13086,NCT05007587,Objective Response Rate and Disease Control Rate of the HCC Participants,2021-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],Hepatitis B infection,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
13087,NCT02441153,Disease-free survival,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,
13088,NCT05878405,Change in oral pain,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Change in the amount of daily requirements of oral morphine equivalents
13089,NCT03908840,Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) observed during the trial,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Determination of Maximum Tolerated Dose
13090,NCT04588909,Early post operative mortality,2020-03-23,UNKNOWN,OBSERVATIONAL,['NA'],,Rate of hospital acquired SARS CoV 2 infection among operated patients.
13091,NCT00265720,"Colorectal Cancer Screening Rate; This measurement(Impact) is taken 90 days from last intervention session. If a person is not screened, an additional measurement(Post-Impact) is taken 90 days from the Impact.",2003-03,COMPLETED,INTERVENTIONAL,['NA'],,"Knowledge, Attitudes and Beliefs; this measurement is taken at baseline and post intervention session. Sessions vary by intervention group after the initial recruitment sessions:"
13092,NCT00003600,Quality of life,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Response rate
13093,NCT03396926,Overall response rate (ORR) (Expansion Cohort),2018-04-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS) (Expansion Cohort)
13094,NCT00911391,Post-operative functional recovery,2009-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Perioperative Complications
13095,NCT05523154,Reduction in surgical site infections,2023-01-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Timeliness of sample analysis
13096,NCT06269445,Progression-free survival(PFS),2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Quality of life of the patients
13097,NCT03814629,Clinical symptom score is assessing a change,2015-08-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,kidney function test
13098,NCT02338752,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,immunology index
13099,NCT00154726,Response rate,1997-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,overall survival
13100,NCT01322815,Number of Participants Alive and Free of Progression at 4 Months (Patients Who Have Undergone Prior Therapy) and 10 Months (Untreated Patients),2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13101,NCT02788955,Change/maintenance in muscle mass,2016-04,COMPLETED,INTERVENTIONAL,['NA'],,Change in physical function
13102,NCT04106167,Overall Survival (OS) post-Infusion,2019-06-11,TERMINATED,OBSERVATIONAL,['NA'],,
13103,NCT03340844,Patient survival,2017-12-15,UNKNOWN,INTERVENTIONAL,['NA'],,Morbidity
13104,NCT04945720,One-Year Overall Survival Rate,2022-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory study endpoints,"Evaluate the patient's cancer-related QoL using the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ), the EORTC QLQ-HCC18."
13105,NCT05837598,Patient satisfaction assessed by patient feedback questionnaire.,2023-05-31,RECRUITING,INTERVENTIONAL,['NA'],Patient receipt of mental health care assess by electronic medical record review.,Tumor board participant satisfaction assessed by in-session feedback questionnaire.
13106,NCT01316679,,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,
13107,NCT02488707,Hospital stay,2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13108,NCT00983268,Maximum tolerated dose of vorinostat when given in combination with capecitabine and radiotherapy,2009-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Biological effect
13109,NCT03271047,Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1,2017-10-18,COMPLETED,INTERVENTIONAL,['PHASE2'],,Concentration Versus Time Summary of Plasma Concentration of Binimetinib
13110,NCT03468231,Overall survival,2018-03-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Tumor response
13111,NCT00968604,Dose-Limiting Toxicity (DLT),2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13112,NCT05804331,Long term outcomes: recurrent and residual disease,2023-03-14,RECRUITING,OBSERVATIONAL,['NA'],,Patient interviews/questionnaires
13113,NCT04708470,Determine RP2D of entinostat,2021-10-05,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Response (DoR)
13114,NCT00826800,To Determine the Pathologic Complete Response (Path CR) Rate in Patients With Locally Advanced (Stage II or III) Colon Cancer to FOLFOX-bevacizumab Administered as Neoadjuvant.,2009-02,TERMINATED,INTERVENTIONAL,['NA'],,
13115,NCT02999295,Progression free survival rate after 6 months,2017-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression free survival (PFS)
13116,NCT03333785,Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,2018-02-05,COMPLETED,INTERVENTIONAL,['NA'],Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire,Patient experience of the care process
13117,NCT05832398,1. Progression-free survival,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Overall survival
13118,NCT03301493,Timing of molecular profiling,2017-03-30,RECRUITING,OBSERVATIONAL,['NA'],,Outcome of treatment
13119,NCT01915602,Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review,2013-09-27,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of participants with adverse events as a measure of safety and tolerability
13120,NCT00024401,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13121,NCT02340117,Objective response rate (ORR),2015-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
13122,NCT03940976,Objective response rate,2019-04-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13123,NCT02070705,Change in tumor margins in patients who have undergone chemotherapy for pancreatic cancer (Group III),2014-01-31,RECRUITING,INTERVENTIONAL,['NA'],,DCE- MRI imaging parameters and descriptional analysis of normal pancreas DCE- MRI images (Group IV)
13124,NCT05394259,Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE1'],,
13125,NCT04671862,Rate of occurence of radiation mucositis,2021-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Radiation dermatitis
13126,NCT01394120,Overall Survival,2011-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13127,NCT02451553,Recommended phase 2 dose (RP2D) (Phase Ib),2015-11-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to progression
13128,NCT01494155,Progression-free survival,2011-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Measure utilization of health services
13129,NCT00574275,Overall Survival (OS),2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Anti-drug Antibodies
13130,NCT03435289,The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel,2017-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The number of participants with complete or partial response
13131,NCT04695964,anastomotic leak,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Length of post-operative hospital stay
13132,NCT01030263,Whether specialized columnar epithelium was detected.,2008-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,
13133,NCT05524428,Primary Outcome 3: Appropriateness of Implementation Strategies,2023-03-24,RECRUITING,INTERVENTIONAL,['NA'],,Secondary Outcome: CRC Screening Rates
13134,NCT05117957,Safety (Adverse events),2022-02-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
13135,NCT06209983,Length of hospital stay,2018-12-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],costs of hospitalization,Complication rates
13136,NCT02498041,Endoscopic Diagnostic Accuracy for Barrett's esophagus,2009-04,COMPLETED,INTERVENTIONAL,['NA'],,Adverse events
13137,NCT01916447,"Safety monitoring including adverse events, vital signs, and laboratory assessments",2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Document any preliminary antitumor activity of TAS-102 administered in combination with CPT-11 and in combination with CPT-11 and Bevacizumab.
13138,NCT05938309,Overall postoperative morbidity,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,3-year recurrence pattern
13139,NCT04250948,TRG0/1,2019-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13140,NCT02586753,Overall survival (OS),2015-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13141,NCT03961945,Aim 3 - Dysplasia Detection Sensitivity and Specificity,2021-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Aim 3 - Dysplasia Detection Rate of Missed Dysplasia
13142,NCT01053390,"(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)",2009-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy"
13143,NCT01811108,Number of Participants with AE,2009-07,COMPLETED,OBSERVATIONAL,['NA'],,Patients Overall Survival
13144,NCT02027311,Number of Intervention,2013-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Event of Hypoxia
13145,NCT05312372,Objective response per central review of antitumor activity (using Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (Phase 2),2025-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Changes in vital signs : SBP, DBP, respiratory rate and temperature (Phase 2)"
13146,NCT05994521,Rate of gastric outlet obstruction (GOO),2024-03-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status
13147,NCT02735941,Analysis of cannabinoid receptors in blood leukocytes and biopsies from patients with IBD and colon cancer,2017-06-13,COMPLETED,OBSERVATIONAL,['NA'],,Assessment of malignancy of colon cancer by tumor staging
13148,NCT04161911,Overall Survival,2018-10-29,COMPLETED,OBSERVATIONAL,['NA'],,
13149,NCT00102700,Document progression free survival after treatment with ARQ 501 and gemcitabine,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Document safety and efficacy of ARQ 501 in combination with gemcitabine
13150,NCT04810910,Relapse Free Survival(RFS),2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE1'],Peripheral blood T cell receptor sequencing analysis,Overall Survival(OS)
13151,NCT03162198,Number of cell-free DNA (cfDNA) in cirrhotic patients with hepatocellular carcinoma (HCC),2017-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Number of cfDNA amount with the Barcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.
13152,NCT06024343,Incidence of Clinically Relevant Postoperative Pancreatic Fistula,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Recurrence-free survival (RFS)
13153,NCT05816187,Changes in Health Related Quality of Life: EORTC QLQ-30,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The five Times Sit to Stand Test (5x Sit-To-Stand Test)
13154,NCT00061932,True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST),2003-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in Patterns of Gene Expression Pre- and Post-treatment Performed by GeneChip Analysis
13155,NCT00252889,"Subjective parameters including ECOG performance status, specific symptoms, and side effects are graded according to standard Common Terminology Criteria for Adverse Events (CTCAE) v.30 criteria.",2004-05,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13156,NCT05266820,Progression-free survival (PFS),2021-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events
13157,NCT05493033,Anastomotic leak,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incision herniation
13158,NCT01249859,To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,"Overall 3 year survival according to tumor stage, node invasion, and tumor localization"
13159,NCT01714466,Cleansing success rate,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,PEG3350 concentration
13160,NCT00019331,,1997-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13161,NCT00003514,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
13162,NCT01228045,Overall Response Rate (ORR),2011-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety Evaluations
13163,NCT01667198,Screening centre leader's adenoma detection rate,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Screening centre leader's withdrawal technique
13164,NCT03683004,Change from Beck Depression Inventory (BDI) from baseline to 12 and 24 weeks (Specific Aim III),2018-01-22,COMPLETED,OBSERVATIONAL,['NA'],,Change from Optical Coherence Tomography baseline at 12 weeks and 24 weeks
13165,NCT04450836,To evaluate the feasibility of treatment sequence (R-TT or TT-R),2020-11-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,To evaluate the safety (Treatment-Emergent Adverse Events) during treatment
13166,NCT03787667,Sensitivity,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13167,NCT01135849,Development of cardiomyopathy,2008-11,COMPLETED,OBSERVATIONAL,['NA'],,
13168,NCT00118339,,2003-07,COMPLETED,INTERVENTIONAL,['NA'],,
13169,NCT00252161,overall survival,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,adverse events
13170,NCT00701857,The maximum tolerated dose (MTD) of pemetrexed,2008-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria"
13171,NCT03445416,Change in vaccine awareness,2018-09,WITHDRAWN,INTERVENTIONAL,['NA'],,Change in healthcare engagement
13172,NCT05112016,"Quality of life, including functional and symptom scales, incontinence scores, sexual function",2007-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Costs
13173,NCT04452357,"Acute grade 3+ gastrointestinal toxicity possibly, probably or definitely related to radiation.",2020-01-13,SUSPENDED,INTERVENTIONAL,['NA'],,
13174,NCT03482609,The incidence of postoperative referred pain in the left shoulder within 1 month,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,inflammatory and immune response
13175,NCT05328765,Overall survival,2023-06-09,RECRUITING,OBSERVATIONAL,['NA'],,
13176,NCT06206733,Progression Free Survival (PFS),2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE3'],Number of anti-drug antibody (ADA) Positive Participants,Overall Survival (OS)
13177,NCT03976960,Number of biological risk factors for colorectal cancer,2018-09-19,RECRUITING,INTERVENTIONAL,['NA'],,
13178,NCT00039208,Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy,2002-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
13179,NCT05098847,Objective Response Rate,2021-10-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
13180,NCT00658840,all cause mortality,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13181,NCT01877135,at least one anal cancer,2013-08,UNKNOWN,OBSERVATIONAL,['NA'],,patient's feelings about his therapeutic care and impact on his emotional life
13182,NCT03392584,Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,2016-10-01,COMPLETED,OBSERVATIONAL,['NA'],,Measure intermediate metabolites and inflammatory mediators after neoadjuvant CRT and subsequent APR for LARC with reconstruction of the perineum with VRAM.
13183,NCT03008980,Outcomes of patients undergoing WATS sampling. Specifically incremental yield for Barrett's Esophagus and Esophageal Dysplasia due to WATS sampling above that noted from routine forceps biopsies in various clinical settings.,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
13184,NCT00609336,Median Overall Survival of Patients With Adenocarcinoma of the Pancreas,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percent of Patients Surviving at Annual Intervals
13185,NCT02250638,A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer,2014-05,COMPLETED,OBSERVATIONAL,['NA'],,
13186,NCT02635087,DFS,2015-12,RECRUITING,OBSERVATIONAL,['NA'],,OS
13187,NCT03043729,Pathologic complete response (pCR),2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,ECOG
13188,NCT01267578,overall survival,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Progression free survival
13189,NCT03798951,Post-operative complications,2019-06-05,TERMINATED,INTERVENTIONAL,['NA'],,
13190,NCT03606785,reduction in blood loss,2018-08-05,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13191,NCT04715581,Recurrence-free survival after surgery.,2021-11-25,RECRUITING,INTERVENTIONAL,['NA'],"Physical activity at 3 months, 6 months and 1 year after surgery.",Physical activity at 30 days after surgery (sub-study).
13192,NCT03109262,Image Quality for 90-Y PET/CT Scans,2017-02-15,COMPLETED,INTERVENTIONAL,['NA'],,Radiopharmaceutical Dosimetry Accuracy for 90-Y PET/CT Scans and 99mTc-MAA SPECT/CT Scans
13193,NCT02449109,Number of participants with Adverse events,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13194,NCT03977077,Progression free survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
13195,NCT02391207,the safety of HV-sparing surgery in terms of operative mortality and morbidity,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13196,NCT03303469,Measure Changes in Treated HCC Tumor Hypoxia Following TACE and Radiotherapy,2017-10-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13197,NCT01733719,Recruitment rate and retention,2013-02,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
13198,NCT05617469,Tumor regression grade,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
13199,NCT03765736,Companion Trial Enrollment,2020-04-20,TERMINATED,OBSERVATIONAL,['NA'],,
13200,NCT03104582,Acute cholangitis,2011-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Overall procedure related complication rate
13201,NCT05438667,The duration of efficacy,2022-06-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events
13202,NCT00072098,toxicity grading,2003-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,tumor response compared at four weeks to baseline
13203,NCT05901194,The proportion of patients with lenvatinib who have a Liver transplantation (LT),2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of Treatment-Emergent Adverse Events
13204,NCT04443309,Objective Response Rate (ORR),2020-09-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Biomarker,Adverse Events (AE)
13205,NCT00911170,Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy,2009-11-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Adverse Events (AEs)
13206,NCT02113384,Overall survival,2012-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
13207,NCT02685553,Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR,2016-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13208,NCT05043532,Rate of ability to perform successful molecular profiling in core tissue obtained during EUS-guided fine needle biopsy,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Type of actionable mutations detected on molecular profiling
13209,NCT00826488,"It is anticipated that out of 100 subjects recalled for additional breast imaging that 10 women will be recalled for biopsy. By adding 2D & 3D imaging, it is anticipated that 30 subjects out of 100 will have needed no workup.",2009-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
13210,NCT00215462,To assess the anti-tumor activity of vinorelbine when administered to patients with locally advanced or metastatic esophageal or gastric adenocarcinoma.,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To evaluate the toxicities of vinorelbine in this patient population.
13211,NCT05871762,3-year OS,2023-06-04,RECRUITING,OBSERVATIONAL,['NA'],,30-day mortality
13212,NCT05942807,Overall survival,2021-05-15,RECRUITING,OBSERVATIONAL,['NA'],,
13213,NCT03149679,Objective response rate (ORR),2017-05-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0
13214,NCT00541047,Freedom from distant metastases (any distance metastases or prostate cancer death) (RADICALS-RT),2007-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Freedom from biochemical progression (RADICALS-RT)
13215,NCT00049023,"Evaluate the short term and long term safety (mild/moderate/severe/life-threatening adverse events, premature discontinuations and serious adverse events)",2002-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13216,NCT00495846,Prolongation of the survival curve (>6 months),2007-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Improvement of quality of life according with SF36 questionnaire
13217,NCT01436617,Validate the utility of an IgE anti-cetuximab test in the treatment strategy,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,
13218,NCT02030561,Time-to-Event Outcome Measure,2014-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13219,NCT06077591,tumor response,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,rate of grade III/IV toxicities.
13220,NCT05780684,Proportion of patients that receive dose intensified infusional 5-FU in Cycle 6 of the FOX regimen,2023-07-14,RECRUITING,INTERVENTIONAL,['NA'],,5-FU drug exposure
13221,NCT01010945,Maximum Tolerated Dose,2010-02-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival
13222,NCT02607332,Disease control rate,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13223,NCT04616196,Objective Response Rate (ORR) by RECIST 1.1 of NKTR-255 in combination with Cetuximab in R/R metastatic HNSCC or CRC for Phase 2 Dose Expansion,2020-10-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The development of anti-drug antibodies (ADA) against NKTR-255 and cetuximab
13224,NCT05213741,Safety of magnetic-assisted colonoscope system,2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
13225,NCT04886635,"Safety of active surveillance (including delayed surgery), measured by the number of patients with adverse events",2021-03-09,RECRUITING,OBSERVATIONAL,['NA'],,The number of biopsies taken and quality of the biopsies
13226,NCT05137782,Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms,2023-01-03,COMPLETED,INTERVENTIONAL,['NA'],,Acceptability as measured by willingness to recommend study participation to others.
13227,NCT00955188,Adherence to colorectal cancer screening at 12 months post-intervention,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,Intention to get screened
13228,NCT01859806,Postoperative pancreatic fistula (POPF),2011-01,COMPLETED,INTERVENTIONAL,['NA'],,hospital stay
13229,NCT03766555,Overall survival,2018-05-21,RECRUITING,INTERVENTIONAL,['NA'],,Hospital stay
13230,NCT03385213,Transcriptional changes in gut microbiota,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Epigenetic changes
13231,NCT01130233,Bladder function,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
13232,NCT01072851,Comparison of the acceptance of colorectal cancer screening by patients who view print or multimedia educational tools,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,Comparative knowledge of colorectal cancer screening by patients who view the print or multi-media educational tools.
13233,NCT04519905,overall survival difference of definitive radiotherapy and chemoradiotherapy groups,2020-01-06,RECRUITING,INTERVENTIONAL,['NA'],,cancer specific survival
13234,NCT03607643,Response rate,2019-01-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.
13235,NCT00789633,Overall Survival (OS),2008-11-25,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS)
13236,NCT00828048,Identify clinical and morphological predictors of cancer or high grade dysplasia in patients with IPMN. Identify predictors of progression to cancer or high grade dysplasia among patients who are followed in surveillance programs.,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,
13237,NCT03745170,Overall survival (OS),2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of participants experiencing clinical and laboratory adverse events (AEs)
13238,NCT02958592,Stage of hepatic fibrosis,2015-06,COMPLETED,OBSERVATIONAL,['NA'],,
13239,NCT03138031,Overall survival rate,2017-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Tumor response rate
13240,NCT05047926,Adherence to each prehabilitation component based on patient reported adherence (Cohorts 2 & 3),2021-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Acceptability of remote setting in Cohort 3
13241,NCT06260150,Incidence rate of DVT,2023-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Amount of bleeding during surgery
13242,NCT04000737,Progression free survival (PFS),2020-01-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Effects of YIV-906 on mean t½ (Hr) of sorafenib in blood
13243,NCT04616131,Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected.,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response."
13244,NCT00660348,Number of Subjects Per Arm With Decrease in Pain Scores,2008-03,TERMINATED,INTERVENTIONAL,['NA'],,
13245,NCT03240679,Completeness of EMR Site Healing at Follow up Endoscopy,2017-03-22,TERMINATED,INTERVENTIONAL,['NA'],,Presence of Stricture Formation at Follow up Endoscopy
13246,NCT05883345,Validity of blood tests for gastric cancer screening and gastritis type,2023-04-24,RECRUITING,OBSERVATIONAL,['NA'],,
13247,NCT01220063,tumor response accoording to recist criteria,2007-10-19,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13248,NCT01872988,overall survival,2012-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,time to liver decompensation
13249,NCT04040842,LARS score change comparing before surgery and 1 year after the surgery.,2019-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13250,NCT01891344,Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study),2013-10-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Steady State Trough (Cmin) Level Rucaparib Concentrations
13251,NCT01310985,"Evaluate the safety of pre-operative concurrent chemotherapy with capacitabine (Xeloda), weekly cetuximab (Erbitux), and external beam radiation.",2008-03,COMPLETED,OBSERVATIONAL,['NA'],,"Evaluate efficacy of sphincter preserving surgery rate, local recurrence rate and the disease free and overall survival in patients."
13252,NCT05866783,Disease-free survival,2023-04-28,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
13253,NCT01808599,Complete remission rate,2013-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Event-free-survival (EFS)
13254,NCT02333279,Number of solid cancers,2008-05,COMPLETED,OBSERVATIONAL,['NA'],,
13255,NCT06164691,Clinical Complete Response,2022-08-14,TERMINATED,INTERVENTIONAL,['NA'],,Prealbumin Level
13256,NCT02063529,"the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.",2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QLQ C30)
13257,NCT00774501,To assess safety & feasibility of single dose image-guided intensity modulated radio (IG-IMRT) using gen anesthesia with apneic oxygenation & controlled ventilation to temp suspend respiratory motion for tx of mets liver disease during localization & tx.,2008-10,COMPLETED,INTERVENTIONAL,['NA'],,
13258,NCT00603577,"Neurological sensory assessment using the National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE, Version 3.0)",2008-01,TERMINATED,INTERVENTIONAL,['PHASE3'],,"AE graded with NCI-CTCAE (Version 3.0) and coded using Medical Dictionary for Regulatory Activities (MedDRA, version 9.1)"
13259,NCT01545804,disease stabilization,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13260,NCT00441155,Safety and tolerability of nilotinib either as single agent or in combination with Imatinib,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,To assess any clinical responses in Imatinib-resistant GIST patients. Assessment of tumor response will be made based on modified RECIST criteria - to be assessed at the end of every cycle of treatment
13261,NCT03076957,Maximum Tolerated Dose(MTD),2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Number of participants with toxicity as assessed by CTCAE v4.03 through study completion, an average of 1 year"
13262,NCT03231917,Adenoma Miss Rate,2017-03-01,COMPLETED,INTERVENTIONAL,['NA'],,Adenoma < 6mm Detection Rate
13263,NCT00003055,,1997-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13264,NCT05235490,The main objective of this work is to identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for an early recurrence in patients with hepatocellular cancer.,2021-01-28,COMPLETED,OBSERVATIONAL,['NA'],To correlate the imaging signatures predictive of recurrence with the cell population molding of tissue microenvironment (TME) and the tumor biology using tissue assessment as reference.,Identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for a tardive recurrence in patients with hepatocellular cancer.
13265,NCT02810418,Maximum Tolerated Dose (MTD) of Continuous Infusion LMB-100,2016-08-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Maximum Observed (Peak) Plasma Concentration (Cmax)/D (Dose) of LMB-100 in Arm B1 and Arm B2,Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
13266,NCT03635021,Progression-free survival rate at 35 months,2018-10-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],clinical impact of clonal dynamics by longitudinal analysis of circulating tumour deoxyribonucleic acid (ctDNA) in plasma,Incidence and severity of AEs CTCAE v4.03 criteria
13267,NCT00123760,To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values
13268,NCT04848051,Total number of participants who completed their colorectal cancer screening,2021-10-12,COMPLETED,INTERVENTIONAL,['NA'],,Screening outcomes: diagnostic results
13269,NCT01397019,2 year survival rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13270,NCT00238199,Time to progression,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Change in pancreatic cancer-induced pain
13271,NCT05369117,Three-year disease-free survival rate,2022-05-31,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,operative mortality
13272,NCT03896399,Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning,2019-04-09,UNKNOWN,INTERVENTIONAL,['NA'],,Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography
13273,NCT00842348,Adverse Events,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression Free Survival (PFS): Kaplan-Meier Estimate
13274,NCT01820091,Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis,2013-04,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Impact of Fusilev on number of Folotyn doses delivered
13275,NCT03600623,Number of participants with adverse events as a measure of safety and tolerability,2017-09-25,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Proportion of participants undergoing surgery after preoperative chemoradiation therapy
13276,NCT05493215,Incidence of Grade 3/4 adverse events attributable to imatinib per CTCAE v5.0,2024-03-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,Average dose of imatinib required to achieve therapeutic levels and drug dose over 3 years
13277,NCT06055543,Improvement in nutritional status,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE4'],,ONS Satisfaction
13278,NCT00112580,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR),2005-07-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13279,NCT01501903,Diagnostic accuracy,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of passes for diagnosis
13280,NCT02506842,Overall survival,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
13281,NCT02562755,Overall Response Rate (ORR),2015-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13282,NCT01326390,"Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)",2010-05,TERMINATED,OBSERVATIONAL,['NA'],,
13283,NCT02644603,Treatment related complications,2016-02,UNKNOWN,INTERVENTIONAL,['NA'],,Serum complement
13284,NCT02325986,overall response rate,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
13285,NCT01675999,Histological tumor response in the primary tumor according to the simplified Tumor Regression Grade (TRG) of Ryan,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,•Evaluation of another histopathological grade
13286,NCT04072445,Progression-free Survival (PFS),2019-10-18,COMPLETED,INTERVENTIONAL,['PHASE2'],Prediction of Clinical Benefit by Thymidine Kinase 1 (TK1),Number of Participants With Adverse Events
13287,NCT00006050,,1999-04-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13288,NCT03981614,Progression Free Survival (PFS),2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13289,NCT01505400,Molecular profiling data to be made available in patient's electronic medical records.,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Clinical trial accrual rates among patients with available molecular profiling data
13290,NCT04456699,Progression Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR).,2020-08-19,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number of Participants Discontinuing Study Intervention Due to an AE
13291,NCT00303940,,2005-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13292,NCT06219031,CR、PR、SD、PD,2023-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13293,NCT05460403,Overall survival (OS),2022-04-23,RECRUITING,OBSERVATIONAL,['NA'],Adverse events,Distant metastasis (DM)
13294,NCT04674696,Evaluate MRI good response rate after the total neoadjuvant treatment,2020-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Describe the safety and tolerability of total neoadjuvant treatment.
13295,NCT00701012,Assessment of bowel function,2008-01,COMPLETED,INTERVENTIONAL,['NA'],,comparison of leakage rate
13296,NCT02311205,Overall survival (OS),2014-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
13297,NCT03587480,3-year disease-free survival,2018-12-17,RECRUITING,INTERVENTIONAL,['NA'],,the score of quality of life
13298,NCT06251973,Overall Response Rate,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13299,NCT04959617,Specificity of quantitative FIT,2019-01-06,UNKNOWN,OBSERVATIONAL,['NA'],,
13300,NCT03591965,ORR,2018-08-07,TERMINATED,INTERVENTIONAL,['PHASE2'],Additional metabolites of ATG-008 in plasma and urine,"6, 9 and 12 month of survival rate"
13301,NCT05653427,Objective Response Rate (ORR),2022-12-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-amivantamab Antibodies
13302,NCT00848510,Whole Tumor Volume and Enhancing Tumor Volume,2009-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Progression-Free Survival (PFS) Time
13303,NCT04905030,(Long Term) Posterior beliefs about false risks of the HPV vaccine,2021-04-28,UNKNOWN,INTERVENTIONAL,['NA'],,Subjective vs Objective vaccination measure (binary indicators)
13304,NCT05613465,Cancer-related fatigue,2022-10-25,RECRUITING,INTERVENTIONAL,['NA'],,Immunologic function
13305,NCT02518373,Change in plasma gastrin level.,2000-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13306,NCT03015298,The results of the PET/MRI and PET/CT examination,2017-01,UNKNOWN,OBSERVATIONAL,['NA'],,Follow-up data
13307,NCT02833506,Incidence of adverse events defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03,2017-12-08,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Time to disease progression as documented by Response Evaluation Criteria in Solid Tumors version 1.1
13308,NCT00152906,Phase II: To determine with more confidence the rate and spectrum of all toxicities that occur at the maximally tolerated dose of radiation.,2003-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To determine whether serum cytokines and P-III-P can help predict RILD.
13309,NCT04921488,Estimation of the sensitivity of the automatic characterization system CAD EYE.,2021-10-21,COMPLETED,INTERVENTIONAL,['NA'],,"Compare the diagnostic performance to determine the malignancy of polyps between the automated colonic polyp detection device by the CAD EYE system, and the investigator performing the colonoscopy for colorectal cancer screening."
13310,NCT05745415,Progression free survival,2018-03-29,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13311,NCT02234180,Disease Free Survival (DFS),2014-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13312,NCT05429190,Increased sensitivity for HCC detection,2023-11-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],Patients acceptance of the SMS protocol (through a questionnaire),Cost-effectiveness analysis of SMS protocol
13313,NCT06026943,"Safety- Adverse events, Safety will be determined according to the overall incidence of device-related SAE's graded according to CTCAE v5.0 criteria",2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Exploratory Objective -to evaluate the changes in the immune markers by Blood samples for immune response,Efficacy- Alpha DaRT seeds
13314,NCT00390182,Overall Response,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Time of Advanced/Recurrent Disease Without Distant Metastases.,
13315,NCT02043730,Progression Rate,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13316,NCT06140823,Performance metrics for LIRIC model risk quantiles,2023-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Tumor stage at HCC diagnosis
13317,NCT06314750,OS,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13318,NCT00094445,Six-Month Participant Survival,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13319,NCT00828607,"Malignancy of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.",2009-01,COMPLETED,OBSERVATIONAL,['NA'],,"Diagnosis of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI."
13320,NCT01652482,Progression-free Survival (PFS) According to Modified RECIST v1.1 Criteria,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Minimum Observed Serum Concentration (Cmin) of MEHD7945A
13321,NCT04134104,Sexual Dysfunction,2014-12,COMPLETED,OBSERVATIONAL,['NA'],,
13322,NCT01704820,Per patient adenoma detection rate (average # adenomas detected/ patient in each arm of the study).,2012-09,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluate endoscopist comfort with performing retroflexion in the proximal colon.
13323,NCT02520141,Progression Free Survival of Ramucirumab in Advanced Biliary Cancers,2015-12-29,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Disease Control Rate
13324,NCT04567459,5)Sarcopenia assessment,2021-01-27,UNKNOWN,INTERVENTIONAL,['NA'],,
13325,NCT04600518,Prognostic equivalence,2020-10-07,COMPLETED,OBSERVATIONAL,['NA'],,Multivariate analysis
13326,NCT05610592,5-year event-free survival rate,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Local recurrence
13327,NCT06071598,To define the functional role of MFSD2A in CRC through Polyunsaturated fatty acid (PUFA) ad genes analysis.,2023-03-15,RECRUITING,OBSERVATIONAL,['NA'],,
13328,NCT01006369,Progression-free Survival,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13329,NCT00439179,Toxicity (Number of Patients Who Experiened DLTs),2006-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Patients Who Experienced a Partial Response
13330,NCT02279771,anastomotic leak,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Number of overall postoperative complications
13331,NCT00113256,survival,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13332,NCT06113796,Costs of treatment,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,30-days Readmission
13333,NCT01434459,The maximum tolerated dose of gemcitabine when given in combination with therasphere,2011-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,The progression free of patients treated on the trial
13334,NCT01125111,The difference in 1 month between two surgical methods in terms of Bladder function.,2009-06,COMPLETED,OBSERVATIONAL,['NA'],,"The serial change of Bladder and sexual function according to times, in each operation method."
13335,NCT05387005,Detection rates of H. pylori infection,2022-05-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The compliance(/adherence) of screening tests for H. pylori infection in the two randomized groups
13336,NCT00483405,Disease Response Rate,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Progression
13337,NCT06046963,Ascites objective response rate (ORR),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes of ascite cell subsets in patients
13338,NCT05964621,VTE incidence in primary pancreatic cancer resection,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,
13339,NCT03081988,Prediction model for CCRT response based on clinical and genetic molecular factors,2015-10-19,RECRUITING,OBSERVATIONAL,['NA'],Clinical prediction factors for CCRT response (retrospective study),in-vitro prediction of CCRT using primary esophageal cancer organoid
13340,NCT05411432,SUV of organs,2022-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,radioactivity of blood sample
13341,NCT03662841,Time to progression,2018-07-13,TERMINATED,INTERVENTIONAL,['NA'],,Tumor response
13342,NCT04622176,Accuracy of lymph node diagnosis compared to MRI,2021-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
13343,NCT04523818,Incidence of adverse events,2020-08-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
13344,NCT04977453,Objective Response Rate (ORR) according to RECIST version 1.1,2021-08-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points,DCR per iRECIST guidelines
13345,NCT05980624,Nutrition status - scored Patient-Generated Subjective Global Assessment (PG-SGA),2023-07-20,RECRUITING,INTERVENTIONAL,['NA'],,common adverse effects
13346,NCT05863195,Overall survival (OS),2023-12-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of adverse events
13347,NCT02277093,Progression-free Survival (PFS),2015-09-22,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13348,NCT06089590,"Number of SAE declared by patients (cancer, serious infections, arterial and venous thrombotic events)",2023-11-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Number and duration of hospitalization, surgery, endoscopy and other imaging"
13349,NCT02685228,overall survival,2016-03,UNKNOWN,INTERVENTIONAL,['NA'],,Evidence of the size of the lesion in pancreas confirmed by non-investigational CT or MRI
13350,NCT01137084,patient and graft survival,2005-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complications
13351,NCT06094140,The proportion of patients receiving at least 80% of planned neoadjuvant treatment.,2022-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],Analysis of tumour tissue (baseline and surgical resection) for molecular changes and gene expression profile.,Objective response rate.
13352,NCT02221700,"Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy",2015-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Baseline treatment expectations
13353,NCT05866510,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants,2023-05-15,RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Related Adverse Events
13354,NCT00002884,,1996-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13355,NCT03427346,Eradication rate of neoplastic Barrett's Esophagus,2016-12,RECRUITING,INTERVENTIONAL,['NA'],,Intervention time
13356,NCT00004189,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13357,NCT04220151,Percentages of methylation of DNA in patients with HCC,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13358,NCT00087282,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13359,NCT00963794,"Electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.",2008-01,COMPLETED,INTERVENTIONAL,['NA'],,
13360,NCT02749513,Inhibition of Hedgehog pathway signaling as measured by real-time PCR.,2016-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Inhibition of VEGFR2 pathway signaling as measured by Western blot
13361,NCT04934618,Overall Suvival time（OS）,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE2'],Safety and tolerability,Disease control rate（DCR）
13362,NCT05606094,Percentage of Participants Receiving Locoregional Treatment for Localized Disease and Metastasis (Radiotherapy and/or Surgery),2023-03-09,COMPLETED,OBSERVATIONAL,['NA'],,Number of Participants with Adverse Events of Special Interest (AESI) In Each Line of Treatment
13363,NCT02179970,Safety of Investigational Medicinal Product (IMP),2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],Disease status,Pharmacokinetics of the Investigational Medicinal Product (IMP) within the body.
13364,NCT00408564,Progression-free Survival at 6 Months,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Determine the Biomarker Response of CA 19-9 to Therapy
13365,NCT04524702,Change from baseline tumor size as measured by cross sectional imaging at 8 weeks.(every 8 weeks),2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Changes in selected biomarkers in tumor microenvironment and circulation,Overall survival
13366,NCT03752398,Treatment-related adverse events as assessed by CTCAE v4.03,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13367,NCT02151864,Rate of dose limiting toxicities,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13368,NCT06217042,Disease-free survival (DFS),2024-02-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,5-year overall survival rate
13369,NCT05417386,R0 Resection Rate,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,Resection rate
13370,NCT02079220,anti-tumor activity of ziv-aflibercept in combination with XELOX in the first-line treatment of patients with metastatic colorectal cancer (mCRC),2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival (PFS)
13371,NCT04102436,Response rate,2024-03-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Immune monitoring
13372,NCT04044326,the efficacy of microwave ablation for the treatment of primary or secondary liver cancers: modified RECIST criteria,2019-09-01,WITHDRAWN,INTERVENTIONAL,['NA'],,safety and local tumor recurrences
13373,NCT06244225,Progression free survival (PFS) per RECIST v1.1,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,The treatment-related adverse events (TRAEs）
13374,NCT06222255,The LARS (Low Anterior Resection Syndrome) Score with Night symptoms,2023-12-06,RECRUITING,INTERVENTIONAL,['NA'],,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - CR29
13375,NCT01882972,Retention feasibility,2013-06,WITHDRAWN,INTERVENTIONAL,['NA'],,Self-reported Exercise-related Injury
13376,NCT06182072,Determine a single ideal dose which will be selected for further investigation in the dose escalation cohort.,2023-12-29,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],Evaluate patient tumor blood perfusion pre and post treatment with ProAgio.,Evaluate patient tumor response.
13377,NCT06013943,6-month progression-free survival rate (PFS),2023-03-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Objective response rate (ORR) per RECIST 1.1
13378,NCT04153721,"Change, during the preoperative phase, of the psychological condition of the patients, assessed by GAD7 questionnaire scoring.",2020-03-11,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of the number of postoperative critical values
13379,NCT04455945,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29) Symptom scales,2017-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13380,NCT06274879,Any grade 3 or 4 adverse events (AE) leading to chemo-immune checkpoint inhibitor-therapy (CICI) discontinuation up to six months after enrolment.,2024-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Overall survival,Total dose of CICI applied
13381,NCT00260364,Part B (Phase II): Overall response rate (complete response and partial response),2005-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,and Assessment of pain
13382,NCT00614913,Median Survival Without Tumor Progression,1998-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13383,NCT06120803,Grade 2 or higher radiation induced esophagitis,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,
13384,NCT04482608,Progression-Free Survival (PFS),2019-09-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13385,NCT00078468,To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response."
13386,NCT02868255,evaluation of the SIRP/CD47 expression,2016-01-03,COMPLETED,OBSERVATIONAL,['NA'],,
13387,NCT00697047,Long-term adherence to CRC screening,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,Impact of SOS interventions on outcomes and CRC-related costs
13388,NCT04297254,Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs),2021-02-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Time to First Dose Reduction
13389,NCT00004885,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13390,NCT01149642,The rate of grade 3 and 4 acute mucosal toxicity,2009-11,COMPLETED,INTERVENTIONAL,['NA'],,overall survival rates
13391,NCT05806151,Progression/Recurrence,2023-01-17,RECRUITING,OBSERVATIONAL,['NA'],,
13392,NCT00463840,Resectability After Chemoradiation,2004-06,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival
13393,NCT02078362,Percentage of cell lysis,2013-09,UNKNOWN,OBSERVATIONAL,['NA'],,
13394,NCT06023966,hepatic metastasis,2023-09-01,RECRUITING,OBSERVATIONAL,['NA'],,interval between the surgery and hepatic metastasis
13395,NCT01373346,Operation Related Mortality,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Albumin : Good Response Group
13396,NCT04288323,Reader reliability of screening modalities,2018-04-27,RECRUITING,INTERVENTIONAL,['PHASE4'],,
13397,NCT05433467,The position of the needle,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Intraoperative bleeding
13398,NCT04248647,"Functional capacity: Six-minute walk test (Enright, 2003)",2016-10-26,COMPLETED,INTERVENTIONAL,['NA'],,"Nutritional status: body weight loss, serum albumin, hand grip strength, body mass index, lean body mass and percentage of body fat"
13399,NCT02332863,Procedure Duration Required for Placing the Fiducial Markers,2016-08-03,COMPLETED,INTERVENTIONAL,['NA'],,Number of Fiducials Placed
13400,NCT04938336,Assessment of the usability of the decision aid tool through individual interviews,2022-04-22,RECRUITING,OBSERVATIONAL,['NA'],,
13401,NCT02072317,Progression-free survival (PFS),2013-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13402,NCT00197470,,2000-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13403,NCT05270824,The number of CD8+ tumor-infiltrating lymphocytes in tumor tissue and adjacent tissue before and after treatment,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Surgical safety
13404,NCT06191120,Tumor-level CMS4 status as assessed by the current RNA-sequencing based CMS4 status reference standard performed on fresh-frozen tissue samples following surgery.,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],RNA-sequencing derived gene-expression levels per tumor lesion,10-120 minutes post-injection dynamic [18F]-ALF-FAPI-74 uptake levels in tumor lesions and reference organs
13405,NCT01270178,The survival rate and recurrence rate between patients receiving ETV therapy and those in historical control,2011-01,UNKNOWN,OBSERVATIONAL,['NA'],,"HBV reactivation, incidence of ALT normalization, reduction of serum HBV DNA level, HBsAg loss and HBsAg seroconversion to anti-HBsAb, emergence of resistance."
13406,NCT05007106,PFS per RECIST 1.1 as Assessed by Investigator at 12 months,2021-09-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Who Discontinued Study Intervention Due to an AE
13407,NCT04414956,HCC occurrence,2016-07-01,RECRUITING,INTERVENTIONAL,['NA'],,Early HCC occurrence
13408,NCT01918644,Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,2014-04-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,OS
13409,NCT00972751,"Correlation of expression of these proteins with tumor stage, disease-free survival, overall survival, and risk of recurrence",2009-02,COMPLETED,OBSERVATIONAL,['NA'],,
13410,NCT05677048,Measure response rate to baseline and follow-up surveys by probands and at-risk relatives,2023-04-14,RECRUITING,INTERVENTIONAL,['NA'],,
13411,NCT02820077,mortality,2016-08-06,TERMINATED,INTERVENTIONAL,['NA'],,Hospital length of stay
13412,NCT04646772,Postoperative mortality,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Disease Free Survival
13413,NCT02768532,Vedolizumab concentration at week 6,2016-07-01,TERMINATED,INTERVENTIONAL,['PHASE4'],,Specific antibodies (anti-integrins) level at week 54
13414,NCT03941561,DFS,2019-01-01,RECRUITING,INTERVENTIONAL,['PHASE3'],Side effects,OS
13415,NCT02687113,RFA feasibility rates on planning USG with/without fusion CT/MR and US,2013-03,COMPLETED,INTERVENTIONAL,['NA'],Anticipated number of overlapping of RFA electrodes on planning USG with/without fusion technique,Number of patients with safety access route on planning USG with/without fusion technique
13416,NCT03864640,Content validity of Mediterranean Colorectal Cancer Registry: answering multiple-choice items,2019-02-27,COMPLETED,OBSERVATIONAL,['NA'],,Face validity of Mediterranean Colorectal Cancer Registry: the major reason behind the negative response
13417,NCT03494946,Overall Survival,2016-12-05,RECRUITING,INTERVENTIONAL,['NA'],,
13418,NCT00558207,Evaluate progression-free survival (PFS) in patients receiving ARQ 197 versus gemcitabine.,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further characterize the safety profile of ARQ 197
13419,NCT06157892,Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment,2024-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of anti-drug antibodies (ADAs) against disitamab vedotin
13420,NCT02678832,Social norms and cognitions toward self-management strategies of cancer patients as assessed by the variables of the theory of planned behavior (TPB),2015-12,COMPLETED,OBSERVATIONAL,['NA'],,Physical activity as assessed with SQUASH
13421,NCT00402961,To determine whether a Phase III trial of acupuncture for postoperative recovery after colorectal surgery is warranted as defined by evidence of reduction of postoperative ileus when compared to sham acupuncture,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of emetic episodes during hospital stay
13422,NCT03997435,Rate of pathologic complete response,2019-09-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of response to neoadjuvant therapy
13423,NCT01972503,3 years disease-free survival,2008-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,3 years overall survival and metastasis-free survival
13424,NCT00677287,safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST),2008-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,To evaluate immunological responses
13425,NCT01388257,Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease,2011-10,UNKNOWN,INTERVENTIONAL,['NA'],,Change in discomfort and impact assessed by the patient using a visual analog scale (VAS)
13426,NCT03228095,Performance of nanoarray sensor testing to detect target lesions and diseases,2017-07-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Groups of gastrointestinal microbiota correlating to VOCs
13427,NCT04766736,Netrin-1 expression patterns in HCC samples,2019-07-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13428,NCT01861483,R0 resection rate,2013-03,COMPLETED,OBSERVATIONAL,['NA'],,
13429,NCT02102646,Change in hepatic fat content,2014-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Correlation between Hepatic fat content and baseline androgen status
13430,NCT05080621,Expansion Phase Only: Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST,2021-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Evaluate the time to response (TTR) of ripretinib in combination with binimetinib
13431,NCT01964430,Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee,2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE3'],,The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4)
13432,NCT06277908,the type of complications and the incidence of it,2024-03-18,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13433,NCT01084330,Progression Free Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Evaluate Safety by measuring cardiac safety, recording Adverse Events (AEs) and tracking the tolerability of AUY922"
13434,NCT02308631,Safety and Tolerability of the procedure,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of animals with Adverse Events in the colostomy.
13435,NCT04755543,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,2019-06-17,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Serum concentration of the antibody against LP002 within 1 hour prior to each administration
13436,NCT00365391,Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to Treatment Failure
13437,NCT03329248,Objective response rate by RECIST,2017-11-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Patient-reported outcomes of pancreatic cancer symptoms
13438,NCT03366961,3-year overall survival,2017-12-01,WITHDRAWN,INTERVENTIONAL,['NA'],,Response rate of chemotherapy
13439,NCT00899158,Urinary 3-methylhistidine levels,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
13440,NCT02312167,"The number of participants with adverse events, their type and severity",2014-10,COMPLETED,INTERVENTIONAL,['NA'],"number of interpretable images per organ, per contrast agent and per pathology",The ease of manipulation of the robotized probe (grade 1 to 5)
13441,NCT01206218,Progression-free Survival,2010-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Response Rate
13442,NCT04965870,Progression Free Survival,2021-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Disease Control Rate
13443,NCT02777437,Disease free survival,2016-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The proportion of completion of laparoscopic surgery
13444,NCT02716688,response rate,2016-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Dysphagia score,Overall survival
13445,NCT04769713,Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver chemoembolization,2021-11-23,RECRUITING,INTERVENTIONAL,['PHASE4'],,Differences in disease response post liver tumoral chemoembolization between patients with hepatic hilar nerve block and those with sham procedure
13446,NCT05475288,Overall survival of patients with locoregionally recurrent colon cancer;,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13447,NCT01959906,overall survival,2013-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13448,NCT03118882,screening-related indicators,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Circulating biomarkers association with breast and colorectal cancer
13449,NCT02521285,Differences in the Activation Status of NF-kB by Assessing Levels of Total and Phospho-p65 and Cytoplasmic to Nuclear Translocation of Phospho-p65 at 12 Months (Location C),2016-01-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Incidence of Barrett's Esophagus (BE) Recurrence,Differences in the Change of a13pge2 at 12 Months (Location C)
13450,NCT01845454,Efficacy of Spray Cryotherapy Dose: Percent Regression of Disease Following Baseline Spray Cryotherapy,2013-04,TERMINATED,INTERVENTIONAL,['NA'],,Safety Outcomes
13451,NCT04392700,Recurrence of HCC,2019-07-25,RECRUITING,INTERVENTIONAL,['PHASE3'],,The number of overall patients
13452,NCT00842647,,2006-07,UNKNOWN,OBSERVATIONAL,['NA'],,
13453,NCT01786200,Klintrup-Makinen immune score,2013-02,UNKNOWN,INTERVENTIONAL,['NA'],,Local inflammatory response
13454,NCT01134640,Safety and toxicity of Erbitux in clinical practice,2008-01,COMPLETED,OBSERVATIONAL,['NA'],,
13455,NCT03601689,Distant recurrence rate,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Predictive factors of disease free survival
13456,NCT00598975,Number of Patients With Dose Limiting Toxicities,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Overall Response
13457,NCT00764140,mortality,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,distant metastasis
13458,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",2015-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Remission rates of co-morbidities
13459,NCT00380588,Percentage of Patients Alive at 1 Year (1-Year Survival Rate),2006-09,COMPLETED,INTERVENTIONAL,['PHASE2'],Survival Time,Progression Free Survival
13460,NCT01132534,"To compare the detection rate of premalignant lesions(intestinal metaplasia, gastric atrophy, dysplasia) and early neoplasia of stomach between combined AFI/NBI endoscopy versus standard endoscopy",2007-06,COMPLETED,OBSERVATIONAL,['NA'],,To assess the diagnostic accuracy AFI and NBI imaging
13461,NCT04532736,Lund-Kennedy endoscopic grading system (NPS),2017-09-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Presence of peripheral eosinophilia (PE, > 500/mcl) in blood samples"
13462,NCT03208335,progress-free survival(PFS),2017-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life (QOL)
13463,NCT01371240,Pancreatic tumor conspicuity on MRI,2011-06,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,post-injection complications and side effects of secretin
13464,NCT02783261,liver hypertrophy,2014-06,UNKNOWN,OBSERVATIONAL,['NA'],,
13465,NCT05494359,"The number of 15 Nitrogen, 14 Nitrogen, 28 Nitrogen, 29 Nitrogen, 30 Nitrogen",2023-04-04,RECRUITING,OBSERVATIONAL,['NA'],,The stage of the cancer
13466,NCT06091592,Serum autotaxın level,2020-12-30,COMPLETED,OBSERVATIONAL,['NA'],,tumor differentiation grade
13467,NCT00339742,Esophageal Cancer,2003-03-25,COMPLETED,OBSERVATIONAL,['NA'],,
13468,NCT06233981,Median Overall Survival,2024-01-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Toxicity
13469,NCT06008054,Recommended Phase II Dose (RP2D),2023-11-16,RECRUITING,INTERVENTIONAL,['PHASE2'],,Treatment-Emergent Adverse Event (TEAE)
13470,NCT05884255,Progression-free survival (PFS) assessed by BICR,2023-07-06,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence and severity of AE and SAE
13471,NCT04682847,Develop a platform to maintain liver functionality during treatment for liver cancer,2020-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Examine the dose-response of tumor and liver tissue in patients who received liver transplant after receiving SBRT
13472,NCT02307812,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
13473,NCT05486572,Hepatocellular Carcinoma Mortality,2023-11-03,RECRUITING,INTERVENTIONAL,['NA'],,Overall Survival
13474,NCT05578430,Major Pathological Response Rate (MPR rate),2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events (AE)
13475,NCT05701436,The one-year DFS rate,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse events
13476,NCT05487924,postoperative complication,2023-12-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,time to first flatus
13477,NCT03026803,Response Rate,2006-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13478,NCT01361035,"Change in cervical, breast and colorectal cancer screening rates",2008-06,COMPLETED,INTERVENTIONAL,['NA'],,Change in standardized patient ratings of physician communication behaviors
13479,NCT02399059,Global survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
13480,NCT05394415,Treatment safety,2022-05-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
13481,NCT00638612,Incidence of treatment emergent adverse events,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Functional Assessment of Cancer Therapy - Pancreas (FACT-Hep)
13482,NCT03380052,The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk,2006-02,COMPLETED,OBSERVATIONAL,['NA'],,
13483,NCT01656746,"Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins",2010-05,COMPLETED,INTERVENTIONAL,['NA'],,"Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is ""worst scar"", and 10 is the ""best scar"""
13484,NCT04032353,"the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.",2018-12-31,UNKNOWN,INTERVENTIONAL,['NA'],adverse events,tthe focal lesions of upper gastrointestinal tract
13485,NCT00077389,Rate of complete remission after completion of study therapy,2004-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Event-free survival
13486,NCT00030082,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13487,NCT01383343,"Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)",2011-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Time until hematologic nadirs (ANC, platelets, hemoglobin)"
13488,NCT03041571,Patient provider orientation scale score (PPOS),2017-03-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Medical honors students focus group
13489,NCT05688176,Identification of biomarkers (messenger RNAs) for therapy response prediction,2016-06,RECRUITING,OBSERVATIONAL,['NA'],,Development of a quantitative Polymerase Chain Reaction (qPCR) test for clinical use
13490,NCT01863420,Hematologic toxicity,2012-11,UNKNOWN,OBSERVATIONAL,['NA'],,Conformity and Homogeneity of IMRT plan
13491,NCT05214222,Objective Response Rate (ORR),2022-09-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,The 3-year OS rate
13492,NCT04151030,Technical success of endoscopic vs radiographic Push-PEG placement in patients who are not candidates for a Pull-PEG placement,2019-06-28,COMPLETED,INTERVENTIONAL,['NA'],,Procedure duration between endoscopic push PEG placement and IR guided push PEG placement
13493,NCT01769534,To validate the Sendai criteria prospectively in patients with pancreatic cysts.,2012-06,TERMINATED,OBSERVATIONAL,['NA'],,
13494,NCT05489250,Tumor mutations and their impact on treatment decisions in gastrointestinal cancer patients,2020-10-28,RECRUITING,OBSERVATIONAL,['NA'],"Feasibility of the PLATON WebApp - an interactive platform that connects the participating physicians on cases, cancer types, mutations, protein expressions and therapies, possible trials and discussion options for medical professionals",QoL via EORTC QLQ-STO22 questionnaire in genetically defined cohorts of EC/GC patients
13495,NCT05830890,Accuracy,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Sensitivity
13496,NCT02972034,Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT),2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by the Investigator
13497,NCT03112837,the incidence of Radiation Therapy Oncology Group grade 3 mucositis,2017-03-10,UNKNOWN,INTERVENTIONAL,['NA'],,
13498,NCT04712643,Overall Survival (OS),2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Adverse Events
13499,NCT00912327,Objective response rate (ORR),2009-06,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
13500,NCT04602117,Overall response rate (ORR),2021-07-28,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR) of patients treated with the weekly paclitaxel with tri-weekly trastuzumab duocarmazine (SYD985) combination
13501,NCT05093920,Tumor size,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Serum Alpha-fetoprotein level ng/ml.
13502,NCT01274143,Colonoscopy,2008-05,COMPLETED,INTERVENTIONAL,['NA'],,Decisional Conflict
13503,NCT03528941,Number of patients with hepatitis B reactivation,2018-11-28,COMPLETED,OBSERVATIONAL,['NA'],,Rate of adverse events during ibrutinib treatment
13504,NCT00003594,time to progression,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,quality of life
13505,NCT00903565,To validate the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage II colorectal cancer.,2008-09,UNKNOWN,OBSERVATIONAL,['NA'],,• Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.
13506,NCT03052556,Prevalence of HPV carriage,2017-03-08,COMPLETED,INTERVENTIONAL,['NA'],,Rate of worsening of cervical dysplasia
13507,NCT04307654,Postoperative complications,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
13508,NCT02954094,"Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice",2016-12,RECRUITING,OBSERVATIONAL,['NA'],,Establish a Biorepository Specimen Bank (BSB)
13509,NCT02021422,The Number of Participants with SAEs and AEs.,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Gather preliminary information on the immune modulation and clinical activity of this therapy
13510,NCT03659903,median OS,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
13511,NCT04761185,tolerable dose,2020-01-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13512,NCT02739698,"The Grouped Miller and Payne (MP) System for Pathological Response: G1 (Minimal Changes and < 30% Cells Tumour Reduction That Includes MP G1-G2), G3 (Microscopic Foci, Cells Tumour Reduction up to >90% That Includes MP G3-G4) and G5 (no Residual Tumour)",2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13513,NCT03852251,Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II),2019-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of subjects who develop detectable anti-drug antibodies (ADAs)
13514,NCT03877601,Fluorescence signal in patients with Barrett's Esophagus,2019-07-29,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Interrogate potential new EC biomarkers
13515,NCT01999634,anastomotic leaks rate,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,functional success of microdialysis
13516,NCT00505024,"To study the effectiveness of the interactive voice response system (IVRS), which is designed to send a report to a patient's doctor about severe symptoms they are experiencing.",2006-07,COMPLETED,INTERVENTIONAL,['NA'],,"To study if systematic symptom assessment (by the use of IVRS) is another way to report symptoms rather than the usual method, which is calling the doctor when there is a problem."
13517,NCT00720512,Progression-free survival,2008-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Safety
13518,NCT03524716,Text message response rate,2018-03-06,COMPLETED,INTERVENTIONAL,['NA'],,Social support
13519,NCT04975256,Establish Maximum Tolerated Dose,2021-08-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,Evaluate preliminary clinical activity of the combination regimen
13520,NCT03941080,Prediction of response to conventional systemic anti-tumor therapy conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,2020-09-09,RECRUITING,OBSERVATIONAL,['NA'],,Prediction of serious side effects to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer
13521,NCT04248634,Perineal complications,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Quality of life assessement: EORTC QLQ30 score
13522,NCT06189846,The rate of complete and/or nearly complete response,2024-01-04,RECRUITING,OBSERVATIONAL,['NA'],,Rate of changing attitude after using the digital rectoscope platform (intra-observer changing management).
13523,NCT05729230,Perception of prognosis and treatment side effects,2021-04-05,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of patient satisfaction with the information received during the consultation
13524,NCT04764643,Mean Visual analogue scale change,2020-02-01,COMPLETED,INTERVENTIONAL,['NA'],,exam time
13525,NCT00514020,"Number of Patients With Each Response in ""Good Risk"" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13526,NCT01247246,Efficacy,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety
13527,NCT03937440,Difference of stress responses between deep block and moderate block,2019-07-03,COMPLETED,INTERVENTIONAL,['NA'],,
13528,NCT02215642,Disease-specific survival,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],Disease-free survival,Overall survival
13529,NCT05228587,To identify IGT PDR cut-off level below which the liver graft is not to be used for solid organ transplantation,2022-02-01,RECRUITING,INTERVENTIONAL,['NA'],,To identify IGT PDR cut-off level(s) below which post-LT organ recovery is impaired (early allograft dysfunction).
13530,NCT02528526,Safety and tolerability as measured by collection of adverse effects information,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy as measured by MRI
13531,NCT03117556,Daily Narcotic Requirements,2017-08-31,WITHDRAWN,INTERVENTIONAL,['NA'],,Use of Anti-emetics
13532,NCT03851887,ORR,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,DCR
13533,NCT02241551,"Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control",2014-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT
13534,NCT02557932,H. pylori eradication rate,2015-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Factors associated with H. pylori reinfection
13535,NCT00684801,Caregiver's satisfaction with end-of-life care,2007-08,COMPLETED,OBSERVATIONAL,['NA'],,
13536,NCT04913376,Time until Grade 2 or higher patient-reported peripheral neuropathy after start of treatment in the first 12 weeks,2021-05-17,UNKNOWN,INTERVENTIONAL,['NA'],,Secondary Outcome Measures regarding comfort hilotherapy
13537,NCT01263171,Proportion of patients who commence neoadjuvant chemotherapy and radiotherapy and then undergo surgical resection,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Local recurrence-free, distant metastasis-free, and overall survival at 1 year after surgery"
13538,NCT05311189,Progression-free survival,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE
13539,NCT06300879,Postoperative TNM staging by Pathological findings .,2024-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life at 3 Months Postoperatively will be assessed by EORTC QLQ-STO22 scale
13540,NCT03277144,incidence of duodenal stump leak,2017-09-11,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of DSF by surgical volume
13541,NCT03825861,Pathologic Complete Response (pCR),2017-02-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of Disease Progression
13542,NCT05937919,Standardized uptake value,2023-05-28,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with drug-related adverse events
13543,NCT04514822,SUVmax 60/30 comparison between MLNs and BLNs,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA'],Accuracy,SUVmax 60/30 comparison from PTs between N0 and non-N0 stage
13544,NCT02041793,Resolution of Pseudocyst,2010-05,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence rate of pseudocyst
13545,NCT05751343,Objective response rate,2023-03-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,progress-free survival
13546,NCT03713593,Overall Survival (OS),2018-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of Participants Who Discontinued Study Drug Due to an Adverse Event
13547,NCT00006117,,1999-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13548,NCT01504477,Maximum Tolerated Dose,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Duration of Disease Control
13549,NCT00826540,Progression-free Survival Rate,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility of Study Treatment
13550,NCT03374254,Percentage of participants with a dose limiting toxicity (DLT),2018-02-16,COMPLETED,INTERVENTIONAL,['PHASE1'],,Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
13551,NCT00705731,"Adherence to colorectal cancer (CRC) screening, defined as completion of the screening strategy (the subject agrees to pursue/scheduled by the primary care provider).",2007-03,COMPLETED,OBSERVATIONAL,['NA'],,Identification of variables in the survey (based on the Health Belief Model) which are associated with non-adherence to screening.
13552,NCT06064344,The cumulative occurrence rate of complications of grade ≥2 within 2 years after the start of treatment,2023-10-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,2-year overall survival rate
13553,NCT04763642,Intra-abdominal infection,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],progression-free survival,Length of hospital stay (day)
13554,NCT01097018,Overall Survival,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression-free Survival
13555,NCT05844046,ORR,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2'],QOL,ORR-BICR
13556,NCT01637194,Number of patients with dose limiting toxicity,2008-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens
13557,NCT00757614,Evaluation of interactions between polymorphisms in predisposition genes and potential lifestyle risk factors,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,
13558,NCT05198856,progression-free survival (PFS),2022-03-10,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Percentage of Participants With Adverse Events (AEs)
13559,NCT04643405,Overall Response Rate (Applicable for: phase II stage) .,2021-03-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events
13560,NCT03942328,Progression-free survival rate at 2 years (Phase II),2019-09-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in immunologic correlates before and after vaccination treatment,Progression-free survival
13561,NCT04931654,Preliminary anti-tumour activity of AZD7789,2021-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Preliminary anti-tumour activity of AZD7789: Changes in circulating tumor DNA (ctDNA)
13562,NCT02072720,Change of VEGFR2 phosphorylation with IHC,2014-02,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Changes in vascular parameters in the tumor tissue to asses ongoing angiogenesis
13563,NCT02190071,positive malignancy rate of cover slides set and base slides set.,2014-06,COMPLETED,OBSERVATIONAL,['NA'],,"positive malignancy rate of (1) cytologic smear, (2) cell block and (3) histologic biopsy"
13564,NCT03052335,Negative predictive value (NPV) of the CCE2 for large polyps (≥ 10 mm),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cost-effectiveness analyses: cost reduction of preventive colonoscopies spared
13565,NCT02205463,Maximum Tolerated Dose (MTD),2014-12,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Pharmacokinetics of KD019
13566,NCT00005876,,2000-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13567,NCT00767273,Evaluate the performance of the novel imaging methods,2006-10,COMPLETED,INTERVENTIONAL,['NA'],,Correlate FLT activity with clinical outcomes
13568,NCT00677456,"Patients should live for 6 months at least, and with acceptable life quality",2008-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,There are significant differences among life qualities of the four reconstructions
13569,NCT02130427,Tumor Volume,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
13570,NCT02210260,Neuroendocrine response to surgery,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Inflammatory pathway
13571,NCT01091207,Disease-control rate,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate
13572,NCT02066974,Response rate,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],,"Overall survival, relapse-free survival"
13573,NCT01151839,operative mortality,2010-06,UNKNOWN,INTERVENTIONAL,['NA'],,Treatment toxicity
13574,NCT04529850,Incidence of Treatment Emergent AE's,2020-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cumulative Incidence of Severe OM
13575,NCT04361708,The maximum dose tolerated,2020-05-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival rate
13576,NCT02921646,Resting energetic expenditure measurement by indirect calorimetry,2017-07-10,TERMINATED,INTERVENTIONAL,['NA'],,
13577,NCT03127774,Progression Free Survival,2017-09-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival
13578,NCT03033446,Response Rate,2016-12-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events from the combination of RE and nivolumab assessed by NCI CTCAE v4.0
13579,NCT00002842,2 Year Disease-free Survival .,1994-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13580,NCT04008082,Presence or absence of factors with a possible influence on OS,2019-05-14,COMPLETED,OBSERVATIONAL,['NA'],,
13581,NCT00077441,"Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 6 weeks apart",2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
13582,NCT02549053,Research of HPV DNA in esophagus biopsies using real time polymerase chain reaction (PCR),2012-02,COMPLETED,INTERVENTIONAL,['NA'],,
13583,NCT01898091,Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.,2013-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13584,NCT00478010,Decision satisfaction,2007-01-19,COMPLETED,INTERVENTIONAL,['NA'],,
13585,NCT01759901,Post-operative surgical complications,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence rate of hepatocellular carcinoma
13586,NCT05396807,Progression Free Survival (PFS),2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life (QoL)
13587,NCT00078975,Prolonged stable disease rate,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety and tolerability
13588,NCT05544253,recurrence-free-survival,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13589,NCT04326296,"Safety, Tolerability",2020-05-30,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
13590,NCT03349957,tumeur response,2017-12-01,COMPLETED,OBSERVATIONAL,['NA'],,
13591,NCT03568019,A retrospective review to determine if PET can be used to identify cachexia-inducing lung and gastrointestinal tumors,2013-11-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13592,NCT06210334,Overall Survival (OS),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events (AE)
13593,NCT02298946,Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0),2014-11-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to Maximum Observed Plasma Concentration (Tmax) of AMP-224
13594,NCT03604653,Disease-free Survival,2018-05-15,COMPLETED,OBSERVATIONAL,['NA'],,Toxicity as measured by treatment related adverse events according to the NCI CTCAE v 4.0
13595,NCT04304131,sensitivity and specificity of EarlyTect,2020-06-07,COMPLETED,INTERVENTIONAL,['NA'],,
13596,NCT03988712,Diagnostic yield of colorectal cancer,2018-04-01,COMPLETED,OBSERVATIONAL,['NA'],,
13597,NCT02730611,Blood bile acids (micromols per liter),2016-03,COMPLETED,OBSERVATIONAL,['NA'],,Hepatic FXR expression
13598,NCT02843581,Relief degree,2016-07-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
13599,NCT00258232,Response rate by RECIST criteria at every other course,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to treatment failure
13600,NCT01952847,Severity of Oral Mucositis for mTOR Inhibitor Patients,2014-07-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,Summary of Adverse Events by Grade and Relationship - mTOR Inhibitor Cohort
13601,NCT03111732,Progression Free Survival (PFS),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),"Number of Participants With Grade 1-4 Adverse Events Unrelated, Unlikely, Possibly, and Probably Related to Capecitabine"
13602,NCT00909350,miR expression between tissue from Barrett's esophagus and that from normal tissues,2008-04,COMPLETED,OBSERVATIONAL,['NA'],,expression of miR in Barrett's esophagus patients with cancer in comparison to those who do not progress to cancer
13603,NCT00055809,Tumor response rate (CR + PR) as measured by RECIST criteria,2003-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity graded according to CTC v3.0 criteria for adverse outcomes
13604,NCT04407247,Treatment-related adverse events,2020-07-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Change in frequencies of immune cells in tissue/blood/stool samples,Recurrent immune-related diarrhea/colitis
13605,NCT04700527,The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo.,2023-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Subject reported acute toxicity profile as ascertained by patient-reported outcomes version of the CTCAE (PRO-CTCAE) for both subjects who receive therapeutic SCFA versus those who receive placebo.
13606,NCT03430440,Postoperative pain (numerical rating scale: 0 ~ 10),2017-03-01,UNKNOWN,INTERVENTIONAL,['NA'],,Side effects of PCA (area and vomiting / hypotension / muscle weakness
13607,NCT05187416,Elastic modulus measured by Ultrasonic shear wave and tumor stromal component assessed by pathological analysis in pancreatic cancer,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13608,NCT04247503,Incidence of cancer in the risk cohort,2019-12-11,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Measurement of test accuracy of biomarkers to detect pancreatic cancer
13609,NCT00002593,"Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival",1994-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Disease free survival
13610,NCT05963191,to evaluate the effectiveness of the CAD EYE system in screening for neoplastic lesions in Lynch syndrome.,2023-10-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Time of Colonoscopies
13611,NCT04673136,Detection of advanced lesions,2021-04-01,COMPLETED,INTERVENTIONAL,['NA'],,Characteristics of GI-GENIUS
13612,NCT00897442,Make available tissue and blood for proposed projects,1992-06,COMPLETED,OBSERVATIONAL,['NA'],,
13613,NCT00820339,Overall survival,2009-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"Blood transfusion ,hepatic function of patients after surgery, the incidence rate of complications"
13614,NCT00867464,Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination,2009-03-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
13615,NCT00618384,determination of time to progression (TTP),2008-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,adverse events
13616,NCT02735317,EORTC QLQ-C30,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The change of body weight from baseline.
13617,NCT05226221,30-day morbidity rate,2021-09-01,RECRUITING,OBSERVATIONAL,['NA'],,Emergency Surgical Frailty Index (EmFSI)
13618,NCT05239546,Major Clinical Response (MCR) Rate,2023-03-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR)
13619,NCT03787056,ROC curve AUC regarding diagnostic accuracy of progastrin levels at baseline in cancer patients compared to non-cancer controls,2018-12-04,RECRUITING,INTERVENTIONAL,['NA'],,"Comparison of the initial values and of the kinetics of other serum tumor markers (CA15-3, CA 19-9, CA125, CEA, PSA, AFP) with those of progastrin"
13620,NCT05526339,The incidence of hypoxia,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,The incidence of other adverse events
13621,NCT00122187,Percent of Patients Receiving GI Consult Plus Anatomic Workup for FOBT+ Results,2005-08,COMPLETED,INTERVENTIONAL,['NA'],,
13622,NCT01909830,Objective Response Rate (ORR),2012-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13623,NCT05287880,Comparison of BP between MLN and BLN.,2022-03-10,UNKNOWN,OBSERVATIONAL,['NA'],,
13624,NCT01286662,mortality,1978-01,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of desmoid tumors
13625,NCT05792735,Pathological Complete Response Rate,2023-04-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life (QoL),Number of participants with treatment-related adverse events (TRAE) as assessed by CTCAE v5.0
13626,NCT03345225,Comparing the change in the Lencioni score between the SureFire infusion system and a standard endhole microcatheter,2018-05,WITHDRAWN,INTERVENTIONAL,['NA'],,Number of Adverse Event
13627,NCT05388513,Survival,2009-01,COMPLETED,OBSERVATIONAL,['NA'],,
13628,NCT03998644,"Gut microbiota structure and function difference between colorectal cancer, precancer and healthy controls",2015-12,RECRUITING,OBSERVATIONAL,['NA'],,"Metabolic difference of blood samples between colorectal cancer, precancer and healthy controls"
13629,NCT02993731,Overall Survival,2016-12,COMPLETED,INTERVENTIONAL,['PHASE3'],Overall Response Rate in Biomarker Positive Patients,Mean Change From Baseline for Global Quality of Life (QoL) at 8 Weeks.
13630,NCT04097067,Response rate,2019-09-01,RECRUITING,INTERVENTIONAL,['NA'],,Acute and chronic toxicities
13631,NCT01919463,Mean Intubation Time (MIT),2015-03,UNKNOWN,INTERVENTIONAL,['NA'],,Polyp Detection Rate (PDR)
13632,NCT00751036,Progression-free Survival (PFS),2009-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Overall Survival (OS)
13633,NCT05884723,Perioperative blood transfusion,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Cancer-related mortality
13634,NCT02521727,number of participants having advanced neoplasms.,2015-11-26,COMPLETED,OBSERVATIONAL,['NA'],,number of participants having advanced neoplasms based on age of the proband
13635,NCT02046356,Technical success,2014-01,UNKNOWN,OBSERVATIONAL,['NA'],RFA complications,IDR-free survival
13636,NCT01643278,Maximum tolerated dose defined as the highest dose studied for which the observed incidence of dose-limiting toxicity is less than 33% according to the National Cancer Institute Common Toxicity Criteria,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],Genotype (v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT] and platelet-derived growth factor receptor-alpha [PDGFR-a]) mutation status,"RR as measured by RECIST 1.1, Choi and immune-related response criteria"
13637,NCT02775227,Comprehensive Complication Index,2016-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Disease specific survival,Readmissions
13638,NCT01586416,Number of participants who withdraw from study after enrollment,2012-12,UNKNOWN,INTERVENTIONAL,['NA'],,Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount
13639,NCT02911961,APAP-CYS Concentrations Over Time - Acetaminophen Group,2021-08,WITHDRAWN,INTERVENTIONAL,['PHASE4'],,Relationship between APAP-CYS and other biochemical markers of liver function
13640,NCT05381038,CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",ctDNA Analysis,Clinically significant dose changes
13641,NCT02657330,Maximum tolerated dose of SBP-101,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma drug half-life
13642,NCT02907086,Number of blood samples collected,2017-07-07,COMPLETED,OBSERVATIONAL,['NA'],,
13643,NCT00007930,Local recurrence at 3 years,1999-08,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Disease-free and overall survival at 5 years
13644,NCT01695863,Bowel Prep Efficacy - Boston Bowel Preparation Scale (BBPS),2012-02,COMPLETED,INTERVENTIONAL,['PHASE4'],Non-Serious Adverse Events on Self Report Scale,Renal Function Pre and Post Bowel Prep - Continued (mmol/L)
13645,NCT05177393,Median Overall Survival,2019-02-28,RECRUITING,OBSERVATIONAL,['NA'],,
13646,NCT03129685,Short term mortality rate,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA'],,Tumor response rate according to mRECIST criteria.
13647,NCT05628441,Combined performance of endoscopist + CADe system in terms of per-patient sensitivity and specificity,2022-05-16,COMPLETED,OBSERVATIONAL,['NA'],,Stand-alone performance of CADe system in terms of per-patient sensitivity and specificity
13648,NCT05738616,Overall survival at 2 years,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,Quality of life assessment
13649,NCT02041325,Positive for Hepatitis B Surface Antigen,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Phenotypic Changes
13650,NCT00267696,Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or Responding.,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival for Patients Treated With the Regimen.
13651,NCT04310540,Association between prostate specific membrane antigen (PSMA) uptake in hepatocellular carcinoma at PET with tissue PSMA expression,2020-06-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13652,NCT01835925,Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.,2013-07,COMPLETED,OBSERVATIONAL,['NA'],,Tumor tissue results with clinical outcome post standard treatment. .
13653,NCT03926338,Pathological complete response (pCR) rates,2019-05-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Surgery feasibility
13654,NCT04949737,Estimation of the prevalence of Helicobacter pylori,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13655,NCT00100815,Progression-free Survival,2004-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13656,NCT00192114,Percentage of Participants With Progression Free Survival (PFS) at 6 Months,2005-08,COMPLETED,INTERVENTIONAL,['PHASE2'],Change From Baseline in Vascular Endothelial Growth Factor (VEGF) to Cycle 2 and Cycle 3,Change From Baseline in Carcinoembryonic Antigen (CEA) Response at Each Cycle
13657,NCT00788697,Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard,2009-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Inter-reader Agreement
13658,NCT04697186,Helicobacter pylori eradication,2021-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,adverse events
13659,NCT05450029,Pathological complete response,2022-01-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Correlation between minimal residual disease (MRD) and survival
13660,NCT01832116,The in vivo biodistribution measured in SUV values and organ pharmacokinetics (PK) of 89Zr-MMOT0530A,2013-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of patients with adverse events after 89Zr-MMOT0530A injection as a measure of safety and tolerability
13661,NCT03035253,Incidence of dose limiting toxicities,2016-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Progression Free Survival
13662,NCT03220009,Recurrence free survival (RFS),2017-11-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],T cell inflammation,Rate of delayed surgery
13663,NCT05817994,"Number of endoscopic, endosonographic, and radiologic interventions undergone to reach a diagnostic liver biopsy [Phase 2]",2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Number of diagnostic liver biopsies
13664,NCT03569761,CRC screening intentions,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,CRC screening completion
13665,NCT04175756,Total operative time,2020-01-02,COMPLETED,OBSERVATIONAL,['NA'],,Quality of excision: M.E.R.C.U.R.Y. criteria
13666,NCT00268411,Objective response rate,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression-free and overall survival
13667,NCT00793871,Progression-free Survival (PFS),2008-11,COMPLETED,INTERVENTIONAL,['PHASE4'],Time to Tumor Response (TTR),Eastern Cooperative Oncology Group (ECOG) Performance Status
13668,NCT00088868,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13669,NCT01292330,postoperative complications,2010-01,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses and length of stay
13670,NCT04239001,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,2020-02,UNKNOWN,INTERVENTIONAL,['NA'],,The proportion of patients receiving antibiotics during the entire chemotherapy period.
13671,NCT06204484,Relapse-free survival (RFS) time in MRD-negative groups,2023-07-26,RECRUITING,INTERVENTIONAL,['NA'],Performance of landmark MRD status and longitudinal MRD status in prediction of recurrence.,OS time in MRD+ groups
13672,NCT00932438,Tumor Response,2009-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Serious Adverse Events
13673,NCT04380545,Incidence of adverse events,2021-01-13,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Tissue and blood immunohistochemistry,Progression-free survival (PFS)
13674,NCT03603366,Patients' benefit/risk trade-offs,2019-08-14,COMPLETED,OBSERVATIONAL,['NA'],,Preferences of aspirin using in different subgroups
13675,NCT02023021,Recurrence-free survival at one year after curative resection,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,CA199 level after curative resection
13676,NCT01739439,MTD defined as the dose level in which 1 out of 6 patients observes dose-limiting toxicity (DLT) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,2013-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13677,NCT03599895,operation time,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA'],,hospitalization expenses
13678,NCT06042998,3-year disease-free survival,2023-07-07,RECRUITING,INTERVENTIONAL,['NA'],,postoperative recovery course
13679,NCT04207489,The imaging effect of indocyanine green,2020-04-15,UNKNOWN,OBSERVATIONAL,['NA'],,
13680,NCT01150630,Event-free survival at 1 year (phase II),2010-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Lymph node status
13681,NCT00006010,six-month overall survival,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,time to progression
13682,NCT00005049,,1997-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13683,NCT00738790,The rate of patients with downstaging after radiotherapy to pathological complete response or ypT1 disease with negative margins.,2003-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"The rate of local control, overall survival and disease-free survival and toxicity."
13684,NCT03667495,Colorectal cancer or adenoma recurred,2017-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13685,NCT00946153,Phase 2: Time to Progression (TTP) by Independent Review Assessment,2009-07-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Overall Survival (OS)
13686,NCT01962168,Freedom from symptomatic recurrent biliary obstruction requiring reintervention,2013-12,COMPLETED,OBSERVATIONAL,['NA'],,Ease of use
13687,NCT03946969,Safety and feasibility,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Exploratory Outcomes,Overall Survival (OS)
13688,NCT03420443,Action of synbiotics on irradiated GI mucosa in rectal cancer treatment,2008-11,COMPLETED,INTERVENTIONAL,['NA'],,
13689,NCT04856761,"RFS, recurrence-free survival",2020-11-01,RECRUITING,OBSERVATIONAL,['NA'],,"OS, overall survival"
13690,NCT01415609,Ease of use of the overall procedure and Time of procedure.,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Complications and Rate of Completion
13691,NCT01839487,Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of PEGPH20
13692,NCT00005860,,2000-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13693,NCT05919264,During dose expansion describe the Overall Response Rate using RECIST v1.1,2023-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,During dose expansion describe Progression Free Survival
13694,NCT00746655,To evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.,2009-07,WITHDRAWN,INTERVENTIONAL,['NA'],,To determine if SBRT and TACE will be able to bridge patients to transplant that were initially ineligible.
13695,NCT00921531,Overall survival,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to progression
13696,NCT02777463,The statistical analysis of the correlation between pretreatment ADC value of diffusion MRI and pathologic response evaluated by Evans grade in patients with borderline resectable pancreatic carcinoma (BRPC) who undergo neoadjuvant therapy.,2016-06,COMPLETED,OBSERVATIONAL,['NA'],,The statistical analysis of the correlation between tumor's limb sign in diffusion MRI and the rate of tumor cell destruction more than 10%.
13697,NCT03619538,Estimate morphine consumption,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
13698,NCT00351195,Response,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,Survival
13699,NCT01929421,Response rate,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,number of participants with adverse events
13700,NCT06028737,Histopathological tumor response rate (Becker regression criteria).,2023-08-25,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Correlation between the pathohistological response and overall and disease-free survival.
13701,NCT00574860,NCI v3 to measure severity of OM,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3'],,WHO criteria for measuring severity of OM
13702,NCT01097083,,2010-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13703,NCT06033976,Rate of curative resection,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],Rate of delayed bleeding,Rate of R0 resection
13704,NCT00913757,Large-scale molecular profiling study to identify HCC biomarkers for early diagnosis and prevention.,2009-07-01,COMPLETED,OBSERVATIONAL,['NA'],,
13705,NCT00915850,Safety (Phase I: toxicities as assessed by NCI CTCAE version3) and efficacy (Phase II: Feasibility as evaluated by RECIST),2007-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,median survival time (Phase II)
13706,NCT00005599,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13707,NCT00268437,Pathologic Complete Response Rate,2006-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
13708,NCT02717091,R0 resection rate,2015-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,quality of the tumor
13709,NCT05568433,Role of the cyst fluid concentrations of the specific biomarkers for differentiation the pancreatic cystic lesions,2018-04-02,COMPLETED,OBSERVATIONAL,['NA'],,The Correlation between cyst fluid concentration and serum level of the specific biomarkers
13710,NCT05797077,5-years Progression Free Survival,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3'],,Complication
13711,NCT03256344,Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT),2018-03-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
13712,NCT01596361,Verify the differences observed in the frequency of germline pharmacogenetic variants related to chemotherapy between Asian and Caucasian CRC patients,2011-08,UNKNOWN,OBSERVATIONAL,['NA'],,Characterise the deletion status of heat shock protein molecules and determine the association between heat shock protein deletion status and clinico-pathological outcomes in Asian and Caucasian patients with CRC
13713,NCT04462042,Acute grade >2 hematological side effects,2021-04-07,RECRUITING,INTERVENTIONAL,['NA'],Cost-utility analysis,Overall survival
13714,NCT01347645,Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),2011-09-30,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 2: Percentage of Participants With Overall Response
13715,NCT03875144,overall survival,2020-08-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life evaluation
13716,NCT04990895,Assessment of the Quality of Life of Colorectal Cancer Patients Using EORTC-QLQ CR29 Questionnaire,2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE3'],,Patient self-efficacy
13717,NCT05976568,Overall Survival (OS) (Phase III),2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to progression (TTP)
13718,NCT06222944,ORR,2024-02-25,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
13719,NCT00985556,Progression-free survival,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to progression
13720,NCT04792801,Rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline,2021-06-22,RECRUITING,OBSERVATIONAL,['NA'],,Binding intensity (SUV) of PET TDM FDG-Choline and the last aFP value before transplantation or WL dropout.
13721,NCT02297269,the incidence of DVT,2014-12,UNKNOWN,OBSERVATIONAL,['NA'],,incidence of incision infection
13722,NCT00397540,"1,3,5 Year-Disease Free Survival (or Recurrence Free Survival)",2004-10,COMPLETED,INTERVENTIONAL,['NA'],,Overall Survival
13723,NCT03117972,Progression Free Survival,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
13724,NCT02742597,Evaluation of Intervention Effectiveness - Change in Patient-Centredness,2016-01-12,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of Intervention Effectiveness - Change in Demographics
13725,NCT02461407,Overall Survival (OS),2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Disease Control Rate (DCR)
13726,NCT01291615,frequency in adverse events,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13727,NCT06293625,DFS (disease Free Survival),2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,
13728,NCT02720666,The maximum-tolerated dose (MTD) of K-001,2016-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Clinical efficacy of K-001 assessed by disease control rate (DCR) according to RECIST V 1.0 criteria
13729,NCT04019808,H. pylori prevalence and drug resistance,2019-07-30,UNKNOWN,OBSERVATIONAL,['NA'],,
13730,NCT01803009,Preferred CRC screening test,2012-11,COMPLETED,INTERVENTIONAL,['NA'],,Uptake of CRC screening
13731,NCT03894618,Maximum Tolerated Dose (MTD) of SL-279252,2019-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Volume of distribution
13732,NCT03311152,Presence of hepatocellular carcinoma.,2018-02-12,RECRUITING,INTERVENTIONAL,['NA'],,Presence of early hepatocellular carcinoma. Early hepatocellular carcinoma will be defined as a tumor smaller than 30 mm according to Kudo M (Liver Cancer. 2013;2:69-72).
13733,NCT00003851,,1999-03,TERMINATED,INTERVENTIONAL,['NA'],,
13734,NCT01560260,Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Determine the Number of Participants With Tumor Metabolic Response Correlating With Anatomic Response and Clinical Benefit.,"Correlations Between Glucose, Insulin, Tumor Tissue and Blood Biomarkers With FDG-PET Metabolic Response."
13735,NCT01426074,Pathologic Complete Response (pCR),2011-08,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
13736,NCT02414100,"Identification of germline mutations in known cancer genes from whole blood genomic deoxyribonucleic acid, and somatic mutations in conditionally reprogrammed cells derived from pre-treatment and post-treatment (e.g., resistant) tumors",2013-12-12,WITHDRAWN,OBSERVATIONAL,['NA'],,
13737,NCT01815359,disease-free survival,2013-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,chemotherapy toxicity grade 3 to 5
13738,NCT00987857,Overall survival,2009-03,UNKNOWN,INTERVENTIONAL,['NA'],,Frequency of endoscopy
13739,NCT02164292,Feasibility of the procedure defined as percentage of patients that complete both surgical stages.,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Risk factors for a reduced kinetic growth rate of the future liver remnant (<35 cc/day)
13740,NCT02007954,Collection of Adverse Events Related to Study Device as a Measure of Safety,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2'],Exploratory Endpoint - Tmax of Doxorubicin and Doxorubicinol Post DEBDOX-M1 TACE,AFP Tumor Marker Pre- and Post-treatment
13741,NCT05813028,"Change of Beck Anxiety Inventory score at baseline and one week later fisrt,second,third and forth chemothraphy.",2022-07-15,RECRUITING,INTERVENTIONAL,['NA'],,
13742,NCT05323058,Severity of mucositis,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Patient-Reported Oral Mucositis( PROMS scale),Pain and burning sensation
13743,NCT05483075,Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention,2022-11-15,RECRUITING,INTERVENTIONAL,['NA'],,Minutes Spent in Rapid Eye Movement (REM) Sleep
13744,NCT01403727,Radiation Dose,2011-11,COMPLETED,OBSERVATIONAL,['NA'],,Accuracy of needle targeting
13745,NCT01412957,Overall Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval
13746,NCT03626922,Objective Response Rate to pembrolizumab and pemetrexed plus oxaliplatin,2019-05-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival
13747,NCT06074536,"The Measurement of the achievement oh the shared decision shared decision making in CRC screening using the patient shared a self-decision-making questionnaire (SDM-Q9), validated in French",2024-03-06,RECRUITING,INTERVENTIONAL,['NA'],,Explore understanding of the shared decision process among general practitioners and patients
13748,NCT03924349,Success rate of localization,2019-07-08,COMPLETED,INTERVENTIONAL,['NA'],,Number of Participants with Complication
13749,NCT05415917,Safety as assessed by number of participants experiencing adverse events,2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2'],To measure the tumor with the Response Evaluation Criteria in Solid Tumors (RECIST),
13750,NCT01710592,"Determine in a randomised study if the response rate to docetaxel and oxaliplatin (ElTax) is comparable to epirubicin, oxaliplatin and capecitabine (EOX) and warrants further evaluation in advanced gastro-oesophageal cancer",2007-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,To examine the effect of treatment on Quality of life.
13751,NCT00274872,Pharmaco-economic evaluation,2004-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
13752,NCT01783158,To detect early synchronous second primary esophageal carcinoma,2004-01,COMPLETED,OBSERVATIONAL,['NA'],,
13753,NCT00460174,Response rate,2005-10-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profile of bevacizumab and gemcitabine with radiation therapy
13754,NCT01216930,,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,
13755,NCT02877056,Predictive Tumor Cell Biomarkers After Chemoradiation Treatment for Colorectal Cancer,2005-08,UNKNOWN,OBSERVATIONAL,['NA'],,
13756,NCT04527068,Progression-free survival (PFS),2020-09-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Duration of Response (DOR)
13757,NCT06011330,overall survival (OS),2019-01-01,COMPLETED,OBSERVATIONAL,['NA'],Treatment-Related Adverse Events (TRAE),progress-free survival (PFS)
13758,NCT01591590,Mortality,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Tumour Progression
13759,NCT03711058,6-month Objective Response Rate (ORR) of Patients Treated With Copanlisib and Nivolumab,2019-01-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants Experiencing Study Drug-related Toxicities
13760,NCT00026091,Response rate (CR or PR),2001-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular change
13761,NCT02812641,Pathological complete response rate (randomized phase),2016-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],Serum biomarker (VEGF-A),Overall survival
13762,NCT05427396,The incidence of adverse events (AE) and serious adverse events (SAE) were assessed,2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE1'],PFS,TTP
13763,NCT05227261,Sensitivity and specificity of the test in early detecting cancers,2022-04-10,RECRUITING,OBSERVATIONAL,['NA'],,Rate of cancer development in the high-risk group as compared to the moderate-risk population
13764,NCT04644315,"Confirmed Objective Response Rate (ORR) as Determined by the Investigator Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",2021-05-24,TERMINATED,INTERVENTIONAL,['PHASE2'],,OS in Participants With Primary CNS Tumors
13765,NCT05400018,Ct Value (Ct Values From PCR Reaction),2020-11-20,COMPLETED,OBSERVATIONAL,['NA'],,Kappa coefficient
13766,NCT05479240,Pathological complete response rate,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],overall survival,
13767,NCT00417209,overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;
13768,NCT00499369,Progression-free Survival (PFS),2007-06,TERMINATED,INTERVENTIONAL,['PHASE3'],,Toxicity
13769,NCT05815290,complete response rate,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE2'],,pCR rate
13770,NCT01824459,Overall Survival,2013-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Adverse events (AE)
13771,NCT03205735,progression free survival,2017-06-29,UNKNOWN,OBSERVATIONAL,['NA'],,toxicities evaluation
13772,NCT04525833,The incidence of a new diagnosis of any event of liver cirrhosis complications,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
13773,NCT05933785,anal preservation rate,2018-01-02,COMPLETED,OBSERVATIONAL,['NA'],,incidence of positive distal resection margin
13774,NCT00718913,The proportion of patients completing protocol therapy (feasibility),2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
13775,NCT01328171,overall response rate,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes
13776,NCT01111604,Progression-Free Survival (PFS),2010-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13777,NCT00114829,Sensitivity in determining malignant or benign diagnose,2005-07,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Sensitivity/specificity of MR colonography
13778,NCT02757391,Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity per Common Terminology Criteria for Adverse Events version 4.0,2019-08-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Overall survival
13779,NCT02960061,Number of survival participants will be assessed according to the data collected by the followed up office.,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Progression Free Survival
13780,NCT00086931,Complete pathological response rate at time of surgery,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Disease-free survival, safety, and overall survival at 5 years"
13781,NCT05396846,Weight Loss,2023-04-29,RECRUITING,INTERVENTIONAL,['NA'],Skin Carotenoids,
13782,NCT00005804,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13783,NCT04384757,3 year relapse-free survival by Kaplan Mayer,2020-07-29,RECRUITING,INTERVENTIONAL,['NA'],,Resected lymph nodes
13784,NCT04891146,investigate the effect of anesthesia management on the change of preoperative systemic inflammatory immune index(SII) and postoperative 2.hour and 24.hour SII value,2020-03-05,COMPLETED,OBSERVATIONAL,['NA'],,
13785,NCT01853774,Primary Outcome is Clinic Attendance,2012-04,COMPLETED,INTERVENTIONAL,['NA'],,The Secondary Outcome is Participant Completion of a CRC Screening Test.
13786,NCT05873699,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,
13787,NCT03717038,Overall survival (OS) time following treatment with Sym004 versus TAS-102.,2019-02,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Pharmacokinetic (PK) Parameters of Sym004: Maximum Concentration (Cmax)
13788,NCT05682157,Change in LARS score,2023-03-21,RECRUITING,INTERVENTIONAL,['NA'],,
13789,NCT04801719,Overall survival,2010-01-04,COMPLETED,INTERVENTIONAL,['NA'],,Complications of endoluminal RFA of biliary tract
13790,NCT05171660,Progression free survival time,2022-02-08,RECRUITING,INTERVENTIONAL,['PHASE3'],,Adverse Events
13791,NCT03269994,Compare the effectiveness of cefoxitin with piperacillin-tazobactam as surgical antibiotic prophylaxis in decreasing the overall rate of postoperative surgical site infections in participants undergoing pancreatoduodenectomy,2017-11-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,
13792,NCT05233007,Predicting treatment resistance to anti-cancer therapy,2022-01-25,SUSPENDED,OBSERVATIONAL,['NA'],,
13793,NCT05290220,PFS,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,DOR
13794,NCT06152757,"AE, SAE, AESI, CRS, ICANS, TEAE",2023-10-09,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13795,NCT05811481,Overall survival,2022-12-27,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival for the first subsequent treatment PFS 2
13796,NCT03851913,OS,2018-07-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,PFS
13797,NCT02028806,Disease control rate,2013-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,EORTC QLQ-C30
13798,NCT05911633,Technical success,2024-02-29,RECRUITING,INTERVENTIONAL,['NA'],,Best overall response
13799,NCT01161186,"to establish the maximal tolerated dose (MTD) of the AGX combination in patients with previously untreated, metastatic pancreatic adenocarcinoma.",2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,"To obtain a preliminary assessment of the clinical efficacy of AGX as measured by time to tumor progression, overall survival, objective radiographic response (ORR), and CA 19-9 biomarker response"
13800,NCT05147545,Change in circulating DNA induced by moderate effort in subjects free of malignacy,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Change in circulating DNA induced by hyperlipidic meal in patients with colon cancer
13801,NCT03679429,Accuracy optical biopsy,2018-11,UNKNOWN,OBSERVATIONAL,['NA'],,Adenoma detection rate
13802,NCT03851471,Overall Survival,2019-04-07,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,10cm-VAS of the pain
13803,NCT03307603,Phase II: Response rate,2018-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase II: Overall survival
13804,NCT05886257,ORR per RECIST 1.1,2022-12-07,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,PD-L1 Biomarker
13805,NCT05420922,The treatment-related adverse events (TRAEs),2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,The progression-free survival (PFS)
13806,NCT03947775,The proportion of participants in each arm with biopsy-proven HGAIN (AIN-2/3).,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Change in anal carriage of vaccine HPV types. Repeated detection of anal HPV will indicate the duration of carriage. This will be compared between the early and delayed vaccine groups.,"The geometric mean titres (GMT) of antibody to each vaccine type above a pre-specified, validated cut-off. F"
13807,NCT01864070,Dose Limiting Toxicities (DLT) for Combination of TheraSphere and Everolimus,2014-05,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
13808,NCT01105169,Expression of Cox2 in rectal epithelia,2010-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Urine excretion of prostaglandin E2 metabolite (PGE-M)
13809,NCT00765180,Colorectal adenoma detection rate,2007-01,COMPLETED,INTERVENTIONAL,['NA'],,"Procedure time, complication"
13810,NCT02575508,Overall survival (Phase II),na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Potential associations between response rate and tumor biomarkers (Phase II)
13811,NCT00732836,Maximum Tolerated Dose (MTD) of HAI Abraxane,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13812,NCT02595424,PFS,2016-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Prognostic significance of well differentiated non-small cell gastroenteropancreatic neuroendocrine tumors,Response rate (complete response or partial response) by RECIST 1.1
13813,NCT00005085,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13814,NCT00440310,Overall Survival,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13815,NCT05480280,Objective Response Rate (ORR),2022-07-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
13816,NCT04591431,OVERALL RESPONSE RATE (ORR),2020-10-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
13817,NCT02132468,"Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline",2014-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1"
13818,NCT01057017,Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,
13819,NCT03708445,The usefulness of new staining method,2018-11-01,COMPLETED,INTERVENTIONAL,['NA'],,
13820,NCT03548961,number of patients whose tumor can be resected by local excision with negative margins,2018-05-11,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Disease-free survival (DFS) of patients
13821,NCT05615103,Pathologic complete response rate (pCR),2022-11-08,RECRUITING,OBSERVATIONAL,['NA'],,Safety as measured by number of participants with Grade 3 and 4 adverse events
13822,NCT03504293,Diagnostic accuracy,2010-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse event rate
13823,NCT00036712,Proportion of patients not experiencing ulcerative mucositis within the first 14 days posttransplant,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Time to heal
13824,NCT05591053,Usability of the device by surgeon and support personnel satisfaction;,2023-04-01,RECRUITING,INTERVENTIONAL,['NA'],,Ability of ActivSightTM to display blood vessels.
13825,NCT03875690,frequency of patients with postoperative major complications occurring within 30 days after surgery,2019-07-02,RECRUITING,INTERVENTIONAL,['PHASE3'],,
13826,NCT06192680,Progression free Survival,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
13827,NCT05053750,To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab and ZA relative to weekly paclitaxel/bevacizumab,2021-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
13828,NCT04195438,Measure the extent of HO-1 induction by measuring endogenous CO production in relationship to the extent of hepatic resection,2014-05-07,RECRUITING,INTERVENTIONAL,['NA'],,Measure the relationship between HO-1 induction and the quality of post-hepatectomy liver regeneration
13829,NCT01715532,Progression free survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
13830,NCT06274190,Responsiveness of the newly developed bowel e-diary in patients after rectal surgery for rectal cancer. The newly validated e-diary is the primary outcome.,2024-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
13831,NCT00470535,Progression-free Survival,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Correlation of Response, QOL, and Survival With EGFR, E-cadherin, P-cadherin, Vimentin, Cytokeratin, ki67, and Fibronectin and With Other Prognostic Variables, Such as Age and Tumor Grade"
13832,NCT02518529,Measurable Gastrin-17 Antibody Titer,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival from date of randomization to death or end of study
13833,NCT01619423,Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia),2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
13834,NCT01348217,Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement),2011-05-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Evaluation of the post-operative morbi-mortalities
13835,NCT04865471,Percent of transplanted patients receiving second stage hepatectomy within 4 weeks of segment 2/3 transplantation,2020-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Complication rate
13836,NCT01164150,Reduction in the incidence of ≥ grade 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity according to NCI CTCAE v.3.0,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall survival rate
13837,NCT04645797,Primary Outcome Measure,2021-01-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Secondary Outcome
13838,NCT00482846,Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Reduction in incidence and duration of mucositis
13839,NCT06031818,Clinical effectiveness of the explanation framework,2023-12-10,RECRUITING,OBSERVATIONAL,['NA'],,Usability of the explanation framework
13840,NCT03718078,malignant pCLE criteria,2019-03,UNKNOWN,INTERVENTIONAL,['NA'],,pCLE criteria diagnostic performance
13841,NCT06035250,Accuracy of TRG prediction by the AI model,2023-09-10,RECRUITING,OBSERVATIONAL,['NA'],,Overall Survival (OS) at 5 years
13842,NCT01584336,The incidence of postoperative morbidity and mortality,2012-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the surgical outcomes according to the method of reconstruction
13843,NCT01908426,Overall Survival (OS),2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective Response Rate (ORR)
13844,NCT04571047,Overall survival,2020-10-15,COMPLETED,OBSERVATIONAL,['NA'],,Radical surgery
13845,NCT05524090,In-hospital major morbidity,2021-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Shared decision-making: patients' healthcare satisfaction
13846,NCT02275403,Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN,2015-04-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Uptake of the offer of acupuncture at 10 weeks
13847,NCT02175095,[18F]FLT-PET SUV_MAX,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,Response evaluation by RECIST 1.1
13848,NCT00216372,Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence),2003-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,Symptom relief duration
13849,NCT02594150,Increase in return rate of completed FIT,2015-12,COMPLETED,INTERVENTIONAL,['NA'],,
13850,NCT00197873,Effect on the treatment-related grade 2 to 4 diarrhoea,2005-09,COMPLETED,INTERVENTIONAL,['NA'],,Effect on resectability of liver metastases
13851,NCT04513431,Adverse events that related to treatment,2020-08-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Maximum tolerated dose (MTD) of CEA targeted CAR T cells
13852,NCT04174339,Objective response rate(ORR),2019-12-10,UNKNOWN,INTERVENTIONAL,['NA'],,Disease control rate(DCR)
13853,NCT03227510,MicroRNAs and its Correlation to Development and prediction of HCC,2017-11,UNKNOWN,OBSERVATIONAL,['NA'],,
13854,NCT03377400,Progression-free survival,2017-12-14,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13855,NCT02970539,Maximum tolerated dose (MTD),2016-12-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Preliminary activity of Oraxol plus ramucirumab as determined by overall survival
13856,NCT05461248,Incidence of low anterior resection syndrome,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life score
13857,NCT06019455,Incidence of >=Grade 3 toxicities,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression-free survival
13858,NCT00314678,Recurrence-Free Interval,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Examine the toxicity of therapy and to develop suitable strategies for dose modification.
13859,NCT01089413,Duration of Bevacizumab Treatment,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
13860,NCT03141437,Patients' decisional conflict (Part 2),2017-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],Feasibility of the multicomponent DS intervention and research methods (Part 2),Patients' decision-making process (Part 2)
13861,NCT01580540,Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin.,2012-03,COMPLETED,OBSERVATIONAL,['NA'],,
13862,NCT03245892,number of patients with dose limiting toxicities weekly paclitaxel/carboplatin plus nivolumab and ipilimumab,2017-08-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13863,NCT04455737,retrieved lymph nodes,2013-10,COMPLETED,OBSERVATIONAL,['NA'],,survival
13864,NCT01299493,Practice-level colon cancer screening rate,2012-06-19,COMPLETED,INTERVENTIONAL,['NA'],,
13865,NCT00001532,evaluating the role of hereditary factor,1996-09-13,RECRUITING,OBSERVATIONAL,['NA'],,"low dose radiation CT scan, and Zoom Scan"
13866,NCT01589900,,2005-01,COMPLETED,OBSERVATIONAL,['NA'],,
13867,NCT01034670,Detection of neoplasia,2009-06,RECRUITING,INTERVENTIONAL,['NA'],,
13868,NCT00564720,Overall Survival,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Symptoms improvement
13869,NCT04543019,Progression free survival (PFS) and overall survival (OS),2020-12,UNKNOWN,OBSERVATIONAL,['NA'],,response to systemic therapy
13870,NCT04294264,Overall response rate,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of adverse events
13871,NCT00135577,"Incidence of reported adverse events, including serious adverse events",2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures"
13872,NCT00409292,To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,to Assess Overall Survival Associated With RAD001 in This Patient Population.
13873,NCT03098589,Adverse Events (AEs),2017-05-30,RECRUITING,OBSERVATIONAL,['NA'],,
13874,NCT00093444,"Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion",2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion
13875,NCT01773980,Number of participants with improved cancer screening,2013-08,COMPLETED,OBSERVATIONAL,['NA'],,
13876,NCT05677724,single cell RNA sequencing,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
13877,NCT01451632,To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan,2011-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Immunogenicity
13878,NCT01023633,DDC: Duration of Disease Control,2009-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"OS, RR, PFS, DCR, safety,"
13879,NCT03215290,Cutting surface related complications,2016-10,COMPLETED,INTERVENTIONAL,['NA'],,Interventions for cutting surface related complications
13880,NCT03036436,Change in quality of life,2017-01,UNKNOWN,INTERVENTIONAL,['NA'],,
13881,NCT02310971,"Assessment of safety and tolerability of CVac. (adverse events, vital signs, 12 lead ECG, relevant changes in physical examination)",2015-02,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Assessment of the change in quality of life (QoL) following the initiation of Cvac in this patient population,Assessment of Progression-Free Survival (PFS) and Overall Survival (OS) following the initiation of Cvac in this patient population
13882,NCT03965325,Assess the most accurate trend of the Global Health Status (Quality of Life evolution) over time in colorectal cancer patients evaluated by the EORTC-QLQ-C30 questionnaire.,2019-06-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Measure healthcare costs during the study period
13883,NCT01547130,Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Total Preparation Time
13884,NCT01858207,The rate of complete necrosis (CN),2012-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Major complication
13885,NCT03264807,Superiority verification of disease-free survival after lymphadenectomy for D2 + 14v lymph node dissection in gastric resection in patients with T3N + and T4N + stomach cancer,2015-08-06,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13886,NCT03564938,Change in heart rate (beats/min),2018-07-30,COMPLETED,INTERVENTIONAL,['PHASE4'],,Overall survival (OS)
13887,NCT04276415,Progression-free Survival (PFS) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Expansion),2020-05-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Anti-drug Antibodies Against DS-6157a Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST)
13888,NCT03060720,"We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool",2017-02-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of patients who disclose genetic testing results to relatives
13889,NCT00745927,Degree of abdominal discomfort during and after colonoscopy,2008-06,UNKNOWN,INTERVENTIONAL,['NA'],,Number of neoplasm detected
13890,NCT03064646,Percentage of organ preservative strategies after neoadjuvant treatment in locally advanced rectal cancer,2017-03-10,RECRUITING,INTERVENTIONAL,['NA'],Colostomy free survival,Quality of Life in patient with rectal cancer
13891,NCT05077839,ORR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
13892,NCT04212273,"The sensitivity, specificity and accuracy of Sonazoid-CEUS and EOB-MRI",2019-12-21,RECRUITING,INTERVENTIONAL,['NA'],,The detection rate of the additionally found HCC
13893,NCT01074216,To Achieve Target Vitamin D Level,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13894,NCT01191138,Gastric Emptying assessed clinically and correlated objectively with liquid and solid emptying of radionucleotide,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Correlation of pancreatic duct leak with gastric emptying
13895,NCT02259647,Overall Survival,2014-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Safety
13896,NCT04543695,The rate of tumor down-staging,2020-08-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of surgical complications
13897,NCT00003995,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13898,NCT03649971,Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24,2018-11-19,COMPLETED,INTERVENTIONAL,['PHASE1'],,Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue
13899,NCT05248581,percentage overall survival,2019-08-16,RECRUITING,OBSERVATIONAL,['NA'],,
13900,NCT00510796,Feasibility to perform both colon and endometrial cancer screening at the time of colonoscopy in women at high risk for colon and endometrial cancer.,2002-03,COMPLETED,OBSERVATIONAL,['NA'],,
13901,NCT04646915,Incidence of transfer to inpatient ward,2019-12-15,UNKNOWN,OBSERVATIONAL,['NA'],,Mortality
13902,NCT00940758,To characterize the pharmacokinetics of biweekly PEP02 in patients with metastatic colorectal cancer who failed to first-line oxaliplatin-based chemotherapy,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,To explore the association of the pharmacogenetics of PEP02 including UGT1A family - UGT1A1 and UGT1A9 with pharmacokinetic parameters and toxicity
13903,NCT04522687,Overall Survival,2012-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Progression Free Survival
13904,NCT00640913,Reversal of defunctioning loop stoma on postoperative day 14 following low anterior resection of the rectum for cancer with or without preoperative adjuvant treatment,2008-02,UNKNOWN,OBSERVATIONAL,['NA'],,Postoperative 30 day morbidity. Postoperative ano-rectal function at 1 and 6 months.
13905,NCT04918472,The combined diagnostic accuracy of MCCE and UBT as gold standard,2021-08-06,COMPLETED,INTERVENTIONAL,['NA'],,"Adverse events up to 2 weeks after UBT, MCCE, UGI endoscopy"
13906,NCT00154817,"The primary objective is to evaluate response rate, tolerability and failure pattern of local radiotherapy for the treatment of locally advanced HCC.",2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,The second objective is to correlate parameters of tumor perfusion assessed by dynamic contrast enhanced MRI (DCEMRI) and serum cytokine levels with clinical outcomes.
13907,NCT05795920,progression free survival progression free survival,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,Duration of response Duration of Response
13908,NCT02432963,"Tolerability of combined modified vaccinia virus Ankara vaccine expressing p53 and pembrolizumab, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.3",2016-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,"T cell reactivity to p53, assessed by flow cytometry"
13909,NCT05059444,Distant Recurrence Free Interval (D-RFi),2021-09-07,RECRUITING,OBSERVATIONAL,['NA'],Rate of ctDNA clearance with adjuvant chemotherapy,Lead Time
13910,NCT01385579,Completion of a Colorectal Cancer Screening,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,
13911,NCT02734849,Change in Total Polys Score (TPS),2016-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13912,NCT04929028,Incidence of adverse events (High-risk stratum),2022-08-09,RECRUITING,INTERVENTIONAL,['PHASE2'],Impact of reduced intensity CRT on quality of life,Change in combination antiretroviral therapy (cART) adherence
13913,NCT00003648,frequency of defective DNA mismatch repair in individuals with familial colon cancer versus all colon cancers by using antibodies to the hMSH2 and hMLH1 protein products,1998-07,COMPLETED,OBSERVATIONAL,['NA'],,
13914,NCT03318562,Level of biomarkers of antitumor activation,2017-11-21,TERMINATED,INTERVENTIONAL,['PHASE2'],,PK plasma concentrations
13915,NCT01595243,12-Item Short Form Survey,2009-10,COMPLETED,INTERVENTIONAL,['NA'],,
13916,NCT00764621,Primary variable is the proportion of patients in each of the three treatment groups for whom further imaging is required after initial imaging to come to a therapy decision.,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,"Proportion of patients with intra-operatively modified surgical plans based on initial imaging with either Primovist-, ECCM-MRI or CE-CT"
13917,NCT05846295,"Participant entered rate of accurate polyp size classification into diminutive (1-5 mm), small (6-9 mm), or large (≥10 mm) category on 40 question polyp sizing test.",2021-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Proportion of participant responses that underestimate actual polyp size category versus overestimate actual polyp size category on the 40-question polyp sizing test.
13918,NCT01210313,feasibility of physical activity,2010-10,COMPLETED,OBSERVATIONAL,['NA'],,gen- and metabolic signs
13919,NCT04513223,DLT and the recommended Phase 2 dose (RP2D),2021-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,
13920,NCT02567331,"Response rate, ie, percentage of participants with complete, partial, and overall response",2004-10,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pharmacoeconomic analysis: Treatment-related and AE-related spending/savings\n
13921,NCT04089631,Disease free Survival (DFS),2020-06-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,Frequency of adverse events from start of chemotherapy until 30 days after chemotherapy
13922,NCT01359410,Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System,2007-06,TERMINATED,INTERVENTIONAL,['NA'],,Number of Non-pancreatic Adverse Events
13923,NCT00813137,Time to progression,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13924,NCT03481920,To assess the safety of this combination in patients with PDAC.,2018-01-10,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],Immune infiltrate.,"Changes in CA 19,9 leves"
13925,NCT01979029,The Blood Pressure of the Arterial Arcade,2013-02,COMPLETED,INTERVENTIONAL,['NA'],Systemic Blood Pressure,Distal Colon Length
13926,NCT03532711,Objective Response Rate (ORR),2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Progression Free Survival (PFS)
13927,NCT06192212,perioperative 90-day mortality.,2023-12-13,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Albumin loss rate
13928,NCT01078415,Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.,2010-02,COMPLETED,INTERVENTIONAL,['NA'],,Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.
13929,NCT00639925,"Adverse effect, toxicities as assessed by NCI CTCAE version3.0",2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,feasibility
13930,NCT02088333,Completion of CRC Screening,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Usability of the mCRC system
13931,NCT04847726,Diagnostic accuracy for HCC: non-inferiority test,2020-06-09,COMPLETED,INTERVENTIONAL,['NA'],Role of perfluorobutane enhanced USG in EASL diagnostic algorithm of HCC,Diagnostic performance of perfulorobutane enhanced USG using different definition of washout
13932,NCT01607957,Overall Survival,2012-06-17,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths"
13933,NCT05027347,The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients,2021-10-10,UNKNOWN,OBSERVATIONAL,['NA'],,The concordance rate of mutation results between plasma and tissue biopsy assay
13934,NCT00243854,"To determine if giving chemotherapy, radiation, and Tarceva,(EGFR-tyrosine kinase inhibitor)will have side effects that will prevent surgery following this therapy",2005-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,
13935,NCT05341206,Change of CTCAE 4.0,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Change of common aerobic culture
13936,NCT02485015,Overall Survival(OS),2015-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Adverse events,Disease-free survival
13937,NCT04837742,Drug spread level of erector spinae plane block,2021-04-14,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative recovery quality
13938,NCT00199862,Toxicity defined by NCI Common Toxicity Criteria,2004-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,HAHA levels - measured by plasmon resonance surface (Biacore®) assay
13939,NCT00569790,Safety,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Progression-free survival, Response rate, Overall survival, Treatment situation"
13940,NCT03556956,Overall survival,2015-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival (PFS)
13941,NCT03821025,Number of patients without stent failure,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Cost
13942,NCT05689918,Level of awareness of esophageal cancer risk factors and alarm symptoms,2022-12-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Beliefs about esophageal cancer
13943,NCT06148155,Complete PET imaging,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
13944,NCT04286984,Transfusion Rate,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of failure-to-rescue
13945,NCT06128785,Time of first postoperative exhaust,2023-11-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],Adverse Event Assessment,Biochemical indexes 3
13946,NCT04022109,Specific chemistry identification in the exhaled breath,2019-11-01,RECRUITING,OBSERVATIONAL,['NA'],Confounding factor analysis,Gut microbiota analysis in relation to breath VOCs
13947,NCT00806611,The primary endpoint is cancer related pain control.,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3'],,
13948,NCT04435652,Overall survival（OS）（stage 2）,2020-07-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Immunogenicity（stage 1 and 2）
13949,NCT04123925,Predictive Biomarkers,2018-06-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Metabolic Response
13950,NCT04920435,Prediction of the complete response (pCR) to neoadjuvant chemoradiotherapy,2019-01-02,COMPLETED,OBSERVATIONAL,['NA'],,
13951,NCT05006092,adenoma detection rate,2021-09-01,COMPLETED,INTERVENTIONAL,['NA'],,Boston Bowl Preparation Score
13952,NCT03826446,Recurrence rate in open and laparoscopic complete mesocolic excision groups in right cancer colon,2016-01-13,COMPLETED,INTERVENTIONAL,['NA'],,
13953,NCT05247515,Severe post-resection bleeding rate up to Day 30,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Rate and duration of hospitalizations
13954,NCT05240040,time to recurrence,2016-04-26,UNKNOWN,OBSERVATIONAL,['NA'],,
13955,NCT02504099,Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12),2015-07,TERMINATED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Recurrent HCV Infection Post Liver Transplant
13956,NCT02707315,percentage of subjects who successfully undergo pancreaticoduodenectomy,2013-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
13957,NCT01380600,Determine the safety of JX-594 administered by biweekly IV infusion,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Determine the anti-tumoral response of JX-594
13958,NCT00826813,Overall survival,2009-01,UNKNOWN,INTERVENTIONAL,['NA'],,Dysphagia relief
13959,NCT02068131,Overall response rate(ORR),2014-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse Events(AEs)
13960,NCT01672892,"Acute Gastrointestinal Toxicity, as Measured by Change in Expanded Prostate Cancer Index Composite (EPIC) Bowel Domain Score at 5 Weeks From the Start of Pelvic Radiation",2012-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Mean Change From Baseline in EPIC Bowel and Urinary Domain (Validation - Sensitivity to Treatment)
13961,NCT03864211,Progression free survival,2019-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,The general health status
13962,NCT03852576,SFE ability to detect dimer with contrast,2019-05-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,
13963,NCT06236386,Clinician Feedback,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Medication Use
13964,NCT01841736,Progression-free Survival (PFS),2013-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Biochemical Response,Time to Second Progression for Patients Who Crossover From Placebo to Active Therapy
13965,NCT04553458,"PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions",2015-06,COMPLETED,OBSERVATIONAL,['NA'],,DEATH (Number of patients died from the disease)
13966,NCT01220934,Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST),2010-04-16,COMPLETED,OBSERVATIONAL,['NA'],,Safety (incidence of adverse events)
13967,NCT01279681,Progression-Free Survival,2011-01,TERMINATED,INTERVENTIONAL,['PHASE3'],Prognostic Single-nucleotide Polymorphisms (SNPs) for Grade 3+ Hypertension,Number of Participants With Grade 3 Adverse Events At Least Possibly Related to Treatment
13968,NCT03682133,Truncated logistic regression analysis,2018-06-27,TERMINATED,OBSERVATIONAL,['NA'],,
13969,NCT01798160,Overall-Survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE4'],,
13970,NCT02724345,Overall survival,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,Time to recurrence
13971,NCT03169777,ORR by Immune-related response criteria (irRC ),2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03"
13972,NCT03939845,OS,2019-04-23,UNKNOWN,INTERVENTIONAL,['PHASE3'],,
13973,NCT01503411,Primary Effectiveness Endpoint,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,
13974,NCT00923481,Response Rate,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
13975,NCT05130684,rate of completion of protocol treatment,2021-02-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
13976,NCT05209750,True malignant node (yes/no),2022-07-13,RECRUITING,INTERVENTIONAL,['NA'],,To describe the value of FAPI PET/CT on tumour response evaluation following neoadjuvant treatment.
13977,NCT05875753,Adverse events after injection of 68Ga-FAPI-FS,2022-06-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,SUVmax of tumor lesions on 68Ga-FAPI-FS
13978,NCT01384695,to determine whether tissue is neoplastic or non-neoplastic,2009-06,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,
13979,NCT05971628,Tolerance of the RAPID procedure,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Comparison of the graft survival at 2 years after LT between RAPID group and control group
13980,NCT04922853,pathological Tumor Regression Grade evaluation,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3'],,cumulative local recurrence rate
13981,NCT02232620,Disease Control Rate (DCR),2017-03-13,TERMINATED,INTERVENTIONAL,['PHASE2'],,Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible
13982,NCT02337946,Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization,2014-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Grade 3 or Higher Skin Toxicity
13983,NCT04258813,Diversity supplement primary outcome: 90-day postoperative cardiovascular complications,2021-06-14,RECRUITING,INTERVENTIONAL,['NA'],PCP-reported care coordination,Provider-reported care coordination
13984,NCT04429841,Operative mortality rate,2010-01,COMPLETED,OBSERVATIONAL,['NA'],,5 years Overall survival rate
13985,NCT05091775,"Acute anal fissure after diarrhea. Standard management of acute fissure (Diltiazem Jelly, supportive care, placebo suppository, sitz bath)",2020-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Acute anal fissure after diarrhea. Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)"
13986,NCT02858141,Collection of oncogeriatric data for future research studies,2015-05,UNKNOWN,OBSERVATIONAL,['NA'],,
13987,NCT00373022,Effect of moderate physical activity on quality of life as measured by the Functional Assessment of Cancer Therapy-Colon questionnaire,2004-01,COMPLETED,INTERVENTIONAL,['NA'],,"Correlation of serum levels and patterns of immune function (cytokine, neutrophil, T cell, B cell, NK cell, and immunoglobulin levels) with physical activity levels"
13988,NCT06013228,Fatigue,2023-08-30,RECRUITING,OBSERVATIONAL,['NA'],,
13989,NCT03483922,DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC,2018-08-20,COMPLETED,OBSERVATIONAL,['NA'],,
13990,NCT01413022,Optimal dose and dose-limiting toxicity of PF-04136309 in combination with FOLFIRINOX,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Prevalence and function of MDSC in peripheral circulation before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone
13991,NCT06200831,"Comprehensive Complication Index, CCI",2024-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life: EORTC QLQ-30
13992,NCT06026774,Number of Participants with Adverse Events (AEs) [safety and tolerability],2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cytokines Level [immunogenicity]
13993,NCT04735107,Defunction ileostomy rate,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative morbidity
13994,NCT01410760,Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis,2011-04,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.
13995,NCT05686122,Feasibility of PainPac,2023-09-28,RECRUITING,INTERVENTIONAL,['NA'],,Change in PROMIS - Emotional Distress (Depression) Short Form
13996,NCT03268499,Time to progression (TTP),2016-09-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
13997,NCT03310008,The objective response rate (ORR) before resection as measured by RECIST (version 1.1),2017-08-07,UNKNOWN,INTERVENTIONAL,['PHASE1'],,The overall survival (OS)
13998,NCT05172310,Diagnostic accuracy of FAPI-PET/CT in primary tumors,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE1'],,Safety of 68Ga-FAPI-46
13999,NCT05209295,Cmax: Observed maximum concentration,2024-03-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,Number of participants with a recording of concomitant procedures
14000,NCT00779272,Postoperative Complications and liver regeneration,2008-09,COMPLETED,OBSERVATIONAL,['NA'],,
14001,NCT00944463,Time to progression,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Correlative analyses
14002,NCT04257955,Patient's Compliance,2020-09-15,COMPLETED,OBSERVATIONAL,['NA'],,
14003,NCT05715775,The LN dissection rate,2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,LN noncompliance
14004,NCT02277392,Number of Adverse Events,2014-09,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,
14005,NCT05513742,Overall Response Rate,2022-12-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Exposure Response by Pharmacokinetic (PK) Sampling
14006,NCT00323518,the incidence of grade 3/4 oral mucositis using WHO grading system,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14007,NCT05812287,Early gastric cancer detection rate,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14008,NCT06279351,ETS,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,PFS
14009,NCT01840592,overall survival,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,toxicity
14010,NCT05235607,Number of participants with treatment-related adverse events as events as assessed by CTCAE v4.0,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Number of participants with Overall survival as assessed by RECIST1.1
14011,NCT06108310,Identification of radiogenomics signature (ATTRACT AI-model) of stage II-III colon tumors,2021-01-02,RECRUITING,OBSERVATIONAL,['NA'],,Correlation of radiogenomics signature (ATTRACT AI-model) of colon cancer with clinical outcomes (DFS and RFS)
14012,NCT03290209,3-year disease specific survival rate,2017-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,operation time
14013,NCT04456140,Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families,2020-06-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Differences in survey responses between patient groups
14014,NCT04288284,early postoperative morbidity after curative resection of colorectal cancer,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,Overall survival
14015,NCT05500248,Positive Predictive Value (PPV),2022-10-01,RECRUITING,INTERVENTIONAL,['NA'],,Adenoma Detection Rate (ADR) in the rectosigmoid tract.
14016,NCT01384864,to determine whether tissue is neoplastic or non-neoplastic,2011-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,
14017,NCT04911959,Recurrence-free survival (RFS) evaluation,2022-07-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival ( OS) evaluation
14018,NCT05079438,≥Grade 2 proctitis,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14019,NCT06334965,Clinical response,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14020,NCT04183712,3-year DFS,2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],sensitivity and specificity of ctDNA,3-year OS
14021,NCT03554356,Incidence of CryoBalloon-related serious adverse events,2018-09-04,RECRUITING,INTERVENTIONAL,['NA'],,Proportion of Barrett's Esophagus surface area reverted to neosquamous epithelium
14022,NCT03492827,infection rate 8 hours after ESD,2017-06-01,UNKNOWN,INTERVENTIONAL,['NA'],complications of ESD,infection rate 72 hours after ESD
14023,NCT00900003,Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy,2007-05,COMPLETED,OBSERVATIONAL,['NA'],,Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population
14024,NCT01315990,Progression-free survival,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Development of acneiforme follicular exanthema >= grade2
14025,NCT01319084,,2011-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14026,NCT01434264,Changes in personal concerns identified by the patient in the MYCaW questionnaire.,2011-09,COMPLETED,INTERVENTIONAL,['NA'],,Changes in Daily physical performance
14027,NCT01259414,overall survival,2011-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14028,NCT03045107,Length of hospital stay,2017-02-01,UNKNOWN,INTERVENTIONAL,['NA'],,Quality of life
14029,NCT04493125,The number of radiopaque markers transferred to the large intestine 3 days after surgery,2020-07-27,UNKNOWN,INTERVENTIONAL,['NA'],,
14030,NCT00800969,Diagnostic Accuracy of PET-CT,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,
14031,NCT05636150,Progression free survival (PFS),2022-03-30,RECRUITING,INTERVENTIONAL,['PHASE2'],,Disease control rate (DCR)
14032,NCT04826107,ORR(Objective Response Rate),2021-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AEs and SAEs
14033,NCT05723107,Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Percentage of Participants who Report Post-Procedural Complications
14034,NCT06042816,analgesic efficacy of free-opioid anesthesia,2019-12-30,COMPLETED,INTERVENTIONAL,['NA'],,Adverse effects of free-opioid anesthesia
14035,NCT06269744,Proportion of Participants who Complete FIT Test by Month 6,2024-03-13,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Proportion of Participants with Positive FIT who Complete Colonoscopy by Month 6
14036,NCT05571839,Number of participants with dose limiting toxicities,2023-01-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
14037,NCT01088815,Safety of Combination Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas as Assessed by Number of Grade 3 or 4 Adverse Events,2010-09-17,COMPLETED,INTERVENTIONAL,['PHASE2'],,Efficacy of Combination of GDC-0449 With Gemcitabine and Nab-Paclitaxel as Assessed by Hedgehog Signaling Pathway Downregulation
14038,NCT01135498,Progression-Free Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14039,NCT05572151,lymph node number,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14040,NCT01480817,Time to Progression (Efficacy),2012-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Alpha feto protein (AFP) responsiveness
14041,NCT02519582,Progression free survival,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Serious Adverse Events
14042,NCT05171309,Objective response rate (ORR),2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
14043,NCT05406206,Progression-Free Survival (PFS),2022-02-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14044,NCT06171854,Progression free survival (PFS),2019-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety as the description of adverse events
14045,NCT03705897,Proportion of patients achieving appropriate screening regimen.,2013-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
14046,NCT00569673,Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Progression-free Survival and Overall Survival
14047,NCT02867839,disease-free survival,2017-04-24,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence of Treatment-Emergent Adverse Events [Safety]
14048,NCT01702558,Phase 1 (LA/mGC): MTD of Capecitabine When Combined With Trastuzumab Emtansine (2.4 mg/kg QW),2012-12-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Phase 1 (LA/mGC): t1/2 of 5-Fluorouracil (Metabolite of Capecitabine)
14049,NCT01887509,Concordance in identification of lower pole of tumor,2013-11-07,TERMINATED,INTERVENTIONAL,['NA'],,Assessment of predictive value of interpretation criteria
14050,NCT04732442,Change in expression of inflammatory cytokines in tumor tissue samples obtained prior and after intervention.,2017-11-01,COMPLETED,INTERVENTIONAL,['NA'],,Changes in tissue neutrophil infiltration after preoperative nutritional intervention in tumor tissue samples obtained prior and after intervention.
14051,NCT05036109,To estimate the ctDNA clearance rate of colorectal cancer patients with minimal residual disease,2021-10-12,RECRUITING,INTERVENTIONAL,['NA'],,
14052,NCT00287768,overall survival,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,safety
14053,NCT02527057,Pathologic response,2014-10,UNKNOWN,OBSERVATIONAL,['NA'],,Progression free survival
14054,NCT00003760,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14055,NCT00490685,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14056,NCT03100461,CRC screening completion rate,2018-01-22,UNKNOWN,INTERVENTIONAL,['NA'],,Cost analysis of each intervention pathway
14057,NCT03413930,Circumferential resection margin (CRM),2019-06,WITHDRAWN,INTERVENTIONAL,['NA'],,5-year overall survival rate
14058,NCT03940027,the incidence of serious complications,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA'],,Improvement of quality of life
14059,NCT02500797,Number of Participants Who Achieved a Confirmed Response,2015-08-13,COMPLETED,INTERVENTIONAL,['PHASE2'],OS in Patients Who Crossover From Single Agent Nivolumab to Dual Agent Treatment Following Progression,Overall Survival (OS)
14060,NCT00138177,"Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0",2005-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,DPD activity
14061,NCT00259844,"To evaluate the safety, toxicity and tolerability of the TroVax vaccine in this setting.",2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,To monitor and collect data on clinical outcomes (time to progression/relapse/death).
14062,NCT03732547,Objective response rate (ORR),2018-10-22,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Level of alpha-fetoprotein (AFP)
14063,NCT01033682,"The percentage of patients who are able to achieve a bladder volume within +/- 30% of planning volume, on all treatment CBCT (cone beam computed tomography) scans",2009-05,UNKNOWN,OBSERVATIONAL,['NA'],,The correlation between bladder volume and small bowel volume planning target volume
14064,NCT02863367,Objective Response Rate (ORR),2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
14065,NCT02568267,Objective Response Rate,2015-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Bone Biomarkers
14066,NCT06239194,Phase 1: Recommended Phase 2 dose (RP2D),2024-05,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001
14067,NCT02506946,Difference in percentage liver fat between PCOS and controls in adolescents and young adults,2013-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,The association of percentage liver fat by magnetic resonance spectroscopy with total body adipose tissue
14068,NCT03817658,OS,2019-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence and severity of adverse events (AEs)
14069,NCT00645710,Recommended Phase II Dose,2005-02-11,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free Survival
14070,NCT01747551,6-month Progression-free Survival (PFS),2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Objective Response
14071,NCT01930942,gene expression in different response groups,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],toxicity,"overall survival, disease free survival and local-regional free survival"
14072,NCT06049901,Evaluating the change in the serum level of Protein disulfide isomerase (PDI),2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,"Evaluating the safety and tolerability of nitazoxanide through investigating Hematological parameters (hemoglobin (mg/dL), erythrocytes (cells/μL), leukocytes (cells/μL), platelets (cells/μL) and ANC (cells/μL))."
14073,NCT02231086,Peritoneal Recurrence Free Survival at 18 Months,2015-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,Quality of Life Questionnaire Survey 5- Year Follow-up
14074,NCT04221165,Average Pain Rating measured on the 11 Numeric Rating Scale,2020-08-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Death
14075,NCT05739045,pathological complete response rate (pCR),2022-11-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,3-year DFS
14076,NCT05899985,Surgical quality,2024-03-21,RECRUITING,INTERVENTIONAL,['NA'],FerroTrace enhanced MRI Response,SLN Ultra-staging Overall Survival
14077,NCT01051765,overall survival,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,polymorphism of UGT1A
14078,NCT03737591,Specificity,2010-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
14079,NCT04790448,"Overall response rate from the date of first drug administration until the date of first documented progression or date of death, whichever came first.",2020-07-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of patients with adverse events and severity according to NCI CTCAE v5.0
14080,NCT06194708,1-year non-reversal rate of temporary stoma,2023-05-15,RECRUITING,OBSERVATIONAL,['NA'],,
14081,NCT01490749,Phase I portion to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RAD001 in combination with radiation,2012-02,COMPLETED,INTERVENTIONAL,['PHASE1'],,Rate of surgical pathologic complete remission (pCR) (absence of evidence of cancer after surgery)
14082,NCT03050268,Identification of novel cancer predisposing genes,2017-04-06,RECRUITING,OBSERVATIONAL,['NA'],,
14083,NCT05600803,detection rate,2022-10-30,RECRUITING,OBSERVATIONAL,['NA'],,Number needed to screen
14084,NCT04279080,functional bowel outcome after low anterior resection,2003-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14085,NCT05806333,Diagnostic performance of FAPI PET,2022-06-01,RECRUITING,INTERVENTIONAL,['NA'],,
14086,NCT05809661,stoma compliance,2021-01-01,COMPLETED,OBSERVATIONAL,['NA'],,life quality
14087,NCT00550108,"Patients not progressing to operation due to the development of symptoms, growth to a maximum diameter of >3cm, or development of a mural nodule.",2007-10,TERMINATED,INTERVENTIONAL,['PHASE3'],,A decrease in size by >1 cm on MRCP Relative decrease in size of cyst after 1 or 2 injections with ethanol Is reduction in size durable (over what length of time)?
14088,NCT00055705,,2003-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14089,NCT01576666,Dose Limiting Toxicities,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Plasma pharmacokinetics (PK) parameters
14090,NCT00247728,Tumour Non-recurrence Rate,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Survival Rate
14091,NCT04423965,MFS,2020-05-12,RECRUITING,INTERVENTIONAL,['PHASE2'],,Reported Adverse events
14092,NCT04638751,Determine whether the microbiome composition can predict risk for colorectal cancer,2022-07-01,RECRUITING,OBSERVATIONAL,['NA'],,Build a library of samples and data for future research
14093,NCT05173077,Specific chemistry identification in the exhaled breath,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA'],Confounding factor analysis,Gut microbiota analysis in relation to breath VOCs
14094,NCT04274790,5-FU in ribosome,2021-06-01,WITHDRAWN,OBSERVATIONAL,['NA'],,Specific molecular signature
14095,NCT05349110,"The Area Under ROC Curve (AUC) of AI4CRP per image modality (HDWL, BLI, LCI, i-scan).",2021-08-20,UNKNOWN,OBSERVATIONAL,['NA'],,The agreement in surveillance interval based on optical diagnosis and histopathology.
14096,NCT04468607,Maximum Tolerated Dose(s) MTD(s) of BLYG8824A,2020-08-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Presence of Anti-drug Antibodies (ADAs)
14097,NCT02095236,Three-dimensional intra- and interfractional measurement of fiducial marker or transponder motion,na,WITHDRAWN,INTERVENTIONAL,['NA'],,
14098,NCT04336397,Colorectal cancer screening,2021-04-29,RECRUITING,INTERVENTIONAL,['NA'],,Diagnostic follow-up
14099,NCT05184751,"incidence of early onset colorectal neoplasias, risk factors",2012-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14100,NCT06256055,Incidence of Dose-limiting Toxicities (DLTs),2024-03-05,RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall Survival (OS)
14101,NCT02372747,Length of the incision,2012-10,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative complication
14102,NCT00874263,Endoscopic Confocal microscopy may help distinguish small adenomatous polyps with malignant potential from non-neoplastic (hyperplastic) polyps in real- time enabling immediate diagnosis and removal of only polyps with truly malignant potential.,2008-03,COMPLETED,OBSERVATIONAL,['NA'],,"Endoscopic Confocal microscopy has the potential to fundamentally change the way endoscopy and pathology interact by allowing near histological-quality imaging in vivo, without the need, risk, and cost of tissue removal."
14103,NCT05494853,HCC screening positive,2022-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14104,NCT02900950,Evaluate R1 rate differences between multicolour and monocolour inking of the specimen,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Relation between Disease Free Survival and Overall Survival of the participants and R status
14105,NCT06308354,DFS,2011-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
14106,NCT01101672,Post-operative pain on coughing,2009-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Recurrence and survival for cancer patient
14107,NCT05490719,PFS assessed by investigators,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,"The rates and severity of Adverse Events, Serious Adverse Events"
14108,NCT01757366,Progression-free survival (PFS),2012-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14109,NCT02970513,Hamilton anxiety and depression score comparison,2017-03-27,COMPLETED,INTERVENTIONAL,['NA'],,personality traits comparison
14110,NCT06059924,Cancer-specific survival,1991-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Recurrence-free survival
14111,NCT02559674,Overall Survival; Phase II,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,Correlation between the level of tumor DNA in patient plasma and response to study treatment
14112,NCT06195514,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14113,NCT02548169,Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03,2015-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,Average of all changes in Quality of Life (QoL) Score
14114,NCT03776591,Complications,2016-09-01,RECRUITING,INTERVENTIONAL,['NA'],Hospitalization,Prognostic significance of CTCs
14115,NCT04160832,Prevalence of germline pathogenic/likely pathogenic variants in cancer predisposition genes in patients with advanced colorectal polyps,2019-10-24,RECRUITING,OBSERVATIONAL,['NA'],,Risk factors for germline pathogenic/likely pathogenic variants in patients with advanced colorectal polyps
14116,NCT00600613,"Number of Participants Eligible for Cone Beam Tumor Localization""",2006-01,COMPLETED,INTERVENTIONAL,['NA'],,
14117,NCT04336202,Workload,2024-08,RECRUITING,INTERVENTIONAL,['NA'],,Local control
14118,NCT04989153,Risk factors for GC,2016-03-05,UNKNOWN,OBSERVATIONAL,['NA'],,
14119,NCT00864513,Progression-free Survival,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
14120,NCT01577511,Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.,2012-06-12,COMPLETED,OBSERVATIONAL,['NA'],,Number of circulating cancer cells per ml blood
14121,NCT01807546,Overall response rate,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Adverse Events
14122,NCT01197820,Temperature standard deviation,2010-09,TERMINATED,INTERVENTIONAL,['NA'],,HIFU platform improvements
14123,NCT02320448,Number of Patients with Adverse Events.,2015-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Feasibility: Completion of procedure in 28:35
14124,NCT02626195,postoperative complication,2013-10,COMPLETED,INTERVENTIONAL,['NA'],immunologic change(CD4/CD8) after nutritional support,postoperative cost( + nutritional support cost)
14125,NCT00051441,The primary endpoint is the cumulative proportion of patients with severe mucositis (WHO mucositis score of at least 3) at a cumulative radiation dose of 5500 cGy,na,COMPLETED,INTERVENTIONAL,['PHASE3'],,Secondary endpoints include cumulative RT to first use of an opioid for oral mucositis; cumulative RT to first ulceration; cumulative RT to first RT suspension due to oral mucositis
14126,NCT02942563,Pelvic complete resection rate,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,The incidence of >=3 grade adverse events
14127,NCT00862342,Progression free survival,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles
14128,NCT00004236,,1998-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14129,NCT03778710,The correlation of lymph node ratio and prognosis of recurrence of gastric cancer patients,2018-12-18,COMPLETED,OBSERVATIONAL,['NA'],,The correlation of total of lymph node retrieved less than 15 and more than 15 nodes and survival of gastric cancer patients
14130,NCT02121405,Disease-free survival,2015-10,SUSPENDED,INTERVENTIONAL,['PHASE3'],,Overall survival
14131,NCT04842006,Postoperative ctDNA,2021-12-20,RECRUITING,INTERVENTIONAL,['NA'],,Treatment response by patient-derived organoid (PDO) therapy response
14132,NCT03178929,Time to tumor recurrence,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Overall survival
14133,NCT04761536,Anastomotic leak,2006-01,COMPLETED,OBSERVATIONAL,['NA'],,need of postoperative blood transfusion
14134,NCT05345613,Postprocedural bleeding,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,Intraprocedural bleeding
14135,NCT05638984,PFS,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14136,NCT00813293,Coagulation Zone Volume,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Treatment-Related Grade 1-4 Adverse Events (AEs) One Month After Radiofrequency Ablation (RFA)
14137,NCT06080854,R0 resection rate,2023-11-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14138,NCT04796948,RP2D,2021-04-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,CL
14139,NCT00361244,To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population.,2006-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"to assess overall survival, progression-free survival, time to progression and duration of response."
14140,NCT00060021,,2003-03,COMPLETED,INTERVENTIONAL,['NA'],,
14141,NCT00969124,Detection Rates for All Polyps,2009-01,COMPLETED,INTERVENTIONAL,['NA'],,Time Spent During Withdrawal Phase and Total Procedure
14142,NCT00070122,Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab,2004-04,TERMINATED,INTERVENTIONAL,['PHASE3'],,Whether gene expression variables are predictive of survival and progression-free survival
14143,NCT00229554,colorectal cancer screening compliance,2006-03,COMPLETED,OBSERVATIONAL,['NA'],,
14144,NCT05795010,Positive rate of preoperative MRD test,2023-03-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Positive rate of MRD test 1 month and 3 months after operation
14145,NCT02758587,Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD)),2017-07-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change in immune cell infiltrate
14146,NCT03422835,Positive rate of circumferential resection margin (CRM) of the specimens,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2'],Quality of life outcomes evaluation,the rate of postoperative complications
14147,NCT03061058,Progression-free Survival (PFS),2013-04-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Adverse Events
14148,NCT04213118,Disease free survival,2020-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Incidence of Treatment-Emergent Adverse Events Safety and Tolerability
14149,NCT02577263,Quality of life deterioration > 10% (dichotomic),2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,Significant chemotherapy induced neurotoxicity > 10%
14150,NCT00819650,Overall survival,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to recurrence
14151,NCT04543617,Arm B vs Arm C: OS,2020-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With ADAs to Atezolizumab
14152,NCT02366039,distinguishing between normal esophageal squamous mucosa and Barrett's dysplasia,2014-09,COMPLETED,OBSERVATIONAL,['NA'],,
14153,NCT00337389,Progression Free Survival,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Incidence and Severity of Adverse Events
14154,NCT02430948,Effect of educational intervention on providers' recommendations,2014-01,COMPLETED,INTERVENTIONAL,['NA'],,Patient compliance
14155,NCT00587964,Local Control,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14156,NCT06175845,"Time to first event, ie stent dysfunction",2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Total days of overnight-hospital-stays
14157,NCT00821912,Response rate,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
14158,NCT05502835,Intraoperative fluid volume,2022-08-20,COMPLETED,INTERVENTIONAL,['NA'],,intestinal oedema
14159,NCT03990025,Difference in detection rate of duodenal lesions between Linked Color Imaging and White Light Imaging,2019-03-27,COMPLETED,INTERVENTIONAL,['NA'],,Sensitivity and Specificity of detection of duodenal lesions
14160,NCT03153280,Incidence of dose limiting toxicity (DLT) within the two first cycles at each dose level.,2022-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events reported as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (Safety and Tolerability).
14161,NCT01760616,Time to significant progression after surgery and postoperative survival period.,2011-11-07,TERMINATED,INTERVENTIONAL,['PHASE4'],,Alpha-fetoprotein quantitation and related biochemical indicators
14162,NCT05218889,ORR,2021-08-04,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and tolerability by incidence, severity and outcome of adverse events"
14163,NCT03051802,Optimize the clinical protocol using this technology,2017-01-27,TERMINATED,INTERVENTIONAL,['NA'],,
14164,NCT00004860,,2000-10-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14165,NCT02650635,Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide,2016-02-05,TERMINATED,INTERVENTIONAL,['PHASE1'],Changes in immunomodulation,PFS as measured by serial imaging studies and assessed by irRECIST
14166,NCT04996446,recurrence free survival,2020-08-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,overall survival
14167,NCT01522937,The Percentage of Patients With Local Control at 1 Year Post Treatment,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,The Number of Patients That Experience Grade 4+ Gastrointestinal Bleeding
14168,NCT05528614,Postoperative morbidity and mortality of simultaneous pancreatic and hepatic resectio,2022-01-13,COMPLETED,OBSERVATIONAL,['NA'],,
14169,NCT05420259,Mean Change in interleukin 6 (IL6),2022-03-21,RECRUITING,INTERVENTIONAL,['NA'],,Change in skeletal muscle
14170,NCT01210495,"Overall Survival (OS) - Stratified Analysis, Randomized Portion",2010-12-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Treatment-Related Adverse Events (AEs) in Randomized Portion
14171,NCT02445014,Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule.,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,
14172,NCT01183494,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2009-12-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,To evaluate the pharmacokinetic profile of irinotecan in combination with bevacizumab.
14173,NCT00832299,Pathologic Complete Response,2009-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,"Observation of Overall Pathologic Response Rate, Correlation of Pathologic Staging With Pre-op Ultrasound and Pelvic MRI Staging Observed Toxicities Patterns of Disease Relapse Disease-free Survival Overall Survival"
14174,NCT05361252,The incidence of postoperative complications in the two groups.,2017-02-01,COMPLETED,INTERVENTIONAL,['NA'],,The pain scale
14175,NCT00276744,6-month Overall Survival,2005-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14176,NCT01404650,Progression-free Survival (PFS),2011-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Patients With Adverse Events as a Measure of Safety and Tolerability
14177,NCT01858662,Major Pathological Response Rate,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Chemotherapy-associated hepatotoxicity:
14178,NCT04774198,Number of patients with persistent postoperative hypotension (<65 mmHg) after surgery,2021-02-01,RECRUITING,OBSERVATIONAL,['NA'],,Number of patients with development of delirium after surgery
14179,NCT01621451,delayed ulcer bleeding,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4'],,ulcer healing rate
14180,NCT00361842,Progression-free Survival (PFS) Per RECIST Version 1.0,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response (DoR) Per RECIST Version 1.0
14181,NCT03082586,Number of Dose Limiting Toxicities (DLTs) Occurring in Participants,2016-11-20,COMPLETED,INTERVENTIONAL,['NA'],,Local Failure
14182,NCT05914597,Feasibility of home delivery of CCE service,2022-12-12,RECRUITING,INTERVENTIONAL,['NA'],,assessing the patient's acceptability of home delivery of CCE service
14183,NCT05403177,Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data,2022-06-23,RECRUITING,OBSERVATIONAL,['NA'],,Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine
14184,NCT02704143,One-year Overall Survival Rate,2016-02,COMPLETED,INTERVENTIONAL,['NA'],,Median Overall Survival Will be Determined.
14185,NCT02920554,Survival rates,2014-07,UNKNOWN,INTERVENTIONAL,['NA'],,
14186,NCT05129605,Diagnosis of prostate cancer,2020-02-12,RECRUITING,OBSERVATIONAL,['NA'],,Positive predictive value of multiparametric MRI for detection of prostate cancer
14187,NCT00399035,Overall Survival,2006-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to Wound Healing Complications
14188,NCT01793207,"Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects",2012-12,COMPLETED,OBSERVATIONAL,['NA'],,"Methylation markers present in peripheral blood of patients with hyperplastic polyps(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects"
14189,NCT04505553,Severity of chemotherapy-induced peripheral neuropathy (CIPN),2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,"Incidence of pain, fatigue, nausea, and anxiety"
14190,NCT00570635,"Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ≥16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib",2007-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST
14191,NCT00547144,To determine the time to tumor progression for this regimen.,2005-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14192,NCT00576992,"Determine the prevalence of gastric and esophageal disease in patients presenting with the complaints of dyspepsia, GERD, or extraesophageal symptoms",2003-01,TERMINATED,OBSERVATIONAL,['NA'],,"Determine whether the presence of any factors (hiatal hernia, NSAID use, age, race, gender, etc.) contribute to the above endoscopic diagnoses"
14193,NCT02574663,"Adverse events as a measure of safety and tolerability of TGR-1202 as a single agent and in combination in combination with nab-paclitaxel + gemcitabine, or with oxaliplatin + leucovorin + 5-FU (FOLFOX) or with FOLFOX + bevacizumab.",2015-09-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Pharmacokinetic (PK) profile of TGR-1202. Area under the plasma concentration versus time curve (AUC)
14194,NCT01227018,Disease Control Rate,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarker Evaluation,Number of Patients With Each Worst Grade Toxicity
14195,NCT04529135,postoperative recovery time,2020-08-26,COMPLETED,INTERVENTIONAL,['NA'],,opioid related side effect.
14196,NCT04778566,Evaluate the feasibility of the Cologuard test for Lynch Syndrome,2021-11,WITHDRAWN,OBSERVATIONAL,['NA'],,Evaluate bowel preparation tolerability
14197,NCT05356520,Disease-free survival time,2022-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Tumor recurrence
14198,NCT05327400,High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.,2022-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14199,NCT05069571,Adenoma detection rate,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,Proportion of withdrawal overspeed
14200,NCT02015065,Number of Participants With a Clinical Activity-radiographic Response,2013-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
14201,NCT01582178,Cecal Intubation Time,2012-06,COMPLETED,INTERVENTIONAL,['NA'],,Patient Comfort During Insertion Phase of the Colonoscopy
14202,NCT02415101,"Complete histological response proportion, using the Chirieac grading system.",2015-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Nutritional status of patients in each study arm.
14203,NCT05327751,The change in HFS-specific QOL questionnaire (HFS-14).,2022-04-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,The change in serum levels of malondialdehyde (MDA).
14204,NCT00034619,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14205,NCT05580835,Degree of PSMA uptake by HCC,2022-09-05,RECRUITING,INTERVENTIONAL,['NA'],,Presence of PSMA uptake on treated liver lesions
14206,NCT04864067,Quality of Life and Funcional Outcomes,2021-06-09,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
14207,NCT05913141,Objective response rate (ORR),2023-06,RECRUITING,OBSERVATIONAL,['NA'],,12-month survival rate
14208,NCT02304445,Tumor response rate,2015-11,WITHDRAWN,INTERVENTIONAL,['NA'],Overall survival,Number of patients eligibility for liver transplantation
14209,NCT03380130,"Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.",2017-09-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pattern of progression according to RECIST 1.1 criteria.
14210,NCT04611997,3-year disease free survival rate,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Total number of retrieved lymph nodes
14211,NCT01754987,Number of Participants That Experience Serious Adverse Events.,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants That Are Alive After 15 Weeks of Treatment.
14212,NCT01808638,"Maximum concentration (Cmax), area under the curve (AUC), time to maximum concentration (tmax), and half life (t½) of the Atu027 siRNA single strand (A-strand), and of AtuFect01 and the helper lipid DPyPE",2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quality of life
14213,NCT04425239,Progression-free Survival,2018-05-21,COMPLETED,INTERVENTIONAL,['PHASE2'],Metabolomic profiling,Overall Survival (OS)
14214,NCT03892252,"According to the 16s rDNA sequencing results, analyze the differences in intestinal flora of colon cancer patients with different TCM syndromes and TCM constitutions before and after surgery and their correlations",2019-03-10,COMPLETED,OBSERVATIONAL,['NA'],,
14215,NCT05195294,Objective response rate (ORR),2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
14216,NCT00926757,The primary endpoint is the incidence of HBV reactivation during and within 12 months after chemotherapy,2009-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,The incidence of HBsAg reverse seroconversion during and within 12 months after completing chemotherapy.
14217,NCT05721651,Progression free survival (PFS),2023-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,"Safety and tolerance evaluated by incidence, severity and outcomes of AEs"
14218,NCT05966194,Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Narcotic use through resolution of SOM
14219,NCT01365130,Number of Patients Without Progression at 3 Months,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Patients Experienced a Toxicity Associated With Cabazitaxel for Patients With Metastatic Gastroesophageal Adenocarcinomas That Have Progressed After at Least One Line of Therapy for Metastatic Disease.
14220,NCT06134700,To compare the efficacy of low pressure versus standard pressure pneumoperitoneum in laparoscopic nephrectomy,2023-11-15,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
14221,NCT05513183,Association between the concentration of intraoperative mitomycin-C absoprtion and severe neutropenia after CRS/HIPEC,2021-05-20,COMPLETED,OBSERVATIONAL,['NA'],,Quality of Life: QoR-40 questionnaire
14222,NCT04196803,Plasma methionine cycle metabolites,2016-02-01,COMPLETED,INTERVENTIONAL,['NA'],,
14223,NCT04969887,Determine the proportion of participants with progression free survival at 6 months,2021-08-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quantification of treatment related toxicities to ipi/nivo according to CTCAE V5.0
14224,NCT01791140,Median progression-free survival,2011-03,COMPLETED,OBSERVATIONAL,['NA'],,Median progression-free survival according to age group (65-74 years; >/= 75 years)
14225,NCT02096666,Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1),2014-04-15,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1- Overall Survival
14226,NCT02809716,"HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles",2016-08-01,COMPLETED,OBSERVATIONAL,['NA'],,"HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles"
14227,NCT02148159,Percentage weight change over 8 weeks between two arms,2014-10,COMPLETED,INTERVENTIONAL,['NA'],symptom experience,body composition
14228,NCT04185272,"evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry",2020-06-30,RECRUITING,INTERVENTIONAL,['NA'],,
14229,NCT01877187,Baseline Enhancing Tumor and Response by RECIST Criteria,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,6-month Survival Rate of Patients With HCC and Liver Metastases Treated With Conventional TACE
14230,NCT03713749,Rate of unsuccessful LND along the left RLN,2018-10-22,UNKNOWN,INTERVENTIONAL,['NA'],,"European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30 , QLQ-OES18"
14231,NCT01579357,Influence of Cetuximab on metabolic activation of Capecitabine,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14232,NCT04394572,"Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases",2021-01-07,COMPLETED,OBSERVATIONAL,['NA'],,
14233,NCT05355298,Part B: efficacy of AMP945,2022-05-31,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Effects on biomarkers,AMP945 levels in plasma
14234,NCT05818072,The yield rate of intestinal metaplasia,2023-03-13,RECRUITING,INTERVENTIONAL,['NA'],,Procedure time
14235,NCT02194959,Colonoscopy completion,2011-07,COMPLETED,INTERVENTIONAL,['NA'],,
14236,NCT03216395,Bleeding free probability in 30 days after randomization,2018-01-02,COMPLETED,INTERVENTIONAL,['NA'],,cost analysis (Based on the cost data from the Hospital
14237,NCT03679039,The sensitivity and specificity of the model to predict the drug resistance,2018-09-20,UNKNOWN,OBSERVATIONAL,['NA'],,
14238,NCT02548403,the quality of the bowel preparation using Preparation Scale,2014-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,the endoscopist's tolerability[Visual Analog Score for fatigue]
14239,NCT02495337,"Effectively culture, proliferate, and store primary gastro-esophageal cell lines in order to create a bank of primary esophageal / gastric cancers for research purposes",2015-05,RECRUITING,OBSERVATIONAL,['NA'],,
14240,NCT05569343,postoperative complications,2020-05-08,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
14241,NCT02215577,"Surgical success rate, the rate of liver resection in each study arm",2014-06,UNKNOWN,INTERVENTIONAL,['NA'],Health economy,Liver growth rate
14242,NCT01525706,Efficacy: Degree of Ablation,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1'],,Efficacy: Cyst Resolution
14243,NCT04527666,Changes of portal vein thrombosis,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
14244,NCT03018418,Rates of Acute Toxicity,2017-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of Life Changes
14245,NCT05039983,Recommended phase 2 dose (RP2D),2021-08-20,UNKNOWN,INTERVENTIONAL,['NA'],,change in blood biochemical indicators
14246,NCT00399750,To evaluate the safety and efficacy of three oxaliplatin-fluoropyrimidine regimens when combined with bevacizumab as therapy for previously untreated metastatic colorectal cancer (TREE 2),2002-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Patients enrolled prior to the initiation of Amendment 3 (TREE1) will not be eligible to receive Avastin as a component of their treatment regimen.
14247,NCT01996059,Body Mass Index,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],Visick rates,Onodera Prognosis Nutritional Index
14248,NCT04659018,The ability to predict the presence of adenomas and colorectal cancers.,2020-08-24,COMPLETED,OBSERVATIONAL,['NA'],,
14249,NCT03546127,Delay time to send a validated exome sequencing report from sample receipt,2017-05-23,COMPLETED,OBSERVATIONAL,['NA'],,The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB
14250,NCT03530267,Progression-free survival (PFS),2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,PRO: Overall treatment utility
14251,NCT01834170,Number of participants with adverse events as a measure of safety and tolerability,2013-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Proportion of participants who remain alive one year after enrollment compared to the historical matched control group
14252,NCT02497820,cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer,2016-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Overall cumulative of of new adenomas at five years
14253,NCT01711242,disease free survival,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of participants with adverse events as a measure of safety and tolerability,5 year Overall Survival
14254,NCT05757336,Safety：the incidence of adverse events and serious adverse events,2022-12-22,RECRUITING,INTERVENTIONAL,['PHASE2'],,Proportion of acceptable radical resection of primary lesions
14255,NCT05339919,Long-term results after operation,2020-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Hospitalization expenses
14256,NCT01764438,"incidence of change of BCLC stage after add-on Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.",2012-08,UNKNOWN,OBSERVATIONAL,['NA'],,"Sensitivity, specificity, false positive predictive value, false negative predictive value, and accuracy of Primovist-enhanced MRI"
14257,NCT04186234,Best objective response,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA'],Changes in Child-Pugh status,Overall survival
14258,NCT04835896,Phase 2: Progression-free survival in subjects with M7824 and paclitaxel combination treatment,2021-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Safety and Tolerability, in terms of the number, severity, and duration of treatment-emergent adverse events as assessed by CTCAE v5.0"
14259,NCT02567045,Proportion of patients who participate in each screening arm,2016-02-25,COMPLETED,INTERVENTIONAL,['NA'],,Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions
14260,NCT00619242,Ki-67,2006-06,TERMINATED,INTERVENTIONAL,['NA'],,
14261,NCT04163887,Rate of overall complications using the comprehensive complication Index (CCI),2021-01-27,RECRUITING,INTERVENTIONAL,['NA'],,Disease-free and overall survival at 3 years.
14262,NCT04063293,Wexner fecal incontinence score change,2019-05-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Number of participants with PRP injection-related adverse events as assessed by CTCAE v4.0
14263,NCT00030667,Toxicity reported using the CTC version 2.0,2002-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Time to disease progression
14264,NCT00882765,Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"To evaluate the impact of genistein on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8"
14265,NCT01137123,survival rate,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14266,NCT05667181,Incidence of anastomotic complications,2022-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
14267,NCT01741363,Detection rate of upper gastrointestinal tract diseases,2012-07,UNKNOWN,INTERVENTIONAL,['NA'],,Helicobacter pylori eradication rate
14268,NCT03890926,Local control time,2015-12,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of adverse events
14269,NCT00909987,"Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria",2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Complete Phatologic Response (pCR)
14270,NCT04715061,"Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)",2020-11-04,COMPLETED,INTERVENTIONAL,['NA'],,Heart rate variability
14271,NCT03739801,Progression-free survival (PFS) (Phase II),2020-04-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence of adverse events graded according to CTCAE version 4.0
14272,NCT01545687,The AUC of the MTS score,2012-04,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,DFS at 12 months after treatment
14273,NCT04915326,Nodal metastasis in early rectalò cancer,2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
14274,NCT01713387,Maximum tolerated dose,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants with dose limiting toxicity
14275,NCT03484299,Incidence of Adverse and Serious Adverse events will be captured (safety and tolerability),2018-05-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Progression free survival
14276,NCT02527785,overall response rate,2015-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity profiles - The number of participants and grade of intensity of treatment related adverse events
14277,NCT04404101,Safety of EUS-FNA plus MFB with that of EUS-FNA by recording adverse events per published ASGE (American Society for Gastrointestinal Endoscopy) criteria.,2021-05-11,RECRUITING,INTERVENTIONAL,['NA'],,Time taken for FNA and time for MFB
14278,NCT04514341,Time to completion of diagnostic colonoscopy,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Navigation Services Provided
14279,NCT01238653,The number of accurate liver surface registrations obtained in the laparoscopic environment compared to accurate liver surface registrations obtained in open procedures,2010-11,TERMINATED,OBSERVATIONAL,['NA'],,
14280,NCT02967887,Objective tumor response,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],Exploratory endpoint: Diagnostic performance of biomarkers,Progression-free-survival
14281,NCT05690490,R0 resection rate,2020-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,intra- and postoperative complications rate
14282,NCT03637491,Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,2018-08-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Phase 2: Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression, DNA Damage Repair (DDR) Gene Alterations, and Tumor Mutational Burden (TMB) in Baseline Tumor Tissue."
14283,NCT06157060,2-year recurrence-free survival rate,2023-11-20,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between ctDNA-MRD status dynamic changes and relapse
14284,NCT06102902,Recommended phase 2 dose (dose escalation cohort),2024-11-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Presence or absence of a given gene mutation,MAPK inhibition
14285,NCT06254521,Pathological complete response (pCR) rate,2024-02-22,RECRUITING,INTERVENTIONAL,['PHASE2'],Molecular pathological analysis of tumor tissue,3-year local recurrence rate
14286,NCT05240625,Adenoma detection rate,2022-03-01,RECRUITING,INTERVENTIONAL,['NA'],,Withdrawal time
14287,NCT00389870,Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab
14288,NCT01742065,FIT Completion,2013-01,COMPLETED,INTERVENTIONAL,['NA'],,Any CRC Screening
14289,NCT04231526,To measure the feasibility of neoadjuvant pembrolizumab in early stage colon cancer,2020-05-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,Measure the immune response in early stage colon cancer after neoadjuvant pembrolizumab
14290,NCT05643391,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,2020-06-15,COMPLETED,INTERVENTIONAL,['NA'],"Comparison between ""pre-scout"" HBS and HBS just after ""scout dose""",Evaluation of efficacy of 166Ho radioembolization in unresectable hepatocellular using metabolic assessments (FDG and choline PET/CT)
14291,NCT02114411,Sensitivity and Specificity of the GastroPanel test for the detection of AG,2017-01-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14292,NCT00005956,Safety,2000-02,COMPLETED,INTERVENTIONAL,['NA'],,
14293,NCT05176002,Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.,2021-09-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant
14294,NCT00217087,Change in Quality of Life,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14295,NCT00555334,Overall survivals,2007-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Recurrence rates
14296,NCT05411718,To establish the effect of naproxen or aspirin on the abundance of T cells and other immune,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14297,NCT04989985,pCR,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
14298,NCT05508126,Diagnostic performance of DECT and mpMRI in tumor restaging assessment,2021-11-01,RECRUITING,OBSERVATIONAL,['NA'],,Contrast-to-noise Ratio (CNR)
14299,NCT05281328,Height-adjusted total liver volume (htTLV),2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Adverse events (AEs)
14300,NCT00785421,DVT/TVE event rate,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"TTP, OS, side effects"
14301,NCT03985644,Overall survival,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence rate
14302,NCT04400903,Compliance statistics for wristband use (Stage II),2020-09-21,TERMINATED,OBSERVATIONAL,['NA'],,Time of PDAC diagnosis among high-risk participants who developed PDAC (Stage II)
14303,NCT05582031,Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment,2023-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities
14304,NCT01453153,Recommended Phase 2 Dose (RP2D),2011-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders
14305,NCT06135896,Primary endpoint,2023-12-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,biomarkers
14306,NCT01097239,"Quality of life scores (EORTC QLQ-C30 and/or EORTC QLQ-CR38, EORTC QLQ-CX24, EORTC QLQ-EN24 or EORTC QLQ-OV24)",2009-11,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumour marker changes (CEA and CA19.9)
14307,NCT03002831,Overall Survival,2016-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Quality of life assessed by Questionnaire
14308,NCT04895722,Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR),2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants Discontinuing Study Treatment Due to an AE
14309,NCT03311451,Safety: Incidence of Dose-related SAEs,2023-01-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Efficacy: Treatment
14310,NCT01339832,Progression-free Survival,2010-08,COMPLETED,OBSERVATIONAL,['NA'],,Incidence of Adverse Event (AE) and Serious Adverse Event (SAE)
14311,NCT04530890,To assess the prognostic impact of ctDNA (mortality) in digestive and gynecological / breast cancers.,2021-01-20,RECRUITING,INTERVENTIONAL,['NA'],,Evaluate the possibility of detecting certain molecular alterations using ctDNA and exosomes
14312,NCT00220077,To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.,2002-06,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.
14313,NCT05059119,Rate of associated comorbidity or intervention,2020-09-01,COMPLETED,OBSERVATIONAL,['NA'],,
14314,NCT01294085,One year survival rate,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,Progression free survival
14315,NCT00313859,overall response rate,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,duration of response
14316,NCT00446290,Number of Participants With DLTs,2006-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14317,NCT06064331,Cost of Desflurane used to maintain BIS 40-60,2021-01-21,COMPLETED,INTERVENTIONAL,['NA'],,Opioid usage (mcg/kg)
14318,NCT00985400,Effect size of the exercise intervention on physical function,2010-11-05,UNKNOWN,INTERVENTIONAL,['NA'],,Effect size of the exercise intervention on symptoms and quality of life
14319,NCT01643811,Proportion of patients who quit previous medication for hypertension because of improved disease,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,"difference of serum levels of c-peptide, Ghrelin, GIP, GLP-1, glucagon, insulin between before and after operation"
14320,NCT04924686,NOD2 ligands in fecal and plasma,2020-05-10,UNKNOWN,OBSERVATIONAL,['NA'],,
14321,NCT03784677,Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events,2019-07-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,Predictive biomarkers
14322,NCT04223102,16s rRNA gene sequencing to study bacterial phylogeny and taxonomy,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,rectal microbiota to study bacteria strains
14323,NCT06294873,Detection of colon cancer or precancer,2023-07-20,RECRUITING,OBSERVATIONAL,['NA'],,
14324,NCT05089266,Dose-limiting toxicity （DLT）,2021-11-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate (ORR)
14325,NCT01440127,Expression of CD133 in tumors from patients treated or not treated with metformin,2011-08,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14326,NCT03211806,Adherence,2019-06-06,COMPLETED,INTERVENTIONAL,['NA'],,Readmission
14327,NCT02607982,response rate,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
14328,NCT00291486,Number of Patients With Dose-Limiting Toxicities (DLT),2003-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Patients With Human Anti-human Antibodies (HAHA) to 131I-huA33
14329,NCT01074385,Impact of Dignity Therapy,2010-04,COMPLETED,INTERVENTIONAL,['NA'],,Establish a correlation between terminal illness acknowledgement and presence of peaceful awareness with preferences for life sustaining therapy and end-of-life goals of care.
14330,NCT04851119,Area under the drug concentration curve of tegavivint,2021-11-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Antitumor effects of tegavivint in patients with solid tumors
14331,NCT03193424,Progression-free survival (PFS),2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Total Survival (OS)
14332,NCT06015971,Functionality,2023-07-01,RECRUITING,INTERVENTIONAL,['NA'],,C-RP
14333,NCT05131776,Adverse events,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Progression Free Survival
14334,NCT04677413,To determine the maximal tolerated dose (MTD) of dose-escalated hypofractionated RT.,2021-06-03,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To evaluate the rate of distant failure, defined as development of disease outside of the pelvis."
14335,NCT02001623,Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events,2013-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Dose Expansion Part: Duration of Response (DOR)
14336,NCT04368507,"2a cohort: Safety, Tolerability of YYB101 by ORR",2019-08-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,2a cohort
14337,NCT06192771,Study feasibility as measured by data fidelity for patient-reported outcomes,2023-12-01,RECRUITING,INTERVENTIONAL,['NA'],,
14338,NCT02944006,T-staging,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA'],transient dyspnea,mean diffusivity
14339,NCT04393584,median overall survival,2019-01-29,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,R0-Resection rate
14340,NCT00434109,Percentage of Participants With Progression Free Survival (PFS) at 12 Months,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Overall Survival (OS) at 4 Years
14341,NCT01151761,Progression-free Survival at 12 Months,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2'],,Median Time to Overall Survival
14342,NCT03019016,Chart review on PeriOperative Information,2016-08,COMPLETED,OBSERVATIONAL,['NA'],,Chart review on Postoperative Information
14343,NCT00834860,"Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.",2007-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Safety: adverse event rate and profile.
14344,NCT00862680,Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients,2009-03-12,COMPLETED,OBSERVATIONAL,['NA'],,
14345,NCT00003907,Time to Progression,1999-12-15,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14346,NCT04731441,Feasibility of doing exercises,2021-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life after CRS-HIPEC
14347,NCT04000425,Description of ctDNA changing to adjuvant chemotherapy response,2018-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,The ctDNA level/mutations in gastric cancer preoperatively
14348,NCT04534218,objective response rate,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14349,NCT06293612,Heterochronous distant metastasis,2015-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Distant metastasis-free survival
14350,NCT04193553,Progression-Free Survival (PFS),2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study,Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group
14351,NCT03590119,The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.,2018-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,The difference in kidney uptake of 177Lu-dotatate between the IA treated patients and historical controls
14352,NCT02426879,Safety measured by the percentage of overall postoperative complications grade 3b and higher as stated by the modified Clavien-Dindo classification (MCDC),2015-02-11,COMPLETED,INTERVENTIONAL,['NA'],pathology results 10,postoperative recovery
14353,NCT05935189,Creation of a registry,2023-07-01,RECRUITING,OBSERVATIONAL,['NA'],,
14354,NCT01653301,Pathological major downstaging,2005-10,UNKNOWN,INTERVENTIONAL,['PHASE3'],,survival
14355,NCT05534906,Biomarkers associated with small HCC (Early detection [EDx] biomarkers),2022-05-23,RECRUITING,OBSERVATIONAL,['NA'],,Proportion of patients with HCC events according to time since treatment with curative intent.
14356,NCT00048529,,2002-09,SUSPENDED,INTERVENTIONAL,['PHASE2'],,
14357,NCT03965546,Frequency of ARTEMIS T cell treatment-related adverse events,2019-05-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,IFN-γ serum levels
14358,NCT04232176,Precision in polyps sizing the pathologist,2019-12-22,COMPLETED,OBSERVATIONAL,['NA'],,Rate of polyps' recurrence at the end of the follow-up.
14359,NCT03785938,Cost-benefit evaluation of the study,2019-01-20,UNKNOWN,INTERVENTIONAL,['NA'],,Evaluate responsible guardian/participants experience of the MaCROS study
14360,NCT01349075,Response to Treatment,2007-10,COMPLETED,OBSERVATIONAL,['NA'],,Survival Time
14361,NCT01618253,Maximum Tolerated Dose,2012-06,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Health Related Quality of Life
14362,NCT05552755,Percent change from baseline in polyp burden,2023-07-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,"Assess the pharmacodynamic (PD) effect of REC-4881, and correlation between PD and clinical outcome"
14363,NCT00965172,"Incidence/Severity of Oral Mucositis WHO Grades 1, 2, 3, and 4",2010-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14364,NCT02528643,Overall Survival (OS),2015-11-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
14365,NCT04273061,"Overall response rate (ORR) in each tumour-defined cohort, as defined by RECIST 1.1",2020-06-17,RECRUITING,INTERVENTIONAL,['PHASE2'],Compare the utility of iRECIST for response assessment to RECIST 1.1 in each tumour-defined cohort,Duration of response (DoR) in each tumour-defined cohort
14366,NCT00003951,,1999-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14367,NCT03849469,"Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.",2019-05-29,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14368,NCT04962958,2-year cumulative recurrence-free survival rate,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14369,NCT03645876,Objective response rate,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2'],Biomarkers and ADA,12month and 24 month OS rate
14370,NCT00154544,,2004-08,UNKNOWN,OBSERVATIONAL,['NA'],,
14371,NCT05404503,Choledochal cyst and cholangiocarcinoma,2022-10,RECRUITING,OBSERVATIONAL,['NA'],,
14372,NCT03175016,Tumor Response of six months,2017-06-20,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life
14373,NCT02896907,Number of Participants With Adverse Events as Determined by CTCAE Version 4.03,2016-10-18,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30
14374,NCT05262452,Percentage of subjects that were subject to surgical resection,2021-08-09,RECRUITING,INTERVENTIONAL,['NA'],,Survival time
14375,NCT02146352,Safety/Adverse Event Outcome Measure 6,2014-06,COMPLETED,INTERVENTIONAL,['NA'],,Technical Success Outcome Measure 2
14376,NCT02715804,Overall Survival,2016-03-14,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of Participants With Clinically Significant Abnormalities in Vital Signs
14377,NCT03910634,Overall objective response rate,2019-04-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Incidence of toxic and side effects above 3 degrees
14378,NCT01959672,"Number of Participants With Progressive Disease,",2013-09-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Number of Participants With CA-125-Specific T-cell Signal.,"Tumor Response Rate, Evaluated on the Pathology Specimen"
14379,NCT04524650,the severity of portal hypertension,2020-08-31,UNKNOWN,OBSERVATIONAL,['NA'],,
14380,NCT05566093,The Chang The change of tumor size,2018-09-28,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of Treatment-Emergent Adverse Events
14381,NCT02978313,PFS,2016-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,QoL
14382,NCT01419860,Evaluation of microcirculation in colon wall and bowel anastomosis by laser induced fluorescence video angiography of indocyanine green,2010-01,COMPLETED,INTERVENTIONAL,['NA'],,Predicting perfusion deficit with laser-induced ICG fluorescence video angiography
14383,NCT00370513,Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD).,2006-12-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans
14384,NCT03038256,Pathological complete response rate,2018-01-31,RECRUITING,INTERVENTIONAL,['PHASE2'],,quality of surgery
14385,NCT00999921,Number of Participants Analysed for Reduction in Mastalgia (Cardiff Breast Pain Score).,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,Number of Participants Analysed for Response of Cyclical Mastalgia (Good Response Was Defined as Disappearance of Mastalgia)
14386,NCT05743036,Dose Expansion Phase - Objective response rate (ORR),2023-02-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor tissue BRAF V600E mutational status
14387,NCT05199259,Independent performance measure of sensitivity and specificity of a multi-analyte blood test,2022-03-01,RECRUITING,OBSERVATIONAL,['NA'],,Ascertain Sample Stability
14388,NCT06304974,Overall survival (OS),2024-03-19,RECRUITING,INTERVENTIONAL,['PHASE3'],,Anti-drug antibody (ADA)
14389,NCT03957460,difference between SpHb value in g/dL and SaHb value in g/dL (SpHb - SaHb),2017-11-20,COMPLETED,OBSERVATIONAL,['NA'],,
14390,NCT05416073,Pain intensity at 3 hours after HAIC treatment,2022-06-22,RECRUITING,INTERVENTIONAL,['PHASE4'],Degree of satisfaction,Pain intensity on the 21st after HAIC treatment
14391,NCT00108745,Overall Survival,2005-03-21,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Patient-Reported Peripheral Neuropathy Symptoms
14392,NCT05592873,Lateral nodal recurrence,2014-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14393,NCT02130726,Extent of lymph node dissection,2014-12,COMPLETED,INTERVENTIONAL,['NA'],,Disease-free survival
14394,NCT03530969,Participants satisfaction with Health Care Provider (HCP) training,2018-05-07,COMPLETED,INTERVENTIONAL,['NA'],,
14395,NCT03765450,Inter-compartmental Difference in Infliximab Concentration,2018-12-21,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Change in Mayo Clinic Endoscopic Score
14396,NCT02529761,Overall survival,2015-08,UNKNOWN,INTERVENTIONAL,['NA'],,Prognostic factor
14397,NCT06197178,Area Under the Curve (AUC) last,2024-01,RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of anti-LCAR-G08 antibody and positive sample titer
14398,NCT04068103,"Recurrence-free survival (RFS) the ""baseline ctDNA detected"" patient subset (Phase III)",2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",Cost effectiveness of the use of ctDNA versus standard of care,Incidence (presence or absence) of ctDNA in blood following resection of stage II colon cancer
14399,NCT05150548,Sepsis or septic shock,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14400,NCT04518774,Safety evaluation: Maximum-tolerated dose (MTD),2020-08-15,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Efficacy evaluation: γδT cells in peripheral blood
14401,NCT04632303,Adjusted mean change in global health status/QoL score at 12 weeks,2021-06-23,RECRUITING,INTERVENTIONAL,['NA'],,Chemotherapy dose intensity.
14402,NCT05438927,Participant Rating on Ease of Use for the Mobile Application - Usability,2022-07-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Participant Compliance with Dietary Log - Intervention Adherence
14403,NCT03823846,pain at rest (Numerical rating scale),2017-11-01,UNKNOWN,INTERVENTIONAL,['NA'],,adverse events during rehabilitation
14404,NCT05090215,Anaerobic threshold change,2022-05-13,RECRUITING,INTERVENTIONAL,['NA'],,Change to the values inflammatory markers using venous blood samples after the application of a 12 week postoperative exercise programme
14405,NCT00005818,Time to disease progression (TTP),2000-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Toxicity graded using the NCI CTC version 2.0
14406,NCT02578602,"Precision in tumor measurement for each type of image (CT vs. MRI), for each phase ( 4 for CT and 5 for MRI), and for each method of measuring ""size"" (1-,2-, and 3-dimensional), assessed by low inter- and intra-reader variability",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in apparent diffusion coefficient (ADC) values within lesions and within normal liver before and after administration of Gadoxetate
14407,NCT03377270,Change in MBSImP physiologic function metrics of the oropharyngeal swallow,2018-10-01,COMPLETED,INTERVENTIONAL,['NA'],,Functional Oral Intake Scale (FOIS)
14408,NCT00095966,Response rate as measured by RECIST criteria,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14409,NCT02838836,"CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome",2016-07-01,RECRUITING,OBSERVATIONAL,['NA'],,ctDNA characteristics will be correlated with survival data
14410,NCT04300114,PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1,2020-08-19,TERMINATED,INTERVENTIONAL,['PHASE3'],,Number of participants with treatment-emergent adverse events
14411,NCT05896956,overall survival,2023-07-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,progression-free survival
14412,NCT01234935,Disease-free survival,2011-01-13,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease-free survival
14413,NCT00293397,Efficacy - Overall Survival,2005-11,COMPLETED,INTERVENTIONAL,['NA'],,
14414,NCT00090025,To compare survival duration for XL119 and 5-FU/LV treated subjects,2004-09,TERMINATED,INTERVENTIONAL,['PHASE3'],,"To determine time to progressive disease for XL119 and 5-FU/LV treated subjects, to evaluate clinical benefit for XL119 and 5-FU/LV treated subjects, and to assess the safety profile of XL119"
14415,NCT05969860,Mean patient-reported rating of Cancer Connected Access and Remote Expertise,2023-08-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival
14416,NCT05788484,Tumor-specific expansion cohorts: To further evaluate the safety of CDX-585 by tumor type.,2023-05-11,RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity Evaluation
14417,NCT02887365,3-year disease-free survival Safety profile of tegafur-uracil,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE4'],,5-year overall survival
14418,NCT03558945,Incidence and grades of adverse events as assessed by CTCAE v5.0,2018-07-12,RECRUITING,INTERVENTIONAL,['PHASE1'],Percentages of immune cell populations in peripheral blood during the vaccination,Serum CA19-9 or CA72-4 levels
14419,NCT03403049,Dose-limiting toxicity,2016-04-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire
14420,NCT04726800,Frequency of positive ctDNA preoperative converted to negative postoperatively.,2020-10-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14421,NCT06302179,Venous Thromboembolism,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
14422,NCT00259363,Phase II : Response and resectability rate.,2002-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14423,NCT06194461,Incidence of specific AEs,2024-06-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,"Kinetics parameters that indicate persistence (eg, Clast and Tlast)"
14424,NCT02393755,"Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)",2015-05-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II)
14425,NCT04767295,pathologic complete response (pCR),2021-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14426,NCT04035096,"Change from baseline by computerized tomography of Chest, abdomen and pelvis",2020-01-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with changes of tumor markers
14427,NCT00544908,Progression-free Survival (PFS) Rate at 4 Months,2007-09,TERMINATED,INTERVENTIONAL,['PHASE2'],,Response Rate
14428,NCT04681248,,na,AVAILABLE,EXPANDED_ACCESS,['NA'],,
14429,NCT03997617,"Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP",2019-03-11,RECRUITING,INTERVENTIONAL,['NA'],,Number of patients for which the treatment recommendation issued by PFP were followed by the investigator
14430,NCT04301986,7 Days Post-EGD Impact of Events Score (IES),2020-08-11,COMPLETED,INTERVENTIONAL,['NA'],,Factors Influencing the Preferred Screening Modality
14431,NCT04281667,Comprehensive Complication Index,2020-03-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE4'],Bowel microbiota,Adjuvant therapy
14432,NCT02947971,Assessment of quality and performance of Compact Imaging System (CIS),2016-04-15,RECRUITING,INTERVENTIONAL,['NA'],,
14433,NCT05414383,Diagnostic accuracy,2024-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Diagnostic time
14434,NCT05336617,percentage of complete colonoscopies,2022-05-13,COMPLETED,OBSERVATIONAL,['NA'],,Quality of colonic preparation (Boston score)
14435,NCT00814359,The severity of patient-reported symptoms of mucositis as determined by the change in Oral Mucositis Weekly Questionnaire - Head and Neck Cancer (OMWQ-HN) score from baseline to 6 weeks.,2009-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,Incidence of WHO Grade 3 or 4 oral mucositis after 4 weeks of radiotherapy.
14436,NCT04101747,Number of intestinal flora,2019-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14437,NCT05160753,Disease-free survival (DFS) at three years,2022-01-10,RECRUITING,INTERVENTIONAL,['NA'],,
14438,NCT00222079,,2004-11,TERMINATED,INTERVENTIONAL,['NA'],,
14439,NCT03958240,Percentage of CD4 and CD8 T cells expressing PD-1,2020-01-17,RECRUITING,INTERVENTIONAL,['NA'],,Rate of patients presenting a high Trm (Tissue resident memory) infiltrate in tumor samples
14440,NCT03981848,tumor recurrent status,2019-07,UNKNOWN,OBSERVATIONAL,['NA'],,
14441,NCT02479984,Probability of diagnosis of metastasis (frequency),2011-08,UNKNOWN,INTERVENTIONAL,['NA'],,
14442,NCT01707641,incidence of grade III/IV mucositis,2012-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],percentage of patients who need enteral nutrition,percentage of patients able to complete the chemo-radiotherapy treatment
14443,NCT01588990,Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio,2012-06-26,COMPLETED,INTERVENTIONAL,['PHASE4'],,FACT-C Score: Phase B
14444,NCT00100321,,2004-12-21,TERMINATED,OBSERVATIONAL,['NA'],,
14445,NCT02727894,Colorectal Cancer Stage (pTNM),2013-03,COMPLETED,OBSERVATIONAL,['NA'],,Colorectal Cancer and Palliative Therapy
14446,NCT02381847,overall survival,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,time to distant metastasis
14447,NCT05945901,Progression-Free Survival (PFS) Assessed by IRC（Phase III）,2023-08-14,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Serious Adverse Events (SAE)（Phase III）
14448,NCT06044961,Use of radiomics,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14449,NCT00524498,Antitumor effect (tumor size reduction),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease control rate Overall survival Progression-free survival
14450,NCT03202758,Evaluation of the safety of Durvalumab plus Tremelimumab in combination with FOLFOX chemotherapy,2017-08-29,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14451,NCT05776940,Occurrence of diarrhea,2023-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Involved organ response（kidney）at 3 and 6 months after enrollment
14452,NCT01907230,HBV reactivation,2013-09-10,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Hepatitis flare (ALT > 100 U/L) related to biological treatments
14453,NCT06204497,Incidence of severe complications within 90-day,2024-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life evaluation
14454,NCT03594448,Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens,2018-09-05,RECRUITING,OBSERVATIONAL,['NA'],,
14455,NCT04817826,Primary outcome of Cohort 2: 2-year complete response rate,2021-04-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Post gastrectomy complications
14456,NCT04895137,PCR rate,2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,3 years OS Rate
14457,NCT01949545,Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,Number of Participants With Adverse Events (AEs)
14458,NCT01403064,Number of Participants With All Grades of OM at a Radiation Dose of 55 Gy,2011-07,TERMINATED,INTERVENTIONAL,['PHASE2'],,Mean Change From Baseline in C-reactive Protein (CRP) Values at Varying Weeks
14459,NCT03518632,Change of Oxgen consumption at anaerobic threshold :,2018-03-27,COMPLETED,INTERVENTIONAL,['NA'],,Changes in Fatigue :
14460,NCT00003993,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14461,NCT02004769,PFS(Progression-free survival ),2013-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety
14462,NCT04239573,"Occurrence of an ""unfavorable"" outcome",2020-06-16,RECRUITING,INTERVENTIONAL,['NA'],Predictive accuracy of radiomic markers for dysplasia and pancreatic cancer,Biomarker analysis from collected samples to compare the predictive performance of known and future biomarkers for dysplasia or cancer
14463,NCT00001569,,1997-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14464,NCT04035876,Recurrence-free survival,2019-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse effect
14465,NCT03876106,"Safety and tolerability (maximum tolerated dose, MTD) of LUT014 topically applied qd for 4 weeks in metastatic colorectal cancer (mCRC) patients with epidermal growth factor receptor inhibitor (EGFRI) induced acneiform lesions.",2019-08-21,COMPLETED,INTERVENTIONAL,['PHASE1'],,Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI-18) on health-related quality of life (HRQoL) questionnaire
14466,NCT03302403,Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03,2017-12-29,UNKNOWN,INTERVENTIONAL,['NA'],Changes of cell subsets for CAR T cells against T cells,Engraftment
14467,NCT04933435,change in quality of life in patient cohorts receiving either Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy,2020-11-12,RECRUITING,INTERVENTIONAL,['NA'],,total healthcare system cost associated with Hypofractionated Liver Directed Therapy
14468,NCT03773367,To determine the rate of histopathological response according to Becker criteria.,2018-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,
14469,NCT00425152,,1989-07,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14470,NCT02640898,overall survival rate,2015-12,UNKNOWN,INTERVENTIONAL,['NA'],,progression free survival rate
14471,NCT00222378,Prevalence of Cytomegalovirus and Epstein Barr Virus in inflamed colonic tissue from patient with mild to moderate IBD as compared to inflamed mucosa from patients with other inflammatory diseases of the colon,2005-04,COMPLETED,OBSERVATIONAL,['NA'],,
14472,NCT04078828,The rate of general complications,2019-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,"White blood cells(WBC) ,C-reactive protein (CRP) and procalcitonin (PCT) count in the blood sample"
14473,NCT02163291,Pathological complete response rate,2013-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"R0 rate, surgical morbidity and mortality"
14474,NCT04020276,Number of Participants with Acute Dose Limiting Toxicity (DLT),2019-11-04,SUSPENDED,INTERVENTIONAL,['PHASE1'],,Local Control Rates
14475,NCT02682082,Difference in pain scores at 1 month and end of the trial,2016-05-27,TERMINATED,INTERVENTIONAL,['NA'],,Difference in survival
14476,NCT00892242,Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.,2009-12,TERMINATED,INTERVENTIONAL,['PHASE1'],,Determine the pharmacodynamics of neoadjuvant zoledronic acid therapy on selected immune cell subgroups in the hepatic metastatic niche by flow cytometric analysis of pancreatic tumor samples
14477,NCT02830737,Recurrence Rate,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Number of Participants with Adverse Events,Overall Survival Rate
14478,NCT02356406,Numerical Rating Scale (NRS) pain score difference from baseline,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"Safety profile of the procedure - measuring the frequency and severity of treatment side effects, mainly GI toxicities"
14479,NCT02856126,Overall survival,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Number of of Patients developed Adverse Events
14480,NCT01935700,Overall Survival,2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Grade III Severe Adverse Events
14481,NCT04379232,Symptoms of Covid after surgery,2020-03-19,COMPLETED,OBSERVATIONAL,['NA'],,
14482,NCT05052723,Progression-free survival,2022-01-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall participant survival rate
14483,NCT03641976,6-month PFS rate (%),2019-01-03,RECRUITING,INTERVENTIONAL,['PHASE2'],,surrogate markers predictive of survival: ctDNA
14484,NCT00546468,5 year disease free survival,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,Overall survival
14485,NCT05580887,Intestinal bacterial structure in BC and PnC (separately) patients with disease progression,2022-05-12,RECRUITING,OBSERVATIONAL,['NA'],,Change from baseline in intestinal bacterial structure in PnC patients with disease relapse on or after combined treatment completion (follow up 12 months)
14486,NCT01448668,Overall survival time (OS).,2010-09,UNKNOWN,OBSERVATIONAL,['NA'],,"Number of patients with adverse events (AE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy)."
14487,NCT01238939,Number of patients with dose-limiting toxicity as determinant of the maximum tolerated dose/recommended dose,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Peak Plasma Concentration (Cmax) of NK012 and fluorouracil
14488,NCT05698082,Original survival,2020-12-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14489,NCT01329458,evaluation of contrast enhanced ultrasound in the assessment of de novo focal liver lesions,2010-12,UNKNOWN,OBSERVATIONAL,['NA'],,
14490,NCT06203821,Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])
14491,NCT01896778,"Changes in tumor vascular (blood flow, blood volume)",2013-10-04,COMPLETED,INTERVENTIONAL,['NA'],,Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
14492,NCT05596188,Independent risk factors of preoperative anxiety and establishment of prediction model,2022-11-10,RECRUITING,OBSERVATIONAL,['NA'],,Incidence of preoperative anxiety
14493,NCT04079946,Lymph nodes harvest,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14494,NCT05781074,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,2023-03-23,RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
14495,NCT01086059,Major malformations,2003-11,COMPLETED,OBSERVATIONAL,['NA'],,Infant follow-up
14496,NCT04729738,"correlation between the development of a postoperative complication within 30 days from surgery and patient-related characteristics (comorbidity, frailty, malnutrition and sarcopenia)",2012-06-01,COMPLETED,OBSERVATIONAL,['NA'],,"relatedness between the average density sarcopenia indices, HUAC, PI, TPA and the distance between the anterior-superior iliac spines and the size of the psoas muscles (RPSI)"
14497,NCT01219829,Number of subjects with histological features of PanIN lesions assessed,2009-03-18,COMPLETED,OBSERVATIONAL,['NA'],,Evaluation of Recurrence Mechanism in PDC
14498,NCT00142350,overall survival,2000-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,non-hospitalized survival
14499,NCT01814969,• The rate of patients with downstaging after radiotherapy or radiochemotherapy to pathological response or disease with negative margins,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 4.0)
14500,NCT03846882,Can FDG-PET / MR in combination with blood and tumor tissue biomarkers provide additional prognostic information for intermediate and high-risk rectal cancer?,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA'],,How does the accumulation of FDG change in rectal cancer tissue when examined after 60 minutes vs examination after 90 minutes?
14501,NCT03961646,Diagnostic accuracy,2019-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Image quality
14502,NCT05344664,Percentage of adverse events,2022-04-14,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,
14503,NCT01075555,Overall survival,2010-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14504,NCT05548114,Composite end point of inability to tolerate a solid diet (defined as gastric outlet obstruction scoring system score <2) or requiring endoscopic or surgical intervention or supplemental nutrition or procedure-related adverse events.,2022-09-15,RECRUITING,INTERVENTIONAL,['NA'],,Overall treatment costs from index procedure until 6 months post-index procedure.
14505,NCT05253430,Disease-free survival,1990-04,COMPLETED,OBSERVATIONAL,['NA'],,Postoperative mortality
14506,NCT00179348,Program satisfaction measured by Yoga - Daily Practice Calendar and Yoga Class Attendance Record and Yoga Evaluation Form,2001-02-08,COMPLETED,INTERVENTIONAL,['NA'],,spiritual well-being
14507,NCT01706822,The Ability to Achieve Adequate Distal Margins (Defined as >2cm [or >1cm With Clear Histologic Evaluation]) in the Low Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4'],,Maneuverability Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree
14508,NCT03426722,Proportion of patients who have occurrence of muscle cramps ( numeric rating scale score > 4),2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,recurrence rate
14509,NCT00002796,"Efficacy of FU in combination with PB, indomethacin and rhIFNg in patients with advanced colorectal cancer (Phase II)",1997-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14510,NCT05044065,Skeletal muscle cross sectional area,2021-05-01,RECRUITING,INTERVENTIONAL,['NA'],,Prognostic markers
14511,NCT00937079,"Detection of insulinomas, cure rate",2007-11,COMPLETED,OBSERVATIONAL,['NA'],,
14512,NCT00140894,Safety and tolerability,2002-08-06,TERMINATED,INTERVENTIONAL,['PHASE4'],,Proportions of patients with improved overall colon rating
14513,NCT01280058,Progression-free Survival Using RECIST v. 1.1,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2'],Percentage of Patients With Ras Pathway Activation,Overall Survival
14514,NCT04006275,CEUS LI-RADS Grades of SonoVue and Sonazoid agents in enrolled patients.,2019-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,The sensitivity and specificity of CEUS-LI-RADS by different contrast agencies.
14515,NCT02776527,disease free survival,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,overall survival
14516,NCT03161379,CD8 count (cells/mm^3) in the tumor microenvironment,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Pathologic complete response (pCR) rate at surgical resection
14517,NCT01556490,Overall Survival (OS) Per Protocol (PP) Population,2012-03,COMPLETED,INTERVENTIONAL,['NA'],,Tumor Response
14518,NCT04707118,Ascites control,2021-02-23,UNKNOWN,INTERVENTIONAL,['PHASE1'],,
14519,NCT02282839,Oral mucositis,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
14520,NCT01288339,Progression-free survival time according to the MMP7 status (PFS),2010-11-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Molecular predictive markers for response.
14521,NCT05432492,Objective Response Rate (ORR) Per mRECIST,2022-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Percentage of participants who obtain a pathologic complete response (pCR),Overall survival (OS)
14522,NCT02321813,proportion of patients in both groups with diseased quality of life (<50 points in at least one dimension),2014-01,COMPLETED,INTERVENTIONAL,['NA'],,rates of patients with diseased quality of life in each dimension of the profile
14523,NCT02287727,Disease free survival (DFS),2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall survival
14524,NCT06137248,Change in the hydrogen sulfide-metabolizing species of bacteria,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE2'],,Microbiome changes and tolerance
14525,NCT02599116,"Determine whether the intestinal microbiome of patients with appendiceal tumors with peritoneal carcinomatosis differs from that of a healthy, age-matched cohort",2015-12,RECRUITING,INTERVENTIONAL,['NA'],Identify alterations in the gut microbiome post-CRS/HIPEC,Compare the gut microbiome of appendiceal tumors by histopathology
14526,NCT02682992,Percentage of Participants With Severe (CTCAE v. 4.0 Grade 3-5) Oral Mucositis,2016-06,COMPLETED,INTERVENTIONAL,['NA'],,Breaks in Chemoradiotherapy
14527,NCT00493025,Pathologic Complete Response Rate to the Neoadjuvant Regimen,2005-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival
14528,NCT03264274,Overall survival,2017-02-06,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Progression-free survival
14529,NCT03228407,Correlation between the time from intravenous injection of fluorescein to visualization of fluorescein on probe based confocal endomicroscopy (pCLE) with esophageal permeability (i.e. - epithelial barrier function).,2017-04-28,UNKNOWN,INTERVENTIONAL,['NA'],,Correlation between the Ussing's chamber findings (esophageal permeability) and Mucosal impedance findings of patients with symptoms of refractory GERD and controls
14530,NCT02257541,Phase Ib Portion: Response Rate (RR),2014-10-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase Ib Study: Response Rate (RR)
14531,NCT03700411,Change in number of circulating tumor cells prior to surgery to 2 - 4 weeks after surgery,2019-01-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,Pain assessment
14532,NCT04491565,Adequacy of bowel prep,2019-11-13,COMPLETED,INTERVENTIONAL,['NA'],,
14533,NCT01170299,"Change in IBDQ-B (Inflammatory Bowel Disease Questionnaire - Bowel Subset) score between baseline (i.e., Day 1 of radiotherapy treatment) and the nadir score during treatment",2009-10,COMPLETED,INTERVENTIONAL,['NA'],,Costs for symptom management
14534,NCT02894801,death due to recurrence,2013-01,COMPLETED,OBSERVATIONAL,['NA'],,
14535,NCT04225026,Number of Subjects With of Acute Radiation Esophagitis (Defined as Grade >/= 2; NCI CTCAE Version 5) Through the End of Chemoradiotherapy for Non-Small Cell Lung (NSCLC) or Small Cell Lung Cancer (SCLC) When Avasopasem Was Added.,2019-12-19,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Subjects With Acute Severe Radiation Esophagitis (Defined as Grade 3-4; NCI CTCAE Version 5) Through Completion of Chemoradiotherapy.
14536,NCT03214991,Overall survival rate,2017-05-12,UNKNOWN,OBSERVATIONAL,['NA'],,"Overall survival rate (K-ras mutation type, EUS-FNA)"
14537,NCT04973475,False negative rate,2021-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,The variation of C-reactive protein
14538,NCT01575717,Change in serum levels of 25-hydroxyvitamin D,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Model for End stage Liver Disease score (MELD)
14539,NCT04122937,P2X7R-inflammasome activity,2017-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14540,NCT01227707,Percentage of Participants With Pathological Complete Response (pCR),2005-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,TTP - Time to Event
14541,NCT01232374,3-yr overall survival,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life
14542,NCT04788368,Complications after surgery,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,
14543,NCT02055560,Overall survival,2014-01,COMPLETED,OBSERVATIONAL,['NA'],,
14544,NCT04909671,Mean number of adenomas per colonoscopy,2021-09-13,UNKNOWN,INTERVENTIONAL,['NA'],,Subjective endoscopist measures
14545,NCT01974661,Registration of adverse events as a measure of safety and tolerability,2013-10,COMPLETED,INTERVENTIONAL,['PHASE1'],"Local tissue changes in injected/non-injected tumor and surrounding tissue, assessed by MRI",To study overall survival (OS)
14546,NCT03663712,Non-dose limiting toxicities for talimogene laherparepvec,2019-05-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14547,NCT03435588,Final diagnosis of benign pancreatic mass,2018-02-14,COMPLETED,INTERVENTIONAL,['NA'],,Rate of procedure-related adverse events
14548,NCT02146508,Complete resolution of advanced esophageal squamous dysplasia,2013-06,SUSPENDED,INTERVENTIONAL,['NA'],,Safety of endoscopic interventions
14549,NCT00258323,Distant metastatic control at 1 year,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity of maintenance gefitinib as measured by CTC version 2.0 every 8 weeks after the completion of radiotherapy
14550,NCT00687570,Bowel purity degree,2008-07,COMPLETED,INTERVENTIONAL,['NA'],,physiological function
14551,NCT00374036,Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The tolerance, the quality of life, duration of hospitalization"
14552,NCT04393116,Development of patients' Distress,2017-07-11,COMPLETED,OBSERVATIONAL,['NA'],,Patient's global health status
14553,NCT03220984,the disease control rate (DCR),2017-03-16,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14554,NCT00093548,,na,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14555,NCT03951792,Microbial 16S rDNA Biomarkers,2021-06-30,RECRUITING,OBSERVATIONAL,['NA'],,Protein Measurements
14556,NCT05792254,1-year progression-free survival rate,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,the Rates of AE and SAE
14557,NCT02909478,Complete response,2017-09-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Complete response in the delay phase (25 hours-120 hours)
14558,NCT05273489,Survival,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Neoadjuvant Chemotherapy
14559,NCT02107105,Health state utilities,2014-05-16,RECRUITING,OBSERVATIONAL,['NA'],,
14560,NCT04759235,change of metabolites,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
14561,NCT01320267,Successful completion of the right hemicolectomy,2011-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Postoperative Measure of Pain
14562,NCT00284817,The recommended Phase II dose will be based on acceptable dose-limiting toxicity,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response
14563,NCT03659448,Surgical resection histopathology.,2019-06-17,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14564,NCT00582660,Subjects With Positive Response 72 Hours After Administration of Study Treatment as Measured by Immunoblot,2001-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14565,NCT02726360,study-specific coding structure,2015-12-14,COMPLETED,OBSERVATIONAL,['NA'],,
14566,NCT04471272,Ideal technical success rate,2020-01-06,UNKNOWN,INTERVENTIONAL,['NA'],,Technical time
14567,NCT02786342,PFS,2016-02-15,UNKNOWN,OBSERVATIONAL,['NA'],,OS
14568,NCT04444544,Health-related Quality of Life,2020-09-05,RECRUITING,OBSERVATIONAL,['NA'],,Health-related Quality of Life
14569,NCT04637061,Rate of 30 day-anastomotic failure (AF),2021-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,Procalcitonin (PCT) measurement
14570,NCT01854749,Progression Free Survival,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14571,NCT00004870,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14572,NCT05891730,Number of colorectal cancer patients who remain in clinical trial until completion.,2024-06,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14573,NCT01591135,3-yr overall survival,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Number and grade of Participants with Adverse Events
14574,NCT05300789,Metachronous peritoneal carcinomatosis,2021-03-01,COMPLETED,OBSERVATIONAL,['NA'],,Time to metachronous peritoneal carcinomatosis diagnosis
14575,NCT01787539,cancer free and overall survival,2013-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",quality of life,the rate of chemotherapy cessation
14576,NCT06214572,Median overall survival,2024-01-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Quality of life assessment (Liver specific)
14577,NCT01474694,"TRE, measuring the error in the prediction of a surgical target location when using the navigation system.",2011-10,COMPLETED,OBSERVATIONAL,['NA'],,1.Identification of suitable landmarks for registration
14578,NCT05557955,overall survival.,2022-09-27,COMPLETED,OBSERVATIONAL,['NA'],,recurrence.
14579,NCT03049124,Number of Participants with Adverse Events,2017-11-01,WITHDRAWN,INTERVENTIONAL,['NA'],Socio-Demographic and Medical Information Questionnaire,
14580,NCT05638243,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,2022-08-20,RECRUITING,OBSERVATIONAL,['NA'],,
14581,NCT01123473,Progression-free survival,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2'],,Concordance of diagnostic tests
14582,NCT02906059,"Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.",2016-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Tumor assessment by imaging techniques using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1"
14583,NCT05323201,Objective response of fhB7H3.CAR-T cells,2022-02-10,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Overall survival (OS),In vivo persistence of fhB7H3.CAR-T cells
14584,NCT00005997,Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue.,1999-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Assess the toxicity associated with this drug in this patient population.
14585,NCT04605185,Dose limiting toxicity(DLT),2021-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Duration of response (DOR)
14586,NCT01110785,Percentage of patients free from progression and alive at 11 weeks after the first dose of panitumumab measured by RECIST v 1.1,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Correlation between proteomics and objective response rate
14587,NCT05837767,Overall Response Rate (ORR),2023-07-24,RECRUITING,INTERVENTIONAL,['NA'],,
14588,NCT01961791,Prognostic performance,2000-01,COMPLETED,OBSERVATIONAL,['NA'],,
14589,NCT01727570,Six-Minute Walk Test (6MWT),2012-09,COMPLETED,INTERVENTIONAL,['NA'],,
14590,NCT06004687,Postoperative delirium,2023-07-26,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Neurotransmitters in the blood,Recovery time
14591,NCT03623737,pathological complete response,2017-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Number of participants with treatment-related adverse events as assessed by the NCI Common Toxicity Criteria (CTC)
14592,NCT02508077,4-month Progression-free Survival (PFS) Rate,2016-02-16,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14593,NCT01847599,evaluation of the efficacy of the implementation of an educational program on adherence to capecitabine alone or in combination to lapatinib,2011-09-06,TERMINATED,INTERVENTIONAL,['NA'],,safety and tolerability as determined by adverse events frequency
14594,NCT04264754,To develop a molecular blood test that will be able to detect HCC based on change in methylation patterns between HCC and normal hepatic tissue,2018-02-13,TERMINATED,OBSERVATIONAL,['NA'],,Liver EpiCheck Performance
14595,NCT05278039,Change in Penetration-Aspiration Scale scores,2021-08-12,RECRUITING,INTERVENTIONAL,['NA'],Change in M.D. Anderson Dysphagia Inventory (MDADI) scores,Change in Modified Barium Swallow Impairment Profile (MBSImP) scores
14596,NCT05602974,marginal recurrence rate,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Quality of life by EORTC QLQ-C30
14597,NCT02101580,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer,2014-11-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14598,NCT03385148,diagnosis effecacy,2017-01-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
14599,NCT00209664,objective tumor response,2004-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,"Response duration, time to progression, median survival time, and safety will also be assessed."
14600,NCT00336141,Toxicity,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,Response
14601,NCT05023863,Incidence and severity of radiation induced oral mucositis,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Time to develop grade III or IV radiation induced oral mucositis:
14602,NCT02757846,quantitative image features extracted from CT images can be used as imaging marker for prognosis,2017-04,UNKNOWN,OBSERVATIONAL,['NA'],,
14603,NCT04692051,PFS,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,AEs
14604,NCT01900691,Number of Patients With Successful Removal of Study Stent,2013-09,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With Benign Indications That Achieved Clinical Success
14605,NCT06147414,% of inconclusive results,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Estimated delay for result in standard care diagnosis condition
14606,NCT03416777,DNA damage,2019-06-01,COMPLETED,INTERVENTIONAL,['NA'],,Oxidative stress
14607,NCT02458664,Recurrence free survival and Recurrence free survival after resection of the colon cancer,2013-11,UNKNOWN,OBSERVATIONAL,['NA'],,Overall survival
14608,NCT04230642,Evaluation of the feasibility of the Quantum Surgical device: Number of targets reached,2020-05-25,COMPLETED,INTERVENTIONAL,['NA'],,Evaluation of the safety not related to the procedure
14609,NCT00436137,Performance of colonoscopy,2007-06,COMPLETED,INTERVENTIONAL,['NA'],,
14610,NCT02972372,2-year disease-free survival rate,2016-11,UNKNOWN,INTERVENTIONAL,['NA'],,2 year overall survival
14611,NCT04015466,"Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape",2019-06-12,UNKNOWN,OBSERVATIONAL,['NA'],,Daily routines as assessed by a new study-specific questionnaire
14612,NCT03451370,Progression Free Survival (PFS),2017-11-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14613,NCT01399190,Progression-free Survival,2011-07,COMPLETED,OBSERVATIONAL,['NA'],,Percentage of Participants With Adverse Events
14614,NCT02077296,Plasma and tissue cytokine levels,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,
14615,NCT00773097,Number of Participants With Anti Muc-1 Antibody,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events Associated With the Study Agent
14616,NCT00058149,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14617,NCT01604564,Evaluation of postoperatieve recovery,2012-05,COMPLETED,OBSERVATIONAL,['NA'],,
14618,NCT00965718,Progressive Disease(PD),2009-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life (QoL) Assessed Using Quality of Life Questionnaire Core 30(QLQ-C30) in Patients With Pancreatic Cancer(QLQ-PAN26 Questionnaire)
14619,NCT06102278,overall survival,2020-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14620,NCT03856437,Intention to Vaccinate Free of Cost,2021-01-22,COMPLETED,INTERVENTIONAL,['NA'],,Intention to Vaccinate With Cost
14621,NCT00006198,,na,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14622,NCT00707889,Progression-free survival,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective response rate
14623,NCT00511862,Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST),2007-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14624,NCT03852836,Global quality of the images evaluated with a Likert score,2019-02-26,TERMINATED,INTERVENTIONAL,['NA'],,"Performance of each sequence in the visualization of the pathology and / or an anatomical variant in the 1.5T magnetic field group, evaluated in percentage"
14625,NCT02586610,Pathological Complete Response (pCR) Rate,2016-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Overall Survival (OS)
14626,NCT00019630,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14627,NCT03337347,CEA mRNA positive circulating tumor cells in colorectal cancer patients,2004-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Cancer specific survival in CTC positive CRC patients
14628,NCT04754672,Progression free survival,2021-03-02,RECRUITING,INTERVENTIONAL,['NA'],,Physical activity
14629,NCT03053284,Hypoglycemia,2017-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Serum glucose regulators
14630,NCT01937780,Disease-free survival,2013-10-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],Overall survival,Pain relief of palliative radiotherapy
14631,NCT00016133,,2001-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14632,NCT00233415,Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14633,NCT03066167,Translation of scores to the Swedish language,2010-11,COMPLETED,OBSERVATIONAL,['NA'],,
14634,NCT03418298,Recruitment rate,2018-02-27,COMPLETED,INTERVENTIONAL,['NA'],,Change in anxiety and depression
14635,NCT01239381,Local Control Rate,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,Median Survival Among Participants With Colorectal Cancer
14636,NCT05563441,perioperative complications,2015-01-20,COMPLETED,OBSERVATIONAL,['NA'],,disease free survival
14637,NCT02859324,Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2016-09-20,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Apparent Volume of Distribution (Vz/F)
14638,NCT02016326,Adenoma Detection Rate (ADR) in the right colon using High Definition White Light Colonoscopy Versus I-Scan enhanced Colonoscopy.,2012-11,UNKNOWN,INTERVENTIONAL,['NA'],Presence or absence of learning effect while using this technology,Adenoma Detection Rate (ADR) of High Definition White Light Colonoscopy Versus I-Scan colonoscopy through out the entire colon.
14639,NCT03265483,"Blood 1,25-dihydroxyvitamin D2",2014-09,COMPLETED,INTERVENTIONAL,['NA'],,
14640,NCT01152164,To prospectively evaluate the quality of life of patients one year after rectal cancer resection,2008-01,UNKNOWN,OBSERVATIONAL,['NA'],,To prospectively evaluate the quality of life of patients two years after rectal cancer resection
14641,NCT00220155,Proportion of patients obtaining disease control in the form of tumour response or stabilisation,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression free survival
14642,NCT02220088,Progression free survival,2014-12,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,overall survival
14643,NCT05808790,Local recurrence-free survival,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Multiparameter flow cytometric analyses (FACS)
14644,NCT05501353,the correlation between ctDNA mutations with methylation status and recurrence,2022-07-22,RECRUITING,OBSERVATIONAL,['NA'],,Compare the difference of DNA with ctDNA in predicting postoperative recurrence through statistical method
14645,NCT02222844,Randomised Phase: To measure the difference in treatment stratification policy caused by the difference in staging on CT and MRI.,2014-08,RECRUITING,INTERVENTIONAL,['NA'],,To compare permanent defunctioning stoma rates in patients staged by CT and MRI according to predicted prognostic risk.
14646,NCT02582541,Stent patency rate,2014-02,UNKNOWN,INTERVENTIONAL,['NA'],,Change from Baseline in Bile Duct Stricture Diameter
14647,NCT00960349,"Safety of each treatment arm will be measured in terms of adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, and physical examinations.",2009-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Pharmacokinetics will be assessed in terms of Css,max, Css,min, tmax, AUCss and AUC0-8 for cediranib, and Cmax, tmax, AUC, AUC(0-t), CL or CL/F, t½λz for capecitabine, cisplatin and TS-1. Additional PK parameters may be determined."
14648,NCT04799080,Semmens Weinstein Monofilament Test (SWMT),2021-03-06,COMPLETED,OBSERVATIONAL,['NA'],,Functional Assessment of Cancer Therapy-Breast (FACT-B+)
14649,NCT01985698,postoperative complications,2013-12,COMPLETED,INTERVENTIONAL,['NA'],self reported sexual function for female patients,locoregional recurrence rate
14650,NCT00755118,Objective Response Rate,2008-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Overall Survival
14651,NCT05760404,Evaluate the motor effects of drugs that act on the various components of this system,2022-12-19,RECRUITING,OBSERVATIONAL,['NA'],,
14652,NCT06317103,Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%),2023-08-22,COMPLETED,OBSERVATIONAL,['NA'],,"Accuracy in classifying the depth of invasion categories (""Mucosa"" or ""Submucosa"") for early gastric cancer (%)"
14653,NCT00847119,Pathologic complete response rate. % patients with pathologic complete response (absence of tumoral cells in the resected piece),2007-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,To determine the angiogenic profile changes in tumour.
14654,NCT04294498,The rate of HBV reactivation during durvalumab treatment,2020-11-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,To assess the adverse events during durvalumab treatment.
14655,NCT01848015,CTCs,2013-06,UNKNOWN,OBSERVATIONAL,['NA'],,Recurrence of gastric cancer after radical resection
14656,NCT02908048,Diagnosis of liver cancer based on tumor markers and imaging studies.,2014-07,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14657,NCT01923337,"MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0",2013-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Time to failure
14658,NCT03878550,AUROC,2019-05-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Sensitivity
14659,NCT02748811,Number of patients completing planned treatment without dose reductions,2015-05,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life prior
14660,NCT00002527,Disease free survival,1993-05,COMPLETED,INTERVENTIONAL,['PHASE3'],,
14661,NCT05062720,Progression free survival,2021-07-29,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Patient reported outcomes (PROs)
14662,NCT00006340,,1994-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14663,NCT03130790,Overall Survival (OS) - Phase 3 part,2017-08-31,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part
14664,NCT05468827,proportion of pN+ patients in which affected lymph nodes are detected only within margins of ICG distribution,2022-07-26,RECRUITING,INTERVENTIONAL,['NA'],,feasibility of ICG mapping for colon flexure tumours
14665,NCT01494324,Tumor response,2009-10-27,RECRUITING,INTERVENTIONAL,['NA'],,Duration of treatment response
14666,NCT03797209,Removal success,2019-01-15,COMPLETED,OBSERVATIONAL,['NA'],,
14667,NCT04814030,overall response rate,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14668,NCT04785287,Incidence of adverse events,2021-03-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Tumor response
14669,NCT00637247,To Evaluate and Compare the Tolerability and Toxicity of the Two Treatment Arms by Comparing Adverse Events,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14670,NCT03377972,Comparison WHO diagnosis standard with JAPAN in Early Esophageal Cancer patients by accessing pathological section.,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14671,NCT03833466,Tumor microenvironment,2019-02-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Rate of pathologic complete response（pCR）
14672,NCT01937286,Recurrence of Hepatocellular carcinoma after LDLT,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
14673,NCT02794337,In-field Progression Free Survival,2014-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Toxicity Assessment
14674,NCT02439008,"Analyse of immunological parameters, decription of secreted markers and nanovesicles production",2015-09-16,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants with Adverse Events related to radiotherapy
14675,NCT00630552,Safety,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Response
14676,NCT04449679,Post-intervention evaluation,2020-04-15,COMPLETED,INTERVENTIONAL,['NA'],,
14677,NCT03190265,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),2017-12-14,COMPLETED,INTERVENTIONAL,['PHASE2'],,Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Events (AEs)
14678,NCT06113718,Length of hospital,2023-01-01,COMPLETED,INTERVENTIONAL,['NA'],,Postoperative gastrointestinal symptoms
14679,NCT02949596,Evaluate quality of sexual life validated questionnaire (IIEF) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men,2015-10,COMPLETED,OBSERVATIONAL,['NA'],,Evaluate quality of life among patients who are HIV positive in this cohort with the use of questionnaire HAT-QoL
14680,NCT03498326,disease free survival,2018-04-02,RECRUITING,INTERVENTIONAL,['PHASE2'],,Common Toxicity Criteria for Adverse Effects
14681,NCT00079274,Disease-free Survival (Arms A and D: Wild-type KRAS Patients),2004-02,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)"
14682,NCT05809999,Proportion of persons with ≥ 1 neoplastic lesion detected,2022-09-23,RECRUITING,INTERVENTIONAL,['NA'],,CRC incidence over five years following study colonoscopy (obtained through patient linkage to provincial cancer registries five years following trial completion)
14683,NCT03701373,maintenance progression-free survival (PFS),2016-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,toxicity relevant to S-1 maintenance/observation
14684,NCT06256289,liver steatosis index CAP (Controlled Attenuation Parameter) measured by FibroScan,2024-03-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4'],,Gut Microbiota diversity sequencing by 16s rRNA Amplicon Sequencing Analysis
14685,NCT00811590,The Size of Intestinal Polyps,2008-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14686,NCT00600496,Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.,2007-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Tumor response.
14687,NCT00026468,,1999-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14688,NCT05674422,ctDNA from liquid biopsy,2023-05-26,RECRUITING,OBSERVATIONAL,['NA'],,TNT compliance
14689,NCT02870153,Response Rate,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
14690,NCT01661686,Number of Participants With Recurrent Dysphagia.,2012-07,COMPLETED,INTERVENTIONAL,['NA'],,Median Survival After SEMS Placement
14691,NCT03338166,serum LDH level as a predictor of response in hepatocellular carcinoma,2018-01-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14692,NCT02416466,Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1'],,"CAR-T detection in liver tumors, normal liver, and extrahepatic sites"
14693,NCT01216202,Sexual Function,2010-04,COMPLETED,OBSERVATIONAL,['NA'],,
14694,NCT01380392,,2011-02,UNKNOWN,OBSERVATIONAL,['NA'],,
14695,NCT00068432,Overall Survival at 6 months,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall response rate
14696,NCT00509444,"The primary outcome variable will be difference between the two intervention groups in the time to initiation of therapy, beginning on the date of randomization.",2006-10,COMPLETED,INTERVENTIONAL,['PHASE3'],,"The proportion receiving recommended screenings for breast, cervix, colon/rectum and prostate cancer."
14697,NCT00796718,Percentage of Participants With Pathological Complete Response,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Percentage of Participants With Adverse Events
14698,NCT00632268,To evaluate the confirmed objective response rates (complete and partial responses),2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To assess the overall survival(OS), progression-free survival(PFS), treatment-related toxicities, and pharmacokinetic profile of RAD001 used in combination with 5-FU and cisplatin"
14699,NCT01974869,changes in inflammatory cytokines,2014-03,COMPLETED,OBSERVATIONAL,['NA'],,30 postoperative day complications.
14700,NCT00408551,Hepatic toxicity,2005-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients
14701,NCT00025350,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14702,NCT04898842,"Symptoms of sub-acute bowel obstruction: abdominal pain, feeling bloated, feeling full-up quickly, nausea and / or vomiting",2021-03-02,UNKNOWN,INTERVENTIONAL,['NA'],,Weight
14703,NCT01045538,"Phase 1 - maximum tolerated dose, Phase 2 - response rate",2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
14704,NCT00192075,Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST),2003-06,COMPLETED,INTERVENTIONAL,['PHASE2'],Duration of Response - A+FOLFOX4 - Avastin Subgroup,Duration of Response
14705,NCT04426955,PFS assessed by IRC,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3'],,AE
14706,NCT01468623,Overall response rate (ORR),2011-09,TERMINATED,INTERVENTIONAL,['PHASE4'],,Progression-free survival (PFS)
14707,NCT03182894,Phase ll: Objective Response Rate (ORR),2018-09-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival (OS)
14708,NCT03307811,Diagnostic adequacy of the liver biopsy specimen,2017-08-01,COMPLETED,INTERVENTIONAL,['NA'],,Complications/Infection
14709,NCT06319924,Assess the quality of the bowel preparation assessed by Boston Bowel Preparation Scale (BBPS),2020-02-01,COMPLETED,OBSERVATIONAL,['NA'],,Caecal intubation rate
14710,NCT05773105,Desease control rate (DCR),2023-02-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse Events (AEs)
14711,NCT02487017,Overall survival,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Phenotypic analysis of T cells
14712,NCT01944540,En Bloc resection rate,2013-08,UNKNOWN,INTERVENTIONAL,['NA'],,complication rate
14713,NCT04338542,Change of RAS mutant clones in the metastatic lesion,2020-04-08,COMPLETED,OBSERVATIONAL,['NA'],,Molecular patterns other than RAS
14714,NCT03843398,"3-year overall survival, 3y OS",2019-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative mortality at 30 days
14715,NCT01073358,rate of disease recurrence,2010-03-09,UNKNOWN,INTERVENTIONAL,['NA'],,
14716,NCT00559598,Gather information about clinical factors surrounding the date of blood extraction that may influence the proteomic patterns of the blood samples by reviewing clinical records of participants,2004-08,COMPLETED,OBSERVATIONAL,['NA'],,
14717,NCT02514031,Maximum Tolerated Dose,2016-03-24,TERMINATED,INTERVENTIONAL,['PHASE1'],,Tolerability
14718,NCT01219192,MDT,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1'],,PFS
14719,NCT05660915,Rate of mortality after surgery,2023-06-01,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of postoperative complications
14720,NCT03519295,Progression free survival rate (PFS),2018-07-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Tolerance graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] criteria v4.03
14721,NCT04870034,Incidence of adverse events,2024-01-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,Immune subsets within the pre and posttreatment tumor tissue
14722,NCT02853422,"Survey on the clinical utility of the QLQ-GINET21, which the investigator is to complete for each patient enrolled",2016-04,COMPLETED,OBSERVATIONAL,['NA'],,Clinical assessment of patient's health status by the investigator
14723,NCT06168825,Acceptability of the MOM intervention,2024-01-17,RECRUITING,OBSERVATIONAL,['NA'],,Number of participants who reported MOM intervention as linguistically appropriate
14724,NCT01296763,Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD),2011-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Number of Years From Cycle 1, Day 1 On-Study to Date of Death"
14725,NCT03081637,Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.,2004-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14726,NCT05214495,Oral Mucositis Severity,2022-02-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,
14727,NCT00075556,Objective tumor response rate,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation
14728,NCT00031681,Side effect profile of 7-hydroxystaurosporine in combination with irinotecan hydrochloride in triple negative recurrent breast cancer (Part II),2001-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,In vivo mechanistic basis for 7-hydroxystaurosporine activity
14729,NCT04627012,Overall survival (OS),2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Adverse events
14730,NCT02186236,To validate the Trovagene urine assay,2014-07,COMPLETED,OBSERVATIONAL,['NA'],,EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA)
14731,NCT02477553,Colorectal Cancer (CRC) Screening Intention: Change From Baseline to Post-intervention,2015-06,COMPLETED,INTERVENTIONAL,['NA'],,Number of Patients With High and Low Subjective Numeracy
14732,NCT03133273,Occurrence of the progression or death of the patient.,2017-07-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Grade 3 and higher adverse events related to chemotherapy
14733,NCT03002727,Differential expression of CD133 based on microsatellite status and correlation with clinicopathological features.,2016-12,UNKNOWN,OBSERVATIONAL,['NA'],,"If radiotherapy increases the count of CD +ve 133 cells , does that increase significantly affects the progression free survival"
14734,NCT04349384,Morbidity,2018-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Readmission
14735,NCT02379520,Number of patients with dose limiting toxicity (DLT),2015-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Overall response rate
14736,NCT02833753,Define the maximum tolerated dose (MTD) of intraperitoneal (IP) oxaliplatin given with systemic FOLFIRI in patients with peritoneal carcinomatosis (PC) of colorectal or appendiceal origin,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14737,NCT05368636,Accuracy,2022-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14738,NCT03449966,The percentage of remnant cancer cells in biopsy samples,2018-02-20,UNKNOWN,INTERVENTIONAL,['NA'],,pCLE findings of residual cancer cells after chemotherapy
14739,NCT03365882,Progression-free Survival(PFS),2017-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs.
14740,NCT00769535,Clinical relevance,2006-01,COMPLETED,INTERVENTIONAL,['NA'],,Clinical relevance
14741,NCT04067778,Adverse Events occurrence,2020-11-06,COMPLETED,INTERVENTIONAL,['NA'],,Rate of Missed 2-Week Post-Procedural Assessment for Complications
14742,NCT00134095,Safety,2004-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14743,NCT02322736,To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.,2014-11-21,COMPLETED,OBSERVATIONAL,['NA'],"Frequency of primary tumor resection, of metastatic lesion resection, of BRAF testing in the entire number of the study participants and frequency of BRAF mutation in the unselected Greek patient population with WT RAS mCRC included in the study.","To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®."
14744,NCT02451124,Average Methylation of Zinc Finger Protein 793 Assay,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,
14745,NCT04588246,Time to Neurologic Death,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE3'],,Incidence of Adverse Events associated with the interventions
14746,NCT01770431,Incidence of Recurrence and Metastasis After Hepatectomy,2011-08,COMPLETED,INTERVENTIONAL,['PHASE4'],,Postoperative Survival Period
14747,NCT02729506,Time to Progression (TTP) is the primary outcome.,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,"Treatment-related costs, in terms of cost of therapy and number of hospitalization days."
14748,NCT03588442,Liver-related disease progression,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA'],,Non-hepatocellular carcinoma malignant neoplasm
14749,NCT00885248,Staging of pancreatic cancer,2009-01,UNKNOWN,OBSERVATIONAL,['NA'],,Diagnosis of pancreatic cancer
14750,NCT02365896,postoperative early anastomotic morbidity,2015-06,UNKNOWN,INTERVENTIONAL,['NA'],,Nutrition
14751,NCT00342641,,2005-06-08,COMPLETED,OBSERVATIONAL,['NA'],,
14752,NCT00099346,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE1'],,
14753,NCT04211168,Rate of adverse events (AE),2020-08-11,RECRUITING,INTERVENTIONAL,['PHASE2'],Biomarkers,6-months and 1-year mortality rate
14754,NCT04839471,ORR (RECIST 1.1),2021-08-06,UNKNOWN,INTERVENTIONAL,['PHASE2'],,To explore the treatment-related adverse events as assessed by CTCAE v5.0
14755,NCT03825289,Rate of dose-limiting toxicities during the DLT assessment window.,2019-01-18,RECRUITING,INTERVENTIONAL,['PHASE1'],,Response Rate
14756,NCT05894369,Tumor diameter,2023-05-04,RECRUITING,OBSERVATIONAL,['NA'],,Overall survival
14757,NCT00756782,radiologically proven progression-free survival (PFS),2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,The relationship between tumor gene expression (mRNA expression) of co-activators and co-repressors and efficacy parameters
14758,NCT04803851,Disease control rate (DCR) based on RECIST v. 1 1,2021-05-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
14759,NCT05571293,Number of complications leading to delays of 12 weeks or more in surgery after initiation of treatment,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Changes in Minimal Residual Disease assessed using ctDNA pre- and post-surgical resection
14760,NCT01969110,"plasma resolvin E1, cell-mediated immunity",2013-01,UNKNOWN,INTERVENTIONAL,['PHASE4'],,infectious complication rate
14761,NCT02850536,Safety of CAR-T cell hepatic artery infusions delivered using the Surefire Infusion System (SIS) as Measured by Number of Participants with Adverse Events,2017-02-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety of Direct Intrapancreatic CAR-T Retrograde Venous Infusions (RVI) Delivered Using the Surefire Infusion System (SIS)
14762,NCT03899870,Recurrence,2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14763,NCT01392274,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l,2012-04,COMPLETED,OBSERVATIONAL,['NA'],,Comparative histopathology-confirmed measures of Cellvizio endomicroscopy and ERCP accuracy in the differential diagnosis of suspicious l
14764,NCT03245554,Tumor size will be measured.,2018-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,
14765,NCT04629677,Bleeding risk (Cohort A and B),2019-04-02,RECRUITING,OBSERVATIONAL,['NA'],,
14766,NCT00002608,,1994-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14767,NCT05931068,Change in energy expenditure using indirect calorimetry,2023-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Hospital anxiety and depression scale
14768,NCT00537901,Effectiveness,2007-10,COMPLETED,INTERVENTIONAL,['NA'],,Quality of life
14769,NCT05526443,Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy,2023-01-13,RECRUITING,OBSERVATIONAL,['NA'],,To analyze the mutational landscape of advanced pancreatic cancer and its impact on treatment decision making and clinical outcome
14770,NCT02346032,Response rate,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14771,NCT03084380,Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0,2017-06-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Persistence: Duration of CAR-positive T cells in circulation
14772,NCT03179657,Nonalcoholic fatty liver disease (NAFLD),2008-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Cognitive function
14773,NCT06217224,Evaluate the best photobiomodulation protocol for preventing oral mucositis,2022-10-17,RECRUITING,INTERVENTIONAL,['NA'],,Hospital internment
14774,NCT02894944,Number of participants with treatment-related adverse events assessed by CTCAE v4.03,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Detection of adenoviral DNA in blood by PCR
14775,NCT02591407,Post-operative pain control day 3 using the numeric pain scale,2016-01,UNKNOWN,INTERVENTIONAL,['NA'],Patient use of supplemental narcotic analgesia post-operative day 3,Overall benefits of analgesia treatment post-operative day 3
14776,NCT04680260,Recurrence Free Rate,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2'],,Cost-effectiveness analysis
14777,NCT03765411,In-hospital Complications,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Costs and Charges
14778,NCT00892736,"MTD, DLT, recommended phase II dose of chronically dosed single-agent veliparib in patients with either a refractory BRCA 1/2- mutated solid cancer; platinum- refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer",2009-04-20,COMPLETED,INTERVENTIONAL,['PHASE1'],,Changes in BRCA 1/2 expression in tumor blocks
14779,NCT04764084,Dose limiting toxicity (DLT) and maximum tolerated dose (MTD),2021-04-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Progression-free survival (PFS)
14780,NCT05130021,progress free survival(PFS)[Part 2],2022-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety and tolerability assessed by incidence and severity of adverse events
14781,NCT01273402,Determine the number of adverse events,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE1'],,Efficacy will be evaluating using CT scans and possibly PET imaging.
14782,NCT02510066,"Pain scores, assessed with numeric rating scale (NRS)",2015-07,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Blood levels of nerve growth factor
14783,NCT03787251,PFS,2019-01-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,ORR
14784,NCT04006951,Proportion of patients who gave their consent to participate in the study,2014-10-08,RECRUITING,INTERVENTIONAL,['NA'],,
14785,NCT05551832,Marginal ulcer incidence,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE3'],,QOL
14786,NCT04526470,Progression-free survival rate at 4 months,2020-09-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Exploratory biomarker analysis for efficacy and resistance of alpelisib plus paclitaxel combination (using collected clinical samples) including mutations and RNA/protein expression levels of PI3K pathway genes,Time to response
14787,NCT04648917,overall survival (OS),2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,progression-free survival (PFS)
14788,NCT01791309,objective response rate (ORR),2013-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,efficacy
14789,NCT04494022,Compared diagnostic performance of Gd-EOB-MRI alone and Gd-EOB-MRI with CEUS.,2020-06-08,UNKNOWN,INTERVENTIONAL,['NA'],,Comparing image characters between two types of ultrasound contrast media
14790,NCT01463501,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall Survival
14791,NCT02562924,Change in Lund-Kennedy Endoscopic Scores,2015-11,COMPLETED,INTERVENTIONAL,['NA'],,Change in SNOT-22 Nasal Symptom Scores
14792,NCT05684432,Frequency and classification of radiation-induced diarrhrea in patients with prostate and rectal cancer during curative external radiotherapy,2022-06-01,RECRUITING,OBSERVATIONAL,['NA'],,
14793,NCT04401813,Evaluation of the objective response rate of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma,2020-06-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Evaluate the ORR of IBI310 combined with 308 in the second-line treatment of advanced hepatocellular carcinoma (researched by the investigator according to RECIST V1.1).
14794,NCT01011478,"Occurrence of ≥ 1 Adenomatous Polyp of the Colon or Rectum, Metachronous Colorectal Carcinoma, or Colon Cancer Recurrence (APMC+R)",2010-03,TERMINATED,INTERVENTIONAL,['PHASE3'],,Measurements of Relevant Tumor and Blood Markers
14795,NCT03480256,Maximum Tolerated Dose (MTD),2018-07-27,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Area Under the Curve
14796,NCT03224221,One-year survival rate,2017-03-23,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Quality of life using EORTC QLQ C30 - scale
14797,NCT03200366,Participants Completing CRC Screening Per Electronic Medical Record Documentation,2017-07-26,COMPLETED,INTERVENTIONAL,['NA'],,Change in Perceived Self-Efficacy for CRC Screening by FIT
14798,NCT04985084,Acceptability outcome: participants' satisfaction and perspectives of the intervention,2021-07-12,UNKNOWN,INTERVENTIONAL,['NA'],,Dietary behavior self-efficacy
14799,NCT02754115,Changes in arterial blood gas in perioperative period,2016-04,RECRUITING,OBSERVATIONAL,['NA'],,Mortality
14800,NCT05496777,Therapist appreciation,2022-01-01,RECRUITING,INTERVENTIONAL,['NA'],,Quality of life measurement
14801,NCT04652986,Disease-free survival at five years,2004-01,UNKNOWN,OBSERVATIONAL,['NA'],Operative morbidity,Five years overall survival
14802,NCT04526080,Overall Survival,2021-04,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Response Rates
14803,NCT06106568,Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group,2023-11-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Descriptive summary of the likelihood of open-close laparotomy in patients with confirmed diagnosis of pancreatic cancer who is intended the surgical intervention between those in the EOB-MRI group and non-EOB-MRI group
14804,NCT04954794,Objective Response Rate (ORR),2021-07-14,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
14805,NCT05215964,Total psoas muscle change,2020-09-29,UNKNOWN,OBSERVATIONAL,['NA'],,Total kidney volume change
14806,NCT05740137,Adenoma detection rate (ADR),2022-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Polyps per positive patient (PPP)
14807,NCT05040646,Consensus in / No important outcome,2021-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
14808,NCT01920113,A comparison of safety during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil,2012-10,COMPLETED,INTERVENTIONAL,['NA'],"A comparison of gastric motility, easiness for procedure, operator's satisfaction during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil",A comparison of efficacy during endoscopic submucosal dissection between dexmedetomidine-remifentanil and propofol-remifentanil
14809,NCT00574327,"The goal of this study is to follow GERD and BE pts prospectively for development of dysplasia and adenocarcinoma, to identify factors responsible for progression of GERD to BE to dysplasia and adenocarcinoma.",2006-01,RECRUITING,OBSERVATIONAL,['NA'],,The secondary goal is to create a tissue and serum repository for future biomarker studies.
14810,NCT06027775,relapse-free survival,2013-01-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival
14811,NCT02774161,Spectral slope,2016-05,COMPLETED,INTERVENTIONAL,['NA'],,
14812,NCT05787197,Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM),2024-01-09,RECRUITING,OBSERVATIONAL,['NA'],,Association between ctDNA and clinical features.
14813,NCT00414232,Quality of Life (QoL),2006-11,COMPLETED,OBSERVATIONAL,['NA'],,
14814,NCT02399631,Actual hospital stay,2012-01,TERMINATED,INTERVENTIONAL,['NA'],,Nutritional status
14815,NCT00998751,Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST),2005-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14816,NCT04572711,Number of adverse events,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,Healthcare Utilization
14817,NCT05717738,Number of Patients Amendable to Curative Surgical Interventions,2022-01-20,RECRUITING,OBSERVATIONAL,['NA'],,Quality of Life (QoL) after treatment
14818,NCT03357276,Relief degree of tumors,2017-11-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival（OS）
14819,NCT00339469,Biomarkers of insulin resistance and inflammation,2005-08-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Weight loss
14820,NCT03415802,Objective response rate（ORR）,2015-05-11,COMPLETED,INTERVENTIONAL,['PHASE2'],,Safety profile: Adverse events of nab-Paclitaxel plus S-1 for advanced pancreatic cancer
14821,NCT00919659,nutritional status presented by phase angle,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,"quantity of port infections, quantity of oedema, quantity of diarrhea"
14822,NCT04945733,Objective Response Rate (ORR),2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants with Anti-Amivantamab Antibodies
14823,NCT02463877,Rate of postoperative complications,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14824,NCT04993261,Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors,2015-09-23,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,
14825,NCT03996031,Patient activation,2019-08-19,COMPLETED,OBSERVATIONAL,['NA'],,Patient satisfaction
14826,NCT04773080,Incidence of postoperative acute kidney injury,2021-01-21,COMPLETED,OBSERVATIONAL,['NA'],,Increase in length of hospital stay
14827,NCT00618319,Changes in FDG-PET imaging,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,Characterize the safety profile of BIIB021
14828,NCT04653480,Overall Response Rate,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Progression Free Survival
14829,NCT06176885,PFS（Disease-free Survival）,2023-12-20,RECRUITING,INTERVENTIONAL,['PHASE2'],,DCR（Disease control rate）
14830,NCT00562068,"Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)",2007-05,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Epstein-Barr virus copy number (measured retrospectively)
14831,NCT05601323,Overall Survival,2023-01-31,RECRUITING,INTERVENTIONAL,['NA'],,Adverse Events
14832,NCT00805896,Time to tumor progression(TTP),2008-12,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
14833,NCT01646112,,2012-04-25,COMPLETED,OBSERVATIONAL,['NA'],,
14834,NCT02865135,Changes in CD8+ T Cells in Peripheral Blood and Tumor Tissue,2017-03-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Time to Progression (TTP)
14835,NCT00028002,Rate of Disease Progression at 2 Years,2002-03-31,COMPLETED,INTERVENTIONAL,['PHASE2'],,"FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy"
14836,NCT02289300,Change from baseline in liver stiffness measurement (kPa) assessed by Fibroscan® at Final visit,2020-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,"Changes from baseline to post-treatment visits in vital signs, laboratory examination, and physical examinations results"
14837,NCT01333332,To determine the safety of neoadjuvant accelerated fraction standard dose radiotherapy to 50 Gy with concomitant capecitabine in patients with resectable and borderline resectable pancreas cancer.,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14838,NCT03615326,Overall Survival (OS),2018-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Treatment Discontinuations Due to AEs
14839,NCT04143230,Accuracy of the Simplified Screening Tool (SST) with respect to the SIAARTI/NCCN screening tool (EST),2017-05-23,COMPLETED,INTERVENTIONAL,['NA'],,Clinical characteristics and outcomes of palliative care patients referred to an acute palliative care unit
14840,NCT04763408,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Lenvatinib,2021-04-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Number of Participants with one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations of Sorafenib
14841,NCT03454035,Overall Survival,2018-01-30,RECRUITING,INTERVENTIONAL,['PHASE1'],,Cancer Antigen 19-9 (CA19-9) response
14842,NCT05322590,Objective Response Rate (ORR),2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Post Oxaliplatin Assessment
14843,NCT03434379,PFS-IRF Per RECIST v1.1 in the China Population,2018-03-15,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population
14844,NCT00487695,Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia),2007-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Mean Number of Biopsies Taken in Barrett's Surveillance Patients
14845,NCT03803891,Technical Success,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,Histologically confirmed full-thickness resection
14846,NCT03300843,Percentage of Patients Who Had a Clinical Response (Complete Response (CR) + Partial Response (PR)) to Treatment,2018-04-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Serious and Non-serious Adverse Events
14847,NCT03667612,correlation between the expression levels of the genes involved in the regulation of endothelial activation and the degree of tumor-infiltrating lymphocytes,2018-01-31,UNKNOWN,OBSERVATIONAL,['NA'],,The RER phenotype (the replication error phenotype)
14848,NCT01639703,Permeability Surface (PS) According to Degree of Lesions Differentiation,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,Permeability Surface According to Immunohistochemistry Parameter (CD31)
14849,NCT03767660,Total venous malformation lesion load,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Concentration of D-dimer in blood
14850,NCT01294072,Concentration of curcumin in normal and cancerous tissue,2011-01,RECRUITING,INTERVENTIONAL,['NA'],,measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors
14851,NCT01204476,"Safety profile of cixutumumab and everolimus with octreotide acetate among patients with advanced neuroendocrine tumors, defined by the incidence of adverse events",2010-10,COMPLETED,INTERVENTIONAL,['PHASE1'],Changes in molecular markers,Anti-tumor activity as determined by RECIST
14852,NCT04430452,Objective response rate (ORR),2022-02-04,RECRUITING,INTERVENTIONAL,['PHASE2'],,Overall survival (OS)
14853,NCT00744640,Response rate,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Progression-free survival and overall survival
14854,NCT01642875,Frequency of delayed gastric emptying,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Rehospitalization rate
14855,NCT04197856,Uptake of genetic counselling among the patient's at-risk relatives,2020-02-06,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],Intervention - Collection of letters (only intervention group),
14856,NCT04635423,Percentage of participants with ≥1 serious adverse events (SAEs),2020-11-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Geometric mean titers (GMTs) to HPV 6/11/16/18/31/33/45/52/58
14857,NCT06129422,Safety and tolerability of a single infusion of NMK89: Frequency and severity of abnormal ECOG PS (Eastern Cooperative Oncology Group Performance Status),2023-10-31,RECRUITING,INTERVENTIONAL,['PHASE1'],,Public Safety: Radiation measurement
14858,NCT02138370,Time to disease recurrence,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,overall survival
14859,NCT02172690,Peritoneal Metastasis or Positive Cytology,2014-06,UNKNOWN,INTERVENTIONAL,['NA'],,Safety
14860,NCT06130280,Local control rate CRC liver metastasis,2023-11-08,RECRUITING,INTERVENTIONAL,['PHASE2'],,
14861,NCT05543057,"1-, 2-, 3-year overall survival",2020-01-01,RECRUITING,OBSERVATIONAL,['NA'],Biomarkers to predict radiotherapy efficacy,Quality of life of patients with oesophageal cancer
14862,NCT05626985,GAMAD,2022-10-19,RECRUITING,OBSERVATIONAL,['NA'],,circulating tumor DNA methylation
14863,NCT05515705,Evaluation of the EUS navigation system's procedure duration compared to standard procedure times,2023-01-10,RECRUITING,INTERVENTIONAL,['NA'],,Assessment of technological maturity and ergonomics
14864,NCT05239338,Disease-free survival,2021-12-06,RECRUITING,OBSERVATIONAL,['NA'],,Physical activity (Accelerometer)
14865,NCT04727541,Major Pathologic Response (MPR) measured in the surgically resected tumor,2021-07-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Adverse Events of Special Interest
14866,NCT06139926,Changes in perioperative HADS scale scores.,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE3'],,
14867,NCT05161585,Secondary resection rate,2021-11-01,RECRUITING,INTERVENTIONAL,['NA'],,ctDNA clearance rate
14868,NCT00535652,Tissue (Total) Concentrations of Ertapenem in the Colorectal Tissue,2007-09,COMPLETED,INTERVENTIONAL,['PHASE4'],,Safety Assessment
14869,NCT01339000,Evaluate and Quantify the Impact of Interleukin-7 (CYT107) Therapy on Specific Immune Responses to Vaccines (in Particular to Neo Antigens) in Older Subjects Following Chemotherapy,2011-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
14870,NCT05957289,Fear of Progression Questionaire-Short Form (FoP-Q-SF),2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Semi-structured interviews
14871,NCT04168788,Correlate pharmacogenetic analysis with veno-occlusive disease.,2020-01-01,UNKNOWN,INTERVENTIONAL,['NA'],,Participant characteristics.
14872,NCT06283238,Number of participants with Progressive Disease,2024-04-25,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
14873,NCT03712566,"Characterization of Genomic, epigenetic and Immune Profiling Features",2018-11-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Enable Data-Sharing
14874,NCT01045941,To determine if it is safe to administer gemcitabine to patients with pancreatic cancer one week after laparoscopic distal pancreatectomy.,na,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,To determine the if the 1-year survival in patients with pancreatic cancer is improved with administration of gemcitabine one week following laparoscopic distal pancreatectomy
14875,NCT04101292,Evaluation of the sensitivity of Bevacizumab-IRDye800 to visualize tumour tissue compared to anti-VEGF antibodies by the means of fluorescence intensity measurements,2021-04,WITHDRAWN,INTERVENTIONAL,['NA'],,Level of accuracy of Full-field optical coherence tomography (FF-OCT) by the means of a qualitative analysis
14876,NCT00846313,Body weight,2003-12,WITHDRAWN,INTERVENTIONAL,['NA'],,Dietary intake
14877,NCT03578874,Resectability,2016-06-20,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall survival
14878,NCT00614393,Percentage of Participants Who Experience an AE of Infusion Site Reaction,2007-12-24,COMPLETED,INTERVENTIONAL,['PHASE2'],,Overall Response Rate (ORR) of Dalotuzumab in Combination With Cetuximab + Irinotecan Versus ORR of Cetuximab + Irinotecan Alone in Participants With Wild Type of Colorectal Cancer
14879,NCT06168552,Accuracy and sensitivity of the imaging agent,2023-12-15,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14880,NCT03234842,Compare the rate of a clinically significant reduction of DLCO (defined as a decrease of ≥ 10% from baseline) between protons and photons after preoperative or definitive chemoradiation,2017-10-30,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Compare overall survival rates
14881,NCT05167409,"Objective response rate (ORR, per RECIST v1.1) (%)",2022-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety and tolerability according to the NCI CTCAE v5.0
14882,NCT02008929,"Disease free survival, DFS",2014-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Overall survival, OS"
14883,NCT00994721,The primary end-point is recurrence-free survival.,2009-02,COMPLETED,OBSERVATIONAL,['NA'],,"The secondary end-points are overall survival; local and distant control rate, and the quality of life."
14884,NCT00568971,"Response rate, overall survival",2007-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Side effects
14885,NCT03799380,ED visits,2019-11-05,COMPLETED,INTERVENTIONAL,['NA'],,Missed days of radiation +/- chemotherapy/immunotherapy treatment
14886,NCT00805688,Patient Reported Symptom Severity and Interference,2008-11-12,COMPLETED,OBSERVATIONAL,['NA'],,
14887,NCT01693276,Increase overall survival,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Rate of local control
14888,NCT04805788,3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC),2021-08-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Blood bank patient specimens for future analysis,Value of volumetric imaging analysis
14889,NCT02264496,Length of stay,2014-03,COMPLETED,INTERVENTIONAL,['NA'],,Quality of Life Questionnaires
14890,NCT04767568,correlation between the biological signature of the test and the stage of the disease in patients whose diagnosis of adenocarcinoma was identified by pathology prior to surgery.,2021-03-30,RECRUITING,INTERVENTIONAL,['NA'],,
14891,NCT00493441,Pharmacokinetics,2007-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14892,NCT02753881,Pharmacokinetics Profile-- Time of Maximum Concentration,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1'],,Assessment and Frequency of Toxicities (Laboratory and Clinical Adverse Events) According to NCI Common Toxicity Criteria for AE (CTCAE) 5.0.
14893,NCT03702985,the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0,2018-05-28,UNKNOWN,INTERVENTIONAL,['PHASE2'],,the morbidity of late radiation proctitis
14894,NCT05475041,Major complications,2022-06-30,COMPLETED,OBSERVATIONAL,['NA'],,Intraoperative incidents
14895,NCT01086332,Dose limiting toxicities,2009-05,TERMINATED,INTERVENTIONAL,['PHASE1'],,Surgical resection rate
14896,NCT00019825,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14897,NCT00141466,Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.,2005-09,UNKNOWN,INTERVENTIONAL,['NA'],,Cost efficacy of the implementation procedures.
14898,NCT02963831,Progression-free Survival (PFS) at Week 24 as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1),2017-09-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method
14899,NCT03001596,Overall survival(OS),2017-01,COMPLETED,INTERVENTIONAL,['NA'],,Recurrence-free survival (RFS)
14900,NCT06071845,Accuracy of the Oncoguard Esophagus (OGE) test,2023-10-16,RECRUITING,INTERVENTIONAL,['NA'],,Trauma to the esophagus from the passage of the Cytosponge device
14901,NCT00012220,Overall Survival,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Toxicity
14902,NCT01707511,,2012-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14903,NCT02615210,"Number of malignant diagnoses across hree-sample techniques (Spy bite, forceps biopsy, brushings)",2015-11,TERMINATED,INTERVENTIONAL,['NA'],,Time from procedure to the initiation of treatment (in cases of malignancy)
14904,NCT01853241,Comparison of the depth of insertion into the small bowel of SBE compared with SE from the pylorus.,2010-05,TERMINATED,OBSERVATIONAL,['NA'],,A comparison of the mean adjusted diagnostic procedure time
14905,NCT01634685,dose-limiting toxicities (DLT),2012-08-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,maximally tolerated dose (MTD)
14906,NCT03409848,Overall Survival,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Central Imaging Review - PFS
14907,NCT04316507,Days from decision to test to receiving genetic test results,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA'],,
14908,NCT04641455,"Visibility score"" evaluated by blinded performing endoscopist",2020-12-01,UNKNOWN,INTERVENTIONAL,['NA'],Duration of endoscopy,"Visibility score"" evaluated by two blinded endoscopists using 10 endoscopic images captured during endoscopy"
14909,NCT00250328,Functioning anastomosis without leaks or obstructions,2006-01,UNKNOWN,INTERVENTIONAL,['PHASE1'],,Functioning anastomosis without stenosis
14910,NCT01927393,Symptom burden using the FACT-Trial Outcome Index (TOI),2014-12,WITHDRAWN,INTERVENTIONAL,['NA'],,"Health care resource use including presence of advanced care planning, chemotherapy in the last 14 days of life, and length of time between hospice referral and death"
14911,NCT06292975,withdrawal rate,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Physical activity levels
14912,NCT05659914,Overall Response Rate (ORR),2022-11-28,RECRUITING,INTERVENTIONAL,['PHASE2'],"To characterize the immune microenvironment of this tumours and biomarkers of HRD status, and RAD51 status in tumour tissue samples and blood samples",Incidence and severity of AEs CTCAE v5 criteria
14913,NCT02820194,Control of local disease,2016-06,TERMINATED,INTERVENTIONAL,['NA'],,Incidence of acute and late complications
14914,NCT00079027,Overall survival,2004-04,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Proteomic and immunological analysis
14915,NCT00003192,Objective response rate Objective response rate Objective response rate Objective response rate,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14916,NCT02724475,Overall survival,2012-12,COMPLETED,INTERVENTIONAL,['NA'],,
14917,NCT01486992,adverse events,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2'],,disease control rate
14918,NCT01313442,Collected samples,2011-03-02,RECRUITING,OBSERVATIONAL,['NA'],,
14919,NCT00643877,5 years disease-free survival,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE3'],,5 years overall survival and liver metastasis-free survival
14920,NCT05627635,Overall response (phase II),2023-05-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Surgical resection (phase II)
14921,NCT05354882,Change of physical activity (connected device),2022-03-29,RECRUITING,INTERVENTIONAL,['NA'],Socio-demographic variables,Motivation to physical activity pratice
14922,NCT02903771,Pharmacokinetic (PK) profile of Cantrixil after intra-peritoneal (IP) administration,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1'],Expression of Stem Cell Markers,CA-125 level
14923,NCT01485679,"Specificity of TEP-CT to point out malignant lesions in pancreas, the gold standard being the anatomopathological analysis of the piece of pancreas removed during the surgery.",2011-01,COMPLETED,INTERVENTIONAL,['NA'],,Number of patients for which metastasis will be detected through TEP-CT and confirmed by biopsy and/or conventional specific device
14924,NCT05911425,ORR,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,OS
14925,NCT02923921,Overall Survival,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Percentage of Participants Alive at 1 Year (12-Month Survival Rate)
14926,NCT06106308,Objective Response Rate (ORR),2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE2'],,Safety: Exposure Response Evaluation of Onvansertib
14927,NCT04297202,Major pathologic response,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Safety as measured by the rate of AEs
14928,NCT02709070,recurrence free survival,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,overall survival
14929,NCT01186237,urinary retention,2010-06,COMPLETED,INTERVENTIONAL,['NA'],,
14930,NCT01647828,Phase 2: Median OS by Notch 3 Percentile (ITT Population),2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14931,NCT05490147,Intraoperative blood loss,2022-08-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Satisfaction scale of the operator and participants
14932,NCT02031939,overall survival,2014-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Respond rate
14933,NCT03253185,Number of participants with dose-limiting toxicities (DLTs),2017-09-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Maximum observed serum concentration (Cmax) of SC-007
14934,NCT03520946,Overall survival,2019-01-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],Explorative: Progression-free survival (PFS),Quality of life II (QoL)
14935,NCT01766219,Overall Survival,2013-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Adverse Events Using the National Cancer Institute Common Terminology Criteria
14936,NCT00084383,Disease-free Survival,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.
14937,NCT03410732,progression-free survival,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse event rate
14938,NCT03730545,Change from baseline serum concentration of immune markers to postoperative day 5,2017-01-01,COMPLETED,INTERVENTIONAL,['NA'],,"Change among baseline, postoperative day 3 and 5 serum nutritional markers"
14939,NCT04242901,Number of participants who yield sequential FIT results in divergent strata used for clinical decision making,2020-10-20,COMPLETED,OBSERVATIONAL,['NA'],,"Calculation of Odds Ratios for age, gender, family history of CRC, hypertension, obesity, smoking status, excessive alcohol intake, right sided tumour, stage 1 cancer"
14940,NCT03922230,Hydroxymethylation level,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA'],,
14941,NCT05611658,"Change of interobserver variability in target volume delineation on CT, PET CT and MR.",2020-05-20,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
14942,NCT03247296,HCC,2017-02-28,UNKNOWN,OBSERVATIONAL,['NA'],,
14943,NCT03332498,Phase II - Disease Control Rate at 4 Months,2018-01-24,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14944,NCT04191928,Serum Apixaban Level,2020-03-03,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14945,NCT01613430,"Completing at least one recommended cancer screenings (colorectal, breast, cervical)",2012-06,COMPLETED,INTERVENTIONAL,['NA'],,"Time to completion of cancer screenings, and the effect of comorbid conditions, health literacy, patient satisfaction,and health care costs on cancer screening"
14946,NCT02448953,Long term survival,2015-01,UNKNOWN,INTERVENTIONAL,['NA'],,Postoperative complications
14947,NCT04866862,Objective response rate(ORR),2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],immunocytes and cell factor,Tumor Mutation Burden (TMB)
14948,NCT00938210,Fatigue,2009-05,COMPLETED,INTERVENTIONAL,['NA'],,Social support
14949,NCT02746796,Overall survival (only Part 2),2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Safety will be analyzed through the incidence of laboratory abnormalities
14950,NCT01950403,Dose of linaclotide acetate that produces a 60% response rate for cGMP levels in rectal tissue by radioimmunoassay (RIA),2013-09,COMPLETED,INTERVENTIONAL,['PHASE1'],"PD effect of linaclotide acetate on GCC signaling (i.e., VASP phosphorylation) and general proliferation (Ki67 expression)",PD effect on cGMP levels (Stage II)
14951,NCT00701168,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA'],,
14952,NCT05648682,Thyme honey group patients' quality-of-life scores as assessed by The University of Washington Quality of Life Questionnaire,2020-01-01,COMPLETED,INTERVENTIONAL,['NA'],,
14953,NCT03941457,Occurrence of treatment related adverse events as assessed by CTCAE v4.03,2019-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
14954,NCT01290926,Overall survival at 6 months fixed endpoint,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To determine the correlation of growth modulation index (GMI), defined as the time to progression under the study regimen over the time to progression un-der the latest prior regimen administered to the patient, with overall survival and progression-free"
14955,NCT04471480,overall survival (OS),2020-09-01,UNKNOWN,INTERVENTIONAL,['NA'],,progression-free survival(PFS)
14956,NCT05526079,Local recurrence free survival,2018-07-10,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life using LARS score
14957,NCT00096330,•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints,2004-09,COMPLETED,INTERVENTIONAL,['PHASE1'],,
14958,NCT02204124,Post-op Morbidity,2015-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Number of Participants Who Experienced Postoperative Complications
14959,NCT01229111,The Response Rate of Patients Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2010-10,TERMINATED,INTERVENTIONAL,['PHASE2'],,Identification of Factors That Predict Survival
14960,NCT00032175,Survival at 1 year,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3'],,Objective response rate
14961,NCT01490996,Completion of dose escalation over 2 cycles of therapy,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Efficacy in terms of disease response and survival
14962,NCT04581005,Oxygen consumption (VO2),2019-08-19,UNKNOWN,INTERVENTIONAL,['NA'],,
14963,NCT00311116,"Objective mucositis score at 7, 10, 14, and 17 days post initiation of chemotherapy",2002-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Chemotherapy decrements or delays due to mucositis
14964,NCT01279837,Clinical swallowing Ability,2006-06,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,Swallowing Quality of Life
14965,NCT05475054,Major complications,2020-12-01,COMPLETED,OBSERVATIONAL,['NA'],,Red blood cell transfusion
14966,NCT03049345,Specificity of Sentinel Lymph Node Sampling Method,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA'],,Adverse surgical events
14967,NCT01833299,Effectiveness of sorafenib combined with TACE,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3'],,Time to progression
14968,NCT00005607,,2000-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,
14969,NCT03575117,Change in physical active level,2018-05-01,COMPLETED,INTERVENTIONAL,['NA'],,Change in colorectal cancer risk and physical activity coherence
14970,NCT02297217,Proportion of patients who achieve relief of dysphagia,2019-11-21,RECRUITING,INTERVENTIONAL,['PHASE2'],,Dysphagia progression free survival
14971,NCT05390684,anastomotic leak,2022-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA'],,infection
14972,NCT01327794,Association between 25(OH)D level and OS,2011-06,COMPLETED,OBSERVATIONAL,['NA'],,Association between 25(OH)D level and PFS
14973,NCT06037902,absolute mean heart radiation dose,2023-08-21,RECRUITING,INTERVENTIONAL,['NA'],,movement of tumor in cm
14974,NCT02379377,Immunohistochemistry,2022-02-15,RECRUITING,INTERVENTIONAL,['PHASE1'],,Milan classification
14975,NCT03329664,Time to progression (TTP),2020-02-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Patient quality of life
14976,NCT01877018,Patient's status participation to colorectal cancer screening program,2010-09,COMPLETED,INTERVENTIONAL,['NA'],,
14977,NCT05293054,The rate of successful use and application of Obsidian as a supplemental procedure in the creation of rectal anastomosis with minimal invasive technique,2021-12-15,COMPLETED,OBSERVATIONAL,['NA'],,2-year mortality
14978,NCT05959213,Quantitative data - Preoperatory levels of CA 19.9 (U/ml),2000-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
14979,NCT04370418,Incidence of treatment adverse events as assessed by National Cancer Institute Common Terminology Criteria for adverse events version 4.0,2020-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery.
14980,NCT04791982,The effects of education provided to family members caring for colorectal cancer patients receiving chemotherapy on Caregiver Reaction Assessment Scala.,2018-08-18,COMPLETED,INTERVENTIONAL,['NA'],,
14981,NCT01553019,Radiation Toxicity,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response rate via CA 19-9
14982,NCT05609448,Feasibility of performing intraprocedural treatment planning,2023-05-23,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,Dosimetry optimization
14983,NCT00006332,,na,COMPLETED,INTERVENTIONAL,['PHASE2'],,
14984,NCT06118125,time from date of first symptoms of cancer to the date of first MDT,2019-06-01,COMPLETED,OBSERVATIONAL,['NA'],,overall survival.
14985,NCT04149691,Safety profile,2019-07-19,RECRUITING,INTERVENTIONAL,['PHASE1'],,Kel: Terminal elimination rate constant
14986,NCT01127815,,2010-03,UNKNOWN,OBSERVATIONAL,['NA'],,
14987,NCT00888888,Short-term survival,2009-04,COMPLETED,OBSERVATIONAL,['NA'],,Long-term survival
14988,NCT03445260,The number of patients randomized to the study,2018-10-17,COMPLETED,INTERVENTIONAL,['NA'],,Length of Hospital Stay
14989,NCT00378482,Efficacy Endpoints: Survival,2007-03-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,Disease Free Survival
14990,NCT06118047,Remission rate of EGFR inhibitor-related acneiform eruption,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Quality of life（EORTC QLQ-C30)
14991,NCT00888407,Obtain HBV Screening Test,2006-09,COMPLETED,INTERVENTIONAL,['NA'],,"Knowledge and Attitudes Regarding Hepatitis B, Health and Nutrition"
14992,NCT03269955,Incidence of clinically relevant pancreatic fistula,2017-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4'],,Period of hospitalization after surgery
14993,NCT02371655,"overall quality of bowel preparation using a 0-3 scale for each parameter (Homogeneity of solid-fluid fecal tagging, volume of residual fluid, colon distension).",2015-10-01,COMPLETED,INTERVENTIONAL,['NA'],,compliance of patients
14994,NCT02020707,Maximum tolerated dose,2014-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Incidence of adverse events (soft tissue expansion cohort)
14995,NCT06023004,ctDNA analysis,2022-05-01,RECRUITING,OBSERVATIONAL,['NA'],,Cost-effectiveness of treatment
14996,NCT05517408,Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.,2022-09-19,RECRUITING,INTERVENTIONAL,['NA'],,Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.
14997,NCT00040391,,2002-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,
14998,NCT04889859,diabetes remission rate (%),2019-05-01,COMPLETED,INTERVENTIONAL,['NA'],,changes in gut microbiota
14999,NCT06312982,CR,2024-02-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,immune-related adverse event rate
15000,NCT02464930,Sensitivity and specificity of tissue and serum microRNA expression by digital polymerase chain reaction for diagnosis of BE neoplasia,2015-04,UNKNOWN,OBSERVATIONAL,['NA'],,"Differences in the microRNA expression of biliary exosomes between GERD, Barrett's esophagus and Cancer"
15001,NCT05671315,Change of HBsAg level compared to baseline,2019-07-03,RECRUITING,INTERVENTIONAL,['NA'],,Incidence of liver cirrhosis and hepatocellular carcinoma
15002,NCT00023751,disease-free survival,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,colostomy-free survival
15003,NCT01337492,Adverse events associated with technical aspects of the operation,2010-09,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1'],,Waiting Time
15004,NCT02843425,Changes in Blood Markers and Metabolites,2016-07-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,
15005,NCT05344339,Reflux esophagistis,2022-10-08,RECRUITING,INTERVENTIONAL,['NA'],,6th month reflux esophagistis
15006,NCT05039762,Overall complication rate,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Hernia rate
15007,NCT06327568,Sensitivity and specificity of BD Onclarity HPV assay for HPV detection and genotyping in case/control patients.,2022-06-17,RECRUITING,OBSERVATIONAL,['NA'],,
15008,NCT00642239,tumour local control rate,2008-04,UNKNOWN,INTERVENTIONAL,['PHASE4'],,survival rate
15009,NCT00499265,"Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events",2007-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15010,NCT06271837,Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR),2024-02-18,RECRUITING,INTERVENTIONAL,['PHASE2'],,Immunogenicity of T-DXd
15011,NCT01299688,To survey the frequency of HER2(+) CTC in gastric cancer,2010-03,COMPLETED,OBSERVATIONAL,['NA'],,
15012,NCT00004074,Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0),1999-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15013,NCT03880747,Dumping syndrome,2017-08-09,COMPLETED,OBSERVATIONAL,['NA'],Hospital stay,Incidence of gallstones
15014,NCT05495672,Progression-free survival (PFS) in advanced colorectal cancer patients with metastatic small pulmonary nodules under ctDNA guided therapeutic strategies,2022-08-01,RECRUITING,INTERVENTIONAL,['NA'],,The ctDNA clearance rate after chemotherapy in patients achieving NED (Cohort 2)
15015,NCT05410847,Conversion to negative rate,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse events
15016,NCT06039202,Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0,2024-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],Quality of life measured by European Organization for the research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30).,To evaluate the efficacy of CA102N in combination with trifluridine/tipiracil (TAS-102) by overall survival (OS).
15017,NCT02514434,Resectability rate of HCC,2015-03-30,UNKNOWN,INTERVENTIONAL,['NA'],,Post-treatment recurrence rate
15018,NCT02082210,Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)],2014-03-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies
15019,NCT06141564,HCC recurrence diagnosed by dynamic contrast enhanced CT,2023-10-16,RECRUITING,OBSERVATIONAL,['NA'],,
15020,NCT00003441,Antitumor Activity of MGI-114,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15021,NCT05001204,Standardized uptake value of 68Ga-NOTA-RM26 in gastrointestinal stromal tumor,2021-05-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Adverse events collection
15022,NCT00165867,The objective response rate as defined by RECIST criteria.,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,safety and tolerability of the combination
15023,NCT03366883,Overall Survival,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Rate of R0 resection
15024,NCT04351867,disease free survival,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3'],,Assessment of life quality
15025,NCT04762888,Correlate biomarkers derived from PET/MRI with PSMA immuno-histochemical (IHC) grading,2021-02-24,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15026,NCT01614522,The percentage of patients demonstrating clear evidence of inhibition of receptor auto-phosphorylation in HER-1 and HER-2 co-expressing patients on Day 29.,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
15027,NCT04398446,Change in sleep quality,2020-05-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],,Rate of side effects using medical-grade CBD concentrates
15028,NCT00046995,Disease-free survival,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE3'],,Quality of life
15029,NCT05553080,Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1,2022-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15030,NCT06149923,assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls.,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
15031,NCT03115372,Proportion of participants who report ever having had a CRC screening test,2012-02,COMPLETED,INTERVENTIONAL,['NA'],,Proportion of participants who intend to obtain CRC screening in the next 6 months
15032,NCT04020614,The awareness of patients about colorectal cancer,2019-05-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15033,NCT02579616,Objective Response Rate (ORR),2015-10-23,COMPLETED,INTERVENTIONAL,['PHASE2'],,Plasma Concentrations of Lenvatinib
15034,NCT03859869,Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer,2020-02-25,TERMINATED,INTERVENTIONAL,['PHASE4'],,Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer
15035,NCT04536220,Status of survival,2024-01-01,RECRUITING,OBSERVATIONAL,['NA'],,
15036,NCT04012645,Anastomotic leakage,2023-11-16,RECRUITING,INTERVENTIONAL,['NA'],,the change of surgical precedure
15037,NCT02305914,Change in the Levels of fecal elastase-1,2014-11,UNKNOWN,OBSERVATIONAL,['NA'],,outpatient clinic and phone questionnaire
15038,NCT05405673,Sensitivity of FIT/FOBT,2022-06-29,RECRUITING,OBSERVATIONAL,['NA'],,Microbiota changes in subjects with adenomas or normal findings after polypectomy
15039,NCT00250029,To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen,2004-04,COMPLETED,INTERVENTIONAL,['NA'],,
15040,NCT03418909,Altered salivatory function,2017-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Treatment related pain
15041,NCT04947956,The incidence of treatment-emergent adverse events (TEAE),2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,Time to progression
15042,NCT01374100,Change in Quality of Life (QoL),2009-02,TERMINATED,INTERVENTIONAL,['NA'],,Program Satisfaction
15043,NCT03138239,Measure the absorption of PET-CT F-18-FDG and of PET -CT Ga-68-PSMA,2017-07-02,UNKNOWN,INTERVENTIONAL,['NA'],,
15044,NCT00621725,"To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).",2008-01,COMPLETED,INTERVENTIONAL,['PHASE1'],,Safety/tolerability of Cediranib (single and multiple dose PK)
15045,NCT01926197,Progression-free Survival (PFS),2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,Grade 2 or Greater Gastrointestinal (GI) Toxicity
15046,NCT05462314,Levels of gene expression of the identified species in Gastrointestinal Malignancy,2022-03-29,RECRUITING,OBSERVATIONAL,['NA'],,Relationship between treatment efficacy and microbiome diversity
15047,NCT00316888,Local Failure Rate at 3 Years,2007-02-28,COMPLETED,INTERVENTIONAL,['PHASE2'],,3-year Colostomy-free Survival Rate
15048,NCT03289988,Diagnostic Power for prediction of advanced colorectal neoplasms,2017-06-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15049,NCT01498952,Phase 2: Time to Progression,2012-01-17,COMPLETED,INTERVENTIONAL,['PHASE1'],,Phase 1b and Phase 2: Area Under Serum Concentration-time Curve From Time Zero to Day 22 (AUC0-Day22) of MEDI-573 for Cycle 1
15050,NCT00510107,response rate,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety
15051,NCT00833859,Number of Participants With Resectability,2009-03,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Overall Survival
15052,NCT01986738,Distance traveled by the pancreatic tumor between radiation treatments using Computed Tomography (CT) Scans and an Active Breathing Control (ABC) Device,2012-01,COMPLETED,OBSERVATIONAL,['NA'],,Assess the impact of the determined treatment margins on the radiation dose to normal tissues and the ability to escalate dose to the tumor using Intensity-Modulated Radiation Therapy (IMRT)
15053,NCT03129074,Biomarker,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Incidence of Adverse Events and changes from baseline in safety parameters
15054,NCT05511688,"Time to recurrence for stage I , II or III colorectal cancers",2017-03-22,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,
15055,NCT03576963,Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab,2020-01-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Incidence and severity of adverse events
15056,NCT05003895,"To determine the safety and feasibility of T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor, in patients with advanced HCC, expressing GPC3",2021-12-08,RECRUITING,INTERVENTIONAL,['PHASE1'],,"To determine the best overall response (BOR) rate according to Response Evaluation Criteria (by RECIST v 1.1) of treatment with T-cells, expressing a novel humanized anti-GPC3 chimeric antigen receptor in participants with advanced HCC, expressi..."
15057,NCT02273713,Progression Free survival,2014-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall survival
15058,NCT04974281,Resection rate,2021-01-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1'],,Progression free survival (PFS)
15059,NCT04494282,The impact of the pancreatography in the endoscopic treatment of pancreatic pseudocysts,2015-08,COMPLETED,INTERVENTIONAL,['NA'],,
15060,NCT02683200,"Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI",2015-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1'],,Validity of automatically segmented contours generated by the MRI-guided tri-60Co teletherapy system through independent evaluation of images obtained
15061,NCT00004003,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15062,NCT06005740,Recommended Phase 2 Dose (RP2D),2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE1'],,Accumulation ratio (Rac) of TORL-4-500
15063,NCT03808766,arterial flow through the tumor,2018-08-13,TERMINATED,INTERVENTIONAL,['NA'],,The degree of tumor necrosis
15064,NCT05256459,Time the patients were diagnosed.,2022-05-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],,
15065,NCT05166772,ORR（Objective Response Rate）,2021-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,AE（Adverse events）
15066,NCT04090463,Disease-specific survival,2019-10-01,SUSPENDED,INTERVENTIONAL,['PHASE2'],,Resection rate
15067,NCT05794737,Detection of INHBA in Colorectal Carcinoma.,2021-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.
15068,NCT02311712,Death from all causes,2016-12,UNKNOWN,INTERVENTIONAL,['NA'],,Change in Quality of life
15069,NCT01732380,Progression-Free-Survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2'],Overall survival,Response Rate
15070,NCT05729737,Evaluate if the time to peak (TP) is predictive of response to chemotherapy therapy measured by comparison of TP at CEUS imaging prior to the start of first-line chemotherapy and TP at imaging performed after 2 cycles chemotherapy,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Assessment of overall survival
15071,NCT04687280,arterial enhancement,2009-04-22,COMPLETED,OBSERVATIONAL,['NA'],,
15072,NCT05680077,validity,2022-10-28,COMPLETED,OBSERVATIONAL,['NA'],,reliability
15073,NCT03326791,Disease Free Survival (DFS) after three years treatment,2017-12-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,ASA in CRC and Cost-Effectiveness Analyses III
15074,NCT02482701,"Successful endoscopic resection defined as complete resection of the delineated area, including all delineation markings, in a single procedure.",2015-08,COMPLETED,OBSERVATIONAL,['NA'],,Histopathology
15075,NCT03566355,3-year local control ratio of the treated lung area,2018-05-23,RECRUITING,INTERVENTIONAL,['NA'],,3-year disease-free survival rate of treated patients
15076,NCT05795725,The diagnostic accuracy of the AI-assisted fecal microbiome testing in detecting colon cancer compared to colonoscopy,2023-05-01,RECRUITING,INTERVENTIONAL,['NA'],,
15077,NCT02928510,The Mechanism of Action (MOA) of idelalisib will be assessed with a number of tests in order to provide variability in comparisons for the units of measure.,2016-02-01,TERMINATED,OBSERVATIONAL,['NA'],,
15078,NCT05061199,length of the resection margin,2022-08-01,COMPLETED,OBSERVATIONAL,['NA'],,
15079,NCT05466019,Pathological complete response (pCR),2021-05-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,type and number of intestinal flora
15080,NCT02461836,disease-free survival (DFS),2015-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4
15081,NCT03063840,tumor evaluation,2016-07,WITHDRAWN,INTERVENTIONAL,['NA'],,Assess for presence of adverse events
15082,NCT03989115,Number of Participants With Dose Limiting Toxicities (DLTs),2019-07-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Overall Response Rate (ORR)
15083,NCT00178867,,2002-01,COMPLETED,OBSERVATIONAL,['NA'],,
15084,NCT00582257,"Create registry of families w/ early onset & familial gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of gastric cancer",2005-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,To determine the gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC.
15085,NCT00352703,The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4).,2006-04,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15086,NCT00596401,the annual incidence of gastric cancer in Iijima town,2007-09,COMPLETED,OBSERVATIONAL,['NA'],,The annual medical care cost in Iijima town
15087,NCT03213444,cardiac function evaluation,2015-07,COMPLETED,INTERVENTIONAL,['NA'],,Proinflammatory cytokines
15088,NCT05717998,Changes in myocardial metabolism,2021-04-02,RECRUITING,OBSERVATIONAL,['NA'],,Blood-based biomarkers
15089,NCT05823272,incidence of sarcopenia 6-month after discharge,2024-03-22,RECRUITING,INTERVENTIONAL,['NA'],,Changes in BMI (weight and height will be combined to report BMI in kg/m^2)
15090,NCT02654639,Length of Progression-Free Survival,2016-02,TERMINATED,INTERVENTIONAL,['PHASE2'],,
15091,NCT00325871,,2006-04,COMPLETED,OBSERVATIONAL,['NA'],,
15092,NCT05265962,OS,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],PD-L1 CPS,Adverse Events (Safety)
15093,NCT02501980,5-year HCC specific mortality rate,2012-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA'],,Identification of early diagnosis markers of HCC
15094,NCT02942862,survival,2015-02,COMPLETED,OBSERVATIONAL,['NA'],,
15095,NCT02335619,Total symptom distress score,2015-02,COMPLETED,INTERVENTIONAL,['NA'],,"Details of death (survival time from first oncology appointment at BC Cancer location of death (home, hospice, Cancer Centre)"
15096,NCT05384496,best objective response,2022-05-17,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15097,NCT04034251,Progression Free Survival (PFS) in Participants With Peritoneal Metastases From Gastric Cancer After Repeated Intraperitoneal Chemotherapeutic Infusion (IPC) and Systemic Paclitaxel Administration With Concomitant Capecitabine Therapy,2020-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2'],Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),Number of Participants With Intra-peritoneal Progression Free Survival (iPFS)
15098,NCT00543842,Maximal tolerated dose (MTD),2007-12,COMPLETED,INTERVENTIONAL,['PHASE1'],,
15099,NCT03879109,Proportion of curative surgery,2019-07-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3'],,Tolerance to treatment
15100,NCT03206073,Number of Participants With Grade 1-5 Adverse Events,2017-12-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3),Number of Participants With Response
15101,NCT00506168,Maximal response rate and toxicities,2001-11,TERMINATED,INTERVENTIONAL,['PHASE2'],,Progression-free survival and overall survival
15102,NCT01844817,Overall Survival,2013-09,COMPLETED,INTERVENTIONAL,['PHASE2'],,Objective Response Rate
15103,NCT04185350,Standardized uptake value,2019-05-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1'],,Incidence of Adverse Events
15104,NCT00992199,Metastasis in Peritoneum and peritoneal cavity,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival
15105,NCT04901585,Postoperative complications,2009-01-01,COMPLETED,OBSERVATIONAL,['NA'],,
15106,NCT05960955,Pathological complete response (pCR) rates,2023-11-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,ADA
15107,NCT00387842,Primary endpoint is cancer free survival at three years.,1997-03,UNKNOWN,INTERVENTIONAL,['PHASE3'],,"Secondary endpoints are overall survival at three and five years, 28 day mortality and morbidity, quality of life, costs, location and rates of recurrences and pathologic anatomic characteristics of the resected specimen."
15108,NCT00149201,overall survival,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3'],,toxicity
15109,NCT05035147,Progression-free Survival (PFS),2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE4'],,Overall survival(OS)
15110,NCT02962219,Change in Quality of Life,2016-09,UNKNOWN,INTERVENTIONAL,['NA'],,
15111,NCT05634564,Objective Response Rate (ORR),2020-06-01,RECRUITING,INTERVENTIONAL,['PHASE2'],,Adverse Events
15112,NCT03427242,PFS,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,OS
15113,NCT04070677,Symptomatic relief of radiation-induced esophagitis grade ≥2 in cancer patients undergoing radiotherapy and radiochemotherapy after administration of ZIVEREL®.,2019-06-15,UNKNOWN,INTERVENTIONAL,['NA'],,Analyze the health-related quality of life during the treatment
15114,NCT01775501,Time to Progression,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Duration of Response
15115,NCT02650804,Overall Response Rate (ORR),2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE2'],,Progression Free Survival (PFS)
15116,NCT02123511,Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC),2014-04,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Adverse Event, as Measured by the Number of Patients With a Maximum Grade of Any Adverse Event"
15117,NCT02026362,Time of tumor recurrence or metastasis,2013-07,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,overall survival
15118,NCT05067413,Rate of anastomotic leakage,2020-12-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA'],,3-year disease-free survival
15119,NCT06285591,The duration of Severe Oral mucositis (WHO grade ≥3),2023-11-10,RECRUITING,INTERVENTIONAL,['NA'],,Mouth and throat soreness (MTS) scores
15120,NCT04564482,Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT,2022-11-01,RECRUITING,INTERVENTIONAL,['NA'],,Pathological therapy response
15121,NCT04086901,Loco-regional control,2020-01-01,TERMINATED,INTERVENTIONAL,['NA'],,Treatment completion rate
15122,NCT05062317,To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15123,NCT00251485,"To assess the response rate, progression-free survival, and overall safety profile of a modified FOLFOX 6 plus cetuximab regimen in the first-line treatment of patients with metastatic colorectal cancer.",2004-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,To assess overall survival of patients with metastatic colorectal cancer who receive first-line therapy with a modified FOLFOX 6 + cetuximab regimen
15124,NCT03880617,"Change in Background, Disease and Treatment Information Form (BDTIF)",2015-03-25,COMPLETED,OBSERVATIONAL,['NA'],,
15125,NCT05842174,Local Progression Free Survival,2024-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15126,NCT02056015,Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance,2015-06,COMPLETED,INTERVENTIONAL,['PHASE1'],,"Correlate tumor uptake of [68Ga]MLN6907 measured by PET and the level of guanylyl cyclase C (GCC) expression in tumor lesions from surgical specimens , for tumors in individual patients and for aggregated liver tumors across patients"
15127,NCT04943484,Surgical conduct,2022-01-01,RECRUITING,OBSERVATIONAL,['NA'],,Clinical variables associated with change of the surgical conduct
15128,NCT00579748,The OCT images will be correlated to the specific biopsy site and biopsy number.,2005-06,COMPLETED,OBSERVATIONAL,['NA'],,
15129,NCT02130648,Analysis circulating free fetal DNA,2012-10,UNKNOWN,OBSERVATIONAL,['NA'],,
15130,NCT00668863,Progression-Free Survival (PFS),2008-05,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE)."
15131,NCT02512328,Feasibility,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE1'],,patient´s satification
15132,NCT04803890,Local tumor progression (LTP) rate,2019-04-01,TERMINATED,INTERVENTIONAL,['NA'],,Complication rate
15133,NCT00866944,Disease free survival rate (DFS),2009-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of Life
15134,NCT02041936,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA'],,Quality of Life on the EORTC QLQ-PAN26 and EORTC QLQ-C30
15135,NCT01679327,Overall response rate,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Number of Participants with Adverse Events
15136,NCT01517152,Perceptions of the clarity and ease of response to a series of questions,2012-01-04,COMPLETED,OBSERVATIONAL,['NA'],,
15137,NCT05260385,Objective Response Rate (ORR),2022-01-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Adverse events (AEs)
15138,NCT03532347,The sensitivity of standard Beacon FNA needle compared with the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.,2017-05-22,COMPLETED,INTERVENTIONAL,['NA'],,Duration of sampling procedures
15139,NCT05706779,To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010),2023-02-13,RECRUITING,INTERVENTIONAL,['PHASE2'],,
15140,NCT02686567,Incidence of AL,2016-02,COMPLETED,INTERVENTIONAL,['NA'],Incidence of DT-related adverse events : iatrogenic colonic perforations,Incidence of TDT-related Adverse Events: bleeding
15141,NCT00142480,"To determine the progression free survival rate at one year for locally advanced, or resected with positive margins, biliary tract and gallbladder cancer patients",2004-12,COMPLETED,INTERVENTIONAL,['PHASE2'],,"To evaluate the safety of the combination capecitabine, oxaliplatin, bevacizumab in patients with biliary tract and gallbladder cancer"
15142,NCT01124214,compare diagnostic yield,2010-07,COMPLETED,INTERVENTIONAL,['NA'],,compare the specificity and sensitivity of HRE with EM
15143,NCT03552458,Quality of Life post Radiation,2018-06-26,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Oral Bacteria Analysis and Gene Expression Analysis
15144,NCT04763174,Change in psychological distress,2021-09-15,RECRUITING,INTERVENTIONAL,['NA'],Change in Parenting Concerns,Change in Self-Efficacy for Symptom Management
15145,NCT03604926,immunological features of metastasis,2017-10-05,COMPLETED,OBSERVATIONAL,['NA'],,
15146,NCT01542281,Change in six minute walk test,2012-01,UNKNOWN,INTERVENTIONAL,['NA'],,Nutritional status
15147,NCT03923400,Location,2016-11-01,COMPLETED,OBSERVATIONAL,['NA'],,
15148,NCT05406089,Recurrence of the hepatocellular carcinoma after hepatectomy,2016-01-01,COMPLETED,OBSERVATIONAL,['NA'],,Surgery information
15149,NCT04813783,oral mucositis area measurement,2021-05-01,COMPLETED,OBSERVATIONAL,['NA'],,
15150,NCT02715362,Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serum cytokine levels
15151,NCT00268346,"The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",2005-10,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15152,NCT02171429,"Percentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population",2014-11-14,COMPLETED,INTERVENTIONAL,['PHASE3'],,"Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Anytime Post-Baseline, GA28949 Population"
15153,NCT04933227,Objective Response Rate (ORR) in the Full Analysis Set (FAS) Population,2021-08-06,TERMINATED,INTERVENTIONAL,['PHASE2'],,Number of Participants With Adverse Events
15154,NCT02788565,Proportion of subjects with injection problems according to the subject,2016-03,COMPLETED,OBSERVATIONAL,['NA'],,"Proportion of nurses who reported ""moderately"" or ""very"" or ""very much"" confidence in giving injections"
15155,NCT02642809,Tolerability of localized esophageal hypofractionated brachytherapy administered in two fractions when combined with pembrolizumab as measured by treatment related adverse events,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE1'],,Overall survival (OS)
15156,NCT03428425,Conversion to negative rate,2018-02,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Adverse events
15157,NCT06158139,Neurotoxicity,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Objective response rate- no bridging therapy
15158,NCT04616040,Adverse events of Camrelizumab,2020-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA'],Correlations between biomarkers and clinical activity,Objective Response Rate (ORR)
15159,NCT02324868,Self-reported autonomy score regarding bathing activities,2016-01,TERMINATED,INTERVENTIONAL,['NA'],Catheter/Huber needle status,Laboratory-Confirmed Bloodstream Infection
15160,NCT05740267,C-reactive protein (CRP) level,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Postoperative Recovery course:
15161,NCT04053998,Morbidity assessed according to the Comprehensive Complications Index® (CCI®),2019-08-09,COMPLETED,OBSERVATIONAL,['NA'],,Disease free survival rate
15162,NCT02682446,To estimate the incidence (number of participants) of metachronous gastric neoplasm after ESD between H. pylori eradicated group and H. pylori persistent group,2007-01,COMPLETED,OBSERVATIONAL,['NA'],,To evaluate the incidence of metachronous gastric neoplasm after ESD based on diffferent cut off point of serum pepsinogen.
15163,NCT04331535,Time-to-new diagnosis of common complex disease,2020-07-17,RECRUITING,INTERVENTIONAL,['NA'],Health status and quality of life,Medication adherence
15164,NCT03397199,Progression-free Survival (PFS),2018-01-09,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Overall survival(OS)
15165,NCT04234113,Part B: Number of Participants With Eastern Cooperative Oncology Group [ECOG],2019-06-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1'],,Immunogenicity analysis to assess antibodies to SO-C101
15166,NCT03157128,Phase 2: Objective Response Rate,2017-05-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)
15167,NCT00900094,Potential markers for early detection of cancer,2000-06,COMPLETED,OBSERVATIONAL,['NA'],,
15168,NCT00914355,"Determine one year local progression free rate, defined as lack of progression within the irradiated volume, using RECIST criteria",2007-08,COMPLETED,INTERVENTIONAL,['PHASE2'],,Cytokine response to radiation and association with complications
15169,NCT04994548,technical success of early esophageal cancer resection,2005-01-01,COMPLETED,OBSERVATIONAL,['NA'],,preemptive methods to the risk of bleeding
15170,NCT00354367,"Investigation of Clinical efficacy of certolizumab pegol for fistula closure, as measured by the proportion of patients with fistula improvement after 16 weeks of treatment.",2007-01,WITHDRAWN,INTERVENTIONAL,['PHASE3'],,Investigation of Clinical efficacy of certolizumab pegol for maintenance of fistula closure.
15171,NCT05985707,Overall response rate,2023-08-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Frequency of adverse events
15172,NCT04989764,The disease-free survival,2015-01,COMPLETED,OBSERVATIONAL,['NA'],,
15173,NCT02086968,Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).,2014-01-01,COMPLETED,INTERVENTIONAL,['PHASE4'],,
15174,NCT03515824,Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE),2018-08-13,TERMINATED,INTERVENTIONAL,['PHASE1'],,Minimum Serum Concentration (Cmin) of MK-1697
15175,NCT01040000,Efficacy OS,2012-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Pharmacokinetics and select immune responses to the antibody will be assessed.
15176,NCT01968629,Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases,2013-12,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1'],,
15177,NCT01331928,objective tumor response rate,2011-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,"the progression-free survival, overall survival, toxicity profiles"
15178,NCT02848066,AUC(Area Under the Curve),2015-07,COMPLETED,OBSERVATIONAL,['NA'],,Relative abundance of glycosylations
15179,NCT00520091,Rate of pathologic complete remission in patients with resectable disease,2005-03,COMPLETED,INTERVENTIONAL,['PHASE2'],,Response Rate
15180,NCT05667415,Disease progression (PD),2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,
15181,NCT03170180,response rate,2017-03-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,
15182,NCT04270890,To measure change in treatment volume between freebreathing and abdominal compression scans,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA'],,Reported patient feedback regarding device comfort and compliance of use.
15183,NCT04576858,Time to recurrence,2020-02-03,RECRUITING,OBSERVATIONAL,['NA'],,Response duration RECIST 1.1
15184,NCT00735345,Percentage of complete remissions and resection rate,2008-08,TERMINATED,INTERVENTIONAL,['PHASE2'],,Evaluation of Quality of Life
15185,NCT05071755,Overall survival,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA'],,
15186,NCT05625841,oral mucositis severity,2022-11-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,microbiota level
15187,NCT02823678,Percent resected volume of pancreas and diabetes development,2013-10,UNKNOWN,OBSERVATIONAL,['NA'],,Blood glucose control
15188,NCT00201838,Anti-tumor Effect as Measured by the Proportion of Patients Free of Disease-progression at Six Months After Treatment Initiation,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Serial Levels of TNF (Tumor Necrosis Factor) and Other Inflammatory Cytokines
15189,NCT05125393,Operation time,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA'],,Incidence of at least one serious complication within 30 days after resection
15190,NCT02013778,Number of Participants With Adverse Events,2013-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,
15191,NCT04247984,Progression-free survival (PFS),2018-05-01,COMPLETED,INTERVENTIONAL,['PHASE2'],,Quality of life (QoL) Questionnaire
15192,NCT03828396,Assay sensitivity and specificity for colorectal cancer and advanced adenoma,2018-10-26,UNKNOWN,OBSERVATIONAL,['NA'],,
15193,NCT00085371,Survival in patients receiving triapine as second-line therapy,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2'],,"Confirmed tumor response, defined to be a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart"
15194,NCT01406574,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs),2011-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Best Overall Response
15195,NCT05107674,Objective Response Rate (ORR) per disease-specific response criteria as assessed by the Investigator,2021-09-29,RECRUITING,INTERVENTIONAL,['PHASE1'],,PD Biomarkers: Changes from baseline in tumor tissue biopsies of immune cell infiltration or other histological features
15196,NCT03780634,Progression Free Survival (PFS),2019-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE2'],,Adverse Events
15197,NCT05249569,Response Rate of Combination Therapy,2022-11-04,TERMINATED,INTERVENTIONAL,['PHASE2'],,Safety Profile as Measured by the Number of Participants With Lab Abnormalities as Graded by NCI CTCAE v5.0
15198,NCT06169410,pCR,2023-12-30,RECRUITING,INTERVENTIONAL,['PHASE4'],,total response time
15199,NCT02666976,Changes of symptoms,2014-07,COMPLETED,INTERVENTIONAL,['PHASE4'],,changes of inflammatory biomarkers
15200,NCT06204094,Complete response,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2'],,Validation of the Wexner score
15201,NCT00835055,,2005-04,WITHDRAWN,OBSERVATIONAL,['NA'],,
15202,NCT04619082,The rate of HBV reactivation during TAF prophylaxis,2021-07-01,RECRUITING,INTERVENTIONAL,['PHASE4'],,The dynamic change of eGFR during TAF prophylaxis
15203,NCT03963193,Progression-free Survival (PFS),2019-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2'],,Assessment of Health-related quality of life
15204,NCT06205849,Safety and tolerability,2024-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1'],,Systemic immune effects
15205,NCT02423954,The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer.,2015-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Quantify changes in amount of blood proteins and circulating tumor DNA in patients enrolled on this study
15206,NCT05155189,AESIs,2021-12-09,RECRUITING,INTERVENTIONAL,['PHASE1'],,progression-free survival by mRECIST 1.1
15207,NCT04180371,Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatment,2019-11-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']",,Part B: The association between EphA2 expression level and overall survival (OS) at 1 year by RECIST v1.1 in participants with advanced solid tumors with high EphA2 levels receiving BT5528 treatment
15208,NCT00693173,The Genital Drop Technique (IMRT-GD) decreased the radiation dose to the testicles scrotal skin and penile shaft compared to standard prone technique.,2007-07,COMPLETED,OBSERVATIONAL,['NA'],,Dosimetry comparison details.
15209,NCT01065870,To determine the effect of neoadjuvant regimen of GTX on the 2-year disease free survival rate,2009-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']",,"To describe the effect of neoadjuvant GTX regimen on resectability for those with arterial involvement and those with venous involvement, separately"
15210,NCT04586491,development of oral mucositis,2019-10-07,COMPLETED,INTERVENTIONAL,['NA'],,recovery time of oral mucositis
15211,NCT03746392,Documentation of goals of care,2018-07-01,COMPLETED,INTERVENTIONAL,['NA'],,
15212,NCT05924789,Describe the treatment patterns,2023-08-11,RECRUITING,OBSERVATIONAL,['NA'],,
15213,NCT00640471,Overall survival,2008-05-12,COMPLETED,INTERVENTIONAL,['PHASE3'],,Molecular markers
15214,NCT00454363,Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST),2007-03,COMPLETED,INTERVENTIONAL,['PHASE2'],Plasma Trough Level of GW786034,Percent Change in Tumor Blood Flow Assessed by Functional CT
